PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lashuel, HA; Hartley, DM; Balakhaneh, D; Aggarwal, A; Teichberg, S; Callaway, DJE				Lashuel, HA; Hartley, DM; Balakhaneh, D; Aggarwal, A; Teichberg, S; Callaway, DJE			New class of inhibitors of amyloid-beta fibril formation - Implications for the mechanism of pathogenesis in Alzheimer's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; SELECTIVE-INHIBITION; OXIDATIVE STRESS; PEPTIDE; PROTEIN; NEUROTOXICITY; APOMORPHINE; AGGREGATION; TOXICITY; STATE	The amyloid hypothesis suggests that the process of amyloid-beta protein (Abeta) fibrillogenesis is responsible for triggering a cascade of physiological events that contribute directly to the initiation and progression of Alzheimer's disease. Consequently, preventing this process might provide a viable therapeutic strategy for slowing and/or preventing the progression of this devastating disease. A promising strategy to achieve prevention of this disease is to discover compounds that inhibit Abeta polymerization and deposition. Herein, we describe a new class of small molecules that inhibit Abeta aggregation, which is based on the chemical structure of apomorphine. These molecules were found to interfere with Abeta1-40 fibrillization as determined by transmission electron microscopy, Thioflavin T fluorescence and velocity sedimentation analytical ultracentrifugation studies. Using electron microscopy, time-dependent studies demonstrate that apomorphine and its derivatives promote the oligomerization of Abeta but inhibit its fibrillization. Preliminary structural activity studies demonstrate that the 10,11-dihydroxy substitutions of the D-ring of apomorphine are required for the inhibitory effectiveness of these aporphines, and methylation of these hydroxyl groups reduces their inhibitory potency. The ability of these small molecules to inhibit Abeta amyloid fibril formation appears to be linked to their tendency to undergo rapid autoxidation, suggesting that autoxidation product(s) acts directly or indirectly on Abeta and inhibits its fibrillization. The inhibitory properties of the compounds presented suggest a new class of small molecules that could serve as a scaffold for the design of more efficient inhibitors of Abeta amyloidogenesis in vivo.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Cambridge, MA 02139 USA; N Shore Long Isl Jewish Res Inst, Ctr Neurosci, Manhasset, NY 11030 USA; Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10010 USA; N Shore Univ Hosp, Dept Pathol, Manhasset, NY 11030 USA	Harvard University; Brigham & Women's Hospital; Northwell Health; Icahn School of Medicine at Mount Sinai; Northwell Health; North Shore University Hospital	Lashuel, HA (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Cambridge, MA 02139 USA.		Lashuel, Hilal/M-3500-2017					Buchet R, 1996, BBA-MOL BASIS DIS, V1315, P40, DOI 10.1016/0925-4439(95)00102-6; Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6; CASTANO EM, 1988, LAB INVEST, V58, P122; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; CORBOY DL, 1995, ANN PHARMACOTHER, V29, P282, DOI 10.1177/106002809502900310; Cutler NR, 2001, PROG NEURO-PSYCHOPH, V25, P27, DOI 10.1016/S0278-5846(00)00147-0; Dikalov SI, 1999, J BIOL CHEM, V274, P9392, DOI 10.1074/jbc.274.14.9392; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; El-Bacha RD, 2001, BIOCHEM PHARMACOL, V61, P73, DOI 10.1016/S0006-2952(00)00524-4; Findeis Mark A., 2002, Current Topics in Medicinal Chemistry, V2, P417, DOI 10.2174/1568026024607508; Frenkel D, 2000, J NEUROIMMUNOL, V106, P23, DOI 10.1016/S0165-5728(99)00232-5; Fu WM, 1998, NEUROBIOL DIS, V5, P229, DOI 10.1006/nbdi.1998.0192; Gassen M, 1996, EUR J PHARMACOL, V308, P219, DOI 10.1016/0014-2999(96)00291-9; Gordon DJ, 2001, BIOCHEMISTRY-US, V40, P8237, DOI 10.1021/bi002416v; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hatters DM, 2002, J BIOL CHEM, V277, P7824, DOI 10.1074/jbc.M110429200; HOU L, 2002, IN PRESS J BIOL CHEM; Howlett DR, 1999, BIOCHEM J, V340, P283, DOI 10.1042/0264-6021:3400283; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; Jacobsen J. Steven, 2002, Current Topics in Medicinal Chemistry, V2, P343, DOI 10.2174/1568026024607481; Janus C, 2001, Curr Neurol Neurosci Rep, V1, P451, DOI 10.1007/s11910-001-0105-8; KAUL PN, 1961, J PHARM SCI, V50, P266, DOI 10.1002/jps.2600500323; Kelly JW, 1997, ADV PROTEIN CHEM, V50, P161, DOI 10.1016/S0065-3233(08)60321-6; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lashuel HA, 1998, BIOCHEMISTRY-US, V37, P17851, DOI 10.1021/bi981876+; LeVine H, 1999, METHOD ENZYMOL, V309, P274; LeVine H, 2002, CURR MED CHEM, V9, P1121, DOI 10.2174/0929867023370167; Lichtenthaler SF, 1997, BIOCHEMISTRY-US, V36, P15396, DOI 10.1021/bi971071m; LINDE HHA, 1968, HELV CHIM ACTA, V51, P683, DOI 10.1002/hlca.660510411; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; LUNDGREN P, 1970, ACTA PHARM SUEC, V7, P133; McLaurin J, 2000, J BIOL CHEM, V275, P18495, DOI 10.1074/jbc.M906994199; Miroy GJ, 1996, P NATL ACAD SCI USA, V93, P15051, DOI 10.1073/pnas.93.26.15051; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Pallitto MM, 1999, BIOCHEMISTRY-US, V38, P3570, DOI 10.1021/bi982119e; Palmblad M, 2002, J BIOL CHEM, V277, P19506, DOI 10.1074/jbc.M112218200; Perkins SJ, 1998, INT J BIOL MACROMOL, V22, P1, DOI 10.1016/S0141-8130(97)00088-3; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Poduslo JF, 1999, J NEUROBIOL, V39, P371, DOI 10.1002/(SICI)1097-4695(19990605)39:3<371::AID-NEU4>3.3.CO;2-5; SAM E, 1994, J CHROMATOGR B, V658, P311, DOI 10.1016/0378-4347(94)00239-8; Schenk D, 2001, J MOL NEUROSCI, V17, P259, DOI 10.1385/JMN:17:2:259; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Selkoe DJ, 1997, SCIENCE, V275, P630, DOI 10.1126/science.275.5300.630; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SMITH RV, 1985, J MED CHEM, V28, P613, DOI 10.1021/jm50001a014; SNYDER SW, 1994, BIOPHYS J, V67, P1216, DOI 10.1016/S0006-3495(94)80591-0; Soto C, 1999, MOL MED TODAY, V5, P343, DOI 10.1016/S1357-4310(99)01508-7; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; UBEDA A, 1993, FREE RADICAL RES COM, V18, P167, DOI 10.3109/10715769309147490; Uversky VN, 2002, FEBS LETT, V517, P239, DOI 10.1016/S0014-5793(02)02638-8; Varadarajan S, 2000, J STRUCT BIOL, V130, P184, DOI 10.1006/jsbi.2000.4274; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang R, 1996, J BIOL CHEM, V271, P31894, DOI 10.1074/jbc.271.50.31894; White JT, 2001, P NATL ACAD SCI USA, V98, P13019, DOI 10.1073/pnas.241406698; WILCOX RE, 1980, J PHARM SCI, V69, P974, DOI 10.1002/jps.2600690830; Wolfe Michael S., 2002, Current Topics in Medicinal Chemistry, V2, P371, DOI 10.2174/1568026024607535; Wood SJ, 1996, J BIOL CHEM, V271, P4086; Yang DS, 2001, AMYLOID, V8, P10; Zou K, 2002, J NEUROSCI, V22, P4833, DOI 10.1523/JNEUROSCI.22-12-04833.2002	65	126	147	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42881	42890		10.1074/jbc.M206593200	http://dx.doi.org/10.1074/jbc.M206593200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12167652	hybrid			2022-12-27	WOS:000179081200061
J	Wiame, E; Delpierre, G; Collard, F; Van Schaftingen, E				Wiame, E; Delpierre, G; Collard, F; Van Schaftingen, E			Identification of a pathway for the utilization of the Amadori product fructoselysine in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSAMINE 6-PHOSPHATE SYNTHASE; ANGSTROM CRYSTAL-STRUCTURE; D-TAGATOSE 3-EPIMERASE; AMINO-ACID OXIDASE; SP SOIL STRAIN; DIABETIC COMPLICATIONS; PURIFICATION; FRUCTOSAMINE; EXPRESSION; BINDING	Escherichia coli was found to grow on fructoselysine as an energetic substrate at a rate of about one-third of that observed with glucose. Extracts of cells grown on fructoselysine catalyzed in the presence of ATP the phosphorylation of fructoselysine and a delayed formation of glucose 6-phosphate from this substrate. Data base searches allowed us to identify an operon containing a putative kinase (YhfQ) belonging to the PfkB/ ribokinase family, a putative deglycase (YhfN), homologous to the isomerase domain of glucosamine-6-phosphate synthase, and a putative cationic amino acid transporter (YhfM). The proteins encoded by YhfQ and YhfN were overexpressed in E. coli, purified, and shown to catalyze the ATP-dependent phosphorylation of fructoselysine to a product identified as fructoselysine 6-phosphate by P-31 NMR (YhfQ), and the reversible conversion of fructoselysine 6-phosphate and water to lysine and glucose 6-phosphate (YhfN). The K. of the kinase for fructoselysine amounted to 18 gm, and the K-m of the deglycase for fructoselysine 6-phosphate, to 0.4 mm. A value of 0.15 m was found for the equilibrium constant of the deglycase reaction. The kinase and the deglycase were both induced when E. coli was grown on fructoselysine and then reached activities sufficient to account for the rate of fructoselysine utilization.	Univ Catholique Louvain, Physiol Chem Lab, B-1200 Brussels, Belgium; Christian De Duve Inst Cellular Pathol, B-1200 Brussels, Belgium	Universite Catholique Louvain	Van Schaftingen, E (corresponding author), Univ Catholique Louvain, Physiol Chem Lab, B-1200 Brussels, Belgium.		Van+Schaftingen, Emile/AAF-5532-2020	Van Schaftingen, Emile/0000-0002-6199-7647				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARMBRUSTER DA, 1987, CLIN CHEM, V33, P2153; BAYNES JW, 1991, DIABETES, V40, P405, DOI 10.2337/diabetes.40.4.405; BORK P, 1993, PROTEIN SCI, V2, P31; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; BROWNLEE M, 1994, DIABETES, V43, P836, DOI 10.2337/diab.43.6.836; Delpierre G, 2000, DIABETES, V49, P1627, DOI 10.2337/diabetes.49.10.1627; Delpierre G, 2002, BIOCHEM J, V365, P801, DOI 10.1042/BJ20020325; Delpierre G, 2000, BIOCHEM J, V352, P835, DOI 10.1042/0264-6021:3520835; Erbersdobler HF, 2001, NAHRUNG, V45, P177, DOI 10.1002/1521-3803(20010601)45:3&lt;177::AID-FOOD177&gt;3.0.CO;2-A; GERHARDINGER C, 1995, J BIOL CHEM, V270, P218, DOI 10.1074/jbc.270.1.218; GOLDSTEIN DE, 1986, CLIN CHEM, V32, P64; GOLINELLIPIMPANEAU B, 1991, EUR J BIOCHEM, V201, P175, DOI 10.1111/j.1432-1033.1991.tb16271.x; HORIUCHI T, 1991, AGR BIOL CHEM TOKYO, V55, P333, DOI 10.1080/00021369.1991.10870584; HORIUCHI T, 1989, AGR BIOL CHEM TOKYO, V53, P103, DOI 10.1080/00021369.1989.10869245; Ishida Y, 1997, J FERMENT BIOENG, V83, P529, DOI 10.1016/S0922-338X(97)81132-4; Isupov MN, 1996, STRUCTURE, V4, P801, DOI 10.1016/S0969-2126(96)00087-1; ITOH H, 1995, J FERMENT BIOENG, V80, P101, DOI 10.1016/0922-338X(95)98186-O; JOHNSON RN, 1982, CLIN CHIM ACTA, V127, P87; Kim KS, 1996, J BACTERIOL, V178, P3275, DOI 10.1128/jb.178.11.3275-3284.1996; ORCHARD LMD, 1990, P ROY SOC B-BIOL SCI, V242, P87, DOI 10.1098/rspb.1990.0108; RAVANDI A, 1995, LIPIDS, V30, P885, DOI 10.1007/BF02537478; Saxena AK, 1996, J BIOL CHEM, V271, P32803, DOI 10.1074/jbc.271.51.32803; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Szwergold BS, 2001, DIABETES, V50, P2139, DOI 10.2337/diabetes.50.9.2139; Takahashi M, 1997, J BIOL CHEM, V272, P12505, DOI 10.1074/jbc.272.19.12505; Teplyakov A, 1998, STRUCTURE, V6, P1047, DOI 10.1016/S0969-2126(98)00105-1; Teplyakov A, 1999, PROTEIN SCI, V8, P596; WU LF, 1991, J BACTERIOL, V173, P3117, DOI 10.1128/JB.173.10.3117-3127.1991	31	99	104	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42523	42529		10.1074/jbc.M200863200	http://dx.doi.org/10.1074/jbc.M200863200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12147680	hybrid			2022-12-27	WOS:000179081200014
J	Kuksa, V; Franz, B; Maeda, T; Jang, GF; Ritter, E; Heck, M; Van Hooser, JP; Liang, Y; Filipek, S; Gelb, MH; Hofmann, KP; Palczewski, K				Kuksa, V; Franz, B; Maeda, T; Jang, GF; Ritter, E; Heck, M; Van Hooser, JP; Liang, Y; Filipek, S; Gelb, MH; Hofmann, KP; Palczewski, K			Biochemical and physiological properties of rhodopsin regenerated with 11-cis-6-ring- and 7-ring-retinals	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL-PIGMENT EPITHELIUM; LEBER CONGENITAL AMAUROSIS; LIGHT-STABLE RHODOPSIN; METARHODOPSIN-II; BINDING PROTEIN; VISUAL PIGMENT; MOUSE MODEL; CHILDHOOD BLINDNESS; VERTEBRATE RETINA; CRYSTAL-STRUCTURE	Phototransduction is initiated by the photoisomerization of rhodopsin (Rho) chromophore 11-cis-retinylidene to all-trans-retinylidene. Here, using Rho regenerated with retinal analogs with different ring sizes, which prevent isomerization around the C-11=C-12 double bond, the activation mechanism of this G-protein-coupled receptor was investigated. We demonstrate that 11-cis-7-ring-Rho, does not activate G-protein in vivo and in vitro, and that it does not isomerize along other double bonds, suggesting that it fits tightly into the binding site of opsin. In contrast, bleaching 11-cis-6-ring-Rho modestly activates phototransduction in vivo and at low pH in vitro. These results reveal that partial activation is caused by isomerization along other double bonds in more rigid 6-locked retinal isomers and protonation of key residues by lowering pH in 11-cis-6-ring-Rhos. Full activation is not achieved, because isomerization does not induce a complete set of conformational rearrangements of Rho. These results with 6- and 7-ring-constrained retinoids provide new insights into Rho activation and suggest a potential use of locked retinals, particularly 11-cis-7-ring-retinal, to inactivate opsin in some retinal degeneration diseases.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Warsaw, Int Inst Mol & Cell Bio, PL-02109 Warsaw, Poland; Univ Warsaw, Dept Chem, PL-02109 Warsaw, Poland; Humboldt Univ, Klinikum Charite, Inst Med Phys & Biophys, D-10098 Berlin, Germany	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; University of Warsaw; University of Warsaw; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.		Filipek, Slawomir/A-2985-2008	Filipek, Slawomir/0000-0003-3147-3858; gelb, michael/0000-0001-7000-5219	NATIONAL EYE INSTITUTE [R01EY009339, R01EY013385] Funding Source: NIH RePORTER; NEI NIH HHS [EY09339, R01 EY009339, R01 EY013385, EY13385] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/88327; AKITA A, 1980, J AM CHEM SOC, V102, P6372; AKITA H, 1980, J AM CHEM SOC, V102, P6370, DOI 10.1021/ja00540a047; ALBECK A, 1989, BIOPHYS J, V55, P233, DOI 10.1016/S0006-3495(89)82798-5; ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; ARNIS S, 1994, J BIOL CHEM, V269, P23879; Bartl F, 2000, FEBS LETT, V473, P259, DOI 10.1016/S0014-5793(00)01544-1; BAUMANN C, 1972, J PHYSIOL-LONDON, V222, P643, DOI 10.1113/jphysiol.1972.sp009819; BAVIK CO, 1992, J BIOL CHEM, V267, P23035; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALDWELL CG, 1993, J ORG CHEM, V58, P3533, DOI 10.1021/jo00065a014; CANADA FJ, 1990, BIOCHEMISTRY-US, V29, P9690, DOI 10.1021/bi00493a026; Choo DW, 1998, FEBS LETT, V440, P195, DOI 10.1016/S0014-5793(98)01459-8; Cremers FPM, 2002, HUM MOL GENET, V11, P1169, DOI 10.1093/hmg/11.10.1169; CROUCH R, 1981, PHOTOCHEM PHOTOBIOL, V33, P91, DOI 10.1111/j.1751-1097.1981.tb04302.x; CROUCH R, 1984, INVEST OPHTH VIS SCI, V25, P419; DEFOE DM, 1983, INVEST OPHTH VIS SCI, V24, P1211; Fujimoto Y, 2002, CHIRALITY, V14, P340, DOI 10.1002/chir.10076; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; Heck M, 2000, METHOD ENZYMOL, V315, P329; Hicks D, 1999, INVEST OPHTH VIS SCI, V40, P3071; Hofmann K P, 1999, Novartis Found Symp, V224, P158; HU SH, 1994, BIOCHEMISTRY-US, V33, P408, DOI 10.1021/bi00168a004; JAGER F, 1994, BIOCHEMISTRY-US, V33, P10878; Jang GF, 2001, J BIOL CHEM, V276, P26148, DOI 10.1074/jbc.M102212200; Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200; Jang GF, 2000, J BIOL CHEM, V275, P28128; KANDORI H, 1989, BIOCHEMISTRY-US, V28, P6460, DOI 10.1021/bi00441a045; Kefalov VJ, 2001, NEURON, V29, P749, DOI 10.1016/S0896-6273(01)00249-5; KROLL AJ, 1964, ARCH OPHTHALMOL-CHIC, V71, P683; LEBER T, 1869, A VONGRAEFES ARCH OP, V15, P1, DOI DOI 10.1007/BF02721213; Lorenz B, 2000, INVEST OPHTH VIS SCI, V41, P2735; Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; Morimura H, 1998, P NATL ACAD SCI USA, V95, P3088, DOI 10.1073/pnas.95.6.3088; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; PARKES JH, 1984, BIOCHEMISTRY-US, V23, P5054, DOI 10.1021/bi00316a035; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; Pugh EN, 1999, CURR OPIN NEUROBIOL, V9, P410, DOI 10.1016/S0959-4388(99)80062-2; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2000, METHOD ENZYMOL, V316, P705; RIDGE KD, 1992, J BIOL CHEM, V267, P6770; Ripps H, 2002, EXP EYE RES, V74, P327, DOI 10.1006/exer.2002.1155; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; SCHAPPERTKIMMIJ.J, 1949, OPHTHALMOLOGICA, V137, P420; Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Stecher H, 1999, J BIOL CHEM, V274, P8577, DOI 10.1074/jbc.274.13.8577; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Thompson DA, 2000, INVEST OPHTH VIS SCI, V41, P4293; Tsilou E, 1997, ARCH BIOCHEM BIOPHYS, V346, P21, DOI 10.1006/abbi.1997.0276; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; Vogel R, 2001, J BIOL CHEM, V276, P38487, DOI 10.1074/jbc.M105423200; WALD G, 1968, SCIENCE, V162, P230, DOI 10.1126/science.162.3850.230	63	35	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42315	42324		10.1074/jbc.M206014200	http://dx.doi.org/10.1074/jbc.M206014200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12176994	Green Accepted, hybrid			2022-12-27	WOS:000178985300127
J	Menges, M; Hennig, L; Gruissem, W; Murray, JAH				Menges, M; Hennig, L; Gruissem, W; Murray, JAH			Cell cycle-regulated gene expression in Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROARRAY ANALYSIS; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; PLANT-CELLS; S-PHASE; A-TYPE; TRANSCRIPTIONAL REGULATION; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; HORMONAL-CONTROL	Regulated gene expression is an important mechanism for controlling cell cycle progression in yeast and mammals, and genes involved in cell division-related processes often show transcriptional regulation dependent on cell cycle position. Analysis of cell cycle processes in plants has been hampered by the lack of synchronizable cell suspensions for Arabidopsis, and few cell cycle-regulated genes are known. Using a recently described synchrony system, we have analyzed RNA from sequential samples of Arabidopsis cells progressing through the cell cycle using Affymetrix Gene-arrays. We identify nearly 500 genes that robustly display significant fluctuation in expression, representing the first genomic analysis of cell cycle-regulated gene expression in any plant. In addition to the limited number of genes previously identified as cell cycle-regulated in plants, we also find specific patterns of regulation for genes known or suspected to be involved in signal transduction, transcriptional regulation, and hormonal regulation, including key genes of cytokinin response. Genes identified represent pathways that are cell cycle-regulated in other organisms and those involved in plant-specific processes. The range and number of cell cycle-regulated genes show the close integration of the plant cell cycle into a variety of cellular control and response pathways.	Univ Cambridge, Inst Biotechnol, Cambridge CB2 1QT, England; Swiss Fed Inst Technol, Inst Plant Sci, CH-8092 Zurich, Switzerland	University of Cambridge; Swiss Federal Institutes of Technology Domain; ETH Zurich	Murray, JAH (corresponding author), Univ Cambridge, Inst Biotechnol, Tennis Court Rd, Cambridge CB2 1QT, England.	j.murray@biotech.cam.ac.uk	Murray, James AH/D-3399-2009; Gruissem, Wilhelm/H-1752-2013; Hennig, Lars/G-2081-2011	Murray, James AH/0000-0002-2282-3839; Gruissem, Wilhelm/0000-0002-1872-2998; Hennig, Lars/0000-0002-6645-1862				Beemster GTS, 2002, PLANT PHYSIOL, V129, P854, DOI 10.1104/pp.002923; Boudolf V, 2001, J EXP BOT, V52, P1381, DOI 10.1093/jexbot/52.359.1381; Breyne P, 2001, CURR OPIN PLANT BIOL, V4, P136, DOI 10.1016/S1369-5266(00)00149-7; Callard D, 1997, PLANT PHYSIOL, V115, P1385, DOI 10.1104/pp.115.4.1385; Castellano MM, 2001, PLANT CELL, V13, P2671, DOI 10.1105/tpc.13.12.2671; Chaboute ME, 1998, PLANT MOL BIOL, V38, P797, DOI 10.1023/A:1006083318906; Charrasse S, 2000, EXP CELL RES, V254, P249, DOI 10.1006/excr.1999.4740; Chaubet N, 1996, PLANT J, V10, P425, DOI 10.1046/j.1365-313X.1996.10030425.x; Chaudhry MA, 2002, ONCOGENE, V21, P1934, DOI 10.1038/sj.onc.1205264; Chen WQ, 2002, PLANT CELL, V14, P559, DOI 10.1105/tpc.010410; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Cockcroft CE, 2000, NATURE, V405, P575, DOI 10.1038/35014621; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; COOKE R, 1981, PLANTA, V152, P1, DOI 10.1007/BF00384976; de Jager SM, 2001, PLANT MOL BIOL, V47, P555, DOI 10.1023/A:1011848528377; De Veylder L, 1999, PLANTA, V208, P453, DOI 10.1007/s004250050582; De Veylder L, 2001, PLANT CELL, V13, P1653, DOI 10.2307/3871392; Durfee T, 2000, PLANT MOL BIOL, V43, P635, DOI 10.1023/A:1006426808185; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FERREIRA P, 1994, P NATL ACAD SCI USA, V91, P11313, DOI 10.1073/pnas.91.24.11313; FERREIRA PCG, 1991, PLANT CELL, V3, P531, DOI 10.1105/tpc.3.5.531; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; Fuerst RAUA, 1996, PLANT PHYSIOL, V112, P1023, DOI 10.1104/pp.112.3.1023; Harmer SL, 2000, SCIENCE, V290, P2110, DOI 10.1126/science.290.5499.2110; HESLOPHARRISON JS, 1994, ARABIDOPSIS, P63; HIRAYAMA T, 1991, GENE, V105, P159, DOI 10.1016/0378-1119(91)90146-3; Holt CL, 1996, GENETICS, V142, P777; HOWARD A, 1953, HEREDITY S, V6, P216; Hu YX, 2000, PLANT J, V24, P693, DOI 10.1046/j.1365-313x.2000.00915.x; Huntley RP, 1999, CURR OPIN PLANT BIOL, V2, P440, DOI 10.1016/S1369-5266(99)00027-8; Ichimura K, 2002, TRENDS PLANT SCI, V7, P301, DOI 10.1016/S1360-1385(02)02302-6; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Ito M, 2000, PLANT MOL BIOL, V43, P677, DOI 10.1023/A:1006336005587; Ito M, 1997, PLANT J, V11, P983, DOI 10.1046/j.1365-313X.1997.11050983.x; Ito M, 2001, PLANT CELL, V13, P1891, DOI 10.1105/tpc.13.8.1891; Joubes J, 2000, PLANT MOL BIOL, V43, P607, DOI 10.1023/A:1006470301554; Kaya H, 2001, CELL, V104, P131, DOI 10.1016/S0092-8674(01)00197-0; Keddie JS, 1998, PLANT CELL, V10, P877, DOI 10.1105/tpc.10.6.877; Kong LJ, 2000, EMBO J, V19, P3485, DOI 10.1093/emboj/19.13.3485; Kovar DR, 2000, PLANT J, V24, P625, DOI 10.1046/j.1365-313x.2000.00907.x; Li Y, 2002, PLANT PHYSIOL, V128, P854, DOI 10.1104/pp.010658; Lui H, 2000, PLANT J, V21, P379, DOI 10.1046/j.1365-313x.2000.00688.x; Maleck K, 2000, NAT GENET, V26, P403, DOI 10.1038/82521; Menand B, 1998, P NATL ACAD SCI USA, V95, P11014, DOI 10.1073/pnas.95.18.11014; Menges M, 2002, PLANT J, V30, P203, DOI 10.1046/j.1365-313X.2002.01274.x; Mews M, 2000, PROTOPLASMA, V212, P236, DOI 10.1007/BF01282924; MEYER Y, 1979, PLANTA, V147, P181, DOI 10.1007/BF00388735; Mironov V, 1999, PLANT CELL, V11, P509; Morel JB, 2002, PLANT CELL, V14, P629, DOI 10.1105/tpc.010358; NAGATA T, 1992, INT REV CYTOL, V132, P1, DOI 10.1016/S0074-7696(08)62452-3; Nakaya M, 2002, PLANT CELL PHYSIOL, V43, P239, DOI 10.1093/pcp/pcf024; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; Oakenfull EA, 2002, PHILOS T R SOC B, V357, P749, DOI 10.1098/rstb.2002.1085; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; Ouellet F, 2001, PLANT CELL, V13, P829, DOI 10.1105/tpc.13.4.829; Pysh LD, 1999, PLANT J, V18, P111, DOI 10.1046/j.1365-313X.1999.00431.x; Ramirez-Parra E, 1999, NUCLEIC ACIDS RES, V27, P3527, DOI 10.1093/nar/27.17.3527; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; Redig P, 1996, FEBS LETT, V391, P175, DOI 10.1016/0014-5793(96)00728-4; Reichheld JP, 1996, P NATL ACAD SCI USA, V93, P13819, DOI 10.1073/pnas.93.24.13819; Reichheld JP, 1998, NUCLEIC ACIDS RES, V26, P3255, DOI 10.1093/nar/26.13.3255; Renaudin JP, 1996, PLANT MOL BIOL, V32, P1003, DOI 10.1007/BF00041384; Reymond P, 2000, PLANT CELL, V12, P707, DOI 10.1105/tpc.12.5.707; Richmond T, 2000, CURR OPIN PLANT BIOL, V3, P108, DOI 10.1016/S1369-5266(99)00049-7; Riou-Khamlichi C, 2000, MOL CELL BIOL, V20, P4513, DOI 10.1128/MCB.20.13.4513-4521.2000; Riou-Khamlichi C, 1999, SCIENCE, V283, P1541, DOI 10.1126/science.283.5407.1541; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Roje S, 1999, J BIOL CHEM, V274, P36089, DOI 10.1074/jbc.274.51.36089; SALA F, 1980, FEBS LETT, V117, P93, DOI 10.1016/0014-5793(80)80920-3; Schaffer R, 2001, PLANT CELL, V13, P113, DOI 10.1105/tpc.13.1.113; Schenk PM, 2000, P NATL ACAD SCI USA, V97, P11655, DOI 10.1073/pnas.97.21.11655; Segers G, 1996, PLANT J, V10, P601, DOI 10.1046/j.1365-313X.1996.10040601.x; Seki M, 2001, PLANT CELL, V13, P61, DOI 10.1105/tpc.13.1.61; Sekine M, 1999, FEBS LETT, V460, P117, DOI 10.1016/S0014-5793(99)01296-X; Shaul O, 1996, P NATL ACAD SCI USA, V93, P4868, DOI 10.1073/pnas.93.10.4868; Shedden K, 2002, NUCLEIC ACIDS RES, V30, P2920, DOI 10.1093/nar/gkf414; Shedden K, 2002, P NATL ACAD SCI USA, V99, P4379, DOI 10.1073/pnas.062569899; Sheen J, 2002, SCIENCE, V296, P1650, DOI 10.1126/science.1071883; Shen B, 2002, PLANT J, V29, P371, DOI 10.1046/j.1365-313X.2002.01221.x; SONI R, 1995, PLANT CELL, V7, P85, DOI 10.1105/tpc.7.1.85; Souer E, 1996, CELL, V85, P159, DOI 10.1016/S0092-8674(00)81093-4; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Stals H, 1997, FEBS LETT, V418, P229, DOI 10.1016/S0014-5793(97)01368-9; Stals H, 2001, TRENDS PLANT SCI, V6, P359, DOI 10.1016/S1360-1385(01)02016-7; Sweere U, 2001, SCIENCE, V294, P1108, DOI 10.1126/science.1065022; Swiatek A, 2002, PLANT PHYSIOL, V128, P201, DOI 10.1104/pp.010592; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Urao T, 1998, FEBS LETT, V427, P175, DOI 10.1016/S0014-5793(98)00418-9; van der Meijden CMJ, 2002, CANCER RES, V62, P3233; VANTHOF J, 1974, CELL CYCLE CONTROLS, P77; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; Walker L, 1998, CURR OPIN PLANT BIOL, V1, P434, DOI 10.1016/S1369-5266(98)80269-0; Wang H, 1998, PLANT J, V15, P501, DOI 10.1046/j.1365-313X.1998.00231.x; Wang HY, 2002, PLANT PHYSIOL, V129, P638, DOI 10.1104/pp.002675; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; Whitfield ML, 2002, MOL BIOL CELL, V13, P1977, DOI 10.1091/mbc.02-02-0030; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Yanow SK, 2001, EMBO J, V20, P4648, DOI 10.1093/emboj/20.17.4648; Zelenaya-Troitskaya O, 1998, GENETICS, V148, P1763; Zink D, 2002, ONCOGENE, V21, P4788, DOI 10.1038/sj.onc.1205614	100	174	200	1	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41987	42002		10.1074/jbc.M207570200	http://dx.doi.org/10.1074/jbc.M207570200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12169696	hybrid			2022-12-27	WOS:000178985300088
J	Lafont, J; Laurent, M; Thibout, H; Lallemand, F; Le Bouc, Y; Atfi, A; Martinerie, C				Lafont, J; Laurent, M; Thibout, H; Lallemand, F; Le Bouc, Y; Atfi, A; Martinerie, C			The expression of novH in adrenocortical cells is down-regulated by TGF beta 1 through c-Jun in a Smad-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; TGF-BETA; PROTEIN-KINASE; IGF-II; TRANSCRIPTIONAL ACTIVITY; ENDOTHELIAL-CELLS; ACTIVATION DOMAIN; PROMOTER ACTIVITY; WILMS-TUMORS	The human NOV secreted glycoprotein (NOVH) is abundant in the fetal and adult adrenal cortex. The amount of NOVH increases in benign adrenocortical tumors and decreases in malignant adrenocortical tumors, suggesting that NOVH plays a role in tumorigenesis in the adrenal cortex. Transforming growth factor beta1 (TGFbeta1), fibroblast growth factor 2 (FGF2), and insulin growth factors (IGFs) play crucial roles in the physiology of the adrenal cortex. We investigated the effects of these factors on the expression of novH in the NCI H295R adrenocortical cell line. The amounts of NOVH protein and novH transcripts were down-regulated by TGFbeta1 and up-regulated by FGF2, whereas IGFs had no effect. Furthermore, the TGFbeta1-dependent inhibition of novH promoter activity was completely abrogated following site-directed mutation of two activating protein (AP-1) sequences (positions -473 and -447), whereas the stimulatory effect of FGF2 was not affected. Co-transfection with dominant negative forms of c-Jun and MEKK1 also abrogated novH-targeted regulation by TGFbeta1, whereas the overproduction of Smad proteins or dominant negative forms of Smad had no effect. Taken together, these results suggest that c-Jun and MEKK1 signaling but not Smad signaling are involved in the TGFbeta1-dependent decrease in NOVH in NCI H295R cells. In conclusion, our data provide evidence that novH is a new target of TGFbeta1; unlike other members of the CCN ((c) under bar yr61, (c) under bar tgf, (n) under bar ov) family, however, its expression is repressed rather than induced.	Hop St Antoine, INSERM U515, F-75571 Paris 12, France; Hop St Antoine, INSERM U482, F-75571 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Martinerie, C (corresponding author), Hop St Antoine, INSERM U515, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	martiner@st-antoine.inserm.fr	Lafont, Jerome E/AAY-2277-2020	Lafont, Jerome E/0000-0001-8313-9873				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; BALBONA K, 1992, J BIOL CHEM, V267, P20120; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Boulle N, 2000, ENDOCRINOLOGY, V141, P3127, DOI 10.1210/en.141.9.3127; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brand C, 1998, BIOCHEM BIOPH RES CO, V253, P780, DOI 10.1006/bbrc.1998.9829; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; Chevalier G, 1998, AM J PATHOL, V152, P1563; Chung KY, 1996, J BIOL CHEM, V271, P3272, DOI 10.1074/jbc.271.6.3272; DARVILLE MI, 1992, NUCLEIC ACIDS RES, V20, P3575, DOI 10.1093/nar/20.14.3575; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Dennler S, 1999, ONCOGENE, V18, P1643, DOI 10.1038/sj.onc.1202729; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; Eickelberg O, 1999, AM J PHYSIOL-LUNG C, V276, pL814, DOI 10.1152/ajplung.1999.276.5.L814; Ellis PD, 2000, ARTERIOSCL THROM VAS, V20, P1912, DOI 10.1161/01.ATV.20.8.1912; Feige JJ, 1998, J ENDOCRINOL, V158, P7, DOI 10.1677/joe.0.1580007; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; GAZDAR AF, 1990, CANCER RES, V50, P5488; Gicquel C, 1997, J CLIN ENDOCR METAB, V82, P2559, DOI 10.1210/jc.82.8.2559; Gicquel C, 1998, CURR OPIN ENDOCRINOL, V5, P189; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; Hashimoto Y, 1998, J EXP MED, V187, P289, DOI 10.1084/jem.187.3.289; Hata A, 1998, MOL MED TODAY, V4, P257, DOI 10.1016/S1357-4310(98)01247-7; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hocevar BA, 2000, METH MOL B, V142, P97; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; ILVESMAKI V, 1993, MOL CELL ENDOCRINOL, V91, P59, DOI 10.1016/0303-7207(93)90255-I; ILVESMAKI V, 1993, J CLIN ENDOCR METAB, V77, P852, DOI 10.1210/jc.77.3.852; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kumar S, 1999, J BIOL CHEM, V274, P17123, DOI 10.1074/jbc.274.24.17123; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Latronico AC, 1997, J CLIN ENDOCR METAB, V82, P1317, DOI 10.1210/jc.82.5.1317; LAU L, 1985, P NATL ACAD SCI USA, V84, P1182; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; Liu CL, 1999, GENE, V238, P471, DOI 10.1016/S0378-1119(99)00364-9; Logie A, 1999, J MOL ENDOCRINOL, V23, P23, DOI 10.1677/jme.0.0230023; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; Martinerie C, 1996, ONCOGENE, V12, P1479; MARTINERIE C, 1994, ONCOGENE, V9, P2729; Martinerie C, 2001, J CLIN ENDOCR METAB, V86, P3929, DOI 10.1210/jc.86.8.3929; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Messiano S, 1997, ENDOCR REV, V18, P378; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Natarajan D, 2000, DEV DYNAM, V219, P417, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1058>3.0.CO;2-2; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; PERBAL B, 1994, CRIT REV ONCOGENESIS, V5, P589; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; Prunier C, 1999, J BIOL CHEM, V274, P22919, DOI 10.1074/jbc.274.33.22919; Prunier C, 2001, MOL CELL BIOL, V21, P3302, DOI 10.1128/MCB.21.10.3302-3313.2001; Rich CB, 1999, J BIOL CHEM, V274, P33433, DOI 10.1074/jbc.274.47.33433; Rousse S, 2001, J BIOL CHEM, V276, P46961, DOI 10.1074/jbc.M104440200; Scholz G, 1996, MOL CELL BIOL, V16, P481; See RH, 2001, J BIOL CHEM, V276, P16310, DOI 10.1074/jbc.M008113200; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; Snaith MR, 1996, GENOMICS, V38, P425, DOI 10.1006/geno.1996.0647; Stanhope-Baker P, 2000, J BIOL CHEM, V275, P38139, DOI 10.1074/jbc.M004901200; Su BY, 1998, CR ACAD SCI III-VIE, V321, P883, DOI 10.1016/S0764-4469(99)80002-X; Tang WL, 1998, J BIOL CHEM, V273, P5506, DOI 10.1074/jbc.273.10.5506; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; Varghese S, 2000, ENDOCRINOLOGY, V141, P2185, DOI 10.1210/en.141.6.2185; Weber MM, 1997, ENDOCRINOLOGY, V138, P2207, DOI 10.1210/en.138.5.2207; Wenger C, 1999, ONCOGENE, V18, P1073, DOI 10.1038/sj.onc.1202395; WENXIN L, 1996, J CLIN PATHOL-MOL PA, V49, pM91; Zatelli MC, 2000, J CLIN ENDOCR METAB, V85, P847, DOI 10.1210/jc.85.2.847; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZHANG HY, 1993, DIFFERENTIATION, V52, P211, DOI 10.1111/j.1432-0436.1993.tb00633.x; Zhang R, 1998, MOL CELL BIOL, V18, P6131, DOI 10.1128/MCB.18.10.6131; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	86	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41220	41229		10.1074/jbc.M204405200	http://dx.doi.org/10.1074/jbc.M204405200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12149257	hybrid			2022-12-27	WOS:000178791400133
J	Luberto, C; Hassler, DF; Signorelli, P; Okamoto, Y; Sawai, H; Boros, E; Hazen-Martin, DJ; Obeid, LM; Hannun, YA; Smith, GK				Luberto, C; Hassler, DF; Signorelli, P; Okamoto, Y; Sawai, H; Boros, E; Hazen-Martin, DJ; Obeid, LM; Hannun, YA; Smith, GK			Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; NERVE GROWTH-FACTOR; INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; LYSOSOMAL SPHINGOMYELINASE; QUANTITATIVE-DETERMINATION; CERAMIDE GENERATION; INVOLVEMENT; GLUTATHIONE; ACTIVATION	A high throughput screen for neutral, magnesium-dependent sphingomyelinase (SMase) was performed. One inhibitor discovered in the screen, GW4869, functioned as a noncompetitive inhibitor of the enzyme in vitro with an IC50 of 1 mum. It did not inhibit acid SMase at up to at least 150 mum. The compound was then evaluated for its ability to inhibit tumor necrosis factor (TNF)-induced activation of neutral SMase (N-SMase) in MCF7 cells. GW4869 (10 mum) partially inhibited TNF-induced sphingomyelin (SM) hydrolysis, and 20 mum of the compound was protected completely from the loss of SM. The addition of 10-20 mum GW4869 completely inhibited the initial accumulation of ceramide, whereas this effect was partially lost at later time points (24 h). These data therefore support the inhibitory action of GW4869 on N-SMase not only in vitro but also in a cellular model. The addition of GW4869 at both 10 and 20 mum did not modify cellular glutathione levels in response to TNF, suggesting that the action of GW4869 occurred downstream of the drop in glutathione, which was shown previously to occur upstream of the activation of N-SMase. Further, whereas TNF treatment also caused a 75% increase of de novo synthesized ceramide after 20 h of incubation, GW4869, at either 10 or 20 mum, had no effect on this pathway of ceramide generation. In addition, GW4869 did not significantly impair TNF-induced NF-kappaB translocation to nuclei. Therefore, GW4869 does not interfere with other key TNF-mediated signaling effects. GW4869 was able, in a dose-dependent manner, to significantly protect from cell death as measured by nuclear condensation, caspase activation, PARP degradation, and trypan blue uptake. These protective effects were accompanied by significant inhibition of cytochrome c release from mitochondria and caspase 9 activation, therefore localizing N-SMase activation upstream of mitochondrial dysfunction. In conclusion, our results indicate that N-SMase activation is a necessary step for the full development of the cytotoxic program induced by TNF.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA; GlaxoSmithKline, Div Discovery Chem, Res Triangle Pk, NC 27709 USA; GlaxoSmithKline, Div Biol, Res Triangle Pk, NC 27709 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; GlaxoSmithKline; GlaxoSmithKline	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.	hannun@muse.edu		obeid, lina/0000-0002-0734-0847; signorelli, paola/0000-0003-2368-2393	NCI NIH HHS [CA 87584] Funding Source: Medline; NIA NIH HHS [AG 16583] Funding Source: Medline; NIGMS NIH HHS [GM 43825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016583] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; ANDRIEU N, 1994, BIOCHEM J, V303, P341, DOI 10.1042/bj3030341; Belaud-Rotureau MA, 2000, APOPTOSIS, V5, P551, DOI 10.1023/A:1009693630664; Bernardo K, 2000, J BIOL CHEM, V275, P7641, DOI 10.1074/jbc.275.11.7641; Bezombes C, 2001, FASEB J, V15, P297; Bilderback TR, 2001, J NEUROCHEM, V76, P1540, DOI 10.1046/j.1471-4159.2001.00171.x; Birbes H, 2001, FASEB J, V15, P2669, DOI 10.1096/fj.01-0539com; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Brann AB, 2002, J BIOL CHEM, V277, P9812, DOI 10.1074/jbc.M109862200; Brann AB, 1999, J NEUROSCI, V19, P8199; Daniel PT, 2000, LEUKEMIA, V14, P2035, DOI 10.1038/sj.leu.2401940; Dbaibo GS, 2001, FEBS LETT, V503, P7, DOI 10.1016/S0014-5793(01)02625-4; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; Doman RK, 1999, J INTERF CYTOK RES, V19, P261, DOI 10.1089/107999099314199; Gamard CJ, 1997, J BIOL CHEM, V272, P16474, DOI 10.1074/jbc.272.26.16474; Ghafourifar P, 1999, J BIOL CHEM, V274, P6080, DOI 10.1074/jbc.274.10.6080; Gouaze V, 2001, MOL PHARMACOL, V60, P488; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Gupta S, 2001, LIFE SCI, V69, P2957, DOI 10.1016/S0024-3205(01)01404-7; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hanada K, 2000, BIOCHEM PHARMACOL, V59, P1211, DOI 10.1016/S0006-2952(00)00251-3; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Hassler DF, 2000, METHOD ENZYMOL, V311, P176; Ito A, 1999, BBA-MOL CELL RES, V1452, P263, DOI 10.1016/S0167-4889(99)00131-7; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; Jones JA, 2002, J BIOL CHEM, V277, P15530, DOI 10.1074/jbc.M111555200; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; KALEN A, 1992, BIOCHIM BIOPHYS ACTA, V1125, P90, DOI 10.1016/0005-2760(92)90160-W; Keppler-Hafkemeyer A, 1998, BIOCHEMISTRY-US, V37, P16934, DOI 10.1021/bi980995m; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; Koppenhoefer U, 1997, FEBS LETT, V414, P444, DOI 10.1016/S0014-5793(97)01035-1; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Lehtonen JYA, 1999, J BIOL CHEM, V274, P16901, DOI 10.1074/jbc.274.24.16901; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Levade T, 1999, CHEM PHYS LIPIDS, V102, P167, DOI 10.1016/S0009-3084(99)00085-7; Liu B, 1998, J BIOL CHEM, V273, P34472, DOI 10.1074/jbc.273.51.34472; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; Luberto C, 2000, J BIOL CHEM, V275, P14760, DOI 10.1074/jbc.275.19.14760; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Merrill AH, 2001, ENVIRON HEALTH PERSP, V109, P283, DOI 10.2307/3435020; Nara F, 1999, J ANTIBIOT, V52, P525, DOI 10.7164/antibiotics.52.525; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Sawai H, 1999, J BIOL CHEM, V274, P38131, DOI 10.1074/jbc.274.53.38131; Schimmer AD, 2001, BLOOD, V98, P3541, DOI 10.1182/blood.V98.13.3541; Segui B, 2000, FASEB J, V14, P36, DOI 10.1096/fasebj.14.1.36; Segui B, 2001, J CLIN INVEST, V108, P143, DOI 10.1172/JCI200111498; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Sofic E, 2001, J NEURAL TRANSM, V108, P541, DOI 10.1007/s007020170055; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; Yoshimura S, 1999, J NEUROCHEM, V73, P675, DOI 10.1046/j.1471-4159.1999.0730675.x; Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	59	234	246	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41128	41139		10.1074/jbc.M206747200	http://dx.doi.org/10.1074/jbc.M206747200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12154098	hybrid			2022-12-27	WOS:000178791400123
J	Vachette, P; Dainese, E; Vasyliev, VB; Di Muro, P; Beltramini, M; Svergun, DI; De Filippis, V; Salvato, B				Vachette, P; Dainese, E; Vasyliev, VB; Di Muro, P; Beltramini, M; Svergun, DI; De Filippis, V; Salvato, B			A key structural role for active site type 3 copper ions in human ceruloplasmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY-SCATTERING; AMINO-ACID-SEQUENCE; ASPARTATE-TRANSCARBAMYLASE; BIOLOGICAL MACROMOLECULES; ASCORBATE OXIDASE; CRYSTAL-STRUCTURE; MOLTEN GLOBULE; RESOLUTION; SERUM; IRON	Human ceruloplasmin is a copper containing serum glycoprotein with multiple functions. The crystal structure shows that its six domains are arranged in three pairs with a pseudo-ternary axis. Both the holo and apo forms of human ceruloplasmin were studied by size exclusion chromatography and small angle x-ray scattering in solution. The experimental curve of the holo form displays conspicuous differences with the scattering pattern calculated from the crystal structure. Once the carbohydrate chains and flexible loops not visible in the crystal are accounted for, remaining discrepancies suggest that the central pair of domains may move as a whole with respect to the rest of the molecule. The quasi-symmetrical crystal structure therefore appears to be stabilized by crystal packing forces. Upon copper removal, the scattering pattern of human ceruloplasmin exhibits very large differences with that of the holoprotein, which are interpreted in terms of essentially preserved domains freely moving in solution around flexible linkers and exploring an ensemble of open conformations. This model, which is supported by the analysis of domain interfaces, provides a structural explanation for the differences in copper reincorporation into the apoprotein and activity recovery between human ceruloplasmin and two other multicopper oxidases, ascorbate oxidase and laccase. Our results demonstrate that, beyond catalytic activity, the three-copper cluster at the N-terminal-C-terminal interface plays a crucial role in the structural stability of human ceruloplasmin.	Univ Paris 11, LURE, F-91898 Orsay, France; Univ Teramo, Dept Biomed Sci, I-64100 Teramo, Italy; Inst Expt Med, St Petersburg 197376, Russia; Univ Padua, Dept Biol, I-35100 Padua, Italy; Univ Padua, CNR, Ctr Biomed Technol, I-35100 Padua, Italy; EMBL, Hamburg Outstn, D-22603 Hamburg, Germany; Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia; Univ Padua, CRIBI Biotechnol Ctr, Padua, Italy	UDICE-French Research Universities; Universite Paris Saclay; University of Teramo; Institute of Experimental Medicine; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; European Molecular Biology Laboratory (EMBL); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; University of Padua	Vachette, P (corresponding author), Univ Paris 11, LURE, Bat 209d,BP 34, F-91898 Orsay, France.			Svergun, Dmitri/0000-0003-0830-5696; Dainese, Enrico/0000-0001-7163-9344				ANDO K, 1970, J BIOCHEM-TOKYO, V68, P501, DOI 10.1093/oxfordjournals.jbchem.a129380; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; Cha MK, 1999, BIOCHEMISTRY-US, V38, P12104, DOI 10.1021/bi990444b; DeFilippis V, 1996, BBA-PROTEIN STRUCT M, V1297, P119, DOI 10.1016/S0167-4838(96)00139-2; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; Dubuisson JM, 1997, J APPL CRYSTALLOGR, V30, P49, DOI 10.1107/S002188989600876X; Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310; Feigin L.A., 1987, STRUCTURE ANAL SMALL; FETLER L, 1995, J MOL BIOL, V251, P243, DOI 10.1006/jmbi.1995.0432; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GITLIN D, 1960, NATURE, V185, P693, DOI 10.1038/185693a0; GROSSMANN JG, 1992, J MOL BIOL, V225, P811, DOI 10.1016/0022-2836(92)90402-6; Guinier A., 1955, SMALL ANGLE SCATTERI; GUTTERIDGE JMC, 1980, FEBS LETT, V112, P269, DOI 10.1016/0014-5793(80)80195-5; Harris ZL, 1999, P NATL ACAD SCI USA, V96, P10812, DOI 10.1073/pnas.96.19.10812; Hellman NE, 2002, ANNU REV NUTR, V22, P439, DOI 10.1146/annurev.nutr.22.012502.114457; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KACHURIN AM, 1989, BIOCHEMISTRY-MOSCOW+, V54, P26; KASPER CB, 1963, J BIOL CHEM, V238, P2325; KATAOKA M, 1993, J MOL BIOL, V229, P591, DOI 10.1006/jmbi.1993.1064; Konarev PV, 2001, J APPL CRYSTALLOGR, V34, P527, DOI 10.1107/S0021889801006100; Kozin MB, 1997, J APPL CRYSTALLOGR, V30, P811, DOI 10.1107/S0021889897001830; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; Lindley PF, 1997, J BIOL INORG CHEM, V2, P454, DOI 10.1007/s007750050156; MALMSTROM BG, 1978, NEW TRENDS BIOINORGA, P59; MATSUDA I, 1974, PEDIATR RES, V8, P821, DOI 10.1203/00006450-197410000-00001; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; MORPURGO L, 1981, ISRAEL J CHEM, V21, P26, DOI 10.1002/ijch.198100007; MORRIS MC, 1983, BIOCHIM BIOPHYS ACTA, V743, P389, DOI 10.1016/0167-4838(83)90397-7; OSAKI S, 1971, J BIOL CHEM, V246, P3018; OSAKI S, 1966, J BIOL CHEM, V241, P2746; PROZOROVSKI VN, 1982, INT J PEPT PROT RES, V19, P40; PTITSYN OB, 1995, PROTEIN FOLDING, P243; Roussel A., 1989, SILICON GRAPHICS GEO; Ryden L., 1984, COPP PROTEINS COPP E, V3, P37; SATO M, 1991, J BIOL CHEM, V266, P5128; SAVINI I, 1990, EUR J BIOCHEM, V190, P491, DOI 10.1111/j.1432-1033.1990.tb15600.x; SAVINI I, 1985, BIOCHEM BIOPH RES CO, V131, P25; Segel DJ, 1999, BIOCHEMISTRY-US, V38, P15352, DOI 10.1021/bi991337k; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; Svergun DI, 2000, J BIOL CHEM, V275, P297, DOI 10.1074/jbc.275.1.297; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 1997, PROTEINS, V27, P110; TAKAHASHI N, 1984, P NATL ACAD SCI-BIOL, V81, P390, DOI 10.1073/pnas.81.2.390; Takahashi Y, 1996, HUM MOL GENET, V5, P81, DOI 10.1093/hmg/5.1.81; TUROVEROV KK, 1982, BIOORG KHIM+, V8, P1165; VACHETTE P, 2000, BIOMOLECULAR STRUCTU, V4, P199; Varghese JN, 1998, STRUCT FOLD DES, V6, P735, DOI 10.1016/S0969-2126(98)00075-6; Vassiliev VB, 1997, J INORG BIOCHEM, V65, P167, DOI 10.1016/S0162-0134(96)00119-5; VASSILIEV VB, 1988, BIOCHEMISTRY-US, V53, P1756; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018; ZAKHAROVA E T, 1983, Biokhimiya, V48, P1709	56	41	43	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40823	40831		10.1074/jbc.M207188200	http://dx.doi.org/10.1074/jbc.M207188200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177070	Green Published, hybrid			2022-12-27	WOS:000178791400086
J	Paulucci, AA; Hicks, L; Machado, A; Miranda, MTM; Kay, CM; Farah, CS				Paulucci, AA; Hicks, L; Machado, A; Miranda, MTM; Kay, CM; Farah, CS			Specific sequences determine the stability and cooperativity of folding of the C-terminal half of tropomyosin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; MUSCLE ALPHA-TROPOMYOSIN; SYNTHETIC MODEL PROTEINS; AMINO-ACID SUBSTITUTIONS; COILED-COILS; THERMAL-DENATURATION; CRYSTAL-STRUCTURE; OLIGOMERIZATION STATE; REGULATORY PROPERTIES; SELF-ASSOCIATION	Tropomyosin is a flexible 410 A coiled-coil protein in which the relative stabilities of specific regions may be important for its proper function in the control of muscle contraction. In addition, tropomyosin can be used as a simple model of natural occurrence to understand the inter- and intramolecular interactions that govern the stability of coiled-coils. We have produced eight recombinant tropomyosin fragments (Tm141-284(50HW), Tm189-284(5OHW), Tm189-284, TM220-284(5OHW), TM220-284, Tm143-235, Tm167-260, and Tm143-260) and one synthetic peptide (Ac-TM215-235) to investigate the relative conformational stability of different regions derived from the C-terminal region of the protein, which is known to interact with the troponin complex. Analytical ultracentrifugation experiments show that the fragments that include the last 24 residues of the molecule (Tm143-284(5OHW), Tm189-284(50HW), TM220-284(5OHW), TM220-284) are completely dimerized at 10 mum dimer (50 mm phosphate, 100 mm NaCl, 1.0 mm dithiothreitol, and 0.5 mm EDTA, 10 degreesC), whereas fragments that lack the native C terminus (Tm143-235,Tm167-260, and Tm143-260) are in a monomer-dimer equilibrium under these conditions. The presence of trifluoroethanol resulted in a reduction in the [theta](222)/[theta](208) circular dichroism ratio in all of the fragments and induced stable trimer formation only in those containing residues 261-284. Urea denaturation monitored by circular dichroism and fluorescence revealed that residues 261-284 of tropomyosin are very important for the stability of the C-terminal half of the molecule as a whole. Furthermore, the absence of this region greatly increases the cooperativity of urea-induced unfolding. Temperature and urea denaturation experiments show that Tm143-235 is less stable than other fragments of the same size. We have identified a number of factors that may contribute to this particular instability, including an interhelix repulsion between g and e' positions of the heptad repeat, a charged residue at the hydrophobic coiled-coil interface, and a greater fraction of beta-branched residues located at d positions.	Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-05508900 Sao Paulo, Brazil; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Prot Engn Network Ctr Excellence, Edmonton, AB T6G 2H7, Canada	Universidade de Sao Paulo; University of Alberta; University of Alberta	Farah, CS (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, 748 Av Prof Lineu Prestes,CP 26-077, BR-05508900 Sao Paulo, Brazil.	chsfarah@iq.usp.br	Lunkes, Alessandra/G-8501-2015; Farah, Chuck Shaker/G-5565-2012; Machini, M. Teresa/D-2009-2012	Lunkes, Alessandra/0000-0002-7258-9905; Farah, Chuck Shaker/0000-0003-3110-6302; Machini, M. Teresa/0000-0001-5772-004X				CLARK ID, 1990, BIOCHEMISTRY-US, V29, P10842, DOI 10.1021/bi00500a018; de Sousa AD, 2001, BIOPHYS J, V80, p91A; Farah CS, 1999, BIOCHEMISTRY-US, V38, P10543, DOI 10.1021/bi982813u; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; GOODING C, 1987, NUCLEIC ACIDS RES, V15, P8105, DOI 10.1093/nar/15.19.8105; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; HODGES RS, 1973, COLD SPRING HARB SYM, V37, P299, DOI 10.1101/SQB.1973.037.01.040; HOLTZER A, 1990, PROTEIN FOLDING : DECIPHERING THE SECOND HALF OF THE GENETIC CODE, P177; HOLTZER ME, 1995, BIOPOLYMERS, V35, P125, DOI 10.1002/bip.360350113; HOLTZER ME, 1991, J AM CHEM SOC, V113, P7444, DOI 10.1021/ja00019a064; HOLTZER ME, 1983, MACROMOLECULES, V16, P173, DOI 10.1021/ma00236a004; HOLTZER ME, 1990, BIOPOLYMERS, V30, P985, DOI 10.1002/bip.360300913; Holtzer ME, 2001, BIOPOLYMERS, V59, P257, DOI 10.1002/1097-0282(20011005)59:4<257::AID-BIP1022>3.0.CO;2-7; HOLTZER ME, 1995, BIOPOLYMERS, V36, P365, DOI 10.1002/bip.360360310; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Kammerer RA, 1998, P NATL ACAD SCI USA, V95, P13419, DOI 10.1073/pnas.95.23.13419; Lacroix E, 1998, J MOL BIOL, V284, P173, DOI 10.1006/jmbi.1998.2145; LAU SYM, 1984, J BIOL CHEM, V259, P3253; Laue TM, 1999, ANNU REV BIOPH BIOM, V28, P75, DOI 10.1146/annurev.biophys.28.1.75; LAUE TM, 1991, ANAL ULTRACENTRIFUGA, P125; Lee DL, 2001, J MOL BIOL, V306, P539, DOI 10.1006/jmbi.2000.4351; LEESMILLER JP, 1990, J MOL BIOL, V213, P399, DOI 10.1016/S0022-2836(05)80202-5; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHRER SS, 1978, J MOL BIOL, V118, P209, DOI 10.1016/0022-2836(78)90413-8; Lehrer SS, 1998, J STRUCT BIOL, V122, P176, DOI 10.1006/jsbi.1998.3973; Li Y, 2002, P NATL ACAD SCI USA, V99, P7378, DOI 10.1073/pnas.102179999; MacPhee CE, 1997, FEBS LETT, V416, P265, DOI 10.1016/S0014-5793(97)01224-6; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; Maroun RG, 1999, J BIOL CHEM, V274, P34174, DOI 10.1074/jbc.274.48.34174; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; MO JM, 1991, P NATL ACAD SCI USA, V88, P916, DOI 10.1073/pnas.88.3.916; MO JM, 1990, BIOPOLYMERS, V30, P921, DOI 10.1002/bip.360300907; MONERA OD, 1993, J BIOL CHEM, V268, P19218; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; MUNOZ V, 1995, J MOL BIOL, V245, P297, DOI 10.1006/jmbi.1994.0024; MUNOZ V, 1995, J MOL BIOL, V245, P275, DOI 10.1006/jmbi.1994.0023; Narita A, 2001, J MOL BIOL, V308, P241, DOI 10.1006/jmbi.2001.4598; Oakley MG, 1998, BIOCHEMISTRY-US, V37, P12603, DOI 10.1021/bi981269m; PACE CN, 1987, PROTEIN STRUCTURE PR, P299; PATO MD, 1981, J BIOL CHEM, V256, P593; PEARLSTONE JR, 1977, CAN J BIOCHEM CELL B, V55, P1032, DOI 10.1139/o77-154; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; POTEKHIN SA, 1982, J MOL BIOL, V159, P519, DOI 10.1016/0022-2836(82)90299-6; QUADRIFO.F, 1968, J AM CHEM SOC, V90, P2755, DOI 10.1021/ja01013a004; STEWART JM, 1984, SOLID PHASE PEPTIDE, P1; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU JY, 1994, BIOCHEMISTRY-US, V33, P15501, DOI 10.1021/bi00255a032; Suarez MC, 2001, BIOCHEMISTRY-US, V40, P1300, DOI 10.1021/bi0020978; Tripet B, 2000, J MOL BIOL, V300, P377, DOI 10.1006/jmbi.2000.3866; Varanda LM, 1997, J PEPT RES, V50, P102; Wagschal K, 1999, J MOL BIOL, V285, P785, DOI 10.1006/jmbi.1998.2284; WAHL P, 1978, EUR J BIOCHEM, V88, P421, DOI 10.1111/j.1432-1033.1978.tb12464.x; Whitby FG, 2000, PROTEINS, V38, P49; WHITE SP, 1987, NATURE, V325, P826, DOI 10.1038/325826a0; Yu Y, 1996, J MOL BIOL, V255, P367, DOI 10.1006/jmbi.1996.0030; ZHOU NE, 1992, J BIOL CHEM, V267, P2664; ZHOU NE, 1992, BIOCHEMISTRY-US, V31, P5739, DOI 10.1021/bi00140a008; ZHOU NE, 1994, J MOL BIOL, V237, P500, DOI 10.1006/jmbi.1994.1250; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365	61	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39574	39584		10.1074/jbc.M204749200	http://dx.doi.org/10.1074/jbc.M204749200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167616	hybrid			2022-12-27	WOS:000178662500068
J	Schubert, W; Frank, PG; Woodman, SE; Hyogo, H; Cohen, DE; Chow, CW; Lisanti, MP				Schubert, W; Frank, PG; Woodman, SE; Hyogo, H; Cohen, DE; Chow, CW; Lisanti, MP			Microvascular hyperpermeability in caveolin-1 (-/-) knock-out mice - Treatment with a specific nitric-oxide synthase inhibitor, L-name, restores normal microvascular permeability in Cav-1 null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL PERMEABILITY; PLASMALEMMAL VESICLES; IN-VIVO; PROTEIN; ACTIVATION; PATHWAYS; RAS	Microvascular permeability is mediated by W the caveolar transcytosis of molecules across endothelial cells and (ii) the paracellular movement of ions and nutrients. Recently, we derived Cav-1 (-/-) knock-out mice using standard homologous recombination techniques. These mice are viable but show a loss of endothelial cell caveolae and striking defects in caveolae-mediated endocytosis. Thus, a compensatory mechanism must be operating in these mice. One possible compensatory response would be an increase in the paracellular pathway, resulting in increased microvascular permeability. To test this hypothesis directly, we studied the microvascular permeability of Cav-1 null mice using a variety of complementary in vivo approaches. Radio-iodinated bovine serum albumin was injected into Cav-1-deficient mice, and its rate of clearance from the circulatory system was compared with that of wild type control mice. Our results indicate that iodinated bovine serum albumin is removed from the circulatory system of Cav-1-deficient mice at a substantially faster rate. To determine whether this defect is restricted to the paracellular movement of albumin, lungs from Cav-1-deficient mice were next perfused with the electron dense dye Ruthenium Red. Micrographs of lung endothelial cells from Cav-1-deficient mice demonstrate that the paracellular movement of Ruthenium Red is dramatically increased. In addition, electron micrographs of Cav-1-deficient lung capillaries reveal defects in tight junction morphology and abnormalities in capillary endothelial cell adhesion to the basement membrane. This defect in cell-substrate attachment is consistent with the postulated role of caveolin-1 in positively regulating integrin signaling. Because loss of caveolin-1 expression results in constitutive activation of eNOS activity, we also examined whether these increases in microvascular permeability are NO-dependent. Interestingly, treatment with L-NAME (a well established nitric-oxide synthase inhibitor) successfully reversed the microvascular hyperpermeability phenotype of Cav-1 knock-out mice. Thus, caveolin-1 plays a dual regulatory role in controlling microvascular permeability: (i) as a structural protein that is required for caveolae formation and caveolar transcytosis and (ii) as a tonic inhibitor of eNOS activity to negatively regulate the paracellular pathway.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Div Hormone Dependent Tumor Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael P/C-6866-2013; Lisanti, Michael/B-6131-2018; Frank, Philippe G/A-3463-2011	Lisanti, Michael/0000-0003-2034-1382; Frank, Philippe G/0000-0003-4857-5279	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bucci M, 2000, NAT MED, V6, P1362, DOI 10.1038/82176; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; DRAIJER R, 1995, CIRC RES, V76, P199, DOI 10.1161/01.RES.76.2.199; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; GARCIA JGN, 1995, J INVEST MED, V43, P117; GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437; GHITESCU L, 1986, J CELL BIOL, V102, P1304, DOI 10.1083/jcb.102.4.1304; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; Haynes J, 1996, J PHARMACOL EXP THER, V276, P752; He P, 1998, AM J PHYSIOL-HEART C, V274, pH1865, DOI 10.1152/ajpheart.1998.274.6.H1865; Hinder F, 1997, J APPL PHYSIOL, V83, P1941, DOI 10.1152/jappl.1997.83.6.1941; Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054; Inoue H, 2001, NITRIC OXIDE-BIOL CH, V5, P334, DOI 10.1006/niox.2001.0350; Ju H, 1997, J BIOL CHEM, V272, P18522, DOI 10.1074/jbc.272.30.18522; Lal BK, 2001, MICROVASC RES, V62, P252, DOI 10.1006/mvre.2001.2338; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LUM H, 1994, AM J PHYSIOL, V267, pL223, DOI 10.1152/ajplung.1994.267.3.L223; MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P571, DOI 10.1083/jcb.11.3.571; Michel JB, 1997, J BIOL CHEM, V272, P25907, DOI 10.1074/jbc.272.41.25907; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; PREDESCU D, 1993, AM J PHYSIOL, V265, pH725, DOI 10.1152/ajpheart.1993.265.2.H725; RAMIREZ MM, 1995, MICROVASC RES, V50, P223, DOI 10.1006/mvre.1995.1055; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Razani B, 2001, J BIOL CHEM, V276, P38121; Schubert W, 2001, J BIOL CHEM, V276, P48619, DOI 10.1074/jbc.C100613200; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Suttorp N, 1996, AM J PHYSIOL-CELL PH, V270, pC778, DOI 10.1152/ajpcell.1996.270.3.C778; Takeda N, 2001, DIABETOLOGIA, V44, P1043, DOI 10.1007/s001250100588; Titheradge MA, 1999, BBA-BIOENERGETICS, V1411, P437, DOI 10.1016/S0005-2728(99)00031-6; Tsukahara H, 2000, LIFE SCI, V67, P1, DOI 10.1016/S0024-3205(00)00598-1; Vallance P, 2001, HEART, V85, P342, DOI 10.1136/heart.85.3.342; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P445, DOI 10.1083/jcb.1.5.445; YUAN YA, 1993, AM J PHYSIOL, V264, pH1734, DOI 10.1152/ajpheart.1993.264.5.H1734	37	254	262	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40091	40098		10.1074/jbc.M205948200	http://dx.doi.org/10.1074/jbc.M205948200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167625	hybrid			2022-12-27	WOS:000178662500130
J	Shi, WX; Sarver, AE; Wang, CC; Tanaka, KSE; Almo, SC; Schramm, VL				Shi, WX; Sarver, AE; Wang, CC; Tanaka, KSE; Almo, SC; Schramm, VL			Closed site complexes of adenine phosphoribosyltransferase from Giardia lamblia reveal a mechanism of ribosyl migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOXANTHINE-GUANINE PHOSPHORIBOSYLTRANSFERASE; TRANSITION-STATE STRUCTURE; 2.0 ANGSTROM STRUCTURE; CRYSTAL-STRUCTURES; ANALOG INHIBITOR; ATOMIC MOTION; CATALYSIS; PURINE	The adenine phosphoribosyltransferase (APRTase) from Giardia lamblia was co-crystallized with 9-deazaadenine and sulfate or with 9-deazaadenine and Mg-phosphoribosylpyrophosphate. The complexes were solved and refined to 1.85 and 1.95 Angstrom resolution. Giardia APRTase is a symmetric homodimer with the monomers built around Rossman fold cores, an element common to all known purine phosphoribosyltransferases. The catalytic sites are capped with a small hood domain that is unique to the APRTases. These structures reveal several features relevant to the catalytic function of APRTase: 1) a non-proline cis peptide bond (Glu(61)-Ser(62)) is required to form the pyrophosphate binding site in the APRTase.9dA.MgPRPP complex but is a trans peptide bond in the absence of pyrophosphate group, as observed in the APRTase.9dA.SO4 complex; 2) a catalytic site loop is closed and fully ordered in both complexes, with Glu(100) from the catalytic loop acting as the acid/base for protonation/deprotonation of N-7 of the adenine ring, 3) the pyrophosphoryl charge is neutralized by a single Mg2+ ion and Arg(63), in contrast to the hypoxanthine-guanine phosphoribosyltransferases, which use two Mg2+ ions; and 4) the nearest structural neighbors to APRTases are the orotate phosphoribosyltransferases, suggesting different paths of evolution for adenine relative to other purine PRTases. An overlap comparison of AMP and 9-deazaadenine plus Mg-PRPP at the catalytic sites of APRTases indicated that reaction coordinate motion involves a 2.1-Angstrom excursion of the ribosyl anomeric carbon, whereas the adenine ring and the 5-phosphoryl group remained fixed. G. lamblia APRTase therefore provides another example of nucleophilic displacement by electrophile migration.	Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, Program Chem & Chem Biol, San Francisco, CA 94143 USA	Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California San Francisco	Almo, SC (corresponding author), Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	almo@aecom.yu.edu; vern@aecom.yu.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041916, R37GM041916] Funding Source: NIH RePORTER; NIAID NIH HHS [AI19391] Funding Source: Medline; NIGMS NIH HHS [GM41916] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bashor C, 2002, BIOCHEMISTRY-US, V41, P4020, DOI 10.1021/bi0158730; Berens Randolph L., 1995, P89, DOI 10.1016/B978-012473345-9/50007-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DESPOMMIER DD, 1994, PARASITIC DIS, P144; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fedorov A, 2001, BIOCHEMISTRY-US, V40, P853, DOI 10.1021/bi002499f; FLAKS JG, 1957, J BIOL CHEM, V228, P201; Focia PJ, 1998, BIOCHEMISTRY-US, V37, P17120, DOI 10.1021/bi9821465; HAMMOND DJ, 1984, MOL BIOCHEM PARASIT, V13, P243, DOI 10.1016/0166-6851(84)90117-8; Heroux A, 2000, STRUCTURE, V8, P1309, DOI 10.1016/S0969-2126(00)00546-3; HORI M, 1966, J BIOL CHEM, V241, P3404; JONES TA, 1985, METHOD ENZYMOL, V115, P157; Katz AK, 1996, J AM CHEM SOC, V118, P5752, DOI 10.1021/ja953943i; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li CM, 1999, NAT STRUCT BIOL, V6, P582, DOI 10.1038/9367; MYERS RW, 1989, J BIOL CHEM, V264, P10547; *NAT I ALL INF DIS, 1998, GIARD FACT SHEET; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page JP, 1999, EUR J BIOCHEM, V259, P565, DOI 10.1046/j.1432-1327.1999.00020.x; PANNEERSELVAM K, 2002, IN PRESS BIOCHEMISTR; Phillips CL, 1999, EMBO J, V18, P3533, DOI 10.1093/emboj/18.13.3533; SAHITA AS, 2001, METABOLIC MOL BASES, P2571; Sarver AE, 2002, J BIOL CHEM, V277, P39973, DOI 10.1074/jbc.M205595200; Schramm VL, 2001, CURR OPIN STRUC BIOL, V11, P657, DOI 10.1016/S0959-440X(01)00269-X; Shi WX, 2000, BIOCHEMISTRY-US, V39, P6781, DOI 10.1021/bi000128t; Shi WX, 1999, NAT STRUCT BIOL, V6, P588; Shi WX, 2001, BIOCHEMISTRY-US, V40, P10800, DOI 10.1021/bi010465h; Shi WX, 1999, BIOCHEMISTRY-US, V38, P9872, DOI 10.1021/bi990664p; Sinha SC, 2001, CURR OPIN STRUC BIOL, V11, P733, DOI 10.1016/S0959-440X(01)00274-3; Sommer JM, 1996, MOL BIOCHEM PARASIT, V78, P185, DOI 10.1016/S0166-6851(96)02623-0; Tao W, 1996, BIOCHEMISTRY-US, V35, P14, DOI 10.1021/bi951898l; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; WANG CC, 1983, J EXP MED, V158, P1703, DOI 10.1084/jem.158.5.1703; Xu YM, 1998, BIOCHEMISTRY-US, V37, P4114, DOI 10.1021/bi972519m	36	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39981	39988		10.1074/jbc.M205596200	http://dx.doi.org/10.1074/jbc.M205596200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171925	hybrid			2022-12-27	WOS:000178662500117
J	Tokumura, A; Majima, E; Kariya, Y; Tominaga, K; Kogure, K; Yasuda, K; Fukuzawa, K				Tokumura, A; Majima, E; Kariya, Y; Tominaga, K; Kogure, K; Yasuda, K; Fukuzawa, K			Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; SMOOTH-MUSCLE-CELLS; MOLECULAR-CLONING; IN-VITRO; SERUM; PYROPHOSPHATASE; EXPRESSION; LOCALIZATION; INVOLVEMENT; INHIBITION	We purified human plasma lysophospholipase D that produces physiologically active lysophosphatidic acid and showed that it is a soluble form of autotaxin, an ecto-nucleotide pyrophosphatase/phosphodiesterase, originally found as a tumor cell motility-stimulating factor. Its lower K-m value for a lysophosphatidylcholine than that for a synthetic substrate of nucleotide suggests that lysophosphatidylcholine is a more likely physiological substrate for autotaxin and that its predicted physiological and pathophysiological functions could be mediated by its activity to produce lysophosphate acid, an intercellular mediator. Recombinant autotaxin was found to have lysophospholipase D activity; its substrate specificity and metal ion requirement were the same as those of the purified plasma enzyme. The activity of lysophospholipase, D for exogenous lysophosphatidylcholine in human serum was found to increase in normal pregnant women at the third trimester of pregnancy and to a higher extent in patients in threatened preterm delivery, suggesting its roles in induction of parturition.	Univ Tokushima, Fac Pharmaceut Sci, Tokushima, Japan; APRO Life Sci Inst, Naruto 7720001, Japan; Kansai Med Univ, Dept Obstet & Gynecol, Moriguchi, Osaka 5708507, Japan	Tokushima University; Kansai Medical University	Tokumura, A (corresponding author), 1-78 Shomachi, Tokushima 7708505, Japan.	tokumura@ph.tokushima-u.ac.jp						Allard J, 1998, EUR J NEUROSCI, V10, P1045, DOI 10.1046/j.1460-9568.1998.00117.x; Bachner D, 1999, MECH DEVELOP, V84, P121, DOI 10.1016/S0925-4773(99)00048-9; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Bollen M, 2000, CRIT REV BIOCHEM MOL, V35, P393, DOI 10.1080/10409230091169249; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Fuss B, 1997, J NEUROSCI, V17, P9095; Gaits F, 1997, FEBS LETT, V410, P54, DOI 10.1016/S0014-5793(97)00411-0; Goding JW, 2000, J LEUKOCYTE BIOL, V67, P285, DOI 10.1002/jlb.67.3.285; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Grey A, 2001, ENDOCRINOLOGY, V142, P1098, DOI 10.1210/en.142.3.1098; Hayashi K, 2001, CIRC RES, V89, P251, DOI 10.1161/hh1501.094265; Hinokio K, 2002, LIFE SCI, V70, P759, DOI 10.1016/S0024-3205(01)01448-5; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; KAWAGOE H, 1995, GENOMICS, V30, P380, DOI 10.1006/geno.1995.0036; Lee HY, 1996, BIOCHEM BIOPH RES CO, V218, P714, DOI 10.1006/bbrc.1996.0127; LUTHJE J, 1988, CLIN CHIM ACTA, V177, P131, DOI 10.1016/0009-8981(88)90134-9; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; MURATA J, 1994, J BIOL CHEM, V269, P30479; Nakane S, 2001, LIPIDS, V36, P413, DOI 10.1007/s11745-001-0737-1; Nam SW, 2001, CANCER RES, V61, P6938; NARITA M, 1994, J BIOL CHEM, V269, P28235; Panetti TS, 1997, J LAB CLIN MED, V129, P208, DOI 10.1016/S0022-2143(97)90141-4; Park W, 1996, J RHEUMATOL, V23, P1233; RAZZELL WE, 1963, METHOD ENZYMOL, V6, P236, DOI 10.1016/0076-6879(63)06169-3; SATOUCHI K, 1994, BBA-LIPID LIPID MET, V1214, P303; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Stracke ML, 1997, ADV ENZYME REGUL, V37, P135, DOI 10.1016/S0065-2571(96)00017-9; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; TAKAYAMA M, 1977, CLIN CHIM ACTA, V79, P93, DOI 10.1016/0009-8981(77)90465-X; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; Tokumura A, 1999, BBA-MOL CELL BIOL L, V1437, P235, DOI 10.1016/S1388-1981(99)00011-6; Tokumura A, 1999, BIOL REPROD, V61, P195, DOI 10.1095/biolreprod61.1.195; Tokumura A, 1998, LIPIDS, V33, P1009, DOI 10.1007/s11745-998-0299-2; TOKUMURA A, 1994, AM J PHYSIOL, V267, pC204, DOI 10.1152/ajpcell.1994.267.1.C204; Tokumura A, 2002, J LIPID RES, V43, P307; TOKUMURA A, 1995, PROG LIPID RES, V34, P151, DOI 10.1016/0163-7827(95)00001-G; Tokumura A, 2000, ANN NY ACAD SCI, V905, P347; TOKUMURA A, 1986, BIOCHIM BIOPHYS ACTA, V875, P31; TOKUMURA A, 1980, ARCH INT PHARMACOD T, V245, P74; ZAITSU K, 1980, ANAL BIOCHEM, V109, P109, DOI 10.1016/0003-2697(80)90017-2; Zimmermann H, 1999, PROG BRAIN RES, V120, P371	42	592	616	1	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39436	39442		10.1074/jbc.M205623200	http://dx.doi.org/10.1074/jbc.M205623200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176993	hybrid			2022-12-27	WOS:000178662500049
J	Conus, NM; Hannan, KM; Cristiano, BE; Hemmings, BA; Pearson, RB				Conus, NM; Hannan, KM; Cristiano, BE; Hemmings, BA; Pearson, RB			Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; PHOSPHATASE INHIBITORS; ACTIVATION; INSULIN; PATHWAY; DOMAIN; PKB; PHOSPHOTYROSINE	Understanding the regulation of Akt has been of major interest for elucidating the control of normal cellular physiology as well as malignant transformation. The paradigm for activation of Akt involves phosphatidylinositol 3-kinase-dependent membrane localization followed by activating phosphorylation of Thr-308 and Ser-473. Many of the activating signals for Akt involve the stimulation of receptor and non-receptor tyrosine kinases, and the most potent activator known is the tyrosine phosphatase inhibitor pervanadate, highlighting a possible role for tyrosine phosphorylation. in the regulation of the enzyme. In this study we show that activation of Akt by pervanadate or serum is associated with tyrosine phosphorylation of Akt. In addition, in SKOV3 ovarian carcinoma cells that exhibit high basal levels of Akt activity, Akt was tyrosine-phosphorylated in the basal state, and this phosphorylation was further enhanced by both pervanadate and insulin-like growth factor-1. We have used NH2-terminal sequencing and phosphate release analysis to directly identify Tyr-474 as the site of tyrosine phosphorylation. Substitution of Tyr-474 with phenylalanine abolished tyrosine phosphorylation of Akt and resulted in up to 55% inhibition of Akt activation, indicating phosphorylation at Tyr-474 is required for full activation of the kinase. Our data identifies a novel regulatory mechanism for this pleiotropic enzyme that may be applicable to the AGC family of protein kinases given the conserved nature of the COOH-terminal hydrophobic motif containing Tyr-474.	Peter MacCallum Canc Inst, Trescowthick Res Labs, Melbourne, Vic 8006, Australia; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Peter Maccallum Cancer Center; Friedrich Miescher Institute for Biomedical Research	Pearson, RB (corresponding author), Peter MacCallum Canc Inst, Trescowthick Res Labs, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia.		Pearson, Richard Bruce/I-1451-2013	Pearson, Richard Bruce/0000-0001-5919-5090; Hannan, Katherine/0000-0003-4186-8167				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Craxton A, 1999, J BIOL CHEM, V274, P30644, DOI 10.1074/jbc.274.43.30644; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; Hemmings BA, 1997, SCIENCE, V275, P628, DOI 10.1126/science.275.5300.628; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Mitchelhill KI, 1997, J BIOL CHEM, V272, P24475, DOI 10.1074/jbc.272.39.24475; MITCHELHILL KI, 1999, PROTEIN PHOSPHORYLAT, P127; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Stephens LR, 2001, J BIOL CHEM, V276, P42767, DOI 10.1074/jbc.M107194200; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wang Y, 1999, FEBS LETT, V462, P25, DOI 10.1016/S0014-5793(99)01496-9; Xu AM, 2001, MOL CELL BIOL, V21, P2981, DOI 10.1128/MCB.21.9.2981-2990.2001; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	39	79	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38021	38028		10.1074/jbc.M203387200	http://dx.doi.org/10.1074/jbc.M203387200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12149249	hybrid			2022-12-27	WOS:000178529600008
J	Dhanak, D; Duffy, KJ; Johnston, VK; Lin-Goerke, J; Darey, M; Shaw, AN; Gu, BH; Silverman, C; Gates, AT; Nonnemacher, MR; Earnshaw, DL; Casper, DJ; Kaura, A; Baker, A; Greenwood, C; Gutshall, LL; Maley, D; DelVecchio, A; Macarron, R; Hofmann, GA; Alnoah, Z; Cheng, HY; Chan, G; Khandekar, S; Keenan, RM; Sarisky, RT				Dhanak, D; Duffy, KJ; Johnston, VK; Lin-Goerke, J; Darey, M; Shaw, AN; Gu, BH; Silverman, C; Gates, AT; Nonnemacher, MR; Earnshaw, DL; Casper, DJ; Kaura, A; Baker, A; Greenwood, C; Gutshall, LL; Maley, D; DelVecchio, A; Macarron, R; Hofmann, GA; Alnoah, Z; Cheng, HY; Chan, G; Khandekar, S; Keenan, RM; Sarisky, RT			Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; DE-NOVO INITIATION; CRYSTAL-STRUCTURE; E2-NS2 REGION; NON-A; NS5B; REPLICATION; TEMPLATE; CLEAVAGE; GENOME	The hepatitis C virus (HCV) NS5B protein encodes an RNA-dependent RNA polymerase (RdRp), the primary catalytic enzyme of the HCV replicase complex. We established a biochemical RNA synthesis assay, using purified recombinant NS5B lacking the C-terminal 21 amino acid residues, to identify potential polymerase inhibitors from a high throughput screen of the Glaxo-SmithKline proprietary compound collection. The benzo-1,2,4-thiadiazine compound 1 was found to be a potent, highly specific inhibitor of NS5B. This agent interacts directly with the viral polymerase and inhibits RNA synthesis in a manner noncompetitive with respect to GTP. Furthermore, in the absence of an in vitro-reconstituted HCV replicase assay employing viral and host proteins, the ability of compound 1 to inhibit NS5B-directed viral RNA replication was determined using the Huh7 cell-based HCV replicon system. Compound 1 reduced viral RNA in replicon cells with an IC50 of similar to0.5 muM, suggesting that the inhibitor was able to access the perinuclear membrane and inhibit the polymerase activity in the context of a replicase complex. Preliminary structure-activity studies on compound 1 led to the identification of a modified inhibitor, compound 4, showing an improvement in both biochemical and cell-based potency. Lastly, data are presented suggesting that these compounds interfere with the formation of negative and positive strand progeny RNA by a similar mode of action. Investigations are ongoing to assess the potential utility of such agents in the treatment of chronic HCV disease.	GlaxoSmithKline, Dept Virol, Metab & Viral Dis Ctr Excellence Drug Discovery, Collegeville, PA 19426 USA; GlaxoSmithKline, Dept Med Chem, Musculoskeletal Microbial & Proliferat Dis Ctr Ex, Collegeville, PA 19426 USA; GlaxoSmithKline, Discovery Res, Collegeville, PA 19426 USA; GlaxoSmithKline, Metab & Viral Dis Ctr Excellence Drug Discovery, Dept Med Chem, Collegeville, PA 19426 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Sarisky, RT (corresponding author), GlaxoSmithKline, Dept Virol, Metab & Viral Dis Ctr Excellence Drug Discovery, 1250 S Collegeville Rd,UP1450, Collegeville, PA 19426 USA.	robert_t_sarisky@gsk.com		Earnshaw, David/0000-0002-0650-1362; Nonnemacher, Michael/0000-0003-4299-3779; Duffy, Kevin/0000-0002-7184-2059				BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Cecchetti V, 2000, J MED CHEM, V43, P3799, DOI 10.1021/jm9903390; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Craggs JK, 2001, J VIROL METHODS, V94, P111, DOI 10.1016/S0166-0934(01)00281-6; DOYLE ML, 1997, ADV MOL CEL A&B, V22, P279; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; Kao CC, 1999, VIROLOGY, V253, P1, DOI 10.1006/viro.1998.9517; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; LIN C, 1994, J VIROL, V68, P5063, DOI 10.1128/JVI.68.8.5063-5073.1994; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lohmann V, 1998, VIROLOGY, V249, P108, DOI 10.1006/viro.1998.9311; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Oh JW, 2000, J BIOL CHEM, V275, P17710, DOI 10.1074/jbc.M908781199; Ranjith-Kumar CT, 2001, J VIROL, V75, P8615, DOI 10.1128/JVI.75.18.8615-8623.2001; SELBY MJ, 1994, VIROLOGY, V204, P114, DOI 10.1006/viro.1994.1515; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; Ukrainets I.V., 2000, CHEM HETEROCYC COMPO, V36, P346; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; Zhong WD, 1998, J VIROL, V72, P9365, DOI 10.1128/JVI.72.11.9365-9369.1998	26	186	214	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38322	38327		10.1074/jbc.M205566200	http://dx.doi.org/10.1074/jbc.M205566200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167642	hybrid			2022-12-27	WOS:000178529600043
J	Cassel, TN; Berg, T; Suske, G; Nord, M				Cassel, TN; Berg, T; Suske, G; Nord, M			Synergistic transactivation of the differentiation-dependent lung gene Clara cell secretory protein (secretoglobin 1a1) by the basic region leucine zipper factor CCAAT/enhancer-binding protein A and the homeodomain factor Nkx2.1/thyroid transcription factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C/EBP-ALPHA; ACTIVATION DOMAIN; FACTOR-I; EXPRESSION; PROMOTER; FAMILY; MOUSE; LIVER; PROLIFERATION; MORPHOGENESIS	The basic region-leucine zipper transcription factor CCAAT/enhancer-binding protein alpha (C/EBPalpha) and the homeodomain transcription factor Nkx2.1/thyroid transcription factor-1 are essential for normal lung morphogenesis. Nkx2.1 is expressed from the onset of lung development, whereas C/EBPalpha expression is turned on at later stages. The expression of C/EBPalpha correlates to the appearance of lung-specific proteins with differentiation-dependent expression patterns, such as the Clara cell secretory protein (secretoglobin 1a1 (Scgb1a1), CCSP). In this study, we demonstrate synergistic transactivation by C/EBPalpha and Nkx2.1 in the regulation of the CCSP gene. We show that the synergistic activity of C/EBPalpha and Nkx2.1 originates from cis-acting elements in the proximal promoter of CCSP and that the synergism is dependent on NH2-terminal transactivation domains of C/EBPalpha and Nkx2.1. Our results suggest that the cooperation of C/EBPalpha and N-kx2.1 is a major determinant for the high level, lung epithelial-specific expression of CCSP during the later stages of lung development and in the adult lung.	Karolinska Inst, Dept Med Nutr, Novum, SE-14186 Huddinge, Sweden; Univ Marburg, Inst Mol Biol & Tumorforsch, D-35033 Marburg, Germany	Karolinska Institutet; Philipps University Marburg	Nord, M (corresponding author), Karolinska Inst, Dept Med Nutr, Novum, SE-14186 Huddinge, Sweden.		berg, tove/H-9916-2012	Suske, Guntram/0000-0002-4807-0513				BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Braun H, 1998, J BIOL CHEM, V273, P9821, DOI 10.1074/jbc.273.16.9821; BRUNO MD, 1995, J BIOL CHEM, V270, P6531, DOI 10.1074/jbc.270.12.6531; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Cassel TN, 2000, AM J RESP CELL MOL, V22, P469, DOI 10.1165/ajrcmb.22.4.3916; Cassel Tobias N., 2000, Molecular Cell Biology Research Communications, V3, P42, DOI 10.1006/mcbr.2000.0187; Charles A, 2001, J CELL BIOCHEM, V83, P414, DOI 10.1002/jcb.1239; Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DEFELICE M, 1995, J BIOL CHEM, V270, P26649, DOI 10.1074/jbc.270.44.26649; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; Flodby P, 1996, J BIOL CHEM, V271, P24753, DOI 10.1074/jbc.271.40.24753; Kelly SE, 1996, J BIOL CHEM, V271, P6881, DOI 10.1074/jbc.271.12.6881; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; LI F, 1995, AM J PHYSIOL-LUNG C, V269, pL241, DOI 10.1152/ajplung.1995.269.2.L241; Liu C, 2002, J BIOL CHEM, V277, P4519, DOI 10.1074/jbc.M107585200; Mendelson CR, 2000, ANNU REV PHYSIOL, V62, P875, DOI 10.1146/annurev.physiol.62.1.875; Minoo P, 1999, DEV BIOL, V209, P60, DOI 10.1006/dbio.1999.9234; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; NORD M, 1992, ARCH BIOCHEM BIOPHYS, V296, P302, DOI 10.1016/0003-9861(92)90576-I; Nord M, 1998, DNA CELL BIOL, V17, P481, DOI 10.1089/dna.1998.17.481; Nord M, 2000, ANN NY ACAD SCI, V923, P154; Patrone C, 1998, MOL ENDOCRINOL, V12, P835, DOI 10.1210/me.12.6.835; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Ray MK, 1996, MOL CELL BIOL, V16, P2056; Sambrook J., 2002, MOL CLONING LAB MANU; SMITH CI, 1995, AM J PHYSIOL-LUNG C, V269, pL603, DOI 10.1152/ajplung.1995.269.5.L603; Sugahara K, 1999, CELL TISSUE RES, V297, P261, DOI 10.1007/s004410051354; Suske G, 2000, Methods Mol Biol, V130, P175; Tell G, 1998, BIOCHEM J, V329, P395, DOI 10.1042/bj3290395; TENHAVEOPBROEK AAW, 1993, MICROSC RES TECHNIQ, V26, P400, DOI 10.1002/jemt.1070260508; TENHAVEOPBROEK AAW, 1981, AM J ANAT, V162, P201, DOI 10.1002/aja.1001620303; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Whitsett JA, 1996, AM J RESP CELL MOL, V14, P118, DOI 10.1165/ajrcmb.14.2.8630260; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Yi M, 2002, J BIOL CHEM, V277, P2997, DOI 10.1074/jbc.M109793200	42	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36970	36977		10.1074/jbc.M201293200	http://dx.doi.org/10.1074/jbc.M201293200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12161423	hybrid			2022-12-27	WOS:000178447100010
J	Figueroa, Y; Wald, FA; Salas, PJI				Figueroa, Y; Wald, FA; Salas, PJI			p34(cdc2)-mediated phosphorylation mobilizes microtubule-organizing centers from the apical intermediate filament scaffold in CACO-2 epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILIZED CELLS; ORGANIZATION; PROTEINS; POLARITY; GLYCOSYLATION; CYTOSKELETON	We have shown previously that centrosomes and other microtubule-organizing centers (MTOCs) attach to the apical intermediate filament (IF) network in CACO-2 cells. In this cell line, intermediate filaments do not disorganize during mitosis. Therefore, we speculated that the trigger of the G(2)-M boundary may also detach MTOCs from their IF anchor. If that was the case, at least one of the proteins involved in the attachment must be phosphorylated by p34(cdc2) (cdk1). Using confocal microscopy and standard biochemical analysis, we found that p34(cdc2)-mediated phosphorylation indeed released MTOCs from IFs in permeabilized cells. In isolated, immunoprecipitated multiprotein complexes containing both gamma-tubulin and cytokeratin 19, p34(cdc2) phosphorylated only one protein, and phosphorylation released cytokeratin 19 from the complexes. We conclude that this as yet unidentified protein is a part of the molecular mechanism that attaches MTOCs to IFs in interphase.	Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA	University of Miami	Salas, PJI (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat, R-124,POB 016960, Miami, FL 33101 USA.	psalas@miami.edu	Salas, Pedro J./AAS-9455-2021	Salas, Pedro/0000-0002-7411-1366	NIDDK NIH HHS [R01 DK57805] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057805] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APODACA G, 1994, J CELL BIOL, V125, P67, DOI 10.1083/jcb.125.1.67; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BUENDIA B, 1990, J CELL BIOL, V110, P1123, DOI 10.1083/jcb.110.4.1123; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; CHOU CF, 1993, J BIOL CHEM, V268, P4465; Csala M, 2000, BIOCHEM PHARMACOL, V59, P801, DOI 10.1016/S0006-2952(99)00392-5; Foisner R, 1997, BIOESSAYS, V19, P297, DOI 10.1002/bies.950190407; Foisner R, 1996, MOL BIOL CELL, V7, P273, DOI 10.1091/mbc.7.2.273; FRANKE WW, 1982, CELL, V30, P103, DOI 10.1016/0092-8674(82)90016-2; Goncalves CA, 2000, NEUROCHEM RES, V25, P885, DOI 10.1023/A:1007533927813; HERSEY SJ, 1990, ANNU REV PHYSIOL, V52, P345; HIEDA Y, 1992, J CELL BIOL, V116, P1497, DOI 10.1083/jcb.116.6.1497; LANE EB, 1982, EMBO J, V1, P1365, DOI 10.1002/j.1460-2075.1982.tb01324.x; LEPERS A, 1990, BIOCHIMIE, V72, P1, DOI 10.1016/0300-9084(90)90166-E; Liu JM, 1999, METHODS, V19, P403, DOI 10.1006/meth.1999.0876; MEADS T, 1995, CELL MOTIL CYTOSKEL, V32, P273, DOI 10.1002/cm.970320404; Melan M A, 1994, Methods Mol Biol, V34, P55; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; PINTO M, 1983, BIOL CELL, V47, P323; REINSCH S, 1994, J CELL BIOL, V126, P1509, DOI 10.1083/jcb.126.6.1509; RODRIGUEZ ML, 1994, J CELL SCI, V107, P3145; Salas PJI, 1999, J CELL BIOL, V146, P645, DOI 10.1083/jcb.146.3.645; Salas PJI, 1997, J CELL BIOL, V137, P359, DOI 10.1083/jcb.137.2.359; SCHULZ I, 1990, METHOD ENZYMOL, V192, P280; STEARNS T, 1994, CELL, V76, P623, DOI 10.1016/0092-8674(94)90503-7; Tang BL, 1998, J BIOL CHEM, V273, P6944, DOI 10.1074/jbc.273.12.6944; Yeaman C, 1999, CURR BIOL, V9, pR515, DOI 10.1016/S0960-9822(99)80324-8	28	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37848	37854		10.1074/jbc.M207037200	http://dx.doi.org/10.1074/jbc.M207037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151413	hybrid			2022-12-27	WOS:000178447100120
J	Flemmer, AW; Gimenez, I; Dowd, BFX; Darman, RB; Forbush, B				Flemmer, AW; Gimenez, I; Dowd, BFX; Darman, RB; Forbush, B			Activation of the Na-K-Cl cotransporter NKM detected with a phospho-specific antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHARK RECTAL GLAND; PAROTID ACINAR-CELLS; NA+-K+-2CL(-) COTRANSPORTER; NA-K-2CL COTRANSPORTER; UP-REGULATION; DIRECT PHOSPHORYLATION; EXPRESSION; SECRETION; PROTEIN; EPITHELIUM	The Na-K-Cl cotransporter NKCC1 is activated by phosphorylation of a regulatory domain in its N terminus. In the accompanying paper (Darman, R. B., and Forbush, B. (2002) J. Biol. Chem. 277, 37542-37550), we identify three phosphothreonines important in this process. Using a phospho-specific antibody (anti-phospho-NKCC1 antibody R5) raised against a diphosphopeptide containing Thr(212) and Thr(217) of human NKCC, we were readily able to monitor the cotransporter activation state. In P-32 phosphorylation experiments with rectal gland tubules, we show that the R5 antibody signal is proportional to the amount of P-32 incorporated into NKCC1; and in experiments with NKCC1-transfected HEK-293 cells, we demonstrate that R5-detected phosphorylation directly mirrors functional activation. Immunofluorescence analysis of shark rectal gland shows activation-dependent R5 antibody staining along the basolateral membrane. In perfused rat parotid glands, isoproterenol induced staining of both acinar and ductal cells along the basolateral membrane. Isoproterenol also induced basolateral staining of the epithelial cells in rat trachea, whereas basal cells in the subepithelial tissue displayed heavy, non-polarized staining of the cell membrane. In rat colon, agonist stimulation induced staining along the basolateral membrane of crypt cells. These data provide direct evidence of NKCC1 regulation in these tissues, and they further link phosphorylation of NKCC1 with its activation in transfected cells and native tissue. The high conservation of the regulatory threonine residues among NKCC1, NKCC2, and NCC family members, together with the fact that tissues from divergent vertebrate species exhibit similar R5-binding profiles, lends further support to the role of this regulatory locus in vivo.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Mt Desert Isl Biol Lab, Salsbury Cove, ME 04672 USA	Yale University; Mount Desert Island Biological Laboratory	Forbush, B (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, 333 Cedar St, New Haven, CT 06520 USA.	biff.forbush@yale.edu	Giménez, Ignacio/B-6322-2013; W., Andreas Flemmer/AAQ-5654-2021	Giménez, Ignacio/0000-0002-6043-4869; 	NIDDK NIH HHS [DK47661] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047661] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boers JE, 1998, AM J RESP CRIT CARE, V157, P2000, DOI 10.1164/ajrccm.157.6.9707011; DAndrea L, 1996, J BIOL CHEM, V271, P28969, DOI 10.1074/jbc.271.46.28969; Darman RB, 2002, J BIOL CHEM, V277, P37542, DOI 10.1074/jbc.M206293200; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; DHARMSATHAPHORN K, 1985, J CLIN INVEST, V75, P462, DOI 10.1172/JCI111721; Evans RL, 1997, J PHYSIOL-LONDON, V499, P351, DOI 10.1113/jphysiol.1997.sp021932; Flemmer AW, 1999, FASEB J, V13, pA399; FORBUSH B, 1992, AM J PHYSIOL, V262, pC1000, DOI 10.1152/ajpcell.1992.262.4.C1000; HAAS M, 1990, AM J PHYSIOL, V259, pC557, DOI 10.1152/ajpcell.1990.259.4.C557; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; HALM DR, 1986, AM J PHYSIOL, V251, pC252, DOI 10.1152/ajpcell.1986.251.2.C252; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Kurihara K, 2002, AM J PHYSIOL-CELL PH, V282, pC817, DOI 10.1152/ajpcell.00352.2001; Kurihara K, 1999, AM J PHYSIOL-CELL PH, V277, pC1184, DOI 10.1152/ajpcell.1999.277.6.C1184; LYTLE C, 1992, AM J PHYSIOL, V262, pC1009, DOI 10.1152/ajpcell.1992.262.4.C1009; LYTLE C, 1992, J BIOL CHEM, V267, P25428; LYTLE C, 1992, J BIOL CHEM, V267, P25438; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; Matthews JB, 1998, J CLIN INVEST, V101, P2072, DOI 10.1172/JCI1042; McDaniel N, 1999, AM J PHYSIOL-GASTR L, V276, pG1273, DOI 10.1152/ajpgi.1999.276.5.G1273; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Panet R, 2000, J CELL PHYSIOL, V182, P109, DOI 10.1002/(SICI)1097-4652(200001)182:1<109::AID-JCP12>3.0.CO;2-A; PAULAIS M, 1992, J CLIN INVEST, V89, P1142, DOI 10.1172/JCI115695; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; Schultheiss G, 2000, EUR J PHARMACOL, V403, P251, DOI 10.1016/S0014-2999(00)00487-8; TANIMURA A, 1995, J BIOL CHEM, V270, P25252, DOI 10.1074/jbc.270.42.25252	28	154	156	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37551	37558		10.1074/jbc.M206294200	http://dx.doi.org/10.1074/jbc.M206294200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145305	hybrid			2022-12-27	WOS:000178447100082
J	Velling, T; Risteli, J; Wennerberg, K; Mosher, DF; Johansson, S				Velling, T; Risteli, J; Wennerberg, K; Mosher, DF; Johansson, S			Polymerization of type I and III collagens is dependent on fibronectin and enhanced by integrins alpha(11)beta(1) and alpha(2)beta(1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING SITE; 3-DIMENSIONAL COLLAGEN; FIBRILLAR COLLAGENS; GENE-EXPRESSION; MATRIX PROTEIN; BLOOD-VESSELS; HUMAN-SKIN; DECORIN; CELLS; FIBRILLOGENESIS	Polymerization of the ECM proteins fibronectin and laminin has been shown to take place in close vicinity to the cell surface and be facilitated by beta(1), integrins (Lohikangas, L., Gullberg, D., and Johansson, S. (2001) Exp. Cell Res. 265, 135-144 and Wennerberg, K., Lohikangas, L., Gullberg, D., Pfaff, M., Johansson, S., and Fassler, R. (1996) J. Cell Biol. 132,227-238). We have studied the role of collagen receptors, integrins alpha(11)beta(1) and alpha(2)beta(1), and fibronectin in collagen polymerization using fibronectin-deficient mouse embryonic fibroblast cell lines. In contrast to the earlier belief that collagen polymerization occurs via self-assembly of collagen molecules we show that a preformed fibronectin matrix is essential for collagen network formation and that collagen-binding integrins strongly enhance this process. Thus, collagen deposition is regulated by the cells, both indirectly through integrin alpha(5)beta(1)-dependent polymerization of fibronectin and directly through collagen-binding integrins.	Inst Med Biochem & Microbiol, S-75123 Uppsala, Sweden; Univ Oulu, Dept Clin Chem, FIN-90014 Oulu, Finland; Univ Wisconsin, Dept Med, Madison, WI 53706 USA	University of Oulu; University of Wisconsin System; University of Wisconsin Madison	Velling, T (corresponding author), Inst Med Biochem & Microbiol, Box 582, S-75123 Uppsala, Sweden.		Velling, Teet/G-6129-2016; Wennerberg, Krister/AAH-2919-2022; Wennerberg, Krister/AFM-0539-2022	Wennerberg, Krister/0000-0002-1352-4220; Wennerberg, Krister/0000-0002-1352-4220	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021644] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL21644] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANYAI L, 1990, EUR J BIOCHEM, V193, P801, DOI 10.1111/j.1432-1033.1990.tb19403.x; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chernousov MA, 1998, J CELL SCI, V111, P2763; CIDADAO AJ, 1989, EUR J CELL BIOL, V48, P303; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DZAMBA BJ, 1993, J CELL BIOL, V121, P1165, DOI 10.1083/jcb.121.5.1165; ENGVALL E, 1978, J EXP MED, V147, P1584, DOI 10.1084/jem.147.6.1584; FESSLER LI, 1981, J BIOL CHEM, V256, P2531; FLEISCHMAJER R, 1981, P NATL ACAD SCI-BIOL, V78, P7360, DOI 10.1073/pnas.78.12.7360; FLEISCHMAJER R, 1990, ANN NY ACAD SCI, V580, P161, DOI 10.1111/j.1749-6632.1990.tb17927.x; Gardner H, 1999, J CELL SCI, V112, P263; Graham HK, 2000, J MOL BIOL, V295, P891, DOI 10.1006/jmbi.1999.3384; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEDLUND H, 1994, MATRIX BIOL, V14, P227, DOI 10.1016/0945-053X(94)90186-4; HEDMAN K, 1982, EMBO J, V1, P47, DOI 10.1002/j.1460-2075.1982.tb01122.x; Henry MD, 1998, CELL, V95, P859, DOI 10.1016/S0092-8674(00)81708-0; Henry MD, 2001, J CELL SCI, V114, P1137; Holmes DF, 2001, MICRON, V32, P273, DOI 10.1016/S0968-4328(00)00040-8; Holtkotter O, 2002, J BIOL CHEM, V277, P10789, DOI 10.1074/jbc.M112307200; JOHANSSON S, 1984, J CELL BIOL, V98, P810, DOI 10.1083/jcb.98.3.810; JOHANSSON S, 1980, BIOCHEM J, V187, P521, DOI 10.1042/bj1870521; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KAMATA T, 1994, J BIOL CHEM, V269, P9659; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; KURKINEN M, 1980, LAB INVEST, V43, P47; Kypreos KE, 2000, J CELL BIOCHEM, V80, P146; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; Lafrenie RM, 1998, J CELL PHYSIOL, V175, P163, DOI 10.1002/(SICI)1097-4652(199805)175:2<163::AID-JCP6>3.0.CO;2-M; Langholz O, 1995, J CELL BIOL, V131, P1903, DOI 10.1083/jcb.131.6.1903; LAPIERE JC, 1994, J INVEST DERMATOL, V103, P637, DOI 10.1111/1523-1747.ep12398270; Lohikangas L, 2001, EXP CELL RES, V265, P135, DOI 10.1006/excr.2001.5170; Mao JR, 2002, NAT GENET, V30, P421, DOI 10.1038/ng850; MCDONALD JA, 1982, J CELL BIOL, V92, P485, DOI 10.1083/jcb.92.2.485; MOSHER DF, 1995, THROMB HAEMOSTASIS, V74, P529; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Obara M, 1997, FEBS LETT, V412, P48, DOI 10.1016/S0014-5793(97)00737-0; OWENS RJ, 1986, EMBO J, V5, P2825, DOI 10.1002/j.1460-2075.1986.tb04575.x; PAYNE KJ, 1988, BIOPOLYMERS, V27, P1749, DOI 10.1002/bip.360271105; PRINGLE GA, 1990, J HISTOCHEM CYTOCHEM, V38, P1405, DOI 10.1177/38.10.1698203; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Ravanti L, 1999, J BIOL CHEM, V274, P2446, DOI 10.1074/jbc.274.4.2446; RIIKONEN T, 1995, J BIOL CHEM, V270, P13548, DOI 10.1074/jbc.270.22.13548; RISTELI J, 1988, CLIN CHEM, V34, P715; RISTELI J, 1993, CLIN CHEM, V39, P635; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; SKERJANC IS, 1994, MOL CELL BIOL, V14, P8451, DOI 10.1128/MCB.14.12.8451; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; Tiger CF, 2001, DEV BIOL, V237, P116, DOI 10.1006/dbio.2001.0363; Tomasini-Johansson BR, 2001, J BIOL CHEM, V276, P23430, DOI 10.1074/jbc.M103467200; UGAROVA T, 1995, THROMB HAEMOSTASIS, V74, P253; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; Velling T, 1999, J BIOL CHEM, V274, P25735, DOI 10.1074/jbc.274.36.25735; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Wennerberg K, 1996, J CELL BIOL, V132, P227, DOI 10.1083/jcb.132.1.227; WILLIAMS EC, 1982, J BIOL CHEM, V257, P4973; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x	58	276	281	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37377	37381		10.1074/jbc.M206286200	http://dx.doi.org/10.1074/jbc.M206286200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145303	hybrid			2022-12-27	WOS:000178447100060
J	Sun, JM; Chen, HY; Moniwa, M; Litchfield, DW; Seto, E; Davie, JR				Sun, JM; Chen, HY; Moniwa, M; Litchfield, DW; Seto, E; Davie, JR			The transcriptional repressor Sp3 is associated with CK2-phosphorylated histone deacetylase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE CK2; NUCLEAR MATRIX; MAMMARY-GLAND; ACTIVATION; ACETYLATION; FAMILY; TUMORIGENESIS; MECHANISM; CELLS; GENES	Spl and Sp3 are ubiquitously expressed mammalian transcription factors that function as activators or repressors. Although both transcription factors share a common domain involved in forming multimers, we demonstrate that Sp1 and Sp3 form separate complexes in estrogen-dependent human breast cancer cells. Sp1 and Sp3 complexes associate with histone deacetylases (HDACs) 1 and 2. Although most HDAC2 is not phosphorylated in the breast cancer cells, HDAC2 bound to Sp1 and Sp3 and cross-linked to chromatin in situ is highly enriched in a phosphorylated form . that has a reduced mobility in SDS-polyacrylamide gels. We show that protein kinase CK2 is associated with and phosphorylates HDAC2. Alkaline phosphatase treatment of HDAC2 and Sp1 and Sp3 complexes reduced the associated HDAC activity. Protein kinase CK2 is up-regulated in several cancers including breast cancer, and Sp1 and Sp3 have key roles in estrogen-induced proliferation and gene expression in estrogen-dependent breast cancer cells. CK2 phosphorylation of HDAC2 recruited by Sp1 or SP3 could regulate HDAC activity and alter the balance of histone deacetylase and histone acetyltransferase activities and dynamic chromatin remodeling of estrogen-regulated genes.	Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	Western University (University of Western Ontario); H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Davie, JR (corresponding author), Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	davie@cc.umanitoba.ca	Litchfield, David/E-4636-2015	Litchfield, David/0000-0002-2425-6620; Davie, James/0000-0002-0420-6888				Abdelrahim M, 2002, J BIOL CHEM, V277, P28815, DOI 10.1074/jbc.M203828200; Apt D, 1996, VIROLOGY, V224, P281, DOI 10.1006/viro.1996.0530; Cai R, 2001, BIOCHEM BIOPH RES CO, V283, P445, DOI 10.1006/bbrc.2001.4786; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Davie JR, 2000, CRIT REV EUKAR GENE, V10, P303; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; DUBIK D, 1992, ONCOGENE, V7, P1587; Ferreira R, 2001, ONCOGENE, V20, P3128, DOI 10.1038/sj.onc.1204337; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; Gartel AL, 2000, ONCOGENE, V19, P5182, DOI 10.1038/sj.onc.1203900; GIETZ RD, 1995, J BIOL CHEM, V270, P13017, DOI 10.1074/jbc.270.22.13017; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; Kennett SB, 2002, J BIOL CHEM, V277, P9780, DOI 10.1074/jbc.M108661200; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Lai A, 2001, MOL CELL BIOL, V21, P2918, DOI 10.1128/MCB.21.8.2918-2932.2001; Landesman-Bollag E, 2001, MOL CELL BIOCHEM, V227, P153, DOI 10.1023/A:1013108822847; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200; Safe S, 2001, VITAM HORM, V62, P231, DOI 10.1016/S0083-6729(01)62006-5; Samuel SK, 1998, CANCER RES, V58, P3004; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Spencer VA, 2001, J BIOL CHEM, V276, P34810, DOI 10.1074/jbc.M104886200; Spencer VA, 2002, PROTEIN PROTOCOLS HD, P753; SPENCER VA, 2002, PROTEIN PROTOCOLS HD, P747; Sun JM, 2001, J BIOL CHEM, V276, P49435, DOI 10.1074/jbc.M108364200; Sun JM, 1996, J CELL BIOCHEM, V62, P454, DOI 10.1002/(SICI)1097-4644(19960915)62:4<454::AID-JCB3>3.0.CO;2-L; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tawfic S, 2001, HISTOL HISTOPATHOL, V16, P573, DOI 10.14670/HH-16.573; Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629; Wang XY, 2001, J BIOL CHEM, V276, P12764, DOI 10.1074/jbc.M100501200; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Zhao H, 2002, J CELL BIOCHEM, V86, P365, DOI 10.1002/jcb.10215	34	78	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35783	35786		10.1074/jbc.C200378200	http://dx.doi.org/10.1074/jbc.C200378200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12176973	hybrid			2022-12-27	WOS:000178275100002
J	Isshiki, M; Ying, YS; Fujita, T; Anderson, RGW				Isshiki, M; Ying, YS; Fujita, T; Anderson, RGW			A molecular sensor detects signal transduction from caveolae in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PLASMA-MEMBRANE; SMOOTH-MUSCLE; RECEPTOR; CALCIUM; TRANSPORT; INTERNALIZATION; LOCALIZATION; CHOLESTEROL; ACTIVATION	Biochemical and cell fractionation studies suggest caveolae contain functionally organized sets of signaling molecules that are capable of transmitting specific signals to the cell. It is not known, however, whether any signals actually originate from caveolae in living cells. To address this question, we have engineered the calcium sensor yellow cameleon so that it is targeted either to the plasma membrane, caveolae, or the cytoplasm of endothelial cells. Quantitative measurements of the three Ca2+ pools detected by these probes indicate that caveolae are preferred sites of Ca2+ entry when Ca2+ stores in the endoplasmic reticulum are depleted. These results suggest that the signaling machinery in control of Ca2+ entry is functionally organized in the caveolae of living cells.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75235 USA; Univ Tokyo, Dept Nephrol & Endocrinol, Tokyo 1138688, Japan	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Tokyo	Anderson, RGW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	richard.anderson@utsouthwestern.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052016] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline; NIGMS NIH HHS [GM 52016] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; ANDERSON RGW, 1993, P NATL ACAD SCI USA, V90, P10909, DOI 10.1073/pnas.90.23.10909; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Benlimame N, 1998, MOL BIOL CELL, V9, P1773, DOI 10.1091/mbc.9.7.1773; Chambliss KL, 2000, CIRC RES, V87, pE44, DOI 10.1161/01.RES.87.11.e44; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Isshiki M, 1999, CELL CALCIUM, V26, P201, DOI 10.1054/ceca.1999.0073; Isshiki M, 2002, J CELL SCI, V115, P475; Isshiki M, 1998, P NATL ACAD SCI USA, V95, P5009, DOI 10.1073/pnas.95.9.5009; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Lin S, 2000, J BIOL CHEM, V275, P17979, DOI 10.1074/jbc.275.24.17979; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 2000, J BIOL CHEM, V275, P31648, DOI 10.1074/jbc.M004599200; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Lockwich TP, 2000, J BIOL CHEM, V275, P11934, DOI 10.1074/jbc.275.16.11934; Lohn M, 2000, CIRC RES, V87, P1034, DOI 10.1161/01.RES.87.11.1034; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; Michel JB, 1997, J BIOL CHEM, V272, P15583, DOI 10.1074/jbc.272.25.15583; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PATHAK RK, 1989, J HISTOCHEM CYTOCHEM, V37, P69, DOI 10.1177/37.1.2491753; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; SUGI H, 1982, CAN J PHYSIOL PHARM, V60, P576, DOI 10.1139/y82-077; SUZUKI S, 1989, CELL TISSUE RES, V257, P237, DOI 10.1007/BF00261826; TORIHASHI S, 2002, J BIOL CHEM; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5	46	104	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43389	43398		10.1074/jbc.M205411200	http://dx.doi.org/10.1074/jbc.M205411200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12177060	hybrid			2022-12-27	WOS:000179081200123
J	Berggard, T; Szczepankiewicz, O; Thulin, E; Linse, S				Berggard, T; Szczepankiewicz, O; Thulin, E; Linse, S			Myo-inositol monophosphatase is an activated target of calbindin D-28k	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; RAT HIPPOCAMPUS; MESSENGER-RNA; CA2+-BINDING PROTEIN; PUTATIVE TARGET; PARVALBUMIN; EXPRESSION; NEURONS; D28K; SECRETAGOGIN	Calbindin D-28k (calbindin) is a member of the calmodulin superfamily of Ca2+-binding proteins. An intracellular target of calbindin was discovered using bacteriophage display. Human recombinant calbindin was immobilized on magnetic beads and used in affinity purification of phage-displayed peptides from a random 12-mer peptide library. One sequence, SYSSLAKYPSHS, was strongly selected both in the presence of Mg2+ and in the presence of Ca2+. Homology search against the protein sequence data base identified a closely similar sequence, ISSIKEKYPSHS, at residues 55-66 in myo-inositol-1(or 4)-monophosphatase (IMPase, EC 3.1.3.25), which constitute a strongly conserved and exposed region in the three-dimensional structure. IMPase is a key enzyme in the regulation of the activity of the phosphatidylinositol-signaling pathway. It catalyzes the hydrolysis of myo-inositol-1(or 4)-monophosphate to form free myo-inositol, maintaining a supply that represents the precursor for inositol phospholipid second messenger signaling systems. Fluorescence spectroscopy showed that isolated calbindin and IMPase interact with an apparent equilibrium dissociation constant, K-D, of 0.9 mum. Both apo and Ca2+-bound calbindin was found to activate IMPase up to 250-fold, depending on the pH and substrate concentration. The activation is most pronounced at conditions that otherwise lead to a very low activity of IMPase, i.e. at reduced pH and at low substrate concentration.	Lund Univ, Dept Biophys Chem, Ctr Chem, S-22100 Lund, Sweden	Lund University	Linse, S (corresponding author), Lund Univ, Dept Biophys Chem, Ctr Chem, POB 124, S-22100 Lund, Sweden.			Linse, Sara/0000-0001-9629-7109				Airaksinen MS, 1997, P NATL ACAD SCI USA, V94, P1488, DOI 10.1073/pnas.94.4.1488; ATACK JR, 1995, TRENDS NEUROSCI, V18, P343, DOI 10.1016/0166-2236(95)93926-O; Bellido T, 2000, J BIOL CHEM, V275, P26328, DOI 10.1074/jbc.M003600200; Berggard T, 2000, BIOCHEMISTRY-US, V39, P6864, DOI 10.1021/bi992394g; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BONE R, 1992, P NATL ACAD SCI USA, V89, P10031, DOI 10.1073/pnas.89.21.10031; CHARD PS, 1993, J PHYSIOL-LONDON, V472, P341, DOI 10.1113/jphysiol.1993.sp019950; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; Fortin M, 1997, J CHEM NEUROANAT, V14, P51, DOI 10.1016/S0891-0618(97)10012-6; Gartner W, 2001, CEREB CORTEX, V11, P1161, DOI 10.1093/cercor/11.12.1161; Giri TK, 2002, J BIOL CHEM, V277, P15099, DOI 10.1074/jbc.M103036200; ITAYA K, 1966, CLIN CHIM ACTA, V14, P361, DOI 10.1016/0009-8981(66)90114-8; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lee S, 1997, MOL BRAIN RES, V47, P183, DOI 10.1016/S0169-328X(97)00043-0; LOWENSTEIN DH, 1991, NEURON, V6, P627, DOI 10.1016/0896-6273(91)90065-8; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; MATTSON MP, 1991, NEURON, V6, P41, DOI 10.1016/0896-6273(91)90120-O; Mikkonen M, 1997, J COMP NEUROL, V388, P64; MORGAN DW, 1986, BIOCHEM BIOPH RES CO, V138, P547, DOI 10.1016/S0006-291X(86)80531-9; OBERHOLTZER JC, 1988, P NATL ACAD SCI USA, V85, P3387, DOI 10.1073/pnas.85.10.3387; REISNER PD, 1992, FEBS LETT, V297, P127, DOI 10.1016/0014-5793(92)80342-E; ROBERTS WM, 1994, J NEUROSCI, V14, P3246; SLOVITER RS, 1989, J COMP NEUROL, V280, P183, DOI 10.1002/cne.902800203; Thulin E, 1999, PROTEIN EXPRES PURIF, V15, P265, DOI 10.1006/prep.1999.1028; Wagner L, 2000, J BIOL CHEM, V275, P24740, DOI 10.1074/jbc.M001974200; Williams RSB, 2002, NATURE, V417, P292, DOI 10.1038/417292a; WINSKY L, 1995, J NEUROCHEM, V65, P381	29	52	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41954	41959		10.1074/jbc.M203492200	http://dx.doi.org/10.1074/jbc.M203492200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12176979	hybrid			2022-12-27	WOS:000178985300084
J	Kerkhoff, C; Hofmann, HA; Vormoor, J; Melkonyan, H; Roth, J; Sorg, C; Klempt, M				Kerkhoff, C; Hofmann, HA; Vormoor, J; Melkonyan, H; Roth, J; Sorg, C; Klempt, M			Binding of two nuclear complexes to a novel regulatory element within the human S100A9 promoter drives the. S100A9 gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KRUPPEL-ASSOCIATED BOX; ZINC-FINGER PROTEINS; TRANSCRIPTIONAL REGULATION; ARACHIDONIC-ACID; REPRESSION DOMAIN; C/EBP-ALPHA; CELL-LINES; MRP14; DIFFERENTIATION; COREPRESSOR	S100A9, also referred to as MRP14, is a calcium-binding protein whose expression is tightly regulated during differentiation of myeloid cells. The present study was performed to study the cell type- and differentiation-specific transcriptional regulation of the S100A9 gene. Analysis of the S100A9 promoter in MonoMac-6 cells revealed evidence for a novel regulatory region from position -400 to -374 bp, termed myeloid-related protein regulatory element (MRE). MRE deletion resulted in a 5.2-fold reduction of promoter activity. By electrophoretic mobility shift analysis two nuclear complexes binding to this region were identified and referred to as MRE-binding complex A (MbcA) and MRE-binding complex B (MbcB). By mutagenesis the MRE-binding motif could be narrowed to a 12-bp region. The relevance of MRE is deduced from the observations that the formation of either MRE-binding complex A or MRE-binding complex B strongly correlated with S100A9 gene expression in a cell type-specific, activation- and differentiation-dependent manner. Moreover, DNA affinity chromatography and Western blot studies indicate that a Kruppel-related zinc finger protein and the transcriptional intermediary factor 1beta (TIF1beta) are involved in an MRE-binding complex, thereby regulating the S100A9 gene expression.	Inst Expt Dermatol, D-48149 Munster, Germany; Univ Munster, Inst Expt Dermatol, D-48149 Munster, Germany; Univ Munster, Dept Pediat Hematol Oncol, D-48149 Munster, Germany	University of Munster; University of Munster	Kerkhoff, C (corresponding author), Inst Expt Dermatol, von Esmarch Str 58, D-48149 Munster, Germany.	kerkhoc@uni-muenster.de	Vormoor, Josef/GPS-7248-2022	Vormoor, Josef/0000-0002-1825-1890				ABRINK M, 1995, DNA CELL BIOL, V14, P125, DOI 10.1089/dna.1995.14.125; Abrink M, 2001, P NATL ACAD SCI USA, V98, P1422, DOI 10.1073/pnas.041616998; Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1993, EMBO J, V12, P1363, DOI 10.1002/j.1460-2075.1993.tb05781.x; BRAVO R, 1990, CELL GROWTH DIFFER, V1, P305; BRUN JG, 1994, J RHEUMATOL, V21, P733; Cammas F, 2000, DEVELOPMENT, V127, P2955; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; Ciotti P, 2001, EUR J BIOCHEM, V268, P225, DOI 10.1046/j.1432-1327.2001.01859.x; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; Dreier J, 1998, DNA CELL BIOL, V17, P321, DOI 10.1089/dna.1998.17.321; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; GOEBELER M, 1994, TRANSPLANTATION, V58, P355; HAMILTON JA, 1993, IMMUNOL TODAY, V14, P18, DOI 10.1016/0167-5699(93)90319-G; Kerkhoff C, 1999, J BIOL CHEM, V274, P32672, DOI 10.1074/jbc.274.46.32672; Kerkhoff C, 1998, BBA-MOL CELL RES, V1448, P200, DOI 10.1016/S0167-4889(98)00144-X; Kerkhoff C, 2001, BIOCHEMISTRY-US, V40, P241, DOI 10.1021/bi001791k; Klempt M, 1997, FEBS LETT, V408, P81, DOI 10.1016/S0014-5793(97)00394-3; Klempt M, 1999, J CELL BIOCHEM, V73, P49, DOI 10.1002/(SICI)1097-4644(19990401)73:1<49::AID-JCB6>3.0.CO;2-2; Klempt M, 1998, IMMUNOBIOLOGY, V199, P148, DOI 10.1016/S0171-2985(98)80070-3; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Kuruto-Niwa R, 1998, CELL STRUCT FUNCT, V23, P109, DOI 10.1247/csf.23.109; KUWAYAMA A, 1993, BLOOD, V81, P3116; LAGASSE E, 1988, MOL CELL BIOL, V8, P2402, DOI 10.1128/MCB.8.6.2402; Lenny N, 1997, MOL BIOL REP, V24, P157, DOI 10.1023/A:1006859700409; LOVERING R, 1991, NUCLEIC ACIDS RES, V19, P2921, DOI 10.1093/nar/19.11.2921; Mark C, 1999, DNA CELL BIOL, V18, P381, DOI 10.1089/104454999315277; Melkonyan H, 1996, NUCLEIC ACIDS RES, V24, P4356, DOI 10.1093/nar/24.21.4356; Melkonyan H, 1998, J BIOL CHEM, V273, P27026, DOI 10.1074/jbc.273.41.27026; Moosmann P, 1996, NUCLEIC ACIDS RES, V24, P4859, DOI 10.1093/nar/24.24.4859; MULLER G, 1993, ARTERIOSCLER THROMB, V13, P1317, DOI 10.1161/01.ATV.13.9.1317; NATSUKA S, 1992, BLOOD, V79, P460; OGAWA M, 1993, BLOOD, V81, P2844; Peng HZ, 2000, J BIOL CHEM, V275, P18000, DOI 10.1074/jbc.M001499200; Poncelet DA, 1998, DNA CELL BIOL, V17, P931, DOI 10.1089/dna.1998.17.931; PREISS A, 1985, NATURE, V313, P27, DOI 10.1038/313027a0; Rammes A, 1997, J BIOL CHEM, V272, P9496; ROTH J, 1992, IMMUNOBIOLOGY, V186, P304, DOI 10.1016/S0171-2985(11)80259-7; ROTH J, 1994, BIOCHEM J, V301, P655, DOI 10.1042/bj3010655; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Siegenthaler G, 1997, J BIOL CHEM, V272, P9371; TERSTAPPEN LWMM, 1990, LEUKEMIA, V4, P657; TERSTAPPEN LWMM, 1992, LEUKEMIA, V6, P1001; TOMMERUP N, 1993, HUM MOL GENET, V2, P1571, DOI 10.1093/hmg/2.10.1571; Valledor AF, 1998, J LEUKOCYTE BIOL, V63, P405, DOI 10.1002/jlb.63.4.405; VANROOZENDAAL KEP, 1990, EXP CELL RES, V190, P137, DOI 10.1016/0014-4827(90)90155-4; WILLIAMS AJ, 1995, J BIOL CHEM, V270, P22143, DOI 10.1074/jbc.270.38.22143; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m; ZWADLO G, 1988, CLIN EXP IMMUNOL, V72, P510	52	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41879	41887		10.1074/jbc.M207990200	http://dx.doi.org/10.1074/jbc.M207990200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12167632	hybrid			2022-12-27	WOS:000178985300075
J	Courselaud, B; Pigeon, C; Inoue, Y; Inoue, J; Gonzalez, FJ; Leroyer, P; Gilot, D; Boudjema, K; Guguen-Guillouzo, C; Brissott, P; Loreal, O; Ilyin, G				Courselaud, B; Pigeon, C; Inoue, Y; Inoue, J; Gonzalez, FJ; Leroyer, P; Gilot, D; Boudjema, K; Guguen-Guillouzo, C; Brissott, P; Loreal, O; Ilyin, G			C/EBP alpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; LIVER-SPECIFIC GENE; HEREDITARY HEMOCHROMATOSIS; INNATE IMMUNITY; KNOCKOUT MICE; MOUSE LIVER; EXPRESSION; TISSUE; BETA; DIFFERENTIATION	Originally identified as a gene up-regulated by iron overload in mouse liver, the HEPC gene encodes hepcidin, the first mammalian liver-specific antimicrobial peptide and potential key regulator of iron metabolism. Here we demonstrate that during rat liver development, amounts of HEPC transcripts were very low in fetal liver, strongly and transiently increased shortly after birth, and reappeared in adult liver. To gain insight into mechanisms that regulate hepatic expression of hepcidin, 5'-flanking regions of human and mouse HEPC genes were isolated and analyzed by functional and DNA binding assays. Human and mouse HEPC promoter-luciferase reporter vectors exhibited strong basal activity in hepatoma HuH-7 and mouse hepatocytes, respectively, but not in non-hepatic U-2OS cells. We found that CCAAT/enhancer-binding protein alpha (C/EBPalpha) and C/EBPbeta were respectively very potent and weak activators of both human and mouse promoters. In contrast, co-expression of hepatocyte nuclear factor 4alpha (HNF4alpha) failed to induce HEPC promoter activity. By electrophoretic mobility shift assay we demonstrated that one putative C/EBP element found in the human HEPC promoter (-250/-230) predominantly bound C/EBPalpha from rat liver nuclear extracts. Hepatic deletion of the C/EBPalpha gene resulted in reduced expression of HEPC transcripts in mouse liver. In contrast, amounts of HEPC transcripts increased in liver-specific HNF4alpha-null mice. Decrease of hepcidin mRNA in mice lacking hepatic C/EBPalpha was accompanied by iron accumulation in periportal hepatocytes. Finally, iron overload led to a significant increase of C/EBPalpha protein and HEPC transcripts in mouse liver. Taken together, these data demonstrate that C/EBPalpha is likely to be a key regulator of HEPC gene transcription and provide a novel mechanism for cross-talk between the C/EBP pathway and iron metabolism.	CHRU Pontchaillou, INSERM U522, F-35033 Rennes, France; NCI, Lab Metab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; CHRU Pontchaillou, Serv Malad Foie, F-35033 Rennes, France	CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); CHU Rennes	Ilyin, G (corresponding author), CHRU Pontchaillou, INSERM U522, F-35033 Rennes, France.		Inoue, Yusuke/O-6207-2018; Loreal, Olivier/G-3366-2013	Inoue, Yusuke/0000-0002-9710-7482; Loreal, Olivier/0000-0002-7428-3766; Boudjema, Karim/0000-0002-3894-8767				Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; CHEN WS, 1994, GENE DEV, V8, P2466, DOI 10.1101/gad.8.20.2466; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; Darlington GJ, 1999, CURR OPIN CELL BIOL, V11, P678, DOI 10.1016/S0955-0674(99)00035-6; Elizondo G, 2000, J BIOL CHEM, V275, P39747, DOI 10.1074/jbc.M004987200; Fleming RE, 2001, P NATL ACAD SCI USA, V98, P8160, DOI 10.1073/pnas.161296298; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Gilot D, 2002, J GENE MED, V4, P415, DOI 10.1002/jgm.279; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Hancock REW, 2000, TRENDS MICROBIOL, V8, P402, DOI 10.1016/S0966-842X(00)01823-0; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; HOFFMANN JA, 1995, CURR OPIN IMMUNOL, V7, P4, DOI 10.1016/0952-7915(95)80022-0; Inoue Y, 2002, J BIOL CHEM, V277, P25257, DOI 10.1074/jbc.M203126200; Krause A, 2000, FEBS LETT, V480, P147, DOI 10.1016/S0014-5793(00)01920-7; Lee YH, 1997, MOL CELL BIOL, V17, P6014, DOI 10.1128/MCB.17.10.6014; LEE YH, 1994, MOL CELL BIOL, V14, P1383, DOI 10.1128/MCB.14.2.1383; Lehrer RI, 1999, CURR OPIN IMMUNOL, V11, P23, DOI 10.1016/S0952-7915(99)80005-3; Li J, 2000, NAT MED, V6, P49, DOI 10.1038/71527; Li JX, 2000, GENE DEV, V14, P464; NAGY P, 1994, J CELL BIOL, V126, P223, DOI 10.1083/jcb.126.1.223; Nicolas G, 2002, P NATL ACAD SCI USA, V99, P4596, DOI 10.1073/pnas.072632499; Nicolas G, 2001, P NATL ACAD SCI USA, V98, P8780, DOI 10.1073/pnas.151179498; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; Ohtake T, 1999, BRIT J CANCER, V81, P393, DOI 10.1038/sj.bjc.6690707; PANDURO A, 1987, GENE DEV, V1, P1172, DOI 10.1101/gad.1.10.1172; Park CH, 2001, J BIOL CHEM, V276, P7806, DOI 10.1074/jbc.M008922200; Pigeon C, 2001, J BIOL CHEM, V276, P7811, DOI 10.1074/jbc.M008923200; Pigeon C, 1999, J HEPATOL, V30, P926, DOI 10.1016/S0168-8278(99)80149-4; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; RUPPERT S, 1990, CELL, V61, P895, DOI 10.1016/0092-8674(90)90200-X; RYDEN TA, 1989, MOL CELL BIOL, V9, P1155, DOI 10.1128/MCB.9.3.1155; Schroder JM, 1999, CELL MOL LIFE SCI, V56, P32, DOI 10.1007/s000180050004; Shike H, 2002, EUR J BIOCHEM, V269, P2232, DOI 10.1046/j.1432-1033.2002.02881.x; SONDERGAARD L, 1993, TRENDS GENET, V9, P193, DOI 10.1016/0168-9525(93)90113-V; Wakabayashi H, 1999, BIOSCI BIOTECH BIOCH, V63, P955, DOI 10.1271/bbb.63.955; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324	39	205	217	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41163	41170		10.1074/jbc.M202653200	http://dx.doi.org/10.1074/jbc.M202653200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183449	hybrid			2022-12-27	WOS:000178791400127
J	Nassar, T; Haj-Yehia, A; Akkawi, S; Kuo, A; Bdeir, K; Mazar, A; Cines, DB; Higazi, A				Nassar, T; Haj-Yehia, A; Akkawi, S; Kuo, A; Bdeir, K; Mazar, A; Cines, DB; Higazi, A			Binding of urokinase to low density lipoprotein-related receptor (LRP) regulates vascular smooth muscle cell contraction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; ANGIOTENSIN-CONVERTING ENZYME; SINGLE-CHAIN UROKINASE; PROTEIN LRP; ENDOCYTIC RECEPTOR; HYPERTENSION; COMPLEX; RATS; FIBRINOLYSIS; INTERNALIZES	Urokinase plasminogen activator (uPA) is a multifunctional protein that has been implicated in several physiological and pathological processes involving cell adhesion and migration in addition to fibrinolysis. In a previous study we found that two-chain urokinase plasminogen activator (tcuPA) stimulates phenylephrine-induced vasoconstriction of isolated rat aortic rings. In the present paper we report that uPA(-/-) mice have a significantly lower mean arterial blood pressure than do wild type mice and that aortic rings from uPA(-/-) mice show an attenuated contractile response to phenylephrine. In contrast, the blood pressure of urokinase receptor knockout (uPAR(-/-)) mice and the response of their isolated aortic rings to phenylephrine were normal, indicating that the effect of uPA on vascular contraction is independent of uPAR. Addition of mouse and human uPA almost completely reversed both the impaired vascular contractility and the lower arterial blood pressure in vivo. The in vitro and in vivo effects of infused uPA on aortic contractility and the restoration of normal blood pressure in uPA(-/-) mice were prevented by antibody to low-density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor (LRP). A modified form of uPA that lacks the kringle failed to restore the blood pressure in uPA(-/-) mice, notwithstanding having a longer half-life in the circulation. Ligands that regulate the interaction of uPA with LRP, such as PAI-1 or the PAI-1-derived peptide (EEIIMD), abolished the vasoactivity of tcuPA in vitro and in vivo. These studies identify a novel signal transducing cellular receptor pathway involved in the regulation of vascular contractility.	Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Ateenuon LLC, Dept Pathol & Lab Med, San Diego, CA 92121 USA; Hadassah Univ Hosp, Dept Clin Biochem, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Sch Pharm, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Med, IL-91120 Jerusalem, Israel	University of Pennsylvania; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew University of Jerusalem	Higazi, A (corresponding author), Univ Penn, Dept Pathol & Lab Med, 513A Stellar Chance,422 Curie Blvd, Philadelphia, PA 19104 USA.				FOGARTY INTERNATIONAL CENTER [R03TW001468] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067381, R01HL060169] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW 01468] Funding Source: Medline; NHLBI NIH HHS [HL 60169, HL 58107, HL 67381] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS DS, 1991, J BIOL CHEM, V266, P8476; Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Bdeir K, 2000, BLOOD, V96, P1820, DOI 10.1182/blood.V96.5.1820.h8001820_1820_1826; Brown NJ, 1999, HYPERTENSION, V34, P285, DOI 10.1161/01.HYP.34.2.285; Bugge TH, 1996, P NATL ACAD SCI USA, V93, P5899, DOI 10.1073/pnas.93.12.5899; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; Carmeliet P, 1996, HAEMOSTASIS, V26, P132; Erdem Y, 1999, AM J HYPERTENS, V12, P1071, DOI 10.1016/S0895-7061(99)00145-4; Gyetko MR, 1996, J CLIN INVEST, V97, P1818, DOI 10.1172/JCI118611; Haj-Yehia A, 2000, FASEB J, V14, P1411, DOI 10.1096/fj.14.10.1411; HEKMAN CM, 1988, ARCH BIOCHEM BIOPHYS, V262, P199, DOI 10.1016/0003-9861(88)90182-8; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; Higazi AAR, 1996, BLOOD, V88, P542, DOI 10.1182/blood.V88.2.542.bloodjournal882542; KOUNNAS MZ, 1992, J BIOL CHEM, V267, P12420; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; KYONG SK, 1992, BRIT J PHARMACOL, V107, P983; Levi M, 2001, CIRCULATION, V103, P2014; Liu Y, 2000, NAT MED, V6, P1380, DOI 10.1038/82199; Mitsui T, 1999, BIOL PHARM BULL, V22, P863; NYKJAER A, 1994, J BIOL CHEM, V269, P25668; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; OYAMA Y, 1986, EUR J PHARMACOL, V132, P75, DOI 10.1016/0014-2999(86)90013-0; Pinsky DJ, 1998, J CLIN INVEST, V102, P919, DOI 10.1172/JCI307; QUAX PHA, 1991, CELL REGUL, V2, P713; Sakata K, 1999, AM HEART J, V137, P1094, DOI 10.1016/S0002-8703(99)70368-6; Sisson TH, 1999, HUM GENE THER, V10, P2315, DOI 10.1089/10430349950016960; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; vanderKaaden ME, 1997, THROMB HAEMOSTASIS, V77, P710; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; YOHTARO O, 1987, EUR J PHARMACOL, V131, P75; Zhang LT, 1997, J BIOL CHEM, V272, P27053, DOI 10.1074/jbc.272.43.27053	32	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40499	40504		10.1074/jbc.M207172200	http://dx.doi.org/10.1074/jbc.M207172200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171938	hybrid			2022-12-27	WOS:000178791400045
J	deSouza, N; Reiken, S; Ondrias, K; Yang, YM; Matkovich, S; Marks, AR				deSouza, N; Reiken, S; Ondrias, K; Yang, YM; Matkovich, S; Marks, AR			Protein kinase A and two phosphatases are components of the inositol 1,4,5-trisphosphate receptor macromolecular signaling complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP-DEPENDENT PHOSPHORYLATION; RECONSTITUTED LIPID VESICLES; TYROSINE PHOSPHORYLATION; TRISPHOSPHATE RECEPTOR; RYANODINE RECEPTOR; CA2+ RELEASE; CALCIUM; CAMP; FLUX; CALCINEURIN	The inositol 1,4,5-trisphosphate receptor (IP3R) is a ubiquitously expressed intracellular calcium (Ca2+) release channel on the endoplasmic reticulum. IP3Rs play key roles in controlling Ca2+ signals that activate numerous cellular functions including T cell activation, neurotransmitter release, oocyte fertilization and apoptosis. There are three forms of IP3R, all of which are ligand-gated channels activated by the second messenger inositol 1,4,5-trisphosphate. Channel function is modulated via cross-talk with other signaling pathways including those mediated by kinases and phosphatases. In particular IP3Rs are known to be regulated by cAMP-dependent protein kinase (PKA) phosphorylation. In the present study we show that PKA and the protein phosphatases PP1 and PP2A are components of the IP3R1 macromolecular signaling complex. PKA phosphorylation of IP3R1 increases channel activity in planar lipid bilayers. These studies indicate that regulation of IP3R1 function via PKA phosphorylation involves components of a macromolecular signaling complex.	Columbia Univ Coll Phys & Surg, Ctr Mol Cardiol, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Slovak Acad Sci, Inst Mol Physiol, Bratislava 83334, Slovakia	Columbia University; Columbia University; Slovak Academy of Sciences	Marks, AR (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Mol Cardiol, Dept Med, Box 65,Rm 9-401,630 W 168th St, New York, NY 10032 USA.		Matkovich, Scot J/AFP-0908-2022; Matkovich, Scot J/B-9077-2009	Matkovich, Scot J/0000-0002-7398-6857; Matkovich, Scot J/0000-0002-7398-6857; Ondrias, Karol/0000-0001-8329-3563	FOGARTY INTERNATIONAL CENTER [R03TW000949] Funding Source: NIH RePORTER; FIC NIH HHS [R03 TW00949] Funding Source: Medline; NIAID NIH HHS [R01 AI37994] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Bruce JIE, 2002, J BIOL CHEM, V277, P1340, DOI 10.1074/jbc.M106609200; Bultynck G, 2000, J PHYSIOL-LONDON, V525, P681, DOI 10.1111/j.1469-7793.2000.t01-1-00681.x; Bultynck G, 2001, J BIOL CHEM, V276, P47715, DOI 10.1074/jbc.M106573200; Bultynck G, 2001, BIOCHEM J, V354, P413, DOI 10.1042/0264-6021:3540413; Cameron AM, 1997, J BIOL CHEM, V272, P27582, DOI 10.1074/jbc.272.44.27582; CAMERON AM, 1995, P NATL ACAD SCI USA, V92, P1784, DOI 10.1073/pnas.92.5.1784; CAMERON AM, 1995, CELL, V83, P463, DOI 10.1016/0092-8674(95)90124-8; Chatton JY, 1998, BIOCHEM J, V330, P1411, DOI 10.1042/bj3301411; DANOFF SK, 1991, P NATL ACAD SCI USA, V88, P2951, DOI 10.1073/pnas.88.7.2951; FERRIS CD, 1991, BIOCHEM BIOPH RES CO, V175, P192, DOI 10.1016/S0006-291X(05)81219-7; FERRIS CD, 1992, J BIOL CHEM, V267, P7036; FERRIS CD, 1991, P NATL ACAD SCI USA, V88, P2232, DOI 10.1073/pnas.88.6.2232; Giovannucci DR, 2000, J KOREAN MED SCI, V15, pS55, DOI 10.3346/jkms.2000.15.S.S55; HAJNOCZKY G, 1993, BIOCHEM J, V293, P413, DOI 10.1042/bj2930413; HARNICK DJ, 1995, J BIOL CHEM, V270, P2833, DOI 10.1074/jbc.270.6.2833; Haug LS, 1999, J BIOL CHEM, V274, P7467, DOI 10.1074/jbc.274.11.7467; Hulme JT, 2002, J BIOL CHEM, V277, P4079, DOI 10.1074/jbc.M109814200; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; Kaznacheyeva E, 1998, J GEN PHYSIOL, V111, P847, DOI 10.1085/jgp.111.6.847; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; Komalavilas P, 1996, J BIOL CHEM, V271, P21933, DOI 10.1074/jbc.271.36.21933; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 2002, SCIENCE, V295, P496, DOI 10.1126/science.1066843; Marx SO, 2001, J CELL BIOL, V153, P699, DOI 10.1083/jcb.153.4.699; Miller C., 1986, ION CHANNEL RECONSTI; MOSCHELLA MC, 1993, J CELL BIOL, V120, P1137, DOI 10.1083/jcb.120.5.1137; NAKADE S, 1994, J BIOL CHEM, V269, P6735; Pieper AA, 2001, NEUROSCIENCE, V102, P433, DOI 10.1016/S0306-4522(00)00470-X; Straub SV, 2002, J BIOL CHEM, V277, P31949, DOI 10.1074/jbc.M204318200; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; Tertyshnikova S, 1998, P NATL ACAD SCI USA, V95, P1613, DOI 10.1073/pnas.95.4.1613; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; VOLPE P, 1990, AM J PHYSIOL, V258, pC1086, DOI 10.1152/ajpcell.1990.258.6.C1086; Wojcikiewicz RJH, 1998, J BIOL CHEM, V273, P5670, DOI 10.1074/jbc.273.10.5670; YAMADA M, 1995, BIOCHEM J, V308, P83, DOI 10.1042/bj3080083; Yang J, 2002, P NATL ACAD SCI USA, V99, P7711, DOI 10.1073/pnas.102006299	37	114	116	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39397	39400		10.1074/jbc.M207059200	http://dx.doi.org/10.1074/jbc.M207059200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167631	hybrid			2022-12-27	WOS:000178662500044
J	Lee, JY; Urbatsch, IL; Senior, AE; Wilkens, S				Lee, JY; Urbatsch, IL; Senior, AE; Wilkens, S			Projection structure of P-glycoprotein by electron microscopy - Evidence for a closed conformation of the nucleotide binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE CROSS-LINKING; PICHIA-PASTORIS CELLS; ABC TRANSPORTER; MULTIDRUG TRANSPORTER; CRYSTAL-STRUCTURE; 2-DIMENSIONAL CRYSTALLIZATION; MEMBRANE-PROTEINS; ACTIVE-SITE; WALKER-A; ATPASE	The structure of P-glycoprotein (Pgp) from mouse has been studied by electron microscopy and image analysis. Two-dimensional crystals of Pgp in a lipid bilayer were generated by reconstituting pure, detergent-solubilized protein containing a C-terminal six-histidine tag using the lipid monolayer technique. The crystals belong to plane group P1 with a = b = 104 +/- 2 Angstrom and gamma = 90 +/- 4degrees. The projection structure of Pgp calculated at a resolution of 22 A shows two closely interacting protein domains that can be interpreted as the N- and C-terminal halves of the protein. The projection structure of Pgp is consistent with the recently published x-ray structure of MsbA, a lipid A flippase from Escherichia coli with high sequence homology to Pgp but only when the two MsbA subunits are rotated to bring their nucleotide binding domains together.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA; Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of California System; University of California Riverside; University of Rochester	Wilkens, S (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.		Lee, Jyh-Yeuan/ACA-2717-2022	Lee, Jyh-Yeuan/0000-0003-1799-2416	NIGMS NIH HHS [GM50156, GM58600] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058600, R01GM050156] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Dey S, 1997, P NATL ACAD SCI USA, V94, P10594, DOI 10.1073/pnas.94.20.10594; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Gaudet R, 2001, EMBO J, V20, P4964, DOI 10.1093/emboj/20.17.4964; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Gros P, 1993, Int Rev Cytol, V137C, P169; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Karpowich N, 2001, STRUCTURE, V9, P571, DOI 10.1016/S0969-2126(01)00617-7; KESSEL M, 1985, J MICROSC-OXFORD, V139, P63, DOI 10.1111/j.1365-2818.1985.tb04662.x; Lebeau L, 2001, J MOL BIOL, V308, P639, DOI 10.1006/jmbi.2001.4629; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Levy D, 1999, J STRUCT BIOL, V127, P44, DOI 10.1006/jsbi.1999.4155; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; SAXTON WO, 1982, J MICROSC-OXFORD, V127, P127, DOI 10.1111/j.1365-2818.1982.tb00405.x; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Sherman MB, 1998, ULTRAMICROSCOPY, V74, P179, DOI 10.1016/S0304-3991(98)00041-2; Stein WD, 1997, PHYSIOL REV, V77, P545, DOI 10.1152/physrev.1997.77.2.545; Tribet C, 1996, P NATL ACAD SCI USA, V93, P15047, DOI 10.1073/pnas.93.26.15047; Urbatsch IL, 2000, J BIOL CHEM, V275, P25031, DOI 10.1074/jbc.M003962200; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; Urbatsch IL, 2001, J BIOL CHEM, V276, P26980, DOI 10.1074/jbc.M010829200; Urbatsch IL, 2001, ARCH BIOCHEM BIOPHYS, V388, P171, DOI 10.1006/abbi.2001.2299; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; Yuan YR, 2001, J BIOL CHEM, V276, P32313, DOI 10.1074/jbc.M100758200; Zhou TQ, 2000, EMBO J, V19, P4838, DOI 10.1093/emboj/19.17.4838	35	80	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40125	40131		10.1074/jbc.M206871200	http://dx.doi.org/10.1074/jbc.M206871200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163504	hybrid			2022-12-27	WOS:000178662500135
J	Gotoh, M; Sato, T; Akashima, T; Iwasaki, H; Kameyama, A; Mochizuki, H; Yada, T; Inaba, N; Zhang, Y; Kikuchi, N; Kwon, YD; Togayachi, A; Kudo, T; Nishihara, S; Watanabe, H; Kimata, K; Narimatsu, H				Gotoh, M; Sato, T; Akashima, T; Iwasaki, H; Kameyama, A; Mochizuki, H; Yada, T; Inaba, N; Zhang, Y; Kikuchi, N; Kwon, YD; Togayachi, A; Kudo, T; Nishihara, S; Watanabe, H; Kimata, K; Narimatsu, H			Enzymatic synthesis of chondroitin with a novel chondroitin sulfate N-acetylgalactosaminyltransferase that transfers N-acetylgalactosamine to glucuronic acid in initiation and elongation of chondroitin sulfate synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-D-GALACTOSAMINE; BETA-D-XYLOSYLTRANSFERASE; UDP-D-XYLOSE; BETA-4-GALACTOSYLTRANSFERASE GENE FAMILY; PROTEIN LINKAGE REGION; HEPARAN-SULFATE; MOLECULAR-CLONING; TUMOR SUPPRESSORS; CDNA CLONING; BIOSYNTHESIS	We found a novel glycosyltransferase gene having a hypothetical beta1,4-galactosyltransferase motif (GenBank(TM) accession number AB081516) by a BLAST search and cloned its full-length open reading frame using the 5'-rapid amplification of cDNA ends method. The truncated form was expressed in insect cells as a soluble enzyme. It transferred N-acetylgalactosamine, not galactose, to para-nitrophenyl-p-glucuronic acid. The N-acetylgalactosamine-glucuronic acid linkage has been identified only in chondroitin sulfate; therefore, we examined its chondroitin elongation and initiation activities. N-Acetylgalactosaminyltransferase activity was observed toward chondroitin poly- and oligosaccharides, chondroitin sulfate oligosaccharides, and linkage tetrasaccharide (GlcA-Gal-Gal-Xyl-O-methoxyphenyl), and the chondroitin polysaccharide and linkage tetrasaccharide were better acceptor substrates than the others. Northern blot analysis and quantitative real-time PCR analysis revealed that its 4-kb transcripts were highly expressed in thyroid and placenta, although they were ubiquitously expressed in various tissues and cells. These results suggest that this enzyme has N-acetylgalactosaminyltransferase activity in both the elongation and initiation of chondroitin sulfate synthesis. Furthermore, we performed enzymatic synthesis of chondroitin pentasaccharide in vitro. In one tube reaction with four enzymes, B1,4-galactosyltransferase-VII, B1,3-galactosyltransferase-VI, glucuronyltransferase-I, and this enzyme, and a synthetic xylose-peptide acceptor, the structure GalNAc-GlcA-Gal-Gal-Xyl-peptide was constructed. This is the first report of a chondroitin pentasaccharide constructed with recombinant glycosyltransferases in vitro.	Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Glycogene Funct Team, Open Space Lab C2, Tsukuba, Ibaraki 3058568, Japan; Amersham Biosci KK, Shinjuku Ku, Tokyo 1690073, Japan; Seikagaku Corp, Tokyo 2070021, Japan; Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan; Japan Genome Solut Inc, Tokyo 1920031, Japan; Mitsui Knowledge Ind Co Ltd, Nakano Ku, Tokyo 1648721, Japan; New Energy & Ind Technol Dev Org, Toshima Ku, Tokyo 1706028, Japan; Soka Univ, Inst Life Sci, Tokyo 1928577, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Seikagaku Corporation; Aichi Medical University; Soka University	Narimatsu, H (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Glycogene Funct Team, Open Space Lab C2, 1-1-1 Umezono, Tsukuba, Ibaraki 3058568, Japan.		Togayachi, Akira/M-4144-2018; Sato, Takashi/M-2577-2018; Narimatsu, Hisashi/M-4757-2018; Kameyama, Akihiko/A-9641-2008	Togayachi, Akira/0000-0003-3600-9149; Sato, Takashi/0000-0002-9973-8923; Narimatsu, Hisashi/0000-0002-8402-133X; Kameyama, Akihiko/0000-0002-8229-4449; Watanabe, Hideto/0000-0001-5291-0696; Nishihara, Shoko/0000-0002-1668-2603				Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Bennett EP, 1999, FEBS LETT, V460, P226, DOI 10.1016/S0014-5793(99)01268-5; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; Gastinel LN, 2001, TRENDS GLYCOSCI GLYC, V13, P131, DOI 10.4052/tigg.13.131; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gotoh M, 2002, J BIOL CHEM, V277, P38179, DOI 10.1074/jbc.M202601200; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; GUNDLACH MW, 1985, BIOCHEM J, V226, P705, DOI 10.1042/bj2260705; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; IYAMA T, 2002, J BIOL CHEM, V277, P8841; JERONIMO SMB, 1994, BRAZ J MED BIOL RES, V27, P2253; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Kitagawa H, 2001, J BIOL CHEM, V276, P4834, DOI 10.1074/jbc.C000835200; Kuhn J, 2001, J BIOL CHEM, V276, P4940, DOI 10.1074/jbc.M005111200; Kutyavin IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/nar/28.2.655; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; NAGATA Y, 1992, J BIOL CHEM, V267, P12082; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Ramakrishnan B, 2001, J MOL BIOL, V310, P205, DOI 10.1006/jmbi.2001.4757; SAMPAIO LO, 1977, BIOCHIM BIOPHYS ACTA, V498, P123, DOI 10.1016/0304-4165(77)90093-9; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; WASSERMAN L, 1980, AM J OBSTET GYNECOL, V138, P763, DOI 10.1016/S0002-9378(16)32733-8; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156	43	56	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38189	38196		10.1074/jbc.M203619200	http://dx.doi.org/10.1074/jbc.M203619200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163485	hybrid			2022-12-27	WOS:000178529600028
J	Holmes, VF; Scandellari, F; Benjamin, KR; Cozzarelli, NR				Holmes, VF; Scandellari, F; Benjamin, KR; Cozzarelli, NR			Structure of reaction intermediates formed during Saccharomyces cerevisiae Rad51-catalyzed strand transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RECA PROTEIN; PROMOTED BRANCH MIGRATION; DUPLEX DNA-MOLECULES; YEAST RAD51 PROTEIN; ESCHERICHIA-COLI; GENETIC-RECOMBINATION; ATP HYDROLYSIS; EXCHANGE-REACTIONS; PAIRING SEQUENCES; BINDING-PROTEINS	The process by which the Saccharomyces cerevisiae strand transfer protein, Rad51, seeks out homologous sequences in vivo can be modeled by an in vitro reaction between a single-stranded DNA circle and a double-stranded linear DNA. In addition to the substrates and products, electrophoresis of reaction mixtures resolves two groups of low mobility bands. Here we show that the low mobility bands formed during strand transfer by Rad51 (or Escherichia coli RecA) represent joint molecules (JM) between the two substrates. One group, which we name JM1, is an obligatory reaction intermediate in which the complementary strand from the duplex substrate has been partially transferred to the single-stranded circle. Our assignment is based on pulse-chase and restriction enzyme digestion experiments and verified by electron microscopy. The slower moving group of bands, designated JM2, is formed by an unexpected reaction between JM1 and a second double-stranded linear substrate. Strand transfer of the second duplex initiates noncanonically from the end where the complementary strand is recessed. Thus JM2 is formed by two strand transfer reactions with the same single-stranded circular substrate but with opposite polarities. Finally, we show that the multiple sharp bands in JM1 and JM2 are the result of substrate sequences that pause strand transfer.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Cozzarelli, NR (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 401 Barker Hall,3204, Berkeley, CA 94720 USA.	neozzare@socrates.berkeley.edu	Scandellari, Francesca/ABI-6248-2020	Scandellari, Francesca/0000-0002-2242-2656; Benjamin, Kirsten/0000-0003-4267-1972				ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; CHRYSOGELOS S, 1982, P NATL ACAD SCI-BIOL, V79, P5803, DOI 10.1073/pnas.79.19.5803; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P6018, DOI 10.1073/pnas.78.10.6018; CUNNINGHAM RP, 1980, CELL, V20, P223, DOI 10.1016/0092-8674(80)90250-0; DASGUPTA C, 1982, P NATL ACAD SCI-BIOL, V79, P762, DOI 10.1073/pnas.79.3.762; HAHN TR, 1988, J BIOL CHEM, V263, P7431; HE M, 1988, BIOTECHNIQUES, V6, P728; Holmes VF, 2001, NUCLEIC ACIDS RES, V29, P5052, DOI 10.1093/nar/29.24.5052; JAIN SK, 1994, J BIOL CHEM, V269, P20653; KAHN R, 1981, P NATL ACAD SCI-BIOL, V78, P4786, DOI 10.1073/pnas.78.8.4786; KONFORTI BB, 1987, P NATL ACAD SCI USA, V84, P690, DOI 10.1073/pnas.84.3.690; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; McIlwraith MJ, 2000, J MOL BIOL, V304, P151, DOI 10.1006/jmbi.2000.4180; MENETSKI JP, 1990, P NATL ACAD SCI USA, V87, P21, DOI 10.1073/pnas.87.1.21; Namsaraev EA, 1998, P NATL ACAD SCI USA, V95, P10477, DOI 10.1073/pnas.95.18.10477; Namsaraev EA, 2000, J BIOL CHEM, V275, P3970, DOI 10.1074/jbc.275.6.3970; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; RADDING CM, 1978, ANNU REV BIOCHEM, V47, P847, DOI 10.1146/annurev.bi.47.070178.004215; REGISTER JC, 1987, J BIOL CHEM, V262, P12812; RIDDLES PW, 1985, J BIOL CHEM, V260, P165; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHIBATA T, 1981, J BIOL CHEM, V256, P7565; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; THURING RWJ, 1975, ANAL BIOCHEM, V66, P213, DOI 10.1016/0003-2697(75)90739-3; Tracy RB, 1996, GENE DEV, V10, P1890, DOI 10.1101/gad.10.15.1890; Tracy RB, 1997, GENE DEV, V11, P3423, DOI 10.1101/gad.11.24.3423; WEST SC, 1984, CELL, V37, P683, DOI 10.1016/0092-8674(84)90401-X; WEST SC, 1982, MOL GEN GENET, V186, P333, DOI 10.1007/BF00729451; WEST SC, 1981, P NATL ACAD SCI-BIOL, V78, P2100, DOI 10.1073/pnas.78.4.2100; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P2311, DOI 10.1073/pnas.74.6.2311; YAMAMOTO KR, 1970, VIROLOGY, V40, P734, DOI 10.1016/0042-6822(70)90218-7	40	4	4	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38945	38953		10.1074/jbc.M206962200	http://dx.doi.org/10.1074/jbc.M206962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12147704	hybrid			2022-12-27	WOS:000178529600118
J	Pesu, M; Aittomaki, S; Takaluoma, K; Lagerstedt, A; Silvennoinen, O				Pesu, M; Aittomaki, S; Takaluoma, K; Lagerstedt, A; Silvennoinen, O			p38 mitogen-activated protein kinase regulates interleukin-4-induced gene expression by stimulating STAT6-mediated transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ANTI-CD40 MONOCLONAL-ANTIBODY; GERMLINE EPSILON-PROMOTER; SERINE PHOSPHORYLATION; SIGNALING PATHWAY; MAP KINASE; SYNERGISTIC ACTIVATION; C/EBP-BETA; CD40; STAT6	STAT6 functions as a critical mediator of IL-4-stimulated gene activation, and the function of STAT6 is regulated by both tyrosine and serine kinase activities. Here we analyzed the role of serine phosphorylation in regulation of STAT6-mediated transcription. Optimal transcriptional response of IL-4-inducible promoters requires costimulatory signals through CD40-stimulated intracellular kinases such as p38 MAPK. We found that the p38 MAPK inhibitor SB202190 as well as the dominant negative p38 MAPK inhibited interleukin (IL)-4 regulated expression of CD23 in Ramos B cells. IL-4 stimulation did not stimulate p38 MAPK activity, but inhibition of p38 MAPK activity directly correlated with inhibition of IL-4-induced gene activation. Dissection of individual response elements on IL-4-regulated promoter showed that C/EBPbeta-mediated transcription was insensitive to SB202190 treatment in B cells whereas STAT6-mediated transcription was regulated by p38 MAPK. The IL-4-induced immediate activation events of STAT6 were not affected by p38 MAPK activity. Furthermore, phosphoamino acid analysis and phosphopeptide mapping indicated that STAT6 is not a direct substrate for p38 MAPK. Instead, p38 MAPK was found to directly regulate the activity of the transactivation domain of STAT6. These results show that, in addition to the well established proinflammatory effects, p38 MAPK also provides a costimulatory signal for IL-4-induced gene responses by directly stimulating the transcriptional activation of STAT6.	Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland; Tampere Univ Hosp, Dept Clin Microbiol, FIN-33521 Tampere, Finland; Univ Tampere, Dept Pathol, FIN-33014 Tampere, Finland	Tampere University; Tampere University; Tampere University Hospital; Tampere University	Silvennoinen, O (corresponding author), Univ Tampere, Inst Med Technol, FIN-33014 Tampere, Finland.	olli.silvennoinen@uta.fi	Pesu, Marko/L-6344-2013	Pesu, Marko/0000-0002-7541-3921				BERBERICH I, 1994, J IMMUNOL, V153, P4357; Birrell M, 2000, EUR RESPIR J, V16, P947, DOI 10.1183/09031936.00.16594700; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brady K, 2001, BIOCHEM BIOPH RES CO, V289, P276, DOI 10.1006/bbrc.2001.5968; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Carter AB, 1999, J BIOL CHEM, V274, P30858, DOI 10.1074/jbc.274.43.30858; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Craxton A, 1998, J IMMUNOL, V161, P3225; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; FARIS M, 1994, J EXP MED, V179, P1923, DOI 10.1084/jem.179.6.1923; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; Gupta S, 1999, J EXP MED, V190, P1837, DOI 10.1084/jem.190.12.1837; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; Iciek LA, 1997, J IMMUNOL, V158, P4769; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; Karras JG, 1997, J IMMUNOL, V159, P4350; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; McDonald C, 1999, J INTERF CYTOK RES, V19, P711, DOI 10.1089/107999099313550; Mikita T, 1998, J IMMUNOL, V161, P1822; Mikita T, 1996, MOL CELL BIOL, V16, P5811; Moriggl R, 1997, MOL CELL BIOL, V17, P3663, DOI 10.1128/MCB.17.7.3663; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Paterson RLK, 1996, EUR J IMMUNOL, V26, P1979, DOI 10.1002/eji.1830260902; Pesu M, 2000, BLOOD, V95, P494, DOI 10.1182/blood.V95.2.494; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Richards ML, 1997, J IMMUNOL, V158, P263; Saharinen P, 1997, BLOOD, V90, P4341; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SIEGEL JP, 1990, J IMMUNOL METHODS, V132, P287, DOI 10.1016/0022-1759(90)90040-3; Sutherland CL, 1996, J IMMUNOL, V157, P3381; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; Underwood DC, 2000, J PHARMACOL EXP THER, V293, P281; Visconti R, 2000, BLOOD, V96, P1844, DOI 10.1182/blood.V96.5.1844.h8001844_1844_1852; WARREN WD, 1995, J IMMUNOL, V155, P5637; Wick KR, 2000, MOL IMMUNOL, V37, P641, DOI 10.1016/S0161-5890(00)00088-2; Yamashita Y, 1998, BLOOD, V91, P1496, DOI 10.1182/blood.V91.5.1496.1496_1496_1507; Zauberman A, 1999, ONCOGENE, V18, P3886, DOI 10.1038/sj.onc.1202738; Zhang JJ, 1998, EMBO J, V17, P6963, DOI 10.1093/emboj/17.23.6963	47	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38254	38261		10.1074/jbc.M201427200	http://dx.doi.org/10.1074/jbc.M201427200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161424	hybrid			2022-12-27	WOS:000178529600036
J	Maekawa, M; Nishida, E; Tanoue, T				Maekawa, M; Nishida, E; Tanoue, T			Identification of the anti-proliferative protein Tob as a MAPK substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; TOB/BTG1 FAMILY; KINASE CASCADES; MEMBER; ACTIVATION; CELLS; PHOSPHORYLATION; TRANSCRIPTION; COMPONENT; COMPLEX	Mitogen-activated protein kinases (MAPKs) regulate a wide variety of cellular functions by phosphorylating their specific substrates. Here we have identified Tob as a novel substrate of MAPK Tob, a member of the Tob and B-cell translocation gene anti-proliferative protein family, is shown to negatively regulate the proliferation of osteoblasts and T cells. In this study, our two-hybrid screening has identified Tob as an ERK2-interacting protein. Biochemical analyses have then shown that ERK MAPK (ERK2) and JNK/SAPK (JNK2) bind to and phosphorylate Tob in vitro. ERK catalyzes the phosphorylation more efficiently than JNK. When the ERK pathway is activated in cells, phosphorylation of Tob is induced. An ERK-binding or -docking site locates in the N-terminal portion of Tob, and phosphorylation sites reside in the C-terminal stretch region. The docking is crucial for efficient phosphorylation. Mutant forms of Tob, in which serines are replaced by glutamic acids to mimic phosphorylation, show a much reduced ability to inhibit the cell cycle progression to S phase from G(0)/G(1) phase, as compared with wild-type Tob, indicating that ERK phosphorylation negatively regulates the anti-proliferative function of Tob.	Kyoto Univ, Dept Cell & Dev Biol, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Dept Cell & Dev Biol, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan.							Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; Badarinarayana V, 2000, GENETICS, V155, P1045; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; Chen PJ, 2000, DEV BIOL, V217, P77, DOI 10.1006/dbio.1999.9521; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Denis CL, 2001, GENETICS, V158, P627; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Gotoh I, 1999, J BIOL CHEM, V274, P11874, DOI 10.1074/jbc.274.17.11874; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Holland ND, 1997, DEV DYNAM, V210, P11, DOI 10.1002/(SICI)1097-0177(199709)210:1<11::AID-AJA2>3.0.CO;2-4; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuda S, 1996, ONCOGENE, V12, P705; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PRITCHARD CA, 1995, MOL CELL BIOL, V15, P6430; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tzachanis D, 2001, NAT IMMUNOL, V2, P1174, DOI 10.1038/ni730; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Yoshida Y, 1998, ONCOGENE, V16, P2687, DOI 10.1038/sj.onc.1201805	31	56	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37783	37787		10.1074/jbc.M204506200	http://dx.doi.org/10.1074/jbc.M204506200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151396	hybrid			2022-12-27	WOS:000178447100112
J	Wagner, S; Flood, TA; O'Reilly, P; Hume, K; Sabourin, LA				Wagner, S; Flood, TA; O'Reilly, P; Hume, K; Sabourin, LA			Association of the Ste20-like kinase (SLK) with the microtubule - Role in Rac1-mediated regulation of actin dynamics during cell adhesion and spreading	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; FOCAL ADHESIONS; STE20-RELATED KINASE; ACTIVATES RAC1; STRESS FIBERS; CYTOSKELETON; MIGRATION; BINDING; RHO; STABILIZATION	Cytoskeletal remodeling events are tightly regulated by signal transduction systems that impinge on adhesion components and modulators of cellular architecture. We have previously shown that the Ste20-like kinase (SLK) can induce apoptosis through the induction of actin disassembly and cellular retraction (Sabourin, L. A., Tamai, K., Seale, P., Wagner, J., and Rudnicki, M. A. (2000) Mol. Cell. Biol. 20, 684-696). Using immunofluorescence studies, we report that SLK is redistributed with adhesion components at large podosome-like adhesion sites in fibronectin-stimulated fibroblasts. However, in vitro kinase assays demonstrate that its activity is not modulated following fibronectin stimulation. Double immunofluorescence studies in exponentially growing or spreading fibroblasts show that SLK is associated with the microtubule network and can be coprecipitated with alpha-tubulin. Furthermore, the stimulation of adhesion site formation by microtubule-disrupting agents induces the relocalization of SLK with unpolymerized alpha-tubulin to large vinculin-containing adhesion complexes. Using microinjection studies, we show that ectopic expression of activated SLK induces the disassembly of actin stress fibers, a process that can be inhibited by dominant negative Rac1. Significantly, endogenous SLK can be colocalized with Rac1 in spreading cells on FN. Finally, the overexpression of SLK by adenoviral infection inhibits cell spreading on fibronectin. These results suggest that SLK is part of a microtubule-associated complex that is targeted to adhesion sites and implicated in the regulation of cytoskeletal dynamics.	Univ Ottawa, Dept Cellular & Mol Med, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada; Ottawa Hlth Res Inst, Program Neurosci, Ottawa, ON K1H 8M5, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Sabourin, LA (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Neurosci Res Inst, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	lsab@uottawa.ca		Flood, Trevor/0000-0002-5227-2708				Ballestrem C, 2000, MOL BIOL CELL, V11, P2999, DOI 10.1091/mbc.11.9.2999; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; Best A, 1996, J BIOL CHEM, V271, P3756; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; DANOWSKI BA, 1989, J CELL SCI, V93, P255; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Herreros L, 2000, J BIOL CHEM, V275, P26436, DOI 10.1074/jbc.M003970200; Hollenbeck P, 2001, CURR BIOL, V11, pR820, DOI 10.1016/S0960-9822(01)00494-8; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Ilic D, 1997, J CELL SCI, V110, P401; Itoh S, 1997, ARCH BIOCHEM BIOPHYS, V340, P201, DOI 10.1006/abbi.1997.9893; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Kaverina I, 2000, CURR BIOL, V10, P739, DOI 10.1016/S0960-9822(00)00544-3; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; Krylyshkina O, 2002, J CELL BIOL, V156, P349, DOI 10.1083/jcb.200105051; Lezama R, 2001, CELL MOTIL CYTOSKEL, V50, P147, DOI 10.1002/cm.10003; Liu BP, 1998, CELL ADHES COMMUN, V5, P249, DOI 10.3109/15419069809040295; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; PARSONS JT, 1994, J CELL SCI, P109; Pytowski B, 1998, ARCH BIOCHEM BIOPHYS, V359, P310, DOI 10.1006/abbi.1998.0907; Ridley AJ, 1999, BIOCHEM SOC SYMP, V65, P111; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Sieg DJ, 1999, J CELL SCI, V112, P2677; Small JV, 1999, FEBS LETT, V452, P96, DOI 10.1016/S0014-5793(99)00530-X; Small JV, 1998, BBA-MOL CELL RES, V1404, P271, DOI 10.1016/S0167-4889(98)00080-9; Small JV, 1999, CURR OPIN CELL BIOL, V11, P54, DOI 10.1016/S0955-0674(99)80007-6; VAN AL, 1997, GENE DEV, V11, P2295; Waterman-Storer CM, 1999, CURR OPIN CELL BIOL, V11, P61, DOI 10.1016/S0955-0674(99)80008-8; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Zhou XM, 2001, J BIOL CHEM, V276, P44762, DOI 10.1074/jbc.M104029200	37	52	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37685	37692		10.1074/jbc.M205899200	http://dx.doi.org/10.1074/jbc.M205899200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151406	hybrid			2022-12-27	WOS:000178447100100
J	Xia, GQ; Chen, JH; Tiwari, V; Ju, WJ; Li, JP; Malmstrom, A; Shukla, D; Liu, J				Xia, GQ; Chen, JH; Tiwari, V; Ju, WJ; Li, JP; Malmstrom, A; Shukla, D; Liu, J			Heparan sulfate 3-O-sulfotransferase isoform 5 generates both an antithrombin-binding site and an entry receptor for herpes simplex virus, type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-GLUCOSAMINYL 3-O-SULFOTRANSFERASE; HUMAN CDNAS; EXPRESSION; SULFOTRANSFERASE; DIVERSITY; DOMAIN; PROTEOGLYCANS; SYNDECAN-1; ISOZYMES; SEQUENCE	Heparan sulfate 3-O-sulfotransferase transfers sulfate to the 3-OH position of a glucosamine residue of heparan sulfate (HS) to form 3-O-sulfated HS. The 3-O-sulfated glucosamine residue contributes to two important biological functions of HS: binding to antithrombin and thereby carrying anticoagulant activity, and binding to herpes simplex viral envelope glycoprotein D to serve as an entry receptor for herpes simplex virus 1. A total of five HS 3-O-sulfotransferase isoforms were reported previously. Here we report the isolation and characterization of a novel HS 3-O-sulfotransferase isoform, designated as HS 3-O-sulfotransferase isoform 5 (3-OST-5). 3-OST-5 cDNA was isolated from a human placenta cDNA library and expressed in COS-7 cells. The disaccharide analysis of 3-OST-5-modified HS revealed that 3-OST-5 generated at least three 3-O-sulfated disaccharides as follows: IdoUA2S-AnMan3S, GlcUA-AnMan3S6S, and IdoUA2S-AnMan3S6S. Transfection of the plasmid expressing 3-OST-5 rendered wild type Chinese hamster ovary cells susceptible to the infection by herpes simplex virus 1, suggesting that 3-OST-5-modified HS serves as an entry receptor for herpes simplex virus 1. In addition, 3-OST-5-modified HS bound to herpes simplex viral envelope protein glycoprotein D. Furthermore, we found that 3-OST-5-modified HS also bound to antithrombin, suggesting that 3-OST-5 also produces anticoagulant HS. In summary, our results indicate that a new member of 3-OST family generates both anticoagulant HS and an entry receptor for herpes simplex virus 1. These results provide a new insight regarding the mechanism for the biosynthesis of biologically active HS.	Univ N Carolina, Div Med Chem & Nat Prod, Sch Pharm, Chapel Hill, NC 27599 USA; Lund Univ, Biomed Ctr C13, S-22184 Lund, Sweden; Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA; Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA; Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Uppsala Univ, Dept Med Biochem & Microbiol, S-75123 Uppsala, Sweden	University of North Carolina; University of North Carolina Chapel Hill; Lund University; University of North Carolina; University of North Carolina Chapel Hill; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Uppsala University	Liu, J (corresponding author), Univ N Carolina, Div Med Chem & Nat Prod, Sch Pharm, Rm 309,Beard Hall,CB7360, Chapel Hill, NC 27599 USA.	jian_liu@unc.edu	Xia, Guoqing/C-2365-2015	Xia, Guoqing/0000-0003-4492-9156; Malmstrom, Anders/0000-0002-6691-146X; Shukla, Deepak/0000-0002-3039-6953	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050050, K22AI053836] Funding Source: NIH RePORTER; NIAID NIH HHS [AI50050-01, AI053836-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; Akkaraju GR, 1999, J GENE MED, V1, P280, DOI 10.1002/(SICI)1521-2254(199907/08)1:4<280::AID-JGM45>3.0.CO;2-L; Alexander CM, 2000, NAT GENET, V25, P329, DOI 10.1038/77108; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BJORNSSON S, 1993, ANAL BIOCHEM, V210, P282, DOI 10.1006/abio.1993.1197; Carfi A, 2001, MOL CELL, V8, P169, DOI 10.1016/S1097-2765(01)00298-2; Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Grobe K, 2002, J BIOL CHEM, V277, P30699, DOI 10.1074/jbc.M111904200; Habuchi H, 2000, J BIOL CHEM, V275, P2859, DOI 10.1074/jbc.275.4.2859; Hernaiz M, 2000, BIOCHEM BIOPH RES CO, V276, P292, DOI 10.1006/bbrc.2000.3453; Jenniskens GJ, 2000, J NEUROSCI, V20, P4099; Krummenacher C, 1999, J VIROL, V73, P8127, DOI 10.1128/JVI.73.10.8127-8137.1999; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; Liu J, 1996, J BIOL CHEM, V271, P27072, DOI 10.1074/jbc.271.43.27072; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Liu J, 2002, J BIOL CHEM, V277, P33456, DOI 10.1074/jbc.M202034200; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; Liu JA, 1999, J BIOL CHEM, V274, P5185, DOI 10.1074/jbc.274.8.5185; Liu Jian, 2002, P475; McKeehan WL, 1999, J BIOL CHEM, V274, P21511, DOI 10.1074/jbc.274.31.21511; Negishi M, 2001, ARCH BIOCHEM BIOPHYS, V390, P149, DOI 10.1006/abbi.2001.2368; Nicola AV, 1996, J VIROL, V70, P3815, DOI 10.1128/JVI.70.6.3815-3822.1996; Reizes O, 2001, CELL, V106, P105, DOI 10.1016/S0092-8674(01)00415-9; Rosenberg RD, 1997, J CLIN INVEST, V99, P2062, DOI 10.1172/JCI119377; SHIEH MT, 1992, J CELL BIOL, V116, P1273, DOI 10.1083/jcb.116.5.1273; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; Shworak NW, 1997, J BIOL CHEM, V272, P28008, DOI 10.1074/jbc.272.44.28008; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; SHWORAK NW, 1994, J BIOL CHEM, V269, P24941; Wang Y, 2000, AM J PHYSIOL-CELL PH, V278, pC619, DOI 10.1152/ajpcell.2000.278.3.C619; Willis SH, 1998, J VIROL, V72, P5937, DOI 10.1128/JVI.72.7.5937-5947.1998; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; Yabe T, 2001, BIOCHEM J, V359, P235, DOI 10.1042/0264-6021:3590235; Ye S, 2001, BIOCHEMISTRY-US, V40, P14429, DOI 10.1021/bi011000u; Zhang LJ, 2001, J BIOL CHEM, V276, P42311, DOI 10.1074/jbc.M101441200; Zhang LJ, 1999, J BIOL CHEM, V274, P5681, DOI 10.1074/jbc.274.9.5681	40	140	146	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37912	37919		10.1074/jbc.M204209200	http://dx.doi.org/10.1074/jbc.M204209200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138164	Green Published, hybrid			2022-12-27	WOS:000178447100128
J	Deming, PB; Flores, KG; Downes, CS; Paules, RS; Kaufmann, WK				Deming, PB; Flores, KG; Downes, CS; Paules, RS; Kaufmann, WK			ATR enforces the topoisomerase II-dependent G(2) checkpoint through inhibition of Plk1 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLO-LIKE KINASE; CELL-CYCLE CHECKPOINTS; DNA-DAMAGE CHECKPOINT; NUCLEAR EXPORT; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; PROTEIN-KINASE; PHOSPHORYLATION; B1; LOCALIZATION	An ATR-dependent G(2) checkpoint responds to inhibition of topoisomerase 11 and delays entry into mitosis by sustaining nuclear exclusion of cyclin B1-Cdk1 complexes. Here we report that induction of this checkpoint with ICRF-193, a topoisomerase H catalytic inhibitor that does not cause DNA damage, was associated with an ATR-dependent inhibition of polo-like kinase 1 (Plk1) kinase activity and a decrease in cyclin B1 phosphorylation. Expression of constitutively active Plk1 but not wild type Plk1 reversed ICRF-193-induced mitotic delay in HeLa cells, suggesting that Plk1 kinase activity is important for the checkpoint response to ICRF-193. G(2)/M synchronized normal human fibroblasts, when treated with ICRF-193, showed a decrease in cyclin B1 phosphorylation and Plk1 kinase activity despite high cyclin B1-Cdk1 kinase activity. G(2) fibroblasts that were treated with caffeine to override the checkpoint response to ICRF-193 displayed a high incidence of chromosomal aberrations. Taken together, these results suggest that ATR-dependent inhibition of Plk1 kinase activity may be one mechanism to regulate cyclin B1 phosphorylation and sustain nuclear exclusion during the G(2) checkpoint response to topoisomerase 11 inhibition. Moreover, the results demonstrate an important role for the topoisomerase II-dependent G(2) checkpoint in the preservation of human genomic stability.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Environm Hlth & Susceptibil, Chapel Hill, NC 27599 USA; NIEHS, Growth Control & Canc Grp, NIH, Res Triangle Pk, NC 27709 USA; Univ Ulster, Sch Biomed Sci, Coleraine BT52 1SA, Londonderry, North Ireland	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Ulster University	Kaufmann, WK (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.			Deming, Paula/0000-0003-3278-1705; Paules, Richard S/0000-0001-9106-7486	NCI NIH HHS [R01 CA081343, CA42765, P30-CA16086] Funding Source: Medline; NIEHS NIH HHS [P30-ES10126, T32-ES07017] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016086, P01CA042765, R01CA081343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES021157, T32ES007017, P30ES010126] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abrieu A, 1998, J CELL SCI, V111, P1751; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; Borgne A, 1999, J BIOL CHEM, V274, P11977, DOI 10.1074/jbc.274.17.11977; Brown EJ, 2000, GENE DEV, V14, P397; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Deming PB, 2001, P NATL ACAD SCI USA, V98, P12044, DOI 10.1073/pnas.221430898; DOWNES CS, 1994, NATURE, V372, P467, DOI 10.1038/372467a0; Ellinger-Ziegelbauer H, 2000, GENES CELLS, V5, P491, DOI 10.1046/j.1365-2443.2000.00337.x; Gimenez-Abian JF, 2000, CHROMOSOMA, V109, P235, DOI 10.1007/s004120000065; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; Jensen LH, 2000, J BIOL CHEM, V275, P2137, DOI 10.1074/jbc.275.3.2137; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Kaufmann WK, 1996, FASEB J, V10, P238, DOI 10.1096/fasebj.10.2.8641557; KAUFMANN WK, 1994, MUTAT RES, V314, P67, DOI 10.1016/0921-8777(94)90062-0; Kaufmann WK, 1997, CELL GROWTH DIFFER, V8, P1105; Kelm O, 2002, J BIOL CHEM, V277, P25247, DOI 10.1074/jbc.M202855200; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; Liu QH, 2000, GENE DEV, V14, P1448; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; PAULES RS, 1995, CANCER RES, V55, P1763; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; ROCA J, 1994, P NATL ACAD SCI USA, V91, P1781, DOI 10.1073/pnas.91.5.1781; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Takaha N, 2002, CANCER RES, V62, P647; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; WOOD ER, 1990, J CELL BIOL, V111, P2839, DOI 10.1083/jcb.111.6.2839; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yang J, 2001, J BIOL CHEM, V276, P3604, DOI 10.1074/jbc.M008151200; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001	46	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36832	36838		10.1074/jbc.M206109200	http://dx.doi.org/10.1074/jbc.M206109200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12147700	Green Published, hybrid			2022-12-27	WOS:000178275100135
J	Eklund, EA; Goldenberg, I; Lu, YF; Andrejic, J; Kakar, R				Eklund, EA; Goldenberg, I; Lu, YF; Andrejic, J; Kakar, R			SHP1 protein-tyrosine phosphatase regulates HoxA10 DNA binding and transcriptional repression activity in undifferentiated myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTH-EATEN MICE; CHRONIC GRANULOMATOUS-DISEASE; HEMATOPOIETIC-CELLS; GP91(PHOX) EXPRESSION; HOMEOBOX GENE; PU.1; MACROPHAGE; P67(PHOX); LEUKEMIA; DIFFERENTIATION	The homeodomain protein HoxA10 interacts with negative cis elements to repress gene transcription in undifferentiated myeloid cells. The CYBB and NCF2 genes, which encode the gp91(PHOX) and p67(PHOX) proteins, are two such HoxA10 target genes. During interferon gamma-induced myeloid differentiation, tyrosine phosphorylation decreases HoxA10 DNA binding affinity and transcriptional repression. Therefore, decreased HoxA10 repression contributes to increased CYBB and NCF2 transcription in differentiating myeloid cells. The current studies investigate modulation of HoxA10 repression activity during myelopoiesis. We determine that phosphorylation of tyrosine residues in the conserved homeodomain decreases HoxA10-DNA binding. We also determine that interaction of the homeodomain phosphotyrosine residues with an adjacent domain in the HoxA10 protein is necessary for decreased DNA binding affinity. Since SHP1 protein-tyrosine phosphatase antagonizes myeloid differentiation and decreases CYBB and NCF2 transcription, we investigated the influence of SHP1-protein-tyrosine phosphatase (PTP) on HoxA10 tyrosine phosphorylation. We find that SHP1-PTP activity increases HoxA10 target gene repression in undifferentiated myeloid cells. Consistent with this, SHP1-PTP interacts with HoxA10 and decreases homeodomain-tyrosine phosphorylation. These investigations suggest that SHP1-PTP activity, in undifferentiated myeloid cells, influences HoxA10 repression of myeloid-specific genes. Therefore, increased HoxA10 repression of myeloid gene transcription is a molecular mechanism for SHP1 inhibition of myeloid differentiation.	Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Chicago Lakeside Vet Adm Hosp, Chicago, IL 60611 USA; Birmingham Vet Adm Hosp, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA	Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of Alabama System; University of Alabama Birmingham	Eklund, EA (corresponding author), Northwestern Univ, Sch Med, Dept Med, Olson Pavil,Rm 8527,710 N Fairbanks Ct, Chicago, IL 60611 USA.				NCI NIH HHS [CA95266] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095266] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Calvo KR, 2000, MOL CELL BIOL, V20, P3274, DOI 10.1128/MCB.20.9.3274-3285.2000; DAVID M, 1995, MOL CELL BIOL, V15, P7050; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong Q, 1999, J IMMUNOL, V162, P3220; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Eklund EA, 2000, J BIOL CHEM, V275, P20117, DOI 10.1074/jbc.M907915199; Gabriele L, 1999, J EXP MED, V190, P411, DOI 10.1084/jem.190.3.411; Kautz B, 2001, J BIOL CHEM, V276, P37868; KENNEY RT, 1993, BLOOD, V82, P3739; Kim CH, 1999, J EXP MED, V190, P681, DOI 10.1084/jem.190.5.681; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LARRICK JW, 1980, J IMMUNOL, V125, P6; LAWRENCE HJ, 1995, EXP HEMATOL, V23, P1160; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; LOWNEY P, 1991, NUCLEIC ACIDS RES, V19, P3443, DOI 10.1093/nar/19.12.3443; MCCOY KL, 1982, J IMMUNOL, V128, P1797; MCCOY KL, 1983, AM J PATHOL, V112, P18; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sambrook H., 1989, MOL CLONING LAB MANU; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tapley P, 1997, EXP HEMATOL, V25, P122; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Thorsteinsdottir U, 1997, MOL CELL BIOL, V17, P495, DOI 10.1128/MCB.17.1.495	30	43	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36878	36888		10.1074/jbc.M203917200	http://dx.doi.org/10.1074/jbc.M203917200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145285	hybrid			2022-12-27	WOS:000178275100141
J	Siow, NL; Choi, RCY; Cheng, AWM; Jiang, JXS; Wan, DCC; Zhu, SQ; Tsim, KWK				Siow, NL; Choi, RCY; Cheng, AWM; Jiang, JXS; Wan, DCC; Zhu, SQ; Tsim, KWK			A cyclic AMP-dependent pathway regulates the expression of acetylcholinesterase during myogenic differentiation of C2C12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-RELATED PEPTIDE; CULTURED CHICK MYOTUBES; PROTEIN-KINASE-C; NEUROMUSCULAR-JUNCTION; MESSENGER-RNA; MOUSE ACETYLCHOLINESTERASE; TRANSCRIPTIONAL REGULATION; MUSCLE DIFFERENTIATION; PROMOTER ELEMENTS; CAMP	The expression of acetylcholinesterase (AChE) is markedly increased during myogenic differentiation of C2C12 myoblasts to myotubes; the expression is mediated by intrinsic factor(s) during muscle differentiation. In order to analyze the molecular mechanisms regulating AChE expression during myogenic differentiation, a similar to2.2-kb human AChE promoter tagged with a luciferase reporter gene, namely pAChE-Luc, was stably transfected into C2C12 cells. The profile of promoter-driven luciferase activity during myogenic differentiation of C2C12 myotubes was found to be similar to that of endogenous expression of AChE catalytic subunit. The increase of AChE expression was reciprocally regulated by a cAMP-dependent signaling pathway. The level of intracellular cAMP, the activity of cAMP-dependent protein kinase, the phosphorylation of cAMP-responsive element binding protein and the activity of cAMP-responsive element (CRE) were down-regulated during the myotube formation. Mutating the CRE site of human AChE promoter altered the original myogenic profile of the promoter activity and its suppressive response to cAMP. In addition, the suppressive effect of the CRE site is dependent on its location on the promoter. Therefore, our results suggest that a cAMP-dependent signaling pathway serves as a suppressive element in regulating the expression of AChE during early myogenesis.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Kowloon, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; Chinese University of Hong Kong	Tsim, KWK (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay Rd, Kowloon, Hong Kong, Peoples R China.		Wan, David C/H-3335-2014	Tsim, Karl/0000-0003-4808-1674				ANGLISTER L, 1994, NEURON, V12, P783, DOI 10.1016/0896-6273(94)90331-X; Angus LM, 2001, J BIOL CHEM, V276, P17603, DOI 10.1074/jbc.M100916200; Atanasova E, 1999, J BIOL CHEM, V274, P21078, DOI 10.1074/jbc.274.30.21078; BENAZIZALOYA R, 1993, P NATL ACAD SCI USA, V90, P2471, DOI 10.1073/pnas.90.6.2471; Boudreau-Lariviere C, 1999, FEBS LETT, V444, P22, DOI 10.1016/S0014-5793(99)00015-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chan RYY, 1999, P NATL ACAD SCI USA, V96, P4627, DOI 10.1073/pnas.96.8.4627; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Choi RCY, 2000, NEUROREPORT, V11, P801, DOI 10.1097/00001756-200003200-00029; Choi RCY, 2001, J NEUROSCI, V21, P9224, DOI 10.1523/JNEUROSCI.21-23-09224.2001; Choi RCY, 1998, J NEUROCHEM, V71, P152; Choi RCY, 2001, MOL CELL NEUROSCI, V17, P732, DOI 10.1006/mcne.2001.0968; Choi RCY, 1996, NEUROSCI LETT, V217, P165, DOI 10.1016/0304-3940(96)13102-5; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; EKSTROM TJ, 1993, DNA CELL BIOL, V12, P63, DOI 10.1089/dna.1993.12.63; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FONTAINE B, 1987, J CELL BIOL, V105, P1337, DOI 10.1083/jcb.105.3.1337; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; FUENTES ME, 1993, NEURON, V10, P679, DOI 10.1016/0896-6273(93)90169-R; Garcia MA, 1999, FEBS LETT, V444, P27, DOI 10.1016/S0014-5793(99)00021-6; GETMAN DK, 1995, J BIOL CHEM, V270, P23511, DOI 10.1074/jbc.270.40.23511; Grisaru D, 1999, EUR J BIOCHEM, V264, P672, DOI 10.1046/j.1432-1327.1999.00693.x; HU JS, 1988, J BIOL CHEM, V263, P19670; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; Lagord C, 1996, CELL BIOL TOXICOL, V12, P177, DOI 10.1007/BF00148171; LEGAY C, 1995, EUR J NEUROSCI, V7, P1803, DOI 10.1111/j.1460-9568.1995.tb00699.x; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Luo ZD, 1998, J BIOL CHEM, V273, P28486, DOI 10.1074/jbc.273.43.28486; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MCMAHAN UJ, 1978, NATURE, V271, P172, DOI 10.1038/271172a0; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; Peng HB, 1999, J CELL BIOL, V145, P911, DOI 10.1083/jcb.145.4.911; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; Rossi SG, 1996, J BIOL CHEM, V271, P1979, DOI 10.1074/jbc.271.4.1979; SALMINEN A, 1991, J CELL BIOL, V115, P905, DOI 10.1083/jcb.115.4.905; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; TOUTANT JP, 1988, REPROD NUTR DEV, V28, P693, DOI 10.1051/rnd:19880503; Tsim KWK, 1997, J NEUROCHEM, V68, P479; Tsim KWK, 2002, NEUROSIGNALS, V11, P58, DOI 10.1159/000057322; Wan DCC, 2000, NEUROSCI LETT, V288, P81, DOI 10.1016/S0304-3940(00)01200-3; WINTER B, 1993, J BIOL CHEM, V268, P9869; Xu Q, 2000, J BIOL CHEM, V275, P36750, DOI 10.1074/jbc.M005030200; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	43	64	64	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36129	36136		10.1074/jbc.M206498200	http://dx.doi.org/10.1074/jbc.M206498200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12140295	hybrid			2022-12-27	WOS:000178275100047
J	Folli, C; Calderone, V; Ramazzina, I; Zanotti, G; Berni, R				Folli, C; Calderone, V; Ramazzina, I; Zanotti, G; Berni, R			Ligand binding and structural analysis of a human putative cellular retinol-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; FATTY-ACID; APO; PURIFICATION; FAMILY; HOLO; ESTERIFICATION; IDENTIFICATION; MICROSOMES; ALIGNMENT	Three cellular retinol-binding protein (CRBP) types (CRBP I, II, and III) with distinct tissue distributions and retinoid binding properties have been structurally characterized thus far. A human binding protein, whose mRNA is expressed primarily in kidney, heart, and transverse colon, is shown here to be a CRBP family member (human CRBP IV), according to amino acid sequence, phylogenetic analysis, gene structure organization, and x-ray structural analysis. Retinol binding to CRBP IV leads to an absorption spectrum distinct from a typical holo-CRBP spectrum and is characterized by an affinity (K-d = similar to200 nm) lower than those for CRBP I, II, and III, as established in direct and competitive binding assays. As revealed by mutagenic analysis, the presence in CRBP IV of His(108) in place of Gln(108) is not responsible for the unusual holo-CRBP IV spectrum. The 2-Angstrom resolution crystal structure of human apo-CRBP IV is very similar to those of other structurally characterized CRBPs. The side chain of Tyr(60) is present within the binding cavity of the apoprotein and might affect the interaction with the retinol molecule. These results indicate that human CRBP IV belongs to a clearly distinct CRBP subfamily and suggest a relatively different mode of retinol binding for this binding protein.	Univ Padua, Dept Organ Chem, I-35131 Padua, Italy; Univ Parma, Dept Biochem & Mol Biol, I-43100 Parma, Italy; Italian Natl Res Council, Biopolymer Res Ctr, I-35131 Padua, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy	University of Padua; University of Parma; Consiglio Nazionale delle Ricerche (CNR); Veneto Institute Molecular Medicine	Zanotti, G (corresponding author), Univ Padua, Dept Organ Chem, Via Marzolo 1, I-35131 Padua, Italy.	giuseppe.zanotti@unipd.it; rodolfo.berni@unipr.it	Calderone, Vito/A-2917-2014	Calderone, Vito/0000-0002-7963-6241; Berni, Rodolfo/0000-0002-1839-0479; Zanotti, Giuseppe/0000-0002-0945-6501; Ramazzina, Ileana/0000-0003-1009-2917				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; Bernlohr DA, 1997, ANNU REV NUTR, V17, P277, DOI 10.1146/annurev.nutr.17.1.277; BOERMAN MHEM, 1991, J BIOL CHEM, V266, P22273; Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calderone V, 2002, J MOL BIOL, V321, P527, DOI 10.1016/S0022-2836(02)00628-9; Conforti L, 2000, P NATL ACAD SCI USA, V97, P11377, DOI 10.1073/pnas.97.21.11377; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; Folli C, 2001, P NATL ACAD SCI USA, V98, P3710, DOI 10.1073/pnas.061455898; Franzoni L, 2002, J BIOL CHEM, V277, P21983, DOI 10.1074/jbc.M201994200; Ghyselinck NB, 1999, EMBO J, V18, P4903, DOI 10.1093/emboj/18.18.4903; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HERR FM, 1992, BIOCHEMISTRY-US, V31, P6748, DOI 10.1021/bi00144a014; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; Li E, 1996, ANNU REV NUTR, V16, P205, DOI 10.1146/annurev.nu.16.070196.001225; LI E, 1991, J BIOL CHEM, V266, P3622; Lu JY, 1999, J MOL BIOL, V286, P1179, DOI 10.1006/jmbi.1999.2544; Lu JY, 2000, J MOL BIOL, V300, P619, DOI 10.1006/jmbi.2000.3883; MALPELI G, 1995, EUR J BIOCHEM, V229, P486, DOI 10.1111/j.1432-1033.1995.0486k.x; Malpeli G, 1998, METH MOL B, V89, P111; Mansfield SG, 1998, P NATL ACAD SCI USA, V95, P6825, DOI 10.1073/pnas.95.12.6825; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Newcomer ME, 1998, SUB CELL BIOCHEM, V30, P53; Ong David E., 1994, P283; ONG DE, 1984, J BIOL CHEM, V259, P1476; ONG DE, 1978, J BIOL CHEM, V253, P828; ONG DE, 1988, J BIOL CHEM, V263, P5789; OTTONELLO S, 1993, J BIOL CHEM, V268, P27133; OTTONELLO S, 1987, J BIOL CHEM, V262, P3975; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Sundaram M, 1998, J BIOL CHEM, V273, P3336, DOI 10.1074/jbc.273.6.3336; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TROEN G, 1994, BIOCHEM J, V300, P793, DOI 10.1042/bj3000793; Vogel S, 2001, J BIOL CHEM, V276, P1353, DOI 10.1074/jbc.M005118200; Werten PJL, 2000, P NATL ACAD SCI USA, V97, P3282, DOI 10.1073/pnas.050500597; WINTER NS, 1993, J MOL BIOL, V230, P1247, DOI 10.1006/jmbi.1993.1239; YOST RW, 1988, J BIOL CHEM, V263, P18693	42	53	58	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41970	41977		10.1074/jbc.M207124200	http://dx.doi.org/10.1074/jbc.M207124200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12177003	hybrid			2022-12-27	WOS:000178985300086
J	Becker, A; Kabsch, W				Becker, A; Kabsch, W			X-ray structure of pyruvate formate-lyase in complex with pyruvate and CoA - How the enzyme uses the Cys-418 thiyl radical for pyruvate cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOTIDE REDUCTASE; ESCHERICHIA-COLI; DIFFRACTION DATA; MOLSCRIPT; ALIGNMENT; MECHANISM; ROTATION	The glycyl radical enzyme pyruvate formate-lyase (PFL) synthesizes acetyl-CoA and formate from pyruvate and CoA. With the crystal structure of the non-radical form of PFL in complex with its two substrates, we have trapped the moment prior to pyruvate cleavage. The structure reveals how the active site aligns the scissile bond of pyruvate for radical attack, prevents non-radical side reactions of the pyruvate, and confines radical migration. The structure shows CoA in a syn conformation awaiting pyruvate cleavage. By changing to an anti conformation, without affecting the adenine binding mode of CoA, the thiol of CoA could pick up the acetyl group resulting from pyruvate cleavage.	Max Planck Inst Med Res, Biophys Abt, D-69120 Heidelberg, Germany	Max Planck Society	Becker, A (corresponding author), Max Planck Inst Med Res, Biophys Abt, Jahnstr 29, D-69120 Heidelberg, Germany.	abecker@mpimf-heidelberg.mpg.de						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Becker A, 1999, NAT STRUCT BIOL, V6, P969; BECKER A, 1995, THESIS U HEIDELBERG; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Eklund H, 1999, STRUCT FOLD DES, V7, pR257, DOI 10.1016/S0969-2126(00)80019-2; Engel C, 1996, CURR OPIN STRUC BIOL, V6, P790, DOI 10.1016/S0959-440X(96)80009-1; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FREY M, 1994, J BIOL CHEM, V269, P12432; Himo F, 1998, J AM CHEM SOC, V120, P11449, DOI 10.1021/ja9820947; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KNAPPE J, 1974, EUR J BIOCHEM, V50, P253, DOI 10.1111/j.1432-1033.1974.tb03894.x; KNAPPE J, 1984, P NATL ACAD SCI-BIOL, V81, P1332, DOI 10.1073/pnas.81.5.1332; KNAPPE J, 1995, METHOD ENZYMOL, V258, P343; KNAPPE J, 1993, BIOCHEM SOC T, V21, P731, DOI 10.1042/bst0210731; Knappe J, 2001, ADV PROTEIN CHEM, V58, P277; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leppanen VM, 1999, STRUCT FOLD DES, V7, P733, DOI 10.1016/S0969-2126(99)80098-7; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; REICHARD P, 1983, SCIENCE, V221, P514, DOI 10.1126/science.6306767; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; Sun XY, 1996, J BIOL CHEM, V271, P6827, DOI 10.1074/jbc.271.12.6827; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van Aalten DMF, 2001, EMBO J, V20, P2041, DOI 10.1093/emboj/20.8.2041; WAGNER AFV, 1992, P NATL ACAD SCI USA, V89, P996, DOI 10.1073/pnas.89.3.996	30	75	77	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40036	40042		10.1074/jbc.M205821200	http://dx.doi.org/10.1074/jbc.M205821200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163496	hybrid			2022-12-27	WOS:000178662500124
J	Bernaudin, M; Tang, Y; Reilly, M; Petit, E; Sharp, FR				Bernaudin, M; Tang, Y; Reilly, M; Petit, E; Sharp, FR			Brain genomic response following hypoxia and re-oxygenation in the neonatal rat - Identification of genes that might contribute to hypoxia-induced ischemic tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; FOCAL CEREBRAL-ISCHEMIA; MICROARRAY ANALYSIS; INDUCIBLE FACTOR-1; GLUCOSE-TRANSPORT; FACTOR-I; EXPRESSION; CELLS; TRANSCRIPTION; ACTIVATION	Hypoxic preconditioning (8% O-2, 3 h) produces tolerance 24 h after hypoxic-ischemic brain injury in neonatal rats. To better understand the ischemic tolerance mechanisms induced by hypoxia, we used oligonucleotide microarrays to examine genomic responses in neonatal rat brain following 3 h of hypoxia (8% O-2) and either 0, 6, 18, or 24 h of re-oxygenation. The results showed that hypoxia-inducible factor (HIF)-1- but not HIF-2-mediated gene expression may be involved in brain hypoxia-induced tolerance. Among the genes regulated by hypoxia, 12 genes were confirmed by real time reverse transcriptase-PCR as follows: VEGF, EPO, GLUT-1, adrenomedullin, propyl 4-hydroxylase alpha, MT-1, MKP-1, CELF, 12-lipoxygenase, t-PA, CAR-1, and an expressed sequence tag. Some genes, for example GLUT-1, MT-1, CELF, MKP-1, and t-PA did not show any hypoxic regulation in either astrocytes or neurons, suggesting that other cells are responsible for the up-regulation of these genes in the hypoxic brain. These genes were expressed in normal and hypoxic brain, heart, kidney, liver, and lung, with adrenomedullin, MT-1, and VEGF being prominently induced in brain by hypoxia. These results suggest that a number of endogenous molecular mechanisms may explain how hypoxic preconditioning protects against subsequent ischemia, and may provide novel therapeutic targets for treatment of cerebral ischemia.	Univ Caen, UMR CNRS 6551, F-14074 Caen, France; Univ Cincinnati, Dept Neurol, Cincinnati, OH 45267 USA; Univ Cincinnati, Neurosci Program, Cincinnati, OH 45267 USA	Universite de Caen Normandie; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Bernaudin, M (corresponding author), Univ Caen, UMR CNRS 6551, Bd Henri Becquerel,BP5229,IFR 47, F-14074 Caen, France.	m_bernaudin@hotmail.com	PETIT, Edwige/C-1896-2008; Bernaudin, Myriam/B-7663-2008	Bernaudin, Myriam/0000-0003-0778-3397	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028167, R01NS038743, R01NS042774, R01NS043252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG019561] Funding Source: NIH RePORTER; NIA NIH HHS [AG19561] Funding Source: Medline; NINDS NIH HHS [NS28167, NS38743, NS42774, NS43252] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Beitner-Johnson D, 2001, PARKINSONISM RELAT D, V7, P273, DOI 10.1016/S1353-8020(00)00070-5; Bergeron M, 2000, ANN NEUROL, V48, P285, DOI 10.1002/1531-8249(200009)48:3<285::AID-ANA2>3.0.CO;2-8; Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.3.CO;2-8; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bruckner BA, 1999, METABOLISM, V48, P422, DOI 10.1016/S0026-0495(99)90098-7; Brusselmans K, 2001, J BIOL CHEM, V276, P39192, DOI 10.1074/jbc.C100428200; Caivano M, 2001, J BIOL CHEM, V276, P48693, DOI 10.1074/jbc.M108282200; Campagne MV, 1999, P NATL ACAD SCI USA, V96, P12870; Cau E, 2000, DEVELOPMENT, V127, P2323; Chen W, 1999, AM J PHYSIOL-HEART C, V276, pH2094, DOI 10.1152/ajpheart.1999.276.6.H2094; CHOPP M, 1989, NEUROLOGY, V39, P1396, DOI 10.1212/WNL.39.10.1396; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; Colangelo AM, 1998, P NATL ACAD SCI USA, V95, P10920, DOI 10.1073/pnas.95.18.10920; Cormier-Regard S, 1998, J BIOL CHEM, V273, P17787, DOI 10.1074/jbc.273.28.17787; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Ehleben W, 1997, KIDNEY INT, V51, P483, DOI 10.1038/ki.1997.67; Emerson MR, 2000, CELL MOL BIOL, V46, P619; Ford-Perriss M, 2001, CLIN EXP PHARMACOL P, V28, P493, DOI 10.1046/j.1440-1681.2001.03477.x; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Fukamachi S, 2001, DEV BRAIN RES, V132, P131, DOI 10.1016/S0165-3806(01)00303-0; Gabel SA, 2001, AM J PHYSIOL-HEART C, V280, pH1963, DOI 10.1152/ajpheart.2001.280.5.H1963; GIDDAY JM, 1994, NEUROSCI LETT, V168, P221, DOI 10.1016/0304-3940(94)90455-3; Gidday JM, 1999, J CEREBR BLOOD F MET, V19, P331, DOI 10.1097/00004647-199903000-00011; Giralt M, 2002, EXP NEUROL, V173, P114, DOI 10.1006/exnr.2001.7772; Gracey AY, 2001, P NATL ACAD SCI USA, V98, P1993, DOI 10.1073/pnas.98.4.1993; Gu ZL, 2001, NEUROREPORT, V12, P3487, DOI 10.1097/00001756-200111160-00023; Guo YL, 1998, J BIOL CHEM, V273, P10362, DOI 10.1074/jbc.273.17.10362; HAMANN GF, 1995, STROKE, V26, P2120, DOI 10.1161/01.STR.26.11.2120; Hayashi T, 1998, J CEREBR BLOOD F MET, V18, P887, DOI 10.1097/00004647-199808000-00009; HEURTEAUX C, 1995, P NATL ACAD SCI USA, V92, P4666, DOI 10.1073/pnas.92.10.4666; Hsu L, 2001, J NEUROSCI RES, V64, P193, DOI 10.1002/jnr.1065; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Jones NM, 2001, J CEREBR BLOOD F MET, V21, P1105, DOI 10.1097/00004647-200109000-00008; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; Kobayashi S, 2001, J NEUROCHEM, V76, P1935, DOI 10.1046/j.1471-4159.2001.00214.x; KOBAYASHI S, 1995, J CEREBR BLOOD F MET, V15, P721, DOI 10.1038/jcbfm.1995.92; Lal A, 2001, JNCI-J NATL CANCER I, V93, P1337, DOI 10.1093/jnci/93.17.1337; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; MASUDA S, 1994, J BIOL CHEM, V269, P19488; Miller BA, 2001, NEUROREPORT, V12, P1663, DOI 10.1097/00001756-200106130-00030; Murphy BJ, 1999, CANCER RES, V59, P1315; Nagayama M, 1999, J CEREBR BLOOD F MET, V19, P1213, DOI 10.1097/00004647-199911000-00005; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Nishio S, 2000, J NEUROSURG, V93, P845, DOI 10.3171/jns.2000.93.5.0845; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Ota A, 1998, AM J OBSTET GYNECOL, V179, P1075, DOI 10.1016/S0002-9378(98)70218-2; Prass K, 2000, BRAIN RES, V871, P146, DOI 10.1016/S0006-8993(00)02264-2; Rumora L, 2001, NEUROCHEM INT, V39, P25, DOI 10.1016/S0197-0186(01)00004-3; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Scandurro AB, 2001, INT J ONCOL, V19, P129; Seta KA, 2001, J BIOL CHEM, V276, P44405, DOI 10.1074/jbc.M103346200; Shinmura K, 2000, P NATL ACAD SCI USA, V97, P10197, DOI 10.1073/pnas.97.18.10197; Sinor AD, 1998, BRAIN RES, V812, P289, DOI 10.1016/S0006-8993(98)00976-7; Takagi H, 1998, DIABETES, V47, P1480, DOI 10.2337/diabetes.47.9.1480; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vannucci RC, 1998, J NEUROCHEM, V71, P1215; VANNUCCI SJ, 1994, MOL CELL BIOCHEM, V140, P177, DOI 10.1007/BF00926756; Vivien D, 2000, J CEREBR BLOOD F MET, V20, P755, DOI 10.1097/00004647-200005000-00001; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Watanabe K, 2001, ACTA NEUROCHIR, V143, P1157, DOI 10.1007/s007010100007; Wiegand F, 1999, J CEREBR BLOOD F MET, V19, P1229, DOI 10.1097/00004647-199911000-00007; Wiesener MS, 1998, BLOOD, V92, P2260, DOI 10.1182/blood.V92.7.2260.2260_2260_2268; Yan SF, 2000, J APPL PHYSIOL, V88, P2303, DOI 10.1152/jappl.2000.88.6.2303; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030	69	239	263	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39728	39738		10.1074/jbc.M204619200	http://dx.doi.org/10.1074/jbc.M204619200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12145288	hybrid			2022-12-27	WOS:000178662500087
J	Dasgupta, S; Jana, M; Liu, XJ; Pahan, K				Dasgupta, S; Jana, M; Liu, XJ; Pahan, K			Myelin basic protein-primed T cells induce nitric oxide synthase in microglial cells - Implications for multiple sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PRIMARY ASTROCYTES; NF-KAPPA-B; INTERFERON-BETA; GLIAL-CELLS; IN-VITRO; EXPRESSION; ACTIVATION; INHIBITION; BRAIN; DISEASES	The presence of autoreactive T cells recognizing self myelin antigens is necessary for the development of central nervous system autoimmune diseases such as multiple sclerosis (MS). The present study was undertaken to investigate the role of myelin basic protein (AMP)primed T cells in the expression of inducible nitric oxide synthase (iNOS) in microglial cells. AMP-primed T cells alone markedly induced the production of NO and the expression of iNOS protein and mRNA in mouse BV-2 microglial cells. Similarly, AMP-primed T cells also induced the production of NO in mouse primary microglia. This induction of NO production was primarily dependent on the contact between AMP-primed T cells and microglia. The expression of very late antigen-4 (VLA-4) on the surface of MIBP-primed T cells and inhibition of AMP-primed T cell-induced microglial NO production by functional blocking of antibodies to the alpha(4) chain of VLA-4 (CD49d) suggest that VLA-4 integrin on MBP-primed T cells plays an important role in contact-mediated induction of iNOS. Since IFN-beta has been used to treat MS patients, we examined the effect of IFN-beta on AMP-primed T cell-induced the production of NO. Surprisingly, IFN-beta alone induced the production of NO in microglial cells. However, the pretreatment of MBP-primed T cells with IFN-beta inhibited the expression of VLA-4 integrin on the surface of AMP-primed T cells and thereby inhibited the ability of those T cells to induce the production of NO in microglial cells. This study illustrates a novel role of neuroantigen-primed T cells in inducing contact-mediated expression of iNOS in microglial cells that may participate in the pathogenesis of MS.	Univ Nebraska, Med Ctr, Dept Oral Biol, Lincoln, NE 68583 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center	Pahan, K (corresponding author), Univ Nebraska, Med Ctr, Dept Oral Biol, 40th & Holdrege, Lincoln, NE 68583 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039940] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS039940, R01 NS039940-02, NS39940] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bagasra O, 1995, P NATL ACAD SCI USA, V92, P12041, DOI 10.1073/pnas.92.26.12041; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenner T, 1997, J IMMUNOL, V158, P2940; BROSNAN CF, 1994, DEV NEUROSCI-BASEL, V16, P152, DOI 10.1159/000112102; Calabresi PA, 1997, NEUROLOGY, V49, P1111, DOI 10.1212/WNL.49.4.1111; CANNELLA B, 1995, ANN NEUROL, V37, P424, DOI 10.1002/ana.410370404; Chabot S, 2000, NEUROLOGY, V55, P1497, DOI 10.1212/WNL.55.10.1497; Chabot S, 1997, J CLIN INVEST, V100, P604, DOI 10.1172/JCI119571; CONNELLY JF, 1994, ANN PHARMACOTHER, V28, P610, DOI 10.1177/106002809402800511; Ding MZ, 1998, J IMMUNOL, V160, P2560; DUQUETTE P, 1993, NEUROLOGY, V43, P655, DOI 10.1212/wnl.43.4.655; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; GALEA E, 1992, P NATL ACAD SCI USA, V89, P10945, DOI 10.1073/pnas.89.22.10945; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Hooper DC, 2000, FASEB J, V14, P691, DOI 10.1096/fasebj.14.5.691; Hurst RD, 2001, BRAIN RES, V894, P181, DOI 10.1016/S0006-8993(01)01992-8; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; Jana M, 2001, J BIOL CHEM, V276, P44527, DOI 10.1074/jbc.M106771200; JOHNSON AW, 1995, J NEUROL NEUROSUR PS, V58, P107, DOI 10.1136/jnnp.58.1.107; KOLB H, 1992, IMMUNOL TODAY, V13, P157, DOI 10.1016/0167-5699(92)90118-Q; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; MARTIN R, 1992, ANNU REV IMMUNOL, V10, P153, DOI 10.1146/annurev.iy.10.040192.001101; MCCARTNEYFRANCIS N, 1993, J EXP MED, V178, P749, DOI 10.1084/jem.178.2.749; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; Murphy GM, 1998, J BIOL CHEM, V273, P20967, DOI 10.1074/jbc.273.33.20967; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NORONHA A, 1993, J NEUROIMMUNOL, V46, P145, DOI 10.1016/0165-5728(93)90244-S; NORONHA A, 1995, ANN NEUROL, V37, P7; OGORMAN MRG, 1987, CLIN EXP IMMUNOL, V67, P66; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Pahan K, 2000, FEBS LETT, V472, P203, DOI 10.1016/S0014-5793(00)01465-4; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 1998, J BIOL CHEM, V273, P12219, DOI 10.1074/jbc.273.20.12219; Pahan K, 2001, J BIOL CHEM, V276, P7899, DOI 10.1074/jbc.M008262200; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; PATY DW, 1993, NEUROLOGY, V43, P662, DOI 10.1212/WNL.43.4.662; PETERSON PK, 1994, J INFECT DIS, V170, P457, DOI 10.1093/infdis/170.2.457; RUDICK RA, 1993, NEUROLOGY, V43, P2080, DOI 10.1212/WNL.43.10.2080; Sedgwick JD, 1998, J IMMUNOL, V160, P5320; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Thiel VE, 2001, ANTIOXID REDOX SIGN, V3, P273, DOI 10.1089/152308601300185223; TRAUGOTT U, 1983, SCIENCE, V219, P308, DOI 10.1126/science.6217550; Tubridy N, 1999, NEUROLOGY, V53, P466, DOI 10.1212/WNL.53.3.466; UTZ U, 1994, J NEUROPATH EXP NEUR, V53, P351, DOI 10.1097/00005072-199407000-00005; WHITAKER JN, 1994, ANN NEUROL, V36, pS103, DOI 10.1002/ana.410360724; XIE QW, 1994, J BIOL CHEM, V269, P4705; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; Yong VW, 1998, NEUROLOGY, V51, P682; Zhao ML, 1998, BRAIN RES, V813, P402, DOI 10.1016/S0006-8993(98)01023-3	56	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39327	39333		10.1074/jbc.M111841200	http://dx.doi.org/10.1074/jbc.M111841200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176974	Green Accepted, hybrid			2022-12-27	WOS:000178662500036
J	Ishii, J; Adachi, H; Aoki, J; Koizumi, H; Tomita, S; Suzuki, T; Tsujimoto, M; Inoue, K; Arai, H				Ishii, J; Adachi, H; Aoki, J; Koizumi, H; Tomita, S; Suzuki, T; Tsujimoto, M; Inoue, K; Arai, H			SREC-II, a new member of the scavenger receptor type F family, trans-interacts with SREG-I through its extracellular domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; HUMAN ENDOTHELIAL-CELLS; SMOOTH-MUSCLE CELLS; ADHESION MOLECULE-1; EXPRESSION CLONING; BINDING-SITE; HOST-DEFENSE; ATHEROSCLEROSIS; THROMBOSPONDIN; GROWTH	The scavenger receptor expressed by endothelial cells (SREC) with an extremely large cytoplasmic domain, was originally identified in a human endothelial cell line. In this study, we have cloned a second isoform named SREC-H and shown that there is a heterophilic interaction between SREC-I and -II at their extracellular domains. The cDNA for murine SREC-II encodes an 834-amino acid protein with 35% homology to SREC-I. Similar to SREC-I, SREC-II contains multiple epidermal growth factor-like repeats in its extracellular domain. However, in contrast to SREG-I, SREG-II had little activity to internalize modified low density lipoproteins (LDL). A Northern blot analysis revealed a tissue expression pattern of SREG-II similar to that of SREC-I with predominant expression in human heart, lung, ovary, and placenta. Mouse fibroblast L cells with no tendency to associate showed noticeable aggregation when SREC-I was overexpressed in these cells, whereas overexpression of SREC-II caused only slight aggregation. Remarkably, intense aggregation was observed when SREC-I-expressing cells were mixed with those expressing SREC-II. Deletion of almost all of the cytoplasmic receptor domain had no effect on the receptor expression and cell aggregation, indicating that solely the extracellular domain is involved in cell aggregation. The association of SREC-I and -II was effectively suppressed by the presence of scavenger receptor ligands such as acetylated LDL and oxidized LDL. These findings suggest that SREC-I and -II show weak cell-cell interaction by their extracellular domains (termed homophilic trans-interaction) but display strong heterophilic trans-interaction through the extracellular epidermal growth factor-like repeat domains.	Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neurobiophys, Bunkyo Ku, Tokyo 1130033, Japan; RIKEN, Inst Phys & Chem Res, Lab Cellular Biochem, Wako, Saitama 3510198, Japan	University of Tokyo; University of Tokyo; RIKEN	Arai, H (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Suzuki, Toshiharu/B-5342-2013	Aoki, Junken/0000-0001-9435-1896				ACTON S, 1997, SCIENCE, V271, P518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; Baruch DI, 1996, P NATL ACAD SCI USA, V93, P3497, DOI 10.1073/pnas.93.8.3497; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BOULANGER CM, 1992, CIRC RES, V70, P1191, DOI 10.1161/01.RES.70.6.1191; BROMQUIST MC, 1984, P NATL ACAD SCI USA, V81, P7363; Claise C, 1996, FEBS LETT, V398, P223, DOI 10.1016/S0014-5793(96)01255-0; DUNNE DW, 1994, P NATL ACAD SCI USA, V91, P1863, DOI 10.1073/pnas.91.5.1863; FRASER I, 1993, NATURE, V364, P343, DOI 10.1038/364343a0; GEBUHRER V, 1995, BIOCHEM J, V306, P293, DOI 10.1042/bj3060293; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Greaves DR, 1998, CURR OPIN LIPIDOL, V9, P425, DOI 10.1097/00041433-199810000-00006; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; Hayashida K, 2002, FEBS LETT, V511, P133, DOI 10.1016/S0014-5793(01)03297-5; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; KHAN BV, 1995, J CLIN INVEST, V95, P1262, DOI 10.1172/JCI117776; Khoury J, 1994, J BIOL CHEM, V269, P10197; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; KRIEGER M, 1992, TRENDS BIOCHEM SCI, V17, P141, DOI 10.1016/0968-0004(92)90322-Z; KRIEGER M, 1993, J BIOL CHEM, V268, P4569; Kusuhara M, 1997, ARTERIOSCL THROM VAS, V17, P141, DOI 10.1161/01.ATV.17.1.141; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LI WX, 1993, J BIOL CHEM, V268, P16179; Li XA, 2002, J BIOL CHEM, V277, P11058, DOI 10.1074/jbc.M110985200; MCMURRAY HF, 1993, J CLIN INVEST, V92, P1004, DOI 10.1172/JCI116605; MIURA M, 1992, J BIOL CHEM, V90, P55; MURUGESAN G, 1993, J CELL BIOL, V120, P1011, DOI 10.1083/jcb.120.4.1011; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; ROHER L, 1990, NATURE, V343, P570; Sakaguchi H, 1998, LAB INVEST, V78, P423; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Wahl SM, 1996, J LEUKOCYTE BIOL, V59, P789, DOI 10.1002/jlb.59.6.789; Yokota T, 1998, EXP CELL RES, V239, P16, DOI 10.1006/excr.1997.3876; Yuhanna IS, 2001, NAT MED, V7, P853, DOI 10.1038/89986; YUI S, 1993, ARTERIOSCLER THROMB, V13, P331, DOI 10.1161/01.ATV.13.3.331; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8	47	69	72	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39696	39702		10.1074/jbc.M206140200	http://dx.doi.org/10.1074/jbc.M206140200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12154095	hybrid			2022-12-27	WOS:000178662500083
J	Kavli, B; Sundheim, O; Akbari, M; Otterlei, M; Nilsen, H; Skorpen, F; Aas, PA; Hagen, L; Krokan, HE; Slupphaug, G				Kavli, B; Sundheim, O; Akbari, M; Otterlei, M; Nilsen, H; Skorpen, F; Aas, PA; Hagen, L; Krokan, HE; Slupphaug, G			HUNG2 is the major repair enzyme for removal of uracil from U : A matches, U : G mismatches, and U in single-stranded DNA, with hSMUG1 as a broad specificity backup	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; GLYCOSYLASE ACTIVITY; SUBSTRATE-SPECIFICITY; CYTOSINE DEAMINATION; N-GLYCOSYLASE; NUCLEAR; ENDONUCLEASE; EXPRESSION; MECHANISM; THYMINE	hUNG2 and hSMUG1 are the only known glycosylases that may remove uracil from both double- and single-stranded DNA in nuclear chromatin, but their relative contribution to base excision repair remains elusive. The present study demonstrates that both enzymes are strongly stimulated by physiological concentrations of Mg2+ at which the activity of hUNG2 is 2-3 orders of magnitude higher than of hSMUG1. Moreover, Mg2+ increases the preference of hUNG2 toward uracil in ssDNA nearly 40-fold. APE1 has a strong stimulatory effect on hSMUG1 against dsU, apparently because of enhanced dissociation of hSMUG1 from AP sites in dsDNA. hSMUG1 also has a broader substrate specificity than hUNG2, including 5-hydroxymethyluracil and 3,N-4-ethenocytosine. hUNG2 is excluded from, whereas hSMUG1 accumulates in, nucleoli in living cells. In contrast, only hUNG2 accumulates in replication foci in the S-phase. hUNG2 in nuclear extracts initiates base excision repair of plasmids containing either U:A and U:G in vitro. Moreover, an additional but delayed repair of the U:G plasmid is observed that is not inhibited by neutralizing antibodies against hUNG2 or hSMUG1. We propose a model in which hUNG2 is responsible for both prereplicative removal of deaminated cytosine and postreplicative removal of misincorporated uracil at the replication fork. We also provide evidence that hUNG2 is the major enzyme for removal of deaminated cytosine outside of replication foci, with hSMUG1 acting as a broad specificity backup.	Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, N-7489 Trondheim, Norway	Norwegian University of Science & Technology (NTNU)	Slupphaug, G (corresponding author), Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, N-7489 Trondheim, Norway.	geir.slupphaug@medisin.ntnu.no	Slupphaug, Geir/AAN-3794-2020; Nilsen, Hilde/F-6432-2014	Otterlei, Marit/0000-0002-5232-1186; Nilsen, Hilde/0000-0003-2115-2663; Slupphaug, Geir/0000-0002-7498-3500; Akbari, Mansour/0000-0002-6490-7766; Skorpen, Frank/0000-0001-7093-8000				Aravind L, 2000, GENOME BIOL, V1, P1, DOI DOI 10.1186/GB-2000-1-4-RESEARCH0007; Baker D, 2002, CHEM RES TOXICOL, V15, P33, DOI 10.1021/tx010113b; Bellacosa A, 2001, J CELL PHYSIOL, V187, P137, DOI 10.1002/jcp.1064; Blatny JM, 1997, PLASMID, V38, P35, DOI 10.1006/plas.1997.1294; Boorstein RJ, 2001, J BIOL CHEM, V276, P41991, DOI 10.1074/jbc.M106953200; BOORSTEIN RJ, 1989, NUCLEIC ACIDS RES, V17, P7653, DOI 10.1093/nar/17.19.7653; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Dizdaroglu M, 1996, NUCLEIC ACIDS RES, V24, P418, DOI 10.1093/nar/24.3.418; Dogliotti E, 2001, PROG NUCLEIC ACID RE, V68, P3; DUNCAN BK, 1982, J BACTERIOL, V151, P750, DOI 10.1128/JB.151.2.750-755.1982; EFTEDAL I, 1993, NUCLEIC ACIDS RES, V21, P2095, DOI 10.1093/nar/21.9.2095; EFTEDAL I, 1994, ANN NY ACAD SCI, V726, P312, DOI 10.1111/j.1749-6632.1994.tb52836.x; FONDA L, 2002, SCI WORLD J, V2, P1312; FREDERICO LA, 1990, BIOCHEMISTRY-US, V29, P2532, DOI 10.1021/bi00462a015; FROSINA G, 1998, METHOD MOL BIOL, P301; Hardeland U, 2001, PROG NUCLEIC ACID RE, V68, P235; Haug T, 1998, NUCLEIC ACIDS RES, V26, P1449, DOI 10.1093/nar/26.6.1449; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; Hill JW, 2001, NUCLEIC ACIDS RES, V29, P430, DOI 10.1093/nar/29.2.430; IMPELLIZZERI KJ, 1991, J BACTERIOL, V173, P6807, DOI 10.1128/jb.173.21.6807-6810.1991; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; KROKAN H, 1981, NUCLEIC ACIDS RES, V9, P2599, DOI 10.1093/nar/9.11.2599; Krokan HE, 1997, BIOCHEM J, V325, P1; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; Morey NJ, 2000, GENETICS, V154, P109; Muller-Weeks S, 1998, J BIOL CHEM, V273, P21909, DOI 10.1074/jbc.273.34.21909; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Nilsen H, 1997, NUCLEIC ACIDS RES, V25, P750, DOI 10.1093/nar/25.4.750; Nilsen H, 2001, EMBO J, V20, P4278, DOI 10.1093/emboj/20.15.4278; Otterlei M, 2000, EMBO J, V19, P5542, DOI 10.1093/emboj/19.20.5542; Otterlei M, 1998, NUCLEIC ACIDS RES, V26, P4611, DOI 10.1093/nar/26.20.4611; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Parikh SS, 2000, P NATL ACAD SCI USA, V97, P5083, DOI 10.1073/pnas.97.10.5083; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Radany EH, 2000, MUTAT RES-DNA REPAIR, V461, P41, DOI 10.1016/S0921-8777(00)00040-9; SLUPPHAUG G, 1991, NUCLEIC ACIDS RES, V19, P5131, DOI 10.1093/nar/19.19.5131; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; SLUPPHAUG G, 1995, BIOCHEMISTRY-US, V34, P128, DOI 10.1021/bi00001a016; Spek EJ, 2001, J BACTERIOL, V183, P131, DOI 10.1128/JB.183.1.131-138.2001; Spek EJ, 2002, J BACTERIOL, V184, P3501, DOI 10.1128/JB.184.13.3501-3507.2002; Vidal AE, 2001, NUCLEIC ACIDS RES, V29, P1285, DOI 10.1093/nar/29.6.1285; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; WITTWER CU, 1989, BIOCHEMISTRY-US, V28, P780, DOI 10.1021/bi00428a055; Zhu B, 2000, NUCLEIC ACIDS RES, V28, P4157, DOI 10.1093/nar/28.21.4157	48	268	278	3	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39926	39936		10.1074/jbc.M207107200	http://dx.doi.org/10.1074/jbc.M207107200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161446	hybrid			2022-12-27	WOS:000178662500110
J	Lefrere, I; de Coppet, P; Camelin, JC; Le Lay, S; Mercier, N; Elshourbagy, N; Bril, A; Berrebi-Bertrand, I; Feve, B; Krief, S				Lefrere, I; de Coppet, P; Camelin, JC; Le Lay, S; Mercier, N; Elshourbagy, N; Bril, A; Berrebi-Bertrand, I; Feve, B; Krief, S			Neuropeptide AF and FF modulation of adipocyte metabolism - Primary insights from functional genomics and effects on beta-adrenergic responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL REGULATORY ELEMENT; 3T3-F442A ADIPOCYTES; BETA(3)-ADRENERGIC RECEPTOR; BETA-3-ADRENERGIC RECEPTOR; ADIPOSE CONVERSION; BETA-2-ADRENERGIC RECEPTORS; MAMMALIAN NEUROPEPTIDE; TRANSCRIPTION FACTORS; DIFFERENTIATION; PROTEIN	The presence of a neuropeptide AF and FF receptor (NPFF-R2) mRNA in human adipose tissue (Elshourbagy, N.A., Ames, R.S., Fitzgerald, L.R, Foley, J.J., Chambers, J.K, Szekeres, P.G., Evans, N.A., Schmidt, D.B., Buckley, P.T., Dytko, G.M, Murdock, P.R, Tan, K.B., Shabon, U., Nuthulaganti, P., Wang, D.Y., Wilson, S., Bergsma, D.J., and Sarau, H.M. (2000) J. Biol. Chem 275, 25965-25971) suggested these peptides, principally recognized for their pain modulating effects, may also impact on adipocyte metabolism, an aspect that has not been explored previously. Our aim was thus to obtain more insights into the actions of these peptides on adipocytes, an approach initially undertaken with a functional genomic assay. First we showed that 3T3-L1 adipocytes express both NPFF-R1 and NPFF-R2 transcripts, and that NPAF binds adipocyte membranes with a nanomolar affinity as assessed by surface plasmon resonance technology. Then, and following a 24-h treatment with NPFF or NPAF (1 mum), we have measured using real-time quantitative reverse transcriptase-PCR the mRNA steady state levels of already well characterized genes involved in key pathways of adipose metabolism. Among the 45 genes tested, few were modulated by NPFF (similar to10%) and a larger number by NPAF (similar to27%). Interestingly, NPAF increased the mRNA levels of beta2- and beta3-adrenergic receptors (AR), and to a lesser extent those of beta1-ARs. These variations in catecholamine receptor mRNAs correlated with a clear induction in the density of beta2- and beta3-AR proteins, and in the potency of beta-AR subtype-selective agonists to stimulate adenylyl cyclase activity. Altogether, these data show that NPFF-R1 and NPFF-R2 are functionally present in adipocytes and suggest that besides their well described pain modulation effects, NPAF and to a lesser extent NPFF, may have a global impact on body energy storage and utilization.	GlaxoSmithKline Labs Pharmaceut, F-35762 St Gregoire, France; GlaxoSmithKline, King Of Prussia, PA 19406 USA; Ctr Rech Biomed Cordeliers, UMR CNRS Paris 6 7079, F-75270 Paris 06, France	GlaxoSmithKline; GlaxoSmithKline	Krief, S (corresponding author), Bioprojet Biotech, 4 Rue Chesnay Beauregard,BP 96205, F-35762 St Gregoire, France.	S.Krief@bioprojet.com	Le Lay, Soazig/N-6862-2018; Le Lay, Soazig/AAI-2442-2021; Mercier, Nathalie/P-6814-2016	Le Lay, Soazig/0000-0003-2456-2422; Mercier, Nathalie/0000-0002-3983-2336; Krief, Stephane/0000-0002-5543-731X; Feve, Bruno/0000-0001-6577-9009				ALLARD M, 1995, J PHARMACOL EXP THER, V274, P577; Boizard M, 1998, J BIOL CHEM, V273, P29164, DOI 10.1074/jbc.273.44.29164; Bonini JA, 2000, J BIOL CHEM, V275, P39324, DOI 10.1074/jbc.M004385200; Bradley RL, 2001, RECENT PROG HORM RES, V56, P329, DOI 10.1210/rp.56.1.329; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Collins S, 1997, ENDOCRINOLOGY, V138, P405, DOI 10.1210/en.138.1.405; Deedwania PC, 1997, AM J HYPERTENS, V10, pS280, DOI 10.1016/S0895-7061(97)00335-X; Desprat C, 1997, PHARMACOL BIOCHEM BE, V58, P559, DOI 10.1016/S0091-3057(97)00249-9; EBBERINK RHM, 1987, PEPTIDES, V8, P515, DOI 10.1016/0196-9781(87)90018-0; ElHadri K, 1997, J BIOL CHEM, V272, P24514, DOI 10.1074/jbc.272.39.24514; Elshourbagy NA, 2000, J BIOL CHEM, V275, P25965, DOI 10.1074/jbc.M004515200; FEHMANN HC, 1990, NEUROPEPTIDES, V17, P87, DOI 10.1016/0143-4179(90)90054-3; FEVE B, 1991, J BIOL CHEM, V266, P20329; FEVE B, 1990, J BIOL CHEM, V265, P16343; FEVE B, 1992, J BIOL CHEM, V267, P15909; FEVE B, 1994, P NATL ACAD SCI USA, V91, P5677, DOI 10.1073/pnas.91.12.5677; FEVE B, 1995, J BIOL CHEM, V270, P10952, DOI 10.1074/jbc.270.18.10952; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GREEN SA, 1992, MOL PHARMACOL, V41, P889; Hinuma S, 2000, NAT CELL BIOL, V2, P703, DOI 10.1038/35036326; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Kim S, 2000, J NUTR, V130, p3110S; Kotani M, 2001, BRIT J PHARMACOL, V133, P138, DOI 10.1038/sj.bjp.0704038; KOZAK LP, 1974, J BIOL CHEM, V249, P7775; KRIEF S, 1994, J BIOL CHEM, V269, P6664; Labrouche S, 1998, J NEUROENDOCRINOL, V10, P559, DOI 10.1046/j.1365-2826.1998.00241.x; LAFONTAN M, 1993, J LIPID RES, V34, P1057; Laguzzi R, 1996, BRAIN RES, V711, P193, DOI 10.1016/0006-8993(95)01382-2; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; LEVY FO, 1993, P NATL ACAD SCI USA, V90, P10798, DOI 10.1073/pnas.90.22.10798; Liu QY, 2001, J BIOL CHEM, V276, P36961, DOI 10.1074/jbc.M105308200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Moldes M, 1997, MOL CELL BIOL, V17, P1796, DOI 10.1128/MCB.17.4.1796; Murase T, 1996, PEPTIDES, V17, P353, DOI 10.1016/0196-9781(95)02137-X; Orlicky DJ, 1998, J LIPID RES, V39, P1152; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; PAIRAULT J, 1982, EUR J BIOCHEM, V127, P351, DOI 10.1111/j.1432-1033.1982.tb06879.x; PAIRAULT J, 1979, P NATL ACAD SCI USA, V76, P5138, DOI 10.1073/pnas.76.10.5138; Panula P, 1996, PROG NEUROBIOL, V48, P461, DOI 10.1016/0301-0082(96)00001-9; *PE APPL BIOS, 1997, US B, V2, P1; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; Perry SJ, 1997, FEBS LETT, V409, P426, DOI 10.1016/S0014-5793(97)00557-7; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; Roumy M, 1998, EUR J PHARMACOL, V345, P1, DOI 10.1016/S0014-2999(97)01604-X; Schoonjans K, 2000, J MOL BIOL, V304, P323, DOI 10.1006/jmbi.2000.4218; SORENSON RL, 1984, PEPTIDES, V5, P777, DOI 10.1016/0196-9781(84)90021-4; Sundblom DM, 1998, PEPTIDES, V19, P1165, DOI 10.1016/S0196-9781(98)00060-6; Tabor DE, 1999, J BIOL CHEM, V274, P20603, DOI 10.1074/jbc.274.29.20603; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Vilim FS, 1999, MOL PHARMACOL, V55, P804	52	30	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39169	39178		10.1074/jbc.M205084200	http://dx.doi.org/10.1074/jbc.M205084200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12149260	hybrid			2022-12-27	WOS:000178662500016
J	Li, J; Barnard, DC; Patton, JG				Li, J; Barnard, DC; Patton, JG			A unique glutamic acid-lysine (EK) domain acts as a splicing inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; PROTEIN-PROTEIN INTERACTIONS; SR PROTEINS; PREMESSENGER RNA; RECOGNITION MOTIFS; POLYPYRIMIDINE TRACT; FUNCTIONAL-ANALYSIS; FACTORS ASF/SF2; SITE SELECTION; FACTOR SF2/ASF	SRrp86 is a unique member of the SR protein superfamily of splicing factors containing one RNA recognition motif and two serine-arginine (SR)-rich domains separated by an unusual glutamic acid-lysine (EK) rich region. Previously, we showed that SRrp86 could regulate alternative splicing by both positively and negatively modulating the activity of other SR proteins as long as the entire region encompassing the RS-EK-RS domains was intact. To further investigate the function and domains of SRrp86, we generated a series of chimeric proteins by swapping the RNA recognition motif and RS domains between SRrp86 and two canonical members of the SR superfamily, ASF/SF2 and SRp75. Although domain swaps between SRrp86 and ASF/SF2 showed that the RRMs primarily determined splicing activity, swaps between SRrp86 and SRp75 demonstrated that the RS domains could also determine activity. Because SRp75 also has two RS domains but lacks the EK domain, we further investigated the role of the EK domain and found that it acts to repress splicing and splice-site selection, both in vitro and in vivo. Incubation of extracts with peptides encompassing the EK-rich region inactivated splicing and insertion of the EK region into SRp75 abolished its ability to activate splicing. Thus, the unique EK domain of SRrp86 plays a modulatory role controlling RS domain function.	Vanderbilt Univ, Dept Sci Biol, Nashville, TN 37235 USA	Vanderbilt University	Patton, JG (corresponding author), Vanderbilt Univ, Dept Sci Biol, Box 1820 Stn B, Nashville, TN 37235 USA.	James.G.Patton@Vanderbilt.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062487] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM62487] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abovich N, 1997, CELL, V89, P403, DOI 10.1016/S0092-8674(00)80221-4; AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; Barnard DC, 2000, MOL CELL BIOL, V20, P3049, DOI 10.1128/MCB.20.9.3049-3057.2000; Barnard DC, 2002, RNA, V8, P526, DOI 10.1017/S1355838202029928; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; Blencowe BJ, 1998, GENE DEV, V12, P996, DOI 10.1101/gad.12.7.996; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; Brett D, 2002, NAT GENET, V30, P29, DOI 10.1038/ng803; Burge CB, 1999, RNA WORLD, P525; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; Chandler SD, 1997, P NATL ACAD SCI USA, V94, P3596, DOI 10.1073/pnas.94.8.3596; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; Coolidge CJ, 1997, NUCLEIC ACIDS RES, V25, P888, DOI 10.1093/nar/25.4.888; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cowper AE, 2001, J BIOL CHEM, V276, P48908, DOI 10.1074/jbc.M103967200; Dye DT, 1998, RNA, V4, P1523, DOI 10.1017/S1355838298980360; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; HEINRICHS V, 1995, EMBO J, V14, P3987, DOI 10.1002/j.1460-2075.1995.tb00070.x; Jumaa H, 2000, BBA-GENE STRUCT EXPR, V1494, P137, DOI 10.1016/S0167-4781(00)00233-5; Jumaa H, 1997, EMBO J, V16, P5077, DOI 10.1093/emboj/16.16.5077; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; Kennedy CF, 1998, MOL CELL BIOL, V18, P5425, DOI 10.1128/MCB.18.9.5425; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; KRAWCZAK M, 1992, HUM GENET, V90, P41; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Longman D, 2000, EMBO J, V19, P1625, DOI 10.1093/emboj/19.7.1625; Mayeda A, 1999, MOL CELL BIOL, V19, P1853; MAYEDA A, 1993, MOL CELL BIOL, V13, P2993, DOI 10.1128/MCB.13.5.2993; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; Nikolakaki E, 2001, J BIOL CHEM, V276, P40175, DOI 10.1074/jbc.M104755200; PATTON JG, 2001, ENCY MOL MED; Perez I, 1997, BIOCHEMISTRY-US, V36, P11881, DOI 10.1021/bi9711745; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; RING HJ, 1994, MOL CELL BIOL, V14, P7499, DOI 10.1128/MCB.14.11.7499; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Shi H, 1997, MOL CELL BIOL, V17, P2649, DOI 10.1128/MCB.17.5.2649; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; STAKNIS D, 1994, MOL CELL BIOL, V14, P7670, DOI 10.1128/MCB.14.11.7670; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; TARN WY, 1995, P NATL ACAD SCI USA, V92, P2504, DOI 10.1073/pnas.92.7.2504; Tronchere H, 1997, NATURE, V388, P397, DOI 10.1038/41137; van Oordt WVH, 2000, NUCLEIC ACIDS RES, V28, P4822, DOI 10.1093/nar/28.24.4822; Wang J, 1996, GENE DEV, V10, P2588, DOI 10.1101/gad.10.20.2588; WANG J, 1995, RNA, V1, P335; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; Zhang WJ, 1996, MOL CELL BIOL, V16, P5400; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	63	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39485	39492		10.1074/jbc.M201784200	http://dx.doi.org/10.1074/jbc.M201784200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12183448	hybrid			2022-12-27	WOS:000178662500056
J	Lopato, S; Forstner, C; Kalyna, M; Hilscher, J; Langhammer, U; Indrapichate, K; Lorkovic, ZJ; Barta, A				Lopato, S; Forstner, C; Kalyna, M; Hilscher, J; Langhammer, U; Indrapichate, K; Lorkovic, ZJ; Barta, A			Network of interactions of a novel plant-specific Arg/Ser-rich protein, atRSZ33, with atSC35-like splicing factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SR PROTEINS; FACTOR U2AF(35); MEDIATED TRANSFORMATION; ARABIDOPSIS-THALIANA; SITE SELECTION; RECOGNITION; TRANSCRIPTION; SC35; PHOSPHORYLATION	Arg/Ser-rich (RS) proteins play a crucial role in splicing and are implicated in splice site selection in metazoa. In plants, intron recognition seems to differ from the one in animals due to specific factor requirements. Here we describe a new plant-specific RS-rich protein, atRSZ33, with a unique domain structure consisting of an RNA recognition motif (RRM), two zinc knuckles embedded in a basic RS region, and an acidic C-terminal domain. atRSZ33 was found to be a phosphoprotein that concentrates in nuclear speckles and is predominantly present in roots and flowers. In a yeast two-hybrid screen, atRSZ33 interacted with splicing factors atSRp34/SR1, an Arabidopsis ortholog of human SF2/ASF; atRSZp21 and atRSZp22, which are similar to the human 9G8; and three novel SC35-like splicing factors termed atSCL28, atSCL30, and atSCL33/SR33. Two further members of the SCL family, namely SCL30a and the ortholog of mammalian SC35, atSC35, were also found to interact with atRSZ33. These interactions were verified by in vitro binding assays; furthermore, the transcriptional activity of atRSZ33 was found to overlap with the ones of its interacting partners. These specific interactions coupled with the many similarities of atRSZ33 to SR proteins suggest that its main activity is in spliceosome assembly. Mapping of regions necessary for protein-protein interaction between atRSZ33 and atSCL33/SR33 revealed that both zinc knuckles together with a small part of the RS and the RRM domain are required for efficient binding. However, the interacting domain is relatively small, allowing binding of additional proteins, a feature that is consistent with the proposed role of atRSZ33 in spliceosome assembly.	Univ Vienna, Vienna Bioctr, Inst Med Biochem, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Barta, A (corresponding author), Univ Vienna, Vienna Bioctr, Inst Med Biochem, Dr Bohrgasse 9-3, A-1030 Vienna, Austria.	Andrea@bch.univie.ac.at	Kalyna, Maria/N-7051-2017	Kalyna, Maria/0000-0003-4702-7625; Hilscher, Julia/0000-0001-5942-8931; Lorkovic, Zdravko/0000-0002-3074-7258; Barta, Andrea/0000-0002-8851-406X				AMREIN H, 1994, CELL, V76, P735, DOI 10.1016/0092-8674(94)90512-6; BARTA A, 1986, PLANT MOL BIOL, V6, P347, DOI 10.1007/BF00034942; Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Bhalerao RP, 1999, P NATL ACAD SCI USA, V96, P5322, DOI 10.1073/pnas.96.9.5322; Blanc G, 2000, PLANT CELL, V12, P1093, DOI 10.1105/tpc.12.7.1093; Blencowe BJ, 1999, BIOCHEM CELL BIOL, V77, P277, DOI 10.1139/bcb-77-4-277; Brown JWS, 1998, ANNU REV PLANT PHYS, V49, P77, DOI 10.1146/annurev.arplant.49.1.77; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Domon C, 1998, J BIOL CHEM, V273, P34603, DOI 10.1074/jbc.273.51.34603; FU XD, 1995, RNA, V1, P663; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Gniadkowski M, 1996, NUCLEIC ACIDS RES, V24, P619, DOI 10.1093/nar/24.4.619; Golovkin M, 1998, PLANT CELL, V10, P1637, DOI 10.1105/tpc.10.10.1637; Golovkin M, 1999, J BIOL CHEM, V274, P36428, DOI 10.1074/jbc.274.51.36428; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Guth S, 1999, MOL CELL BIOL, V19, P8263; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Koop HU, 1996, PLANTA, V199, P193, DOI 10.1007/BF00196559; Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367; Lambermon MHL, 2000, EMBO J, V19, P1638, DOI 10.1093/emboj/19.7.1638; Lambermon MHL, 2002, MOL CELL BIOL, V22, P4346, DOI 10.1128/MCB.22.12.4346-4357.2002; LAZAR G, 1995, P NATL ACAD SCI USA, V92, P7672, DOI 10.1073/pnas.92.17.7672; LAZO GR, 1991, BIO-TECHNOL, V9, P963, DOI 10.1038/nbt1091-963; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; Lopato S, 1996, P NATL ACAD SCI USA, V93, P3074, DOI 10.1073/pnas.93.7.3074; Lopato S, 1999, PLANT MOL BIOL, V39, P761, DOI 10.1023/A:1006129615846; Lopato S, 1999, GENE DEV, V13, P987, DOI 10.1101/gad.13.8.987; Lopato S, 1996, PLANT CELL, V8, P2255, DOI 10.1105/tpc.8.12.2255; Lorkovic ZJ, 2000, RNA, V6, P1610, DOI 10.1017/S1355838200001163; Lorkovic ZJ, 2000, TRENDS PLANT SCI, V5, P160, DOI 10.1016/S1360-1385(00)01595-8; Lorkovic ZJ, 2002, NUCLEIC ACIDS RES, V30, P623, DOI 10.1093/nar/30.3.623; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; Merendino L, 1999, NATURE, V402, P838, DOI 10.1038/45602; Misteli T, 1999, CURR BIOL, V9, pR198, DOI 10.1016/S0960-9822(99)80128-6; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Misteli T, 1997, TRENDS CELL BIOL, V7, P135, DOI 10.1016/S0962-8924(96)20043-1; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; Misteli T, 1999, MOL CELL, V3, P697, DOI 10.1016/S1097-2765(01)80002-2; Moore MJ, 2000, NAT STRUCT BIOL, V7, P14, DOI 10.1038/71207; REED R, 1997, SPLICEOSOME ASSEMBLY, P103; Riechmann JL, 2000, SCIENCE, V290, P2105, DOI 10.1126/science.290.5499.2105; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stojdl DF, 1999, BIOCHEM CELL BIOL, V77, P293, DOI 10.1139/bcb-77-4-293; Tacke R, 1999, CURR OPIN CELL BIOL, V11, P358, DOI 10.1016/S0955-0674(99)80050-7; Tronchere H, 1997, NATURE, V388, P397, DOI 10.1038/41137; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Wang HY, 2001, MOL CELL, V7, P331, DOI 10.1016/S1097-2765(01)00181-2; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; Xiao SH, 1998, EMBO J, V17, P6359, DOI 10.1093/emboj/17.21.6359; XIAO SH, 1997, P NATL ACAD SCI USA, V94, P1148; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; ZAHLER AM, 1993, MOL CELL BIOL, V13, P4023, DOI 10.1128/MCB.13.7.4023; Zorio DAR, 1999, RNA, V5, P487, DOI 10.1017/S1355838299982225; ZUO P, 1994, P NATL ACAD SCI USA, V91, P3363, DOI 10.1073/pnas.91.8.3363; Zuo P, 1996, GENE DEV, V10, P1356, DOI 10.1101/gad.10.11.1356	65	67	82	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39989	39998		10.1074/jbc.M206455200	http://dx.doi.org/10.1074/jbc.M206455200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176998	hybrid			2022-12-27	WOS:000178662500118
J	Rudra-Ganguly, N; Reddy, ST; Korge, P; Herschman, HR				Rudra-Ganguly, N; Reddy, ST; Korge, P; Herschman, HR			Diesel exhaust particle extracts and associated polycyclic aromatic hydrocarbons inhibit Cox-2-dependent prostaglandin synthesis in murine macrophages and fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; CYCLOOXYGENASE-2 GENE; IGE PRODUCTION; ADJUVANT ACTIVITY; SYNTHASE GENE; EXPRESSION; INDUCTION; CELLS; ACTIVATION; CHEMICALS	Diesel exhaust particles (DEP) and their organic constituents modulate the immune system and exacerbate allergic airway inflammation. We investigated the role of DEP extract and associated polycyclic aromatic hydrocarbons (PAHs) on prostaglandin synthesis in endotoxin-activated murine macrophages and in mitogen-stimulated fibroblasts. In both macrophages and fibroblasts, DEP extract, phenanthrene, anthracene, phenanthrenequinone, and beta-napthoflavone inhibit prostaglandin production from endogenous arachidonic acid in response to ligand stimulation. However, DEP extract and PAHs do not block ligand induction of cyclooxygenase-2 (COX-2) protein, either in mitogen-stimulated fibroblasts or endotoxin-treated macrophages. Release of total arachidonic acid and total lipid products is not reduced by DEP or PAHs following ligand stimulation of macrophages or fibroblasts. DEP extract and the PAHs inhibit the activity of purified COX-2 enzyme in vitro but do not inhibit COX-1 activity. Thus, DEP and PAHs do not affect ligand-induced COX-2 gene expression, phospholipase activation, or arachidonic acid release in macrophages and fibroblasts but exert their inhibitory effect on prostaglandin production by preferentially blocking COX-2 enzyme activity.	Univ Calif Los Angeles, Hlth Sci Ctr, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Hlth Sci Ctr, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Hlth Sci Ctr, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Hlth Sci Ctr, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Herschman, HR (corresponding author), Univ Calif Los Angeles, Hlth Sci Ctr, Inst Mol Biol, 341 Boyer Hall,611 Charles E Young Dr E, Los Angeles, CA 90095 USA.	hherschman@mednet.ucla.edu			NIAID NIH HHS [AI50495] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050495] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BUTLERGRALLA E, 1983, BIOCHEM BIOPH RES CO, V111, P194, DOI 10.1016/S0006-291X(83)80135-1; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; DiazSanchez D, 1997, ALLERGY, V52, P52; Ehrich EW, 1999, CLIN PHARMACOL THER, V65, P336, DOI 10.1016/S0009-9236(99)70113-X; FLETCHER JR, 1993, ARCH SURG-CHICAGO, V128, P1192; Gavett SH, 1999, J CLIN INVEST, V104, P721, DOI 10.1172/JCI6890; Goldenberg MM, 1999, CLIN THER, V21, P1497, DOI 10.1016/S0149-2918(00)80005-3; Han JY, 2001, FREE RADICAL BIO MED, V30, P516, DOI 10.1016/S0891-5849(00)00501-3; Heo Y, 2001, TOXICOLOGY, V159, P143, DOI 10.1016/S0300-483X(00)00418-2; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Herschman HR, 1998, TRENDS CARDIOVAS MED, V8, P145, DOI 10.1016/S1050-1738(98)00004-8; Hiura TS, 1999, J IMMUNOL, V163, P5582; Hiura TS, 2000, J IMMUNOL, V165, P2703, DOI 10.4049/jimmunol.165.5.2703; Irvin CG, 1997, AM J PHYSIOL-LUNG C, V272, pL1053, DOI 10.1152/ajplung.1997.272.6.L1053; Johnson JL, 1995, ARCH BIOCHEM BIOPHYS, V324, P26, DOI 10.1006/abbi.1995.9934; Kawasaki S, 2001, AM J RESP CELL MOL, V24, P419, DOI 10.1165/ajrcmb.24.4.4085; Kelley DJ, 1997, CARCINOGENESIS, V18, P795, DOI 10.1093/carcin/18.4.795; Korge P, 2002, P NATL ACAD SCI USA, V99, P3312, DOI 10.1073/pnas.052713199; LEVINE L, 1977, PROSTAGLANDINS, V14, P1, DOI 10.1016/0090-6980(77)90152-6; Li N, 2000, J IMMUNOL, V165, P3393, DOI 10.4049/jimmunol.165.6.3393; Marston CP, 2001, CARCINOGENESIS, V22, P1077, DOI 10.1093/carcin/22.7.1077; Miyamoto T, 1997, ALLERGY, V52, P30, DOI 10.1111/j.1398-9995.1997.tb04867.x; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Ng D, 1998, J IMMUNOL, V161, P942; Peebles RS, 2000, AM J RESP CRIT CARE, V162, P676; Pei XH, 1999, J BIOL CHEM, V274, P35240, DOI 10.1074/jbc.274.49.35240; Peterson B, 1996, ANN ALLERG ASTHMA IM, V77, P263, DOI 10.1016/S1081-1206(10)63318-2; Reddy ST, 2000, J BIOL CHEM, V275, P3107, DOI 10.1074/jbc.275.5.3107; REDDY ST, 1994, J BIOL CHEM, V269, P15473; Reynolds LJ, 2001, TOXICOLOGY, V165, P145, DOI 10.1016/S0300-483X(01)00417-6; Sagai M, 1996, FREE RADICAL BIO MED, V21, P199, DOI 10.1016/0891-5849(96)00032-9; Salvi SS, 1999, CLIN EXP ALLERGY, V29, P4; Sydbom A, 2001, EUR RESPIR J, V17, P733, DOI 10.1183/09031936.01.17407330; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; Takano H, 1997, AM J RESP CRIT CARE, V156, P36, DOI 10.1164/ajrccm.156.1.9610054; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Takizawa H, 2000, CLIN EXP IMMUNOL, V120, P356, DOI 10.1046/j.1365-2249.2000.01213.x; Tsien A, 1997, TOXICOL APPL PHARM, V142, P256, DOI 10.1006/taap.1996.8063; Wadleigh DJ, 1999, BIOCHEM BIOPH RES CO, V264, P865, DOI 10.1006/bbrc.1999.1606; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Williams JA, 1997, J BIOL CHEM, V272, P25693, DOI 10.1074/jbc.272.41.25693; WILLIAMS TJ, 1973, NATURE, V246, P215, DOI 10.1038/246215a0; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Yan ZP, 2000, J BIOL CHEM, V275, P4949, DOI 10.1074/jbc.275.7.4949	47	10	11	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39259	39265		10.1074/jbc.M110215200	http://dx.doi.org/10.1074/jbc.M110215200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163478	hybrid			2022-12-27	WOS:000178662500027
J	Tang, YJ; Zaitseva, F; Lamb, RA; Pinto, LH				Tang, YJ; Zaitseva, F; Lamb, RA; Pinto, LH			The gate of the influenza virus M-2 proton channel is formed by a single tryptophan residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEIN; M(2) ION-CHANNEL; SHAKER POTASSIUM CHANNEL; INFECTED-CELL SURFACE; A VIRUS; M2 PROTEIN; K+ CHANNEL; TRANSMEMBRANE DOMAIN; NUCLEAR TRANSPORT; LIPID BILAYERS	The influenza virus M-2 proton-selective ion channel is known to be essential for acidifying the interior of virions during virus uncoating in the lumen of endosomes. The M-2 protein is a homotetramer that contains four 19-residue transmembrane (TM) domains. These TM domains are multifunctional, because they contain the channel pore and also anchor the protein in membranes. The M-2 protein is gated by pH, and thus we have measured pH-gated currents, the accessibility of the pore to Cu2+, and the effect of a protein-modifying reagent for a series of TM domain mutant M-2 proteins. The results indicate that gating of the M-2 ion channel is governed by a single side chain at residue 41 of the TM domain and that this property is mediated by an indole moiety. Unlike many ion channels where the gate is formed by a whole segment of a protein, our data suggest a model of striking simplicity for the M-2 ion channel protein, with the side chain of Trp(41) blocking the pore of the M-2 channel when pH(out) is high and with this side chain leaving the pore when pH(out) is low. Thus, the Trp(41) side chain acts as the gate that opens and closes the pore.	Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Northwestern Univ, Howard Hughes Med Inst, Evanston, IL 60208 USA	Northwestern University; Northwestern University; Howard Hughes Medical Institute; Northwestern University	Pinto, LH (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, Hogan Hall,2153 N Campus Dr, Evanston, IL 60208 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020201, R01AI031882] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI-31882, R37 AI-20201] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arias HR, 2000, NEUROCHEM INT, V36, P595, DOI 10.1016/S0197-0186(99)00154-0; Bauer CM, 1999, VIROLOGY, V254, P196, DOI 10.1006/viro.1998.9552; Bui M, 1996, J VIROL, V70, P8391, DOI 10.1128/JVI.70.12.8391-8401.1996; BUKRINSKAYA AG, 1982, J GEN VIROL, V60, P49, DOI 10.1099/0022-1317-60-1-49; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Chizhmakov IV, 1996, J PHYSIOL-LONDON, V494, P329, DOI 10.1113/jphysiol.1996.sp021495; CIAMPOR F, 1992, VIRUS RES, V22, P247, DOI 10.1016/0168-1702(92)90056-F; Cortes DM, 2001, J GEN PHYSIOL, V117, P165, DOI 10.1085/jgp.117.2.165; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; DUFF KC, 1994, VIROLOGY, V202, P287, DOI 10.1006/viro.1994.1345; DUFF KC, 1992, VIROLOGY, V190, P485, DOI 10.1016/0042-6822(92)91239-Q; Flynn GE, 2001, NEURON, V30, P689, DOI 10.1016/S0896-6273(01)00324-5; Flynn GE, 2001, NAT REV NEUROSCI, V2, P643, DOI 10.1038/35090015; Gandhi CS, 2000, NEURON, V27, P585, DOI 10.1016/S0896-6273(00)00068-4; Gandhi CS, 1999, J BIOL CHEM, V274, P5474, DOI 10.1074/jbc.274.9.5474; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; GRAMBAS S, 1992, VIROLOGY, V191, P541, DOI 10.1016/0042-6822(92)90229-I; GRAMBAS S, 1992, VIROLOGY, V190, P11, DOI 10.1016/0042-6822(92)91187-Y; Hay A.J., 1992, SEMIN VIROL, V3, P21, DOI DOI 10.1016/J.BMC.2015.06.030; HAY AJ, 1985, EMBO J, V4, P3021, DOI 10.1002/j.1460-2075.1985.tb04038.x; HELENIUS A, 1992, CELL, V69, P577, DOI 10.1016/0092-8674(92)90219-3; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; HOLSINGER LJ, 1995, J VIROL, V69, P1219, DOI 10.1128/JVI.69.2.1219-1225.1995; HOLSINGER LJ, 1994, J VIROL, V68, P1551, DOI 10.1128/JVI.68.3.1551-1563.1994; HOLSINGER LJ, 1991, VIROLOGY, V183, P32, DOI 10.1016/0042-6822(91)90115-R; HULL JD, 1988, J CELL BIOL, V106, P1489, DOI 10.1083/jcb.106.5.1489; ITO T, 1991, J VIROL, V65, P5491, DOI 10.1128/JVI.65.10.5491-5498.1991; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Johnson JP, 2001, NATURE, V412, P917, DOI 10.1038/35091089; Lamb R.A., 2001, FIELDS VIROLOGY, P1487; Lamb R. A., 1994, RECEPTOR MEDIATED VI, P303; Lamb RA, 1997, VIROLOGY, V229, P1, DOI 10.1006/viro.1997.8451; LAMB RA, 1985, CELL, V40, P627, DOI 10.1016/0092-8674(85)90211-9; LAMB RA, 1981, VIROLOGY, V112, P746, DOI 10.1016/0042-6822(81)90319-6; LAMB RA, 1981, VIROLOGY, V112, P729, DOI 10.1016/0042-6822(81)90317-2; Lin TI, 2001, J VIROL, V75, P3647, DOI 10.1128/JVI.75.8.3647-3656.2001; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Liu YS, 2001, NAT STRUCT BIOL, V8, P883, DOI 10.1038/nsb1001-883; LOEWENTHAL R, 1992, J MOL BIOL, V224, P759, DOI 10.1016/0022-2836(92)90560-7; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; Mecozzi S, 1996, P NATL ACAD SCI USA, V93, P10566, DOI 10.1073/pnas.93.20.10566; Mould JA, 2000, J BIOL CHEM, V275, P31038, DOI 10.1074/jbc.M003663200; Mould JA, 2000, J BIOL CHEM, V275, P8592, DOI 10.1074/jbc.275.12.8592; OHUCHI M, 1994, J VIROL, V68, P920, DOI 10.1128/JVI.68.2.920-926.1994; Okada A, 2001, BIOCHEMISTRY-US, V40, P6053, DOI 10.1021/bi0028441; PANAYOTOV PP, 1992, VIROLOGY, V186, P352, DOI 10.1016/0042-6822(92)90096-8; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Sakaguchi T, 1997, P NATL ACAD SCI USA, V94, P5000, DOI 10.1073/pnas.94.10.5000; Sakaguchi T, 1996, J CELL BIOL, V133, P733, DOI 10.1083/jcb.133.4.733; SCHROEDER C, 1994, J GEN VIROL, V75, P3477, DOI 10.1099/0022-1317-75-12-3477; SHIMBO K, 1996, BIOPHYS J, V70, P1336; Shuck K, 2000, J VIROL, V74, P7755, DOI 10.1128/JVI.74.17.7755-7761.2000; SKEHEL JJ, 1978, J GEN VIROL, V38, P97, DOI 10.1099/0022-1317-38-1-97; Sorensen JB, 2000, J GEN PHYSIOL, V115, P209, DOI 10.1085/jgp.115.2.209; SUGRUE RJ, 1990, EMBO J, V9, P3469, DOI 10.1002/j.1460-2075.1990.tb07555.x; SUGRUE RJ, 1991, VIROLOGY, V180, P617, DOI 10.1016/0042-6822(91)90075-M; TAKEUCHI K, 1994, J VIROL, V68, P911, DOI 10.1128/JVI.68.2.911-919.1994; Tobler K, 1999, J VIROL, V73, P9695, DOI 10.1128/JVI.73.12.9695-9701.1999; TOSTESON MT, 1994, J MEMBRANE BIOL, V142, P117; Tu Q, 1996, J VIROL, V70, P4246, DOI 10.1128/JVI.70.7.4246-4252.1996; Unwin N, 2000, PHILOS T R SOC B, V355, P1813, DOI 10.1098/rstb.2000.0737; WANG C, 1995, BIOPHYS J, V69, P1363, DOI 10.1016/S0006-3495(95)80003-2; WANG C, 1993, J VIROL, V67, P5585, DOI 10.1128/JVI.67.9.5585-5594.1993; WANG C, 1994, VIROLOGY, V205, P133, DOI 10.1006/viro.1994.1628; Yi BA, 2000, NEURON, V27, P423, DOI 10.1016/S0896-6273(00)00052-0; ZEBEDEE SL, 1985, J VIROL, V56, P502, DOI 10.1128/JVI.56.2.502-511.1985; Zhang J, 1996, VIROLOGY, V225, P255, DOI 10.1006/viro.1996.0599; ZHIRNOV OP, 1992, VIROLOGY, V186, P324, DOI 10.1016/0042-6822(92)90090-C; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	70	197	200	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39880	39886		10.1074/jbc.M206582200	http://dx.doi.org/10.1074/jbc.M206582200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12183461	hybrid			2022-12-27	WOS:000178662500105
J	Woodside, DG; Obergfell, A; Talapatra, A; Calderwood, DA; Shattil, SJ; Ginsberg, MH				Woodside, DG; Obergfell, A; Talapatra, A; Calderwood, DA; Shattil, SJ; Ginsberg, MH			The N-terminal SH2 domains of Syk and ZAP-70 mediate phosphotyrosine-independent binding to integrin beta cytoplasmic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SEVERE COMBINED IMMUNODEFICIENCY; HIGH-AFFINITY RECEPTOR; CELL ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; HUMAN NEUTROPHILS; CRYSTAL-STRUCTURE; CALPAIN CLEAVAGE; FAMILY KINASES; ACTIVATION	Syk and ZAP-70 form a subfamily of nonreceptor tyrosine kinases that contain tandem SH2 domains at their N termini. Engagement of these SH2 domains by tyrosine-phosphorylated immunoreceptor tyrosine-based activation motifs leads to kinase activation and downstream signaling. These kinases are also regulated by beta(3) integrin-dependent cell adhesion via a phosphorylation-independent interaction with the beta(3) integrin cytoplasmic domain. Here, we report that the interaction of integrins with Syk and ZAP-70 depends on the N-terminal SH2 domain and the interdomain A region of the kinase. The N-terminal SH2 domain alone is sufficient for weak binding, and this interaction is independent of tyrosine phosphorylation of the integrin tail. Indeed, phosphorylation of tyrosines within the two conserved NXXY motifs in the integrin beta(3) cytoplasmic domain blocks Syk binding. The tandem SH2 domains of these kinases bind to multiple integrin 13 cytoplasmic domains with varying affinities (beta(3), (K-d = 24 n(M)) > beta(2) (K-d = 38 n(M)) > beta(1) (K-d = 71 n(M))) as judged by both affinity chromatography and surface plasmon resonance. Thus, the binding of Syk and ZAP-70 to integrin beta cytoplasmic domains represents a novel phosphotyrosine-independent interaction mediated by their N-terminal SH2 domains.	Scripps Res Inst, Div Vasc Biol, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Ginsberg, MH (corresponding author), Scripps Res Inst, Div Vasc Biol, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Calderwood, David A/AAC-6954-2019	Calderwood, David A/0000-0002-0791-4142	NHLBI NIH HHS [HL 48728, HL 31950, HL 59007] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, P01HL048728] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; Chen LL, 1999, J BIOL CHEM, V274, P13167, DOI 10.1074/jbc.274.19.13167; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Chu DH, 1998, IMMUNOL REV, V165, P167, DOI 10.1111/j.1600-065X.1998.tb01238.x; CLARK EA, 1994, J BIOL CHEM, V269, P28859; Cowan KJ, 2000, J BIOL CHEM, V275, P36423, DOI 10.1074/jbc.M004068200; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Fernandez R, 1998, J IMMUNOL, V160, P5154; Futterer K, 1998, J MOL BIOL, V281, P523, DOI 10.1006/jmbi.1998.1964; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; GRABER M, 1991, J IMMUNOL, V146, P2935; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hwang PM, 2002, EMBO J, V21, P314, DOI 10.1093/emboj/21.3.314; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; Li SC, 1999, CURR BIOL, V9, P1355, DOI 10.1016/S0960-9822(00)80080-9; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miller LA, 1999, EUR J IMMUNOL, V29, P1426, DOI 10.1002/(SICI)1521-4141(199905)29:05<1426::AID-IMMU1426>3.0.CO;2-J; Miranti CK, 1998, CURR BIOL, V8, P1289, DOI 10.1016/S0960-9822(07)00559-3; Mocsai A, 2002, IMMUNITY, V16, P547, DOI 10.1016/S1074-7613(02)00303-5; Negulescu PA, 1996, IMMUNITY, V4, P421, DOI 10.1016/S1074-7613(00)80409-4; Obergfell A, 2001, J BIOL CHEM, V276, P5916, DOI 10.1074/jbc.M010639200; OHALLORAN T, 1985, NATURE, V317, P449, DOI 10.1038/317449a0; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; Pelosi M, 1999, J BIOL CHEM, V274, P14229, DOI 10.1074/jbc.274.20.14229; Pfaff M, 1998, J BIOL CHEM, V273, P6104, DOI 10.1074/jbc.273.11.6104; Phillips DR, 2001, CURR OPIN CELL BIOL, V13, P546, DOI 10.1016/S0955-0674(00)00250-7; Poy F, 1999, MOL CELL, V4, P555, DOI 10.1016/S1097-2765(00)80206-3; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P1694, DOI 10.1074/jbc.272.3.1694; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; Soede RDM, 1998, J CELL BIOL, V142, P1371, DOI 10.1083/jcb.142.5.1371; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 1997, J EXP MED, V186, P2013, DOI 10.1084/jem.186.12.2013; WANGE RL, 1993, J BIOL CHEM, V268, P19797; Woodside DG, 2001, CURR BIOL, V11, P1799, DOI 10.1016/S0960-9822(01)00565-6; Yan B, 2001, J BIOL CHEM, V276, P28164, DOI 10.1074/jbc.M104161200; Yan SR, 1997, J IMMUNOL, V158, P1902	47	94	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39401	39408		10.1074/jbc.M207657200	http://dx.doi.org/10.1074/jbc.M207657200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171941	hybrid			2022-12-27	WOS:000178662500045
J	Zhang, H; Zha, XM; Tan, Y; Hornbeck, PV; Mastrangelo, AJ; Alessi, DR; Polakiewicz, RD; Comb, MJ				Zhang, H; Zha, XM; Tan, Y; Hornbeck, PV; Mastrangelo, AJ; Alessi, DR; Polakiewicz, RD; Comb, MJ			Phosphoprotein analysis using antibodies broadly reactive against phosphorylated motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; ANTI-PHOSPHOTYROSINE ANTIBODIES; P70 S6 KINASE; MONOCLONAL-ANTIBODIES; MAPKAP KINASE-1; SEQUENCE MOTIFS; C ISOZYMES; PDK1; SUBSTRATE; GENERATION	The substrates of most protein kinases remain unknown because of the difficulty tracing signaling pathways and identifying sites of protein phosphorylation. Here we describe a method useful in detecting subclasses of protein kinase substrates. Although the method is broadly applicable to any protein kinase for which a substrate consensus motif has been identified, we illustrate here the use of antibodies broadly reactive against phosphorylated Ser/Thr-motifs typical of AGC kinase substrates. Phosphopeptide libraries with fixed residues corresponding to consensus motifs RXRXXT-*/S* (Akt motif) and S*XR (protein kinase C motif) were used as antigens to generate antibodies that recognize many different phosphoproteins containing the fixed motif. Because most AGC kinase members are phosphorylated and activated by phosphoinositide-dependent protein kinase-1 (PDK1), we used PDK1-/- ES cells to profile potential AGC kinase substrates downstream of PDK1. To identify phosphoproteins detected using the Akt substrate antibody, we characterized the antibody binding specificity to generate a specificity matrix useful in predicting antibody reactivity. Using this approach we predicted and then identified a 30-kDa phosphoprotein detected by both Akt and protein kinase C substrate antibodies as S6 ribosomal protein. Phosphospecific motif antibodies offer a new approach to protein kinase substrate identification that combines immunoreactivity data with protein data base searches based upon antibody specificity.	Cell Signaling Technol, Beverly, MA 01915 USA; Univ Dundee, Med Res Council Prot Phosphorylat Unit, Dept Biochem, Dundee DD1 5EH, Scotland	University of Dundee	Comb, MJ (corresponding author), Cell Signaling Technol, 166B Cummings Ctr, Beverly, MA 01915 USA.	mcomb@cellsignal.com	Hornbeck, Peter V/K-2226-2017	Hornbeck, Peter V/0000-0002-1126-5149; Zha, Xiangming/0000-0001-9490-2731; Alessi, Dario/0000-0002-2140-9185				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Cohen P, 2002, NAT CELL BIOL, V4, pE127, DOI 10.1038/ncb0502-e127; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; CZERNIK AJ, 1991, METHOD ENZYMOL, V201, P264; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Ficarro SB, 2002, NAT BIOTECHNOL, V20, P301, DOI 10.1038/nbt0302-301; FLOTOW H, 1992, J BIOL CHEM, V267, P3074; FRACKELTON AR, 1991, METHOD ENZYMOL, V201, P79; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; GALSKI H, 1983, BIOCHIM BIOPHYS ACTA, V761, P284, DOI 10.1016/0304-4165(83)90078-8; GLENNEY JR, 1991, METHOD ENZYMOL, V201, P92; Hunter T, 1998, Harvey Lect, V94, P81; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Jackson JG, 2000, ONCOGENE, V19, P4574, DOI 10.1038/sj.onc.1203825; Jensen CJ, 1999, J BIOL CHEM, V274, P27168, DOI 10.1074/jbc.274.38.27168; KAMPS MP, 1991, METHOD ENZYMOL, V201, P101; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEIGHTON IA, 1995, FEBS LETT, V375, P289, DOI 10.1016/0014-5793(95)01170-J; Mann M, 2002, TRENDS BIOTECHNOL, V20, P261, DOI 10.1016/S0167-7799(02)01944-3; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Oda Y, 2001, NAT BIOTECHNOL, V19, P379, DOI 10.1038/86783; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; PERLMANN H, 1994, CELL BIOL LAB HDB; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Volarevic S, 2001, PROG NUCLEIC ACID RE, V65, P101; WHITE MF, 1991, METHOD ENZYMOL, V201, P65; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yaffe MB, 1999, NATURE, V402, P30; Zhou HL, 2002, NAT BIOTECHNOL, V20, P512, DOI 10.1038/nbt0502-512; Zhou SY, 1998, METH MOL B, V87, P87; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zhou SY, 2001, METHOD ENZYMOL, V332, P171	48	217	232	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39379	39387		10.1074/jbc.M206399200	http://dx.doi.org/10.1074/jbc.M206399200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12151408	hybrid			2022-12-27	WOS:000178662500042
J	Cave, JS; Meng, WM; Pennella, MA; Applehoff, RJ; Giedroc, DP; Robinson, NJ				Cave, JS; Meng, WM; Pennella, MA; Applehoff, RJ; Giedroc, DP; Robinson, NJ			A nickel-cobalt-sensing ArsR-SmtB family repressor - Contributions of cytosol and effector binding sites to metal selectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI ENCODES; METALLOREGULATORY PROTEIN; STAPHYLOCOCCUS-AUREUS; COORDINATION CHEMISTRY; METALLOTHIONEIN LOCUS; PLASMID PI258; ZNTA GENE; OPERON; IDENTIFICATION; ATPASE	NmtR from Mycobacterium tuberculosis is a new member of the ArsR-SmtB family of metal sensor transcriptional repressors. NmtR binds to the operator-promoter of a gene encoding a P-1 type ATPase (NmtA), repressing transcription in vivo except in medium supplemented with nickel or, to some extent, cobalt. In a cyanobacterial host, Synechococcus PCC 7942 strain R2-PIM8(smt), NmtR-mediated repression is alleviated by cobalt but not nickel or zinc addition, while the related sensor SmtB responds exclusively to zinc. Quantification of the number of atoms of nickel per cell shows that NmtR nickel sensitivity correlates with cytosolic nickel contents. Differential metal discrimination in a common cytosol by SmtB (zinc) and NmtR (cobalt) is not simply explained by affinities at equilibrium; although NmtR does bind nickel substantially more tightly than SmtB, it has a higher affinity for zinc than for cobalt and binds cobalt more weakly than SmtB. SmtB is known to bind and sense zinc at interhelical four-coordinate, tetrahedral sites across the C-terminal alpha5 helices, while absorption spectroscopy of Co(II)- and Ni(II)-substituted NmtR reveals five- and six-coordinate metal complexes. Site-directed mutagenesis identifies six potential cobalt/ nickel ligands that are obligatory for inducer recognition but not repression by NmtR, four of which (Asp(91), His(93), His(104), His(107)) align with alpha5 ligands of SmtB with two additional His provided by a carboxyl-terminal "extension" (designated alpha5C). Gel retardation assays reveal that zinc does not allosterically regulate NmtR-DNA binding at concentrations where lower affinity cobalt does. These data suggest that two additional ligands form hexacoordinate metal complexes and are crucial for driving allosteric regulation of DNA binding by NmtR, thereby allowing NmtR to preferentially sense metals that favor higher coordination numbers relative to SmtB.	Texas A&M Univ, Ctr Adv Biomol Res, Dept Biochem & Biophys, College Stn, TX 77843 USA; Univ Newcastle Upon Tyne, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Texas A&M University System; Texas A&M University College Station; Newcastle University - UK	Robinson, NJ (corresponding author), Texas A&M Univ, Ctr Adv Biomol Res, Dept Biochem & Biophys, College Stn, TX 77843 USA.		Robinson, Nigel J/J-6363-2012; Giedroc, David/A-8608-2018	Robinson, Nigel J/0000-0001-5586-1092; Giedroc, David/0000-0002-2342-1620; Cavet, Jennifer/0000-0001-5913-7157				Beard SJ, 1997, MOL MICROBIOL, V25, P883, DOI 10.1111/j.1365-2958.1997.mmi518.x; BICKNELL R, 1986, BIOCHEMISTRY-US, V25, P4219, DOI 10.1021/bi00363a008; Busenlehner LS, 2002, J MOL BIOL, V319, P685, DOI 10.1016/S0022-2836(02)00299-1; Busenlehner LS, 2001, BIOCHEMISTRY-US, V40, P4426, DOI 10.1021/bi010006g; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cook WJ, 1998, J MOL BIOL, V275, P337, DOI 10.1006/jmbi.1997.1443; CORWIN DT, 1987, INORG CHEM, V26, P3079, DOI 10.1021/ic00266a001; Da Silva J. F., 2001, BIOL CHEM ELEMENTS I; ENDO G, 1995, J BACTERIOL, V177, P4437, DOI 10.1128/jb.177.15.4437-4441.1995; Gordon SV, 1999, MOL MICROBIOL, V32, P643, DOI 10.1046/j.1365-2958.1999.01383.x; Hausinger RP, 1997, J BIOL INORG CHEM, V2, P279, DOI 10.1007/s007750050133; He MM, 2000, BIOCHEMISTRY-US, V39, P8719, DOI 10.1021/bi000856g; HUCKLE JW, 1993, MOL MICROBIOL, V7, P177, DOI 10.1111/j.1365-2958.1993.tb01109.x; Kuroda M, 1999, MICROBIOL IMMUNOL, V43, P115, DOI 10.1111/j.1348-0421.1999.tb02382.x; MORBY AP, 1993, NUCLEIC ACIDS RES, V21, P921, DOI 10.1093/nar/21.4.921; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Outten CE, 2001, BIOCHEMISTRY-US, V40, P10417, DOI 10.1021/bi0155448; POSEWITZ MC, 1995, CHEM RES TOXICOL, V8, P1020, DOI 10.1021/tx00050a005; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; Robinson NJ, 2001, ADV MICROB PHYSIOL, V44, P183, DOI 10.1016/S0065-2911(01)44014-8; Rosa DT, 2001, INORG CHEM, V40, P1606, DOI 10.1021/ic000971f; Rulisek L, 1998, J INORG BIOCHEM, V71, P115, DOI 10.1016/S0162-0134(98)10042-9; Rutherford JC, 1999, J BIOL CHEM, V274, P25827, DOI 10.1074/jbc.274.36.25827; Sambrook J., 2002, MOL CLONING LAB MANU; SCANLAN DJ, 1990, GENE, V90, P43, DOI 10.1016/0378-1119(90)90437-V; Shi WP, 1996, J BIOL CHEM, V271, P9291, DOI 10.1074/jbc.271.16.9291; Singh VK, 1999, MOL MICROBIOL, V33, P200, DOI 10.1046/j.1365-2958.1999.01466.x; Sun Y, 2001, J BIOL CHEM, V276, P14955, DOI 10.1074/jbc.M010595200; Thelwell C, 1998, P NATL ACAD SCI USA, V95, P10728, DOI 10.1073/pnas.95.18.10728; TIMM JL, 1994, J BACTERIOL, V176, P6749, DOI 10.1128/JB.176.21.6749-6753.1994; Tottey S, 2002, J BIOL CHEM, V277, P5490, DOI 10.1074/jbc.M105857200; Turner JS, 1996, NUCLEIC ACIDS RES, V24, P3714, DOI 10.1093/nar/24.19.3714; TURNER JS, 1993, J BIOL CHEM, V268, P4494; VanZile ML, 2000, BIOCHEMISTRY-US, V39, P11818, DOI 10.1021/bi001140o; VanZile ML, 2002, BIOCHEMISTRY-US, V41, P9776, DOI 10.1021/bi020178t; VanZile ML, 2002, BIOCHEMISTRY-US, V41, P9765, DOI 10.1021/bi0201771; Xu C, 1996, J BIOL CHEM, V271, P2427, DOI 10.1074/jbc.271.5.2427; Zhang B, 2001, MOL CELL BIOL, V21, P4505, DOI 10.1128/MCB.21.14.4505-4514.2001	41	120	127	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38441	38448		10.1074/jbc.M207677200	http://dx.doi.org/10.1074/jbc.M207677200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163508	hybrid			2022-12-27	WOS:000178529600058
J	Gotoh, M; Yada, T; Sato, T; Akashima, T; Iwasaki, H; Mochizuki, H; Inaba, N; Togayachi, A; Kudo, T; Watanabe, H; Kimata, K; Narimatsu, H				Gotoh, M; Yada, T; Sato, T; Akashima, T; Iwasaki, H; Mochizuki, H; Inaba, N; Togayachi, A; Kudo, T; Watanabe, H; Kimata, K; Narimatsu, H			Molecular cloning and characterization of a novel chondroitin sulfate glucuronyltransferase that transfers glucuronic acid to N-acetylgalactosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-4-GALACTOSYLTRANSFERASE GENE FAMILY; BETA-D-XYLOSYLTRANSFERASE; PROTEIN LINKAGE REGION; UDP-D-XYLOSE; HEPARAN-SULFATE; BETA-1,3-GALACTOSYLTRANSFERASE FAMILY; TUMOR SUPPRESSORS; BIOSYNTHESIS; EXPRESSION; GALACTOSE	We found a novel human gene (GenBank(TM) accession number AB037823, Kazusa DNA Research Institute KIAA1402) that possesses homology with chondroitin synthase. The full-length open reading frame consists of 772 amino acids and encodes a typical type 11 membrane protein. This enzyme had a domain containing beta3-glycosyltransferase motifs, which might be a beta3-glucuronyltransferase domain, but no domain with beta4-glycosyltransferase motifs, although both are found in chondroitin synthase. The putative catalytic domain was expressed in COS-7 cells as a soluble enzyme. Its glucuronyltransferase activity was observed when chondroitin and chondroitin sulfate polysaccharides and oligosaccharides were used as acceptor substrates. However, it was not detected when dermatan sulfate, hyaluronan, heparan sulfate, heparin, N-acetylheparosan, lactosamine tetrasaccharide, and linkage tri- and tetrasaccharide acceptors were employed. The reaction product, which was speculated to exhibit a GlcAbeta1-3GalNAc linkage structure at its non-reducing terminus, showed the following characteristics. 1) It was catabolized by beta-glucuronidase. 2) It was an acceptor for Escherichia coli K4 chondroitin polymerase (K4 chondroitin polymerase). 3) The product of K4 chondroitin polymerase was cleaved by chondroitinase ACII. On the other hand, no N-acetylgalactosaminyltransferase activity was detected toward any acceptors. Quantitative real time PCR analysis revealed that its transcripts were highly expressed in the placenta, small intestine, and pancreas, although they were ubiquitously expressed in various tissues and cell lines. This enzyme could play a role in the synthesis of chondroitin sulfate as a glucuronyltransferase.	Natl Inst Adv Ind Sci & Technol, Open Space Lab, Res Ctr Glycosci, Glycogene Funct Team, Tsukuba, Ibaraki 3058568, Japan; Amersham Biosci KK, Shinjuku Ku, Tokyo 1690073, Japan; Aichi Med Univ, Inst Mol Sci, Aichi 4801195, Japan; Seikagaku Corp, Tokyo 2070021, Japan; JGS Japan Genome Solut Inc, Tokyo 1920031, Japan; New Energy & Ind Technol Dev Org, Toshima Ku, Tokyo 1706028, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Aichi Medical University; Seikagaku Corporation	Narimatsu, H (corresponding author), Natl Inst Adv Ind Sci & Technol, Open Space Lab, Res Ctr Glycosci, Glycogene Funct Team, C-2,1-1-1 Umezono, Tsukuba, Ibaraki 3058568, Japan.		Yang, Fang/AAF-3024-2019; Togayachi, Akira/M-4144-2018; Sato, Takashi/M-2577-2018; Narimatsu, Hisashi/M-4757-2018	Togayachi, Akira/0000-0003-3600-9149; Sato, Takashi/0000-0002-9973-8923; Narimatsu, Hisashi/0000-0002-8402-133X; Watanabe, Hideto/0000-0001-5291-0696				Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Bayliss MT, 1999, J BIOL CHEM, V274, P15892, DOI 10.1074/jbc.274.22.15892; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gotoh M, 2002, J BIOL CHEM, V277, P38189, DOI 10.1074/jbc.M203619200; Gotting C, 2000, J MOL BIOL, V304, P517, DOI 10.1006/jmbi.2000.4261; GUNDLACH MW, 1985, BIOCHEM J, V226, P705, DOI 10.1042/bj2260705; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P531, DOI 10.1093/glycob/7.4.531; Kitagawa H, 1997, GLYCOBIOLOGY, V7, P905, DOI 10.1093/glycob/7.7.905; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Kitagawa H, 2001, J BIOL CHEM, V276, P4834, DOI 10.1074/jbc.C000835200; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; KUBOTA T, 1992, J BIOCHEM-TOKYO, V111, P91, DOI 10.1093/oxfordjournals.jbchem.a123725; Kuhn J, 2001, J BIOL CHEM, V276, P4940, DOI 10.1074/jbc.M005111200; Kutyavin IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/nar/28.2.655; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; Mitsumoto Y, 2000, GENOMICS, V65, P166, DOI 10.1006/geno.2000.6152; Ninomiya T, 2002, J BIOL CHEM, V277, P21567, DOI 10.1074/jbc.M201719200; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; ROHRMANN K, 1985, EUR J BIOCHEM, V148, P463, DOI 10.1111/j.1432-1033.1985.tb08862.x; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; SCHONHERR E, 1995, J BIOL CHEM, V270, P8877, DOI 10.1074/jbc.270.15.8877; Schwientek T, 1998, J BIOL CHEM, V273, P29331, DOI 10.1074/jbc.273.45.29331; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Shiina T, 2000, IMMUNOGENETICS, V51, P75, DOI 10.1007/s002510050012; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Terayama K, 1998, J BIOL CHEM, V273, P30295, DOI 10.1074/jbc.273.46.30295; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; Zhou DP, 1999, EUR J BIOCHEM, V263, P571, DOI 10.1046/j.1432-1327.1999.00541.x	48	60	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38179	38188		10.1074/jbc.M202601200	http://dx.doi.org/10.1074/jbc.M202601200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145278	hybrid			2022-12-27	WOS:000178529600027
J	He, C; Hobert, M; Friend, L; Carlin, C				He, C; Hobert, M; Friend, L; Carlin, C			The epidermal growth factor receptor juxtamembrane domain has multiple basolateral plasma membrane localization determinants, including a dominant signal with a polyproline core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERIC IMMUNOGLOBULIN RECEPTOR; POLARIZED EPITHELIAL-CELLS; POLYCYSTIC KIDNEY-DISEASE; GPI-ANCHORED PROTEINS; MDCK CELLS; CYTOPLASMIC DOMAIN; EGF RECEPTOR; APICAL DISTRIBUTION; SORTING SIGNALS; PDZ PROTEIN	The epidermal growth factor (EGF) receptor is located predominantly in the basolateral membrane of polarized epithelia, where it plays a pivotal role during organogenesis and tissue homeostasis. We have shown previously that a 22-amino acid sequence in the EGF receptor juxtamembrane domain contains autonomous sorting information necessary for basolateral localization using the Madin-Darby canine kidney epithelial cell model. The goal of this study was to determine the molecular basis of EGF receptor basolateral membrane expression using site-directed mutagenesis to modify specific residues in this region. We now show that this sequence has two different, functionally redundant basolateral sorting signals with distinct amino acid requirements: one dependent on residues (LL659)-L-658 conforming to well-characterized leucine-based sorting signals, and a second containing a polyproline core comprising residues Pro(667) and Pro(670) ((PXXP670)-P-667). Our data also suggest that Arg(662) contributes to the function of the proline-based signal. (PXXP670)-P-667 was the dominant signal when both motifs were present and was more effective than (LL659)-L-658 at overriding strong apical sorting signals located in the same molecule. Site-directed mutations at Arg(662), Pro(667), and Pro(670) were also associated with increased apical expression of full-length EGF receptors, demonstrating for the first time that the juxtamembrane region is necessary for accurate polarized expression of the native molecule.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Canc, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Rainbow Babies & Childrens Hosp, Rainbow Ctr Childhood PKD, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital	Carlin, C (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK054178] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL07717] Funding Source: Medline; NIDDK NIH HHS [P50 DK54178] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alonso MA, 1997, J BIOL CHEM, V272, P30748, DOI 10.1074/jbc.272.49.30748; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CARLIN CR, 1984, J BIOL CHEM, V259, P7902; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CHANG CP, 1993, J BIOL CHEM, V268, P19312; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; DARGEMONT C, 1993, EMBO J, V12, P1713, DOI 10.1002/j.1460-2075.1993.tb05816.x; DENHARTIGH JC, 1992, J CELL BIOL, V119, P349, DOI 10.1083/jcb.119.2.349; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; FISH EM, 1994, NEW ENGL J MED, V330, P1580; Futter CE, 1998, J CELL BIOL, V141, P611, DOI 10.1083/jcb.141.3.611; Grantham JJ, 1996, AM J KIDNEY DIS, V28, P788, DOI 10.1016/S0272-6386(96)90378-9; HOBERT M, 1995, J CELL PHYSIOL, V162, P434, DOI 10.1002/jcp.1041620316; Hobert ME, 1997, J BIOL CHEM, V272, P32901, DOI 10.1074/jbc.272.52.32901; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Keller P, 1997, J CELL SCI, V110, P3001; Kil SJ, 1999, J BIOL CHEM, V274, P3141, DOI 10.1074/jbc.274.5.3141; Kil SJ, 2000, J CELL PHYSIOL, V185, P47, DOI 10.1002/1097-4652(200010)185:1<47::AID-JCP4>3.3.CO;2-F; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; Kuwada SK, 1998, AM J PHYSIOL-CELL PH, V275, pC1419, DOI 10.1152/ajpcell.1998.275.6.C1419; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LISANTI MP, 1990, J MEMBRANE BIOL, V113, P155, DOI 10.1007/BF01872889; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; LIVNEH E, 1986, J BIOL CHEM, V261, P2490; Marks MS, 1997, TRENDS CELL BIOL, V7, P124, DOI 10.1016/S0962-8924(96)10057-X; MATLIN KS, 1992, KIDNEY PHYSL PATHOPH, P447; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; MOSTOV KE, 1995, BIOESSAYS, V17, P129, DOI 10.1002/bies.950170208; MULLIN JM, 1988, CANCER RES, V48, P4886; Odorizzi G, 1997, J BIOL CHEM, V272, P11757, DOI 10.1074/jbc.272.18.11757; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; Ohno H, 1999, FEBS LETT, V449, P215, DOI 10.1016/S0014-5793(99)00432-9; ORELLANA SA, 1995, SEMIN NEPHROL, V15, P341; Orzech E, 1999, J BIOL CHEM, V274, P2201, DOI 10.1074/jbc.274.4.2201; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PRILL V, 1993, EMBO J, V12, P2181, DOI 10.1002/j.1460-2075.1993.tb05866.x; Richards WG, 1998, J CLIN INVEST, V101, P935, DOI 10.1172/JCI2071; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; Sweeney WE, 2000, KIDNEY INT, V57, P33, DOI 10.1046/j.1523-1755.2000.00829.x; TAKASHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520; THOMAS DC, 1993, J BIOL CHEM, V268, P3313; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; WATERFIELD MD, 1982, J CELL BIOCHEM, V20, P149, DOI 10.1002/jcb.240200207; Whitfield CW, 1999, MOL BIOL CELL, V10, P2087, DOI 10.1091/mbc.10.6.2087; WILSON PD, 1991, KIDNEY INT, V39, P450, DOI 10.1038/ki.1991.56; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73	58	58	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38284	38293		10.1074/jbc.M104646200	http://dx.doi.org/10.1074/jbc.M104646200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161422	hybrid			2022-12-27	WOS:000178529600039
J	Li, CG; Zhu, NL; Tan, RC; Ballard, PL; Derynck, R; Minoo, P				Li, CG; Zhu, NL; Tan, RC; Ballard, PL; Derynck, R; Minoo, P			Transforming growth factor-beta inhibits pulmonary surfactant protein B gene transcription through SMAD3 interactions with NKX2.1 and HNF-3 transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG MORPHOGENESIS; FAMILY MEMBERS; FACTOR-I; PROMOTER; EXPRESSION; ACTIVATION; DEFECTS; MICE; DIFFERENTIATION; IDENTIFICATION	Transforming growth factor-beta (TGF-beta) represses surfactant protein B (Sp-B) gene transcription through a mechanism that remains unknown. A homeodomain and a forkhead transcription factor, NKX2.1 and HNF-3, respectively, are known activators of Sp-B transcription. Because SMADs are the effectors of TGF-beta-induced gene activation, we examined the possibility that gene repression by TGF-beta may also occur through interactions of SMADs with NKX2.1 and HNF-3. We found that lung epithelial carcinoma H441 cells contain SMAD2/3 and -4, which localize to the nucleus in response to TGF-beta treatment. The activity of a transfected Sp-B promoter/reporter construct was reduced in a dose-dependent manner by TGF-beta. Cotransfection with a mutant, constitutively activated form of the Tgf-beta type I receptor repressed Sp-B promoter activity in the absence of TGF-beta ligand. Dominant negative mutants of Smads blocked the repressor activity of TGF-beta. SMAD3, but not SMAD2, mediated the repressor activity of TGF-beta on the Sp-B promoter. Mutations within a 70-base pair domain that includes binding sites for NKX2.1, hepatocyte nuclear factor 3 (HNF-3), or cAMP response element-binding protein (CREB) eliminated SMAD3-dependent repression of Sp-B transcription. Electrophoretic mobility shift analysis showed no evidence for direct binding of SMAD3 to the Sp-B promoter, and a DNA binding mutant of SMAD3 also repressed Sp-B, suggesting that direct DNA binding of SMAD3 may not be required. Using a mammalian two hybrid assay, we found physical and functional interactions between SMAD3 and both NKX2.1 and HNF-3. Also, a glutathione S-transferase-fused SMAD3 directly binds to in vitro synthesized NKX2.1 or HNF-3, demonstrating protein-protein interactions between SMAD3 and the two transcriptional factors. The DNA binding of NKX2.1 to Sp-B promoter was reduced in response to TGF-beta treatment, although expression of Nkx2.1 was not affected. We conclude that SMAD3 interactions with the positive regulators NKX2.1 and HNF-3 underlie the molecular basis for TGF-beta-induced repression of Sp-B gene transcription.	Univ So Calif, Sch Med, Womens & Childrens Hosp, Dept Pediat, Los Angeles, CA 90033 USA; Univ Penn, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA	Children's Hospital Los Angeles; University of Southern California; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of California System; University of California San Francisco	Minoo, P (corresponding author), Univ So Calif, Sch Med, Womens & Childrens Hosp, Dept Pediat, Gen Labs Bldg,1801 E Marengo St,Rm 1G38, Los Angeles, CA 90033 USA.	minoo@hse.usc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL019737, R01HL056590, P01HL060231] Funding Source: NIH RePORTER; NHLBI NIH HHS [PM-HL56590, PM-HL60231, PB-HL19737] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alliston T, 2001, EMBO J, V20, P2254, DOI 10.1093/emboj/20.9.2254; Beers MF, 1998, AM J PHYSIOL-LUNG C, V275, pL950, DOI 10.1152/ajplung.1998.275.5.L950; Berhane K, 2001, GENE, V268, P141, DOI 10.1016/S0378-1119(01)00417-6; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Braun H, 1998, J BIOL CHEM, V273, P9821, DOI 10.1074/jbc.273.16.9821; CENTRELLA M, 1994, ENDOCR REV, V15, P27, DOI 10.1210/er.15.1.27; Chang A, 2000, ANN NY ACAD SCI, V923, P181, DOI 10.1111/j.1749-6632.2000.tb05529.x; Choy L, 1998, J BIOL CHEM, V273, P31455, DOI 10.1074/jbc.273.47.31455; CLARK JC, 1995, P NATL ACAD SCI USA, V92, P7794, DOI 10.1073/pnas.92.17.7794; Cole FS, 2001, PEDIATR RES, V50, P157, DOI 10.1203/00006450-200108000-00001; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Denissova NG, 2000, P NATL ACAD SCI USA, V97, P6397, DOI 10.1073/pnas.090099297; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Dunbar AE, 2000, PEDIATR RES, V48, P275, DOI 10.1203/00006450-200009000-00003; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Germain S, 2000, GENE DEV, V14, P435; Gonzales LW, 2001, PEDIATR PATHOL MOL M, V20, P387, DOI 10.1080/15513810109168622; Hamdan H, 1998, BBA-GENE STRUCT EXPR, V1396, P336, DOI 10.1016/S0167-4781(97)00210-8; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kumar AS, 2000, BBA-GENE STRUCT EXPR, V1492, P45, DOI 10.1016/S0167-4781(00)00058-0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lecart C, 2000, BIOL NEONATE, V77, P217, DOI 10.1159/000014219; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Margana RK, 1997, J BIOL CHEM, V272, P3083, DOI 10.1074/jbc.272.5.3083; MARGRAF LR, 1991, AM REV RESPIR DIS, V143, P391; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Minoo P, 1999, DEV BIOL, V209, P60, DOI 10.1006/dbio.1999.9234; Miyazono K, 2000, J CELL SCI, V113, P1101; Naltner A, 2000, J BIOL CHEM, V275, P56, DOI 10.1074/jbc.275.1.56; OLSON EN, 1992, DEV BIOL, V154, P261, DOI 10.1016/0012-1606(92)90066-P; PILOTMATIAS TJ, 1989, DNA-J MOLEC CELL BIO, V8, P75, DOI 10.1089/dna.1.1989.8.75; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Sanford LP, 1997, DEVELOPMENT, V124, P2659; VENKATESH VC, 1995, AM J PHYSIOL-LUNG C, V268, pL674, DOI 10.1152/ajplung.1995.268.4.L674; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yan C, 1997, J BIOL CHEM, V272, P17327, DOI 10.1074/jbc.272.28.17327; Zhou L, 1996, DEV BIOL, V175, P227, DOI 10.1006/dbio.1996.0110	43	66	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38399	38408		10.1074/jbc.M203188200	http://dx.doi.org/10.1074/jbc.M203188200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161428	hybrid			2022-12-27	WOS:000178529600053
J	Park, S; Gakh, O; Mooney, SM; Isaya, G				Park, S; Gakh, O; Mooney, SM; Isaya, G			The ferroxidase activity of yeast frataxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL IRON ACCUMULATION; FRIEDREICH ATAXIA; HEME-SYNTHESIS; HORSE SPLEEN; HOMOLOG; FERRITIN; REQUIREMENT; HOMEOSTASIS; DEFICIENCY; OXIDATION	Frataxin is required for maintenance of normal mitochondrial iron levels and respiration. The mature form of yeast frataxin (mYfh1p) assembles stepwise into a multimer of 840 kDa (alpha(48)) that accumulates iron in a water-soluble form. Here, two distinct iron oxidation reactions are shown to take place during the initial assembly step (alpha --> alpha(3)). A ferroxidase reaction with a stoichiometry of 2 Fe(II)/O-2 is detected at Fe(II)/mYfh1p ratios of less than or equal to0.5. Ferroxidation is progressively overcome by autoxidation at Fe(II)/mYfh1p ratios of >0.5. Gel filtration analysis indicates that an oligomer of mYfh1p, as, is responsible for both reactions. The observed 2 Fe(II)/O-2 stoichiometry implies production of H2O2 during the ferroxidase reaction. However, only a fraction of the expected total H2O2 is detected in solution. Oxidative degradation of mYfh1p during the ferroxidase reaction suggests that most H2O2 reacts with the protein. Accordingly, the addition of mYfh1p to a mixture of Fe(II) and H2O2 results in significant attenuation of Fenton chemistry. Multimer assembly is fully inhibited under anaerobic conditions, indicating that mYfh1p is activated by Fe(II) in the presence of O-2. This combination induces oligomerization and mYfh1p-catalyzed Fe(II) oxidation, starting a process that ultimately leads to the sequestration of as many as 50 Fe(II)/subunit inside the multimer.	Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Isaya, G (corresponding author), Mayo Clin & Mayo Fdn, Dept Pediat & Adolescent Med, 200 1st St SW,Stabile 7-52, Rochester, MN 55905 USA.	isaya@mayo.edu			NATIONAL INSTITUTE ON AGING [R01AG015709] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG015709, AG15709] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adamec J, 2000, AM J HUM GENET, V67, P549, DOI 10.1086/303056; Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Branda SS, 1999, HUM MOL GENET, V8, P1099, DOI 10.1093/hmg/8.6.1099; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Cavadini P, 2000, HUM MOL GENET, V9, P2523, DOI 10.1093/hmg/9.17.2523; Cavadini P, 2002, HUM MOL GENET, V11, P217, DOI 10.1093/hmg/11.3.217; Chantrel-Groussard K, 2001, HUM MOL GENET, V10, P2061, DOI 10.1093/hmg/10.19.2061; Corsi B, 2002, J BIOL CHEM, V277, P22430, DOI 10.1074/jbc.M105372200; DARNELL J, 1990, MOL CELL BIOL, P583; FLATMARK T, 1975, J BIOL CHEM, V250, P6433; Foury F, 1999, FEBS LETT, V456, P281, DOI 10.1016/S0014-5793(99)00961-8; Foury F, 1997, FEBS LETT, V411, P373, DOI 10.1016/S0014-5793(97)00734-5; Foury F, 2002, J BIOL CHEM, V277, P24475, DOI 10.1074/jbc.M111789200; Gakh O, 2002, BIOCHEMISTRY-US, V41, P6798, DOI 10.1021/bi025566+; HALLIWELL B, 1981, FEBS LETT, V128, P347, DOI 10.1016/0014-5793(81)80114-7; Halliwell B., 1999, FREE RADICAL BIO MED, P1, DOI DOI 10.1093/ACPROF:OSO/9780198717478.001.0001; Karthikeyan G, 2002, HUM MOL GENET, V11, P1351, DOI 10.1093/hmg/11.11.1351; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Lange H, 1999, J BIOL CHEM, V274, P18989, DOI 10.1074/jbc.274.27.18989; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Lindsay S, 2001, BIOCHEMISTRY-US, V40, P3340, DOI 10.1021/bi001981v; Muhlenhoff U, 2002, J BIOL CHEM, V277, P29810, DOI 10.1074/jbc.M204675200; Patel PI, 2001, AM J HUM GENET, V69, P15, DOI 10.1086/321283; Petrat F, 2001, BIOCHEM J, V356, P61, DOI 10.1042/0264-6021:3560061; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; Richards TD, 1996, J INORG BIOCHEM, V61, P1, DOI 10.1016/0162-0134(95)00029-1; Ristow M, 2000, P NATL ACAD SCI USA, V97, P12239, DOI 10.1073/pnas.220403797; TANGERAS A, 1985, BIOCHIM BIOPHYS ACTA, V843, P199, DOI 10.1016/0304-4165(85)90140-0; WALDO GS, 1993, BIOCHEMISTRY-US, V32, P13262, DOI 10.1021/bi00211a039; Yang XK, 1999, BIOCHEM J, V338, P615, DOI 10.1042/0264-6021:3380615; Yang XK, 1998, BIOCHEMISTRY-US, V37, P9743, DOI 10.1021/bi973128a; Zhao GH, 2001, BIOCHEMISTRY-US, V40, P10832, DOI 10.1021/bi011052j	33	75	75	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38589	38595		10.1074/jbc.M206711200	http://dx.doi.org/10.1074/jbc.M206711200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12149269	Green Accepted, hybrid			2022-12-27	WOS:000178529600076
J	Sobott, F; Benesch, JLP; Vierling, E; Robinson, CV				Sobott, F; Benesch, JLP; Vierling, E; Robinson, CV			Subunit exchange of multimeric protein complexes - Real-time monitoring of subunit exchange between small heat shock proteins by using electrospray mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERMOLECULAR EXCHANGE; DENATURED PROTEINS; OLIGOMER FORMATION; CHAPERONE ACTIVITY; CRYSTAL-STRUCTURE; ALPHA-CRYSTALLIN; EVOLUTION; HSP25	The subunit exchange of the small heat shock proteins (sHSPs) PsHSP18.1 from pea and TaHSP16.9 from wheat has been monitored in real-time using nanoelectrospray mass spectrometry. By preserving the noncovalent interactions between subunits in the mass spectrometer, we show that these proteins are dodecameric. After mixing PsHSP18.1 and TaHSP16.9, a distribution of heterododecamers is formed. A comparison with spectra obtained from statistical modeling demonstrates that after equilibration the distribution of these heterocomplexes is governed by the starting ratio of the two components rather than an inherent preference for certain stoichiometries. This finding suggests that the two different sHSP subunits interact in a very similar manner. Following the kinetics of this reaction by mass spectrometry reveals that exchange proceeds via sequential incorporation of subunits with dimeric species being the principal units of exchange. Therefore, we conclude that sHSP complexes are in rapid dissociation/reassociation equilibria with suboligomeric forms. More generally, these experiments illustrate a powerful approach for the real-time analysis of the evolution of transient species and their relative populations during the subunit exchange of multimeric protein complexes.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA	University of Cambridge; University of Arizona	Robinson, CV (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cvr24@cam.ac.uk	Benesch, Justin/A-4250-2008	Vierling, Elizabeth/0000-0002-0066-4881; Sobott, Frank/0000-0001-9029-1865; Benesch, Justin/0000-0002-1507-3742; robinson, carol/0000-0001-7829-5505	NIGMS NIH HHS [GM-42762] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRIGO AP, 2002, PROGR MOL SUBCELLULA, P1; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; Bruce JE, 1998, PROTEIN SCI, V7, P1180, DOI 10.1002/pro.5560070512; Datta SA, 2000, J BIOL CHEM, V275, P41004, DOI 10.1074/jbc.M007686200; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Fandrich M, 2000, P NATL ACAD SCI USA, V97, P14151, DOI 10.1073/pnas.240326597; GAESTEL M, 1997, GUIDEBOOK MOL CHAPER, P269; Garnier C, 2001, EUR J BIOCHEM, V268, P2402, DOI 10.1046/j.1432-1327.2001.02121.x; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haslbeck Martin, 2002, Prog Mol Subcell Biol, V28, P37; Helm KW, 1997, PLANT PHYSIOL, V114, P1477, DOI 10.1104/pp.114.4.1477; Hernandez H, 2001, J BIOL CHEM, V276, P46685, DOI 10.1074/jbc.R100024200; Kappe Guido, 2002, Prog Mol Subcell Biol, V28, P1; Kebarle P, 2000, J MASS SPECTROM, V35, P804, DOI 10.1002/1096-9888(200007)35:7<804::AID-JMS22>3.3.CO;2-H; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189; LEE GJ, 1995, J BIOL CHEM, V270, P10432, DOI 10.1074/jbc.270.18.10432; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Lindner RA, 2000, EUR J BIOCHEM, V267, P1923, DOI 10.1046/j.1432-1327.2000.01188.x; Loo JA, 2000, INT J MASS SPECTROM, V200, P175, DOI 10.1016/S1387-3806(00)00298-0; Nettleton EJ, 1998, J MOL BIOL, V281, P553, DOI 10.1006/jmbi.1998.1937; Rostom AA, 1999, J AM CHEM SOC, V121, P4718, DOI 10.1021/ja990238r; Schneider F, 2001, PROTEIN SCI, V10, P1606, DOI 10.1110/ps.8901; Smith VF, 1996, PROTEIN SCI, V5, P488; Sobott F, 2002, ANAL CHEM, V74, P1402, DOI 10.1021/ac0110552; Studer S, 2000, J BIOL CHEM, V275, P37212, DOI 10.1074/jbc.M004701200; Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; Tito MA, 2000, J AM CHEM SOC, V122, P3550, DOI 10.1021/ja993740k; Torok Z, 2001, P NATL ACAD SCI USA, V98, P3098, DOI 10.1073/pnas.051619498; van den IJssel P, 1999, CURR BIOL, V9, pR103, DOI 10.1016/S0960-9822(99)80061-X; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; VANDENOETELAAR PJM, 1990, BIOCHEMISTRY-US, V29, P3488, DOI 10.1021/bi00466a010; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; WATERS ER, 1995, GENETICS, V141, P785; Waters ER, 1999, MOL BIOL EVOL, V16, P127, DOI 10.1093/oxfordjournals.molbev.a026033; Waters ER, 1996, J EXP BOT, V47, P325, DOI 10.1093/jxb/47.3.325	42	166	169	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38921	38929		10.1074/jbc.M206060200	http://dx.doi.org/10.1074/jbc.M206060200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138169	hybrid			2022-12-27	WOS:000178529600115
J	Detich, N; Theberge, J; Szyf, M				Detich, N; Theberge, J; Szyf, M			Promoter-specific activation and demethylation by MBD2/demethylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE COMPLEX; CPG-BINDING PROTEIN; DNA METHYLATION; TRANSCRIPTIONAL REPRESSION; GENE PROMOTER; FAMILY; DOMAIN; MECP2; MBD2; SP1	MBD2 is the only member of a family of methyl-CpG-binding proteins that has been reported to be both a transcriptional repressor and a DNA demethylase (dMTase). To understand the apparently contradictory function of MBD2/dMTase, we studied the effects of dMTase overexpression on the activity of various in vitro methylated promoters transiently transfected into HEK293 cells. We found that forced expression of a MBD2/dMTase expression vector (His-dMTase) differentially activated two methylated reporters, pSV40-CAT (the SV40 enhancerless promoter adjacent to the chloramphenicol acetyltransferase (CAT) reporter gene) and pGL2T+I4xTBRE (a region of the p21 promoter next to the luciferase reporter gene), in a time- and dose-dependent manner. His-dMTase increased pSV40-CAT expression by 3-10-fold after 96 h, while pGL2T+I4xTBRE expression was increased by 2-3-fold after only 48 h and did not further increase at 96 h. Gene activation was not universal because no effect was seen with the p19-ARF promoter. We then assessed whether activation might be due to demethylation within the promoter region. Using bisulfite mapping, we found that exogenous expression of His-dMTase induced demethylation at 8 of the 10 CpG sites within the SV40 promoter. The observation that His-dMTase increases the demethylase activity in the cells was also confirmed using an in vitro CpG demethylase assay with a mC32pG oligonucleotide, substrate and purified Q-Sepharose fractions from HEK293 cells transfected with His-dMTase or empty pcDNA3.1His vector. We propose that a single protein possessing both repressor and demethylase functions has evolved to coordinate a program that requires suppression of some methylated genes and activation of others.	McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada	McGill University	Szyf, M (corresponding author), McGill Univ, Dept Pharmacol & Therapeut, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	mszyf@pharma.mcgill.ca						Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200; CEDAR H, 1982, COLD SPRING HARB SYM, V47, P605, DOI 10.1101/SQB.1983.047.01.071; Cervoni N, 2002, J BIOL CHEM, V277, P25026, DOI 10.1074/jbc.M202256200; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Feng Q, 2001, GENE DEV, V15, P827; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hattori M, 2001, CANCER LETT, V169, P155, DOI 10.1016/S0304-3835(01)00499-2; Marhold J, 2002, CHROMOSOMA, V111, P13, DOI 10.1007/s00412-002-0188-2; Muller H, 2000, BBA-REV CANCER, V1470, pM1, DOI 10.1016/S0304-419X(99)00030-X; NAN XS, 1993, NUCLEIC ACIDS RES, V21, P4886, DOI 10.1093/nar/21.21.4886; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Plumb JA, 2000, CANCER RES, V60, P6039; RAZIN A, 1984, BIOCHIM BIOPHYS ACTA, V782, P331, DOI 10.1016/0167-4781(84)90043-5; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; ROULEAU J, 1992, J BIOL CHEM, V267, P7368; Sekimata M, 2001, J BIOL CHEM, V276, P42632, DOI 10.1074/jbc.M107048200; Szyf M, 2001, PROG NUCLEIC ACID RE, V69, P47, DOI 10.1016/S0079-6603(01)69044-5; Szyf M, 2001, TRENDS PHARMACOL SCI, V22, P350, DOI 10.1016/S0165-6147(00)01713-2; Szyf Moshe, 2002, Methods Mol Biol, V200, P163; Szyf Moshe, 2002, Methods Mol Biol, V200, P155; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	30	144	157	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35791	35794		10.1074/jbc.C200408200	http://dx.doi.org/10.1074/jbc.C200408200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12177048	hybrid			2022-12-27	WOS:000178275100004
J	Dan, HC; Sun, M; Yang, L; Feldman, RI; Sui, XM; Ou, CC; Nellist, M; Yeung, RS; Halley, DJJ; Nicosia, SV; Pledger, WJ; Cheng, JQ				Dan, HC; Sun, M; Yang, L; Feldman, RI; Sui, XM; Ou, CC; Nellist, M; Yeung, RS; Halley, DJJ; Nicosia, SV; Pledger, WJ; Cheng, JQ			Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-GROWTH; GENE; HAMARTIN; TSC1; KINASE; PROLIFERATION; IDENTIFICATION; ACTIVATION; MUTATIONS; P27(KIP1)	Normal cellular functions of hamartin and tuberin, encoded by the TSC1 and TSC2 tumor suppressor genes, are closely related to their direct interactions. However, the regulation of the hamartin-tuberin complex in the context of the physiologic role as tumor suppressor genes has not been documented. Here we show that insulin or insulin growth factor (IGF) 1 stimulates phosphorylation of tuberin, which is inhibited by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 but not by the mitogen-activated protein kinase inhibitor PD98059. Expression of constitutively active PI3K or active Akt, including Akt1 and Akt2, induces tuberin phosphorylation. We further demonstrate that Akt/PKB associates with hamartin-tuberin complexes, promoting phosphorylation of tuberin and increased degradation of hamartin-tuberin complexes. The ability to form complexes, however, is not blocked. Akt also inhibits tuberin-mediated degradation of p27(kip1), thereby promoting CDK2 activity and cellular proliferation. Our results indicate that tuberin is a direct physiological substrate of Akt and that phosphorylation of tuberin by PI3K/Akt is a major mechanism controlling hamartin-tuberin function.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol,Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol,Drug Discovery Program, Tampa, FL 33612 USA; Berlex Biosci, Dept Canc Res, Richmond, CA 94804 USA; Univ Washington, Med Ctr, Seattle, WA 98195 USA; Erasmus Univ, Dept Clin Genet, NL-3015 GE Rotterdam, Netherlands	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; University of Washington; University of Washington Seattle; Erasmus University Rotterdam	Cheng, JQ (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr, 12901 Bruce B Downs Blvd,MDC 11, Tampa, FL 33612 USA.	jcheng@hsc.usf.edu			NATIONAL CANCER INSTITUTE [R01CA089242, R01CA077935, R29CA077935] Funding Source: NIH RePORTER; NCI NIH HHS [CA89242, CA77935] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 2001, CURR OPIN NEUROBIOL, V11, P297, DOI 10.1016/S0959-4388(00)00211-7; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Gesbert F, 2000, J BIOL CHEM, V275, P39223, DOI 10.1074/jbc.M007291200; Hengstschlager M, 2001, MUTAT RES-REV MUTAT, V488, P233, DOI 10.1016/S1383-5742(01)00058-8; Hodges AK, 2001, HUM MOL GENET, V10, P2899, DOI 10.1093/hmg/10.25.2899; Jiang K, 2000, MOL CELL BIOL, V20, P139, DOI 10.1128/MCB.20.1.139-148.2000; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mohapatra S, 2001, J BIOL CHEM, V276, P21976, DOI 10.1074/jbc.M009788200; Montagne J, 2001, Sci STKE, V2001, ppe36, DOI 10.1126/stke.2001.105.pe36; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Plank TL, 1998, CANCER RES, V58, P4766; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 2001, ONCOGENE, V20, P4904, DOI 10.1038/sj.onc.1204627; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805	24	320	332	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35364	35370		10.1074/jbc.M205838200	http://dx.doi.org/10.1074/jbc.M205838200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12167664	hybrid			2022-12-27	WOS:000178117000091
J	Pan, YH; Yu, BZ; Singer, AG; Ghomashchi, F; Lambeau, G; Gelb, MH; Jain, MK; Bahnson, BJ				Pan, YH; Yu, BZ; Singer, AG; Ghomashchi, F; Lambeau, G; Gelb, MH; Jain, MK; Bahnson, BJ			Crystal structure of human group X secreted phospholipase A(2) - Electrostatically neutral interfacial binding surface targets zwitterionic membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; STRUCTURE-BASED DESIGN; ARACHIDONIC-ACID; KINETIC BASIS; COMPETITIVE INHIBITORS; VENOM PHOSPHOLIPASE-A2; BILAYER INTERFACE; RAY STRUCTURE; CATALYSIS; ACTIVATION	The crystal structure of human group X (hGX) secreted phospholippse A(2) (sPLA(2)) has been solved to a resolution of 1.97 Angstrom. As expected the protein fold is similar to previously reported sPLA(2) structures. The active site architecture, including the positions of the catalytic residues and the first and second shell water around the Ca2+ cofactor, are highly conserved and remarkably similar to the group IB and group IIA enzymes. Differences are seen in the structures following the (1-12)-N-terminal helix and at the C terminus. These regions are proposed to interact with the substrate membrane surface. The opening to the active site slot is considerably larger in hGX than in human group IIA sPLA(2). Furthermore, the electrostatic surface potential of the hGX interfacial-binding surface does not resemble that of the human group IIA sPLA(2); the former is highly neutral, whereas the latter is highly cationic. The cationic residues on this face of group IB and IIA enzymes have been implicated in membrane binding and in k*(cat) allostery. In contrast, hGX does not show activation by the anionic charge at the lipid interface when acting on phospholipid vesicles or short-chain phospholipid micelles. Together, the crystal structure and kinetic results of hGX supports the conclusion that it is as active onzwitterionic as on anionic interfaces, and thus it is predicted to target the zwitterionic membrane surfaces of mammalian cells.	Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France	University of Delaware; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Bahnson, BJ (corresponding author), Univ Delaware, Dept Chem & Biochem, Newark, DE 19716 USA.		Lambeau, Gerard/GRJ-5624-2022	Lambeau, Gerard/0000-0002-9239-518X; gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL-36235] Funding Source: Medline; NIGMS NIH HHS [GM-29703] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL036235, R37HL036235, R01HL036235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; APITZCASTRO R, 1982, BIOCHIM BIOPHYS ACTA, V688, P349, DOI 10.1016/0005-2736(82)90346-7; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; Berg OG, 2001, CHEM REV, V101, P2613, DOI 10.1021/cr990139w; Berg OG, 1997, BIOCHEMISTRY-US, V36, P14512, DOI 10.1021/bi970855x; Berg OG, 2002, INTERFACIAL ENZYME K; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7330, DOI 10.1021/bi00243a038; JAIN MK, 1982, BIOCHIM BIOPHYS ACTA, V688, P341, DOI 10.1016/0005-2736(82)90345-5; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P10256, DOI 10.1021/bi00106a025; JAIN MK, 1992, BIOCHEMISTRY-US, V31, P7841, DOI 10.1021/bi00149a014; JAIN MK, 1995, METHOD ENZYMOL, V249, P567; JAIN MK, 1995, PHYTOCHEMISTRY, V39, P537, DOI 10.1016/0031-9422(94)00960-2; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Lin Y, 1998, SCIENCE, V279, P1925, DOI 10.1126/science.279.5358.1925; Mihelich ED, 1999, BBA-MOL CELL BIOL L, V1441, P223, DOI 10.1016/S1388-1981(99)00157-2; Morioka Y, 2000, ARCH BIOCHEM BIOPHYS, V381, P31, DOI 10.1006/abbi.2000.1977; Morioka Y, 2000, FEBS LETT, V487, P262, DOI 10.1016/S0014-5793(00)02350-4; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan YH, 2001, BIOCHEMISTRY-US, V40, P609, DOI 10.1021/bi002514g; RAMIREZ F, 1991, PROTEINS, V9, P229, DOI 10.1002/prot.340090402; Rogers J, 1996, BIOCHEMISTRY-US, V35, P9375, DOI 10.1021/bi960526p; Sack JS, 1997, METHOD ENZYMOL, V277, P158, DOI 10.1016/S0076-6879(97)77011-3; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1991, SCIENCE, V254, P1007, DOI 10.1126/science.1948070; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; STEIN RL, 1993, ADV PROTEIN CHEM, V44, P1, DOI 10.1016/S0065-3233(08)60562-8; Steiner RA, 2001, ACTA CRYSTALLOGR D, V57, P516, DOI 10.1107/S0907444901002530; Suzuki N, 2000, J BIOL CHEM, V275, P5785, DOI 10.1074/jbc.275.8.5785; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; Valentin E, 2000, BIOCHEM BIOPH RES CO, V279, P223, DOI 10.1006/bbrc.2000.3908; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; VANEIJK JH, 1983, EUR J BIOCHEM, V132, P183; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787; Yu BZ, 2000, BIOCHEMISTRY-US, V39, P12312, DOI 10.1021/bi000740k; Yu BZ, 1999, BIOCHEMISTRY-US, V38, P10449, DOI 10.1021/bi990194z	53	72	73	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					29086	29093		10.1074/jbc.M202531200	http://dx.doi.org/10.1074/jbc.M202531200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12161451	hybrid			2022-12-27	WOS:000177342600096
J	Kim, HS; Skurk, C; Thomas, SR; Bialik, A; Suhara, T; Kureishi, Y; Birnbaum, M; Keaney, JF; Walsh, K				Kim, HS; Skurk, C; Thomas, SR; Bialik, A; Suhara, T; Kureishi, Y; Birnbaum, M; Keaney, JF; Walsh, K			Regulation of angiogenesis by glycogen synthase kinase-3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; PROTEIN-KINASE AKT; TRANSCRIPTION FACTOR; GLUCOSE-METABOLISM; CELLS; EXPRESSION; 3-BETA; MIGRATION; MANNER; GSK3	Glycogen synthase kinase-3beta (GSK3beta) plays important roles in metabolism, embryonic development, and tumorigenesis. Here we investigated the role of GSK3beta signaling in vascular biology by examining its function in endothelial cells (ECs). In EC, the regulatory phosphorylation of GSK3beta,6 was found to be under the control of phosphoinositide 3-kinase-, MAPK-, and protein kinase A-dependent signaling pathways. The transduction of a nonphosphorylatable constitutively active mutant of GSKbeta promoted apoptosis under the conditions of prolonged serum deprivation or the disruption of eel matrix attachments. Conversely, the transduction of catalytically inactive GSK3beta promoted EC survival under the conditions of cellular stress. Under normal cell culture conditions, the activation of GSK3beta signaling inhibited the migration of EC to vascular endothelial growth factor or basic fibroblast growth factor. Angiogenesis was inhibited by GSK3beta activation in an in vivo Matrigel plug assay, whereas the inhibition of GSK3beta signaling enhanced capillary formation. These data suggest that GSK3beta functions at the nodal point of converging signaling pathways in EC to regulate vessel growth through its control of vascular cell migration and survival.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea; Tufts Univ, St Elizabeths Med Ctr, Sch Med, Div Cardiovasc Res, Boston, MA 02135 USA	Boston University; Howard Hughes Medical Institute; University of Pennsylvania; Seoul National University (SNU); Seoul National University Hospital; St. Elizabeth's Medical Center; Tufts University	Walsh, K (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W611, Boston, MA 02118 USA.		Kim, Hyo Soo/J-2753-2012; Bando, Yasuko K./M-4831-2014	Bando, Yasuko K./0000-0003-4166-6784; Birnbaum, Morris/0000-0001-9972-8680; Keaney, John/0000-0002-0866-1837	NHLBI NIH HHS [HL-50692] Funding Source: Medline; NIAMS NIH HHS [AR-40197] Funding Source: Medline; NIA NIH HHS [AG-15052, AG-17241] Funding Source: Medline; NICHD NIH HHS [HD-23681] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017241, R37AG015052, R01AG015052] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Boo YC, 2002, J BIOL CHEM, V277, P3388, DOI 10.1074/jbc.M108789200; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Duplaa C, 1999, CIRC RES, V84, P1433; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Hall JL, 2001, DIABETES, V50, P1171, DOI 10.2337/diabetes.50.5.1171; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Huang A, 2000, J BIOL CHEM, V275, P17399, DOI 10.1074/jbc.M002248200; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Luo ZY, 2000, J CLIN INVEST, V106, P493, DOI 10.1172/JCI9419; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Morisco C, 2001, J BIOL CHEM, V276, P28586, DOI 10.1074/jbc.M103166200; PASSANITI A, 1992, LAB INVEST, V67, P519; Ruel L, 1999, J BIOL CHEM, V274, P21790, DOI 10.1074/jbc.274.31.21790; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Summers SA, 1999, J BIOL CHEM, V274, P17934, DOI 10.1074/jbc.274.25.17934; Thomas SR, 2002, J BIOL CHEM, V277, P6017, DOI 10.1074/jbc.M109107200; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Witzenbichler B, 1999, J CLIN INVEST, V104, P1469, DOI 10.1172/JCI7251	27	109	111	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41888	41896		10.1074/jbc.M206657200	http://dx.doi.org/10.1074/jbc.M206657200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12167628	hybrid			2022-12-27	WOS:000178985300076
J	Stahl, A; Moberg, P; Ytterberg, J; Panfilov, O; von Lowenhielm, HB; Nilsson, F; Glaser, E				Stahl, A; Moberg, P; Ytterberg, J; Panfilov, O; von Lowenhielm, HB; Nilsson, F; Glaser, E			Isolation and identification of a novel mitochondrial metalloprotease (PreP) that degrades targeting presequences in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP-DEPENDENT PROTEASE; OPPOSITE MEMBRANE SURFACES; AAA PROTEASES; IMPORT MACHINERY; CATALYTIC SITES; INNER MEMBRANE; RAT-LIVER; DEGRADATION; COMPLEX; RESPIRATION	Most of the nuclear encoded mitochondrial precursor proteins contain an N-terminal extension called the presequence that carries targeting information and that is cleaved off after import into mitochondria. The presequences are amphiphilic, positively charged, membrane-interacting peptides with a propensity to form a-helices. Here we have investigated the proteolysis of the presequences that have been cleaved off inside mitochondria. A presequence derived from the overexpressed F(1)beta subunit of the ATP synthase and specific synthetic fluorescent peptides (Pep Tag Protease assay) have been shown to undergo rapid degradation catalyzed by a matrix located protease. We have developed a three-step chromatographic procedure including affinity and anion exchange chromatography for isolation of the protease from potato tuber mitochondria. Two-dimensional gel electrophoresis of the isolated proteolytically active fraction followed by electrospray ionization-mass spectrometry/mass spectrometry and data base searches allowed identification of the presequence peptide-degrading protease in Arabidopsis thaliana data base as a novel mitochondrial metalloendoprotease with a molecular mass of 105 kDa. The identified metalloprotease contains an inverted zinc-binding motif and belongs to the pitrilysin family.	Stockholm Univ, Arrhenius Labs Nat Sci, Dept Biochem & Biophys, S-10691 Stockholm, Sweden; Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA; AstraZeneca R & D Molndal, Dept Biochem & Cell Biol, Res Area Cardiovasc Gastrointestinal, S-43183 Molndal, Sweden	Stockholm University; Cornell University; AstraZeneca	Glaser, E (corresponding author), Stockholm Univ, Arrhenius Labs Nat Sci, Dept Biochem & Biophys, S-10691 Stockholm, Sweden.	e_glaser@dbb.su.se	Ytterberg, Anders/E-1773-2016	Ytterberg, Anders/0000-0002-1485-2314				Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Ackrell BAC, 2000, FEBS LETT, V466, P1, DOI 10.1016/S0014-5793(99)01749-4; AUTHIER F, 1995, P NATL ACAD SCI USA, V92, P3859, DOI 10.1073/pnas.92.9.3859; Barakat S, 1998, PLANT MOL BIOL, V37, P141, DOI 10.1023/A:1005912831051; BRANDT U, 1993, J BIOL CHEM, V268, P8387; Cabezon E, 2001, EMBO J, V20, P6990, DOI 10.1093/emboj/20.24.6990; Deng KP, 1998, J BIOL CHEM, V273, P20752, DOI 10.1074/jbc.273.33.20752; Donate F, 2000, J BIOL CHEM, V275, P34147, DOI 10.1074/jbc.M004494200; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; DYCK LV, 1999, CELL MOL LIFE SCI, V30, P825; DYCK LV, 1998, GENE DEV, V15, P1515; ERIKSSON AC, 1994, BBA-BIOENERGETICS, V1186, P221, DOI 10.1016/0005-2728(94)90181-3; Faure M, 2000, EUR J BIOCHEM, V267, P2890, DOI 10.1046/j.1432-1033.2000.01330.x; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; Fluckiger S, 2002, J IMMUNOL, V168, P1267, DOI 10.4049/jimmunol.168.3.1267; FURUYA S, 1991, EMBO J, V10, P1759, DOI 10.1002/j.1460-2075.1991.tb07700.x; Glaser E, 1999, J BIOENERG BIOMEMBR, V31, P259, DOI 10.1023/A:1005475930477; GLASER SM, 1990, J BIOL CHEM, V265, P8817; GLASER SM, 1990, J BIOL CHEM, V265, P8808; Goodfellow BJ, 2001, FEBS LETT, V505, P325, DOI 10.1016/S0014-5793(01)02818-6; Gotoh T, 1996, FEBS LETT, V395, P119, DOI 10.1016/0014-5793(96)01015-0; Halperin T, 2001, PLANT MOL BIOL, V45, P461, DOI 10.1023/A:1010677220323; Hammen PK, 1996, BIOCHEMISTRY-US, V35, P3772, DOI 10.1021/bi951848g; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; HUGOSSON M, 1994, EUR J BIOCHEM, V223, P1027, DOI 10.1111/j.1432-1033.1994.tb19081.x; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Kaiser R, 1999, ANAL BIOCHEM, V266, P1, DOI 10.1006/abio.1998.2945; Kaser M, 2000, SEMIN CELL DEV BIOL, V11, P181, DOI 10.1006/scdb.2000.0166; Klanner C, 2001, MOL BIOL CELL, V12, P2858, DOI 10.1091/mbc.12.9.2858; KUZELA S, 1994, METHOD ENZYMOL, V244, P376; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langer T, 2000, TRENDS BIOCHEM SCI, V25, P247, DOI 10.1016/S0968-0004(99)01541-8; Lanne B, 2001, PROTEOMICS, V1, P819, DOI 10.1002/1615-9861(200107)1:7<819::AID-PROT819>3.3.CO;2-M; Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x; Leveque VJP, 2000, BIOCHEMISTRY-US, V39, P7131, DOI 10.1021/bi9929958; Lu Y, 1997, J BIOL CHEM, V272, P13555, DOI 10.1074/jbc.272.21.13555; MADUKE M, 1993, SCIENCE, V260, P364, DOI 10.1126/science.8385804; Martoglio B, 1998, TRENDS CELL BIOL, V8, P410, DOI 10.1016/S0962-8924(98)01360-9; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; Matsuzaki K, 1996, BIOCHEMISTRY-US, V35, P11361, DOI 10.1021/bi960016v; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; Meisinger C, 1999, CELL MOL LIFE SCI, V56, P817, DOI 10.1007/s000180050028; Millar AH, 2001, PLANT PHYSIOL, V127, P1711, DOI 10.1104/pp.010387; Mzhavia N, 1999, DNA CELL BIOL, V18, P369, DOI 10.1089/104454999315268; NICOLAY K, 1994, J BIOENERG BIOMEMBR, V26, P327, DOI 10.1007/BF00763104; Omura T, 1998, J BIOCHEM-TOKYO, V123, P1010; ONO H, 1988, J BIOL CHEM, V263, P3188; Paschen SA, 2001, IUBMB LIFE, V52, P101, DOI 10.1080/15216540152845894; PAVLOV P, 1999, BIOCHEM J, V1, P95; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Rassow J, 2000, TRAFFIC, V1, P457, DOI 10.1034/j.1600-0854.2000.010603.x; RAWLINGS N, 1991, BIOCHEM J, V15, P389; Rehling P, 2001, CRIT REV BIOCHEM MOL, V36, P291, DOI 10.1080/20014091074200; Richter S, 1999, J CELL BIOL, V147, P33, DOI 10.1083/jcb.147.1.33; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; RYAN CA, 1974, J BIOL CHEM, V249, P5495; SAGARRA MD, 1999, J MOL BIOL, V1, P819; Savel'ev AS, 1998, J BIOL CHEM, V273, P20596, DOI 10.1074/jbc.273.32.20596; Schneider G, 1998, PROTEINS, V30, P49, DOI 10.1002/(SICI)1097-0134(19980101)30:1<49::AID-PROT5>3.3.CO;2-P; Shah ZH, 2000, FEBS LETT, V478, P267, DOI 10.1016/S0014-5793(00)01859-7; Stahl A, 2000, BIOCHEM J, V349, P703, DOI 10.1042/bj3490703; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; Truscott KN, 2001, REV PHYSIOL BIOCH P, V143, P81, DOI 10.1007/BFb0115593; VANDYCK L, 1994, J BIOL CHEM, V269, P238; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; Wieprecht T, 2000, BIOCHEMISTRY-US, V39, P15297, DOI 10.1021/bi001774v; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Young L, 2001, SCIENCE, V291, P2135, DOI 10.1126/science.1056957; ZARDENETA G, 1992, J BIOL CHEM, V267, P24193; Zhang XP, 1999, J MOL BIOL, V288, P177, DOI 10.1006/jmbi.1999.2669; Zhang XP, 2002, TRENDS PLANT SCI, V7, P14, DOI 10.1016/S1360-1385(01)02180-X; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	75	99	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41931	41939		10.1074/jbc.M205500200	http://dx.doi.org/10.1074/jbc.M205500200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12138166	hybrid			2022-12-27	WOS:000178985300081
J	Romanelli, A; Dreisbach, VC; Blenis, J				Romanelli, A; Dreisbach, VC; Blenis, J			Characterization of phosphatidylinositol 3-kinase-dependent phosphorylation of the hydrophobic motif site Thr(389) in p70 S6 kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; C-ZETA; PHOSPHOINOSITIDE 3-KINASE; IN-VIVO; DOCKING SITE; ACTIVATION; PDK1; P70(S6K); IDENTIFICATION; DISRUPTION	Phosphorylation of the highly conserved hydrophobic motif site in AGC kinases is necessary for phosphotransferase activity. Phosphorylation of this motif (FLGFT389Y) in p70 S6 kinase (S6K1) is both rapamycin-and wortmannin-sensitive, suggesting a role for both mammalian target of rapamycin- and phosphatidylinositol 3-kinase-dependent pathways. We report here that co-expression of phosphoinositide-dependent kinase-1 (PDK1) and the phosphatidylinositol 3-kinase-regulated atypical protein kinase Q cooperate to increase both phosphorylation of the hydrophobic motif site Thr(389), as well as the activation loop site Thr(229). Interestingly, although PDK1 alone can promote an increase in Thr(389) phosphorylation in both wild type S6K1 and a kinase-inactive mutant of S6K1, the cooperative effect between PDK1 and protein kinase Q required S6K1 activity. Furthermore, Akt, another phosphatidylinositol 3-kinase effector and regulator of S6K1, also increased Thr(389) phosphorylation in a S6K1 activity-dependent manner. Consistent with this, epidermal growth factor-induced Thr(389) phosphorylation in wild type S6K1 persisted for up to 120 min, whereas kinase-inactive mutants of S6K1 displayed only a reduced and transient increase in Thr(389) phosphorylation. We conclude that S6K1 activity is required for maximal Thr(389) phosphorylation by mitogens and by multiple phosphatidylinositol 3-kinase-dependent inputs including PDK1, PKCzeta, and Akt, and we propose that autophosphorylation is an important regulatory mechanism for phosphorylation of the hydrophobic motif Thr(389) site in S6K1.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Blenis, J (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.				NIGMS NIH HHS [GM 51405] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akimoto K, 1998, BIOCHEM J, V335, P417, DOI 10.1042/bj3350417; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Ballif BA, 2001, J BIOL CHEM, V276, P12466, DOI 10.1074/jbc.M009939200; Behn-Krappa A, 1999, CURR BIOL, V9, P728, DOI 10.1016/S0960-9822(99)80332-7; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; Biondi RM, 2001, EMBO J, V20, P4380, DOI 10.1093/emboj/20.16.4380; Biondi RM, 2000, EMBO J, V19, P979, DOI 10.1093/emboj/19.5.979; BLENIS J, 1986, P NATL ACAD SCI USA, V82, P1733; Bornancin F, 1997, J BIOL CHEM, V272, P3544, DOI 10.1074/jbc.272.6.3544; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Kohn AD, 1998, J BIOL CHEM, V273, P11937, DOI 10.1074/jbc.273.19.11937; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lizcano JM, 2002, CURR BIOL, V12, pR236, DOI 10.1016/S0960-9822(02)00777-7; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Martin KA, 2001, J BIOL CHEM, V276, P7884, DOI 10.1074/jbc.M006969200; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Proud CG, 2001, BIOCHEM SOC T, V29, P541, DOI 10.1042/BST0290541; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Remy I, 2001, P NATL ACAD SCI USA, V98, P7678, DOI 10.1073/pnas.131216098; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Weng QP, 1998, J BIOL CHEM, V273, P16621, DOI 10.1074/jbc.273.26.16621; WENG QP, 1995, MOL CELL BIOL, V15, P2333; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	48	66	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40281	40289		10.1074/jbc.M205168200	http://dx.doi.org/10.1074/jbc.M205168200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183455	hybrid			2022-12-27	WOS:000178791400018
J	Wang, DX; Esselman, WJ; Cole, PA				Wang, DX; Esselman, WJ; Cole, PA			Substrate conformational restriction and CD45-catalyzed dephosphorylation of tail tyrosine-phosphorylated Src protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOCYTE-ACTIVATION; RECIPROCAL REGULATION; KINASE HCK; MECHANISM; CD45; PHOSPHATASES; SPECIFICITY; INSIGHTS; DOMAINS; CSK	Hydrolysis of the tail phosphotyrosine in Src family members is catalyzed by the protein-tyrosine phosphatase CD45, activating Src family-related signaling pathways. Using purified recombinant phospho-Src (P-Src) (amino acid residues 83-533) and purified recombinant CD45 catalytic (cytoplasmic) domain (amino acid residues 565-1268), we have analyzed the kinetic behavior of dephosphorylation. A time course of phosphatase activity showed the presence of a burst phase. By varying the concentration of P-Src, it was shown that the amplitude of this burst phase increased linearly with respect to P-Src concentration. Approximately 2% of P-Src was shown to be rapidly dephosphorylated followed by a slower linear phase. A P-Src protein substrate containing a functional point mutation in the Src homology domain 2 (SH2) led to more rapid dephosphorylation catalyzed by CD45, and this reaction showed only a single linear kinetic phase. These results were interpreted in terms of a model in which P-Src exists in a relatively slow dynamic equilibrium between "closed" and "open" conformational forms. Combined mutations in the SH2 and SH3 domain or the addition of an SH3 domain ligand peptide enhanced the accessibility of P-Src to CD45 by biasing P-Src to a more open form. Consistent with this model, a phosphotyrosine peptide that behaved as an SH2 domain binding ligand showed similar to100-fold greater affinity for unphosphorylated Src versus P-Src. Surprisingly, P-Src possessing combined SH3 and SH2 functional inactivating point mutations was dephosphorylated by CD45 more slowly compared with P-Src completely lacking SH3 and SH2 domains. Additional data suggest that the SH3 and SH2 domains can inhibit accessibility of the P-Src tail to CD45 by interactions other than direct phosphotyrosine binding by the SH2 domain. Taken together, these results suggest how activation of Src family member signaling pathways by CD45 may be influenced by the presence or absence of ligand interactions remote from the tail.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA	Johns Hopkins University; Michigan State University	Cole, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA.	pcole@jhmi.edu			NCI NIH HHS [CA 74305] Funding Source: Medline; NIAID NIH HHS [AI 42794] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074305, R01CA074305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042794] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Boerner RJ, 1996, BIOCHEMISTRY-US, V35, P9519, DOI 10.1021/bi960248u; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; CHO HJ, 1992, BIOCHEMISTRY-US, V31, P133, DOI 10.1021/bi00116a019; Feng SB, 1995, P NATL ACAD SCI USA, V92, P12408, DOI 10.1073/pnas.92.26.12408; GHOSE C, 1985, BIOCHEMISTRY-US, V24, P5894, DOI 10.1021/bi00342a031; Grace MR, 1997, BIOCHEMISTRY-US, V36, P1874, DOI 10.1021/bi962138t; Hermiston ML, 2002, J CLIN INVEST, V109, P9; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jiang YL, 2001, J BIOL CHEM, V276, P42347, DOI 10.1074/jbc.M106594200; JOHNSON P, 1992, J BIOL CHEM, V267, P8035; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Ogawa A, 2002, J BIOL CHEM, V277, P14351, DOI 10.1074/jbc.C200086200; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; Shekhtman A, 2001, J MOL BIOL, V314, P129, DOI 10.1006/jmbi.2001.5126; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Sondhi D, 1999, BIOCHEMISTRY-US, V38, P11147, DOI 10.1021/bi990827+; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; THOMAS ML, 1994, CURR OPIN CELL BIOL, V6, P247, DOI 10.1016/0955-0674(94)90143-0; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Wang DX, 2001, BIOCHEMISTRY-US, V40, P2004, DOI 10.1021/bi002342n; Wang DX, 2001, J AM CHEM SOC, V123, P8883, DOI 10.1021/ja010540b; Wang Y, 1999, J BIOL CHEM, V274, P7454, DOI 10.1074/jbc.274.11.7454; Wang ZX, 2002, BIOCHEMISTRY-US, V41, P7849, DOI 10.1021/bi025776m; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Zhao Y, 2001, J BIOL CHEM, V276, P32382, DOI 10.1074/jbc.M103369200	33	20	20	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40428	40433		10.1074/jbc.M206467200	http://dx.doi.org/10.1074/jbc.M206467200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181320	hybrid			2022-12-27	WOS:000178791400036
J	Yu, ZB; Fotouhi-Ardakani, N; Wu, LT; Maoui, M; Wang, SL; Banville, D; Shen, SH				Yu, ZB; Fotouhi-Ardakani, N; Wu, LT; Maoui, M; Wang, SL; Banville, D; Shen, SH			PTEN associates with the vault particles in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; TUMOR-SUPPRESSOR PTEN; RESISTANCE-RELATED PROTEIN; GERMLINE MUTATIONS; COWDEN-DISEASE; PHOSPHATIDYLINOSITOL 3-KINASE; RIBONUCLEOPROTEIN-PARTICLES; SIGNALING PATHWAYS; BREAST-CANCER; PDZ DOMAIN	PTEN is a tumor suppressor that primarily dephosphorylates phosphatidylinositol 3,4,5-trisphosphate to down-regulate the phosphoinositide 3-kinase/Akt signaling pathway. Although the cellular functions of PTEN as a tumor suppressor have been well characterized, the mechanism by which PTEN activity is modulated by other signal molecules in vivo remains poorly understood. In searching for potential PTEN modulators through protein-protein interaction, we identified the major vault protein (MVP) as a dominant PTEN-binding protein in a yeast two-hybrid screen. MVP is the major structural component of vault, the largest intracellular ribonucleoprotein particle. Co-immunoprecipitation confirmed the interaction between PTEN and MVP in transfected mammalian cells. More importantly, we found that a significant portion of endogenous PTEN associates with vault particles in human HeLa cells. Deletion mutation analysis demonstrated that MVP binds to the C2 domain of PTEN and that PTEN interacts with MVP through its EF hand-like motif. Furthermore, the in vitro binding experiments revealed that the interaction of PTEN with MVP is Ca2+-dependent.	Natl Res Council Canada, Biotechnol Res Inst, Hlth Sector, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada	National Research Council Canada; McGill University	Shen, SH (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Hlth Sector, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.							Abbondanza C, 1998, J CELL BIOL, V141, P1301, DOI 10.1083/jcb.141.6.1301; Adey NB, 2000, CANCER RES, V60, P35; Cheng SH, 2000, TOXICOL APPL PHARM, V164, P134, DOI 10.1006/taap.2000.8903; CHUGANI DC, 1993, J CELL SCI, V106, P23; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Downes CP, 2001, BIOCHEM SOC T, V29, P846, DOI 10.1042/BST0290846; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Hu Y, 2002, INT J CANCER, V97, P149, DOI 10.1002/ijc.1590; KEDERSHA NL, 1991, J CELL BIOL, V112, P225, DOI 10.1083/jcb.112.2.225; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; Keegan K, 1996, ONCOGENE, V12, P1537; KICKHOEFER VA, 1993, J BIOL CHEM, V268, P7868; Kickhoefer VA, 1999, J BIOL CHEM, V274, P32712, DOI 10.1074/jbc.274.46.32712; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kitazono M, 1999, JNCI-J NATL CANCER I, V91, P1647, DOI 10.1093/jnci/91.19.1647; Kong LB, 1999, STRUCT FOLD DES, V7, P371, DOI 10.1016/S0969-2126(99)80050-1; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Leslie NR, 2000, BIOCHEM J, V346, P827, DOI 10.1042/0264-6021:3460827; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Lynch ED, 1997, AM J HUM GENET, V61, P1254, DOI 10.1086/301639; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; Mills GB, 2001, SEMIN ONCOL, V28, P125, DOI 10.1053/sonc.2001.28554; Morimoto AM, 1999, ONCOGENE, V18, P1261, DOI 10.1038/sj.onc.1202441; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nelen MR, 1997, HUM MOL GENET, V6, P1383, DOI 10.1093/hmg/6.8.1383; Perren A, 2000, AM J PATHOL, V157, P1097, DOI 10.1016/S0002-9440(10)64624-X; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Scheffer GL, 2000, CURR OPIN ONCOL, V12, P550, DOI 10.1097/00001622-200011000-00007; SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; VANZON, 2002, BIOCH BIOPHYS RES CO, V291, P535; Waite KA, 2002, AM J HUM GENET, V70, P829, DOI 10.1086/340026; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Williams RL, 1999, BBA-MOL CELL BIOL L, V1441, P255, DOI 10.1016/S1388-1981(99)00150-X; Wu LT, 2002, MOL CELL BIOL, V22, P2673, DOI 10.1128/MCB.22.8.2673-2686.2002; Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233; Wu Y, 2000, J BIOL CHEM, V275, P21477, DOI 10.1074/jbc.M909741199; Yamada KM, 2001, J CELL SCI, V114, P2375; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687	51	84	88	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40247	40252		10.1074/jbc.M207608200	http://dx.doi.org/10.1074/jbc.M207608200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177006	hybrid			2022-12-27	WOS:000178791400013
J	Cao, GQ; Beyer, TP; Yang, XP; Schmidt, RJ; Zhang, YY; Bensch, WR; Kauffman, RF; Gao, H; Ryan, TP; Liang, Y; Eacho, PI; Jiang, XC				Cao, GQ; Beyer, TP; Yang, XP; Schmidt, RJ; Zhang, YY; Bensch, WR; Kauffman, RF; Gao, H; Ryan, TP; Liang, Y; Eacho, PI; Jiang, XC			Phospholipid transfer protein is regulated by liver X receptors in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E; OXYSTEROL RECEPTORS; INTERNAL PROMOTER; TRANSGENIC MICE; TANGIER-DISEASE; LXR-ALPHA; GENE; CHOLESTEROL; EXPRESSION; EFFLUX	Liver X receptors (LXR) belong to the nuclear receptor superfamily that can regulate important lipid metabolic pathways. The plasma phospholipid transfer protein (PLTP) is known to mediate transfer of phospholipids from triglyceride-rich lipoproteins to high density lipoprotein (HDL) and plays a critical role in HDL metabolism. We report here that a specific LXR agonist, T0901317, elevated HDL cholesterol and phospholipid in C57/BL6 mice and generated enlarged HDL particles that were enriched in cholesterol, ApoAI, ApoE, and phospholipid. The appearance of these HDL particles upon oral dosing of T0901317 in C57/BL6 mice was closely correlated with the increased plasma PLTP activity and liver PLTP mRNA levels. Nuclear run-on assay indicated that the effect of LXR agonist on PLTP expression was at the transcriptional level. In mouse peritoneal macrophage cells, PLTP expression was also up-regulated by the LXR/RXR (retinoid X receptor) heterodimer. However, cholesterol efflux in mouse peritoneal macrophage cells from PLTP-deficient mice (PLTP0) was not significantly different from wild type animals. Although in PLTP-deficient mice, the induction of HDL cholesterol as well as HDL particle size increase persisted, the extent of the induction was greatly attenuated. We conclude that PLTP is a direct target gene of LXRs in vivo and plays an important role in LXR agonist-mediated HDL cholesterol and size increase in mice.	Eli Lilly & Co, Cardiovasc Res, Lilly Res Labs, Indianapolis, IN 46285 USA; Suny Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA	Eli Lilly; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Cao, GQ (corresponding author), Eli Lilly & Co, Cardiovasc Res, Lilly Res Labs, Indianapolis, IN 46285 USA.	Guoqing_Cao@lilly.com			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069817] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 69817] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baez JM, 2002, J BIOL CHEM, V277, P6198, DOI 10.1074/jbc.M106799200; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bouly M, 2001, J BIOL CHEM, V276, P25841, DOI 10.1074/jbc.M101160200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Costet P, 2000, J BIOL CHEM, V275, P28240; Edwards PA, 2002, J LIPID RES, V43, P2; GLOMSET JA, 1968, J LIPID RES, V9, P155; GOLDMAN MJ, 1985, J BIOL CHEM, V260, P4404; HA YC, 1982, COMP BIOCHEM PHYS B, V71, P265, DOI 10.1016/0305-0491(82)90252-8; Huuskonen J, 1998, J LIPID RES, V39, P2021; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Kennedy MA, 2001, J BIOL CHEM, V276, P39438, DOI 10.1074/jbc.M105863200; KIEFT KA, 1991, J LIPID RES, V32, P859; Kirschning CJ, 1997, GENOMICS, V46, P416, DOI 10.1006/geno.1997.5030; KOO C, 1985, J BIOL CHEM, V260, P1934; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Luo Y, 2000, J CLIN INVEST, V105, P513, DOI 10.1172/JCI8573; Mak PA, 2002, J BIOL CHEM, V277, P31900, DOI 10.1074/jbc.M202993200; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Oram JF, 2001, EXPERT OPIN INV DRUG, V10, P427, DOI 10.1517/13543784.10.3.427; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Qin SC, 2000, J LIPID RES, V41, P269; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHIBLER U, 1983, CELL, V33, P501, DOI 10.1016/0092-8674(83)90431-2; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Singaraja RR, 2001, J BIOL CHEM, V276, P33969, DOI 10.1074/jbc.M102503200; Vaisman BL, 2001, J CLIN INVEST, V108, P303; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; YAMASHITA S, 1990, J CLIN INVEST, V86, P688, DOI 10.1172/JCI114764; Zhang Y, 2001, J BIOL CHEM, V276, P43018, DOI 10.1074/jbc.M107823200	36	149	158	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39561	39565		10.1074/jbc.M207187200	http://dx.doi.org/10.1074/jbc.M207187200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177004	hybrid			2022-12-27	WOS:000178662500066
J	Jung, H; Buchholz, M; Clausen, J; Nietschke, M; Revermann, A; Schmid, R; Jung, K				Jung, H; Buchholz, M; Clausen, J; Nietschke, M; Revermann, A; Schmid, R; Jung, K			CaiT of Escherichia coli, a new transporter catalyzing L-carnitine/gamma-butyrobetaine exchange	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORYNEBACTERIUM-GLUTAMICUM; GLYCINE BETAINE; CROTONOBETAINE REDUCTASE; MELIBIOSE PERMEASE; METABOLISM; PROTEINS; RECONSTITUTION; PURIFICATION; EXPRESSION; SYSTEM	L-Carnitine is essential for 6-oxidation of fatty acids in mitochondria. Bacterial metabolic pathways are used for the production of this medically important compound. Here, we report the first detailed functional characterization of the caiT gene product, a putative transport protein whose function is required for L-carnitine conversion in Escherichia coli. The caiT gene was overexpressed in E. coli, and the gene product was purified by affinity chromatography and reconstituted into proteoliposomes. Functional analyses with intact cells and proteoliposomes demonstrated that CaiT is able to catalyze the exchange of L-carnitine for gamma-butyrobetaine, the excreted end product of L-carnitine conversion in E. coli, and related betaines. Electrochemical ion gradients did not significantly stimulate L-carnitine uptake. Analysis of L-carnitine counterflow yielded an apparent external K. of 105 mum and a turnover number of 5.5 s(-1). Contrary to related proteins, CaiT activity was not modulated by osmotic stress. L-Carnitine binding to CaiT increased the protein fluorescence and caused a red shift in the emission maximum, an observation explained by ligand-induced conformational alterations. The fluorescence effect was specific for betaine structures, for which the distance between trimethylammonium and carboxyl groups proved to be crucial for affinity. Taken together, the results suggest that CaiT functions as an exchanger (antiporter) for L-carnitine and gamma-butyrobetaine according to the substrate/product antiport principle.	Univ Osnabruck, Abt Mikrobiol, Fachbereich Biol Chem, D-49069 Osnabruck, Germany	University Osnabruck	Jung, H (corresponding author), Univ Osnabruck, Abt Mikrobiol, Fachbereich Biol Chem, Barbarastr 11, D-49069 Osnabruck, Germany.		Jung, Heinrich/K-3790-2014	Jung, Heinrich/0000-0002-5450-3063				BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BREMER J, 1983, PHYSIOL REV, V63, P1420, DOI 10.1152/physrev.1983.63.4.1420; Buchet A, 1999, MOL MICROBIOL, V34, P562, DOI 10.1046/j.1365-2958.1999.01622.x; CULHAM DE, 1993, J MOL BIOL, V229, P268, DOI 10.1006/jmbi.1993.1030; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; EICHLER K, 1994, MOL MICROBIOL, V13, P775, DOI 10.1111/j.1365-2958.1994.tb00470.x; EICHLER K, 1994, J BACTERIOL, V176, P2970, DOI 10.1128/JB.176.10.2970-2975.1994; EICHLER K, 1995, J BASIC MICROB, V35, P217, DOI 10.1002/jobm.3620350404; Elssner T, 2000, BIOCHEMISTRY-US, V39, P10761, DOI 10.1021/bi000776c; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; INDIVERI C, 1991, BIOCHIM BIOPHYS ACTA, V1065, P231, DOI 10.1016/0005-2736(91)90235-Z; JUNG H, 1990, J BASIC MICROB, V30, P409, DOI 10.1002/jobm.3620300605; JUNG H, 1989, BIOCHIM BIOPHYS ACTA, V1003, P270, DOI 10.1016/0005-2760(89)90232-4; Jung H, 1998, BIOCHEMISTRY-US, V37, P11083, DOI 10.1021/bi980684b; JUNG H, 1990, J BASIC MICROB, V30, P507, DOI 10.1002/jobm.3620300711; Jung H, 1993, Adv Biochem Eng Biotechnol, V50, P21; JUNG K, 1987, J BASIC MICROB, V27, P131, DOI 10.1002/jobm.3620270303; Kappes RM, 1996, J BACTERIOL, V178, P5071, DOI 10.1128/jb.178.17.5071-5079.1996; Kleber HP, 1997, FEMS MICROBIOL LETT, V147, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MILLER JH, 1992, SHORT COURSE BACTERI, P102; MUSVETEAU I, 1995, BIOCHEMISTRY-US, V34, P6775, DOI 10.1021/bi00020a024; MusVeteau I, 1996, BIOCHEMISTRY-US, V35, P12053, DOI 10.1021/bi961372g; Obon JM, 1999, APPL MICROBIOL BIOT, V51, P760, DOI 10.1007/s002530051459; Peter H, 1998, J BIOL CHEM, V273, P2567, DOI 10.1074/jbc.273.5.2567; Peter H, 1996, J BACTERIOL, V178, P5229, DOI 10.1128/jb.178.17.5229-5234.1996; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Poolman B, 1996, MOL MICROBIOL, V19, P911, DOI 10.1046/j.1365-2958.1996.397949.x; POOLMAN B, 1990, MOL MICROBIOL, V4, P1629, DOI 10.1111/j.1365-2958.1990.tb00539.x; Preusser A, 1999, BBA-PROTEIN STRUCT M, V1431, P166, DOI 10.1016/S0167-4838(99)00032-1; Quick M, 1996, EUR J BIOCHEM, V239, P732, DOI 10.1111/j.1432-1033.1996.0732u.x; Racher KI, 1999, BIOCHEMISTRY-US, V38, P1676, DOI 10.1021/bi981279n; Rebouche CJ, 1998, ANNU REV NUTR, V18, P39, DOI 10.1146/annurev.nutr.18.1.39; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; ROTH S, 1994, ANTON LEEUW INT J G, V65, P63, DOI 10.1007/BF00878280; Rubenhagen R, 2000, J BIOL CHEM, V275, P735, DOI 10.1074/jbc.275.2.735; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schmid R, 1997, MICROBIOL-UK, V143, P991, DOI 10.1099/00221287-143-3-991; SEIM H, 1980, Z ALLG MIKROBIOL, V20, P591, DOI 10.1002/jobm.3630200909; SEIM H, 1982, ACTA BIOL MED GER, V41, P1009; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Veenstra M, 2002, J MEMBRANE BIOL, V185, P249, DOI 10.1007/s00232-001-0127-9; Verheul A, 1998, J APPL MICROBIOL, V85, P1036, DOI 10.1111/j.1365-2672.1998.tb05269.x; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	50	43	45	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39251	39258		10.1074/jbc.M206319200	http://dx.doi.org/10.1074/jbc.M206319200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163501	hybrid			2022-12-27	WOS:000178662500026
J	Li, JH; Park, SW; Loh, HH; Wei, LN				Li, JH; Park, SW; Loh, HH; Wei, LN			Induction of the mouse kappa-opioid receptor gene by retinoic acid in P19 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; BOX-BINDING-PROTEINS; HAMSTER OVARY CELLS; SIGNAL-TRANSDUCTION; SP1 PHOSPHORYLATION; DNA-BINDING; C-ZETA; EXPRESSION; CLONING; DIFFERENTIATION	The mouse K-opioid receptor (KOR) gene is expressed in mouse embryonal carcinoma P19 cells and induced by retinoic acid (RA) within 24 h. An RA-responsive cis-acting element is identified within promoter I of the KOR gene. This element contains a GC box, a putative binding site for transcription factor Sp1. Enhanced binding of Sp1 to this GC box correlates with RA induction of KOR gene. Phosphatase inhibitor (sodium pyrophosphate) decreases RA induction of this promoter, whereas hypophosphorylation of Sp1 results in an increase in its DNA binding affinity to this promoter as demonstrated by in vitro gel retardation and in vivo chromatin immunoprecipitation assays. Consistently, the inhibitor of MEK, PD98058, dose-dependently enhances RA induction of this promoter, suggesting that the ERK signaling pathway is negatively involved in the RA induction of mouse KOR gene activities. Collectively, enhanced binding of Sp1 to promoter I of the KOR gene as a result of inhibiting the ERK pathway contributes to RA induction of this gene in P19.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wei, LN (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.			Park, Sung Wook/0000-0002-3393-8826	NIDA NIH HHS [DA00564, DA11190, DA11806] Funding Source: Medline; NIDDK NIH HHS [DK 54733, DK60521] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060521, R01DK054733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011190, R56DA000564, P50DA011806, R01DA000564] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALESSI DR, 1995, CURR BIOL, V5, P1275; Alroy I, 1999, MOL CELL BIOL, V19, P1961; ARMSTRONG DL, 1992, TRENDS NEUROSCI, V15, P403, DOI 10.1016/0166-2236(92)90192-B; Bi J, 2001, J NEUROSCI, V21, P1590, DOI 10.1523/JNEUROSCI.21-05-01590.2001; CHILDERS SR, 1991, LIFE SCI, V48, P1991, DOI 10.1016/0024-3205(91)90154-4; Fukuda K, 1996, J NEUROCHEM, V67, P1309; Fukunaga R, 1997, EMBO J, V16, P1921, DOI 10.1093/emboj/16.8.1921; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; Hu XL, 2001, J BIOL CHEM, V276, P4597, DOI 10.1074/jbc.M005477200; Hu XL, 1999, MOL BRAIN RES, V69, P35, DOI 10.1016/S0169-328X(99)00077-7; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KITCHEN I, 1990, EUR J PHARMACOL, V175, P93, DOI 10.1016/0014-2999(90)90157-2; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; Lee YI, 1998, ONCOGENE, V16, P2367, DOI 10.1038/sj.onc.1201760; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Li LY, 1996, MOL PHARMACOL, V50, P599; LIU HC, 1995, BIOCHEM BIOPH RES CO, V209, P639, DOI 10.1006/bbrc.1995.1547; Lu SL, 1997, MOL PHARMACOL, V52, P415, DOI 10.1124/mol.52.3.415; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; PARK SK, 2001, BIOCHEM BIOPH RES CO, V283, P303; Piros ET, 1996, MOL PHARMACOL, V50, P947; Rafty LA, 2001, NUCLEIC ACIDS RES, V29, P1027, DOI 10.1093/nar/29.5.1027; ROHLFF C, 1997, J BIOL CHEM, V272, P22199; SHARMA SK, 1977, P NATL ACAD SCI USA, V74, P3365, DOI 10.1073/pnas.74.8.3365; Standifer KM, 1997, CELL SIGNAL, V9, P237, DOI 10.1016/S0898-6568(96)00174-X; TALLENT M, 1994, NEUROSCIENCE, V63, P1033, DOI 10.1016/0306-4522(94)90570-3; Wei LN, 2000, MOL PHARMACOL, V57, P401; WEI LN, 1996, HDB PSYCHIAT GENETIC, P77; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Zhu QW, 2000, BIOCHEM BIOPH RES CO, V271, P100, DOI 10.1006/bbrc.2000.2586; Zhu YX, 1998, BIOL REPROD, V59, P925, DOI 10.1095/biolreprod59.4.925; Zhu YX, 1998, J NEUROSCI, V18, P2538	36	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39967	39972		10.1074/jbc.M200840200	http://dx.doi.org/10.1074/jbc.M200840200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171913	hybrid			2022-12-27	WOS:000178662500115
J	Liu, YQ; Jetton, TL; Leahy, JL				Liu, YQ; Jetton, TL; Leahy, JL			beta-cell adaptation to insulin resistance - Increased pyruvate carboxylase and malate-pyruvate shuttle activity in islets of nondiabetic Zucker fatty rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCEROL PHOSPHATE DEHYDROGENASE; GLUCOSE-REGULATED ANAPLEROSIS; PANCREATIC-ISLETS; ACID CYCLE; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; PHOSPHOFRUCTOKINASE ACTIVITY; MITOCHONDRIAL METABOLISM; GK RAT; SECRETION; OBESITY	The beta-cell biochemical mechanisms that account for the compensatory hyperfunction with insulin resistance (so-called beta-cell adaptation) are unknown. We investigated glucose metabolism in isolated islets from 10-12-week-old Zucker fatty (ZF) and Zucker lean (ZL) rats (results expressed per mg/islet of protein). ZF rats were obese, hyperlipidemic, and normoglycemic. They had a 3.8-fold increased beta-cell mass along with 3-10-fold increases in insulin secretion to various stimuli during pancreas perfusion despite insulin content per milligram of beta-cells being only one-third that of ZL rats. Islet glucose metabolism (utilization and oxidation) was 1.5-2-fold increased in the ZF islets despite pyruvate dehydrogenase activity being 30% lowered compared with the ZL islets. The reason was increased flux through pyruvate carboxylase (PC) and the malate-pyruvate and citrate-pyruvate shuttles based on the following observations (% ZL islets): increased V-max of PC (160%), malate dehydrogenase (170%), and malic enzyme (275%); elevated concentrations of oxaloacetate (150%), malate (250%), citrate (140%), and pyruvate (250%); and 2-fold increased release of malate from isolated mitochondria. Inhibition of PC by 5 mm phenylacetic acid markedly lowered glucose-induced insulin secretion in ZF and ZL islets. Thus, our results suggest that PC and the pyruvate shuttles are increased in ZF islets, and this accounts for glucose mitochondrial metabolism being increased when pyruvate dehydrogenase activity is reduced. As the anaplerosis pathways are implicated in glucose-induced insulin secretion and the synthesis of glucose-derived lipid and amino acids, our results highlight the potential importance of PC and the anaplerosis pathways in the enhanced insulin secretion and beta-cell growth that characterize beta-cell adaptation to insulin resistance.	Univ Vermont, Coll Med, Div Endocrinol Diabet & Metab, Burlington, VT 05405 USA	University of Vermont	Leahy, JL (corresponding author), Univ Vermont, Coll Med, Div Endocrinol Diabet & Metab, Given C331, Burlington, VT 05405 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK056818, R01DK056818] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK56818] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANO JDM, 1972, ACTA ENDOCRINOL-COP, V70, P487, DOI 10.1530/acta.0.0700487; Bollheimer LC, 1998, J CLIN INVEST, V101, P1094, DOI 10.1172/JCI420; Brunzell JD, 1999, DIABETES CARE, V22, pC10; Cockburn BN, 1997, DIABETES, V46, P1434, DOI 10.2337/diabetes.46.9.1434; Corkey BE, 2000, J NUTR, V130, p299S, DOI 10.1093/jn/130.2.299S; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Farfari S, 2000, DIABETES, V49, P718, DOI 10.2337/diabetes.49.5.718; Flamez D, 2002, DIABETES, V51, P2018, DOI 10.2337/diabetes.51.7.2018; GOTOH M, 1987, TRANSPLANTATION, V43, P725, DOI 10.1097/00007890-198705000-00024; Gremlich S, 1997, J BIOL CHEM, V272, P30261, DOI 10.1074/jbc.272.48.30261; Hosokawa H, 1997, DIABETOLOGIA, V40, P392, DOI 10.1007/s001250050692; Hosokawa YA, 1997, DIABETES, V46, P808, DOI 10.2337/diabetes.46.5.808; Iizuka K, 2002, BBA-MOL BASIS DIS, V1586, P23, DOI 10.1016/S0925-4439(01)00082-5; KAHN SE, 1993, DIABETES, V42, P1663, DOI 10.2337/diabetes.42.11.1663; Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374; Khan A, 1996, J BIOL CHEM, V271, P2539, DOI 10.1074/jbc.271.5.2539; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Laclau M, 2001, MOL CELL BIOCHEM, V225, P151, DOI 10.1023/A:1012238709063; Liu YQ, 1999, DIABETES, V48, P1747, DOI 10.2337/diabetes.48.9.1747; Liu YQ, 1998, J CLIN INVEST, V101, P1870, DOI 10.1172/JCI1211; Liu YQ, 1998, DIABETES, V47, P1889, DOI 10.2337/diabetes.47.12.1889; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MACDONALD MJ, 1995, ARCH BIOCHEM BIOPHYS, V319, P128, DOI 10.1006/abbi.1995.1274; MACDONALD MJ, 1993, METABOLISM, V42, P1229, DOI 10.1016/0026-0495(93)90118-8; MacDonald MJ, 1996, DIABETES, V45, P1626, DOI 10.2337/diabetes.45.11.1626; MacDonald MJ, 2002, METABOLISM, V51, P318, DOI 10.1053/meta.2002.29960; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1995, J BIOL CHEM, V270, P20051; MacDonald MJ, 1996, DIABETES, V45, P886, DOI 10.2337/diabetes.45.7.886; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; Nicholls LI, 2002, BIOCHEM BIOPH RES CO, V291, P1081, DOI 10.1006/bbrc.2002.6567; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Prentki M, 1996, EUR J ENDOCRINOL, V134, P272, DOI 10.1530/eje.0.1340272; Randle PJ, 1998, DIABETES METAB REV, V14, P263, DOI 10.1002/(SICI)1099-0895(199812)14:4&lt;263::AID-DMR233&gt;3.0.CO;2-C; REAVEN GM, 1993, ANNU REV MED, V44, P121, DOI 10.1146/annurev.me.44.020193.001005; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; SENER A, 1984, BIOCHEM J, V220, P433, DOI 10.1042/bj2200433; Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649; Ueda K, 1998, DIABETOLOGIA, V41, P649, DOI 10.1007/s001250050963; Unger RH, 2001, DIABETES, V50, pS118, DOI 10.2337/diabetes.50.2007.S118; WEIR GC, 1974, J CLIN INVEST, V54, P1403, DOI 10.1172/JCI107887; ZHOU YP, 1994, J CLIN INVEST, V93, P870, DOI 10.1172/JCI117042; ZHOU YP, 1995, DIABETES, V44, P394, DOI 10.2337/diabetes.44.4.394; Zhou YP, 1999, METABOLISM, V48, P857, DOI 10.1016/S0026-0495(99)90219-6	47	125	128	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39163	39168		10.1074/jbc.M207157200	http://dx.doi.org/10.1074/jbc.M207157200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12147706	hybrid			2022-12-27	WOS:000178662500015
J	Miyata, S; Minami, J; Tamai, E; Matsushita, O; Shimamoto, S; Okabe, A				Miyata, S; Minami, J; Tamai, E; Matsushita, O; Shimamoto, S; Okabe, A			Clostridium perfringens epsilon-toxin forms a heptameric pore within the detergent-insoluble microdomains of Madin-Darby canine kidney cells and rat synaptosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID RAFTS; PLASMA-MEMBRANE; ANCHORED PROTEIN; MDCK CELLS; CHOLESTEROL; AEROLYSIN; BINDING; SURFACE; CYCLODEXTRIN; HIPPOCAMPUS	Clostridium perfringens E-toxin, which is responsible for enterotoxaemia in ungulates, forms a heptamer in rat synaptosomal and Madin-Darby canine kidney (MDCK) cell membranes, leading to membrane permealization. Thus, the toxin may target the detergent-resistant membrane domains (DRMs) of these membranes, in analogy to aerolysin, a heptameric pore-forming toxin that associates with DRMs. To test this idea, we examined the distribution of radiolabeled E-toxin in DRM and detergent-soluble membrane fractions of MDCK cells and rat synaptosomal membranes. When MDCK cells and synaptosomal membranes were incubated with the toxin and then fractionated by cold Triton X-100 extraction and flotation on sucrose gradients, the heptameric toxin was detected almost exclusively in DRMs. The results of a toxin overlay assay revealed that the toxin preferentially bound to and heptamerized in the isolated DRMs. Furthermore, cholesterol depletion by methyl-beta-cyclodextrin abrogated their association and lowered the cytotoxicity of the toxin toward MDCK cells. When c-protoxin, an inactive precursor able to bind to but unable to heptamerized in the membrane, was incubated with MDCK cell membranes, it was detected mainly in their DRMs. These results suggest that the toxin is concentrated and induced to heptamerize on binding to a putative receptor located preferentially in DRMs, with all steps from initial binding through pore formation completed within the same DRMs.	Kagawa Med Univ, Fac Med, Dept Microbiol, Kagawa 7610793, Japan; Kagawa Prefectural Coll Hlth Sci, Dept Med Technol, Kagawa 7610123, Japan	Kagawa University	Okabe, A (corresponding author), Kagawa Med Univ, Fac Med, Dept Microbiol, 1750-1 Mik Cho, Kagawa 7610793, Japan.			TAMAI, EIJI/0000-0002-0338-5095				Abrami L, 2000, TRENDS MICROBIOL, V8, P168, DOI 10.1016/S0966-842X(00)01722-4; Abrami L, 1998, J BIOL CHEM, V273, P32656, DOI 10.1074/jbc.273.49.32656; Abrami L, 1998, J CELL BIOL, V140, P525, DOI 10.1083/jcb.140.3.525; Abrami L, 1999, J CELL BIOL, V147, P175, DOI 10.1083/jcb.147.1.175; Awasthi-Kalia M, 2001, BIOCHEM BIOPH RES CO, V287, P77, DOI 10.1006/bbrc.2001.5536; Borrmann E, 2001, FEMS IMMUNOL MED MIC, V31, P85, DOI 10.1111/j.1574-695X.2001.tb00503.x; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; Edidin M, 2001, TRENDS CELL BIOL, V11, P492, DOI 10.1016/S0962-8924(01)02139-0; Finnie JW, 1999, J COMP PATHOL, V120, P415, DOI 10.1053/jcpa.1998.0289; Fivaz M, 2001, TOXICON, V39, P1637, DOI 10.1016/S0041-0101(01)00151-9; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Germain RN, 2001, J BIOL CHEM, V276, P35223, DOI 10.1074/jbc.R100025200; HABEEB AFSA, 1973, BIOCHIM BIOPHYS ACTA, V322, P245, DOI 10.1016/0005-2795(73)90300-0; Ilangumaran S, 1998, BIOCHEM J, V335, P433, DOI 10.1042/bj3350433; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Minami J, 1997, MICROBIOL IMMUNOL, V41, P527, DOI 10.1111/j.1348-0421.1997.tb01888.x; Miyamoto O, 1998, INFECT IMMUN, V66, P2501, DOI 10.1128/IAI.66.6.2501-2508.1998; Miyamoto O, 2000, FEMS MICROBIOL LETT, V189, P109, DOI 10.1111/j.1574-6968.2000.tb09215.x; MIYATA S, 1995, MICROBIOL-SGM, V141, P2643, DOI 10.1099/13500872-141-10-2643; Miyata S, 2001, J BIOL CHEM, V276, P13778, DOI 10.1074/jbc.M011527200; NAGAHAMA M, 1992, INFECT IMMUN, V60, P1237, DOI 10.1128/IAI.60.3.1237-1240.1992; NAGAHAMA M, 1991, TOXICON, V29, P211, DOI 10.1016/0041-0101(91)90105-Z; Nelson KL, 2000, J BIOL CHEM, V275, P19839, DOI 10.1074/jbc.M002785200; Nelson KL, 1999, CELL MICROBIOL, V1, P69, DOI 10.1046/j.1462-5822.1999.00009.x; Payne D.W., 1997, CLOSTRIDIA MOL BIOL, P439; Petit L, 1997, J BACTERIOL, V179, P6480, DOI 10.1128/jb.179.20.6480-6487.1997; Petit L, 2001, J BIOL CHEM, V276, P15736, DOI 10.1074/jbc.M010412200; Rosenberger CM, 2000, CURR BIOL, V10, pR823, DOI 10.1016/S0960-9822(00)00788-0; Shin JS, 2001, SCIENCE, V293, P1447, DOI 10.1126/science.1061079; Shortt SJ, 2000, HUM EXP TOXICOL, V19, P108, DOI 10.1191/096032700678815710; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; van der Goot FG, 2001, SEMIN IMMUNOL, V13, P89, DOI 10.1006/smim.2000.0300; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; Zhu C, 2001, EXP NEUROL, V169, P72, DOI 10.1006/exnr.2001.7652; Zhuang MB, 2002, J BIOL CHEM, V277, P13863, DOI 10.1074/jbc.M110057200	39	105	109	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39463	39468		10.1074/jbc.M206731200	http://dx.doi.org/10.1074/jbc.M206731200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177068	hybrid			2022-12-27	WOS:000178662500053
J	Panagotopulos, SE; Witting, SR; Horace, EM; Hui, DY; Maiorano, JN; Davidson, WS				Panagotopulos, SE; Witting, SR; Horace, EM; Hui, DY; Maiorano, JN; Davidson, WS			The role of apolipoprotein A-I helix 10 in apolipoprotein-mediated cholesterol efflux via the ATP-binding cassette transporter ABCA1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; CELLULAR CHOLESTEROL; LIPID-FREE; TANGIER-DISEASE; HELICAL PEPTIDES; PLASMA; HDL; REMOVAL; DOMAINS	Recent studies of Tangier disease have shown that the ATP-binding cassette transporter A1 (ABCA1)/apolipoprotein A-I (apoA-I) interaction is critical for high density lipoprotein particle formation, apoA-I integrity, and proper reverse cholesterol transport. However, the specifics of this interaction are unknown. It has been suggested that amphipathic helices of apoA-I bind to a lipid domain created by the ABCA1 transporter. Alternatively, apoA-I may bind directly to ABCA1 itself. To better understand this interaction, we created several truncation mutants of apoA-I and then followed up with more specific point mutants and helix translocation mutants to identify and characterize the locations of apoA-I required for ABCA1-mediated cholesterol efflux. We found that deletion of residues 221-243 (helix 10) abolished ABCA1-mediated cholesterol efflux from cultured RAW mouse macrophages treated with 8-bromo-cAMP. Point mutations in helix 10 that affected the helical charge distribution reduced ABCA1-mediated cholesterol efflux versus the wild type. We noted a strong positive correlation between cholesterol efflux and the lipid binding characteristics of apoA-I when mutations were made in helix 10. However, there was no such correlation for helix translocations in other areas of the protein as long as helix 10 remained intact at the C terminus. From these observations, we propose an alternative model for apolipoprotein-mediated efflux.	Univ Cincinnati, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Davidson, WS (corresponding author), Univ Cincinnati, Dept Pathol & Lab Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	Sean.Davidson@UC.edu		Davidson, William/0000-0003-2756-2989	NHLBI NIH HHS [R01 HL62542] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062542] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe-Dohmae S, 2000, BIOCHEMISTRY-US, V39, P11092, DOI 10.1021/bi0008175; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; Burgess JW, 1999, BIOCHEMISTRY-US, V38, P14524, DOI 10.1021/bi990930z; Burgess JW, 2002, J BIOL CHEM, V277, P31318, DOI 10.1074/jbc.M204200200; CHAMBENOIT O, 2001, J BIOL CHEM, V281; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; DAVIDSON WS, 1994, J BIOL CHEM, V269, P22975; DAVIDSON WS, 1995, J BIOL CHEM, V270, P5882, DOI 10.1074/jbc.270.11.5882; Davidson WS, 1996, P NATL ACAD SCI USA, V93, P13605, DOI 10.1073/pnas.93.24.13605; FITZGERALD ML, 2002, J BIOL CHEM; Frank PG, 1997, BIOCHEMISTRY-US, V36, P1798, DOI 10.1021/bi962118r; Gillotte KL, 1998, J LIPID RES, V39, P1918; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; HARA H, 1992, LIPIDS, V27, P302, DOI 10.1007/BF02536480; HARA H, 1991, J BIOL CHEM, V266, P3080; HOROWITZ BS, 1993, J CLIN INVEST, V91, P1743, DOI 10.1172/JCI116384; JI Y, 1995, J BIOL CHEM, V270, P11290, DOI 10.1074/jbc.270.19.11290; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; JONAS A, 1986, METHOD ENZYMOL, V128, P553; Langmann T, 1999, BIOCHEM BIOPH RES CO, V257, P29, DOI 10.1006/bbrc.1999.0406; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Lin GR, 2000, ATHEROSCLEROSIS, V149, P359, DOI 10.1016/S0021-9150(99)00503-1; MCLEAN LR, 1993, BIOCHIM BIOPHYS ACTA, V1167, P289, DOI 10.1016/0005-2760(93)90231-W; MENDEZ AJ, 1994, J CLIN INVEST, V94, P1698, DOI 10.1172/JCI117515; MINNICH A, 1992, J BIOL CHEM, V267, P16553; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Palgunachari MN, 1996, ARTERIOSCL THROM VAS, V16, P328, DOI 10.1161/01.ATV.16.2.328; Panagotopulos SE, 2002, PROTEIN EXPRES PURIF, V25, P353, DOI 10.1016/S1046-5928(02)00020-7; Remaley AT, 2001, BIOCHEM BIOPH RES CO, V280, P818, DOI 10.1006/bbrc.2000.4219; Roberts LM, 1997, BIOCHEMISTRY-US, V36, P7615, DOI 10.1021/bi962952g; Rogers DP, 1997, BIOCHEMISTRY-US, V36, P288, DOI 10.1021/bi961876e; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sakr SW, 1999, BBA-MOL CELL BIOL L, V1438, P85, DOI 10.1016/S1388-1981(99)00041-4; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; SEGREST JP, 1992, J LIPID RES, V33, P141; Smith JD, 1996, J BIOL CHEM, V271, P30647, DOI 10.1074/jbc.271.48.30647; Smith JD, 2002, J BIOL CHEM, V277, P17797, DOI 10.1074/jbc.M201594200; SPARKS DL, 1992, J BIOL CHEM, V267, P25839; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021	44	103	113	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39477	39484		10.1074/jbc.M207005200	http://dx.doi.org/10.1074/jbc.M207005200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12181325	hybrid			2022-12-27	WOS:000178662500055
J	Munshi, HG; Ghosh, S; Mukhopadhyay, S; Wu, YI; Sen, R; Green, KJ; Stack, MS				Munshi, HG; Ghosh, S; Mukhopadhyay, S; Wu, YI; Sen, R; Green, KJ; Stack, MS			Proteinase suppression by E-cadherin-mediated cell-cell attachment in premalignant oral keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; PHOSPHATIDYLINOSITOL 3-KINASE; METALLOPROTEINASE EXPRESSION; MATRIX METALLOPROTEINASES; EPITHELIAL-CELLS; ADHESION; ACTIVATION; CARCINOMA; MIGRATION; PROTEOLYSIS	The expression and activity of epithelial proteinases is under stringent control to prevent aberrant hydrolysis of structural proteins and disruption of tissue architecture. E-cadherin-dependent cell-cell adhesion is also important for maintenance of epithelial structural integrity, and loss of E-cadherin expression has been correlated with enhanced invasive potential in multiple tumor models. To address the hypothesis that there is a functional link between E-cadherin and proteinase expression, we have examined the role of E-cadherin in proteinase regulation. By using a calcium switch protocol to manipulate junction assembly, our data demonstrate that initiation of de novo E-cadherin-mediated adhesive contacts suppresses expression of both relative matrix metalloproteinase-9 levels and net urinary-type plasminogen activator activity. E-cadherin-mediated cell-cell adhesion increases both phosphatidylinositol W-kinase (PI3-kinase)-dependent AKT phosphorylation and epidermal growth factor receptor-dependent MAPK/ERK activation. Pharmacologic inhibition of the PI3-kinase pathway, but not the epidermal growth factor receptor/MAPK pathway, prevents E-cadherin-mediated suppression of proteinases and delays junction assembly. Moreover, inhibition of junction assembly with a function-blocking anti-E-cadherin antibody stimulates proteinase-dependent Matrigel invasion. As matrix metalloproteinase-9 and urinary-type plasminogen activator potentiate the invasive activity of oral squamous cell carcinoma, these data suggest E-cadherin-mediated signaling through PI3-kinase can regulate the invasive behavior of cells by modulating proteinase secretion.	Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Obstet & Gynecol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Pathol & Dermatol, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Stack, MS (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave,Tarry 8-715, Chicago, IL 60611 USA.	mss130@northwestern.edu			NATIONAL CANCER INSTITUTE [T32CA079447, R01CA085870] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012328] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 85870, T32 CA79447] Funding Source: Medline; NIDCR NIH HHS [DE12328] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Angst BD, 2001, J CELL SCI, V114, P629; Ara T, 2000, CANCER LETT, V157, P115, DOI 10.1016/S0304-3835(00)00494-8; Barker N, 2000, BIOESSAYS, V22, P961; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Braga VMM, 1999, MOL BIOL CELL, V10, P9, DOI 10.1091/mbc.10.1.9; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; Ellis V, 2001, FEBS LETT, V506, P1, DOI 10.1016/S0014-5793(01)02845-9; FRIXEN UH, 1993, CANCER RES, V53, P3618; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Ghosh S, 2000, J BIOL CHEM, V275, P23869, DOI 10.1074/jbc.M000935200; Ghosh S, 2000, FIBRINOLYSIS PROTEOL, V14, P87, DOI 10.1054/fipr.2000.0060; Houde M, 2001, J BIOL CHEM, V276, P21885, DOI 10.1074/jbc.M100236200; Huber AH, 2001, CELL, V105, P391, DOI 10.1016/S0092-8674(01)00330-0; Itoh T, 1999, CLIN EXP METASTAS, V17, P177, DOI 10.1023/A:1006603723759; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; KOOK YH, 1994, EMBO J, V13, P3983, DOI 10.1002/j.1460-2075.1994.tb06714.x; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li G, 2001, CANCER RES, V61, P3819; Llorens A, 1998, LAB INVEST, V78, P1131; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Luo J, 1999, CANCER RES, V59, P3552; Mann B, 1999, P NATL ACAD SCI USA, V96, P1603, DOI 10.1073/pnas.96.4.1603; Marchenko GN, 2002, BIOCHEM J, V363, P253, DOI 10.1042/0264-6021:3630253; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Mignatti P, 2000, ADV CANCER RES, V78, P103; Miyaki M, 1995, ONCOGENE, V11, P2547; Munshi HG, 2002, METHOD CELL BIOL, V69, P195, DOI 10.1016/S0091-679X(02)69013-2; Murphy G, 1999, CURR OPIN CELL BIOL, V11, P614, DOI 10.1016/S0955-0674(99)00022-8; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakagawa M, 2001, J CELL SCI, V114, P1829; Noe V, 2001, J CELL SCI, V114, P111; Noe V, 1999, BIOCHEM SOC SYMP, V65, P43; Oda D, 1996, EXP CELL RES, V226, P164, DOI 10.1006/excr.1996.0215; Parks WC, 1998, BIOL EXTRAC, P263; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; Ryniers F, 2002, BIOL CHEM, V383, P159, DOI 10.1515/BC.2002.016; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SCHIPPER JH, 1991, CANCER RES, V51, P6328; Shinohara M, 2001, J BIOL CHEM, V276, P18941, DOI 10.1074/jbc.M100909200; Somasiri A, 2000, DIFFERENTIATION, V66, P116, DOI 10.1046/j.1432-0436.2000.660206.x; STACK S, 1990, BIOCHEMISTRY-US, V29, P4966, DOI 10.1021/bi00472a029; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Vu TH, 1998, BIOL EXTRAC, P115; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wijnhoven BPL, 2000, BRIT J SURG, V87, P992, DOI 10.1046/j.1365-2168.2000.01513.x; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; YU H, 1990, CANCER RES, V50, P7623	58	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38159	38167		10.1074/jbc.M202384200	http://dx.doi.org/10.1074/jbc.M202384200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138162	hybrid			2022-12-27	WOS:000178529600025
J	Podrez, EA; Poliakov, E; Shen, ZZ; Zhang, RL; Deng, YJ; Sun, MJ; Finton, PJ; Shan, L; Febbraio, M; Hajjar, DP; Silverstein, RL; Hoff, HF; Salomon, RG; Hazen, SL				Podrez, EA; Poliakov, E; Shen, ZZ; Zhang, RL; Deng, YJ; Sun, MJ; Finton, PJ; Shan, L; Febbraio, M; Hajjar, DP; Silverstein, RL; Hoff, HF; Salomon, RG; Hazen, SL			A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor CD36 and is enriched in atherosclerotic lesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MONOCYTE-DERIVED MACROPHAGES; INSULIN-RESISTANCE; FATTY-ACID; PPAR-GAMMA; IN-VITRO; LDL; EXPRESSION; METABOLISM; THROMBOSPONDIN-1	The macrophage scavenger receptor CD36 plays an important role in binding and uptake of oxidized forms of low-density lipoprotein (LDL), foam cell formation, and lesion development during atherosclerosis. The structural basis of CD36-lipoprotein ligand recognition is an area of intense interest. In a companion article we reported the characterization of a structurally conserved family of oxidized choline glycerophospholipids (oxPC(CD36)) that serve as novel high affinity ligands for cells stably transfected with CD36, mediating recognition of multiple oxidized forms of LDL (Podrez, E. A., Poliakov, E., Shen, Z., Zhang, R., Deng, Y., Sun, M., Finton, P., Shan, L., Gugiu, B., Fox, P. L., Hoff, H. F., Salomon, R. G., and Hazen, S. L. (July 8, 2002) J. Biol. Chem. 277, 10.1074/ jbc.M203318200). Here we use macrophages from wildtype and CD36 null mice to demonstrate that CD36 is the major receptor on macrophages mediating recognition of oxPC(CD36) species when presented (+/- plasma) in pure form, within PC bilayers in small unilamellar vesicles, and within liposomes generated from lipid extracts of native LDL. We also show that oxPC(CD36) promote CD36-dependent recognition when present at only a few molecules per particle, resulting in macrophage binding, uptake, metabolism, cholesterol accumulation, and foam cell formation. Finally, using high performance liquid chromatography with on-line electrospray ionization tandem mass spectrometry (LC/ESI/MS/MS), we demonstrate that oxPC(CD36) are generated in vivo and are enriched in atherosclerotic lesions. Collectively, our data suggest that formation of this novel family of oxidized phospholipids participates in CD36-mediated recognition of oxidized lipoproteins and foam cell formation in vivo.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Prevent Cardiol Sect, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA; Cornell Univ, Weill Med Coll, Dept Med, Div Hematol & Med Oncol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Pathol, New York, NY 10021 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; Cornell University; Cornell University; University System of Ohio; Cleveland State University	Hazen, SL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.		Hazen, Stanley L/ABD-5845-2021; Salomon, Robert G/C-3463-2008	Salomon, Robert/0000-0001-9456-3557	NHLBI NIH HHS [HL53315, HL62526, HL70621, HL61878] Funding Source: Medline; NIGMS NIH HHS [GM21249] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053315, R01HL070621, R01HL061878, R01HL062526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021249] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACTON SL, 1994, J BIOL CHEM, V269, P21003; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boullier A, 2000, J BIOL CHEM, V275, P9163, DOI 10.1074/jbc.275.13.9163; Colles SM, 1996, J LIPID RES, V37, P2018; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Daviet L, 1997, THROMB HAEMOSTASIS, V78, P65; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; Deng YH, 1998, J ORG CHEM, V63, P7789, DOI 10.1021/jo980861e; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Hirano K, 1999, CIRC RES, V85, P108; HOPPE G, 1994, J CLIN INVEST, V94, P1506, DOI 10.1172/JCI117490; Horkko S, 1999, J CLIN INVEST, V103, P117, DOI 10.1172/JCI4533; Huh HY, 1996, BLOOD, V87, P2020; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Leitinger N, 1999, P NATL ACAD SCI USA, V96, P12010, DOI 10.1073/pnas.96.21.12010; Miyaoka K, 2001, LANCET, V357, P686, DOI 10.1016/S0140-6736(00)04138-6; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; NOZAKI S, 1995, J CLIN INVEST, V96, P1859, DOI 10.1172/JCI118231; Panini SR, 2001, CURR OPIN LIPIDOL, V12, P529, DOI 10.1097/00041433-200110000-00008; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Shimaoka T, 2000, J BIOL CHEM, V275, P40663, DOI 10.1074/jbc.C000761200; Steinberg D, 1997, J BIOL CHEM, V272, P20963, DOI 10.1074/jbc.272.34.20963; Sun MJ, 2002, J ORG CHEM, V67, P3575, DOI 10.1021/jo0105383; Terpstra V, 1998, P NATL ACAD SCI USA, V95, P1806, DOI 10.1073/pnas.95.4.1806; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; ZHANG R, 2002, BLOOD, V85, P950; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136	34	303	333	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38517	38523		10.1074/jbc.M205924200	http://dx.doi.org/10.1074/jbc.M205924200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145296	hybrid			2022-12-27	WOS:000178529600067
J	Toustrup-Jensen, M; Vilsen, B				Toustrup-Jensen, M; Vilsen, B			Importance of Glu(282) in transmembrane segment M3 of the Na+,K+-ATPase for control of cation interaction and conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY NA+,K+-ATPASE; SARCOPLASMIC-RETICULUM CA2+-ATPASE; TRANSPORT ADENOSINE-TRIPHOSPHATASE; NA,K-ATPASE ALPHA-SUBUNIT; FUNCTIONAL CONSEQUENCES; AMINO-ACIDS; COORDINATING RESIDUES; RENAL NA,K-ATPASE; BINDING POCKET; POTASSIUM-IONS	Glu(282) located in the NH2-terminal part of transmembrane helix M3 of the Na+,K+-ATPase was replaced by alanine, glycine, leucine, lysine, aspartate, or glutamine, and the effects of the mutations on the overall and partial reactions of the enzyme were analyzed. The mutations affected at least 3 important functions of the Na+,K+-ATPase: (i) the conformational transitions between E-1 and E-2 forms of dephospho- and phosphoenzyme, (ii) Na+ binding at the cytoplasmically facing sites of E-1, and (iii) long-range interaction controlling dephosphorylation. In mutants Glu(282) --> Lys and Glu(282) --> Asp, the E, form was favored during ATP hydrolysis, whereas the E-2 form was favored in Glu(282) --> Ala and Glu(282) --> Gly. Regardless of the change of conformational. equilibrium, all the mutants displayed a reduced apparent affinity for Na+, at least 3-fold for Glu(282) --> Lys and Glu(282) --> Asp, suggesting a direct effect on the Na+ binding properties of E-1. Glu(282) --> Ala and Glu(282) --> Gly exhibited an extraordinary high rate of ATP hydrolysis in the mere presence of Na+ without K+ ("Na+-ATPase activity"), because of an increased rate of dephosphorylation of E2P. These results are in accordance with the hypothesis that Glu(282) is involved in the communication between the cation binding pocket and the catalytic site and in control of the cytoplasmic entry pathway for Na+.	Aarhus Univ, Dept Physiol, DK-8000 Aarhus C, Denmark	Aarhus University	Vilsen, B (corresponding author), Aarhus Univ, Dept Physiol, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	bv@fi.au.dk		Vilsen, Bente/0000-0002-4727-9382; Toustrup-Jensen, Mads Schak/0000-0003-2064-5861				ALBERS RW, 1967, ANNU REV BIOCHEM, V36, P727, DOI 10.1146/annurev.bi.36.070167.003455; ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; HANSEN O, 1984, PHARMACOL REV, V36, P143; Hermsen HPH, 2000, BIOCHEMISTRY-US, V39, P1330, DOI 10.1021/bi991396y; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; Jorgensen PL, 2001, BBA-BIOENERGETICS, V1505, P57, DOI 10.1016/S0005-2728(00)00277-2; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; JORGENSEN PL, 1985, BIOCHIM BIOPHYS ACTA, V821, P319, DOI 10.1016/0005-2736(85)90102-6; Koenderink JB, 2000, BIOCHEMISTRY-US, V39, P9959, DOI 10.1021/bi0001168; KUNKEL TA, 1985, P NATL ACAD SCI USA, V85, P3314; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; NORREGAARD A, 1994, J BIOL CHEM, V269, P26598; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; Petrov VV, 2000, J BIOL CHEM, V275, P15709, DOI 10.1074/jbc.M000546200; POST RL, 1969, J GEN PHYSIOL, V54, pS306, DOI 10.1085/jgp.54.1.306; POST RL, 1972, J BIOL CHEM, V247, P6530; Suzuki K, 1997, J GEN PHYSIOL, V109, P537, DOI 10.1085/jgp.109.5.537; Toustrup-Jensen M, 2001, BIOCHEMISTRY-US, V40, P5521, DOI 10.1021/bi002367m; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Vilsen B, 1999, BIOCHEMISTRY-US, V38, P11389, DOI 10.1021/bi990951t; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1992, J BIOL CHEM, V267, P25739; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; VILSEN B, 1992, FEBS LETT, V314, P301, DOI 10.1016/0014-5793(92)81494-7; VILSEN B, 1995, FEBS LETT, V363, P179, DOI 10.1016/0014-5793(95)00313-X; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; VILSEN B, 1989, J BIOL CHEM, V264, P21024; Zhong L, 1998, J BIOL CHEM, V273, P12994, DOI 10.1074/jbc.273.21.12994; ZHONGSEN Z, 2000, BIOCHEMISTRY-US, V39, P8758	40	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38607	38617		10.1074/jbc.M203665200	http://dx.doi.org/10.1074/jbc.M203665200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12149251	hybrid			2022-12-27	WOS:000178529600078
J	Ilari, A; Ceci, P; Ferrari, D; Rossi, GL; Chiancone, E				Ilari, A; Ceci, P; Ferrari, D; Rossi, GL; Chiancone, E			Iron incorporation into Escherichia coli Dps gives rise to a ferritin-like microcrystalline core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; RELEASE	Escherichia coli Dps belongs to a family of bacterial stress-induced proteins to protect DNA from oxidative damage. It shares with Listeria innocua ferritin several structural features, such as the quaternary assemblage and the presence of an unusual ferroxidase center. Indeed, it was recently recognized to be able to oxidize and incorporate iron. Since ferritins are endowed with the unique capacity to direct iron deposition toward formation of a microcrystalline core, the structure of iron deposited in the E. coli Dps cavity was studied. Polarized single crystal absorption microspectrophotometry of iron-loaded Dps shows that iron ions are oriented. The spectral properties in the high spin 3d(5) configuration point to a crystal form with tetrahedral symmetry where the tetrahedron center is occupied by iron ions and the vertices by oxygen. Crystals of iron-loaded Dps also show that, as in mammalian ferritins, iron does not remain bound to the site after oxidation has taken place. The kinetics of the iron reduction/release process induced by dithionite were measured in the crystal and in solution. The reaction appears to have two phases, with t(1/2) of a few seconds and several minutes at neutral pH values, as in canonical ferritins. This behavior is attributed to a similar composition of the iron core.	Univ Roma La Sapienza, CNR, Ctr Studio Biol Mol, I-00185 Rome, Italy; Univ Roma La Sapienza, CNR, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; Univ Parma, Dipartmento Biochim & Biol Mol, I-43100 Parma, Italy	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of Parma	Chiancone, E (corresponding author), Univ Roma La Sapienza, CNR, Ctr Studio Biol Mol, I-00185 Rome, Italy.	emilia.chiancone@uniroma1.it	Ilari, Andrea/T-5501-2017; Ilari, Andrea/AAC-7670-2022	Ilari, Andrea/0000-0002-7754-399X; Ilari, Andrea/0000-0002-7754-399X; Ceci, Pierpaolo/0000-0001-7712-8430; ferrari, davide/0000-0001-7084-6800				ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; BOTHWELL TH, 1955, BIOCHEM J, V59, P599, DOI 10.1042/bj0590599; BOYD D, 1985, J BIOL CHEM, V260, P1755; Bozzi M, 1997, J BIOL CHEM, V272, P3259, DOI 10.1074/jbc.272.6.3259; CLEGG GA, 1980, PROG BIOPHYS MOL BIO, V36, P53; FORD GC, 1984, PHILOS T R SOC B, V304, P551, DOI 10.1098/rstb.1984.0046; FUNK F, 1985, EUR J BIOCHEM, V152, P167, DOI 10.1111/j.1432-1033.1985.tb09177.x; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; HAGGIS GH, 1965, J MOL BIOL, V14, P598, DOI 10.1016/S0022-2836(65)80210-8; HALLIGAN BD, 1993, NUCLEIC ACIDS RES, V21, P5520, DOI 10.1093/nar/21.23.5520; Harrison P.M., 1989, IRON CARRIERS IRON P, P123; HARRISON PM, 1967, NATURE, V216, P1188, DOI 10.1038/2161188a0; Huang HQ, 1999, J PROTEIN CHEM, V18, P497, DOI 10.1023/A:1020653028685; Ilari A, 2000, NAT STRUCT BIOL, V7, P38; MASSOVER WH, 1973, P NATL ACAD SCI USA, V70, P3847, DOI 10.1073/pnas.70.12.3847; MCREE DE, 1993, PRACTICAL PROTEIN CR, P365; Mozzarelli A, 1996, ANNU REV BIOPH BIOM, V25, P343; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Richards TD, 1996, J INORG BIOCHEM, V61, P1, DOI 10.1016/0162-0134(95)00029-1; RIVETTI C, 1993, BIOCHEMISTRY-US, V32, P2888, DOI 10.1021/bi00062a021; STEFANINI S, 1975, PROTEINS IRON STORAG, P295; Tonello F, 1999, MOL MICROBIOL, V34, P238, DOI 10.1046/j.1365-2958.1999.01584.x; TOWE KM, 1967, J COLLOID INTERF SCI, V24, P384, DOI 10.1016/0021-9797(67)90266-4; TREFFRY A, 1984, J INORG BIOCHEM, V21, P9, DOI 10.1016/0162-0134(84)85035-7; WEBB J, 1974, BIOCHIM BIOPHYS ACTA, V351, P224, DOI 10.1016/0005-2795(74)90184-6; Yang XK, 2000, BIOCHEM J, V349, P783, DOI 10.1042/bj3490783; Zhao GH, 2002, J BIOL CHEM, V277, P27689, DOI 10.1074/jbc.M202094200	28	111	116	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37619	37623		10.1074/jbc.M206186200	http://dx.doi.org/10.1074/jbc.M206186200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12163499	hybrid			2022-12-27	WOS:000178447100091
J	Lai-Kee-Him, J; Chanzy, H; Muller, M; Putaux, JL; Imai, T; Bulone, V				Lai-Kee-Him, J; Chanzy, H; Muller, M; Putaux, JL; Imai, T; Bulone, V			In vitro versus in vivo cellulose microfibrils from plant primary wall synthases: Structural differences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GLUCAN SYNTHESIS; COTTON FIBER; X-RAY; MOLECULAR DIRECTIONALITY; ELECTRON-DIFFRACTION; MAGNETIC-RESONANCE; BIOSYNTHESIS; CHITIN; ELONGATION; EXTRACTS	Detergent extracts of microsomal fractions from suspension cultured cells of Rubus fruticosus (blackberry) were tested for their ability to synthesize in vitro sizable quantities of cellulose from UDP-glucose. Both Brij 58 and taurocholate were effective and yielded a substantial percentage of cellulose microfibrils together with (1-->3)-beta-D-glucan (callose). The taurocholate extracts, which did not require the addition of Mg2+, were the most efficient, yielding roughly 20% of cellulose. This cellulose was characterized after callose removal by methylation analysis, electron microscopy, and electron and x-ray synchrotron diffractions; its resistance toward the acid Updegraff reagent was also evaluated. The cellulose microfibrils synthesized in vitro had the same diameter as the endogenous microfibrils isolated from primary cell walls. Both polymers diffracted as cellulose IVI, a disorganized form of cellulose I. Besides these similarities, the in vitro microfibrils had a higher perfection and crystallinity as well as a better resistance toward the Updegraff reagent. These differences can be attributed to the mode of synthesis of the in vitro microfibrils that are able to grow independently in a neighbor-free environment, as opposed to the cellulose in the parent cell walls where new microfibrils have to interweave with the already laid polymers, with the result of a number of structural defects.	Univ Grenoble 1, Ctr Rech Macromol Vegetales, CERMAV, UPR 5301,CNRS, F-38041 Grenoble 9, France; European Synchrotron Radiat Facil, F-38043 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); European Synchrotron Radiation Facility (ESRF)	Bulone, V (corresponding author), Univ Lyon 1, Lab Physicochim Biol, UMR 5013, CNRS, Batiment Chevreul 4 Eme Etage,43 Blvd 11 Novembr, F-69622 Villeurbanne, France.	Vincent.Bulone@univ-lyon1.fr	PUTAUX, Jean-Luc/ABC-5309-2020; Chanzy, Henri D/A-3526-2012; Bulone, Vincent/D-7469-2013; 今井, 友也/M-1834-2019; Putaux, Jean-Luc/A-3488-2012; Bulone, Vincent/C-8492-2019; Müller, Martin/I-9328-2017	PUTAUX, Jean-Luc/0000-0002-9760-5369; 今井, 友也/0000-0001-7026-0287; Putaux, Jean-Luc/0000-0002-9760-5369; Bulone, Vincent/0000-0003-2809-4160; LAI KEE HIM, Josephine/0000-0001-6303-1224				AMOR Y, 1991, PLANT CELL, V3, P989, DOI 10.1105/tpc.3.9.989; AMOR Y, 1995, P NATL ACAD SCI USA, V92, P9353, DOI 10.1073/pnas.92.20.9353; Arioli T, 1998, SCIENCE, V279, P717, DOI 10.1126/science.279.5351.717; ATALLA R, 1999, COMPREHENSIVE NATURA, P573; BLASCHEK W, 1983, Z PFLANZENPHYSIOL, V111, P357, DOI 10.1016/S0044-328X(83)80097-X; Brown RM, 1996, J MACROMOL SCI PURE, VA33, P1345, DOI 10.1080/10601329608014912; BULONE V, 1992, EXP MYCOL, V16, P8, DOI 10.1016/0147-5975(92)90037-R; BULONE V, 1995, PLANT J, V8, P213, DOI 10.1046/j.1365-313X.1995.08020213.x; CHANZY H, 1979, PROTOPLASMA, V100, P303, DOI 10.1007/BF01279318; CHANZY H, 1978, PROTOPLASMA, V94, P299, DOI 10.1007/BF01276778; Delmer DP, 1999, ANNU REV PLANT PHYS, V50, P245, DOI 10.1146/annurev.arplant.50.1.245; DELMER DP, 1995, PLANT CELL, V7, P987, DOI 10.1105/tpc.7.7.987; Dinand E., 1999, US Patent, Patent No. 5964983; EMONS AMC, 1991, BIOSYNTHESIS BIODEGR, P71; Fagard M, 2000, PLANT CELL, V12, P2409, DOI 10.1105/tpc.12.12.2409; FAVIER V, 1995, MACROMOLECULES, V28, P6365, DOI 10.1021/ma00122a053; FEINGOLD DS, 1958, J BIOL CHEM, V233, P783; Franz G, 1990, METHODS PLANT BIOCH, V2, P291; Gautheret R.J., 1959, CULTURE TISSUS VEGET; HAASE J, 1974, COLLOID POLYM SCI, V252, P712, DOI 10.1007/BF01554496; HAMMERSLEY AP, 1994, NUCL INSTRUM METH A, V346, P312, DOI 10.1016/0168-9002(94)90720-X; Han NS, 1998, CARBOHYD RES, V313, P125, DOI 10.1016/S0008-6215(98)00253-5; HARRIS PJ, 1984, CARBOHYD RES, V127, P59, DOI 10.1016/0008-6215(84)85106-X; HAYASHI T, 1987, PLANT PHYSIOL, V83, P1054, DOI 10.1104/pp.83.4.1054; HELLER RENE, 1953, ANN SCI NAT BOT 11E SER, V14, P1; HERTH W, 1984, NATURWISSENSCHAFTEN, V71, P216, DOI 10.1007/BF00490440; Hestrin S., 1963, METHODS CARBOHYDRATE, V3, P4; Him JLK, 2001, EUR J BIOCHEM, V268, P4628, DOI 10.1046/j.1432-1327.2001.02382.x; HRMOVA M, 1993, BIOCHEM J, V289, P453, DOI 10.1042/bj2890453; Imai T, 2002, FEBS LETT, V510, P201, DOI 10.1016/S0014-5793(01)03249-5; Kimura S, 1999, PLANT CELL, V11, P2075, DOI 10.1105/tpc.11.11.2075; Kobayashi S, 2000, BIOMACROMOLECULES, V1, P168, DOI 10.1021/bm990010w; KOBAYASHI S, 1994, MACROMOL CHEM PHYSIC, V195, P1319, DOI 10.1002/macp.1994.021950416; KOGAN G, 1988, BIOPOLYMERS, V27, P1055, DOI 10.1002/bip.360270702; Koyama M, 1997, P NATL ACAD SCI USA, V94, P9091, DOI 10.1073/pnas.94.17.9091; KUBO T, 1940, J SOC CHEM IND JAPAN, V43, pB341; KUDLICKA K, 1995, PLANT PHYSIOL, V107, P111, DOI 10.1104/pp.107.1.111; Kudlicka K, 1997, PLANT PHYSIOL, V115, P643, DOI 10.1104/pp.115.2.643; Kudlicka K, 1996, AM J BOT, V83, P274, DOI 10.2307/2446162; KULSHRESHTHA AK, 1973, J POLYM SCI POL PHYS, V11, P487, DOI 10.1002/pol.1973.180110307; KULSHRESHTHA AK, 1979, J TEXT I, V70, P13, DOI 10.1080/00405007908631510; LI LK, 1993, PLANT PHYSIOL, V101, P1143, DOI 10.1104/pp.101.4.1143; MUELLER SC, 1980, J CELL BIOL, V84, P315, DOI 10.1083/jcb.84.2.315; MUELLER SC, 1976, SCIENCE, V194, P949, DOI 10.1126/science.194.4268.949; NIKAIDO H, 1971, ADV CARBOHYD CHEM BI, V26, P386; NORTHCOTE DH, 1991, BIOSYNTHESIS BIODEGR, P165; OKUDA K, 1993, PLANT PHYSIOL, V101, P1131, DOI 10.1104/pp.101.4.1131; Peng LC, 2002, SCIENCE, V295, P147, DOI 10.1126/science.1064281; PRESTON RD, 1962, POLYMER, V3, P511, DOI 10.1016/0032-3861(62)90099-X; READ SM, 1991, BIOSYNTHESIS BIODEGR, P177; Riekel C, 2000, REP PROG PHYS, V63, P233, DOI 10.1088/0034-4885/63/3/201; Roelofsen PA, 1959, PLANT CELL WALL, P126; RUIZHERRERA J, 1975, P NATL ACAD SCI USA, V72, P2706, DOI 10.1073/pnas.72.7.2706; RUIZHERRERA J, 1974, SCIENCE, V186, P357, DOI 10.1126/science.186.4161.357; SAITO H, 1977, BIOCHEMISTRY-US, V16, P908, DOI 10.1021/bi00624a015; SAITO H, 1979, CARBOHYD RES, V74, P227, DOI 10.1016/S0008-6215(00)84779-5; SAMAIN E, 1995, CARBOHYD RES, V271, P217, DOI 10.1016/0008-6215(95)00022-L; Schulein M, 1997, J BIOTECHNOL, V57, P71, DOI 10.1016/S0168-1656(97)00090-4; SEGAL L, 1971, DECRYSTALLIZED COTTO, P23; SUGIYAMA J, 1991, MACROMOLECULES, V24, P4168, DOI 10.1021/ma00014a033; Sugiyama J, 1999, J MOL BIOL, V286, P247, DOI 10.1006/jmbi.1998.2458; SUGIYAMA J, 1989, CELLULOSE STRUCTURAL, P75; Taylor NG, 1999, PLANT CELL, V11, P769, DOI 10.1105/tpc.11.5.769; Taylor NG, 2000, PLANT CELL, V12, P2529, DOI 10.1105/tpc.12.12.2529; Turbak AF, 1983, J APPL POLYM SCI POL, V37, P815; Turner SR, 1997, PLANT CELL, V9, P689, DOI 10.1105/tpc.9.5.689; UPDEGRAFF DM, 1969, ANAL BIOCHEM, V32, P420, DOI 10.1016/S0003-2697(69)80009-6; Wada M, 1997, CELLULOSE, V4, P221, DOI 10.1023/A:1018435806488; WANG MC, 1976, ARCH BIOCHEM BIOPHYS, V175, P351, DOI 10.1016/0003-9861(76)90517-8; WARDROP AB, 1949, NATURE, V164, P366, DOI 10.1038/164366a0; Warren BE, 1990, XRAY DIFFRACTION, P251; WILLISON JHM, 1985, BOTANICAL MICROSCOPY, P181	72	116	126	7	44	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36931	36939		10.1074/jbc.M203530200	http://dx.doi.org/10.1074/jbc.M203530200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145282	hybrid			2022-12-27	WOS:000178447100005
J	Liu, LP; Pegg, AE; Williams, KM; Guengerich, FP				Liu, LP; Pegg, AE; Williams, KM; Guengerich, FP			Paradoxical enhancement of the toxicity of 1,2-dibromoethane by O-6-alkylguanine-DNA alkyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-ADDUCTS S-<2-(N-7-GUANYL)ETHYL>GLUTATHIONE; MAMMALIAN GLUTATHIONE TRANSFERASES; ESCHERICHIA-COLI; ETHYLENE DIBROMIDE; ALKYLATING-AGENTS; O6-ALKYLGUANINE-DNA ALKYLTRANSFERASES; REPAIR METHYLTRANSFERASES; EXCISION-REPAIR; VINYL-CHLORIDE; CONJUGATION	The presence of the DNA repair protein O-6-alkylguanine-DNA alkyltransferase (AGT) paradoxically increases the mutagenicity and cytotoxicity of 1,2-dibromoethane (DBE) in Escherichia coli. This enhancement of genotoxicity did not occur when the inactive C145A mutant of human AGT (hAGT) was used. Also, hAGT did not enhance the genotoxicity of S-(2-haloethyl)glutathiones that mimic the reactive product of the reaction of DBE with glutathione, which is catalyzed by glutathione S-transferase. These experiments support a mechanism by which hAGT activates DBE. Studies in vitro showed a direct reaction between purified recombinant hAGT and DBE resulting in a loss of AGT repair activity and a formation of an hAGT-DBE conjugate at Cys(145). A 2-hydroxyethyl adduct was found by mass spectrometry to be present in the Gly(136)-Arg(147) peptide from tryptic digests of AGT reacted with DBE. Incubation of AGT with DBE and oligodeoxyribonucleotides led to the formation of covalent AGT-oligonucleotide complexes. These results indicate that DBE reacts at the active site of AGT to generate an S-(2-bromoethyl) intermediate, which forms a highly reactive half-mustard at Cys(145). In the presence of DNA, the DNA-binding function of AGT facilitates formation of DNA adducts. In the absence of DNA, the intermediate undergoes hydrolytic decomposition to form AGT-Cys(145)-SCH2CH2OH.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol, Hershey, PA 17033 USA; Vanderbilt Univ, Dept Biochem, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Toxicol, Sch Med, Nashville, TN 37232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Vanderbilt University; Vanderbilt University	Pegg, AE (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Cellular & Mol Physiol, RM C4739B,POB 850,500 Univ Dr, Hershey, PA 17033 USA.		Williams, Kevin/C-3804-2011	Williams, Kevin/0000-0003-4019-8528	NCI NIH HHS [R01-CA18137] Funding Source: Medline; NIEHS NIH HHS [R01-ES10546, P30ES00267, T32-ES07028] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA018137] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES010546, T32ES007028, P30ES000267] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abril N, 1997, CARCINOGENESIS, V18, P1883, DOI 10.1093/carcin/18.10.1883; Abril N, 2001, MUTAT RES-GEN TOX EN, V497, P111, DOI 10.1016/S1383-5718(01)00235-2; ABRIL N, 1995, MOL CARCINOGEN, V12, P110, DOI 10.1002/mc.2940120208; Abril N, 1999, CARCINOGENESIS, V20, P2089, DOI 10.1093/carcin/20.11.2089; Abril N, 1999, CHEM RES TOXICOL, V12, P544, DOI 10.1021/tx980250h; Daniels DS, 2000, EMBO J, V19, P1719, DOI 10.1093/emboj/19.7.1719; DOLAN ME, 1991, CARCINOGENESIS, V12, P2305, DOI 10.1093/carcin/12.12.2305; DOLAN ME, 1990, P NATL ACAD SCI USA, V87, P5368, DOI 10.1073/pnas.87.14.5368; Edara S, 1999, CARCINOGENESIS, V20, P103, DOI 10.1093/carcin/20.1.103; FOSTER PL, 1988, MUTAT RES, V194, P171, DOI 10.1016/0167-8817(88)90019-3; GONZAGA PE, 1992, CANCER RES, V52, P6052; GONZAGA PE, 1990, NUCLEIC ACIDS RES, V18, P3961, DOI 10.1093/nar/18.13.3961; Goodtzova K, 1997, J BIOL CHEM, V272, P8332, DOI 10.1074/jbc.272.13.8332; GUENGERICH FP, 1994, CHEM RES TOXICOL, V7, P205, DOI 10.1021/tx00038a014; GUENGERICH FP, 1981, CANCER RES, V41, P4391; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; GUENGERICH FP, 1992, CHEM RES TOXICOL, V5, P2, DOI 10.1021/tx00025a001; HUMPHREYS WG, 1990, BIOCHEMISTRY-US, V29, P10342, DOI 10.1021/bi00497a008; Kim MS, 1998, CHEM RES TOXICOL, V11, P311, DOI 10.1021/tx970206m; Kim MS, 1997, CHEM RES TOXICOL, V10, P1133, DOI 10.1021/tx9701081; LETZ GA, 1984, JAMA-J AM MED ASSOC, V252, P2428, DOI 10.1001/jama.252.17.2428; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; Liu H, 2000, MUTAT RES-FUND MOL M, V452, P1, DOI 10.1016/S0027-5107(00)00062-2; Liu LP, 2002, CANCER RES, V62, P3037; OLSON WA, 1973, JNCI-J NATL CANCER I, V51, P1993, DOI 10.1093/jnci/51.6.1993; Ozaki K, 1998, CANCER RES, V58, P3806; OZAKI K, 1993, JPN J CANCER RES, V84, P1245, DOI 10.1111/j.1349-7006.1993.tb02829.x; OZAWA N, 1983, P NATL ACAD SCI-BIOL, V80, P5266, DOI 10.1073/pnas.80.17.5266; OZAWA N, 1983, TOXICOLOGIST, V3, P114; Pegg AE, 2000, MUTAT RES-REV MUTAT, V462, P83, DOI 10.1016/S1383-5742(00)00017-X; PEGG AE, 1993, BIOCHEMISTRY-US, V32, P11998, DOI 10.1021/bi00096a009; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; PETERSON LA, 1988, J AM CHEM SOC, V110, P3284, DOI 10.1021/ja00218a045; Pieper RO, 1997, PHARMACOL THERAPEUT, V74, P285, DOI 10.1016/S0163-7258(97)00003-X; RANNUG U, 1980, MUTAT RES, V76, P269, DOI 10.1016/0165-1110(80)90020-2; Samson L, 1997, CARCINOGENESIS, V18, P919, DOI 10.1093/carcin/18.5.919; SAMSON L, 1992, MOL MICROBIOL, V6, P825, DOI 10.1111/j.1365-2958.1992.tb01533.x; Sekiguchi M, 1996, J CANCER RES CLIN, V122, P199, DOI 10.1007/BF01209646; Sekiguchi M, 1997, JPN J HUM GENET, V42, P389, DOI 10.1007/BF02766939; VANBLADEREN PJ, 1981, BIOCHEM PHARMACOL, V30, P2499, DOI 10.1016/0006-2952(81)90352-X; VANBLADEREN PJ, 1980, BIOCHEM PHARMACOL, V29, P2975, DOI 10.1016/0006-2952(80)90047-7; Wang LJ, 1997, CHEM RES TOXICOL, V10, P562, DOI 10.1021/tx9602067; Wheeler JB, 2001, CHEM RES TOXICOL, V14, P1107, DOI 10.1021/tx0100183; Wheeler JB, 2001, CHEM RES TOXICOL, V14, P1118, DOI 10.1021/tx010019v; Wibley JEA, 2000, NUCLEIC ACIDS RES, V28, P393, DOI 10.1093/nar/28.2.393; Xu-Welliver M, 1998, CANCER RES, V58, P1936; Xu-Welliver M, 2002, CARCINOGENESIS, V23, P823, DOI 10.1093/carcin/23.5.823	47	43	43	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37920	37928		10.1074/jbc.M205548200	http://dx.doi.org/10.1074/jbc.M205548200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151404	hybrid			2022-12-27	WOS:000178447100129
J	Sato, K; Yomogida, K; Wada, T; Yorihuzi, T; Nishimune, Y; Hosokawa, N; Nagata, K				Sato, K; Yomogida, K; Wada, T; Yorihuzi, T; Nishimune, Y; Hosokawa, N; Nagata, K			Type XXVI collagen, a new member of the collagen family, is specifically expressed in the testis and ovary	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS PROTEIN HSP47; MOLECULAR CHAPERONE HSP47; TRIPLE-HELIX; PROCOLLAGEN; DOMAIN; BIOSYNTHESIS; REQUIREMENTS; RECOGNITION; SEQUENCE; DISEASES	HSP47 is a collagen-specific molecular chaperone that specifically recognizes and binds to the triple helical domain of various types of collagens. Here we report the cloning of the entire coding region of a novel collagen-like protein by yeast two-hybrid screening of a 17.5-day whole mouse embryo cDNA library using HSP47 as a bait. The cDNA of this protein and its deduced amino acid sequence are 2,690 bp and 438 amino acids long, respectively. The protein contains two clusters of Gly-X-Y collagenous repeats and three noncollagenous domains. Northern blot analysis showed that its mRNA is specifically expressed in the testis and ovary in adult tissues and that expression in these tissues is highest in the neonate. Biochemical characterization of this protein revealed that its proline residues are hydroxylated, it undergoes N-linked glycosylation, it forms trimers, and it is secreted in vitro. Immunohistochemical studies showed that the myoid cells and the pre-theca cells synthesized it in the testis and ovary, respectively, resulting in the accumulation of this protein in the extracellular spaces of these organs. these observations suggest that this protein is a new member of the collagen protein family. We thus designated this protein as type XXVI collagen.	Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Sakyo Ku, Kyoto 6068397, Japan; Osaka Univ, Dept Sci Lab Anim Expt, Microbial Dis Res Inst, Suita, Osaka 565, Japan	Kyoto University; Osaka University	Nagata, K (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Dept Mol & Cellular Biol, Sakyo Ku, Kyoto 6068397, Japan.	nagata@frontier.kyoto-u.ac.jp						ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BACHINGER HP, 1991, INT J BIOL MACROMOL, V13, P152, DOI 10.1016/0141-8130(91)90040-2; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; Bulleid NJ, 1997, EMBO J, V16, P6694, DOI 10.1093/emboj/16.22.6694; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; Fitzgerald J, 2001, FEBS LETT, V505, P275, DOI 10.1016/S0014-5793(01)02754-5; Gordon MK, 2000, INVEST OPHTH VIS SCI, V41, pS752; GORDON MK, 2002, IN PRESS INVEST OPHT; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Hosokawa N, 1998, J BIOCHEM-TOKYO, V124, P654, DOI 10.1093/oxfordjournals.jbchem.a022162; Kadler KE, 1996, BIOCHEM J, V316, P1; Koch M, 2001, J BIOL CHEM, V276, P23120, DOI 10.1074/jbc.M009912200; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; Koide T, 2002, J BIOL CHEM, V277, P6178, DOI 10.1074/jbc.M106497200; Koide T, 2000, J BIOL CHEM, V275, P27957; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; Nagata K, 1996, TRENDS BIOCHEM SCI, V21, P23, DOI 10.1016/0968-0004(96)80881-4; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; NATSUME T, 1994, J BIOL CHEM, V269, P31224; Olsen BR, 1997, INT J BIOCHEM CELL B, V29, P555, DOI 10.1016/S1357-2725(96)00100-8; PIHLAJANIEMI T, 1995, PROG NUCLEIC ACID RE, V50, P225, DOI 10.1016/S0079-6603(08)60816-8; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; Snellman A, 2000, EMBO J, V19, P5051, DOI 10.1093/emboj/19.19.5051; Sumiyoshi H, 1997, J BIOL CHEM, V272, P17104, DOI 10.1074/jbc.272.27.17104; TAKECHI H, 1992, EUR J BIOCHEM, V206, P323, DOI 10.1111/j.1432-1033.1992.tb16930.x; Tasab M, 2000, EMBO J, V19, P2204, DOI 10.1093/emboj/19.10.2204; Tuckwell D, 2002, MATRIX BIOL, V21, P63, DOI 10.1016/S0945-053X(01)00176-7	31	63	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37678	37684		10.1074/jbc.M205347200	http://dx.doi.org/10.1074/jbc.M205347200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145293	hybrid			2022-12-27	WOS:000178447100099
J	Smith, TK; Crossman, A; Paterson, MJ; Borissow, CN; Brimacombe, JS; Ferguson, MAJ				Smith, TK; Crossman, A; Paterson, MJ; Borissow, CN; Brimacombe, JS; Ferguson, MAJ			Specificities of enzymes of glycosylphosphatidylinositol biosynthesis in trypanosoma brucei and HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFRICAN SLEEPING SICKNESS; INOSITOL-ACYLATION; MEMBRANE ANCHOR; PLASMODIUM-FALCIPARUM; SUBSTRATE-ANALOGS; TOXOPLASMA-GONDII; D-GLUCOSAMINYLPHOSPHATIDYLINOSITOL; GLUCOSAMINYL PHOSPHATIDYLINOSITOL; PARASITIC PROTOZOA; GPI BIOSYNTHESIS	A series of synthetic analogues Of D-GlcNalpha1-6-D-myo-inositol-1-HPO4-sn-1,2-dipalmitoylglycerol, consisting of 22 variants of the D-GlcN or lipid components, were tested in trypanosomal and human (HeLa) cell-free systems. The assays measured the abilities of the analogues to act as substrates or inhibitors of the enzymes of glycosylphosphatidylinositol biosynthesis downstream of GlcNAc-phosphatidylinositol (GlcNAc-PI) de-N-acetylase. One compound, 4-deoxy-D-GlcNalpha1-6-D-myo-inositol-1-HP04-Sn-1,2-dipalmitoylglycerol, proved to be an inhibitor of both the trypanosomal and HeLa pathways, whereas 4-O-methyl-D-GlcNalpha1-6-D-myo-inositol-1-HPO(4)sn-1,2-dipalmitoylglycerol and the 4'-epimer, D-GalN-alpha1-6-D-myo-inositol-1-HPO4-sn-1,2-dipalmitoylglycerol, were neither substrates nor inhibitors. The results with other analogues showed that the 6-OH of the alpha-D-GlcN residue is not required for substrate recognition in the trypanosomal and human pathways, whereas the 3-OH group is essential for both. Parasite-specific recognition of the P-linked analogue D-GlcNbeta1-6-D-myo-inositol-1-HPO4-sn-1,2-dipalmitoylglycerol is striking. This suggests that, like the GlcNAc-PI de-N-acetylase, the trypanosomal glycosylphosphatidylinositol alpha-mannosyltransferases, inositol acyltransferse and ethanolamine phosphate transferase, do not recognize the 2-, 3-, 4-, and 5-OH groups of the D-myo-inositol residue, whereas the human inositol acyltransferase and/or first alpha-mannosyltransferase recognizes one or more of these groups. All of the various lipid analogues tested served as substrates in both the trypanosomal and HeLa cell-free systems, suggesting that a precise lipid structure and stereochemistry are not essential for substrate recognition. However, an analogue containing a single C18:0 alkyl chain in place of sn-1,2-dipalmitoylglycerol proved to be a better substrate in the trypanosomal than in the HeLa cell-free system. These findings should have a bearing on the design of future generations of specific inhibitors of the trypanosomal glycosylphosphatidylinositol biosynthetic pathway.	Univ Dundee, Div Biol Chem & Mol Microbiol, Sch Life Sci, Dundee DD1 5EH, Scotland	University of Dundee	Ferguson, MAJ (corresponding author), Univ Dundee, Div Biol Chem & Mol Microbiol, Sch Life Sci, Dundee DD1 5EH, Scotland.		Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714				Borissow CN, 2001, TETRAHEDRON LETT, V42, P121, DOI 10.1016/S0040-4039(00)01901-8; Chen R, 1998, P NATL ACAD SCI USA, V95, P9512, DOI 10.1073/pnas.95.16.9512; COTTAZ S, 1993, J CHEM SOC P1, P945; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; Crossman A, 1999, CARBOHYD RES, V321, P42, DOI 10.1016/S0008-6215(99)00170-6; Dix AP, 2001, TETRAHEDRON LETT, V42, P117, DOI 10.1016/S0040-4039(00)01900-6; Doerrler WT, 1996, J BIOL CHEM, V271, P27031, DOI 10.1074/jbc.271.43.27031; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; Ferguson MAJ, 2000, P NATL ACAD SCI USA, V97, P10673, DOI 10.1073/pnas.97.20.10673; FERGUSON MAJ, 1994, GLYCOBIOLOGY PRACTIC, P349; Flury I, 2000, J BIOL CHEM, V275, P24458, DOI 10.1074/jbc.M003844200; Franzot SP, 1999, BIOCHEM J, V340, P25, DOI 10.1042/0264-6021:3400025; Gerold P, 1999, BIOCHEM J, V344, P731, DOI 10.1042/0264-6021:3440731; Gerold P, 1996, MOL BIOCHEM PARASIT, V75, P131, DOI 10.1016/0166-6851(95)02518-9; Grimme SJ, 2001, J BIOL CHEM, V276, P27731, DOI 10.1074/jbc.M101986200; Guha-Niyogi A, 2001, GLYCOBIOLOGY, V11, p45R, DOI 10.1093/glycob/11.4.45R; GUTHER MLS, 1994, J BIOL CHEM, V269, P18694; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; Heise N, 1996, J BIOL CHEM, V271, P16877, DOI 10.1074/jbc.271.28.16877; HIROSE S, 1992, J BIOL CHEM, V267, P16968; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; Maeda Y, 2001, EMBO J, V20, P250, DOI 10.1093/emboj/20.1.250; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; McConville MJ, 2000, MOL MEMBR BIOL, V17, P1; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MILNE KG, 1992, EUR J BIOCHEM, V208, P309, DOI 10.1111/j.1432-1033.1992.tb17188.x; Moody-Haupt S, 2000, J MOL BIOL, V297, P409, DOI 10.1006/jmbi.2000.3577; Morita Y. S., 2000, OLIGOSACCHARIDES CHE, P417; Morita YS, 2000, J BIOL CHEM, V275, P14147, DOI 10.1074/jbc.275.19.14147; Morita YS, 2001, MOL BIOCHEM PARASIT, V115, P157, DOI 10.1016/S0166-6851(01)00279-1; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Naik RS, 2000, J EXP MED, V192, P1563, DOI 10.1084/jem.192.11.1563; PUOTI A, 1993, J BIOL CHEM, V268, P7215; Ralton JE, 1998, J BIOL CHEM, V273, P4245, DOI 10.1074/jbc.273.7.4245; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; SINGH BN, 1994, ARCH BIOCHEM BIOPHYS, V309, P273, DOI 10.1006/abbi.1994.1113; Smith TK, 1997, BIOCHEM J, V326, P393, DOI 10.1042/bj3260393; Smith TK, 2000, BIOCHEMISTRY-US, V39, P11801, DOI 10.1021/bi000854w; Smith TK, 1997, EMBO J, V16, P6667, DOI 10.1093/emboj/16.22.6667; Smith TK, 1996, J BIOL CHEM, V271, P6476, DOI 10.1074/jbc.271.11.6476; Smith TK, 1999, EMBO J, V18, P5922, DOI 10.1093/emboj/18.21.5922; Smith TK, 2001, EMBO J, V20, P3322, DOI 10.1093/emboj/20.13.3322; Striepen B, 1999, BIOCHEMISTRY-US, V38, P1478, DOI 10.1021/bi981884q; Striepen B, 1997, J MOL BIOL, V266, P797, DOI 10.1006/jmbi.1996.0806; Sutterlin C, 1997, EMBO J, V16, P6374, DOI 10.1093/emboj/16.21.6374; YE J, 1996, BIOORG MED CHEM LETT, V14, P1715; Zinecker CF, 2001, MOL BIOCHEM PARASIT, V116, P127, DOI 10.1016/S0166-6851(01)00313-9	52	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37147	37153		10.1074/jbc.M203371200	http://dx.doi.org/10.1074/jbc.M203371200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147686	hybrid			2022-12-27	WOS:000178447100032
J	Zou, WQ; Cashman, NR				Zou, WQ; Cashman, NR			Acidic pH and detergents enhance in vitro conversion of human brain PrPc to a PrPsc-like form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE PRION PROTEINS; CELL-SURFACE; CONFORMATION; ISOFORM; DISEASE; BINDING; INTERMEDIATE; TERMINUS; FEATURES; PATHWAY	In the presence of a low concentration of denaturants or detergents, acidic pH triggers a conformational transition of alpha-helices into beta-sheets in recombinant prion protein (PrP), likely mimicking some aspects of the transformation of host-encoded normal cellular PrP (PrPC) into its pathogenic isoform (PrPSc). Here we observed the effects of acidic pH and guanidine hydrochloride (GdnHCl) on the physicochemical and structural properties of PrPC derived from normal human brain and determined the ability of the acid/GdnHCl-treated PrP to form a proteinase K(PK)-resistant species in the absence and presence of PrPSc template. After treatment with 1.5 M GdnHCl at pH 3.5, PrPC from normal brain homogenates was converted into a detergent-insoluble form similar to PrPSc. Unlike PrPSc, however, the treated brain PrPC was protease-sensitive and retained epitope accessibility to monoclonal antibodies 3F4 and 6H4. Brain PrPC treated with acidic pH/GdnHCl acquired partial PK resistance upon further treatment with low concentrations of sodium dodecyl sulfate (SDS). Formation of this PrPSc-like isoform was greatly enhanced by incubation with trace quantities of PrPSc from Creutzfeldt-Jakob disease brain. Acid/GdnHCl-treated brain PrP may constitute a "recruitable intermediate" in PrPSc formation. Further structural rearrangement seems essential for this species to acquire PK resistance, which can be promoted by the presence of a PrPSc template.	Univ Toronto, CRND, Toronto, ON M5S 3H2, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M5S 3H2, Canada	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Cashman, NR (corresponding author), Univ Toronto, CRND, 6 Queens Pk Crescent W, Toronto, ON M5S 3H2, Canada.	neil.cashman@utoronto.ca	Zou, Wenquan/ABF-2875-2020; Zou, Wenquan/GWQ-3489-2022					Alonso DOV, 2001, P NATL ACAD SCI USA, V98, P2985, DOI 10.1073/pnas.061555898; ARNOLD JE, 1995, J PATHOL, V176, P403, DOI 10.1002/path.1711760412; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Buschmann A, 1998, BIOCHEM BIOPH RES CO, V253, P693, DOI 10.1006/bbrc.1998.9838; CASHMAN NR, 2001, 31 ANN M NEUR NOV 10; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; Cereghetti GM, 2001, BIOPHYS J, V81, P516, DOI 10.1016/S0006-3495(01)75718-9; Cohen FE, 1998, ANNU REV BIOCHEM, V67, P793, DOI 10.1146/annurev.biochem.67.1.793; Harris DA, 1999, CLIN MICROBIOL REV, V12, P429, DOI 10.1128/CMR.12.3.429; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; Jackson GS, 1999, BBA-PROTEIN STRUCT M, V1431, P1, DOI 10.1016/S0167-4838(99)00038-2; Jansen K, 2001, BIOL CHEM, V382, P683, DOI 10.1515/BC.2001.081; Kanyo ZF, 1999, J MOL BIOL, V293, P855, DOI 10.1006/jmbi.1999.3193; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Korth C, 1999, METHOD ENZYMOL, V309, P106; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Leclerc E, 2001, EMBO J, V20, P1547, DOI 10.1093/emboj/20.7.1547; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; LOWE J, 1992, J PATHOL, V168, P169, DOI 10.1002/path.1711680204; MAYER RJ, 1994, BIOMED PHARMACOTHER, V48, P282, DOI 10.1016/0753-3322(94)90173-2; MCKINLEY MP, 1991, J VIROL, V65, P1340, DOI 10.1128/JVI.65.3.1340-1351.1991; MCKINLEY MP, 1991, LAB INVEST, V65, P622; PEPYS MB, 1993, NATURE, V362, P553, DOI 10.1038/362553a0; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Prusiner SB, 1999, COLD SPRING HARBOR M, V38, P349; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Race R, 1998, NATURE, V392, P770, DOI 10.1038/33834; Race R, 2001, J VIROL, V75, P10106, DOI 10.1128/JVI.75.21.10106-10112.2001; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Saborio GP, 1999, BIOCHEM BIOPH RES CO, V258, P470, DOI 10.1006/bbrc.1999.0660; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Xiong LW, 2001, J NEUROCHEM, V79, P669, DOI 10.1046/j.1471-4159.2001.00606.x; Yokoyama T, 2001, J BIOL CHEM, V276, P11265, DOI 10.1074/jbc.M008734200; ZHANG H, 1995, J MOL BIOL, V250, P514, DOI 10.1006/jmbi.1995.0395; Zou WQ, 2001, EUR J BIOCHEM, V268, P4885, DOI 10.1046/j.1432-1327.2001.02415.x	44	71	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43942	43947		10.1074/jbc.M203611200	http://dx.doi.org/10.1074/jbc.M203611200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12161431	hybrid			2022-12-27	WOS:000179272000054
J	Ward, BK; Allan, RK; Mok, D; Temple, SE; Taylor, P; Dornan, J; Mark, PJ; Shaw, DJ; Kumar, P; Walkinshaw, MD; Ratajczak, T				Ward, BK; Allan, RK; Mok, D; Temple, SE; Taylor, P; Dornan, J; Mark, PJ; Shaw, DJ; Kumar, P; Walkinshaw, MD; Ratajczak, T			A structure-based mutational analysis of cyclophilin 40 identifies key residues in the core tetratricopeptide repeat domain that mediate binding to Hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; PROGESTERONE-RECEPTOR COMPLEXES; ESTROGEN-RECEPTOR; GLUCOCORTICOID RECEPTOR; IMMUNOPHILIN FKBP51; ESCHERICHIA-COLI; SQUIRREL-MONKEY; CHAPERONE SITES; HEAT-SHOCK-PROTEIN-90; MUTANTS	Cyclophilin 40 (CyP40) is a tetratricopeptide repeat (TPR)-containing immunophilin and a modulator of steroid receptor function through its binding to heat shock protein 90 (Hsp90). Critical to this binding are the carboxyl-terminal MEEVD motif of Hsp90 and the TPR domain of CyP40. Two different models of the CyP40-MEEVD peptide interaction were used as the basis for a comprehensive mutational analysis of the Hsp90-interacting domain of CyP40. Using a carboxyl-terminal CyP40 construct as template, 24 amino acids from the TPR and flanking acidic and basic domains were individually mutated by site-directed mutagenesis, and the mutants were coexpressed in yeast with a carboxyl-terminal Hsp90beta construct and qualitatively assessed for binding using a beta-galactosidase filter assay. For quantitative assessment, mutants were expressed as glutathione S-transferase fusion proteins and assayed for binding to carboxyl-terminal Hsp90beta using conventional pulldown and enzyme-linked immunosorbent assay microtiter plate assays. Collectively, the models predict that the following TPR residues help define a binding groove for the MEEVD peptide: Lys-227, Asn-231, Phe234, Ser-274, Asn-278, Lys-308, and Arg-312. Mutational analysis identified five of these residues (Lys-227, Asn-231, Asn-278, Lys-308, and Arg-312) as essential for Hsp90 binding. The other two residues (Phe-234 and Ser-274) and another three TPR domain residues not definitively associated with the binding groove (Leu-284, Lys-285, and Asp-329) are required for efficient Hsp90 binding. These data confirm the critical importance of the MEEVD binding groove in CyP40 for Hsp90 recognition and reveal that additional charged and hydrophobic residues within the CyP40 TPR domain are required for Hsp90 binding.	Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Queen Elizabeth Med Ctr 2, Nedlands, WA 6009, Australia; Western Australian Inst Med Res, Perth, WA, Australia; Univ Western Australia, Dept Pharmacol, Nedlands, WA 6009, Australia; Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland	University of Western Australia; University of Western Australia; University of Western Australia; University of Edinburgh	Ratajczak, T (corresponding author), Sir Charles Gairdner Hosp, Dept Endocrinol & Diabet, Queen Elizabeth Med Ctr 2, Block C, Nedlands, WA 6009, Australia.		walkinshaw, malcolm/AAB-7497-2019; Mok, Danny/A-5328-2011; Mark, Peter/H-5365-2014	walkinshaw, malcolm/0000-0001-5955-9325				Barent RL, 1998, MOL ENDOCRINOL, V12, P342, DOI 10.1210/me.12.3.342; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BINART N, 1995, BIOCHEM J, V311, P797, DOI 10.1042/bj3110797; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Davies TH, 2002, J BIOL CHEM, V277, P4597, DOI 10.1074/jbc.C100531200; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Denny WB, 2000, ENDOCRINOLOGY, V141, P4107, DOI 10.1210/en.141.11.4107; Dornan A, 1999, ACTA CRYSTALLOGR D, V55, P1079, DOI 10.1107/S0907444999003017; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; Hernandez MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HONIG B, 1993, J PHYS CHEM-US, V97, P1101, DOI 10.1021/j100108a002; HONORE B, 1992, J BIOL CHEM, V267, P8485; Irmer H, 1997, J BIOL CHEM, V272, P2230; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; Meng X, 1996, J CELL SCI, V109, P1677; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; Pratt WB, 1999, CELL SIGNAL, V11, P839, DOI 10.1016/S0898-6568(99)00064-9; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Ramsey AJ, 2000, J BIOL CHEM, V275, P17857, DOI 10.1074/jbc.M001625200; RATAJCZAK T, 1995, BIOCHEM BIOPH RES CO, V209, P117, DOI 10.1006/bbrc.1995.1478; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; RATAJCZAK T, 1990, J STEROID BIOCHEM, V35, P543, DOI 10.1016/0022-4731(90)90197-Z; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Scheibel T, 1998, P NATL ACAD SCI USA, V95, P1495, DOI 10.1073/pnas.95.4.1495; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SHI Y, 1994, P NATL ACAD SCI USA, V91, P2767, DOI 10.1073/pnas.91.7.2767; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Silverstein AM, 1997, J BIOL CHEM, V272, P16224, DOI 10.1074/jbc.272.26.16224; Smith DF, 1998, BIOL CHEM, V379, P283; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SULLIVAN WP, 1993, J BIOL CHEM, V268, P20373; Taylor P, 2001, STRUCTURE, V9, P431, DOI 10.1016/S0969-2126(01)00603-7; Toft DO, 1998, TRENDS ENDOCRIN MET, V9, P238, DOI 10.1016/S1043-2760(98)00060-5; van der Spuy J, 2000, BIOCHEM J, V345, P645, DOI 10.1042/0264-6021:3450645; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Widmer A., 1997, WITNOTP COMPUTER PRO; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007	51	57	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40799	40809		10.1074/jbc.M207097200	http://dx.doi.org/10.1074/jbc.M207097200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12145316	hybrid			2022-12-27	WOS:000178791400083
J	Han, XB; Patters, AB; Chesney, RW				Han, XB; Patters, AB; Chesney, RW			Transcriptional repression of taurine transporter gene (TauT) by p53 in renal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROXIMAL TUBULE; PROMOTER; BINDING; ACTIVATION; EXPRESSION; CLONING; CANCER; SITE	Taurine, an intracellular osmolyte whose body pool size is adaptively regulated by the kidney, is required for normal renal development. Overexpression of the p53 tumor suppressor gene in p53 transgenic mice results in renal malformation, suggesting that altered expression of certain p53 target gene(s) involved in renal development may be responsible. This study shows that the taurine transporter gene (TauT is a transcriptional target of p53. Expression of TauT was decreased after activation of p53 by doxorubicin, a DNA-damaging drug, in 293 and NRK-52E renal cells. TauT promoter activity was decreased 5-10-fold by cotransfection of a full-length TauT promoter-reporter construct with p53, which was reversed by cotransfection with a mutant p53 (p53-281). Electrophoretic mobility shift assays using nuclear extracts from p53-expressing (10)1val cells showed a putative p53-binding site in the TauT promoter region, which bound to the p53 in electrophoretic mobility shift assays. Mutation of this p53 consensus sequence abolished binding of p53. These results demonstrate that TauT may represent a downstream target gene of p53 that could link the roles of p53 in renal development and apoptosis.	Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN 38103 USA; Lebonheur Childrens Hosp & Med Ctr, Childrens Fdn Res Ctr, Memphis, TN 38103 USA	University of Tennessee System; University of Tennessee Health Science Center	Chesney, RW (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Pediat, 50 N Dunlap, Memphis, TN 38103 USA.	rchesney@utmem.edu						Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen XC, 1998, ADV EXP MED BIOL, V442, P397; CHESNEY RW, 1985, J CLIN INVEST, V76, P2213, DOI 10.1172/JCI112230; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; GEDLEY LA, 1996, GENE DEV, V110, P836; Han XB, 2000, ADV EXP MED BIOL, V483, P535; Han XB, 2000, ADV EXP MED BIOL, V483, P97; Han XB, 1999, J AM SOC NEPHROL, V10, P1874; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Heller-Stilb B, 2001, FASEB J, V15, P231, DOI 10.1096/fj.01-0691fje; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; IMAKI H, 1986, DEV NEUROSCI-BASEL, V8, P160, DOI 10.1159/000112251; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Lang F, 1998, PFLUG ARCH EUR J PHY, V436, P377, DOI 10.1007/s004240050646; LEIBBRANDT MEI, 1995, KIDNEY INT, V48, P761, DOI 10.1038/ki.1995.348; Matsell DG, 1997, KIDNEY INT, V52, P748, DOI 10.1038/ki.1997.391; Nylander K, 2000, J PATHOL, V190, P39, DOI 10.1002/(SICI)1096-9896(200001)190:1<39::AID-PATH492>3.0.CO;2-V; Oz E, 1999, GEN PHARMACOL-VASC S, V33, P137, DOI 10.1016/S0306-3623(98)00284-5; Pei XH, 1999, J BIOL CHEM, V274, P35240, DOI 10.1074/jbc.274.49.35240; Saad SY, 2002, CHEMOTHERAPY, V48, P42, DOI 10.1159/000048587; Schaffer SW, 1998, AMINO ACIDS, V15, P135, DOI 10.1007/BF01345286; Sheard MA, 1997, INT J CANCER, V73, P757, DOI 10.1002/(SICI)1097-0215(19971127)73:5<757::AID-IJC24>3.0.CO;2-1; SMITH KE, 1992, MOL PHARMACOL, V42, P563; STURMAN JA, 1985, ADV EXP MED BIOL, V179, P43; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Yamabe Y, 1998, MOL CELL BIOL, V18, P6191, DOI 10.1128/MCB.18.11.6191	30	32	32	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39266	39273		10.1074/jbc.M205939200	http://dx.doi.org/10.1074/jbc.M205939200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163498	hybrid			2022-12-27	WOS:000178662500028
J	Peters, MA; Jackson, DC; Crabb, BS; Browning, GF				Peters, MA; Jackson, DC; Crabb, BS; Browning, GF			Chicken anemia virus VP2 is a novel dual specificity protein phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TT-VIRUS; TYROSINE PHOSPHATASES; VACCINIA VIRUS; HIGH PREVALENCE; DNA; PHOSPHORYLATION; VH1; BACULOVIRUS; EXPRESSION; MECHANISM	The function of viral protein 2 (VP2) of the immunosuppressive circovirus chicken anemia virus (CAV) has not yet been established. We show that the CAV VP2 amino acid sequence has some similarity to a number of eukaryotic, receptor, protein-tyrosine phosphatase (PTPase) alpha proteins as well as to a cluster of human TT viruses within the Sanban group. To investigate if CAV VP2 functions as a PTPase, purified glutathione S-transferase (GST)-VP2 fusion protein was assayed for PTPase activity using the generalized peptide substrates ENDpYINASL and DADEpYLIPQQG (where pY represents phosphotyrosine), with free phosphate detected using the malachite green colorimetric assay. CAV GST-VP2 was shown to catalyze dephosphorylation of both substrates. CAV GST-VP2 PTPase activity for the ENDpYINASL substrate had a V-max of 14,925 units/mg.min and a K-m of 18.88 muM. Optimal activity was observed between pH 6 and 7, and activity was specifically inhibited by 0.01 mm orthovanadate. We also show that the ORF2 sequence of the CAV-related human virus TT-like minivirus (TLMV) possessed PTPase activity and steady state kinetics equivalent to CAV GST-VP2 when expressed as a GST fusion protein. To establish whether these viral proteins were dual specificity protein phosphatases, the CAV GST-VP2 and TLMV GST-ORF2 fusion proteins were also assayed for serine/threonine phosphatase (S/T P'Pase) activity using the generalized peptide substrate RRApTVA, with free phosphate detected using the malachite green colorimetric assay. Both CAV GST-VP2 and TLMV GST-ORF2 fusion proteins possessed S/T PPase activity, which was specifically inhibited by 50 mm sodium fluoride. CAV GST-VP2 exhibited S/T P'Pase activity with a V-max. of 28,600 units/mg.min and a K-m of 76 muM. Mutagenesis of residue Cys(95) to serine in CAV GST-VP2 abrogated both PTPase and S/T PPase activity, identifying it as the catalytic cysteine within the proposed signature motif. These studies thus show that the circoviruses CAV and TLAW encode dual specificity protein phosphatases (DSP) with an unusual signature motif that may play a role in intracellular signaling during viral replication. This is the first DSP gene to be identified in a small viral genome.	Univ Melbourne, Dept Vet Sci, Melbourne, Vic 3010, Australia; Univ Melbourne, Dept Microbiol & Immunol, Melbourne, Vic 3010, Australia; Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Div Infect & Immun, Melbourne, Vic 3050, Australia	University of Melbourne; University of Melbourne; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Browning, GF (corresponding author), Univ Melbourne, Dept Vet Sci, Melbourne, Vic 3010, Australia.	glenfb@unimelb.edu.au	Crabb, Brendan/F-5287-2013; Browning, Glenn Francis/P-4459-2014	Browning, Glenn Francis/0000-0002-0903-2469; Jackson, David/0000-0001-7255-270X				Asabe S, 2001, BIOCHEM BIOPH RES CO, V286, P298, DOI 10.1006/bbrc.2001.5385; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Brown K, 2000, AUST VET J, V78, P637, DOI 10.1111/j.1751-0813.2000.tb11942.x; CHUI D, 1994, EMBO J, V13, P798, DOI 10.1002/j.1460-2075.1994.tb06322.x; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; Dai Chia-Yen, 2000, Kaohsiung Journal of Medical Sciences, V16, P500; DAUM G, 1993, ANAL BIOCHEM, V211, P50, DOI 10.1006/abio.1993.1231; Dhenain M, 2000, CLIN INVEST MED, V23, P307; DUTZ JP, 1995, J IMMUNOL, V154, P2588; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; GELADOPOULOS TP, 1991, ANAL BIOCHEM, V192, P112, DOI 10.1016/0003-2697(91)90194-X; HAKES DJ, 1993, P NATL ACAD SCI USA, V90, P4017, DOI 10.1073/pnas.90.9.4017; HANCOCK WS, 1976, ANAL BIOCHEM, V71, P260, DOI 10.1016/0003-2697(76)90034-8; HOWARD PK, 1993, SCIENCE, V259, P241, DOI 10.1126/science.7678470; Huang LY, 2001, J MED VIROL, V64, P381, DOI 10.1002/jmv.1062; Itoh M, 2001, DIGEST DIS SCI, V46, P457, DOI 10.1023/A:1005618308943; Kanda Y, 2001, LEUKEMIA LYMPHOMA, V40, P483, DOI 10.3109/10428190109097647; Kozieradzki I, 1997, J IMMUNOL, V158, P3130; Li LW, 2000, SEMIN IMMUNOL, V12, P75, DOI 10.1006/smim.2000.0209; LI YH, 1995, J VIROL, V69, P4533, DOI 10.1128/JVI.69.7.4533-4537.1995; Ling MM, 1997, ANAL BIOCHEM, V254, P157, DOI 10.1006/abio.1997.2428; LIU K, 1995, J VIROL, V69, P7823, DOI 10.1128/JVI.69.12.7823-7834.1995; MARTH JD, 1994, ADV EXP MED BIOL, V365, P149; MEEHAN BM, 1992, ARCH VIROL, V124, P301, DOI 10.1007/BF01309811; MILLAR JBA, 1991, P NATL ACAD SCI USA, V88, P10500, DOI 10.1073/pnas.88.23.10500; MOONEY RA, 1992, J BIOL CHEM, V267, P23443; Najarro P, 2001, J VIROL, V75, P3185, DOI 10.1128/JVI.75.7.3185-3196.2001; NOTEBORN MHM, 1991, J VIROL, V65, P3131, DOI 10.1128/JVI.65.6.3131-3139.1991; ONG CJ, 1994, J IMMUNOL, V152, P3793; Ong CJ, 1997, IMMUNOLOGY, V91, P95, DOI 10.1046/j.1365-2567.1997.00216.x; PHENIX KV, 1994, J GEN VIROL, V75, P905, DOI 10.1099/0022-1317-75-4-905; Poovorawan Y, 2001, HEPATO-GASTROENTEROL, V48, P256; Ragnarsson U, 1995, J Pept Sci, V1, P149, DOI 10.1002/psc.310010302; Safadi R, 2001, BONE MARROW TRANSPL, V27, P183, DOI 10.1038/sj.bmt.1702749; SCHIEVELLA AR, 1993, CELL GROWTH DIFFER, V4, P239; Shibayama T, 2001, AIDS, V15, P563, DOI 10.1097/00002030-200103300-00004; Takagi T, 1998, P NATL ACAD SCI USA, V95, P9808, DOI 10.1073/pnas.95.17.9808; Takahashia K, 2000, INTERVIROLOGY, V43, P119, DOI 10.1159/000025034; TONKS NK, 1991, METHOD ENZYMOL, V201, P442; Vasconcelos HCF, 2001, MEM I OSWALDO CRUZ, V96, P519, DOI 10.1590/S0074-02762001000400013; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1	42	83	92	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39566	39573		10.1074/jbc.M201752200	http://dx.doi.org/10.1074/jbc.M201752200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12151384	hybrid			2022-12-27	WOS:000178662500067
J	Spiers, A; Lamb, HK; Cocklin, S; Wheeler, KA; Budworth, J; Dodds, AL; Pallen, MJ; Maskell, DJ; Charles, IG; Hawkins, AR				Spiers, A; Lamb, HK; Cocklin, S; Wheeler, KA; Budworth, J; Dodds, AL; Pallen, MJ; Maskell, DJ; Charles, IG; Hawkins, AR			PDZ domains facilitate binding of high temperature requirement protease A (HtrA) and tail-specific protease (Tsp) to heterologous substrates through recognition of the small stable RNA A (ssrA)-encoded peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI SURVIVAL; 10SA RNA; SERINE-PROTEASE; CELL-ENVELOPE; DEGP; PROTEINS; GENE; DETERMINANTS; DEGRADATION	The Escherichia coli protease HtrA has two PDZ domains, and sequence alignments predict that the E. coli protease Tsp has a single PDZ domain. PDZ domains are composed of short sequences (80-100 amino acids) that have been implicated in a range of protein:protein interactions. The PDZ-like domain of Tsp may be involved in binding to the extreme COOH-terminal sequence of its substrate, whereas the HtrA PDZ domains are involved in subunit assembly and are predicted to be responsible for substrate binding and subsequent translocation into the active site. E. coli has a system of protein quality control surveillance mediated by the ssrA-encoded peptide tagging system. This system tags misfolded proteins or protein fragments with an 11-amino acid peptide that is recognized by a battery of cytoplasmic and periplasmic proteases as a degradation signal. Here we show that both HtrA and Tsp are able to recognize the ssrA-encoded peptide tag with apparent KD values of similar to5 and 390 nm, respectively, and that their PDZ-like domains mediate this recognition. Fusion of the ssrA-encoded peptide tag to the COOH terminus of a heterologous protein (glutathione S-transferase) renders it sensitive to digestion by Tsp but not HtrA. These observations support the prediction that the HtrA PDZ domains facilitate substrate binding and the differential proteolytic responses of HtrA and Tsp to SsrA-tagged glutathione S-transferase are interpreted in terms of the structure of HtrA.	Newcastle Univ, Sch Med, Sch Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Arrow Therapeut Ltd, London SE1 1DA, England; Univ Birmingham, Sch Med, Div Immun & Infect, Microbial Genomics & Pathogenesis Unit, Birmingham B15 2TT, W Midlands, England; Univ Cambridge, Dept Clin Vet Med, Ctr Vet Sci, Cambridge CB3 0ES, England	Newcastle University - UK; AstraZeneca; University of Birmingham; University of Cambridge	Hawkins, AR (corresponding author), Newcastle Univ, Sch Med, Sch Biochem & Genet, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	a.r.hawkins@ncl.ac.uk	Pallen, Mark J./E-7619-2011	Pallen, Mark/0000-0003-1807-3657				Bass S, 1996, J BACTERIOL, V178, P1154, DOI 10.1128/jb.178.4.1154-1161.1996; Beebe KD, 2000, BIOCHEMISTRY-US, V39, P3149, DOI 10.1021/bi992709s; Felden B, 1997, RNA, V3, P89; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Karzai AW, 2000, NAT STRUCT BIOL, V7, P449; Keiler KC, 1996, J BIOL CHEM, V271, P2589, DOI 10.1074/jbc.271.5.2589; KEILER KC, 1995, PROTEIN SCI, V4, P1507, DOI 10.1002/pro.5560040808; Kolmar H, 1996, J BACTERIOL, V178, P5925, DOI 10.1128/jb.178.20.5925-5929.1996; KOMINE Y, 1994, P NATL ACAD SCI USA, V91, P9223, DOI 10.1073/pnas.91.20.9223; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; Langmuir I, 1918, J AM CHEM SOC, V40, P1361, DOI 10.1021/ja02242a004; Liao DI, 2000, NAT STRUCT BIOL, V7, P749, DOI 10.1038/78973; LIPINSKA B, 1989, J BACTERIOL, V171, P1574, DOI 10.1128/jb.171.3.1574-1584.1989; LIPINSKA B, 1990, J BACTERIOL, V172, P1791, DOI 10.1128/jb.172.4.1791-1797.1990; Missiakas D, 1997, TRENDS BIOCHEM SCI, V22, P59, DOI 10.1016/S0968-0004(96)10072-4; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; PARSELL DA, 1990, GENE DEV, V4, P277, DOI 10.1101/gad.4.2.277; Ponting CP, 1997, PROTEIN SCI, V6, P464; Rawlings ND, 1997, BIOM HLTH R, V13, P13; SEOL JH, 1991, BIOCHEM BIOPH RES CO, V176, P730; SILBER KR, 1992, P NATL ACAD SCI USA, V89, P295, DOI 10.1073/pnas.89.1.295; SKORKOGLONEK J, 1995, GENE, V163, P47, DOI 10.1016/0378-1119(95)00406-V; SKORKOGLONEK J, 1995, J BIOL CHEM, V270, P11140, DOI 10.1074/jbc.270.19.11140; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; STRAUCH KL, 1989, J BACTERIOL, V171, P2689, DOI 10.1128/jb.171.5.2689-2696.1989; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; Williams KP, 1996, RNA, V2, P1306	31	40	41	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39443	39449		10.1074/jbc.M202790200	http://dx.doi.org/10.1074/jbc.M202790200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177052	hybrid			2022-12-27	WOS:000178662500050
J	Tanaka, AR; Tanabe, K; Morita, M; Kurisu, M; Kasiwayama, Y; Matsuo, M; Kioka, N; Amachi, T; Imanaka, T; Ueda, K				Tanaka, AR; Tanabe, K; Morita, M; Kurisu, M; Kasiwayama, Y; Matsuo, M; Kioka, N; Amachi, T; Imanaka, T; Ueda, K			ATP binding/hydrolysis by and phosphorylation of peroxisomal ATP-binding cassette proteins PMP70 (ABCD3) and adrenoleukodystrophy protein (ABCD1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED ADRENOLEUKODYSTROPHY; TRANSMEMBRANE CONDUCTANCE REGULATOR; MEMBRANE-PROTEIN; SACCHAROMYCES-CEREVISIAE; SULFONYLUREA RECEPTOR; P-GLYCOPROTEIN; GENE-PRODUCT; TRANSPORTER; NUCLEOTIDE; SUR1	The 70-kDa peroxisomal membrane protein (PMP70) and adrenoleukodystrophy protein (ALDP), half-size ATP-binding cassette transporters, are involved in metabolic transport of long and very long chain fatty acids into peroxisomes. We examined the interaction of peroxisomal ATP-binding cassette transporters with ATP using rat liver peroxisomes. PMP70 was photoaffinity-labeled at similar efficiencies with 8-azido-[alpha-P-32]ATP and 8-azido-[gamma-P-32]ATp when peroxisomes were incubated with these nucleotides at 37 degreesC in the absence Mg2+ and exposed to UV light without removing unbound nucleotides. The photoaffinity-labeled PMP70 and ALDP were co-immunoprecipitated together with other peroxisomal proteins, which also showed tight ATP binding properties. Addition of Mg2+ reduced the photoaffinity labeling of PMP70 with 8-azido-[gamma-P-32]ATp by 70%, whereas it reduced photoaffinity labeling with 8-azido-[alpha-P-32]ATP by only 20%. However, two-thirds of nucleotide (probably ADP) was dissociated during removal of unbound nucleotides. These results suggest that ATP binds to PMP70 tightly in the absence of Mg2+, the bound ATP is hydrolyzed to ADP in the presence of Mg2+, and the produced ADP is dissociated from PMP70, which allows ATP hydrolysis turnover. Properties of photoaffinity labeling of ALDP were essentially similar to those of PMP70. Vanadate-induced nucleotide trapping in PMP70 and ALDP was not observed. PMP70 and ALDP were also phosphorylated at a tyrosine residue(s). ATP binding/hydrolysis by and phosphorylation of PMP70 and ALDP are involved in the regulation of fatty acid transport into peroxisomes.	Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Lab Cellular Biochem, Kyoto 6068502, Japan; Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Biol Chem, Toyama 9300194, Japan	Kyoto University; University of Toyama	Ueda, K (corresponding author), Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Lab Cellular Biochem, Kyoto 6068502, Japan.	uedak@kais.kyoto-u.ac.jp		Imanaka, Tsuneo/0000-0003-4677-1356; Ueda, Kazumitsu/0000-0003-2980-6078; Kioka, Noriyuki/0000-0002-2708-537X				Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; Aleksandrov L, 2001, J BIOL CHEM, V276, P12918, DOI 10.1074/jbc.M100515200; Aubourg P, 1999, NEUROCHEM RES, V24, P515, DOI 10.1023/A:1022583813171; Aubourg P, 1996, ANN NY ACAD SCI, V804, P461, DOI 10.1111/j.1749-6632.1996.tb18637.x; Contreras M, 1996, ARCH BIOCHEM BIOPHYS, V334, P369, DOI 10.1006/abbi.1996.0467; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GARTNER J, 1992, NAT GENET, V1, P16, DOI 10.1038/ng0492-16; Hettema EH, 1996, EMBO J, V15, P3813, DOI 10.1002/j.1460-2075.1996.tb00755.x; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holzinger A, 1997, BIOCHEM BIOPH RES CO, V239, P261, DOI 10.1006/bbrc.1997.7391; Imanaka T, 1999, J BIOL CHEM, V274, P11968, DOI 10.1074/jbc.274.17.11968; Imanaka T, 1996, J BIOL CHEM, V271, P3706; IMANAKA T, 1991, BIOCHIM BIOPHYS ACTA, V1062, P264, DOI 10.1016/0005-2736(91)90401-S; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KAMIJO K, 1992, BIOCHIM BIOPHYS ACTA, V1129, P323, DOI 10.1016/0167-4781(92)90510-7; Kashiwayama Y, 2002, BIOCHEM BIOPH RES CO, V291, P1245, DOI 10.1006/bbrc.2002.6588; KOBAYASHI T, 1994, BIOCHEM BIOPH RES CO, V201, P1029, DOI 10.1006/bbrc.1994.1805; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Li YH, 2000, J BIOL CHEM, V275, P24130, DOI 10.1074/jbc.M003617200; Liu LX, 1999, J BIOL CHEM, V274, P32738, DOI 10.1074/jbc.274.46.32738; LombardPlatet G, 1996, P NATL ACAD SCI USA, V93, P1265, DOI 10.1073/pnas.93.3.1265; MANNAERTS GP, 1982, BIOCHEM J, V204, P17, DOI 10.1042/bj2040017; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; Moser HW, 1995, METABOLIC MOL BASES, V7h, P2325; MOSSER J, 1993, NATURE, V361, P726, DOI 10.1038/361726a0; Reguenga C, 2001, J BIOL CHEM, V276, P29935, DOI 10.1074/jbc.M104114200; Roerig P, 2001, FEBS LETT, V492, P66, DOI 10.1016/S0014-5793(01)02235-9; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Shan N, 1996, J BIOL CHEM, V271, P8725, DOI 10.1074/jbc.271.15.8725; Shani N, 1997, HUM MOL GENET, V6, P1925, DOI 10.1093/hmg/6.11.1925; SHANI N, 1995, P NATL ACAD SCI USA, V92, P6012, DOI 10.1073/pnas.92.13.6012; SHIMIZU S, 1992, J BIOCHEM-TOKYO, V112, P733, DOI 10.1093/oxfordjournals.jbchem.a123967; Smith KD, 1999, NEUROCHEM RES, V24, P521, DOI 10.1023/A:1022535930009; Steinberg SJ, 1999, ANN NEUROL, V46, P409, DOI 10.1002/1531-8249(199909)46:3<409::AID-ANA18>3.0.CO;2-9; Swartzman EE, 1996, J CELL BIOL, V132, P549, DOI 10.1083/jcb.132.4.549; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; Szakacs G, 2001, BIOCHEM BIOPH RES CO, V288, P1258, DOI 10.1006/bbrc.2001.5905; Taguchi Y, 1997, FEBS LETT, V401, P11, DOI 10.1016/S0014-5793(96)01421-4; Takeda Y, 1998, BBA-BIOMEMBRANES, V1373, P131, DOI 10.1016/S0005-2736(98)00099-6; Ueda K, 1999, BBA-BIOMEMBRANES, V1461, P305, DOI 10.1016/S0005-2736(99)00157-1; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383	44	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40142	40147		10.1074/jbc.M205079200	http://dx.doi.org/10.1074/jbc.M205079200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176987	hybrid			2022-12-27	WOS:000178662500137
J	Yang, FM; Liu, XB; Quinones, M; Melby, PC; Ghio, A; Haile, DJ				Yang, FM; Liu, XB; Quinones, M; Melby, PC; Ghio, A; Haile, DJ			Regulation of reticuloendothelial iron transporter MTP1 (Slc11a3) by inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; AUTOSOMAL-DOMINANT HEMOCHROMATOSIS; RECOMBINANT HUMAN INTERLEUKIN-6; CANCER-PATIENTS; STORAGE IRON; SERUM IRON; TNF-ALPHA; ANEMIA; MICE; METABOLISM	Acute and chronic inflammation cause many changes in total body iron metabolism including the sequestration of iron in phagocytic cells of the reticuloendothelial system. This change in iron metabolism contributes to the development of the anemia of inflammation. MTP1, the duodenal enterocyte basolateral iron exporter, is also expressed in the cells of the reticuloendothelial system (RES) and is likely to be involved in iron recycling of these cells. In this study, we use a lipopolysaccharide model of the acute inflammation in the mouse and demonstrate that MTP1 expression in RES cells of the spleen, liver, and bone marrow is down-regulated by inflammation. The down-regulation of splenic expression of MTP1 by inflammation was also observed in a Leishmania donovani model of chronic infection. The response of MTP1 to lipopolysaccharide (LPS) requires signaling through the LPS receptor, Toll-like receptor 4 (TLR4). In mice lacking TLR4, MTP1 expression is not altered in response to LPS. In addition, mice lacking tumor necrosis factor-receptor 1a respond appropriately to LPS with down-regulation of MTP1, despite hyporesponsiveness to tumor necrosis factor-alpha signaling, suggesting that this cytokine may not be required for the LPS effect. We hypothesize that the iron sequestration in the RES system that accompanies inflammation is because of down-regulation of MTP1.	S Texas Vet Hlth Syst, Audie L Murphy Mem Vet Affairs Med Ctr, San Antonio, TX 78229 USA; US EPA, Natl Hlth & Environm Effect Res Lab, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; United States Environmental Protection Agency; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Haile, DJ (corresponding author), S Texas Vet Hlth Syst, Audie L Murphy Mem Vet Affairs Med Ctr, San Antonio, TX 78229 USA.	Haile@uthscsa.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053079] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK53079] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abboud S, 2000, J BIOL CHEM, V275, P19906, DOI 10.1074/jbc.M000713200; ALVAREZHERNANDEZ X, 1989, LAB INVEST, V61, P319; BEGUIN Y, 1989, J LAB CLIN MED, V113, P346; Bertero MT, 1997, HAEMATOLOGICA, V82, P375; BERTINI R, 1989, J LEUKOCYTE BIOL, V46, P254, DOI 10.1002/jlb.46.3.254; CORTELL S, 1967, AM J PHYSIOL, V213, P43, DOI 10.1152/ajplegacy.1967.213.1.43; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; ELSHOBAKI F, 1985, BLUT, V50, P95, DOI 10.1007/BF00321172; Feelders RA, 1998, EUR J CLIN INVEST, V28, P520; FELDMAN BF, 1981, AM J VET RES, V42, P1109; FELDMAN BF, 1981, AM J VET RES, V42, P583; FELDMAN BF, 1981, AM J VET RES, V42, P586; FILLET G, 1989, BLOOD, V74, P844; FILLET G, 1974, J CLIN INVEST, V53, P1527, DOI 10.1172/JCI107703; FISCHER E, 1991, AM J PHYSIOL, V261, pR442, DOI 10.1152/ajpregu.1991.261.2.R442; GORDEUK VR, 1988, J CLIN INVEST, V82, P1934, DOI 10.1172/JCI113812; GUTTEBERG TJ, 1989, SCAND J INFECT DIS, V21, P709, DOI 10.3109/00365548909021701; HERSHKO C, 1974, BRIT J HAEMATOL, V28, P67, DOI 10.1111/j.1365-2141.1974.tb06640.x; Hill AG, 1997, ANN SURG, V225, P246, DOI 10.1097/00000658-199703000-00002; Jurado RL, 1997, CLIN INFECT DIS, V25, P888, DOI 10.1086/515549; KAMPSCHMIDT RF, 1985, P SOC EXP BIOL MED, V179, P197; KAMPSCHMIDT RF, 1965, AM J PHYSIOL, V208, P68, DOI 10.1152/ajplegacy.1965.208.1.68; KAMPSCHMIDT RF, 1980, J LAB CLIN MED, V95, P616; KAMPSCHMIDT RF, 1963, P SOC EXP BIOL MED, V113, P142; KOBUNE M, 1994, HEPATOLOGY, V19, P1468, DOI 10.1002/hep.1840190623; KONIJN AM, 1977, BRIT J HAEMATOL, V37, P7, DOI 10.1111/j.1365-2141.1977.tb08806.x; Lauzurica P, 1999, EUR J IMMUNOL, V29, P1890, DOI 10.1002/(SICI)1521-4141(199906)29:06<1890::AID-IMMU1890>3.0.CO;2-F; Mabika M, 1999, PFLUG ARCH EUR J PHY, V438, P218, DOI 10.1007/s004240050901; McKie AT, 2000, MOL CELL, V5, P299, DOI 10.1016/S1097-2765(00)80425-6; Means RT, 1999, INT J HEMATOL, V70, P7; Melby PC, 1998, INFECT IMMUN, V66, P18, DOI 10.1128/IAI.66.1.18-27.1998; MOLDAWER LL, 1989, FASEB J, V3, P1637, DOI 10.1096/fasebj.3.5.2784116; Montosi G, 2001, J CLIN INVEST, V108, P619, DOI 10.1172/JCI200113468; NIEKEN J, 1995, BLOOD, V86, P900, DOI 10.1182/blood.V86.3.900.bloodjournal863900; Njajou OT, 2001, NAT GENET, V28, P213, DOI 10.1038/90038; Patruta SI, 1999, KIDNEY INT, V55, pS125, DOI 10.1046/j.1523-1755.1999.055Suppl.69125.x; PEKAREK RS, 1969, AM J MED SCI, V258, P14, DOI 10.1097/00000441-196907000-00003; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RAJA KB, 1990, INT J EXP PATHOL, V71, P785; TANAKA T, 1987, J BIOL RESP MODIF, V6, P484; UCHIDA T, 1991, EUR J HAEMATOL, V46, P1; UCHIDA T, 1983, TOHOKU J EXP MED, V139, P293, DOI 10.1620/tjem.139.293; VANGAMEREN MM, 1994, BLOOD, V84, P1434; Weiss G, 1999, KIDNEY INT, V55, pS12, DOI 10.1046/j.1523-1755.1999.055Suppl.69012.x	45	168	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39786	39791		10.1074/jbc.M201485200	http://dx.doi.org/10.1074/jbc.M201485200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161425	hybrid			2022-12-27	WOS:000178662500093
J	Gomez-Gaviro, MV; Gonzalez-Alvaro, I; Dominguez-Jimenez, C; Peschon, J; Black, RA; Sanchez-Madrid, F; Diaz-Gonzalez, F				Gomez-Gaviro, MV; Gonzalez-Alvaro, I; Dominguez-Jimenez, C; Peschon, J; Black, RA; Sanchez-Madrid, F; Diaz-Gonzalez, F			Structure-function relationship and role of tumor necrosis factor-alpha-converting enzyme in the down-regulation of L-selectin by non-steroidal anti-inflammatory drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATTENUATES REPERFUSION INJURY; LEUKOCYTE ADHESION; RAT-KIDNEY; INHIBITION; NEUTROPHILS; EXPRESSION; MAC-1; SALICYLATE; EMIGRATION; MECHANISM	It has been recently described that some non-steroidal anti-inflammatory drugs (NSAIDs) are able to induce the shedding of L-selectin in neutrophils, an adhesion molecule that plays an essential role in the inflammatory response. We have found that, according to this capability, NSAIDs could be grouped into three categories. A high releaser group (flufenamic, meclofenamic, and mefenamic acids, diclofenac and aceclofenac), a group of moderate releasers (aspirin, indomethacin, nimesulide, flurbiprofen, and ketoprofen), and a non-releaser group (phenylbutazone and the oxicams, piroxicam and meloxicam). Only NSAIDs from the high releaser group shared diphenylamine in their chemical structure. The amine group of this chemical agent proved to be essential for the anti-L-selectin activity of diphenylamine-based NSAIDs. The presence of a carboxylic acid group in the diphenylamine (N-phenylanthranilic acid) highly increased its ability to reduce the L-selectin surface expression in neutrophils. Diphenylamine and N-phenylanthranilic acid neither affected COX activity in platelets nor modified the activation state of neutrophils. Diphenylamine-related compounds, which include the diphenylamine-based NSAIDs caused a variable reduction in the neutrophil intracellular ATP concentration, which correlated with the differential ability of such compounds to trigger L-selectin shedding (r = 0.97, p < 0.01). Diphenylamine-related compounds failed to down-regulate L-selectin in a tumor necrosis factor-a-converting enzyme (TACE)deficient murine monocytic cell line. Our data indicate that diphenylamine seems to be the structural core of NSAIDs accounting for their down-regulatory activity of L-selectin leukocyte expression. Diphenylamine and its related compounds exert this action on L-selectin through a prostaglandin-independent, TACE-dependent mechanism that seems to be linked to the capability of these agents to uncouple the mitochondrial oxidative phosphorylation.	Univ La Laguna, Hosp Univ Canarias, Serv Reumatol, San Cristobal la Laguna 38320, St Cruz Tenerif, Spain; Univ Autonoma Madrid, Hosp Princesa, Serv Reumatol, Madrid 28006, Spain; Univ Autonoma Madrid, Hosp Princesa, Serv Inmunol, Madrid 28006, Spain; Immunex Corp, Seattle, WA 98101 USA	Universidad de la Laguna; Autonomous University of Madrid; Hospital de La Princesa; Autonomous University of Madrid; Hospital de La Princesa; Immunex Corporation	Diaz-Gonzalez, F (corresponding author), Univ La Laguna, Hosp Univ Canarias, Serv Reumatol, Ofra S-N, San Cristobal la Laguna 38320, St Cruz Tenerif, Spain.	fdiaz@cnb.uam.es	Diaz-Gonzalez, Federico/R-2382-2019; Sanchez-Madrid, Francisco/M-7889-2016	Diaz-Gonzalez, Federico/0000-0002-4139-9295; Sanchez-Madrid, Francisco/0000-0001-5303-0762; Gomez-Gaviro, Maria Victoria/0000-0002-8683-5150				ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; ALTMAN RD, 1990, AM J PHYSIOL, V4, P1; AMIN AR, 1995, P NATL ACAD SCI USA, V92, P7926, DOI 10.1073/pnas.92.17.7926; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; Bennett TA, 1996, J IMMUNOL, V156, P3093; BERG M, 1990, BLOOD, V76, P2381; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; BOMBARDIER C, 1995, J RHEUMATOL, V22, P617; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CARLOS TM, 1994, BLOOD, V84, P2068; Diaz-Gonzalez F, 1998, IMMUNOL TODAY, V19, P169, DOI 10.1016/S0167-5699(97)01216-4; DIAZGONZALEZ F, 1995, J CLIN INVEST, V95, P1756, DOI 10.1172/JCI117853; Dong JY, 1999, P NATL ACAD SCI USA, V96, P6235, DOI 10.1073/pnas.96.11.6235; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; Featherstone C, 1996, LANCET, V347, P1106, DOI 10.1016/S0140-6736(96)90297-4; FORTENBERRY JD, 1994, BLOOD, V84, P889, DOI 10.1182/blood.V84.3.889.bloodjournal843889; Gomez-Gaviro MV, 2000, BLOOD, V96, P3592, DOI 10.1182/blood.V96.10.3592.h8003592_3592_3600; GonzalezAlvaro I, 1996, J RHEUMATOL, V23, P723; HUMBRIA A, 1994, ARTHRITIS RHEUM, V37, P342, DOI 10.1002/art.1780370307; JUNG U, 1998, AM J PHYSIOL, V274, P1785; JUTILA MA, 1989, J IMMUNOL, V143, P3318; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; LACAL P, 1988, J BIOL CHEM, V263, P9946; Mahmud T, 1996, ARTHRITIS RHEUM, V39, P1998, DOI 10.1002/art.1780391208; Masubuchi Y, 1999, BIOCHEM PHARMACOL, V58, P861, DOI 10.1016/S0006-2952(99)00163-X; MIHELCIC D, 1994, BLOOD, V84, P2322; Mingatto FE, 1996, ARCH BIOCHEM BIOPHYS, V334, P303, DOI 10.1006/abbi.1996.0459; NISHIHARA KK, 1997, ARTHRITIS ALLIED CON, V1, P611; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Ramamoorthy C, 1996, AM J PHYSIOL-HEART C, V271, pH1871, DOI 10.1152/ajpheart.1996.271.5.H1871; Rovida E, 2001, J IMMUNOL, V166, P1583, DOI 10.4049/jimmunol.166.3.1583; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; Simon LS, 1997, ARTHRITIS RHEUM, V40, P1940; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Takada M, 1997, J CLIN INVEST, V99, P2682, DOI 10.1172/JCI119457; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; TRAVIS J, 1993, SCIENCE, V260, P906, DOI 10.1126/science.8493523; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0	43	47	51	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38212	38221		10.1074/jbc.M205142200	http://dx.doi.org/10.1074/jbc.M205142200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12147693	hybrid			2022-12-27	WOS:000178529600031
J	Kaup, M; Dassler, K; Weise, C; Fuchs, H				Kaup, M; Dassler, K; Weise, C; Fuchs, H			Shedding of the transferrin receptor is mediated constitutively by an integral membrane metalloprotease sensitive to tumor necrosis factor alpha protease inhibitor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ANGIOTENSIN-CONVERTING ENZYME; LINKED GLYCOSYLATION SITE; DISINTEGRIN-METALLOPROTEASE; SECRETASE CLEAVAGE; INTRACELLULAR MATURATION; IRON-DEFICIENCY; GROWTH-FACTOR; SERUM; CELLS	The transferrin receptor (TfR) is a transmembrane protein that mediates cellular uptake of iron. Although the serum concentration of the soluble TfR (sTfR) is altered in several diseases and used for diagnostic purposes, the identity and regulation of the shedding protease is unknown. In this study we quantified sTfR release from microsomal membranes and leukocytic cell lines in the presence of numerous protease inhibitors and cell activating compounds. We show that sTfR release is mediated by an integral membrane metalloprotease and can be inhibited by matrix metalloproteinase inhibitor 2 and tumor necrosis factor a protease inhibitor-2 (TAPI-2). Cleavage is also inhibited by a specific furin inhibitor, indicating that the protease is activated by a furin-like proprotein convertase. Whereas stimulation of the cells by the ectodomain shedding activator phorbol 12-N-myristate 13-acetate did not alter sTfR release significantly, the phosphatase inhibitor pervanadate led to an increase of TfR shedding in several leukocytic cell lines. Our results suggest that TfR shedding is constitutively mediated by a member of the metalloprotease family known as ADAM (for a disintegrin and metalloprotease).	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Chem & Pathobiochem, D-12200 Berlin, Germany; Free Univ Berlin, Inst Chem Biochem, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin	Fuchs, H (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Chem & Pathobiochem, Hindenburgdamm 30, D-12200 Berlin, Germany.		Fuchs, Hendrik/AAE-7379-2019	Fuchs, Hendrik/0000-0001-9153-9594				AHN JH, 1993, BLOOD, V81, P2442; Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Amour A, 2000, FEBS LETT, V473, P275, DOI 10.1016/S0014-5793(00)01528-3; Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X; Anders A, 2001, FASEB J, V15, P1837, DOI 10.1096/fj.01-0007fje; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; BAYNES RD, 1994, J LAB CLIN MED, V123, P407; BAYNES RD, 1991, BRIT J HAEMATOL, V78, P450, DOI 10.1111/j.1365-2141.1991.tb04463.x; BAYNES RD, 1993, P SOC EXP BIOL MED, V204, P65; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Borland G, 1999, J BIOL CHEM, V274, P2810, DOI 10.1074/jbc.274.5.2810; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; CHITAMBAR CR, 1989, BLOOD, V74, P602; CHITAMBAR CR, 1991, BLOOD, V78, P2444; Codony-Servat J, 1999, CANCER RES, V59, P1196; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; DO SI, 1992, GLYCOBIOLOGY, V2, P345, DOI 10.1093/glycob/2.4.345; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; FERGUSON BJ, 1992, J LAB CLIN MED, V119, P385; Fuchs H, 1998, STRUCTURE, V6, P1235, DOI 10.1016/S0969-2126(98)00124-5; Fuchs H, 2001, BIOTECHNIQUES, V31, P584, DOI 10.2144/01313rr03; FUCHS H, 1995, BIOCHEMISTRY-US, V34, P6196, DOI 10.1021/bi00018a024; GomezOrtiz M, 1997, FEBS LETT, V400, P336, DOI 10.1016/S0014-5793(96)01412-3; Haro H, 2000, J CLIN INVEST, V105, P143, DOI 10.1172/JCI7091; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HAYES GR, 1992, GLYCOBIOLOGY, V2, P355, DOI 10.1093/glycob/2.4.355; Howard L, 1996, BIOCHEM J, V317, P45, DOI 10.1042/bj3170045; HUEBERS HA, 1990, BLOOD, V75, P102; Inoue D, 1998, J BIOL CHEM, V273, P4180, DOI 10.1074/jbc.273.7.4180; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Johnstone RM, 1996, J CELL PHYSIOL, V168, P333, DOI 10.1002/(SICI)1097-4652(199608)168:2<333::AID-JCP12>3.0.CO;2-4; KATO J, 1992, INT J HEMATOL, V56, P161; Kaup M, 2002, BIOL CHEM, V383, P1011, DOI 10.1515/BC.2002.108; KOHGO Y, 1988, JPN J MED, V27, P64, DOI 10.2169/internalmedicine1962.27.64; KOHGO Y, 1986, BRIT J HAEMATOL, V64, P277, DOI 10.1111/j.1365-2141.1986.tb04120.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Lopez-Perez E, 2001, J NEUROCHEM, V76, P1532, DOI 10.1046/j.1471-4159.2001.00180.x; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Lunn CA, 1997, FEBS LETT, V400, P333, DOI 10.1016/S0014-5793(96)01410-X; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Parvathy S, 1997, BIOCHEM J, V327, P37, DOI 10.1042/bj3270037; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pikul S, 1998, J MED CHEM, V41, P3568, DOI 10.1021/jm980253r; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; R'zik S, 2001, EXP HEMATOL, V29, P677, DOI 10.1016/S0301-472X(01)00641-5; RAMCHANDRAN R, 1995, BIOCHEMISTRY-US, V34, P12645, DOI 10.1021/bi00039a021; ROBACHEGALLEA S, 1995, J BIOL CHEM, V270, P23688, DOI 10.1074/jbc.270.40.23688; ROBERTS SB, 1994, J BIOL CHEM, V269, P3111; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Rutledge EA, 1998, J BIOL CHEM, V273, P12169, DOI 10.1074/jbc.273.20.12169; RUTLEDGE EA, 1994, BLOOD, V83, P580; RUTLEDGE EA, 1994, J BIOL CHEM, V269, P31864; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schlondorff J, 2001, J BIOL CHEM, V276, P14665, DOI 10.1074/jbc.M010741200; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; Shirakabe K, 2001, J BIOL CHEM, V276, P9352, DOI 10.1074/jbc.M007913200; SKIKNE BS, 1990, BLOOD, V75, P1870; Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787; SPRINGMAN EB, 1990, P NATL ACAD SCI USA, V87, P364, DOI 10.1073/pnas.87.1.364; Steinhusen U, 2001, J BIOL CHEM, V276, P4972, DOI 10.1074/jbc.M006102200; STOCKER W, 1995, PROTEIN SCI, V4, P823; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; VIDRICAIRE G, 1993, BIOCHEM BIOPH RES CO, V195, P1011, DOI 10.1006/bbrc.1993.2145; WOITH W, 1993, CLIN EXP IMMUNOL, V92, P537; XU QY, 1988, ANAL BIOCHEM, V170, P19, DOI 10.1016/0003-2697(88)90084-X	73	34	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38494	38502		10.1074/jbc.M203461200	http://dx.doi.org/10.1074/jbc.M203461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163483	hybrid			2022-12-27	WOS:000178529600065
J	Kaul, S; Murphy, PJM; Chen, J; Brown, L; Pratt, WB; Simons, SS				Kaul, S; Murphy, PJM; Chen, J; Brown, L; Pratt, WB; Simons, SS			Mutations at positions 547-553 of rat glucocorticoid receptors reveal that hsp90 binding requires the presence, but not defined composition, of a seven-amino acid sequence at the amino terminus of the ligand binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; NUCLEAR-RECEPTOR; STEROID-BINDING; PROGESTERONE-RECEPTOR; INTERDOMAIN COMMUNICATION; CONFORMATIONAL-CHANGES; RETICULOCYTE LYSATE; ESTROGEN-RECEPTOR; GENE-EXPRESSION; DNA-BINDING	Glucocorticoid receptors (GRs) must heterocomplex with hsp90 to have an open steroid binding cleft that can be accessed by steroid. We reported that a seven-amino acid sequence (547-553 of rat GR) overlapping the amino-terminal end of the ligand binding domain is required for hsp90 binding to GR. We have now conducted saturation mutagenesis of this sequence, which appears to be part of the surface where the ligand binding cleft merges with the surface of the ligand binding domain. No single point mutation causes significant changes in any of a variety of biochemical and biological properties in addition to hsp90 binding. A triple mutation (P548A/T549A/V551A) increases by > 100-fold the steroid concentration required for half-maximal induction without affecting the level of maximal induction or coactivator response. Interestingly, this triple mutant displays reduced binding of steroid and hsp90 in whole cells, but it possesses wild type affinity for steroid and normal hsp90 binding capacity under cell-free conditions. This phenotype of a dramatic shift in the dose response for transactivation would be expected from an increase in the rate of disassembly of the triple mutant GR-hsp90 heterocomplex in the cell. Mutation of the entire seven-amino acid region to CAAAAAC maintains the presence of a critical alpha-helical structure and heterocomplex formation with hsp90 but eliminates steroid binding and transcriptional activation, thus disconnecting hsp90 binding from opening of the ligand binding cleft and steroid binding.	NIDDK, LMCB, Steroid Hormones Sect, NIH, Bethesda, MD 20892 USA; Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Michigan System; University of Michigan	Simons, SS (corresponding author), NIDDK, LMCB, Steroid Hormones Sect, NIH, Bldg 8,Rm B2A-07, Bethesda, MD 20892 USA.				NIDDK NIH HHS [DK31753] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Billecke SS, 2002, J BIOL CHEM, V277, P20504, DOI 10.1074/jbc.M201940200; BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; CARSONJURICA MA, 1989, J STEROID BIOCHEM, V34, P1, DOI 10.1016/0022-4731(89)90060-5; Chen SY, 2000, J BIOL CHEM, V275, P30106, DOI 10.1074/jbc.M005418200; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Gee AC, 2001, MOL ENDOCRINOL, V15, P421, DOI 10.1210/me.15.3.421; Giannoukos G, 1999, J BIOL CHEM, V274, P36527, DOI 10.1074/jbc.274.51.36527; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HOECK W, 1989, J BIOL CHEM, V264, P14396; HOWARD KJ, 1990, J BIOL CHEM, V265, P11928; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Kaul S, 2002, J BIOL CHEM, V277, P12541, DOI 10.1074/jbc.M112330200; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; Kumar R, 1999, J BIOL CHEM, V274, P24737, DOI 10.1074/jbc.274.35.24737; Mackem S, 2001, J BIOL CHEM, V276, P45501, DOI 10.1074/jbc.C100269200; Modarress KJ, 1997, J BIOL CHEM, V272, P23986, DOI 10.1074/jbc.272.38.23986; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Murphy PJM, 2001, J BIOL CHEM, V276, P30092, DOI 10.1074/jbc.M103773200; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; PONS M, 1981, J ORG CHEM, V46, P3262, DOI 10.1021/jo00329a024; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; PRATT WB, 1988, J BIOL CHEM, V263, P267; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; SCHOWALTER DB, 1991, J BIOL CHEM, V266, P21165; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; SIMONS SS, 1980, J ORG CHEM, V45, P3084, DOI 10.1021/jo01303a030; SIMONS SS, 1984, BIOCHEMISTRY-US, V23, P6876, DOI 10.1021/bi00321a092; SIMONS SS, 1989, J BIOL CHEM, V264, P14493; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; Song LN, 2001, J BIOL CHEM, V276, P24806, DOI 10.1074/jbc.M102610200; Stancato LF, 1996, J BIOL CHEM, V271, P8831, DOI 10.1074/jbc.271.15.8831; Szapary D, 1999, MOL ENDOCRINOL, V13, P2108, DOI 10.1210/me.13.12.2108; SZAPARY D, 1993, MOL ENDOCRINOL, V7, P941, DOI 10.1210/me.7.8.941; Tetel MJ, 1999, MOL ENDOCRINOL, V13, P910, DOI 10.1210/me.13.6.910; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu M, 1998, J BIOL CHEM, V273, P13918, DOI 10.1074/jbc.273.22.13918; Xu M, 1996, J BIOL CHEM, V271, P21430, DOI 10.1074/jbc.271.35.21430; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	56	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36223	36232		10.1074/jbc.M206748200	http://dx.doi.org/10.1074/jbc.M206748200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145311	hybrid			2022-12-27	WOS:000178275100058
J	Matsui, T; Kinoshita, T; Hirano, T; Yokota, T; Miyajima, A				Matsui, T; Kinoshita, T; Hirano, T; Yokota, T; Miyajima, A			STAT3 down-regulates the expression of cyclin D during liver development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-B VIRUS; EMBRYONIC STEM-CELLS; MOUSE ONCOSTATIN-M; BREAST-CANCER; HEPATOCELLULAR-CARCINOMA; MACROPHAGE DIFFERENTIATION; SIGNALING MOLECULES; HEMATOPOIETIC-CELLS; HUMAN INTERLEUKIN-6; BINDING PROTEIN	As the expression of cyclin D1 is induced during liver regeneration and also in hepatic tumor cells, cyclin D1 is likely to play an important role in the proliferation and transformation of hepatocytes. However, the role of cyclin D1 in liver development remains unknown. Here we show that the expression of D-type cyclins including cyclin D1, D2, and D3 is down-regulated along with liver development. In addition, oncostatin M (OSM), an interleukin-6 family cytokine, down-regulated the expression of cyclin D1 and D2 in a primary culture of fetal hepatocytes in which OSM induces hepatic differentiation. Ectopic expression of receptor mutants defective in the activation of either STAT3 or SHP-2/Ras indicated that the down-regulation of D1 and D2 cyclins by OSM was mediated by STAT3 but not by SHP-2/Ras. Consistently, expression of dominant negative STAT3 but not Ras relieved OSM-induced suppression of cyclin D expression. Activation of STAT3 in fetal hepatocytes of transgenic mice expressing the STAT3-estrogen receptor fusion protein by 4-hydroxytamoxifen resulted in the suppression of cyclin D1 and D2 expression. These results indicate that STAT3 activation is necessary and sufficient for down-regulation of D1 and D2 cyclins in fetal hepatocytes. Furthermore, STAT3-C, a constitutively active form of STAT3, suppressed transcription of the cyclin D1 promoter in fetal hepatocytes, whereas it activated the transcription in hepatic tumor cells, huH7 and HepG2. Thus, STAT3-mediated down-regulation of cyclin D expression is rather specific to fetal hepatocytes that are undergoing maturation processes including a reduction of their proliferation potential.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Osaka Univ, Grad Sch Frontier Biosci, Dept Frontier Biosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Dept Mol Oncol, Suita, Osaka 5650871, Japan; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1188639, Japan; Teikyo Univ, Biotechnol Res Ctr, Kanagawa Acad Sci & Technol, Miyamae Ku, Kawasaki, Kanagawa 2160001, Japan	University of Tokyo; Osaka University; Osaka University; University of Tokyo; Kanagawa Academy Science & Technology; Teikyo University	Miyajima, A (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.		Yokota, Takashi/F-6021-2011; Yokota, Takashi/J-8483-2015; Hirano, Toshio/C-8194-2009					ALBRECHT JH, 1995, BIOCHEM BIOPH RES CO, V209, P648, DOI 10.1006/bbrc.1995.1548; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chida D, 1999, BLOOD, V93, P1567, DOI 10.1182/blood.V93.5.1567.405k29_1567_1578; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DEJUAN C, 1992, EXP CELL RES, V202, P495, DOI 10.1016/0014-4827(92)90104-G; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Fukada T, 1998, EMBO J, V17, P6670, DOI 10.1093/emboj/17.22.6670; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; GILLETT C, 1994, CANCER RES, V54, P1812; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; ISHIBASHI T, 1989, P NATL ACAD SCI USA, V86, P5953, DOI 10.1073/pnas.86.15.5953; Ito Y, 2000, HEPATOLOGY, V32, P1370, DOI 10.1053/jhep.2000.19815; Joo M, 2001, LIVER, V21, P89, DOI 10.1034/j.1600-0676.2001.021002089.x; Kamiya A, 1999, EMBO J, V18, P2127, DOI 10.1093/emboj/18.8.2127; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kornmann M, 1998, J CLIN INVEST, V101, P344, DOI 10.1172/JCI1323; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Lindberg RA, 1998, MOL CELL BIOL, V18, P3357, DOI 10.1128/MCB.18.6.3357; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Matsui T, 2002, EMBO J, V21, P1021, DOI 10.1093/emboj/21.5.1021; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MCDONALD VL, 1993, GROWTH FACTORS, V9, P167; MIYAURA C, 1988, FEBS LETT, V234, P17, DOI 10.1016/0014-5793(88)81293-6; NAKAMURA T, 1985, BIOCHEM BIOPH RES CO, V133, P1042, DOI 10.1016/0006-291X(85)91241-0; ORITANI K, 1992, BLOOD, V80, P2298; Oritani K, 1999, BLOOD, V93, P1346, DOI 10.1182/blood.V93.4.1346.404k15_1346_1354; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Ramana CV, 2001, P NATL ACAD SCI USA, V98, P6674, DOI 10.1073/pnas.111164198; Schrump DS, 1996, CANCER GENE THER, V3, P131; SHERR CJ, 1994, STEM CELLS, V12, P47; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tanaka H, 2000, BLOOD, V95, P1264, DOI 10.1182/blood.V95.4.1264.004k09_1264_1273; Tanaka M, 1999, BLOOD, V93, P804, DOI 10.1182/blood.V93.3.804.403a16_804_815; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; YAGINUMA K, 1985, P NATL ACAD SCI USA, V82, P4458, DOI 10.1073/pnas.82.13.4458; YAGINUMA K, 1987, P NATL ACAD SCI USA, V84, P2678, DOI 10.1073/pnas.84.9.2678; YAGINUMA K, 1989, J VIROL, V63, P2914, DOI 10.1128/JVI.63.7.2914-2920.1989; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yoshikawa H, 2001, NAT GENET, V28, P29, DOI 10.1038/88225	50	57	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36167	36173		10.1074/jbc.M203184200	http://dx.doi.org/10.1074/jbc.M203184200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12147685	hybrid			2022-12-27	WOS:000178275100052
J	Katsu, R; Onogi, H; Wada, K; Kawaguchi, Y; Hagiwara, M				Katsu, R; Onogi, H; Wada, K; Kawaguchi, Y; Hagiwara, M			Novel SR-rich-related protein clasp specifically interacts with inactivated Clk4 and induces the exon EB inclusion of Clk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICING FACTORS; DOA LOCUS; KINASE; LOCALIZATION; DROSOPHILA; SERINE; PHOSPHORYLATION; NUCLEAR; FAMILY; IDENTIFICATION	We identified a novel serine/arginine (SR)-rich-related protein as a binding partner of Clk4 mutant lacking kinase activity (Clk4 K189R) in the two-hybrid screen and designated it Clasp (Clk4-associating SR-related protein). Northern blot analysis revealed that Clasp mRNA was highly expressed in brain, and in situ hybridization of a mouse brain sagittal section hybridized with antisense probes revealed that both Clasp and Clk4 mRNAs were expressed in the hippocampus, the cerebellum, and the olfactory bulb. Two forms of Clasp were produced by a frameshift following alternative splicing. The staining of An HA-tagged short form of Clasp (ClaspS) showed a nucleoplasmic pattern, while the long form of Clasp (ClaspL) was localized as nuclear dots. In vitro protein interaction assay demonstrated that Clk4 K189R was bound to Clasp while wild Clk4 was not. Overexpression of ClaspL, promoted accumulation of Clk4 K189R in the nuclear dots and the exon EB inclusion from CR-1 and CR-2 pre-mRNA of Clk1. These data suggest that Clasp is a binding partner of Clk4 and may be involved in the regulation of the activity of Clk kinase family.	Tokyo Med & Dent Univ, Dept Funct Genom, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Dept Cell Regulat, Med Res Inst, Bunkyo Ku, Tokyo 1138510, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Hagiwara, M (corresponding author), Tokyo Med & Dent Univ, Dept Funct Genom, Med Res Inst, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	m.hagiwara.end@mri.tmc.ac.jp	Wada, Kazuhiro/A-6548-2012	Kawaguchi, Yasushi/0000-0001-8232-6925				BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; BENDER J, 1994, P NATL ACAD SCI USA, V91, P12105, DOI 10.1073/pnas.91.25.12105; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Caceres JF, 1998, GENE DEV, V12, P55, DOI 10.1101/gad.12.1.55; Colwill K, 1996, EMBO J, V15, P265, DOI 10.1002/j.1460-2075.1996.tb00357.x; DENHEZ F, 1994, J BIOL CHEM, V269, P16170; Du C, 1998, MOL CELL, V2, P741, DOI 10.1016/S1097-2765(00)80289-0; Duncan PI, 1997, MOL CELL BIOL, V17, P5996, DOI 10.1128/MCB.17.10.5996; Duncan PI, 1998, EXP CELL RES, V241, P300, DOI 10.1006/excr.1998.4083; DUNCAN PI, 1995, J BIOL CHEM, V270, P21524, DOI 10.1074/jbc.270.37.21524; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUI JF, 1994, P NATL ACAD SCI USA, V91, P10824, DOI 10.1073/pnas.91.23.10824; HANES J, 1994, J MOL BIOL, V244, P665, DOI 10.1006/jmbi.1994.1763; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; JOHNSON KW, 1991, J BIOL CHEM, V266, P3402; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Koizumi J, 1999, J BIOL CHEM, V274, P11125, DOI 10.1074/jbc.274.16.11125; Kojima T, 2001, J BIOL CHEM, V276, P32247, DOI 10.1074/jbc.M103790200; Kuroyanagi N, 1998, BIOCHEM BIOPH RES CO, V242, P357, DOI 10.1006/bbrc.1997.7913; Menegay HJ, 2000, J CELL SCI, V113, P3241; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; Misteli T, 1996, MOL BIOL CELL, V7, P1559, DOI 10.1091/mbc.7.10.1559; MYERS MP, 1994, MOL CELL BIOL, V14, P6954, DOI 10.1128/MCB.14.10.6954; Nayler O, 1998, J BIOL CHEM, V273, P34341, DOI 10.1074/jbc.273.51.34341; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; Nayler O, 1997, BIOCHEM J, V326, P693, DOI 10.1042/bj3260693; Nestel FP, 1996, GENE, V180, P151, DOI 10.1016/S0378-1119(96)00436-2; PADMANABHA R, 1991, MOL GEN GENET, V229, P1; Prasad J, 1999, MOL CELL BIOL, V19, P6991; RABINOW L, 1989, EMBO J, V8, P879, DOI 10.1002/j.1460-2075.1989.tb03449.x; RABINOW L, 1993, GENETICS, V134, P1175; Sanford JR, 1999, GENE DEV, V13, P1513, DOI 10.1101/gad.13.12.1513; Sarkissian M, 1996, J BIOL CHEM, V271, P31106, DOI 10.1074/jbc.271.49.31106; Serebriiskii I, 1999, J BIOL CHEM, V274, P17080, DOI 10.1074/jbc.274.24.17080; Wang HY, 1998, J CELL BIOL, V140, P737, DOI 10.1083/jcb.140.4.737; Yoshida K, 1998, MOL BRAIN RES, V57, P241, DOI 10.1016/S0169-328X(98)00089-8; Yun B, 2000, GENETICS, V156, P749; YUN B, 1994, GENE DEV, V8, P1160, DOI 10.1101/gad.8.10.1160; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	42	14	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44220	44228		10.1074/jbc.M206504200	http://dx.doi.org/10.1074/jbc.M206504200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12169693	hybrid			2022-12-27	WOS:000179272000090
J	Miranda, M; Pardo, JP; Allen, KE; Slayman, CW				Miranda, M; Pardo, JP; Allen, KE; Slayman, CW			Stalk segment 5 of the yeast plasma membrane H+-ATPase - Labeling with a fluorescent maleimide reveals a conformational change during glucose activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; SACCHAROMYCES-CEREVISIAE; DIRECTED MUTAGENESIS; SECRETORY VESICLES; CALCIUM-PUMP; IDENTIFICATION; RESOLUTION; S5	Glucose is well known to cause a rapid, reversible activation of the yeast plasma membrane H+-ATPase, very likely mediated by phosphorylation of two or more Ser/Thr residues near the C terminus. Recent mutagenesis studies have shown that glucose-dependent activation can be mimicked constitutively by amino acid substitutions in stalk segment 5 (S5), an alpha-helical stretch connecting the catalytic part of the ATPase with transmembrane segment 5 (Miranda, M., Allen, K. E., Pardo, J. P., and Slayman, C. W. (2001) J. Biol. Chem. 276,2248522490). In the present work, the fluorescent maleimide Alexa-488 has served as a probe for glucose-dependent changes in the conformation of S5. Experiments were carried out in a "3C" version of the ATPase, from which six of nine native cysteines had been removed by site-directed mutagenesis to eliminate background labeling by Alexa-488. In this construct, three of twelve cysteines introduced at various positions along S5 (A668C, S672C, and D676C) reacted with the Alexa dye in a glucose-independent manner, as shown by fluorescent labeling of the 100 kDa Pma1 polypeptide and by isolation and identification of the corresponding tryptic peptides. Especially significant was the fact that three additional cysteines reacted with Alexa-488 more rapidly (Y689C) or only (V665C and L678C) in plasma membranes from glucose-metabolizing cells. The results support a model in which the S5 alpha-helix undergoes a significant change in conformation to expose positions 665, 678, and 689 during glucose-dependent activation of the ATPase.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA	Yale University; Yale University	Miranda, M (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.				NIGMS NIH HHS [GM 15761] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015761, R37GM015761] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambesi A, 1997, ANAL BIOCHEM, V251, P127, DOI 10.1006/abio.1997.2257; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; Chiu I, 1999, P NATL ACAD SCI USA, V96, P13944, DOI 10.1073/pnas.96.24.13944; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; ERASO P, 1994, J BIOL CHEM, V269, P10393; Fiske CH, 1925, J BIOL CHEM, V66, P375; Goossens A, 2000, MOL CELL BIOL, V20, P7654, DOI 10.1128/MCB.20.20.7654-7661.2000; GRADMANN D, 1978, J MEMBRANE BIOL, V39, P333, DOI 10.1007/BF01869898; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Miranda M, 2001, J BIOL CHEM, V276, P22485, DOI 10.1074/jbc.M102332200; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; PERLIN DS, 1989, J BIOL CHEM, V264, P21857; PETROV VV, 1995, J BIOL CHEM, V270, P28535, DOI 10.1074/jbc.270.48.28535; Portillo F, 2000, BBA-REV BIOMEMBRANES, V1469, P31, DOI 10.1016/S0304-4157(99)00011-8; PORTILLO F, 1991, FEBS LETT, V287, P71, DOI 10.1016/0014-5793(91)80018-X; SERRANO R, 1983, FEBS LETT, V156, P11, DOI 10.1016/0014-5793(83)80237-3; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Sorensen T, 1997, J BIOL CHEM, V272, P30244, DOI 10.1074/jbc.272.48.30244; Sorensen TLM, 2000, J BIOL CHEM, V275, P28954, DOI 10.1074/jbc.M004072200; Soteropoulos P, 2001, J BIOL CHEM, V276, P16265, DOI 10.1074/jbc.M011115200; Stone Kathryn L., 1996, P427, DOI 10.1007/978-1-60327-259-9_72; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WANG G, 1989, J BIOL CHEM, V271, P25438; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	29	3	3	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40981	40988		10.1074/jbc.M206793200	http://dx.doi.org/10.1074/jbc.M206793200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12169695	hybrid			2022-12-27	WOS:000178791400106
J	Palmieri, D; Lee, JW; Juliano, RL; Church, FC				Palmieri, D; Lee, JW; Juliano, RL; Church, FC			Plasminogen activator inhibitor-1 and-3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-C INHIBITOR; REACTIVE-SITE MUTANTS; UROKINASE RECEPTOR; SEMINAL PLASMA; MIGRATION; INTEGRIN; INVASION; VITRONECTIN; CHEMOTAXIS; COMPLEXES	Plasminogen activator inhibitor-1 (PAI-1), an inhibitor of urokinase plasminogen activator, is paradoxically associated with a poor prognosis in breast cancer. PAI-1 is linked to several processes in the metastatic cascade. However, the role of PAI-1 in metastatic processes, which may be independent of protease inhibitory activity, is not fully understood. We report herein that PAI-1, when added exogenously to or stably transfected in human MDA-MB-435 breast carcinoma cells, had disparate effects on adhesion to extracellular matrix proteins and motility in vitro. Specifically, exogenously added PAI-1 inhibited cell adhesion to vitronectin but not fibronectin, in agreement with the literature. By contrast, stably transfected PAI-1 stimulated adhesion to both proteins. Wild-type PAI-1 was required for this stimulation, because expression of a non-protease inhibitory P14 (T333R) PAI-1 mutant failed to enhance adhesion. Compared with non-inhibitory PAI-1, wild-type PAI-1 also increased cell motility in chemotaxic assays. Furthermore, stable transfection of a related serine protease inhibitor, plasminogen activator inhibitor-3 (PAI-3, or protein C inhibitor) gave results similar to wild-type PAI-1. The stimulatory activity of PAI-3 was not seen with a non-protease inhibitory P14 PAI-3 mutant (T341R). We show that a downstream effect of endogenous wild-type PAI-1 and PAI-3 overexpression, but not their non-inhibitory counterparts, was the altered expression of alpha(2), alpha(3), alpha(4), alpha(5), and beta(1) integrin subunits. Additionally, blocking antibodies to beta(1) integrin inhibited PAI-1-induced adhesion. Our data provide experimental support for the stimulatory and inhibitory effects of PAI-1 in metastasis and introduce PAI-3 as another serpin potentially important in malignant disease.	Univ N Carolina, Div Hematol Oncol, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Div Hematol Oncol, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Div Hematol Oncol, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Church, FC (corresponding author), Univ N Carolina, Div Hematol Oncol, Dept Med, Campus Box 7035,932 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	fchurch@email.unc.edu	Palmieri, Diane/B-4258-2015; Lee, Jung Weon/F-9149-2012; Lee, Jung Weon/AAC-1146-2020	Lee, Jung Weon/0000-0003-2722-8200	NATIONAL CANCER INSTITUTE [R01CA074966] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007017] Funding Source: NIH RePORTER; NCI NIH HHS [CA 74966] Funding Source: Medline; NHLBI NIH HHS [HL 06350] Funding Source: Medline; NIEHS NIH HHS [5T32 ES 07017] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Andreasen PA, 2000, CELL MOL LIFE SCI, V57, P25, DOI 10.1007/s000180050497; AZNAVOORIAN S, 1990, J CELL BIOL, V110, P1427, DOI 10.1083/jcb.110.4.1427; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; CAJOT JF, 1990, P NATL ACAD SCI USA, V87, P6939, DOI 10.1073/pnas.87.18.6939; Chazaud B, 2002, AM J PATHOL, V160, P237, DOI 10.1016/S0002-9440(10)64367-2; CHURCH FC, 1997, ADV EXPT MED BIOL, V425; Clezardin P, 1998, CELL MOL LIFE SCI, V54, P541, DOI 10.1007/s000180050182; Degryse B, 2001, FEBS LETT, V505, P249, DOI 10.1016/S0014-5793(01)02797-1; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; Elisen MGLM, 1998, FIBRINOLYSIS PROTEOL, V12, P283, DOI 10.1016/S0268-9499(98)80021-0; ESPANA F, 1991, THROMB RES, V64, P309, DOI 10.1016/0049-3848(91)90002-E; ESPANA F, 1993, THROMB HAEMOSTASIS, V70, P989; Ghosh S, 2000, J BIOL CHEM, V275, P23869, DOI 10.1074/jbc.M000935200; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; HolstHansen C, 1996, CLIN EXP METASTAS, V14, P297; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Jackson TP, 1997, J PROTEIN CHEM, V16, P819, DOI 10.1023/A:1026324102618; Jo M, 2002, J BIOL CHEM, V277, P12479, DOI 10.1074/jbc.M111147200; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; Knoop A, 1998, BRIT J CANCER, V77, P932, DOI 10.1038/bjc.1998.154; LAURELL M, 1992, J CLIN INVEST, V89, P1094, DOI 10.1172/JCI115689; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; LIU GH, 1995, INT J CANCER, V60, P501, DOI 10.1002/ijc.2910600413; Loskutoff DJ, 1999, APMIS, V107, P54, DOI 10.1111/j.1699-0463.1999.tb01526.x; MIHALY J, 2001, INT SOC THROMB HAEM; Mikolajczyk SD, 1999, INT J CANCER, V81, P438, DOI 10.1002/(SICI)1097-0215(19990505)81:3<438::AID-IJC18>3.3.CO;2-L; Minor KH, 2002, J BIOL CHEM, V277, P10337, DOI 10.1074/jbc.M109564200; MO Z, 2001, J CELL SCI, V114, P3387; Morini M, 2000, INT J CANCER, V87, P336, DOI 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NEESE LL, 1994, BLOOD COAGUL FIBRIN, V5, P737, DOI 10.1097/00001721-199410000-00010; Nguyen DHD, 1999, J CELL BIOL, V146, P149, DOI 10.1083/jcb.146.1.149; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PHILLIPS JE, 1994, J BIOL CHEM, V269, P16696; REZAIE AR, 1995, J BIOL CHEM, V270, P25336, DOI 10.1074/jbc.270.43.25336; Seftor REB, 1998, CANCER RES, V58, P5681; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Sliutz G, 1996, BREAST CANCER RES TR, V40, P257, DOI 10.1007/BF01806814; Stahl A, 1997, INT J CANCER, V71, P116, DOI 10.1002/(SICI)1097-0215(19970328)71:1<116::AID-IJC19>3.3.CO;2-Z; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 2001, J BIOL CHEM, V276, P8135, DOI 10.1074/jbc.M007609200; SUZUKI K, 1987, J BIOL CHEM, V262, P611; SUZUKI K, 1983, J BIOL CHEM, V258, P163; TARABOLETTI G, 1987, J CELL BIOL, V105, P2409, DOI 10.1083/jcb.105.5.2409; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; Waltz DA, 2000, AM J RESP CELL MOL, V22, P316, DOI 10.1165/ajrcmb.22.3.3713; Webb DJ, 2001, J CELL BIOL, V152, P741, DOI 10.1083/jcb.152.4.741; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975	56	74	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40950	40957		10.1074/jbc.M202333200	http://dx.doi.org/10.1074/jbc.M202333200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12176977	hybrid			2022-12-27	WOS:000178791400102
J	Ray, AS; Basavapathruni, A; Anderson, KS				Ray, AS; Basavapathruni, A; Anderson, KS			Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POL GENE-MUTATIONS; ANTIVIRAL NUCLEOSIDE ANALOGS; HIGH-LEVEL RESISTANCE; 3'-AZIDO-3'-DEOXYTHYMIDINE AZT; COMBINATION THERAPY; DNA-SYNTHESIS; STEADY-STATE; PHYSIOLOGICAL CONCENTRATIONS; NUCLEOTIDE INCORPORATION; PRIMER/TEMPLATE BINDING	Abacavir has been shown to select for multiple resistant mutations in the human immunodeficiency type 1 (HIV-1) pol gene. In an attempt to understand the molecular mechanism of resistance in response to abacavir, and nucleoside analogs in general, a set of reverse transcriptase mutants were studied to evaluate their kinetics of nucleotide incorporation and removal. It was found that, similar to the multidrug-resistant mutant reverse transcriptase (RT)Q(151M), the mutations L74V, M184V, and a triple mutant containing L74V/Y115F/M184V all caused increased selectivity for dGTP over the active metabolite of abacavir (carbovir triphosphate). However, the magnitude of resistance observed in cell culture to abacavir in previous studies was less than that observed to other compounds. Our mechanistic studies suggest that this may be due to carbovir triphosphate decreasing the overall effect on its efficiency of incorporation by forming strong hydrophobic interactions in the RT active site. Unlike RTAZTR, no increase in the rate of ATP- or PPi-mediated chain terminator removal relative to RTWT could be detected for any of the mutants. However, marked decreases in the steady-state rate may serve as a mechanism for increased removal of a chain-terminating carbovir monophosphate by increasing the time spent at the primer terminus for some of the mutants studied. The triple mutant showed no advantage in selectivity over RTM184V and was severely impaired in its ability to remove a chain terminator, giving no kinetic basis for its increased resistance in a cellular system. Biochemical properties including percentage of active sites, fidelity, and processivity may suggest that the triple mutant's increased resistance to abacavir in cell culture is perhaps due to a fitness advantage, although further cellular studies are needed to verify this hypothesis. These data serve to further the understanding of how mutations in RT confer resistance to nucleoside analogs.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Anderson, KS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.			Ray, Adrian/0000-0002-3508-3008	NIGMS NIH HHS [5T32 GM 07223, GM 49551] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007223] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arion D, 1998, BIOCHEMISTRY-US, V37, P15908, DOI 10.1021/bi981200e; Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; BARSHOP BA, 1991, ANAL BIOCHEM, V197, P266, DOI 10.1016/0003-2697(91)90387-9; Boyer PL, 2000, P NATL ACAD SCI USA, V97, P3056, DOI 10.1073/pnas.97.7.3056; BOYER PL, 1994, P NATL ACAD SCI USA, V91, P4882, DOI 10.1073/pnas.91.11.4882; Boyer PL, 2002, J VIROL, V76, P3248, DOI 10.1128/JVI.76.7.3248-3256.2002; Boyer PL, 2001, J VIROL, V75, P4832, DOI 10.1128/JVI.75.10.4832-4842.2001; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; DECLERCQ E, 1995, J MED CHEM, V38, P2491, DOI 10.1021/jm00014a001; DeClercq E, 1997, CLIN MICROBIOL REV, V10, P674, DOI 10.1128/CMR.10.4.674; Faletto MB, 1997, ANTIMICROB AGENTS CH, V41, P1099, DOI 10.1128/AAC.41.5.1099; Feng JY, 2001, J BIOL CHEM, V276, P23832, DOI 10.1074/jbc.M101156200; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; Feng JY, 1999, BIOCHEMISTRY-US, V38, P55, DOI 10.1021/bi982340r; FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153; Ford H, 2000, BIOCHEMISTRY-US, V39, P2581, DOI 10.1021/bi992112c; Gao HQ, 2000, J MOL BIOL, V300, P403, DOI 10.1006/jmbi.2000.3823; Gotte M, 2000, J VIROL, V74, P3579, DOI 10.1128/JVI.74.8.3579-3585.2000; GU Z, 1994, LEUKEMIA S1, V8, P166; Harrigan PR, 2000, J INFECT DIS, V181, P912, DOI 10.1086/315317; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Isel C, 2001, J BIOL CHEM, V276, P48725, DOI 10.1074/jbc.M108352200; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200; Jonckheere H, 2000, EUR J BIOCHEM, V267, P2658, DOI 10.1046/j.1432-1327.2000.01272.x; KATI WM, 1992, J BIOL CHEM, V267, P25988; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14056, DOI 10.1021/bi971385+; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14064, DOI 10.1021/bi9713862; Khanna N, 2000, AIDS, V14, P791, DOI 10.1097/00002030-200005050-00004; Kosalaraksa P, 1999, J VIROL, V73, P5356, DOI 10.1128/JVI.73.7.5356-5363.1999; Krebs R, 1997, BIOCHEMISTRY-US, V36, P10292, DOI 10.1021/bi970512z; LACEY SF, 1994, ANTIMICROB AGENTS CH, V38, P1428, DOI 10.1128/AAC.38.6.1428; LARDER BA, 1994, J GEN VIROL, V75, P951, DOI 10.1099/0022-1317-75-5-951; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Lennerstrand J, 2001, J VIROL, V75, P7202, DOI 10.1128/JVI.75.15.7202-7205.2001; Lennerstrand J, 2001, ANTIMICROB AGENTS CH, V45, P2144, DOI 10.1128/AAC.45.7.2144-2146.2001; Maeda Y, 1998, J INFECT DIS, V177, P1207, DOI 10.1086/515282; MARTIN JL, 1994, ANTIMICROB AGENTS CH, V38, P2743, DOI 10.1128/AAC.38.12.2743; MARTIN JL, 1993, P NATL ACAD SCI USA, V90, P6135, DOI 10.1073/pnas.90.13.6135; Meyer PR, 1999, MOL CELL, V4, P35, DOI 10.1016/S1097-2765(00)80185-9; Meyer PR, 2000, ANTIMICROB AGENTS CH, V44, P3465, DOI 10.1128/AAC.44.12.3465-3472.2000; Meyer PR, 1998, P NATL ACAD SCI USA, V95, P13471, DOI 10.1073/pnas.95.23.13471; Miller MD, 2001, J ACQ IMMUN DEF SYND, V27, P450, DOI 10.1097/00126334-200108150-00005; MITSUYA H, 1991, FASEB J, V5, P2369, DOI 10.1096/fasebj.5.10.1712326; MOYLE GJ, 1997, J ANTIMICROB CHEMOTH, V40, P767; Mu L, 2000, BIOCHEMISTRY-US, V39, P11205, DOI 10.1021/bi001090n; Naeger LK, 2001, ANTIVIR THER, V6, P115; PARKER WB, 1994, J NIH RES, V6, P57; Patel PH, 2001, J MOL BIOL, V308, P823, DOI 10.1006/jmbi.2001.4619; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Ray AS, 2002, ANTIMICROB AGENTS CH, V46, P887, DOI 10.1128/AAC.46.3.887-891.2002; Ray AS, 2002, BIOCHEMISTRY-US, V41, P5150, DOI 10.1021/bi0121858; Ray AS, 2001, NUCLEOS NUCLEOT NUCL, V20, P1247, DOI 10.1081/NCN-100002528; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REARDON JE, 1990, J BIOL CHEM, V265, P20303; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Sarafianos SG, 1999, P NATL ACAD SCI USA, V96, P10027, DOI 10.1073/pnas.96.18.10027; Selmi B, 2001, J BIOL CHEM, V276, P13965, DOI 10.1074/jbc.M009837200; SHAFER RW, 1994, J INFECT DIS, V169, P722, DOI 10.1093/infdis/169.4.722; Sharma PL, 1997, J VIROL, V71, P8846, DOI 10.1128/JVI.71.11.8846-8851.1997; SHIRASAKA T, 1993, P NATL ACAD SCI USA, V90, P562, DOI 10.1073/pnas.90.2.562; Skoog D.A., 1992, PRINCIPLES INSTRUMEN; Sluis-Cremer N, 2000, BIOCHEM J, V348, P77, DOI 10.1042/0264-6021:3480077; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TANTILLO C, 1994, J MOL BIOL, V243, P369, DOI 10.1006/jmbi.1994.1665; Thrall SH, 1996, BIOCHEMISTRY-US, V35, P4609, DOI 10.1021/bi9526387; Tisdale M, 1997, ANTIMICROB AGENTS CH, V41, P1094, DOI 10.1128/AAC.41.5.1094; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; UENO T, 1995, J BIOL CHEM, V270, P23605, DOI 10.1074/jbc.270.40.23605; Urban S, 2001, P NATL ACAD SCI USA, V98, P4984, DOI 10.1073/pnas.091324398; Vaccaro JA, 1998, BIOCHEMISTRY-US, V37, P14189, DOI 10.1021/bi9810353; Vaccaro JA, 2000, ANTIMICROB AGENTS CH, V44, P217, DOI 10.1128/AAC.44.1.217-221.2000; Walter H, 2002, ANTIMICROB AGENTS CH, V46, P89, DOI 10.1128/AAC.46.1.89-94.2002; WHITE EL, 1989, BIOCHEM BIOPH RES CO, V161, P393, DOI 10.1016/0006-291X(89)92611-9; Wohrl BM, 1999, J MOL BIOL, V292, P333, DOI 10.1006/jmbi.1999.3057	79	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40479	40490		10.1074/jbc.M205303200	http://dx.doi.org/10.1074/jbc.M205303200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12176989	hybrid			2022-12-27	WOS:000178791400043
J	Schluter, OM; Khvotchev, M; Jahn, R; Sudhof, TC				Schluter, OM; Khvotchev, M; Jahn, R; Sudhof, TC			Localization versus function of Rab3 proteins - Evidence for a common regulatory role in controlling fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SYNAPTIC VESICLE PROTEIN; PLASMA-MEMBRANE; CA2+-DEPENDENT EXOCYTOSIS; SUBCELLULAR-DISTRIBUTION; SECRETORY GRANULES; CHROMAFFIN; SYNAPTOPHYSIN; ASSOCIATION; INHIBITION	Rab3A, Rab3B, Rab3C, and Rab3D constitute a family of GTP-binding proteins that are implicated in regulated exocytosis. Various localizations and distinct functions have been proposed for different and occasionally even for the same Rab3 protein. This is exemplified by studies demonstrating that deletion of Rab3A in knock-out mice results in dysregulation of the final stages of exocytosis, whereas overexpression of Rab3A in neuroendocrine cells causes nearly complete inhibition of Ca2+-triggered exocytosis. We have now examined the properties of all Rab3 proteins in the same assays, with the long-term goal of identifying a common conceptual framework for their functions. Using quantitative immunoblotting, we found that all four Rab3 proteins were expressed in brain and endocrine tissues, although at widely different levels. Rab3A, Rab3B, and Rab3C co-localized to synaptic and secretory vesicles consistent with potential redundancy, whereas Rab3D was expressed at high levels only in the endocrine pituitary (where it was more abundant than Rab3A, Rab3B, and Rab3C combined), in exocrine glands, and in adipose tissue. In transfected PC12 cells, all four Rab3 proteins strongly inhibited Ca2+-triggered exocytosis. Except for a mutation that fixes Rab3 into a permanently GDP-bound state, all Rab3 mutations tested had no effect on this inhibition, including a mutation in the calmodulin-binding site that was described as inactivating (Coppola, T., Perret-Menoud, V., Luthi, S., Farnsworth, C. C., Glomset, J. A., and Regazzi, R. (1999) EMBO J. 18, 5885-5891).:Unexpectedly, overexpression of wild type Rab3A and permanently GTP-bound mutant Rab3A in PC12 cells caused a loss of secretory vesicles and an increase in constitutive, Ca2+-independent exocytosis that correlated with the inhibition of regulated Ca2+-triggered exocytosis. Our data indicate that overexpression of Rab3 in PC12 cells impairs the normal control of the final step in exocytosis, thereby converting the regulated secretory pathway into a constitutive pathway. These results offer an hypothesis that reconciles Rab3 transfection and knockout studies by suggesting that Rab3 functions as a gatekeeper of a late stage in exocytosis.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Ctr Basic Neurosci, Dallas, TX 75390 USA; Max Planck Inst Expt Med, D-37075 Gottingen, Germany; Max Planck Inst Biophys Chem, D-37075 Gottingen, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Max Planck Society; Max Planck Society	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, NA4-118,6000 Harry Hines Blvd, Dallas, TX 75390 USA.	Thomas.Sudhof@UTSouthwestern.edu	Khvotchev, Mikhail/G-5411-2013	Khvotchev, Mikhail/0000-0001-9328-8549; Jahn, Reinhard/0000-0003-1542-3498				Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; BALDINI G, 1995, P NATL ACAD SCI USA, V92, P4284, DOI 10.1073/pnas.92.10.4284; BALDINI G, 1992, P NATL ACAD SCI USA, V89, P5049, DOI 10.1073/pnas.89.11.5049; BAUMERT M, 1993, BIOCHEM J, V293, P157, DOI 10.1042/bj2930157; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROSE N, 1994, J BIOL CHEM, V269, P16780; BURGER PM, 1989, NEURON, V3, P715, DOI 10.1016/0896-6273(89)90240-7; Castillo PE, 1997, NATURE, V388, P590, DOI 10.1038/41574; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; Coppola T, 1999, EMBO J, V18, P5885, DOI 10.1093/emboj/18.21.5885; EDELMANN L, 1995, EMBO J, V14, P224, DOI 10.1002/j.1460-2075.1995.tb06995.x; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; FISCHER V, 1991, NATURE, V349, P79; FYKSE EM, 1993, J NEUROSCI, V13, P4997; GEPPERT M, 1994, NATURE, V369, P493, DOI 10.1038/369493a0; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; Iezzi M, 1999, MOL ENDOCRINOL, V13, P202, DOI 10.1210/me.13.2.202; JAHN R, 1985, P NATL ACAD SCI USA, V82, P4137, DOI 10.1073/pnas.82.12.4137; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; JOHNSTON PA, 1989, J BIOL CHEM, V264, P1268; JOHNSTON PA, 1991, NEURON, V7, P101, DOI 10.1016/0896-6273(91)90078-E; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; Klenchin VA, 1998, METHODS, V16, P204, DOI 10.1006/meth.1998.0668; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1994, NEURON, V13, P885, DOI 10.1016/0896-6273(94)90254-2; Lin CG, 1997, BIOCHEM J, V324, P85, DOI 10.1042/bj3240085; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; MANDELL JW, 1990, NEURON, V5, P19, DOI 10.1016/0896-6273(90)90030-J; Martelli AM, 2000, TRAFFIC, V1, P976, DOI 10.1034/j.1600-0854.2000.011207.x; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; NAGY A, 1976, BRAIN RES, V109, P285, DOI 10.1016/0006-8993(76)90531-X; Ohnishi H, 1996, AM J PHYSIOL-GASTR L, V271, pG531, DOI 10.1152/ajpgi.1996.271.3.G531; Piiper A, 2001, BIOCHEM BIOPH RES CO, V287, P746, DOI 10.1006/bbrc.2001.5651; Schluter OM, 1999, J NEUROSCI, V19, P5834, DOI 10.1523/JNEUROSCI.19-14-05834.1999; STETTLER O, 1995, EUR J NEUROSCI, V7, P702, DOI 10.1111/j.1460-9568.1995.tb00674.x; Sudhof TC, 2001, ANNU REV NEUROSCI, V24, P933, DOI 10.1146/annurev.neuro.24.1.933; Sugita S, 2002, EMBO J, V21, P270, DOI 10.1093/emboj/21.3.270; Sugita S, 2001, NEURON, V30, P459, DOI 10.1016/S0896-6273(01)00290-2; Takamori S, 2000, J NEUROSCI, V20, P4904; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tuvim MJ, 1999, AM J RESP CELL MOL, V20, P79, DOI 10.1165/ajrcmb.20.1.3279; Valentijn JA, 1996, EUR J CELL BIOL, V70, P33; VONMOLLARD GF, 1994, J BIOL CHEM, V269, P10971; VONMOLLARD GF, 1994, EUR J CELL BIOL, V65, P319; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; Ward CR, 1999, MOL REPROD DEV, V53, P413, DOI 10.1002/(SICI)1098-2795(199908)53:4&lt;413::AID-MRD7&gt;3.0.CO;2-W; Weber E, 1996, J BIOL CHEM, V271, P6963, DOI 10.1074/jbc.271.12.6963; Yunes R, 2000, BIOL REPROD, V62, P1084, DOI 10.1095/biolreprod62.4.1084	52	126	128	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40919	40929		10.1074/jbc.M203704200	http://dx.doi.org/10.1074/jbc.M203704200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12167638	hybrid			2022-12-27	WOS:000178791400098
J	Eberhardy, SR; Farnham, PJ				Eberhardy, SR; Farnham, PJ			Myc recruits P-TEFb to mediate the final step in the transcriptional activation of the cad promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CARBOXYL-TERMINAL DOMAIN; HUMAN C-MYC; HISTONE ACETYLATION; ESSENTIAL COFACTOR; DNA-BINDING; HIV-1 TAT; CELL-GROWTH; IN-VIVO; ELONGATION	The c-Myc protein is up-regulated in many different types of cancer, suggesting that a detailed understanding of Myc function is an important goal. Our previous studies have focused on determining the mechanism by which Myc activates transcription using the target gene cad as an experimental model. Previously, we found that Myc activates cad transcription at a post-RNA polymerase II recruitment step and that the Myc transactivation domain interacts with a number of cdk-cyclin complexes. We now extend these studies to determine the role of these cyclin-cdk complexes in Myc-mediated transactivation. We have found that cyclin T1 binding to Myc localizes to the highly conserved Myc Box I, whereas cdk8 binding localizes to the amino-terminal 41 amino acids of the Myc transactivation domain. We showed that recruitment of cdk8 is sufficient for activation of a synthetic promoter construct. In contrast, the ability of Myc to activate transcription of the cad promoter correlates with binding of cyclin T1. Furthermore, recruitment of cyclin T1 to the cad promoter via a Gal4 fusion protein or through protein-protein interaction with the HIV-1 Tat protein can also activate cad transcription. These results suggest that Myc activates transcription by stimulating elongation and that P-TEFb is a key mediator of this process.	Univ Wisconsin, Sch Med, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Farnham, PJ (corresponding author), Univ Wisconsin, Sch Med, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	farnham@oncology.wisc.edu		Farnham, Peggy/0000-0003-4469-7914	NATIONAL CANCER INSTITUTE [P30CA007175, R01CA045240, R29CA045240] Funding Source: NIH RePORTER; NCI NIH HHS [CA07175, CA45240, CA09135] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blau J, 1996, MOL CELL BIOL, V16, P2044; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Calabretta B, 1997, ANTI-CANCER DRUG DES, V12, P373; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; Flinn EM, 2002, J BIOL CHEM, V277, P23399, DOI 10.1074/jbc.M201704200; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Giorello L, 1998, CANCER RES, V58, P3654; Gold MO, 1996, NUCLEIC ACIDS RES, V24, P3771, DOI 10.1093/nar/24.19.3771; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; Law A, 1998, NUCLEIC ACIDS RES, V26, P919, DOI 10.1093/nar/26.4.919; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; Lin X, 2002, J BIOL CHEM, V277, P16873, DOI 10.1074/jbc.M200117200; Lis JT, 2000, GENE DEV, V14, P792; Majello B, 1999, ONCOGENE, V18, P4598, DOI 10.1038/sj.onc.1202822; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Napolitano G, 2000, GENE, V254, P139, DOI 10.1016/S0378-1119(00)00278-X; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Nikiforov MA, 2002, MOL CELL BIOL, V22, P5054, DOI 10.1128/MCB.22.14.5054-5063.2002; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Park J, 2002, MOL CELL BIOL, V22, P1307, DOI 10.1128/MCB.22.5.1307-1316.2002; Pescarolo MP, 2001, FASEB J, V15, P31; Pinaud S, 1998, J MOL BIOL, V280, P785, DOI 10.1006/jmbi.1998.1905; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; SANDGREN EP, 1989, ONCOGENE, V4, P715; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; SHOR J, 1995, ONCOGENE, V10, P1587; Simone C, 2002, ONCOGENE, V21, P4137, DOI 10.1038/sj.onc.1205493; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Taube R, 2002, MOL CELL BIOL, V22, P321, DOI 10.1128/MCB.22.1.321-331.2002; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	63	184	191	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40156	40162		10.1074/jbc.M207441200	http://dx.doi.org/10.1074/jbc.M207441200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177005	hybrid			2022-12-27	WOS:000178662500139
J	Hermoso, M; Satterwhite, CM; Andrade, YN; Hidalgo, J; Wilson, SM; Horowitz, B; Hume, JR				Hermoso, M; Satterwhite, CM; Andrade, YN; Hidalgo, J; Wilson, SM; Horowitz, B; Hume, JR			ClC-3 is a fundamental molecular component of volume-sensitive outwardly rectifying Cl- channels and volume regulation in HeLa cells and Xenopus laevis oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CHLORIDE CHANNELS; RESISTANCE P-GLYCOPROTEIN; ANION CHANNELS; EPITHELIAL-CELLS; PROTEIN-KINASE; MDCK CELLS; CURRENTS; MECHANISMS; EXPRESSION; DECREASE	Volume-sensitive osmolyte and anion channels (VSOACs) are activated upon cell swelling in most vertebrate cells. Native VSOACs are believed to be a major pathway for regulatory volume decrease (RVD) through efflux of chloride and organic osmolytes. ClC-3 has been proposed to encode native VSOACs in Xenopus laevis oocytes and in some mammalian cells, including cardiac and vascular smooth muscle cells. The relationship between the ClC-3 chloride channel, the native volume-sensitive osmolyte and anion channel (VSOAC) currents, and cell volume regulation in HeLa cells and X. laevis oocytes was investigated using ClC-3 antisense. In situ hybridization in HeLa cells, semiquantitative and real-time PCR, and immunoblot studies in HeLa cells and X. laevis oocytes demonstrated the presence of ClC-3 mRNA and protein, respectively. Exposing both cell types to hypotonic solutions induced cell swelling and activated native VSOACs. Transient transfection of HeLa cells with ClC-3 antisense oligonucleotide or X. laevis oocytes injected with antisense cRNA abolished the native ClC-3 mRNA transcript and protein and significantly reduced the density of native VSOACs activated by hypotonically induced cell swelling. In addition, antisense against native ClC-3 significantly impaired the ability of HeLa cells and X. laevis oocytes to regulate their volume. These results suggest that ClC-3 is an important molecular component underlying VSOACs and the RVD process in HeLa cells and X. laevis oocytes.	Univ Nevada, Sch Med, Ctr Biomed Res Excellence, Dept Pharmacol 318, Reno, NV 89557 USA; Univ Nevada, Sch Med, Ctr Biomed Res Excellence, Dept Physiol & Cell Biol, Reno, NV 89557 USA; Univ Chile, Inst Ciencias Biomed, Fac Med, Santiago 6530499, Chile; Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Ciencias Fisiol, Santiago 6530499, Chile	Nevada System of Higher Education (NSHE); University of Nevada Reno; Nevada System of Higher Education (NSHE); University of Nevada Reno; Universidad de Chile; Pontificia Universidad Catolica de Chile	Hume, JR (corresponding author), Univ Nevada, Sch Med, Ctr Biomed Res Excellence, Dept Pharmacol 318, Reno, NV 89557 USA.	joeh@med.unr.edu	Hermoso, Marcela/L-1500-2014; wilson, sean/D-1206-2017; Hermoso, Marcela A./AAF-6893-2021	wilson, sean/0000-0003-4404-1173; Hermoso, Marcela A./0000-0002-7936-7571	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015581] Funding Source: NIH RePORTER; NCRR NIH HHS [P20RR15581] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ACKERMAN MJ, 1994, J GEN PHYSIOL, V103, P153, DOI 10.1085/jgp.103.2.153; ALVAREZLEEFMANS FJ, 1995, METH NEUROSCI, V27, P361; BANDERALI U, 1992, AM J PHYSIOL, V263, pC1200, DOI 10.1152/ajpcell.1992.263.6.C1200; BARRY PH, 1994, J NEUROSCI METH, V51, P107, DOI 10.1016/0165-0270(94)90031-0; BERNTSSON K, 1965, J CELL COMPAR PHYSL, V65, P101, DOI 10.1002/jcp.1030650113; Bond TD, 1998, METHOD ENZYMOL, V292, P359; Bond TD, 1998, J PHYSIOL-LONDON, V511, P45, DOI 10.1111/j.1469-7793.1998.045bi.x; BORSANI G, 1995, GENOMICS, V27, P131, DOI 10.1006/geno.1995.1015; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Britton FC, 2000, AM J PHYSIOL-HEART C, V279, pH2225, DOI 10.1152/ajpheart.2000.279.5.H2225; CocaPrados M, 1996, J MEMBRANE BIOL, V150, P197, DOI 10.1007/s002329900044; DIAZ M, 1993, PFLUG ARCH EUR J PHY, V422, P347, DOI 10.1007/BF00374290; Duan D, 1999, J GEN PHYSIOL, V113, P57, DOI 10.1085/jgp.113.1.57; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; Duan DY, 2001, J PHYSIOL-LONDON, V531, P437, DOI 10.1111/j.1469-7793.2001.0437i.x; Friedrich T, 1999, J BIOL CHEM, V274, P896, DOI 10.1074/jbc.274.2.896; Furst J, 2000, PFLUG ARCH EUR J PHY, V440, P100; Furukawa T, 1998, AM J PHYSIOL-CELL PH, V274, pC500, DOI 10.1152/ajpcell.1998.274.2.C500; Hallows K.R., 1994, Cellular and molecular physiology of cell volume regulation, P3; Hand M, 1997, J MEMBRANE BIOL, V157, P9, DOI 10.1007/s002329900211; Hatton WJ, 2002, BIOPHYS J, V82, p242A; Heda GD, 2001, AM J PHYSIOL-CELL PH, V280, pC166, DOI 10.1152/ajpcell.2001.280.1.C166; HIGGINS CF, 1999, CHLORIDE CHANNELS, P35; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; Huang P, 2001, J BIOL CHEM, V276, P20093, DOI 10.1074/jbc.M009376200; JACKSON PS, 1993, AM J PHYSIOL, V265, pC1489, DOI 10.1152/ajpcell.1993.265.6.C1489; KAWASAKI M, 1995, NEURON, V14, P1285, DOI 10.1016/0896-6273(95)90275-9; KAWASAKI M, 1994, NEURON, V12, P597, DOI 10.1016/0896-6273(94)90215-1; Keller H, 2000, J PHARMACOL EXP THER, V295, P367; KIRK K, 1992, J BIOL CHEM, V267, P23475; Kirk K, 1997, J MEMBRANE BIOL, V158, P1, DOI 10.1007/s002329900239; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lang F, 1998, CELL PHYSIOL BIOCHEM, V8, P1, DOI 10.1159/000016269; Li CH, 1998, J GEN PHYSIOL, V112, P727, DOI 10.1085/jgp.112.6.727; Li XH, 2000, J BIOL CHEM, V275, P35994, DOI 10.1074/jbc.M002712200; LIPECKA J, 1999, J PHYSIOL-LONDON, V517, P69; Nilius B, 1997, PROG BIOPHYS MOL BIO, V68, P69, DOI 10.1016/S0079-6107(97)00021-7; Okada Y, 1997, AM J PHYSIOL-CELL PH, V273, pC755, DOI 10.1152/ajpcell.1997.273.3.C755; Okada Y, 1998, CONTRIB NEPHROL, V123, P21; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; ROY G, 1992, J MEMBRANE BIOL, V130, P83; SASAKI S, 1994, JPN J PHYSIOL, V44, pS3; Satterwhite CM, 1999, BIOPHYS J, V76, pA402; Satterwhite CM, 2000, BIOPHYS J, V78, p469A; Schmid A, 1998, J PHYSIOL-LONDON, V513, P453, DOI 10.1111/j.1469-7793.1998.453bb.x; SHIMADA K, 2000, AM J PHYSIOL, V279, pG286; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stobrawa SM, 2001, NEURON, V29, P185, DOI 10.1016/S0896-6273(01)00189-1; Strange K, 1996, AM J PHYSIOL-CELL PH, V270, pC711, DOI 10.1152/ajpcell.1996.270.3.C711; Stutzin A, 1999, AM J PHYSIOL-CELL PH, V277, pC392, DOI 10.1152/ajpcell.1999.277.3.C392; Stutzin A, 1998, PFLUG ARCH EUR J PHY, V436, P152, DOI 10.1007/s004240050616; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; TIVEY DR, 1985, J MEMBRANE BIOL, V87, P93, DOI 10.1007/BF01870656; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIDA S, 1994, JPN J PHYSIOL, V44, pS55; Valverde MA, 1996, EMBO J, V15, P4460, DOI 10.1002/j.1460-2075.1996.tb00823.x; VALVERDE MA, 1993, PFLUG ARCH EUR J PHY, V425, P552, DOI 10.1007/BF00374885; Valverde MA, 1999, CURR OPIN CELL BIOL, V11, P509, DOI 10.1016/S0955-0674(99)80074-X; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; von Weikersthal SF, 1999, J PHYSIOL-LONDON, V516, P75, DOI 10.1111/j.1469-7793.1999.075aa.x; WAGNER RW, 1995, ANTISENSE RES DEV, V5, P113, DOI 10.1089/ard.1995.5.113; WAHLESTEDT C, 1994, TRENDS PHARMACOL SCI, V15, P42, DOI 10.1016/0165-6147(94)90107-4; Waldegger S, 1998, NEPHROL DIAL TRANSPL, V13, P867, DOI 10.1093/ndt/13.4.867; Wang LW, 2000, J PHYSIOL-LONDON, V524, P63, DOI 10.1111/j.1469-7793.2000.t01-1-00063.x; Weiss B, 1997, NEUROCHEM INT, V31, P321, DOI 10.1016/S0197-0186(96)00105-2; Weylandt KH, 2001, J BIOL CHEM, V276, P17461, DOI 10.1074/jbc.M011667200; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111	69	99	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40066	40074		10.1074/jbc.M205132200	http://dx.doi.org/10.1074/jbc.M205132200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12183454	hybrid			2022-12-27	WOS:000178662500127
J	Kreienkamp, HJ; Larusson, HJ; Witte, I; Roeder, T; Birgul, N; Honck, HH; Harder, S; Ellinghausen, G; Buck, F; Richter, D				Kreienkamp, HJ; Larusson, HJ; Witte, I; Roeder, T; Birgul, N; Honck, HH; Harder, S; Ellinghausen, G; Buck, F; Richter, D			Functional annotation of two orphan G-protein-coupled receptors, Drostar1 and -2, from Drosophila melanogaster and their ligands by reverse pharmacology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOMATOSTATIN RECEPTOR; TRANSMEMBRANE DOMAIN; MANDUCA-SEXTA; ALLATOSTATIN; IDENTIFICATION; NEUROPEPTIDES; EXPRESSION; INSECTS; PEPTIDE; CLONING	By combining a Drosophila genome data base search and reverse transcriptase-PCR-based cDNA isolation, two G-protein-coupled receptors were cloned, which are the closest known invertebrate homologs of the mammalian opioid/somatostatin receptors. However, when functionally expressed in Xenopus oocytes by injection of Drosophila orphan receptor RNAs together with a coexpressed potassium channel, neither receptor was activated by known mammalian agonists. By applying a reverse pharmacological approach, the physiological ligands were isolated from peptide extracts from adult flies and larvae. Edman sequencing and mass spectrometry of the purified ligands revealed two decapentapeptides, which differ only by an N-terminal pyroglutamate/glutamine. The peptides align to a hormone precursor sequence of the Drosophila genome data base and are almost identical to allatostatin C from Manduca sexta. Both receptors were activated by the synthetic peptides irrespective of the N-terminal modification. Site-directed mutagenesis of a residue in transmembrane region 3 and the loop between transmembrane regions 6 and 7 affect ligand binding, as previously described for somatostatin receptors. The two receptor genes each containing three exons and transcribed in opposite directions are separated by 80 kb with no other genes predicted between. Localization of receptor transcripts identifies a role of the new transmitter system in visual information processing as well as endocrine regulation.	Univ Klinikum Hamburg Eppendorf, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany; Univ Hamburg, Inst Zool, D-20146 Hamburg, Germany; Univ Hamburg, Museum Zool, D-20146 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University of Hamburg	Richter, D (corresponding author), Univ Klinikum Hamburg Eppendorf, Inst Zellbiochem & Klin Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.	richter@uke.uni-hamburg.de	Birgül Iyison, Necla/A-7389-2017; Roeder, Thomas/B-9016-2011	Roeder, Thomas/0000-0002-3489-3834; Harder, Sonke/0000-0002-6352-4771				Auerswald L, 2001, BIOCHEM BIOPH RES CO, V282, P904, DOI 10.1006/bbrc.2001.4659; Birgul N, 1999, EMBO J, V18, P5892, DOI 10.1093/emboj/18.21.5892; Brody T, 2000, J CELL BIOL, V150, pF83, DOI 10.1083/jcb.150.2.F83; Broeck JV, 2001, PEPTIDES, V22, P241, DOI 10.1016/S0196-9781(00)00376-4; BUCHNER E, 1993, CELL TISSUE RES, V273, P119, DOI 10.1007/BF00304618; FISCHBACH KF, 1989, CELL TISSUE RES, V258, P441, DOI 10.1007/BF00218858; Gade G, 1997, PHYSIOL REV, V77, P963, DOI 10.1152/physrev.1997.77.4.963; KAUPMANN K, 1995, EMBO J, V14, P727, DOI 10.1002/j.1460-2075.1995.tb07051.x; KRAMER SJ, 1991, P NATL ACAD SCI USA, V88, P9458, DOI 10.1073/pnas.88.21.9458; LI XJ, 1992, J BIOL CHEM, V267, P9; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MONNIER D, 1992, J BIOL CHEM, V267, P1298; NASSEL DR, 1993, CELL TISSUE RES, V273, P1, DOI 10.1007/BF00304608; NEHRING RB, 1995, DNA CELL BIOL, V14, P939, DOI 10.1089/dna.1995.14.939; Walker CS, 1999, J BIOL CHEM, V274, P30664, DOI 10.1074/jbc.274.43.30664; Williamson M, 2001, BIOCHEM BIOPH RES CO, V282, P124, DOI 10.1006/bbrc.2001.4565; Yoon JG, 1995, J COMP NEUROL, V363, P475, DOI 10.1002/cne.903630310; ZITNAN D, 1993, DEV BIOL, V156, P117, DOI 10.1006/dbio.1993.1063	18	93	94	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39937	39943		10.1074/jbc.M206931200	http://dx.doi.org/10.1074/jbc.M206931200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167655	hybrid			2022-12-27	WOS:000178662500111
J	Vetcher, AA; Napierala, M; Wells, RD				Vetcher, AA; Napierala, M; Wells, RD			Sticky DNA: Effect of the polypurine center dot polypyrimidine sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAA TRIPLET REPEAT; FRIEDREICHS-ATAXIA; TTC REPEATS; GENE; TRANSCRIPTION; EXPANSION; CLONING; INVIVO	The polypurine-polypyrimidine sequence requirements for the formation of sticky DNA were evaluated in Escherichia coli plasmid systems to determine the potential occurrence of this conformation throughout biological systems. A mirror repeat, dinucleotide tract of (GA.TC)(37), which is ubiquitous in eukaryotes, formed sticky DNA, but shorter sequences of 10 or 20 repeats were inert. (GGA.TCC)(n) inserts (where n = 126,159, and 222 bp) also formed sticky DNA. As shown previously, the control sequence (GAA.TTC)(150) (450 bp) readily adopted the X-shaped sticky structure; however, this structure has never been found for the nonpathogenic (GAAGGA.TCCTTC)(65) of the same approximate length (390 bp). A sequence that is replete with polypurine-polypyrimidine tracts that can form triplexes and slipped structures but lacks long repeating motifs (the 2.5-kbp intron 21 sequence from the polycystic kidney disease gene 1) was also inert. Interestingly, tracts of (GAA.TTC)(n) (where n = 176 or 80) readily formed sticky DNA with (GAAGGA.TCCTTC)(65) cloned into the same plasmid when the pair of inserts was in the direct, but not in the indirect (inverted), orientation. The stabilities of the triple base (Watson-Crick and Hoogsteen) interactions in the DNA/DNA associated triplex region of the sticky conformations account for these observations. Our results have significant chemical and biological implications for the structure and function of this unusual DNA conformation in Friedreich's ataxia.	Texas A&M Univ, Med Ctr, Inst Biosci & Technol, Ctr Genome Res, Houston, TX 77030 USA	Texas A&M University System	Wells, RD (corresponding author), Texas A&M Univ, Med Ctr, Inst Biosci & Technol, Ctr Genome Res, 2121 W Holcombe Blvd, Houston, TX 77030 USA.			Vetcher, Alexandre/0000-0002-4828-8571	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES11347] Funding Source: Medline; NIGMS NIH HHS [GM52982] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bacolla A, 2001, J BIOL CHEM, V276, P18597, DOI 10.1074/jbc.M100845200; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; COLLIER DA, 1990, J BIOL CHEM, V265, P10652; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; GRAY HB, 1968, J MOL BIOL, V35, P111, DOI 10.1016/S0022-2836(68)80041-5; HEARST JE, 1962, J CHEM PHYS, V37, P1425, DOI 10.1063/1.1733300; KLEIN RD, 1982, J BIOL CHEM, V257, P2962; KLEIN RD, 1982, J BIOL CHEM, V257, P2954; LE DT, 1987, NUCLEIC ACIDS RES, V15, P7749; LILLEY D, 1986, NATURE, V320, P14, DOI 10.1038/320014a0; Montermini L, 1997, ANN NEUROL, V41, P675, DOI 10.1002/ana.410410518; Montermini L, 1997, HUM MOL GENET, V6, P1261, DOI 10.1093/hmg/6.8.1261; Montermini L, 1997, NEUROLOGY, V49, P606, DOI 10.1212/WNL.49.2.606; Napierala M, 2002, J BIOL CHEM, V277, P34087, DOI 10.1074/jbc.M202128200; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1999, NEUROLOGY, V53, P1854, DOI 10.1212/WNL.53.8.1854; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sakamoto N, 2001, J BIOL CHEM, V276, P27178, DOI 10.1074/jbc.M101852200; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; Toth G, 2000, GENOME RES, V10, P967, DOI 10.1101/gr.10.7.967; Van Raay T J, 1996, Microb Comp Genomics, V1, P317; Vetcher AA, 2002, J BIOL CHEM, V277, P39217, DOI 10.1074/jbc.M205209200; Wells R.D., 1998, GENETIC INSTABILITIE; ZACHARIAS W, 1988, P NATL ACAD SCI USA, V85, P7069, DOI 10.1073/pnas.85.19.7069	27	25	26	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39228	39234		10.1074/jbc.M205210200	http://dx.doi.org/10.1074/jbc.M205210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161438	hybrid			2022-12-27	WOS:000178662500023
J	Beranger, F; Mange, A; Goud, B; Lehmann, S				Beranger, F; Mange, A; Goud, B; Lehmann, S			Stimulation of PrPC retrograde transport toward the endoplasmic reticulum increases accumulation of PrPSc in prion-infected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCRAPIE-ASSOCIATED FORM; CULTURED-CELLS; NEUROBLASTOMA-CELLS; GOLGI NETWORK; RAB PROTEINS; TRAFFICKING; POPULATIONS; DEGRADATION; CONVERSION; COMPLEXES	Prion diseases are fatal and transmissible neurodegenerative disorders characterized by the accumulation of an abnormally folded isoform. of the cellular prion protein (PrPC) denoted PrPSc. To identify intracellular organelles involved in PrPSc formation, we studied the role of the Ras-related GTP-binding proteins Rab4 and Rab6a in intracellular trafficking of the prion protein and production of PrPSc. When a dominant-negative Rab4 mutant or a constitutively active GTP-bound Rab6a protein was overexpressed in prion-infected neuroblastoma N2a cells, there was a marked increase of PrPSc formation. By immunofluoreseence and cell fractionation studies, we have shown that expression of Rab6a-GTP delocalizes PrP within intracellular compartments, leading to an accumulation in the endoplasmic reticulum. These results suggest that prion protein can be subjected to retrograde transport toward the endoplasmic reticulum and that this compartment may play a significant role in PrPSc conversion.	Inst Genet Humaine, CNRS, UPR 1142, F-34396 Montpellier 5, France; Inst Curie, F-75231 Paris, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Beranger, F (corresponding author), Inst Genet Humaine, CNRS, UPR 1142, 141 Rue Cardonille, F-34396 Montpellier 5, France.		Lehmann, Sylvain/P-1301-2017; Goud, Bruno/GWC-4807-2022; Beranger, Florence/R-7581-2019; Mange, Alain/U-1157-2017	Lehmann, Sylvain/0000-0001-6117-562X; Mange, Alain/0000-0002-1566-9407				Barbero P, 2002, J CELL BIOL, V156, P511, DOI 10.1083/jcb.200109030; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; Daude N, 1997, J BIOL CHEM, V272, P11604, DOI 10.1074/jbc.272.17.11604; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; GORODINSKY A, 1995, J CELL BIOL, V129, P619, DOI 10.1083/jcb.129.3.619; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Ivanova L, 2001, J BIOL CHEM, V276, P42409, DOI 10.1074/jbc.M106928200; Jin TC, 2000, J BIOL CHEM, V275, P38699, DOI 10.1074/jbc.M005543200; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; Lee KS, 2001, J NEUROCHEM, V79, P79, DOI 10.1046/j.1471-4159.2001.00529.x; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; Lorenz H, 2002, J BIOL CHEM, V277, P8508, DOI 10.1074/jbc.M110197200; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; Martinez O, 1998, BBA-MOL CELL RES, V1404, P101, DOI 10.1016/S0167-4889(98)00050-0; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; McCaffrey MW, 2001, FEBS LETT, V495, P21, DOI 10.1016/S0014-5793(01)02359-6; MCKINLEY MP, 1991, LAB INVEST, V65, P622; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Negro A, 2001, MOL CELL NEUROSCI, V17, P521, DOI 10.1006/mcne.2000.0953; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Nishida N, 2000, J VIROL, V74, P320, DOI 10.1128/JVI.74.1.320-325.2000; PFEIFER K, 1993, CELL BIOCHEM FUNCT, V11, P1, DOI 10.1002/cbf.290110102; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Rybner C, 2002, J CELL BIOCHEM, V84, P408, DOI 10.1002/jcb.10017; Singh N, 1997, J BIOL CHEM, V272, P28461, DOI 10.1074/jbc.272.45.28461; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Yedidia Y, 2001, EMBO J, V20, P5383, DOI 10.1093/emboj/20.19.5383; Zanusso G, 1999, J BIOL CHEM, V274, P23396, DOI 10.1074/jbc.274.33.23396; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	40	88	92	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38972	38977		10.1074/jbc.M205110200	http://dx.doi.org/10.1074/jbc.M205110200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163492	hybrid			2022-12-27	WOS:000178529600121
J	Gorbunova, V; Seluanov, A; Pereira-Smith, OM				Gorbunova, V; Seluanov, A; Pereira-Smith, OM			Expression of human telomerase (hTERT) does not prevent stress-induced senescence in normal human fibroblasts but protects the cells from stress-induced apoptosis and necrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; HUMAN LUNG FIBROBLASTS; DNA-DAMAGE; PREMATURE SENESCENCE; G(1) ARREST; TREATED FIBROBLASTS; CELLULAR SENESCENCE; TUMOR-SUPPRESSOR; GENE-EXPRESSION; LIFE-SPAN	Cells subjected to sub-lethal doses of stress such as irradiation or oxidative damage enter a state that closely resembles replicative senescence. What triggers stress-induced premature senescence (SIPS) and how similar this mechanism is to replicative senescence are not well understood. It has been suggested that stress-induced senescence is caused by rapid telomere shortening resulting from DNA damage. In order to test this hypothesis directly, we examined whether overexpression of the catalytic subunit of human telomerase (hTERT) can protect cells from SIPS. We therefore analyzed the response of four different lines of normal human fibroblasts with and without hTERT to stress induced by UV, gamma-irradiation, and H2O2. SIPS was induced with the same efficiency in normal and hTERT-immortalized cells. This suggests that SIPS is not triggered by telomere shortening and that nonspecific DNA damage serves as a signal for induction of SIPS. Although telomerase did not protect cells from SIPS, fibroblasts expressing hTERT were more resistant to stress-induced apoptosis and necrosis. We hypothesize that healing of DNA breaks by telomerase inhibits the induction of cell death, but because healing does not provide legitimate DNA repair, it does not protect cells from SIPS.	Baylor Coll Med, Dept Biochem, Huffington Ctr Aging, Houston, TX 77030 USA	Baylor College of Medicine	Gorbunova, V (corresponding author), Baylor Coll Med, Dept Biochem, Huffington Ctr Aging, 1 Baylor Plaza, Houston, TX 77030 USA.			Gorbunova, Vera/0000-0001-8979-0333; Seluanov, Andrei/0000-0003-3400-538X	NIA NIH HHS [R37AG60533, P01AG620752] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chen QM, 2001, EXP CELL RES, V265, P294, DOI 10.1006/excr.2001.5182; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P427; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X; Frippiat C, 2000, EXP GERONTOL, V35, P733, DOI 10.1016/S0531-5565(00)00167-4; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Garkavtsev I, 1998, EXP GERONTOL, V33, P81, DOI 10.1016/S0531-5565(97)00086-7; GELVAN D, 1995, BIOCHEM BIOPH RES CO, V206, P421, DOI 10.1006/bbrc.1995.1058; Hande MP, 1998, MUTAT RES-FUND MOL M, V404, P205, DOI 10.1016/S0027-5107(98)00115-8; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HARRINGTON LA, 1991, NATURE, V353, P451, DOI 10.1038/353451a0; Herbert BS, 1999, P NATL ACAD SCI USA, V96, P14276, DOI 10.1073/pnas.96.25.14276; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Mattson MP, 2001, MECH AGEING DEV, V122, P659, DOI 10.1016/S0047-6374(01)00221-4; MEDRANO EE, 1995, CANCER RES, V55, P4047; Melek M, 1996, BIOESSAYS, V18, P301, DOI 10.1002/bies.950180408; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; Oh CW, 2001, RADIAT RES, V156, P232, DOI 10.1667/0033-7587(2001)156[0232:IOASLP]2.0.CO;2; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; Ramirez RD, 2001, GENE DEV, V15, P398, DOI 10.1101/gad.859201; Ren JG, 2001, FEBS LETT, V488, P133, DOI 10.1016/S0014-5793(00)02397-8; Samuni AM, 2001, BBA-GEN SUBJECTS, V1525, P70, DOI 10.1016/S0304-4165(00)00172-0; Saretzki G, 1998, J GERONTOL A-BIOL, V53, pB438, DOI 10.1093/gerona/53A.6.B438; Seluanov A, 2001, MOL CELL BIOL, V21, P1552, DOI 10.1128/MCB.21.5.1552-1564.2001; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 2001, RADIAT RES, V155, P188, DOI 10.1667/0033-7587(2001)155[0188:TATIFC]2.0.CO;2; Slijepcevic P, 1998, INT J RADIAT BIOL, V73, P1; Stein G H, 1979, Methods Enzymol, V58, P279; Steinert S, 2000, BIOCHEM BIOPH RES CO, V273, P1095, DOI 10.1006/bbrc.2000.3080; Teramoto S, 1999, JPN J PHARMACOL, V79, P33, DOI 10.1254/jjp.79.33; Toussaint O, 2000, EXP GERONTOL, V35, P927, DOI 10.1016/S0531-5565(00)00180-7; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Von Zglinicki T, 2000, FREE RADICAL BIO MED, V28, P64, DOI 10.1016/S0891-5849(99)00207-5; von Zglinicki T, 2001, EXP GERONTOL, V36, P1049, DOI 10.1016/S0531-5565(01)00111-5; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wei S, 1999, CANCER RES, V59, P1539; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Xiang H, 2000, BIOCHEM BIOPH RES CO, V278, P503, DOI 10.1006/bbrc.2000.3834; Yang JW, 1999, J BIOL CHEM, V274, P26141, DOI 10.1074/jbc.274.37.26141; Yeo EJ, 2000, EXP GERONTOL, V35, P553, DOI 10.1016/S0531-5565(00)00108-X; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	55	191	203	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38540	38549		10.1074/jbc.M202671200	http://dx.doi.org/10.1074/jbc.M202671200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12140282	hybrid			2022-12-27	WOS:000178529600070
J	Regula, KM; Ens, K; Kirshenbaum, LA				Regula, KM; Ens, K; Kirshenbaum, LA			IKK beta is required for Bcl-2-mediated NF-kappa B activation in ventricular myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-INDUCED DEGRADATION; PROGRAMMED CELL-DEATH; NECROSIS-FACTOR-ALPHA; BCL-X-L; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; MICE LACKING; KINASE-ALPHA; BH4 DOMAIN; PERMEABILITY TRANSITION	The transcription factor nuclear factor kappaB (NF-kappaB) is regulated by cytoplasmic inhibitor IkappaBalpha. An integral step in the activation of NF-kappaB involves the phosphorylation and degradation of IkappaBalpha. We have previously reported that IkappaBalpha activity is diminished in ventricular myocytes expressing Bcl-2 (de Moissac, D., Zheng, H., and Kirshenbaum, L. A. (1999) J. Biol. Chem. 274, 29505-29509). The underlying mechanism by which Bcl-2 activates NF-kappaB is undefined. In view of growing evidence that the IkappaB kinases (IKKs), notably IKKbeta, are involved in signal induced phosphorylation of IkappaBalpha, we ascertained whether IKKbeta is necessary and sufficient for Bcl-2 mediated NF-kappaB activation. Here we demonstrate that expression of Bcl-2 in ventricular myocytes resulted in an increase in NF-kappaB-dependent DNA binding, NF-kappaB gene transcription and reduced IkappaBalpha levels. An increase in the IKKbeta kinase activity was observed in cells expressing full-length Bcl-2 but not in cells expressing the BH4 deletion mutant of Bcl-2 (DeltaBH4; residues 10-30). Catalytically inactive mutants of IKKbeta, but not IKKalpha, suppressed Bcl-2-mediated IkappaBalpha phosphorylation and NF-kappaB activation. Transfection of human embryonic 293 cells with a kinase-defective Raf-1 or a kinase-defective mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 (MEKK-1) suppressed Bcl2-mediated IKKbeta activity and NF-kappaB activation. Further, Bcl-2-mediated NF-kappaB activity was impaired in nullizygous mouse embryonic fibroblasts deficient for IKKbeta. In this report, we provide the first direct evidence that Bcl-2 activates NF-kappaB by a signaling mechanism that involves Raf-1/MEKK-1 mediated activation of IKKbeta.	St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Winnipeg, MB R2H 2A6, Canada; Univ Manitoba, Fac Med, Dept Physiol, Winnipeg, MB R2H 2A6, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Manitoba	Kirshenbaum, LA (corresponding author), St Boniface Gen Hosp, Res Ctr, Inst Cardiovasc Sci, Rm 3042,351 Tache Ave, Winnipeg, MB R2H 2A6, Canada.	Lorrie@sbrc.ca	Kirshenbaum, Lorrie A./F-5742-2014					ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Barkett M, 1997, J BIOL CHEM, V272, P29419, DOI 10.1074/jbc.272.47.29419; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Bernardi P, 1998, BIOFACTORS, V8, P273, DOI 10.1002/biof.5520080315; Bottero V, 2001, J BIOL CHEM, V276, P21317, DOI 10.1074/jbc.M005850200; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; de Moissac D, 1999, J BIOL CHEM, V274, P29505, DOI 10.1074/jbc.274.41.29505; de Moissac D, 1998, J BIOL CHEM, V273, P23946, DOI 10.1074/jbc.273.37.23946; Folgueira L, 1996, J VIROL, V70, P2332, DOI 10.1128/JVI.70.4.2332-2338.1996; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Hunter JJ, 1996, MOL CELL BIOL, V16, P877; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KRISHENBAUM LA, 1993, J CLIN INVEST, V92, P381, DOI 10.1172/JCI116577; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Marchetti P, 1996, J IMMUNOL, V157, P4830; MARTIN SJ, 1995, CRIT REV ONCOL HEMAT, V18, P137, DOI 10.1016/1040-8428(94)00124-C; May MJ, 1999, SCIENCE, V284, P271, DOI 10.1126/science.284.5412.271; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mustapha S, 2000, AM J PHYSIOL-HEART C, V279, pH939, DOI 10.1152/ajpheart.2000.279.3.H939; NABEL GJ, 1993, GENE DEV, V7, P2063, DOI 10.1101/gad.7.11.2063; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Ozes ON, 1999, NATURE, V401, P82; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Shibasaki F, 1997, NATURE, V386, P728, DOI 10.1038/386728a0; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tang GL, 2001, MOL CELL, V8, P1005, DOI 10.1016/S1097-2765(01)00380-X; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VAN AD, 1996, SCIENCE, V274, P787; VanAntwerp DJ, 1996, MOL CELL BIOL, V16, P6037; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; WYLLIE AH, 1992, CANCER METAST REV, V11, P95, DOI 10.1007/BF00048057; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zen K, 1998, EXP CELL RES, V243, P425, DOI 10.1006/excr.1998.4162	68	48	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38676	38682		10.1074/jbc.M206175200	http://dx.doi.org/10.1074/jbc.M206175200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167626	hybrid			2022-12-27	WOS:000178529600085
J	Yang, KS; Kang, SW; Woo, HA; Hwang, SC; Chae, HZ; Kim, K; Rhee, SG				Yang, KS; Kang, SW; Woo, HA; Hwang, SC; Chae, HZ; Kim, K; Rhee, SG			Inactivation of human peroxiredoxin I during catalysis as the result of the oxidation of the catalytic site cysteine to cysteine-sulfinic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKYL HYDROPEROXIDE REDUCTASE; THIOL-SPECIFIC ANTIOXIDANT; MAMMALIAN PEROXIREDOXIN; SALMONELLA-TYPHIMURIUM; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; NADH PEROXIDASE; SULFENIC ACIDS; SACCHAROMYCES-CEREVISIAE; TRYPAREDOXIN PEROXIDASE	By following peroxiredoxin I (Prx I)-dependent NADPH oxidation spectrophotometrically, we observed that Prx I activity decreased gradually with time. The decay in activity was coincident with the conversion of Prx I to a more acidic species as assessed by two-dimensional gel electrophoresis. Mass spectral analysis and studies with Cys mutants determined that this shift in pI was due to selective oxidation of the catalytic site Cys(51)-SH to Cys(51)-SO2H. Thus, Cys(51)-SOH generated as an intermediate during catalysis appeared to undergo occasional further oxidation to Cys(51)-SO2H, which cannot be reversed by thioredoxin. The presence of H2O2 alone was not sufficient to cause oxidation of Cys(51) to Cys(51)-SO2H. Rather, the presence of complete catalytic components (H2O2, thioredoxin, thioredoxin reductase, and NADPH) was necessary, indicating that such hyperoxidation occurs only when Prx I is engaged in the catalytic cycle. Likewise, hyperoxidation of Cys(172)/Ser(172) mutant Prx I required not only H2O2, but also a catalysis-supporting thiol (dithiothreitol). Kinetic analysis of Prx I inactivation in the presence of a low steady-state level (< 1 &mu;M) of H2O2 indicated that Prx I was hyperoxidized at a rate of 0.072% per turnover at 30 &DEG;C. Hyperoxidation of Prx I was also detected in HeLa cells treated with H2O2.	NHLBI, Lab Cell Signaling, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Rhee, SG (corresponding author), NHLBI, Lab Cell Signaling, NIH, Bldg 50,Rm 3523,South Dr,MSC 8015, Bethesda, MD 20892 USA.		Woo, Hyun Ae/AAT-9586-2021	Hwang, Sung Chul/0000-0003-2401-619X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005506] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chae HZ, 1999, DIABETES RES CLIN PR, V45, P101, DOI 10.1016/S0168-8227(99)00037-6; Chae HZ, 1999, METHOD ENZYMOL, V300, P219; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; CHAE HZ, 1994, BIOFACTORS, V4, P177; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Crane EJ, 2000, BIOCHEMISTRY-US, V39, P10353, DOI 10.1021/bi000553m; DAVIS FA, 1986, J ORG CHEM, V51, P1033, DOI 10.1021/jo00357a017; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P13349, DOI 10.1021/bi9713658; Fisher AB, 1999, J BIOL CHEM, V274, P21326, DOI 10.1074/jbc.274.30.21326; Flohe L, 2002, ARCH BIOCHEM BIOPHYS, V397, P324, DOI 10.1006/abbi.2001.2688; Gay CA, 2002, ANAL BIOCHEM, V304, P42, DOI 10.1006/abio.2001.5566; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kang SW, 1998, J BIOL CHEM, V273, P6303, DOI 10.1074/jbc.273.11.6303; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; Kim JR, 2000, ANAL BIOCHEM, V283, P214, DOI 10.1006/abio.2000.4623; KIM KW, 1988, J BIOL CHEM, V263, P4704; Matsumoto A, 1999, FEBS LETT, V443, P246, DOI 10.1016/S0014-5793(98)01736-0; Mitsumoto A, 2001, FREE RADICAL BIO MED, V30, P625, DOI 10.1016/S0891-5849(00)00503-7; Montemartini M, 1999, EUR J BIOCHEM, V264, P516, DOI 10.1046/j.1432-1327.1999.00656.x; Peshenko IV, 1998, FREE RADICAL BIO MED, V25, P654, DOI 10.1016/S0891-5849(98)00111-7; POOLE LB, 1989, J BIOL CHEM, V264, P12330; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Shen CL, 2002, MOL MED, V8, P95, DOI 10.1007/BF03402079; Singh AK, 1998, J BIOL CHEM, V273, P26171, DOI 10.1074/jbc.273.40.26171; STORZ G, 1989, J BACTERIOL, V171, P2049, DOI 10.1128/jb.171.4.2049-2055.1989; TARTAGLIA LA, 1989, J MOL BIOL, V210, P709, DOI 10.1016/0022-2836(89)90104-6; TARTAGLIA LA, 1990, J BIOL CHEM, V265, P10535; Wood ZA, 2002, BIOCHEMISTRY-US, V41, P5493, DOI 10.1021/bi012173m; Yeh JI, 1996, BIOCHEMISTRY-US, V35, P9951, DOI 10.1021/bi961037s; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615	43	346	358	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38029	38036		10.1074/jbc.M206626200	http://dx.doi.org/10.1074/jbc.M206626200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161445	hybrid			2022-12-27	WOS:000178529600009
J	Gendlina, I; Gutman, DM; Thomas, V; Collins, CM				Gendlina, I; Gutman, DM; Thomas, V; Collins, CM			Urea-dependent signal transduction by the virulence regulator UreR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEUS-MIRABILIS UREASE; GENE-CLUSTER; FAMILY ENTEROBACTERIACEAE; CONTROLLING EXPRESSION; KLEBSIELLA-AEROGENES; IDENTIFICATION; INFECTION; TRANSCRIPTION; PROMOTERS; BACTERIA	Identification of the environmental triggers involved in the expression of virulence genes is a fundamental objective in studies of bacterial pathogens. For uropathogens, urea, found in the urinary tract at concentrations of up to 500 mM, functions as an environmental signal. Urea freely diffuses into the bacterium Providencia stuartii and activates UreR, a member of the AraC family of transcriptional activators. Active UreR promotes transcription of virulence-associated urease genes and alerts the organisms of its immediate milieu. Thus, the UreR.urea complex has a dual role, acting as both a transcriptional activator as well as an environmental sensor. Here, we describe the molecular events associated with activation of gene expression by urea-bound UreR. The K-d of the urea-UreR binding reaction was measured as 0.2 mM by fluorescence quenching assays, and the shape of the binding curve indicated a single specific urea-binding site on UreR. Histidine residues are critical for urea binding in urease, and therefore to identify the urea-binding site in UreR, five mutant UreR forms were generated with histidine to alanine substitutions. Two of the mutants (UreR) exhibited a constitutive phenotype by both activating transcription and binding to DNA with an increased affinity in the absence of urea. The UreR(c) bound urea with an affinity similar to that of wild-type UreR. We concluded, therefore, that the mutations resulting in constitutive activity were not involved in the UreR.urea interaction. UreR was activated, then, either by binding urea or by histidine to alanine substitutions at one of two positions. Circular dichroism indicated little change in the structure of UreR when activated, and size-exclusion chromatography demonstrated that both rUreR and rUreR(c) were dimers in both the presence and absence of urea. Thus, the structural changes associated with activation are subtle.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33101 USA	University of Miami	Collins, CM (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Box 357242, Seattle, WA 98195 USA.				NIDDK NIH HHS [DK60163, DK50495] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050495, R01DK060163] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRAUDE AI, 1960, J BACTERIOL, V80, P171, DOI 10.1128/JB.80.2.171-179.1960; Collins Carleen M., 1996, P299; COLLINS CM, 1993, MOL MICROBIOL, V8, P187, DOI 10.1111/j.1365-2958.1993.tb01215.x; COLLINS CM, 1990, J BACTERIOL, V172, P7138, DOI 10.1128/jb.172.12.7138-7144.1990; Donnenberg Michael S., 1996, P135; DOrazio SEF, 1996, MOL MICROBIOL, V21, P643, DOI 10.1111/j.1365-2958.1996.tb02572.x; DORAZIO SEF, 1993, J BACTERIOL, V175, P3459, DOI 10.1128/jb.175.11.3459-3467.1993; DORAZIO SEF, 1993, J BACTERIOL, V175, P1860, DOI 10.1128/JB.175.6.1860-1864.1993; DORAZIO SEF, 1995, MOL MICROBIOL, V16, P145, DOI 10.1111/j.1365-2958.1995.tb02399.x; FOWLER JE, 1984, J UROLOGY, V131, P213, DOI 10.1016/S0022-5347(17)50311-0; Gallegos MT, 1997, MICROBIOL MOL BIOL R, V61, P393, DOI 10.1128/.61.4.393-410.1997; GRIFFITH DP, 1976, INVEST UROL, V13, P346; HENDRICKSON W, 1984, J MOL BIOL, V178, P611, DOI 10.1016/0022-2836(84)90241-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; LEE MH, 1992, J BACTERIOL, V174, P4324, DOI 10.1128/JB.174.13.4324-4330.1992; LERNER SP, 1989, J UROLOGY, V141, P753, DOI 10.1016/S0022-5347(17)41002-0; MACLAREN DM, 1986, MICROBIAL DISEASES N, P183; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; Miller J.H., 1972, EXPT MOL GENETICS; Mobley Harry L. T., 1996, P245; MOBLEY HLT, 1985, J CLIN MICROBIOL, V22, P851, DOI 10.1128/JCM.22.5.851-853.1985; MOBLEY HLT, 1987, J CLIN MICROBIOL, V25, P2216, DOI 10.1128/JCM.25.11.2216-2217.1987; NICHOLSON EB, 1993, J BACTERIOL, V175, P465, DOI 10.1128/JB.175.2.465-473.1993; Parkinson J.S., 1995, 2 COMPONENT SIGNAL T, P9; Poore CA, 2001, J BACTERIOL, V183, P4526, DOI 10.1128/JB.183.15.4526-4535.2001; REVZIN A, 1989, BIOTECHNIQUES, V7, P346; Thomas VJ, 1999, MOL MICROBIOL, V31, P1417, DOI 10.1046/j.1365-2958.1999.01283.x; Warren John W., 1996, P3	30	26	27	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37349	37358		10.1074/jbc.M203462200	http://dx.doi.org/10.1074/jbc.M203462200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147687	hybrid			2022-12-27	WOS:000178447100057
J	Lamorte, L; Rodrigues, S; Naujokas, M; Park, M				Lamorte, L; Rodrigues, S; Naujokas, M; Park, M			Crk synergizes with epidermal growth factor for epithelial invasion and morphogenesis and is required for the Met morphogenic program	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRB2 BINDING-SITE; PLECKSTRIN HOMOLOGY DOMAIN; KIDNEY-CELLS REQUIRES; DOCKING PROTEIN GAB1; SCATTER FACTOR; ADAPTER PROTEIN; FACTOR-RECEPTOR; C-MET; PHOSPHOINOSITIDE 3-KINASE; SUSTAINED ACTIVATION	Activation of the Met receptor tyrosine kinase through its ligand, hepatocyte growth factor, stimulates cell spreading, cell dispersal, and the inherent morphogenic program of various epithelial cell lines. Although both hepatocyte growth factor and epidermal growth factor (EGF) can activate downstream signaling pathways in Madin-Darby canine kidney epithelial cells, EGF fails to promote the breakdown of cell-cell junctional complexes and initiate an invasive morphogenic program. We have undertaken a strategy to identify signals that synergize with EGF in this process. We provide evidence that the overexpression of the CrkII adapter protein complements EGF-stimulated pathways to induce cell dispersal in two-dimensional cultures and cell invasion and branching morphogenesis in three-dimensional collagen gels. This finding correlates with the ability of CrkII to promote the breakdown of adherens junctions in stable cell lines and the ability of EGF to stimulate enhanced Rac activity in cells overexpressing CrkII. We have previously shown that the Gab1-docking protein is required for branching morphogenesis downstream of the Met receptor. Consistent with a role for CrkII in promoting EGF-dependent branching morphogenesis, the binding of Gab1 to CrkII is required for the branching morphogenic program downstream of Met. Together, our data support a role for the CrkII adapter protein in epithelial invasion and morphogenesis and underscores the importance of considering the synergistic actions of signaling pathways in cancer progression.	McGill Univ, Mol Oncol Grp, Ctr Hosp, Dept Oncol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Biochem, Ctr Hosp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Ctr Hosp, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Mol Oncol Grp, Ctr Hosp, Dept Oncol, Rm H510,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.							Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bowes RC, 1999, J CELL PHYSIOL, V180, P81, DOI 10.1002/(SICI)1097-4652(199907)180:1<81::AID-JCP9>3.0.CO;2-J; Chen YH, 2000, MOL BIOL CELL, V11, P849, DOI 10.1091/mbc.11.3.849; Cho SY, 2000, J CELL BIOL, V149, P223, DOI 10.1083/jcb.149.1.223; El-Obeid A, 1997, CANCER RES, V57, P5598; Engers R, 2001, J BIOL CHEM, V276, P41889, DOI 10.1074/jbc.M105049200; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Feller SM, 1998, J CELL PHYSIOL, V177, P535, DOI 10.1002/(SICI)1097-4652(199812)177:4<535::AID-JCP5>3.3.CO;2-5; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; GUMBINER BM, 1992, CELL, V69, P385, DOI 10.1016/0092-8674(92)90440-N; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Kjelsberg C, 1997, AM J PHYSIOL-RENAL, V272, pF222, DOI 10.1152/ajprenal.1997.272.2.F222; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Lamorte L, 2000, ONCOGENE, V19, P5973, DOI 10.1038/sj.onc.1203977; Lamorte L, 2002, MOL BIOL CELL, V13, P1449, DOI 10.1091/mbc.01-10-0477; Lamorte L, 2001, Surg Oncol Clin N Am, V10, P271; Li DX, 2000, J CELL BIOL, V148, P791, DOI 10.1083/jcb.148.4.791; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Matsumoto K, 1997, BIOCHEM BIOPH RES CO, V239, P639, DOI 10.1006/bbrc.1997.7517; MATTHAY MA, 1993, J CELL SCI, V106, P869; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; Nolan KM, 1998, GENE DEV, V12, P3337, DOI 10.1101/gad.12.21.3337; O'Brien LE, 2001, NAT CELL BIOL, V3, P831, DOI 10.1038/ncb0901-831; Otsuka T, 1998, CANCER RES, V58, P5157; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Pollack AL, 1998, DEV BIOL, V204, P64, DOI 10.1006/dbio.1998.9091; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Sakurai H, 1997, AM J PHYSIOL-RENAL, V273, pF463, DOI 10.1152/ajprenal.1997.273.3.F463; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Simian M, 2001, DEVELOPMENT, V128, P3117; Solic N, 1997, EXP CELL RES, V234, P465, DOI 10.1006/excr.1997.3635; SORIANO JV, 1995, J CELL SCI, V108, P413; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Uemura N, 1999, J BIOL CHEM, V274, P37525, DOI 10.1074/jbc.274.53.37525; Wiesen JF, 1999, DEVELOPMENT, V126, P335; Wolf I, 2002, MOL CELL BIOL, V22, P231, DOI 10.1128/MCB.22.1.231-244.2002; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649; ZHU H, 1994, J BIOL CHEM, V269, P29943; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200	72	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37904	37911		10.1074/jbc.M201743200	http://dx.doi.org/10.1074/jbc.M201743200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138161	hybrid, Green Published			2022-12-27	WOS:000178447100127
J	Said, EA; Krust, B; Nisole, S; Svab, J; Briand, JP; Hovanessian, AG				Said, EA; Krust, B; Nisole, S; Svab, J; Briand, JP; Hovanessian, AG			The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; MOLECULE HB-GAM; GROWTH-FACTOR; WILMS-TUMOR; ACTIN CYTOSKELETON; RICH DOMAIN; V3 LOOP; PROTEIN; IDENTIFICATION; ATTACHMENT	The growth factor midkine (MK) is a cytokine that inhibits the attachment of human immunodeficiency virus particles by a mechanism similar to the nucleolin binding HB-19 pseudopeptide. Here we show that the binding of MK to cells occurs specifically at a high and a low affinity binding site. HB-19 prevents the binding of MK to the low affinity binding site only. Confocal immunofluorescence laser microscopy revealed the colocalization of MK and the cell-surface-expressed nucleolin at distinct spots. The use of various deletion constructs of nucleolin then indicated that the extreme C-terminal end of nucleolin, containing repeats of the amino acid motif RGG, is the domain that binds MK. The specific binding of MK to cells is independent of heparan sulfate and chondroitin sulfate expression. After binding to cells, MK enters cells by an active process. Interestingly, the cross-linking of surface-bound MK with a specific antibody results in the clustering of surface nucleolin along with glycosylphosphatidylinositol-linked proteins CD90 and CD59, thus, pointing out that MK binding induces lateral assemblies of nucleolin with specific membrane components of lipid rafts. Our results suggest that the cell surface-expressed nucleolin serves as a low affinity receptor for MK and could be implicated in its entry process.	Inst Pasteur, Unite Virol & Immunol Cellulaire, CNRS, URA 1930, F-75724 Paris 15, France; CNRS, Inst Biol Mol & Cellulaire, UPR 9021, F-75700 Paris, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS)	Hovanessian, AG (corresponding author), Inst Pasteur, Unite Virol & Immunol Cellulaire, CNRS, URA 1930, 28 Rue Dr Roux, F-75724 Paris 15, France.		Said, Elias/AAY-5557-2020; Nisole, Sébastien/ABA-2367-2021	Nisole, Sébastien/0000-0001-9793-419X; Said, Elias/0000-0003-4224-6351				Adachi Y, 1996, ONCOGENE, V13, P2197; ARIDOME K, 1995, JAP J CANC RES, V118, P88; BERGER EA, 1997, AIDS SA, V1, P3; Bishop NE, 1997, REV MED VIROL, V7, P199, DOI 10.1002/(SICI)1099-1654(199712)7:4<199::AID-RMV203>3.0.CO;2-F; Bouvet P, 1998, J BIOL CHEM, V273, P19025, DOI 10.1074/jbc.273.30.19025; Callebaut C, 1996, VIROLOGY, V218, P181, DOI 10.1006/viro.1996.0178; Callebaut C, 1998, J BIOL CHEM, V273, P21988, DOI 10.1074/jbc.273.34.21988; Callebaut C, 2001, VIROLOGY, V281, P248, DOI 10.1006/viro.2000.0767; Callebaut C, 1997, J BIOL CHEM, V272, P7159, DOI 10.1074/jbc.272.11.7159; Cartegni L, 1996, J MOL BIOL, V259, P337, DOI 10.1006/jmbi.1996.0324; Deng JS, 1996, MOL BIOL REP, V23, P191, DOI 10.1007/BF00351168; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Dumler I, 1999, CURR BIOL, V9, P1468, DOI 10.1016/S0960-9822(00)80116-5; ERARD M, 1990, EUR J BIOCHEM, V191, P19, DOI 10.1111/j.1432-1033.1990.tb19088.x; ESKO JD, 1987, J BIOL CHEM, V262, P12189; ESKO JD, 1988, SCIENCE, V241, P1092, DOI 10.1126/science.3137658; FANG SH, 1993, EXP CELL RES, V208, P48, DOI 10.1006/excr.1993.1221; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Ginisty H, 1999, J CELL SCI, V112, P761; GUO N, 1989, J BIOL CHEM, V264, P13267; Haluska P, 1998, NUCLEIC ACIDS RES, V26, P1841, DOI 10.1093/nar/26.7.1841; Hanakahi LA, 1999, J BIOL CHEM, V274, P15908, DOI 10.1074/jbc.274.22.15908; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Holowka D, 2000, J CELL SCI, V113, P1009; Hovanessian AG, 2000, EXP CELL RES, V261, P312, DOI 10.1006/excr.2000.5071; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KOJIMA S, 1995, BIOCHEM BIOPH RES CO, V206, P468, DOI 10.1006/bbrc.1995.1066; KRANTZ S, 1995, BBA-MOL CELL RES, V1266, P109, DOI 10.1016/0167-4889(95)00028-Q; KRUST B, 1987, ANN INST PASTEUR VIR, V138, P245, DOI 10.1016/S0769-2617(87)80008-4; Kurosawa N, 2000, EUR J BIOCHEM, V267, P344, DOI 10.1046/j.1432-1327.2000.01005.x; Kurtz A, 1995, CRIT REV ONCOGENESIS, V6, P151; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Larrucea S, 1999, BIOCHEM BIOPH RES CO, V266, P51, DOI 10.1006/bbrc.1999.1766; Limal D, 1998, J PEPT RES, V52, P121; Maeda N, 1999, J BIOL CHEM, V274, P12474, DOI 10.1074/jbc.274.18.12474; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; Mondor I, 1998, J VIROL, V72, P3623, DOI 10.1128/JVI.72.5.3623-3634.1998; MURAMATSU H, 1993, DEV BIOL, V159, P392, DOI 10.1006/dbio.1993.1250; Muramatsu H, 2000, BIOCHEM BIOPH RES CO, V270, P936, DOI 10.1006/bbrc.2000.2549; MURAMATSU H, 1994, BIOCHEM BIOPH RES CO, V203, P1131, DOI 10.1006/bbrc.1994.2300; MURAMATSU T, 1994, DEV GROWTH DIFFER, V36, P1; NEIMARK J, 1993, PEPTIDE RES, V6, P219; Nisole S, 2002, J BIOL CHEM, V277, P20877, DOI 10.1074/jbc.M110024200; Nisole S, 2002, EXP CELL RES, V276, P155, DOI 10.1006/excr.2002.5522; Nisole S, 1999, J BIOL CHEM, V274, P27875, DOI 10.1074/jbc.274.39.27875; Nisole S, 2000, AIDS RES HUM RETROV, V16, P237, DOI 10.1089/088922200309331; OBrien WA, 1996, J VIROL, V70, P2825, DOI 10.1128/JVI.70.5.2825-2831.1996; Ratovitski EA, 1998, J BIOL CHEM, V273, P3654, DOI 10.1074/jbc.273.6.3654; Ratovitski EA, 1997, CELL MOL BIOL, V43, P425; RAULO E, 1994, J BIOL CHEM, V269, P12999; RODERIQUEZ G, 1995, J VIROL, V69, P2233, DOI 10.1128/JVI.69.4.2233-2239.1995; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; ROGHANI M, 1992, J BIOL CHEM, V267, P22156; Salama RHM, 2001, EXP CELL RES, V270, P13, DOI 10.1006/excr.2001.5341; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Takahashi A, 2001, J BIOCHEM-TOKYO, V129, P599, DOI 10.1093/oxfordjournals.jbchem.a002896; TAKE M, 1994, J BIOCHEM-TOKYO, V116, P1063, DOI 10.1093/oxfordjournals.jbchem.a124628; TSUTSUI J, 1993, CANCER RES, V53, P1281; Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2; Valenzuela A, 1997, J VIROL, V71, P8289, DOI 10.1128/JVI.71.11.8289-8298.1997; Vasilyeva E, 1998, J BIOL CHEM, V273, P23823, DOI 10.1074/jbc.273.37.23823; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026; YASUHARA O, 1993, BIOCHEM BIOPH RES CO, V192, P246, DOI 10.1006/bbrc.1993.1406; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zou K, 2000, EUR J BIOCHEM, V267, P4046, DOI 10.1046/j.1432-1327.2000.01440.x	68	115	132	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37492	37502		10.1074/jbc.M201194200	http://dx.doi.org/10.1074/jbc.M201194200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147681	hybrid			2022-12-27	WOS:000178447100075
J	Cho, WJ; Yoon, WJ; Moon, CH; Cha, SJ; Song, H; Cho, HR; Jang, SJ; Chung, DK; Jeong, CS; Park, JW				Cho, WJ; Yoon, WJ; Moon, CH; Cha, SJ; Song, H; Cho, HR; Jang, SJ; Chung, DK; Jeong, CS; Park, JW			Molecular cloning of a novel chaperone-like protein induced by rhabdovirus infection with sequence similarity to the bacterial extracellular solute-binding protein family 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; HEMATOPOIETIC NECROSIS VIRUS; ENDOPLASMIC-RETICULUM; ESCHERICHIA-COLI; IN-VITRO; REVERSE-TRANSCRIPTASE; HUMAN CYTOMEGALOVIRUS; NUCLEOTIDE-SEQUENCE; CALNEXIN; GLYCOPROTEIN	Previously we demonstrated that a novel stress protein is induced in fish cells by the infection of a fish rhabdovirus (Cho W. J., Cha, S. J., Do, J. W., Choi, J. Y., Lee, J. Y., Jeong, C. S., Cho, K. J., Choi, W. S., Kang, H. S., Kim, H. D., and Park, J. W. (1997) Biochem. Biophys. Res. Commun. 233, 316-319). In this paper, we present the molecular cloning and characterization of a gene encoding this protein named virus-inducible stress protein (VISP). The VISP was purified partially by immunoprecipitation using a monoclonal antibody against the VISP and further purified by the electroelution from a SDS-PAGE gel. The protein was subjected to internal protein sequencing, and the sequence of three peptides was determined. Degenerate oligonucleotides based on the three peptide sequences were used to screen a cDNA library from rhabdovirus-infected CHSE-214 fish cells, and a cDNA of a 2193-bp open reading frame encoding the VISP with 730 amino acid residues (M-r = 79.84) was identified. Whereas the nucleotide sequence of VISP shows no similarity with other genes in the GenBank(TM), the amino acid sequence of the VISP has similarity with the bacterial extracellular solute-binding protein family 5 (SBP_bac_5) that is proposed to have chaperone activity. Thus, we explored whether the VISP also had chaperone-like activity. Purified recombinant VISP expressed in Escherichia coli promoted the functional folding of alpha-glucosidase after urea denaturation and also prevented thermal aggregation of alcohol dehydrogenase. These results suggest that the VISP has amino acid sequence similarity with SBP-bac-5 and that it has chaperone activity that may play a role in virus infection.	Univ Ulsan, Dept Biol Sci, Ulsan 680749, South Korea; Univ Ulsan, Immunomodulat Res Ctr, Ulsan 680749, South Korea; Ulsan Univ Hosp, Dept Surg, Coll Med, Ulsan 682060, South Korea; Kyung Hee Univ, Dept Genet Engn, Kyonggi Do 449701, South Korea; Kyung Hee Univ, RNA Inc, Kyonggi Do 449701, South Korea	University of Ulsan; University of Ulsan; University of Ulsan; Ulsan University Hospital; Kyung Hee University; Kyung Hee University	Park, JW (corresponding author), Univ Ulsan, Dept Biol Sci, Ulsan 680749, South Korea.	jwpark@uou.ulsan.ac.kr	chung, dae kyun/AAG-1058-2021					AMES GF, 1992, ADV ENZYMOL RAMB, V65, P1; Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Bao QY, 2002, GENOME RES, V12, P689, DOI 10.1101/gr.219302; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; Cannon KS, 1999, J BIOL CHEM, V274, P7537, DOI 10.1074/jbc.274.11.7537; Cannon KS, 1996, J BIOL CHEM, V271, P14280, DOI 10.1074/jbc.271.24.14280; Cho WJ, 1997, BIOCHEM BIOPH RES CO, V233, P316, DOI 10.1006/bbrc.1997.6387; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Gaudin Y, 1997, J VIROL, V71, P3742, DOI 10.1128/JVI.71.5.3742-3750.1997; Glotzer JB, 2000, NATURE, V407, P207, DOI 10.1038/35025102; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HIGGINS CF, 1982, NATURE, V298, P723, DOI 10.1038/298723a0; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOGG RW, 1991, MOL GEN GENET, V229, P453, DOI 10.1007/BF00267469; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Hu JM, 2002, J VIROL, V76, P269, DOI 10.1128/JVI.76.1.269-279.2002; Hung JJ, 2002, J VIROL, V76, P1379, DOI 10.1128/JVI.76.3.1379-1390.2002; Ishii T, 1999, J IMMUNOL, V162, P1303; JAKOB U, 1993, J BIOL CHEM, V268, P1517; Knarr G, 1999, J BIOL CHEM, V274, P29850, DOI 10.1074/jbc.274.42.29850; Lee JY, 1996, J GEN VIROL, V77, P1731, DOI 10.1099/0022-1317-77-8-1731; Liu JS, 1998, J BIOL CHEM, V273, P30704, DOI 10.1074/jbc.273.46.30704; Manna T, 2001, J BIOL CHEM, V276, P39742, DOI 10.1074/jbc.M104061200; Matsuzaki M, 1998, J BACTERIOL, V180, P2718, DOI 10.1128/JB.180.10.2718-2722.1998; Mirazimi A, 1998, J VIROL, V72, P8705, DOI 10.1128/JVI.72.11.8705-8709.1998; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Muchowski PJ, 1997, J BIOL CHEM, V272, P2578; NEVINS JR, 1982, CELL, V29, P913, DOI 10.1016/0092-8674(82)90453-6; PARK MA, 1993, J FISH DIS, V16, P471, DOI 10.1111/j.1365-2761.1993.tb00880.x; PUIG A, 1994, J BIOL CHEM, V269, P7764; Richarme G, 1997, J BIOL CHEM, V272, P15607, DOI 10.1074/jbc.272.25.15607; SAGARA J, 1992, VIROLOGY, V190, P845, DOI 10.1016/0042-6822(92)90923-D; SANTOMENNA LD, 1990, J VIROL, V64, P2033, DOI 10.1128/JVI.64.5.2033-2040.1990; Sedger L, 1996, VIROLOGY, V225, P423, DOI 10.1006/viro.1996.0619; SEDGER L, 1994, J VIROL, V68, P4685, DOI 10.1128/JVI.68.7.4685-4689.1994; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; TANGUY LGN, 2002, J BIOL CHEM, V277, P5660; WIECH H, 1992, NATURE, V358, P169, DOI 10.1038/358169a0; Xu AM, 1998, J VIROL, V72, P9865, DOI 10.1128/JVI.72.12.9865-9872.1998; Yamashita Y, 1996, J VIROL, V70, P2237, DOI 10.1128/JVI.70.4.2237-2246.1996; [No title captured]	49	6	8	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41489	41496		10.1074/jbc.M207104200	http://dx.doi.org/10.1074/jbc.M207104200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12183466	hybrid			2022-12-27	WOS:000178985300026
J	Ohta, S; Shiomi, Y; Sugimoto, K; Obuse, C; Tsurimoto, T				Ohta, S; Shiomi, Y; Sugimoto, K; Obuse, C; Tsurimoto, T			A proteomics approach to identify proliferating cell nuclear antigen (PCNA)-binding proteins in human cell lysates - Identification of the human CHL12/RFCs2-5 complex as a novel PCNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-C; SISTER-CHROMATID COHESION; DNA-POLYMERASE-DELTA; SIMIAN VIRUS-40 DNA; RUVB-LIKE PROTEIN; SACCHAROMYCES-CEREVISIAE; MISMATCH REPAIR; PURIFICATION; HOLOENZYME; EXTRACTS	Proliferating cell nuclear antigen (PCNA), a eukaryotic DNA replication factor, functions not only as a processivity factor for DNA polymerase 5 but also as a binding partner for multiple other factors. To understand its broad significance, we have carried out systematic studies of PCNA-binding proteins by a combination of affinity chromatography and mass spectrometric analyses. We detected more than 20 specific protein bands of various intensities in fractions bound to PCNA-fixed resin from human cell lysates and determined their peptide sequences by liquid chromatography and tandem mass spectrometry. A search with human protein data bases identified 12 reported PCNA-binding proteins from both cytoplasmic (S100 lysate) and nuclear extracts with substantial significance and four more solely from the nuclear preparation. CHL12, a factor involved in checkpoint response and chromosome cohesion, was a novel example found in both lysates. Further studies with recombinant proteins demonstrated that CHL12 and small subunits of replication factor C form a complex that interacts with PCNA.	Nara Inst Sci & Technol, Nara 6300101, Japan; Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4640814, Japan	Nara Institute of Science & Technology; Nagoya University	Tsurimoto, T (corresponding author), Nara Inst Sci & Technol, Nara 6300101, Japan.		Obuse, Chikashi/F-5273-2011	Tsurimoto, Toshiki/0000-0001-7597-2216				Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Cai JS, 1997, J BIOL CHEM, V272, P18974, DOI 10.1074/jbc.272.30.18974; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Ellison V, 2001, CELL, V106, P655, DOI 10.1016/S0092-8674(01)00498-6; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hannan RD, 1999, NUCLEIC ACIDS RES, V27, P3720, DOI 10.1093/nar/27.18.3720; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lindsey-Boltz LA, 2001, P NATL ACAD SCI USA, V98, P11236, DOI 10.1073/pnas.201373498; Loor G, 1997, NUCLEIC ACIDS RES, V25, P5041, DOI 10.1093/nar/25.24.5041; Makino Y, 1999, J BIOL CHEM, V274, P15329, DOI 10.1074/jbc.274.22.15329; Mayer ML, 2001, MOL CELL, V7, P959, DOI 10.1016/S1097-2765(01)00254-4; Naiki T, 2001, MOL CELL BIOL, V21, P5838, DOI 10.1128/MCB.21.17.5838-5845.2001; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Qiu XB, 1998, J BIOL CHEM, V273, P27786, DOI 10.1074/jbc.273.43.27786; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimizu K, 2002, P NATL ACAD SCI USA, V99, P9133, DOI 10.1073/pnas.142277999; Shiomi Y, 2000, P NATL ACAD SCI USA, V97, P14127, DOI 10.1073/pnas.97.26.14127; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YANEVA M, 1991, BIOCHIM BIOPHYS ACTA, V1090, P181, DOI 10.1016/0167-4781(91)90099-8	40	75	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40362	40367		10.1074/jbc.M206194200	http://dx.doi.org/10.1074/jbc.M206194200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171929	hybrid			2022-12-27	WOS:000178791400027
J	Torok, M; Milton, S; Kayed, R; Wu, P; McIntire, T; Glabe, CG; Langen, R				Torok, M; Milton, S; Kayed, R; Wu, P; McIntire, T; Glabe, CG; Langen, R			Structural and dynamic features of Alzheimer's A beta peptide in amyloid fibrils studied by site-directed spin labeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; X-RAY-DIFFRACTION; SOLID-STATE NMR; T4 LYSOZYME; DISEASE; PROTEIN; AGGREGATION; SHEET; MODEL; PARALLEL	Electron paramagnetic resonance spectroscopy analysis of 19 spin-labeled derivatives of the Alzheimer's amyloid beta (Abeta) peptide was used to reveal structural features of amyloid fibril formation. In the fibril, extensive regions of the peptide show an in-register, parallel arrangement. Based on the parallel arrangement and side chain mobility analysis we find the amyloid structure to be mostly ordered and specific, but we also identify more dynamic regions (N and C termini) and likely turn or bend regions (around residues 23-26). Despite their different aggregation properties and roles in disease, the two peptides, Abeta40 and Abeta42, homogeneously co-mix in amyloid fibrils suggesting that they possess the same structural architecture.	Univ Calif Irvine, Dept Biol Mol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biochem, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Chem, Irvine, CA 92697 USA; Univ So Calif, Keck Sch Med, Neurogenet Inst, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Arnold & Mabel Beckman Macular Res Ctr, Los Angeles, CA 90033 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Southern California; University of Southern California	Glabe, CG (corresponding author), Univ Calif Irvine, Dept Biol Mol, Irvine, CA 92697 USA.	cglabe@uci.edu; langen@usc.edu			NINDS NIH HHS [NS 31230] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15471, DOI 10.1021/bi011544w; Antzutkin ON, 2000, P NATL ACAD SCI USA, V97, P13045, DOI 10.1073/pnas.230315097; Balbach JJ, 2000, BIOCHEMISTRY-US, V39, P13748, DOI 10.1021/bi0011330; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; Benzinger TLS, 2000, BIOCHEMISTRY-US, V39, P3491, DOI 10.1021/bi991527v; Benzinger TLS, 1998, P NATL ACAD SCI USA, V95, P13407, DOI 10.1073/pnas.95.23.13407; Blackley HKL, 1999, EXP NEUROL, V158, P437, DOI 10.1006/exnr.1999.7114; BURDICK D, 1992, J BIOL CHEM, V267, P546; Clements A, 1996, J NEUROCHEM, V66, P740; Coles M, 1998, BIOCHEMISTRY-US, V37, P11064, DOI 10.1021/bi972979f; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; Goldsbury CS, 2000, J STRUCT BIOL, V130, P217, DOI 10.1006/jsbi.2000.4259; Gregory DM, 1998, SOLID STATE NUCL MAG, V13, P149, DOI 10.1016/S0926-2040(98)00086-1; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; HILBICH C, 1991, J MOL BIOL, V218, P149, DOI 10.1016/0022-2836(91)90881-6; Hoshino M, 2002, NAT STRUCT BIOL, V9, P332, DOI 10.1038/nsb792; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; INOUYE H, 1993, BIOPHYS J, V64, P502, DOI 10.1016/S0006-3495(93)81393-6; Isas JM, 2002, BIOCHEMISTRY-US, V41, P1464, DOI 10.1021/bi011856z; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Kheterpal I, 2001, BIOCHEMISTRY-US, V40, P11757, DOI 10.1021/bi010805z; Kheterpal I, 2000, P NATL ACAD SCI USA, V97, P13597, DOI 10.1073/pnas.250288897; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KIRSCHNER DA, 2002, 23 ACS NAT M POLYM P, P187; Kowalewski T, 1999, P NATL ACAD SCI USA, V96, P3688, DOI 10.1073/pnas.96.7.3688; Langen R, 2000, BIOCHEMISTRY-US, V39, P8396, DOI 10.1021/bi000604f; LANSBURY PT, 1995, NAT STRUCT BIOL, V2, P990, DOI 10.1038/nsb1195-990; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Li LP, 1999, BIOPHYS J, V76, P2871, DOI 10.1016/S0006-3495(99)77442-4; Lundberg KM, 1997, CHEM BIOL, V4, P345, DOI 10.1016/S1074-5521(97)90125-3; Lynn DG, 2000, J STRUCT BIOL, V130, P153, DOI 10.1006/jsbi.2000.4287; Malinchik SB, 1998, BIOPHYS J, V74, P537, DOI 10.1016/S0006-3495(98)77812-9; Margittai M, 2001, J BIOL CHEM, V276, P13169, DOI 10.1074/jbc.M010653200; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; Nybo M, 1999, SCAND J IMMUNOL, V49, P219; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; SATO C, 1995, NEUROSCI LETT, V200, P105, DOI 10.1016/0304-3940(95)12089-M; Serag AA, 2001, BIOCHEMISTRY-US, V40, P9089, DOI 10.1021/bi010655s; Serpell LC, 2000, BIOCHEMISTRY-US, V39, P13269, DOI 10.1021/bi000637v; Stine WB, 1996, J PROTEIN CHEM, V15, P193, DOI 10.1007/BF01887400; SZENDREI GI, 1994, EUR J BIOCHEM, V226, P917, DOI 10.1111/j.1432-1033.1994.t01-1-00917.x; Wille H, 2002, P NATL ACAD SCI USA, V99, P3563, DOI 10.1073/pnas.052703499; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133	46	325	333	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40810	40815		10.1074/jbc.M205659200	http://dx.doi.org/10.1074/jbc.M205659200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181315	hybrid			2022-12-27	WOS:000178791400084
J	Yoshimura, K; Yabuta, Y; Ishikawa, T; Shigeoka, S				Yoshimura, K; Yabuta, Y; Ishikawa, T; Shigeoka, S			Identification of a cis element for tissue-specific alternative splicing of chloroplast ascorbate peroxidase pre-mRNA in higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ARABIDOPSIS-THALIANA; DEFENSE SYSTEM; ISOENZYMES; PROTEINS; STRESS; EXON; EXPRESSION; SEQUENCES; CATALASE	Alternative splicing events in the 3'-terminal region of chloroplast ascorbate peroxidase (ch1APX) pre-mRNA in spinach and tobacco, which produced four types of mRNA variants, one form (tAPX-I) encoding thylakoid-bound APX (tAPX) and three forms (sAPX-I, -II, and -III) encoding stromal APX (sAPX), were regulated in a tissue-specific manner. The ratio of the level of sAPX mRNAs (sAPX-I, -II, and -III) to tAPX-I mRNA was close to 1 in leaf, whereas the ratio in root was greatly elevated due to an increase in sAPX-III and a decrease in tAPX-I resulting from the alternative excision of intron 11 and intron 12, respectively. A putative splicing regulatory cis element, (SRE), which is highly conserved in the sequences of ch1APX genes of higher plants, was identified upstream of the acceptor site in intron 12. The deletion of the SRE sequence diminished the splicing efficiency of intron 12 in tobacco leaf in vivo. Gel-shift analysis showed that SRE interacts strongly with a nuclear protein from leaves but not those from the roots of spinach and tobacco. These results indicate that the tissue-specific alternative splicing of ch1APX pre-mRNA is regulated by the splicing enhancer SRE.	Kinki Univ, Fac Agr, Dept Food & Nutr, Nara 6318505, Japan; Shimane Univ, Fac Life & Environm Sci, Matsue, Shimane 6908504, Japan	Kindai University (Kinki University); Shimane University	Shigeoka, S (corresponding author), Kinki Univ, Fac Agr, Dept Food & Nutr, 3327-204 Nakamachi, Nara 6318505, Japan.	shigeoka@nara.kindai.ac.jp	Yabuta, Yukinori/T-3615-2019	Yabuta, Yukinori/0000-0002-6982-8522				Alba MM, 1998, TRENDS PLANT SCI, V3, P15, DOI 10.1016/S1360-1385(97)01151-5; Asada K, 1999, ANNU REV PLANT PHYS, V50, P601, DOI 10.1146/annurev.arplant.50.1.601; Biemelt S, 1998, PLANT PHYSIOL, V116, P651, DOI 10.1104/pp.116.2.651; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; Chandler SD, 1997, P NATL ACAD SCI USA, V94, P3596, DOI 10.1073/pnas.94.8.3596; Dalton DA, 1998, PLANT PHYSIOL, V116, P37, DOI 10.1104/pp.116.1.37; Gontarek RR, 1996, MOL CELL BIOL, V16, P2325; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; GUO W, 1991, GENE DEV, V5, P2096, DOI 10.1101/gad.5.11.2096; Ishikawa T, 1996, FEBS LETT, V384, P289, DOI 10.1016/0014-5793(96)00332-8; Ishikawa T, 1997, BIOCHEM J, V328, P795, DOI 10.1042/bj3280795; Jespersen HM, 1997, BIOCHEM J, V326, P305, DOI 10.1042/bj3260305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambermon MHL, 2000, EMBO J, V19, P1638, DOI 10.1093/emboj/19.7.1638; Lambermon MHL, 2002, MOL CELL BIOL, V22, P4346, DOI 10.1128/MCB.22.12.4346-4357.2002; Lopato S, 1999, GENE DEV, V13, P987, DOI 10.1101/gad.13.8.987; Lopato S, 1996, PLANT CELL, V8, P2255, DOI 10.1105/tpc.8.12.2255; Lorkovic ZJ, 2000, TRENDS PLANT SCI, V5, P160, DOI 10.1016/S1360-1385(00)01595-8; Mano S, 1999, PLANT J, V17, P309, DOI 10.1046/j.1365-313X.1999.00378.x; Mano S, 1997, FEBS LETT, V413, P21, DOI 10.1016/S0014-5793(97)00862-4; Matamoros MA, 1999, PLANT PHYSIOL, V121, P97, DOI 10.1104/pp.121.1.97; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; Miyagawa Y, 2000, PLANT CELL PHYSIOL, V41, P311, DOI 10.1093/pcp/41.3.311; Moore M., 1993, RNA WORLD, P303; Noctor G, 1998, ANNU REV PLANT PHYS, V49, P249, DOI 10.1146/annurev.arplant.49.1.249; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; ROBINSON DG, 2001, PLANT CELL BIOL, P295; RUNDLE SJ, 1991, J BIOL CHEM, V266, P14802; Shigeoka S, 2002, J EXP BOT, V53, P1305, DOI 10.1093/jexbot/53.372.1305; Shikanai T, 1998, FEBS LETT, V428, P47, DOI 10.1016/S0014-5793(98)00483-9; Simpson GG, 1996, PLANT MOL BIOL, V32, P1, DOI 10.1007/BF00039375; VALCARCEL J, 1995, PREMRNA PROCESSING, P97; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; Yoshimura K, 2000, PLANT PHYSIOL, V123, P223, DOI 10.1104/pp.123.1.223; Yoshimura K, 1999, BIOCHEM J, V338, P41, DOI 10.1042/0264-6021:3380041; Yoshimura K, 2001, BBA-GEN SUBJECTS, V1526, P168, DOI 10.1016/S0304-4165(01)00131-3	36	65	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40623	40632		10.1074/jbc.M201531200	http://dx.doi.org/10.1074/jbc.M201531200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12176976	hybrid			2022-12-27	WOS:000178791400061
J	Iwasaki, T; Kounosu, A; Aoshima, M; Ohmori, D; Imai, T; Urushiyama, A; Cosper, NJ; Scott, RA				Iwasaki, T; Kounosu, A; Aoshima, M; Ohmori, D; Imai, T; Urushiyama, A; Cosper, NJ; Scott, RA			Novel [2Fe-2S]-type redox center C in SdhC of archaeal respiratory complex II from Sulfolobus tokodaii strain 7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOACIDOPHILIC ARCHAEON; SUCCINATE-DEHYDROGENASE; FUMARATE REDUCTASE; CRYSTAL-STRUCTURES; PRE-EDGE; FERREDOXIN; RESOLUTION; OXIDASE; SYSTEM; OXIDOREDUCTASE	The SdhC subunit of the archaeal respiratory complex 11 (succinate:quinone oxidoreductase) from Sulfolobus tokodaii strain 7 has a novel cysteine rich motif and is also related to archaeal and bacterial heterodisulfide reductase subunits. We overexpressed the sdhC gene heterologously in Escherichia coli and characterized the gene product in greater detail. Low temperature resonance Raman and x-ray absorption spectroscopic investigation collectively demonstrate the presence of a We-M cluster core with complete cysteinyl ligation (Center C) and an isolated zinc site in the recombinant SdhC. The [2Fe-2S](2+) cluster core is sensitive to dithionite, resulting in irreversible breakdown of the Fe-Fe interaction. EPR analysis confirmed that the novel Center C is an inherent redox center in the archaeal complex II, showing unique EPR signals in the succinate-reduced state. Distinct subunit and cofactor arrangements in the S. tokodaii respiratory complex 11, as compared with those in mitochondrial and some mesophilic bacterial enzymes, indicate modular evolution of this ubiquitous electron entry site in the respiratory chains of aerobic organisms.	Nippon Med Coll, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Tokyo 1138657, Japan; Juntendo Univ, Dept Chem, Inba, Chiba 2701695, Japan; Rikkyo St Pauls Univ, Dept Chem, Toshima Ku, Tokyo 1718501, Japan; Univ Georgia, Dept Chem, Athens, GA 30602 USA	Nippon Medical School; University of Tokyo; Juntendo University; University System of Georgia; University of Georgia	Iwasaki, T (corresponding author), Nippon Med Coll, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1138602, Japan.	tiwasaki@nms.ac.jp		Iwasaki, Toshio/0000-0001-9562-4649; Scott, Robert/0000-0003-2236-1336	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042025] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 42025] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackrell B. A.C, 1992, CHEM BIOCH FLAVOPROT, V3, P229; BERTRAND P, 1985, BIOCHIM BIOPHYS ACTA, V831, P261, DOI 10.1016/0167-4838(85)90044-5; BERTRAND P, 1979, BIOCHIM BIOPHYS ACTA, V579, P107, DOI 10.1016/0005-2795(79)90091-6; Chabriere E, 1999, NAT STRUCT BIOL, V6, P182; Cosper NJ, 1999, J BIOL INORG CHEM, V4, P122, DOI 10.1007/s007750050295; Crouse BR, 1996, BIOCHEMISTRY-US, V35, P16222, DOI 10.1021/bi9620114; DAVYDOV R, 1994, J AM CHEM SOC, V116, P11120, DOI 10.1021/ja00103a029; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; ENROTH C, 1999, FLAVINS FLAVOPROTEIN, P783; Gomes CM, 1999, BBA-BIOENERGETICS, V1411, P134, DOI 10.1016/S0005-2728(99)00046-8; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; HAN S, 1989, J AM CHEM SOC, V111, P3496, DOI 10.1021/ja00192a002; HAN S, 1989, J AM CHEM SOC, V111, P3505, DOI 10.1021/ja00192a003; Hederstedt L, 1999, SCIENCE, V284, P1941, DOI 10.1126/science.284.5422.1941; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Iwasaki T, 2000, J BIOL CHEM, V275, P25391, DOI 10.1074/jbc.M909243199; Iwasaki T, 1995, J BIOL CHEM, V270, P30893, DOI 10.1074/jbc.270.52.30893; Iwasaki T, 1995, J BIOL CHEM, V270, P30881, DOI 10.1074/jbc.270.52.30881; Iwasaki T, 2002, EPR IN THE 21ST CENTURY: BASICS AND APPLICATIONS TO MATERIAL, LIFE AND EARTH SCIENCES, P488, DOI 10.1016/B978-044450973-4/50083-4; Iwasaki T, 2001, METHOD ENZYMOL, V334, P3; Iwasaki T, 1996, FEMS MICROBIOL LETT, V144, P259; Iwasaki T, 1995, J BIOL CHEM, V270, P30902, DOI 10.1074/jbc.270.52.30902; IWASAKI T, 1999, FLAVINS FLAVOPROTEIN, P779; Janssen S, 1997, J BACTERIOL, V179, P5560, DOI 10.1128/jb.179.17.5560-5569.1997; Jormakka M, 2002, SCIENCE, V295, P1863, DOI 10.1126/science.1068186; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Lemos RS, 2001, BIOCHEM BIOPH RES CO, V281, P141, DOI 10.1006/bbrc.2001.4317; Ohnishi T, 2000, STRUCTURE, V8, pR23, DOI 10.1016/S0969-2126(00)00098-8; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RANDALL CR, 1995, INORG CHEM, V34, P1036, DOI 10.1021/ic00109a007; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCOTT RA, 1985, METHOD ENZYMOL, V117, P414; Suzuki T, 2002, EXTREMOPHILES, V6, P39, DOI 10.1007/s007920100221; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; WAKAO H, 1987, J BIOCHEM, V102, P255, DOI 10.1093/oxfordjournals.jbchem.a122049; Westre TE, 1997, J AM CHEM SOC, V119, P6297, DOI 10.1021/ja964352a; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173	39	19	19	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39642	39648		10.1074/jbc.M207312200	http://dx.doi.org/10.1074/jbc.M207312200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167658	hybrid			2022-12-27	WOS:000178662500076
J	Shamri, R; Grabovsky, V; Feigelson, SW; Dwir, O; van Kooyk, Y; Alon, R				Shamri, R; Grabovsky, V; Feigelson, SW; Dwir, O; van Kooyk, Y; Alon, R			Chemokine stimulation of lymphocyte alpha(4) integrin avidity but not of leukocyte function-associated antigen-1 avidity to endothelial ligands under shear flow requires cholesterol membrane rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE-1; LIPID RAFTS; VASCULAR ENDOTHELIUM; T-LYMPHOCYTES; RECEPTOR; ARREST; ACTIVATION; AFFINITY; BINDING; KINASE	VLA-4 and LFA-1 are the major vascular integrins expressed on circulating lymphocytes. Previous studies suggested that intact cholesterol rafts are required for integrin adhesiveness in different leukocytes. We found the alpha(4) integrins VLA-4 and alpha(4)beta(7), as well as the LFA-1 integrin to be excluded from rafts of human peripheral blood lymphocytes. Disruption of cholesterol rafts with the chelator methyl-beta-cyclodextrin did not affect the ability of these lymphocyte integrins to generate high avidity to their respective endothelial ligands and to promote lymphocyte rolling and arrest on inflamed endothelium. under shear flow. In contrast, cholesterol extraction abrogated rapid chemokine triggering of alpha(4)-integrin-dependent peripheral blood lymphocytes adhesion, a process tightly regulated by G(i)-protein activation of G protein-coupled chemokine receptors (GPCR). Strikingly, stimulation of LFA-1 avidity to intercellular adhesion molecule 1 (ICAM-1) by the same chemokines, although G(i)-dependent, was insensitive to raft disruption. Our results suggest that alpha(4) but not LFA-1 integrin avidity stimulation by chemokines involves rapid chemokine-induced GPCR rearrangement that takes place at cholesterol raft platforms upstream to G(i) signaling. Our results provide the first evidence that a particular chemokine/GPCR pair can activate different integrins on the same cell using distinct G(i) protein-associated machineries segregated within defined membrane compartments.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; VU Med Ctr, Dept Mol Cell Biol, NL-1081 BT Amsterdam, Netherlands	Weizmann Institute of Science; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Alon, R (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.		ALON, RONEN/GRX-6987-2022	Alon, Ronen/0000-0001-9161-6369				Alon R, 2002, SEMIN IMMUNOL, V14, P93, DOI 10.1006/smim.2001.0346; Alonso MA, 2001, J CELL SCI, V114, P3957; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Carr MW, 1996, IMMUNITY, V4, P179, DOI 10.1016/S1074-7613(00)80682-2; Chan JR, 2001, J EXP MED, V193, P1149, DOI 10.1084/jem.193.10.1149; Cinamon G, 2001, J LEUKOCYTE BIOL, V69, P860; Cinamon G, 2001, NAT IMMUNOL, V2, P515, DOI 10.1038/88710; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; Dwir O, 2001, J CELL BIOL, V155, P145, DOI 10.1083/jcb.200103042; Feigelson S, 2001, J BIOL CHEM, V276, P13891, DOI 10.1074/jbc.M004939200; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Gupta SK, 2001, IMMUNOL LETT, V78, P29, DOI 10.1016/S0165-2478(01)00228-0; HARDARDOTTIR F, 1995, P NATL ACAD SCI USA, V92, P354, DOI 10.1073/pnas.92.2.354; Harder T, 1999, EUR J IMMUNOL, V29, P556, DOI 10.1002/(SICI)1521-4141(199902)29:02<556::AID-IMMU556>3.0.CO;2-2; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; KANSAS GS, 1994, J CELL BIOL, V124, P609, DOI 10.1083/jcb.124.4.609; Kozak SL, 2002, J VIROL, V76, P1802, DOI 10.1128/JVI.76.4.1802-1815.2002; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Leitinger B, 2002, J CELL SCI, V115, P963; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; LOBB R, 1991, BIOCHEM BIOPH RES CO, V178, P1498, DOI 10.1016/0006-291X(91)91063-I; Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025; Manes S, 1999, MOL CELL BIOL, V19, P3125; Manes S, 2001, SEMIN IMMUNOL, V13, P147, DOI 10.1006/smim.2000.0306; Mitchell JS, 2002, J IMMUNOL, V168, P2737, DOI 10.4049/jimmunol.168.6.2737; Moffett S, 2000, J BIOL CHEM, V275, P2191, DOI 10.1074/jbc.275.3.2191; Peled A, 1999, J CLIN INVEST, V104, P1199, DOI 10.1172/JCI7615; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Sigal A, 2000, J IMMUNOL, V165, P442, DOI 10.4049/jimmunol.165.1.442; Sorice M, 2001, FEBS LETT, V506, P55, DOI 10.1016/S0014-5793(01)02830-7; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; Woods ML, 2001, EMBO J, V20, P1232, DOI 10.1093/emboj/20.6.1232; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Yang CS, 2000, J CELL BIOL, V150, P1001, DOI 10.1083/jcb.150.5.1001	42	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40027	40035		10.1074/jbc.M206806200	http://dx.doi.org/10.1074/jbc.M206806200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163503	hybrid			2022-12-27	WOS:000178662500123
J	Tulik, GR; Chodavarapu, S; Edgar, R; Giannunzio, L; Langland, A; Schultz, B; Beckman, JD				Tulik, GR; Chodavarapu, S; Edgar, R; Giannunzio, L; Langland, A; Schultz, B; Beckman, JD			Inhibition of bovine phenol sulfotransferase (bSULT1A1) by CoA thioesters - Evidence for positive cooperativity and inhibition by interaction with both the nucleotide and phenol binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DOPAMINE SULFOTRANSFERASE; ARYL SULFOTRANSFERASE; COENZYME-A; KINETIC CHARACTERIZATION; POTENT INHIBITORS; MOLECULAR-BIOLOGY; CRYSTAL-STRUCTURE; SULFATING FORM; HUMAN-BRAIN; MECHANISM	Previous work with the bovine phenol sulfotransferase (bSULT1A1, EC 2.8.2.1) demonstrated inhibition by CoA that was competitive with respect to the sulfuryl donor substrate, 3'-phosphoadenosine-5'-phosphosulfate (PAPS) (Leach, M., Cameron, E., Fite, N., Stassinopoulos, J., Palmreuter, N., and Beckmann, J. D. (1999) Biochem. Biophys. Res. Commun. 261, 815-819). Here we report that long chain acyl-CoAs are more potent inhibitors of bSULT1A1 and also of human dopamine sulfotransferase (SULT1A3) when compared with unesterified CoA and short chain-length acyl-CoAs. A complex pattern of inhibition was revealed by systematic variation of palmitoyl-CoA, PAPS, and 7-hydroxy-coumarin, the acceptor substrate. Convex plots of apparent K-m/V-max versus [palmitoyl-CoA] were adequately modeled using an ordered rapid equilibrium scheme with PAPS as the leading substrate and by accounting for the possible binding of two equivalents of inhibitor to the dimeric enzyme. Interestingly, the first K-i of 2-3 muM was followed by a second K-i of only 0.01-0.05 muM, suggesting that positive subunit cooperativity enhances binding of long chain acyl-CoAs to this sulfotransferase. Simultaneous interaction of palmitoyl-CoA with both the nucleotide and phenol binding sites is suggested by two experiments. First, the acyl-CoA displaced 7-hydroxy-coumarin from the highly fluorescent bSULT1A1-PAP-7-HC complex in a cooperative manner. Second, palmitoyl-CoA prevented the quenching of bSULT1A1 fluorescence observed with pentachlorophenol. Finally, titrations of bSLTLT1A1-pentachlorophenol complex with palmitoyl-CoA caused the return of protein fluorescence, and the binding of palmitoyl-CoA was highly cooperative (Hill constant of 1.9). Overall, these results suggest a model of sulfotransferase inhibition in which the 3'-phosphoadenosine-5'-diphosphate moiety of CoA docks to the PAPS domain, and the acyl-pantetheine group docks to the hydrophobic phenol binding domain.	Alma Coll, Dept Biochem, Alma, MI 48801 USA		Beckman, JD (corresponding author), Alma Coll, Dept Biochem, 614 W Superior St, Alma, MI 48801 USA.		chodavarapu, sundari/Q-3279-2019; Beckman, Joan/V-2579-2019; chodavarapu, sundari/Q-3272-2019	Beckman, Joan/0000-0001-7903-944X; 				ARAND M, 1987, ANAL BIOCHEM, V163, P546, DOI 10.1016/0003-2697(87)90261-2; BAMFORTH KJ, 1993, BIOCHEM PHARMACOL, V46, P1713, DOI 10.1016/0006-2952(93)90575-H; BANERJEE RK, 1968, BIOCHIM BIOPHYS ACTA, V151, P573, DOI 10.1016/0005-2744(68)90004-1; BARTZATT R, 1994, BIOCHEM PHARMACOL, V47, P2087, DOI 10.1016/0006-2952(94)90085-X; BECKMANN JD, 1993, CELL TISSUE RES, V274, P475, DOI 10.1007/BF00314544; Beckmann JD, 1998, CHEM-BIOL INTERACT, V109, P93, DOI 10.1016/S0009-2797(97)00123-3; BRASS EP, 1994, CHEM-BIOL INTERACT, V90, P203, DOI 10.1016/0009-2797(94)90010-8; CAMPBELL NRC, 1987, MOL PHARMACOL, V32, P813; Dajani R, 1999, J BIOL CHEM, V274, P37862, DOI 10.1074/jbc.274.53.37862; Dajani R, 1999, PROTEIN EXPRES PURIF, V16, P11, DOI 10.1006/prep.1999.1030; DUFFEL MW, 1981, J BIOL CHEM, V256, P1123; DUFFEL MW, 1993, DRUG METAB DISPOS, V21, P400; Eaton EA, 1996, DRUG METAB DISPOS, V24, P232; Falany C N, 1994, Adv Pharmacol, V27, P301, DOI 10.1016/S1054-3589(08)61037-6; Kakuta Y, 1998, J BIOL CHEM, V273, P27325, DOI 10.1074/jbc.273.42.27325; KIEHLBAUCH CC, 1995, J BIOL CHEM, V270, P18941, DOI 10.1074/jbc.270.32.18941; Leach M, 1999, BIOCHEM BIOPH RES CO, V261, P815, DOI 10.1006/bbrc.1999.1096; MATSUI M, 1994, INT J BIOCHEM, V26, P1237; Negishi M, 2001, ARCH BIOCHEM BIOPHYS, V390, P149, DOI 10.1006/abbi.2001.2368; Pedersen LC, 2002, J BIOL CHEM, V277, P17928, DOI 10.1074/jbc.M111651200; PENNINGS EJM, 1978, BIOCHEM J, V173, P299, DOI 10.1042/bj1730299; POWELL GL, 1981, J BIOL CHEM, V256, P2740; RAO SI, 1991, DRUG METAB DISPOS, V19, P543; RENSDOMIANO SS, 1987, J NEUROCHEM, V48, P1411, DOI 10.1111/j.1471-4159.1987.tb05679.x; ROBERTS BJ, 1995, BIOCHEM PHARMACOL, V49, P1335, DOI 10.1016/0006-2952(94)00516-O; Roy A.B., 1981, SULFATION DRUGS RELA, P83; SCHAUSS SJ, 1995, BIOCHEM J, V311, P209, DOI 10.1042/bj3110209; Schuur AG, 1998, TOXICOL SCI, V45, P188, DOI 10.1093/toxsci/45.2.188; Segel IH, 1975, ENZYME KINETICS BEHA; SEKURA RD, 1979, J BIOL CHEM, V254, P5658; SMITH RH, 1986, ARCH BIOCHEM BIOPHYS, V244, P357, DOI 10.1016/0003-9861(86)90124-4; Varela A, 1997, ARCH PHYSIOL BIOCHEM, V105, P572, DOI 10.1076/apab.105.6.572.3276; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; WHITTEMORE RM, 1986, ARCH BIOCHEM BIOPHYS, V249, P464, DOI 10.1016/0003-9861(86)90023-8; WHITTEMORE RM, 1985, BIOCHEMISTRY-US, V24, P2477, DOI 10.1021/bi00331a013; WILKINSON G, 1961, BIOCHEM J, V80, P324, DOI 10.1042/bj0800324; Yang YS, 1996, PROTEIN EXPRES PURIF, V8, P423, DOI 10.1006/prep.1996.0120; [No title captured]	38	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39296	39303		10.1074/jbc.M206017200	http://dx.doi.org/10.1074/jbc.M206017200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167648	hybrid			2022-12-27	WOS:000178662500032
J	Yellaturu, CR; Bhanoori, M; Neeli, I; Rao, GN				Yellaturu, CR; Bhanoori, M; Neeli, I; Rao, GN			N-ethylmaleimide inhibits platelet-derived growth factor BB-stimulated Akt phosphorylation via activation of protein phosphatase 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; HYDROGEN-PEROXIDE; REDOX REGULATION; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION FACTOR; CELL-SURVIVAL; CYTOCHROME-C; 4E-BINDING PROTEIN-1; IN-VIVO; APOPTOSIS	The redox state plays an important role in gene regulation. Thiols maintain the intracellular redox homeostasis. To understand the role of thiols in redox signaling, we have studied the effect of thiol alkylation on platelet-derived growth factor-BB (PDGF-BB)-induced cell survival events in vascular smooth muscle cells. PDGF-BB stimulated Akt phosphorylation predominantly at Ser-473. N-Ethylmaleimide (NEM), a thiol alkylating agent, blocked PDGF-BB-induced Akt phosphorylation without affecting its upstream phosphatidylinositol 3-kinase (PI3K). On the other hand, LY294002 and wortmannin, specific inhibitors of PI3K, prevented PDGF-BB-induced phosphorylation of Akt and its downstream effector molecules, p70S6K, ribosomal protein S6, 4E-BP1, and eIF4E. NEM also abrogated the phosphorylation of p70S6K, ribosomal protein S6, 4E-BP1, and eIF4E induced by PDGF-BB, suggesting that thiol alkylation interferes with the PI3K/Akt pathway at the level of Akt. In addition, NEM blocked PDGF-BB-induced phosphorylation of BAD and forkhead transcription factor FKHR-L1, and these events correlated with increased apoptosis. NEM alone and in concert with PDGF-BB increased reactive oxygen species (ROS) production and protein phosphatase 2A (PP2A) activity in VSMC. The inhibition of PDGF-BB-induced Akt phosphorylation by NEM was completely reversed by PP2A inhibitors fostriecin and okadaic acid, ceramide synthase inhibitor fumonisin B1, and ROS scavenger N-acetylcysteine (NAC). NAC also attenuated the apoptosis induced by NEM, alone or in combination with PDGF-BB. Together, these findings demonstrate for the first time that PP2A mediates thiol alkylation-dependent redox regulation of Akt and cell survival.	Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Tennessee, Ctr Hlth Sci, Ctr Vasc Biol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Rao, GN (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Physiol, 894 Union Ave, Memphis, TN 38163 USA.	grao@physio1.utmem.edu	Bhanoori, Manjula/ACH-9333-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064165] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL64165] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Chandel NS, 2000, ONCOGENE, V19, P3840, DOI 10.1038/sj.onc.1203727; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; Clottes E, 1998, J BIOL CHEM, V273, P19391, DOI 10.1074/jbc.273.31.19391; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; Dahl J, 1996, MOL CELL BIOL, V16, P2728; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; delPeso L, 1997, SCIENCE, V278, P687; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Dufner A, 1999, MOL CELL BIOL, V19, P4525; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ERIKSSON JE, 1992, P NATL ACAD SCI USA, V89, P11093, DOI 10.1073/pnas.89.22.11093; Evans DRH, 2001, FEBS LETT, V498, P110, DOI 10.1016/S0014-5793(01)02448-6; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Herbert TP, 2000, CURR BIOL, V10, P793, DOI 10.1016/S0960-9822(00)00567-4; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; HOSHI T, 2001, J PHYSL, V15, P1; Ivaska J, 2002, MOL CELL BIOL, V22, P1352, DOI 10.1128/MCB.22.5.1352-1359.2002; Kageyama K, 2002, J BIOL CHEM, V277, P19255, DOI 10.1074/jbc.M112377200; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Khaleghpour K, 1999, MOL CELL BIOL, V19, P4302; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; KRIEGERBRAUER HI, 1992, J CLIN INVEST, V89, P1006, DOI 10.1172/JCI115641; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuge S, 2001, MOL CELL BIOL, V21, P6139, DOI 10.1128/MCB.21.18.6139-6150.2001; Lee SR, 1998, J BIOL CHEM, V273, P15366, DOI 10.1074/jbc.273.25.15366; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; Rao GN, 1996, ONCOGENE, V13, P713; Rao GN, 1999, J BIOL CHEM, V274, P12925, DOI 10.1074/jbc.274.18.12925; Rao GN, 1999, J BIOL CHEM, V274, P6003, DOI 10.1074/jbc.274.9.6003; Reusch JEB, 2002, J BIOL CHEM, V277, P1426, DOI 10.1074/jbc.M107923200; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Schmidt KN, 1996, ADV EXP MED BIOL, V387, P63; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Shtrichman R, 1999, P NATL ACAD SCI USA, V96, P10080, DOI 10.1073/pnas.96.18.10080; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Ueki K, 2002, MOL CELL BIOL, V22, P965, DOI 10.1128/MCB.22.3.965-977.2002; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; WADZINSKI BE, 1993, MOL CELL BIOL, V13, P2822, DOI 10.1128/MCB.13.5.2822; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	62	110	115	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40148	40155		10.1074/jbc.M206376200	http://dx.doi.org/10.1074/jbc.M206376200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171932	hybrid			2022-12-27	WOS:000178662500138
J	Brewer, L; Corzett, M; Balhorn, R				Brewer, L; Corzett, M; Balhorn, R			Condensation of DNA by spermatid basic nuclear proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION PROTEIN-2; NUCLEOTIDE-SEQUENCE; SECONDARY STRUCTURE; ZINC-DEFICIENCY; MOUSE SPERM; PROTAMINE; TP2; STABILITY; BINDING; GENE	Two transition proteins, TP1 and TP2, participate in the repackaging of the spermatid genome early in mammalian spermiogenesis, coincident with the first detectable changes in chromatin condensation. Using an optical trap and a two-channel flow cell to move single DNA molecules into buffer containing protein, we have measured the rates of DNA condensation and decondensation induced by the binding of Syrian hamster transition proteins TP1 and TP2 and protamines P1 and P2. The results show that both transition proteins condense free DNA, with rates similar to those of protamine 1 and 2. DNA molecules condensed with TP1 were significantly less stable than DNA condensed by protamine or by TP2. Experiments conducted with a peptide corresponding to the C-terminal 25 residues of TP2 showed that this domain is responsible for condensing DNA. Experiments conducted with two fragments of TP1 containing arginine and lysine residues demonstrated that DNA binding by TP1 must involve more than these basic sequences. Zinc facilitated the condensation of DNA by P2 but not by TP2. The dissociation rates of TP2 and P2 from DNA were not affected by the addition of zinc.	Lawrence Livermore Natl Lab, Elect Engn Technol Div, Livermore, CA 94550 USA; Lawrence Livermore Natl Lab, Biol & Biotechnol Res Program, Livermore, CA 94550 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Brewer, L (corresponding author), Lawrence Livermore Natl Lab, Elect Engn Technol Div, Livermore, CA 94550 USA.	brewer1@llnl.gov	Brewer, Laurence/G-4056-2012		NICHD NIH HHS [1 K25 HD01387-02] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K25HD001387] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABBASI AA, 1980, J LAB CLIN MED, V96, P544; ALFONSO PJ, 1993, BIOL REPROD, V48, P522, DOI 10.1095/biolreprod48.3.522; Allen MJ, 1997, NUCLEIC ACIDS RES, V25, P2221, DOI 10.1093/nar/25.11.2221; BALHORN R, 1977, BIOCHEMISTRY-US, V16, P4074, DOI 10.1021/bi00637a021; BALHORN R, 1984, EXP CELL RES, V150, P298, DOI 10.1016/0014-4827(84)90572-X; Balhorn R, 1999, MALE GAMETE: FROM BASIC SCIENCE TO CLINICAL APPLICATIONS, P55; Balhorn R, 2000, MOL REPROD DEV, V56, P230, DOI 10.1002/(SICI)1098-2795(200006)56:2+<230::AID-MRD3>3.3.CO;2-M; BASKARAN R, 1990, J BIOL CHEM, V265, P21039; Bench G, 2000, MOL REPROD DEV, V56, P512, DOI 10.1002/1098-2795(200008)56:4&lt;512::AID-MRD9&gt;3.0.CO;2-M; Bench GS, 1996, CYTOMETRY, V23, P263, DOI 10.1002/(SICI)1097-0320(19960401)23:4<263::AID-CYTO1>3.3.CO;2-9; BIANCHI F, 1994, BIOCHEM BIOPH RES CO, V201, P1197, DOI 10.1006/bbrc.1994.1832; Bloomfield VA, 1997, BIOPOLYMERS, V44, P269, DOI 10.1002/(SICI)1097-0282(1997)44:3<269::AID-BIP6>3.0.CO;2-T; Brewer LR, 1999, SCIENCE, V286, P120, DOI 10.1126/science.286.5437.120; Caceres C, 1999, J BIOL CHEM, V274, P649, DOI 10.1074/jbc.274.2.649; Caron N, 2001, MOL REPROD DEV, V58, P437, DOI 10.1002/1098-2795(20010401)58:4&lt;437::AID-MRD12&gt;3.0.CO;2-Q; COLE KD, 1987, BIOCHEM BIOPH RES CO, V147, P437, DOI 10.1016/S0006-291X(87)80140-7; Corzett M, 1999, MOL REPROD DEV, V54, P273, DOI 10.1002/(SICI)1098-2795(199911)54:3&lt;273::AID-MRD8&gt;3.0.CO;2-X; DINCER SL, 1990, HOSP PRACT, V25, P20; GATEWOOD JM, 1990, J BIOL CHEM, V265, P20667; HEIDARAN MA, 1989, GENE, V75, P39, DOI 10.1016/0378-1119(89)90381-8; HUD NV, 1993, BIOCHEM BIOPH RES CO, V193, P1347, DOI 10.1006/bbrc.1993.1773; HUD NV, 1995, P NATL ACAD SCI USA, V92, P3581, DOI 10.1073/pnas.92.8.3581; HUD NV, 1994, BIOCHEMISTRY-US, V33, P7528, DOI 10.1021/bi00190a005; KIERSZENBAUM AL, 1975, J CELL BIOL, V65, P258, DOI 10.1083/jcb.65.2.258; Kierszenbaum AL, 2001, MOL REPROD DEV, V58, P357, DOI 10.1002/1098-2795(20010401)58:4<357::AID-MRD1>3.0.CO;2-T; Kistler WS, 1996, EXP CELL RES, V225, P374, DOI 10.1006/excr.1996.0188; KISTLER WS, 1975, J BIOL CHEM, V250, P1847; KLEENE KC, 1990, GENE, V95, P301, DOI 10.1016/0378-1119(90)90376-3; KLEENE KC, 1988, BIOCHIM BIOPHYS ACTA, V950, P215, DOI 10.1016/0167-4781(88)90013-9; KUNDU TK, 1995, BIOCHEMISTRY-US, V34, P5143, DOI 10.1021/bi00015a027; Kundu TK, 1996, BIOCHEMISTRY-US, V35, P15626, DOI 10.1021/bi961271i; Levesque D, 1998, BIOCHEM BIOPH RES CO, V252, P602, DOI 10.1006/bbrc.1998.9687; MANNING GS, 1980, BIOPOLYMERS, V19, P37, DOI 10.1002/bip.1980.360190104; Matulis D, 2000, J MOL BIOL, V296, P1053, DOI 10.1006/jmbi.1999.3470; Meetei AR, 2000, J BIOL CHEM, V275, P38500, DOI 10.1074/jbc.M002734200; Meetei AR, 2002, BIOCHEMISTRY-US, V41, P185, DOI 10.1021/bi0117652; Meistrich M., 1989, HISTONES OTHER BASIC, P165; Oko RJ, 1996, BIOL REPROD, V54, P1141, DOI 10.1095/biolreprod54.5.1141; PERREAULT SD, 1988, BIOL REPROD, V39, P157, DOI 10.1095/biolreprod39.1.157; POGANY GC, 1981, EXP CELL RES, V136, P127, DOI 10.1016/0014-4827(81)90044-6; Sato H, 1999, PROTEIN EXPRES PURIF, V16, P454, DOI 10.1006/prep.1999.1095; SINGH J, 1987, J BIOL CHEM, V262, P734; Vijayanathan V, 2001, BIOCHEMISTRY-US, V40, P13644, DOI 10.1021/bi010993t; Ward WS, 1996, CRIT REV EUKAR GENE, V6, P139, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.30; YELICK PC, 1991, GENOMICS, V11, P687, DOI 10.1016/0888-7543(91)90076-Q	45	101	107	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38895	38900		10.1074/jbc.M204755200	http://dx.doi.org/10.1074/jbc.M204755200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12140285	hybrid			2022-12-27	WOS:000178529600112
J	Kim, J; Cantwell, CA; Johnson, PF; Pfarr, CM; Williams, SC				Kim, J; Cantwell, CA; Johnson, PF; Pfarr, CM; Williams, SC			Transcriptional activity of CCAAT/enhancer-binding proteins is controlled by a conserved inhibitory domain that is a target for sumoylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM FACILITATION; DNA-BINDING; C/EBP-BETA; COVALENT MODIFICATION; SUMO-1 MODIFICATION; ACTIVATION DOMAINS; NUCLEAR-BODIES; C-MYB; CCAAT; UBIQUITIN	CCAAT/enhancer-binding proteins (C/EBPs) are basic region/leucine zipper transcription factors that function as regulators of cell growth and differentiation in numerous cell types. We previously localized transcriptional activation and inhibitory regions in one family member, C/EBPepsilon. Here we describe the further characterization of a C/EBPepsilon inhibitory domain termed regulatory domain 1. We show that functionally related domains are present in C/EBPalpha, C/EBPbeta, and C/EBPdelta. These domains contain an evolutionarily conserved five-amino acid motif (the regulatory domain motif (RDM)) that conforms to the consensus sequence (I/V/ L)KXEP. Mutagenesis studies revealed that the residues at positions 1, 2, and 4 of the RDM are critical for inhibitory domain function. Data base searches identified RDM-like sequences in a number of nuclear proteins. We found that small regions from c-Jun, JunB, and JunD containing this sequence also function as transcriptional inhibitory domains. Importantly, the RDM is similar to the recognition sequence for attachment of the ubiquitin-like protein, small ubiquitin-like modifier-1 (SUMO-1), and the conserved lysine residue of each C/EBP RDM served as an attachment site for SUMO-1. SUMO-1 attachment decreased the inhibitory effect of the C/EBPepsilon regulatory domain, suggesting that sumoylation may play an important role in modulating C/EBPepsilon activity as well as that of the other C/EBP family members.	Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA; UMC Lubbock, SW Canc Ctr, Lubbock, TX 79430 USA; NCI Frederick, Regulat Cell Growth Lab, Frederick, MD 21702 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Williams, SC (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA.		Pfarr, Curt/HHD-1410-2022; Johnson, Peter/A-1940-2012	Johnson, Peter/0000-0002-4145-4725				ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Angerer ND, 1999, J BIOL CHEM, V274, P4147, DOI 10.1074/jbc.274.7.4147; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; BROWN HJ, 1995, EMBO J, V14, P124, DOI 10.1002/j.1460-2075.1995.tb06982.x; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chen SS, 2000, MOL CELL BIOL, V20, P7292, DOI 10.1128/MCB.20.19.7292-7299.2000; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FRIEDMAN AD, 1990, GENE DEV, V4, P1416, DOI 10.1101/gad.4.8.1416; Garriga-Canut M, 2001, J BIOL CHEM, V276, P14821, DOI 10.1074/jbc.M011619200; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Huse B, 1998, MOL ENDOCRINOL, V12, P1334, DOI 10.1210/me.12.9.1334; Iniguez-Lluhi JA, 2000, MOL CELL BIOL, V20, P6040, DOI 10.1128/MCB.20.16.6040-6050.2000; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; JOHNSON PF, 1993, MOL CELL BIOL, V13, P6919, DOI 10.1128/MCB.13.11.6919; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; KALKBRENNER F, 1990, ONCOGENE, V5, P657; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Lee JA, 2001, LEARN MEMORY, V8, P220, DOI 10.1101/lm.40201; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lekstrom-Himes JA, 1999, J EXP MED, V189, P1847, DOI 10.1084/jem.189.11.1847; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Nalbant D, 1998, ENDOCRINOLOGY, V139, P272, DOI 10.1210/en.139.1.272; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; PEI DQ, 1991, MOL CELL BIOL, V11, P1480, DOI 10.1128/MCB.11.3.1480; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rorth P, 2000, MOL CELL, V6, P23; RORTH P, 1992, GENE DEV, V6, P2299, DOI 10.1101/gad.6.12a.2299; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; VANWIJNEN AJ, 1993, BIOCHEMISTRY-US, V32, P8397, DOI 10.1021/bi00084a003; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Williamson EA, 1998, J BIOL CHEM, V273, P14796, DOI 10.1074/jbc.273.24.14796; Yamamoto N, 1999, J NEUROCHEM, V73, P2415, DOI 10.1046/j.1471-4159.1999.0732415.x; Yamanaka R, 1997, P NATL ACAD SCI USA, V94, P13187, DOI 10.1073/pnas.94.24.13187	50	131	135	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38037	38044		10.1074/jbc.M207235200	http://dx.doi.org/10.1074/jbc.M207235200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161447	hybrid			2022-12-27	WOS:000178529600010
J	Kim, PKM; Wang, YN; Gambotto, A; Kim, YM; Weller, R; Zuckerbraun, BS; Hua, Y; Watkins, SC; Billiar, TR				Kim, PKM; Wang, YN; Gambotto, A; Kim, YM; Weller, R; Zuckerbraun, BS; Hua, Y; Watkins, SC; Billiar, TR			Hepatocyte Fas-associating death domain protein/mediator of receptor-induced toxicity (FADD/MORT1) levels increase in response to pro-apoptotic stimuli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; KAPPA-B ACTIVATION; GLIOMAS IN-VITRO; CELL-DEATH; INHIBITS APOPTOSIS; MEDIATED APOPTOSIS; SIGNALING PATHWAY; RAT HEPATOCYTES; GENE-TRANSFER; FADD	We examined the regulation of Fas-associating death domain (FADD) protein as an important adaptor molecule in apoptosis signaling and hypothesized that the regulation of FADD could contribute to hepatocyte death. FADD/mediator of receptor-induced toxicity (MORT1) is required for activation of several signaling pathways of cell death. In this study we report the interesting and unexpected result that actinomycin D increased the expression of FADD protein, and we demonstrate that other cellular stresses like ultraviolet irradiation or heat shock could also increase FADD levels in hepatocytes. In cells treated with actinomycin D, FADD levels were elevated homogeneously in the cytoplasm. The increase in cytoplasmic FADD protein by actinomycin D or FADD overexpression alone both correlated with cell death, and specific antisense inhibition of FADD expression consistently diminished similar to30% of the cell death induced by actinomycin D. These data indicate that FADD protein expression can increase rapidly in hepatocytes exposed to broadly cytotoxic agents.	Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Ctr Biol Imaging, Pittsburgh, PA 15213 USA; Kangwon Natl Univ, Coll Med, Chungchon 200701, Kangwon Do, South Korea	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Kangwon National University	Kim, PKM (corresponding author), NW607 MUH,3459 5th Ave, Pittsburgh, PA 15213 USA.		Watkins, Simon/ABG-2590-2021; Weller, Richard/B-4954-2010	Watkins, Simon/0000-0003-4092-1552; Weller, Richard/0000-0003-2550-9586	NIGMS NIH HHS [R01-GM-44100, R01-GM-50441] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044100, R01GM050441] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Beere HM, 2001, TRENDS CELL BIOL, V11, P6, DOI 10.1016/S0962-8924(00)01874-2; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Fulda S, 2000, CANCER RES, V60, P3947; Galle PR, 1998, SEMIN LIVER DIS, V18, P141, DOI 10.1055/s-2007-1007150; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hofmann WK, 2001, BLOOD, V98, P787, DOI 10.1182/blood.V98.3.787; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Jolly C, 2000, JNCI-J NATL CANCER I, V92, P1564, DOI 10.1093/jnci/92.19.1564; Kawahara A, 1998, J CELL BIOL, V143, P1353, DOI 10.1083/jcb.143.5.1353; Khwaja A, 1999, J BIOL CHEM, V274, P36817, DOI 10.1074/jbc.274.51.36817; Kim YM, 2000, HEPATOLOGY, V32, P770, DOI 10.1053/jhep.2000.18291; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2001, J BIOL CHEM, V276, P46639, DOI 10.1074/jbc.M105102200; Komata T, 2001, INT J ONCOL, V19, P1015; Kondo S, 1998, HUM GENE THER, V9, P1599, DOI 10.1089/hum.1998.9.11-1599; Kondo T, 1997, NAT MED, V3, P409, DOI 10.1038/nm0497-409; LEIST M, 1994, J IMMUNOL, V153, P1778; Leist M, 1997, GASTROENTEROLOGY, V112, P923, DOI 10.1053/gast.1997.v112.pm9041255; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; Martin DA, 1998, J BIOL CHEM, V273, P4345, DOI 10.1074/jbc.273.8.4345; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; MCGUIRE RF, 1992, HEPATOLOGY, V15, P989, DOI 10.1002/hep.1840150603; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Morgan MJ, 2001, CELL DEATH DIFFER, V8, P696, DOI 10.1038/sj.cdd.4400866; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Perez D, 1998, J CELL BIOL, V141, P1255, DOI 10.1083/jcb.141.5.1255; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; Seino K, 2001, ANN SURG, V234, P681, DOI 10.1097/00000658-200111000-00015; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; STADLER J, 1993, ARCH BIOCHEM BIOPHYS, V302, P4, DOI 10.1006/abbi.1993.1173; Strasser A, 1999, INT J BIOCHEM CELL B, V31, P533, DOI 10.1016/S1357-2725(99)00003-5; Streetz K, 2000, GASTROENTEROLOGY, V119, P446, DOI 10.1053/gast.2000.9364; Suzuki A, 1999, P SOC EXP BIOL MED, V221, P72, DOI 10.1046/j.1525-1373.1999.d01-56.x; Takahashi Y, 2000, SURGERY, V128, P345, DOI 10.1067/msy.2000.107415; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Wajant H, 2000, J BIOL CHEM, V275, P24357, DOI 10.1074/jbc.M000811200; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhang G, 2001, Zhonghua Gan Zang Bing Za Zhi, V9, P10	52	26	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38855	38862		10.1074/jbc.M203484200	http://dx.doi.org/10.1074/jbc.M203484200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167637	hybrid			2022-12-27	WOS:000178529600107
J	Woodman, SE; Park, DS; Cohen, AW; Cheung, MWC; Chandra, M; Shirani, J; Tang, BY; Jelicks, LA; Kitsis, RN; Christ, GJ; Factor, SM; Tanowitz, HB; Lisanti, MP				Woodman, SE; Park, DS; Cohen, AW; Cheung, MWC; Chandra, M; Shirani, J; Tang, BY; Jelicks, LA; Kitsis, RN; Christ, GJ; Factor, SM; Tanowitz, HB; Lisanti, MP			Caveolin-3 knock-out mice develop a progressive cardiomyopathy and show hyperactivation of the p42/44 MAPK cascade	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GIRDLE MUSCULAR-DYSTROPHY; DELTA-SARCOGLYCAN GENE; RAT CARDIAC MYOCYTES; GLYCOPROTEIN COMPLEX; BETA-SARCOGLYCAN; ALPHA-SARCOGLYCAN; ADENYLYL-CYCLASE; SYRIAN-HAMSTER; SMOOTH-MUSCLE	A growing body of evidence suggests that muscle cell caveolae may function as specialized membrane microdomains in which the dystrophin-glycoprotein complex and cellular signaling molecules reside. Caveolin-3 (Cav-3) is the only caveolin family member expressed in striated muscle cell types (cardiac and skeletal). Interestingly, skeletal muscle fibers from Cav-3 (-/-) knockout mice show a number of myopathic changes, consistent with a mild-to-moderate muscular dystrophy phenotype. However, it remains unknown whether a loss of Cav-3 affects the phenotypic behavior cardiac myocytes in vivo. Here, we present a detailed characterization of the hearts of Cav-3 knock-out mice. We show that these mice develop a progressive cardiomyopathic phenotype. At four months of age, Cav-3 knock-out hearts display significant hypertrophy, dilation, and reduced fractional shortening, as revealed by gated cardiac MRI and transthoracic echocardiography. Histological analysis reveals marked cardiac myocyte hypertrophy, with accompanying cellular infiltrates and progressive interstitial/peri-vascular fibrosis. Interestingly, loss of Cav-3 expression in the heart does not change the expression or the membrane association of the dystrophin-glycoprotein (DG) complex. However, a marker of the DG complex, alpha-sarcoglycan, was specifically excluded from lipid raft domains in the absence of Cav-3. Because activation of the Ras-p42/44 MAPK pathway in cardiac myocytes can drive cardiac hypertrophy, we next assessed the activation state of this pathway using a phospho-specific antibody probe. We show that p42/44 MAPK (ERK1/2) is hyperactivated in hearts derived from Cav-3 knock-out mice. These results are consistent with previous in vitro data demonstrating that caveolins may function as negative regulators of the p42/44 MAPK cascade. Taken together, our data argue that loss of Cav-3 expression is sufficient to induce a molecular program leading to cardiac myocyte hypertrophy and cardiomyopathy.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Div Hormone Dependent Tumor Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Div Cardiol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Div Infect Dis, Bronx, NY 10461 USA; Montefiore Med Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Albert Einstein Coll Med, Inst Smooth Muscle Biol, Dept Urol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Inst Smooth Muscle Biol, Dept Physiol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Inst Smooth Muscle Biol, Dept Biophys, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael P/C-6866-2013; Jelicks, Linda/L-9740-2019; Lisanti, Michael/B-6131-2018	Jelicks, Linda/0000-0002-6438-1792; Lisanti, Michael/0000-0003-2034-1382	NCI NIH HHS [TG-CA09475] Funding Source: Medline; NIAID NIH HHS [AI-12770] Funding Source: Medline; NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI012770, R01AI012770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Betto R, 1999, J BIOL CHEM, V274, P7907, DOI 10.1074/jbc.274.12.7907; Biederer CH, 2000, J BIOL CHEM, V275, P26245, DOI 10.1074/jbc.M001430200; Bogoyevitch MA, 1996, BIOCHEM J, V314, P115, DOI 10.1042/bj3140115; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; Chan YM, 1998, J CELL BIOL, V143, P2033, DOI 10.1083/jcb.143.7.2033; Chandra M, 2002, INT J PARASITOL, V32, P207, DOI 10.1016/S0020-7519(01)00320-4; Coral-Vazquez R, 1999, CELL, V98, P465, DOI 10.1016/S0092-8674(00)81975-3; Crosbie RH, 1998, FEBS LETT, V427, P279, DOI 10.1016/S0014-5793(98)00442-6; Doyle DD, 1997, CIRC RES, V81, P86, DOI 10.1161/01.RES.81.1.86; Doyle DD, 2000, CIRC RES, V87, P480; Durbeej M, 2000, MOL CELL, V5, P141, DOI 10.1016/S1097-2765(00)80410-4; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; FACTOR SM, 1988, J AM COLL CARDIOL, V12, P1599, DOI 10.1016/S0735-1097(88)80031-7; FACTOR SM, 1982, CIRCULATION, V66, P342, DOI 10.1161/01.CIR.66.2.342; Feron O, 1997, J BIOL CHEM, V272, P17744, DOI 10.1074/jbc.272.28.17744; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Fujita T, 2001, CARDIOVASC RES, V51, P709, DOI 10.1016/S0008-6363(01)00348-0; Galbiati F, 2001, J BIOL CHEM, V276, P21425, DOI 10.1074/jbc.M100828200; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GEE SH, 1994, CELL, V77, P675, DOI 10.1016/0092-8674(94)90052-3; GILLESPIEBROWN J, 1995, J BIOL CHEM, V270, P28092; Glennon PE, 1996, CIRC RES, V78, P954, DOI 10.1161/01.RES.78.6.954; Hack AA, 1998, J CELL BIOL, V142, P1279, DOI 10.1083/jcb.142.5.1279; James M, 2000, J CELL SCI, V113, P1717; Jelicks LA, 1999, AM J TROP MED HYG, V61, P207, DOI 10.4269/ajtmh.1999.61.207; Lasley RD, 2000, J BIOL CHEM, V275, P4417, DOI 10.1074/jbc.275.6.4417; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu PS, 1997, P NATL ACAD SCI USA, V94, P13666, DOI 10.1073/pnas.94.25.13666; Minetti C, 2002, AM J PATHOL, V160, P265, DOI 10.1016/S0002-9440(10)64370-2; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Nigro V, 1996, NAT GENET, V14, P195, DOI 10.1038/ng1096-195; Ostrom RS, 2000, MOL PHARMACOL, V57, P1075; Park WY, 2000, J BIOL CHEM, V275, P20847, DOI 10.1074/jbc.M908162199; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; Piech A, 2002, AM J PHYSIOL-HEART C, V282, pH219, DOI 10.1152/ajpheart.2002.282.1.H219; Politano L, 2001, NEUROMUSCULAR DISORD, V11, P178, DOI 10.1016/S0960-8966(00)00174-7; Rando TA, 2001, MUSCLE NERVE, V24, P1575, DOI 10.1002/mus.1192; Razani B, 2001, J CLIN INVEST, V108, P1553, DOI 10.1172/JCI14611; Repetto S, 1999, BIOCHEM BIOPH RES CO, V261, P547, DOI 10.1006/bbrc.1999.1055; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Rybin VO, 1999, CIRC RES, V84, P980, DOI 10.1161/01.RES.84.9.980; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sakamoto A, 1997, P NATL ACAD SCI USA, V94, P13873, DOI 10.1073/pnas.94.25.13873; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHILLER NB, 1991, CIRCULATION, V84, pI280; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Sotgia F, 2000, J BIOL CHEM, V275, P38048, DOI 10.1074/jbc.M005321200; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Teixeira A, 1999, J NEUROCHEM, V72, P120, DOI 10.1046/j.1471-4159.1999.0720120.x; Tsubata S, 2000, J CLIN INVEST, V106, P655, DOI 10.1172/JCI9224; Vaghy PL, 1998, FEBS LETT, V431, P125, DOI 10.1016/S0014-5793(98)00738-8; van der Kooi AJ, 1998, HEART, V79, P73, DOI 10.1136/hrt.79.1.73; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; Yoshida T, 1998, J BIOL CHEM, V273, P1583, DOI 10.1074/jbc.273.3.1583; Yoshida T, 1996, BIOCHEM BIOPH RES CO, V225, P11, DOI 10.1006/bbrc.1996.1123	62	227	235	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38988	38997		10.1074/jbc.M205511200	http://dx.doi.org/10.1074/jbc.M205511200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138167	hybrid			2022-12-27	WOS:000178529600123
J	Bommer, M; Benecke, A; Gronemeyer, H; Rochette-Egly, C				Bommer, M; Benecke, A; Gronemeyer, H; Rochette-Egly, C			TIF2 mediates the synergy between RAR alpha 1 activation functions AF-1 and AF-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR-ALPHA; RETINOIC ACID RECEPTORS; LIGAND-BINDING DOMAIN; NUCLEAR RECEPTORS; WW DOMAINS; COACTIVATOR; PROTEINS; PHOSPHORYLATION; TRANSCRIPTION; TRANSACTIVATION	Nuclear receptors recruit coregulator complexes through both their AF-1 and AF-2 activation domains. Here we demonstrate that TIF2, a p160 coactivator, is able to bridge the two activation domains of the retinoic acid (RA) receptor isotype RARalpha1, resulting in synergistic activation of transcription. Bridging requires the presence of motifs in region A of RARalpha1 and in the activation domain AD1 of TIF2. Notably, only RARalpha1 exerted this interaction, which requires additional unknown factors. This is the first observation of a RAR isotype-selective coactivator interaction. Because another p160 coactivator, SRC-1, has no effect, this is also the first demonstration of a difference between the members of this coactivator family.	Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM, F-67404 Illkirch Graffenstaden, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Rochette-Egly, C (corresponding author), CU Strasbourg, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Graffenstaden, France.	cegly@igbmc.u-strasbg.fr	Benecke, Arndt G./T-1079-2019; Gronemeyer, Hinrich/AAH-5575-2019; Gronemeyer, Hinrich/G-6240-2011; Gronemeyer, Hinrich/H-7002-2016	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449				Almlof T, 1998, BIOCHEMISTRY-US, V37, P9586, DOI 10.1021/bi973029x; Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; Baur EV, 1996, EMBO J, V15, P110, DOI 10.1002/j.1460-2075.1996.tb00339.x; Bedford MT, 2000, J BIOL CHEM, V275, P10359, DOI 10.1074/jbc.275.14.10359; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Dilworth FJ, 2001, ONCOGENE, V20, P3047, DOI 10.1038/sj.onc.1204329; Endoh H, 1999, MOL CELL BIOL, V19, P5363; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Glass CK, 2000, GENE DEV, V14, P121; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Kumar R, 2001, J BIOL CHEM, V276, P18146, DOI 10.1074/jbc.M100825200; Laudet V., 2001, NUCL RECEPTOR FACTSB; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NAGPAL S, 1992, CELL, V70, P1007, DOI 10.1016/0092-8674(92)90250-G; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; vom Baur E, 1998, GENE DEV, V12, P1278, DOI 10.1101/gad.12.9.1278; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; Woychik NA, 2002, CELL, V108, P453, DOI 10.1016/S0092-8674(02)00646-3; Zarrinpar A, 2000, NAT STRUCT BIOL, V7, P611, DOI 10.1038/77891	34	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37961	37966		10.1074/jbc.M206001200	http://dx.doi.org/10.1074/jbc.M206001200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149266	hybrid			2022-12-27	WOS:000178447100134
J	Chiarugi, P; Cirri, P; Taddei, ML; Giannoni, E; Fiaschi, T; Buricchi, F; Camici, G; Raugei, G; Ramponi, G				Chiarugi, P; Cirri, P; Taddei, ML; Giannoni, E; Fiaschi, T; Buricchi, F; Camici, G; Raugei, G; Ramponi, G			Insight into the role of low molecular weight phosphotyrosine phosphatase (LAM-PTP) on platelet-derived growth factor receptor (PDGF-r) signaling - LMW-PTP controls PDGF-r kinase activity through TYR-857 dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; FACTOR-BETA-RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; FACTOR-I; ACTIVATION; PHOSPHORYLATION; STIMULATION; INHIBITION; CELLS	Low molecular weight phosphotyrosine phosphatase (LMW-PTP) is an enzyme involved in platelet-derived growth factor-induced mitogenesis and cytoskeleton rearrangement. Our previous results demonstrated that LMW-PTP is able to bind and dephosphorylate activated platelet-derived growth factor receptor (PDGF-r), thus inhibiting cell proliferation. Here we revisit the role of LMW-PTP on activated PDGF-r dephosphorylation. We demonstrate that LMW-PTP preferentially acts on cell surface PDGF-r, excluding the internalized activated receptor pool. Many phosphotyrosine phosphatases act by site-selective dephosphorylation on several sites of PDGF-r, but until now, there has been no evidence of a direct involvement of a specific phosphotyrosine phosphatase in the dephosphorylation of the 857 kinase domain activation tyrosine. Here we report that LMW-PTP affects the kinase activity of the receptor through the binding and dephosphorylation of Tyr-857 and influences many of the signal outputs from the receptor. In particular, we demonstrate a down-regulation of phosphatidylinositol 3-kinase, Src homology phosphatase-2, and phospholipase C-gamma1 binding but not of MAPK activation. In addition, we report a slight action of LMW-PTP on Tyr-716, which directs MAPK activation through Grb2 binding. On the basis of these results, we propose a key role for LMW-PTP in PDGF-r down-regulation through the dephosphorylation of the activation loop Tyr-857, thus determining a general negative regulation of all downstream signals, with the exception of those elicited by internalized receptors.	Univ Florence, Dept Biochem Sci, I-50134 Florence, Italy	University of Florence	Raugei, G (corresponding author), Univ Florence, Dept Biochem Sci, Viale Morgagni 50, I-50134 Florence, Italy.		Chiarugi, Paola/CDD-7988-2022; Giannoni, Elisa/AAE-2092-2020; Camici, Giovanni/H-1631-2018	Giannoni, Elisa/0000-0001-7136-1098; Chiarugi, Paola/0000-0001-7655-2969; Camici, Giovanni/0000-0002-0523-0695; raugei, giovanni/0000-0003-1294-786X				ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Bernard A, 1999, EXP CELL RES, V253, P704, DOI 10.1006/excr.1999.4715; BERTI A, 1994, FEBS LETT, V349, P7, DOI 10.1016/0014-5793(94)00620-2; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Chiarugi P, 1998, J BIOL CHEM, V273, P6776, DOI 10.1074/jbc.273.12.6776; Chiarugi P, 2000, J BIOL CHEM, V275, P4640, DOI 10.1074/jbc.275.7.4640; Chiarugi P, 2002, J CELL SCI, V115, P2219; CHIARUGI P, 1995, FEBS LETT, V372, P49, DOI 10.1016/0014-5793(95)00947-8; Chiarugi P, 2001, J BIOL CHEM, V276, P33478, DOI 10.1074/jbc.M102302200; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Cirri P, 1998, J BIOL CHEM, V273, P32522, DOI 10.1074/jbc.273.49.32522; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DeMali KA, 1997, J BIOL CHEM, V272, P9011; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; Faure R, 1999, Mol Cell Biol Res Commun, V1, P132, DOI 10.1006/mcbr.1999.0120; Fiaschi T, 2001, J BIOL CHEM, V276, P49156, DOI 10.1074/jbc.M107538200; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; JALLAL B, 1992, J BIOL CHEM, V267, P4357; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; Jones SM, 1999, CURR BIOL, V9, P512, DOI 10.1016/S0960-9822(99)80235-8; Jones SM, 2001, NAT CELL BIOL, V3, P165, DOI 10.1038/35055073; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Leof EB, 2000, TRENDS CELL BIOL, V10, P343, DOI 10.1016/S0962-8924(00)01795-5; MARRA F, 1995, FEBS LETT, V376, P141, DOI 10.1016/0014-5793(95)01261-0; Mooney RA, 1997, BIOCHEM BIOPH RES CO, V235, P709, DOI 10.1006/bbrc.1997.6889; Ostman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0; Qi JH, 1999, J BIOL CHEM, V274, P14455, DOI 10.1074/jbc.274.20.14455; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sorby M, 1996, J BIOL CHEM, V271, P10963; SORKIN A, 1993, J CELL PHYSIOL, V156, P373, DOI 10.1002/jcp.1041560221; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WAY BA, 1993, J BIOL CHEM, V268, P26409	42	39	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37331	37338		10.1074/jbc.M205203200	http://dx.doi.org/10.1074/jbc.M205203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149261	hybrid			2022-12-27	WOS:000178447100055
J	Fezoui, Y; Teplow, DB				Fezoui, Y; Teplow, DB			Kinetic studies of amyloid beta-protein fibril assembly - Differential effects of alpha-helix stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINEAR EXTRAPOLATION METHOD; CENTRAL HYDROPHOBIC CLUSTER; ALZHEIMERS-DISEASE; CIRCULAR-DICHROISM; ALTERNATIVE CONFORMATIONS; SECONDARY STRUCTURE; FIBRILLOGENESIS; PEPTIDES; INTERMEDIATE; PATHWAYS	Amyloid beta-protein (Abeta) fibril assembly is a defining characteristic of Alzheimer's disease. Fibril formation is a complex nucleation-dependent polymerization process characterized in vitro by an initial lag phase. To a significant degree, this phase is a consequence of the energy barrier that must be overcome in order for Abeta monomers to fold and oligomerize into fibril nuclei. Here we show that low concentrations of 2,2,2-trifluoroethanol (TFE) convert predominately unstructured Abeta monomers into partially ordered, quasistable conformers. Surprisingly, this results in a temporal decrease in the lag phase for fibril formation and a significant increase in the rate of fibril elongation. The TFE effect is concentration dependent and is maximal at similar to20% (v/v). In the presence of low concentrations of TFE, fibril formation is observed in Abeta samples at nanomolar concentration, well below the critical concentration for Abeta fibril formation in the absence of TFE. As the amount of TFE is increased above 20%, helix content progressively rises to similar to80%, a change paralleled first by a decrease in elongation rate and then by a complete cessation of fibril growth. These findings are consistent with the hypothesis that a partially folded helix-containing conformer is an intermediate in Abeta fibril assembly. The requirement that Abeta partially folds in order to assemble into fibrils contrasts with the mechanism of amyloidogenesis of natively folded proteins such as transthyretin and lysozyme, in which partial unfolding is a prerequisite. Our results suggest that in vivo, factors that affect helix formation and stability will have significant effects on the kinetics of Abeta fibril formation.	Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Teplow, DB (corresponding author), Brigham & Womens Hosp, Ctr Neurol Dis, 77 Ave Louis Pasteur,HIM-756, Boston, MA 02115 USA.				NIA NIH HHS [T32-AG00222, 1P01AG14366] Funding Source: Medline; NINDS NIH HHS [1R01NS38328] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000222, P01AG014366] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BALDWIN RL, 1995, J BIOMOL NMR, V5, P103; BARROW CJ, 1992, J MOL BIOL, V225, P1075, DOI 10.1016/0022-2836(92)90106-T; Bitan G, 2001, J BIOL CHEM, V276, P35176, DOI 10.1074/jbc.M102223200; BOLEN DW, 1988, BIOCHEMISTRY-US, V27, P8069, DOI 10.1021/bi00421a015; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; Chan HS, 1998, PROTEINS, V30, P2, DOI 10.1002/(SICI)1097-0134(19980101)30:1<2::AID-PROT2>3.0.CO;2-R; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 1999, NAT STRUCT BIOL, V6, P380; Coles M, 1998, BIOCHEMISTRY-US, V37, P11064, DOI 10.1021/bi972979f; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; Dobson CM, 1998, ANGEW CHEM INT EDIT, V37, P868, DOI 10.1002/(SICI)1521-3773(19980420)37:7<868::AID-ANIE868>3.0.CO;2-H; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Esler WP, 1996, BIOCHEMISTRY-US, V35, P13914, DOI 10.1021/bi961302+; Fezoui Y, 2000, NAT STRUCT BIOL, V7, P1095, DOI 10.1038/81937; GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037; GEDDES AJ, 1968, J MOL BIOL, V32, P343, DOI 10.1016/0022-2836(68)90014-4; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; GLENNER GG, 1981, PROG HISTOCHEM CYTOC, V13, P1; Gross M, 1999, PROTEIN SCI, V8, P1350, DOI 10.1110/ps.8.6.1350; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; Janek K, 2001, BIOCHEMISTRY-US, V40, P5457, DOI 10.1021/bi002005e; Kallberg Y, 2001, J BIOL CHEM, V276, P12945, DOI 10.1074/jbc.M010402200; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; KIRSCHNER DA, 1986, P NATL ACAD SCI USA, V83, P503, DOI 10.1073/pnas.83.2.503; KYTE J, 1995, STRUCTURE PROTEIN CH, P77; Lai ZH, 1996, BIOCHEMISTRY-US, V35, P6470, DOI 10.1021/bi952501g; Lomakin A, 1999, METHOD ENZYMOL, V309, P429; Luo PZ, 1997, BIOCHEMISTRY-US, V36, P8413, DOI 10.1021/bi9707133; Otzen DE, 2000, P NATL ACAD SCI USA, V97, P9907, DOI 10.1073/pnas.160086297; PERCZEL A, 1992, ANAL BIOCHEM, V203, P83, DOI 10.1016/0003-2697(92)90046-A; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Shao HY, 1999, J MOL BIOL, V285, P755, DOI 10.1006/jmbi.1998.2348; Sipe JD, 2000, J STRUCT BIOL, V130, P88, DOI 10.1006/jsbi.2000.4221; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; SOTO C, 1995, J BIOL CHEM, V270, P3063, DOI 10.1074/jbc.270.7.3063; STICHT H, 1995, EUR J BIOCHEM, V233, P293, DOI 10.1111/j.1432-1033.1995.293_1.x; Teplow DB, 1998, AMYLOID, V5, P121, DOI 10.3109/13506129808995290; THOMAS PD, 1993, PROTEIN SCI, V2, P2050, DOI 10.1002/pro.5560021206; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Zhang S, 2000, J STRUCT BIOL, V130, P130, DOI 10.1006/jsbi.2000.4288; Zhang SS, 1998, FOLD DES, V3, P413, DOI 10.1016/S1359-0278(98)00054-6	50	290	294	1	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36948	36954		10.1074/jbc.M204168200	http://dx.doi.org/10.1074/jbc.M204168200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149256	hybrid			2022-12-27	WOS:000178447100007
J	Fischhaber, PL; Gerlach, VL; Feaver, WJ; Hatahet, Z; Wallace, SS; Friedberg, EC				Fischhaber, PL; Gerlach, VL; Feaver, WJ; Hatahet, Z; Wallace, SS; Friedberg, EC			Human DNA polymerase kappa bypasses and extends beyond thymine glycols during translesion synthesis in vitro, preferentially incorporating correct nucleotides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DINB1 GENE; LESION-BYPASS; THYMIDINE GLYCOL; CRYSTAL-STRUCTURE; FREE-RADICALS; ERROR-PRONE; POL-KAPPA; Y-FAMILY; INVITRO; FIDELITY	Human polymerase kappa (polkappa), the product of the human POLK (DINB1) gene, is a member of the Y superfamily of DNA polymerases that support replicative bypass of chemically modified DNA bases (Ohmori, H., Friedberg, E. C., Fuchs, R. P., Goodman, M. F., Hanaoka, F., Hinkle, D., Kunkel, T. A., Lawrence, C. W., Livneh, Z., Nohmi, T., Prakash, L., Prakash, S., Todo, T., Walker, G. C., Wang, Z., and Woodgate, R. (2001) Mol. Cell 8, 7-8; Gerlach, V. L., Aravind, L., Gotway, G., Schultz, R. A., Koonin, E. V., and Friedberg, E. C. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 11922-11927). Polkappa is shown here to bypass 5,6-dihydro-5,6-dihydroxythymine (thymine glycol) generated in two different DNA substrate preparations. Polkappa inserts the correct base adenine opposite thymine glycol in preference to the other three bases. Additionally, the enzyme correctly extends beyond the site of the thymine glycol lesion when presented with adenine opposite thymine glycol at the primer terminus. However, steady state kinetic analysis of nucleotides incorporated opposite thymine glycol demonstrates different misincorporation rates for guanine with each of the two DNA substrates. The two substrates differ only in the relative proportions of thymine glycol stereoisomers, suggesting that polkappa distinguishes among stereoisomers and exhibits reduced discrimination between purines when incorporating a base opposite a 5R thymine glycol stereoisomer. When extending beyond the site of the lesion, the misincorporation rate of polkappa for each of the three incorrect nucleotides (adenine, guanine, and thymine) is dramatically increased. Our findings suggest a role for polkappa in both nonmutagenic and mutagenic bypass of oxidative damage.	Univ Texas, SW Med Ctr, Lab Mol Pathol, Dept Pathol, Dallas, TX 75390 USA; Univ Vermont, Markey Ctr Mol Genet, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Vermont	Friedberg, EC (corresponding author), Univ Texas, SW Med Ctr, Lab Mol Pathol, Dept Pathol, Dallas, TX 75390 USA.			Wallace, Susan S./0000-0002-3906-0321	NATIONAL CANCER INSTITUTE [F32CA075733, F32CA083314, R01CA044247, R01CA052040] Funding Source: NIH RePORTER; NCI NIH HHS [CA83314, CA4424717, CA52040, CA75733] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; AMES BN, 1989, FREE RADICAL RES COM, V7, P121, DOI 10.3109/10715768909087933; BACHUR NR, 1978, CANCER RES, V38, P1745; BASU AK, 1989, P NATL ACAD SCI USA, V86, P7677, DOI 10.1073/pnas.86.20.7677; Benkovic SJ, 1995, METHOD ENZYMOL, V262, P257; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; CLARK JM, 1986, NUCLEIC ACIDS RES, V14, P737, DOI 10.1093/nar/14.2.737; CLARK JM, 1989, BIOCHEMISTRY-US, V28, P775, DOI 10.1021/bi00428a054; CLARK JM, 1987, BIOCHEMISTRY-US, V26, P5398, DOI 10.1021/bi00391a027; Creighton S, 1995, METHOD ENZYMOL, V262, P232; DEMPSEY ME, 1974, ANNU REV BIOCHEM, V43, P967, DOI 10.1146/annurev.bi.43.070174.004535; Friedberg E. C., 1995, DNA REPAIR MUTAGENES, P1; Friedberg EC, 2002, SCIENCE, V296, P1627, DOI 10.1126/science.1070236; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Gerlach VL, 2001, J BIOL CHEM, V276, P92, DOI 10.1074/jbc.M004413200; Gewirtz DA, 1999, BIOCHEM PHARMACOL, V57, P727, DOI 10.1016/S0006-2952(98)00307-4; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; Goodman MF, 2000, CURR OPIN GENET DEV, V10, P162, DOI 10.1016/S0959-437X(00)00057-5; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Haracska L, 2002, MOL CELL BIOL, V22, P784, DOI 10.1128/MCB.22.3.784-791.2002; HAYES RC, 1986, NUCLEIC ACIDS RES, V14, P1045, DOI 10.1093/nar/14.2.1045; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; IDE H, 1987, BIOCHEMISTRY-US, V26, P964, DOI 10.1021/bi00377a042; IDE H, 1988, NUCLEIC ACIDS RES, V16, P11339, DOI 10.1093/nar/16.23.11339; IDE H, 1985, NUCLEIC ACIDS RES, V13, P8035, DOI 10.1093/nar/13.22.8035; Iwai S, 2000, ANGEW CHEM INT EDIT, V39, P3874, DOI 10.1002/1521-3773(20001103)39:21<3874::AID-ANIE3874>3.0.CO;2-O; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Kusumoto R, 2002, BIOCHEMISTRY-US, V41, P6090, DOI 10.1021/bi025549k; Levine RL, 2001, J BIOL CHEM, V276, P18717, DOI 10.1074/jbc.M102158200; Ling H, 2001, CELL, V107, P91, DOI 10.1016/S0092-8674(01)00515-3; LUSTIG MJ, 1992, NUCLEIC ACIDS RES, V20, P4839, DOI 10.1093/nar/20.18.4839; Magalhaes MM, 1997, MICROSC RES TECHNIQ, V36, P493, DOI 10.1002/(SICI)1097-0029(19970315)36:6<493::AID-JEMT6>3.0.CO;2-J; Miller WL, 1998, BAILLIERE CLIN ENDOC, V12, P67, DOI 10.1016/S0950-351X(98)80461-8; Ogi T, 2001, GENES CELLS, V6, P943, DOI 10.1046/j.1365-2443.2001.00478.x; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Purmal AA, 1998, J BIOL CHEM, V273, P10026, DOI 10.1074/jbc.273.16.10026; SCANDALIOS JG, 1997, COLD SPRING HARBOR M, V34, P1; Scharffetter-Kochanek K, 1997, BIOL CHEM, V378, P1247; SINHA BK, 1989, CHEM-BIOL INTERACT, V69, P293, DOI 10.1016/0009-2797(89)90117-8; TEOULE R, 1987, INT J RADIAT BIOL, V51, P573, DOI 10.1080/09553008414552111; Tippin B, 2001, PHILOS T R SOC B, V356, P47, DOI 10.1098/rstb.2000.0747; Trincao J, 2001, MOL CELL, V8, P417, DOI 10.1016/S1097-2765(01)00306-9; Washington MT, 2001, J BIOL CHEM, V276, P2263, DOI 10.1074/jbc.M009049200; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; ZHANG Y, 2002, IN PRESS DNA REPAIR; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4138, DOI 10.1093/nar/28.21.4138; Zhang YB, 2002, NUCLEIC ACIDS RES, V30, P1630, DOI 10.1093/nar/30.7.1630; Zhou BL, 2001, MOL CELL, V8, P427, DOI 10.1016/S1097-2765(01)00310-0	50	98	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37604	37611		10.1074/jbc.M206027200	http://dx.doi.org/10.1074/jbc.M206027200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145297	hybrid			2022-12-27	WOS:000178447100089
J	Goicoechea, S; Pallero, MA; Eggleton, P; Michalak, M; Murphy-Ullrich, JE				Goicoechea, S; Pallero, MA; Eggleton, P; Michalak, M; Murphy-Ullrich, JE			The anti-adhesive activity of thrombospondin is mediated by the N-terminal domain of cell surface calreticulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; RETICULUM LUMINAL ENVIRONMENT; GROWTH-FACTOR-BETA; ENDOTHELIAL-CELLS; GENE-EXPRESSION; TUMOR-GROWTH; IDENTIFICATION; ACTIVATION; RECEPTOR; CONFORMATION	Thrombospondin (TSP) induces reorganization of the actin cytoskeleton and restructuring of focal adhesions through binding of amino acids (aa) 17-35 (hep I peptide) of thrombospondin to a cell surface form of calreticulin (CRT). In this report we provide further evidence for the involvement of calreticulin in thrombospondin signaling and characterize thrombospondin-calreticulin interactions. Wild type but not crt(-/-) cells respond to hep I/TSP. Responsiveness can be restored by incubation of cells with exogenous calreticulin or by transfection with calreticulin. Thrombospondin forms complexes with the CRT-N-domain that are enhanced by physiologic levels of calcium and zinc. Consistent with thrombospondin/CRT-N-domain binding, only the CRT-N-domain blocks hep I- and thrombospondin-stimulated focal adhesion disassembly. A series of glutathione S-transferase-N-domain mutants were used to map the sequence within the N-domain that interacts with TSP/ hep I. A construct containing aa 1-43 but not a construct of aa 1-31 supported thrombospondin binding and focal adhesion disassembly. A series of overlapping peptides were used to further map the thrombospondin-binding site. Peptides spanning aa 19-36 (RWIESKHKSDFGKFVLSS) blocked hep I-stimulated focal adhesion disassembly, indicating that the TSP/hep I-binding site is located to this sequence in calreticulin. A mutant fusion protein lacking aa 19-36 (glutathione S-transferase-CRTDeltahep 1) failed to restore responsiveness to hep I in crt(-/-) cells, bind thrombospondin, or competitively block focal adhesion disassembly, providing evidence for the role of this calreticulin sequence in mediating thrombospondin signaling.	Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Cell Adhes & Matrix Res Ctr, Birmingham, AL 35294 USA; Univ Oxford, MRC, Immunochem Unit, Oxford & Peninsula Med Sch, Oxford 0X1 3QU, Devon, England; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Canadian Inst Hlth Res, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Oxford; University of Alberta; Institute for Work & Health; University of Alberta	Murphy-Ullrich, JE (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, VH 668B,1530 3rd Ave S, Birmingham, AL 35294 USA.	Murphy@path.uab.edu		Goicoechea, Silvia/0000-0003-1107-389X; Eggleton, Paul/0000-0001-8244-2125	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044575] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44575] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; Andrin C, 1998, BIOCHEMISTRY-US, V37, P10386, DOI 10.1021/bi980595z; ATREYA CD, 1995, J VIROL, V69, P3848, DOI 10.1128/JVI.69.6.3848-3851.1995; Baksh S, 1995, J BIOL CHEM, V270, P31338, DOI 10.1074/jbc.270.52.31338; BAKSH S, 1995, FEBS LETT, V376, P53, DOI 10.1016/0014-5793(95)01246-4; BAKSH S, 1991, J BIOL CHEM, V266, P21458; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; BLALOCK JE, 1995, NAT MED, V1, P876, DOI 10.1038/nm0995-876; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; Bouvier M, 2000, BIOCHEMISTRY-US, V39, P14950, DOI 10.1021/bi0019545; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; Coppolino MG, 2000, INT J BIOCHEM CELL B, V32, P171, DOI 10.1016/S1357-2725(99)00043-6; Coppolino MG, 1999, BIOCHEM J, V340, P41, DOI 10.1042/0264-6021:3400041; Coppolino MG, 1997, NATURE, V386, P843, DOI 10.1038/386843a0; Corbett EF, 2000, J BIOL CHEM, V275, P27177; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; Ellgaard L, 2001, P NATL ACAD SCI USA, V98, P3133, DOI 10.1073/pnas.051630098; Fadel MP, 1999, J BIOL CHEM, V274, P15085, DOI 10.1074/jbc.274.21.15085; Fadel MP, 2001, J BIOL CHEM, V276, P27083, DOI 10.1074/jbc.M101676200; Goicoechea S, 2000, J BIOL CHEM, V275, P36358, DOI 10.1074/jbc.M005951200; Greenwood JA, 1998, MICROSC RES TECHNIQ, V43, P420, DOI 10.1002/(SICI)1097-0029(19981201)43:5<420::AID-JEMT8>3.0.CO;2-B; HEILMANN C, 1993, BIOCHEM BIOPH RES CO, V193, P611, DOI 10.1006/bbrc.1993.1668; KHANNA NC, 1986, J BIOL CHEM, V261, P8883; Kishore U, 1997, BIOCHEM J, V322, P543, DOI 10.1042/bj3220543; Kovacs H, 1998, BIOCHEMISTRY-US, V37, P17865, DOI 10.1021/bi973197p; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; KUWABARA K, 1995, J BIOL CHEM, V270, P8179, DOI 10.1074/jbc.270.14.8179; Labriola C, 1999, MOL BIOL CELL, V10, P1381, DOI 10.1091/mbc.10.5.1381; LEUNGHAGESTEIJN CY, 1994, J CELL SCI, V107, P589; Li ZJ, 2001, BIOCHEMISTRY-US, V40, P11193, DOI 10.1021/bi010948l; McDonnell JM, 1996, J BIOL CHEM, V271, P7891, DOI 10.1074/jbc.271.14.7891; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Michalak M, 1996, J BIOL CHEM, V271, P29436, DOI 10.1074/jbc.271.46.29436; MICHALAK M, 1992, BIOCHEM J, V285, P681, DOI 10.1042/bj2850681; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; MURPHYULLRICH JE, 1989, J CELL BIOL, V109, P1309, DOI 10.1083/jcb.109.3.1309; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; MURPHYULLRICH JE, 1991, J CELL BIOL, V115, P1127, DOI 10.1083/jcb.115.4.1127; MURPHYULLRICH JE, 1993, J BIOL CHEM, V268, P26784; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Nakamura K, 2001, J CELL BIOL, V154, P961, DOI 10.1083/jcb.200102073; NAKHASI HL, 1994, ARCH VIROL, P255; NASH PD, 1994, MOL CELL BIOCHEM, V135, P71, DOI 10.1007/BF00925962; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Opas M, 1996, J CELL BIOL, V135, P1913, DOI 10.1083/jcb.135.6.1913; OSTWALD TJ, 1974, J BIOL CHEM, V249, P5867; Pike SE, 1999, BLOOD, V94, P2461, DOI 10.1182/blood.V94.7.2461.419a26_2461_2468; Pike SE, 1998, J EXP MED, V188, P2349, DOI 10.1084/jem.188.12.2349; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; ROJIANI MV, 1991, BIOCHEMISTRY-US, V30, P9859, DOI 10.1021/bi00105a008; SAGE EH, 1991, J BIOL CHEM, V266, P14831; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; SINGH NK, 1994, P NATL ACAD SCI USA, V91, P12770, DOI 10.1073/pnas.91.26.12770; Villain M, 2000, J BIOL CHEM, V275, P2676, DOI 10.1074/jbc.275.4.2676; WAISMAN DM, 1985, J BIOL CHEM, V260, P1652; Yao L, 2002, J LEUKOCYTE BIOL, V71, P47	62	87	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37219	37228		10.1074/jbc.M202200200	http://dx.doi.org/10.1074/jbc.M202200200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147682	hybrid			2022-12-27	WOS:000178447100042
J	Shiota, C; Larsson, O; Shelton, KD; Shiota, M; Efanov, AM; Hoy, M; Lindner, J; Kooptiwut, S; Juntti-Berggren, L; Gromada, J; Berggren, PO; Magnuson, MA				Shiota, C; Larsson, O; Shelton, KD; Shiota, M; Efanov, AM; Hoy, M; Lindner, J; Kooptiwut, S; Juntti-Berggren, L; Gromada, J; Berggren, PO; Magnuson, MA			Sulfonylurea receptor type 1 knock-out mice have intact feeding-stimulated insulin secretion despite marked impairment in their response to glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K-ATP CHANNEL; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; PANCREATIC BETA-CELL; PEPTIDE-1 GLP-1; EXOCYTOSIS; HORMONE; ISLETS; MOUSE; SUR1; RAT	The ATP-sensitive potassium channel is a key molecular complex for glucose-stimulated insulin secretion in pancreatic beta cells. In humans, mutations in either of the two subunits for this channel, the sulfonylurea type 1 receptor (Sur1) or Kir6.2, cause persistent hyperinsulinemic hypoglycemia of infancy. We have generated and characterized Sur1 null mice. Interestingly, these animals remain euglycemic for a large portion of their life despite constant depolarization of membrane, elevated cytoplasmic free Ca2+ concentrations, and intact sensitivity of the exocytotic machinery to Ca2+. A comparison of glucose- and meal-stimulated insulin secretion showed that, although Sur1 null mice do not secrete insulin in response to glucose,. they secrete nearly normal amounts of insulin in response to feeding. Because Sur1 null mice lack an insulin secretory response to GLP-1, even though their islets exhibit a normal rise in cAMP by GLP-1, we tested their response to cholinergic stimulation. We found that perfused Sur1 null pancreata secreted insulin in response to the cholinergic agonist carbachol in a glucose-dependent manner. Together, these findings suggest that cholinergic stimulation is one of the mechanisms that compensate for the severely impaired response to glucose and GLP-1 brought on by the absence of Sur1, thereby allowing euglycemia to be maintained.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Karolinska Hosp, Karolinska Inst, Rolf Luft Ctr Diabet Res, Dept Mol Med, S-17176 Stockholm, Sweden; Novo Nordisk AS, Lab Islet Cell Physiol, DK-2880 Bagsvaerd, Denmark	Vanderbilt University; Karolinska Institutet; Karolinska University Hospital; Novo Nordisk	Magnuson, MA (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 747 Light Hall, Nashville, TN 37232 USA.	mark.magnusson@vanderbilt.edu	Magnuson, Mark/AAY-7172-2021; Magnuson, Mark A/B-1335-2009; Efanov, Alexander/R-3630-2019; Lindner, Jill/K-5511-2012	Magnuson, Mark/0000-0002-8824-6499; Magnuson, Mark A/0000-0002-8824-6499; Efanov, Alexander/0000-0002-8630-1503; Lindner, Jill/0000-0002-8897-7494; Berggren, Per-Olof/0000-0001-8991-413X	NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042612, P60DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593, DK42612, DK42502] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1998, PHYSIOL REV, V78, P227, DOI 10.1152/physrev.1998.78.1.227; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ahren B, 1998, BIOESSAYS, V20, P642, DOI 10.1002/(SICI)1521-1878(199808)20:8<642::AID-BIES7>3.0.CO;2-K; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; Babenko AP, 1999, FEBS LETT, V459, P367, DOI 10.1016/S0014-5793(99)01215-6; Beguin P, 1999, EMBO J, V18, P4722, DOI 10.1093/emboj/18.17.4722; Branstrom R, 1998, J BIOL CHEM, V273, P14113, DOI 10.1074/jbc.273.23.14113; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Daniel S, 1999, DIABETES, V48, P1686, DOI 10.2337/diabetes.48.9.1686; DEAN PM, 1973, DIABETOLOGIA, V9, P115, DOI 10.1007/BF01230690; Deeney JT, 2000, J BIOL CHEM, V275, P9363, DOI 10.1074/jbc.275.13.9363; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; Eliasson L, 1997, J PHYSIOL-LONDON, V503, P399, DOI 10.1111/j.1469-7793.1997.399bh.x; Gilon P, 2001, ENDOCR REV, V22, P565, DOI 10.1210/er.22.5.565; Gromada J, 1998, PFLUG ARCH EUR J PHY, V435, P583, DOI 10.1007/s004240050558; Holst JJ, 1999, TRENDS ENDOCRIN MET, V10, P229, DOI 10.1016/S1043-2760(99)00157-5; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Koster JC, 2000, CELL, V100, P645, DOI 10.1016/S0092-8674(00)80701-1; Kunst A., 1984, METHOD ENZYMAT AN, VVI, P163; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LERNMARK A, 1974, DIABETOLOGIA, V10, P431, DOI 10.1007/BF01221634; MA YH, 1995, EUR J ENDOCRINOL, V132, P370, DOI 10.1530/eje.0.1320370; MacFarlane WM, 1999, J BIOL CHEM, V274, P34059, DOI 10.1074/jbc.274.48.34059; Martell A. E., 1974, CRITICAL STABILITY C, V2; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P3805, DOI 10.1074/jbc.C100712200; Otonkoski T, 1999, DIABETES, V48, P408, DOI 10.2337/diabetes.48.2.408; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; PERSAUD SJ, 1989, BIOCHEM J, V264, P753, DOI 10.1042/bj2640753; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Shepherd RM, 2000, ARCH DIS CHILD-FETAL, V82, pF87, DOI 10.1136/fn.82.2.F87; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Smith RM, 1974, CRITICAL STABILITY C, V1-6; Taschenberger G, 2002, J BIOL CHEM, V277, P17139, DOI 10.1074/jbc.M200363200; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Zawalich WS, 1996, AM J PHYSIOL-ENDOC M, V271, pE409, DOI 10.1152/ajpendo.1996.271.3.E409	43	166	167	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37176	37183		10.1074/jbc.M206757200	http://dx.doi.org/10.1074/jbc.M206757200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149271	hybrid			2022-12-27	WOS:000178447100036
J	Velasco, G; Cal, S; Quesada, V; Sanchez, LM; Lopez-Otin, C				Velasco, G; Cal, S; Quesada, V; Sanchez, LM; Lopez-Otin, C			Matriptase-2, a membrane-bound mosaic serine proteinase predominantly expressed in human liver and showing degrading activity against extracellular matrix proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER; HUMAN BREAST; MOLECULAR-CLONING; PROTEASE; GENE; HEPSIN; CDNA; IDENTIFICATION; ACTIVATOR; CELLS	We have identified and cloned a fetal liver cDNA encoding a new serine proteinase that has been called matriptase-2. This protein exhibits a domain organization similar to other members of an emerging family of membrane-bound serine proteinases known as type II transmembrane serine proteinases. Matriptase-2 contains a short cytoplasmic domain, a type II transmembrane sequence, a central region with several modular structural domains including two CUB (complement factor C1s/C1r, urchin embryonic growth factor, bone morphogenetic protein) domains and three low density lipoprotein receptor tandem repeats, and finally, a C-terminal catalytic domain with all typical features of serine proteinases. The human matriptase-2 gene maps to 22q12-q13, a location that differs from all type II transmembrane serine proteinase genes mapped to date. Immunofluorescence and Western blot analysis of COS-7 cells transfected with the isolated cDNA confirmed that matriptase-2 is anchored to the cell surface. Matriptase-2 was expressed in Escherichia coli, and the purified recombinant protein hydrolyzed synthetic substrates used for assaying serine proteinases and endogenous proteins such as type I collagen, fibronectin, and fibrinogen. Matriptase-2 could also activate single-chain urokinase plasminogen activator, albeit with low efficiency. These activities were abolished by inhibitors of serine proteinases but not by inhibitors of other classes of proteolytic enzymes. Northern blot analysis demonstrated that matriptase-2 transcripts are only detected at significant levels in both fetal and adult liver, suggesting that this novel serine proteinase may play a specialized role in matrix remodeling processes taking place in this tissue during development or in adult tissues.	Univ Oviedo, Dept Bioquim & Biol Mol, Fac Med, Inst Univ Oncol, E-33006 Oviedo, Spain	University of Oviedo; Instituto Universitario de Oncologia de Asturias	Lopez-Otin, C (corresponding author), Univ Oviedo, Dept Bioquim & Biol Mol, Fac Med, Inst Univ Oncol, E-33006 Oviedo, Spain.	CLO@correo.uniovi.es	Velasco, Gloria/AAS-5842-2021	Velasco, Gloria/0000-0001-8032-5056				Afar DEH, 2001, CANCER RES, V61, P1686; APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; Bicknell AB, 2001, CELL, V105, P903, DOI 10.1016/S0092-8674(01)00403-2; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; BODE W, 1992, PROTEIN SCI, V1, P426; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Castells A, 2000, CANCER RES, V60, P2836; Caterina JJ, 2000, MOL BIOL REP, V27, P73, DOI 10.1023/A:1007196529604; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Enyedy IJ, 2001, J MED CHEM, V44, P1349, DOI 10.1021/jm000395x; Fass D, 1997, NATURE, V388, P691, DOI 10.1038/41798; FREIJE JMP, 1994, J BIOL CHEM, V269, P16766; Friedrich R, 2002, J BIOL CHEM, V277, P2160, DOI 10.1074/jbc.M109830200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Ihara S, 2002, J BIOL CHEM, V277, P16960, DOI 10.1074/jbc.M200673200; Jacquinet E, 2001, EUR J BIOCHEM, V268, P2687, DOI 10.1046/j.1432-1327.2001.02165.x; KALSI G, 1995, AM J MED GENET, V60, P298, DOI 10.1002/ajmg.1320600407; KAZAMA Y, 1995, J BIOL CHEM, V270, P66, DOI 10.1074/jbc.270.1.66; Kim DR, 2001, BBA-GENE STRUCT EXPR, V1518, P204, DOI 10.1016/S0167-4781(01)00184-1; KITAMOTO Y, 1995, BIOCHEMISTRY-US, V34, P4562, DOI 10.1021/bi00014a008; Kiuru-Kuhlefelt S, 2001, CYTOGENET CELL GENET, V92, P192, DOI 10.1159/000056901; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lang JC, 2001, BRIT J CANCER, V84, P237, DOI 10.1054/bjoc.2000.1586; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lin BY, 1999, CANCER RES, V59, P4180; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; List K, 2002, ONCOGENE, V21, P3765, DOI 10.1038/sj.onc.1205502; Llano E, 1999, CANCER RES, V59, P2570; Lu DS, 1997, J BIOL CHEM, V272, P31293, DOI 10.1074/jbc.272.50.31293; Luo J, 2001, CANCER RES, V61, P4683; Magee JA, 2001, CANCER RES, V61, P5692; Mueller MS, 2000, GENE, V256, P101, DOI 10.1016/S0378-1119(00)00369-3; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Rousseau-Merck MF, 2000, CANCER GENET CYTOGEN, V121, P223, DOI 10.1016/S0165-4608(00)00262-4; Satomi S, 2001, BIOCHEM BIOPH RES CO, V287, P995, DOI 10.1006/bbrc.2001.5686; Scott HS, 2001, NAT GENET, V27, P59, DOI 10.1038/83768; SHI YE, 1993, CANCER RES, V53, P1409; Shibata K, 2000, GENOME RES, V10, P1757, DOI 10.1101/gr.152600; Southan C, 2001, FEBS LETT, V498, P214, DOI 10.1016/S0014-5793(01)02490-5; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; Tanimoto H, 1997, CANCER RES, V57, P2884; TORRESROSADO A, 1993, P NATL ACAD SCI USA, V90, P7181, DOI 10.1073/pnas.90.15.7181; TSUJI A, 1991, J BIOL CHEM, V266, P16948; Underwood LJ, 2000, BBA-MOL BASIS DIS, V1502, P337, DOI 10.1016/S0925-4439(00)00058-2; Vaarala MH, 2001, INT J CANCER, V94, P705, DOI 10.1002/ijc.1526; Vu TKH, 1997, J BIOL CHEM, V272, P31315, DOI 10.1074/jbc.272.50.31315; Wallrapp C, 2000, CANCER RES, V60, P2602; Welsh JB, 2001, CANCER RES, V61, P5974; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; Wild A, 2001, J CLIN ENDOCR METAB, V86, P5782, DOI 10.1210/jc.86.12.5782; Yamada K, 2000, GENE, V252, P209, DOI 10.1016/S0378-1119(00)00225-0; Yamaguchi N, 2002, J BIOL CHEM, V277, P6806, DOI 10.1074/jbc.M103645200; Yamaoka K, 1998, J BIOL CHEM, V273, P11895, DOI 10.1074/jbc.273.19.11895; Yan W, 1999, J BIOL CHEM, V274, P14926, DOI 10.1074/jbc.274.21.14926; Yan W, 2000, P NATL ACAD SCI USA, V97, P8525, DOI 10.1073/pnas.150149097	63	149	164	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37637	37646		10.1074/jbc.M203007200	http://dx.doi.org/10.1074/jbc.M203007200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149247	hybrid			2022-12-27	WOS:000178447100094
J	Duffy, HS; Sorgen, PL; Girvin, ME; O'Donnell, P; Coombs, W; Taffet, SM; Delmar, M; Spray, DC				Duffy, HS; Sorgen, PL; Girvin, ME; O'Donnell, P; Coombs, W; Taffet, SM; Delmar, M; Spray, DC			pH-dependent intramolecular binding and structure involving Cx43 cytoplasmic domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP JUNCTION PROTEIN; CORRELATION SPECTROSCOPY; NMR-SPECTROSCOPY; H-1-NMR SPECTRA; CHEMICAL-SHIFT; CONNEXIN43; CHANNELS; PHOSPHORYLATION; PROGRAM; CONDUCTANCE	pH-induced closure of connexin43 (Cx43) channels involves interaction of the Cx43 carboxyl-terminal (Cx43CT) with a separate "receptor" domain. The receptor location and structure and whether the interaction is directly intramolecular are unknown. Here we show resonant mirror technology, enzyme-linked sorbent assays, and nuclear magnetic resonance (NMR) experiments demonstrating pH-dependent binding of Cx43CT to region 119-144 of Cx43 (Cx43L2), which we propose is the receptor. NAIR showed that acidification induced a-helical order in Cx43L2, whereas only a minor modification in Cx43CT structure was detected. These data provide the first demonstration of chemically induced structural order and binding between cytoplasmic connexin domains.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; SUNY Upstate Med Univ, Dept Microbiol, Syracuse, NY 13210 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Delmar, M (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 766 Irving Ave, Syracuse, NY 13210 USA.			Spray, David/0000-0001-8368-5073; Delmar, Mario/0000-0002-2085-5589	NINDS NIH HHS [NS07098] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ai ZW, 2000, J CLIN INVEST, V105, P161, DOI 10.1172/JCI7798; Anumonwo JMB, 2001, CIRC RES, V88, P666, DOI 10.1161/hh0701.088833; BAX A, 1990, J MAGN RESON, V87, P620, DOI 10.1016/0022-2364(90)90320-9; Calero G, 1998, CIRC RES, V82, P929, DOI 10.1161/01.RES.82.9.929; Chandonia JM, 1999, PROTEINS, V35, P293; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P338; DAVIS DG, 1985, J AM CHEM SOC, V107, P2820, DOI 10.1021/ja00295a052; DELAGLIO F, 1995, J BIOMOL NMR, V6, P689; Delmar M, 2000, J CARDIOVASC ELECTR, V11, P118, DOI 10.1111/j.1540-8167.2000.tb00747.x; Duffy HS, 2001, CELL COMMUN ADHES, V8, P225, DOI 10.3109/15419060109080728; DUFFY HS, 2001, SOC NEUR ABSTR, V27; EK JF, 1994, CIRC RES, V74, P1058, DOI 10.1161/01.RES.74.6.1058; Francis D, 1999, DEV GENET, V24, P123, DOI 10.1002/(SICI)1520-6408(1999)24:1/2<123::AID-DVG12>3.0.CO;2-H; GEORGE AJT, 1995, J IMMUNOL METHODS, V183, P51, DOI 10.1016/0022-1759(95)00031-5; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; GLASOE PK, 1960, J PHYS CHEM-US, V64, P188, DOI 10.1021/j100830a521; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Homma N, 1998, CIRC RES, V83, P27, DOI 10.1161/01.RES.83.1.27; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; LASTOWSKY RA, 1996, J BIOMOL NMR, V8, P477; Lin JHC, 1998, NAT NEUROSCI, V1, P494, DOI 10.1038/2210; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; Mayer BJ, 2001, J CELL SCI, V114, P1253; Moreno AP, 2002, CIRC RES, V90, P450, DOI 10.1161/hh0402.105667; Morley GE, 1996, BIOPHYS J, V70, P1294, DOI 10.1016/S0006-3495(96)79686-8; Nusrat A, 2000, J BIOL CHEM, V275, P29816, DOI 10.1074/jbc.M002450200; Peracchia C, 2000, J BIOL CHEM, V275, P26220, DOI 10.1074/jbc.M004007200; Peters NS, 1997, CIRCULATION, V95, P988; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Purnick PEM, 2000, ARCH BIOCHEM BIOPHYS, V381, P181, DOI 10.1006/abbi.2000.1989; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Salamon Z, 1999, TRENDS BIOCHEM SCI, V24, P213, DOI 10.1016/S0968-0004(99)01394-8; Schubert AL, 2002, BIOCHEMISTRY-US, V41, P5754, DOI 10.1021/bi0121656; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; SPRAY DC, 1985, ANNU REV PHYSIOL, V47, P281, DOI 10.1146/annurev.ph.47.030185.001433; SPRAY DC, 1981, SCIENCE, V211, P712, DOI 10.1126/science.6779379; Spray DC, 1999, ADV EXP MED BIOL, V468, P339; SPRAY DC, 1990, AM J PHYSIOL, V258, P195; Stergiopoulos K, 1999, CIRC RES, V84, P1144, DOI 10.1161/01.RES.84.10.1144; Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200; Trexler EB, 1999, J GEN PHYSIOL, V113, P721; Unger VM, 1999, SCIENCE, V283, P1176, DOI 10.1126/science.283.5405.1176; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; WU DH, 1995, J MAGN RESON SER A, V115, P260, DOI 10.1006/jmra.1995.1176; Xu X, 2001, J CELL BIOL, V154, P217, DOI 10.1083/jcb.200105047; Yahuaca P, 2000, BRAZ J MED BIOL RES, V33, P399, DOI 10.1590/S0100-879X2000000400005; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520; Zhou L, 1999, J CELL BIOL, V144, P1033, DOI 10.1083/jcb.144.5.1033	54	142	148	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36706	36714		10.1074/jbc.M207016200	http://dx.doi.org/10.1074/jbc.M207016200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12151412	hybrid			2022-12-27	WOS:000178275100117
J	Spiegelman, VS; Tang, WG; Chan, AM; Igarashi, M; Aaronson, SA; Sassoon, DA; Katoh, M; Slaga, TJ; Fuchs, SY				Spiegelman, VS; Tang, WG; Chan, AM; Igarashi, M; Aaronson, SA; Sassoon, DA; Katoh, M; Slaga, TJ; Fuchs, SY			Induction of homologue of slimb ubiquitin ligase receptor by mitogen signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-KAPPA-B; RIBOSOMAL S6 KINASE; H-BETA-TRCP; ONCOGENIC RAS; CYCLIN-E; TRANSCRIPTIONAL ACTIVITY; CELLULAR-TRANSFORMATION; ALPHA UBIQUITINATION; NIH3T3 FIBROBLASTS; VIRUS TYPE-1	Homologue of Slimb (HOS) is the substrate-recognizing component of the SCFHOS-Roc1 E3 ubiquitin protein ligase. This ligase mediates ubiquitination of the inhibitor of NF-kappaB transcription factor (IkappaB). We have found that HOS is highly expressed in a number of human cancer cell lines. The rates of the HOS gene transcription as well as HOS mRNA and protein levels were upregulated in cells treated with mitogens or transfected with the inducers of mitogen-activated protein kinase pathway. Conversely, mitogen withdrawal strikingly reduced HOS levels during differentiation of mouse myoblasts. Activators of mitogen-activated protein kinase accelerated IkappaBalpha degradation and increased NF-kappaB transcriptional activity. Inhibition of HOS function via expression of dominant negative HOS (HOSDeltaF) initiated mouse myoblast differentiation and prevented Ras-mediated acceleration of IkappaBalpha degradation as well as NF-kappaB trans-activation and transformation of NIH3T3 cells. These data link the induction of HOS in proliferating cells with mitogen-signaling-dependent inhibition of cell differentiation and promotion of cell transformation.	Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; AMC Canc Res Ctr, Lakewood, CO 80214 USA; Mt Sinai Sch Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA; Natl Canc Ctr, Res Inst, Div Genet, Tokyo 1040045, Japan	University of Pennsylvania; AMC Cancer Research Center; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; National Cancer Center - Japan	Fuchs, SY (corresponding author), Univ Penn, Sch Vet Med, Dept Anim Biol, 3800 Spruce St,Rm 161E VET, Philadelphia, PA 19104 USA.	sfuks@vet.upenn.edu	Chan, Andrew Man-Lok/J-9497-2013; SASSOON, David A/G-2502-2013; Chan, Andrew/AAC-1145-2020	Chan, Andrew Man-Lok/0000-0001-9923-5464; SASSOON, David A/0000-0001-6074-048X; Chan, Andrew/0000-0001-9923-5464; Spiegelman, Vladimir S/0000-0003-4847-155X	NATIONAL CANCER INSTITUTE [R01CA092900] Funding Source: NIH RePORTER; NCI NIH HHS [CA 92900] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; Bafico A, 1998, ONCOGENE, V16, P2819, DOI 10.1038/sj.onc.1201797; Bhatia N, 2002, ONCOGENE, V21, P1501, DOI 10.1038/sj.onc.1205311; Bour S, 2001, J BIOL CHEM, V276, P15920, DOI 10.1074/jbc.M010533200; CAMPBELL JS, 1995, RECENT PROG HORM RES, V50, P131; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CUADRADO A, 1993, ONCOGENE, V8, P2443; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Fong A, 2002, J BIOL CHEM, V277, P22111, DOI 10.1074/jbc.C200151200; FRIEDMAN J, 1983, CARCINOGENESIS, V4, P1425, DOI 10.1093/carcin/4.11.1425; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Joyce D, 2001, CYTOKINE GROWTH F R, V12, P73, DOI 10.1016/S1359-6101(00)00018-6; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Lassot I, 2001, MOL CELL BIOL, V21, P2192, DOI 10.1128/MCB.21.6.2192-2202.2001; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; McKinsey TA, 1996, MOL CELL BIOL, V16, P2083; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Osada M, 1999, MOL CELL BIOL, V19, P6333; PELLING JC, 1987, CARCINOGENESIS, V8, P1481, DOI 10.1093/carcin/8.10.1481; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Saitoh T, 2001, INT J ONCOL, V18, P959; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Sharpe C, 2001, BIOESSAYS, V23, P311, DOI 10.1002/bies.1045; Soldatenkov VA, 1999, CANCER RES, V59, P5085; Speigelman VS, 2001, J BIOL CHEM, V276, P27152, DOI 10.1074/jbc.M100031200; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Spiegelman V, 2002, ONCOGENE, V21, P856, DOI 10.1038/sj.onc.1205132; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	51	56	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36624	36630		10.1074/jbc.M204524200	http://dx.doi.org/10.1074/jbc.M204524200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12151397	hybrid			2022-12-27	WOS:000178275100107
J	Michell, BJ; Harris, MB; Chen, ZP; Ju, H; Venema, VJ; Blackstone, MA; Huang, W; Venema, RC; Kemp, BE				Michell, BJ; Harris, MB; Chen, ZP; Ju, H; Venema, VJ; Blackstone, MA; Huang, W; Venema, RC; Kemp, BE			Identification of regulatory sites of phosphorylation of the bovine endothelial nitric-oxide synthase at serine 617 and serine 635	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASES; ACTIVATION; AKT; 3-KINASE; INHIBITOR; LY294002; ISOFORMS; SUBUNIT; CELLS; ENOS	Endothelial nitric-oxide synthase (eNOS) is regulated by signaling pathways involving multiple sites of phosphorylation. The coordinated phosphorylation of eNOS at Ser(1179) and dephosphorylation at Thr(497) activates the enzyme, whereas inhibition results when Thr(497) is phosphorylated and Ser(1179) is dephosphorylated. We have identified two further phosphorylation sites, at Ser(617) and Ser(635), by phosphopeptide mapping and matrix-assisted laser desorption ionization time of flight mass spectrometry. Purified protein kinase A (PKA) phosphorylates both sites in purified eNOS, whereas purified Akt phosphorylates only Ser(617). In bovine aortic endothelial cells, bradykinin (BK), ATP, and vascular endothelial growth factor stimulate phosphorylation of both sites. BK-stimulated phosphorylation of Ser(617) is Ca2+-dependent and is partially inhibited by LY294002 and wortmannin, phosphatidylinositol 3-kinase inhibitors, suggesting signaling via Akt. BK-stimulated phosphorylation of Ser(635) is Ca2+-independent and is completely abolished by the PKA inhibitor, KT5720, suggesting signaling via PKA. Activation of PKA with isobutylmethyl-xanthine also causes Ser(635), but not Ser(617), phosphorylation. Mimicking phosphorylation at Ser(635) by Ser to Asp mutation results in a greater than 2-fold increase in activity of the purified protein, whereas mimicking phosphorylation at Ser(617) does not alter maximal activity but significantly increases Ca2+-calmodulin sensitivity. These data show that phosphorylation of both Ser(617) and Ser(635) regulates eNOS activity and contributes to the agonist-stimulated eNOS activation process.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA	St. Vincent's Institute of Medical Research; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Venema, RC (corresponding author), St Vincents Inst Med Res, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.		Harris, M. Brennan/F-7772-2015; Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014	Harris, M. Brennan/0000-0002-2908-1647; Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Bernier SG, 2000, J BIOL CHEM, V275, P30707, DOI 10.1074/jbc.M005116200; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014-5793(98)01705-0; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Feron O, 1999, J CLIN INVEST, V103, P897, DOI 10.1172/JCI4829; FLEMING I, 1994, CIRC RES, V74, P1220, DOI 10.1161/01.RES.74.6.1220; Fleming I, 2001, CIRC RES, V88, pE68, DOI 10.1161/hh1101.092677; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Gallis B, 1999, J BIOL CHEM, V274, P30101, DOI 10.1074/jbc.274.42.30101; Harris MB, 2001, J BIOL CHEM, V276, P16587, DOI 10.1074/jbc.M100229200; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; Lee SJ, 1998, J BIOL CHEM, V273, P27430, DOI 10.1074/jbc.273.42.27430; MARMYCONUS NJ, 1998, J BIOL CHEM, V273, P4776; Marrero MB, 1999, BIOCHEM J, V343, P335, DOI 10.1042/0264-6021:3430335; McCabe TJ, 2000, J BIOL CHEM, V275, P6123, DOI 10.1074/jbc.275.9.6123; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; Michell BJ, 1999, CURR BIOL, V9, P845, DOI 10.1016/S0960-9822(99)80371-6; Mitchelhill KI, 1997, J BIOL CHEM, V272, P24475, DOI 10.1074/jbc.272.39.24475; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Scotland RS, 2002, CIRC RES, V90, P904, DOI 10.1161/01.RES.0000016506.04193.96; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Venema RC, 1997, J BIOL CHEM, V272, P1276, DOI 10.1074/jbc.272.2.1276; VENEMA RC, 1995, J BIOL CHEM, V270, P14705, DOI 10.1074/jbc.270.24.14705; Venema RC, 1996, J BIOL CHEM, V271, P6435, DOI 10.1074/jbc.271.11.6435; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241	29	175	178	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42344	42351		10.1074/jbc.M205144200	http://dx.doi.org/10.1074/jbc.M205144200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12171920	hybrid			2022-12-27	WOS:000178985300130
J	Abbas, T; Olivier, M; Lopez, J; Houser, S; Xiao, G; Kumar, GS; Tomasz, M; Bargonetti, J				Abbas, T; Olivier, M; Lopez, J; Houser, S; Xiao, G; Kumar, GS; Tomasz, M; Bargonetti, J			Differential activation of p53 by the various adducts of mitomycin C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR CELLS; DNA-DAMAGE; IN-VIVO; ALKYLATING-AGENTS; CANCER CELLS; 2,7-DIAMINOMITOSENE; INDUCTION; GADD45; REPAIR; EXPRESSION	Mitomycin C (MC) is a cytotoxic chemotherapeutic agent that causes DNA damage in the form of DNA crosslinks as well as a variety of DNA monoadducts and is known to induce p53. The various DNA adducts formed upon treatment of mouse mammary tumor cells with MC as well as 10-decarbamoyl MC (DMC) and 2,7-diaminomitosene (2,7-DAM), the major MC metabolite, have been elucidated. The cytotoxicity of DMC parallels closely that of MC in a number of rodent cell lines tested, whereas 2,7-DAM is relatively noncytotoxic. In this study, we investigate the ability of MC, DMC, and 2,7-DAM to activate p53 at equidose concentrations by treating tissue culture cell lines with the three mitomycins. Whereas MC and DMC induced p53 protein levels and increased the levels of p21 and Gadd45 mRNA, 2,7-DAM did not. Furthermore, MC and DMC, but not 2,7-DAM, were able to induce apoptosis efficiently in ML-1 cells. Therefore the 2,7-DAM monoadducts were unable to activate the p53 pathway. Interestingly, DMC was able to initiate apoptosis via a p53-independent pathway whereas MC was not. This is the first finding that adducts of a multiadduct type DNA-damaging agent are differentially recognized by DNA damage sensor pathways.	CUNY Hunter Coll, Inst Biomol Struct & Funct, New York, NY 10021 USA; CUNY Hunter Coll, Dept Sci Biol, New York, NY 10021 USA; Grad Sch, New York, NY 10021 USA; CUNY Hunter Coll, Dept Chem, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY)	Bargonetti, J (corresponding author), CUNY Hunter Coll, Inst Biomol Struct & Funct, New York, NY 10021 USA.	bargonetti@genectr.hunter.cuny.edu	KUMAR, P. SURESH/AAT-8951-2020; Olivier, Magali/G-3728-2010; Kumar, Gopinatha Suresh/W-1461-2019; Kumar, Dr Suresh/HHZ-2615-2022	KUMAR, P. SURESH/0000-0003-3222-2604; Olivier, Magali/0000-0002-8202-342X; Kumar, Dr Suresh/0000-0002-2539-6553; Bargonetti, Jill/0000-0003-2692-0991	NCI NIH HHS [CA 71961, CA 28681] Funding Source: Medline; NCRR NIH HHS [RR 03037] Funding Source: Medline; NIGMS NIH HHS [1S06 GM 60754] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA028681, R01CA071961, R37CA028681] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIZANEK R, 1993, CANCER RES, V53, P5127; CARRANO AV, 1979, MUTAT RES, V63, P175, DOI 10.1016/0027-5107(79)90114-3; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; CHIRREY L, 1995, CANCER CHEMOTH PHARM, V35, P318, DOI 10.1007/BF00689451; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HESS R, 1994, TOXICOL LETT, V72, P43, DOI 10.1016/0378-4274(94)90008-6; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; HOBAN PR, 1990, CANCER RES, V50, P4692; Inoue T, 2001, FEBS LETT, V490, P196, DOI 10.1016/S0014-5793(01)02123-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Khan QA, 1998, MOL CARCINOGEN, V23, P115, DOI 10.1002/(SICI)1098-2744(199810)23:2<115::AID-MC8>3.0.CO;2-R; Kumar GS, 1996, J AM CHEM SOC, V118, P9209; LAW JC, 1993, LEUKEMIA RES, V17, P1045, DOI 10.1016/0145-2126(93)90161-D; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Mu D, 2000, MOL CELL BIOL, V20, P2446, DOI 10.1128/MCB.20.7.2446-2454.2000; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; Palom Y, 2001, BIOCHEM PHARMACOL, V61, P1517, DOI 10.1016/S0006-2952(01)00609-8; Palom Y, 1998, ONCOL RES, V10, P509; Palom Y, 2000, CHEM RES TOXICOL, V13, P479, DOI 10.1021/tx000024j; PAN SS, 1993, MOL PHARMACOL, V43, P870; RAMET M, 1995, CARCINOGENESIS, V16, P2117, DOI 10.1093/carcin/16.9.2117; ROCKWELL S, 1995, ONCOL RES, V7, P39; SZYBALSKI W, 1964, FED PROC, V23, P946; TOMASZ M, 1988, J AM CHEM SOC, V110, P5892, DOI 10.1021/ja00225a048; Verweij J., 1990, ANTITUMOR ANTIBIOTIC, P382; Wani MA, 2000, CANCER RES, V60, P2273; Warren AJ, 2001, CLIN CANCER RES, V7, P1033; Warren AJ, 1998, CANCER RES, V58, P453; Xiao G, 2000, CANCER RES, V60, P1711; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zhao RB, 2000, GENE DEV, V14, P981	35	45	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40513	40519		10.1074/jbc.M205495200	http://dx.doi.org/10.1074/jbc.M205495200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183457	hybrid			2022-12-27	WOS:000178791400047
J	Chen, HC; Lin, WC; Tsay, YG; Lee, SC; Chang, CJ				Chen, HC; Lin, WC; Tsay, YG; Lee, SC; Chang, CJ			An RNA helicase, DDX1, interacting with poly(A) RNA and heterogeneous nuclear ribonucleoprotein K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA CELL-LINES; VIRUS CORE PROTEIN; MESSENGER-RNA; HNRNP-K; IN-VITRO; BINDING; ASSOCIATION; DOMAIN; GENE; IDENTIFICATION	Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a multifunctional protein known to be involved in the regulation of transcription, translation, nuclear transport, and signal transduction. To systematically obtain insight into mechanisms of hnRNP K activities, we set out to identify protein factors that interact with hnRNP K by using glutathione S-transferase-hnRNP K affinity chromatography followed by liquid chromatography/mass spectrometry/mass spectrometry analysis. Several partner proteins in the K562 cell lysates were identified through this method. One of them is a DEAD box-containing putative RNA helicase, DDX1. In vitro binding and co-immunoprecipitation studies confirmed the protein-protein interaction between hnRNP K with DDX1, and the region spanning amino acids 1-276 of hnRNP K is apparently responsible for its physical interaction with DDX1. Interestingly, their interaction was disrupted by the addition of poly(C), poly(A), and poly(U) RNA substrates. We found that DDX1 was a homopolymeric poly(A) RNA-binding protein. On the other hand, the ATPase activity of the purified recombinant DDX1 protein was stimulated by these homopolymeric RNAs and yeast total RNA but not by DNA. Moreover, the immunoprecipitated DDX1 complex but not purified DDX1 can unwind double-stranded RNA having single-stranded poly(A) overhangs.	Acad Sinica, Inst Biol Chem, Taipei 106, Taiwan; Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Clin Med, Taipei, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Taiwan University	Chang, CJ (corresponding author), Acad Sinica, Inst Biol Chem, 1 Sec 4 Roosevelt Rd, Taipei 106, Taiwan.		Chang, Ching-Jin/G-4511-2019; Tsay, Yeou-Guang/HGE-2076-2022	Chang, Ching-Jin/0000-0001-7129-8092				Bleoo S, 2001, MOL BIOL CELL, V12, P3046, DOI 10.1091/mbc.12.10.3046; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; Chang CJ, 2001, DNA CELL BIOL, V20, P569, DOI 10.1089/104454901317094981; Collier B, 1998, J BIOL CHEM, V273, P22648, DOI 10.1074/jbc.273.35.22648; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; FULLERPACE FV, 1993, EMBO J, V12, P3619, DOI 10.1002/j.1460-2075.1993.tb06035.x; Godbout R, 1998, J BIOL CHEM, V273, P21161, DOI 10.1074/jbc.273.33.21161; GODBOUT R, 1993, P NATL ACAD SCI USA, V90, P7578, DOI 10.1073/pnas.90.16.7578; Gururajan R, 1997, BBA-GENE STRUCT EXPR, V1350, P169, DOI 10.1016/S0167-4781(96)00155-8; GURURAJAN R, 1994, P NATL ACAD SCI USA, V91, P2056, DOI 10.1073/pnas.91.6.2056; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; HOBERT O, 1994, J BIOL CHEM, V269, P20225; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; LIANG L, 1994, DEVELOPMENT, V120, P1201; Linder P, 2001, TRENDS BIOCHEM SCI, V26, P339, DOI 10.1016/S0968-0004(01)01870-9; Mandal M, 2001, J BIOL CHEM, V276, P9699, DOI 10.1074/jbc.M008514200; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; Schullery DS, 1999, J BIOL CHEM, V274, P15101, DOI 10.1074/jbc.274.21.15101; Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SQUIRE JA, 1995, ONCOGENE, V10, P1417; TAKIMOTO M, 1993, J BIOL CHEM, V268, P18249; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; Tseng SSL, 1998, EMBO J, V17, P2651, DOI 10.1093/emboj/17.9.2651; VANSEUNINGEN I, 1995, J BIOL CHEM, V270, P26976, DOI 10.1074/jbc.270.45.26976; WASSARMAN DA, 1991, NATURE, V349, P463, DOI 10.1038/349463a0; Weighardt F, 1996, BIOESSAYS, V18, P747, DOI 10.1002/bies.950180910; Xu DM, 1996, NATURE, V381, P709, DOI 10.1038/381709a0	39	51	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40403	40409		10.1074/jbc.M206981200	http://dx.doi.org/10.1074/jbc.M206981200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183465	hybrid, Green Published			2022-12-27	WOS:000178791400033
J	Guo, J; McLachlan, SM; Rapoport, B				Guo, J; McLachlan, SM; Rapoport, B			Localization of the thyroid peroxidase autoantibody immunodominant region to a junctional region containing portions of the domains homologous to complement control protein and myeloperoxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-CELL EPITOPE; CONFORMATIONAL EPITOPES; 3-DIMENSIONAL MODEL; MOLECULAR-CLONING; MAJOR AUTOANTIGEN; DISEASE; ANTIGEN; GENE; IDENTIFICATION; THYROPEROXIDASE	Thyroid peroxidase (TPO) autoantibody epitopes are largely restricted to an immunodominant region (IDR) on the extracellular region of the native molecule. Localization of the IDR has been a longstanding and difficult goal. The TPO extracellular region comprises a large myeloperoxidase-like domain, linked to the plasma membrane by two smaller domains with homology to complement control protein (CCP) and epidermal growth factor (EGF), respectively. Recent studies have focused on the CCP- and EGF-like domains as the putative location of the TPO autoantibody IDR. To address this issue, we attempted to express on the surface of transfected cells native TPO in which the CCP- and EGF-like domains were deleted, either together or individually. We used a quartet of human monoclonal autoantibodies that define the TPO IDR, as well as polyclonal TPO autoantibodies in patients' sera, to detect these mutated TPO molecules by flow cytometry. The combined CCP/EGF-like domain deletion did not produce a signal with TPO autoantibodies but did not traffic to the cell surface. In contrast, both monoclonal and polyclonal autoantibodies recognized TPO with the juxtamembrane EGF-like domain deleted equally as well as the wild-type TPO on the cell surface. TPO with the CCP-like domain deleted expressed normally on the cell surface, as determined using the polyclonal mouse antiserum. Nevertheless, this modified TPO molecule was recognized very poorly by both the human monoclonal autoantibodies and the polyclonal autoantibodies in patients' sera. In conclusion, we have clearly excluded the juxtamembrane EGF-like domain as being part of the IDR. In contrast, a component of the CCP-like domain does contribute to the IDR. These data, together with findings from other studies, localize the TPO autoantibody IDR to the junction of the CCP-like domain and the much larger myeloperoxidase-like domain on TPO.	Cedars Sinai Med Ctr, Autoimmune Dis Unit, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles	Rapoport, B (corresponding author), Cedars Sinai Med Ctr, Autoimmune Dis Unit, 8700 Beverly Blvd,Suite B-131, Los Angeles, CA 90048 USA.				NIDDK NIH HHS [DK 36182] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036182] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arscott PL, 1996, J BIOL CHEM, V271, P4966; CHAZENBALK GD, 1993, J CLIN INVEST, V92, P62, DOI 10.1172/JCI116600; CZARNOCKA B, 1985, FEBS LETT, V190, P147, DOI 10.1016/0014-5793(85)80446-4; Estienne V, 1998, J BIOL CHEM, V273, P8056, DOI 10.1074/jbc.273.14.8056; Estienne V, 2002, INT IMMUNOL, V14, P359, DOI 10.1093/intimm/14.4.359; Estienne V, 1999, J BIOL CHEM, V274, P35313, DOI 10.1074/jbc.274.50.35313; FINKE R, 1991, J CLIN ENDOCR METAB, V73, P919, DOI 10.1210/jcem-73-4-919; FRORATH B, 1992, J BIOCHEM-TOKYO, V111, P633, DOI 10.1093/oxfordjournals.jbchem.a123810; Gardas A, 2000, REDOX REP, V5, P237, DOI 10.1179/135100000101535681; Guo J, 1997, J CLIN ENDOCR METAB, V82, P925, DOI 10.1210/jc.82.3.925; Guo J, 1999, CLIN EXP IMMUNOL, V117, P19; Guo J, 2001, J IMMUNOL, V166, P1327, DOI 10.4049/jimmunol.166.2.1327; Hobby P, 2000, ENDOCRINOLOGY, V141, P2018, DOI 10.1210/en.141.6.2018; Jaume JC, 1999, J CLIN ENDOCR METAB, V84, P1424, DOI 10.1210/jc.84.4.1424; Jaume JC, 1999, J CLIN ENDOCR METAB, V84, P1651, DOI 10.1210/jc.84.5.1651; Jaume JC, 1996, CLIN EXP IMMUNOL, V104, P115, DOI 10.1046/j.1365-2249.1996.d01-659.x; Jones FG, 1999, AUTOIMMUNITY, V30, P157, DOI 10.3109/08916939908993850; KIMURA S, 1987, P NATL ACAD SCI USA, V84, P5555, DOI 10.1073/pnas.84.16.5555; KIMURA S, 1988, PROTEINS, V3, P113, DOI 10.1002/prot.340030206; LIBERT F, 1987, EMBO J, V6, P4193, DOI 10.1002/j.1460-2075.1987.tb02766.x; MAASTRICHT J, 1992, J CLIN ENDOCR METAB, V75, P121, DOI 10.1210/jc.75.1.121; MAGNUSSON RP, 1987, MOL ENDOCRINOL, V1, P856, DOI 10.1210/mend-1-11-856; McLachlan S M, 2000, Int Rev Immunol, V19, P587, DOI 10.3109/08830180009088514; Nishikawa T, 1996, ENDOCRINOLOGY, V137, P1000, DOI 10.1210/en.137.3.1000; NISHIKAWA T, 1994, J CLIN ENDOCR METAB, V79, P1648, DOI 10.1210/jc.79.6.1648; Pichurin P, 2001, THYROID, V11, P301, DOI 10.1089/10507250152039037; PORTMANN L, 1985, J CLIN ENDOCR METAB, V61, P1001, DOI 10.1210/jcem-61-5-1001; Rapoport B, 2001, J CLIN INVEST, V108, P1253, DOI 10.1172/JCI14321; RODIEN P, 1992, AUTOIMMUNITY, V13, P177, DOI 10.3109/08916939209004822; RUF J, 1989, ENDOCRINOLOGY, V125, P1211, DOI 10.1210/endo-125-3-1211; SETO P, 1987, J CLIN INVEST, V80, P1205, DOI 10.1172/JCI113181; SIMITSEK PD, 1995, J EXP MED, V181, P1957, DOI 10.1084/jem.181.6.1957; TONACCHERA M, 1995, EUR J ENDOCRINOL, V132, P53, DOI 10.1530/eje.0.1320053; Xiong ZG, 2001, THYROID, V11, P227, DOI 10.1089/105072501750159598; ZANELLI E, 1992, CLIN EXP IMMUNOL, V87, P80; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	36	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40189	40195		10.1074/jbc.M205524200	http://dx.doi.org/10.1074/jbc.M205524200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12167622	hybrid			2022-12-27	WOS:000178791400006
J	Pawar, A; Xu, JH; Jerks, E; Mangelsdorf, DJ; Jump, DB				Pawar, A; Xu, JH; Jerks, E; Mangelsdorf, DJ; Jump, DB			Fatty acid regulation of liver X receptors (LXR) and peroxisome proliferator-activated receptor alpha (PPAR alpha) in HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEIN-1 EXPRESSION; GENE-TRANSCRIPTION; NUCLEAR RECEPTORS; SUPPRESSION; EICOSANOIDS; METABOLISM; SREBP-1C; BETA	Fatty acids bind to and regulate the activity of peroxisome proliferator-activated (PPAR) and liver X receptors (LXR). However, the role lipid metabolism plays in the control of intracellular fatty acid ligands is poorly understood. We have identified two strains of HEK293 cells that display differences in fatty acid regulation of nuclear receptors. Using full-length and Ga14-LBD chimeric receptors in functional assays, 20:4,n6 induced PPARalpha activity -2.2-fold and suppressed LXRalpha activity by 80% (ED50 similar to25-50 mum) in HEK293-E (early passage) cells but had no effect on PPARalpha or LXRalpha receptor activity in HEK293-L (late passage) cells. LXRbeta was insensitive to fatty acid regulation in both HEK293 strains. Metabolic labeling studies using [C-14]20:4,n6 (at 100 mum) indicated that the uptake of 20:4,n6 and its assimilation into triacylglycerol, diacylglycerol, and polar lipids revealed no difference between the two strains. Such treatment increased total cellular 20:4,n6 (similar to11-fold) and its elongation product, 22:4,n6 (similar to3.6-fold), within 6 h. Non-esterified 20:4,n6 and 22:4,n6 represented less than or equal to3% of the total cellular 20:4,n6 and 22:4,n6. In HEK293-E cells, non-esterified 20:4,n6 and 22:4,n6 increased 8- and 18-fold, respectively, by 6 h and was sustained at that level for 24 h. In HEK293-L cells, non-esterified 20:4,n6 also increased (5-fold) at 6 h but fell by 70% within 24 h. In contrast to HEK293-E cells, non-esterified 22:4,n6 did not accumulate in HEK293-L cells. Functional assays showed that 22:4,n6 was similar to2-fold more effective than 20: 4,n6 at inhibiting oxysterol-induced LXRa activity in HEK293-E cells, but had no effect on LXRa activity in HEK293-L cells. Taken together, these findings demonstrate that the rate of assimilation of exogenously added fatty acids and their metabolites into complex lipids plays an important role in regulating PPARa and LXRa activity.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biol Mol, E Lansing, MI 48824 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	Michigan State University; Michigan State University; Michigan State University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Jump, DB (corresponding author), Michigan State Univ, Dept Physiol, 3165 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.		Pawar, Anjali/AAT-8945-2020	Pawar, Anjali/0000-0002-2133-8663; Mangelsdorf, David/0000-0002-4355-0796	NIDDK NIH HHS [R01 DK043220, DK43220] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043220] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; CLARKE SD, 1994, ANNU REV NUTR, V14, P83, DOI 10.1146/annurev.nu.14.070194.000503; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; KARARA A, 1989, J BIOL CHEM, V264, P19822; KIM HY, 1990, J LIPID RES, V31, P2285; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Pan DA, 2000, J LIPID RES, V41, P742; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Rudel LL, 2001, CURR OPIN LIPIDOL, V12, P121, DOI 10.1097/00041433-200104000-00005; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; SNYDER F, 1985, BIOCH LIPIDS MEMBRAN, P271; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Xu J, 2001, J BIOL CHEM, V276, P9800, DOI 10.1074/jbc.M008973200; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	23	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39243	39250		10.1074/jbc.M206170200	http://dx.doi.org/10.1074/jbc.M206170200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161442	hybrid			2022-12-27	WOS:000178662500025
J	Hu, WW; Feng, ZH; Chasin, LA; Tang, MS				Hu, WW; Feng, ZH; Chasin, LA; Tang, MS			Transcription-coupled and transcription-independent repair of cyclobutane pyrimidine dimers in the dihydrofolate reductase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; HAMSTER OVARY CELLS; INDUCED DNA-DAMAGE; ACTIVE GENES; DHFR GENE; COCKAYNES-SYNDROME; MAMMALIAN-CELLS; CHO CELLS; STRAND; NUCLEOSOME	Using a ligation-mediated polymerase chain reaction technique, we have mapped the repair of ultraviolet light-induced cyclobutane pyrimidine dimers (CPDs) at the nucleotide level in exons 1, 2, and 5 of the dihydrofolate reductase (DHFR) gene in Chinese hamster ovary cells. We found that CPDs are preferentially repaired in the transcribed strand (T strand) and that the order of repair efficiency is exon 1 > exon 2 > exon 5. In the cells with a deletion of the DHFR gene encompassing the promoter region and the first four exons, CPDs are not repaired in the T strand of the residual DHFR gene. These results substantiate the idea that the preferential repair of CPDs in the T strand is transcription dependent. However, in the wild type gene we have found that CPDs are efficiently repaired in the nontranscribed strand (NT strand) of exon 1 but not in the NT strand of exons 2 and 5. Probing the chromatin structure of exons 1, 2, and 5 of the DHFR gene with micrococcal nuclease revealed that the exon 1 region is much more sensitive to micrococcal nuclease digestion than the exon 2 and exon 5 regions, suggesting that the chromatin structure in the exon 1 region is much more open. These results suggest that, although preferential repair of the T strand of the DHFR gene is transcription dependent, repair of the NT strand is greatly affected by chromatin structure.	NYU, Sch Med, Dept Environm Med Pathol & Med, Tuxedo Pk, NY 10987 USA; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	New York University; Columbia University	Tang, MS (corresponding author), NYU, Sch Med, Dept Environm Med Pathol & Med, Tuxedo Pk, NY 10987 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003124, R01ES008389] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES03124, ES08389] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Balajee AS, 2000, GENE, V250, P15, DOI 10.1016/S0378-1119(00)00172-4; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1986, J BIOL CHEM, V261, P6666; CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Feng ZH, 2002, J BIOL CHEM, V277, P12777, DOI 10.1074/jbc.M112297200; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P283; FRIEDBERG EC, 1985, DNA REPAIR, P1; George JW, 2001, MOL CELL BIOL, V21, P7355, DOI 10.1128/MCB.21.21.7355-7365.2001; Hanawalt PC, 2001, ENVIRON MOL MUTAGEN, V38, P89, DOI 10.1002/em.1057; Hanawalt PC, 2001, MUTAT RES-DNA REPAIR, V485, P3, DOI 10.1016/S0921-8777(00)00071-9; Hara R, 2000, MOL CELL BIOL, V20, P9173, DOI 10.1128/MCB.20.24.9173-9181.2000; ISLAS AL, 1995, CANCER RES, V55, P336; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; KUHNERT P, 1992, NUCLEIC ACIDS RES, V20, P1943, DOI 10.1093/nar/20.8.1943; Liu XQ, 2000, J BIOL CHEM, V275, P23729, DOI 10.1074/jbc.M002206200; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MITCHELL PJ, 1986, MOL CELL BIOL, V6, P425, DOI 10.1128/MCB.6.2.425; Morales V, 2001, BIOCHIMIE, V83, P1029, DOI 10.1016/S0300-9084(01)01347-5; Nouspikel T, 2000, MOL CELL BIOL, V20, P1562, DOI 10.1128/MCB.20.5.1562-1570.2000; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Spivak G, 1996, MUTAT RES-FUND MOL M, V350, P207, DOI 10.1016/0027-5107(95)00107-7; TANG MS, 1994, J BIOL CHEM, V269, P12749; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; Tu YQ, 1996, EMBO J, V15, P675, DOI 10.1002/j.1460-2075.1996.tb00400.x; Ura K, 2001, EMBO J, V20, P2004, DOI 10.1093/emboj/20.8.2004; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941; VANHOFFEN A, 1995, EMBO J, V14, P360, DOI 10.1002/j.1460-2075.1995.tb07010.x; VANHOFFEN A, 1993, NUCLEIC ACIDS RES, V21, P5890, DOI 10.1093/nar/21.25.5890; VANZEELAND AA, 1981, MUTAT RES, V82, P173, DOI 10.1016/0027-5107(81)90148-2; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; VENEMA J, 1992, J BIOL CHEM, V267, P8852; VREESWIJK MPG, 1994, J BIOL CHEM, V269, P31858; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Zheng Y, 2001, J BIOL CHEM, V276, P16786, DOI 10.1074/jbc.M010973200	36	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38305	38310		10.1074/jbc.M206375200	http://dx.doi.org/10.1074/jbc.M206375200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167651	hybrid			2022-12-27	WOS:000178529600041
J	Lazetic, S; Leong, SR; Chang, JCC; Ong, R; Dawes, G; Punnonen, J				Lazetic, S; Leong, SR; Chang, JCC; Ong, R; Dawes, G; Punnonen, J			Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; CD28-DEFICIENT MICE; DIRECTED EVOLUTION; IMMUNE-RESPONSE; DOWN-REGULATION; IGE SYNTHESIS; CLASS-II; B-CELLS; INDUCTION; ANTIGEN	CD28 and CTLA-4 (CD152) play a pivotal role in the regulation of T cell activation. Upon ligation by CD80 (B7-1) or CD86 (B7-2), CD28 induces T cell proliferation, cytokine production, and effector functions, whereas CTLA-4 signaling inhibits expansion of activated T cells and induces tolerance. Therefore, we hypothesized that co-stimulatory molecules that preferentially bind CD28 or CTLA-4 would have dramatically altered biological properties. We describe directed molecular evolution of CD80 genes derived from human, orangutan, rhesus monkey, baboon, cat, cow, and rabbit by DNA shuffling and screening. In contrast to wild-type CD80, the evolved co-stimulatory molecules, termed CD28-binding protein (CD28BP) and CTLA-4-binding protein (CTLA-4BP), selectively bind to CD28 or CTLA-4, respectively. Furthermore, CD28BP has improved capacity to induce human T cell proliferation and interferon-gamma production compared with wild-type CD80. In contrast, CTLA-4BP inhibited human mixed leukocyte reaction (MLR) and enhanced interleukin 10 production in MLR, supporting a role for CTLA-BP in inducing T cell anergy and tolerance. In addition, co-stimulation of purified human T cells was significantly suppressed when CTLA-4BP was cotransfected with either CD80 or CD28BP. The amino acid sequences of CD28BP and CTLA-4BP were 61 and 96% identical with that of human CD80 and provide insight into the residues that are critical in the ligand binding. These molecules provide a new approach to characterization of CD28 and CTLA-4 signals and to manipulation of the T cell response.	Maxygen Inc, Dept Vaccines, Redwood City, CA 94063 USA		Punnonen, J (corresponding author), Maxygen Inc, Dept Vaccines, Redwood City, CA 94063 USA.							Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Allavena P, 1998, EUR J IMMUNOL, V28, P359, DOI 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO;2-4; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493; BOUSSIOTIS VA, 1993, J EXP MED, V178, P1753, DOI 10.1084/jem.178.5.1753; Boussiotis VA, 1996, IMMUNOL REV, V153, P5, DOI 10.1111/j.1600-065X.1996.tb00918.x; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; Carreno BM, 2002, ANNU REV IMMUNOL, V20, P29, DOI 10.1146/annurev.immunol.20.091101.091806; Chan K, 2001, J IMMUNOL, V166, P3061, DOI 10.4049/jimmunol.166.5.3061; Chang CCJ, 1999, NAT BIOTECHNOL, V17, P793, DOI 10.1038/11737; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Darlington PJ, 2002, J EXP MED, V195, P1337, DOI 10.1084/jem.20011868; Egen JG, 2002, IMMUNITY, V16, P23, DOI 10.1016/S1074-7613(01)00259-X; FARGEAS CA, 1995, J EXP MED, V182, P667, DOI 10.1084/jem.182.3.667; Ferguson SE, 1996, J IMMUNOL, V156, P4576; FERNANDEZRUIZ E, 1995, EUR J IMMUNOL, V25, P1453, DOI 10.1002/eji.1830250548; Frauwirth KA, 2002, J CLIN INVEST, V109, P295, DOI 10.1172/JCI200214941; FREEMAN GJ, 1989, J IMMUNOL, V143, P2714; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; GREEN JM, 1994, IMMUNITY, V1, P501, DOI 10.1016/1074-7613(94)90092-2; Greenwald RJ, 2001, IMMUNITY, V14, P145, DOI 10.1016/S1074-7613(01)00097-8; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; HODGE JW, 1995, CANCER RES, V55, P3598; ISONO T, 1995, IMMUNOGENETICS, V42, P217, DOI 10.1007/BF00191228; Kim JJ, 1998, VACCINE, V16, P1828, DOI 10.1016/S0264-410X(98)00177-7; LUCAS PJ, 1995, J IMMUNOL, V154, P5757; MALEFYT RD, 1991, J EXP MED, V174, P915; McAdam AJ, 1998, IMMUNOL REV, V165, P231; Metzler WJ, 1997, NAT STRUCT BIOL, V4, P527, DOI 10.1038/nsb0797-527; OZATO K, 1981, J IMMUNOL, V126, P317; Parsons KR, 1999, IMMUNOGENETICS, V49, P231, DOI 10.1007/s002510050484; PEACH RJ, 1995, J BIOL CHEM, V270, P21181, DOI 10.1074/jbc.270.36.21181; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; Perez VL, 1997, IMMUNITY, V6, P411, DOI 10.1016/S1074-7613(00)80284-8; Prud'Homme GJ, 2002, HUM GENE THER, V13, P395, DOI 10.1089/10430340252792521; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Punnonen J, 2000, INT ARCH ALLERGY IMM, V121, P173, DOI 10.1159/000024315; Rizzo LV, 1999, J IMMUNOL, V162, P2613; Schwartz JCD, 2002, NAT IMMUNOL, V3, P427, DOI 10.1038/ni0502-427; Schwartz JCD, 2001, NATURE, V410, P604, DOI 10.1038/35069112; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; Soong NW, 2000, NAT GENET, V25, P436, DOI 10.1038/78132; Stamper CC, 2001, NATURE, V410, P608, DOI 10.1038/35069118; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; Sturmhoefel K, 1999, CANCER RES, V59, P4964; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Tobin MB, 2000, CURR OPIN STRUC BIOL, V10, P421, DOI 10.1016/S0959-440X(00)00109-3; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; Truneh A, 1996, MOL IMMUNOL, V33, P321, DOI 10.1016/0161-5890(95)00077-1; van Elsas A, 1999, J EXP MED, V190, P355, DOI 10.1084/jem.190.3.355; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Zhang YX, 2002, NATURE, V415, P644, DOI 10.1038/415644a	56	18	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38660	38668		10.1074/jbc.M205808200	http://dx.doi.org/10.1074/jbc.M205808200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167647	hybrid			2022-12-27	WOS:000178529600083
J	Ranganathan, G; Song, W; Dean, N; Monia, B; Barger, SW; Kern, PA				Ranganathan, G; Song, W; Dean, N; Monia, B; Barger, SW; Kern, PA			Regulation of lipoprotein lipase by protein kinase Ca in 3T3-F442A adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSLATIONAL REGULATION; DOWN-REGULATION; MESSENGER-RNA; ANTISENSE OLIGONUCLEOTIDES; DE-NOVO; ALPHA; EXPRESSION; INSULIN; GLUCOSE; HORMONE	Lipoprotein lipase (LPL) is an important enzyme in adipocyte and lipid metabolism with complex cellular regulation. Previous studies demonstrated an inhibition of LPL activity and synthesis following depletion of protein kinase C (PKC) isoforms with long term treatment of 3T3-F442A adipocytes with 12-O-tetradecanoylphorbol-13-acetate. To identify the specific PKC isoforms involved, we treated cells with antisense oligonucleotides that block expression of specific PKC isoforms. An antisense oligonucleotide to PKCalpha inhibited LPL activity by 78 +/- 8%, whereas antisense oligonucleotides directed against PKCdelta or PKCepsilon had no effect on LPL activity. The change in LPL activity was maximal at 72 h and was accompanied by a decrease in LPL protein and LPL synthetic rate but no change in LPL mRNA, suggesting regulation at the level of translation. However, PKC depletion resulted in no change in the polysome profile, indicating that translation initiation was not affected. However, the addition of cytoplasmic extracts from adipocytes treated with 12-O-tetradecanoylphorbol-13-acetate or PKCa antisense oligomers inhibited LPL translation in vitro. This inhibition of LPL translation in vitro was lost when the LPL mRNA transcript did not contain nucleotides 1599-3200, thus implicating the 3'-untranslated region of LPL in the regulation of translation by PKC depletion. Both LPL activity and Raf1 activity were decreased in parallel following depletion of either total PKC or specific inhibition of PKCa. An antisense oligonucleotide to RAF1, which inhibited RAF1 activity, also inhibited LPL activity by 48 +/- 10%, and this decrease in LPL activity was not accompanied by a change in LPL mRNA. Cells were treated with U0126, a specific inhibitor of the ERK-activating kinases MEK1 and MEK2. Although U0126 inhibited ERK1 and ERK2 phosphorylation, U0126 had no effect on LPL activity, indicating that MEK/ERK pathways were not involved in this mechanism of LPL regulation. Together, these data indicate that PKCa and RAF1 are important in the translational regulation of LPL in adipocytes and that the mechanism of regulation is probably through an ERK-independent pathway.	Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Med, Div Endocrinol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA; ISIS Pharmaceut, San Diego, CA 92008 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System; University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Isis Pharmaceuticals Inc	Ranganathan, G (corresponding author), Cent Arkansas Healthcare Syst, 151LR,4300 W 7th St, Little Rock, AR 72205 USA.	Ranganathangovx1@UAMS.edu		Barger, Steven/0000-0001-6049-6480				ADAMS JC, 1989, BIOCHEM J, V257, P905, DOI 10.1042/bj2570905; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BORNER C, 1988, P NATL ACAD SCI USA, V85, P2110, DOI 10.1073/pnas.85.7.2110; CHNG JLC, 1989, P NATL ACAD SCI USA, V86, P10006, DOI 10.1073/pnas.86.24.10006; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAVEN PA, 1990, DIABETES, V39, P667, DOI 10.2337/diabetes.39.6.667; Dean NM, 1996, BIOCHEM SOC T, V24, P623, DOI 10.1042/bst0240623; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DEAN NM, 2000, ANTISENSE NUCLEIC A, V7, P229; DRAZNIN B, 1988, BIOCHEM BIOPH RES CO, V156, P570, DOI 10.1016/S0006-291X(88)80880-5; ENERBACK S, 1993, BIOCHIM BIOPHYS ACTA, V1169, P107, DOI 10.1016/0005-2760(93)90196-G; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; ETO A, 1995, J BIOL CHEM, V270, P25115, DOI 10.1074/jbc.270.42.25115; FARESE RV, 1991, ANTISENSE RES DEV, V1, P35, DOI 10.1089/ard.1991.1.35; FARESE RV, 1994, J CLIN INVEST, V93, P1894, DOI 10.1172/JCI117180; FARESE RV, 1992, BIOCHEM J, V288, P319, DOI 10.1042/bj2880319; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; GOERS JWF, 1987, ANAL BIOCHEM, V166, P27, DOI 10.1016/0003-2697(87)90541-0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HOLM C, 1988, SCIENCE, V241, P1503, DOI 10.1126/science.3420405; ISHIZUKA T, 1989, FEBS LETT, V249, P234, DOI 10.1016/0014-5793(89)80630-1; Janulis M, 2001, MOL CELL BIOL, V21, P2235, DOI 10.1128/MCB.21.6.2235-2247.2001; JUNCO M, 1994, EUR J BIOCHEM, V223, P259, DOI 10.1111/j.1432-1033.1994.tb18990.x; Keller U, 1995, Biotechnology, V28, P173; Kern PA, 1996, J LIPID RES, V37, P2332; KLAUSNER RD, 1989, SCIENCE, V246, P870, DOI 10.1126/science.2683086; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; MAIER JAM, 1993, EXP CELL RES, V205, P52, DOI 10.1006/excr.1993.1057; Marcusson EG, 1998, NUCLEIC ACIDS RES, V26, P2016, DOI 10.1093/nar/26.8.2016; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; NILSSONEHLE P, 1976, J LIPID RES, V17, P536; O'Dwyer PJ, 1999, CLIN CANCER RES, V5, P3977; OLIVECRONA G, 1995, CURR OPIN LIPIDOL, V6, P291, DOI 10.1097/00041433-199510000-00009; ONG JM, 1988, J BIOL CHEM, V263, P12933; OSTARECKLEDERER A, 1994, EMBO J, V13, P1476, DOI 10.1002/j.1460-2075.1994.tb06402.x; Ranganathan G, 1997, J BIOL CHEM, V272, P2515; Ranganathan G, 1999, J BIOL CHEM, V274, P9122, DOI 10.1074/jbc.274.13.9122; Ranganathan G, 1999, METH MOL B, V109, P329; Ranganathan G, 2000, J BIOL CHEM, V275, P40986, DOI 10.1074/jbc.M008775200; Ranganathan S, 1998, J BIOL CHEM, V273, P26117, DOI 10.1074/jbc.273.40.26117; WOOLF TM, 1990, NUCLEIC ACIDS RES, V18, P1763, DOI 10.1093/nar/18.7.1763; YUKHT A, 1995, J CLIN INVEST, V96, P2438, DOI 10.1172/JCI118301	45	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38669	38675		10.1074/jbc.M206917200	http://dx.doi.org/10.1074/jbc.M206917200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12149272	hybrid			2022-12-27	WOS:000178529600084
J	Vercammen, J; Maertens, G; Gerard, M; De Clercq, E; Debyser, Z; Engelborghs, Y				Vercammen, J; Maertens, G; Gerard, M; De Clercq, E; Debyser, Z; Engelborghs, Y			DNA-induced polymerization of HIV-1 integrase analyzed with fluorescence fluctuation spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; IN-VITRO; TERMINAL DOMAINS; BINDING; MULTIMERIZATION; ANISOTROPY; PROMOTES; ASSAYS; CORE; FORM	Human immunodeficiency virus type 1 (HIV-1) integrase is essential for viral replication. Integrase inserts the viral DNA into the host DNA. We studied the association of integrase to fluorescently labeled oligonucleotides using fluorescence correlation spectroscopy. The binding of integrase to the fluorescent oligonucleotides resulted in the appearance of bright spikes during fluorescence correlation spectroscopy measurements. These spikes arise from the formation of high molecular mass protein-DNA complexes. The fluorescence of the free DNA was separated from the spikes with a statistical method. From the decrease of the concentration of free oligonucleotides, a site association constant was determined. The DNA-protein complexes were formed rapidly in a salt-dependent manner with site association constants ranging between 5 and 40 muM(-1) under different conditions. We also analyzed the kinetics of the DNA-protein complex assembly and the effect of different buffer components. The formation of the fluorescent protein-DNA complex was inhibited by guanosine quartets, and the inhibition constant was determined at 1.8 +/- 0.6 x 10(8) M-1. Displacement of bound DNA with G-quartets allowed the determination of the dissociation rate constant and proves the reversibility of the association process.	Katholieke Univ Leuven, Lab Biomol Dynam, B-3001 Louvain, Belgium; Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium	KU Leuven; KU Leuven	Engelborghs, Y (corresponding author), Katholieke Univ Leuven, Lab Biomol Dynam, Celestijnenlaan 200D, B-3001 Louvain, Belgium.		Maertens, Goedele/D-8628-2015; Gerard, Melanie/B-6898-2019	Maertens, Goedele/0000-0002-1963-8026; Gerard, Melanie/0000-0003-0585-6978; De Clercq, Erik/0000-0002-2985-8890				BRINKLEY M, 1992, BIOCONJUGATE CHEM, V3, P2, DOI 10.1021/bc00013a001; Brown P.O., 1997, INTEGRATION RETROVIR, P161; Cai ML, 1997, NAT STRUCT BIOL, V4, P839; Chen JCH, 2000, P NATL ACAD SCI USA, V97, P8233, DOI 10.1073/pnas.150220297; Chen Y, 1999, BIOPHYS J, V77, P553, DOI 10.1016/S0006-3495(99)76912-2; Cherepanov P, 1997, MOL PHARMACOL, V52, P771, DOI 10.1124/mol.52.5.771; Chow SA, 1997, METHODS, V12, P306, DOI 10.1006/meth.1997.0484; Connolly KM, 1999, J BIOMOL NMR, V14, P95, DOI 10.1023/A:1008328323180; Debyser Z, 1995, METHOD ENZYMOL, V262, P457; Deprez E, 2000, BIOCHEMISTRY-US, V39, P9275, DOI 10.1021/bi000397j; Deprez E, 2001, P NATL ACAD SCI USA, V98, P10090, DOI 10.1073/pnas.181024498; ELSON EL, 1974, BIOPOLYMERS, V17, P1; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; Haugan IR, 1995, BIOCHEM BIOPH RES CO, V217, P802, DOI 10.1006/bbrc.1995.2843; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; Leh H, 2000, BIOCHEMISTRY-US, V39, P9285, DOI 10.1021/bi000398b; MADGE D, 1974, BIOPOLYMERS, V13, P29; Magde D, 1977, Mol Biol Biochem Biophys, V24, P43; Marchand C, 2001, METHOD ENZYMOL, V340, P624; Minton AP, 2000, CURR OPIN STRUC BIOL, V10, P34, DOI 10.1016/S0959-440X(99)00045-7; OOSAWA F, 1962, J MOL BIOL, V4, P10, DOI 10.1016/S0022-2836(62)80112-0; Pemberton IK, 1996, J BIOL CHEM, V271, P1498, DOI 10.1074/jbc.271.3.1498; Pluymers Wim, 2001, Current Drug Targets - Infectious Disorders, V1, P133, DOI 10.2174/1568005014606044; RANDO RF, 1995, J BIOL CHEM, V270, P1754, DOI 10.1074/jbc.270.4.1754; Sambrook J., 2002, MOL CLONING LAB MANU; SHERMAN PA, 1990, P NATL ACAD SCI USA, V87, P5119, DOI 10.1073/pnas.87.13.5119; Van Craenenbroeck E, 1999, BIOCHEMISTRY-US, V38, P5082, DOI 10.1021/bi9821925; Van Craenenbroeck  E, 2000, J MOL RECOGNIT, V13, P93, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<93::AID-JMR492>3.0.CO;2-6; Van Craenenbroeck E, 2001, BIOL CHEM, V382, P355; Wang JY, 2001, EMBO J, V20, P7333, DOI 10.1093/emboj/20.24.7333; Wennmalm S, 1997, P NATL ACAD SCI USA, V94, P10641, DOI 10.1073/pnas.94.20.10641; Yoder KE, 2000, J VIROL, V74, P11191, DOI 10.1128/JVI.74.23.11191-11200.2000; Zheng RL, 1996, P NATL ACAD SCI USA, V93, P13659, DOI 10.1073/pnas.93.24.13659	34	31	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38045	38052		10.1074/jbc.M205842200	http://dx.doi.org/10.1074/jbc.M205842200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12147698	hybrid			2022-12-27	WOS:000178529600011
J	Yaguchi, H; Ohkura, N; Tsukada, T; Yamaguchi, K				Yaguchi, H; Ohkura, N; Tsukada, T; Yamaguchi, K			Menin, the multiple endocrine neoplasia type 1 gene product, exhibits GTP-hydrolyzing activity in the presence of the tumor metastasis suppressor nm23	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE DIPHOSPHATE KINASE; PROTEIN; RAS; INTERACTS; EXPRESSION; DYNAMIN; PHOSPHORYLATION; MECHANISM; CLONING; P190	MEN1, the gene responsible for multiple endocrine neoplasia type 1, is a tumor suppressor gene that encodes a protein called menin, of unknown function with no homology to any known protein. Here we demonstrate that menin interacts with a putative tumor metastasis suppressor nm23H1/nucleoside diphosphate (NDP) kinase A in mammalian cells. Given the roles of nm23 as a multi-functional protein, we searched for the possible function of menin. Menin has no effect on the known activities of nm23; that is, nucleoside diphosphate kinase, protein kinase, or GTPase-activating protein for Ras-related GTPase Rad. However, we found that menin hydrolyzes GTP to GDP efficiently in the presence of nm23, whereas nm23 or menin alone shows little or no detectable GTPase activity. Furthermore, menin contains sequence motifs similar to those found in all known GTPases or GTP-binding proteins and shows low affinity but specific binding to GTP/GDP. These results suggest that menin is an atypical GTPase stimulated by nm23.	Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Ohkura, N (corresponding author), Natl Canc Ctr, Res Inst, Div Growth Factor, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	nohkura@gan2.ncc.go.jp						BALLARD HS, 1964, MEDICINE, V43, P481, DOI 10.1097/00005792-196407000-00003; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Bross P, 1999, HUM MUTAT, V14, P186, DOI 10.1002/(SICI)1098-1004(1999)14:3<186::AID-HUMU2>3.0.CO;2-J; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; DELAROSA A, 1995, BIOESSAYS, V17, P53, DOI 10.1002/bies.950170111; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; ENGEL M, 1995, EUR J BIOCHEM, V234, P200, DOI 10.1111/j.1432-1033.1995.200_c.x; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; Guo SS, 2001, MOL ENDOCRINOL, V15, P1653, DOI 10.1210/me.15.10.1653; Guru SC, 1998, P NATL ACAD SCI USA, V95, P1630, DOI 10.1073/pnas.95.4.1630; Heppner C, 2001, ONCOGENE, V20, P4917, DOI 10.1038/sj.onc.1204529; Huang SC, 1999, LAB INVEST, V79, P301; JOHN J, 1993, J BIOL CHEM, V268, P923; Kaji H, 1999, CANCER RES, V59, P5097; Kaji H, 2001, P NATL ACAD SCI USA, V98, P3837, DOI 10.1073/pnas.061358098; KANTOR JD, 1993, CANCER RES, V53, P1971; KIMURA N, 1988, J BIOL CHEM, V263, P4647; Krishnan KS, 2001, NEURON, V30, P197, DOI 10.1016/S0896-6273(01)00273-2; LARSSON C, 1988, NATURE, V332, P85, DOI 10.1038/332085a0; Lemmens IH, 2001, BIOCHEM BIOPH RES CO, V286, P426, DOI 10.1006/bbrc.2001.5405; LEONE A, 1991, CELL, V65, P25, DOI 10.1016/0092-8674(91)90404-M; MACDONALD NJ, 1993, J BIOL CHEM, V268, P25780; Manickam P, 2000, MAMM GENOME, V11, P448, DOI 10.1007/s003350010085; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Maruyama K, 1999, MOL CELL ENDOCRINOL, V156, P25, DOI 10.1016/S0303-7207(99)00150-1; Maruyama K, 2000, MOL CELL ENDOCRINOL, V168, P135, DOI 10.1016/S0303-7207(00)00307-5; Min K, 2002, PROTEINS, V46, P340, DOI 10.1002/prot.10038; Morra M, 2001, J BIOL CHEM, V276, P36809, DOI 10.1074/jbc.M101305200; Ohkura N, 2001, BIOCHEM BIOPH RES CO, V282, P1206, DOI 10.1006/bbrc.2001.4723; Ohkura N, 2002, J BIOL CHEM, V277, P535, DOI 10.1074/jbc.M109018200; Recio JA, 2000, CANCER RES, V60, P1720; REYNET C, 1993, SCIENCE, V262, P1441, DOI 10.1126/science.8248782; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; SCHWEMMLE M, 1994, J BIOL CHEM, V269, P11299; Seewald MJ, 2002, NATURE, V415, P662, DOI 10.1038/415662a; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; STAHL JA, 1991, CANCER RES, V51, P445; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Stewart C, 1998, ONCOGENE, V17, P2485, DOI 10.1038/sj.onc.1202164; Stowell MHB, 1999, NAT CELL BIOL, V1, P27, DOI 10.1038/8997; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tsukada T, 2001, ENDOCR PATHOL, V12, P259, DOI 10.1385/EP:12:3:259; WAGNER PD, 1995, J BIOL CHEM, V270, P21758, DOI 10.1074/jbc.270.37.21758; Wautot V, 2000, INT J CANCER, V85, P877, DOI 10.1002/(SICI)1097-0215(20000315)85:6<877::AID-IJC23>3.0.CO;2-F; WERMER P, 1954, AM J MED, V16, P363, DOI 10.1016/0002-9343(54)90353-8; Yang WN, 1999, CURR BIOL, V9, pR511, DOI 10.1016/S0960-9822(99)80323-6; Yu YH, 1999, P NATL ACAD SCI USA, V96, P214, DOI 10.1073/pnas.96.1.214; Zhu JH, 1999, P NATL ACAD SCI USA, V96, P14911, DOI 10.1073/pnas.96.26.14911	51	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38197	38204		10.1074/jbc.M204132200	http://dx.doi.org/10.1074/jbc.M204132200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145286	hybrid			2022-12-27	WOS:000178529600029
J	Darman, RB; Forbush, B				Darman, RB; Forbush, B			A regulatory locus of phosphorylation in the N terminus of the Na-K-Cl cotransporter, NKCC1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHARK RECTAL GLAND; FUNCTIONAL EXPRESSION; NA+-K+-2CL(-) COTRANSPORTER; NA-K-2CL COTRANSPORTER; MOLECULAR-CLONING; PROTEIN; ACTIVATION; DOMAINS; KINASE; CAMP	The secretory Na-K-Cl cotransporter NKCC1 is activated by secretagogues through a phosphorylation-dependent mechanism. We found a phosphorylation stoichiometry of 3.0 +/- 0.4 phosphorylated residues/ NKCC1 protein harvested from shark rectal gland tubules maximally stimulated with forskolin and calyculin A, showing that at least three sites on the cotransporter are phosphorylated upon stimulation. Three phosphoacceptor sites were identified in the N-terminal domain of the protein (at Thr(184), Thr(189), and Thr(202)) using high pressure liquid chromatography and matrix-assisted laser desorption ionization time-of-flight mass spectrometry to analyze tryptic fragments of the radiolabeled cotransporter. None of these residues occurs in the context of strong consensus sites for known Ser/Thr kinases. The threonines and the surrounding amino acids are highly conserved between NKCC1 and NKCC2, and similarities are also present in the Na-Cl cotransporter NCC (or TSC). This strongly suggests that the phosphoregulatory mechanism is conserved among isoforms. Through expression of shark NKCC1 mutants in HEK-293 cells, Thr(189) was found to be necessary for activation of the protein, whereas phosphorylation at Thr(184) and Thr(202) was modulatory, but not required. In conjunction with the recent finding (Darmen, R. B., Flemmer, A., and Forbush, B. (2001) J. Biol. Chem. 276, 34359-34362) that protein phosphatase-1 binds to residues 107-112 in the shark NKCC1 sequence, these results demonstrate that the N terminus of NKCC1 constitutes a phosphoregulatory domain of the transporter.	Yale Univ, Dept Cellular & Mol Physiol, New Haven, CT 06510 USA; Mt Desert Isl Biol Lab, Salsbury Cove, ME 04672 USA	Yale University; Mount Desert Island Biological Laboratory	Darman, RB (corresponding author), Harvard Univ, Sch Med, Dept Mol Med, Beth Israel Deaconess Med Ctr, 330 Brookline Ave, Boston, MA 02215 USA.	rdarman@caregroup.harvard.edu			NIDDK NIH HHS [DK47661] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047661] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Annan RS, 1996, ANAL CHEM, V68, P3413, DOI 10.1021/ac960221g; Casula S, 2001, J BIOL CHEM, V276, P41870, DOI 10.1074/jbc.M107155200; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; Flemmer AW, 2002, J BIOL CHEM, V277, P37551, DOI 10.1074/jbc.M206294200; Garon L, 2000, J BIOL CHEM, V275, P32027, DOI 10.1074/jbc.M000108200; Gillen CM, 1996, J BIOL CHEM, V271, P16237, DOI 10.1074/jbc.271.27.16237; Gimenez Ignacio, 2000, Journal of the American Society of Nephrology, V11, p28A; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; HAAS M, 1995, J BIOL CHEM, V270, P28955, DOI 10.1074/jbc.270.48.28955; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; Isenring P, 1998, J BIOL CHEM, V273, P11295, DOI 10.1074/jbc.273.18.11295; Isenring P, 1997, J BIOL CHEM, V272, P24556, DOI 10.1074/jbc.272.39.24556; Klein JD, 1999, AM J PHYSIOL-CELL PH, V277, pC425, DOI 10.1152/ajpcell.1999.277.3.C425; Kurihara K, 2002, AM J PHYSIOL-CELL PH, V282, pC817, DOI 10.1152/ajpcell.00352.2001; Kurihara K, 1999, AM J PHYSIOL-CELL PH, V277, pC1184, DOI 10.1152/ajpcell.1999.277.6.C1184; LYTLE C, 1992, AM J PHYSIOL, V262, pC1009, DOI 10.1152/ajpcell.1992.262.4.C1009; LYTLE C, 1992, J BIOL CHEM, V267, P25428; LYTLE C, 1992, J BIOL CHEM, V267, P25438; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; Lytle C, 1995, AM J PHYSIOL-CELL PH, V269, pC1496, DOI 10.1152/ajpcell.1995.269.6.C1496; Lytle C, 1997, J BIOL CHEM, V272, P15069, DOI 10.1074/jbc.272.24.15069; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Plata C, 1999, AM J PHYSIOL-RENAL, V276, pF359, DOI 10.1152/ajprenal.1999.276.3.F359; QUIRK PG, 1995, FEBS LETT, V370, P175, DOI 10.1016/0014-5793(95)00812-N; Russell JM, 2000, PHYSIOL REV, V80, P211, DOI 10.1152/physrev.2000.80.1.211; TANIMURA A, 1995, J BIOL CHEM, V270, P25252, DOI 10.1074/jbc.270.42.25252; TORCHIA J, 1994, J BIOL CHEM, V269, P29778; Waldegger S, 1998, PFLUG ARCH EUR J PHY, V436, P575, DOI 10.1007/s004240050674; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	29	185	188	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37542	37550		10.1074/jbc.M206293200	http://dx.doi.org/10.1074/jbc.M206293200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145304	hybrid			2022-12-27	WOS:000178447100081
J	Ross, K; Yang, L; Dower, S; Volpe, F; Guesdon, F				Ross, K; Yang, L; Dower, S; Volpe, F; Guesdon, F			Identification of threonine 66 as a functionally critical residue of the interleukin-1 receptor-associated kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; IL-1 RECEPTOR; ACCESSORY PROTEIN; DEATH DOMAIN; TNF RECEPTOR; IRAK; ACTIVATION; COMPLEX; PATHWAY; FAMILY	We have mutated a conserved residue of the death domain of the interleukin-1 (IL-1) receptor-associated kinase (IRAK), threonine 66. The substitution of Thr-66 with alanine or glutamate prevented spontaneous activation of NF-kappaB by overexpressed IRAK but enhanced IL-1-induced activation of the factor. Like the kinase-inactivating mutation, K239S, the T66A and T66E mutations interfered with the ability of IRAK to autophosphorylate and facilitated the interactions of IRAK with TRAF6 and with the IL-1 receptor accessory protein, AcP. Wild-type IRAK constructs tagged with fluorescent proteins formed complexes that adopted a punctate distribution in the cytoplasm. The Thr-66 mutations prevented the formation of these complexes. Measurements of fluorescence resonance energy transfer among fluorescent constructs showed that the Thr-66 mutations abolished the capacity of IRAK to dimerize. In contrast, the K239S mutation did not inhibit dimerization of IRAK as evidenced by fluorescence resonance energy transfer measurements, even though microscopy showed that it prevented the formation of punctate complexes. Our results show that Thr-66 plays a crucial role in the ability of IRAK to form homodimers and that its kinase activity regulates its ability to form high molecular weight complexes. These properties in turn determine key aspects of the signaling function of IRAK.	Univ Sheffield, Royal Hallamshire Hosp, Div Genom Med, Sheffield S10 2JF, S Yorkshire, England; GlaxoSmithKline R&D, Dept Mol Pharmacol, Med Res Ctr, Stevenage SG1 2NY, Herts, England	University of Sheffield; GlaxoSmithKline	Guesdon, F (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Div Genom Med, M Floor,Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.			dower, steve/0000-0002-4675-4225				Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Bol GF, 2000, FEBS LETT, V477, P73, DOI 10.1016/S0014-5793(00)01759-2; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Cooke EL, 2001, BIOCHEM J, V359, P403, DOI 10.1042/0264-6021:3590403; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; ITOH N, 1993, J BIOL CHEM, V268, P10932; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Li XX, 1999, MOL CELL BIOL, V19, P4643; Li XX, 2001, P NATL ACAD SCI USA, V98, P4461, DOI 10.1073/pnas.071054198; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; McDermott EP, 2002, J BIOL CHEM, V277, P7808, DOI 10.1074/jbc.M108133200; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Tauszig S, 2000, P NATL ACAD SCI USA, V97, P10520, DOI 10.1073/pnas.180130797; Volpe F, 1997, FEBS LETT, V419, P41, DOI 10.1016/S0014-5793(97)01426-9; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; Xiao T, 1999, CELL, V99, P545, DOI 10.1016/S0092-8674(00)81542-1; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Zhang GL, 2002, J BIOL CHEM, V277, P7059, DOI 10.1074/jbc.M109537200	37	27	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37414	37421		10.1074/jbc.M205160200	http://dx.doi.org/10.1074/jbc.M205160200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138165	hybrid			2022-12-27	WOS:000178447100065
J	Singh, R; Pervin, S; Chaudhuri, G				Singh, R; Pervin, S; Chaudhuri, G			Caspase-8-mediated BID cleavage and release of mitochondrial cytochrome c during N-omega-hydroxy-L-arginine-induced apoptosis in MDA-MB-468 cells - Antagonistic effects of L-ornithine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; NITRIC-OXIDE; INHIBITOR; ARGINASE; IDENTIFICATION; BIOSYNTHESIS; CARDIOLIPIN; POLYAMINES; ACTIVATION; MEMBRANE	We have previously reported that N-omega-hydroxy-L-arginine (NOHA), a stable intermediate product formed during the conversion Of L-arginine to nitric oxide, induced apoptosis in MDA-MB-468 cells, and this action was antagonized in the presence of L-ornithine. We also reported that apoptosis induced by NOHA in this cell line could not be explained on the basis of a reduction of intracellular polyamines. In the current study, we investigated other potential mechanism(s) by which NOHA may have induced apoptosis in this cell line. We observed that NOHA initially activated caspase-8 and induced cleavage of BH3 interacting domain. This was followed by release of cytochrome c and subsequently, activation of downstream caspases-9 and -3 to cleave poly(ADP-ribose) polymerase. We also observed that NOHA induced a rapid and persistent hyperpolarization of the mitochondrial membrane potential rather than depolarization indicating that the release of cytochrome c by NOHA was by a mechanism independent of the mitochondrial transition pore. Exogenous L-ornithine did not inhibit NOHA-induced caspase-8 activation and cleavage of BH3 interacting domain but acted at the mitochondrial level and inhibited the NOHA-induced cytochrome c release and apoptosis.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Chaudhuri, G (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.				NATIONAL CANCER INSTITUTE [R01CA078357] Funding Source: NIH RePORTER; NCI NIH HHS [CA-78357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Buga GM, 1998, AM J PHYSIOL-REG I, V275, pR1256, DOI 10.1152/ajpregu.1998.275.4.R1256; De Nadai C, 2000, P NATL ACAD SCI USA, V97, P5480, DOI 10.1073/pnas.070062397; Decker P, 2000, J BIOL CHEM, V275, P9043, DOI 10.1074/jbc.275.12.9043; DORHOUT B, 1995, INT J CANCER, V62, P738, DOI 10.1002/ijc.2910620615; Esch F, 1998, J NEUROSCI, V18, P4083; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Finucane DM, 1999, EXP CELL RES, V251, P166, DOI 10.1006/excr.1999.4527; Fukuto JM, 1996, METHOD ENZYMOL, V268, P365; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hatch GM, 1998, INT J MOL MED, V1, P33; Jenkinson CP, 1996, COMP BIOCHEM PHYS B, V114, P107, DOI 10.1016/0305-0491(95)02138-8; Kaneko H, 1998, ANTICANCER RES, V18, P891; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; Lee YJ, 2001, ONCOGENE, V20, P1476, DOI 10.1038/sj.onc.1204225; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; Patterson SD, 2000, CELL DEATH DIFFER, V7, P137, DOI 10.1038/sj.cdd.4400640; PEGG AE, 1982, AM J PHYSIOL, V243, P212; Pervin S, 2001, P NATL ACAD SCI USA, V98, P3583, DOI 10.1073/pnas.041603998; Pervin S, 2001, CANCER RES, V61, P4701; REGENASS U, 1994, CANCER RES, V54, P3210; Saio M, 2001, J IMMUNOL, V167, P5583, DOI 10.4049/jimmunol.167.10.5583; Secchiero P, 2001, BLOOD, V98, P2220, DOI 10.1182/blood.V98.7.2220; SHAPIRO HM, 1997, CURRENT PROTOCOLS CY; Singh R, 2000, CANCER RES, V60, P3305; Singh R, 2001, CARCINOGENESIS, V22, P1863, DOI 10.1093/carcin/22.11.1863; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Thomas T, 1999, J CELL PHYSIOL, V179, P257, DOI 10.1002/(SICI)1097-4652(199906)179:3<257::AID-JCP3>3.0.CO;2-4; THOMSEN LL, 1995, BRIT J CANCER, V72, P41, DOI 10.1038/bjc.1995.274; Wei MC, 2000, GENE DEV, V14, P2060; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761	35	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37630	37636		10.1074/jbc.M203648200	http://dx.doi.org/10.1074/jbc.M203648200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145284	hybrid			2022-12-27	WOS:000178447100093
J	You, ZB; Madrid, LV; Saims, D; Sedivy, J; Wang, CY				You, ZB; Madrid, LV; Saims, D; Sedivy, J; Wang, CY			c-Myc sensitizes cells to tumor necrosis factor-mediated apoptosis by inhibiting nuclear factor kappa B transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-ALPHA; TNF; EXPRESSION; PHOSPHORYLATION; PROTEINS; DEATH; ACTIVATION; INDUCTION; RELA/P65; SUBUNIT	Nuclear factor kappaB (NF-kappaB) plays a key role in suppression of tumor necrosis factor (TNF)-mediated apoptosis by inducing a variety of anti-apoptotic genes. Expression of c-Myc has been shown to sensitize cells to TNF-mediated apoptosis by inhibiting NF-kappaB activation. However, the precise step in the NF-kappaB signaling pathway and apoptosis modified by c-Myc has not been identified. Using the inducible c-MycER system and c-Myc null fibroblasts, we found that expression of c-Myc inhibited NF-kappaB activation by interfering with ReLA/p65 transactivation but not nuclear translocation of NF-kappaB. Activation of c-Myc promoted TNF-induced release of cytochrome c from mitochondria to the cytosol because of the inhibition of NF-kappaB. Furthermore, we found that NF-kappaB-inducible gene A1 was attenuated by expression of c-Myc and that the restoration of A1 expression suppressed c-Myc-induced TNF sensitization. Our results elucidate the molecular mechanisms by which c-Myc increases cell susceptibility to TNF-mediated apoptosis, indicating that c-Myc may exhibit its pro-apoptotic activities by repression of cell survival genes.	Univ Michigan, Lab Mol Signaling & Apoptosis, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA USA; Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA	University of Michigan System; University of Michigan; Fred Hutchinson Cancer Center; Brown University	Wang, CY (corresponding author), Univ Michigan, Lab Mol Signaling & Apoptosis, Dept Biol & Mat Sci, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	cunywang@umich.edu			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE013848] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013335, R01DE013788, R01DE013848] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE13788, DE13335, DE13848] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; ASKEW DS, 1991, ONCOGENE, V6, P1915; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Dang CV, 1999, MOL CELL BIOL, V19, P1; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; Eischen CM, 2001, MOL CELL BIOL, V21, P7653, DOI 10.1128/MCB.21.22.7653-7662.2001; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Li JM, 1998, MOL CELL BIOL, V18, P110, DOI 10.1128/MCB.18.1.110; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Perez D, 2000, MOL CELL, V6, P53, DOI 10.1016/S1097-2765(00)00007-1; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shao RP, 1999, J BIOL CHEM, V274, P21495, DOI 10.1074/jbc.274.31.21495; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Stehlik C, 1998, J EXP MED, V188, P211, DOI 10.1084/jem.188.1.211; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang XD, 2001, GENE DEV, V15, P2922; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; You ZB, 2001, J BIOL CHEM, V276, P26398, DOI 10.1074/jbc.M102464200; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	49	53	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36671	36677		10.1074/jbc.M203213200	http://dx.doi.org/10.1074/jbc.M203213200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12149248	hybrid			2022-12-27	WOS:000178275100113
J	Scales, SJ; Hesser, BA; Masuda, ES; Scheller, RH				Scales, SJ; Hesser, BA; Masuda, ES; Scheller, RH			Amisyn, a novel syntaxin-binding protein that may regulate SNARE complex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI MATRIX PROTEIN; MEMBRANE-FUSION; PLASMA-MEMBRANE; SYNAPTIC EXOCYTOSIS; ALPHA-SNAP; NEUROTRANSMITTER RELEASE; STRUCTURAL INSIGHTS; CYTOSOLIC PROTEINS; KINETIC COMPONENTS; CHROMAFFIN CELLS	The regulation of SNARE complex assembly likely plays an important role in governing the specificity as well as the timing of membrane fusion. Here we identify a novel brain-enriched protein, amisyn, with a tomosyn-and VAMP-like coiled-coil-forming domain that binds specifically to syntaxin 1a and syntaxin 4 both in vitro and in vivo, as assessed by co-immunoprecipitation from rat brain. Amisyn is mostly cytosolic, but a fraction co-sediments with membranes. The amisyn coil domain can form SNARE complexes of greater thermostability than can VAMP2 with syntaxin 1a and SNAP-25 in vitro, but it lacks a transmembrane anchor and so cannot act as a v-SNARE in this complex. The amisyn coil domain prevents the SNAP-25 C-terminally mediated rescue of botulinum neurotoxin E inhibition of norepinephrine exocytosis in permeabilized PC12 cells to a greater extent than it prevents the regular exocytosis of these vesicles. We propose that amisyn forms nonfusogenic complexes with syntaxin la and SNAP-25, holding them in a conformation ready for VAMP2 to replace it to mediate the membrane fusion event, thereby contributing to the regulation of SNARE complex formation.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Mol & Cellular Physiol, Stanford, CA 94305 USA; Rigel Inc, San Francisco, CA 94080 USA	Howard Hughes Medical Institute; Stanford University	Scheller, RH (corresponding author), Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.	Scheller@gene.com	Scales, Suzie J./H-4507-2019	Scales, Suzie J./0000-0003-2544-0283; Masuda, Esteban/0000-0002-3175-2868				Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Antonin W, 2000, EMBO J, V19, P6453, DOI 10.1093/emboj/19.23.6453; Ashery U, 2000, EMBO J, V19, P3586, DOI 10.1093/emboj/19.14.3586; Barlowe C, 1997, J CELL BIOL, V139, P1097, DOI 10.1083/jcb.139.5.1097; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Bock JB, 1999, P NATL ACAD SCI USA, V96, P12227, DOI 10.1073/pnas.96.22.12227; Bock JB, 2001, NATURE, V409, P839, DOI 10.1038/35057024; Brunger AT, 2000, CURR OPIN NEUROBIOL, V10, P293, DOI 10.1016/S0959-4388(00)00098-2; Bui TD, 1998, GENOMICS, V54, P579, DOI 10.1006/geno.1998.5596; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Chen YA, 1999, J BIOL CHEM, V274, P26469, DOI 10.1074/jbc.274.37.26469; Chen YA, 2001, NEURON, V30, P161, DOI 10.1016/S0896-6273(01)00270-7; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Fasshauer D, 1998, P NATL ACAD SCI USA, V95, P15781, DOI 10.1073/pnas.95.26.15781; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; Hsu SC, 1999, TRENDS CELL BIOL, V9, P150, DOI 10.1016/S0962-8924(99)01516-0; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; INOUE A, 1992, J BIOL CHEM, V267, P10613; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KUNIMOTO M, 1989, J BIOCHEM-TOKYO, V105, P190, DOI 10.1093/oxfordjournals.jbchem.a122638; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LINSTEDT AD, 1993, MOL BIOL CELL, V4, P679, DOI 10.1091/mbc.4.7.679; Littleton JT, 1998, NEURON, V21, P401, DOI 10.1016/S0896-6273(00)80549-8; MAGEE AI, 1989, J CELL SCI, P149; Masuda ES, 1998, NEURON, V21, P479, DOI 10.1016/S0896-6273(00)80559-0; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; NAKAJIMA H, 1991, J CELL BIOL, V113, P245, DOI 10.1083/jcb.113.2.245; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Prekeris R, 1999, MOL BIOL CELL, V10, P3891, DOI 10.1091/mbc.10.11.3891; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; Prekeris R, 2000, EUR J CELL BIOL, V79, P771, DOI 10.1078/0171-9335-00109; Press B, 1998, J CELL BIOL, V140, P1075, DOI 10.1083/jcb.140.5.1075; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Scales SJ, 2001, P NATL ACAD SCI USA, V98, P14262, DOI 10.1073/pnas.251547598; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; Steegmaier M, 1999, MOL BIOL CELL, V10, P1957, DOI 10.1091/mbc.10.6.1957; Steegmaier M, 1998, J BIOL CHEM, V273, P34171, DOI 10.1074/jbc.273.51.34171; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tang BL, 1998, BIOCHEM BIOPH RES CO, V245, P627, DOI 10.1006/bbrc.1998.8490; VanRheenen SM, 1999, J CELL BIOL, V147, P729, DOI 10.1083/jcb.147.4.729; Veit M, 2001, EMBO J, V20, P3145, DOI 10.1093/emboj/20.12.3145; Vogel K, 1999, BIOCHEM BIOPH RES CO, V258, P407, DOI 10.1006/bbrc.1999.0652; Wang YX, 1998, J CELL BIOL, V140, P1063, DOI 10.1083/jcb.140.5.1063; Waters MG, 2000, TRAFFIC, V1, P588, DOI 10.1034/j.1600-0854.2000.010802.x; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; Xu T, 1999, CELL, V99, P713, DOI 10.1016/S0092-8674(00)81669-4; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Xu T, 1999, EMBO J, V18, P3293, DOI 10.1093/emboj/18.12.3293; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Yokoyama S, 1999, BIOCHEM BIOPH RES CO, V256, P218, DOI 10.1006/bbrc.1999.0300; Zhang QH, 2000, GENOME RES, V10, P1546, DOI 10.1101/gr.140200	74	69	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 2	2002	277	31					28271	28279		10.1074/jbc.M204929200	http://dx.doi.org/10.1074/jbc.M204929200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	579QR	12145319	hybrid			2022-12-27	WOS:000177189800086
J	Matuschewski, K; Ross, J; Brown, SM; Kaiser, K; Nussenzweig, V; Kappe, SHI				Matuschewski, K; Ross, J; Brown, SM; Kaiser, K; Nussenzweig, V; Kappe, SHI			Infectivity-associated changes in the transcriptional repertoire of the malaria parasite sporozoite stage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM PROTEIN; MOSQUITO SALIVARY-GLANDS; ORNITHINE DECARBOXYLASE; PROTECTIVE IMMUNITY; INVASION; BERGHEI; HOST; ANTIBODIES; POLYAMINES; MEROZOITE	Injection of Plasmodium salivary gland sporozoites into the vertebrate host by Anopheles mosquitoes initiates malaria infection. Sporozoites develop within oocysts in the mosquito midgut and then enter and mature in the salivary glands. Although morphologically similar, oocyst sporozoites and salivary gland sporozoites differ strikingly in their infectivity to the mammalian host, ability to elicit protective immune responses, and cell motility. Here, we show that differential gene expression coincides with these dramatic phenotypic differences. Using suppression subtractive cDNA hybridization we identified highly up-regulated mRNAs transcribed from 30 distinct genes in salivary gland sporozoites. Of those genes, 29 are not significantly expressed in the parasite's blood stages. The most frequently recovered transcript encodes a protein kinase. Developmental up-regulation of specific mRNAs in the infectious transmission stage of Plasmodium indicates that their translation products may have unique roles in hepatocyte infection and/or development of liver stages.	Univ Heidelberg, Sch Med, Dept Parasitol, D-69120 Heidelberg, Germany; NYU, Sch Med, Dept Pathol, Michael Heidelberger Div, New York, NY 10016 USA; NYU, Med Ctr, New York, NY 10016 USA	Ruprecht Karls University Heidelberg; New York University; New York University	Matuschewski, K (corresponding author), Univ Heidelberg, Sch Med, Dept Parasitol, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.			Matuschewski, Kai/0000-0001-6147-8591				AIKAWA M, 1981, J IMMUNOL, V126, P2494; Al-Olayan EM, 2002, SCIENCE, V295, P677, DOI 10.1126/science.1067159; Barreau C, 1995, EXP PARASITOL, V81, P332, DOI 10.1006/expr.1995.1124; Brennan JDG, 2000, P NATL ACAD SCI USA, V97, P13859, DOI 10.1073/pnas.250472597; Coppens I, 2000, J CELL BIOL, V149, P167, DOI 10.1083/jcb.149.1.167; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; FOX BA, 1993, MOL BIOCHEM PARASIT, V61, P37, DOI 10.1016/0166-6851(93)90156-R; Francois G, 1997, ANN TROP MED PARASIT, V91, P103, DOI 10.1080/00034983.1997.11813117; Ghosh A, 2000, PARASITOL TODAY, V16, P196, DOI 10.1016/S0169-4758(99)01626-9; Ghosh AK, 2001, P NATL ACAD SCI USA, V98, P13278, DOI 10.1073/pnas.241491198; HOLLINGDALE MR, 1985, EXP PARASITOL, V60, P111, DOI 10.1016/S0014-4894(85)80028-X; HUDSONTAYLOR DE, 1995, MOL MICROBIOL, V15, P463, DOI 10.1111/j.1365-2958.1995.tb02260.x; Jonas A, 2000, BBA-MOL CELL BIOL L, V1529, P245, DOI 10.1016/S1388-1981(00)00153-0; Kappe SHI, 2001, P NATL ACAD SCI USA, V98, P9895, DOI 10.1073/pnas.171185198; KLOTZ FW, 1989, MOL BIOCHEM PARASIT, V36, P177, DOI 10.1016/0166-6851(89)90190-4; Matuschewski K, 2002, EMBO J, V21, P1597, DOI 10.1093/emboj/21.7.1597; Matuschewski K, 2001, MOL BIOCHEM PARASIT, V112, P157, DOI 10.1016/S0166-6851(00)00360-1; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; Miller LH, 1998, NAT MED, V4, P520, DOI 10.1038/nm0598supp-520; Muller S, 2000, J BIOL CHEM, V275, P8097, DOI 10.1074/jbc.275.11.8097; Natarajan R, 2001, CELL MICROBIOL, V3, P371, DOI 10.1046/j.1462-5822.2001.00117.x; NUSSENZWEIG RS, 1969, NATURE, V222, P488, DOI 10.1038/222488a0; Pinder JC, 1998, J CELL SCI, V111, P1831; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TOURAY MG, 1992, J EXP MED, V175, P1607, DOI 10.1084/jem.175.6.1607; Tsuji M, 2001, BIOL CHEM, V382, P553, DOI 10.1515/BC.2001.069; VANDERBERG JP, 1975, J PARASITOL, V61, P43, DOI 10.2307/3279102; VANDERBERG JP, 1974, J PROTOZOOL, V21, P527, DOI 10.1111/j.1550-7408.1974.tb03693.x; VANDERBERG JP, 1972, P HELM SOC WASH, V39, P514	30	155	164	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41948	41953		10.1074/jbc.M207315200	http://dx.doi.org/10.1074/jbc.M207315200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12177071	hybrid			2022-12-27	WOS:000178985300083
J	Agirre, A; Barco, A; Carrasco, L; Nieva, JL				Agirre, A; Barco, A; Carrasco, L; Nieva, JL			Viroporin-mediated membrane permeabilization - Pore formation by nonstructural poliovirus 2B protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; VIRUS PROTEIN; BACILLUS-THURINGIENSIS; LIPID-BILAYERS; HELIX 4; PEPTIDE; CHANNEL; FUSION; CHOLESTEROL; MECHANISM	Enterovirus nonstructural 2B protein is involved in cell membrane permeabilization during late viral infection. Here we analyze the pore forming activity of poliovirus 2B and several of its variants. Solubilization of 2B protein was achieved by generating a fusion protein comprised of poliovirus 2B attached to a maltose-binding protein (MEP) as an N-terminal solubilization. partner. MEP-2B was assayed using large unilamellar vesicles as target membranes. This fusion protein was able to assemble into discrete structures that disrupted the permeability barrier of vesicles composed of anionic phospholipids. The transbilayer aqueous connections generated by MBP-2B were stable over time, allowing the passage of solutes of molecular mass under 1,000 Da. Oligomerization was investigated using fluorescence resonance energy transfer. Our data indicate that MBP-2B aggregation occurs at the membrane surface. Moreover, MBP-2B binding to membranes promoted the formation of SDS-resistant tetramers. We conclude that MBP-2B forms oligomers capable of generating a tetrameric aqueous pore in lipid bilayers. These findings are the first evidence of viroporin activity shown by a protein from a naked animal virus.	Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain; Univ Basque Country, Unidad Biofis, Ctr Super Investigac Cientificas, E-48080 Bilbao, Spain; Univ Autonoma Madrid, Ctr Biol Mol, E-28049 Madrid, Spain	University of Basque Country; Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; Autonomous University of Madrid	Nieva, JL (corresponding author), Univ Basque Country, Dept Bioquim, Aptdo 644, E-48080 Bilbao, Spain.	gbpniesj@lg.ehu.es	Carrasco, Luis/H-3001-2017; Nieva, Jose L/Q-2063-2019; Barco, Angel/ABF-1864-2021; Carrasco, Luis/E-2435-2012; Barco, Angel/C-3062-2008	Carrasco, Luis/0000-0003-3833-8835; Nieva, Jose L/0000-0001-6446-5649; Barco, Angel/0000-0002-0653-3751; Barco, Angel/0000-0002-0653-3751				Agirre A, 2000, J LIPID RES, V41, P621; Aldabe R, 1997, J VIROL, V71, P6214, DOI 10.1128/JVI.71.8.6214-6217.1997; Aldabe R, 1996, J BIOL CHEM, V271, P23134, DOI 10.1074/jbc.271.38.23134; Barco A, 1998, J VIROL, V72, P3560, DOI 10.1128/JVI.72.5.3560-3570.1998; BARCO A, 1995, EMBO J, V14, P3349, DOI 10.1002/j.1460-2075.1995.tb07341.x; Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; BRON R, 1993, EMBO J, V12, P693, DOI 10.1002/j.1460-2075.1993.tb05703.x; Buckley JT, 1995, BIOCHEMISTRY-US, V34, P16450, DOI 10.1021/bi00050a028; CARRASCO L, 1993, NATO ADV SCI INST SE, V240, P283; CARRASCO L, 1978, NATURE, V272, P694, DOI 10.1038/272694a0; CARRASCO L, 1995, ADV VIRUS RES, V45, P61, DOI 10.1016/S0065-3527(08)60058-5; CARRASCO L, 1976, NATURE, V264, P807, DOI 10.1038/264807a0; CARRASCO L, 2002, PICORNAVIRUSES, P337; CRAMER WA, 1995, ANNU REV BIOPH BIOM, V24, P611, DOI 10.1146/annurev.biophys.24.1.611; Cuconati A, 1998, J VIROL, V72, P1297, DOI 10.1128/JVI.72.2.1297-1307.1998; de Jong AS, 2002, J GEN VIROL, V83, P783, DOI 10.1099/0022-1317-83-4-783; De los Rios V, 1998, EUR J BIOCHEM, V252, P284, DOI 10.1046/j.1432-1327.1998.2520284.x; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; FRANZEN JS, 1980, BIOCHEMISTRY-US, V19, P6080, DOI 10.1021/bi00567a021; Gerber D, 2000, J BIOL CHEM, V275, P23602, DOI 10.1074/jbc.M002596200; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Huang HW, 2000, BIOCHEMISTRY-US, V39, P8347, DOI 10.1021/bi000946l; LAMA J, 1992, J BIOL CHEM, V267, P15932; Masson L, 1999, J BIOL CHEM, V274, P31996, DOI 10.1074/jbc.274.45.31996; Matsuzaki K, 1998, BBA-REV BIOMEMBRANES, V1376, P391, DOI 10.1016/S0304-4157(98)00014-8; MCINTYRE JC, 1991, BIOCHEMISTRY-US, V30, P11819, DOI 10.1021/bi00115a012; Nagle JF, 2000, BBA-REV BIOMEMBRANES, V1469, P159, DOI 10.1016/S0304-4157(00)00016-2; Nicol F, 2000, BIOPHYS J, V78, P818, DOI 10.1016/S0006-3495(00)76639-2; Nir S, 2000, PROG LIPID RES, V39, P181, DOI 10.1016/S0163-7827(00)00004-7; PARENTE RA, 1990, BIOCHEMISTRY-US, V29, P8720, DOI 10.1021/bi00489a031; Rawicz W, 2000, BIOPHYS J, V79, P328, DOI 10.1016/S0006-3495(00)76295-3; ROST B, 1995, PROTEIN SCI, V4, P521; ROST B, 1993, P NATL ACAD SCI USA, V90, P7558, DOI 10.1073/pnas.90.16.7558; Sandoval IV, 1997, J VIROL, V71, P4679, DOI 10.1128/JVI.71.6.4679-4693.1997; Schwartz JL, 1997, FEBS LETT, V410, P397, DOI 10.1016/S0014-5793(97)00626-1; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; Shepard LA, 2000, BIOCHEMISTRY-US, V39, P10284, DOI 10.1021/bi000436r; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; Ubarretxena-Belandia I, 1999, BIOCHEMISTRY-US, V38, P7398, DOI 10.1021/bi983077x; VanKuppeveld FJM, 1997, VIROLOGY, V227, P111, DOI 10.1006/viro.1996.8320; vanKuppeveld FJM, 1997, EMBO J, V16, P3519, DOI 10.1093/emboj/16.12.3519; VANKUPPEVELD FJM, 1995, J VIROL, V69, P7782, DOI 10.1128/JVI.69.12.7782-7790.1995; vanKuppeveld FJM, 1996, J VIROL, V70, P3876, DOI 10.1128/JVI.70.6.3876-3886.1996; White SH, 1998, METHOD ENZYMOL, V295, P62; Zitzer A, 1999, J BIOL CHEM, V274, P1375, DOI 10.1074/jbc.274.3.1375	48	112	117	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40434	40441		10.1074/jbc.M205393200	http://dx.doi.org/10.1074/jbc.M205393200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183456	hybrid			2022-12-27	WOS:000178791400037
J	Krem, MM; Prasad, S; Di Cera, E				Krem, MM; Prasad, S; Di Cera, E			Ser(214) is crucial for substrate binding to serine proteases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; THROMBIN; SPECIFICITY; SUBSITE; PROTEIN; TRYPSIN; FORM; S2	Highly conserved amino acids that form crucial structural elements of the catalytic apparatus can be used to account for the evolutionary history of serine proteases and the cascades into which they are organized. One such evolutionary marker in chymotrypsin-like proteases is Ser(214), located adjacent to the active site and forming part of the primary specificity pocket. Here we report the mutation of Ser(214) in thrombin to Ala, Thr, Cys, Asp, Glu, and Lys. None of the mutants seriously compromises active site catalytic function as measured by the kinetic parameter k(cat). However, the least conservative mutations result in large increases in K-m because of lower rates of substrate diffusion into the active site. Therefore, the role of Ser(214) is to promote the productive formation of the enzyme-substrate complex. The S214C mutant is catalytically inactive, which suggests that during evolution the TCN-->AGY codon transitions for Ser(214) occurred through Thr intermediates.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, Box 8231, St Louis, MO 63110 USA.	enrico@biochem.wustl.edu			NHLBI NIH HHS [HL 49413, HL 58141] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049413, R01HL058141, R29HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arosio D, 2000, BIOCHEMISTRY-US, V39, P8095, DOI 10.1021/bi0006215; Ayala YM, 2000, PROTEIN SCI, V9, P1589, DOI 10.1110/ps.9.8.1589; Ayala YM, 2001, PROTEINS, V45, P107, DOI 10.1002/prot.1130; BARRETT AJ, 1995, ARCH BIOCHEM BIOPHYS, V318, P247, DOI 10.1006/abbi.1995.1227; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; EPSTEIN DM, 1992, BIOCHEMISTRY-US, V31, P11216, DOI 10.1021/bi00160a036; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; Guinto ER, 1997, BIOPHYS CHEM, V64, P103, DOI 10.1016/S0301-4622(96)02211-9; KIM S, 1995, J BIOL CHEM, V270, P24399, DOI 10.1074/jbc.270.41.24399; Krem MM, 2002, TRENDS BIOCHEM SCI, V27, P67, DOI 10.1016/S0968-0004(01)02007-2; Krem MM, 2001, EMBO J, V20, P3036, DOI 10.1093/emboj/20.12.3036; MCGRATH ME, 1992, BIOCHEMISTRY-US, V31, P3059, DOI 10.1021/bi00127a005; PERONA JJ, 1995, PROTEIN SCI, V4, P337; Pineda AO, 2002, J BIOL CHEM, V277, P40177, DOI 10.1074/jbc.C200465200; Pletnev VZ, 2000, PROTEINS, V41, P8, DOI 10.1002/1097-0134(20001001)41:1<8::AID-PROT30>3.0.CO;2-2; Rezaie AR, 1998, PROTEIN SCI, V7, P349; Rose T, 2002, J BIOL CHEM, V277, P19243, DOI 10.1074/jbc.C200132200; RUDENKO G, 1995, STRUCTURE, V3, P1249, DOI 10.1016/S0969-2126(01)00260-X; Shilton BH, 1997, BIOCHEMISTRY-US, V36, P9002, DOI 10.1021/bi970433n; Siezen RJ, 1997, PROTEIN SCI, V6, P501	21	42	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40260	40264		10.1074/jbc.M206173200	http://dx.doi.org/10.1074/jbc.M206173200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181318	hybrid			2022-12-27	WOS:000178791400015
J	Liou, GG; Chang, HY; Lin, CS; Sue, LC				Liou, GG; Chang, HY; Lin, CS; Sue, LC			Dead box Rh1B RNA helicase physically associates with exoribonuclease PNPase to degrade double-stranded RNA independent of the degradosome-assembling region of RNase E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; NUCLEOTIDE-SEQUENCE; RIBONUCLEASE-E; RIBOSOMAL-RNA; TERMINAL HALF; E-CLEAVAGE; PROTEIN; BACTERIA; COMPLEX	The Escherichia coli RNA degradosome is a multicomportent ribonucleolytic complex consisting of three major proteins that assemble on a scaffold provided by the C-terminal region of the endonuclease, RNase E. Using an E. coli two-hybrid system, together with BIAcore apparatus, we investigated the ability of three proteins, polynucleotide phosphorylase (PNPase), Rh1B RNA helicase, and enolase, a glycolytic protein, to interact physically and functionally independently of RNase E. Here ;we report that Rh1B can physically bind to PNPase, both in vitro and in vivo, and can also form homodimers with itself. However, binding of Rh1B or PNPase to enolase was not detected under the same conditions. BIAcore analysis revealed real-time, direct binding for bimolecular interactions between Rh1B units and for the Rh1B interaction with PNPase. Furthermore, in the absence of RNase E, purified Rh1B can carry out ATP-dependent unwinding of double-stranded RNA and consequently modulate degradation of double-stranded RNA together with the exonuclease activity of PNPase. These results provide evidence for the first time that both functional and physical interactions of individual degradosome protein components can occur in the absence of RNase E and raise the prospect that the RNase E-independent complexes of Rh1B RNA helicase and PNPase, detected in vivo, may constitute mini-machines that assist in the degradation of duplex RNA in structures physically distinct from multicomponent RNA degradosomes.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei 100, Taiwan; Natl Yang Ming Univ, Inst Biochem, Taipei 112, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Yang Ming Chiao Tung University	Sue, LC (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.	mbsue@ccvax.sinica.edu.tw	Lin-Chao, Sue/AGI-2030-2022; Liou, Gunn‐Guang/AAI-9787-2020; Lin-Chao, Sue/AAZ-8246-2021; Liou, Gan-Guang/E-3976-2010	Lin-Chao, Sue/0000-0002-8415-9304; Lin-Chao, Sue/0000-0002-8415-9304; Chang, Hsiang-Yu/0000-0001-5369-4016				Aloy P, 2002, EMBO REP, V3, P628, DOI 10.1093/embo-reports/kvf135; APIRION D, 1978, GENETICS, V90, P659; Bessarab DA, 1998, P NATL ACAD SCI USA, V95, P3157, DOI 10.1073/pnas.95.6.3157; Blum E, 1997, MOL MICROBIOL, V26, P387, DOI 10.1046/j.1365-2958.1997.5901947.x; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Coburn GA, 1999, GENE DEV, V13, P2594, DOI 10.1101/gad.13.19.2594; Coburn GA, 1999, PROG NUCLEIC ACID RE, V62, P55; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; Grunberg-Manago M, 1999, ANNU REV GENET, V33, P193, DOI 10.1146/annurev.genet.33.1.193; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HUTCHINSON AM, 1995, MOL BIOTECHNOL, V3, P47, DOI 10.1007/BF02821334; Jain C, 2002, MOL MICROBIOL, V43, P1053, DOI 10.1046/j.1365-2958.2002.02808.x; Kaberdin VR, 1998, P NATL ACAD SCI USA, V95, P11637, DOI 10.1073/pnas.95.20.11637; KALMAN M, 1991, NEW BIOL, V3, P886; Karimova G, 1998, P NATL ACAD SCI USA, V95, P5752, DOI 10.1073/pnas.95.10.5752; Kido M, 1996, J BACTERIOL, V178, P3917, DOI 10.1128/jb.178.13.3917-3925.1996; Kuhnel K, 2001, J MOL BIOL, V313, P583, DOI 10.1006/jmbi.2001.5065; Lee K, 2001, J BIOL CHEM, V276, P23268, DOI 10.1074/jbc.M102408200; Lin-Chao S, 1999, P NATL ACAD SCI USA, V96, P12406, DOI 10.1073/pnas.96.22.12406; LINCHAO S, 1994, J BIOL CHEM, V269, P10797; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; Liou GG, 2001, P NATL ACAD SCI USA, V98, P63, DOI 10.1073/pnas.011535498; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; Matson SW, 1995, METHOD ENZYMOL, V262, P389; MCDOWALL KJ, 1995, NATURE, V374, P287, DOI 10.1038/374287a0; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; Miller J. H, 1972, EXPT MOL GENETICS; Mitchell P, 2000, NAT STRUCT BIOL, V7, P843, DOI 10.1038/82817; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; Nicholson AW, 1999, FEMS MICROBIOL REV, V23, P371, DOI 10.1016/S0168-6445(99)00013-3; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Rauhut R, 1999, FEMS MICROBIOL REV, V23, P353, DOI 10.1016/S0168-6445(99)00012-1; Regnier P, 2000, BIOESSAYS, V22, P235; REGNIER P, 1987, J BIOL CHEM, V262, P63; SPRING TG, 1971, J BIOL CHEM, V246, P6797; Steege DA, 2000, RNA, V6, P1079, DOI 10.1017/S1355838200001023; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Vanzo NF, 1998, GENE DEV, V12, P2770, DOI 10.1101/gad.12.17.2770	45	94	95	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41157	41162		10.1074/jbc.M206618200	http://dx.doi.org/10.1074/jbc.M206618200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181321	hybrid			2022-12-27	WOS:000178791400126
J	Smedberg, JL; Smith, ER; Capo-chichi, CD; Frolov, A; Yang, DH; Godwin, AK; Xu, XX				Smedberg, JL; Smith, ER; Capo-chichi, CD; Frolov, A; Yang, DH; Godwin, AK; Xu, XX			Ras/MAPK pathway confers basement membrane dependence upon endoderm differentiation of embryonic carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR ELK-1; F9 TERATOCARCINOMA CELLS; MAP KINASE ACTIVATION; C-FOS EXPRESSION; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; TARGETED DISRUPTION; VISCERAL ENDODERM; PARIETAL ENDODERM	The formation of extraembryonic endoderm is one of the earliest steps in the differentiation of pluripotent cells of the inner cell mass during the early stages of embryonic development. The primitive endoderm cells and the derived parietal and visceral endoderm cells gain the capacity to produce collagen IV and laminin. The deposition of these components results in the formation of basement membrane and epithelium of the endoderm, with polarized cells covering the inner surface of the blastocoels. We used retinoic acid-induced endoderm differentiation of stem cell-like F9 embryonic carcinoma cells to study the role of the Ras pathway and its regulation in the formation of the visceral endoderm. Upon endoderm differentiation of F9 cells induced by retinoic acid, c-Fos expression, the downstream target of the Ras pathway, is suppressed by uncoupling Elk-1 phosphorylation/activation to MAPK activity. However, attachment to matrix gel greatly enhances the activation of MAPK in endoderm cells but not in undifferentiated F9 cells. Enhanced MAPK activation as a result of contact with basement membrane is able to compensate for reduced Elk-1 phosphorylation and c-Fos expression. We conclude that endoderm differentiation renders the activation of the Ras pathway basement membrane dependent, contributing to the epithelial organization of the visceral endoderm.	Fox Chase Canc Ctr, Div Med Sci, Dept Med Oncol, Ovarian Canc Program, Philadelphia, PA 19111 USA; Fox Chase Canc Ctr, Div Med Sci, Dept Med Oncol, Tumor Cell Biol Program, Philadelphia, PA 19111 USA	Fox Chase Cancer Center; Fox Chase Cancer Center	Xu, XX (corresponding author), Fox Chase Canc Ctr, Div Med Sci, Dept Med Oncol, Ovarian Canc Program, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	X_XU@fccc.edu	Capo-chichi, Deylosse Callinice/AAP-4937-2020		NCI NIH HHS [R01 CA 095071, R01 CA 75389, P50 CA 83638, R01 CA 79716] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079716, P50CA083638, R01CA075389, R01CA095071] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1993, DEVELOPMENT, V117, P1183; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Arteaga CL, 1996, CANCER RES, V56, P1098; BEERS WH, 1975, CELL, V6, P387, DOI 10.1016/0092-8674(75)90188-9; Bielinska M, 1999, INT J DEV BIOL, V43, P183; BISSELL MJ, 1987, J CELL SCI, P327; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Buss F, 2001, FEBS LETT, V508, P295, DOI 10.1016/S0014-5793(01)03065-4; CAPOCHICHI CD, 2002, IN PRESS CANCER; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Cho SY, 1999, MOL CELLS, V9, P179; COUCHMAN JR, 1990, J INVEST DERMATOL, V94, pS7, DOI 10.1111/1523-1747.ep12874973; Cruzalegui FH, 1999, ONCOGENE, V18, P7948, DOI 10.1038/sj.onc.1203362; CURRAN T, 1985, CANCER SURV, V4, P655; DENNEFORS B, 1982, PROSTAGLANDINS, V24, P295, DOI 10.1016/0090-6980(82)90156-3; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; Faria TN, 1998, MOL CELL ENDOCRINOL, V143, P155, DOI 10.1016/S0303-7207(98)00127-0; Faria TN, 1999, J BIOL CHEM, V274, P26783, DOI 10.1074/jbc.274.38.26783; Fazili Z, 1999, ONCOGENE, V18, P3104, DOI 10.1038/sj.onc.1202649; Gajovic S, 1998, EXP CELL RES, V242, P138, DOI 10.1006/excr.1998.4058; Goldstein LSB, 2001, SCIENCE, V291, P2102, DOI 10.1126/science.1059766; GROVE A, 1986, DEV BIOL, V114, P492, DOI 10.1016/0012-1606(86)90213-7; He JQ, 2001, J BIOL CHEM, V276, P26814, DOI 10.1074/jbc.M101820200; Holt J, 1992, Cancer Treat Res, V63, P301; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Howell BW, 2001, CURR OPIN NEUROBIOL, V11, P74, DOI 10.1016/S0959-4388(00)00176-8; HU ED, 1994, EMBO J, V13, P3094, DOI 10.1002/j.1460-2075.1994.tb06608.x; INGBER DE, 1986, AM J PATHOL, V122, P129; Inoue A, 2002, BIOCHEM BIOPH RES CO, V292, P300, DOI 10.1006/bbrc.2002.6636; Iwata A, 2001, J NEUROCHEM, V77, P239, DOI 10.1046/j.1471-4159.2001.t01-1-00232.x; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Martin G R, 1983, Monogr Pathol, V24, P16; MARTINEZHERNANDEZ A, 1976, LAB INVEST, V34, P455; MASON I, 1985, DIFFERENTIATION, V30, P76, DOI 10.1111/j.1432-0436.1985.tb00516.x; Mok SC, 1998, ONCOGENE, V16, P2381, DOI 10.1038/sj.onc.1201769; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Morrisey EE, 2000, J BIOL CHEM, V275, P19949, DOI 10.1074/jbc.M001331200; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; Okamura H, 1985, Adv Prostaglandin Thromboxane Leukot Res, V15, P597; Oleinikov AV, 2000, BIOCHEM J, V347, P613, DOI 10.1042/0264-6021:3470613; PANARETTO BA, 1994, J CELL SCI, V107, P747; PAWSON T, 1993, DEV GENET, V14, P333, DOI 10.1002/dvg.1020140502; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; Schlaepfer DD, 1996, CELL STRUCT FUNCT, V21, P445, DOI 10.1247/csf.21.445; Sheng ZJ, 2001, GENE, V268, P31, DOI 10.1016/S0378-1119(01)00401-2; Sheng ZJ, 2000, ONCOGENE, V19, P4847, DOI 10.1038/sj.onc.1203853; SHERMAN MI, 1978, DEV BIOL, V63, P27, DOI 10.1016/0012-1606(78)90110-0; Smith ER, 2001, J BIOL CHEM, V276, P47303, DOI 10.1074/jbc.M106158200; Smith ER, 2001, J BIOL CHEM, V276, P32094, DOI 10.1074/jbc.M105009200; Sugimoto T, 1997, J BIOL CHEM, V272, P29415, DOI 10.1074/jbc.272.47.29415; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; TALBOT P, 1987, GAMETE RES, V17, P287, DOI 10.1002/mrd.1120170403; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yang DH, 2002, CANCER-AM CANCER SOC, V94, P2380, DOI 10.1002/cncr.10497; YANG DH, 2002, IN PRESS DEV BIOL; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	69	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40911	40918		10.1074/jbc.M205178200	http://dx.doi.org/10.1074/jbc.M205178200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12145292	hybrid			2022-12-27	WOS:000178791400097
J	Gao, NG; Lehrman, MA				Gao, NG; Lehrman, MA			Coupling of the dolichol-P-P-oligosaccharide pathway to translation by perturbation-sensitive regulation of the initiating enzyme, GlcNAc-1-P transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-ISOPRENYLTRANSFERASE ACTIVITY; LIPID-LINKED OLIGOSACCHARIDES; PHOSPHATE-MANNOSE SYNTHASE; HAMSTER OVARY CELLS; ENDOPLASMIC-RETICULUM; PROTEIN-SYNTHESIS; N-GLYCOSYLATION; GENE ENCODES; BIOSYNTHESIS; RESISTANCE	In mammalian cells, inhibition of translation interferes with synthesis of the lipid-linked oligosaccharide (LLO) Glc(3)Man(9)GlcNAc(2)-P-P-dolichol as measured with radioactive sugar precursors. Conflicting hypotheses have been proposed, and the fundamental basis for this regulation has remained elusive. Here, fluorophore-assisted carbohydrate electrophoresis (FACE) was used to measure LLO concentrations directly in cells treated with translation blockers. Further, LLO biosynthetic enzymes were assayed in vitro with endogenous acceptor substrates using either cells gently permeabilized with streptolysin-O (SLO) or microsomes from homogenized cells. In Chinese hamster ovary (CHO)-K1 cells treated with translation blockers, FACE did not detect changes in concentrations of Glc(3)Man(9)GlcNAc(2)-P-P-dolichol or early LLO intermediates. These results do not support earlier proposals for feedback repression of LLO initiation by accumulated Glc(3)Man(9)GlcNAc(2)-P-P-dolichol, or inhibition of a GDP-mannose dependent transferase. With microsomes from cells treated with translation blockers, there was no interference with LLO initiation by GlcNAc-1-P transferase (GPT), mannose-P-dolichol synthase, glucose-P-dolichol synthase, or LLO synthesis in vitro, as reported previously. Surprisingly, inhibition of all of these was detected with the SLO in vitro system. Additional experiments with the SLO system showed that the three transferases shared a limited pool of dolichol-P that was trapped as Glc(3)Man(9)GlcNAc(2)-P-P-dolichol by translation arrest. Overexpression of GPT was unable to reverse the effects of translation arrest on LLO initiation, and experiments with FACE and the SLO system showed that overexpressed GPT was not functional in vivo, although it was highly active in microsomal assays. Thus, the combined use of the SLO in vitro system and FACE showed that LLO biosynthesis depends upon a limited primary pool of dolichol-P. Physical perturbation associated with microsome preparation appears to make available a secondary pool of dolichol-P, masking inhibition by translation arrest, as well as activating a nonfunctional fraction of GPT. The implications of these results for the organization of the LLO pathway are discussed.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Lehrman, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	mlehrm@mednet.swmed.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM038545, R01GM038545] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38545] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anand M, 2001, MOL BIOL CELL, V12, P487, DOI 10.1091/mbc.12.2.487; Chantret I, 2002, J BIOL CHEM, V277, P25815, DOI 10.1074/jbc.M203285200; CRICK DC, 1994, J BIOL CHEM, V269, P10559; CRICK DC, 1994, J NEUROCHEM, V62, P247; CRISCUOLO BA, 1982, J CELL BIOL, V94, P586, DOI 10.1083/jcb.94.3.586; Dan N, 1996, J BIOL CHEM, V271, P30717, DOI 10.1074/jbc.271.48.30717; DATTA AK, 1993, J BIOL CHEM, V268, P12663; Doerrler WT, 1999, P NATL ACAD SCI USA, V96, P13050, DOI 10.1073/pnas.96.23.13050; Fernandez F, 2001, J BIOL CHEM, V276, P41455, DOI 10.1074/jbc.M105544200; Gao NG, 2002, GLYCOBIOLOGY, V12, P353, DOI 10.1093/glycob/12.5.353; GRANT SR, 1983, EUR J BIOCHEM, V134, P575, DOI 10.1111/j.1432-1033.1983.tb07605.x; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Helenius J, 2002, NATURE, V415, P447, DOI 10.1038/415447a; HUBBARD SC, 1980, J BIOL CHEM, V255, P1782; Kean EL, 1999, J BIOL CHEM, V274, P34072, DOI 10.1074/jbc.274.48.34072; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KRAG SS, 1977, J BIOL CHEM, V252, P2621; LEHRMAN M A, 1991, Glycobiology, V1, P553, DOI 10.1093/glycob/1.6.553; LEHRMAN MA, 1989, J BIOL CHEM, V264, P1584; LEHRMAN MA, 1988, J BIOL CHEM, V263, P19796; Lehrman MA, 2001, J BIOL CHEM, V276, P8623, DOI 10.1074/jbc.R100002200; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Marquardt T, 2001, BIOL CHEM, V382, P161, DOI 10.1515/BC.2001.024; MARTYS JL, 1995, J BIOL CHEM, V270, P25976, DOI 10.1074/jbc.270.43.25976; PAN YT, 1990, BIOCHEMISTRY-US, V29, P8077, DOI 10.1021/bi00487a013; ROSENWALD AG, 1990, J BIOL CHEM, V265, P14544; Schenk B, 2001, GLYCOBIOLOGY, V11, p61R, DOI 10.1093/glycob/11.5.61R; SCHER MG, 1984, ARCH BIOCHEM BIOPHYS, V231, P293, DOI 10.1016/0003-9861(84)90391-6; SCHMITT JW, 1979, J BIOL CHEM, V254, P2291; SCHUTZBACH JS, 1993, J BIOL CHEM, V268, P24190; Shang J, 2002, GLYCOBIOLOGY, V12, P307, DOI 10.1093/glycob/12.5.307; SNIDER MD, 1984, CELL, V36, P753, DOI 10.1016/0092-8674(84)90355-6; SPIRO MJ, 1986, J BIOL CHEM, V261, P4725; SPIRO MJ, 1976, J BIOL CHEM, V251, P6400; SPIRO MJ, 1991, J BIOL CHEM, V266, P5311; ZENG Y, 1991, ANAL BIOCHEM, V193, P266, DOI 10.1016/0003-2697(91)90020-T; ZENG YC, 1990, J BIOL CHEM, V265, P2296; ZHU XY, 1992, J BIOL CHEM, V267, P8895; ZIMMERMAN JW, 1993, J BIOL CHEM, V268, P16746	40	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39425	39435		10.1074/jbc.M205195200	http://dx.doi.org/10.1074/jbc.M205195200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176988	hybrid			2022-12-27	WOS:000178662500048
J	Jona, G; Livi, LL; Gileadi, O				Jona, G; Livi, LL; Gileadi, O			Mutations in the RING domain of TFB3, a subunit of yeast transcription factor IIH, reveal a role in cell cycle progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; CDK-ACTIVATING KINASE; NUCLEOTIDE EXCISION-REPAIR; C-TERMINAL DOMAIN; IN-VIVO; SACCHAROMYCES-CEREVISIAE; DEPENDENT KINASE; FACTOR TFIIH; FISSION YEAST; BUDDING YEAST	The RNA polymerase II general transcription factor TFIIH is composed of 9 known subunits and possesses DNA helicase and protein kinase activities. The kinase subunits of TFIIH in animal cells, Cdk7, cyclin H, and MAT1, were independently isolated as an activity termed CAK (Cdk-activating kinase), which phosphorylates and activates cell cycle kinases. However, CAK activity of TFIIH subunits could not be demonstrated in budding yeast. TFB3, the 38-kDa subunit of yeast TFIIH, is the homolog of mammalian MAT1. By random mutagenesis we have isolated a temperature-sensitive mutation in the conserved RING domain. The mutant Tfb3 protein associates less efficiently with the kinase moiety of TFIIH than the wild type protein. In contrast to lethal mutants in other subunits of TFIIH, this mutation does not impair general transcription. Transcription of CLB2, and possibly other genes, is reduced in the mutant. At the restrictive temperature, the cells display a defect in cell cycle progression, which is manifest at more than one phase of the cycle. To conclude, in the present study we bring another demonstration of the multifunctional nature of TFIIH.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Gileadi, O (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, POB 208103, New Haven, CT 06520 USA.	opher@quantomix.com	Gileadi, Opher/F-1105-2013	Gileadi, Opher/0000-0001-6886-898X; Jona, Ghil/0000-0002-4526-6182				Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Buck V, 1995, EMBO J, V14, P6173, DOI 10.1002/j.1460-2075.1995.tb00308.x; Buratowski S, 2000, CURR OPIN CELL BIOL, V12, P320, DOI 10.1016/S0955-0674(00)00095-8; Busso D, 2000, J BIOL CHEM, V275, P22815, DOI 10.1074/jbc.M002578200; Chi Y, 2001, GENE DEV, V15, P1078, DOI 10.1101/gad.867501; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Damagnez V, 1995, EMBO J, V14, P6164, DOI 10.1002/j.1460-2075.1995.tb00307.x; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; Espinoza FH, 1998, MOL CELL BIOL, V18, P6365, DOI 10.1128/MCB.18.11.6365; Faye G, 1997, MOL GEN GENET, V255, P460, DOI 10.1007/s004380050518; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; Feaver WJ, 2000, J BIOL CHEM, V275, P5941, DOI 10.1074/jbc.275.8.5941; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Frit P, 1999, BIOCHIMIE, V81, P27, DOI 10.1016/S0300-9084(99)80035-2; Gervais V, 2001, J BIOL CHEM, V276, P7457, DOI 10.1074/jbc.M007963200; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; Guzman E, 1999, MOL CELL BIOL, V19, P5652; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Hermand D, 1998, EMBO J, V17, P7230, DOI 10.1093/emboj/17.24.7230; Hermand D, 2001, EMBO J, V20, P82, DOI 10.1093/emboj/20.1.82; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jona G, 2000, BBA-GENE STRUCT EXPR, V1491, P37, DOI 10.1016/S0167-4781(00)00016-6; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Kaiser C., 1994, METHODS YEAST GENETI; Kaldis P, 2000, EUR J BIOCHEM, V267, P4213, DOI 10.1046/j.1432-1327.2000.01455.x; Kaldis P, 1996, CELL, V86, P553, DOI 10.1016/S0092-8674(00)80129-4; Kaldis P, 1998, J CELL SCI, V111, P3585; Keogh MC, 2002, MOL CELL BIOL, V22, P1288, DOI 10.1128/MCB.22.5.1288-1297.2002; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; Lee TI, 2000, ANNU REV GENET, V34, P77, DOI 10.1146/annurev.genet.34.1.77; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; Ostapenko D, 2000, GENE, V245, P109, DOI 10.1016/S0378-1119(00)00029-9; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; SIKORSKI RS, 1989, GENETICS, V122, P19; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; Spangler L, 2001, P NATL ACAD SCI USA, V98, P5544, DOI 10.1073/pnas.101004498; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; Svejstrup JQ, 1996, TRENDS BIOCHEM SCI, V21, P346, DOI 10.1016/0968-0004(96)10046-3; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; Umeda M, 1998, P NATL ACAD SCI USA, V95, P5021, DOI 10.1073/pnas.95.9.5021; Walker SS, 1997, CELL, V90, P607, DOI 10.1016/S0092-8674(00)80522-X; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7	55	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39409	39416		10.1074/jbc.M202733200	http://dx.doi.org/10.1074/jbc.M202733200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176978	hybrid			2022-12-27	WOS:000178662500046
J	Ostrovsky, O; Bengal, E; Aronheim, A				Ostrovsky, O; Bengal, E; Aronheim, A			Induction of terminal differentiation by the c-Jun dimerization protein JDP2 in C2 myoblasts and rhabdomyosarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE DIFFERENTIATION; DIAGNOSTIC UTILITY; REGULATORY FACTORS; AP-1 REPRESSOR; KINASE PATHWAY; DNA-BINDING; CYCLIN D1; MYOD; EXPRESSION; ACTIVATION	Muscle cell differentiation is a result of a complex interplay between transcription factors and cell signaling proteins. Proliferating myoblasts must exit from the cell cycle prior to their differentiation. The muscle regulatory factor and myocyte enhancer factor-2 protein families play a major role in promoting muscle cell differentiation. Conversely, members of the AP-1 family of transcription factors that promote cell proliferation antagonize muscle cell differentiation. Here we tested the role of the c-Jun dimerization protein JDP2 in muscle cell differentiation. Endogenous expression of JDP2 was induced in both C2C12 myoblast and rhabdomyosarcoma (RD) cells programmed to differentiate. Ectopic expression of JDP2 in C2C12 myoblast cells inhibited cell cycle progression and induced spontaneous muscle cell differentiation. Likewise, constitutive expression of JDP2 in RD cells reduced their tumorigenic characteristics and restored their ability to differentiate into myotubes. JDP2 potentiated and synergized with 12-O-tetradecanoylphorbol-13-acetate to induce muscle cell differentiation of RD cells. In addition, JDP2 induced p38 activity in both C2 and RD cells programmed to differentiate. This is the first demonstration of a single transcription factor that rescues the myogenic program in an otherwise non-differentiating cancer cell line. Our results indicate that the JDP2 protein plays a major role in promoting skeletal muscle differentiation via its involvement in cell cycle arrest and activation of the myogenic program.	Technion Israel Inst Technol, Fac Med, B Rappaport Inst Res Med Sci, Dept Mol Genet, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, B Rappaport Inst Res Med Sci, Dept Biochem, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Bengal, E (corresponding author), Technion Israel Inst Technol, B Rappaport Fac Med, Dept Mol Genet, 7 Efron St Bat Galim,POB 9649, IL-31096 Haifa, Israel.			Aronheim, Ami/0000-0002-8575-4092				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Allan AL, 2001, J BIOL CHEM, V276, P27272, DOI 10.1074/jbc.M103196200; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BOUCHE M, 1993, EXP CELL RES, V208, P209, DOI 10.1006/excr.1993.1239; Broder YC, 1998, CURR BIOL, V8, P1121, DOI 10.1016/S0960-9822(98)70467-1; DEGIOVANNI C, 1995, BRIT J CANCER, V72, P1224, DOI 10.1038/bjc.1995.490; DIAS P, 1992, CANCER RES, V52, P6431; DIAS P, 1990, AM J PATHOL, V137, P1283; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Heller H, 2001, J BIOL CHEM, V276, P37307, DOI 10.1074/jbc.M103195200; Jin CY, 2002, MOL CELL BIOL, V22, P4815, DOI 10.1128/MCB.22.13.4815-4826.2002; Jin CY, 2001, FEBS LETT, V489, P34, DOI 10.1016/S0014-5793(00)02387-5; Katz S, 2001, FEBS LETT, V506, P196, DOI 10.1016/S0014-5793(01)02907-6; Knudsen ES, 1998, CANCER RES, V58, P2042; Lehtinen SK, 1996, BIOCHEM BIOPH RES CO, V229, P36, DOI 10.1006/bbrc.1996.1754; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 2000, GENE DEV, V14, P574; Reynaud EG, 2000, J BIOL CHEM, V275, P18767, DOI 10.1074/jbc.M907412199; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Tamir Y, 2000, J BIOL CHEM, V275, P34424, DOI 10.1074/jbc.M005815200; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Wardell SE, 2002, MOL CELL BIOL, V22, P5451, DOI 10.1128/MCB.22.15.5451-5466.2002; Wei Q, 2001, FEBS LETT, V490, P171, DOI 10.1016/S0014-5793(01)02120-2; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	31	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40043	40054		10.1074/jbc.M205494200	http://dx.doi.org/10.1074/jbc.M205494200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171923	hybrid			2022-12-27	WOS:000178662500125
J	Sato, S; Fujita, N; Tsuruo, T				Sato, S; Fujita, N; Tsuruo, T			Regulation of kinase activity of 3-phosphoinositide-dependent protein kinase-1 by binding to 14-3-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; PDK1; ACTIVATION; 14-3-3-PROTEINS; IDENTIFICATION; TRANSLOCATION; PHOSPHOSERINE; 3-KINASE; SIGNAL; SITES	3-Phosphoinositide-dependent protein kinase-1 (PDK1) plays a central role in activating the protein kinase A, G, and C subfamily. In particular, PDK1 plays an important role in regulating the Akt survival pathway by phosphorylating Akt on Thr-308. PDK1 kinase activity was thought to be constitutively active; however, recent reports suggested that its activity is regulated by binding to other proteins, such as protein kinase G-related kinase-2 (PRK2), p90 ribosomal protein S6 kinase-2 (RSK2), and heat-shock protein 90 (Hsp90). Here we report that PDK1 binds to 14-3-3 proteins in vivo and in vitro through the sequence surrounding Ser-241, a residue that is phosphorylated by itself and is critical for its kinase activity. Mutation of PDK1 to increase its binding to 14-3-3 decreased its kinase activity in vivo. By contrast, mutation of PDK1 to decrease its interaction with 14-3-3 resulted in increased PDK1 kinase activity. Moreover, incubation of wild-type PDK1 with recombinant 14-3-3 in vitro decreased its kinase activity. These data indicate that PDK1 kinase activity is negatively regulated by binding to 14-3-3 through the PDK1 autophosphorylation site Ser-241.	Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Tokyo 1130032, Japan.		Fujita, Naoya/A-7349-2010	Fujita, Naoya/0000-0002-9631-9264				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Grillo S, 2000, EUR J BIOCHEM, V267, P6642, DOI 10.1046/j.1432-1327.2000.01759.x; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Mils V, 2000, ONCOGENE, V19, P1257, DOI 10.1038/sj.onc.1203419; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Sato S, 2002, ONCOGENE, V21, P1727, DOI 10.1038/sj.onc.1205225; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	31	79	83	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39360	39367		10.1074/jbc.M205141200	http://dx.doi.org/10.1074/jbc.M205141200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177059	hybrid			2022-12-27	WOS:000178662500040
J	Callejo, M; Alvarez, D; Price, GB; Zannis-Hadjopoulos, M				Callejo, M; Alvarez, D; Price, GB; Zannis-Hadjopoulos, M			The 14-3-3 protein homologues from Saccharomyces cerevisiae, Bmh1p and Bmh2p, have cruciform DNA-binding activity and associate in vivo with ARS307	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-FREQUENCY TRANSFORMATION; MONOCLONAL-ANTIBODIES; 14-3-3-PROTEIN FAMILY; REPLICATION ORIGIN; MAMMALIAN ORIGINS; MOLECULAR-CLONING; CHROMOSOME-III; YEAST; BRAIN; SPECIFICITY	We have previously shown that, in human cells, cruciform DNA-binding activity is due to 14-3-3 proteins (Todd, A., Cossons, N., Aitken, A., Price, G. B., and Zannis-Hadjopoulos, M. (1998) Biochemistry 37, 14317-14325). Here, wild-type and single- and double-knockout nuclear extracts from the 14-3-3 Saccharomyces cerevisiae homologues Bmh1p and Bmh2p were analyzed for similar cruciform-binding activities in relation to these proteins. The Bmh1p-Bmh2p heterodimer, present in the wild-type strain, bound efficiently to cruciform-containing DNA in a structure-specific manner because cruciform DNA efficiently competed with the formation of the complex, whereas linear DNA did not. In contrast, the band-shift ability of the Bmh1p-Bmh1p and Bmh2p-Bmh2p homodimers present in the bmh2(-) and bmh1(-) single-knockout cells, respectively, was reduced by similar to93 and 82%, respectively. The 14-3-3 plant homologue GF14 was also able to bind to cruciform DNA, suggesting that cruciform-binding activity is a common feature of the family of 14-3-3 proteins across species. Bmh1p and Bmh2p were found to associate in vivo with the yeast autonomous replication sequence ARS307, as assayed by formaldehyde cross-linking, followed by immunoprecipitation with anti-Bmh1p/Bmh2p antibody and conventional PCR. In agreement with the finding of an association of Bmh1p and Bmh2p with ARS307, another immunoprecipitation experiment using 2D3, an anti-cruciform DNA monoclonal antibody, revealed the presence of cruciform-containing DNA in ARS307.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Zannis-Hadjopoulos, M (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	maria.zannis@mcgill.ca						AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; AUSUBEL F, 2001, CURRENT PROTOCOLS MO, V2; BELL D, 1991, BIOCHIM BIOPHYS ACTA, V1089, P299, DOI 10.1016/0167-4781(91)90169-M; CELIS JE, 1990, ELECTROPHORESIS, V11, P989, DOI 10.1002/elps.1150111202; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; FRAPPIER L, 1987, J MOL BIOL, V193, P751, DOI 10.1016/0022-2836(87)90356-1; FRAPPIER L, 1989, J BIOL CHEM, V264, P334; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Garcia-Guzman M, 1999, J BIOL CHEM, V274, P5762, DOI 10.1074/jbc.274.9.5762; HSIAO CL, 1979, P NATL ACAD SCI USA, V76, P3829, DOI 10.1073/pnas.76.8.3829; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; Jin RZ, 2001, PLASMID, V46, P95, DOI 10.1006/plas.2001.1535; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; LIN LS, 1987, NUCLEIC ACIDS RES, V15, P8319, DOI 10.1093/nar/15.20.8319; LU GH, 1992, P NATL ACAD SCI USA, V89, P11490, DOI 10.1073/pnas.89.23.11490; MARTIN H, 1993, FEBS LETT, V331, P296, DOI 10.1016/0014-5793(93)80356-Y; Moore BE, 1967, PHYSL BIOCH ASPECTS, P343; NOIROT P, 1990, P NATL ACAD SCI USA, V87, P8560, DOI 10.1073/pnas.87.21.8560; Novac O, 2002, J BIOL CHEM, V277, P11174, DOI 10.1074/jbc.M107902200; Novac O, 2001, MOL BIOL CELL, V12, P3386, DOI 10.1091/mbc.12.11.3386; PALZKILL TG, 1986, NUCLEIC ACIDS RES, V14, P6247, DOI 10.1093/nar/14.15.6247; PEARSON CE, 1995, EMBO J, V14, P1571, DOI 10.1002/j.1460-2075.1995.tb07143.x; PEARSON CE, 1994, BIOCHEMISTRY-US, V33, P14185, DOI 10.1021/bi00251a030; POGUE GP, 1992, J VIROL, V66, P674, DOI 10.1128/JVI.66.2.674-684.1992; RAO H, 1994, MOL CELL BIOL, V14, P7643, DOI 10.1128/MCB.14.11.7643; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rosenquist M, 2000, J MOL EVOL, V51, P446, DOI 10.1007/s002390010107; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; STEINMETZER K, 1995, J MOL BIOL, V254, P29, DOI 10.1006/jmbi.1995.0596; STRUHL K, 1979, P NATL ACAD SCI USA, V76, P1035, DOI 10.1073/pnas.76.3.1035; TAKAHASHI K, 2000, SCI STKE, V56, P1; Tang SJ, 1998, J BIOL CHEM, V273, P25356, DOI 10.1074/jbc.273.39.25356; THEIS JF, 1994, MOL CELL BIOL, V14, P7652, DOI 10.1128/MCB.14.11.7652; Todd A, 1998, BIOCHEMISTRY-US, V37, P14317, DOI 10.1021/bi980768k; van Hemert MJ, 2001, YEAST, V18, P889, DOI 10.1002/yea.739; vanHeusden GPH, 1996, FEBS LETT, V391, P252, DOI 10.1016/0014-5793(96)00746-6; VANHEUSDEN GPH, 1995, EUR J BIOCHEM, V229, P45; VANHEUSDEN GPH, 1992, FEBS LETT, V302, P145, DOI 10.1016/0014-5793(92)80426-H; VANHOUTEN JV, 1990, MOL CELL BIOL, V10, P3917, DOI 10.1128/MCB.10.8.3917; Wang WF, 1996, J MOL EVOL, V43, P384; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; ZANNISHADJOPOULOS M, 1988, EMBO J, V7, P1837, DOI 10.1002/j.1460-2075.1988.tb03016.x	44	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38416	38423		10.1074/jbc.M202050200	http://dx.doi.org/10.1074/jbc.M202050200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167636	hybrid			2022-12-27	WOS:000178529600055
J	Lu, M; Vergara, S; Zhang, L; Holliday, LS; Aris, J; Gluck, SL				Lu, M; Vergara, S; Zhang, L; Holliday, LS; Aris, J; Gluck, SL			The amino-terminal domain of the E subunit of vacuolar H+-ATPase (V-ATPase) interacts with the H subunit and is required for V-ATPase function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; SYNTHASE; MEMBRANE; PROTEIN; COMPLEX; KIDNEY; (H+)-ATPASE; STALK; FORMS; YEAST	Vacuolar H+-ATPases (V-ATPases) are highly conserved proton pumps that couple hydrolysis of cytosolic ATP to proton transport out of the cytosol. Although it is generally believed that V-ATPases transport protons by a rotary catalytic mechanism analogous to that used by F1F0-ATPases, the structure and subunit composition of the central or peripheral stalk of the multisubunit complex are not well understood. We searched for proteins that bind to the E subunit of V-ATPase using the yeast two-hybrid assay and identified the H subunit as an interacting partner. Physical association between the E and H subunits of V-ATPase was confirmed in vitro by precipitation assays. Deletion mapping analysis revealed that a 78-amino acid fragment at the amino terminus of the E subunit was sufficient for binding to the H subunit. Expression of the amino-terminal fragments of the E subunits from human and yeast as dominant-negative mutants resulted in dramatic decreases in bafilomycin A(1)-sensitive ATP hydrolysis and proton transport activities of V-ATPase. Our data demonstrate the physiological significance of the interaction between the E and H subunits of V-ATPase and extend previous studies on the arrangement of subunits on the peripheral stalk of V-ATPase.	Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ Florida, Coll Dent, Dept Orthodont, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Lu, M (corresponding author), Univ Florida, Coll Med, Dept Med, Campus Box 100224,Rm CG-98,1600 SW Archer Rd, Gainesville, FL 32610 USA.		Holliday, Lexie/GYQ-4972-2022	Holliday, Lexie/0000-0002-0844-1965; Aris, John/0000-0002-6475-064X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054362, R01DK038848] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK54362, R01 DK38848] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arata Y, 2002, J BIOL CHEM, V277, P3357, DOI 10.1074/jbc.M109967200; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; Boekema EJ, 1997, P NATL ACAD SCI USA, V94, P14291, DOI 10.1073/pnas.94.26.14291; Breton S, 2000, J BIOL CHEM, V275, P18219, DOI 10.1074/jbc.M909857199; Cherepanov DA, 1999, FEBS LETT, V449, P1, DOI 10.1016/S0014-5793(99)00386-5; FOURY F, 1990, J BIOL CHEM, V265, P18554; GLUCK S, 1982, P NATL ACAD SCI-BIOL, V79, P4327, DOI 10.1073/pnas.79.14.4327; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; HEMKEN P, 1992, J BIOL CHEM, V267, P9948; HIRSCH S, 1988, P NATL ACAD SCI USA, V85, P3004, DOI 10.1073/pnas.85.9.3004; HO MN, 1993, J BIOL CHEM, V268, P18286; Holliday LS, 2000, J BIOL CHEM, V275, P32331, DOI 10.1074/jbc.M004795200; James P, 1996, GENETICS, V144, P1425; Kane PM, 2000, FEBS LETT, V469, P137, DOI 10.1016/S0014-5793(00)01265-5; Landolt-Marticorena C, 2000, J BIOL CHEM, V275, P15449, DOI 10.1074/jbc.M000207200; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; Lu XB, 1998, IMMUNITY, V8, P647, DOI 10.1016/S1074-7613(00)80569-5; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; NELSON N, 1992, BIOCHIM BIOPHYS ACTA, V1100, P109; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Skinner MA, 1999, J BIOL CHEM, V274, P23119, DOI 10.1074/jbc.274.33.23119; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; UCHIDA E, 1985, J BIOL CHEM, V260, P1090; Wilkens S, 1999, J BIOL CHEM, V274, P31804, DOI 10.1074/jbc.274.45.31804; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908; Xu T, 1999, J BIOL CHEM, V274, P28909, DOI 10.1074/jbc.274.41.28909	28	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38409	38415		10.1074/jbc.M203521200	http://dx.doi.org/10.1074/jbc.M203521200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163484	hybrid			2022-12-27	WOS:000178529600054
J	Benesch, S; Lommel, S; Steffen, A; Stradal, TEB; Scaplehorn, N; Way, M; Wehland, J; Rottner, K				Benesch, S; Lommel, S; Steffen, A; Stradal, TEB; Scaplehorn, N; Way, M; Wehland, J; Rottner, K			Phosphatidylinositol 4,5-biphosphate (PIP2)-induced vesicle movement depends on N-WASP and involves Nck, WIP, and Grb2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; ACTIN-BASED MOTILITY; ARP2/3 COMPLEX; CDC42; RECRUITMENT; ACTIVATION; ENDOSOMES; LYSOSOMES; PATHWAYS; SIGNALS	Wiskott-Aldrich syndrome protein (WASP)/Scar family proteins promote actin polymerization by stimulating the actin-nucleating activity of the Arp2/3 complex. While Scar/WAVE proteins are thought to be involved in lamellipodia protrusion, the hematopoietic WASP has been implicated in various actin-based processes such as chemotaxis, podosome formation, and phagocytosis. Here we show that the ubiquitously expressed N-WASP is essential for actin assembly at the surface of endomembranes induced as a consequence of increased phosphatidylinositol 4,5-biphosphate (PIP2) levels. This process resulting in the motility of intracellular vesicles at the tips of actin comets involved the recruitment of the Src homology 3 (SH3)-SH2 adaptor proteins Nck and Grb2 as well as of WASP interacting protein (WIP). Reconstitution of vesicle movement in N-WASP-defective cells by expression of various N-WASP mutant proteins revealed three independent domains capable of interaction with the vesicle surface, of which both the WH1 and the polyproline domains contributed significantly to N-WASP recruitment and/or activation. In contrast, the direct interaction of N-WASP with the Rho-GTPase Cdc42 was not required for reconstitution of vesicle motility. Our data reveal a distinct cellular phenotype for N-WASP loss of function, which adds to accumulating evidence that the proposed link between actin and membrane dynamics may, at least partially, be reflected by the actin-based movement of vesicles through the cytoplasm.	Gesell Biotechnol Forsch mbH, Dept Cell Biol, D-38124 Braunschweig, Germany; Canc Res UK, Cell Motil Grp, Lincolns Inn Fields Labs, London WC2A 3PX, England	Gesellschaft fur Biotechnologische Forschung mbH; Cancer Research UK	Rottner, K (corresponding author), Gesell Biotechnol Forsch mbH, Dept Cell Biol, Mascheroder Weg 1, D-38124 Braunschweig, Germany.	kro@gbf.de	Rottner, Klemens/AAE-5030-2020	Scaplehorn, Niki/0000-0001-9451-8748; Rottner, Klemens/0000-0003-4244-4198; Stradal, Theresia/0000-0002-0352-9474; Way, Michael/0000-0001-7207-2722; Steffen, Anika/0000-0002-2933-0543				Anton IM, 1998, J BIOL CHEM, V273, P20992, DOI 10.1074/jbc.273.33.20992; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Cannon JL, 2001, IMMUNITY, V15, P249, DOI 10.1016/S1074-7613(01)00178-9; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; Caron E, 2002, CURR OPIN CELL BIOL, V14, P82, DOI 10.1016/S0955-0674(01)00298-8; Cooper JA, 2001, CELL, V107, P703, DOI 10.1016/S0092-8674(01)00605-5; Frischknecht F, 1999, NATURE, V401, P926, DOI 10.1038/44860; Frishknecht F, 2001, TRENDS CELL BIOL, V11, P30, DOI 10.1016/S0962-8924(00)01871-7; Hahne P, 2001, FEBS LETT, V492, P215, DOI 10.1016/S0014-5793(01)02239-6; HERZOG M, 1994, CELL BIOL LAB HDB, P355; Jeng RL, 2001, CURR BIOL, V11, pR691, DOI 10.1016/S0960-9822(01)00410-9; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Lee E, 2002, P NATL ACAD SCI USA, V99, P161, DOI 10.1073/pnas.012607799; Lommel S, 2001, EMBO REP, V2, P850, DOI 10.1093/embo-reports/kve197; Merrifield CJ, 2001, CURR BIOL, V11, P1136, DOI 10.1016/S0960-9822(01)00321-9; Merrifield CJ, 1999, NAT CELL BIOL, V1, P72, DOI 10.1038/9048; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Mimuro H, 2000, J BIOL CHEM, V275, P28893, DOI 10.1074/jbc.M003882200; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Rietdorf J, 2001, NAT CELL BIOL, V3, P992, DOI 10.1038/ncb1101-992; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Scaplehorn N, 2002, CURR BIOL, V12, P740, DOI 10.1016/S0960-9822(02)00812-6; Schafer DA, 2000, TRAFFIC, V1, P892; Schafer DA, 2002, CURR OPIN CELL BIOL, V14, P76, DOI 10.1016/S0955-0674(01)00297-6; Snapper SB, 2001, NAT CELL BIOL, V3, P897, DOI 10.1038/ncb1001-897; Takenawa T, 2001, J CELL SCI, V114, P1801; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Taunton J, 2000, J CELL BIOL, V148, P519, DOI 10.1083/jcb.148.3.519; Taunton J, 2001, CURR OPIN CELL BIOL, V13, P85, DOI 10.1016/S0955-0674(00)00178-2	34	119	123	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37771	37776		10.1074/jbc.M204145200	http://dx.doi.org/10.1074/jbc.M204145200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147689	hybrid			2022-12-27	WOS:000178447100110
J	Huang, TM; Deng, HT; Wolkoff, AW; Stockert, RJ				Huang, TM; Deng, HT; Wolkoff, AW; Stockert, RJ			Phosphorylation-dependent interaction of the asialoglycoprotein receptor with molecular chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; MANNOSE 6-PHOSPHATE RECEPTOR; PROTEIN-KINASE CK2; VARICELLA-ZOSTER VIRUS; CELL-LINE HUH-7; CYTOPLASMIC DOMAIN; INTRACELLULAR TRAFFICKING; RAT HEPATOCYTES; GLYCOPROTEIN-I; MDCK CELLS	A membrane protein trafficking mutant (Trf1) of HuH-7 alters the asialoglycoprotein (ASGPR) and transferrin receptor subcellular distribution. Expression cloning of a cDNA complementing the trf1 mutation led to the discovery of a novel casein Kinase 2 catalytic subunit (CK2alpha"). To purify potential CK2alpha" phosphorylation-dependent sorting proteins from cytosol, the ASGPR cytoplasmic domain was expressed as a GST fusion protein and immobilized on glutathione-agarose. In the absence of phosphorylation, only trace amounts of cytosol protein were bound and eluted. When the fusion protein was phosphorylated, a heterocomplex of potential sorting proteins was recovered. Mass spectrometer and immunoblot analysis identified five of these proteins as gp96, HSP70, HSP90, cyclophilin-A, and FKBP18. Treatment of HuH-7 with rapamycin to disrupt the heterocomplex reduced surface ASGPR binding activity by 65 +/- 5.7%. In Trf1 cells, surface-binding activity was 48 +/- 7% of that in HuH-7 and was not further reduced by rapamycin treatment. Immunoanalysis showed significantly fewer surface receptors on rapamycin-treated HuH7 cells than on nontreated cells, with no affect on the level of surface receptors in Trf1 cells. The data presented provide evidence that phosphorylation of the ASGPR cytoplasmic domain is required for the binding of specific molecular chaperones with the potential to regulate receptor trafficking.	Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Stockert, RJ (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Marion Bessin Liver Res Ctr, 1300 Morris Pk Ave,Ullmann 611, Bronx, NY 10461 USA.				NIDDK NIH HHS [DK 17702, DK 41918] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK041918, P50DK017702] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed K, 2002, TRENDS CELL BIOL, V12, P226, DOI 10.1016/S0962-8924(02)02279-1; Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; Bananis E, 2000, J CELL BIOL, V151, P179, DOI 10.1083/jcb.151.1.179; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Eng FJ, 1999, MOL BIOL CELL, V10, P35, DOI 10.1091/mbc.10.1.35; Faust M, 2000, CELL TISSUE RES, V301, P329, DOI 10.1007/s004410000256; GEUZE HJ, 1984, EMBO J, V3, P2677, DOI 10.1002/j.1460-2075.1984.tb02193.x; HAYNES PA, 1994, J BIOL CHEM, V269, P33152; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; Ishii T, 1999, J IMMUNOL, V162, P1303; JONES BG, 1995, EMBO J, V14, P5869, DOI 10.1002/j.1460-2075.1995.tb00275.x; Karki S, 1997, J BIOL CHEM, V272, P5887, DOI 10.1074/jbc.272.9.5887; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; MOSTOV KE, 1995, HISTOL HISTOPATHOL, V10, P423; Orsel JG, 2000, P NATL ACAD SCI USA, V97, P9047, DOI 10.1073/pnas.160251397; PAIETTA E, 1992, J BIOL CHEM, V267, P11078; Pearl LH, 2000, CURR OPIN STRUC BIOL, V10, P46, DOI 10.1016/S0959-440X(99)00047-0; Penner CG, 1997, J CELL BIOCHEM, V64, P525; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; RON D, 1992, BIOTECHNIQUES, V13, P866; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; Shi XY, 2001, J BIOL CHEM, V276, P2075, DOI 10.1074/jbc.M008583200; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; Simmen T, 1999, MOL CELL BIOL, V19, P3136; STOCKERT RJ, 1995, PHYSIOL REV, V75, P591, DOI 10.1152/physrev.1995.75.3.591; STOCKERT RJ, 1995, J BIOL CHEM, V270, P16107, DOI 10.1074/jbc.270.27.16107; STOCKERT RJ, 1980, J BIOL CHEM, V255, P9028; Stockert RJ, 1999, HEPATOLOGY, V30, P740, DOI 10.1002/hep.510300304; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; TREICHEL U, 1994, J CELL PHYSIOL, V158, P527, DOI 10.1002/jcp.1041580319; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Weigel P H, 1993, Subcell Biochem, V19, P125; WEIGEL PH, 1984, J BIOL CHEM, V259, P1150; WEIGEL PH, 1993, J BIOL CHEM, V268, P27186; Yik JHN, 2002, J BIOL CHEM, V277, P23076, DOI 10.1074/jbc.M202748200; Zhu ZL, 1996, J VIROL, V70, P6563, DOI 10.1128/JVI.70.10.6563-6575.1996	47	22	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37798	37803		10.1074/jbc.M204786200	http://dx.doi.org/10.1074/jbc.M204786200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12167617	hybrid			2022-12-27	WOS:000178447100114
J	Hut, QH; Bhattacharya, C; Maity, SN				Hut, QH; Bhattacharya, C; Maity, SN			CCAAT binding factor (CBF) binding mediates cell cycle activation of topoisomerase II alpha - Conventional CBF activation domains are not required	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DNA TOPOISOMERASE; TRANSCRIPTION ACTIVATION; GENE PROMOTER; B1 GENE; SUBUNIT; EXPRESSION; MUTATIONS; COMPLEX; GROWTH; BOX	To understand the role of the CCAAT binding factor (CBF) in transcription during the cell cycle, we studied the mouse topoisomerase IIalpha (topo IIalpha) promoter, which is activated during the late S and G(2)/M phases of the cell cycle and contains multiple CBF binding sites. Mutational analysis of the promoter shows that CBF binding to an inverted orientation of the CCAAT motif in the topo IIalpha promoter, but not to a direct orientation, is required for transcription activation during the cell cycle. In contrast, analysis of the promoter in an in vitro reconstituted transcription system shows that CBF activates transcription of the topo IIalpha promoter irrespective of the orientation of the CBF binding sites. This analysis demonstrates that only one of the three transcription start sites of the topo IIalpha promoter is stimulated by CBF, indicating that transcription activation by CBF is dependent on basal promoter structure. Interestingly, mutations of the start site that abolish CBF-dependent transcription activation in vitro do not inhibit activation of the promoter during the cell cycle. Consistent with this observation, expression of a truncated CBF-B subunit lacking a transcription activation domain, which inhibits activity of a collagen promoter, does not affect activity of the topo IIalpha promoter in fibroblast cells. In contrast, expression of an allele-specific CBF-B mutant that binds high affinity to a mutant CBF binding site containing a CCAAC motif revives transcription activation of an inactive mutant topo IIalpha promoter containing CCAAC during the cell cycle. Altogether, this study indicates that CBF binding, but not conventional CBF activation domains, are required for activation of the topo IIalpha promoter during the cell cycle. Considering these results together with results of another recent study, we hypothesize that binding of CBF that disrupts the nucleosomal. structure in the topo IIalpha promoter is a major function of CBF by which it regulates the cell cycle-dependent transcription of the topo IIalpha promoter and possibly many other cell cycle-regulated promoters containing CBF binding sites.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Maity, SN (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Box 11,1515 Holcombe Blvd, Houston, TX 77030 USA.			Maity, Sankar/0000-0002-2387-6545	NIAMS NIH HHS [R01 AR46264] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046264] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adachi N, 1997, BIOCHEM BIOPH RES CO, V230, P105, DOI 10.1006/bbrc.1996.5893; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Coustry F, 1996, J BIOL CHEM, V271, P14485, DOI 10.1074/jbc.271.24.14485; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; Coustry F, 2001, J BIOL CHEM, V276, P40621, DOI 10.1074/jbc.M106918200; Falck J, 1999, J BIOL CHEM, V274, P18753, DOI 10.1074/jbc.274.26.18753; Furukawa M, 1998, J BIOL CHEM, V273, P10550, DOI 10.1074/jbc.273.17.10550; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Hu QH, 2000, J BIOL CHEM, V275, P4435, DOI 10.1074/jbc.275.6.4435; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; Liang SG, 1998, J BIOL CHEM, V273, P31590, DOI 10.1074/jbc.273.47.31590; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sciortino S, 2001, EMBO REP, V2, P1018, DOI 10.1093/embo-reports/kve223; Sinha S, 1996, MOL CELL BIOL, V16, P328; Wang QJ, 1997, MOL CELL BIOL, V17, P389, DOI 10.1128/MCB.17.1.389; Withoff S, 1996, ANTICANCER RES, V16, P1867; Wolner BS, 2000, MOL CELL BIOL, V20, P3608, DOI 10.1128/MCB.20.10.3608-3615.2000; XING YY, 1993, EMBO J, V12, P4647, DOI 10.1002/j.1460-2075.1993.tb06153.x; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822	21	27	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37191	37200		10.1074/jbc.M205985200	http://dx.doi.org/10.1074/jbc.M205985200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149265	hybrid			2022-12-27	WOS:000178447100038
J	Toniato, E; Chen, XP; Losman, J; Flati, V; Donahue, L; Rothman, P				Toniato, E; Chen, XP; Losman, J; Flati, V; Donahue, L; Rothman, P			TRIM8/GERP RING finger protein interacts with SOCS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE REGULATION; BOX MOTIF; T-CELLS; CYTOKINE; REGULATORS; GENE; TRANSCRIPTION; EXPRESSION; FAMILY; PHOSPHATASE	Members of the suppressor of cytokine signaling (SOCS) family of signaling molecules regulate the activation of cytokine signaling. Experimental evidence indicates that SOCS expression is induced by cytokines and pro-inflammatory stimuli and is controlled at both the transcriptional and post-transcriptional levels. SOCS proteins are unstable and seem to be rapidly degraded by proteasomal pathways. However, the mechanisms by which SOCS protein levels are regulated remain unclear. Here, we show that TRIM8/GERP, a RING finger protein, interacts with SOCS-1 in vitro and in vivo. TRIM8/GERP, previously identified as a new member of the family of proteins containing a tripartite motif (TRIM), is a 551-amino acid RING finger protein conserved across species. TRIM8/GERP expression can be induced by interferon-gamma in epithelial and lymphoid cells. Coexpression of TRIM8/GERP with SOCS-1 decreases SOCS-1 protein stability and levels. Functionally, expression of TRIM8/GERP decreases the repression of interferon-gamma signaling mediated by SOCS-1. These data suggest that TRIM8/GERP may be a regulator of SOCS-1 function.	Columbia Univ Coll Phys & Surg, Dept Med & Microbiol, New York, NY 10032 USA	Columbia University	Rothman, P (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med & Microbiol, P&S 8-425,630 W 168th St, New York, NY 10032 USA.	pbr3@columbia.edu	FLATI, VINCENZO/R-6231-2018	FLATI, VINCENZO/0000-0003-1014-297X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI050514] Funding Source: NIH RePORTER; NIAID NIH HHS [P01-AI50514] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alexander WS, 1999, CELL, V98, P597, DOI 10.1016/S0092-8674(00)80047-1; Aringer M, 1999, LIFE SCI, V64, P2173, DOI 10.1016/S0024-3205(98)00538-4; Auernhammer CJ, 2000, ENDOCR REV, V21, P313, DOI 10.1210/er.21.3.313; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Chen XP, 2000, IMMUNITY, V13, P287, DOI 10.1016/S1074-7613(00)00028-5; Chen XP, 2002, P NATL ACAD SCI USA, V99, P2175, DOI 10.1073/pnas.042035699; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Friedman JR, 1996, GENE DEV, V10, P2067, DOI 10.1101/gad.10.16.2067; Fujimoto M, 2000, J IMMUNOL, V165, P1799, DOI 10.4049/jimmunol.165.4.1799; Gisselbrecht S, 1999, EUR CYTOKINE NETW, V10, P463; Gregorieff A, 2000, J BIOL CHEM, V275, P21596, DOI 10.1074/jbc.M910087199; Haque SJ, 2000, J BIOL CHEM, V275, P26500, DOI 10.1074/jbc.275.34.26500; Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638; HUSSEINI AEE, 1999, J BIOL CHEM, V274, P19771; Imada K, 2000, MOL IMMUNOL, V37, P1, DOI 10.1016/S0161-5890(00)00018-3; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; LEDUARIN B, EMBO J, V14, P2020; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Marine JC, 1999, CELL, V98, P617, DOI 10.1016/S0092-8674(00)80049-5; Marine JC, 1999, CELL, V98, P609, DOI 10.1016/S0092-8674(00)80048-3; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; Morita Y, 2000, P NATL ACAD SCI USA, V97, P5405, DOI 10.1073/pnas.090084797; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; Naka T, 1999, TRENDS BIOCHEM SCI, V24, P394, DOI 10.1016/S0968-0004(99)01454-1; Naka T, 1998, P NATL ACAD SCI USA, V95, P15577, DOI 10.1073/pnas.95.26.15577; Nicholson SE, 1998, J LEUKOCYTE BIOL, V63, P665, DOI 10.1002/jlb.63.6.665; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PELLE R, 1993, NUCLEIC ACIDS RES, V21, P2783, DOI 10.1093/nar/21.11.2783; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Saito H, 2000, J IMMUNOL, V164, P5833, DOI 10.4049/jimmunol.164.11.5833; Sakamoto H, 2000, LEUKEMIA LYMPHOMA, V38, P49, DOI 10.3109/10428190009060318; Schluter G, 2000, BIOCHEM BIOPH RES CO, V268, P255, DOI 10.1006/bbrc.2000.2109; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; Tamir I, 2000, CURR OPIN IMMUNOL, V12, P307, DOI 10.1016/S0952-7915(00)00092-3; Terstegen L, 2000, FEBS LETT, V478, P100, DOI 10.1016/S0014-5793(00)01826-3; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Vincent SR, 2000, BIOCHEM BIOPH RES CO, V279, P482, DOI 10.1006/bbrc.2000.3984; WILLIAMS BRG, 1991, EUR J BIOCHEM, V200, P1, DOI 10.1111/j.1432-1033.1991.tb21041.x; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Zhang JG, 1999, P NATL ACAD SCI USA, V96, P2071, DOI 10.1073/pnas.96.5.2071	45	88	98	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37315	37322		10.1074/jbc.M205900200	http://dx.doi.org/10.1074/jbc.M205900200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12163497	hybrid			2022-12-27	WOS:000178447100053
J	Tumbula-Hansen, D; Feng, L; Toogood, H; Stetter, KO; Soll, D				Tumbula-Hansen, D; Feng, L; Toogood, H; Stetter, KO; Soll, D			Evolutionary divergence of the archaeal aspartyl-tRNA synthetases into discriminating and nondiscriminating forms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; COMPLETE GENOME SEQUENCE; ASPARAGINYL-TRANSFER-RNA; PYROCOCCUS SP KOD1; HYPERTHERMOPHILIC ARCHAEON; THERMOPLASMA-ACIDOPHILUM; THERMUS-THERMOPHILUS; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; AMINO-ACIDS	Asparaginyl-tRNA (Asn-tRNA) is generated in nature via two alternate routes, either direct acylation of tRNA with asparagine by asparaginyl-tRNA synthetase (AsnRS) or in a two-step pathway that requires misacylated Asp-tRNA(Asn) as an intermediate. This misacylated aminoacyl-tRNA is formed by a nondiscriminating aspartyl-tRNA synthetase (AspRS), an enzyme that in addition to forming Asp-tRNA(Asp) also misacylates tRNA(Asn). In contrast, a discriminating AspRS cannot acylate tRNA(Asn). It has been suggested that the archaeal AspRS enzymes are nondiscriminating, whereas the bacterial ones discriminate. The archaeal and bacterial AspRS proteins are indeed distinct in sequence and structure. However, we show that both discriminating and nondiscriminating forms of AspRS exist among the archaea. Using unfractionated methanobacterial and pyrococcal tRNA, the Methanothermobacter thermautotrophicus AspRS acylated approximately twice as much tRNA as did AspRS from Pyrococcus kodakaraensis or Ferroplasma acidarmanus. Proof that Asp-tRNA(Asn) was generated by the methanogen synthetase was the conversion of Asp-tRNA formed by M. thermautotrophicus AspRS to Asn-tRNA by M. thermautotrophicus Asp-tRNA(Asn) amidotransferase. In contrast, Asp-tRNA formed by the Pyrococcus or Ferroplasma enzymes was not a substrate for the amidotransferase. Also, although all three AspRS enzymes charged tRNA(Asp) transcripts, only M. thermautotrophicus AspRS aspartylated the tRNA(Asn) transcript. Genomic analysis provides a rationale for the nature of these enzymes. The mischarging AspRS correlates with the absence in the genome of AsnRS and the presence of Asp-tRNA(Asn) amidotransferase, employed by the transamidation pathway. In contrast, the discriminating AspRS correlates with the absence of the amidotransferase and the presence of AsnRS, forming Asn-tRNA by direct aminoacylation. The high sequence identity, up to 60% between discriminating and nondiscriminating archaeal AspRSs, suggests that few mutational steps may be necessary to convert the tRNA-discriminating ability of a tRNA synthetase.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Univ Regensburg, Lehrstuhl Mikrobiol, D-8400 Regensburg, Germany; Univ Regensburg, Archaeenzentrum, D-8400 Regensburg, Germany	Yale University; Yale University; University of Regensburg; University of Regensburg	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.			Toogood, Helen/0000-0003-4797-0293; Hansen, Debra T./0000-0003-4395-8297				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Anderson JC, 2002, CHEM BIOL, V9, P237, DOI 10.1016/S1074-5521(02)00094-7; Becker HD, 2000, BIOCHEMISTRY-US, V39, P3216, DOI 10.1021/bi992573y; Becker HD, 1998, P NATL ACAD SCI USA, V95, P12832, DOI 10.1073/pnas.95.22.12832; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; Curnow AW, 1998, P NATL ACAD SCI USA, V95, P12838, DOI 10.1073/pnas.95.22.12838; DELARUE M, 1994, EMBO J, V13, P3219, DOI 10.1002/j.1460-2075.1994.tb06623.x; Edwards KJ, 2000, SCIENCE, V287, P1796, DOI 10.1126/science.287.5459.1796; Eiler S, 1999, EMBO J, V18, P6532, DOI 10.1093/emboj/18.22.6532; Fitz-Gibbon ST, 2002, P NATL ACAD SCI USA, V99, P984, DOI 10.1073/pnas.241636498; Fujiwara S, 1996, FEBS LETT, V394, P66, DOI 10.1016/0014-5793(96)00904-0; Galagan JE, 2002, GENOME RES, V12, P532, DOI 10.1101/gr.223902; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; GUPTA R, 1984, J BIOL CHEM, V259, P9461; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; Ibba M, 2000, TRENDS BIOCHEM SCI, V25, P311, DOI 10.1016/S0968-0004(00)01600-5; IMANAKA T, 1995, GENE, V164, P153, DOI 10.1016/0378-1119(95)00491-N; Kanaya S, 1999, GENE, V238, P143, DOI 10.1016/S0378-1119(99)00225-5; Kawarabayasi Y, 2001, DNA RES, V8, P123, DOI 10.1093/dnares/8.4.123; Kawarabayasi Y, 1999, DNA Res, V6, P83, DOI 10.1093/dnares/6.2.83; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Kawashima T, 1999, P JPN ACAD B-PHYS, V75, P213, DOI 10.2183/pjab.75.213; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; MICHELS M, 1985, J BACTERIOL, V161, P231, DOI 10.1128/JB.161.1.231-237.1985; Min B, 2002, P NATL ACAD SCI USA, V99, P2678, DOI 10.1073/pnas.012027399; NAMEKI N, 1992, BIOCHEM BIOPH RES CO, V189, P856, DOI 10.1016/0006-291X(92)92282-3; Ng WV, 2000, P NATL ACAD SCI USA, V97, P12176, DOI 10.1073/pnas.190337797; Raczniak G, 2001, J BIOL CHEM, V276, P45862, DOI 10.1074/jbc.M109494200; Ruepp A, 2000, NATURE, V407, P508, DOI 10.1038/35035069; RUFF M, 1988, J MOL BIOL, V201, P235, DOI 10.1016/0022-2836(88)90450-0; SAKS ME, 1994, SCIENCE, V263, P191, DOI 10.1126/science.7506844; Schmitt E, 1998, EMBO J, V17, P5227, DOI 10.1093/emboj/17.17.5227; She Q, 2001, P NATL ACAD SCI USA, V98, P7835, DOI 10.1073/pnas.141222098; Shiba K, 1998, NUCLEIC ACIDS RES, V26, P5045, DOI 10.1093/nar/26.22.5045; Slesarev AI, 2002, P NATL ACAD SCI USA, V99, P4644, DOI 10.1073/pnas.032671499; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Tumbula DL, 2000, NATURE, V407, P106, DOI 10.1038/35024120; Watanabe M, 2001, J BIOL CHEM, V276, P2387, DOI 10.1074/jbc.M005043200; Woese CR, 2000, MICROBIOL MOL BIOL R, V64, P202, DOI 10.1128/MMBR.64.1.202-236.2000; Wolf YI, 1999, GENOME RES, V9, P689; ZEIKUS JG, 1972, J BACTERIOL, V109, P707, DOI 10.1128/JB.109.2.707-713.1972	43	27	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37184	37190		10.1074/jbc.M204767200	http://dx.doi.org/10.1074/jbc.M204767200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149259	hybrid			2022-12-27	WOS:000178447100037
J	Swain, E; Stukey, J; McDonough, V; Germann, M; Liu, Y; Sturley, SL; Nickels, JT				Swain, E; Stukey, J; McDonough, V; Germann, M; Liu, Y; Sturley, SL; Nickels, JT			Yeast cells lacking the ARV1 gene harbor defects in sphingolipid metabolism - Complementation by human ARV1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYSTEROL-BINDING-PROTEIN; INOSITOL PHOSPHORYLCERAMIDE SYNTHASE; SACCHAROMYCES-CEREVISIAE; SERINE PALMITOYLTRANSFERASE; PHOSPHOLIPID BIOSYNTHESIS; SUBCELLULAR-LOCALIZATION; ALKALINE CERAMIDASE; GOLGI-APPARATUS; ACYL-COENZYME; CHOLESTEROL	arv1Delta mutant cells have an altered sterol distribution within cell membranes (Tinkelenberg, A.H., Liu, Y., Alcantara, F., Khan, S., Guo, Z., Bard, M., and Sturley, S. L. (2000) J. Biol. Chem. 275, 40667-40670), and thus it has been suggested that Arv1p may be involved in the trafficking of sterol in the yeast Saccharomyces cerevisiae and also in humans. Here we present data showing that arv1Delta mutants also harbor defects in sphingolipid metabolism. [3H]inositol and [H-3]dihydrosphingosine radiolabeling studies demonstrated that mutant cells had reduced rates of biosynthesis and lower steady-state levels of complex sphingolipids while accumulating certain hydroxylated ceramide species. Phospholipid radiolabeling studies showed that arv1Delta cells harbored defects in the rates of biosynthesis and steady-state levels of phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, and phosphatidylglycerol. Neutral lipid radiolabeling studies indicated that the rate of biosynthesis and steady-state levels of sterol ester were increased in arv1Delta cells. Moreover, these same studies demonstrated that arv1Delta cells had decreased rates of biosynthesis and steady-state levels of total fatty acid and fatty acid alcohols. Gas chromatography/mass spectrometry analyses examining different fatty acid species showed that arv1Delta cells had decreased levels of C18:1 fatty acid. Additional gas chromatography/mass spectrometry analyses determining the levels of various molecular sterol species in arv1Delta cells showed that mutant cells accumulated early sterol intermediates. Using fluorescence microscopy we found that GFP-Arv1p localizes to the endoplasmic reticulum and Golgi. Interestingly, the heterologous expression of the human ARV1 cDNA suppressed the sphingolipid metabolic defects of arv1Delta cells. We hypothesize that in eukaryotic cells, Arv1p functions in the sphingolipid metabolic pathway perhaps as a transporter of ceramides between the endoplasmic reticulum and Golgi.	Med Coll Penn & Hahnemann Univ, Dept Biochem, Philadelphia, PA 19102 USA; Hope Coll, Dept Biol, Holland, MI 49422 USA; Columbia Univ, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ, Dept Pediat, New York, NY 10032 USA	Drexel University; Hope College; Columbia University; Columbia University	Nickels, JT (corresponding author), Med Coll Penn & Hahnemann Univ, Dept Biochem, Philadelphia, PA 19102 USA.	Joseph.Nickels@drexel.edu			NHLBI NIH HHS [HL67401-01A1] Funding Source: Medline; NIDDK NIH HHS [DK54320] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067401] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054320] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATKINSON K, 1980, J BIOL CHEM, V255, P6653; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Bagnat M, 2001, MOL BIOL CELL, V12, P4129, DOI 10.1091/mbc.12.12.4129; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; Bard M, 1996, P NATL ACAD SCI USA, V93, P186, DOI 10.1073/pnas.93.1.186; Baudry K, 2001, J BIOL CHEM, V276, P12702, DOI 10.1074/jbc.M100274200; Beh CT, 2001, GENETICS, V157, P1117; Bischoff F, 1977, Adv Lipid Res, V15, P61; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BROWSE J, 1986, ANAL BIOCHEM, V152, P141, DOI 10.1016/0003-2697(86)90132-6; BUEDE R, 1991, J BACTERIOL, V173, P4325, DOI 10.1128/JB.173.14.4325-4332.1991; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHAMBAZ EM, 1969, ANAL BIOCHEM, V30, P7, DOI 10.1016/0003-2697(69)90368-6; CLARKE NG, 1981, BIOCHEM J, V195, P301, DOI 10.1042/bj1950301; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; DICKESON SK, 1994, GENE, V142, P301, DOI 10.1016/0378-1119(94)90279-8; Dickson RC, 1998, ANNU REV BIOCHEM, V67, P27, DOI 10.1146/annurev.biochem.67.1.27; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; Fang M, 1996, EMBO J, V15, P6447, DOI 10.1002/j.1460-2075.1996.tb01036.x; Funato K, 2001, J CELL BIOL, V155, P949, DOI 10.1083/jcb.200105033; Gachotte D, 1999, P NATL ACAD SCI USA, V96, P12655, DOI 10.1073/pnas.96.22.12655; Gachotte D, 1998, P NATL ACAD SCI USA, V95, P13794, DOI 10.1073/pnas.95.23.13794; Gaigg B, 2001, MOL BIOL CELL, V12, P1147, DOI 10.1091/mbc.12.4.1147; Haak D, 1997, J BIOL CHEM, V272, P29704, DOI 10.1074/jbc.272.47.29704; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HECHTBERGER P, 1994, EUR J BIOCHEM, V225, P641, DOI 10.1111/j.1432-1033.1994.00641.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JEDD G, 1995, J CELL BIOL, V131, P583, DOI 10.1083/jcb.131.3.583; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; KO JS, 1994, J BACTERIOL, V176, P5181, DOI 10.1128/jb.176.16.5181-5183.1994; Kragelund BB, 1999, BBA-MOL CELL BIOL L, V1441, P150, DOI 10.1016/S1388-1981(99)00151-1; Lange Y, 1997, J BIOL CHEM, V272, P13103, DOI 10.1074/jbc.272.20.13103; Lechner M, 1999, J CHROMATOGR A, V857, P231, DOI 10.1016/S0021-9673(99)00751-7; LESTER RL, 1993, ADV LIPID RES, V26, P253; Levine TP, 2000, MOL BIOL CELL, V11, P2267, DOI 10.1091/mbc.11.7.2267; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mandala SM, 2001, PROSTAG OTH LIPID M, V64, P143, DOI 10.1016/S0090-6980(01)00111-3; Mao CG, 2000, J BIOL CHEM, V275, P6876, DOI 10.1074/jbc.275.10.6876; Mao CG, 2000, METHOD ENZYMOL, V311, P223; Mao CG, 2000, J BIOL CHEM, V275, P31369, DOI 10.1074/jbc.M003683200; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nagiec MM, 1996, GENE, V177, P237, DOI 10.1016/0378-1119(96)00309-5; NAGIEC MM, 1994, P NATL ACAD SCI USA, V91, P7899, DOI 10.1073/pnas.91.17.7899; Nagiec MM, 1997, J BIOL CHEM, V272, P9809, DOI 10.1074/jbc.272.15.9809; NES W D, 1989, Steroids, V53, P533, DOI 10.1016/0039-128X(89)90030-5; NICKELS JT, 1994, J BIOL CHEM, V269, P11018; Nohturfft A, 1998, J BIOL CHEM, V273, P17243, DOI 10.1074/jbc.273.27.17243; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; Ory DS, 2000, BBA-MOL CELL BIOL L, V1529, P331, DOI 10.1016/S1388-1981(00)00158-X; Pagano RE, 2000, TRAFFIC, V1, P807, DOI 10.1034/j.1600-0854.2000.011101.x; PATTERSON GW, 1971, ANAL CHEM, V43, P1165, DOI 10.1021/ac60304a015; Phillips KM, 1999, J CHROMATOGR B, V732, P17, DOI 10.1016/S0378-4347(99)00257-1; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Ridgway ND, 2000, BBA-MOL CELL BIOL L, V1484, P129, DOI 10.1016/S1388-1981(00)00006-8; Ridgway ND, 1998, J BIOL CHEM, V273, P31621, DOI 10.1074/jbc.273.47.31621; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Schuchman EHDR, 1995, METABOLIC MOL BASIS, V7th, P2601; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; Spiegel S, 1998, ANN NY ACAD SCI, V845, P11, DOI 10.1111/j.1749-6632.1998.tb09658.x; Stefan CJ, 2002, MOL BIOL CELL, V13, P542, DOI 10.1091/mbc.01-10-0476; Storey MK, 1998, BIOCHEM J, V336, P247, DOI 10.1042/bj3360247; Swain E, 2002, J BIOL CHEM, V277, P26177, DOI 10.1074/jbc.M204115200; TAYLOR FR, 1984, J BIOL CHEM, V259, P2382; Tinkelenberg AH, 2000, J BIOL CHEM, V275, P40667, DOI 10.1074/jbc.C000710200; van Meer G, 2000, BBA-MOL CELL BIOL L, V1486, P145, DOI 10.1016/S1388-1981(00)00054-8; Vik A, 2001, MOL CELL BIOL, V21, P6395, DOI 10.1128/MCB.21.19.6395-6405.2001; Weiss B, 1997, EUR J BIOCHEM, V249, P239, DOI 10.1111/j.1432-1033.1997.00239.x; WHITNEY JA, 1995, CELL, V83, P703; Worgall TS, 2002, J BIOL CHEM, V277, P3878, DOI 10.1074/jbc.M102393200; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171; XU SH, 1988, J CHROMATOGR, V452, P377, DOI 10.1016/S0021-9673(01)81462-X; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Zweytick D, 2000, FEBS LETT, V470, P83, DOI 10.1016/S0014-5793(00)01290-4	78	50	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36152	36160		10.1074/jbc.M206624200	http://dx.doi.org/10.1074/jbc.M206624200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145310	hybrid			2022-12-27	WOS:000178275100050
J	Wang, DK; Li, ZB; Messing, EM; Wu, G				Wang, DK; Li, ZB; Messing, EM; Wu, G			Activation of Ras/Erk pathway by a novel MET-interacting protein RanBPM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE GROWTH-FACTOR; FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; INCREASING COMPLEXITY; SIGNALING PATHWAY; TYROSINE KINASES; DOCKING SITE; SH3 DOMAIN; RAS; BINDING	MET is a receptor protein-tyrosine kinase (RPTK) for hepatocyte growth factor (HGF), which is a multifunctional cytokine controlling cell growth, morphogenesis, and motility. MET overexpression has been identified in a variety of human cancers. Oncogenic missense mutations of the tyrosine kinase domain of the MET gene have been identified in human papillary renal cell carcinomas. In this study, RanBPM, also known as RanBP9, is identified as a novel interacting protein of MET through yeast two-hybrid screen. RanBPM contains a conserved SPRY (repeats in VIA and RyR) domain. We demonstrate that RanBPM can interact with MET in vitro and in vivo, and the interaction can be strengthened by HGF stimulation. RanBPM interacts with the tyrosine kinase domain of MET through its SPRY domain. We show that RanBPM can induce GTP-Ras association and Erk phosphorylation and elevate serum response element-luciferase (SRE-LUC) expression, indicating that RanBPM can activate the Ras-Erk-SRE pathway. We demonstrate that RanBPM, which itself is not a guanine exchange protein, stimulates Ras activation by recruiting Sos. On the cellular level, A704 cells, a human renal carcinoma cell line, transfected with RanBPM exhibit increased migration ability. Our data suggest that RanBPM, functioning as an adaptor protein for the MET tyrosine kinase domain, can augment the HGF-MET signaling pathway and that RanBPM overexpression may cause constitutive activation of the Ras signaling pathway.	Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA; Univ Rochester, Med Ctr, James P Wilmot Canc Ctr, Rochester, NY 14642 USA	University of Rochester; University of Rochester; University of Rochester	Wu, G (corresponding author), Univ Rochester, Med Ctr, Dept Urol, 601 Elmwood Ave,Box 656, Rochester, NY 14642 USA.							Balkovetz DF, 1999, INT REV CYTOL, V186, P225; BARDELLI A, 1992, ONCOGENE, V7, P1973; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; Grisendi S, 2001, J BIOL CHEM, V276, P46632, DOI 10.1074/jbc.M104323200; Hoshinoso M, 1999, J BIOL CHEM, V274, P17837, DOI 10.1074/jbc.274.25.17837; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Li ZB, 2002, J BIOL CHEM, V277, P4656, DOI 10.1074/jbc.M108269200; LINNEMANN T, 2001, J BIOL CHEM, V17, P17; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; Olson MF, 2000, SEMIN IMMUNOL, V12, P63, DOI 10.1006/smim.2000.0208; OVERBECK AF, 1995, MOL REPROD DEV, V42, P468, DOI 10.1002/mrd.1080420415; PELICCI G, 1995, ONCOGENE, V10, P1631; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SPAARGAREN M, 1994, P NATL ACAD SCI USA, V91, P12609, DOI 10.1073/pnas.91.26.12609; Steiner G, 2000, J BIOMOL NMR, V18, P73, DOI 10.1023/A:1008373529242; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tulasne D, 1999, MOL BIOL CELL, V10, P551, DOI 10.1091/mbc.10.3.551; van der Voort R, 2000, ADV CANCER RES, V79, P39, DOI 10.1016/S0065-230X(00)79002-6; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; Zwartkruis FJT, 1999, EXP CELL RES, V253, P157, DOI 10.1006/excr.1999.4695	38	122	154	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36216	36222		10.1074/jbc.M205111200	http://dx.doi.org/10.1074/jbc.M205111200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12147692	hybrid			2022-12-27	WOS:000178275100057
J	Wang, QD; Wang, XF; Hernandez, A; Hellmich, MR; Gatalica, Z; Evers, BM				Wang, QD; Wang, XF; Hernandez, A; Hellmich, MR; Gatalica, Z; Evers, BM			Regulation of TRAIL expression by the phosphatidylinositol 3-kinase/Akt/GSK-3 pathway in human colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; APOPTOSIS-INDUCING LIGAND; CHAIN FATTY-ACIDS; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAY; TUMOR SUPPRESSION; CYCLE PROGRESSION; TRANSCRIPTION FACTOR; GENE-TRANSCRIPTION; ENDOMETRIAL CANCER	The intestinal mucosa is a rapidly-renewing tissue characterized by cell proliferation, differentiation, and eventual apoptosis with progression up the vertical gut axis. The inhibition of phosphatidylinositol (PI) 3-kinase by specific chemical inhibitors or overexpression of the lipid phosphatase PTEN enhances enterocyte-like differentiation in human colon cancer cell models of intestinal differentiation. In this report, we examined the role of PI 3-kinase inhibition in the regulation of apoptotic gene expression in human colon cancer cell lines HT29, HCT-116, and Caco-2. Inhibition of PI 3-kinase with the chemical inhibitor wortmannin increased TNF-related apoptosis-inducing ligand (TRAIL; Apo2) mRNA and protein expression. Similarly, overexpression of the tumor suppressor protein PTEN, an antagonist of PI 3-kinase signaling, resulted in the increased expression of TRAIL. Activation of PI 3-kinase by pretreatment with IGF-1, a gut trophic factor, markedly attenuated the induction of TRAIL by wortmannin. Moreover, overexpression of active Akt, a downstream target of PI 3-kinase, or inhibition of GSK-3, a downstream target of active Akt, completely blocked the induction of TRAIL by wortmannin. Consistent with findings that TRAIL is induced by agents that enhance intestinal cell differentiation, TRAIL expression was specifically localized to the differentiated cells of the colon and small bowel. Adenovirus-mediated overexpression of TRAIL increased DNA fragmentation of HCT-116 cells, demonstrating the functional activity of TRAIL induction. Taken together, our findings demonstrate induction of the TRAIL by inhibition of PI 3-kinase in colon cancer cell lines. These results identify TRAIL, a novel TNF family member, as a downstream target of the PI 3-kinase/Akt/GSK-3 pathway and may have important implications for better understanding the role of the PI 3-kinase pathway in intestinal cell homeostasis.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pathol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Evers, BM (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.				NIA NIH HHS [R37 AG10885] Funding Source: Medline; NIDDK NIH HHS [R01 DK48498, T32 DK07639, P01 DK305608] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048498, T32DK007639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG010885] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ali A, 2001, CHEM REV, V101, P2527, DOI 10.1021/cr000110o; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Basson MD, 1998, P SOC EXP BIOL MED, V217, P476, DOI 10.3181/00379727-217-44261; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Busca R, 1996, J BIOL CHEM, V271, P31824, DOI 10.1074/jbc.271.50.31824; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chakravarthy MV, 2000, J BIOL CHEM, V275, P35942, DOI 10.1074/jbc.M005832200; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; Crowder RJ, 2000, J BIOL CHEM, V275, P34266, DOI 10.1074/jbc.M006160200; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; DAVIDSON HW, 1995, J CELL BIOL, V130, P797, DOI 10.1083/jcb.130.4.797; DEL PL, 1997, SCIENCE, V278, P687; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Domon-Dell C, 2002, GUT, V50, P525, DOI 10.1136/gut.50.4.525; Dong ZZ, 2000, AM J PHYSIOL-GASTR L, V279, pG1139, DOI 10.1152/ajpgi.2000.279.6.G1139; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Duan CM, 1999, J BIOL CHEM, V274, P37147, DOI 10.1074/jbc.274.52.37147; Eickholt BJ, 2002, J CELL BIOL, V157, P211, DOI 10.1083/jcb.200201098; EVERS BM, 1995, J CLIN INVEST, V95, P2822, DOI 10.1172/JCI117987; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; Griffith TS, 2000, J IMMUNOL, V165, P2886, DOI 10.4049/jimmunol.165.5.2886; HEERDT BG, 1994, CANCER RES, V54, P3288; Hers I, 1999, FEBS LETT, V460, P433, DOI 10.1016/S0014-5793(99)01389-7; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Jones SM, 1997, J CELL BIOL, V139, P339, DOI 10.1083/jcb.139.2.339; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kayagaki N, 1999, J IMMUNOL, V162, P2639; KELLER SR, 1993, MOL REPROD DEV, V35, P346, DOI 10.1002/mrd.1080350405; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Lacour S, 2001, CANCER RES, V61, P1645; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Litvak DA, 1998, SURGERY, V124, P161, DOI 10.1067/msy.1998.90365; Lunemann JD, 2002, J IMMUNOL, V168, P4881, DOI 10.4049/jimmunol.168.10.4881; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Matsushima-Nishiu M, 2001, CANCER RES, V61, P3741; Musgrave BL, 1999, EXP CELL RES, V252, P96, DOI 10.1006/excr.1999.4631; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789; Philpott KL, 1997, J CELL BIOL, V139, P809, DOI 10.1083/jcb.139.3.809; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; PODOLSKY DK, 1995, TXB GASTROENTEROLOGY, P546; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Potten CS, 1997, AM J PHYSIOL-GASTR L, V273, pG253, DOI 10.1152/ajpgi.1997.273.2.G253; Pritchard DM, 1996, PHARMACOL THERAPEUT, V72, P149, DOI 10.1016/S0163-7258(96)00102-7; READ LC, 1991, MODERN CONCEPTS INSU, P225; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Sakaue H, 1998, J BIOL CHEM, V273, P28945, DOI 10.1074/jbc.273.44.28945; Sakurada A, 1999, INT J ONCOL, V15, P1069; Song KM, 2000, J EXP MED, V191, P1095, DOI 10.1084/jem.191.7.1095; Strater J, 2002, GASTROENTEROLOGY, V122, P659, DOI 10.1053/gast.2002.31889; Suhara T, 2002, MOL CELL BIOL, V22, P680, DOI 10.1128/MCB.22.2.680-691.2002; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang QD, 2001, GASTROENTEROLOGY, V120, P1381, DOI 10.1053/gast.2001.24044; Wang QD, 2000, ANTICANCER RES, V20, P75; Wang QD, 2000, BIOCHEM BIOPH RES CO, V276, P466, DOI 10.1006/bbrc.2000.3512; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zheng WH, 2000, J BIOL CHEM, V275, P39152, DOI 10.1074/jbc.M002417200; Zweibaum A, 1989, ADAPTATION DEV GASTR, P103	71	96	102	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36602	36610		10.1074/jbc.M206306200	http://dx.doi.org/10.1074/jbc.M206306200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12140294	hybrid			2022-12-27	WOS:000178275100104
J	Lei, HT; An, P; Song, SM; Liu, XY; He, LW; Wu, J; Meng, L; Liu, MS; Yang, JS; Shou, CC				Lei, HT; An, P; Song, SM; Liu, XY; He, LW; Wu, J; Meng, L; Liu, MS; Yang, JS; Shou, CC			A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE; ANGIOGENESIS; IDENTIFICATION; EXPRESSION; INTEGRIN; CANCER; ALPHA(V)BETA(3); REGRESSION; SUPPRESSES; SELECTION	Vascular endothelial growth factor (VEGF), one of the most important angiogenic factors, plays an essential role in both physiological and pathological angiogenesis. The VEGF receptor KDR/Flk-1 (a kinase domain receptor) mediates various biological activities of VEGF related to proliferation, differentiation, and migration of endothelial cells. Here we present a novel peptide designated K237-(HTMYYHHYQHHL), which was isolated from a phage-displayed peptide library, binding to KDR with high affinity and specificity. By interfering with the VEGF-KDR interaction, the peptide K237 inhibited proliferation of cultured primary human umbilical vein endothelial cells induced by recombinant human VEGF,,, in a dose-dependent and cell type-specific manner. The peptide also exerted an anti-angiogenesis activity in vivo as revealed using the chick embryo chorioallantoic membrane angiogenesis assay. Moreover, the peptide K237 significantly inhibited the growth of solid tumors implanted beneath the breasts and their metastases to lungs in severe combined immunodeficient mice. Taken together, these findings suggest that the peptide K237 can functionally disrupt the interaction between VEGF and the KDR receptor and cause potent biological effects that include the inhibition of angiogenesis and tumor growth. As a consequence, this peptide (and its future derivatives) may have use as a potential cancer therapy.	Peking Univ, Sch Oncol, Beijing Inst Canc Res, Beijing 100034, Peoples R China; Peking Union Med Coll, Chinese Acad Med Sci, Inst Med Plant, Beijing 100094, Peoples R China	Peking University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Shou, CC (corresponding author), Peking Univ, Sch Oncol, Beijing Inst Canc Res, 1 Da Hong Luo Chang St, Beijing 100034, Peoples R China.			Lei, Hetian/0000-0003-4091-1936				ASANO M, 1995, CANCER RES, V55, P5296; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Binetruy-Tournaire R, 2000, EMBO J, V19, P1525, DOI 10.1093/emboj/19.7.1525; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; CLIFF WJ, 1963, PHILOS T ROY SOC B, V246, P305, DOI 10.1098/rstb.1963.0008; Cortese R, 1996, CURR OPIN BIOTECH, V7, P616, DOI 10.1016/S0958-1669(96)80072-3; Felici F, 1995, Biotechnol Annu Rev, V1, P149, DOI 10.1016/S1387-2656(08)70051-6; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; Kumar CC, 2001, CANCER RES, V61, P2232; MELINYK O, 1996, CANCER RES, V56, P921; Millauer B, 1996, CANCER RES, V56, P1615; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; SCHOEFL GI, 1963, VIRCHOWS ARCH A, V337, P97, DOI 10.1007/BF00963592; SENGER DR, 1986, CANCER RES, V46, P5629; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; Yen L, 2000, ONCOGENE, V19, P3460, DOI 10.1038/sj.onc.1203685; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765	28	100	140	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43137	43142		10.1074/jbc.M203103200	http://dx.doi.org/10.1074/jbc.M203103200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12183450	hybrid			2022-12-27	WOS:000179081200094
J	Mann, T; Gaskins, E; Beckers, C				Mann, T; Gaskins, E; Beckers, C			Proteolytic processing of TgIMC1 during maturation of the membrane skeleton Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; REPRODUCTION; CYTOSKELETON; PARASITE; ARTICULINS; FILAMENTS	Membrane skeletons play an important role in the maintenance of cell shape and integrity in many cell types. In the protozoan parasite Toxoplasma gondii this function is performed by the subpellicular network, a resilient structure composed of tightly interwoven 10-nm filaments. We report here that this network is assembled at an early stage in the development of daughter parasites. The networks of immature and mature parasites differ dramatically with respect to their stability. Although in immature parasites the network is completely solubilized by detergent, the network in mature parasites is entirely detergent-resistant. Conversion of the detergent-labile to the detergent-resistant network occurs late in daughter cell development and appears to be coupled to proteolytic processing of the carboxyl terminus of TgIMC1, the major subunit of the network filaments. A single cysteine residue in the TgIMC1 carboxyl terminus was found to be essential for this processing event. The dramatic change in resistance to detergent extraction probably reflects an overall change in structural stability of the subpellicular network that accompanies maturation of daughter parasites and allows a switch from an assembly-competent but loose structure to one that is rigid and offers mechanical strength to the mature parasite.	Univ Alabama Birmingham, Dept Geog Med, Div Geog Med, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Beckers, C (corresponding author), Univ Alabama Birmingham, Dept Geog Med, Div Geog Med, 845 19th St S,BBRB 206, Birmingham, AL 35294 USA.	cbeckers@uab.edu						BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; BECKERS CJM, 1994, J CELL BIOL, V127, P947, DOI 10.1083/jcb.127.4.947; Bennett V, 2001, PHYSIOL REV, V81, P1353, DOI 10.1152/physrev.2001.81.3.1353; CHOBOTAR WM, 1985, BIOL COCCIDIA, P101; CROSSLEY R, 1983, J CELL SCI, V59, P81; DUBREUIL RR, 1985, J CELL BIOL, V101, P1884, DOI 10.1083/jcb.101.5.1884; GOLDMAN M, 1958, J PARASITOL, V44, P161, DOI 10.2307/3274692; HONTS JE, 1990, J CELL SCI, V96, P293; Hu K, 2002, MOL BIOL CELL, V13, P593, DOI 10.1091/mbc.01-06-0309; Huttenlauch I, 1998, J CELL SCI, V111, P1909; Jackson M. H., 1989, Advances in Parasitology, V28, P55, DOI 10.1016/S0065-308X(08)60331-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECHTRECK KF, 1991, J CELL BIOL, V115, P705, DOI 10.1083/jcb.115.3.705; Luft B. J., 1989, Parasitic infections in the compromised host., P179; Mann T, 2001, MOL BIOCHEM PARASIT, V115, P257, DOI 10.1016/S0166-6851(01)00289-4; MARRS JA, 1992, J CELL BIOL, V118, P1465, DOI 10.1083/jcb.118.6.1465; NICHOLS BA, 1987, J PROTOZOOL, V34, P217, DOI 10.1111/j.1550-7408.1987.tb03162.x; PEATTIE DA, 1989, J CELL BIOL, V109, P2323, DOI 10.1083/jcb.109.5.2323; RUSSELL DG, 1982, INT J PARASITOL, V12, P221, DOI 10.1016/0020-7519(82)90020-0; RUSSELL DG, 1984, J CELL SCI, V65, P193; SHEFFIELD HG, 1968, J PARASITOL, V54, P209, DOI 10.2307/3276925; SINENSKY M, 1994, J CELL SCI, V107, P61; Sinensky M, 2000, BBA-MOL CELL BIOL L, V1484, P93, DOI 10.1016/S1388-1981(00)00009-3; VIVIER E, 1969, J CELL BIOL, V43, P329, DOI 10.1083/jcb.43.2.312; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; [No title captured]	27	59	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41240	41246		10.1074/jbc.M205056200	http://dx.doi.org/10.1074/jbc.M205056200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177058	hybrid			2022-12-27	WOS:000178791400135
J	Basso, AD; Solit, DB; Chiosis, G; Giri, B; Tsichlis, P; Rosen, N				Basso, AD; Solit, DB; Chiosis, G; Giri, B; Tsichlis, P; Rosen, N			Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER CELLS; CHEMOTHERAPY-INDUCED APOPTOSIS; UBIQUITIN-PROTEASOME PATHWAY; GLUCOCORTICOID RECEPTOR; ONCOGENIC TRANSFORMATION; SIGNALING PATHWAY; ANSAMYCINS CAUSES; BINDING-SITE; MUTATED P53; RAF KINASE	Hsp90 is a chaperone required for the conformational maturation of certain signaling proteins including Raf, cdk4, and steroid receptors. Natural products and synthetic small molecules that bind to the ATP-binding pocket in the amino-terminal domain of Hsp90 inhibit its function and cause the degradation of these client proteins. Inhibition of Hsp90 function in cells causes down-regulation of an Akt kinase-dependent pathway required for D-cyclin expression and retinoblastoma protein-dependent G, arrest. Intracellular Akt is associated with Hsp90 and Cdc37 in a complex in which Akt kinase is active and regulated by phosphatidylinositol 3-kinase. Functional Hsp90 is required for the stability of Akt in the complex. Occupancy of the ATP-binding pocket by inhibitors is associated with the ubiquitination of Akt and its targeting to the proteasome, where it is degraded. This results in a shortening of the half-life of Akt from 36 to 12 h and an 80% reduction in its expression. Akt and its activating kinase, PDK1, are the only members of the protein kinase A/protein kinase B/protein kinase C-like kinase family that are affected by Hsp90 inhibitors. Thus, transduction of growth factor signaling via the Akt and Raf pathways requires functional Hsp90 and can be coordinately blocked by its inhibition.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Thomas Jefferson Univ, Kimmel Canc, Philadelphia, PA 19107 USA; Cornell Univ, Weill Grad Sch Med Sci, Program Pharmacol, Philadelphia, PA 19107 USA	Jefferson University; Memorial Sloan Kettering Cancer Center; Jefferson University; Cornell University	Rosen, N (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Program, 1275 York Ave,Box 271, New York, NY 10021 USA.		Solit, David B./AAC-5309-2019; Rosen, Neal/ABF-2677-2020; 高, 雨莉/HGU-8187-2022		NCI NIH HHS [P50CA9262901, R01 CA57436, U01CA91178] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA091178, P50CA092629, R01CA057436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; An WG, 2000, CELL GROWTH DIFFER, V11, P355; BANSAL GS, 1991, EXP CELL RES, V195, P303, DOI 10.1016/0014-4827(91)90377-7; Bardelli A, 1999, ONCOGENE, V18, P1139, DOI 10.1038/sj.onc.1202607; Basso AD, 2002, ONCOGENE, V21, P1159, DOI 10.1038/sj.onc.1205184; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; Chen CF, 1996, MOL CELL BIOL, V16, P4691; Chiosis G, 2001, CHEM BIOL, V8, P289, DOI 10.1016/S1074-5521(01)00015-1; CHIOSIS G, 2002, IN PRESS BIOORG MED; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Czar MJ, 1997, BIOCHEMISTRY-US, V36, P7776, DOI 10.1021/bi970648x; DATTA K, 1995, MOL CELL BIOL, V15, P2304; DEDUVE C, 1983, EUR J BIOCHEM, V137, P391, DOI 10.1111/j.1432-1033.1983.tb07841.x; Dittmar KD, 1997, J BIOL CHEM, V272, P13047, DOI 10.1074/jbc.272.20.13047; DOLLE RE, 1994, J MED CHEM, V37, P3863, DOI 10.1021/jm00049a001; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fujita N, 2002, J BIOL CHEM, V277, P10346, DOI 10.1074/jbc.M106736200; Grammatikakis N, 1999, MOL CELL BIOL, V19, P1661; Hostein I, 2001, CANCER RES, V61, P4003; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Malstrom S, 2001, P NATL ACAD SCI USA, V98, P14967, DOI 10.1073/pnas.231467698; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Moasser MM, 2001, CANCER RES, V61, P7184; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Munster PN, 2001, CLIN CANCER RES, V7, P2228; Munster PN, 2001, CANCER RES, V61, P2945; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Page C, 2000, ANTICANCER RES, V20, P407; Page C, 2000, INT J ONCOL, V17, P23; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Schulte TW, 1998, CELL STRESS CHAPERON, V3, P100, DOI 10.1379/1466-1268(1998)003<0100:ARBTTN>2.3.CO;2; Schulte TW, 1997, BIOCHEM BIOPH RES CO, V239, P655, DOI 10.1006/bbrc.1997.7527; SEPPLORENZINO L, 1995, J BIOL CHEM, V270, P16580, DOI 10.1074/jbc.270.28.16580; SHIMADA Y, 1995, J ANTIBIOT, V48, P824, DOI 10.7164/antibiotics.48.824; Siligardi G, 2002, J BIOL CHEM, V277, P20151, DOI 10.1074/jbc.M201287200; Silverstein AM, 1998, J BIOL CHEM, V273, P20090, DOI 10.1074/jbc.273.32.20090; Soga S, 1998, J BIOL CHEM, V273, P822, DOI 10.1074/jbc.273.2.822; SORGER PK, 1987, J MOL BIOL, V194, P341, DOI 10.1016/0022-2836(87)90380-9; Srethapakdi M, 2000, CANCER RES, V60, P3940; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stancato LF, 1997, J BIOL CHEM, V272, P4013, DOI 10.1074/jbc.272.7.4013; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stepanova L, 1996, GENE DEV, V10, P1491, DOI 10.1101/gad.10.12.1491; Stepanova L, 2000, MOL CELL BIOL, V20, P4462, DOI 10.1128/MCB.20.12.4462-4473.2000; Sun M, 2001, AM J PATHOL, V159, P431, DOI 10.1016/S0002-9440(10)61714-2; TSUJINAKA T, 1988, BIOCHEM BIOPH RES CO, V153, P1201, DOI 10.1016/S0006-291X(88)81355-X; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; Webb CP, 2000, CANCER RES, V60, P342; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Xu WP, 2001, J BIOL CHEM, V276, P3702, DOI 10.1074/jbc.M006864200	62	512	536	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39858	39866		10.1074/jbc.M206322200	http://dx.doi.org/10.1074/jbc.M206322200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176997	hybrid			2022-12-27	WOS:000178662500102
J	Bourguignon, LYW; Singleton, PA; Zhu, HB; Zhou, B				Bourguignon, LYW; Singleton, PA; Zhu, HB; Zhou, B			Hyaluronan promotes signaling interaction between CD44 and the transforming growth factor beta receptor I in metastatic breast tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RELATED PROTEIN; LYMPHOCYTE HOMING RECEPTOR; ANKYRIN-BINDING DOMAIN; TGF-BETA; CANCER CELLS; TRANSMEMBRANE GLYCOPROTEIN; EXPRESSION; CARCINOMA; OVARIAN; CYTOSKELETON	In this study we have examined the interaction between CD44 (a hyaluronan (HA) receptor) and the transforming growth factor beta (TGF-beta) receptors (a family of serine/threonine kinase membrane receptors) in human metastatic breast tumor cells (MDA-MB-231 cell line). Immunological data indicate that both CD44 and TGF-beta receptors are expressed in NMA-MB-231 cells and that CD44 is physically linked to the TGF-beta receptor I (TGF-betaRI) (and to a lesser extent to the TGF-beta receptor II (TGF-betaRII)) as a complex in vivo. Scatchard plot analyses and in vitro binding experiments show that the cytoplasmic domain of CD44 binds to TGF-betaRI at a single site with high affinity (an apparent dissociation constant (K-d) of similar to1.78 nm). These findings indicate that TGF-betaRI contains a CD44-binding site. Furthermore,we have found that the binding of HA to CD44 in MDA-MB-231 cells stimulates TGF-betaRI serine/threonine kinase activity which, in turn, increases Smad2/Smad3 phosphorylation and parathyroid hormone-related protein (PTHrP) production (well known downstream effector functions of TGF-13 signaling). Most importantly, TGF-betaRI kinase activated by RA phosphorylates CD44, which enhances its binding interaction with the cytoskeletal protein, ankyrin, leading to HA-mediated breast tumor cell migration. Overexpression of TGF-betaRI by transfection of MDA-MB-231 cells with TGF-betaRIcDNA stimulates formation of the CD44.TGF-betaRI complex, the association of ankyrin with membranes, and HA-dependent/CD44-specific breast tumor migration. Taken together, these findings strongly suggest that CD44 interaction with the TGF-betaRI kinase promotes activation of multiple signaling pathways required for ankyrin-membrane interaction, tumor cell migration, and important oncogenic events (e.g. Smad2/Smad3 phosphorylation and PTH-rP production) during HA and TGF-beta-mediated metastatic breast tumor progression.	Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, San Francisco, CA 94121 USA; Vet Affairs Med Ctr, Endocrine Unit, San Francisco, CA 94121 USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bourguignon, LYW (corresponding author), Univ Calif San Francisco, Dept Med, Endocrine Unit 111N, 4150 Clement St, San Francisco, CA 94121 USA.	lillyb@itsa.ucsf.edu			NCI NIH HHS [CA66163, CA78633] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078633, R01CA066163] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AARON AD, 1994, JAMA-J AM MED ASSOC, V272, P1206, DOI 10.1001/jama.272.15.1206; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; Bourguignon LYW, 2001, J BIOL CHEM, V276, P7327, DOI 10.1074/jbc.M006498200; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Bourguignon LYW, 1996, CURR TOP MEMBR, V43, P293; BOURGUIGNON LYW, 1992, MOL CELL BIOL, V12, P4464, DOI 10.1128/MCB.12.10.4464; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; BOURGUIGNON LYW, 1998, FRONT BIOSCI, V3, P637; BUDAYR AA, 1989, ANN INTERN MED, V111, P807, DOI 10.7326/0003-4819-111-10-807; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chirgwin JM, 2000, CRIT REV EUKAR GENE, V10, P159; DALL P, 1995, INT J CANCER, V60, P471, DOI 10.1002/ijc.2910600408; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; Goltzman David, 1996, P809; Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18; HAWKER CD, 1983, ASSAY CALCIUM REGULA, P218; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401; Iida N, 1997, J CELL PHYSIOL, V171, P152, DOI 10.1002/(SICI)1097-4652(199705)171:2<152::AID-JCP5>3.3.CO;2-6; IIDA N, 1995, J CELL PHYSIOL, V162, P127, DOI 10.1002/jcp.1041620115; KADIN ME, 1994, P NATL ACAD SCI USA, V91, P6002, DOI 10.1073/pnas.91.13.6002; KAI HY, 1996, PRINCIPLES BONE BIOL, P347; KALISH ED, 1999, FRONT BIOSCI, V4, P1; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KAUFMANN M, 1995, LANCET, V345, P615, DOI 10.1016/S0140-6736(95)90521-9; Koli KM, 1997, CANCER RES, V57, P970; LEWIS CA, 2001, BIOCHEM J, V357, P834; Lindemann RK, 2001, J BIOL CHEM, V276, P46661, DOI 10.1074/jbc.M105816200; LOCCI P, 1995, CELL TISSUE RES, V281, P317; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; LOPEZCASILLAS F, 1991, CELL, V67, P785, DOI 10.1016/0092-8674(91)90073-8; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1992, CANCER SURV, V12, P81; MERRYMAN JI, 1994, ENDOCRINOLOGY, V134, P2424, DOI 10.1210/en.134.6.2424; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; Peck D, 1998, J CELL SCI, V111, P1595; POWELL GJ, 1991, CANCER RES, V51, P3059; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Segre Gino V., 1996, P377; Shi YG, 2001, BIOESSAYS, V23, P223, DOI 10.1002/1521-1878(200103)23:3<223::AID-BIES1032>3.3.CO;2-L; Smith H S, 1991, Basic Life Sci, V57, P329; Sy Man-Sun, 1997, Current Opinion in Oncology, V9, P108; Tobin SW, 2002, ONCOGENE, V21, P108, DOI 10.1038/sj.onc.1205026; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; WANG XF, 1991, CELL, V67, P797, DOI 10.1016/0092-8674(91)90074-9; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu GF, 1998, J BIOL CHEM, V273, P7749, DOI 10.1074/jbc.273.13.7749; Xie W, 2002, CANCER RES, V62, P497; Yeo TK, 1996, AM J PATHOL, V148, P1733; Yin JJ, 1999, J CLIN INVEST, V103, P197, DOI 10.1172/JCI3523; Yin JJ, 1996, J BONE MINER RES, V11, P180; Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486; Yu Q, 2000, GENE DEV, V14, P163; Zhu D, 2000, J CELL PHYSIOL, V183, P182, DOI 10.1002/(SICI)1097-4652(200005)183:2<182::AID-JCP5>3.0.CO;2-O; Zhu D, 1998, CELL MOTIL CYTOSKEL, V39, P209, DOI 10.1002/(SICI)1097-0169(1998)39:3<209::AID-CM4>3.0.CO;2-#	70	178	181	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39703	39712		10.1074/jbc.M204320200	http://dx.doi.org/10.1074/jbc.M204320200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12145287	hybrid			2022-12-27	WOS:000178662500084
J	Inoue, K; Zhuang, L; Maddox, DM; Smith, SB; Ganapathy, V				Inoue, K; Zhuang, L; Maddox, DM; Smith, SB; Ganapathy, V			Structure, function, and expression pattern of a novel sodium-coupled citrate transporter (NaCT) cloned from mammalian brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC CATION TRANSPORTER; AFFINITY DICARBOXYLATE TRANSPORTER; TISSUE DISTRIBUTION PATTERN; SIGMA-RECEPTOR; CLONING; COTRANSPORTER; PROTEINS; PLACENTA; SEQUENCE; IDENTITY	Citrate plays a pivotal role not only in the generation of metabolic energy but also in the synthesis of fatty acids, isoprenoids, and cholesterol in mammalian cells. Plasma levels of citrate are the highest (similar to 135 muM) among the intermediates of the tricarboxylic acid cycle. Here we report on the cloning and functional characterization of a plasma membrane transporter (NaCT for Na+-coupled citrate transporter) from rat brain that mediates uphill cellular uptake of citrate coupled to an electrochemical Na+ gradient. NaCT consists of 572 amino acids and exhibits structural similarity to the members of the Na+-dicarboxylate cotransporter/Na+-sulfate cotransporter (NaDC/NaSi) gene family including the recently identified Drosophila Indy. In rat, the expression of NaCT is restricted to liver, testis, and brain. When expressed heterologously in mammalian cells, rat NaCT mediates the transport of citrate with high affinity (Michaelis-Menten constant, similar to20 muM) and with a Na+:citrate stoichiometry of 4:1. The transporter does interact with other dicarboxylates and tricarboxylates but with considerably lower affinity. In mouse brain, the expression of NaCT mRNA is evident in the cerebral cortex, cerebellum, hippocampus, and olfactory bulb. NaCT represents the first transporter to be identified in mammalian cells that shows preference for citrate over dicarboxylates. This transporter is likely to play an important role in the cellular utilization of citrate in blood for the synthesis of fatty acids and cholesterol (liver) and for the generation of energy (liver and brain). NaCT thus constitutes a potential therapeutic target for the control of body weight, cholesterol levels, and energy homeostasis.	Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cell Biol & Anat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Obstet & Gynecol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Ganapathy, V (corresponding author), Med Coll Georgia, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.							Bai LQ, 1997, AM J PHYSIOL-GASTR L, V273, pG267, DOI 10.1152/ajpgi.1997.273.2.G267; BRIDGES CD, 2000, J BIOL CHEM, V275, P20676; Chen XM, 1999, J CLIN INVEST, V103, P1159, DOI 10.1172/JCI5392; Chen XZ, 1998, J BIOL CHEM, V273, P20972, DOI 10.1074/jbc.273.33.20972; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Helfand SL, 2000, RES PRO CEL, V29, P67; HODGKINSON A, 1963, CLIN SCI, V24, P167; Huang W, 2000, J PHARMACOL EXP THER, V295, P392; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; KASER H., 1961, CLIN CHIM ACTA, V6, P337, DOI 10.1016/0009-8981(61)90060-2; Kekuda R, 1998, J BIOL CHEM, V273, P15971, DOI 10.1074/jbc.273.26.15971; Kekuda R, 1999, J BIOL CHEM, V274, P3422, DOI 10.1074/jbc.274.6.3422; KREBS HA, 1950, ANNU REV BIOCHEM, V19, P409, DOI 10.1146/annurev.bi.19.070150.002205; Nakanishi T, 2001, AM J PHYSIOL-CELL PH, V281, pC1757, DOI 10.1152/ajpcell.2001.281.6.C1757; NORDMANN R, 1965, CLIN CHIM ACTA, V12, P304, DOI 10.1016/0009-8981(65)90050-1; Ola MS, 2001, MOL BRAIN RES, V95, P86; Pajor AM, 2000, AM J PHYSIOL-RENAL, V279, pF482, DOI 10.1152/ajprenal.2000.279.3.F482; Pajor AM, 1996, AM J PHYSIOL-RENAL, V270, pF642, DOI 10.1152/ajprenal.1996.270.4.F642; PAJOR AM, 1995, J BIOL CHEM, V270, P5779, DOI 10.1074/jbc.270.11.5779; Pajor AM, 2001, AM J PHYSIOL-CELL PH, V280, pC1215, DOI 10.1152/ajpcell.2001.280.5.C1215; Pajor AM, 1999, ANNU REV PHYSIOL, V61, P663, DOI 10.1146/annurev.physiol.61.1.663; PALMIERI F, 1972, EUR J BIOCHEM, V26, P587, DOI 10.1111/j.1432-1033.1972.tb01801.x; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Rajan DP, 1999, J BIOL CHEM, V274, P29005, DOI 10.1074/jbc.274.41.29005; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; Seth P, 2001, BBA-MOL CELL RES, V1540, P59, DOI 10.1016/S0167-4889(01)00117-3; Seth P, 1998, J NEUROCHEM, V70, P922; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; VANDERREST ME, 1992, J BIOL CHEM, V267, P8971; Wang H, 1998, AM J PHYSIOL-CELL PH, V275, pC967, DOI 10.1152/ajpcell.1998.275.4.C967; Wang HP, 2000, AM J PHYSIOL-CELL PH, V278, pC1019, DOI 10.1152/ajpcell.2000.278.5.C1019; Wu X, 2000, BBA-BIOMEMBRANES, V1466, P315, DOI 10.1016/S0005-2736(00)00189-9; Wu X, 1998, J BIOL CHEM, V273, P32776, DOI 10.1074/jbc.273.49.32776; Wu X, 1999, J PHARMACOL EXP THER, V290, P1482	34	104	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39469	39476		10.1074/jbc.M207072200	http://dx.doi.org/10.1074/jbc.M207072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177002	hybrid			2022-12-27	WOS:000178662500054
J	Stadler, JA; Schweyen, RJ				Stadler, JA; Schweyen, RJ			The yeast iron regulon is induced upon cobalt stress and crucial for cobalt tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR FACILITATOR SUPERFAMILY; SACCHAROMYCES-CEREVISIAE; ERYTHROPOIETIN GENE; OXYGEN SENSOR; HEME PROTEIN; EXPRESSION; TRANSPORTER; ENCODES; IDENTIFICATION; FAMILY	To identify yeast genes involved in cobalt detoxification, we performed RNA expression profiling experiments and followed changes in gene activity upon cobalt stress on a genome-wide scale. We found that cobalt stress specifically results in an immediate and dramatic induction of genes involved in iron uptake. This response is dependent on the Aft1 protein, a transcriptional factor known to regulate a set of genes involved in iron uptake and homeostasis (iron regulon). Like iron starvation, cobalt stress induces accumulation of the Aft1 protein in the nucleus to activate transcription of its target genes. Cells lacking the AFT1 gene (aft1) are hypersensitive to cobalt as well as to other transition metals, whereas expression of the dominant AFT1-1(up) allele, which results in up-regulation of AFT1-controlled genes, confers resistance. Cobalt resistance correlates with an increase in intracellular iron in AFTI-1(up) cells, and sensitivity of aft1 cells is associated with a lack of iron accumulation. Furthermore, elevated iron levels in the growth medium suppress the cobalt sensitivity of the aft1 mutant cells, even though they increase cellular cobalt. Results presented indicate that yeast cells acquire cobalt tolerance by activating the Aft1p-dependent iron regulon and thereby increasing intracellular iron levels.	Univ Vienna, Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Schweyen, RJ (corresponding author), Univ Vienna, Vienna Bioctr, Inst Microbiol & Genet, Dr Bohrgasse 9, A-1030 Vienna, Austria.							Agency for Toxic Substances and Disease Registry (ATSDR), 1992, AG TOX SUBST DIS REG; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Barceloux DG, 1999, J TOXICOL-CLIN TOXIC, V37, P201, DOI 10.1081/CLT-100102420; BATTERSBY AR, 1994, SCIENCE, V264, P1551, DOI 10.1126/science.8202709; BEYERSMANN D, 1992, TOXICOL APPL PHARM, V115, P137, DOI 10.1016/0041-008X(92)90377-5; Bui DM, 1999, J BIOL CHEM, V274, P20438, DOI 10.1074/jbc.274.29.20438; Bunn HF, 1998, J EXP BIOL, V201, P1197; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; DIX DR, 1994, J BIOL CHEM, V269, P26092; EIDE D, 1992, J BIOL CHEM, V267, P20774; Foury F, 2001, J BIOL CHEM, V276, P7762, DOI 10.1074/jbc.M005804200; Garland SA, 1999, J MOL BIOL, V294, P897, DOI 10.1006/jmbi.1999.3294; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Graschopf A, 2001, J BIOL CHEM, V276, P16216, DOI 10.1074/jbc.M101504200; Heymann P, 2000, BIOMETALS, V13, P65, DOI 10.1023/A:1009250017785; Heymann P, 1999, BIOMETALS, V12, P301, DOI 10.1023/A:1009252118050; Heymann P, 2000, FEMS MICROBIOL LETT, V186, P221, DOI 10.1016/S0378-1097(00)00152-X; Ho VT, 1996, BIOCHEM BIOPH RES CO, V223, P175, DOI 10.1006/bbrc.1996.0865; JENETTE KW, 1981, ENV HLTH PERSPECT, V40, P233; KASPRZAK KS, 1991, CHEM RES TOXICOL, V4, P604, DOI 10.1021/tx00024a002; KAZANTZIS G, 1981, ENVIRON HEALTH PERSP, V40, P143, DOI 10.2307/3429228; Kobayashi M, 1999, EUR J BIOCHEM, V261, P1, DOI 10.1046/j.1432-1327.1999.00186.x; LAUWERYS R, 1994, SCI TOTAL ENVIRON, V150, P1, DOI 10.1016/0048-9697(94)90125-2; Leonard S, 1998, J INORG BIOCHEM, V70, P239, DOI 10.1016/S0162-0134(98)10022-3; LESFARGUES G, 1994, AM J IND MED, V26, P585; Lesuisse E, 1998, MICROBIOL-UK, V144, P3455, DOI 10.1099/00221287-144-12-3455; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 1998, J BIOL CHEM, V273, P1727, DOI 10.1074/jbc.273.3.1727; Maniatis T., 1982, MOL CLONING LAB MANU; Measday V, 1997, MOL CELL BIOL, V17, P1212, DOI 10.1128/MCB.17.3.1212; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; Protchenko O, 2001, J BIOL CHEM, V276, P49244, DOI 10.1074/jbc.M109220200; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WANG XY, 1993, ARCH BIOCHEM BIOPHYS, V306, P402, DOI 10.1006/abbi.1993.1529; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Yamaguchi-Iwai Y, 2002, J BIOL CHEM, V277, P18914, DOI 10.1074/jbc.M200949200; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709	44	70	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39649	39654		10.1074/jbc.M203924200	http://dx.doi.org/10.1074/jbc.M203924200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176980	hybrid			2022-12-27	WOS:000178662500077
J	Baird, TR; Walsh, PN				Baird, TR; Walsh, PN			The interaction of factor XIa with activated platelets but not endothelial cells promotes the activation of factor IX in the consolidation phase of blood coagulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-PROTEIN PRECURSOR; MOLECULAR-WEIGHT KININOGEN; HEPARIN-BINDING SITE; BOUND FACTOR-XIA; FUNCTIONAL-CHARACTERIZATION; CHRISTMAS-FACTOR; APPLE-3 DOMAIN; HEAVY-CHAIN; SURFACE; THROMBIN	We have previously shown that the zymogen factor XI (FXI) binds to activated platelets but not to human umbilical vein endothelial cells (HUVEC), a conclusion that is in conflict with previous reports stating that FXI binds to 2.7-13 x 10(6) high affinity sites per HUVEC (Berrettini, M., Schleef, R. R., Heeb, M. J., Hopmeier, P., and Griffin, J. H. (1992) J. Biol. Chem. 267, 19833-19839; Shariat-Madar, Z., Mahdi, F., and Schmaier, A. H. (2001) Thromb. Haemostasis 85, 544-551). It has also been reported that activated FXI (FXIa) binds to 1.5 x 10(6) sites per HUVEC and promotes the activation of factor IX by cell bound FXIa (Berrettini, M., Schleef, R. R., Heeb, M. J., Hopmeier, P., and Griffin, J. H. (1992) J. Biol. Chem. 267, 19833-19839). Therefore, the binding of FXIa to activated platelets was compared with FXIa binding to HUVEC and HEK293 cells immobilized on microcarrier beads. Specific and saturable zinc-dependent FXIa binding was demonstrated to 250 +/- 48 sites per activated platelet (K-D 1.7 +/- 0.78 nM) and 6.5 +/- 0.4 x 10(4) sites per HUVEC (K-D 2.4 +/- 0.5 nM), whereas no binding to HEK293 cells was detected. A titration with high molecular weight kininogen had no effect on FXIa binding to platelets, but revealed a concentration-dependent decrease in the amount of FXIa bound to HUVEC. The rate of factor IXa generation catalyzed by FXIa was unaffected by the presence of surfaces; however only the activated platelet surface protected FXIa from inhibition by protease nexin 2. The results presented here confirm the conclusion that activated platelets are procoagulant while unstimulated endothelial cells are not.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.				NHLBI NIH HHS [HL46213, HL64943, HL56914] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056914, P01HL064943, R01HL046213] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1989, J BIOL CHEM, V264, P3244; Badellino KO, 2001, BIOCHEMISTRY-US, V40, P7569, DOI 10.1021/bi0027433; Baglia FA, 2000, J BIOL CHEM, V275, P20514, DOI 10.1074/jbc.M000464200; BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; Baird TR, 2002, J BIOL CHEM, V277, P28498, DOI 10.1074/jbc.M203427200; BERRETTINI M, 1992, J BIOL CHEM, V267, P19833; BOUMA BN, 1977, J BIOL CHEM, V252, P6432; Bradford HN, 1997, BLOOD, V90, P1508, DOI 10.1182/blood.V90.4.1508.1508_1508_1515; Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Gailani D, 2001, BLOOD, V97, P3117, DOI 10.1182/blood.V97.10.3117; GREENGARD JS, 1986, BIOCHEMISTRY-US, V25, P3884, DOI 10.1021/bi00361a022; Hasan AAK, 1998, P NATL ACAD SCI USA, V95, P3615, DOI 10.1073/pnas.95.7.3615; Ho DH, 1998, J BIOL CHEM, V273, P16382, DOI 10.1074/jbc.273.26.16382; Ho DH, 2000, BIOCHEMISTRY-US, V39, P316, DOI 10.1021/bi991851q; LINDQUIST PA, 1978, J BIOL CHEM, V253, P1902; Mahdi F, 2001, BLOOD, V97, P2342, DOI 10.1182/blood.V97.8.2342; MANNHALTER C, 1984, BRIT J HAEMATOL, V56, P261, DOI 10.1111/j.1365-2141.1984.tb03954.x; NAITO K, 1991, J BIOL CHEM, V266, P7353; OSTERUD B, 1978, J BIOL CHEM, V253, P5946; Renne T, 2000, J BIOL CHEM, V275, P33688, DOI 10.1074/jbc.M000313200; Scandura JM, 1996, BIOCHEMISTRY-US, V35, P8890, DOI 10.1021/bi9525029; Scandura JM, 1997, BIOCHEMISTRY-US, V36, P412, DOI 10.1021/bi9612576; Shariat-Madar Z, 2001, THROMB HAEMOSTASIS, V85, P544, DOI 10.1055/s-0037-1615619; Shariat-Madar Z, 1999, J BIOL CHEM, V274, P7137, DOI 10.1074/jbc.274.11.7137; SINHA D, 1992, METHOD ENZYMOL, V215, P361; SINHA D, 1985, J BIOL CHEM, V260, P714; SINHA D, 1987, BIOCHEMISTRY-US, V26, P3768, DOI 10.1021/bi00387a005; SINHA D, 1984, J CLIN INVEST, V73, P1550, DOI 10.1172/JCI111361; Sun MF, 1999, J BIOL CHEM, V274, P36373, DOI 10.1074/jbc.274.51.36373; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; TUSZYNSKI GP, 1980, ANAL BIOCHEM, V106, P118, DOI 10.1016/0003-2697(80)90126-8; VANNOSTRAND WE, 1995, THROMB RES, V78, P43, DOI 10.1016/0049-3848(95)00033-X; VANNOSTRAND WE, 1991, BIOCHEM BIOPH RES CO, V175, P15, DOI 10.1016/S0006-291X(05)81193-3; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; Walsh P N, 1977, Br J Haematol, V36, P287; WALSH PN, 1986, BLOOD, V68, P225; WALSH PN, 1987, J CLIN INVEST, V80, P1578, DOI 10.1172/JCI113244; Walsh PN, 2001, THROMB HAEMOSTASIS, V86, P75; Wolberg AS, 1997, BIOCHEMISTRY-US, V36, P4074, DOI 10.1021/bi962274y; Zhao MM, 1998, J BIOL CHEM, V273, P31153, DOI 10.1074/jbc.273.47.31153	43	26	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38462	38467		10.1074/jbc.M205902200	http://dx.doi.org/10.1074/jbc.M205902200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167623	hybrid			2022-12-27	WOS:000178529600061
J	Bova, MP; Huang, QL; Ding, LL; Horwitz, J				Bova, MP; Huang, QL; Ding, LL; Horwitz, J			Subunit exchange, conformational stability, and chaperone-like function of the small heat shock protein 16.5 from Methanococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ALPHA-B-CRYSTALLIN; A-CRYSTALLIN; OLIGOMERIC STRUCTURE; QUATERNARY STRUCTURE; MISSENSE MUTATION; CONSERVED DOMAIN; LIGHT-SCATTERING; CELL-DEATH; PHOSPHORYLATION	Hsp16.5, isolated from the hyperthermophilic Archaea Methanococcus jannaschii, is a member of the small heat-shock protein family. Small Hsps have 12- to 42-kDa subunit sizes and have sequences that are conserved among all organisms. The recently determined crystal structure of Hsp16.5 indicates that it consists discretely of 24 identical subunits. Using fluorescence resonance energy transfer, we show that at temperatures above 60degreesC, the subunits of MjHsp16.5 freely and reversibly exchange with a rate constant of exchange at 68 degreesC of 0.067 min(-1). The subunit exchange reactions were strongly temperature-dependent, similar to the exchange reactions of the alpha-crystallins. The exchange reaction was specific to MjHsp16.5 subunits, as other sHsps such as alpha-crystallin were not structurally compatible and could not integrate into the MjHsp16.5 oligomer. In addition, we demonstrate that at temperatures as high as 70 degreesC, MjHsp16.5 retains its multimeric structure and subunit organization. Using insulin and a-lactalbumin as model target proteins, we also show that MjHsp16.5 at 37degreesC is a markedly inefficient chaperone compared with other sHsps with these substrates. The results of this study support the hypothesis that MjHsp16.5 has a dynamic quaternary structure at temperatures that are physiologically relevant to M. jannaschii.	Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Horwitz, J (corresponding author), Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA.	horwitz@jsei.ucla.edu			NATIONAL EYE INSTITUTE [R37EY003897] Funding Source: NIH RePORTER; NEI NIH HHS [R37-EY3897] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Arrigo AP, 1998, BIOL CHEM, V379, P19; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Arrigo AP, 2000, PATHOL BIOL, V48, P280; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Berengian AR, 1997, BIOCHEMISTRY-US, V36, P9951, DOI 10.1021/bi9712347; Berengian AR, 1999, J BIOL CHEM, V274, P6305, DOI 10.1074/jbc.274.10.6305; Bhat SP, 1999, EUR J CELL BIOL, V78, P143, DOI 10.1016/S0171-9335(99)80016-8; Bova MP, 2000, J BIOL CHEM, V275, P1035, DOI 10.1074/jbc.275.2.1035; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Ehrnsperger M, 1999, J BIOL CHEM, V274, P14867, DOI 10.1074/jbc.274.21.14867; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Folta-Stogniew E, 1999, J Biomol Tech, V10, P51; Haley DA, 2000, J MOL BIOL, V298, P261, DOI 10.1006/jmbi.2000.3657; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Haugland R., 1996, HDB FLUORESCENT PROB; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Horwitz J, 1999, EYE, V13, P403, DOI 10.1038/eye.1999.114; Horwitz J, 1998, METHOD ENZYMOL, V290, P365, DOI 10.1016/S0076-6879(98)90032-5; Huot J, 1996, CANCER RES, V56, P273; JAKOB U, 1993, J BIOL CHEM, V268, P1517; JONES WJ, 1983, ARCH MICROBIOL, V136, P254, DOI 10.1007/BF00425213; KATO K, 1994, J BIOL CHEM, V269, P11274; Kim KK, 1998, J STRUCT BIOL, V121, P76, DOI 10.1006/jsbi.1998.3969; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kim R, 1998, P NATL ACAD SCI USA, V95, P9129, DOI 10.1073/pnas.95.16.9129; Koteiche HA, 1998, BIOCHEMISTRY-US, V37, P12681, DOI 10.1021/bi9814078; Koteiche HA, 1999, J MOL BIOL, V294, P561, DOI 10.1006/jmbi.1999.3242; Koteiche HA, 2002, FEBS LETT, V519, P16, DOI 10.1016/S0014-5793(02)02688-1; Laksanalamai P, 2001, J BACTERIOL, V183, P5198, DOI 10.1128/JB.183.17.5198-5202.2001; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; MEHLEN P, 1994, EUR J BIOCHEM, V221, P327, DOI 10.1111/j.1432-1033.1994.tb18744.x; Narberhaus F, 2002, MICROBIOL MOL BIOL R, V66, P64, DOI 10.1128/MMBR.66.1.64-93.2002; RAMAN B, 1995, FEBS LETT, V365, P133, DOI 10.1016/0014-5793(95)00440-K; Sharma KK, 1997, BIOCHEM BIOPH RES CO, V239, P217, DOI 10.1006/bbrc.1997.7460; Sun TX, 1998, J BIOL CHEM, V273, P286, DOI 10.1074/jbc.273.1.286; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Vanhoudt J, 2000, BIOCHEMISTRY-US, V39, P4483, DOI 10.1021/bi990386u; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wen J, 1996, ANAL BIOCHEM, V240, P155, DOI 10.1006/abio.1996.0345; WYATT PJ, 1993, ANAL CHIM ACTA, V272, P1, DOI 10.1016/0003-2670(93)80373-S	46	114	117	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38468	38475		10.1074/jbc.M205594200	http://dx.doi.org/10.1074/jbc.M205594200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12176992	hybrid			2022-12-27	WOS:000178529600062
J	Christine, KS; MacFarlane, AW; Yang, KS; Stanley, RJ				Christine, KS; MacFarlane, AW; Yang, KS; Stanley, RJ			Cyclobutylpyrimidine dimer base flipping by DNA photolyase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMINE CYCLOBUTANE DIMER; CIS-SYN; DAMAGE RECOGNITION; CRYSTAL-STRUCTURE; ABASIC SITES; 2-AMINOPURINE; FLUORESCENCE; RECONSTITUTION; MECHANISM; FLAVIN	DNA Photolyase is a flavoprotein that uses light to repair cyclobutylpyrimidine dimers in DNA. From considerations of the crystal structure of the protein, it has been hypothesized that the dimer lesion is flipped out of the DNA double helix into the substrate binding pocket. We have used a fluorescent adenine analog, 2-aminopurine (2-Ap), as a probe of local double helical structure upon binding of the substrate to the protein. Our results show that the local structure around the thymidine lesion changes dramatically upon binding to Photolyase. This is consistent with base flipping of the lesion into the protein binding cavity with concomitant destacking of the opposing complementary 2-Ap nucleotide.	Temple Univ, Dept Chem, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Stanley, RJ (corresponding author), Temple Univ, Dept Chem, 201 Beury Hall, Philadelphia, PA 19122 USA.	robert.stanley@temple.edu		Stanley, Robert/0000-0003-4140-4311; MacFarlane IV, Alexander/0000-0003-1740-4848				Allan BW, 1998, J BIOL CHEM, V273, P2368, DOI 10.1074/jbc.273.4.2368; Allan BW, 1996, BIOCHEMISTRY-US, V35, P14757, DOI 10.1021/bi9615708; BANERJEE SK, 1988, P NATL ACAD SCI USA, V85, P8141, DOI 10.1073/pnas.85.21.8141; BERG BJV, 1998, J BIOL CHEM, V273, P20276; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; FISHER GJ, 1976, PHOTOCHEM PHOTOBIOL, V24, P223, DOI 10.1111/j.1751-1097.1976.tb06815.x; Hahn J, 1999, J PHYS CHEM B, V103, P2001, DOI 10.1021/jp984197h; Holz B, 1998, NUCLEIC ACIDS RES, V26, P1076, DOI 10.1093/nar/26.4.1076; HUSAIN I, 1987, J BIOL CHEM, V262, P13188; Jing YQ, 1998, NUCLEIC ACIDS RES, V26, P3845, DOI 10.1093/nar/26.16.3845; JORNS MS, 1990, BIOCHEMISTRY-US, V29, P552, DOI 10.1021/bi00454a032; Kanai S, 1997, J MOL EVOL, V45, P535, DOI 10.1007/PL00006258; KIM ST, 1991, BIOCHEMISTRY-US, V30, P8623, DOI 10.1021/bi00099a019; Komori H, 2001, P NATL ACAD SCI USA, V98, P13560, DOI 10.1073/pnas.241371398; Law SM, 1996, BIOCHEMISTRY-US, V35, P12329, DOI 10.1021/bi9614545; LIPTAY W, 1969, ANGEW CHEM INT EDIT, V8, P177, DOI 10.1002/anie.196901771; MacFarlane AW, 2001, BIOCHEMISTRY-US, V40, P15203, DOI 10.1021/bi0114224; McAteer K, 1998, J MOL BIOL, V282, P1013, DOI 10.1006/jmbi.1998.2062; McCullough AK, 1997, J BIOL CHEM, V272, P27210, DOI 10.1074/jbc.272.43.27210; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; PAYNE G, 1987, BIOCHEMISTRY-US, V26, P7121, DOI 10.1021/bi00396a038; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P5706, DOI 10.1021/bi00476a010; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P946, DOI 10.1021/bi001664o; Rachofsky EL, 2001, BIOCHEMISTRY-US, V40, P957, DOI 10.1021/bi001665g; Rachofsky EL, 1998, ACTA PHYS POL A, V94, P735, DOI 10.12693/APhysPolA.94.735; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; SANCAR GB, 1987, J BIOL CHEM, V262, P492; Sanders DB, 1999, J AM CHEM SOC, V121, P5127, DOI 10.1021/ja982660y; Stivers JT, 1998, NUCLEIC ACIDS RES, V26, P3837, DOI 10.1093/nar/26.16.3837; Tamada T, 1997, NAT STRUCT BIOL, V4, P887, DOI 10.1038/nsb1197-887; WANG BY, 1989, BIOCHEMISTRY-US, V28, P1148, DOI 10.1021/bi00429a032; WARD DC, 1969, J BIOL CHEM, V244, P1228; XU DG, 1994, BIOCHEMISTRY-US, V33, P9592, DOI 10.1021/bi00198a027; Zhao XD, 1997, J BIOL CHEM, V272, P32580, DOI 10.1074/jbc.272.51.32580; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	37	60	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38339	38344		10.1074/jbc.M206531200	http://dx.doi.org/10.1074/jbc.M206531200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12169694	hybrid			2022-12-27	WOS:000178529600045
J	Doering, CB; Healey, JF; Parker, ET; Barrow, RT; Lollar, P				Doering, CB; Healey, JF; Parker, ET; Barrow, RT; Lollar, P			High level expression of recombinant porcine coagulation factor VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLOTTING FACTOR-VIII; HEMOPHILIA-A; SECRETION; CDNA; ANTIGENICITY; DISSOCIATION; INHIBITORS; SEQUENCES; RESIDUES; THERAPY	Recombinant human factor VIII expression levels, in vitro and in vivo, are significantly lower than levels obtained for other recombinant coagulation proteins. Here we describe the generation, high level expression and characterization of a recombinant B-domain-deleted porcine factor VIII molecule. Recombinant B-domain-deleted porcine factor VIII expression levels are 10- to 14-fold greater than recombinant B-domain-deleted human factor VIII levels by transient and stable expression in multiple cell lines. Peak expression of 140 units.10(6) cells(-1).24 h(-1) was observed from a baby hamster kidney-derived cell line stably expressing recombinant porcine factor VIII. Factor VIII expression was performed in serum-free culture medium and in the absence of exogenous von Willebrand factor, thus greatly simplifying protein purification. Real time reverse transcription-PCR analysis demonstrated that the differences in protein production were not caused by differences in steady-state factor VIII mRNA levels. The identification of sequence(s) in porcine factor VIII responsible for high level expression may lead to a better understanding of the mechanisms that limit factor VIII expression.	Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University	Lollar, P (corresponding author), Emory Univ, Winship Canc Inst, 1639 Pierce Dr,Room 1003,Woodruff Mem Bldg, Atlanta, GA 30322 USA.	jlollar@emory.edu	Doering, Christopher/W-2064-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040921] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL40921] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barrow RT, 2001, BLOOD, V97, P169, DOI 10.1182/blood.V97.1.169; Barrow RT, 2000, BLOOD, V95, P564, DOI 10.1182/blood.V95.2.564; CHUAH MKL, 1995, HUM GENE THER, V6, P1363, DOI 10.1089/hum.1995.6.11-1363; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; Fang XD, 2001, THROMB RES, V102, P177, DOI 10.1016/S0049-3848(01)00229-8; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FUNK WD, 1990, BIOCHEMISTRY-US, V29, P1654, DOI 10.1021/bi00458a043; Garber K, 2000, NAT BIOTECHNOL, V18, P1133, DOI 10.1038/81098; GATTI L, 1984, THROMB HAEMOSTASIS, V51, P379; GITSCHIER J, 1984, NATURE, V312, P326, DOI 10.1038/312326a0; Hay CRM, 1996, THROMB HAEMOSTASIS, V75, P25; HEALEY JF, 1995, J BIOL CHEM, V270, P14505, DOI 10.1074/jbc.270.24.14505; Healey JF, 1996, BLOOD, V88, P4209; HOEBEN RC, 1995, BLOOD, V85, P2447, DOI 10.1182/blood.V85.9.2447.bloodjournal8592447; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P1233, DOI 10.1128/MCB.9.3.1233; Kaufman RJ, 1997, BLOOD COAGUL FIBRIN, V8, pS3; KAUFMAN RJ, 1988, J BIOL CHEM, V263, P6352; KINGSTON RE, 1997, CURRENT PROTOCOLS MO, V37; KOEBERL DD, 1995, HUM GENE THER, V6, P469, DOI 10.1089/hum.1995.6.4-469; LIND P, 1995, EUR J BIOCHEM, V232, P19, DOI 10.1111/j.1432-1033.1995.tb20776.x; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1993, METHOD ENZYMOL, V222, P128; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; LUBIN IM, 1994, J BIOL CHEM, V269, P8639; LUSHER JM, 1993, NEW ENGL J MED, V328, P453, DOI 10.1056/NEJM199302183280701; LYNCH CM, 1993, HUM GENE THER, V4, P259, DOI 10.1089/hum.1993.4.3-259; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Pipe SW, 2001, BLOOD, V97, P685, DOI 10.1182/blood.V97.3.685; Pipe SW, 1998, J BIOL CHEM, V273, P8537, DOI 10.1074/jbc.273.14.8537; Pipe SW, 1999, BLOOD, V93, P176, DOI 10.1182/blood.V93.1.176.401k07_176_183; PITTMAN DD, 1993, BLOOD, V81, P2925; Plantier JL, 2001, THROMB HAEMOSTASIS, V86, P596, DOI 10.1055/s-0037-1616092; Roth DA, 2001, NEW ENGL J MED, V344, P1735, DOI 10.1056/NEJM200106073442301; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; Tagliavacca L, 2000, BIOCHEMISTRY-US, V39, P1973, DOI 10.1021/bi991896r; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0	39	79	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38345	38349		10.1074/jbc.M206959200	http://dx.doi.org/10.1074/jbc.M206959200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138172	hybrid			2022-12-27	WOS:000178529600046
J	Huang, XL; Pawliczak, R; Cowan, MJ; Gladwin, MT; Madara, P; Logun, C; Shelhamer, JH				Huang, XL; Pawliczak, R; Cowan, MJ; Gladwin, MT; Madara, P; Logun, C; Shelhamer, JH			Epidermal growth factor induces p11 gene and protein expression and down-regulates calcium ionophore-induced arachidonic acid release in human epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); ANNEXIN-II TETRAMER; GLOMERULAR MESANGIAL CELLS; PROSTAGLANDIN GENERATION; PLASMINOGEN ACTIVATION; BINDING PROTEINS; KINASE; PHOSPHORYLATION; INHIBITION; PLATELETS	p11, a member of the S-100 family of proteins, is the cellular ligand of annexin II and also interacts with the C-terminal region of cytosolic phospholipase A(2) (cPLA(2)), inhibiting cPLA(2) activity and arachidonic acid (AA) release. It has been reported that epidermal growth factor (EGF) induces cPLA(2), activation or cPLA(2) expression and subsequent AA release. It was of interest to study the effect of EGF on p11 production and on AA release in human epithelial cells (HeLa). EGF (20 ng/ml) treatment of HeLa cells increased the cellular p11. protein and the steady-state levels of p11 mRNA in a time- and dose-dependent manner but did not affect cPLA(2) protein expression over a 4-48-h incubation time. Transient transfection experiments of a reporter gene construct containing 1498 bp of the 5'-flanking region of p11 promoter demonstrated that EGF induced p11. gene expression at the transcriptional level. EGF caused a rapid phosphorylation of p44/42 and p38 kinases with a maximum level at 10 min. AG 1478 (EGF receptor tyrosine kinase inhibitor), PD 98059 (ERK1/2 inhibitor), and SB 203580 (p38 inhibitor) significantly inhibited EGF-induced p11. expression. EGF-induced AA release was significantly suppressed by AG 1478, PD 98059, SB 203580, and methyl arachidonyl fluorophosphate (a specific cPLA2 inhibitor). Methyl arachidonyl fluorophosphate (50 pm) also significantly inhibited EGF-induced p11 expression, demonstrating that the activation of cPLA(2) may have a role in the EGF-induced p11. expression. Immunoprecipitation experiments showed that EGF induced increased p11 binding to cPLA(2) in a time- and dose-dependent manner. EGF treatment for 30 min increased A23187-induced AA release, whereas EGF treatment for 24 h inhibited A23187-induced AA release. These results suggest that EGF treatment increased p11. bound to cPLA(2), may lead to the late suppression of AA release induced by EGF.	NIH, Dept Crit Care Med, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; Med Univ Lodz, Dept Allergy & Clin Immunol, PL-92213 Lodz, Poland	National Institutes of Health (NIH) - USA; Medical University Lodz	Shelhamer, JH (corresponding author), NIH, Dept Crit Care Med, Warren G Magnuson Clin Ctr, Bldg 10,Rm 7D43,10 Ctr Dr,MSC1662, Bethesda, MD 20892 USA.		Pawliczak, Rafal Tomasz/S-9649-2016; Pawliczak, Rafa/S-2021-2019	Pawliczak, Rafa/0000-0001-6784-453X	CLINICAL CENTER [Z01CL001160] Funding Source: NIH RePORTER	CLINICAL CENTER		ACKERMANN EJ, 1995, BBA-LIPID LIPID MET, V1259, P125, DOI 10.1016/0005-2760(95)00143-Z; Akiba S, 2000, BRIT J PHARMACOL, V131, P1004, DOI 10.1038/sj.bjp.0703637; Akiba S, 2001, J BIOL CHEM, V276, P21854, DOI 10.1074/jbc.M010201200; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; BorschHaubold AG, 1997, EUR J BIOCHEM, V245, P751, DOI 10.1111/j.1432-1033.1997.t01-1-00751.x; CHEPENIK KP, 1994, J BIOL CHEM, V269, P21786; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; FRITZPATRICK SL, 2000, BIOCHEMISTRY-US, V39, P1021; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; GERKE V, 1985, EMBO J, V4, P2917, DOI 10.1002/j.1460-2075.1985.tb04023.x; GERKE V, 1984, EMBO J, V3, P227, DOI 10.1002/j.1460-2075.1984.tb01789.x; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Gladwin MT, 2000, AM J PHYSIOL-LUNG C, V279, pL1103, DOI 10.1152/ajplung.2000.279.6.L1103; Kang HM, 1999, TRENDS CARDIOVAS MED, V9, P92, DOI 10.1016/S1050-1738(99)00012-2; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; Kim SW, 2001, FEBS LETT, V489, P243, DOI 10.1016/S0014-5793(00)02326-7; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARGOLIS BL, 1988, BIOCHEM J, V249, P587, DOI 10.1042/bj2490587; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MAXWELL AP, 1993, BIOCHEM J, V295, P763, DOI 10.1042/bj2950763; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Munz B, 1997, J INVEST DERMATOL, V108, P307, DOI 10.1111/1523-1747.ep12286470; Pawliczak R, 2001, J BIOL CHEM, V276, P44613, DOI 10.1074/jbc.M104993200; SA G, 1995, J BIOL CHEM, V270, P2360, DOI 10.1074/jbc.270.5.2360; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Wu T, 1997, J BIOL CHEM, V272, P17145, DOI 10.1074/jbc.272.27.17145; Yao XL, 1999, J BIOL CHEM, V274, P17202, DOI 10.1074/jbc.274.24.17202	34	16	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38431	38440		10.1074/jbc.M207406200	http://dx.doi.org/10.1074/jbc.M207406200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163506	hybrid			2022-12-27	WOS:000178529600057
J	Jones, SM; Luo, M; Healy, AM; Peters-Golden, M; Brock, TG				Jones, SM; Luo, M; Healy, AM; Peters-Golden, M; Brock, TG			Structural and functional criteria reveal a new nuclear import sequence on the 5-lipoxygenase protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; CRYSTALLOGRAPHIC ANALYSIS; ALVEOLAR MACROPHAGES; KARYOPHERIN-ALPHA; LOCALIZATION; TRANSLOCATION; RECOGNITION; ACTIVATION; PHOSPHORYLATION; NEUTROPHILS	Leukotrienes are lipid mediators with important roles in immunity. The enzyme 5-lipoxygenase initiates leukotriene synthesis; nuclear import of 5-lipoxygenase modulates leukotriene synthetic capacity. In this study, we used structural and functional criteria to identify potential nuclear import sequences. Specifically, we sought basic residues that 1) were common to different 5-lipoxygenases but not shared with other lipoxygenases, 2) were found on random coil/loop structures, and 3) could be replaced without eliminating catalytic activity. Application of these criteria to the putative bipartite nuclear import sequence of 5-lipoxygenase revealed that this region formed an a-helix rather than a random coil, that the critical residue arginine 651 serves a structural role, and that mutation of this residue eliminated catalytic activity. A previously unrecognized region corresponding to residues 518-530 on human 5-lipoxygenase was found to be unique to 5-lipoxygenase and on a random coil. This region alone was sufficient to drive import of green fluorescent protein to the same degree as complete 5-lipoxygenase. Replacement of basic residues in this region of the complete protein was capable of eliminating nuclear import without abolishing catalytic activity. Surprisingly, two subpopulations of cells expressing 5-lipoxygenase with this mutated region could be discerned: those with strongly impaired import and those with normal import. Taken together, these results show that the previously identified region with a bipartite motif is not a functional import sequence, whereas the newly identified basic region constitutes a true nuclear import sequence. Moreover, we suggest that another sequence that can mediate nuclear import of 5-lipoxygenase remains to be identified.	Univ Michigan Hlth Syst, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Brock, TG (corresponding author), Univ Michigan, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI043574, R21AI048141] Funding Source: NIH RePORTER; NIAID NIH HHS [R21 AI48141, R29 AI43574] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Brock TG, 1997, J BIOL CHEM, V272, P8276, DOI 10.1074/jbc.272.13.8276; BROCK TG, 1994, J BIOL CHEM, V269, P22059; Brock TG, 2001, J BIOL CHEM, V276, P35071, DOI 10.1074/jbc.M105676200; Brock TG, 1999, J IMMUNOL, V162, P1669; CHEN XS, 1995, J BIOL CHEM, V270, P17993, DOI 10.1074/jbc.270.30.17993; Chen XS, 2001, J BIOL CHEM, V276, P811, DOI 10.1074/jbc.M008203200; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Fontes MRM, 2000, J MOL BIOL, V297, P1183, DOI 10.1006/jmbi.2000.3642; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GLASER KB, 1993, BIOCHEM PHARMACOL, V45, P711, DOI 10.1016/0006-2952(93)90147-O; Hanaka H, 2002, BIOCHEM J, V361, P505, DOI 10.1042/0264-6021:3610505; Healy AM, 1999, J BIOL CHEM, V274, P29812, DOI 10.1074/jbc.274.42.29812; Hemak J, 2002, J MOL MODEL, V8, P102, DOI 10.1007/s00894-002-0076-y; HOFFMAN T, 1991, J IMMUNOL, V146, P692; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Lepley RA, 1998, ARCH BIOCHEM BIOPHYS, V356, P71, DOI 10.1006/abbi.1998.0744; Lepley RA, 1996, J BIOL CHEM, V271, P6179, DOI 10.1074/jbc.271.11.6179; Lepley RA, 1996, ARCH BIOCHEM BIOPHYS, V331, P141, DOI 10.1006/abbi.1996.0292; PETERSGOLDEN M, 1991, AM J PHYSIOL, V261, pL462, DOI 10.1152/ajplung.1991.261.6.L462; Sud'ina GF, 2001, BIOCHEM J, V359, P621, DOI 10.1042/0264-6021:3590621; Sweitzer TD, 2000, CURR TOP CELL REGUL, V36, P77; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Werz O, 2001, BLOOD, V97, P2487, DOI 10.1182/blood.V97.8.2487; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935	29	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38550	38556		10.1074/jbc.M206070200	http://dx.doi.org/10.1074/jbc.M206070200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12140292	hybrid			2022-12-27	WOS:000178529600071
J	Cox, KH; Tate, JJ; Cooper, TG				Cox, KH; Tate, JJ; Cooper, TG			Cytoplasmic Compartmentation of Gln3 during nitrogen catabolite repression and the mechanism of its nuclear localization during carbon starvation in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; SIGNALING PATHWAYS; TOR PROTEINS; RAPAMYCIN; MITOCHONDRIA; TARGET; TAP42; URE2P; MKS1P; RTG1	Regulated intracellular localization of Gln3, the transcriptional activator responsible for nitrogen catabolite repression (NCR)-sensitive transcription, permits Saccharomyces cerevisiae to utilize good nitrogen sources (e.g. glutamine and ammonia) in preference to poor ones (e.g. proline). During nitrogen starvation or growth in medium containing a poor nitrogen source, Gln3 is nuclear and NCR-sensitive transcription is high. However, when cells are grown in excess nitrogen, Gln3 is localized to the cytoplasm with a concomitant decrease in gene expression. Treating cells with the Tor protein inhibitor, rapamycin, mimics nitrogen starvation. Recently, carbon starvation has been reported to cause nuclear localization of Gln3 and increased NCR-sensitive transcription. Here we show that nuclear localization of Gln3 during carbon starvation derives from its indirect effects on nitrogen metabolism, i.e. Gln3 does not move into the nucleus of carbon-starved cells if glutamine rather than ammonia is provided as the nitrogen source. In addition, these studies have clearly shown Gln3 is not uniformly distributed in the cytoplasm, but rather localizes to punctate or tubular structures. Analysis of these images by deconvolution microscopy suggests that Gln3 is concentrated in or associated with a highly structured system in the cytosol, one that is possibly vesicular in nature. This finding may impact significantly on how we view (i) the mechanism by which Tor regulates the intracellular localization of Gln3 and (ii) how proteins move into and out of the nucleus.	Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA.	tcooper@utmem.edu		Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35642, R01 GM035642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2002, MOL CELL BIOL, V22, P1246, DOI 10.1128/MCB.22.4.1246-1252.2002; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; BOSSINGER J, 1976, J BACTERIOL, V126, P198, DOI 10.1128/JB.126.1.198-204.1976; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Carvalho J, 2001, J BIOL CHEM, V276, P25359, DOI 10.1074/jbc.M103050200; Cooper TG, 1996, MYCOTA, V3, P139; COOPER TG, 2002, FEMS MICROBIOL REV, V737, P1; Cox KH, 2000, J BIOL CHEM, V275, P17611, DOI 10.1074/jbc.M001648200; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Dilova I, 2002, CURR BIOL, V12, P389, DOI 10.1016/S0960-9822(02)00677-2; Edskes HK, 1999, GENETICS, V153, P585; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; Jacinto E, 2001, MOL CELL, V8, P1017, DOI 10.1016/S1097-2765(01)00386-0; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; Kunz J, 2000, J BIOL CHEM, V275, P37011, DOI 10.1074/jbc.M007296200; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; Liu ZC, 1999, MOL CELL BIOL, V19, P6720; Pierce MM, 2001, P NATL ACAD SCI USA, V98, P13213, DOI 10.1073/pnas.181486098; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; Sekito T, 2000, MOL BIOL CELL, V11, P2103, DOI 10.1091/mbc.11.6.2103; Sekito T, 2002, MOL BIOL CELL, V13, P795, DOI 10.1091/mbc.01-10-0473; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; Smart WC, 1996, MOL CELL BIOL, V16, P5876; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; ter Schure EG, 2000, FEMS MICROBIOL REV, V24, P67, DOI 10.1016/S0168-6445(99)00030-3	33	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37559	37566		10.1074/jbc.M204879200	http://dx.doi.org/10.1074/jbc.M204879200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12140287	hybrid, Green Accepted			2022-12-27	WOS:000178447100083
J	Foukas, LC; Daniele, N; Ktori, C; Anderson, KE; Jensen, J; Shepherd, PR				Foukas, LC; Daniele, N; Ktori, C; Anderson, KE; Jensen, J; Shepherd, PR			Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases - Differential effects on lipid kinase and protein kinase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; GLUCOSE-TRANSPORT; RADIOSENSITIZING AGENT; INSULIN-RECEPTOR; SKELETAL-MUSCLE; RAT ADIPOCYTES; INHIBITION; WORTMANNIN; ADENOSINE; SPECIFICITY	We investigated the effects of methylxanthines on enzymatic activity of phosphoinositide 3-kinases (PI3Ks). We found that caffeine inhibits the in vitro lipid kinase of class I PI3Ks (IC(50) = 75 muM for p110delta, 400 muM for p110alpha and p110beta, and 1 mM for p110gamma), and theophylline has similar effects (IC(50) = 75 muM for p110delta, 300 muM for p110alpha, and 800 muM for p110beta and p110gamma) and also inhibits the alpha isoform. of class II PI3K (PI3K-C2alpha) (IC(50) approximate to 400 muM). However, four other xanthine derivatives tested (3-isobutyl-1-methylxanthine, 3-propylxanthine, alloxazine, and PD116948 (8-cyclopentyl-1,3-dipropylxanthine)) were an order of magnitude less effective. Surprisingly the triazoloquinazoline CGS15943 (9-chloro-2-(2-furyl)(1,2,d)triazolo(1,5-c)quinazolin-5-amine) also selectively inhibits P110delta (IC(50) < 10 mu M). Caffeine and theophylline also inhibit the intrinsic protein kinase activity of the class IA PI3Ks and DNA-dependent protein kinase, although with a much lower potency than that for the lipid kinase (IC(50) approximate to 10 mM for p110 alpha, 3 mM for p110 beta, and 10 mM for DNA-dependent protein kinase). In CHO-IR cells and rat soleus muscle, theophylline and caffeine block the ability of insulin to stimulate protein kinase B with IC(50). values similar to those for inhibition of PI3K activity, whereas insulin stimulation of ERK1 or ERK2 was not inhibited at concentrations up to 10 mm. Theophylline and caffeine also blocked insulin stimulation of glucose transport in CHO-IR cells. These results demonstrate that these methylxanthines are direct inhibitors of PI3K lipid kinase activity but are distinctly less effective against serine kinase activity and thus could be of potential use in dissecting these two distinct kinase activities. Theophylline, caffeine, and CGS15943 may be of particular use in dissecting the specific role of the p110 delta lipid kinase. Finally, we conclude that inhibition of PI3K (p110 delta in particular) is likely explain some of the physiological and pharmacological properties of caffeine and theophylline.	UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Monash Univ, Dept Med, Melbourne, Vic 3128, Australia; Natl Inst Occupat Hlth, Dept Physiol, N-0033 Oslo, Norway	University of London; University College London; Monash University	Shepherd, PR (corresponding author), UCL, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.	p.shepherd@ucl.ac.uk	Jensen, Jørgen/O-2245-2013; Danièle, Nathalie/J-7432-2013	Anderson, Karen/0000-0002-7394-6660; Daniele, Nathalie/0000-0002-7985-2788				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; Basu S, 2000, HAEMATOLOGIA, V30, P225, DOI 10.1163/156855900300109242; Beeton CA, 2000, BIOCHEM J, V350, P353, DOI 10.1042/0264-6021:3500353; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Brown RA, 1999, J BIOL CHEM, V274, P14529, DOI 10.1074/jbc.274.21.14529; BUCKLEY JT, 1977, BIOCHIM BIOPHYS ACTA, V498, P1; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; COX LR, 1990, EXP MOL PATHOL, V53, P52, DOI 10.1016/0014-4800(90)90023-7; Daly JW, 2000, J AUTONOM NERV SYST, V81, P44, DOI 10.1016/S0165-1838(00)00110-7; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Domin J, 1997, BIOCHEM J, V326, P139, DOI 10.1042/bj3260139; GREEN A, 1987, DIABETOLOGIA, V30, P188, DOI 10.1007/BF00274226; Greer F, 2001, DIABETES, V50, P2349, DOI 10.2337/diabetes.50.10.2349; Han DH, 1998, DIABETES, V47, P1671, DOI 10.2337/diabetes.47.11.1671; Hirsch E, 2001, FASEB J, V15, P2019, DOI 10.1096/fj.00-0810fje; HONEYMAN TW, 1983, BIOCHEM J, V212, P489, DOI 10.1042/bj2120489; JOOST HG, 1983, MOL CELL BIOCHEM, V57, P177, DOI 10.1007/BF00849194; Keijzers GB, 2002, DIABETES CARE, V25, P364, DOI 10.2337/diacare.25.2.364; Kim YC, 1996, J MED CHEM, V39, P4142, DOI 10.1021/jm960482i; LAM K, 1994, J BIOL CHEM, V269, P20648; Okkenhaug K, 2002, SCIENCE, V297, P1031; Rondinone CM, 2000, J BIOL CHEM, V275, P10093, DOI 10.1074/jbc.275.14.10093; SAAD MJA, 1993, J CLIN INVEST, V92, P2065, DOI 10.1172/JCI116803; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; Scott PH, 1998, J BIOL CHEM, V273, P34496, DOI 10.1074/jbc.273.51.34496; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Soos MA, 2001, ARCH BIOCHEM BIOPHYS, V396, P244, DOI 10.1006/abbi.2001.2587; STEELE TA, 1988, CELL IMMUNOL, V112, P402, DOI 10.1016/0008-8749(88)90309-7; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; STEINFELDER HJ, 1990, BIOCHEM PHARMACOL, V40, P1154, DOI 10.1016/0006-2952(90)90508-I; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; Takasuga S, 1999, J BIOL CHEM, V274, P19545, DOI 10.1074/jbc.274.28.19545; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Walker EH, 1999, NATURE, V402, P313, DOI 10.1038/46319; Weinberger M, 1996, NEW ENGL J MED, V334, P1380, DOI 10.1056/NEJM199605233342107; Yang J, 2002, MOL CELL, V9, P1227, DOI 10.1016/S1097-2765(02)00550-6; Yasui K, 2001, INT J HEMATOL, V73, P87, DOI 10.1007/BF02981908; YOUN JH, 1991, AM J PHYSIOL, V260, pC555, DOI 10.1152/ajpcell.1991.260.3.C555	46	121	124	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37124	37130		10.1074/jbc.M202101200	http://dx.doi.org/10.1074/jbc.M202101200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145276	hybrid			2022-12-27	WOS:000178447100029
J	Hilber, K; Sandtner, W; Kudlacek, O; Schreiner, B; Glaaser, I; Schutz, W; Fozzard, HA; Dudley, SC; Todt, H				Hilber, K; Sandtner, W; Kudlacek, O; Schreiner, B; Glaaser, I; Schutz, W; Fozzard, HA; Dudley, SC; Todt, H			Interaction between fast and ultra-slow inactivation in the voltage-gated sodium channel - Does the inactivation gate stabilize the channel structure?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPOKALEMIC PERIODIC PARALYSIS; INHERITED CARDIAC-ARRHYTHMIA; EPICARDIAL BORDER ZONE; LONG-QT SYNDROME; NA+-CHANNEL; FUNCTIONAL EXPRESSION; ALPHA-SUBUNIT; SEGMENT IVS6; INFARCTED HEART; DOMAIN-IV	Recently, we reported that mutation A1529D in the domain (D) IV P-loop of the rat skeletal muscle Na+ channel mu(1), (DIV-A1529D) enhanced entry to an inactivated state from which the channels recovered with an abnormally slow time constant on the order of similar to100 s. Transition to this "ultra-slow" inactivated state (USI) was substantially reduced by binding to the outer pore of a mutant mu-conotoxin GIIIA. This indicated that USI reflected a structural rearrangement of the outer channel vestibule and that binding to the pore of a peptide could stabilize the pore structure (Hilber, K., Sandtner, W., Kudlacek, O., Glaaser, I. W., Weisz, E., Kyle, J. W., French, R. J., Fozzard, H. A., Dudley, S. C., and Todt, H. (2001) J. Biol. Chem. 276, 27831-27839). Here, we tested the hypothesis that occlusion of the inner vestibule of the Na+ channel by the fast inactivation gate inhibits ultra-slow inactivation. Stabilization of the fast inactivated state (FI) by coexpression of the rat brain beta(1) subunit in Xenopus oocytes significantly prolonged the time course of entry to the USI. A reduction in USI was also observed when the FI was stabilized in the absence of the 131 subunit, suggesting a causal relation between the occurrence of the FI and inhibition of USI. This finding was further confirmed in experiments where the FI was destabilized by introducing the mutations I1303Q/ F1304Q/M1305Q. In DIV-A1529D + I1303Q/F1304Q/ M1305Q channels, occurrence of USI was enhanced at strongly depolarized potentials and could not be prevented by coexpression of the 6, subunit. These results strongly suggest that FI inhibits USI in DIV-A1529D channels. Binding to the inner pore of the fast inactivation gate may stabilize the channel structure and thereby prevent USI. Some of the data have been published previously in abstract form (Hilber, K., Sandtner, W., Kudlacek, O., Singer, E., and Todt, H. (2002) Soc. Neurosci. Abstr. 27, program number 46.12).	Univ Vienna, Inst Pharmacol, A-1090 Vienna, Austria; Univ Chicago, Cardiac Electrophysiol Labs, Chicago, IL 60637 USA; Atlanta Vet Affairs Hosp, Decatur, GA 30033 USA; Emory Univ, Div Cardiol, Atlanta, GA 30033 USA	University of Vienna; University of Chicago; Emory University	Todt, H (corresponding author), Univ Vienna, Inst Pharmacol, Wahringerstr 13A, A-1090 Vienna, Austria.		Dudley, Samuel/AAR-7950-2021; Dudley, Samuel C/A-7085-2009	Dudley, Samuel/0000-0001-5843-5961; Hilber, Karlheinz/0000-0002-3033-0874; Kudlacek, Oliver/0000-0002-3086-8551	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020592, R01HL064828] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-P01-20592, HL64828] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGNEW WS, 1991, ANN NY ACAD SCI, V625, P200, DOI 10.1111/j.1749-6632.1991.tb33842.x; ALDRICH RW, 1981, BIOPHYS J, V36, P519, DOI 10.1016/S0006-3495(81)84750-9; Alekov AK, 2001, NEUROSCI LETT, V306, P173, DOI 10.1016/S0304-3940(01)01895-X; ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; Balser JR, 1996, J GEN PHYSIOL, V107, P643, DOI 10.1085/jgp.107.5.643; Balser JR, 1996, J PHYSIOL-LONDON, V494, P431, DOI 10.1113/jphysiol.1996.sp021503; Bendahhou S, 2001, ANN NEUROL, V50, P417, DOI 10.1002/ana.1144; Bendahhou S, 2000, J CLIN INVEST, V106, P431, DOI 10.1172/JCI9654; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; CANNON SC, 1993, PFLUG ARCH EUR J PHY, V423, P155, DOI 10.1007/BF00374974; CANNON SC, 1993, NEURON, V10, P317, DOI 10.1016/0896-6273(93)90321-H; Cannon SC, 1996, TRENDS NEUROSCI, V19, P3, DOI 10.1016/0166-2236(96)81859-5; Cha A, 1999, NEURON, V22, P73, DOI 10.1016/S0896-6273(00)80680-7; CHAHINE M, 1994, NEURON, V12, P281, DOI 10.1016/0896-6273(94)90271-2; Chang SY, 1996, BIOPHYS J, V70, P2581, DOI 10.1016/S0006-3495(96)79829-6; Chen LQ, 1996, J GEN PHYSIOL, V108, P549, DOI 10.1085/jgp.108.6.549; Cummins TR, 1996, BIOPHYS J, V71, P227, DOI 10.1016/S0006-3495(96)79219-6; Dumaine R, 1996, CIRC RES, V78, P916, DOI 10.1161/01.RES.78.5.916; Featherstone DE, 1996, BIOPHYS J, V71, P3098, DOI 10.1016/S0006-3495(96)79504-8; Fleidervish IA, 1996, J PHYSIOL-LONDON, V493, P83, DOI 10.1113/jphysiol.1996.sp021366; FOX JM, 1976, BIOCHIM BIOPHYS ACTA, V426, P232, DOI 10.1016/0005-2736(76)90334-5; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; French R J, 1999, Methods Enzymol, V294, P575; French RJ, 1996, NEURON, V16, P407, DOI 10.1016/S0896-6273(00)80058-6; Hayward LJ, 1999, NEUROLOGY, V52, P1447, DOI 10.1212/WNL.52.7.1447; Hayward LJ, 1997, BIOPHYS J, V72, P1204, DOI 10.1016/S0006-3495(97)78768-X; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hilber K, 2001, J BIOL CHEM, V276, P27831, DOI 10.1074/jbc.M101933200; HILBER K, 2002, SOC NEUR ABSTR, V27; ISOM LL, 1992, SCIENCE, V256, P839, DOI 10.1126/science.1375395; Kontis KJ, 1997, J GEN PHYSIOL, V110, P403, DOI 10.1085/jgp.110.4.403; Kuhn FJP, 1999, J GEN PHYSIOL, V114, P167, DOI 10.1085/jgp.114.2.167; McPhee JC, 1998, J BIOL CHEM, V273, P1121, DOI 10.1074/jbc.273.2.1121; MCPHEE JC, 1994, P NATL ACAD SCI USA, V91, P12346, DOI 10.1073/pnas.91.25.12346; MCPHEE JC, 1995, J BIOL CHEM, V270, P12025, DOI 10.1074/jbc.270.20.12025; Mitrovic N, 2000, J GEN PHYSIOL, V115, P707, DOI 10.1085/jgp.115.6.707; Nuss HB, 1996, J PHYSIOL-LONDON, V494, P411, DOI 10.1113/jphysiol.1996.sp021502; PATLAK JB, 1986, J GEN PHYSIOL, V87, P305, DOI 10.1085/jgp.87.2.305; PATTON DE, 1994, J BIOL CHEM, V269, P17649; Pu JL, 1998, CIRC RES, V83, P431, DOI 10.1161/01.RES.83.4.431; Pu JL, 1997, CIRC RES, V81, P110, DOI 10.1161/01.RES.81.1.110; Ren DJ, 2001, SCIENCE, V294, P2372, DOI 10.1126/science.1065635; Richmond JE, 1998, BIOPHYS J, V74, P2945, DOI 10.1016/S0006-3495(98)78001-4; RUDY B, 1978, J PHYSIOL-LONDON, V283, P1; RUFF RL, 1987, J PHYSIOL-LONDON, V383, P339; SCHREIBMAYER W, 1994, RECEPTOR CHANNEL, V2, P339; Sheets MF, 2000, J GEN PHYSIOL, V115, P609, DOI 10.1085/jgp.115.5.609; Stevens EB, 2001, PFLUG ARCH EUR J PHY, V441, P481, DOI 10.1007/s004240000449; Struyk AF, 2000, J NEUROSCI, V20, P8610; Todt H, 1999, BIOPHYS J, V76, P1335, DOI 10.1016/S0006-3495(99)77296-6; Vedantham V, 1998, J GEN PHYSIOL, V111, P83, DOI 10.1085/jgp.111.1.83; Vedantham V, 2000, BIOPHYS J, V78, P2943, DOI 10.1016/S0006-3495(00)76834-2; Wallace RH, 1998, NAT GENET, V19, P366, DOI 10.1038/1252; Wang DW, 1996, BIOPHYS J, V70, P1700, DOI 10.1016/S0006-3495(96)79732-1; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; Wright SN, 1998, MOL PHARMACOL, V54, P733; ZHOU JY, 1991, NEURON, V7, P775, DOI 10.1016/0896-6273(91)90280-D	58	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37105	37115		10.1074/jbc.M205661200	http://dx.doi.org/10.1074/jbc.M205661200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138168	hybrid			2022-12-27	WOS:000178447100027
J	Mandal, S; Kundu, P; Roy, B; Mandal, RK				Mandal, S; Kundu, P; Roy, B; Mandal, RK			Precursor of the inactive 2S seed storage protein from the Indian mustard Brassica juncea is a novel trypsin inhibitor - Characterization, post-translational processing studies, and transgenic expression to develop insect-resistant plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GENE; PURIFICATION; QUALITY; CLONING; SYSTEM; SITES; NAPIN	A number of trypsin inhibitor (TI) genes have been used to generate insect-resistant plants. Here we report a novel trypsin inhibitor from Indian mustard Brassica juncea (BjTI) that is unique in being the precursor of a 2S seed storage protein. The inhibitory activity is lost upon processing. The predicted amino acid sequence of the precursor based on the B. juncea 2S albumin (Bj2S) gene cloned and sequenced in this laboratory (Bj2Sc; GenBank(TM) accession number X65972) showed a soybean-TI active site-like motif GPFRI at the expected processing site. The BjTI was found to be a thermostable Kunitz type TI that inhibits trypsin at a molar ratio of 1:1. The 20-kDa BjTI was purified from midmature seeds and found to be processed in vitro to 9- and 4-kDa subunits upon incubation with seed extract. The Bj2Sc sequence was expressed in Escherichia coli pET systems as the inhibitor precursor. The radiolabeled gene product was expressed in vitro in a coupled transcription-translation system and showed the expected processing into subunits. Two in vitro expressed pre-2S proteins, mutated at Gly and Asp residues, were processed normally to mature subunits, showing thereby no absolute requirement of Gly and Asp residues for processing. Finally, the 2S gene was introduced into tobacco and tomato plants. Third generation transgenics expressing BjTI at 0.28-0.83% of soluble leaf proteins showed remarkable resistance against the tobacco cutworm, Spodoptera litura. This novel TI can be used in transforming seed crops for protection to their vegetative parts and early seed stages, when insect damage is maximal; as the seeds mature, the TI will be naturally processed to the inactive storage protein that is safe for consumption.	Bose Inst, Dept Biochem, Kolkata 700054, W Bengal, India	Department of Science & Technology (India); Bose Institute	Mandal, RK (corresponding author), Bose Inst, Dept Biochem, Kolkata 700054, W Bengal, India.	rkmandal@hotmail.com		Kundu, Surekha/0000-0003-0480-8624				Adamovskaya VG, 2000, RUSS J PLANT PHYSL+, V47, P186; Altpeter F, 1999, MOL BREEDING, V5, P53, DOI 10.1023/A:1009659911798; Bell JM, 1996, CAN J ANIM SCI, V76, P423, DOI 10.4141/cjas96-061; Brauer ABE, 2001, J MOL BIOL, V306, P799, DOI 10.1006/jmbi.2000.4410; Castellino F J, 1976, Methods Enzymol, V45, P273; Czapinska H, 2000, J MOL BIOL, V295, P1237, DOI 10.1006/jmbi.1999.3445; DASGUPTA J, 1995, INDIAN J BIOCHEM BIO, V32, P378; DASGUPTA S, 1993, SEED SCI TECHNOL, V21, P291; DASGUPTA S, 1993, GENE, V133, P301, DOI 10.1016/0378-1119(93)90656-N; delaPena MAG, 1996, EUR J BIOCHEM, V237, P827, DOI 10.1111/j.1432-1033.1996.0827p.x; Draper J., 1988, PLANT GENETIC TRANSF, P199; FILLATTI JJ, 1987, BIO-TECHNOL, V5, P726, DOI 10.1038/nbt0787-726; FUKUSHIMA D, 1991, Food Reviews International, V7, P323; GATEHOUSE AMR, 1980, PHYTOCHEMISTRY, V19, P751, DOI 10.1016/0031-9422(80)85104-1; Genov N, 1997, BBA-PROTEIN STRUCT M, V1341, P157, DOI 10.1016/S0167-4838(97)00049-6; Ghose M, 2001, FEBS LETT, V509, P337, DOI 10.1016/S0014-5793(01)03202-1; Grzesiak A, 2000, J BIOL CHEM, V275, P33346, DOI 10.1074/jbc.M006085200; HEATH RL, 1995, EUR J BIOCHEM, V230, P250, DOI 10.1111/j.1432-1033.1995.tb20558.x; Hilder VA, 1999, CROP PROT, V18, P177, DOI 10.1016/S0261-2194(99)00028-9; HILDER VA, 1987, NATURE, V330, P160, DOI 10.1038/330160a0; Hou WC, 1999, J AGR FOOD CHEM, V47, P2168, DOI 10.1021/jf980738o; HUNG CH, 1993, GENE, V127, P215, DOI 10.1016/0378-1119(93)90722-F; KIM SH, 1985, J BIOCHEM, V98, P435, DOI 10.1093/oxfordjournals.jbchem.a135298; KREBBERS E, 1988, PLANT PHYSIOL, V87, P859, DOI 10.1104/pp.87.4.859; KRYZANIAK A, 1998, NAHRUNG, V42, P201; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; Lee SI, 1999, MOL BREEDING, V5, P1; LING MH, 1993, J BIOL CHEM, V268, P810; Mandal S, 2000, CURR SCI INDIA, V79, P576; Mandal Surekha, 1999, Science & Culture, V65, P169; Mandal Surekha, 2000, Environment and Ecology (Kalyani), V18, P177; MENEGATTI E, 1992, FEBS LETT, V301, P10, DOI 10.1016/0014-5793(92)80199-Q; MILLERD A, 1975, ANNU REV PLANT PHYS, V26, P53, DOI 10.1146/annurev.pp.26.060175.000413; MOGEN BD, 1990, PLANT CELL, V2, P1261; Muntz K, 1998, PLANT MOL BIOL, V38, P77, DOI 10.1023/A:1006020208380; MUREN E, 1995, EUR J BIOCHEM, V227, P316, DOI 10.1111/j.1432-1033.1995.tb20391.x; Muren E, 1996, EUR J BIOCHEM, V242, P214, DOI 10.1111/j.1432-1033.1996.0214r.x; Prakash S., 1980, OPERA BOT, V55, P1, DOI DOI 10.1016/B978-1-891127-79-3.50001-9; Rico M, 1996, BIOCHEMISTRY-US, V35, P15672, DOI 10.1021/bi961748q; Ruoppolo M, 2000, EUR J BIOCHEM, V267, P6486, DOI 10.1046/j.1432-1327.2000.01741.x; RYAN CA, 1990, ANNU REV PHYTOPATHOL, V28, P425, DOI 10.1146/annurev.py.28.090190.002233; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; SHEWRY PR, 1995, PLANT CELL, V7, P945, DOI 10.1105/tpc.7.7.945; SVENDSEN I, 1994, INT J PEPT PROT RES, V43, P425; Ussuf KK, 2001, CURR SCI INDIA, V80, P847; VANDRIESSCHE E, 1988, ADV LECTIN RES, V1, P73; VISENTIN M, 1992, PHYTOCHEMISTRY, V31, P3677, DOI 10.1016/S0031-9422(00)97507-1; Volpicella M, 2001, BIOCHEM BIOPH RES CO, V280, P813, DOI 10.1006/bbrc.2000.4182; Welham T, 2000, PLANT SCI, V159, P289, DOI 10.1016/S0168-9452(00)00358-7; Yamada K, 1999, J BIOL CHEM, V274, P2563, DOI 10.1074/jbc.274.4.2563; YOSHIKAWA H, 1995, BIOSCI BIOTECH BIOCH, V59, P117, DOI 10.1271/bbb.59.117	51	42	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37161	37168		10.1074/jbc.M205280200	http://dx.doi.org/10.1074/jbc.M205280200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147695	hybrid			2022-12-27	WOS:000178447100034
J	Shibayama, S; Shibata-Seita, R; Miura, K; Kirino, Y; Takishima, K				Shibayama, S; Shibata-Seita, R; Miura, K; Kirino, Y; Takishima, K			Identification of a C-terminal region that is required for the nuclear translocation of ERK2 by passive diffusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; MAP KINASE; DOCKING SITE; SUBSTRATE-SPECIFICITY; PORE COMPLEX; PTP-SL; TRANSPORT; PHOSPHORYLATION; BINDING; SEQUENCE	Extracellular signal-regulated kinase 2 (ERK2) is located in the cytoplasm of resting cells and translocates into the nucleus upon extracellular stimuli by active transport of a dimer. Passive transport of an ERK2 monomer through the nuclear pore is also reported to coexist. We attempted to characterize the cytoplasmic retention and nuclear translocation of fusion proteins between deletion and site-directed mutants of ERK2 and green fluorescent protein (GFP). The overexpressed ERK2-GFP fusion protein is usually localized to both the cytoplasm and the nucleus unless a cytoplasmic anchoring protein is coexpressed. Deletion of 45 residues, but not 43 residues, from the C terminus of ERK2 prevented the nuclear distribution of the ERK2-GFP fusion protein. Substitution of a part of residues 299-313 to alanine residues also prevented the nuclear distribution of the ERK2-GFP fusion protein without abrogation of its nuclear active transport. These observations may indicate that the passive diffusion of ERK2 into the nucleus is not simple diffusion but includes a specific interaction process between residues 299-313 and the nuclear pore complex and that this interaction is not required for the active transport. We also showed that substitution of Tyr(314) to alanine residue abrogated the cytoplasmic retention of the ERK2-GFP fusion protein by PTP-SL but not by MEK1.	Natl Def Med Coll, Dept Biochem 1, Tokorozawa, Saitama 3598513, Japan; Univ Tokyo, Lab Neurobiophys, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	National Defense Medical College - Japan; University of Tokyo	Takishima, K (corresponding author), Natl Def Med Coll, Dept Biochem 1, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	ktakishi@cc.ndmc.ac.jp	shibayama, sotaro/N-9565-2019; shibayama, sotaro/K-6005-2012	shibayama, sotaro/0000-0002-6701-9828; shibayama, sotaro/0000-0002-6701-9828				Adachi M, 1999, EMBO J, V18, P5347, DOI 10.1093/emboj/18.19.5347; Adachi M, 2000, J CELL BIOL, V148, P849, DOI 10.1083/jcb.148.5.849; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; Lenormand P, 1998, J CELL BIOL, V142, P625, DOI 10.1083/jcb.142.3.625; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Matsubayashi Y, 2001, J BIOL CHEM, V276, P41755, DOI 10.1074/jbc.M106012200; Meili R, 1996, FEBS LETT, V394, P34, DOI 10.1016/0014-5793(96)00927-1; Muda M, 1998, J BIOL CHEM, V273, P9323, DOI 10.1074/jbc.273.15.9323; Nichols A, 2000, J BIOL CHEM, V275, P24613, DOI 10.1074/jbc.M001515200; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Robinson FL, 2002, J BIOL CHEM, V277, P14844, DOI 10.1074/jbc.M107776200; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Rubinfeld H, 1999, J BIOL CHEM, V274, P30349, DOI 10.1074/jbc.274.43.30349; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Wilsbacher JL, 1999, J BIOL CHEM, V274, P16988, DOI 10.1074/jbc.274.24.16988; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Xu BE, 1999, J BIOL CHEM, V274, P34029, DOI 10.1074/jbc.274.48.34029; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; Zuniga A, 1999, J BIOL CHEM, V274, P21900, DOI 10.1074/jbc.274.31.21900	31	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37777	37782		10.1074/jbc.M206163200	http://dx.doi.org/10.1074/jbc.M206163200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149268	hybrid			2022-12-27	WOS:000178447100111
J	Stano, NM; Levin, MK; Patel, SS				Stano, NM; Levin, MK; Patel, SS			The+2 NTP binding drives open complex formation in T7 RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION; KINETIC MECHANISM; PROMOTER; DNA; EQUILIBRIUM; RELEASE; HAIRPIN; ROLES	Transcription initiation as catalyzed by T7 RNA polymerase consists primarily of promoter binding, strand separation, nucleotide binding, and synthesis of the first phosphodiester bond. The promoter strand separation process occurs at a very fast rate, but promoter opening is incomplete in the absence of the initiating NTPs. In this paper, we investigate how initiating NTPs affect the kinetics and thermodynamics of open complex formation. Transient state kinetic studies show that the open complex, EDo, is formed via an intermediate EDc, and the conversion of EDc to EDo occurs with an unfavorable equilibrium constant. In the presence of the initiating NTP that base-pairs with the template at position +2, the process of open complex formation is nearly complete. Our studies reveal that the nucleotide that drives open complex formation needs to be a triphosphate and to be correctly base-paired with the template. These results indicate that the melted template DNA in the open complex is positioned to bind the +2 NTP. The addition of +1 NTP alone does not stabilize the open complex; nor is it required for +2 NTP binding. However, there appears to be cooperativity in initiating NTP binding in that the binding of +2 NTP facilitates + 1 NTP binding. The dissection of the initiation pathway provides insights into how open complex formation steps that are sensitive to the promoter sequence upstream from the initiation start site modulate the affinity of initiating NTPs and allow transcription initiation to be regulated by initiating NTP concentration.	Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Patel, SS (corresponding author), Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	patelss@umdnj.edu			NIGMS NIH HHS [GM51966] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051966, R37GM051966] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bandwar RP, 2002, BIOCHEMISTRY-US, V41, P3586, DOI 10.1021/bi0158472; Bandwar RP, 2001, J BIOL CHEM, V276, P14075, DOI 10.1074/jbc.M011289200; Barker MM, 2001, J BACTERIOL, V183, P6315, DOI 10.1128/JB.183.21.6315-6323.2001; Brieba LG, 2001, BIOCHEMISTRY-US, V40, P3882, DOI 10.1021/bi002716c; Brieba LG, 2001, EMBO J, V20, P6826, DOI 10.1093/emboj/20.23.6826; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 2000, CURR OPIN STRUC BIOL, V10, P117, DOI 10.1016/S0959-440X(99)00058-5; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; FERSHT AR, 1971, J MOL BIOL, V60, P279, DOI 10.1016/0022-2836(71)90294-4; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; Huang JB, 2000, BIOCHEMISTRY-US, V39, P11571, DOI 10.1021/bi000579d; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; Jia YP, 1996, J BIOL CHEM, V271, P30451, DOI 10.1074/jbc.271.48.30451; Jia YP, 1997, J BIOL CHEM, V272, P30147, DOI 10.1074/jbc.272.48.30147; Jiang ML, 2001, J MOL BIOL, V310, P509, DOI 10.1006/jmbi.2001.4793; JOHNSON KA, 1992, ENZYMES; KING GC, 1986, BIOCHEMISTRY-US, V25, P36, DOI 10.1021/bi00349a006; Lozinski T, 2001, ACTA BIOCHIM POL, V48, P495; MARTIN CT, 1989, BIOCHEMISTRY-US, V28, P2760, DOI 10.1021/bi00433a002; OHLSEN KL, 1992, J BIOL CHEM, V267, P19813; PATEL SS, 2002, KINETIC ANAL MACROMO; Place C, 1999, BIOCHEMISTRY-US, V38, P4948, DOI 10.1021/bi982689e; Stano NM, 2002, J MOL BIOL, V315, P1009, DOI 10.1006/jmbi.2001.5313; Steitz T A, 1997, Harvey Lect, V93, P75; STRAUME M, 1992, METHOD ENZYMOL, V210, P117; SUH WC, 1992, BIOCHEMISTRY-US, V31, P7815, DOI 10.1021/bi00149a011; Sullivan JJ, 1997, BIOCHEMISTRY-US, V36, P8005, DOI 10.1021/bi970363k; Ujvari A, 1996, BIOCHEMISTRY-US, V35, P14574, DOI 10.1021/bi961165g; Villemain J, 1997, J MOL BIOL, V273, P958, DOI 10.1006/jmbi.1997.1358; Weston BF, 1997, J MOL BIOL, V272, P21, DOI 10.1006/jmbi.1997.1199; Wolner BS, 2000, MOL CELL BIOL, V20, P3608, DOI 10.1128/MCB.20.10.3608-3615.2000	34	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37292	37300		10.1074/jbc.M201600200	http://dx.doi.org/10.1074/jbc.M201600200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151383	hybrid			2022-12-27	WOS:000178447100050
J	Wissing, F; Sanchez, CP; Rohrbach, P; Ricken, S; Lanzer, M				Wissing, F; Sanchez, CP; Rohrbach, P; Ricken, S; Lanzer, M			Illumination of the malaria parasite plasmodium falciparum alters intracellular pH - Implications for live cell imaging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACRIDINE-ORANGE FLUORESCENCE; GLUTATHIONE-PEROXIDASE GENE; DIGESTIVE VACUOLAR PH; INFECTED ERYTHROCYTES; FERRIPROTOPORPHYRIN IX; LIPID-PEROXIDATION; CHLOROQUINE; INHIBITION; MECHANISM; RESISTANT	Live cell fluorescence microscopy has been widely used to study physiological processes in the human malarial parasite Plasmodium falciparum, including pH homeostasis, Ca2+ signaling and protein targeting. However, the reproducibility of the data is often poor. Controversial statements exist regarding cytosolic and vacuolar baseline pH, as well as regarding the subcellular localization of some of the fluorochromes used. When trying to reproduce published baseline values, we observed an unexpected light sensitivity of P. falciparum, which manifests itself in the form of a strong cytoplasmic acidification. Even short exposure times with moderate to low light intensities caused the parasite cytosol to acidify. We show that this effect arises from the selective disruption of the parasite's acidic food vacuole, brought about by lipid peroxidation initiated by light-induced generation of hydroxyl radicals. Our data suggest that heme serves as a photosensitizer in this process. Our findings have major implications for the use of live cell microscopy in P. falciparum and add a cautionary note to previous studies where live cell fluorometry has been used to determine physiological parameters in P. falciparum.	Heidelberg Univ, Inst Hyg, Abt Parasitol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Lanzer, M (corresponding author), Heidelberg Univ, Inst Hyg, Abt Parasitol, Neuenheimer Feld 324, D-69120 Heidelberg, Germany.	michael_lanzer@med.uni-heidelberg.de	Lanzer, Michael/E-9752-2013; Rohrbach, Petra/F-3201-2011	Lanzer, Michael/0000-0002-0220-6526; 				ATAMNA H, 1993, MOL BIOCHEM PARASIT, V61, P231, DOI 10.1016/0166-6851(93)90069-A; Becuwe P, 1996, MOL BIOCHEM PARASIT, V76, P125, DOI 10.1016/0166-6851(95)02552-9; Bray PG, 2002, MOL BIOCHEM PARASIT, V119, P311, DOI 10.1016/S0166-6851(01)00405-4; Bray PG, 2002, MOL BIOCHEM PARASIT, V119, P301, DOI 10.1016/S0166-6851(01)00403-0; Bray PG, 1999, PARASITOL TODAY, V15, P360, DOI 10.1016/S0169-4758(99)01500-8; Bray PG, 1999, J CELL BIOL, V145, P363, DOI 10.1083/jcb.145.2.363; Clarebout G, 1998, BRIT J HAEMATOL, V103, P52; Clerc S, 1998, ANAL BIOCHEM, V259, P104, DOI 10.1006/abio.1998.2639; Dzekunov SM, 2000, MOL BIOCHEM PARASIT, V110, P107, DOI 10.1016/S0166-6851(00)00261-9; Dzekunov SM, 2002, MOL BIOCHEM PARASIT, V119, P307, DOI 10.1016/S0166-6851(01)00406-6; Edwards AM, 2001, J PHOTOCH PHOTOBIO B, V63, P126, DOI 10.1016/S1011-1344(01)00209-3; Famin O, 1999, BIOCHEM PHARMACOL, V58, P59, DOI 10.1016/S0006-2952(99)00059-3; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; Gamain B, 1996, MOL BIOCHEM PARASIT, V78, P237, DOI 10.1016/S0166-6851(96)02632-1; Garcia CRS, 1998, EUR J CELL BIOL, V76, P133, DOI 10.1016/S0171-9335(98)80026-5; Ginsburg H, 2000, PARASITOL TODAY, V16, P40, DOI 10.1016/S0169-4758(99)01583-5; Hayashi M, 2000, J BIOL CHEM, V275, P34353, DOI 10.1074/jbc.M003323200; Kneen M, 1998, BIOPHYS J, V74, P1591, DOI 10.1016/S0006-3495(98)77870-1; Lang F, 2000, PFLUG ARCH EUR J PHY, V440, P902, DOI 10.1007/s004240000358; LICHTENFELS R, 1994, J IMMUNOL METHODS, V172, P227, DOI 10.1016/0022-1759(94)90110-4; Liu SX, 2001, P NATL ACAD SCI USA, V98, P1643, DOI 10.1073/pnas.031482998; Makrigiorgos GM, 1997, J BIOCHEM BIOPH METH, V35, P23, DOI 10.1016/S0165-022X(97)00020-1; MARTIN JP, 1990, METHOD ENZYMOL, V186, P635; Martiney James A., 1999, Novartis Foundation Symposium, V226, P265; Millot C, 1997, J HISTOCHEM CYTOCHEM, V45, P1255, DOI 10.1177/002215549704500909; Mylonas C, 1999, IN VIVO, V13, P295; Pagola S, 2000, NATURE, V404, P307, DOI 10.1038/35005132; PAILLOUS N, 1994, BIOCHIMIE, V76, P355, DOI 10.1016/0300-9084(94)90109-0; PALMGREN MG, 1991, ANAL BIOCHEM, V192, P316, DOI 10.1016/0003-2697(91)90542-2; Pandey AV, 2001, BIOCHEM J, V355, P333, DOI 10.1042/0264-6021:3550333; Saliba KJ, 1999, J BIOL CHEM, V274, P33213, DOI 10.1074/jbc.274.47.33213; Staalsoe T, 1999, CYTOMETRY, V35, P329, DOI 10.1002/(SICI)1097-0320(19990401)35:4&lt;329::AID-CYTO5&gt;3.0.CO;2-Y; Sztajer H, 2001, J BIOL CHEM, V276, P7397, DOI 10.1074/jbc.M008631200; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Trigg P. I., 1998, MALARIA PARASITE BIO, P11; Ursos LMB, 2000, MOL BIOCHEM PARASIT, V110, P125, DOI 10.1016/S0166-6851(00)00262-0; van Meer G, 2000, TRENDS CELL BIOL, V10, P550, DOI 10.1016/S0962-8924(00)01851-1; Wickham ME, 2001, EMBO J, V20, P5636, DOI 10.1093/emboj/20.20.5636; Wu MM, 2001, J BIOL CHEM, V276, P33027, DOI 10.1074/jbc.M103917200; Wunsch S, 1998, J CELL BIOL, V140, P335, DOI 10.1083/jcb.140.2.335; Wunsch S, 1999, PARASITOL TODAY, V15, P198, DOI 10.1016/S0169-4758(99)01432-5; Wunsch S, 1997, Behring Inst Mitt, P44	42	47	53	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37747	37755		10.1074/jbc.M204845200	http://dx.doi.org/10.1074/jbc.M204845200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12140286	hybrid			2022-12-27	WOS:000178447100107
J	Zipper, LM; Mulcahy, RT				Zipper, LM; Mulcahy, RT			The Keap1 BTB/POZ dimerization function is required to sequester Nrf2 in cytoplasm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIOXIDANT RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; NAPHTHOFLAVONE-INDUCED EXPRESSION; PROTEIN INTERACTION MOTIF; HUMAN NEUROBLASTOMA-CELLS; REGULATORY SUBUNIT GENE; HEME OXYGENASE-1 GENE; ACTIN-BINDING PROTEIN; SMALL MAF PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE	Transactivation of phase 11 detoxification enzymes and antioxidant proteins is mediated by the Cap'N' Collar transcription factor, Nrf2, which is sequestered in the cytoplasm by the actin-binding protein Keap1. Mutation of a conserved serine (S104A) within the Keap1 BTB/POZ domain disrupts Keap1 dimerization and eliminates the ability of Keap1 to sequester Nrf2 in the cytoplasm and repress Nrf2 transactivation. Disruption of endogenous Keap1 dimerization using BTB/POZ dominant negative proteins also inhibits the ability of Keap1 to retain Nrf2 in the cytoplasm. Exposure to an electrophilic agent that induces Nrf2 release and nuclear translocation disrupts formation of a Keap1 complex in vivo. Collectively, these data support the conclusion that Keap1 dimerization is required for Nrf2 sequestration and transcriptional repression. Furthermore, exposure to inducing agents disrupts the Keap1 dimerization function and results in Nrf2 release.	Univ Wisconsin, Dept Pharmacol, Ctr Comprehens Canc, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison	Zipper, LM (corresponding author), Univ Wisconsin, Dept Pharmacol, Ctr Comprehens Canc, 600 Highland Ave,CSC K4-549, Madison, WI 53792 USA.				NIEHS NIH HHS [ES09749] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009749] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Alam J, 2000, J BIOL CHEM, V275, P27694; Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Cho HY, 2002, AM J RESP CELL MOL, V26, P175, DOI 10.1165/ajrcmb.26.2.4501; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Dhakshinamoorthy S, 2000, J BIOL CHEM, V275, P40134, DOI 10.1074/jbc.M003531200; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Espinas ML, 1999, J BIOL CHEM, V274, P16461, DOI 10.1074/jbc.274.23.16461; FAVREAU LV, 1995, J BIOL CHEM, V270, P24468, DOI 10.1074/jbc.270.41.24468; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; Hernandez MC, 1997, J NEUROSCI, V17, P3038; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jeyapaul J, 2000, BIOCHEM PHARMACOL, V59, P1433, DOI 10.1016/S0006-2952(00)00256-2; Kang KW, 2000, MOL PHARMACOL, V58, P1017, DOI 10.1124/mol.58.5.1017; Kensler T W, 2000, Drug Metabol Drug Interact, V17, P3; Kim IF, 1999, GENE, V228, P73, DOI 10.1016/S0378-1119(99)00006-2; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; Kong ANT, 2001, DRUG METAB REV, V33, P255, DOI 10.1081/DMR-120000652; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; Kwak MK, 2001, MUTAT RES-FUND MOL M, V480, P305, DOI 10.1016/S0027-5107(01)00190-7; Lecuyer C, 2000, BIOL REPROD, V63, P1801, DOI 10.1095/biolreprod63.6.1801; Lee JM, 2001, BIOCHEM BIOPH RES CO, V280, P286, DOI 10.1006/bbrc.2000.4106; Lee JM, 2001, J BIOL CHEM, V276, P20011, DOI 10.1074/jbc.M100734200; Li XM, 1999, CANCER RES, V59, P5275; McMahon M, 2001, CANCER RES, V61, P3299; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Moinova HR, 1998, J BIOL CHEM, V273, P14683, DOI 10.1074/jbc.273.24.14683; Moinova HR, 1999, BIOCHEM BIOPH RES CO, V261, P661, DOI 10.1006/bbrc.1999.1109; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Myhrstad MCW, 2001, BBA-GENE STRUCT EXPR, V1517, P212, DOI 10.1016/S0167-4781(00)00276-1; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Robinson DN, 1997, J CELL BIOL, V138, P799, DOI 10.1083/jcb.138.4.799; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; Velichkova M, 2002, CELL MOTIL CYTOSKEL, V51, P147, DOI 10.1002/cm.10025; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wild AC, 1998, BIOCHEM J, V332, P373, DOI 10.1042/bj3320373; XUE FY, 1993, CELL, V72, P681, DOI 10.1016/0092-8674(93)90397-9; Zipper LM, 2000, BIOCHEM BIOPH RES CO, V278, P484, DOI 10.1006/bbrc.2000.3830	55	268	282	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36544	36552		10.1074/jbc.M206530200	http://dx.doi.org/10.1074/jbc.M206530200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145307	hybrid			2022-12-27	WOS:000178275100097
J	Ma, K; Cabrero, A; Saha, PK; Kojima, H; Li, L; Chang, BHJ; Paul, A; Chan, L				Ma, K; Cabrero, A; Saha, PK; Kojima, H; Li, L; Chang, BHJ; Paul, A; Chan, L			Increased beta-oxidation but no insulin resistance or glucose intolerance in mice lacking adiponectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; PROTEIN ACRP30; OBESITY; GENE; EXPRESSION; MUSCLE; LIVER; MOUSE	Previous reports showed that recombinant fragments of adiponectin (adipo) displayed pharmacological effects when injected into rodents, but the relevance of these observations to the physiological function of adipo is unclear. We generated Adipo(-/-) mice by gene targeting. Adipo(-/-) mice are fertile with normal body and fat pad weights. Plasma glucose and insulin levels of Adipo(-/-) and Adipo(+/+) mice are similar under fasting conditions and during an intraperitoneal glucose tolerance test (GTT). Insulin tolerance test (ITT) also produces similar plasma glucose and insulin levels in the two groups of mice. Hyperinsulinemic-euglycemic clamp analysis showed that Adipo(-/-) and Adipo(+/+) mice have similar glucose infusion rates to maintain a similar serum glucose. High-fat diet feeding for 7 months led to similar weight gain and similar GTT and ITT responses. We next measured beta-oxidation and found it to be significantly increased in muscle and liver of Adipo(-/-) mice. In conclusion, our study indicates that absence of adipo causes increased beta-oxidation but does not cause glucose intolerance or insulin resistance in mice.	Baylor Coll Med, Div Endocrinol & Metab, Dept Med, Sect Endocrinol & Metab, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; St Lukes Episcopal Hosp, Texas Med Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Saint Lukes Episcopal Hospital	Chan, L (corresponding author), Baylor Coll Med, Div Endocrinol & Metab, Dept Med, Sect Endocrinol & Metab, 1 Baylor Plaza, Houston, TX 77030 USA.				NHLBI NIH HHS [HL-16512, HL-51568] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016512, R37HL016512, R01HL051568] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alam N, 1998, BIOCHEM J, V334, P233, DOI 10.1042/bj3340233; Berg AH, 2002, TRENDS ENDOCRIN MET, V13, P84, DOI 10.1016/S1043-2760(01)00524-0; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Chang BHJ, 1999, J BIOL CHEM, V274, P6051, DOI 10.1074/jbc.274.10.6051; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI200114120; Das K, 2001, BIOCHEM BIOPH RES CO, V280, P1120, DOI 10.1006/bbrc.2001.4217; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Fujita Y, 1998, DIABETOLOGIA, V41, P1459, DOI 10.1007/s001250051092; Havel PJ, 2002, CURR OPIN LIPIDOL, V13, P51, DOI 10.1097/00041433-200202000-00008; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Lau PP, 2001, J BIOL CHEM, V276, P46445, DOI 10.1074/jbc.M109215200; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Martinez-Botas J, 2000, NAT GENET, V26, P474, DOI 10.1038/82630; Nagai Y., 1995, BIOL SIALIC ACIDS, P197; Sato C, 2001, J BIOL CHEM, V276, P28849, DOI 10.1074/jbc.M104148200; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; SHARON N, 1997, GLYCOSCIENCES, P95; Weyer C, 2001, J CLIN ENDOCR METAB, V86, P1930, DOI 10.1210/jc.86.5.1930; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yu XX, 1997, J NUTR, V127, P1814, DOI 10.1093/jn/127.9.1814	21	250	261	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34658	34661		10.1074/jbc.C200362200	http://dx.doi.org/10.1074/jbc.C200362200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12151381	hybrid			2022-12-27	WOS:000178117000002
J	Farzan, M; Chung, S; Li, WH; Vasilieva, N; Wright, PL; Schnitzler, CE; Marchione, RJ; Gerard, C; Gerard, NP; Sodroski, J; Choe, H				Farzan, M; Chung, S; Li, WH; Vasilieva, N; Wright, PL; Schnitzler, CE; Marchione, RJ; Gerard, C; Gerard, NP; Sodroski, J; Choe, H			Tyrosine-sulfated peptides functionally reconstitute a CCR5 variant lacking a critical amino-terminal region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CHEMOKINE RECEPTOR CCR5; HIV-1 ENTRY; ENVELOPE GLYCOPROTEIN; GENETIC RESTRICTION; CORECEPTOR ACTIVITY; MOLECULAR-CLONING; N-TERMINUS; INFECTION; BINDING	Entry of most primary human immunodeficiency virus, type 1 (HIV-1) isolates into their target cells requires the cellular receptor CD4 and the G protein-coupled chemokine coreceptor CCR5. An acidic, tyrosine-rich, and tyrosine-sulfated domain of the CCR5 amino terminus plays a critical role in the ability of CCR5 to serve as an HIV-1 coreceptor, and tyrosine-sulfated peptides based on this region physically associate with the HIV-1 envelope glycoprotein gp120 and slow HIV-1 entry into CCR5-expressing cells. Here we show that the same tyrosine-sulfated peptides, but not their unsulfated analogs, can restore the HIV-1 coreceptor activity of a CCR5 variant lacking residues 2-17 of its amino terminus. Additionally, these sulfated peptides restored the ability of this CCR5 variant to mobilize calcium in response to the chemokines macrophage inflammatory factors 1alpha and 1beta. These observations show that a tyrosine-sulfated region of the CCR5 amino terminus can function independently to mediate association of chemokines and the HIV-1 envelope glycoprotein with the remaining domains of CCR5.	Childrens Hosp, Permutter Lab, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital	Choe, H (corresponding author), Childrens Hosp, Permutter Lab, 300 Longwood Ave, Boston, MA 02115 USA.		Schnitzler, Christine/G-8733-2013	Farzan, Michael/0000-0002-2990-5319; Schnitzler, Christine/0000-0002-5001-6524; Li, Wenhui/0000-0003-1305-7404	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043891, R01AI048425] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI043891, AI 48425, AI 43891] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Blanpain C, 1999, J BIOL CHEM, V274, P18902, DOI 10.1074/jbc.274.27.18902; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Connor RI, 1997, J EXP MED, V185, P621, DOI 10.1084/jem.185.4.621; Cormier EG, 2000, P NATL ACAD SCI USA, V97, P5762, DOI 10.1073/pnas.97.11.5762; Cormier EG, 2001, J VIROL, V75, P5541, DOI 10.1128/JVI.75.12.5541-5549.2001; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Farzan M, 2000, J BIOL CHEM, V275, P33516, DOI 10.1074/jbc.M007228200; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 2002, J BIOL CHEM, V277, P29484, DOI 10.1074/jbc.M203361200; Farzan M, 1997, J BIOL CHEM, V272, P6854, DOI 10.1074/jbc.272.11.6854; Farzan M, 1997, J EXP MED, V186, P405, DOI 10.1084/jem.186.3.405; Farzan M, 2001, J EXP MED, V193, P1059, DOI 10.1084/jem.193.9.1059; Farzan M, 1998, J VIROL, V72, P1160, DOI 10.1128/JVI.72.2.1160-1164.1998; FARZAN M, 2002, J BIOL CHEM, V28, P28; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fong AM, 2002, J BIOL CHEM, V277, P19418, DOI 10.1074/jbc.M201396200; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; Horuk R, 1998, J BIOL CHEM, V273, P386, DOI 10.1074/jbc.273.1.386; KLATZMANN D, 1984, NATURE, V312, P767, DOI 10.1038/312767a0; KOLAKOWSKI LF, 1995, J BIOL CHEM, V270, P18077, DOI 10.1074/jbc.270.30.18077; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084, DOI 10.1074/jbc.271.32.19084; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Preobrazhensky AA, 2000, J IMMUNOL, V165, P5295, DOI 10.4049/jimmunol.165.9.5295; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Ross TM, 1998, J VIROL, V72, P1918, DOI 10.1128/JVI.72.3.1918-1924.1998; Rucker J, 1996, CELL, V87, P437, DOI 10.1016/S0092-8674(00)81364-1; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Schwyzer R, 1977, Ann N Y Acad Sci, V297, P3, DOI 10.1111/j.1749-6632.1977.tb41843.x; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Winkler C, 1998, SCIENCE, V279, P389, DOI 10.1126/science.279.5349.389; WU L, 1996, NATURE, V184, P179	45	54	57	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40397	40402		10.1074/jbc.M206784200	http://dx.doi.org/10.1074/jbc.M206784200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183462	hybrid			2022-12-27	WOS:000178791400032
J	Sayama, K; Yamasaki, K; Hanakawa, Y; Shirakata, Y; Tokumaru, S; Ijuin, T; Takenawa, T; Hashimoto, K				Sayama, K; Yamasaki, K; Hanakawa, Y; Shirakata, Y; Tokumaru, S; Ijuin, T; Takenawa, T; Hashimoto, K			Phosphatidylinositol 3-kinase is a key regulator of early phase differentiation in keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INTEGRIN-LINKED KINASE; GLYCOGEN-SYNTHASE KINASE; NF-KAPPA-B; TERMINAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; CELL-ADHESION; BETA-1-INTEGRIN EXPRESSION; MICE LACKING; ACTIVATION	The survival and growth of epithelial cells depend on adhesion to the extracellular matrix. Because epidermal keratinocytes differentiate as they leave the basement membrane, an adhesion signal may regulate the initiation of differentiation. Phosphatidylinositol 3-kinase (PI3K) is a fundamental signaling molecule that regulates the adhesion signal. Transfection of a dominant negative form of PI3K into keratinocytes using an adenovirus vector resulted in significant morphological changes comparable to differentiation and the induction of differentiation markers, keratin (K) 1 and K10. In turn, transfection with the constitutively active form of PI3K almost completely abolished the induction of K1 and K10 by differentiation in suspension cultures using polyhydroxyethylmethacrylate-coated dishes. PI3K activity was lost in suspension culture, except by cells bearing the constitutively active form of PI3K. These data demonstrate that blockade of PI3K results in differentiation and that activation of PI3K prevents differentiation. Furthermore, expression of the dominant negative form of PI3K significantly inhibited keratinocyte adhesion to the extracellular matrix and reduced the surface expression of alpha(6) and beta(1) integrins in suspension culture. Moreover, expression of the active form of PI3K restored the mRNA levels of adhesion molecules that were reduced in suspension culture, including alpha(3), alpha(6), and beta(1) integrins, BP180, and BP230. In conclusion, loss of PI3K activity results in keratinocytes leaving the basement membrane and the initiation of a "default" differentiation mechanism.	Ehime Univ, Sch Med, Dept Dermatol, Ehime 7910295, Japan; Univ Tokyo, Inst Med Sci, Dept Biochem, Tokyo 1138657, Japan	Ehime University; University of Tokyo	Sayama, K (corresponding author), Ehime Univ, Sch Med, Dept Dermatol, Ehime 7910295, Japan.	sayama@m.ehime-u.ac.jp	Yamasaki, Kenshi/C-8905-2018; Ijuin, Takeshi/H-7016-2017	Yamasaki, Kenshi/0000-0002-5495-4956; Ijuin, Takeshi/0000-0002-0618-1776				ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ADAMS JC, 1989, NATURE, V340, P307, DOI 10.1038/340307a0; Brakebusch C, 2000, EMBO J, V19, P3990, DOI 10.1093/emboj/19.15.3990; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Dedhar S, 1999, Curr Opin Hematol, V6, P37, DOI 10.1097/00062752-199901000-00007; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; FISHER GJ, 1993, J INVEST DERMATOL, V101, P553, DOI 10.1111/1523-1747.ep12365967; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; GHERZI R, 1992, BIOCHEM BIOPH RES CO, V184, P283, DOI 10.1016/0006-291X(92)91190-2; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HOTCHIN NA, 1992, J BIOL CHEM, V267, P14852; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Jones JCR, 1998, BIOESSAYS, V20, P488, DOI 10.1002/(SICI)1521-1878(199806)20:6<488::AID-BIES7>3.0.CO;2-I; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; Levy L, 2000, MOL BIOL CELL, V11, P453, DOI 10.1091/mbc.11.2.453; MATSUI MS, 1992, J INVEST DERMATOL, V99, P565, DOI 10.1111/1523-1747.ep12667411; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; OSADA S, 1993, CELL GROWTH DIFFER, V4, P167; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Raghavan S, 2000, J CELL BIOL, V150, P1149, DOI 10.1083/jcb.150.5.1149; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Sayama K, 1999, J CELL PHYSIOL, V179, P40, DOI 10.1002/(SICI)1097-4652(199904)179:1<40::AID-JCP5>3.0.CO;2-Z; Sayama K, 2001, J BIOL CHEM, V276, P999, DOI 10.1074/jbc.M003425200; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; Sokol S, 2000, NAT CELL BIOL, V2, pE124, DOI 10.1038/35017136; Somasiri A, 2001, J CELL SCI, V114, P1125; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wakita N, 1999, J BIOL CHEM, V274, P37285, DOI 10.1074/jbc.274.52.37285; WATT FM, 1988, P NATL ACAD SCI USA, V85, P5576, DOI 10.1073/pnas.85.15.5576; Woods ML, 2001, J LEUKOCYTE BIOL, V69, P874; Woods ML, 2001, EMBO J, V20, P1232, DOI 10.1093/emboj/20.6.1232; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Zhu AJ, 1999, P NATL ACAD SCI USA, V96, P6728, DOI 10.1073/pnas.96.12.6728	51	34	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40390	40396		10.1074/jbc.M112423200	http://dx.doi.org/10.1074/jbc.M112423200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183446	hybrid			2022-12-27	WOS:000178791400031
J	Yamazaki, M; Li, N; Bondarenko, VA; Yamazaki, RK; Baehr, W; Yamazaki, A				Yamazaki, M; Li, N; Bondarenko, VA; Yamazaki, RK; Baehr, W; Yamazaki, A			Binding of cGMP to GAF domains in amphibian rod photoreceptor cGMP phosphodiesterase (PDE)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; TRANSDUCIN ALPHA-SUBUNIT; SITE-DIRECTED MUTAGENESIS; INHIBITORY GAMMA-SUBUNIT; AMINO-ACID SEQUENCE; OUTER SEGMENTS; RETINAL RODS; REGULATORY SUBUNIT; PROTEIN-KINASE; DELTA-SUBUNIT	Retinal cGMP phosphodiesterase (PDE6) is a key enzyme in vertebrate phototransduction. Rod PDE contains two homologous catalytic subunits (Palphabeta) and two identical regulatory subunits (Pgamma). Biochemical studies have shown that amphibian Palphabeta has high affinity, cGMP-specific, non-catalytic binding sites and that Pgamma stimulates cGMP binding to these sites. Here we show by molecular cloning that each catalytic subunit in amphibian PDE, as in its mammalian counterpart, contains two homologous tandem GAF domains in its N-terminal region. In Pgamma-depleted membrane-bound PDE (20-40% Pgamma still present), a single type of cGMP-binding site with a relatively low affinity (K-d similar to 100 nm) was observed, and addition of Pgamma increased both the affinity for cGMP and the level of cGMP binding. We also show that mutations of amino acid residues in four different sites in Pgamma reduced its ability to stimulate cGMP binding. Among these, the site involved in Pgamma phosphorylation by Cdk5 (positions 20-23) had the largest effect on cGMP binding. However, except for the C terminus, these sites were not involved in Pgamma inhibition of the cGMP hydrolytic activity of Palphabeta. In addition, the Pgamma concentration required for 50% stimulation of cGMP binding was much greater than that required for 50% inhibition of cGMP hydrolysis. These results suggest that the Palphabeta heterodimer contains two spatially and functionally distinct types of Pgamma-binding sites: one for inhibition of cGMP hydrolytic activity and the second for activation of cGMP binding to GAF domains. We propose a model for the Palphabeta-Pgamma interaction in which Pgamma, by binding to one of the two sites in Palphabeta, may preferentially act either as an inhibitor of catalytic activity or as an activator of cGMP binding to GAF domains in frog PDE.	Wayne State Univ, Sch Med, Dept Ophthalmol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Kresge Eye Inst, Detroit, MI 48201 USA; Univ Utah, Hlth Sci Ctr, Moran Eye Ctr, Salt Lake City, UT 84132 USA	Wayne State University; Wayne State University; Wayne State University; Utah System of Higher Education; University of Utah	Yamazaki, A (corresponding author), Wayne State Univ, Sch Med, Dept Ophthalmol, 4717 Antoine Blvd, Detroit, MI 48201 USA.	ayamazak@med.wayne.edu	Bondarenko, Vladimir/AFY-8370-2022		NATIONAL EYE INSTITUTE [R01EY008123, R01EY009631] Funding Source: NIH RePORTER; NEI NIH HHS [EY 09631, EY 08123] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANANT JS, 1992, J BIOL CHEM, V267, P687; Ando S, 1997, J BIOCHEM, V122, P409; Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; Artemyev NO, 1996, P NATL ACAD SCI USA, V93, P5407, DOI 10.1073/pnas.93.11.5407; Artemyev NO, 1996, J BIOL CHEM, V271, P25382, DOI 10.1074/jbc.271.41.25382; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BEAUDETTE KN, 1993, J BIOL CHEM, V268, P20825; Berger AL, 1999, BIOCHEMISTRY-US, V38, P1293, DOI 10.1021/bi981683m; Bondarenko VA, 1997, J BIOL CHEM, V272, P15856, DOI 10.1074/jbc.272.25.15856; Bondarenko VA, 1999, BIOCHEMISTRY-US, V38, P7755, DOI 10.1021/bi990106a; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN RL, 1992, BIOCHEMISTRY-US, V31, P5918, DOI 10.1021/bi00140a031; CATTY P, 1992, J BIOL CHEM, V267, P19489; CLERC A, 1992, J BIOL CHEM, V267, P19948; CLERC A, 1992, J BIOL CHEM, V267, P6620; COTE RH, 1994, P NATL ACAD SCI USA, V91, P4845, DOI 10.1073/pnas.91.11.4845; D'Amours MR, 1999, BIOCHEM J, V340, P863, DOI 10.1042/0264-6021:3400863; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; Fink TL, 1999, J BIOL CHEM, V274, P34613, DOI 10.1074/jbc.274.49.34613; Florio SK, 1996, J BIOL CHEM, V271, P24036, DOI 10.1074/jbc.271.39.24036; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; GILLESPIE PG, 1989, P NATL ACAD SCI USA, V86, P4311, DOI 10.1073/pnas.86.11.4311; Granovsky AE, 1997, J BIOL CHEM, V272, P11686, DOI 10.1074/jbc.272.18.11686; Gutierrez-Cirlos EB, 2002, J BIOL CHEM, V277, P1195, DOI 10.1074/jbc.M109097200; HAYASHI F, 1991, P NATL ACAD SCI USA, V88, P4333, DOI 10.1073/pnas.88.10.4333; Hayashi F, 2000, J BIOL CHEM, V275, P32958, DOI 10.1074/jbc.M000703200; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; HURLEY JB, 1987, ANNU REV PHYSIOL, V49, P793; Jindrova H, 1998, PHYSIOL RES, V47, P155; Kachi S, 2000, J ELECTRON MICROSC, V49, P699, DOI 10.1093/oxfordjournals.jmicro.a023861; Li N, 1998, GENOMICS, V49, P76, DOI 10.1006/geno.1998.5210; Li N, 1998, EUR J BIOCHEM, V252, P591, DOI 10.1046/j.1432-1327.1998.2520591.x; LIN W, 1998, J BIOL CHEM, V273, P34284; LIPKIN VM, 1988, FEBS LETT, V234, P287, DOI 10.1016/0014-5793(88)80100-5; LIPKIN VM, 1990, J BIOL CHEM, V265, P12955; LIPKIN VM, 1993, BIOCHIM BIOPHYS ACTA, V1176, P250, DOI 10.1016/0167-4889(93)90052-Q; Matsuura I, 2000, J BIOL CHEM, V275, P32950, DOI 10.1074/jbc.M000702200; Melia TJ, 2000, J BIOL CHEM, V275, P3535, DOI 10.1074/jbc.275.5.3535; MIKI N, 1975, J BIOL CHEM, V250, P6320; Mou HM, 1999, J BIOL CHEM, V274, P18813, DOI 10.1074/jbc.274.26.18813; Mou HM, 2001, J BIOL CHEM, V276, P27527, DOI 10.1074/jbc.M103316200; Muradov KG, 2002, BIOCHEMISTRY-US, V41, P3884, DOI 10.1021/bi015935m; Norton AW, 2000, J BIOL CHEM, V275, P38611, DOI 10.1074/jbc.M004606200; OVCHINNIKOV YA, 1987, FEBS LETT, V223, P169, DOI 10.1016/0014-5793(87)80530-6; OVCHINNIKOV YA, 1986, FEBS LETT, V201, P237, DOI 10.1016/0014-5793(86)80616-0; Paglia MJ, 2002, J BIOL CHEM, V277, P5017, DOI 10.1074/jbc.M106328200; PIRIEV NI, 1993, P NATL ACAD SCI USA, V90, P9340, DOI 10.1073/pnas.90.20.9340; PIRIEV NI, 1994, GENE, V151, P297, DOI 10.1016/0378-1119(94)90674-2; QIN N, 1992, J BIOL CHEM, V267, P8458; QIN N, 1994, J BIOL CHEM, V269, P3265; Seno K, 2001, J BIOL CHEM, V276, P20813, DOI 10.1074/jbc.C100032200; Sharma P, 1998, BIOCHEMISTRY-US, V37, P4759, DOI 10.1021/bi972746o; SUBER ML, 1993, P NATL ACAD SCI USA, V90, P3968, DOI 10.1073/pnas.90.9.3968; Tang WJ, 1998, MOL PHARMACOL, V54, P231, DOI 10.1124/mol.54.2.231; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thompson W J, 1979, Adv Cyclic Nucleotide Res, V10, P69; TSUBOI S, 1994, J BIOL CHEM, V269, P15024; TSUBOI S, 1994, J BIOL CHEM, V269, P15016; TUTEJA N, 1988, FEBS LETT, V232, P182, DOI 10.1016/0014-5793(88)80413-7; UDOVICHENKO IP, 1994, J BIOL CHEM, V269, P9850; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; WENSEL T G, 1986, Proteins Structure Function and Genetics, V1, P90, DOI 10.1002/prot.340010114; WENSEL TG, 1990, BIOCHEMISTRY-US, V29, P2155, DOI 10.1021/bi00460a028; WHALEN MM, 1989, BIOCHEM J, V259, P13, DOI 10.1042/bj2590013; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; WOLODKO WT, 1983, J BIOL CHEM, V258, P4116; Xu LX, 1998, BIOCHEMISTRY-US, V37, P6205, DOI 10.1021/bi973087i; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; YAMAZAKI A, 1982, P NATL ACAD SCI-BIOL, V79, P3702, DOI 10.1073/pnas.79.12.3702; Yamazaki A., 1998, IOVS, V39, pS953; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YAMAZAKI A, 1990, J BIOL CHEM, V265, P11539; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619; Yamazaki A, 1996, J BIOL CHEM, V271, P32495, DOI 10.1074/jbc.271.51.32495; Yamazaki A, 1996, BIOCHEM BIOPH RES CO, V222, P488, DOI 10.1006/bbrc.1996.0771; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445	82	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40675	40686		10.1074/jbc.M203469200	http://dx.doi.org/10.1074/jbc.M203469200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177054	hybrid			2022-12-27	WOS:000178791400067
J	Chiu, CM; Tsay, YG; Chang, CJ; Lee, SC				Chiu, CM; Tsay, YG; Chang, CJ; Lee, SC			Nopp140 is a mediator of the protein kinase A signaling pathway that activates the acute phase response alpha(1)-acid glycoprotein gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; ALPHA-1-ACID GLYCOPROTEIN; C/EBP-BETA; TRANSCRIPTION FACTOR; SOMATOSTATIN GENE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; GLUCOCORTICOID RECEPTOR; CAMP; PHOSPHORYLATION; EXPRESSION	The acute phase response (APR) in liver during inflammation is one of the well known examples for elucidating the signaling pathways that lead to the combinatorial regulation of gene expression. The APR is exemplified by alpha(1)-acid glycoprotein gene (agp) expression. A number of transcription factors, including CCAAT/enhancer-binding protein beta (C/EBPbeta), glucocorticoid receptor, cAMP-response element-binding protein (CREB), and Nopp140, are known to participate in its induction. The underlying mechanism of Nopp140 and other factors for regulating agp expression remains unclear. Here we demonstrate that protein kinase A (PKA)-dependent phosphorylation of Nopp140, together with C/EBPbeta, induces agp gene expression synergistically. The cooperative activation of the agp gene by Nopp140 and forskolin is sensitive to inhibition by PKI. Results from biochemical and functional characterizations of Nopp140 mutants defective in PKA phosphorylation sites suggest that PKA-dependent Nopp140 phosphorylation is important for its role in agp gene activation. Furthermore, maximal activation of the agp gene by PKA-phosphorylated Nopp140 depends on the presence of CREB and C/EBPbeta. The participation of CREB in the activation is, however, independent of its PKA-mediated phosphorylation. In summary, we demonstrate the existence of a novel Nopp140-mediated PKA signaling pathway that leads to the activation of agp, one of the major acute phase response genes.	Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Clin Med, Taipei, Taiwan; Acad Sinica, Inst Biol Chem, Taipei, Taiwan	National Taiwan University; National Taiwan University; Academia Sinica - Taiwan	Lee, SC (corresponding author), Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan.		Chang, Ching-Jin/G-4511-2019; Tsay, Yeou-Guang/HGE-2076-2022	Chang, Ching-Jin/0000-0001-7129-8092				AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ALAM T, 1993, J BIOL CHEM, V268, P15681; Arizmendi C, 1999, J BIOL CHEM, V274, P13033, DOI 10.1074/jbc.274.19.13033; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; Buck M, 2001, MOL CELL, V8, P807, DOI 10.1016/S1097-2765(01)00374-4; Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880; CHANG CJ, 1990, MOL CELL BIOL, V10, P6642, DOI 10.1128/MCB.10.12.6642; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen HK, 1999, MOL CELL BIOL, V19, P8536; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; FOURNIER T, 1995, J IMMUNOL, V155, P2123; Fournier T, 2000, BBA-PROTEIN STRUCT M, V1482, P157, DOI 10.1016/S0167-4838(00)00153-9; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Hanlon M, 2001, J BIOL CHEM, V276, P38449, DOI 10.1074/jbc.M102165200; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Higuchi T, 2002, MOL CELL BIOL, V22, P1, DOI 10.1128/MCB.22.1.1-11.2002; HOFFMANN J, 1989, BIOCHEM J, V263, P785, DOI 10.1042/bj2630785; Isaac C, 1998, J CELL BIOL, V142, P319, DOI 10.1083/jcb.142.2.319; Isaac C, 2001, J CELL SCI, V114, P4253; Kawaguchi T, 2001, P NATL ACAD SCI USA, V98, P13710, DOI 10.1073/pnas.231370798; Koj A, 1996, BBA-MOL BASIS DIS, V1317, P84, DOI 10.1016/S0925-4439(96)00048-8; KULKARNI AB, 1985, J BIOL CHEM, V260, P5386; Lee YM, 1996, MOL CELL BIOL, V16, P4257; LEE YM, 1993, MOL CELL BIOL, V13, P432, DOI 10.1128/MCB.13.1.432; Li DX, 1997, J BIOL CHEM, V272, P3773, DOI 10.1074/jbc.272.6.3773; Lin Y, 2001, J BIOL CHEM, V276, P42077, DOI 10.1074/jbc.M107101200; Liu XD, 2001, AM J PHYSIOL-RENAL, V281, pF649, DOI 10.1152/ajprenal.2001.281.4.F649; MEIER UT, 1992, CELL, V70, P127; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; Miau LH, 1997, MOL CELL BIOL, V17, P230, DOI 10.1128/MCB.17.1.230; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Niehof M, 1997, MOL CELL BIOL, V17, P3600, DOI 10.1128/MCB.17.7.3600; PAI CY, 1995, J CELL SCI, V108, P1911; Pelletier N, 1998, FEBS LETT, V439, P275, DOI 10.1016/S0014-5793(98)01388-X; Roesler WJ, 2000, MOL CELL ENDOCRINOL, V162, P1, DOI 10.1016/S0303-7207(00)00198-2; Sassone-Corsi P, 1998, INT J BIOCHEM CELL B, V30, P27, DOI 10.1016/S1357-2725(97)00093-9; Savoldi G, 1997, DNA CELL BIOL, V16, P1467, DOI 10.1089/dna.1997.16.1467; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SMITH CA, 1993, J VIROL, V67, P4676, DOI 10.1128/JVI.67.8.4676-4687.1993; TAE HJ, 1995, J BIOL CHEM, V270, P21487, DOI 10.1074/jbc.270.37.21487; TRAUTWEIN C, 1994, J CLIN INVEST, V93, P2554, DOI 10.1172/JCI117266; Tsay YG, 2000, ANAL BIOCHEM, V287, P55, DOI 10.1006/abio.2000.4837; Tyson DR, 1999, ENDOCRINOLOGY, V140, P1255, DOI 10.1210/en.140.3.1255; VANNICE JL, 1984, P NATL ACAD SCI-BIOL, V81, P4241, DOI 10.1073/pnas.81.14.4241; Welm AL, 2000, J BIOL CHEM, V275, P27406; YANG TH, 1994, MOL CELL BIOL, V14, P6068, DOI 10.1128/MCB.14.9.6068; Yang YF, 2000, MOL BIOL CELL, V11, P567, DOI 10.1091/mbc.11.2.567	53	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39102	39111		10.1074/jbc.M205915200	http://dx.doi.org/10.1074/jbc.M205915200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167624	hybrid			2022-12-27	WOS:000178662500008
J	Eggler, AL; Inman, RB; Cox, MM				Eggler, AL; Inman, RB; Cox, MM			The Rad51-dependent pairing of long DNA substrates is stabilized by replication protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI RECA; YEAST RAD51 PROTEIN; BINDING-PROTEIN; SACCHAROMYCES-CEREVISIAE; ATP HYDROLYSIS; PARTIAL DENATURATION; BRANCH MIGRATION; STABLE COMPLEXES; EXCHANGE	Rad51 protein forms nucleoprotein filaments on single-stranded DNA (ssDNA) and then pairs that DNA with the complementary strand of incoming duplex DNA. In apparent contrast with published results, we demonstrate that Rad51 protein promotes an extensive pairing of long homologous DNAs in the absence of replication protein A. This pairing exists only within the Rad51 filament; it was previously undetected because it is lost upon deproteinization. We further demonstrate that RPA has a critical postsynaptic role in DNA strand exchange, stabilizing the DNA pairing initiated by Rad51 protein. Stabilization of the Rad51-generated DNA pairing intermediates can be can occur either by binding the displaced strand with RPA or by degrading the same DNA strand using exonuclease VII. The optimal conditions for Rad51-mediated DNA strand exchange used here minimize the secondary structure in single-stranded DNA, minimizing the established presynaptic role of RPA in facilitating Rad51 filament formation. We verify that RPA has little effect on Rad51 filament formation under these conditions, assigning the dramatic stimulation of strand exchange nevertheless afforded by RPA to its postsynaptic function of removing the displaced DNA strand from Rad51 filaments.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.			Eggler, Aimee/0000-0002-7286-2107	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM014711, U01GM032335, R01GM032335] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32335, GM14711-34] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; BEDALE WA, 1993, J BIOL CHEM, V268, P15004; BIANCHI M, 1983, CELL, V34, P931, DOI 10.1016/0092-8674(83)90550-0; COX MM, 1981, P NATL ACAD SCI-BIOL, V78, P3433, DOI 10.1073/pnas.78.6.3433; COX MM, 1982, J BIOL CHEM, V257, P8523; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; Gumbs OH, 1998, BIOCHEMISTRY-US, V37, P11692, DOI 10.1021/bi980646s; Gupta RC, 1999, MOL CELL, V4, P705, DOI 10.1016/S1097-2765(00)80381-0; Gupta RC, 1999, J BIOL CHEM, V274, P1248, DOI 10.1074/jbc.274.3.1248; Haag ES, 2000, GENETICS, V155, P105; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; He ZG, 1996, J BIOL CHEM, V271, P28243, DOI 10.1074/jbc.271.45.28243; INMAN RB, 1970, J MOL BIOL, V49, P93, DOI 10.1016/0022-2836(70)90378-5; INMAN RB, 1987, J MOL BIOL, V193, P377, DOI 10.1016/0022-2836(87)90225-7; JAIN SK, 1994, J BIOL CHEM, V269, P20653; KODADEK T, 1990, J BIOL CHEM, V265, P20966; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LITTLEWOOD RK, 1982, NUCLEIC ACIDS RES, V10, P1691, DOI 10.1093/nar/10.5.1691; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; MORRICAL SW, 1990, BIOCHEMISTRY-US, V29, P837, DOI 10.1021/bi00455a034; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; Namsaraev EA, 2000, J BIOL CHEM, V275, P3970, DOI 10.1074/jbc.275.6.3970; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; Nishinaka T, 1998, P NATL ACAD SCI USA, V95, P11071, DOI 10.1073/pnas.95.19.11071; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Rice KP, 2001, J BIOL CHEM, V276, P38570, DOI 10.1074/jbc.M105678200; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Singleton SF, 2001, BIOPOLYMERS, V61, P145; Smith J, 1999, GENETICS, V151, P447; Soustelle C, 2002, GENETICS, V161, P535; Steffen SE, 2002, J BIOL CHEM, V277, P14493, DOI 10.1074/jbc.M112444200; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Umezu K, 1998, GENETICS, V148, P989; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898	40	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39280	39288		10.1074/jbc.M204328200	http://dx.doi.org/10.1074/jbc.M204328200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12169690	hybrid			2022-12-27	WOS:000178662500030
J	Geisen, C; Moroy, T				Geisen, C; Moroy, T			The oncogenic activity of cyclin E is not confined to Cdk2 activation alone but relies on several other, distinct functions of the protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; CELL-CYCLE; RETINOBLASTOMA PROTEIN; GENE AMPLIFICATION; TRANSGENIC MICE; CDK2/CYCLIN E; HA-RAS; EXPRESSION; P27(KIP1); PHASE	We have previously shown that cyclin E can malignantly transform primary rat embryo fibroblasts in cooperation with constitutively active Ha-Ras. In addition, we demonstrated that high level cyclin E expression potentiates the development of methyl-nitroso-urea-induced T-cell lymphomas in mice. To further investigate the mechanism underlying cyclin E-mediated malignant transformation, we have performed a mutational analysis of cyclin E function. Here we show that cyclin E mutants defective to form an active kinase complex with Cdk2 are unable to drive cells from G, into S phase but can still malignantly transform rat embryo fibroblasts in cooperation with Ha-Ras. In addition, Cdk2 activation is not a prerequisite for the ability of cyclin E to rescue yeast triple cln mutations. We also find that the oncogenic properties of cyclin E did not entirely correspond with its ability to interact with the negative cell cycle regulator p27(Kip1) or the pocket protein p130. These findings suggest that the oncogenic activity of cyclin E does not exclusively rely on its ability as a positive regulator of G, progression. Rather, we propose that cyclin E harbors other functions, independent of Cdk2 activation and P27(Kip1) binding, that contribute significantly to its oncogenic activity.	Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, D-45122 Essen, Germany	University of Duisburg Essen	Moroy, T (corresponding author), Univ Essen Gesamthsch Klinikum, IFZ, Inst Zellbiol Tumorforsch, Virchowstr 173, D-45122 Essen, Germany.	moeroey@uni-essen.de	Moroy, Tarik/D-9923-2011					AKAMA Y, 1995, JPN J CANCER RES, V86, P617, DOI 10.1111/j.1349-7006.1995.tb02442.x; Bartek J, 1996, CURR OPIN CELL BIOL, V8, P805, DOI 10.1016/S0955-0674(96)80081-0; Bortner DM, 1997, MOL CELL BIOL, V17, P453, DOI 10.1128/MCB.17.1.453; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; D'Angiolella V, 2001, CURR BIOL, V11, P1221, DOI 10.1016/S0960-9822(01)00352-9; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DEMETRICK DJ, 1995, CYTOGENET CELL GENET, V69, P190, DOI 10.1159/000133960; Donnellan R, 1999, FASEB J, V13, P773, DOI 10.1096/fasebj.13.8.773; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Erlanson M, 1998, BLOOD, V92, P770; Haas K, 1997, ONCOGENE, V15, P2615, DOI 10.1038/sj.onc.1201434; HALL M, 1995, ONCOGENE, V11, P1581; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Jackman M, 2002, MOL BIOL CELL, V13, P1030, DOI 10.1091/mbc.01-07-0361; JACKSON PK, 1995, J CELL BIOL, V130, P755, DOI 10.1083/jcb.130.4.755; Juan G, 2001, CANCER RES, V61, P1220; Kalejta RF, 1999, EXP CELL RES, V248, P322, DOI 10.1006/excr.1999.4427; Karsunky H, 1999, ONCOGENE, V18, P7816, DOI 10.1038/sj.onc.1203205; Kelly BL, 1998, P NATL ACAD SCI USA, V95, P2535, DOI 10.1073/pnas.95.5.2535; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KEYOMARSI K, 1995, ONCOGENE, V11, P941; KITAHARA K, 1995, INT J CANCER, V62, P25, DOI 10.1002/ijc.2910620107; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LOVEC H, 1994, ONCOGENE, V9, P323; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Marone M, 1998, INT J CANCER, V75, P34, DOI 10.1002/(SICI)1097-0215(19980105)75:1<34::AID-IJC6>3.0.CO;2-2; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Mumberg D, 1997, NUCLEIC ACIDS RES, V25, P2098, DOI 10.1093/nar/25.11.2098; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; PlanasSilva MD, 1997, CURR OPIN CELL BIOL, V9, P768, DOI 10.1016/S0955-0674(97)80076-2; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; SEWING A, 1994, J CELL SCI, V107, P581; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sweeney KJ, 1998, ONCOGENE, V16, P2865, DOI 10.1038/sj.onc.1201814; Tokuyama Y, 2001, J BIOL CHEM, V276, P21529, DOI 10.1074/jbc.M100014200; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLOWIEC D, 1995, LEUKEMIA, V9, P1382; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738	63	60	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39909	39918		10.1074/jbc.M205919200	http://dx.doi.org/10.1074/jbc.M205919200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12149264	hybrid			2022-12-27	WOS:000178662500108
J	Krejci, L; Song, BW; Bussen, W; Rothstein, R; Mortensen, UH; Sung, P				Krejci, L; Song, BW; Bussen, W; Rothstein, R; Mortensen, UH; Sung, P			Interaction with Rad51 is indispensable for recombination mediator function of Rad52	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION PROTEIN-A; DNA STRAND EXCHANGE; SACCHAROMYCES-CEREVISIAE; YEAST RAD51; ALLELE; REPAIR; MUTATIONS; COMPLEX; RPA; SUPPRESSION	In the yeast Saccharomyces cerevisiae, the RAD52 gene is indispensable for homologous recombination and DNA repair. Rad52 protein binds DNA, anneals complementary ssDNA strands, and self-associates to form multimeric complexes. Moreover, Rad52 physically interacts with the Rad51. recombinase and serves as a mediator in the Rad51-catalyzed DNA strand exchange reaction. Here, we examine the functional significance of the Rad51/Rad52 interaction. Through a series of deletions, we have identified residues 409-420 of Rad52 as being indispensable and likely sufficient for its interaction with Rad51. We have constructed a four-amino acid deletion mutation within this region of Rad52 to ablate its interaction with Rad51. We show that the rad52Delta409-412 mutant protein is defective in the mediator function in vitro even though none of the other Rad52 activities, namely, DNA binding, ssDNA annealing, and protein oligomerization, are affected. We also show that the sensitivity of the rad52Delta409-412 mutant to ionizing radiation can be complemented by overexpression of Rad51. These results thus demonstrate the significance of the Rad51-Rad52 interaction in homologous recombination.	Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Tech Univ Denmark, Bioctr, DK-2800 Lyngby, Denmark	University of Texas System; University of Texas Health San Antonio; Columbia University; Technical University of Denmark	Krejci, L (corresponding author), Univ Texas, Hlth Sci Ctr, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA.		Mortensen, Uffe/AAQ-1150-2021; Krejci, Lumir/B-7842-2009	Krejci, Lumir/0000-0002-4732-1405; Rothstein, Rodney/0000-0002-4107-9654	NATIONAL CANCER INSTITUTE [T32CA086800] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057814, R01GM050237] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA86800] Funding Source: Medline; NIEHS NIH HHS [R01 ES07061] Funding Source: Medline; NIGMS NIH HHS [R01 GM50237, R01 GM57814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1984, MOL CELL BIOL, V4, P2735, DOI 10.1128/MCB.4.12.2735; Asleson EN, 1999, GENETICS, V153, P681; Bai Y, 1999, GENETICS, V153, P1117; Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; Beernink HTH, 1999, TRENDS BIOCHEM SCI, V24, P385, DOI 10.1016/S0968-0004(99)01451-6; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; BOUNDYMILLS KL, 1993, GENETICS, V133, P39; Cox MM, 2001, ANNU REV GENET, V35, P53, DOI 10.1146/annurev.genet.35.102401.090016; Erdeniz N, 1997, GENOME RES, V7, P1174, DOI 10.1101/gr.7.12.1174; Fan HY, 1996, GENETICS, V142, P749; Hays SL, 1998, MOL CELL BIOL, V18, P4400, DOI 10.1128/MCB.18.7.4400; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; Kaytor MD, 1996, CURR GENET, V29, P203; Lisby M, 2001, P NATL ACAD SCI USA, V98, P8276, DOI 10.1073/pnas.121006298; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Passy SI, 1999, P NATL ACAD SCI USA, V96, P4279, DOI 10.1073/pnas.96.8.4279; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Pierce AJ, 2001, TRENDS CELL BIOL, V11, pS52, DOI 10.1016/S0962-8924(01)02149-3; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; SHERMAN F, 1991, P3; Sherman F., 1986, METHODS YEAST GENETI; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Sigurdsson S, 2001, J BIOL CHEM, V276, P8798, DOI 10.1074/jbc.M010011200; Smith J, 1999, GENETICS, V151, P447; Song BW, 2000, J BIOL CHEM, V275, P15895, DOI 10.1074/jbc.M910244199; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; Sung P, 2000, MUTAT RES-FUND MOL M, V451, P257, DOI 10.1016/S0027-5107(00)00054-3; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Trujillo KM, 2001, J BIOL CHEM, V276, P35458, DOI 10.1074/jbc.M105482200; Zou H, 1997, CELL, V90, P87, DOI 10.1016/S0092-8674(00)80316-5	36	87	89	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40132	40141		10.1074/jbc.M206511200	http://dx.doi.org/10.1074/jbc.M206511200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171935	hybrid			2022-12-27	WOS:000178662500136
J	Irusta, PM; Luo, Y; Bakht, O; Lai, CC; Smith, SO; DiMaio, D				Irusta, PM; Luo, Y; Bakht, O; Lai, CC; Smith, SO; DiMaio, D			Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor beta receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTROINTESTINAL STROMAL TUMORS; INTERNAL TANDEM DUPLICATION; FAMILY TYROSINE KINASES; C-KIT; CONSTITUTIVE ACTIVATION; PHOSPHORYLATION SITES; AMINO-ACIDS; FLT3 GENE; SRC; PDGF	A variety of tumors contain activating mutations in the cytoplasmic juxtamembrane domain of the type III family of receptor-tyrosine kinases, and some constructed mutations in this domain induce ligand-independent receptor activation. To explore the role of this domain in regulation of receptor activity, we subjected the juxtamembrane domain of the murine platelet-derived growth factor (PDGF) beta receptor to alanine-scanning mutagenesis. The mutant receptors were expressed in Ba/F3 cells and tested for constitutive tyrosine phosphorylation, association with phosphatidylinositol 3'-kinase, and their ability to induce cell survival and proliferation in the absence of interleukin-3. The mutant receptors accumulated to similar levels and appeared to undergo a normal PDGF-induced increase in tyrosine phosphorylation. Alanine substitutions at numerous positions located throughout the juxtamembrane domain caused constitutive receptor activation, as did an alanine insertion in the membrane-proximal segment of the juxtamembrane domain and a six-amino acid deletion in the center of the domain. It is possible to model the PDGF receptor juxtamembrane domain as a short a-helix followed by a three-stranded beta-sheet very similar to the known structures of WW domains. Strikingly, the activating mutations clustered in the central portions of the first and second beta strands and along one face of the beta-sheet, whereas the loops connecting the strands were largely devoid of mutationally sensitive positions. These findings provide strong support for the model that the activating mutations in the juxtamembrane region stimulate receptor activity by disrupting an inhibitory WW-like domain.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; SUNY Stony Brook, Ctr Struct Biol, Stony Brook, NY 11794 USA	Yale University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	DiMaio, D (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.	daniel.dimaio@yale.edu			NCI NIH HHS [CA85757, CA37157] Funding Source: Medline; NIGMS NIH HHS [GM46732] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA037157, R01CA037157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046732, R55GM046732] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; Baxter RM, 1998, J BIOL CHEM, V273, P17050, DOI 10.1074/jbc.273.27.17050; Bell CA, 2000, MOL BIOL CELL, V11, P3589, DOI 10.1091/mbc.11.10.3589; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; DeMali KA, 1998, MOL CELL BIOL, V18, P2014, DOI 10.1128/MCB.18.4.2014; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; Gille H, 2000, EMBO J, V19, P4064, DOI 10.1093/emboj/19.15.4064; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HERBST R, 1995, ONCOGENE, V10, P369; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912; Jiang X, 2001, PROTEIN SCI, V10, P1454, DOI 10.1110/ps.640101; KANAKURA Y, 1994, LEUKEMIA, V8, pS18; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Kiyoi H, 1998, LEUKEMIA, V12, P1333, DOI 10.1038/sj.leu.2401130; Longley BJ, 2001, LEUKEMIA RES, V25, P571, DOI 10.1016/S0145-2126(01)00028-5; Ma YS, 1999, J BIOL CHEM, V274, P13399, DOI 10.1074/jbc.274.19.13399; Macias MJ, 2000, NAT STRUCT BIOL, V7, P375, DOI 10.1038/75144; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; MYLES GM, 1994, MOL CELL BIOL, V14, P4843, DOI 10.1128/MCB.14.7.4843; Nakahara M, 1998, GASTROENTEROLOGY, V115, P1090, DOI 10.1016/S0016-5085(98)70079-4; Nakao M, 1996, LEUKEMIA, V10, P1911; Nishida T, 1998, NAT GENET, V19, P323, DOI 10.1038/1209; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; Sachsenmaier C, 1999, ONCOGENE, V18, P3583, DOI 10.1038/sj.onc.1202694; Sudol M, 2000, CELL, V103, P1001, DOI 10.1016/S0092-8674(00)00203-8; Tsujimura T, 1996, BLOOD, V87, P273; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38627	38634		10.1074/jbc.M204890200	http://dx.doi.org/10.1074/jbc.M204890200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12181311	hybrid			2022-12-27	WOS:000178529600080
J	Qian, SB; Ott, DE; Schubert, U; Bennink, JR; Yewdell, JW				Qian, SB; Ott, DE; Schubert, U; Bennink, JR; Yewdell, JW			Fusion proteins with COOH-terminal ubiquitin are stable and maintain dual functionality in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT-LIVED PROTEIN; A-FACTOR RECEPTOR; DEGRADATION SIGNAL; TAGGED UBIQUITIN; ANTIGEN; RECOGNITION; SUBUNIT; HIV-1; INTERNALIZATION; LOCALIZATION	The ubiquitin (Ub) fusion degradation pathway functions to degrade fusion proteins containing a nonremovable Ub moiety at their NH2 terminus (Johnson, E. S., Ma, P. C., Ota, I. M., and Varshavsky, A. (1995) J. Biol. Chem. 270, 17442-17456). Here we show that ubiquitin fusion degradation also targets proteins for proteasomal degradation when Ub is present in the middle of fusion proteins (X-Ub-Y), in a process that entails polyubiquitylation of Ub Lys(48). By contrast, fusion proteins bearing COOH-terminal Ub (X-Ub) are metabolically stable. Such fusion proteins, either newly biosynthesized or generated by Ub hydrolases, are reversibly conjugated to heterogeneous target proteins in a manner similar to wild-type Ub. Most importantly, the NH2-terminal fusion partner (X) can maintain its structure and function in the formed X-Ub conjugates as inferred from the fluorescence of green fluorescent protein-Ub conjugates and the incorporation of human immunodeficiency virus type 1 Gag-Ub into viral particles. These findings strongly suggest that 26S proteasomes exhibit spatial discrimination of Ub-conjugated proteins, sparing domains extended from the NH2 terminus of Ub from unfolding and degradation. The multifunctionality of X-Ub fusion proteins opens the possibility for a number of novel practical applications, including the imaging of Ub conjugate formation in living cells.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; NCI, AIDS Vaccine Program, NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yewdell, JW (corresponding author), NIAID, Viral Dis Lab, NIH, Rm 205,Bldg 4,4 Ctr Dr, Bethesda, MD 20892 USA.		yewdell, jyewdell@nih.gov jonathan/A-1702-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000658] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anton LC, 1999, J CELL BIOL, V146, P113, DOI 10.1083/jcb.146.1.113; BACHMAIR A, 1989, CELL, V56, P1019, DOI 10.1016/0092-8674(89)90635-1; BEERS EP, 1993, J BIOL CHEM, V268, P21645; Breitschopf K, 1998, EMBO J, V17, P5964, DOI 10.1093/emboj/17.20.5964; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; FUJIMURO M, 1994, FEBS LETT, V349, P173, DOI 10.1016/0014-5793(94)00647-4; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; JOHNSON ES, 1990, NATURE, V346, P287, DOI 10.1038/346287a0; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Levy F, 1996, P NATL ACAD SCI USA, V93, P4907, DOI 10.1073/pnas.93.10.4907; Ott DE, 2000, VIROLOGY, V278, P111, DOI 10.1006/viro.2000.0648; Patnaik A, 2000, P NATL ACAD SCI USA, V97, P13069, DOI 10.1073/pnas.97.24.13069; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Porgador A, 1997, IMMUNITY, V6, P715, DOI 10.1016/S1074-7613(00)80447-1; Roth AF, 2000, J BIOL CHEM, V275, P8143, DOI 10.1074/jbc.275.11.8143; Roth AF, 1996, J CELL BIOL, V134, P661, DOI 10.1083/jcb.134.3.661; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; SOKOLIK CW, 1992, J BIOL CHEM, V267, P1067; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; TOWNSEND A, 1988, J EXP MED, V168, P1211, DOI 10.1084/jem.168.4.1211; Varshavsky A, 2000, METHOD ENZYMOL, V327, P578, DOI 10.1016/S0076-6879(00)27303-5; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Yewdell JW, 2001, TRENDS CELL BIOL, V11, P294, DOI 10.1016/S0962-8924(01)02030-X; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852	42	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38818	38826		10.1074/jbc.M205547200	http://dx.doi.org/10.1074/jbc.M205547200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163494	hybrid			2022-12-27	WOS:000178529600103
J	Rolland, JF; Henquin, JC; Gilon, P				Rolland, JF; Henquin, JC; Gilon, P			G protein-independent activation of an inward Na+ current by muscarinic receptors in mouse pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG VENTRICULAR MYOCYTES; B-CELLS; ACETYLCHOLINE-RECEPTOR; CATION CHANNELS; CALCIUM INFLUX; GLUCOSE; CA2+; SECRETION; INCREASES; CARBACHOL	Depolarization of pancreatic beta-cells is critical for stimulation of insulin secretion by acetylcholine but remains unexplained. Using voltage-clamped beta-cells, we identified a small inward current produced by acetylcholine, which was suppressed by atropine or external Na+ omission, but was not mimicked by nicotine, and was insensitive to nicotinic antagonists, tetrodotoxin, 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DiDS), thapsigargin pretreatment, and external Ca2+ and K+ removal. This suggests that muscarinic receptor stimulation activates voltage-insensitive Na+ channels distinct from store-operated channels. No outward Na+ current was produced by acetylcholine when the electrochemical Na+ gradient was reversed, indicating that the channels are inward rectifiers. No outward K+ current occurred either, and the reversal potential of the current activated by acetylcholine in the presence of Na+ and K+ was close to that expected for a Na+-selective membrane, suggesting that the channels opened by acetylcholine are specific for Na+. Overnight pretreatment with pertussis toxin or the addition of guanosine 5'-O-(3-thiotriphosphate) (GTP-gamma-S) or guanosine-5'-O-(2-thiodiphosphate) (GDP-beta-S) instead of GTP to the pipette solution did not alter this current, excluding involvement of G proteins. Injection of a current of a similar amplitude to that induced by acetylcholine elicited electrical activity in beta-cells perifused with a subthreshold glucose concentration. These results demonstrate that muscarinic receptor activation in pancreatic beta-cells triggers, by a G protein-independent mechanism, a selective Na+ current that explains the plasma membrane depolarization.	Univ Louvain, Fac Med, Unite Endocrinol & Metab, B-1200 Brussels, Belgium	Universite Catholique Louvain	Gilon, P (corresponding author), Univ Louvain, Fac Med, Unite Endocrinol & Metab, UCL 55-30,Av Hippocrate 55, B-1200 Brussels, Belgium.			Rolland, Jean-Francois/0000-0002-7420-8272				Ahren B, 2000, DIABETOLOGIA, V43, P393, DOI 10.1007/s001250051322; Aizawa T, 1998, TRENDS PHARMACOL SCI, V19, P496, DOI 10.1016/S0165-6147(98)01273-5; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; BENHAM CD, 1985, NATURE, V316, P345, DOI 10.1038/316345a0; Best L, 2000, J MEMBRANE BIOL, V177, P169, DOI 10.1007/s002320001110; BROWN LD, 1993, BRAIN RES, V612, P200, DOI 10.1016/0006-8993(93)91661-B; BRUNICARDI FC, 1987, AM J SURG, V153, P34, DOI 10.1016/0002-9610(87)90198-X; Brzostowski JA, 2001, TRENDS BIOCHEM SCI, V26, P291, DOI 10.1016/S0968-0004(01)01804-7; Carroll RC, 1998, EMBO J, V17, P3036, DOI 10.1093/emboj/17.11.3036; Eberhardson M, 2000, CELL SIGNAL, V12, P781, DOI 10.1016/S0898-6568(00)00122-4; GAGERMAN E, 1980, J PHYSIOL-LONDON, V300, P505, DOI 10.1113/jphysiol.1980.sp013175; Gilon P, 1997, J PHYSIOL-LONDON, V499, P65, DOI 10.1113/jphysiol.1997.sp021911; Gilon P, 2002, DIABETES, V51, pS144, DOI 10.2337/diabetes.51.2007.S144; Gilon P, 2001, ENDOCR REV, V22, P565, DOI 10.1210/er.22.5.565; GILON P, 1995, BIOCHEM J, V311, P259, DOI 10.1042/bj3110259; GILON P, 1993, FEBS LETT, V315, P353, DOI 10.1016/0014-5793(93)81193-4; GUERINEAU NC, 1995, J NEUROSCI, V15, P4395; HEIMBERG H, 1995, J BIOL CHEM, V270, P8971, DOI 10.1074/jbc.270.15.8971; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; HENQUIN JC, 1988, ENDOCRINOLOGY, V122, P2134, DOI 10.1210/endo-122-5-2134; HENQUIN JC, 1982, J PHYSIOL-LONDON, V332, P529, DOI 10.1113/jphysiol.1982.sp014429; HENQUIN JC, 1980, BIOCHEM J, V186, P541, DOI 10.1042/bj1860541; HERMANS MP, 1991, BIOCHIM BIOPHYS ACTA, V1092, P205, DOI 10.1016/0167-4889(91)90158-T; Heuss C, 2000, TRENDS NEUROSCI, V23, P469, DOI 10.1016/S0166-2236(00)01643-X; HOSEY MM, 1992, FASEB J, V6, P845, DOI 10.1096/fasebj.6.3.1740234; HUCHO F, 1986, EUR J BIOCHEM, V158, P211, DOI 10.1111/j.1432-1033.1986.tb09740.x; IACONO G, 1989, AM J PHYSIOL, V256, pH1407, DOI 10.1152/ajpheart.1989.256.5.H1407; INOUE M, 1995, EUR J PHARMACOL, V276, P123, DOI 10.1016/0014-2999(95)00029-K; INOUE R, 1990, AM J PHYSIOL, V258, pC1173, DOI 10.1152/ajpcell.1990.258.6.C1173; KINARD TA, 1995, DIABETES, V44, P1461, DOI 10.2337/diabetes.44.12.1461; Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MATSUMOTO K, 1989, J PHYSIOL-LONDON, V415, P487, DOI 10.1113/jphysiol.1989.sp017733; MEISSNER HP, 1990, METHOD ENZYMOL, V192, P235; Miura Y, 1996, BIOCHEM BIOPH RES CO, V224, P67, DOI 10.1006/bbrc.1996.0985; NENQUIN M, 1984, FEBS LETT, V176, P457, DOI 10.1016/0014-5793(84)81218-1; OLESEN SP, 1988, CIRC RES, V62, P1059, DOI 10.1161/01.RES.62.6.1059; PLANT TD, 1988, PFLUG ARCH EUR J PHY, V411, P429, DOI 10.1007/BF00587723; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; Rolland JF, 2002, DIABETES, V51, P376, DOI 10.2337/diabetes.51.2.376; SAHA S, 1991, EUR J PHARMACOL, V204, P211, DOI 10.1016/0014-2999(91)90707-W; Satin LS, 1998, ENDOCRINE, V8, P213, DOI 10.1385/ENDO:8:3:213; SEHLIN J, 1974, J PHYSIOL-LONDON, V242, P505, DOI 10.1113/jphysiol.1974.sp010720; Sehlin J, 1978, AM J PHYSIOL, V235, P501; Seino S, 2000, DIABETES, V49, P311, DOI 10.2337/diabetes.49.3.311; SHIRAYAMA T, 1993, J PHARMACOL EXP THER, V265, P641; TEPEL M, 1994, BBA-MOL CELL RES, V1220, P248, DOI 10.1016/0167-4889(94)90145-7; WESS J, 1995, LIFE SCI, V56, P915, DOI 10.1016/0024-3205(95)00028-5; WORLEY JF, 1994, J BIOL CHEM, V269, P32055	49	29	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38373	38380		10.1074/jbc.M203888200	http://dx.doi.org/10.1074/jbc.M203888200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161432	hybrid			2022-12-27	WOS:000178529600050
J	Tam, EM; Wu, YI; Butler, GS; Stack, MS; Overall, CM				Tam, EM; Wu, YI; Butler, GS; Stack, MS; Overall, CM			Collagen binding properties of the membrane type-1 matrix metalloproteinase (MT1-MMP) hemopexin C domain - The ectodomain of the 44-kDa autocatalytic product of MT1-MMP inhibits cell invasion by disrupting native type I collagen cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUTROPHIL COLLAGENASE; GELATINASE-A ACTIVATION; TISSUE INHIBITOR; FIBROBLAST COLLAGENASE; SUBSTRATE-SPECIFICITY; EXTRACELLULAR-MATRIX; TERMINAL DOMAIN; 1-MATRIX METALLOPROTEINASE; 72-KDA GELATINASE; COMPLEX-FORMATION	Up-regulation of the collagenolytic membrane type-1 matrix metalloproteinase (MT1-AMP) leads to increased MMP2 (gelatinase A) activation and MT1-MMP autolysis. The autocatalytic degradation product is a cell surface 44-kDa fragment of MT1-MMP (Gky(285)-Val(582)) in which the ectodomain consists of only the linker, hemopexin C domain and the stalk segment found before the transmembrane sequence. In the collagenases, hemopexin C domain exosites bind native collagen, which is required for triple helicase activity during collagen cleavage. Here we investigated the collagen binding properties and the role of the hemopexin C domain of MT1-MMP and of the 44-kDa MT1-MMP ectodomain in collagenolysis. Recombinant proteins, MT1-LCD (Gly(285)-Cys(508)), consisting of the linker and the hemopexin C domain, and MT1-CD (Gly(315)-Cys(508)), which consists of the hemopexin C domain only, were found to bind native type I collagen but not gelatin. Functionally, MT1-LCD inhibited collagen-induced MMP2 activation in fibroblasts, suggesting that interactions between collagen and endogenous MT1-MMP directly stimulate the cellular activation of pro-MMP2. MT1-LCD, but not MT1-CD, also blocked the cleavage of native type I collagen by MT1-MMP in vitro, indicating an important role for the MT1-MMP linker region in triple helicase activity. Similarly, soluble MT1-LCD, but not MT1-CD or peptide analogs of the MT1-AMP linker, reduced the invasion of type I collagen matrices by NDA-MB-231 cells as did the expression of recombinant 44-kDa MT1-MMP on the cell surface. Together, these studies demonstrate that generation of the 44-kDa MT1-MMP autolysis product regulates collagenolytic activity and subsequent invasive potential, suggesting a novel feedback mechanism for the control of pericellular proteolysis.	Univ British Columbia, Dept Biochem & Mol Biol, CIHR Grp Matrix Dynam, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Oral Biol & Med Sci, CIHR Grp Matrix Dynam, Vancouver, BC V6T 1Z3, Canada; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	University of British Columbia; University of British Columbia; Northwestern University	Overall, CM (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, CIHR Grp Matrix Dynam, 2199 Wesbrook Mall,JB Macdonald Bldg, Vancouver, BC V6T 1Z3, Canada.	chris.overall@ubc.ca	Butler, Georgina/GQP-7553-2022	Butler, Georgina/0000-0003-1172-1578				AIMES RT, 1995, J BIOL CHEM, V270, P5872, DOI 10.1074/jbc.270.11.5872; ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; ALLAN JA, 1991, J CELL SCI, V99, P789; Aznavoorian S, 2001, CANCER RES, V61, P6264; AZZAM HS, 1992, CANCER RES, V52, P4540; Belien ATJ, 1999, J CELL BIOL, V144, P373, DOI 10.1083/jcb.144.2.373; Bigg HF, 2001, CANCER RES, V61, P3610; Brandstetter H, 2001, J BIOL CHEM, V276, P17405, DOI 10.1074/jbc.M007475200; Butler GS, 1998, J BIOL CHEM, V273, P871, DOI 10.1074/jbc.273.2.871; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; CLARK IM, 1989, BIOCHEM J, V263, P201, DOI 10.1042/bj2630201; Cowell S, 1998, BIOCHEM J, V331, P453, DOI 10.1042/bj3310453; d'Ortho MP, 1997, EUR J BIOCHEM, V250, P751, DOI 10.1111/j.1432-1033.1997.00751.x; DESOUZA SJ, 1992, J BIOL CHEM, V267, P13763; DeSouza SJ, 1996, FASEB J, V10, P927, DOI 10.1096/fasebj.10.8.8666171; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Ellerbroek SM, 1999, BIOESSAYS, V21, P940, DOI 10.1002/(SICI)1521-1878(199911)21:11<940::AID-BIES6>3.3.CO;2-A; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; Fishman DA, 2001, CANCER RES, V61, P3194; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; Galvez BG, 2001, J BIOL CHEM, V276, P37491, DOI 10.1074/jbc.M104094200; Gilles C, 1997, LAB INVEST, V76, P651; Gilles C, 1998, CANCER RES, V58, P5529; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kinoshita T, 1998, J BIOL CHEM, V273, P16098, DOI 10.1074/jbc.273.26.16098; Knauper V, 1997, FEBS LETT, V405, P60, DOI 10.1016/S0014-5793(97)00158-0; KNAUPER V, 1993, BIOCHEM J, V291, P847; Knauper V, 1997, J BIOL CHEM, V272, P7608, DOI 10.1074/jbc.272.12.7608; Knauper V, 2001, EUR J BIOCHEM, V268, P1888, DOI 10.1046/j.1432-1033.2001.02062.x; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; LI J, 1995, STRUCTURE, V3, P541, DOI 10.1016/S0969-2126(01)00188-5; Mancini S, 1999, J PERIODONTOL, V70, P1292, DOI 10.1902/jop.1999.70.11.1292; Martignetti JA, 2001, NAT GENET, V28, P261, DOI 10.1038/90100; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Nabeshima K, 2000, CANCER RES, V60, P3364; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Overall CM, 2000, METH MOL B, V151, P79, DOI 10.1385/1-59259-046-2:079; OVERALL CM, 1990, J BIOL CHEM, V265, P21141; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; OVERALL CM, 1987, J DENT RES, V66, P1271, DOI 10.1177/00220345870660071201; OVERALL CM, 1988, BIOL MECH TOOTH ERUP, P303; Patterson ML, 2001, FEBS LETT, V503, P158, DOI 10.1016/S0014-5793(01)02723-5; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; Ruangpanit N, 2001, MATRIX BIOL, V20, P193, DOI 10.1016/S0945-053X(01)00135-4; Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SELTZER JL, 1994, EXP CELL RES, V213, P365, DOI 10.1006/excr.1994.1211; Sodek J, 1992, Matrix Suppl, V1, P352; Stanton H, 1998, J CELL SCI, V111, P2789; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; Steffensen B, 1998, J BIOL CHEM, V273, P20622, DOI 10.1074/jbc.273.32.20622; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TAKINO T, 1995, GENE, V155, P293, DOI 10.1016/0378-1119(94)00637-8; Tomasek JJ, 1997, J BIOL CHEM, V272, P7482, DOI 10.1074/jbc.272.11.7482; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Turner AJ, 2001, BIOESSAYS, V23, P261, DOI 10.1002/1521-1878(200103)23:3<261::AID-BIES1036>3.0.CO;2-K; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; WELGUS HG, 1980, J BIOL CHEM, V255, P6806; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WINDSOR LJ, 1991, BIOCHEMISTRY-US, V30, P641, DOI 10.1021/bi00217a008; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197	81	119	122	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					39005	39014		10.1074/jbc.M206874200	http://dx.doi.org/10.1074/jbc.M206874200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145314	hybrid			2022-12-27	WOS:000178529600125
J	Ueda, T; Mawji, NR; Bruchovsky, N; Sadar, MD				Ueda, T; Mawji, NR; Bruchovsky, N; Sadar, MD			Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTIONAL ACTIVATION; N-TERMINAL DOMAIN; GROWTH-FACTOR-I; PROGESTERONE-RECEPTOR; ESTROGEN-RECEPTOR; GENE-EXPRESSION; KINASE; BINDING; INDUCTION; PHOSPHORYLATION	The androgen receptor (AR) can be activated in the absence of androgens by interleukin-6 (IL-6) in human prostate cancer cells. The events involved in ligand-independent activation of the AR are unknown, but have been suggested to involve phosphorylation of the AR itself or a receptor-associated protein. Steroid receptor coactivator-1 (SRC-1) has been shown to interact with the human AR and to modulate ligand-dependent AR transactivation and is regulated by phosphorylation by MAPK. To date, no one has examined the role of SRC-1 in ligand-independent activation of the AR by IL-6 or other signaling pathways known to activate the full-length receptor. This study addressed this and has revealed the following. 1) SRC-1 similarly enhanced ligand-independent activation of the AR by IL-6 to the same magnitude as that obtained via ligand-dependent activation. 2) Androgen and IL-6 stimulated the MAPK pathway. 3) MAPK was required for both ligand-dependent and ligand-independent activation of the AR. 4) Phosphorylation of SRC-1 by MAPK was required for optimal ligand-independent activation of the AR by IL-6. 5) Protein-protein interaction between endogenous AR and SRC-1 was dependent upon treatment of LNCaP cells with IL-6 or R1881. 6) Protein-protein interaction between the AR N-terminal domain and SRC-1 was independent of MAPK. 7) Ligand-independent activation of the AR did not occur by a mechanism of overexpression of either solely wild-type SRC-1 or mutant SRC-1 that mimics its phosphorylated form.	British Columbia Canc Agcy, Dept Canc Endocrinol, Vancouver, BC V5Z 4E6, Canada	British Columbia Cancer Agency	Sadar, MD (corresponding author), British Columbia Canc Agcy, Dept Canc Endocrinol, 600 W 10th Ave, Vancouver, BC V5Z 4E6, Canada.	msadar@bccancer.bc.ca	Sadar, Marianne/E-9136-2012	Sadar, Marianne/0000-0003-0599-9215	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047656] Funding Source: NIH RePORTER; NIDDK NIH HHS [P50 DK47656] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu-Martin MT, 1999, MOL CELL BIOL, V19, P5143; Adler HL, 1999, J UROLOGY, V161, P182, DOI 10.1016/S0022-5347(01)62092-5; ARONICA SM, 1991, ENDOCRINOLOGY, V128, P2045, DOI 10.1210/endo-128-4-2045; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; BORSELLINO N, 1995, CANCER RES, V55, P4633; Borsellino N, 1999, CANCER, V85, P134, DOI 10.1002/(SICI)1097-0142(19990101)85:1<134::AID-CNCR19>3.0.CO;2-C; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brady ME, 1999, J BIOL CHEM, V274, P17599, DOI 10.1074/jbc.274.25.17599; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; Chen TS, 2000, CANCER RES, V60, P2132; Chung TDK, 1999, PROSTATE, V38, P199; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P148, DOI 10.1210/me.11.2.148; CULIG Z, 1994, CANCER RES, V54, P5474; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Drachenberg DE, 1999, PROSTATE, V41, P127, DOI 10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H; Fujimoto N, 2001, UROLOGY, V58, P289, DOI 10.1016/S0090-4295(01)01117-7; Gioeli D, 1999, CANCER RES, V59, P279; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2001, CANCER RES, V61, P4315; HAQ M, 1992, CANCER RES, V52, P4613; He B, 2001, J BIOL CHEM, V276, P42293, DOI 10.1074/jbc.M107492200; Hobisch A, 2000, J PATHOL, V191, P239, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH633>3.0.CO;2-X; Hobisch A, 1998, CANCER RES, V58, P4640; HOBISCH A, 1995, CANCER RES, V55, P3068; Hoosein N, 1995, Urol Oncol, V1, P246, DOI 10.1016/1078-1439(96)00012-9; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; KUIL CW, 1995, J BIOL CHEM, V270, P27569, DOI 10.1074/jbc.270.46.27569; Lou W, 2000, PROSTATE, V42, P239, DOI 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G; Ma H, 1999, MOL CELL BIOL, V19, P6164; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; NEWTON CJ, 1994, J STEROID BIOCHEM, V48, P481, DOI 10.1016/0960-0760(94)90197-X; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Okamoto M, 1997, ENDOCRINOLOGY, V138, P5071, DOI 10.1210/en.138.11.5071; ONATE SA, 1995, SCIENCE, V270, P1354; Peterziel H, 1999, ONCOGENE, V18, P6322, DOI 10.1038/sj.onc.1203032; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; RUNDLETT SE, 1990, MOL ENDOCRINOL, V4, P708, DOI 10.1210/mend-4-5-708; Sadar MD, 1999, ENDOCR-RELAT CANCER, V6, P487, DOI 10.1677/erc.0.0060487; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Sadar MD, 1996, J BIOL CHEM, V271, P17635, DOI 10.1074/jbc.271.30.17635; SIEGSMUND MJ, 1994, CANCER RES, V50, P7786; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Snoek R, 1996, J STEROID BIOCHEM, V59, P243, DOI 10.1016/S0960-0760(96)00116-1; TURGEON JL, 1994, MOL ENDOCRINOL, V8, P860, DOI 10.1210/me.8.7.860; TWILLIE DA, 1995, UROLOGY, V45, P542, DOI 10.1016/S0090-4295(99)80034-X; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; WILSON EM, 1976, J BIOL CHEM, V251, P5620; ZHOU ZX, 1995, MOL ENDOCRINOL, V9, P208, DOI 10.1210/me.9.2.208; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	54	232	251	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38087	38094		10.1074/jbc.M203313200	http://dx.doi.org/10.1074/jbc.M203313200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163482	hybrid			2022-12-27	WOS:000178529600016
J	White, AK; Metcalf, WW				White, AK; Metcalf, WW			Isolation and biochemical characterization of hypophosphite/2-oxoglutarate dioxygenase - A novel phosphorus-oxidizing enzyme from Pseudomonas Stutzeri WM88	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; PROLYL 4-HYDROXYLASE ACTIVITY; ISOPENICILLIN-N SYNTHASE; ESCHERICHIA-COLI; KETOGLUTARATE DIOXYGENASE; DEPENDENT DIOXYGENASE; PROLINE 4-HYDROXYLASE; ENDOGENOUS LIGANDS; HISTIDINE-RESIDUES; CATALYTIC ACTIVITY	The htxA gene is required for the oxidation of hypophosphite in Pseudomonas stutzeri WM88 (Metcalf, W. W., and Wolfe, R. S. (1998) J. Bacteriol. 180, 5547-5558). Amino acid sequence comparisons suggest that hypophosphite:2-oxoglutarate dioxygenase (HtxA) is a novel member of the 2-oxoglutarate-dependent dioxygenase enzyme family. To provide experimental support for this hypothesis, HtxA was overproduced in Escherichia coli and purified to apparent homogeneity. Recombinant HtxA is identical to the native enzyme based on amino terminus sequencing and mass spectral analysis, and it catalyzes the oxidation of hypophosphite to phosphite in a process strictly dependent on 2-oxoglutarate, ferrous ions, and oxygen. Succinate and phosphite are stoichiometrically produced, indicating a strict coupling of the reaction. Size exclusion analysis suggests that HtxA is active as a homodimer, and maximal activity is observed at pH 7.0 and at 27 degreesC. The apparent K-m values for hypophosphite and 2-oxoglutarate were 0.58 +/- 0.04 mm and 10.6 +/- 1.4 muM, respectively. V-max and k(cat) values were determined to be 10.9 +/- 0.30 mumol min(-1) mg(-1) and 355 min(-1), respectively. 2-Oxoadipate and pyruvate substitute poorly for 2-oxoglutarate as a cosubstrate. The highest specific activity is observed with hypophosphite as substrate, but HtxA is also able to oxidize formate and arsenite at significant rates. The substrate analog inhibitors, formate and nitrate, significantly reduce HtxA activity.	Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Metcalf, WW (corresponding author), Univ Illinois, Dept Microbiol, Chem & Life Sci Lab B103, 601 S Goodwin Ave, Urbana, IL 61801 USA.				NCRR NIH HHS [RR 11966] Funding Source: Medline; NIGMS NIH HHS [GM59334] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR011966] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059334] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS F, 1953, SOIL SCI, V75, P361, DOI 10.1097/00010694-195305000-00004; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BLANCHARD JS, 1983, BIOCHEMISTRY-US, V22, P5922, DOI 10.1021/bi00294a036; Borovok I, 1996, BIOCHEMISTRY-US, V35, P1981, DOI 10.1021/bi951534t; CASIDA LE, 1960, J BACTERIOL, V80, P237, DOI 10.1128/JB.80.2.237-241.1960; Costas AMG, 2001, J BIOL CHEM, V276, P17429, DOI 10.1074/jbc.M011764200; DECAROLIS E, 1994, PHYTOCHEMISTRY, V36, P1093, DOI 10.1016/S0031-9422(00)89621-1; DEJONG L, 1982, BIOCHIM BIOPHYS ACTA, V704, P326, DOI 10.1016/0167-4838(82)90162-5; DEVAI I, 1988, NATURE, V333, P343, DOI 10.1038/333343a0; Eichhorn E, 1997, J BIOL CHEM, V272, P23031, DOI 10.1074/jbc.272.37.23031; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FOSTER TL, 1978, APPL ENVIRON MICROB, V35, P937, DOI 10.1128/AEM.35.5.937-944.1978; FUKUMORI F, 1993, J BIOL CHEM, V268, P24311; FUKUMORI F, 1993, J BACTERIOL, V175, P2083, DOI 10.1128/JB.175.7.2083-2086.1993; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; HANAUSKEABEL HM, 1982, J THEOR BIOL, V94, P421, DOI 10.1016/0022-5193(82)90320-4; Hegg EL, 1999, BIOCHEMISTRY-US, V38, P16714, DOI 10.1021/bi991796l; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; HEINEN W, 1974, ARCH MICROBIOL, V95, P267, DOI 10.1007/BF02451767; Hogan DA, 1999, J BACTERIOL, V181, P5876, DOI 10.1128/JB.181.18.5876-5879.1999; Hogan DA, 2000, J BIOL CHEM, V275, P12400, DOI 10.1074/jbc.275.17.12400; HOPPER S, 1994, J BIOL CHEM, V269, P19597; Imazu K, 1998, APPL ENVIRON MICROB, V64, P3754; Kahnert A, 2000, J BIOL CHEM, V275, P31661, DOI 10.1074/jbc.M005820200; KENNEDY KE, 1970, SCIENCE, V168, P989, DOI 10.1126/science.168.3934.989; Khaleeli N, 2000, BIOCHEMISTRY-US, V39, P8666, DOI 10.1021/bi000534c; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMBERG A, 1995, J BIOL CHEM, V270, P9926, DOI 10.1074/jbc.270.17.9926; Larsen RA, 2002, ARCH MICROBIOL, V178, P193, DOI 10.1007/s00203-002-0442-2; LAUWERS AM, 1977, ARCH MICROBIOL, V112, P103, DOI 10.1007/BF00446661; Lawrence CC, 1996, BIOCHEM J, V313, P185, DOI 10.1042/bj3130185; Lukacin R, 1997, EUR J BIOCHEM, V249, P748, DOI 10.1111/j.1432-1033.1997.t01-2-00748.x; MAKINO K, 1986, J MOL BIOL, V192, P549, DOI 10.1016/0022-2836(86)90275-5; MALACINS.GM, 1967, J BACTERIOL, V93, P1906, DOI 10.1128/JB.93.6.1906-1910.1967; MALACINSKI G, 1966, J BACTERIOL, V91, P578, DOI 10.1128/JB.91.2.578-582.1966; METCALF WW, 1991, J BACTERIOL, V173, P587, DOI 10.1128/jb.173.2.587-600.1991; Metcalf WW, 1996, PLASMID, V35, P1, DOI 10.1006/plas.1996.0001; Metcalf WW, 1998, J BACTERIOL, V180, P5547, DOI 10.1128/JB.180.21.5547-5558.1998; MYLLYLA R, 1978, BIOCHEM BIOPH RES CO, V83, P441, DOI 10.1016/0006-291X(78)91010-0; NIETFELD JJ, 1981, BIOCHIM BIOPHYS ACTA, V657, P159, DOI 10.1016/0005-2744(81)90139-X; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; PLAGA W, 1988, EUR J BIOCHEM, V178, P445, DOI 10.1111/j.1432-1033.1988.tb14468.x; Prescott AG, 2000, NAT PROD REP, V17, P367, DOI 10.1039/a902197c; Que L, 1996, CHEM REV, V96, P2607, DOI 10.1021/cr960039f; Roach PL, 1997, NATURE, V387, P827, DOI 10.1038/42990; Shibasaki T, 1999, APPL ENVIRON MICROB, V65, P4028; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SZMELCMAN S, 1976, EUR J BIOCHEM, V65, P13, DOI 10.1111/j.1432-1033.1976.tb10383.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSUBOTA G., 1959, Soil and Plant Food, V5, P10; Valegard K, 1998, NATURE, V394, P805, DOI 10.1038/29575; Vrtis JM, 2001, J AM CHEM SOC, V123, P2672, DOI 10.1021/ja004301k; WANNER BL, 1986, J MOL BIOL, V191, P39, DOI 10.1016/0022-2836(86)90421-3	55	23	24	3	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38262	38271		10.1074/jbc.M204605200	http://dx.doi.org/10.1074/jbc.M204605200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161433	hybrid			2022-12-27	WOS:000178529600037
J	Javelaud, D; Besancon, F				Javelaud, D; Besancon, F			Inactivation of p21(WAF1) sensitizes cells to apoptosis via an increase of both p14(ARF) and p53 levels and an alteration of the Bax/Bcl-2 ratio	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HUMAN CANCER-CELLS; INHIBITORY ACTIVITY; THERAPEUTIC AGENTS; TUMOR SUPPRESSION; CARCINOMA CELLS; GROWTH ARREST; P21; DIFFERENTIATION; SURVIVAL	p21(WAF1) appears to be a major determinant of the cell fate in response to anticancer therapy. It was shown previously that HCT116 human colon cancer cells growing in vitro enter a stable arrest upon DNA damage, whereas cells with a defective p21(WAF1) response undergo apoptosis. Here we report that the enhanced sensitivity of HCT116/p21(-/-) cells to chemotherapeutic drug-induced apoptosis correlates with an increased expression of p53 and a modification of their Bax/Bcl-2 ratio in favor of the pro-apoptotic protein Bax. Treatment of HCT116/p21(-/-) cells with daunomycin resulted in a reduction of the mitochondrial membrane potential and in activation of caspase-9, whereas no such changes were observed in HCT116/p21(+/+) cells, providing evidence that p21(WAF1) exerts an antagonistic effect on the mitochondrial pathway of apoptosis. Moreover, the role of p53 in activation of this pathway was demonstrated by the fact that inhibition of p53 activity by pifithrin-a reduced the sensitivity of HCT116/p21(-/-) cells to daunomycin-induced apoptosis and restored a Bax/Bcl-2 ratio similar to that observed in HCT116p21(-/-) cells. Enhancement of p53 expression after disruption of p21(WAF1) resulted from a stabilization of p53, which correlated with an increased expression of the tumor suppressor p14(ARF), an inhibitor of the ubiquitin ligase activity of Mdm2. In accordance with the role of p14ARF in p53 stabilization, overexpression of p14(ARF) in HCT116/p21(+/+) cells resulted in a strong increase in p53 activity. Our results identify a novel mechanism for the antiapoptotic effect of p21(WAF1) consisting in maintenance of mitochondrial homeostasis that occurs in consequence of a negative control of p14(ARF) expression.	Inst Curie, INSERM, U365, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Besancon, F (corresponding author), Inst Curie, INSERM, U365, 26 Rue Ulm, F-75248 Paris 05, France.		Javelaud, Delphine/B-1129-2019	Javelaud, Delphine/0000-0002-7674-7739				Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; Esteller M, 2000, CANCER RES, V60, P129; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Grad JM, 2001, DRUG RESIST UPDATE, V4, P85, DOI 10.1054/drup.2001.0192; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HARPER JW, 1993, CELL, V75, P805; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Javelaud D, 2000, ONCOGENE, V19, P61, DOI 10.1038/sj.onc.1203246; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Lu YJ, 1998, ONCOGENE, V16, P705, DOI 10.1038/sj.onc.1201585; Mahyar-Roemer M, 2001, ONCOGENE, V20, P3387, DOI 10.1038/sj.onc.1204440; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pennington KN, 2001, MOL CELL BIOL, V21, P1930, DOI 10.1128/MCB.21.6.1930-1941.2001; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SIONOV RV, 2001, MOL CELL BIOL, V274, P8371; Suliman A, 2001, ONCOGENE, V20, P2122, DOI 10.1038/sj.onc.1204282; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Tian H, 2000, CANCER RES, V60, P679; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Walczak H, 2000, CANCER RES, V60, P3051; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang XD, 2001, GENE DEV, V15, P2922; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	48	107	114	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37949	37954		10.1074/jbc.M204497200	http://dx.doi.org/10.1074/jbc.M204497200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151395	hybrid			2022-12-27	WOS:000178447100132
J	Meng, WY; Swenson, LL; Fitzgibbon, MJ; Hayakawa, K; ter Haar, E; Behrens, AE; Fulghum, JR; Lippke, JA				Meng, WY; Swenson, LL; Fitzgibbon, MJ; Hayakawa, K; ter Haar, E; Behrens, AE; Fulghum, JR; Lippke, JA			Structure of mitogen-activated protein kinase-activated protein (MAPKAP) kinase 2 suggests a bifunctional switch that couples kinase activation with nuclear export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; SUBSTRATE; DOMAIN; SIGNAL; PHOSPHORYLATION; IDENTIFICATION; SPECIFICITY; PATHWAY; BINDING	MAPK-activated protein kinase 2 (MAPKAPK2), one of several kinases directly phosphorylated and activated by p38 MAPK, plays a central role in the inflammatory response. The activated MAPKAPK2 phosphorylates its nuclear targets CREB/ATF1, serum response factor, and E2A protein E47 and its cytoplasmic targets HSP25/27, LSP-1, 5-lipoxygenase, glycogen synthase, and tyrosine hydroxylase. The crystal structure of unphosphorylated MAPKAPK2, determined at 2.8 Angstrom resolution, includes the kinase domain and the C-terminal regulatory domain. Although the protein is inactive, the kinase domain adopts an active conformation with aspartate 366 mimicking the missing phosphorylated threonine 222 in the activation loop. The C-terminal regulatory domain forms a helix-turn-helix plus a long strand. Phosphorylation of threonine 334, which is located between the kinase domain and the C-terminal regulatory domain, may serve as a switch for MAPKAPK2 nuclear import and export. Phosphorylated MAPKAPK2 masks the nuclear localization signal at its C terminus by binding to p38. It unmasks the nuclear export signal, which is part of the second C-terminal helix packed along the surface of kinase domain Globe, and thereby carries p38 to the cytoplasm.	Vertex Pharmaceut Inc, Cambridge, MA 02139 USA	Vertex Pharmaceuticals	Meng, WY (corresponding author), Vertex Pharmaceut Inc, 130 Waverly St, Cambridge, MA 02139 USA.	wuyi_meng@vpharm.com						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; BENLEVY R, 1995, EMBO J, V14, P5920, DOI 10.1002/j.1460-2075.1995.tb00280.x; Bilsland-Marchesan E, 2000, MOL CELL BIOL, V20, P3887, DOI 10.1128/MCB.20.11.3887-3895.2000; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; Huang CK, 1997, J BIOL CHEM, V272, P17, DOI 10.1074/jbc.272.1.17; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; MEANS AR, 1991, MOL CELL BIOL, V11, P3960, DOI 10.1128/MCB.11.8.3960; Neufeld B, 2000, J BIOL CHEM, V275, P20239, DOI 10.1074/jbc.C901040199; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; PLATH K, 1994, BIOCHEM BIOPH RES CO, V203, P1188, DOI 10.1006/bbrc.1994.2308; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; STOKOE D, 1993, BIOCHEM J, V296, P843, DOI 10.1042/bj2960843; STOKOE D, 1992, EMBO J, V11, P3985, DOI 10.1002/j.1460-2075.1992.tb05492.x; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; SUTHERLAND C, 1993, EUR J BIOCHEM, V217, P715, DOI 10.1111/j.1432-1033.1993.tb18297.x; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; ZU YL, 1994, BIOCHEM BIOPH RES CO, V200, P1118, DOI 10.1006/bbrc.1994.1566; ZU YL, 1995, J BIOL CHEM, V270, P202, DOI 10.1074/jbc.270.1.202	30	98	110	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37401	37405		10.1074/jbc.C200418200	http://dx.doi.org/10.1074/jbc.C200418200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12171911	hybrid			2022-12-27	WOS:000178447100063
J	Norwitz, ER; Xu, SY; Xu, J; Spiryda, LB; Park, JS; Jeong, KH; McGee, EA; Kaiser, UB				Norwitz, ER; Xu, SY; Xu, J; Spiryda, LB; Park, JS; Jeong, KH; McGee, EA; Kaiser, UB			Direct binding of AP-1 (Fos/Jun) proteins to a SMAD binding element facilitates both gonadotropin-releasing hormone (GnRH)- and activin-mediated transcriptional activation of the mouse GnRH receptor gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAYS; GROWTH-FACTOR-BETA; RAT PITUITARY; TRANSGENIC MICE; EXPRESSION; PROMOTER; FOLLISTATIN; INHIBIN; CELLS; ALPHA	The response of pituitary gonadotropes to gonadotropin-releasing hormone (GnRH) correlates directly with the concentration of GnRH receptors (GnRHR) on the cell surface, which is mediated in part at the level of gene expression. Several factors are known to affect expression of the mouse GnRHR (mGnRHR) gene, including GnRH and activin. We have previously shown that activin augments GnRH-mediated transcriptional activation of mGnRHR gene, and that region -387/-308 appears to be necessary to mediate this effect. This region contains two overlapping cis-regulatory elements of interest: GnRHR activating sequence (GRAS) and a putative SALAD-binding element (SBE). This study investigates the role of these elements and their cognate transcription factors in transactivation of the mGnRHR gene. Transfection studies confirm the presence of GnRH- and activin-response elements within -387/-308 of mGnRHR gene promoter. Competition electrophoretic mobility shift assay experiments using -335/-312 as probe and alphaT3-1 nuclear extract or SMAD, Jun, and Fos proteins demonstrate direct binding of AP-1 (Fos/Jun) protein complexes to -327/-322 and SALAD proteins to -329/-328. Further transfection studies using mutant constructs of these cis-regulatory elements confirm that both are functionally important. These data define a novel cis-regulatory element comprised of an overlapping SBE and newly characterized non-consensus AP-1 binding sequence that integrates the stimulatory transcriptional effects of both GnRH and activin on the mGnRHR gene.	Harvard Univ, Brigham & Womens Hosp,Sch Med, Dept Obstet Gynecol & Reprod Biol, Div Maternal Fetal Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp,Sch Med, Dept Med, Boston, MA 02115 USA; Magee Womens Res Inst, Dept Obstet & Gynecol, Pittsburgh, PA 15213 USA; Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul 110744, South Korea	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Seoul National University (SNU)	Norwitz, ER (corresponding author), Harvard Univ, Brigham & Womens Hosp,Sch Med, Dept Obstet Gynecol & Reprod Biol, Div Maternal Fetal Med, 75 Francis St, Boston, MA 02115 USA.		Park, Joong Shin/D-5741-2012	Park, Joong Shin/0000-0002-5246-0477	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD019938, R37HD019938] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K12HD001255] Funding Source: NIH RePORTER; NICHD NIH HHS [R01-HD19938, K12-HD00840, K12-HD01255] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Albarracin CT, 1999, ENDOCRINOLOGY, V140, P2415, DOI 10.1210/en.140.5.2415; ALBARRACIN CT, 1994, ENDOCRINOLOGY, V135, P2300, DOI 10.1210/en.135.6.2300; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ATTARDI B, 1995, MOL ENDOCRINOL, V9, P1737, DOI 10.1210/me.9.12.1737; Attisano L, 1996, MOL CELL BIOL, V16, P1066; Blumenfeld Z, 2001, ANN NY ACAD SCI, V943, P34, DOI 10.1111/j.1749-6632.2001.tb03788.x; CASEY JL, 1988, NUCLEIC ACIDS RES, V16, P629, DOI 10.1093/nar/16.2.629; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; CHONG T, 1990, NUCLEIC ACIDS RES, V18, P465, DOI 10.1093/nar/18.3.465; CLAYTON RN, 1989, J ENDOCRINOL, V120, P11, DOI 10.1677/joe.0.1200011; CORRIGAN AZ, 1991, ENDOCRINOLOGY, V128, P1682, DOI 10.1210/endo-128-3-1682; DEPAOLO LV, 1992, ENDOCRINOLOGY, V130, P1741, DOI 10.1210/en.130.3.1741; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; Drouin J, 1998, MOL CELL ENDOCRINOL, V140, P31, DOI 10.1016/S0303-7207(98)00026-4; Duval DL, 1999, ENDOCRINOLOGY, V140, P1949, DOI 10.1210/en.140.4.1949; Duval DL, 1997, MOL ENDOCRINOL, V11, P1814, DOI 10.1210/me.11.12.1814; ESCUDERO KW, 2002, 84 ANN M END SOC END, pR1; FernandezVazquez G, 1996, MOL ENDOCRINOL, V10, P356, DOI 10.1210/me.10.4.356; FISCH TM, 1989, MOL CELL BIOL, V9, P1327, DOI 10.1128/MCB.9.3.1327; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; Halvorson LM, 1996, FERTIL STERIL, V65, P459; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; JAIN J, 1992, J IMMUNOL, V148, P1240; KAISER UB, 1992, ENDOCRINOLOGY, V130, P3048, DOI 10.1210/en.130.5.3048; KAISER UB, 1993, ENDOCRINOLOGY, V133, P931, DOI 10.1210/en.133.2.931; KAISER UB, 1992, BIOCHEM BIOPH RES CO, V189, P1645, DOI 10.1016/0006-291X(92)90266-N; KATT JA, 1985, ENDOCRINOLOGY, V116, P2113, DOI 10.1210/endo-116-5-2113; KIM SJ, 1989, J BIOL CHEM, V264, P19373; KUSHNER PJ, 1994, MOL ENDOCRINOL, V8, P405, DOI 10.1210/me.8.4.405; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MARIAN J, 1981, MOL PHARMACOL, V19, P399; McCue JM, 1997, ENDOCRINOLOGY, V138, P3154, DOI 10.1210/en.138.8.3154; Mercer JE, 1995, HUM REPROD UPDATE, V1, P363, DOI 10.1093/humupd/1.4.363; MEUNIER H, 1988, P NATL ACAD SCI USA, V85, P247, DOI 10.1073/pnas.85.1.247; MICHEL U, 1993, MOL CELL ENDOCRINOL, V91, P1, DOI 10.1016/0303-7207(93)90248-I; Norwitz ER, 2002, ENDOCRINOLOGY, V143, P985, DOI 10.1210/en.143.3.985; Norwitz ER, 1999, J BIOL CHEM, V274, P867, DOI 10.1074/jbc.274.2.867; PAPAVASILIOU SS, 1986, P NATL ACAD SCI USA, V83, P4026, DOI 10.1073/pnas.83.11.4026; Pernasetti F, 2001, ENDOCRINOLOGY, V142, P2284, DOI 10.1210/en.142.6.2284; PERRIN MH, 1993, BIOCHEM BIOPH RES CO, V191, P1139, DOI 10.1006/bbrc.1993.1335; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; STOJILKOVIC SS, 1995, RECENT PROG HORM RES, V50, P161; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; White BR, 1999, MOL ENDOCRINOL, V13, P566, DOI 10.1210/me.13.4.566; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; Wong C, 1999, MOL CELL BIOL, V19, P1821; Wurthner JU, 2001, J BIOL CHEM, V276, P19495, DOI 10.1074/jbc.M006473200; Xu J, 2002, BIOL REPROD, V66, P1571, DOI 10.1095/biolreprod66.6.1571; YASIN M, 1995, ENDOCRINOLOGY, V136, P1559, DOI 10.1210/en.136.4.1559; Yeo CY, 1999, J BIOL CHEM, V274, P26584, DOI 10.1074/jbc.274.37.26584; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; ZHOU W, 1994, DNA CELL BIOL, V13, P605, DOI 10.1089/dna.1994.13.605	55	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37469	37478		10.1074/jbc.M206571200	http://dx.doi.org/10.1074/jbc.M206571200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145309	hybrid			2022-12-27	WOS:000178447100072
J	Watson, JD; Oster, SK; Shago, M; Khosravi, F; Penn, LZ				Watson, JD; Oster, SK; Shago, M; Khosravi, F; Penn, LZ			Identifying genes regulated in a Myc-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC; RIBOSOME BIOGENESIS; MYC/MAX/MAD NETWORK; ESSENTIAL COFACTOR; BETA-RECEPTOR; CELL-CYCLE; E-BOX; EXPRESSION; TARGET; TRANSCRIPTION	The c-myc proto-oncogene can direct a diverse array of biological activities, including cell cycle progression, apoptosis, and differentiation. It is believed that Myc can affect this wide variety of activities by functioning as a regulator of gene transcription, although few targets have been identified to date. To delineate the molecular program regulated downstream of Myc, we used a cDNA microarray approach and identified 52 putative targets out of >6000 cDNAs analyzed. To further distinguish the subset of genes whose regulation was dependent upon Myc per se from those regulated in response to activation of general mitogenic or apoptotic programs, the putative cDNA targets were then screened by a series of assays. By this approach 37 putative targets were ruled out and 15 Myc target genes were uncovered. Interestingly, comparing our results with other high throughput screens reveals that certain putative Myc targets previously reported are shown not to be regulated downstream of Myc (e.g. ribosomal proteins, HSP90beta), whereas others are further supported by our analyses (e.g. pdgfbetar, nucleolin). The identity of genes specifically regulated downstream of Myc provides the critical tools required to understand the role Myc holds in the transformation process and to delineate how Myc functions as a regulator of gene transcription.	Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Penn, LZ (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Div Cellular & Mol Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Penn, Linda/0000-0001-8133-5459				BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; Bouchard C, 2001, GENE DEV, V15, P2042, DOI 10.1101/gad.907901; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dang CV, 1999, MOL CELL BIOL, V19, P1; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Guo QM, 2000, CANCER RES, V60, P5922; Izumi H, 2001, J CELL SCI, V114, P1533; Jones RM, 1996, MOL CELL BIOL, V16, P4754; Kim S, 2001, ANAL BIOCHEM, V288, P141, DOI 10.1006/abio.2000.4900; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Neiman PE, 2001, P NATL ACAD SCI USA, V98, P6378, DOI 10.1073/pnas.111144898; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; O'Hagan RC, 2000, NAT GENET, V24, P113, DOI 10.1038/72761; Oster SK, 2002, ADV CANCER RES, V84, P81, DOI 10.1016/S0065-230X(02)84004-0; Oster SK, 2000, MOL CELL BIOL, V20, P6768, DOI 10.1128/MCB.20.18.6768-6778.2000; Park DS, 2001, BIOCHEMISTRY-US, V40, P3354, DOI 10.1021/bi002787b; Park J, 2001, GENE DEV, V15, P1619, DOI 10.1101/gad.900101; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Schuldiner O, 2001, ONCOGENE, V20, P4984, DOI 10.1038/sj.onc.1204459; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Wang XY, 1999, MOL ENDOCRINOL, V13, P254, DOI 10.1210/me.13.2.254; Wu KJ, 1999, SCIENCE, V283, P676, DOI 10.1126/science.283.5402.676; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zeller KI, 2001, J BIOL CHEM, V276, P48285, DOI 10.1074/jbc.M108506200	41	101	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36921	36930		10.1074/jbc.M201493200	http://dx.doi.org/10.1074/jbc.M201493200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145275	Green Published, hybrid			2022-12-27	WOS:000178447100004
J	Zhang, D; Li, F; Weidner, D; Mnjoyan, ZH; Fujise, K				Zhang, D; Li, F; Weidner, D; Mnjoyan, ZH; Fujise, K			Physical and functional interaction between myeloid cell leukemia 1 protein (MCL1) and fortilin - The potential role of MCL1 as a fortilin chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-2 FAMILY MEMBER; HAMSTER OVARY CELLS; SIGNALING PATHWAY; INDUCED APOPTOSIS; RNA INTERFERENCE; KINASE PATHWAY; CYCLIN PCNA; EXPRESSION; SURVIVAL; DIFFERENTIATION	Myeloid cell leukemia 1 protein (MCL1) is an anti-apoptotic protein that is structurally related to Bcl-2. Unlike other Bcl-2 family proteins that are constitutively expressed, MCL1 is inducibly expressed in cells that are recently exposed to growth and differentiation stimuli. Here, we report the identification of fortilin as a novel MCL1-interacting protein by screening of a yeast two-hybrid library with MCL1 as bait. Fortilin specifically interacted with MCL1 both in vitro and in vivo. The intracellular localization of fortilin was predominantly nuclear and identical to that of MCL1, as shown by immunostaining and confocal microscopy analysis. Fortilin, like MCL1, was rapidly inducible in serum-stimulated human aortic vascular smooth muscle cells. Although the depletion of intracellular fortilin by small interfering RNA (siRNA) against fortilin (siRNA-fortilin) did not affect intracellular MCL1 level, the depletion of intracellular MCL1 by siRNA-MCL1 was associated with the significant reduction of the fortilin protein level, without affecting the fortilin transcript numbers. In addition, a pulse-chase experiment showed that the depletion of MCL1 by siRNA-MCL1 was associated with the rapid degradation of fortilin protein, which was found quite stable in the presence of MCL1. Furthermore, the half-life of fortilinl(R21A), a point mutant of fortilin lacking the binding to MCL1, was significantly shorter than that of wild-type fortilin as shown by a pulse-chase experiment. These data suggest that MCL1, in addition to being an anti-apoptotic molecule, serves as a chaperone of fortilin, binding and stabilizing fortilin in vivo. Taken together with our previous observation that fortilin overexpression prevents cells from undergoing apoptosis (Li, F., Zhang, D., and Fujise, K. (2001) J. Biol. Chem. 276, 47542-47549), it is likely that MCL1, an anti-apoptotic protein inducible by growth and differentiation stimuli, stabilizes another anti-apoptotic protein fortilin maximizing the prosurvival environment in cells.	Univ Texas, Hlth Sci Ctr, Res Ctr Cardiovasc Dis, Inst Mol Med Prevent Human Dis, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Div Cardiol, Dept Internal Med, Houston, TX 77030 USA; E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of North Carolina; East Carolina University	Fujise, K (corresponding author), Univ Texas, Hlth Sci Ctr, Res Ctr Cardiovasc Dis, Inst Mol Med Prevent Human Dis, 6431 Fannin St,Suite 1-246, Houston, TX 77030 USA.			Weidner, Douglas/0000-0003-1397-1757	NHLBI NIH HHS [HL04015, HL68024] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068024] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BRAVO R, 1986, EXP CELL RES, V163, P287, DOI 10.1016/0014-4827(86)90059-5; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; CHITPATIMA ST, 1988, NUCLEIC ACIDS RES, V16, P2350, DOI 10.1093/nar/16.5.2350; Eichinger L, 1998, J BIOL CHEM, V273, P12952, DOI 10.1074/jbc.273.21.12952; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fujise K, 2000, J BIOL CHEM, V275, P39458, DOI 10.1074/jbc.M006626200; Fukuchi Y, 2001, ONCOGENE, V20, P704, DOI 10.1038/sj.onc.1204142; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; GROSS B, 1989, NUCLEIC ACIDS RES, V17, P8367, DOI 10.1093/nar/17.20.8367; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Klampfer L, 1999, CYTOKINE, V11, P849, DOI 10.1006/cyto.1999.0514; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Kuo ML, 2001, ONCOGENE, V20, P677, DOI 10.1038/sj.onc.1204140; Leo CP, 1999, ENDOCRINOLOGY, V140, P5469, DOI 10.1210/en.140.12.5469; Leu CM, 2000, ONCOGENE, V19, P1665, DOI 10.1038/sj.onc.1203452; Li F, 2001, J BIOL CHEM, V276, P47542, DOI 10.1074/jbc.M108954200; Lomo J, 1996, CANCER RES, V56, P40; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; Moulding DA, 1998, BLOOD, V92, P2495, DOI 10.1182/blood.V92.7.2495.2495_2495_2502; Myklebust JH, 1999, J CELL PHYSIOL, V180, P71; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Reynolds JE, 1996, EXP CELL RES, V225, P430, DOI 10.1006/excr.1996.0194; REYNOLDS JE, 1994, CANCER RES, V54, P6348; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SANFORD KK, 1948, J NATL CANCER I, V9, P229; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630; Zhou P, 1998, BLOOD, V92, P3226, DOI 10.1182/blood.V92.9.3226.421k49_3226_3239	32	119	134	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37430	37438		10.1074/jbc.M207413200	http://dx.doi.org/10.1074/jbc.M207413200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149273	hybrid			2022-12-27	WOS:000178447100067
J	Bodding, M; Wissenbach, U; Flockerzi, V				Bodding, M; Wissenbach, U; Flockerzi, V			The recombinant human TRPV6 channel functions as Ca2+ sensor in human embryonic kidney and rat basophilic leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CALCIUM CURRENT; STORE DEPLETION; MOLECULAR-CLONING; CAT-LIKE; I-CRAC; MODULATION; JURKAT; ENTRY	The activation mechanism of the recently cloned human transient receptor potential vanilloid type 6 (TRPV6) channel, originally termed C2+ transporter-like protein and Ca2+ transporter type 1, was investigated in whole-cell patch-clamp experiments using transiently transfected human embryonic kidney and rat basophilic leukemia cells. The TRPV6-mediated currents are highly Ca2+-selective, show a strong inward rectification, and reverse at positive potentials, which is similar to store-operated Ca2+ entry in electrically non-excitable cells. The gating of TRPV6 channels is strongly dependent on the cytosolic free Ca2+ concentration; lowering the intracellular free Ca2+ concentration results in Ca2+ influx, and current amplitude correlates with the intracellular EGTA or BAPTA concentration. This is also the case for TRPV6-mediated currents in the absence of extracellular divalent cations; compared with endogenous currents in nontransfected rat basophilic leukemia cells, these TRPV6-mediated monovalent currents reveal differences in reversal potential, inward rectification, and slope at very negative potentials. Release of stored Ca2+ by inositol 1,4,5-trisphosphate and/or the sarco/endoplasmic reticulum Ca2+-ATPase inhibitor thapsigargin appears not to be involved in TRPV6 channel gating in both cell lines but, in rat basophilic leukemia cells, readily activates the endogenous Ca2+ release-activated Ca2+ current. In conclusion, TRPV6, expressed in human embryonic kidney cells and in rat basophilic leukemia cells, functions as a Ca2+- sensing Ca2+ channel independently of procedures known to deplete Ca2+ stores.	Univ Saarland, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany	Saarland University	Bodding, M (corresponding author), Univ Saarland, Inst Pharmakol & Toxikol, D-66421 Homburg, Germany.	matthias.boedding@uniklinik-saarland.de						Barritt GJ, 1998, CELL CALCIUM, V23, P65, DOI 10.1016/S0143-4160(98)90075-6; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bodding M, 1999, PFLUG ARCH EUR J PHY, V439, P27, DOI 10.1007/s004240051124; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Fasolato C, 1998, PFLUG ARCH EUR J PHY, V436, P69, DOI 10.1007/s004240050605; Fierro L, 2000, PFLUG ARCH EUR J PHY, V440, P580, DOI 10.1007/s004240050009; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; Krause E, 1999, J BIOL CHEM, V274, P36957, DOI 10.1074/jbc.274.52.36957; Mignen O, 2000, J BIOL CHEM, V275, P9114, DOI 10.1074/jbc.275.13.9114; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Muller D, 2000, GENOMICS, V67, P48, DOI 10.1006/geno.2000.6203; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Niemeyer BA, 2001, P NATL ACAD SCI USA, V98, P3600, DOI 10.1073/pnas.051511398; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Peng JB, 2000, BIOCHEM BIOPH RES CO, V278, P326, DOI 10.1006/bbrc.2000.3716; Peng JB, 2001, GENOMICS, V76, P99, DOI 10.1006/geno.2001.6606; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; Schonherr R, 2000, EMBO J, V19, P3263, DOI 10.1093/emboj/19.13.3263; Stansfeld CE, 1996, P NATL ACAD SCI USA, V93, P9910, DOI 10.1073/pnas.93.18.9910; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Wissenbach U, 2001, J BIOL CHEM, V276, P19461, DOI 10.1074/jbc.M009895200; Xia XM, 1998, NATURE, V395, P503, DOI 10.1038/26758; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	31	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36656	36664		10.1074/jbc.M202822200	http://dx.doi.org/10.1074/jbc.M202822200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138163	hybrid			2022-12-27	WOS:000178275100111
J	Sivaraman, J; Sauve, V; Matte, A; Cygler, M				Sivaraman, J; Sauve, V; Matte, A; Cygler, M			Crystal structure of Escherichia coli glucose-1-phosphate thymidylyltransferase (RffH) complexed with dTTP and Mg2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-DENSITY MAPS; RFB GENE-CLUSTER; CATALYTIC MECHANISM; BIOSYNTHESIS REGION; PATHWAY; PYROPHOSPHORYLASE; MOLSCRIPT; SOFTWARE; LOCATION; GLMU	The enzyme glucose-1-phosphate thymidylyltransferase (RffH), the product of the rffh gene, catalyzes one of the steps in the synthesis of enterobacterial common antigen (ECA), a cell surface glycolipid found in Gram-negative enteric bacteria. In Escherichia coli two gene products, RffH and Rm1A, catalyze the same enzymatic reaction and are homologous in sequence; however, they are part of different operons and function in different pathways. We report the crystal structure of RffH bound to deoxythymidine triphosphate (dTTP), the phosphate donor, and Mg2+, refined at 2.6 Angstrom to an R-factor of 22.3% (R-free = 28.4%). The crystal structure of RffH shows a tetrameric enzyme best described as a dimer of dimers. Each monomer has an overall alpha/beta fold and consists of two domains, a larger nucleotide binding domain (residues 1-115, 222-291) and a smaller sugar-binding domain (116-221), with the active site located at the domain interface. The Mg2+ ion is coordinated by two conserved aspartates and the alpha-phosphate of deoxythymidine triphosphate. Its location corresponds well to that in a structurally similar domain of N-acetylglucosamine-1-phosphate uridylyltransferase (GlmU). Analysis of the RffH, RmIA, and GlmU complexes with substrates and products provides an explanation for their different affinities for Mg2+ and leads to a proposal for the dynamics along the reaction pathway.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; Montreal Joint Ctr Struct Biol, Montreal, PQ H4P 2R2, Canada	National Research Council Canada; McGill University	Cygler, M (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	mirek@bri.nrc.ca	Sivaraman, J/H-8028-2012	J, Sivaraman/0000-0001-9781-5326				Allard STM, 2002, STRUCTURE, V10, P81, DOI 10.1016/S0969-2126(01)00694-3; Allard STM, 2001, J MOL BIOL, V307, P283, DOI 10.1006/jmbi.2000.4470; Barton WA, 2001, NAT STRUCT BIOL, V8, P545, DOI 10.1038/88618; BERNSTEI.RL, 1965, J BIOL CHEM, V240, P391; Blankenfeldt W, 2000, EMBO J, V19, P6652, DOI 10.1093/emboj/19.24.6652; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; Godfroid F, 2000, RES MICROBIOL, V151, P655, DOI 10.1016/S0923-2508(00)90130-X; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1999, ACTA CRYSTALLOGR D, V55, P941, DOI 10.1107/S0907444999001031; Kostrewa D, 2001, J MOL BIOL, V305, P279, DOI 10.1006/jmbi.2000.4296; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHN HM, 1988, FEMS MICROBIOL LETT, V54, P195, DOI 10.1111/j.1574-6968.1988.tb02743.x; MAROLDA CL, 1995, J BACTERIOL, V177, P5539, DOI 10.1128/jb.177.19.5539-5546.1995; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Olsen LR, 2001, BIOCHEMISTRY-US, V40, P1913, DOI 10.1021/bi002503n; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Reeves PR, 1996, TRENDS MICROBIOL, V4, P495, DOI 10.1016/S0966-842X(97)82912-5; SHEU KFR, 1979, BIOCHEMISTRY-US, V18, P5548, DOI 10.1021/bi00592a004; SHIBAEV VN, 1986, ADV CARBOHYD CHEM BI, V44, P277; STEVENSON G, 1991, MOL GEN GENET, V227, P173, DOI 10.1007/BF00259668; Tsukioka Y, 1997, J BACTERIOL, V179, P1126, DOI 10.1128/jb.179.4.1126-1134.1997; Zuccotti S, 2001, J MOL BIOL, V313, P831, DOI 10.1006/jmbi.2001.5073	26	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44214	44219		10.1074/jbc.M206932200	http://dx.doi.org/10.1074/jbc.M206932200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12171937	hybrid			2022-12-27	WOS:000179272000089
J	Hager, J; Staker, BL; Bugl, H; Jakob, U				Hager, J; Staker, BL; Bugl, H; Jakob, U			Active site in RrmJ, a heat shock-induced methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							23S RIBOSOMAL-RNA; MESSENGER-RNA; STIMULATORY ACTIVITIES; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; VACCINIA VIRUS; PROTEIN; BINDING	The heat shock protein RrmJ (FtsJ), highly conserved from eubacteria to eukarya, is responsible for the 2'-O-ribose methylation of the universally conserved base U2552 in the A-loop of the 23 S rRNA. Absence of this methylation, which occurs late in the maturation process of the ribosome, appears to cause the destabilization and premature dissociation of the 50 S ribosomal subunit. To understand the mechanism of 2'-O-ribose methyltransfer reactions, we characterized the enzymatic parameters of RrmJ and conducted site-specific mutagenesis of RrmJ. A structure based sequence alignment with VP39, a structurally related 2'-O-methyltransferase from vaccinia virus, guided our mutagenesis studies. We analyzed the function of our RrmJ mutants in vivo and characterized the methyltransfer reaction of the purified proteins in vitro. The active site of RrmJ appears to be formed by a catalytic triad consisting of two lysine residues, Lys-38 and Lys-164, and the negatively charged residue Asp-124. Another highly conserved residue, Glu-199, that is present in the active site of RrmJ and VP39 appears to play only a minor role in the methyltransfer reaction in vivo. Based on these results, a reaction mechanism for the methyltransfer activity of RrmJ is proposed.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Emerald BioStruct Inc, W Bainbridge Isl, WA 98110 USA	University of Michigan System; University of Michigan	Jakob, U (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.	ujakob@umich.edu		Staker, Bart/0000-0001-9570-5086				Barbas CF, 1997, SCIENCE, V278, P2085, DOI 10.1126/science.278.5346.2085; BARBOSA E, 1978, J BIOL CHEM, V253, P7698; BJOERK GR, 1996, CELLULAR MOL BIOL, P861; Bugl H, 2000, MOL CELL, V6, P349, DOI 10.1016/S1097-2765(00)00035-6; Bujnicki JM, 2001, GENOME BIOL, V2; Bujnicki JM, 2002, J MOL MICROB BIOTECH, V4, P93; Caldas T, 2000, J BIOL CHEM, V275, P16414, DOI 10.1074/jbc.M001854200; Caldas T, 2000, BIOCHEM BIOPH RES CO, V271, P714, DOI 10.1006/bbrc.2000.2702; DENOYA CD, 1987, J BACTERIOL, V169, P3857, DOI 10.1128/jb.169.8.3857-3860.1987; FERSHT A, 2000, STRUCTURE MECH PROTE, P188; GEYL D, 1981, MOL GEN GENET, V181, P309, DOI 10.1007/BF00425603; Hansen MA, 2002, RNA, V8, P202, DOI 10.1017/S1355838202013365; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Hodel AE, 1998, MOL CELL, V1, P443, DOI 10.1016/S1097-2765(00)80044-1; Hodel AE, 1996, CELL, V85, P247, DOI 10.1016/S0092-8674(00)81101-0; HODEL AE, 1999, S ADENOSYLMETHIONINE, P255; Hu GH, 2002, BIOCHEMISTRY-US, V41, P7677, DOI 10.1021/bi0201926; JEFFERY DR, 1987, BIOCHEMISTRY-US, V26, P2955, DOI 10.1021/bi00384a042; Lovgren JM, 2001, J BACTERIOL, V183, P6957, DOI 10.1128/JB.183.23.6957-6960.2001; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; NIERHAUS KH, 1991, BIOCHIMIE, V73, P739, DOI 10.1016/0300-9084(91)90054-5; Pintard L, 2002, EMBO J, V21, P1139, DOI 10.1093/emboj/21.5.1139; Pintard L, 2002, EMBO J, V21, P1811, DOI 10.1093/emboj/21.7.1811; SCHNIERLE BS, 1994, J BIOL CHEM, V269, P20700; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; Vidgren J., 1999, S ADENOSYLMETHIONINE, P55; Wang HM, 2000, EMBO J, V19, P317, DOI 10.1093/emboj/19.3.317	28	71	74	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41978	41986		10.1074/jbc.M205423200	http://dx.doi.org/10.1074/jbc.M205423200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12181314	hybrid			2022-12-27	WOS:000178985300087
J	Jensen, ML; Timmermann, DB; Johansen, TH; Schousboe, A; Varming, T; Ahring, PK				Jensen, ML; Timmermann, DB; Johansen, TH; Schousboe, A; Varming, T; Ahring, PK			The beta subunit determines the ion selectivity of the GABA(A) receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; A RECEPTORS; CHANNEL; STOICHIOMETRY; SUPERFAMILY; MUTAGENESIS; EXPRESSION; LOCATION; REGION	The gamma-aminobutyric acid, type A (GABA(A)) receptor is a chloride-conducting receptor composed of alpha, beta, and gamma subunits assembled in a pentameric structure forming a central pore. Each subunit has a large extracellular agonist binding domain and four transmembrane domains (M1-M4), with the second transmembrane (M2) domain lining the pore. Mutation of five amino acids in the M1-M2 loop of the beta(3) subunit to the corresponding amino acids of the alpha(7) nicotinic acetylcholine subunit rendered the GABA(A) receptor cation-selective upon co-expression with wild type alpha2 and gamma2 subunits. Similar mutations in the a2 or gamma2 subunits did not lead to such a change in ion selectivity. This suggests a unique role for the beta(3) subunit in determining the ion selectivity of the GABA(A) receptor. The pharmacology of the mutated GABA(A) receptor is similar to that of the wild type receptor, with respect to muscimol binding, Zn2+ and bicuculline sensitivity, flumazenil binding, and potentiation of GABA-evoked currents by diazepam. There was, however, an increase in GABA sensitivity (EC50 = 1.3 mum) compared with the wild type receptor (EC50 = 6.4 mum) and a loss of desensitization to GABA of the mutant receptor.	NeuroSearch AS, DK-2750 Ballerup, Denmark; Royal Danish Sch Pharm, Dept Pharmacol, DK-2100 Copenhagen, Denmark	Royal Danish School of Pharmacy	Ahring, PK (corresponding author), NeuroSearch AS, Pederstrupvej 93, DK-2750 Ballerup, Denmark.			Ahring, Joergen Philip Kiaer/0000-0003-1807-3331				Barry PH, 1999, CLIN EXP PHARMACOL P, V26, P935, DOI 10.1046/j.1440-1681.1999.03149.x; Baumann SW, 2001, J BIOL CHEM, V276, P36275, DOI 10.1074/jbc.M105240200; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; CHANG Y, 1996, J NEUROSCI, V16, P5414; COOPER E, 1991, NATURE, V350, P235, DOI 10.1038/350235a0; Corringer PJ, 1999, NEURON, V22, P831, DOI 10.1016/S0896-6273(00)80741-2; Dalziel JE, 1999, EUR J PHARMACOL, V370, P345, DOI 10.1016/S0014-2999(99)00138-7; FATIMASHAD K, 1993, P ROY SOC B-BIOL SCI, V253, P69, DOI 10.1098/rspb.1993.0083; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; GUNTHER U, 1995, P NATL ACAD SCI USA, V92, P7749, DOI 10.1073/pnas.92.17.7749; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; IMOTO K, 1986, NATURE, V324, P670, DOI 10.1038/324670a0; Karlin A, 1995, NEURON, V15, P1231, DOI 10.1016/0896-6273(95)90004-7; Keramidas A, 2000, BIOPHYS J, V79, P247, DOI 10.1016/S0006-3495(00)76287-4; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; MILLER C, 1989, NEURON, V2, P1195, DOI 10.1016/0896-6273(89)90304-8; MOSSIER B, 1994, J BIOL CHEM, V269, P25777; Reeves DC, 2001, J BIOL CHEM, V276, P42035, DOI 10.1074/jbc.M106066200; SLILATY SN, 1990, ANAL BIOCHEM, V185, P194, DOI 10.1016/0003-2697(90)90279-I; Tretter V, 1997, J NEUROSCI, V17, P2728; Wilson GG, 2001, P NATL ACAD SCI USA, V98, P1241, DOI 10.1073/pnas.031567798; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1; XU M, 1993, J BIOL CHEM, V268, P21505; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; YAKEL JL, 1990, BRAIN RES, V533, P46, DOI 10.1016/0006-8993(90)91793-G	27	58	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41438	41447		10.1074/jbc.M205645200	http://dx.doi.org/10.1074/jbc.M205645200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12177063	hybrid			2022-12-27	WOS:000178985300020
J	Biot, C; Buisine, E; Kwasigroch, JM; Wintjens, R; Rooman, M				Biot, C; Buisine, E; Kwasigroch, JM; Wintjens, R; Rooman, M			Probing the energetic and structural role of amino acid/nucleobase cation-pi interactions in protein-ligand complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONEMPIRICAL AB-INITIO; AROMATIC INTERACTIONS; AQUEOUS-SOLUTION; BASE-PAIRS; RECOGNITION; RECEPTOR; STACKING; DNA; BIOLOGY; BINDING	structures of proteins bound to ligand molecules containing a nucleic acid base were systematically searched for cation-pi interactions between the base and a positively charged or partially charged side chain group located above it, using geometric criteria. Such interactions were found in 38% of the complexes and are thus even more frequent than pi-pi stacking interactions. They are moreover well conserved in families of related proteins. The overwhelming majority of cation-pi contacts involve Ade bases, as these constitute by far the most frequent ligand building block; Arg-Ade is; the most frequent cation-pi pair. Ab initio energy calculations at MP2 level were performed on all recorded pairs. Though cation-pi interactions involving the net positive charge carried by Arg or Lys side chains are the most favorable energetically, those involving the partial positive charge of Asn and Gln side chain amino groups (sometimes referred to as amino-pi interactions) are favorable too, owing to the electron correlation energy contribution. Chains of cation-pi interactions with a nucleobase bound simultaneously to two charged groups or a charged group sandwiched between two aromatic moieties are found in several complexes. The systematic association of these motifs with specific ligand molecules in unrelated protein sequences raises the question of their role in protein-ligand structure, stability, and recognition.	Free Univ Brussels, B-1050 Brussels, Belgium; Univ Sci & Tech Lille Flandres Artois, URRESA 8009, CNRS, Lab Chim Organ & Macromol, F-59655 Villeneuve Dascq, France; Univ Lille 2, CNRS, UMR 8525, Inst Biol Lille,Inst Pasteur Lille, F-59021 Lille, France	Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille	Biot, C (corresponding author), Free Univ Brussels, 50 Av F Roosevelt,CP 165-64, B-1050 Brussels, Belgium.		Biot, Christophe/ABG-3796-2020	Biot, Christophe/0000-0002-7396-1959				Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BOUTONNET NS, 1995, PROTEIN ENG, V8, P647, DOI 10.1093/protein/8.7.647; BOYS SF, 1970, MOL PHYS, V19, P553, DOI 10.1080/00268977000101561; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; DUFFY EM, 1993, J AM CHEM SOC, V115, P9271, DOI 10.1021/ja00073a050; FLOCCO MM, 1994, J MOL BIOL, V235, P709, DOI 10.1006/jmbi.1994.1022; Florian J, 1999, J PHYS CHEM B, V103, P884, DOI 10.1021/jp983699s; Frisch M. J., 1998, GAUSSIAN 98; Gallivan JP, 2000, J AM CHEM SOC, V122, P870, DOI 10.1021/ja991755c; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Hendlich M, 1998, ACTA CRYSTALLOGR D, V54, P1178, DOI 10.1107/S0907444998007124; Hobza P, 1999, CHEM REV, V99, P3247, DOI 10.1021/cr9800255; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Hunter CA, 2002, P NATL ACAD SCI USA, V99, P4873, DOI 10.1073/pnas.072647899; Jansen HB, 1969, CHEM PHYS LETT, V3, P140, DOI 10.1016/0009-2614(69)80118-1; KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; Luisi B, 1998, J MOL BIOL, V279, P1123, DOI 10.1006/jmbi.1998.1833; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; Mecozzi S, 1996, P NATL ACAD SCI USA, V93, P10566, DOI 10.1073/pnas.93.20.10566; Minoux H, 1999, J AM CHEM SOC, V121, P10366, DOI 10.1021/ja990914p; MITCHELL JBO, 1994, J MOL BIOL, V239, P315, DOI 10.1006/jmbi.1994.1370; Miura S, 1999, J BIOL CHEM, V274, P7103, DOI 10.1074/jbc.274.11.7103; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Rooman M, 2002, J MOL BIOL, V319, P67, DOI 10.1016/S0022-2836(02)00263-2; SCHWARTZ AW, 1989, SCIENCE, V245, P1102, DOI 10.1126/science.11538344; Scrutton NS, 1996, BIOCHEM J, V319, P1; SHAPIRO R, 1995, ORIGINS LIFE EVOL B, V25, P83, DOI 10.1007/BF01581575; Shi ZS, 2002, J AM CHEM SOC, V124, P3284, DOI 10.1021/ja0174938; SINGH J, 1990, J MOL BIOL, V211, P595, DOI 10.1016/0022-2836(90)90268-Q; Sponer J, 1996, J PHYS CHEM-US, V100, P5590, DOI 10.1021/jp953306e; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wintjens R, 2000, J MOL BIOL, V302, P395, DOI 10.1006/jmbi.2000.4040; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	41	70	71	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40816	40822		10.1074/jbc.M205719200	http://dx.doi.org/10.1074/jbc.M205719200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12167645	hybrid			2022-12-27	WOS:000178791400085
J	Huss, JM; Kopp, RP; Kelly, DP				Huss, JM; Kopp, RP; Kelly, DP			Peroxisome proliferator-activated receptor coactivator-1 alpha (PGC-1 alpha) coactivates the cardiac-enriched nuclear receptors estrogen-related receptor-alpha and -gamma - Identification of novel leucine-rich interaction motif within PGC-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; CHAIN ACYL-COENZYME; TRANSCRIPTIONAL COACTIVATOR; GENE PROMOTER; RESPONSE ELEMENTS; PGC-1; BINDING; MODULATION; OXIDATION; MUSCLE	The transcriptional coactivator PPARgamma coactivator-1alpha (PGC-1alpha) has been characterized as a broad regulator of cellular energy metabolism. Although PGC-1alpha functions through many transcription factors, the PGC-1alpha partners identified to date are unlikely to account for all of its biologic actions. The orphan nuclear receptor estrogen-related receptor alpha (ERRalpha) was identified in a yeast two-hybrid screen of a cardiac cDNA library as a novel PGC-1alpha-binding protein. ERRalpha was implicated previously in regulating the gene encoding medium-chain acyl-CoA dehydrogenase (MCAD), which catalyzes the initial step in mitochondrial fatty acid oxidation. The cardiac perinatal expression pattern of ERRalpha paralleled that of PGC-1alpha and MCAD. Adenoviral-mediated ERRalpha overexpression in primary neonatal cardiac mycoytes induced endogenous MCAD expression. Furthermore, PGC-1alpha enhanced the transactivation of reporter plasmids containing an estrogen response element or the MCAD gene promoter by ERRalpha and the related isoform ERRgamma. In vitro binding experiments demonstrated that ERRa interacts with PGC-1alpha via its activation function-2 homology region. Mutagenesis studies revealed that the LXXLL motif at amino acid position 142-146 of PGC-1alpha (L2), necessary for PGC-1alpha interactions with other nuclear receptors, is not required for the PGC1alpha.ERRalpha interaction. Rather, ERRalpha binds PGC-1alpha primarily through a Leu-rich motif at amino acids 209-213 (Leu-3) and utilizes additional LXXLL-containing domains as accessory binding sites. Thus, the PGC1alpha.ERRalpha interaction is distinct from that of other nuclear receptor PGC-1alpha partners, including PPARalpha, hepatocyte nuclear factor-4alpha, and estrogen receptor alpha. These results identify ERRa and ERRgamma as novel PGC-1alpha interacting proteins, implicate ERR isoforms in the regulation of mitochondrial energy metabolism, and suggest a potential mechanism whereby PGC-1alpha selectively binds transcription factor partners.	Washington Univ, Sch Med, Cardiovasc Res Ctr, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Kelly, DP (corresponding author), Washington Univ, Sch Med, Cardiovasc Res Ctr, 660 S Euclid Ave,Campus Box 8086, St Louis, MO 63110 USA.	dkelly@im.wustl.edu	Kelly, Daniel/ABG-2056-2021	Kopp, Ryan/0000-0003-3478-8564	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058493, F32HL010410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, P30DK052574, R01DK045416] Funding Source: NIH RePORTER; NHLBI NIH HHS [F32 HL 10410, R01 HL 58493] Funding Source: Medline; NIDDK NIH HHS [P30 DK 52574, P30 DK 56341, R01 DK 45416] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAAR K, 2002, IN PRESS FASEB J; Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; Boss O, 1999, BIOCHEM BIOPH RES CO, V261, P870, DOI 10.1006/bbrc.1999.1145; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen S, 2001, J BIOL CHEM, V276, P28465, DOI 10.1074/jbc.M102638200; Delerive P, 2002, J BIOL CHEM, V277, P3913, DOI 10.1074/jbc.M109409200; Disch DL, 1996, MOL CELL BIOL, V16, P4043; Goto M, 2000, BIOCHEM BIOPH RES CO, V274, P350, DOI 10.1006/bbrc.2000.3134; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heard DJ, 2000, MOL ENDOCRINOL, V14, P382, DOI 10.1210/me.14.3.382; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; Huss JM, 2001, J BIOL CHEM, V276, P27605, DOI 10.1074/jbc.M100277200; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; LEONE TC, 1995, J BIOL CHEM, V270, P16308, DOI 10.1074/jbc.270.27.16308; Lu DS, 2001, CANCER RES, V61, P6755; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Pike ACW, 2000, J STEROID BIOCHEM, V74, P261, DOI 10.1016/S0960-0760(00)00102-3; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Sanyal S, 2002, J BIOL CHEM, V277, P1739, DOI 10.1074/jbc.M106140200; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Starr DB, 1996, GENE DEV, V10, P1271, DOI 10.1101/gad.10.10.1271; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Trapp T, 1996, J BIOL CHEM, V271, P9879, DOI 10.1074/jbc.271.17.9879; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Vanacker JM, 1998, ONCOGENE, V17, P2429, DOI 10.1038/sj.onc.1202167; Vega RB, 1997, J BIOL CHEM, V272, P31693, DOI 10.1074/jbc.272.50.31693; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wood JR, 1998, MOL CELL BIOL, V18, P1927, DOI 10.1128/MCB.18.4.1927; Wood JR, 2001, MOL ENDOCRINOL, V15, P1114, DOI 10.1210/me.15.7.1114; Wu YF, 2002, J BIOL CHEM, V277, P8898, DOI 10.1074/jbc.M110761200; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Yang NY, 1996, J BIOL CHEM, V271, P5795, DOI 10.1074/jbc.271.10.5795; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	44	386	395	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40265	40274		10.1074/jbc.M206324200	http://dx.doi.org/10.1074/jbc.M206324200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181319	hybrid			2022-12-27	WOS:000178791400016
J	Wiklund, L; Sokolowski, M; Carlsson, A; Rush, M; Schwartz, S				Wiklund, L; Sokolowski, M; Carlsson, A; Rush, M; Schwartz, S			Inhibition of translation by UAUUUAU and UAUUUUUAU motifs of the AU-rich RNA instability element in the HPV-1 late 3' untranslated region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LATE MESSENGER-RNAS; HUMAN-IMMUNODEFICIENCY-VIRUS; NEGATIVE ELEMENT; CELLULAR FACTORS; HUR PROTEIN; REV PROTEIN; TYPE-1; SEQUENCE; DEGRADATION; INITIATION	The human papillomavirus type I (HPV-1) late mRNAs contain a 57-nucleotide adenosine- and uridine-rich RNA instability element termed MARE in their late 3' untranslated regions. Here we show that five sequence motifs in the h1ARE (named I-V) affect the mRNA half-life in an additive manner. The minimal inhibitory sequence in motifs I and II was mapped to UAUUUAU, and the minimal inhibitory sequence in motifs III-V was mapped to UAUUUUUAU. We also provide evidence that the same motifs in the AU-RNA instability element inhibit mRNA translation, an effect that was entirely dependent on the presence of a poly(A) tail on the mRNA. Additional experiments demonstrated that the h1ARE interacted directly with the poly(A)-binding protein, suggesting that the h1ARE inhibits translation by interfering with the function of the poly(A)-binding protein.	Univ Uppsala, Dept Med Biochem & Microbiol, Ctr Biomed, S-75123 Uppsala, Sweden	Uppsala University	Schwartz, S (corresponding author), Univ Uppsala, Dept Med Biochem & Microbiol, Ctr Biomed, Husargatan 3,Box 582, S-75123 Uppsala, Sweden.			Sokolowski, Marcus/0000-0003-3931-1810				ANTIC D, 1999, GENE DEV, V13, P8684; ARRIGO SJ, 1991, GENE DEV, V5, P808, DOI 10.1101/gad.5.5.808; BAKER CC, 1997, HUMAN PAPILLOMAVIRUS, P11; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Carlsson A, 2000, ARCH VIROL, V145, P491, DOI 10.1007/s007050050041; CHEN CYA, 1994, MOL CELL BIOL, V14, P416, DOI 10.1128/MCB.14.1.416; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; DANOS O, 1982, EMBO J, V1, P231, DOI 10.1002/j.1460-2075.1982.tb01152.x; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Howley M. P., 1996, FIELDS VIROLOGY, P2045; Kasashima K, 1999, GENES CELLS, V4, P667, DOI 10.1046/j.1365-2443.1999.00292.x; Keene JD, 1999, P NATL ACAD SCI USA, V96, P5, DOI 10.1073/pnas.96.1.5; LAGANDO CA, 1994, MOL CELL BIOL, V14, P7984; Piron M, 1998, EMBO J, V17, P5811, DOI 10.1093/emboj/17.19.5811; RAMIREZSOLIS R, 1990, GENE, V87, P291, DOI 10.1016/0378-1119(90)90315-I; ROSS J, 1995, MICROBIOL REV, V59, P15; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Schwartz S, 1998, SEMIN VIROL, V8, P291, DOI 10.1006/smvy.1997.0131; Schwartz S, 2000, UPSALA J MED SCI, V105, P171; SCHWARTZ S, 1999, RRD VIROLOGY 1, V1, P53; Sokolowski M, 1997, ONCOGENE, V15, P2303, DOI 10.1038/sj.onc.1201415; Sokolowski M, 1999, J VIROL, V73, P1080, DOI 10.1128/JVI.73.2.1080-1091.1999; Sokolowski M, 2001, VIRUS RES, V73, P163, DOI 10.1016/S0168-1702(00)00238-0; Sokolowski M, 1998, J VIROL, V72, P1504, DOI 10.1128/JVI.72.2.1504-1515.1998; Spangberg K, 2000, VIROLOGY, V274, P378, DOI 10.1006/viro.2000.0461; STOECKLIN G, 1994, J BIOL CHEM, V269, P28591; TAN W, 1995, J VIROL, V69, P2932, DOI 10.1128/JVI.69.5.2932-2945.1995; TAN W, 1995, J VIROL, V69, P5607, DOI 10.1128/JVI.69.9.5607-5620.1995; Wiklund L, 2001, J HUMAN VIROL, V4, P74; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Zhao CP, 1996, J VIROL, V70, P3659, DOI 10.1128/JVI.70.6.3659-3667.1996; Zhao CP, 1998, VIRUS RES, V55, P1, DOI 10.1016/S0168-1702(98)00033-1; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219; zur Hausen H, 1996, BIOCHIM BIOPHYS ACTA, V1288, P55	36	37	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40462	40471		10.1074/jbc.M205929200	http://dx.doi.org/10.1074/jbc.M205929200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12147699	hybrid			2022-12-27	WOS:000178791400041
J	Chung, PJ; Chang, YS; Liang, CL; Meng, CL				Chung, PJ; Chang, YS; Liang, CL; Meng, CL			Negative regulation of Epstein-Barr virus latent membrane protein 1-mediated functions by the bone morphogenetic protein receptor IA-binding protein, BRAM1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PROGRAMMED CELL-DEATH; IKK-BETA SUBUNIT; GLUCOCORTICOID RECEPTOR; HISTONE DEACETYLASE; CYCLIN D1; ACTIVATION; EXPRESSION; MEMBRANE-PROTEIN-1; PHOSPHORYLATION	The latent membrane protein 1 (LMP1) of Epstein-Barr virus causes cellular transformation and activates several intracellular signals, including NF-kappaB and c-Jun N-terminal kinase. Using yeast two-hybrid screening with the LMP1 C-terminal sequence as bait, we demonstrate that BRAM1 (bone morphogenetic protein receptor-associated molecule 1) is an LMP1-interacting protein. BRAM1 associates with LMP1, both in vitro and in vivo, as revealed by confocal microscopy, glutathione S-transferase pull-down, and co-immunoprecipitation assays. This association mainly involves the C-terminal half of BRAM1 comprising the MYND domain and the CTAR2 region of LMP1, which is critical in LMP1-mediated signaling pathways. We show that BRAM1 interferes with LMP1-mediated NF-kappaB activation but not the JNK signaling pathway. Because the CTAR2 region interacts with the tumor necrosis factor TNF-alpha receptor-associated death domain protein, it is interesting to find that BRAM1 also interferes with NF-kappaB activation mediated by TNF-alpha. BRAM1 interferes LMP1-mediated and TNF-alpha-induced NF-kappaB activation by targeting IkappaBalpha molecules. Moreover, BRAM1 inhibits the resistance of LMP1-expressing cells to TNF-alpha-induced cytotoxicity. We therefore propose that the BRAM1 molecule associates with LMP1 and functions as a negative regulator of LMP1-mediated biological functions.	Natl Def Med Ctr, Grad Inst Life Sci, Taipei 114, Taiwan; Chang Gung Univ, Sch Med, Grad Inst Basic Med Sci, Tao Yuan 333, Taiwan	National Defense Medical Center; Chang Gung University	Meng, CL (corresponding author), Natl Def Med Ctr, Grad Inst Life Sci, POB 90048-517, Taipei 114, Taiwan.							Ansieau S, 2002, J BIOL CHEM, V277, P4906, DOI 10.1074/jbc.M110078200; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BAICHWAL VR, 1988, ONCOGENE, V2, P461; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; FAHRAEUS R, 1992, INT J CANCER, V52, P834, DOI 10.1002/ijc.2910520527; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HAMMARSKJOLD ML, 1992, J VIROL, V66, P6496; He ZM, 2000, CANCER RES, V60, P1845; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; Hinz M, 1999, MOL CELL BIOL, V19, P2690; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HUEN DS, 1995, ONCOGENE, V10, P549; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; Kaykas A, 2001, EMBO J, V20, P2641, DOI 10.1093/emboj/20.11.2641; Kieser A, 1999, EMBO J, V18, P2511, DOI 10.1093/emboj/18.9.2511; Kieser A, 1997, EMBO J, V16, P6478, DOI 10.1093/emboj/16.21.6478; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; Kurozumi K, 1998, GENES CELLS, V3, P257, DOI 10.1046/j.1365-2443.1998.00186.x; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; Li SN, 1996, ONCOGENE, V12, P2129; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Luftig MA, 2001, J BIOL CHEM, V276, P14602, DOI 10.1074/jbc.C100103200; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; MANN KP, 1985, J VIROL, V55, P710, DOI 10.1128/JVI.55.3.710-720.1985; Masselink H, 2000, ONCOGENE, V19, P1538, DOI 10.1038/sj.onc.1203421; Morita K, 2001, P NATL ACAD SCI USA, V98, P6284, DOI 10.1073/pnas.111409798; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Sandberg M, 1997, J VIROL, V71, P4649, DOI 10.1128/JVI.71.6.4649-4656.1997; Sandberg ML, 2000, J VIROL, V74, P9755, DOI 10.1128/JVI.74.20.9755-9761.2000; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; Sugawara K, 2001, GENES CELLS, V6, P599, DOI 10.1046/j.1365-2443.2001.00444.x; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Tsai CN, 2002, P NATL ACAD SCI USA, V99, P10084, DOI 10.1073/pnas.152059399; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; Yeh TS, 1997, DNA CELL BIOL, V16, P1311, DOI 10.1089/dna.1997.16.1311	48	18	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39850	39857		10.1074/jbc.M206736200	http://dx.doi.org/10.1074/jbc.M206736200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12181323	hybrid			2022-12-27	WOS:000178662500101
J	Renaud-Young, M; Gallin, WJ				Renaud-Young, M; Gallin, WJ			In the first extracellular domain of E-cadherin, heterophilic interactions, but not the conserved His-Ala-Val motif, are required for adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SUBSTITUTIONS; CELL-CELL ADHESION; N-CADHERIN; L-CAM; MOLECULE UVOMORULIN; EARLY EMBRYOGENESIS; NEURITE OUTGROWTH; EPITHELIAL-CELLS; STRUCTURAL BASIS; CARCINOMA-CELLS	The classical cadherins, definitive proteins of the cadherin superfamily, are characterized functionally by their ability to mediate calcium-dependent cell aggregation in vitro. To test hypothetical mechanisms of adhesion, we have constructed two mutants of the chicken E-cadherin protein, one with the highly conserved His-Ala-Val (HAV) sequence motif reversed to Val-Ala-His (VAH), the other lacking the first extracellular domain (EC1). The inversion of HAV to VAH has no effect on the capacity of E-cadherin to mediate adhesion. Deletion of EC1 completely eliminates the ability of E-cadherin to mediate homophilic adhesion, but the deletion mutant is capable of adhering heterophilically to both unmutated E-cadherin and to the HAV/VAH mutant. These results demonstrate that the conserved HAV sequence motif is not involved in cadherin-mediated adhesion as has been suggested previously and supports the idea that in the context of the cell surface, cadherin-mediated cell-cell adhesion involves an interaction of EC1 with other domains of the cadherin extracellular moiety and not the "linear zipper" model, which posits trans interactions only between EC1 on apposing cell surfaces.	Univ Alberta, Dept Sci Biol, Edmonton, AB T6G 2E9, Canada; Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2E9, Canada	University of Alberta; University of Alberta	Gallin, WJ (corresponding author), Univ Alberta, Dept Sci Biol, Edmonton, AB T6G 2E9, Canada.		Gallin, Warren/A-2640-2014; Renaud-Young, Margaret M/V-9801-2017	Gallin, Warren/0000-0002-9937-3880; Renaud-Young, Margaret M/0000-0003-0569-6126				ACHESON A, 1992, CELL CELL INTERACTIO, P31; Babb SG, 2001, DEV DYNAM, V221, P231, DOI 10.1002/dvdy.1132; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BLASCHUK OW, 1990, J MOL BIOL, V211, P679, DOI 10.1016/0022-2836(90)90065-T; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; BRACKENBURY R, 1977, J BIOL CHEM, V252, P6835; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; DRAZBA J, 1990, DEV BIOL, V138, P82, DOI 10.1016/0012-1606(90)90178-L; DUNHAM LJ, 1953, JNCI-J NATL CANCER I, V13, P1299; EDELMAN GM, 1987, P NATL ACAD SCI USA, V84, P8502, DOI 10.1073/pnas.84.23.8502; FRIEDLANDER DR, 1989, P NATL ACAD SCI USA, V86, P7043, DOI 10.1073/pnas.86.18.7043; GALLIN WJ, 1987, P NATL ACAD SCI USA, V84, P2808, DOI 10.1073/pnas.84.9.2808; GALLIN WJ, 1983, P NATL ACAD SCI-BIOL, V80, P1038, DOI 10.1073/pnas.80.4.1038; Gallin WJ, 1998, MOL BIOL EVOL, V15, P1099, DOI 10.1093/oxfordjournals.molbev.a026017; GUMBINER B, 1986, J CELL BIOL, V102, P457, DOI 10.1083/jcb.102.2.457; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Handschuh G, 2001, J MOL BIOL, V314, P445, DOI 10.1006/jmbi.2001.5143; Hoffman S., 1992, P1; Huber O, 1999, J CELL SCI, V112, P4415; HYAFIL F, 1981, CELL, V26, P447, DOI 10.1016/0092-8674(81)90214-2; HYAFIL F, 1980, CELL, V21, P927, DOI 10.1016/0092-8674(80)90456-0; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Kitagawa M, 2000, BIOCHEM BIOPH RES CO, V271, P358, DOI 10.1006/bbrc.2000.2636; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leckband D, 2000, CURR OPIN CELL BIOL, V12, P587, DOI 10.1016/S0955-0674(00)00136-8; Li Z, 1998, J CELL SCI, V111, P1005; MARRS JA, 1995, J CELL BIOL, V129, P507, DOI 10.1083/jcb.129.2.507; MATSUZAKI F, 1990, J CELL BIOL, V110, P1239, DOI 10.1083/jcb.110.4.1239; MEGE RM, 1988, P NATL ACAD SCI USA, V85, P7274, DOI 10.1073/pnas.85.19.7274; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; Noe V, 1999, J CELL SCI, V112, P127; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; OGOU SI, 1983, J CELL BIOL, V97, P944, DOI 10.1083/jcb.97.3.944; OGOU SI, 1982, DEV BIOL, V92, P521, DOI 10.1016/0012-1606(82)90196-8; OSBORN M, 1982, METHOD CELL BIOL, V24, P97; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; RINGWALD M, 1987, EMBO J, V6, P3647, DOI 10.1002/j.1460-2075.1987.tb02697.x; Runswick SK, 2001, NAT CELL BIOL, V3, P823, DOI 10.1038/ncb0901-823; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Sivasankar S, 2001, BIOPHYS J, V80, P1758, DOI 10.1016/S0006-3495(01)76146-2; Sivasankar S, 1999, P NATL ACAD SCI USA, V96, P11820, DOI 10.1073/pnas.96.21.11820; SOFRONIEW MV, 1982, J HISTOCHEM CYTOCHEM, V30, P504, DOI 10.1177/30.6.6178778; STAPPERT J, 1992, CELL CELL INTERACTIO, P75; STRAUSS W, 1998, CURRENT PROTOCOLS MO, V1; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; TANIHARA H, 1994, CELL ADHES COMMUN, V2, P15, DOI 10.3109/15419069409014199; TOMASELLI KJ, 1988, NEURON, V1, P33, DOI 10.1016/0896-6273(88)90207-3; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Williams E, 2000, J BIOL CHEM, V275, P4007, DOI 10.1074/jbc.275.6.4007; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Williams EJ, 2001, J BIOL CHEM, V276, P43879, DOI 10.1074/jbc.M105876200; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; YOSHIDA C, 1982, CELL, V28, P217, DOI 10.1016/0092-8674(82)90339-7	61	30	32	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39609	39616		10.1074/jbc.M201256200	http://dx.doi.org/10.1074/jbc.M201256200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12154084	hybrid			2022-12-27	WOS:000178662500072
J	Beinert, H				Beinert, H			Bioinorganic chemistry: A new field or discipline? Words, meanings, and reality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Reprint							IRON-SULFUR CLUSTERS; MAGNETIC CIRCULAR-DICHROISM; X-RAY-ABSORPTION; CLOSTRIDIUM-PASTEURIANUM; MOSSBAUER-SPECTROSCOPY; <4FE-4S>+ CLUSTER; FERREDOXIN; PROTEINS; COPPER; DELOCALIZATION		Univ Wisconsin, Coll Agr & Life Sci, Inst Enzyme Res, Madison, WI 53726 USA; Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53726 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Beinert, H (corresponding author), Univ Wisconsin, Coll Agr & Life Sci, Inst Enzyme Res, Madison, WI 53726 USA.							Achim C, 1996, J AM CHEM SOC, V118, P8168, DOI 10.1021/ja9617698; Anxolabehere-Mallart E, 2001, J AM CHEM SOC, V123, P5444, DOI 10.1021/ja010472t; BALLHAUSEN CJ, 1982, INTRO LIGAND FIELD T; BANCI L, 1993, BIOCHEMISTRY-US, V32, P9387, DOI 10.1021/bi00087a018; Beinert H, 1997, EUR J BIOCHEM, V245, P521, DOI 10.1111/j.1432-1033.1997.t01-1-00521.x; BEINERT H, 1983, P NATL ACAD SCI-BIOL, V80, P393, DOI 10.1073/pnas.80.2.393; Beinert H, 1997, SCIENCE, V277, P653, DOI 10.1126/science.277.5326.653; Beinert H, 2002, BBA-BIOENERGETICS, V1553, P7, DOI 10.1016/S0005-2728(01)00235-3; Beinert H, 1996, J INORG BIOCHEM, V64, P79, DOI 10.1016/0162-0134(96)00083-9; Bertini I, 2001, CURRENT METHODS INOR, V2, P1; Boehnke R., 1995, Biometals, V8, P223; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; DUNHAM WR, 1971, BIOCHIM BIOPHYS ACTA, V253, P134, DOI 10.1016/0005-2728(71)90240-4; Glaser T, 2001, J AM CHEM SOC, V123, P442, DOI 10.1021/ja002183v; GRIFFITHS D, 1961, J BIOL CHEM, V236, P1850; JOHNSON MK, 1983, J AM CHEM SOC, V105, P6671, DOI 10.1021/ja00360a022; JOHNSON MK, 1985, J BIOL CHEM, V260, P7368; KENNEDY MC, 1987, P NATL ACAD SCI USA, V84, P8854, DOI 10.1073/pnas.84.24.8854; Lamb DC, 2002, J BIOL CHEM, V277, P11636, DOI 10.1074/jbc.M109892200; Magnusson OT, 1999, J AM CHEM SOC, V121, P9764, DOI 10.1021/ja9925507; PAPAEFTHYMIOU V, 1987, J AM CHEM SOC, V109, P4703, DOI 10.1021/ja00249a037; Pierik AJ, 1999, J BIOL CHEM, V274, P3331, DOI 10.1074/jbc.274.6.3331; Popescu CV, 1998, P NATL ACAD SCI USA, V95, P13431, DOI 10.1073/pnas.95.23.13431; Sigel H, 2002, CHEM ENG NEWS, V80, P2; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; THOMSON AJ, 1981, BIOCHIM BIOPHYS ACTA, V670, P93, DOI 10.1016/0005-2795(81)90053-2; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; WERST MM, 1990, BIOCHEMISTRY-US, V29, P10526, DOI 10.1021/bi00498a015; Williams R. J. P., 1996, NATURAL SELECTION EL; Wilmanns M, 1995, P NATL ACAD SCI USA, V92, P11955, DOI 10.1073/pnas.92.26.11955	30	7	7	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					37967	37972		10.1074/jbc.X200002200	http://dx.doi.org/10.1074/jbc.X200002200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167661	hybrid			2022-12-27	WOS:000178529600001
J	Finkielstein, CV; Chen, LG; Maller, JL				Finkielstein, CV; Chen, LG; Maller, JL			A role for G(1)/S cyclin-dependent protein kinases in the apoptotic response to ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; XENOPUS EGG EXTRACTS; CELL-FREE APOPTOSIS; RETINOBLASTOMA PROTEIN; MIDBLASTULA TRANSITION; MEDIATED ACTIVATION; DEVELOPMENTAL TIMER; DNA FRAGMENTATION; FAMILY PROTEASES; CASPASE FAMILY	In Xenopus development the mid-blastula transition (MBT) marks a dramatic change in response of the embryo to ionizing radiation. Whereas inhibition of cyclin D1-Cdk4 and cyclin A2-Cdk2 by p27(Xic1) has been linked to cell cycle arrest and prevention of apoptosis in embryos irradiated post-MBT, distinct roles for these complexes during apoptosis are evident in embryos irradiated pre-MBT. Cyclin A2 is cleaved by caspases to generate a truncated complex termed DeltaN-cyclin A2-Cdk2, which is kinase active, not inhibited by p27(Xic1), and not sensitive to degradation by the ubiquitin-mediated proteasome pathway. Moreover, AN-cyclin A2-Cdk2 has an expanded substrate specificity and can phosphorylate histone H2B at Ser-32, which may facilitate DNA cleavage. Consistent with a role for cyclin A2 in apoptosis, the addition of AN-cyclin A2-Cdk2, but not full-length cyclin A2-Cdk2, to Xenopus egg extracts triggers apoptotic DNA fragmentation even when caspases are not activated. Similarly, cyclin D1 is targeted by caspases, and the generated product exhibits higher affinity for p27(Xic1), leading to reduced phosphorylation of the retinoblastoma protein (pRB) during apoptosis. These data suggest that caspase cleavage of both cyclin D1-Cdk4 and cyclin A2-Cdk2 promotes specific apoptotic events in embryos undergoing apoptosis in response to ionizing radiation.	Univ Colorado, Sch Med, Howard Hughes Med Inst, Denver, CO 80262 USA; Univ Colorado, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Maller, JL (corresponding author), Univ Colorado, Sch Med, Howard Hughes Med Inst, 4200 E 9th Ave,Box C-236, Denver, CO 80262 USA.			finkielstein, carla/0000-0002-8417-4643	NCI NIH HHS [CA 46934] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Ajiro K, 2000, J BIOL CHEM, V275, P439, DOI 10.1074/jbc.275.1.439; An B, 1996, CANCER RES, V56, P438; Anderson JA, 1997, MOL BIOL CELL, V8, P1195, DOI 10.1091/mbc.8.7.1195; AUSUBEL FM, 1981, COLD SPRING HARB SYM, V45, P487; Bokoch GM, 1998, CELL DEATH DIFFER, V5, P637, DOI 10.1038/sj.cdd.4400405; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; Counis MF, 2000, BIOCHEM CELL BIOL, V78, P405, DOI 10.1139/bcb-78-4-405; DESTREE OHJ, 1992, DEV BIOL, V153, P141, DOI 10.1016/0012-1606(92)90098-2; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Evans EK, 1997, EMBO J, V16, P230, DOI 10.1093/emboj/16.2.230; Evans EK, 1997, EMBO J, V16, P7372, DOI 10.1093/emboj/16.24.7372; Farschon DM, 1997, J CELL BIOL, V137, P1117, DOI 10.1083/jcb.137.5.1117; Finkielstein CV, 2001, P NATL ACAD SCI USA, V98, P1006, DOI 10.1073/pnas.98.3.1006; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GLAB N, 1994, FEBS LETT, V353, P207, DOI 10.1016/0014-5793(94)01035-8; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Goyal L, 2001, CELL, V104, P805, DOI 10.1016/S0092-8674(01)00276-8; Hartley RS, 1996, DEV BIOL, V173, P408, DOI 10.1006/dbio.1996.0036; Hensey C, 1997, MECH DEVELOP, V69, P183, DOI 10.1016/S0925-4773(97)00191-3; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; Mazumder S, 2002, MOL CELL BIOL, V22, P2398, DOI 10.1128/MCB.22.7.2398-2409.2002; Mazumder S, 2000, ONCOGENE, V19, P2828, DOI 10.1038/sj.onc.1203623; MEIKRANTZ W, 1995, J CELL BIOCHEM, V58, P160, DOI 10.1002/jcb.240580205; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 1997, J NEUROSCI, V17, P8975; REMPEL RE, 1995, J BIOL CHEM, V270, P6843, DOI 10.1074/jbc.270.12.6843; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Sherr CJ, 2000, CANCER RES, V60, P3689; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Sible JC, 1997, DEV BIOL, V189, P335, DOI 10.1006/dbio.1997.8683; Stack JH, 1997, DEVELOPMENT, V124, P3185; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yamashita K, 1999, BLOOD, V93, P674, DOI 10.1182/blood.V93.2.674.402k26_674_685; Yao SL, 1996, CANCER RES, V56, P4551; Zhou BB, 1998, P NATL ACAD SCI USA, V95, P6785, DOI 10.1073/pnas.95.12.6785	62	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38476	38485		10.1074/jbc.M206184200	http://dx.doi.org/10.1074/jbc.M206184200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12176996	hybrid			2022-12-27	WOS:000178529600063
J	Gao, HW; Parkin, S; Johnson, PF; Schwartz, RC				Gao, HW; Parkin, S; Johnson, PF; Schwartz, RC			C/EBP gamma has a stimulatory role on the IL-6 and IL-8 promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MONOCYTE CHEMOATTRACTANT PROTEIN-1; MACROPHAGE INFLAMMATORY PROTEIN-2; LYMPHOBLASTIC CELL-LINE; BINDING-PROTEIN; GENE-EXPRESSION; LEUCINE-ZIPPER; TRANSCRIPTIONAL ACTIVATORS; INTERLEUKIN-8 PRODUCTION; MESSENGER-RNA	CCAAT/enhancer-binding protein gamma (C/EBPgamma) is an ubiquitously expressed member of the C/EBP family of transcription factors that has been shown to be an inhibitor of C/EBP transcriptional activators and has been proposed to act as a buffer against C/EBP-mediated activation. We have now unexpectedly found that C/EBPgamma dramatically augments the activity of C/EBPbeta in lipopolysaccharide induction of the interleukin-6 and interleukin-8 promoters in a B lymphoblast cell line. This activating role for C/EBPgamma is promoter-specific, neither being observed in the regulation of a simple C/EBP-dependent promoter nor the TNFalpha promoter. C/EBPgamma activity also shows cell-type specificity with no activity observed in a macrophage cell line. Studies with chimeric C/EBP proteins implicate the formation of a heterodimeric leucine zipper between C/EBPbeta and C/EBPgamma as the critical structural feature required for C/EBPgamma stimulatory activity. These findings suggest a unique role for C/EBPgamma in B cell gene regulation and, along with our previous observation of the ability of C/EBP basic region-leucine zipper domains to confer lipopolysaccharide inducibility of interleukin-6, suggest that the C/EBP leucine zipper domain has a role in C/EBP function beyond allowing dimerization between C/EBP family members.	Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; NCI, Eukaryot Transcript Regulat Sect, Regulat Cell Growth Lab, Frederick, MD 21702 USA	Michigan State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schwartz, RC (corresponding author), Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA.		Johnson, Peter/A-1940-2012	Johnson, Peter/0000-0002-4145-4725				AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BAUER SR, 1986, J IMMUNOL, V136, P4695; BRETZ JD, 1994, P NATL ACAD SCI USA, V91, P7306, DOI 10.1073/pnas.91.15.7306; COOPER C, 1995, NUCLEIC ACIDS RES, V23, P4371, DOI 10.1093/nar/23.21.4371; COOPER C, 1992, J IMMUNOL, V149, P3225; COOPER CL, 1994, J IMMUNOL, V153, P5049; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GUTMAN GA, 1981, CLIN IMMUNOL IMMUNOP, V18, P230, DOI 10.1016/0090-1229(81)90029-5; HOBBS MV, 1991, CELL IMMUNOL, V132, P442, DOI 10.1016/0008-8749(91)90041-9; Hu HM, 2000, J BIOL CHEM, V275, P16373, DOI 10.1074/jbc.M910269199; Hu HM, 1998, J IMMUNOL, V160, P2334; HUANG S, 1992, AM J PATHOL, V141, P981; JOHNSON PF, 1994, LIVER GENE EXPRESSIO, P231; Kaisho T, 1999, J EXP MED, V190, P1573, DOI 10.1084/jem.190.11.1573; Karafiat V, 2001, BLOOD, V98, P3668, DOI 10.1182/blood.V98.13.3668; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KUNSCH C, 1994, J IMMUNOL, V153, P153; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JR, 1998, EUR J IMMUNOL, V28, P4188, DOI 10.1002/(SICI)1521-4141(199812)28:12<4188::AID-IMMU4188>3.0.CO;2-B; Liu HT, 2000, J IMMUNOL, V164, P4277, DOI 10.4049/jimmunol.164.8.4277; Macfarlane DE, 1998, J IMMUNOL, V160, P1122; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Murayama T, 1997, J VIROL, V71, P5692, DOI 10.1128/JVI.71.7.5692-5695.1997; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; Omori SA, 1997, J IMMUNOL, V159, P1800; Pan Q, 2000, EUR J IMMUNOL, V30, P1019, DOI 10.1002/(SICI)1521-4141(200004)30:4<1019::AID-IMMU1019>3.0.CO;2-W; Parkin SE, 2002, J BIOL CHEM, V277, P23563, DOI 10.1074/jbc.M202184200; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; ROMAN C, 1990, GENE DEV, V4, P1404, DOI 10.1101/gad.4.8.1404; Shapiro VS, 2001, BLOOD, V98, P187, DOI 10.1182/blood.V98.1.187; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; TANABE O, 1988, J IMMUNOL, V141, P3875; Treon S P, 1998, Curr Opin Hematol, V5, P42; Venkataraman C, 1999, IMMUNOL LETT, V69, P233, DOI 10.1016/S0165-2478(99)00068-1; Wall L, 1996, J BIOL CHEM, V271, P16477, DOI 10.1074/jbc.271.28.16477; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WILLIAMS SC, 1995, EMBO J, V14, P3170, DOI 10.1002/j.1460-2075.1995.tb07319.x; Williams SC, 1998, J BIOL CHEM, V273, P13493, DOI 10.1074/jbc.273.22.13493; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Wuyts A, 1996, J IMMUNOL, V157, P1736; Zafarana G, 2000, EMBO J, V19, P5856, DOI 10.1093/emboj/19.21.5856; Zhang X, 2001, J IMMUNOL, V166, P7104, DOI 10.4049/jimmunol.166.12.7104	44	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38827	38837		10.1074/jbc.M206224200	http://dx.doi.org/10.1074/jbc.M206224200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12177065	hybrid			2022-12-27	WOS:000178529600104
J	Golubovskaya, V; Beviglia, L; Xu, LH; Earp, HS; Craven, R; Cance, W				Golubovskaya, V; Beviglia, L; Xu, LH; Earp, HS; Craven, R; Cance, W			Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; C-TERMINAL DOMAIN; EGF RECEPTOR; FACTOR-ALPHA; TUMOR-CELLS; EXPRESSION; FAK; SURVIVAL; MIGRATION; SUPPRESSION	The focal adhesion kinase (FAK) and epidermal growth factor receptor (EGFR) are protein-tyrosine kinases that are overexpressed and activated in human breast cancer. To determine the role of EGFR and FAK survival signaling in breast cancer, EGFR was stably overexpressed in BT474 breast cancer cells, and each signaling pathway was specifically targeted for inhibition. FAK and EGFR constitutively co-immunoprecipitated in EGFR-overexpressing BT474 cells. In low EGFR-expressing BT474-pcDNA3 vector control cells, inhibition of FAK by the FAK C-terminal domain caused detachment and apoptosis via pathways involving activation of caspase-3 and -8, cleavage of poly(ADP-ribose) polymerase, and caspase-3-dependent degradation of AKT. This apoptosis could be rescued by the dominant-negative Fas-associated death domain, indicating involvement of the death receptor pathway. EGFR overexpression did not inhibit detachment induced by the FAK C-terminal domain, but did suppress apoptosis, activating AKT and ERK1/2 survival pathways and inhibiting cleavage of FAK, caspase-3 and -8, and poly(ADPribose) polymerase. Furthermore, this protective effect of EGFR signaling was reversed by EGFR kinase inhibition with AG1478. In addition, inhibition of FAK and EGFR in another breast cancer cell line (BT20) endogenously overexpressing these kinases also induced apoptosis via the same mechanism as in the EGFR-overexpressing BT474 cells. The results of this study indicate that dual inhibition of FAK and EGFR signaling pathways can cooperatively enhance apoptosis in breast cancers.	Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Surg, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Cance, W (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, CB 7210,3010 Old Clin Bldg, Chapel Hill, NC 27599 USA.				NCI NIH HHS [CA65910] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA065910] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bachelder RE, 2001, J BIOL CHEM, V276, P34702, DOI 10.1074/jbc.M102806200; BELLACOSA A, 1993, ONCOGENE, V8, P745; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; BORLINGHAUS P, 1993, CLIN INVESTIGATOR, V71, P903; Cance WG, 2000, CLIN CANCER RES, V6, P2417; Carpenter G, 2000, BIOESSAYS, V22, P697, DOI 10.1002/1521-1878(200008)22:8<697::AID-BIES3>3.3.CO;2-T; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Ciardiello F, 2000, CLIN CANCER RES, V6, P2053; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Gervais FG, 1998, J BIOL CHEM, V273, P17102, DOI 10.1074/jbc.273.27.17102; Gibson EM, 2002, CANCER RES, V62, P488; Gibson S, 1999, J BIOL CHEM, V274, P17612, DOI 10.1074/jbc.274.25.17612; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; HARRIS AL, 1989, J STEROID BIOCHEM, V34, P123, DOI 10.1016/0022-4731(89)90072-1; Hauck CR, 2001, CANCER RES, V61, P7079; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HONEGGER AM, 1989, P NATL ACAD SCI USA, V86, P925, DOI 10.1073/pnas.86.3.925; Ilekis JV, 1997, GYNECOL ONCOL, V66, P250, DOI 10.1006/gyno.1997.4764; Ilic D, 1998, J CELL BIOL, V143, P547; Ilic D, 1997, J CELL SCI, V110, P401; Issing WJ, 1996, ANTICANCER RES, V16, P283; Jones G, 2001, CANCER RES, V61, P4978; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kim ES, 2001, CURR OPIN ONCOL, V13, P506, DOI 10.1097/00001622-200111000-00014; Kitagawa D, 2002, J BIOL CHEM, V277, P366, DOI 10.1074/jbc.M107110200; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001; MERLINO GT, 1985, J CLIN INVEST, V75, P1077, DOI 10.1172/JCI111770; Moulder SL, 2001, CANCER RES, V61, P8887; Nolan K, 1999, MOL CELL BIOL, V19, P6120; OWENS LV, 1995, CANCER RES, V55, P2752; Price JT, 1999, CANCER RES, V59, P5475; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sonoda Y, 1999, J BIOL CHEM, V274, P10566, DOI 10.1074/jbc.274.15.10566; Sonoda Y, 2000, J BIOL CHEM, V275, P16309, DOI 10.1074/jbc.275.21.16309; van de Water B, 2001, J BIOL CHEM, V276, P36183, DOI 10.1074/jbc.M102091200; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; WEINER TM, 1993, LANCET, V342, P1024, DOI 10.1016/0140-6736(93)92881-S; WEINER TM, 1994, ANN SURG ONCOL, V1, P18, DOI 10.1007/BF02303537; Westermark K, 1996, HISTOPATHOLOGY, V28, P221, DOI 10.1046/j.1365-2559.1996.d01-427.x; Witters L, 1999, BREAST CANCER RES TR, V53, P41, DOI 10.1023/A:1006127527107; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199; Xu LH, 1998, CELL GROWTH DIFFER, V9, P999; Xu LH, 1996, CELL GROWTH DIFFER, V7, P413; Zachary I, 1997, INT J BIOCHEM CELL B, V29, P929, DOI 10.1016/S1357-2725(97)00008-3	59	125	129	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38978	38987		10.1074/jbc.M205002200	http://dx.doi.org/10.1074/jbc.M205002200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167618	Green Published, hybrid			2022-12-27	WOS:000178529600122
J	Longo, KA; Kennell, JA; Ochocinska, MJ; Ross, SE; Wright, WS; MacDougald, OA				Longo, KA; Kennell, JA; Ochocinska, MJ; Ross, SE; Wright, WS; MacDougald, OA			Wnt signaling protects 3T3-L1 preadipocytes from apoptosis through induction of insulin-like growth factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITS APOPTOSIS; SURVIVAL FACTOR; P-GLYCOPROTEIN; CELL-SURVIVAL; GENE; AKT; ADIPOGENESIS; ACTIVATION; RESISTANCE; EXPRESSION	Ectopic expression of Wnt-1 in 3T3-L1 preadipocytes stabilizes beta-catenin, activates TCF-dependent gene transcription, and blocks adipogenesis. Here we report that upon serum withdrawal, Wnt-1 causes 3T3-L1 cells to resist apoptosis through a mechanism that is partially dependent on phosphatidylinositol 3-kinase. Although activation of Wnt signaling by inhibition of GSK-3 activity or ectopic expression of dominant stable beta-catenin blocks apoptosis, inhibition of Wnt signaling through expression of dominant negative TCF-4 increases apoptosis. Wnt-1 stimulates 3T3-L1 preadipocytes to secrete factors that increase PKB/Akt phosphorylation at levels comparable with treatment with 10% serum. With DNA microarrays, we identified several secreted antiapoptotic genes that are induced by Wnt-1, notably insulin-like growth factor I (IGF-I) and IGF-II. Consistent with IGFs mediating the antiapoptotic effects of Wnt-1 in preadipocytes, conditioned medium from Wnt-1 expressing 3T3-L1 cells was unable to promote protein kinase B phosphorylation after the addition of recombinant IGFBP-4. Thus, we demonstrated that Wnt-1 induces expression of antiapoptotic genes in 3T3-L1 preadipocytes such as IGF-I and IGF-II, which allows these cells to resist apoptosis in response to serum deprivation.	Univ Michigan, Sch Med, Dept Physiol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	MacDougald, OA (corresponding author), Univ Michigan, Sch Med, Dept Physiol, 7620 Med Sci Bldg 2,1301 E Catherine Dr, Ann Arbor, MI 48109 USA.	macdouga@umich.edu	Longo, Kenneth A/A-5631-2010	MacDougald, Ormond/0000-0001-6907-7960; Kennell, Jennifer/0000-0001-9793-6259; Hahn, Wendy/0000-0002-4374-5876	NIDDK NIH HHS [T32 DK007245, DK 51563, T32-DK07245] Funding Source: Medline; NIGMS NIH HHS [T32-GM08322, T32 GM008322] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007245, R01DK051563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008322] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Bournat JC, 2000, J NEUROSCI RES, V61, P21, DOI 10.1002/1097-4547(20000701)61:1<21::AID-JNR3>3.0.CO;2-7; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Chen RH, 1999, J BIOL CHEM, V274, P23013, DOI 10.1074/jbc.274.33.23013; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225; Dias S, 2002, BLOOD, V99, P2179, DOI 10.1182/blood.V99.6.2179; Fang Y, 1999, ENDOCRINOLOGY, V140, P5239, DOI 10.1210/en.140.11.5239; Fassett JT, 2001, ENDOCRINOLOGY, V142, P2129, DOI 10.1210/en.142.5.2129; Frassanito MA, 2001, BLOOD, V97, P483, DOI 10.1182/blood.V97.2.483; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Gagnon A, 2001, ENDOCRINOLOGY, V142, P205, DOI 10.1210/en.142.1.205; Gollapudi S, 2001, J CLIN IMMUNOL, V21, P420, DOI 10.1023/A:1013177710941; GREEN H, 1979, J CELL PHYSIOL, V101, P169, DOI 10.1002/jcp.1041010119; Howe LR, 1999, CANCER RES, V59, P1572; Howe LR, 2001, J BIOL CHEM, V276, P20108, DOI 10.1074/jbc.M010692200; Inadera H, 2000, BIOCHEM BIOPH RES CO, V275, P108, DOI 10.1006/bbrc.2000.3276; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; Kang Yup, 2000, Molecular Cell Biology Research Communications, V4, P181, DOI 10.1006/mcbr.2001.0276; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; Lane TF, 1997, ONCOGENE, V15, P2133, DOI 10.1038/sj.onc.1201593; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; Magun R, 1998, INT J OBESITY, V22, P567, DOI 10.1038/sj.ijo.0800626; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morali OG, 2001, ONCOGENE, V20, P4942, DOI 10.1038/sj.onc.1204660; Moreno A, 2001, BLOOD, V97, P242, DOI 10.1182/blood.V97.1.242; Niesler CU, 2000, J ENDOCRINOL, V167, P165, DOI 10.1677/joe.0.1670165; Notarbartolo M, 2002, CANCER LETT, V180, P91, DOI 10.1016/S0304-3835(01)00834-5; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Pennica D, 1998, P NATL ACAD SCI USA, V95, P14717, DOI 10.1073/pnas.95.25.14717; Persidis A, 1999, NAT BIOTECHNOL, V17, P94, DOI 10.1038/5289; Plas DR, 2002, TRENDS ENDOCRIN MET, V13, P74; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074-7613(00)00004-2; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; Stewart CEH, 1996, J BIOL CHEM, V271, P11330, DOI 10.1074/jbc.271.19.11330; Su F, 2002, GENE DEV, V16, P46, DOI 10.1101/gad.942902; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; TAYLOR V, 1995, J BIOL CHEM, V270, P28824, DOI 10.1074/jbc.270.48.28824; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Wulf P, 1999, DEV BRAIN RES, V116, P169, DOI 10.1016/S0165-3806(99)00092-9; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zhou Y, 2002, AM J PATHOL, V160, P1405, DOI 10.1016/S0002-9440(10)62567-9; Zoubine MN, 2001, BIOCHEM BIOPH RES CO, V282, P421, DOI 10.1006/bbrc.2001.4584	50	172	179	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38239	38244		10.1074/jbc.M206402200	http://dx.doi.org/10.1074/jbc.M206402200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12154096	hybrid			2022-12-27	WOS:000178529600034
J	Olalla, L; Gutierrez, A; Campos, JA; Khan, ZU; Alonso, FJ; Segura, JA; Marquez, J; Aledo, JC				Olalla, L; Gutierrez, A; Campos, JA; Khan, ZU; Alonso, FJ; Segura, JA; Marquez, J; Aledo, JC			Nuclear localization of L-type glutaminase in mammalian brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE-ACTIVATED GLUTAMINASE; PDZ-DOMAIN; MOLECULAR-CLONING; EXPRESSION; PROTEIN; PURIFICATION; ASSOCIATION; GLUTAMATE; BINDING	In mammals, there are two different genes encoding for glutaminase isoforms, named liver (LGA) and kidney (KGA) types. LGA has long been believed to be present only in liver mitochondria from adult animals. However, we have recently reported the presence of LGA mRNA in human brain. We now describe the expression of LGA mRNA in the brain of other mammals (cow, mouse, rabbit, and rat) and in different areas of human brain as assessed by Northern blot analysis. The presence of mRNA encoding for this isoform in rat brain was further confirmed by reverse transcriptase-PCR cloning and sequencing. Although it has been well accepted that glutaminase is a mitochondrial enzyme, using newly generated isoform-specific antibodies, we have found a differential intracellular immunolocalization of both glutaminase isoforms in rat and monkey brain. In both species, KGA protein was present in mitochondria, whereas LGA protein was localized in nuclei. Furthermore, subcellular fractionation and Western blot analysis revealed that brain LGA was enriched in nuclei where it was catalytically active. Nuclear glutaminase exhibited a kinetic behavior that resembles that of the liver-type enzyme with regard to the low phosphate concentration requirement; however, nuclear glutaminase was susceptible to glutamate inhibition, a property that is absent in the rat liver enzyme.	Univ Malaga, Fac Ciencias, Dept Bioquim & Biol Mol, Lab Quim Prot, E-29071 Malaga, Spain; Univ Malaga, Fac Ciencias, Dept Biol Celular Genet & Fisiol, E-29071 Malaga, Spain; Univ Malaga, Dept Med, Ctr Invest Medicosanitarias, E-29071 Malaga, Spain	Universidad de Malaga; Universidad de Malaga; Universidad de Malaga	Aledo, JC (corresponding author), Univ Malaga, Fac Ciencias, Dept Bioquim & Biol Mol, Lab Quim Prot, Campus Teatinos, E-29071 Malaga, Spain.	caledo@uma.es	Aledo, Juan Carlos/Z-4236-2019; marquez, javier/K-3289-2012; KHAN, Zafaruddin/J-6217-2012; Campos-Sandoval, José/I-7375-2018; Aledo, Juan C/E-6029-2011	Aledo, Juan Carlos/0000-0002-3497-9945; marquez, javier/0000-0003-3317-3963; KHAN, Zafaruddin/0000-0003-0742-399X; Campos-Sandoval, José/0000-0002-2457-9884; Alonso Carrion, Francisco Jose/0000-0002-9431-163X; Gutierrez Perez, Antonia/0000-0002-6264-6152				Aledo JC, 2000, MAMM GENOME, V11, P1107, DOI 10.1007/s003350010190; Aledo JC, 2001, PROTEIN EXPRES PURIF, V23, P411, DOI 10.1006/prep.2001.1522; ALEDO JC, 1994, FEBS LETT, V341, P39, DOI 10.1016/0014-5793(94)80236-X; ALEDO JC, 1996, BIOCHIM BIOPHYS ACTA, V1323, P173; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; BILLETT EE, 1984, BIOCHEM J, V221, P765, DOI 10.1042/bj2210765; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; Gomez-Fabre PM, 2000, BIOCHEM J, V345, P365, DOI 10.1042/0264-6021:3450365; Harlow E., 1988, ANTIBODIES LABORATOR, P1; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HEINI HG, 1987, EUR J BIOCHEM, V162, P541, DOI 10.1111/j.1432-1033.1987.tb10673.x; Hogan A, 2001, J BIOL CHEM, V276, P26526, DOI 10.1074/jbc.M104156200; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Khan ZU, 1998, P NATL ACAD SCI USA, V95, P7731, DOI 10.1073/pnas.95.13.7731; KREBS HANS ADOLF, 1935, BIOCHEM JOUR, V29, P1951; Laake JH, 1999, NEUROSCIENCE, V88, P1137, DOI 10.1016/S0306-4522(98)00298-X; Meertens LM, 1998, EMBO J, V17, P6972, DOI 10.1093/emboj/17.23.6972; Nagase T, 1998, DNA Res, V5, P355, DOI 10.1093/dnares/5.6.355; NICKLAS WJ, 1987, BIOCHEM SOC T, V15, P208, DOI 10.1042/bst0150208; Olalla L, 2001, FEBS LETT, V488, P116, DOI 10.1016/S0014-5793(00)02373-5; Riefler GM, 2001, J BIOL CHEM, V276, P48262, DOI 10.1074/jbc.M106503200; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; SMITH EM, 1990, J BIOL CHEM, V265, P10631; Soltys BJ, 1999, TRENDS BIOCHEM SCI, V24, P174, DOI 10.1016/S0968-0004(99)01390-0; TANIGAWA Y, 1978, EUR J BIOCHEM, V92, P261, DOI 10.1111/j.1432-1033.1978.tb12744.x; Watkins JC, 2000, BIOCHEM SOC T, V28, P297, DOI 10.1042/0300-5127:0280297; Wischmeyer PE, 2002, NUTRITION, V18, P225, DOI 10.1016/S0899-9007(01)00796-1	28	79	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38939	38944		10.1074/jbc.C200373200	http://dx.doi.org/10.1074/jbc.C200373200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163477	hybrid			2022-12-27	WOS:000178529600117
J	Sandgren, S; Cheng, F; Belting, M				Sandgren, S; Cheng, F; Belting, M			Nuclear targeting of macromolecular polyanions by an HIV-Tat derived peptide - Role for cell-surface proteoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; HUMAN-IMMUNODEFICIENCY-VIRUS; FIBROBLAST-GROWTH-FACTOR; MEDIATED GENE-TRANSFER; INTRACELLULAR DELIVERY; BASIC DOMAIN; PROTEIN TRANSDUCTION; IN-VITRO; GLYCOSAMINOGLYCANS; ACCUMULATION	New therapies based on gene transfer and protein delivery require a better understanding of the basic mechanisms of macromolecular membrane transport. We have studied cellular uptake of macromolecular polyanions, i.e. DNA and glycosaminoglycans, and a polybasic HIV-Tat derived peptide (GRKKRRQRRRPPQC) using fluorescence assisted cell sorting and confocal fluorescence microscopy. The transactivator of HIV transcription (Tat) peptide stimulated cellular uptake of both DNA and heparan sulfate in a time-, concentration-, and temperature-dependent manner. Peptide-polyanion complexes accumulated in large, acidic, cytoplasmic vesicles formed de novo. This was followed by transfer of polyanion into the nuclear compartment and subsequent disappearance of the endolysosomal vesicles. In the absence of polyanion the Tat peptide displayed rapid accumulation in the nuclear compartment. However, in the presence of polyanion the peptide was almost exclusively retained in cytoplasmic vesicles. Cell-surface proteoglycans played a pivotal role in the uptake of complexes exhibiting a relatively high peptide to polyanion ratio, corresponding to a net positive charge of the complexes. Uptake of polyanions per se or complexes with a relatively low peptide to polyanion ratio was favored by proteoglycan deficiency in the recipient cells, indicating the existence of distinct transport mechanisms. Moreover, expression of full-length HIV-Tat as well as exogenous addition of HIV-Tat peptide resulted in cellular accumulation of endogenous proteoglycans. We conclude that an HIV-Tat derived peptide efficiently targets extraneous DNA and glycosaminoglycans to the nuclear compartment and that proteoglycans serve a regulatory role in these processes, which may have implications for directed gene and drug delivery in vivo.	Lund Univ, BMC, Sect Cell & Matrix Biol, Dept Cell & Mol Biol, S-22184 Lund, Sweden	Lund University	Belting, M (corresponding author), Lund Univ, BMC, Sect Cell & Matrix Biol, Dept Cell & Mol Biol, C13, S-22184 Lund, Sweden.			Belting, Mattias/0000-0003-1585-5434				Belting M, 1999, BIOCHEM J, V338, P317, DOI 10.1042/0264-6021:3380317; Belting M, 2002, P NATL ACAD SCI USA, V99, P371, DOI 10.1073/pnas.012346499; Belting M, 1999, BIOCHEM J, V342, P281, DOI 10.1042/0264-6021:3420281; Belting M, 1996, GLYCOBIOLOGY, V6, P121, DOI 10.1093/glycob/6.2.121; Belting M, 1999, J BIOL CHEM, V274, P19375, DOI 10.1074/jbc.274.27.19375; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Cheng F, 2001, J CELL BIOCHEM, V83, P597, DOI 10.1002/jcb.1254; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Ding K, 2001, J BIOL CHEM, V276, P46779, DOI 10.1074/jbc.M105419200; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; ESKO JD, 1985, P NATL ACAD SCI USA, V82, P3197, DOI 10.1073/pnas.82.10.3197; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FRANSSON LA, 1980, EUR J BIOCHEM, V106, P59; Fuki IV, 2000, J BIOL CHEM, V275, P25742, DOI 10.1074/jbc.M909173199; Giometto B, 1997, ANN NEUROL, V42, P34, DOI 10.1002/ana.410420108; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Hawiger J, 1999, CURR OPIN CHEM BIOL, V3, P89, DOI 10.1016/S1367-5931(99)80016-7; Hengge UR, 1996, J CLIN INVEST, V97, P2911, DOI 10.1172/JCI118750; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; KOPP JB, 1992, P NATL ACAD SCI USA, V89, P1577, DOI 10.1073/pnas.89.5.1577; Liang Y, 1997, J CELL BIOL, V139, P851, DOI 10.1083/jcb.139.4.851; Liu Y, 2000, NAT MED, V6, P1380, DOI 10.1038/82199; Mahley RW, 1999, J LIPID RES, V40, P1; MANN DA, 1991, EMBO J, V10, P1733, DOI 10.1002/j.1460-2075.1991.tb07697.x; Mislick KA, 1996, P NATL ACAD SCI USA, V93, P12349, DOI 10.1073/pnas.93.22.12349; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027; Rusnati M, 1999, J BIOL CHEM, V274, P28198, DOI 10.1074/jbc.274.40.28198; Rusnati M, 1997, J BIOL CHEM, V272, P11313, DOI 10.1074/jbc.272.17.11313; SABATIER JM, 1991, J VIROL, V65, P961, DOI 10.1128/JVI.65.2.961-967.1991; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Tumova S, 1997, J BIOL CHEM, V272, P9078; Tumova S, 1999, BIOCHEM J, V337, P471, DOI 10.1042/0264-6021:3370471; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; VANPUTTEN JPM, 1995, EMBO J, V14, P2144, DOI 10.1002/j.1460-2075.1995.tb07208.x; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WEEKS BS, 1995, J NEUROSCI RES, V42, P34, DOI 10.1002/jnr.490420105; Wiethoff CM, 2001, J BIOL CHEM, V276, P32806, DOI 10.1074/jbc.M007940200; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	44	153	164	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38877	38883		10.1074/jbc.M205395200	http://dx.doi.org/10.1074/jbc.M205395200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163493	hybrid			2022-12-27	WOS:000178529600110
J	Zhang, LQ; Ikegami, M; Dey, CR; Korfhagen, TR; Whitsett, JA				Zhang, LQ; Ikegami, M; Dey, CR; Korfhagen, TR; Whitsett, JA			Reversibility of pulmonary abnormalities by conditional replacement of surfactant protein D (SP-D) in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-TARGETED MICE; IN-VIVO; EXPRESSION; LUNG; LOCALIZATION; HOMEOSTASIS	Surfactant protein D (SP-D) gene-targeted mice develop severe pulmonary disease associated with emphysema, pulmonary lipidosis, and foamy macrophage infiltrations. To determine the potential reversibility of these abnormalities, transgenic mice were developed in which SP-D was conditionally replaced in the respiratory epithelium of SP-D-/- mice. SP-D was not detected in the absence of doxycycline. Treatment with doxycycline after birth restored pulmonary SP-D concentrations and corrected pulmonary pathology at adulthood. When SP-D was replaced in adult SP-D-/- mice, alveolar SP-D was restored within 3 days, pulmonary lipid abnormalities were corrected, but emphysema persisted. In corrected adult SP-D-/- mice, loss of SP-D caused focal emphysema and pulmonary inflammation but did not cause phospholipid abnormalities characteristic of SP-D-/- mice. Thus, abnormalities in surfactant phospholipid homeostasis and alveolar macrophage abnormalities were readily corrected by restoration of SP-D. However, once established, emphysema was not reversed by SP-D. SP-D-dependent processes regulating surfactant lipid homeostasis were disassociated from those mediating emphysema.	Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center	Whitsett, JA (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Neonatol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NCI NIH HHS [SCOR HL56387] Funding Source: Medline; NHLBI NIH HHS [HL33865, HL63329] Funding Source: Medline; OAPP OPHS HHS [PPG HL61646] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063329, R01HL033865] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OAPP OPHS HHS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARTLETT GR, 1959, J BIOL CHEM, V234, P466; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177, DOI 10.1165/ajrcmb.19.2.140; Fisher JH, 2000, AM J PHYSIOL-LUNG C, V278, pL365, DOI 10.1152/ajplung.2000.278.2.L365; HULL W, 2000, AM J RESP CRIT CARE, V161, pA42; Ikegami M, 2000, AM J PHYSIOL-LUNG C, V279, pL468, DOI 10.1152/ajplung.2000.279.3.L468; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; LeVine AM, 2001, J IMMUNOL, V167, P5868, DOI 10.4049/jimmunol.167.10.5868; Madsen J, 2000, J IMMUNOL, V164, P5866, DOI 10.4049/jimmunol.164.11.5866; MASON RJ, 1976, J LIPID RES, V17, P281; Massaro D, 2002, AM J PHYSIOL-LUNG C, V282, pL345, DOI 10.1152/ajplung.00374.2001; McCormack FX, 2002, J CLIN INVEST, V109, P707, DOI 10.1172/JCI200215293; Perl AKT, 2002, TRANSGENIC RES, V11, P21, DOI 10.1023/A:1013986627504; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; Tichelaar JW, 2000, J BIOL CHEM, V275, P11858, DOI 10.1074/jbc.275.16.11858; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; Wong CJ, 1996, PEDIATR RES, V39, P930, DOI 10.1203/00006450-199606000-00002; Yoshida M, 2001, J IMMUNOL, V166, P7514, DOI 10.4049/jimmunol.166.12.7514; Zhang LQ, 2002, J BIOL CHEM, V277, P22453, DOI 10.1074/jbc.M201632200; Zhang LQ, 2001, J BIOL CHEM, V276, P19214, DOI 10.1074/jbc.M010191200	21	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38709	38713		10.1074/jbc.M206200200	http://dx.doi.org/10.1074/jbc.M206200200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163500	hybrid			2022-12-27	WOS:000178529600089
J	Wadhwa, R; Sugihara, T; Hasan, MK; Taira, K; Reddel, RR; Kaul, SC				Wadhwa, R; Sugihara, T; Hasan, MK; Taira, K; Reddel, RR; Kaul, SC			A major functional difference between the mouse and human ARF tumor suppressor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INK4A LOCUS; ALTERNATIVE PRODUCT; STABILIZES P53; IN-VIVO; P16(INK4A); P19(ARF); MDM2; GENE; P14(ARF); PEX19P	Suppression of tumorigenesis is considerably more stringent in the human than in the much shorter lived mouse species, and the reasons for this difference are poorly understood. We investigated functional differences in the control of the ARF (alternative reading frame) protein that acts upstream of p53 and is encoded along with p16(INK4a) at a major tumor suppressor locus in both the human and mouse genomes. The mouse and human ARF proteins are substantially divergent at their carboxyl termini. We have shown that the mouse ARF protein (p19ARF) interacts with Pex19p in the cell cytoplasm leading to its nuclear exclusion and repression of its p53 activation function. The human ARF protein (p14ARF) is substantially smaller than its mouse counterpart and is not subject to this functional inactivation by Pex19p. In an identical cellular background, ribozymes directed against Pex19p enhanced p19ARF- but not p14ARF-activated p53 function. This is the first demonstration of a functional difference between the mouse and human ARF proteins. In view of the major role of ARF in tumor suppression, this distinction may contribute to the different levels of tumor proneness of these species.	Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan; Natl Inst Adv Ind Sci & Technol, Gene Funct Res Lab, Tsukuba, Ibaraki 3058566, Japan; Chugai Res Inst Med Sci, Ibaraki 3004101, Japan; Inst Environm Sci, Dept Radiobiol, Kamikita, Aomori 0393212, Japan; Childrens Med Res Inst, Westmead, NSW 2145, Australia	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); Chugai Pharmaceutical Co., Ltd.; Chugai Research Institute for Medical Science, Inc.; Children's Medical Research Institute - Australia	Kaul, SC (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, 1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	s-kaul@aist.go.jp	Wadhwa, Renu/L-8898-2018; Kaul, Sunil C/L-8671-2018; Reddel, Roger R/A-6635-2014	Wadhwa, Renu/0000-0001-8248-5192; Kaul, Sunil C/0000-0002-0046-3916; Reddel, Roger R/0000-0002-6302-6107				Bardeesy N, 2002, MOL CELL BIOL, V22, P635, DOI 10.1128/MCB.22.2.635-643.2002; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Castellano M, 1999, MELANOMA RES, V9, P421, DOI 10.1097/00008390-199910000-00001; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; Fujita S, 1997, P NATL ACAD SCI USA, V94, P391, DOI 10.1073/pnas.94.2.391; Fulci G, 2000, ONCOGENE, V19, P3816, DOI 10.1038/sj.onc.1203700; Gotte K, 1998, MOL CELL BIOL, V18, P616; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Huschtscha LI, 1999, CARCINOGENESIS, V20, P921, DOI 10.1093/carcin/20.6.921; Ichimura K, 2000, CANCER RES, V60, P417; Iwato M, 2000, CANCER RES, V60, P2113; Jackson MW, 2001, J BIOL CHEM, V276, P25336, DOI 10.1074/jbc.M010685200; James M C, 2000, Prog Cell Cycle Res, V4, P71; Kamijo T, 1999, CANCER RES, V59, P2464; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Kato Y, 2001, J BIOL CHEM, V276, P15378, DOI 10.1074/jbc.M010570200; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Koseki S, 1999, J VIROL, V73, P1868, DOI 10.1128/JVI.73.3.1868-1877.1999; Kumar R, 1999, MELANOMA RES, V9, P138, DOI 10.1097/00008390-199904000-00005; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Lambkin GR, 2001, MOL BIOL CELL, V12, P3353, DOI 10.1091/mbc.12.11.3353; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lloyd AC, 2000, NAT CELL BIOL, V2, pE48, DOI 10.1038/35004078; Louvet O, 1997, BIOTECHNIQUES, V23, P816, DOI 10.2144/97235bm11; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; Munro J, 1999, CANCER RES, V59, P2516; Parkinson EK, 2000, BIOCHEM SOC T, V28, P226, DOI 10.1042/bst0280226; QUELLE DE, 1995, CELL, V83, P993; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Snyder WB, 1999, MOL BIOL CELL, V10, P1745, DOI 10.1091/mbc.10.6.1745; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugihara T, 2001, J BIOL CHEM, V276, P18649, DOI 10.1074/jbc.C100011200; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Villuendas R, 1998, AM J PATHOL, V153, P887, DOI 10.1016/S0002-9440(10)65630-1; Vivo M, 2001, J BIOL CHEM, V276, P14161, DOI 10.1074/jbc.M006845200; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Weitzman JB, 2001, TRENDS MOL MED, V7, P489, DOI 10.1016/S1471-4914(01)02201-8; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	54	27	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36665	36670		10.1074/jbc.M203222200	http://dx.doi.org/10.1074/jbc.M203222200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145279	hybrid			2022-12-27	WOS:000178275100112
J	Dargis, R; Pearlstone, JR; Barrette-Ng, I; Edwards, H; Smillie, LB				Dargis, R; Pearlstone, JR; Barrette-Ng, I; Edwards, H; Smillie, LB			Single mutation (A162H) in human cardiac troponin I corrects acid pH sensitivity of Ca2+-regulated actomyosin S1 ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TROPOMYOSIN; EXPRESSION; BINDING; COMPLEX; DOMAIN; ACTIN; IDENTIFICATION; MYOFILAMENTS; CONTRACTION	In contrast to skeletal muscle, the efficiency of the contractile apparatus of cardiac tissue has long been known to be severely compromised by acid pH as in the ischemia of myocardial infarction and other cardiac myopathies. Recent reports (Westfall, M. V., and Metzger, J. M. (2001) News Physiol. Sci. 16,278-281; Li, G., Martin, A. F., and Solaro, R. J. (2001) J. Mol. Cell. Cardiol. 33, 1309-1320) have indicated that the reduced Ca2+ sensitivity of cardiac contractility at low pH (less than or equal topH 6.5) is attributable to structural difference(s) in the cardiac and skeletal inhibitory components (TnIs) of their troponins. Here, using a reconstituted Ca2+-regulated human cardiac troponin-tropomyosin actomyosin S1 ATPase assay, we report that a single TnI mutation, A162H, restores Ca2+ sensitivity at pH 6.5 to that at pH 7.0. Levels of inhibition (pCa 7.0), activation (pCa 4.0), and cooperativity of ATPase activity were minimally affected. Two other mutations (Q155R and E164V) also previously suggested by us (Pearlstone, J. R., Sykes, B. D., and Smillie, L. B. (1997) Biochemistry 36, 7601-7606) and involving charged residues showed no such effects. With fast skeletal muscle troponin, a single TnI H130A mutation reduced Ca2+ sensitivity at pH 6.5 to levels approaching the cardiac system at pH 6.5. These observations provide structural insight into long-standing physiological and clinical phenomena and are of potential relevance to therapeutic treatments of heart disease by gene transfer, stem cell, and cell transplantation approaches.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Alberta	Smillie, LB (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.	l.smillie@ualberta.ca						ALHILLAWI E, 1994, EUR J BIOCHEM, V225, P1195, DOI 10.1111/j.1432-1033.1994.1195b.x; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; FARAH CS, 1995, FASEB J, V9, P755, DOI 10.1096/fasebj.9.9.7601340; Gaskell W H, 1880, J Physiol, V3, P48; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; Gordon AM, 2000, PHYSIOL REV, V80, P853, DOI 10.1152/physrev.2000.80.2.853; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; KLUWE L, 1993, FEBS LETT, V323, P83, DOI 10.1016/0014-5793(93)81453-7; Li G, 2001, J MOL CELL CARDIOL, V33, P1309, DOI 10.1006/jmcc.2000.1392; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; MAK AS, 1983, J BIOL CHEM, V258, P4330; Makinde AO, 1998, MOL CELL BIOCHEM, V188, P49, DOI 10.1023/A:1006860104840; Mukherjea P, 1999, BIOCHEMISTRY-US, V38, P13296, DOI 10.1021/bi9906120; Oliveira DM, 2000, J BIOL CHEM, V275, P27513; ORCHARD CH, 1990, AM J PHYSIOL, V258, pC967, DOI 10.1152/ajpcell.1990.258.6.C967; Pearlstone JR, 1997, BIOCHEMISTRY-US, V36, P7601, DOI 10.1021/bi970200w; Pearlstone JR, 2000, J BIOL CHEM, V275, P35106, DOI 10.1074/jbc.M001000200; Perry SV, 1999, MOL CELL BIOCHEM, V190, P9, DOI 10.1023/A:1006939307715; PUTKEY JA, 1993, J BIOL CHEM, V268, P6827; QUAGGIO RB, 1993, PROTEIN SCI, V2, P1053, DOI 10.1002/pro.5560020618; SLUPSKY CM, 1995, BIOCHEMISTRY-US, V34, P7365, DOI 10.1021/bi00022a009; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; Tripet B, 1997, J MOL BIOL, V271, P728, DOI 10.1006/jmbi.1997.1200; VALLINS WJ, 1990, FEBS LETT, V270, P57, DOI 10.1016/0014-5793(90)81234-F; Wang X, 2002, J BIOL CHEM, V277, P31124, DOI 10.1074/jbc.M203896200; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; Westfall MV, 2000, CIRC RES, V86, P470, DOI 10.1161/01.RES.86.4.470; Westfall MV, 2001, NEWS PHYSIOL SCI, V16, P278; Wolska BM, 2001, J PHYSIOL-LONDON, V536, P863, DOI 10.1111/j.1469-7793.2001.00863.x	31	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34662	34665		10.1074/jbc.C200419200	http://dx.doi.org/10.1074/jbc.C200419200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12151382	hybrid			2022-12-27	WOS:000178117000003
J	Mishra-Gorur, K; Singer, HA; Castellot, JJ				Mishra-Gorur, K; Singer, HA; Castellot, JJ			The S18 ribosomal protein is a putative substrate for Ca2+/calmodulin-activated protein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; TRANSFER-RNA; CROSS-LINKS; HEPARIN; PHOSPHORYLATION; BINDING; IDENTIFICATION; PROLIFERATION; NEIGHBORHOOD; EXPRESSION	The delta-isoform of Ca2+/calmodulin-activated protein kinase II (CaMK II) is abundantly expressed in vascular smooth muscle, but relatively little is known about its regulation or its potential cellular substrates. There are few, if any, known substrates of CaMK II that are physiologically relevant in vascular smooth muscle cells. Studies presented earlier (Mishra-Gorur, K., Singer, H. A., and Castellot, J. J., Jr. (2002) Am. J. Pathol, in press) by our laboratory show an inhibitory effect of heparin on CaMK II phosphorylation and activity. During these studies we observed the specific co-immuno-precipitation of a 20-kDa protein with CaMK II. Purification and sequence analysis indicate that this protein is the S18 protein of the 40 S ribosome. S18 was found to be abundantly phosphorylated in response to serum treatment, and this effect was strongly inhibited by heparin. In addition, KN-93, a specific CaMK II inhibitor, blocks S18 phosphorylation in vascular smooth muscle cells; a concomitant 24% reduction in protein synthesis was observed. Taken together these data support the idea that S18 could be a novel substrate for CaMK II, thus providing a potential link between Ca2+-mobilizing agents and protein translation.	Tufts Univ, Sch Med, Dept Anat & Cell Biol, Boston, MA 02111 USA; Tufts Univ, Sackler Sch Biomed Sci, Program Cell Mol & Dev Biol, Boston, MA 02111 USA; Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA	Tufts University; Tufts University; Albany Medical College	Castellot, JJ (corresponding author), Tufts Univ, Sch Med, Dept Anat & Cell Biol, 136 Harrison Ave, Boston, MA 02111 USA.				NHLBI NIH HHS [HL 49973, HL 49426] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049426, R56HL049426, R01HL049973] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham ST, 1997, CIRC RES, V81, P575, DOI 10.1161/01.RES.81.4.575; AUSEBEL FM, 1996, CURRENT PROTOCOLS MO, P286; BENFENATI F, 1992, NATURE, V359, P417, DOI 10.1038/359417a0; BOILEAU G, 1983, BIOCHEMISTRY-US, V22, P3162, DOI 10.1021/bi00282a020; BRONSTEIN JM, 1993, BRAIN RES REV, V18, P135, DOI 10.1016/0165-0173(93)90011-N; Caleb BL, 1996, J CELL PHYSIOL, V167, P185, DOI 10.1002/(SICI)1097-4652(199605)167:2<185::AID-JCP1>3.0.CO;2-L; CASTELLOT JJ, 1986, J CELL BIOL, V102, P1979, DOI 10.1083/jcb.102.5.1979; CASTELLOT JJ, 1989, J CELL BIOL, V109, P3147, DOI 10.1083/jcb.109.6.3147; CHAN YL, 1991, BIOCHEM BIOPH RES CO, V178, P1212, DOI 10.1016/0006-291X(91)91022-5; COCHRAN DL, 1985, J CELL PHYSIOL, V124, P29, DOI 10.1002/jcp.1041240106; ENSLEN H, 1994, J BIOL CHEM, V269, P20872; FAWELL EH, 1989, J BIOL CHEM, V264, P1650; FAXEN M, 1994, BBA-GENE STRUCT EXPR, V1218, P27, DOI 10.1016/0167-4781(94)90097-3; GARWOOD J, 1994, GENE, V141, P231, DOI 10.1016/0378-1119(94)90577-0; GULVE EA, 1989, BIOCHEM J, V260, P377, DOI 10.1042/bj2600377; HARDIE DG, 1993, PROTEIN PHOSPHORYLAT, P113; Heilek GM, 1996, RNA, V2, P597; Herbert JM, 1996, J BIOL CHEM, V271, P25928; ISSINGER OG, 1975, EUR J BIOCHEM, V59, P137, DOI 10.1111/j.1432-1033.1975.tb02434.x; Mishra-Gorurt K., 1997, Molecular Biology of the Cell, V8, p401A; MISHRAGORUR K, 2002, IN PRESS AM J PATHOL; OSSWALD M, 1995, NUCLEIC ACIDS RES, V23, P4635, DOI 10.1093/nar/23.22.4635; OTTLINGER ME, 1993, J BIOL CHEM, V268, P19173; PAULY RR, 1995, CIRCULATION, V91, P1107, DOI 10.1161/01.CIR.91.4.1107; POHL T, 1988, J BIOL CHEM, V263, P4293; POWERS T, 1988, J MOL BIOL, V201, P697, DOI 10.1016/0022-2836(88)90468-8; Pukac LA, 1997, J CELL PHYSIOL, V172, P69, DOI 10.1002/(SICI)1097-4652(199707)172:1<69::AID-JCP8>3.0.CO;2-B; SCHWARZBAUER J, 1985, NUCLEIC ACIDS RES, V13, P6767, DOI 10.1093/nar/13.18.6767; SCHWORER CM, 1993, J BIOL CHEM, V268, P14443; SUMI M, 1991, BIOCHEM BIOPH RES CO, V181, P968, DOI 10.1016/0006-291X(91)92031-E; TANSEY MG, 1992, J BIOL CHEM, V267, P12511; TAZI KA, 1995, BIOCHEM J, V307, P557, DOI 10.1042/bj3070557; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WOWER J, 1990, BIOCHIM BIOPHYS ACTA, V1050, P38, DOI 10.1016/0167-4781(90)90138-R	34	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33537	33540		10.1074/jbc.C200342200	http://dx.doi.org/10.1074/jbc.C200342200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12145273	hybrid			2022-12-27	WOS:000177959100002
J	Torres, J; Di Como, CJ; Herrero, E; de la Torre-Ruiz, MA				Torres, J; Di Como, CJ; Herrero, E; de la Torre-Ruiz, MA			Regulation of the cell integrity pathway by rapamycin-sensitive TOR function in budding yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GTP-BINDING PROTEIN; PEPTIDYL-PROLYL ISOMERASE; EXCHANGE FACTOR ROM2; SACCHAROMYCES-CEREVISIAE; MAP KINASE; WALL INTEGRITY; ACTIN CYTOSKELETON; SIGNALING PATHWAY; IMMUNOSUPPRESSANT FK506	The TOR (target of rapamycin) pathway controls cell growth in response to nutrient availability in eukaryotic cells. Inactivation of TOR function by rapamycin or nutrient exhaustion is accompanied by triggering various cellular mechanisms aimed at overcoming the nutrient stress. Here we report that in Saccharomyces cerevisiae the protein kinase C (PKC)-mediated mitogen-activated protein kinase pathway is regulated by TOR function because upon specific Tor1 and Tor2 inhibition by rapamycin, Mpk1 is activated rapidly in a process mediated by Sit4 and Tap42. Osmotic stabilization of the plasma membrane prevents both Mpk1 activation by rapamycin and the growth defect that occurs upon the simultaneous absence of Tor1 and Mpk1 function, suggesting that, at least partially, TOR inhibition is sensed by the PKC pathway at the cell envelope. This process involves activation of cell surface sensors, Rom2, and downstream elements of the mitogen-activated protein kinase cascade. Rapamycin also induces depolarization of the actin cytoskeleton through the TOR proteins, Sit4 and Tap42, in an osmotically suppressible manner. Finally, we show that entry into stationary phase, a physiological situation of nutrient depletion, also leads to the activation of the PKC pathway, and we provide further evidence demonstrating that Mpk1 is essential for viability once cells enter G(0).	Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Lleida 25198, Spain; Aureon Biosci Corp, Yonkers, NY 10701 USA	Universitat de Lleida	de la Torre-Ruiz, MA (corresponding author), Univ Lleida, Fac Med, Dept Ciencies Med Basiques, Rovira Roure 44, Lleida 25198, Spain.		Herrero, Enrique/B-5592-2009; de la Torre, M Angeles/A-7357-2010; Torres-Rosell, Jordi/A-4213-2010	Herrero, Enrique/0000-0002-6763-111X; de la Torre, M Angeles/0000-0002-6111-1359; Torres-Rosell, Jordi/0000-0003-1308-6926; DiComo, Charles/0000-0003-2818-9215				Alarcon CM, 1999, MOL BIOL CELL, V10, P2531, DOI 10.1091/mbc.10.8.2531; ARNDT KT, 1989, CELL, V56, P527, DOI 10.1016/0092-8674(89)90576-X; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bickle M, 1998, EMBO J, V17, P2235, DOI 10.1093/emboj/17.8.2235; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Chan TF, 2000, P NATL ACAD SCI USA, V97, P13227, DOI 10.1073/pnas.240444197; Chen J, 1998, BIOCHEM BIOPH RES CO, V247, P827, DOI 10.1006/bbrc.1998.8792; CHOWDHURY S, 1992, J CELL BIOL, V118, P561, DOI 10.1083/jcb.118.3.561; Clotet J, 1999, MOL CELL BIOL, V19, P2408; COSTIGAN C, 1994, MOL GEN GENET, V243, P286, DOI 10.1007/BF00301064; COSTIGAN C, 1992, MOL CELL BIOL, V12, P1162, DOI 10.1128/MCB.12.3.1162; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; de la Torre-Ruiz MA, 2002, J BIOL CHEM, V277, P33468, DOI 10.1074/jbc.M203515200; de Nobel H, 2000, MICROBIOL-SGM, V146, P2121, DOI 10.1099/00221287-146-9-2121; Delley PA, 1999, J CELL BIOL, V147, P163, DOI 10.1083/jcb.147.1.163; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; DOSEFF AI, 1995, GENETICS, V141, P857; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goldstein AL, 1999, YEAST, V15, P507, DOI 10.1002/(SICI)1097-0061(199904)15:6<507::AID-YEA369>3.0.CO;2-P; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Gulli MP, 2001, GENE DEV, V15, P365, DOI 10.1101/gad.876901; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Helliwell SB, 1998, GENETICS, V148, P99; Helliwell SB, 1998, CURR BIOL, V8, P1211, DOI 10.1016/S0960-9822(07)00511-8; Inagaki M, 1999, MOL CELL BIOL, V19, P8344; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Kaiser C., 1994, METHODS YEAST GENETI; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Karpova TS, 1998, J CELL SCI, V111, P2689; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Krause SA, 2002, CURR BIOL, V12, P588, DOI 10.1016/S0960-9822(02)00760-1; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kunz J, 2000, J BIOL CHEM, V275, P37011, DOI 10.1074/jbc.M007296200; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; Li Y, 2000, MOL CELL BIOL, V20, P3843, DOI 10.1128/MCB.20.11.3843-3851.2000; Lim YM, 1997, GENETICS, V146, P263; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; Manning BD, 1997, MOL BIOL CELL, V8, P1829, DOI 10.1091/mbc.8.10.1829; Martin H, 2000, J BIOL CHEM, V275, P1511, DOI 10.1074/jbc.275.2.1511; MARTIN H, 1993, MOL GEN GENET, V241, P177, DOI 10.1007/BF00280215; Mazur P, 1996, J BIOL CHEM, V271, P14604, DOI 10.1074/jbc.271.24.14604; MAZZONI C, 1993, J CELL BIOL, V123, P1821, DOI 10.1083/jcb.123.6.1821; Murata K, 1997, P NATL ACAD SCI USA, V94, P10624, DOI 10.1073/pnas.94.20.10624; Nanduri J, 2001, MOL CELL, V8, P281, DOI 10.1016/S1097-2765(01)00312-4; Nierras CR, 1999, J BIOL CHEM, V274, P13235, DOI 10.1074/jbc.274.19.13235; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Ozaki K, 1996, EMBO J, V15, P2196, DOI 10.1002/j.1460-2075.1996.tb00573.x; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Philip B, 2001, MOL CELL BIOL, V21, P271, DOI 10.1128/MCB.21.1.271-280.2001; Powers T, 1999, MOL BIOL CELL, V10, P987, DOI 10.1091/mbc.10.4.987; Rajavel M, 1999, MOL CELL BIOL, V19, P3969; Rohde J, 2001, J BIOL CHEM, V276, P9583, DOI 10.1074/jbc.R000034200; Sabbagh W, 2001, MOL CELL, V8, P683, DOI 10.1016/S1097-2765(01)00322-7; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schmidt A, 1997, CELL, V88, P531, DOI 10.1016/S0092-8674(00)81893-0; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; Verna J, 1997, P NATL ACAD SCI USA, V94, P13804, DOI 10.1073/pnas.94.25.13804; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WERNERWASHBURNE M, 1993, MICROBIOL REV, V57, P383, DOI 10.1128/MMBR.57.2.383-401.1993; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6; Ziegler WH, 1999, CURR BIOL, V9, P522, DOI 10.1016/S0960-9822(99)80236-X	75	108	109	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43495	43504		10.1074/jbc.M205408200	http://dx.doi.org/10.1074/jbc.M205408200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12171921	hybrid, Green Published			2022-12-27	WOS:000179081200134
J	Guillebault, D; Sasorith, S; Derelle, E; Wurtz, JM; Lozano, JC; Bingham, S; Tora, L; Moreau, H				Guillebault, D; Sasorith, S; Derelle, E; Wurtz, JM; Lozano, JC; Bingham, S; Tora, L; Moreau, H			A new class of transcription initiation factors, intermediate between TATA box-binding proteins (TBPs) and TBP-like factors (TLFs), is present in the marine unicellular organism, the dinoflagellate Crypthecodinium cohnii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; UBIQUITOUS PROMOTER ELEMENT; CRYSTAL-STRUCTURE; EUKARYOTIC TRANSCRIPTION; SEQUENCE ALIGNMENT; GENE; CHROMATIN; DNA; ORGANIZATION; DICTYOSTELIUM	Dinoflagellates are marine unicellular eukaryotes that exhibit unique features including a very low level of basic proteins bound to the chromatin and the complete absence of histones and nucleosomal structure. A cDNA encoding a protein with a strong homology to the TATA box-binding proteins (TBP) has been isolated from an expressed sequence tag library of the dinoflagellate Crypthecodinium cohnii. The typical TBP repeat signature and the amino acid motives involved in TFHA and TFHB interactions were conserved in this new TBP-like protein. However, the four phenylalanines known to interact with the TATA box were substituted with hydrophilic residues (His(77), Arg(94), Tyr(171), Thr(188)) as has been described for TBP-like factors (TLF)/TBP-related proteins (TRP). A phylogenetic analysis showed that cTBP is intermediate between TBP and TLF/TRP protein families, and the structural similarity of cTBP with TLF was confirmed by low affinity binding to a consensus' TATA box in an equivalent manner to that usually observed for TLFs. Six 5'-upstream gene regions of dinoflagellate genes have been analyzed and neither a TATA box nor a consensus-promoting element could be found within these different sequences. Our results showed that cTBP could bind stronger to a TTTT box sequence than to the canonical TATA box, especially at high salt concentration. Same binding results were obtained with a mutated cTBP (mcTBP), in which the four phenylalanines were restored. To our knowledge, this is the first description of a TBP-like protein in a unicellular organism, which also appears as the major form of TBP present in C. cohnii.	Univ Paris 06, CNRS, UMR 7628, Observ Oceanol,Lab Arago, F-66651 Banyuls sur Mer, France; CU Strasbourg, CNRS INSERM ULP, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Arizona State Univ, Dept Plant Biol, Tempe, AZ 85287 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Arizona State University; Arizona State University-Tempe	Moreau, H (corresponding author), Univ Paris 06, CNRS, UMR 7628, Observ Oceanol,Lab Arago, BP 44, F-66651 Banyuls sur Mer, France.	h.moreau@arago.obs-banyuls.fr	Tora, Laszlo/E-9999-2018; Wurtz, Jean-Marie/P-4652-2016; Guillebault, Delphine/A-4541-2011	Tora, Laszlo/0000-0001-7398-2250; Wurtz, Jean-Marie/0000-0003-2963-8617; Guillebault, Delphine/0000-0002-1847-4138; Derelle, Evelyne/0000-0002-1499-4240				Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; Ausseil J, 1999, PROTIST, V150, P197, DOI 10.1016/S1434-4610(99)70022-2; Bareket-Samish A, 2000, J MOL BIOL, V299, P965, DOI 10.1006/jmbi.2000.3797; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Berk AJ, 2000, CELL, V103, P5, DOI 10.1016/S0092-8674(00)00098-2; Berk AJ, 1999, CURR OPIN CELL BIOL, V11, P330, DOI 10.1016/S0955-0674(99)80045-3; Bhaud Y, 2000, J CELL SCI, V113, P1231; Bhaud Y, 1999, J EUKARYOT MICROBIOL, V46, P259, DOI 10.1111/j.1550-7408.1999.tb05123.x; BROU C, 1993, EMBO J, V12, P489, DOI 10.1002/j.1460-2075.1993.tb05681.x; Buratowski S, 2000, CURR OPIN CELL BIOL, V12, P320, DOI 10.1016/S0955-0674(00)00095-8; Burley SK, 1996, CURR OPIN STRUC BIOL, V6, P69, DOI 10.1016/S0959-440X(96)80097-2; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; COHEN SM, 1986, EMBO J, V5, P3361, DOI 10.1002/j.1460-2075.1986.tb04651.x; Cox JM, 1998, CURR OPIN CHEM BIOL, V2, P11, DOI 10.1016/S1367-5931(98)80030-6; Dantonel JC, 2000, MOL CELL, V6, P715, DOI 10.1016/S1097-2765(00)00069-1; Dantonel JC, 1999, TRENDS BIOCHEM SCI, V24, P335, DOI 10.1016/S0968-0004(99)01436-X; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Gregory PD, 1998, CURR OPIN CELL BIOL, V10, P339, DOI 10.1016/S0955-0674(98)80009-4; Guillebault D, 2001, PROTIST, V152, P127, DOI 10.1078/1434-4610-00051; HERZOG M, 1982, EUR J CELL BIOL, V27, P151; HERZOG M, 1981, EUR J CELL BIOL, V23, P295; Holmes MC, 2000, SCIENCE, V288, P867, DOI 10.1126/science.288.5467.867; HUANG WB, 1995, J BIOL CHEM, V270, P28839, DOI 10.1074/jbc.270.48.28839; Johnson KM, 2001, CURR BIOL, V11, pR510, DOI 10.1016/S0960-9822(01)00306-2; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kaltenbach L, 2000, MOL CELL, V6, P705, DOI 10.1016/S1097-2765(00)00068-X; KIMMEL AR, 1983, NUCLEIC ACIDS RES, V11, P541, DOI 10.1093/nar/11.2.541; Klug A, 2001, SCIENCE, V292, P1844, DOI 10.1126/science.1062384; Le QH, 1997, MOL GEN GENET, V255, P595, DOI 10.1007/s004380050533; LESCURE A, 1994, EMBO J, V13, P1166, DOI 10.1002/j.1460-2075.1994.tb06366.x; Li LM, 1998, PLANT MOL BIOL, V36, P275, DOI 10.1023/A:1005941421474; Liston DR, 1999, MOL CELL BIOL, V19, P2380; Luo H, 1999, J BIOL CHEM, V274, P31947, DOI 10.1074/jbc.274.45.31947; McAdams HH, 2000, CURR BIOL, V10, pR318, DOI 10.1016/S0960-9822(00)00440-1; MCANDREW MB, 1993, GENE, V124, P165, DOI 10.1016/0378-1119(93)90390-O; Moore PA, 1999, MOL CELL BIOL, V19, P7610; Muller F, 2001, CURR BIOL, V11, P282, DOI 10.1016/S0960-9822(01)00076-8; Nikolov DB, 1996, P NATL ACAD SCI USA, V93, P4862, DOI 10.1073/pnas.93.10.4862; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; O'Brien R, 1998, J MOL BIOL, V279, P117, DOI 10.1006/jmbi.1998.1743; Ohbayashi T, 1999, NUCLEIC ACIDS RES, V27, P750, DOI 10.1093/nar/27.3.750; Patikoglou GA, 1999, GENE DEV, V13, P3217, DOI 10.1101/gad.13.24.3217; Plewniak F, 2000, BIOINFORMATICS, V16, P750, DOI 10.1093/bioinformatics/16.9.750; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; QUON DVK, 1994, P NATL ACAD SCI USA, V91, P4579, DOI 10.1073/pnas.91.10.4579; Quon DVK, 1996, J MOL EVOL, V43, P253, DOI 10.1007/PL00006084; Rabenstein MD, 1999, P NATL ACAD SCI USA, V96, P4791, DOI 10.1073/pnas.96.9.4791; RAIKOV IB, 1995, ACTA PROTOZOOL, V34, P239; Ranish JA, 1996, CURR OPIN GENET DEV, V6, P151, DOI 10.1016/S0959-437X(96)80044-X; RIZZO PJ, 1991, J PROTOZOOL, V38, P246, DOI 10.1111/j.1550-7408.1991.tb04437.x; RIZZO PJ, 1979, J PROTOZOOL, V26, P290, DOI 10.1111/j.1550-7408.1979.tb02783.x; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; ROWLANDS T, 1994, SCIENCE, V264, P1326, DOI 10.1126/science.8191287; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SIGEE DC, 1983, BIOSYSTEMS, V16, P203, DOI 10.1016/0303-2647(83)90004-7; SOYERGOBILLARD MO, 2000, ENCY MICROBIOLOGY, P42; Spector D.L., 1984, P1; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Uhlmann F, 2001, CURR BIOL, V11, pR384, DOI 10.1016/S0960-9822(01)00214-7; Veenstra GJC, 2000, SCIENCE, V290, P2312, DOI 10.1126/science.290.5500.2312; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; WONG JM, 1992, NUCLEIC ACIDS RES, V20, P4817, DOI 10.1093/nar/20.18.4817; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171	65	35	36	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40881	40886		10.1074/jbc.M205624200	http://dx.doi.org/10.1074/jbc.M205624200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12154093	hybrid			2022-12-27	WOS:000178791400093
J	Vogel, R; Fan, GB; Ludeke, S; Siebert, F; Sheves, M				Vogel, R; Fan, GB; Ludeke, S; Siebert, F; Sheves, M			A nonbleachable rhodopsin analogue with a slow photocycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL CHROMOPHORE; BACTERIORHODOPSIN; ISOMERIZATION; ACTIVATION; MECHANISM; PIGMENTS; STATE	Archaeal rhodopsins, e.g. bacteriorhodopsin, all have cyclic photoreactions. Such cycles are achieved by a light-induced isomerization step of their retinal chromophores, which thermally re-isomerize in the dark. Visual pigment rhodopsins, which contain in the dark state an 11-cis retinal Schiff base, do not share such a mechanism, and following light absorption, they experience a bleaching process and a subsequent release of the photo-isomerized all-trans chromophore from the binding pocket. The pigment is eventually regenerated by the rebinding of a new 11-cis retinal. In the artificial visual pigment, Rh-6.10, in which the retinal chromophore is locked in an 11-cis geometry by the introduction of a six-member ring structure, an activated receptor may be formed by light-induced isomerization around other double bonds. We have examined this activation of Rh-6.10 by UV-visible and FTIR spectroscopy and have revealed that Rh-6.10 is a nonbleachable pigment. We could further show that the activated receptor consists of two different subspecies corresponding to 9-trans and 9-cis isomers of the chromophore. Both subspecies relax in the dark via separate pathways back to their respective inactive states by thermal isomerization presumably around the C-13=C-14 double bond. This nonbleachable pigment can be repeatedly photolyzed to undergo identical activation-relaxation cycles. The rate constants of these photocycles are pH-dependent, and the half-times vary between several hours' at acidic pH and about 1.5 min at neutral to alkaline pH, which is several orders of magnitude longer than for bacteriorhodopsin.	Univ Freiburg, Biophys Grp, Inst Mol Med & Zellforsch, D-79104 Freiburg, Germany; Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel	University of Freiburg; Weizmann Institute of Science	Vogel, R (corresponding author), Inst Mol Med & Zellforsch, Arbeitsgrp Biophys, Hermann Herder Str 9, D-79104 Freiburg, Germany.			Ludeke, Steffen/0000-0003-1498-5552				ALBECK A, 1992, J AM CHEM SOC, V114, P2400, DOI 10.1021/ja00033a015; ARNIS S, 1995, BIOCHEMISTRY-US, V34, P9333, DOI 10.1021/bi00029a008; Baylor D, 1996, P NATL ACAD SCI USA, V93, P560, DOI 10.1073/pnas.93.2.560; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BIRGE RR, 1995, BIOPHYS CHEM, V55, P115, DOI 10.1016/0301-4622(94)00145-A; DEGRIP WJ, 1990, EUR J BIOCHEM, V191, P211; Fan GB, 2002, J BIOL CHEM, V277, P40229, DOI 10.1074/jbc.M205033200; Hoff WD, 1997, ANNU REV BIOPH BIOM, V26, P223, DOI 10.1146/annurev.biophys.26.1.223; HU SH, 1994, BIOCHEMISTRY-US, V33, P408, DOI 10.1021/bi00168a004; Imai H, 1997, P NATL ACAD SCI USA, V94, P2322, DOI 10.1073/pnas.94.6.2322; Jang GF, 2001, J BIOL CHEM, V276, P26148, DOI 10.1074/jbc.M102212200; Lanyi JK, 1995, ISR J CHEM, V35, P365; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; Oesterhelt D, 1998, CURR OPIN STRUC BIOL, V8, P489, DOI 10.1016/S0959-440X(98)80128-0; SHEVES M, 1984, J AM CHEM SOC, V106, P6840, DOI 10.1021/ja00334a061; SHICHIDA Y, 1988, BIOCHEMISTRY-US, V27, P6495, DOI 10.1021/bi00417a044; Varo G, 2000, BBA-BIOENERGETICS, V1460, P220, DOI 10.1016/S0005-2728(00)00141-9; Vogel R, 2001, J BIOL CHEM, V276, P38487, DOI 10.1074/jbc.M105423200; Vogel R, 2000, BIOCHEMISTRY-US, V39, P8895, DOI 10.1021/bi000852b; WALD G, 1968, NATURE, V219, P800, DOI 10.1038/219800a0; Yan ECY, 2002, BIOCHEMISTRY-US, V41, P3620, DOI 10.1021/bi0160011	21	6	6	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40222	40228		10.1074/jbc.M205032200	http://dx.doi.org/10.1074/jbc.M205032200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177056	hybrid			2022-12-27	WOS:000178791400010
J	Poon, S; Rybchyn, MS; Easterbrook-Smith, SB; Carver, JA; Pankhurst, GJ; Wilson, MR				Poon, S; Rybchyn, MS; Easterbrook-Smith, SB; Carver, JA; Pankhurst, GJ; Wilson, MR			Mildly acidic pH activates the extracellular molecular chaperone clusterin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ALPHA-A-CRYSTALLIN; 1,1'-BI(4-ANILINO)NAPHTHALENE-5,5'-DISULFONIC ACID; CIRCULAR-DICHROISM; BINDING PROPERTIES; PROTEINS; IDENTIFICATION; BISANS; BRAIN; RAT	Many features of the chaperone action of clusterin are similar to those of the intracellular small heat shock proteins (sHSPs) that, like clusterin, exist in solution as heterogeneous aggregates. Increased temperature induces dissociation of some sHSP aggregates and an enhanced chaperone action, suggesting that a dissociated form is the active chaperone species. We recently reported that clusterin aggregates dissociate at mildly acidic pH. To further explore the similarities between clusterin and the sHSPs, we tested the effects of temperature and pH on the structure of clusterin and its chaperone action. Our results demonstrate that increased temperature does not induce dissociation of clusterin aggregates, or other major structural changes, and has little effect on its chaperone action. However, we show that the chaperone action of clusterin is enhanced at mildly acidic pH. Clusterin is the first chaperone shown to be activated by reduced pH. This unique mode of activation appears to result from an increase in regions of solvent-exposed hydrophobicity, which is independent of any major changes in secondary or tertiary structure. We propose a model in which low pH-induced dissociation of clusterin aggregates increases the abundance of the heterodimeric chaperone-active species, which has greater hydrophobicity exposed to solution.	Univ Wollongong, Dept Sci Biol, Wollongong, NSW 2522, Australia; Univ Wollongong, Dept Chem, Wollongong, NSW 2522, Australia; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia	University of Wollongong; University of Wollongong; University of Sydney	Easterbrook-Smith, SB (corresponding author), Univ Wollongong, Dept Sci Biol, Northfields Ave, Wollongong, NSW 2522, Australia.	sbe@mmb.usyd.edu.au; mrw@uow.edu.au	Wilson, Mark R/B-3254-2018; Carver, John Adrian/J-3825-2014	Wilson, Mark R/0000-0002-9551-7445; Carver, John Adrian/0000-0002-2441-8108; Rybchyn, Mark/0000-0002-4336-6227				BACK T, 1994, STROKE, V25, P494, DOI 10.1161/01.STR.25.2.494; Bova MP, 1997, J BIOL CHEM, V272, P29511, DOI 10.1074/jbc.272.47.29511; CARVER JA, 1995, BBA-PROTEIN STRUCT M, V1252, P251, DOI 10.1016/0167-4838(95)00146-L; Carver JA, 2002, J MOL BIOL, V318, P815, DOI 10.1016/S0022-2836(02)00144-4; Chakraborty S, 1999, BBA-PROTEIN STRUCT M, V1432, P350, DOI 10.1016/S0167-4838(99)00110-7; Datta SA, 1999, J BIOL CHEM, V274, P34773, DOI 10.1074/jbc.274.49.34773; Epps DE, 1998, J PROTEIN CHEM, V17, P699, DOI 10.1007/BF02780973; Gu LX, 2002, J MOL BIOL, V319, P517, DOI 10.1016/S0022-2836(02)00311-X; Han BH, 2001, NAT MED, V7, P338, DOI 10.1038/85487; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; Heuer KH, 1996, BIOCHEMISTRY-US, V35, P9069, DOI 10.1021/bi952817o; Hochgrebe T, 2000, BIOCHEMISTRY-US, V39, P1411, DOI 10.1021/bi991581b; Holtzman DM, 2001, NAT MED, V7, P977, DOI 10.1038/nm0901-977; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; JACOBUS WE, 1977, NATURE, V265, P756, DOI 10.1038/265756a0; JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4; Johnson WC, 1999, PROTEINS, V35, P307, DOI 10.1002/(SICI)1097-0134(19990515)35:3<307::AID-PROT4>3.0.CO;2-3; Kapron JT, 1997, PROTEIN SCI, V6, P2120; Lashuel HA, 1999, BIOCHEMISTRY-US, V38, P13560, DOI 10.1021/bi991021c; Mclaughlin L, 2000, J CLIN INVEST, V106, P1105, DOI 10.1172/JCI9037; Michel D, 1997, BIOCHEM J, V328, P45, DOI 10.1042/bj3280045; Pankhurst GJ, 1998, BIOCHEMISTRY-US, V37, P4823, DOI 10.1021/bi972367v; Poon S, 2002, FEBS LETT, V513, P259, DOI 10.1016/S0014-5793(02)02326-8; Poon S, 2000, BIOCHEMISTRY-US, V39, P15953, DOI 10.1021/bi002189x; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; PUNNIAMOORTHY A, 1987, J ORAL PATHOL MED, V16, P36, DOI 10.1111/j.1600-0714.1987.tb00674.x; Rosenberg ME, 2002, MOL CELL BIOL, V22, P1893, DOI 10.1128/MCB.22.6.1893-1902.2002; Sharma KK, 1998, J BIOL CHEM, V273, P15474, DOI 10.1074/jbc.273.25.15474; Sharma KK, 1998, J BIOL CHEM, V273, P8965, DOI 10.1074/jbc.273.15.8965; SLINGSBY C, 1990, EXP EYE RES, V51, P21, DOI 10.1016/0014-4835(90)90165-Q; STUART WD, 1992, BIOCHEMISTRY-US, V31, P8552, DOI 10.1021/bi00151a024; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; WILSON MR, 1992, BIOCHIM BIOPHYS ACTA, V1159, P319, DOI 10.1016/0167-4838(92)90062-I; Wilson MR, 2000, TRENDS BIOCHEM SCI, V25, P95, DOI 10.1016/S0968-0004(99)01534-0; YATES CM, 1990, J NEUROCHEM, V55, P1624, DOI 10.1111/j.1471-4159.1990.tb04948.x	35	83	87	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39532	39540		10.1074/jbc.M204855200	http://dx.doi.org/10.1074/jbc.M204855200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176985	hybrid, Green Submitted			2022-12-27	WOS:000178662500062
J	Sarver, AE; Wang, CC				Sarver, AE; Wang, CC			The adenine phosphoribosyltransferase from Giardia lamblia has a unique reaction mechanism and unusual substrate binding properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-XANTHINE PHOSPHORIBOSYLTRANSFERASE; STATE ANALOG INHIBITOR; 2.0 ANGSTROM STRUCTURE; TRITRICHOMONAS-FETUS; CRYSTAL-STRUCTURE; OROTATE PHOSPHORIBOSYLTRANSFERASE; TRANSITION-STATE; SALMONELLA-TYPHIMURIUM; PYRIMIDINE METABOLISM; ESCHERICHIA-COLI	Purine phosphoribosyltransferases catalyze the Mg2+-dependent reaction that transforms a purine base into its corresponding nucleotide. They are present in a wide variety of organisms including plants, mammals, and parasitic protozoa. Giardia lamblia, the causative agent of giardiasis, lacks de novo purine biosynthesis and relies primarily on adenine and guanine phosphoribosyltransferases (APRTase and GPRTase) constituting two independent and essential purine salvage pathways. The APRTase from G. lamblia was cloned and expressed with a 6-His tag at its C terminus and purified to apparent homogeneity. Adenine and alpha-D-5-phosphoribosyl-1-pyrophosphate (PRPP) have K-m values of 4.2 and 143 mum with a k(cat) of 2.8 s(-1) in the forward reaction, whereas AMP and PPi have K-m values of 87 and 450 mum with a k(cat) of 9.5 x 10(-3) s(-1) in the reverse reaction. Product inhibition studies indicated that the forward reaction follows a random Bi Bi mechanism. Results from the kinetics of equilibrium isotope exchange further verified a random Bi Bi mechanism in the forward reaction. In a mutant enzyme, F25W, with kinetic constants similar to those of the wild type and a tryptophan residue at the adenine binding site, the addition of adenine or AMP to the free mutant enzyme resulted, in fluorescence quenching, whereas PRPP caused fluorescence enhancement. The dissociation constants thus estimated are 16.5 mum for adenine, 14.3 mum for AMP, and 83.0 mum for PRPP. PPi exerted no detectable effect on the tryptophan fluorescence at all, suggesting a lack of PPi binding to the free enzyme. An ordered substrate binding in the reverse reaction with AMP bound first followed by PPi is thus postulated.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wang, CC (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, Box 0446,513 Parnassus Ave, San Francisco, CA 94143 USA.	ccwang@cgl.ucsf.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019391] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-19391] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAM RD, 1991, MICROBIOL REV, V55, P706, DOI 10.1128/MMBR.55.4.706-732.1991; Aronov AM, 2001, ANTIMICROB AGENTS CH, V45, P2571, DOI 10.1128/AAC.45.9.2571-2576.2001; Aronov AM, 2000, BIOCHEMISTRY-US, V39, P4684, DOI 10.1021/bi992555g; Bashor C, 2002, BIOCHEMISTRY-US, V41, P4020, DOI 10.1021/bi0158730; BECK JT, 1993, MOL BIOCHEM PARASIT, V60, P187, DOI 10.1016/0166-6851(93)90130-P; BHATIA MB, 1990, BIOCHEMISTRY-US, V29, P10480, DOI 10.1021/bi00498a009; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P104, DOI 10.1016/0926-6569(63)90211-6; CRAIG SP, 1991, P NATL ACAD SCI USA, V88, P2500, DOI 10.1073/pnas.88.6.2500; Donald RGK, 1996, J BIOL CHEM, V271, P14010, DOI 10.1074/jbc.271.24.14010; Focia PJ, 1998, BIOCHEMISTRY-US, V37, P17120, DOI 10.1021/bi9821465; Heroux A, 1999, BIOCHEMISTRY-US, V38, P14495, DOI 10.1021/bi990508i; Munagala N, 2000, J BIOL CHEM, V275, P37072, DOI 10.1074/jbc.M007239200; Munagala N, 2001, BIOCHEMISTRY-US, V40, P4303, DOI 10.1021/bi0026932; Munagala N, 2002, MOL MICROBIOL, V44, P1073, DOI 10.1046/j.1365-2958.2002.02942.x; Munagala NR, 1998, BIOCHEMISTRY-US, V37, P4045, DOI 10.1021/bi972515h; MUSICK WDL, 1981, CRC CR REV BIOCH MOL, V11, P1, DOI 10.3109/10409238109108698; Page JP, 1999, EUR J BIOCHEM, V259, P565, DOI 10.1046/j.1432-1327.1999.00020.x; PARSONSON IM, 1974, AUST VET J, V50, P421, DOI 10.1111/j.1751-0813.1974.tb06861.x; Phillips CL, 1999, EMBO J, V18, P3533, DOI 10.1093/emboj/18.13.3533; Purich D L, 1980, Methods Enzymol, V64, P1; SCAPIN G, 1995, BIOCHEMISTRY-US, V34, P10744, DOI 10.1021/bi00034a006; SCAPIN G, 1994, BIOCHEMISTRY-US, V33, P1287, DOI 10.1021/bi00172a001; SEGEL IH, 1993, ENZYME KINETICS BEHA, P505; Shi WX, 2000, BIOCHEMISTRY-US, V39, P6781, DOI 10.1021/bi000128t; Shi WX, 1999, NAT STRUCT BIOL, V6, P588; Shi WX, 2002, J BIOL CHEM, V277, P39981, DOI 10.1074/jbc.M205596200; Shi WX, 2001, BIOCHEMISTRY-US, V40, P10800, DOI 10.1021/bi010465h; Shi WX, 1999, BIOCHEMISTRY-US, V38, P9872, DOI 10.1021/bi990664p; Simmonds H, 1995, METABOLIC MOL BASES, P1707; Sommer JM, 1996, MOL BIOCHEM PARASIT, V78, P185, DOI 10.1016/S0166-6851(96)02623-0; Somoza JR, 1998, BIOCHEMISTRY-US, V37, P5344, DOI 10.1021/bi973095z; Somoza JR, 1996, BIOCHEMISTRY-US, V35, P7032, DOI 10.1021/bi953072p; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; Tao W, 1996, BIOCHEMISTRY-US, V35, P14, DOI 10.1021/bi951898l; Vos S, 1998, J MOL BIOL, V282, P875, DOI 10.1006/jmbi.1998.2051; WANG CC, 1983, J EXP MED, V158, P1703, DOI 10.1084/jem.158.5.1703; WANG CC, 1984, J MED CHEM, V27, P1, DOI 10.1021/jm00367a001; WANG CC, 1983, P NATL ACAD SCI-BIOL, V80, P2564, DOI 10.1073/pnas.80.9.2564; WYNGAARDEN JB, 1957, ARCH BIOCHEM BIOPHYS, V70, P150, DOI 10.1016/0003-9861(57)90088-7; Xu YM, 1997, BIOCHEMISTRY-US, V36, P3700, DOI 10.1021/bi9616007; YUAN L, 1992, BIOCHEMISTRY-US, V31, P806, DOI 10.1021/bi00118a024	41	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39973	39980		10.1074/jbc.M205595200	http://dx.doi.org/10.1074/jbc.M205595200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171924	hybrid			2022-12-27	WOS:000178662500116
J	Bontron, S; Lin-Marq, N; Strubin, M				Bontron, S; Lin-Marq, N; Strubin, M			Hepatitis B virus X protein associated with UV-DDB1 induces cell death in the nucleus and is functionally antagonized by UV-DDB2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEIN; GLOBAL GENOMIC REPAIR; NF-KAPPA-B; DAMAGED-DNA; HBX PROTEIN; GENE-PRODUCT; HEPATOCELLULAR CARCINOMAS; VIRAL REPLICATION; EXCISION-REPAIR; MAMMALIAN-CELLS	The hepatitis B virus X protein (HBx) is essential for viral infection and strongly interferes with cell growth and viability in culture. These activities involve interaction of HBx with the DDB1 subunit of UV-damaged DNA-binding factor UV-DDB. UV-DDB consists of DDB1 and a DDB2 subunit that mediates nuclear import and has recognized functions in DNA repair and E2F1-mediated transcription. Here we show that HBx retains DDB1-binding-dependent cytotoxic activities when engineered to accumulate in the nucleus but not when excluded from the nucleus. Nuclear localization of HBx does not require binding to DDB1 and remains unaffected by ectopically expressed UV-DDB subunits, indicating that HBx reaches the nuclear compartment independently of UV-DDB. Unexpectedly, HBx appears to largely exist in association with DDB1 and is in direct competition with DDB2 for binding to DDB1. Hence, HBx-mediated cell death can be relieved by increased levels of DDB2, an effect that is not observed with a naturally occurring mutant of DDB2 that lacks DDB1-binding activity. These findings indicate that HBx acts through a pathway that involves a DDB2-independent nuclear function of DDB1 and that this activity will depend on the relative concentration of DDB1 and DDB2 in cells.	Ctr Med Univ Geneva, Dept Genet & Microbiol, CH-1211 Geneva 4, Switzerland	University of Geneva	Strubin, M (corresponding author), Ctr Med Univ Geneva, Dept Genet & Microbiol, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland.	Michel.Strubin@medecine.unige.ch						ABRAMIC M, 1991, J BIOL CHEM, V266, P22493; Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENN J, 1995, P NATL ACAD SCI USA, V92, P11215, DOI 10.1073/pnas.92.24.11215; Bontron S, 1997, MOL CELL BIOL, V17, P4249, DOI 10.1128/MCB.17.8.4249; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; CHANG H, 1988, Taiwan yixuehui zazhi, V87, P948; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Dandri M, 1996, J VIROL, V70, P5246, DOI 10.1128/JVI.70.8.5246-5254.1996; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; Forgues M, 2001, J BIOL CHEM, V276, P22797, DOI 10.1074/jbc.M101259200; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Groisman IJ, 1999, CARCINOGENESIS, V20, P479, DOI 10.1093/carcin/20.3.479; Henkler F, 2001, J GEN VIROL, V82, P871, DOI 10.1099/0022-1317-82-4-871; Hoare J, 2001, J MED VIROL, V64, P419, DOI 10.1002/jmv.1067; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Jacob JR, 1997, HEPATOLOGY, V26, P1607; Jia L, 1999, INT J CANCER, V80, P875, DOI 10.1002/(SICI)1097-0215(19990315)80:6<875::AID-IJC13>3.3.CO;2-Q; KEENEY S, 1993, J BIOL CHEM, V268, P21293; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kim HT, 2001, BIOCHEM BIOPH RES CO, V286, P886, DOI 10.1006/bbrc.2001.5496; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin GY, 2000, J VIROL, V74, P9152, DOI 10.1128/JVI.74.19.9152-9166.2000; Lin-Marq N, 2001, VIROLOGY, V287, P266, DOI 10.1006/viro.2001.1036; Melegari M, 1998, J VIROL, V72, P1737, DOI 10.1128/JVI.72.3.1737-1743.1998; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; Nag A, 2001, J VIROL, V75, P10383, DOI 10.1128/JVI.75.21.10383-10392.2001; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Nichols AF, 2000, J BIOL CHEM, V275, P21422, DOI 10.1074/jbc.M000960200; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Otrin VR, 1997, J CELL SCI, V110, P1159; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; Rahmani Z, 2000, J VIROL, V74, P2840, DOI 10.1128/JVI.74.6.2840-2846.2000; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Sirma H, 1998, ONCOGENE, V16, P2051, DOI 10.1038/sj.onc.1201737; Sitterlin D, 2000, ONCOGENE, V19, P4427, DOI 10.1038/sj.onc.1203770; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Su Q, 1998, HEPATOLOGY, V27, P1109, DOI 10.1002/hep.510270428; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; TAKAO M, 1993, NUCLEIC ACIDS RES, V21, P4111, DOI 10.1093/nar/21.17.4111; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Weil R, 1999, MOL CELL BIOL, V19, P6345; Zolezzi F, 2000, GENE, V245, P151, DOI 10.1016/S0378-1119(00)00022-6; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	57	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38847	38854		10.1074/jbc.M205722200	http://dx.doi.org/10.1074/jbc.M205722200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151405	hybrid			2022-12-27	WOS:000178529600106
J	Herbig, K; Chiang, EP; Lee, LR; Hills, J; Shane, B; Stover, PJ				Herbig, K; Chiang, EP; Lee, LR; Hills, J; Shane, B; Stover, PJ			Cytoplasmic serine hydroxymethyltransferase mediates competition between folate-dependent deoxyribonucleotide and S-adenosylmethionine biosyntheses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE COMBINED DEGENERATION; METHYL-GROUP DEFICIENCY; ONE-CARBON METABOLISM; METHIONINE SYNTHETASE; CEREBROSPINAL-FLUID; GLYCINE; CELLS; REMETHYLATION; EXPRESSION; CATABOLISM	Folate-dependent one-carbon metabolism is required for the synthesis of purines and thymidylate and for the remethylation of homocysteine to methionine. Methionine is subsequently adenylated to S-adenosylmethionine (SAM), a cofactor that methylates DNA, RNA, proteins, and many metabolites. Previous experimental and theoretical modeling studies have indicated that folate cofactors are limiting for cytoplasmic folate-dependent reactions and that the synthesis of DNA precursors competes with SAM synthesis. Each of these studies concluded that SAM synthesis has a higher metabolic priority than dTMP synthesis. The influence of cytoplasmic serine hydroxymethyltransferase (cSHMT) on this competition was examined in MCF-7 cells. Increases in cSHMT expression inhibit SAM concentrations by two proposed mechanisms: (1) cSHMT-catalyzed serine synthesis competes with the enzyme methylenetetrahydrofolate reductase for methylenetetrahydrofolate in a glycine-dependent manner, and (2) cSHMT, a high affinity 5-methyltetrahydrofolate-binding protein, sequesters this cofactor and inhibits methionine synthesis in a glycine-independent manner. Stable isotope tracer studies indicate that cSHMT plays an important role in mediating the flux of one-carbon units between dTMP and SAM syntheses. We conclude that cSHMT has three important functions in the cytoplasm: (1) it preferentially supplies one-carbon units for thymidylate biosynthesis, (2) it depletes methylenctetrahydrofolate pools for SAM synthesis by synthesizing serine, and (3) it sequesters 5-methyltetrahydrofolate and inhibits SAM synthesis. These results indicate that cSHMT is a metabolic switch that, when activated, gives dTMP synthesis higher metabolic priority than SAM synthesis.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA; Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA	Cornell University; University of California System; University of California Berkeley	Stover, PJ (corresponding author), Cornell Univ, Div Nutr Sci, 315 Savage Hall, Ithaca, NY 14853 USA.		Chiang, EnPei/K-1694-2013	Chiang, EnPei/0000-0002-0158-0962	NIDDK NIH HHS [DK42033, DK58144] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042033, R01DK058144] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ames BN, 1999, ANN NY ACAD SCI, V889, P87, DOI 10.1111/j.1749-6632.1999.tb08727.x; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; Bailey LB, 1999, J NUTR, V129, P779, DOI 10.1093/jn/129.4.779; BAUMGARTNER ER, 1985, PEDIATR RES, V19, P1288, DOI 10.1203/00006450-198512000-00017; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Clarke S, 2001, HOMOCYSTEINE IN HEALTH AND DISEASE, P63; DUDLEY MA, 1992, J NUTR, V122, P528, DOI 10.1093/jn/122.3.528; FELL D, 1990, BIOCHIM BIOPHYS ACTA, V1033, P80, DOI 10.1016/0304-4165(90)90197-5; Fowler B, 1997, PEDIATR RES, V41, P145, DOI 10.1203/00006450-199701000-00023; Girgis S, 1998, GENE, V210, P315, DOI 10.1016/S0378-1119(98)00085-7; Girgis S, 1997, J BIOL CHEM, V272, P4729, DOI 10.1074/jbc.272.8.4729; GREEN JM, 1988, BIOCHEMISTRY-US, V27, P8014, DOI 10.1021/bi00421a007; HORNE DW, 1989, ARCH BIOCHEM BIOPHYS, V270, P729, DOI 10.1016/0003-9861(89)90556-0; LICHTENSTEIN AH, 1990, J LIPID RES, V31, P1693; LIU QR, 1992, FEBS LETT, V305, P110, DOI 10.1016/0014-5793(92)80875-H; Nakshatri H, 1996, GENE, V174, P79, DOI 10.1016/0378-1119(96)00391-5; Oppenheim EW, 2001, J BIOL CHEM, V276, P19855, DOI 10.1074/jbc.M100039200; PENAFIEL R, 1990, BIOCHEM INT, V22, P649; PETZKE KJ, 1986, J NUTR, V116, P742, DOI 10.1093/jn/116.5.742; PFENDNER W, 1980, ARCH BIOCHEM BIOPHYS, V200, P503, DOI 10.1016/0003-9861(80)90382-3; REEDS PJ, 1992, J NUTR, V122, P457; ROSENBLATT DS, 1979, J CLIN INVEST, V63, P1019, DOI 10.1172/JCI109370; SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3; SCOTT JM, 1981, LANCET, V2, P334; SCOTT JM, 1981, LANCET, V2, P337; Selhub J, 1999, ANNU REV NUTR, V19, P217, DOI 10.1146/annurev.nutr.19.1.217; Shane B., 1995, FOLATE HLTH DIS, V2, P1; STOVER P, 1991, J BIOL CHEM, V266, P1543; Stover PJ, 1997, J BIOL CHEM, V272, P1842, DOI 10.1074/jbc.272.3.1842; STRONG WB, 1990, J BIOL CHEM, V265, P12149; Struys EA, 2000, CLIN CHEM, V46, P1650; Suh JR, 2001, ANNU REV NUTR, V21, P255, DOI 10.1146/annurev.nutr.21.1.255; Van Hove JLK, 1998, J INHERIT METAB DIS, V21, P799, DOI 10.1023/A:1005462400552; Wagner PJ, 1995, WOMEN HEALTH, V23, P1; Yeo EJ, 1999, J BIOL CHEM, V274, P37559, DOI 10.1074/jbc.274.53.37559	36	195	206	1	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38381	38389		10.1074/jbc.M205000200	http://dx.doi.org/10.1074/jbc.M205000200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161434	hybrid			2022-12-27	WOS:000178529600051
J	Lye, LF; Cunningham, ML; Beverley, SM				Lye, LF; Cunningham, ML; Beverley, SM			Characterization of quinonoid-dihydropteridine reductase (QDPR) from the lower eukaryote Leishmania major	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; PARASITE LEISHMANIA; PROTOZOAN PARASITE; METHOTREXATE RESISTANCE; DIHYDROFOLATE-REDUCTASE; THYMIDYLATE SYNTHASE; PHENYLALANINE-HYDROXYLASE; PTERIDINE REDUCTASE-1; GENE REPLACEMENT; FERRIC REDUCTASE	Biopterin is required for growth of the protozoan parasite Leishmania and is salvaged from the host through the activities of a novel biopterin transporter (BT1) and broad-spectrum pteridine reductase (PTR1). Here we characterize Leishmania major quinonoid-dihydropteridine reductase (LmQDPR), the key enzyme required for regeneration and maintenance of H(4)biopterin pools. LmQDPR shows good homology to metazoan quinonoid-dihydropteridine reductase and conservation of domains implicated in catalysis and regulation. Unlike other organisms, LmQDPR is encoded by a tandemly repeated array of 8-9 copies containing LmQDPR plus two other genes. QDPR mRNA and enzymatic activity were expressed at similar levels throughout the infectious cycle. The pH optima, kinetic properties, and substrate specificity of purified LmQDPR were found to be similar to that of other qDPRs, although it lacked significant activity for non-quinonoid pteridines. These and other data suggest that LmQDPR is unlikely to encode the dihydrobiopterin reductase activity (PTR2) described previously. Similarly LmQDPR is not inhibited by a series of antifolates showing anti-leishmanial activity beyond that attributable to dihydrofolate reductase or PTR1 inhibition. qDPR activity was found in crude lysates of Trypanosoma brucei and Trypanosoma cruzi, further emphasizing the importance of H(4)biopterin throughout this family of human parasites.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Beverley, SM (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, Campus Box 8230,660 S Euclid Ave, St Louis, MO 63110 USA.			Beverley, Stephen/0000-0001-5319-0811	NIAID NIH HHS [AI29646, AI21903] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021903, R37AI021903, R01AI029646] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akopyants NS, 2001, MOL BIOCHEM PARASIT, V113, P337, DOI 10.1016/S0166-6851(01)00227-4; Basu NK, 1997, FEMS MICROBIOL LETT, V156, P43, DOI 10.1016/S0378-1097(97)00401-1; BECK JT, 1990, MOL BIOCHEM PARASIT, V43, P221, DOI 10.1016/0166-6851(90)90147-E; BELLO AR, 1994, P NATL ACAD SCI USA, V91, P11442, DOI 10.1073/pnas.91.24.11442; BEVERLEY SM, 1988, NUCLEIC ACIDS RES, V16, P925, DOI 10.1093/nar/16.3.925; BEVERLEY SM, 1984, CELL, V38, P431, DOI 10.1016/0092-8674(84)90498-7; BEVERLEY SM, 1991, ANNU REV MICROBIOL, V45, P417, DOI 10.1146/annurev.mi.45.100191.002221; BEVERLEY SM, 1986, P NATL ACAD SCI USA, V83, P2584, DOI 10.1073/pnas.83.8.2584; Blau N, 1996, J INHERIT METAB DIS, V19, P8, DOI 10.1007/BF01799342; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALLAHAN HL, 1992, J BIOL CHEM, V267, P24165; Chang CF, 1999, ADV EXP MED BIOL, V463, P403; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; COLIGAN JE, 1997, CURRENT PROTOCOLS PR, V1; CRUZ A, 1990, NATURE, V348, P171, DOI 10.1038/348171a0; Cunningham ML, 2001, MOL BIOCHEM PARASIT, V113, P199, DOI 10.1016/S0166-6851(01)00213-4; Cunningham ML, 2001, SCIENCE, V292, P285, DOI 10.1126/science.1057740; DASILVA R, 1987, INFECT IMMUN, V55, P2802, DOI 10.1128/IAI.55.11.2802-2806.1987; Dianzani I, 1998, HUM MUTAT, V12, P267, DOI 10.1002/(SICI)1098-1004(1998)12:4<267::AID-HUMU8>3.0.CO;2-C; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIRGAIRA FA, 1981, BIOCHEM J, V197, P31, DOI 10.1042/bj1970031; Golderer G, 2001, GENE DEV, V15, P1299, DOI 10.1101/gad.890501; GRIMSHAW CE, 1992, J BIOL CHEM, V267, P15334; GROGL M, 1992, AM J TROP MED HYG, V47, P117, DOI 10.4269/ajtmh.1992.47.117; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; HARDY LW, 1997, EXP PARASITOL, V87, P158; HAUER CR, 1993, J BIOL CHEM, V268, P4828; HIRAYAMA K, 1980, BIOCHIM BIOPHYS ACTA, V612, P337, DOI 10.1016/0005-2744(80)90116-3; Homuth M, 1998, INFECT IMMUN, V66, P710, DOI 10.1128/IAI.66.2.710-716.1998; Huang L, 2001, J BIOL CHEM, V276, P28327, DOI 10.1074/jbc.M008342200; IVANETICH KM, 1990, EXP PARASITOL, V70, P367, DOI 10.1016/0014-4894(90)90119-W; IWAI K, 1976, BIOCHIM BIOPHYS ACTA, V444, P618, DOI 10.1016/0304-4165(76)90406-2; KAPLER GM, 1990, MOL CELL BIOL, V10, P1084, DOI 10.1128/MCB.10.3.1084; KAUFMAN S, 1963, P NATL ACAD SCI USA, V50, P1085, DOI 10.1073/pnas.50.6.1085; Kaufman S., 1997, TETRAHYDROBIOPTERIN; KERLER F, 1990, EXP CELL RES, V189, P151, DOI 10.1016/0014-4827(90)90229-4; Kiefer PM, 1997, BIOCHEMISTRY-US, V36, P9438, DOI 10.1021/bi970585i; Kiefer PM, 1996, J BIOL CHEM, V271, P3437; Kundig C, 1999, EMBO J, V18, P2342, DOI 10.1093/emboj/18.9.2342; Lee PL, 2000, BIOCHEM BIOPH RES CO, V271, P788, DOI 10.1006/bbrc.2000.2708; Lemley C, 1999, MOL BIOCHEM PARASIT, V104, P93, DOI 10.1016/S0166-6851(99)00132-2; LOCKYER J, 1987, P NATL ACAD SCI USA, V84, P3329, DOI 10.1073/pnas.84.10.3329; Ma DQ, 1996, BIOCHEM BIOPH RES CO, V227, P885, DOI 10.1006/bbrc.1996.1600; MEDINAACOSTA E, 1993, MOL BIOCHEM PARASIT, V59, P327, DOI 10.1016/0166-6851(93)90231-L; MYLER PJ, 1994, MOL BIOCHEM PARASIT, V66, P11, DOI 10.1016/0166-6851(94)90031-0; Nagatsu T, 1999, MOL NEUROBIOL, V19, P79, DOI 10.1007/BF02741379; Nare B, 1997, J BIOL CHEM, V272, P13883, DOI 10.1074/jbc.272.21.13883; Nare B, 1997, PARASITOLOGY, V114, pS101, DOI 10.1017/S0031182097001133; Ouellette M, 1996, TROP MED INT HEALTH, V1, pA33; PAPADOPOULOU B, 1994, J BIOL CHEM, V269, P7310; Park D, 2000, BBA-GENE STRUCT EXPR, V1492, P247, DOI 10.1016/S0167-4781(00)00084-1; PAVETO C, 1995, J BIOL CHEM, V270, P16576, DOI 10.1074/jbc.270.28.16576; PETRILLOPEIXOTO MP, 1987, ANTIMICROB AGENTS CH, V31, P1575; RYAN KA, 1993, GENE, V131, P145, DOI 10.1016/0378-1119(93)90684-U; SACKS DL, 1984, SCIENCE, V223, P1417, DOI 10.1126/science.6701528; SAMBROOK J, 1989, MOL CLONING, V1, P7; SCOTT DA, 1987, MOL BIOCHEM PARASIT, V23, P139, DOI 10.1016/0166-6851(87)90149-6; SHAHBAZ M, 1987, J BIOL CHEM, V262, P16412; SMOOKER PM, 1993, BIOCHEMISTRY-US, V32, P6443, DOI 10.1021/bi00076a018; SMOOKER PM, 1995, HUM MUTAT, V5, P279, DOI 10.1002/humu.1380050402; Stiles JK, 1999, ANN TROP MED PARASIT, V93, P781, DOI 10.1080/00034989957781; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SU Y, 1993, J BIOL CHEM, V268, P26836; Timmerman MM, 1999, INFECT IMMUN, V67, P6403; TITUS RG, 1995, P NATL ACAD SCI USA, V92, P10267, DOI 10.1073/pnas.92.22.10267; TRAGER W, 1969, J PROTOZOOL, V16, P372, DOI 10.1111/j.1550-7408.1969.tb02284.x; VARUGHESE KI, 1994, P NATL ACAD SCI USA, V91, P5582, DOI 10.1073/pnas.91.12.5582; VARUGHESE KI, 1992, P NATL ACAD SCI USA, V89, P6080, DOI 10.1073/pnas.89.13.6080; VASUDEVAN SG, 1988, BIOCHEM J, V255, P581; Wang YX, 1998, MOL BIOCHEM PARASIT, V96, P139, DOI 10.1016/S0166-6851(98)00121-2; Werner ER, 1996, BIOCHEM J, V320, P193, DOI 10.1042/bj3200193; Werner ER, 2000, BIOCHEM J, V348, P579, DOI 10.1042/0264-6021:3480579; WHITELEY JM, 1993, ADV EXP MED BIOL, V338, P115; WHO Expert Committee, 1984, LEISHM; WILLIAMS CD, 1976, J BACTERIOL, V127, P1197, DOI 10.1128/JB.127.3.1197-1207.1976; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	76	26	26	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38245	38253		10.1074/jbc.M206543200	http://dx.doi.org/10.1074/jbc.M206543200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151409	hybrid			2022-12-27	WOS:000178529600035
J	Zhu, W; Mustelin, T; David, M				Zhu, W; Mustelin, T; David, M			Arginine methylation of STAT1 regulates its dephosphorylation by T cell protein tyrosine phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER; HISTONE H3; TRANSCRIPTION; INTERFERON; ACTIVATION; INACTIVATION; INHIBITION; LIGANDS; DOMAINS	Transcriptional induction by interferons requires the tyrosine and serine phosphorylation of the STAT1 transcription factor as well as its amino-terminal arginine methylation. Here we show that arginine methylation of STAT1 controls the rate of STAT1 dephosphorylation by modulating its interaction with PIAS1 and the nuclear tyrosine phosphatase TcPTP. Inhibition of STAT1 arginine methylation, or mutation of STAT1 Arg-31, results in a prolonged half-life of STAT1 tyrosine phosphorylation. This effect appears to be mediated by an increased binding of PIAS1 to STAT1 in the absence of STAT1 arginine methylation and a concomitant decrease in the association of STAT1 with TcPTP. Furthermore, inhibitors of arginine methylation require the presence of PIAS1 to exert their negative regulatory effect on the dephosphorylation of STAT1.	Univ Calif San Diego, Div Biol, Mol Biol Sect, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Burnham Inst, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Sanford Burnham Prebys Medical Discovery Institute	David, M (corresponding author), Univ Calif San Diego, Div Biol, Mol Biol Sect, Bonner Hall 3138,9500 Gilman Dr, La Jolla, CA 92093 USA.	midavid@ucsd.edu		Mustelin, Tomas/0000-0001-5912-8840	NATIONAL CANCER INSTITUTE [R01CA080105] Funding Source: NIH RePORTER; NCI NIH HHS [CA80105] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; BERGMANN S, 1994, J IMMUNOL, V153, P1736; Chen SL, 2002, J BIOL CHEM, V277, P4324, DOI 10.1074/jbc.M109835200; Cimato TR, 2002, J NEUROSCI RES, V67, P435, DOI 10.1002/jnr.10123; DAVID M, 1993, MOL CELL BIOL, V13, P7515, DOI 10.1128/MCB.13.12.7515; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; Hilton DJ, 1999, CELL MOL LIFE SCI, V55, P1568, DOI 10.1007/s000180050396; Ibarra-Sanchez MD, 2000, SEMIN IMMUNOL, V12, P379, DOI 10.1006/smim.2000.0220; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Liao JY, 2000, P NATL ACAD SCI USA, V97, P5267, DOI 10.1073/pnas.97.10.5267; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Saxena M, 1998, J BIOL CHEM, V273, P15340, DOI 10.1074/jbc.273.25.15340; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Shuai K, 1996, MOL CELL BIOL, V16, P4932; Strehlow I, 1998, J BIOL CHEM, V273, P28049, DOI 10.1074/jbc.273.43.28049; ten Hoeve J, 2002, MOL CELL BIOL, V22, P5662, DOI 10.1128/MCB.22.16.5662-5668.2002; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; YouTen KE, 1997, J EXP MED, V186, P683, DOI 10.1084/jem.186.5.683	26	71	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35787	35790		10.1074/jbc.C200346200	http://dx.doi.org/10.1074/jbc.C200346200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12171910	hybrid			2022-12-27	WOS:000178275100003
J	Hill, WG; An, B; Johnson, JP				Hill, WG; An, B; Johnson, JP			Endogenously expressed epithelial sodium channel is present in lipid rafts in A6 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL MEMBRANE; ALPHA-SUBUNIT; NA+ CHANNEL; C2 DOMAIN; ALDOSTERONE; CAVEOLAE; SURFACE; PROTEIN; LOCALIZATION; MICRODOMAINS	The epithelial sodium channel (ENaC) present in the kidney collecting duct, distal colon, and the lung is responsible for salt reabsorption and whole body volume regulation. It is composed of three homologous subunits, alpha, beta, and gamma, and mutations to these subunits can lead to the salt wasting disease pseudohypoaldosteronism type I, associated with decreased channel density at the plasma membrane or to the hypertensive disorder, Liddle's syndrome, in which channel residency time at the plasma membrane is enhanced. Regulation of ENaC trafficking and turnover is therefore critical to sodium homeostasis. In this study we examined whether ENaC is present in the cholesterol-enriched microdomains commonly called lipid rafts, in the endogenously expressing A6 cell line. We demonstrate that a fraction of alpha, beta, and gamma ENaC is present in detergent-insoluble membranes, that subunits exist in membranes that float on discontinuous sucrose density gradients, and that methyl-beta-cyclodextrin treatment causes a redistribution of ENaC subunits to higher density membranes. Furthermore, chronic aldosterone stimulation results in a shift in the membrane density of all three subunits. Biotinylation of apical membrane proteins revealed that ENaC is present in lipid rafts on the plasma membrane. In conclusion, these results show that ENaC is present in lipid rafts both intracellularly and on the cell surface. Raft association may be important for trafficking and/or function of the channel.	Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Lab Epithelial Cell Biol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hill, WG (corresponding author), Univ Pittsburgh, Sch Med, Renal Electrolyte Div, Lab Epithelial Cell Biol, A1222 Scaife Hall, Pittsburgh, PA 15261 USA.	whill@pitt.edu	Hill, Warren/AAM-1917-2020	Hill, Warren/0000-0002-2772-7264	NIDDK NIH HHS [DK 57718, DK 47874] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047874, R01DK057718] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bonny O, 1999, J CLIN INVEST, V104, P967, DOI 10.1172/JCI6821; Bravo-Zehnder M, 2000, P NATL ACAD SCI USA, V97, P13114, DOI 10.1073/pnas.240455697; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; Fisher RS, 1996, AM J PHYSIOL-CELL PH, V270, pC138, DOI 10.1152/ajpcell.1996.270.1.C138; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GOODMAN DBP, 1975, BIOCHEMISTRY-US, V14, P2803, DOI 10.1021/bi00684a003; GOODMAN DBP, 1971, BIOCHEMISTRY-US, V10, P3825, DOI 10.1021/bi00797a004; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Kamynina E, 2001, AM J PHYSIOL-RENAL, V281, pF469, DOI 10.1152/ajprenal.2001.281.3.F469; Kleyman TR, 2001, AM J PHYSIOL-RENAL, V281, pF213, DOI 10.1152/ajprenal.2001.281.2.F213; LIEN EL, 1975, BIOCHEMISTRY-US, V14, P2749, DOI 10.1021/bi00683a030; Martens JR, 2000, J BIOL CHEM, V275, P7443, DOI 10.1074/jbc.275.11.7443; Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Mrnka L, 2000, J STEROID BIOCHEM, V73, P11, DOI 10.1016/S0960-0760(00)00050-9; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Plant PJ, 2000, J CELL BIOL, V149, P1473, DOI 10.1083/jcb.149.7.1473; Rokaw MD, 1998, J BIOL CHEM, V273, P28746, DOI 10.1074/jbc.273.44.28746; SARIBANSOHRABY S, 1984, SCIENCE, V225, P745, DOI 10.1126/science.6463652; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Trouet D, 2001, BIOCHEM BIOPH RES CO, V284, P461, DOI 10.1006/bbrc.2001.4995; Wang TY, 2000, BIOPHYS J, V79, P919, DOI 10.1016/S0006-3495(00)76347-8; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIESMANN WP, 1985, AM J PHYSIOL, V248, pF43, DOI 10.1152/ajprenal.1985.248.1.F43; Yarbrough TL, 2002, CIRC RES, V90, P443, DOI 10.1161/hh0402.105177	31	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					33541	33544		10.1074/jbc.C200309200	http://dx.doi.org/10.1074/jbc.C200309200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12167633	hybrid			2022-12-27	WOS:000177959100003
J	Xu, J; Xiao, G; Trujillo, C; Chang, V; Blanco, L; Joseph, SB; Bassilian, S; Saad, MF; Tontonoz, P; Lee, WNP; Kurland, IJ				Xu, J; Xiao, G; Trujillo, C; Chang, V; Blanco, L; Joseph, SB; Bassilian, S; Saad, MF; Tontonoz, P; Lee, WNP; Kurland, IJ			Peroxisome proliferator-activated receptor alpha (PPAR alpha) influences substrate utilization for hepatic glucose production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; NULL MICE; GLUCONEOGENESIS; GLYCEROL; HUMANS; TURNOVER; LACTATE; BLOOD	The hypoglycemia seen in the fasting PPARalpha null mouse is thought to be due to impaired liver fatty acid beta-oxidation. The etiology of hypoglycemia in the PPARalpha null mouse was determined via stable isotope studies. Glucose, lactate, and glycerol flux was assessed in the fasted and fed states in 4-month-old PPARalpha null mice and in C57BL/6 WT maintained on standard chow using a new protocol for flux assessment in the fasted and fed states. Hepatic glucose production (HGP) and glucose carbon recycling were estimated using [U-C-13(6)]glucose, and HGP, lactate, and glycerol turnover was estimated utilizing either [U-C-13(3)]lactate or [2-C-13]glycerol infused subcutaneously via Alza miniosmotic pumps. At the end of a 17-h fast, HGP was higher in the PPARalpha null mice than in WT by 37% (p < 0.01). However, recycling of glucose carbon from lactate back to glucose was lower in the PPAR&alpha; null than in WT (39% versus 51%, p < 0.02). The lack of conversion of lactate to glucose was confirmed using an [U-C-13(3)]lactate infusion. In the fasted state, HGP from lactate and lactate production were decreased by 65 and 55%, respectively (p < 0.05) in PPARa null mice. In contrast, when [2-C-13]glycerol was infused, glycerol production and HGP from glycerol increased by 80 and 250%, respectively (p < 0.01), in the fasted state of PPARalpha null mice. The increased HGP from glycerol was not suppressed in the fed state. While little change was evident for phosphoenolpyruvate carboxykinase (PEPCK) expression, pyruvate kinase expression was decreased 16-fold in fasted PPAR null mice as compared with the wild-type control. The fasted and fed insulin levels were comparable, but blood glucose levels were lower in the PPARalpha null mice than in controls. In conclusion, PPARalpha receptor function creates a setpoint for a metabolic network that regulates the rate and route of HGP in the fasted and fed states, in part, by controlling the flux of glycerol and lactate between the triose-phosphate and pyruvate/lactate pools.	Univ Calif Los Angeles, Lab Metabolom, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Dept Pediat, Torrance, CA 90502 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Kurland, IJ (corresponding author), Univ Calif Los Angeles, Lab Metabolom, Los Angeles, CA 90095 USA.			Joseph, Sean/0000-0002-2602-8517	NCI NIH HHS [P01-CA42710] Funding Source: Medline; NCRR NIH HHS [M01-RR00425] Funding Source: Medline; NHLBI NIH HHS [HL66088] Funding Source: Medline; NIDDK NIH HHS [DK56090-A1] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042710] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066088] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056090] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; EXTON JH, 1967, J BIOL CHEM, V242, P2622; Guerre-Millo M, 2001, DIABETES, V50, P2809, DOI 10.2337/diabetes.50.12.2809; Guerre-Millo M, 2000, J BIOL CHEM, V275, P16638, DOI 10.1074/jbc.275.22.16638; Hellerstein MK, 1999, AM J PHYSIOL-ENDOC M, V276, pE1146, DOI 10.1152/ajpendo.1999.276.6.E1146; JAHOOR F, 1992, AM J PHYSIOL, V262, pE353, DOI 10.1152/ajpendo.1992.262.3.E353; Jensen MD, 2001, AM J PHYSIOL-ENDOC M, V281, pE998, DOI 10.1152/ajpendo.2001.281.5.E998; KATZ J, 1988, METABOLISM, V37, P1078, DOI 10.1016/0026-0495(88)90071-6; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Landau BR, 1996, J CLIN INVEST, V98, P378, DOI 10.1172/JCI118803; Landau BR, 1996, AM J PHYSIOL-ENDOC M, V271, pE1110, DOI 10.1152/ajpendo.1996.271.6.E1110; Landau BR, 1998, AM J PHYSIOL-ENDOC M, V274, pE954, DOI 10.1152/ajpendo.1998.274.5.E954; Landau BR, 1999, P NUTR SOC, V58, P973, DOI 10.1017/S0029665199001287; Landau BR, 1999, AM J PHYSIOL-ENDOC M, V277, pE408, DOI 10.1152/ajpendo.1999.277.3.E408; Le May C, 2000, FEBS LETT, V475, P163, DOI 10.1016/S0014-5793(00)01648-3; Lee W. N. P., 1989, J BIOL CHEM, V264, P13002; LEE WNP, 1991, BIOL MASS SPECTROM, V20, P451, DOI 10.1002/bms.1200200804; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Peroni O, 1996, METABOLISM, V45, P897, DOI 10.1016/S0026-0495(96)90166-3; Roden M, 2000, DIABETES, V49, P701, DOI 10.2337/diabetes.49.5.701; SZAFRANECK J, 1974, CARBOHYD RES, V38, P97, DOI 10.1016/S0008-6215(00)82341-1; Tordjman K, 2001, J CLIN INVEST, V107, P1025, DOI 10.1172/JCI11497; TSERNG KY, 1984, ANAL CHEM, V56, P517, DOI 10.1021/ac00267a049; WOLFE RR, 1992, RADIOACTIVE STABLE I, P119	26	121	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50237	50244		10.1074/jbc.M201208200	http://dx.doi.org/10.1074/jbc.M201208200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12176975	hybrid			2022-12-27	WOS:000180177700006
J	Krauss, SW; Heald, R; Lee, G; Nunomura, W; Gimm, JA; Mohandas, N; Chasis, JA				Krauss, SW; Heald, R; Lee, G; Nunomura, W; Gimm, JA; Mohandas, N; Chasis, JA			Two distinct domains of protein 4.1 critical for assembly of functional nuclei in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOTIC APPARATUS PROTEIN; ACTIN BINDING DOMAIN; INTERPHASE NUCLEI; CYCLIN SYNTHESIS; 4.1 FAMILY; NUMA; SPECTRIN; SPINDLE; COMPLEX; EXPRESSION	Protein 4.1R, a multifunctional structural protein, acts as an adaptor in mature red cell membrane skeletons linking spectrin-actin complexes to plasma membrane-associated proteins. In nucleated cells protein 4.1 is not associated exclusively with plasma membrane but is also detected at several important subcellular locations crucial for cell division. To identify 4.1 domains having critical functions in nuclear assembly, 4.1 domain peptides were added to Xenopus egg extract nuclear reconstitution reactions. Morphologically disorganized, replication deficient nuclei assembled when spectrin-actin-binding domain or NuMA-binding C-terminal domain peptides were present. However, control variant spectrin-actin-binding domain peptides incapable of binding actin or mutant C-terminal domain peptides with reduced NuMA binding had no deleterious effects on nuclear reconstitution. To test whether 4.1 is required for proper nuclear assembly, 4.1 isoforms were depleted with spectrin-actin binding or C-terminal domain-specific antibodies. Nuclei assembled in the depleted extracts were deranged. However, nuclear assembly could be rescued by the addition of recombinant 4.1R. Our data establish that protein 4.1 is essential for nuclear assembly and identify two distinct 4.1 domains, initially characterized in cytoskeletal interactions, that have crucial and versatile functions in nuclear assembly.	Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Dept Subcellular Struct, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Div Cell & Dev Biol, Berkeley, CA 94720 USA; Tokyo Womens Med Univ, Sch Med, Dept Biochem, Shinju Ku, Tokyo 1628666, Japan	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Tokyo Women's Medical University	Krauss, SW (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Dept Subcellular Struct, 1 Cyclotron Rd,MS 74-157, Berkeley, CA 94720 USA.	sakrauss@lbl.gov		Heald, Rebecca/0000-0001-6671-6528	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059079, P01DK032094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057839] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59079, DK32094] Funding Source: Medline; NIGMS NIH HHS [GM57839] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENZ EJ, 1994, MOL BASIS BLOOD DIS, P257; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; COHEN CM, 1984, BIOCHEMISTRY-US, V23, P6091, DOI 10.1021/bi00320a029; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; COMPTON DA, 1994, CURR OPIN CELL BIOL, V6, P343, DOI 10.1016/0955-0674(94)90024-8; CONBOY JG, 1993, SEMIN HEMATOL, V30, P58; CONBOY JG, 1988, P NATL ACAD SCI USA, V85, P9062, DOI 10.1073/pnas.85.23.9062; CORREAS I, 1986, J BIOL CHEM, V261, P3362; CORREAS I, 1991, BIOCHEM J, V279, P581, DOI 10.1042/bj2790581; CORREAS I, 1986, J BIOL CHEM, V261, P3310; DeCarcer G, 1995, BIOCHEM J, V312, P871, DOI 10.1042/bj3120871; DISCHER D, 1993, J BIOL CHEM, V268, P7186; GAGLIO T, 1995, J CELL BIOL, V131, P693, DOI 10.1083/jcb.131.3.693; Gant TM, 1997, ANNU REV CELL DEV BI, V13, P669, DOI 10.1146/annurev.cellbio.13.1.669; Gascard P, 1999, MOL BIOL CELL, V10, P1783, DOI 10.1091/mbc.10.6.1783; Gimm JA, 2002, BIOCHEMISTRY-US, V41, P7275, DOI 10.1021/bi0256330; Gueth-Hallonet C, 1998, EXP CELL RES, V243, P434, DOI 10.1006/excr.1998.4178; Han BG, 2000, NAT STRUCT BIOL, V7, P871; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; HORNE WC, 1990, BIOCHIM BIOPHYS ACTA, V1055, P87, DOI 10.1016/0167-4889(90)90095-U; HUANG JP, 1993, J BIOL CHEM, V268, P3758; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; KALLAJOKI M, 1991, EMBO J, V10, P3351, DOI 10.1002/j.1460-2075.1991.tb04899.x; Krauss SW, 1997, J CELL BIOL, V137, P275, DOI 10.1083/jcb.137.2.275; Krauss SW, 1997, P NATL ACAD SCI USA, V94, P7297, DOI 10.1073/pnas.94.14.7297; Krauss SW, 1998, MOL BIOL CELL, V9, p294A; Lallena MJ, 1997, J CELL SCI, V110, P239; Lallena MJ, 1998, J CELL SCI, V111, P1963; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; MARCOTTE P, 1990, ABA J, V76, P12; MATTAGAJASINGH S, 1997, BLOOD, V90, P408; Mattagajasingh SN, 1999, J CELL BIOL, V145, P29, DOI 10.1083/jcb.145.1.29; Mattagajasingh SN, 2000, J BIOL CHEM, V275, P30573, DOI 10.1074/jbc.M004578200; Mattagajasingh SN, 1998, BLOOD, V92, p300A; Merdes A, 1996, CELL, V87, P447, DOI 10.1016/S0092-8674(00)81365-3; Merdes A, 2000, J CELL BIOL, V149, P851, DOI 10.1083/jcb.149.4.851; Merdes A, 1998, J CELL SCI, V111, P71; MILANKOV K, 1993, EXP CELL RES, V209, P189, DOI 10.1006/excr.1993.1301; Mintz PJ, 2000, J STRUCT BIOL, V129, P241, DOI 10.1006/jsbi.2000.4213; MOHANDAS N, 1993, SEMIN HEMATOL, V30, P171; MORRIS MB, 1995, BIOCHEMISTRY-US, V34, P4538, DOI 10.1021/bi00014a006; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1987, CELL, V48, P205, DOI 10.1016/0092-8674(87)90424-7; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; Nowak G, 1997, J BIOL CHEM, V272, P17176, DOI 10.1074/jbc.272.27.17176; Nunomura W, 2000, J BIOL CHEM, V275, P24540, DOI 10.1074/jbc.M002492200; Nunomura W, 2000, J BIOL CHEM, V275, P6360, DOI 10.1074/jbc.275.9.6360; Nunomura W, 1997, J BIOL CHEM, V272, P30322, DOI 10.1074/jbc.272.48.30322; OHANIAN V, 1984, EUR J BIOCHEM, V144, P375, DOI 10.1111/j.1432-1033.1984.tb08474.x; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; Parra M, 1998, GENOMICS, V49, P298, DOI 10.1006/geno.1998.5265; PRICE CM, 1986, EXP CELL RES, V166, P295, DOI 10.1016/0014-4827(86)90478-7; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; SAHLAS DJ, 1993, J CELL SCI, V105, P347; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; Schirmer EC, 2001, J CELL BIOL, V153, P479, DOI 10.1083/jcb.153.3.479; SCHISCHMANOFF PO, 1995, J BIOL CHEM, V270, P21243, DOI 10.1074/jbc.270.36.21243; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; Smrzka OW, 2000, CURR BIOL, V10, P413, DOI 10.1016/S0960-9822(00)00418-8; Spann TP, 1997, J CELL BIOL, V136, P1201, DOI 10.1083/jcb.136.6.1201; SUBRAHMANYAM G, 1991, P NATL ACAD SCI USA, V88, P5222, DOI 10.1073/pnas.88.12.5222; Taimen P, 2000, EXP CELL RES, V256, P140, DOI 10.1006/excr.2000.4799; TAKAKUWA Y, 1986, J CLIN INVEST, V78, P80, DOI 10.1172/JCI112577; Tse WT, 2001, J BIOL CHEM, V276, P23974, DOI 10.1074/jbc.M009307200; UNGEWICKELL E, 1979, NATURE, V280, P811, DOI 10.1038/280811a0; Walensky LD, 1998, J CELL BIOL, V141, P143, DOI 10.1083/jcb.141.1.143; Walensky LD, 1999, J NEUROSCI, V19, P6457; WINARDI R, 1995, BLOOD, V86, P4315, DOI 10.1182/blood.V86.11.4315.bloodjournal86114315; Woulfe J, 2000, NEUROPATH APPL NEURO, V26, P161, DOI 10.1046/j.1365-2990.2000.026002161.x; Zeng CQ, 2000, MICROSC RES TECHNIQ, V49, P467, DOI 10.1002/(SICI)1097-0029(20000601)49:5<467::AID-JEMT9>3.3.CO;2-M; ZENG CQ, 1994, P NATL ACAD SCI USA, V91, P1505, DOI 10.1073/pnas.91.4.1505; ZENG CQ, 1994, CELL MOTIL CYTOSKEL, V29, P167, DOI 10.1002/cm.970290208; Zhang SS, 2002, J BIOL CHEM, V277, P843, DOI 10.1074/jbc.M109393200; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	77	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					44339	44346		10.1074/jbc.M204135200	http://dx.doi.org/10.1074/jbc.M204135200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12171917	hybrid			2022-12-27	WOS:000179272000105
J	Lampinen, M; Settimo, L; Pentikainen, OT; Jouppila, A; Mottershead, DG; Johnson, MS; Keinanen, K				Lampinen, M; Settimo, L; Pentikainen, OT; Jouppila, A; Mottershead, DG; Johnson, MS; Keinanen, K			Discrimination between agonists and antagonists by the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid-selective glutamate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING CORE; AMPA RECEPTOR; NUCLEIC-ACIDS; NMDA RECEPTOR; FORCE-FIELD; PROTEINS; IDENTIFICATION; SITE; ACTIVATION; MECHANISM	dThe crystal structures of the ligand-binding core of the agonist complexes of the glutamate receptor-B (GluR-B) subunit of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-selective glutamate receptor indicate that the distal anionic group of agonist molecules are stabilized by interactions with an N-terminal region of an a-helix (helix F) in the lobe 2 ("domain 2," Armstrong, N., and Gouaux, E. (2000) Neuron 28, 165-181) of the two-lobed ligand-binding domain. We used site-directed mutagenesis to further analyze the role of this region in the recognition of both agonists and antagonists by the AMPA receptor. Wild-type and mutated versions of the ligand-binding domain of GluR-D were expressed in insect cells as secreted soluble polypeptides and subjected to binding assays using [H-3]AMPA, an agonist, and [H-3]Ro 48-8587 (9-imidazol-1-yl-8-nitro-2,3,5,6-tetrahydro[1,2,4]triazolo[1,5-c] quinazoline-2,5-dione), a high affinity AMPA receptor antagonist, as radioligands. Single alanine substitutions at residues Leu-672 and Thr-677 severely affected the affinities for all agonists, as seen in ligand competition assays, whereas similar mutations at residues Asp-673, Ser-674, Gly-675, Ser-676, and Lys-678 selectively affected the binding affinities of one or two of the agonists. In striking contrast, the binding affinities of [H-3]Ro 48-8587 and of another competitive antagonist, 6,7-dinitroquinoxaline-2,3-dione, were not affected by any of these alanine mutations, suggesting the absence of critical side-chain interactions. Together with ligand docking experiments, our results indicate a selective engagement of the side chains of the helix F region in agonist binding, and suggest that conformational changes involving this region may play a critical role in receptor activation.	Univ Helsinki, Dept Biosci, Div Biochem, Helsinki 00014, Finland; Univ Helsinki, Viikki Bioctr, Inst Biotechnol, Helsinki 00014, Finland; Abo Akad Univ, Dept Biochem & Pharm, Turku 20520, Finland	University of Helsinki; University of Helsinki; Abo Akademi University	Keinanen, K (corresponding author), Univ Helsinki, Dept Biosci, Div Biochem, Viikinkaari 5D, Helsinki 00014, Finland.		Keinanen, Kari/E-9122-2010; Mottershead, David G/B-7749-2013; Pentikäinen, Olli T/E-1980-2012	Mottershead, David G/0000-0003-2593-0725; Pentikäinen, Olli T/0000-0001-7188-4016				Abele R, 2000, J BIOL CHEM, V275, P21355, DOI 10.1074/jbc.M909883199; Abele R, 1999, BIOCHEMISTRY-US, V38, P10949, DOI 10.1021/bi982928y; Allen F.H., 1993, CHEM DESIGN AUTOMATI, V8, P31; Anson LC, 1998, J NEUROSCI, V18, P581; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; HONORE T, 1988, J NEUROCHEM, V51, P457, DOI 10.1111/j.1471-4159.1988.tb01060.x; Johnson MS, 1996, METHOD ENZYMOL, V266, P575; JOHNSON MS, 1993, J MOL BIOL, V233, P716, DOI 10.1006/jmbi.1993.1548; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Lampinen M, 1998, EMBO J, V17, P4704, DOI 10.1093/emboj/17.16.4704; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Mano I, 1996, J BIOL CHEM, V271, P15299, DOI 10.1074/jbc.271.26.15299; Matzen L, 1997, J MED CHEM, V40, P520, DOI 10.1021/jm9607212; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Mutel V, 1998, J NEUROCHEM, V71, P418; Paas Y, 1996, NEURON, V17, P979, DOI 10.1016/S0896-6273(00)80228-7; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STEMBACH Y, 1994, NEURON, V13, P1345; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Wo ZG, 1996, MOL PHARMACOL, V50, P770	28	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41940	41947		10.1074/jbc.M205242200	http://dx.doi.org/10.1074/jbc.M205242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12167621	hybrid			2022-12-27	WOS:000178985300082
J	Opresko, PL; von Kobbe, C; Laine, JP; Harrigan, J; Hickson, ID; Bohr, VA				Opresko, PL; von Kobbe, C; Laine, JP; Harrigan, J; Hickson, ID; Bohr, VA			Telomere-binding protein TRF2 binds to and stimulates the Werner and Bloom syndrome helicases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME CELLS; DNA HELICASE; SYNDROME FIBROBLASTS; RECQ FAMILY; WRN; REPLICATION; EXONUCLEASE; INTERACTS; REPEATS; REPAIR	Werner syndrome is a human premature aging disorder displaying cellular defects associated with telomere maintenance including genomic instability, premature senescence, and accelerated telomere erosion. The yeast homologue of the Werner protein (WRN), Sgs1, is required for recombination-mediated lengthening of telomeres in telomerase-deficient cells. In human cells, we report that WRN co-localizes and physically interacts with the critical telomere maintenance protein TRF2. This interaction is mediated by the RecQ conserved G terminal region of WRN. In vitro, TRF2 demonstrates high affinity for WRN and for another RecQ family member, the Bloom syndrome protein (BLM). TRF2 interaction with either WRN or BLM results in a notable stimulation of their helicase activities. Furthermore, the WRN and BLM helicases, partnered with replication protein A, actively unwind long telomeric duplex regions that are pre-bound by TRF2. These results suggest that TRF2 functions with WRN, and possibly BLM, in a common pathway at telomeric ends.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Univ Strasbourg 1, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Cancer Research UK; University of Oxford	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Hickson, Ian/AAJ-7548-2020; Bohr, Vilhelm/AAP-5931-2020	Hickson, Ian/0000-0002-0583-566X; von Kobbe, Cayetano/0000-0003-3895-3790; Opresko, Patricia/0000-0002-6470-2189	NATIONAL INSTITUTE ON AGING [Z01AG000726, ZIAAG000726] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Blackburn EH, 2000, NATURE, V408, P53, DOI 10.1038/35040500; Bohr VA, 2000, EXP GERONTOL, V35, P695, DOI 10.1016/S0531-5565(00)00145-5; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200; Brosh RM, 2001, EMBO J, V20, P5791; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P35093, DOI 10.1074/jbc.M103332200; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Campisi J, 2001, EXP GERONTOL, V36, P1619, DOI 10.1016/S0531-5565(01)00160-7; Chakraverty RK, 1999, BIOESSAYS, V21, P286; Cohen H, 2001, P NATL ACAD SCI USA, V98, P3174, DOI 10.1073/pnas.061579598; Constantinou A, 2000, EMBO REP, V1, P80, DOI 10.1093/embo-reports/kvd004; Cooper MP, 2000, GENE DEV, V14, P907; DADDA DF, 2001, CURR BIOL, V11, P1192; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hisama FM, 2000, CANCER RES, V60, P2372; Huang PH, 2001, CURR BIOL, V11, P125, DOI 10.1016/S0960-9822(01)00021-5; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Johnson FB, 2001, EMBO J, V20, P905, DOI 10.1093/emboj/20.4.905; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Kitao S, 1998, GENOMICS, V54, P443, DOI 10.1006/geno.1998.5595; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; MARTIN GM, 1970, LAB INVEST, V23, P86; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Ranganathan V, 2001, CURR BIOL, V11, P962, DOI 10.1016/S0960-9822(01)00267-6; Sakamoto S, 2001, GENES CELLS, V6, P421, DOI 10.1046/j.1365-2443.2001.00433.x; Schulz VP, 1996, HUM GENET, V97, P750; Smogorzewska A, 2000, MOL CELL BIOL, V20, P1659, DOI 10.1128/MCB.20.5.1659-1668.2000; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; STEFANINI M, 1989, MUTAT RES, V219, P179, DOI 10.1016/0921-8734(89)90013-1; Tahara H, 1997, ONCOGENE, V15, P1911, DOI 10.1038/sj.onc.1201377; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; von Kobbe C, 2002, J BIOL CHEM, V277, P22035, DOI 10.1074/jbc.M200914200; Wyllie FS, 2000, NAT GENET, V24, P16, DOI 10.1038/71630; Yankiwski V, 2000, P NATL ACAD SCI USA, V97, P5214, DOI 10.1073/pnas.090525897; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Yeager TR, 1999, CANCER RES, V59, P4175; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834; Zhu XD, 2000, NAT GENET, V25, P347, DOI 10.1038/77139	51	306	318	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41110	41119		10.1074/jbc.M205396200	http://dx.doi.org/10.1074/jbc.M205396200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181313	hybrid			2022-12-27	WOS:000178791400121
J	Shanks, RA; Steadman, BT; Schmidt, PH; Goldenring, JR				Shanks, RA; Steadman, BT; Schmidt, PH; Goldenring, JR			AKAP350 at the Golgi apparatus - I. Identification of a distinct Golgi apparatus targeting motif in AKAP350	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; ASSOCIATION; CENTROSOME; INTERACTS; SUBUNIT; FAMILY	The protein kinase A-anchoring proteins (AKAPs) are defined by their ability to scaffold protein kinase A to specific subcellular compartments. Each of the AKAP family members utilizes unique targeting domains specific for a particular subcellular compartment. AKAP350 is a multiply spliced AKAP family member localized to the centrosome and the Golgi apparatus. Three splicing events in the carboxyl terminus of AKAP350 generate the AKAP350A, AKAP350B, and AKAP350C proteins. A monoclonal antibody recognizing all three splice variants as well as a polyclonal antibody specific for AKAP350A demonstrated both centrosomal and Golgi apparatus staining in paraformaldehyde-fixed HCA-7 cells. Golgi apparatus-associated ARAP350A staining was dispersed following brefeldin A treatment. Using GFP chimeric constructs of the carboxyl-terminal regions of AKAP350A, a Golgi apparatus targeting domain was identified between amino acids 3259 and 3307 of AKAP350A. This domain was functionally distinguishable from the recently described centrosomal targeting domain (PACT domain, amino acids 3308-3324) located adjacent to the Golgi targeting domain. These data definitively establish the specific association of AKAP350A with the Golgi apparatus in HCA-7 cells.	Med Coll Georgia, Inst Mol Med & Genet, Dept Med, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Dept Surg, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Dept Cellular Biol, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Dept Anat, Augusta, GA 30912 USA; Augusta Vet Affairs Med Ctr, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Goldenring, JR (corresponding author), Vanderbilt Univ, Sch Med, Epithelial Biol Program, 4160A MRB 3,465 21st Ave So, Nashville, TN 37232 USA.	jim.goldenring@vanderbilt.edu			NIDDK NIH HHS [DK 48370, DK 43405] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043405, R29DK043405, R01DK048370] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barr FA, 1999, CURR BIOL, V9, P381, DOI 10.1016/S0960-9822(99)80167-5; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Dodge K, 2000, FEBS LETT, V476, P58, DOI 10.1016/S0014-5793(00)01671-9; Dransfield DT, 1997, BIOCHEM J, V322, P801, DOI 10.1042/bj3220801; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Gillingham AK, 2000, EMBO REP, V1, P524; Huang LJS, 1999, J CELL BIOL, V145, P951, DOI 10.1083/jcb.145.5.951; KERYER G, 1993, P NATL ACAD SCI USA, V90, P5418, DOI 10.1073/pnas.90.12.5418; Lin JW, 1998, J NEUROSCI, V18, P2017; Puthenveedu MA, 2001, J CELL BIOL, V155, P227, DOI 10.1083/jcb.200105005; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; Shanks RA, 2002, J BIOL CHEM, V277, P40973, DOI 10.1074/jbc.M112277200; Steadman BT, 2002, J BIOL CHEM, V277, P30165, DOI 10.1074/jbc.M201914200; Takahashi M, 2000, J BIOL CHEM, V275, P34592, DOI 10.1074/jbc.M005285200; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858	19	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40967	40972		10.1074/jbc.M203307200	http://dx.doi.org/10.1074/jbc.M203307200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12163481	hybrid			2022-12-27	WOS:000178791400104
J	Wu, LT; Yu, ZB; Shen, SH				Wu, LT; Yu, ZB; Shen, SH			SKAP55 recruits to lipid rafts and positively mediates the MAPK pathway upon T cell receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; ADAPTER PROTEIN; MEMBRANE MICRODOMAINS; LYMPHOCYTE-ACTIVATION; LAT; COMPLEX; CD45	T cell receptor (TCR) engagement triggers a series of events including protein tyrosine kinase activation, tyrosine phosphorylation of adapter proteins, and multiple protein-protein interactions. We observed that adapter protein SKAP55, the Src kinase-associated phosphoprotein, formed homodimers through its SH3 domain and SK region. SKAP55 as a substrate interacted with Fyn kinase in vivo. In Jurkat cells, interaction between SKAP55 and Fyn kinase depended on TCR activation. Stable overexpression of SKAP55 in Jurkat cells caused mitogen-activated protein kinase activation following TCR engagement. Anti-CD3 stimulation also promoted the interaction of SKAP55 with Grb-2 in T cells. Mutational analysis revealed that tyrosine 271 in SKAP55 played a pivotal role for interaction with both Fyn kinase and adapter protein Grb-2, indicating that the Fyn-phosphorylated SKAP55 transiently associates with adapter Grb-2 to mediate mitogen-activated protein kinase activation. Intriguingly, T cell receptor engagement dramatically induced the translocation of endogenous SKAP55 to lipid rafts where SKAP55 was found to interact with Fyn kinase, suggesting that the positive function of SKAP55 via its association with Fyn and other signaling components may have been involved in raft-mediated T cell activation.	Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1A4, Canada	National Research Council Canada; McGill University	Shen, SH (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	shi.shen@nrc.ca						Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Harder T, 2000, J CELL BIOL, V151, P199, DOI 10.1083/jcb.151.2.199; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Kang H, 2000, EMBO J, V19, P2889, DOI 10.1093/emboj/19.12.2889; Koretzky GA, 2001, NAT REV IMMUNOL, V1, P95, DOI 10.1038/35100523; Leitenberg D, 2001, SEMIN IMMUNOL, V13, P129, DOI 10.1006/smim.2000.0304; Lin J, 2001, J CELL SCI, V114, P243; Marie-Cardine A, 1999, EUR J IMMUNOL, V29, P1175, DOI 10.1002/(SICI)1521-4141(199904)29:04<1175::AID-IMMU1175>3.0.CO;2-Z; Marie-Cardine A, 1998, FEBS LETT, V435, P55, DOI 10.1016/S0014-5793(98)01040-0; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; Songyang Z, 2001, J BIOL CHEM, V276, P2459, DOI 10.1074/jbc.M005504200; Tang J, 1999, P NATL ACAD SCI USA, V96, P9775, DOI 10.1073/pnas.96.17.9775; THOMAS ML, 1994, CURR OPIN CELL BIOL, V6, P247, DOI 10.1016/0955-0674(94)90143-0; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Viola A, 2001, TRENDS IMMUNOL, V22, P322, DOI 10.1016/S1471-4906(01)01938-X; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wu LT, 2002, MOL CELL BIOL, V22, P2673, DOI 10.1128/MCB.22.8.2673-2686.2002; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	24	22	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40420	40427		10.1074/jbc.M206023200	http://dx.doi.org/10.1074/jbc.M206023200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171928	hybrid			2022-12-27	WOS:000178791400035
J	Bahar, R; O-Wang, JY; Kawamura, K; Seimiya, M; Wang, YQ; Hatano, M; Okada, S; Tokuhisa, T; Watanabe, T; Tagawa, M				Bahar, R; O-Wang, JY; Kawamura, K; Seimiya, M; Wang, YQ; Hatano, M; Okada, S; Tokuhisa, T; Watanabe, T; Tagawa, M			Growth retardation, polyploidy, and multinucleation induced by Clast3, a novel cell cycle-regulated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HOMOLOGOUS KINASE CHK; CHECKPOINT; EXPRESSION; OVEREXPRESSION; ANEUPLOIDY; ANTIGEN; GENE; ONCOPROTEIN; INSTABILITY; APOPTOSIS	We have identified a novel gene, Clast3, by subtraction of cDNAs derived from activated and naive B lymphocytes. Clast3 expression is elevated in cycling cells and down-regulated in cells undergoing growth arrest, indicating that its expression is controlled in a cell cycle-dependent manner. The deduced amino acid sequence of Clast3 cDNA exhibits no significant homology to the known proteins in mammalian and other species. Immunofluorescence staining revealed that Clast3 localizes into discrete nuclear foci. Forced expression of Clast3 results in growth retardation, polyploidy, and generation of multinucleated cells. Treatment of Clast3 transfectants with nocodazole, a spindle-damaging agent, greatly enhances the incidence of the multinucleated cells, suggesting that Clast3 overexpression impairs the same checkpoint activated by nocodazole. Down-regulation of Clast3 expression by antisense oligonucleotides results in a decrease of cells at G2-M phase and a concomitant increase of apoptotic cells. These findings indicate that Clast3 is a novel cell cycle-regulated protein and that its constitutive overexpression induces polyploidy and multinucleation by interfering with the mitotic spindle checkpoint.	Chiba Canc Ctr, Inst Res, Div Pathol, Chou Ku, Chiba 2608717, Japan; Chiba Univ, Grad Sch Med, Dept Med & Clin Oncol, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Dev Genet, Chiba 2608670, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol Immunol, Fukuoka 8128582, Japan	Chiba Cancer Center; Chiba University; Chiba University; Kyushu University	O-Wang, JY (corresponding author), Chiba Canc Ctr, Inst Res, Div Pathol, Chou Ku, 666-2 Nitona Cho, Chiba 2608717, Japan.	oh@chiba-cc.pref.chiba.jp	Okada, Seiji/F-5785-2013					Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chang THT, 1997, ONCOGENE, V14, P2383, DOI 10.1038/sj.onc.1201196; Chen J, 1996, ONCOGENE, V13, P1395; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Fode C, 1996, MOL CELL BIOL, V16, P4665; Grgurevich S, 1997, GROWTH FACTORS, V14, P103, DOI 10.3109/08977199709021514; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; JALLEPALLI VP, 2001, NATURE MILESTONES, pS36; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Khan SH, 1998, CANCER RES, V58, P396; Knecht H, 1996, ONCOGENE, V13, P947; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LEONARDO DA, 1997, CANCER RES, V57, P1013; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Saez C, 1999, ONCOGENE, V18, P5473, DOI 10.1038/sj.onc.1202914; Samokhvalov I, 1997, BIOCHEM MOL BIOL INT, V43, P115; Seimiya M, 2002, BIOCHEM BIOPH RES CO, V292, P121, DOI 10.1006/bbrc.2002.6605; Shekhar MPV, 2002, CANCER RES, V62, P2115; Shimura M, 1999, FASEB J, V13, P621, DOI 10.1096/fasebj.13.6.621; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Townson SM, 2000, CLIN CANCER RES, V6, P3788; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; Wang JY, 1996, J EXP MED, V184, P831, DOI 10.1084/jem.184.3.831; Yamaguchi N, 2001, J CELL SCI, V114, P1631	30	15	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40012	40019		10.1074/jbc.M205345200	http://dx.doi.org/10.1074/jbc.M205345200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12147697	hybrid			2022-12-27	WOS:000178662500121
J	Boyer, PD				Boyer, PD			A research journey with ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							NUCLEOTIDE BINDING-SITES; MITOCHONDRIAL ADENOSINE-TRIPHOSPHATASE; BOVINE HEART-MITOCHONDRIA; COUPLING FACTOR-I; COLI F1 ATPASE; ESCHERICHIA-COLI; CATALYTIC SITES; NONCATALYTIC SITES; OXYGEN-EXCHANGE; BETA-SUBUNIT	These reflections present a perspective of how I and my graduate students and postdoctoral fellows, over a span of many years, arrived at the concept that ATP is made by an unusual rotational catalysis of the ATP synthase. A recent sketch of the structure of this remarkable enzyme is given in Fig. 1. Such a depiction is the culmination of the efforts of many investigators.(1) The two portions of the enzyme are the membrane-imbedded F-0 and the attached F-1 that has three catalytic sites, principally on the large beta subunits. ATP is formed when protons pass through the F-0, driving the rotation of the ring-shaped cluster of c subunits and the attached epsilon and gamma subunits. Other subunits attached to outer portions of the F-0 and F-1 served as a stator. The internal rotary movement of the gamma subunit is coupled to sequential changes in the conformation of the catalytic sites. During ATP synthesis these conformational changes promote the binding of ADP and P-i, the formation of tightly bound ATP, and the release of ATP. Revealing the mechanism of the ATP synthase became a major. research goal in the latter part of my long career. This paper recalls how my career developed as related to the remarkable progress in biochemical knowledge. It presents the background and results of fruitful, as well as mistaken, approaches that were explored.	Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Boyer, PD (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BAGSHAW CR, 1975, P NATL ACAD SCI USA, V72, P2592, DOI 10.1073/pnas.72.7.2592; BALTSCHEFFSKY H, 1974, ANNU REV BIOCHEM, V43, P871, DOI 10.1146/annurev.bi.43.070174.004255; BERKICH DA, 1991, J BIOL CHEM, V266, P123; BIANCHET M, 1991, J BIOL CHEM, V266, P21197; BIEBER LL, 1966, J BIOL CHEM, V241, P5375; Boyer P. D., 1958, P INT S ENZYME CHEM, P301; Boyer P.D., 1981, PRESENT STATUS BINDI, P231; Boyer P. D., 1979, MEMBRANE BIOENERGETI, P461; Boyer Paul D., 1942, JOUR BIOL CHEM, V146, P673; BOYER PD, 1959, ARCH BIOCHEM BIOPHYS, V82, P387, DOI 10.1016/0003-9861(59)90136-5; BOYER PD, 1973, P NATL ACAD SCI USA, V70, P2837, DOI 10.1073/pnas.70.10.2837; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1975, FEBS LETT, V58, P1, DOI 10.1016/0014-5793(75)80212-2; BOYER PD, 1975, FEBS LETT, V50, P91, DOI 10.1016/0014-5793(75)80464-9; Boyer PD, 2002, FEBS LETT, V512, P29, DOI 10.1016/S0014-5793(02)02293-7; BOYER PD, 1966, J BIOL CHEM, V241, P5384; BOYER PD, 1954, NATURE, V174, P401, DOI 10.1038/174401b0; BOYER PD, 1956, J AM CHEM SOC, V78, P356, DOI 10.1021/ja01583a029; BOYER PD, 1947, J BIOL CHEM, V167, P407; BOYER PD, 1956, ACTA CHEM SCAND, V10, P447, DOI 10.3891/acta.chem.scand.10-0447; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Boyer PD, 1943, J BIOL CHEM, V149, P529; BOYER PD, 1983, BIOCH METABOLIC PROC, P465; BOYER PD, 1974, DYNAMICS ENERGY TRAN, P289; CHANEY G, 1972, J BIOL CHEM, V247, P2145; CHANEY SG, 1969, J BIOL CHEM, V244, P5773; COHN M, 1953, J BIOL CHEM, V201, P735; COHN M, 1958, J BIOL CHEM, V230, P369; CROSS RL, 1987, P NATL ACAD SCI USA, V84, P5715, DOI 10.1073/pnas.84.16.5715; CROSS RL, 1982, J BIOL CHEM, V257, P2101; CROSS RL, 1975, BIOCHEMISTRY-US, V14, P392, DOI 10.1021/bi00673a028; DELUCA M, 1963, BIOCHEM Z, V338, P52; DEMEIS L, 1978, J BIOL CHEM, V253, P1556; DEMPSEY ME, 1961, J BIOL CHEM, V236, pPCL; Dou C, 1998, BIOCHEMISTRY-US, V37, P16757, DOI 10.1021/bi981717q; DU ZY, 1989, BIOCHEMISTRY-US, V28, P873, DOI 10.1021/bi00428a070; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; ENGELHARDT WA, 1982, ANNU REV BIOCHEM, V51, P1, DOI 10.1146/annurev.bi.51.070182.000245; FELDMAN RI, 1982, J BIOL CHEM, V257, P1676; GRAVES DJ, 1962, BIOCHEMISTRY-US, V1, P739, DOI 10.1021/bi00911a003; GUERRERO KJ, 1988, BIOCHEM BIOPH RES CO, V154, P854, DOI 10.1016/0006-291X(88)90218-5; HACKNEY DD, 1978, J BIOL CHEM, V253, P3164; HACKNEY DD, 1979, P NATL ACAD SCI USA, V76, P3646, DOI 10.1073/pnas.76.8.3646; HACKNEY DD, 1979, BIOCH BIOPHYS RES CO; HAROLD FM, 1972, BACTERIOL REV, V36, P172, DOI 10.1128/MMBR.36.2.172-230.1972; HARRISON WH, 1955, J BIOL CHEM, V215, P303; HARROW B, 1946, TXB BIOCH, P43; HILL RD, 1967, J BIOL CHEM, V242, P4320; Hutcheon ML, 2001, P NATL ACAD SCI USA, V98, P8519, DOI 10.1073/pnas.151236798; HUTTON RL, 1979, J BIOL CHEM, V254, P9990; JANSON CA, 1979, J BIOL CHEM, V254, P3743; JAULT JM, 1993, J BIOL CHEM, V268, P1558; KANAZAWA T, 1973, J BIOL CHEM, V248, P3163; KANDPAL RP, 1987, BIOCHIM BIOPHYS ACTA, V890, P97, DOI 10.1016/0005-2728(87)90073-9; KASHO VN, 1989, P NATL ACAD SCI USA, V86, P8708, DOI 10.1073/pnas.86.22.8708; KASHO VN, 1989, BIOCHEMISTRY-US, V28, P6949, DOI 10.1021/bi00443a026; KAUFMAN S, 1955, J BIOL CHEM, V216, P153; KAYALAR C, 1977, J BIOL CHEM, V252, P2486; KLEIN WL, 1972, J BIOL CHEM, V247, P7257; KOHLBRENNER WE, 1983, J BIOL CHEM, V258, P881; LARDY HA, 1969, ANNU REV BIOCHEM, V38, P991, DOI 10.1146/annurev.bi.38.070169.005015; LARDY HA, 1952, J BIOL CHEM, V195, P219; Larsen TM, 1998, BIOCHEMISTRY-US, V37, P6247, DOI 10.1021/bi980243s; LUTTER R, 1993, J MOL BIOL, V229, P787, DOI 10.1006/jmbi.1993.1081; MCCARTY RE, 1972, J BIOL CHEM, V247, P3048; MELESE T, 1988, J BIOL CHEM, V263, P5833; MELESE T, 1985, J BIOL CHEM, V260, P5398; MILGROM YM, 1990, J BIOL CHEM, V265, P18725; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1974, FEBS LETT, V43, P189, DOI 10.1016/0014-5793(74)80997-X; MITCHELL P, 1975, FEBS LETT, V50, P95, DOI 10.1016/0014-5793(75)80465-0; MITCHELL RA, 1964, BIOCHEM BIOPH RES CO, V16, P545, DOI 10.1016/0006-291X(64)90190-1; MOYLE J, 1975, FEBS LETT, V56, P55, DOI 10.1016/0014-5793(75)80110-4; MURATALIEV MB, 1992, EUR J BIOCHEM, V209, P681, DOI 10.1111/j.1432-1033.1992.tb17336.x; MUSIER KM, 1987, BIOCHEMISTRY-US, V26, P5982, DOI 10.1021/bi00393a006; MUSIER KM, 1988, BIOCHEMISTRY-US, V27, P7015, DOI 10.1021/bi00418a052; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; ONEAL CC, 1984, J BIOL CHEM, V259, P5761; PENEFSKY HS, 1985, J BIOL CHEM, V260, P3735; PETER JB, 1963, J BIOL CHEM, V238, P1180; PULLMAN ME, 1967, ANNU REV BIOCHEM, V36, P539, DOI 10.1146/annurev.bi.36.070167.002543; RABINOVITZ M, 1951, SCIENCE, V114, P641, DOI 10.1126/science.114.2972.641; RABINOVITZ M, 1951, P SOC EXP BIOL MED, V77, P103, DOI 10.3181/00379727-77-18691; RACKER E, 1952, J BIOL CHEM, V198, P731; ROSEN G, 1979, J BIOL CHEM, V254, P654; ROSING J, 1977, J BIOL CHEM, V252, P2478; ROSING J, 1976, BIOCHEM BIOPH RES CO, V72, P1, DOI 10.1016/0006-291X(76)90952-9; RUSSO JA, 1978, BIOCHEMISTRY-US, V17, P473, DOI 10.1021/bi00596a016; Sabbert D, 1997, P NATL ACAD SCI USA, V94, P4401, DOI 10.1073/pnas.94.9.4401; SEGAL HL, 1953, J BIOL CHEM, V204, P265; SHAVIT N, 1967, J BIOL CHEM, V242, P5125; SLATER EC, 1974, DYNAMICS ENERGY TRAN, P1; SLEEP JA, 1978, J BIOL CHEM, V253, P5235; SMITH DJ, 1976, P NATL ACAD SCI USA, V73, P4314, DOI 10.1073/pnas.73.12.4314; SMITH LT, 1983, J BIOL CHEM, V258, P887; UPPER CD, 1964, THESIS U ILLINOIS UR; VANDAM K, 1971, ANNU REV BIOCHEM, V40, P118; VASILYEVA EA, 1982, BIOCHEM J, V202, P15, DOI 10.1042/bj2020015; Weber J, 2001, J BIOL CHEM, V276, P35422, DOI 10.1074/jbc.M104946200; WILLIAMS N, 1987, BIOCHEMISTRY-US, V26, P162, DOI 10.1021/bi00375a023; WIMMER MJ, 1977, J BIOL CHEM, V252, P6769; WISE JG, 1987, FEBS LETT, V223, P395, DOI 10.1016/0014-5793(87)80326-5; WOLCOTT RG, 1974, BIOCHEM BIOPH RES CO, V57, P709, DOI 10.1016/0006-291X(74)90604-4; WOOD JM, 1987, J BIOL CHEM, V262, P2180; WU D, 1986, BIOCHEMISTRY-US, V25, P3390, DOI 10.1021/bi00359a044; XUE ZX, 1987, BIOCHEMISTRY-US, V26, P3749, DOI 10.1021/bi00387a001; XUE ZX, 1987, FEBS LETT, V223, P391, DOI 10.1016/0014-5793(87)80325-3; 1942, S RESP ENZ MAD WI	111	95	99	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39045	39061		10.1074/jbc.X200001200	http://dx.doi.org/10.1074/jbc.X200001200			17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12181328	hybrid			2022-12-27	WOS:000178662500001
J	Marchal, S; Branlant, G				Marchal, S; Branlant, G			Characterization of the amino acids involved in substrate specificity of nonphosphorylating glyceraldehyde-3-phosphate dehydrogenase from Streptococcus mutans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ALDEHYDE DEHYDROGENASE; SITE-DIRECTED MUTAGENESIS; CATALYTIC MECHANISM; ANGSTROM RESOLUTION; METABOLISM; GLUTAMATE-268	In order to address the molecular basis of the specificity of aldehyde dehydrogenase for aldehyde substrates, enzymatic characterization of the glyceraldehyde 3-phosphate (G3P) binding site of non-phosphorylating glyceraldehyde-3-phosphate dehydrogenase (GAPN) from Streptococcus mutans has been undertaken. In this work, residues Arg-124, Tyr-170, Arg-301, and Arg-459 were changed by site-directed mutagenesis and the catalytic properties of GAPN mutants investigated. Changing Tyr-170 into phenylalanine induces no major effect on k(cat) and K-m for D-G3P in both acylation and deacylation steps. Substitutions of Arg-124 and Arg-301 by leucine and Arg-459 by isoleucine led to distinct effects on K-m, on k(cat), or on both. The rate-limiting step of the R124L GAPN remains deacylation. Pre-steady-state analysis and substrate isotope measurements show that hydride transfer remains rate-determining in acylation. Only the apparent affinity for D-G3P is decreased in both acylation and deacylation steps. Substitution of Arg-459 by isoleucine leads to a drastic effect on the catalytic efficiency by a factor of 10(5). With this R459L GAPN, the rate-limiting step is prior to hydride transfer, and the K-m of D-G3P is increased by at least 2 orders of magnitude. Binding of NADP leads to a time-dependent formation of a charge transfer transition at 333 nm between the pyridinium ring of NADP and the thiolate of Cys-302, which is not observed with the holo-wild type. Accessibility of Cys-302 is shown to be strongly decreased within the holostructure. The substitution of Arg-301 by leucine leads to an even more drastic effect with a change of the rate-limiting step similar to that observed for R4591 GAPN. Taking into account the three-dimensional structure of GAPN from S. mutans and the data of the present study, it is proposed that 1) Tyr-170 is not essential for the catalytic event, 2) Arg-124 is only involved in stabilizing D-G3P binding via an interaction with the C-3 phosphate, and 3) Arg-301 and Arg-459 participate not only in D-G3P binding via interaction with C-3 phosphate but also in positioning efficiently D-G3P relative to Cys-302 within the ternary complex GAPN-NADP-D-G3P.	Univ Nancy 1, Fac Sci, UMR CNRS 7567, Lab Maturat ARN & Enzymol Mol, F-54506 Vandoeuvre Les Nancy, France	Universite de Lorraine	Branlant, G (corresponding author), Univ Nancy 1, Fac Sci, UMR CNRS 7567, Lab Maturat ARN & Enzymol Mol, BP 239, F-54506 Vandoeuvre Les Nancy, France.		MARCHAL, stéphane/M-4324-2017	MARCHAL, stéphane/0000-0002-1101-7890				Ahvazi B, 2000, BIOCHEM J, V349, P853, DOI 10.1042/bj3490853; Casati DFG, 2000, PLANT SCI, V154, P107, DOI 10.1016/S0168-9452(99)00241-1; Cobessi D, 1999, J MOL BIOL, V290, P161, DOI 10.1006/jmbi.1999.2853; Cobessi D, 2000, J MOL BIOL, V300, P141, DOI 10.1006/jmbi.2000.3824; CORBIER C, 1990, BIOCHIMIE, V72, P545, DOI 10.1016/0300-9084(90)90119-2; HOCHACHKA PW, 2002, BIOCH ADAPTATION MEC, P290; Johansson K, 1998, PROTEIN SCI, V7, P2106, DOI 10.1002/pro.5560071007; Klyosov AA, 1996, BIOCHEMISTRY-US, V35, P4445, DOI 10.1021/bi9521093; Klyosov AA, 1996, BIOCHEMISTRY-US, V35, P4457, DOI 10.1021/bi9521102; Lamb AL, 1999, BIOCHEMISTRY-US, V38, P6003, DOI 10.1021/bi9900471; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; Marchal S, 2000, BIOCHEMISTRY-US, V39, P3327, DOI 10.1021/bi9914208; Marchal S, 1999, BIOCHEMISTRY-US, V38, P12950, DOI 10.1021/bi990453k; Moore SA, 1998, STRUCTURE, V6, P1541, DOI 10.1016/S0969-2126(98)00152-X; MOUGIN A, 1988, PROTEIN ENG, V2, P45, DOI 10.1093/protein/2.1.45; Ni L, 1997, J BIOL CHEM, V272, P18823, DOI 10.1074/jbc.272.30.18823; Ni L, 1999, PROTEIN SCI, V8, P2784; Pohl E, 2002, J BIOL CHEM, V277, P19938, DOI 10.1074/jbc.M112244200; RACKER E, 1952, J BIOL CHEM, V198, P731; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; Vasiliou V, 2000, CHEM-BIOL INTERACT, V129, P1, DOI 10.1016/S0009-2797(00)00211-8; Vasiliou V, 2000, PHARMACOLOGY, V61, P192, DOI 10.1159/000028400; WANG XP, 1995, BIOCHEMISTRY-US, V34, P237, DOI 10.1021/bi00001a028	24	12	12	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39235	39242		10.1074/jbc.M205633200	http://dx.doi.org/10.1074/jbc.M205633200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163495	hybrid			2022-12-27	WOS:000178662500024
J	Elad-Sfadia, G; Haklai, R; Ballan, E; Gabius, HJ; Kloog, Y				Elad-Sfadia, G; Haklai, R; Ballan, E; Gabius, HJ; Kloog, Y			Galectin-1 augments Ras activation and diverts Ras signals to Raf-1 at the expense of phosphoinositide 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-CELL LINES; K-RAS; HUMAN GLIOMAS; H-RAS; FAMILY; PROTEIN; BINDING; COMPLEX; SURFACE; GROWTH	Ras proteins activate diverse effector molecules. Depending on the cellular context, Ras activation may have different biological consequences: induction of cell proliferation, senescence, survival, or death. Augmentation and selective activation of particular effector molecules may underlie various Ras actions. In fact, Ras effector-loop mutants interacting with distinctive effectors provide evidence for such selectivity. Interactions of active Ras with escort proteins, such as galectin-1, could also direct Ras selectivity. Here we show that in comparison with Ras transfectants, H-Ras/galectin-1 or K-Ras4B/galectin-1 co-transfectants exhibit enhanced and prolonged epidermal growth factor (EGF)-stimulated increases in Ras-GTP, Raf-1 activity, and active extracellular signal-regulated kinase. Galectin-1 antisense RNA inhibited these EGF responses. Conversely, Ras and galectin-1 co-transfection inhibited the EGF-stimulated increase in phosphoinositide 3-kinase (PI3K) activity. Galectin-1 transfection also inhibited Ras(G12V)-induced PI3K but not Raf-1 activity. Galectin-1 co-immunoprecipitated with Ras(G12V) or with Ras(G12V/T35S) that activate Raf-1 but not with Ras(G12V/ Y40C) that activates PI3K. Thus, galectin-1 binds active Ras and diverts its signal to Raf-1 at the expense of PI3K. This demonstrates a novel mechanism controlling the duration and selectivity of the Ras signal. Ras gains selectivity when it is associated with galectin-1, mimicking the selectivity of Ras(T35S), which activates Raf-1 but not PI3K.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel; Univ Munich, Fac Med Vet, Inst Physiol Chem, D-80539 Munich, Germany	Tel Aviv University; University of Munich	Kloog, Y (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiochem, IL-69978 Tel Aviv, Israel.	kloog@post.tau.ac.il		Gabius, Hans-Joachim/0000-0003-3467-3900				Andre S, 1999, J CANCER RES CLIN, V125, P461, DOI 10.1007/s004320050303; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Fiordalis JJ, 2002, J BIOL CHEM, V277, P10813, DOI 10.1074/jbc.M107684200; Fridman M, 2000, J BIOL CHEM, V275, P30363, DOI 10.1074/jbc.M003193200; Gabius HJ, 1997, EUR J BIOCHEM, V243, P543, DOI 10.1111/j.1432-1033.1997.t01-1-00543.x; Haklai R, 1998, BIOCHEMISTRY-US, V37, P1306, DOI 10.1021/bi972032d; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; HORI Y, 1991, ONCOGENE, V6, P515; Hughes RC, 1999, BBA-GEN SUBJECTS, V1473, P172, DOI 10.1016/S0304-4165(99)00177-4; Jones MK, 1998, J BIOL CHEM, V273, P1782, DOI 10.1074/jbc.273.3.1782; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; Lahm H, 2001, J CANCER RES CLIN, V127, P375, DOI 10.1007/s004320000207; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Niv H, 1999, J BIOL CHEM, V274, P1606, DOI 10.1074/jbc.274.3.1606; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; OHANNESIAN DW, 1995, CANCER RES, V55, P2191; Pardo OE, 2002, J BIOL CHEM, V277, P12040, DOI 10.1074/jbc.M109006200; Paz A, 2001, ONCOGENE, V20, P7486, DOI 10.1038/sj.onc.1204950; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Rorive S, 2001, GLIA, V33, P241, DOI 10.1002/1098-1136(200103)33:3<241::AID-GLIA1023>3.0.CO;2-1; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; VICIANA PR, 1997, CELL, V89, P457; VICIANA PR, 1996, EMBO J, V15, P2442; VICIANA PR, 1994, NATURE, V370, P527; Voice JK, 1999, J BIOL CHEM, V274, P17164, DOI 10.1074/jbc.274.24.17164; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Yamaoka K, 2000, J NEUROSCI RES, V59, P722, DOI 10.1002/(SICI)1097-4547(20000315)59:6<722::AID-JNR4>3.0.CO;2-H; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052	45	181	185	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37169	37175		10.1074/jbc.M205698200	http://dx.doi.org/10.1074/jbc.M205698200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149263	hybrid			2022-12-27	WOS:000178447100035
J	Ettema, TJG; Brinkman, AB; Tani, TH; Rafferty, JB; van der Oost, J				Ettema, TJG; Brinkman, AB; Tani, TH; Rafferty, JB; van der Oost, J			A novel ligand-binding domain involved in regulation of amino acid metabolism in prokaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; D-3-PHOSPHOGLYCERATE DEHYDROGENASE; PROTEIN; LEUCINE; LRP; MUTAGENESIS; ENZYME; SITE	A combination of sequence profile searching and structural protein analysis has revealed a novel type of small molecule binding domain that is involved in the allosteric regulation of prokaryotic amino acid metabolism. This domain, designated RAM, has been found to be fused to the DNA-binding domain of Lrp-like transcription regulators and to the catalytic domain of some metabolic enzymes, and has been found as a stand-alone module. Structural analysis of the RAM domain of Lrp reveals a betaalphabetaalphabeta-fold that is strikingly similar to that of the recently described ACT domain, a ubiquitous allosteric regulatory domain of many metabolic enzymes. However, structural alignment and re-evaluation of previous mutagenesis data suggest that the effector-binding sites of both modules are significantly different. By assuming that the RAM and ACT domains originated from a common ancestor, these observations suggest that their ligand-binding sites have evolved independently. Both domains appear to play analogous roles in controlling key steps in amino acid metabolism at the level of gene expression as well as enzyme activity.	Wageningen Univ, Microbiol Lab, NL-6307 CT Wageningen, Netherlands; Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst Biomolec Res, Sheffield S10 2TN, S Yorkshire, England; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA	Wageningen University & Research; University of Sheffield; University of Michigan System; University of Michigan	Ettema, TJG (corresponding author), Wageningen Univ, Microbiol Lab, Hesselink Suchtelenweg 4, NL-6307 CT Wageningen, Netherlands.		Brinkman, Arie/V-1533-2018; van+der+Oost, John/Y-2548-2019	Brinkman, Arie/0000-0002-9875-1835; Rafferty, John/0000-0003-1183-7474				AlRabiee R, 1996, J BIOL CHEM, V271, P23235, DOI 10.1074/jbc.271.38.23235; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anantharaman V, 2001, J MOL BIOL, V307, P1271, DOI 10.1006/jmbi.2001.4508; Aravind L, 1999, J MOL BIOL, V287, P1023, DOI 10.1006/jmbi.1999.2653; BARTHOLOMEW JC, 1971, BIOCHIM BIOPHYS ACTA, V250, P568, DOI 10.1016/0005-2744(71)90257-9; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; Brinkman AB, 2002, J BIOL CHEM, V277, P29537, DOI 10.1074/jbc.M203528200; CALVO JM, 1994, MICROBIOL REV, V58, P466, DOI 10.1128/MMBR.58.3.466-490.1994; CALVO RA, 1967, SCIENCE, V156, P1107, DOI 10.1126/science.156.3778.1107; Chen S, 2001, J MOL BIOL, V312, P625, DOI 10.1006/jmbi.2001.4955; Chipman DM, 2001, CURR OPIN STRUC BIOL, V11, P694, DOI 10.1016/S0959-440X(01)00272-X; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; Grant GA, 1996, PROTEIN SCI, V5, P34; Kikuchi Y, 1999, FEMS MICROBIOL LETT, V173, P211, DOI 10.1111/j.1574-6968.1999.tb13504.x; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; KOHLHAW G, 1969, J BIOL CHEM, V244, P2218; KOLLING R, 1988, MOL GEN GENET, V212, P99, DOI 10.1007/BF00322450; LEARY TR, 1970, BIOCHEM BIOPH RES CO, V39, P494, DOI 10.1016/0006-291X(70)90605-4; Leonard PM, 2001, EMBO J, V20, P990, DOI 10.1093/emboj/20.5.990; Madhusudhan KT, 1997, J BACTERIOL, V179, P276, DOI 10.1128/jb.179.1.276-279.1997; Mendel S, 2001, J MOL BIOL, V307, P465, DOI 10.1006/jmbi.2000.4413; PLATKO JV, 1993, J BACTERIOL, V175, P1110, DOI 10.1128/JB.175.4.1110-1117.1993; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schwede T, 2000, RES MICROBIOL, V151, P107, DOI 10.1016/S0923-2508(00)00121-2; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	26	63	65	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37464	37468		10.1074/jbc.M206063200	http://dx.doi.org/10.1074/jbc.M206063200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12138170	hybrid			2022-12-27	WOS:000178447100071
J	Paolini, R; Molfetta, R; Beitz, LO; Zhang, J; Scharenberg, AM; Piccoli, M; Frati, L; Siraganian, R; Santoni, A				Paolini, R; Molfetta, R; Beitz, LO; Zhang, J; Scharenberg, AM; Piccoli, M; Frati, L; Siraganian, R; Santoni, A			Activation of Syk tyrosine kinase is required for c-Cbl-mediated ubiquitination of Fc epsilon RI and Syk in RBL cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; HUMAN NK CELLS; HIGH-AFFINITY; SIGNAL-TRANSDUCTION; NEGATIVE REGULATOR; RECEPTOR-ZETA; BETA-SUBUNIT; PHOSPHORYLATION; ANTIGEN; CHAIN	Engagement of the high affinity receptor for IgE (FcepsilonRI) on mast cells and basophils results in FcepsilonRI beta and gamma subunits ubiquitination by an as yet undefined mechanism. Here we show that, upon FcepsilonRI engagement on RBL-2H3 cells Syk undergoes ubiquitination and Syk kinase activity is required for its own ubiquitination and that of FcepsilonRI beta and gamma chains. This requirement was demonstrated by overexpression of Syk wild-type or its kinase-dead mutant in RBL cells or using an Syk-deficient RBL-derived cell line transfected with wild-type or a kinase inactive form of Syk. We also identify c-Cbl as the E3 ligase responsible for both Syk and receptor ubiquitination. Furthermore, we demonstrate that Syk controls tyrosine phosphorylation of Syk-associated Cbl induced after receptor engagement. These data suggest a mutual regulation between Syk and Cbl activities. Finally, we show that a selective inhibitor of proteasome degradation induces persistence of tyrosine-phosphorylated receptor complexes, of activated Syk, and of FcepsilonRI-triggered degranulation. Our results provide a molecular mechanism for down-regulation of engaged receptor complexes by targeting ubiquitinated FcepsilonRI and activated Syk to the proteasome for degradation.	Univ Roma La Sapienza, Dept Expt Med & Pathol, Inst Pasteur, Fdn Cenci Bolognetti, I-00161 Rome, Italy; Univ Washington, Dept Pediat Rheumatol, Seattle, WA 98195 USA; Univ Washington, Dept Immunol, Seattle, WA 98195 USA; NIDCR, Receptors & Signal Transduct Sect, Oral Infect & Immun Branch, NIH, Bethesda, MD 20892 USA; Mediterranean Inst Neurosci Neuromed, I-86077 Pozzilli, IS, Italy	Fondazione Cenci Bolognetti; Sapienza University Rome; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); IRCCS Neuromed	Paolini, R (corresponding author), Univ Roma La Sapienza, Dept Expt Med & Pathol, Inst Pasteur, Fdn Cenci Bolognetti, Viale Regina Elena 324, I-00161 Rome, Italy.	rossella.paolini@uniroma1.it	Frati, Luigi/ABI-7437-2020; Molfetta, Rosa/N-4529-2015; santoni, angela/K-8997-2016	Molfetta, Rosa/0000-0003-2904-6371; santoni, angela/0000-0003-1206-7731; PAOLINI, Rossella/0000-0001-7605-1531	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000696, Z01DE000696] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BASCIANO LK, 1986, J BIOL CHEM, V261, P1823; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHUN DH, 1998, IMMUNOL REV, V165, P176; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; Donnadieu E, 2000, IMMUNITY, V12, P515, DOI 10.1016/S1074-7613(00)80203-4; ElHillal O, 1997, P NATL ACAD SCI USA, V94, P1919, DOI 10.1073/pnas.94.5.1919; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; LETOURNEUR O, 1991, J IMMUNOL, V147, P2652; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Nadler M J, 2000, Adv Immunol, V76, P325; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; OSHEA JJ, 1991, P NATL ACAD SCI USA, V88, P350, DOI 10.1073/pnas.88.2.350; Ota Y, 1996, J EXP MED, V184, P1713, DOI 10.1084/jem.184.5.1713; Ota Y, 1997, SCIENCE, V276, P418, DOI 10.1126/science.276.5311.418; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; Paolini R, 1996, J BIOL CHEM, V271, P15987, DOI 10.1074/jbc.271.27.15987; Paolini R, 1999, EUR J IMMUNOL, V29, P3179, DOI 10.1002/(SICI)1521-4141(199910)29:10<3179::AID-IMMU3179>3.0.CO;2-9; Paolini R, 2001, P NATL ACAD SCI USA, V98, P9611, DOI 10.1073/pnas.161298098; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; RIVERA J, 1988, MOL IMMUNOL, V25, P647, DOI 10.1016/0161-5890(88)90100-9; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; Sada K, 2000, J IMMUNOL, V164, P338, DOI 10.4049/jimmunol.164.1.338; Sada K, 2001, BLOOD, V97, P1352, DOI 10.1182/blood.V97.5.1352; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; Sawasdikosol S, 2000, BBA-REV CANCER, V1471, pM1, DOI 10.1016/S0304-419X(00)00013-5; Tamir I, 1998, ONCOGENE, V17, P1353, DOI 10.1038/sj.onc.1202187; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Turner M, 2000, IMMUNOL TODAY, V21, P148, DOI 10.1016/S0167-5699(99)01574-1; VIVIER E, 1991, J IMMUNOL, V146, P206; VIVIER E, 1991, J IMMUNOL, V147, P4263; Wang HY, 2001, J BIOL CHEM, V276, P26004, DOI 10.1074/jbc.M010738200; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; Weiss RA, 2000, EMBO REP, V1, P2, DOI 10.1093/embo-reports/kvd017; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	54	70	71	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36940	36947		10.1074/jbc.M204948200	http://dx.doi.org/10.1074/jbc.M204948200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145291	hybrid			2022-12-27	WOS:000178447100006
J	Saxowsky, TT; Matsumoto, Y; Englund, PT				Saxowsky, TT; Matsumoto, Y; Englund, PT			The mitochondrial DNA polymerase beta from Crithidia fasciculata has 5 '-deoxyribose phosphate (dRP) lyase activity but is deficient in the release of dRP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; N-TERMINAL DOMAIN; KINETOPLAST DNA; TOPOISOMERASE-II; MAMMALIAN-CELLS; REPLICATION; SITE; MECHANISM; SEQUENCE; BINDING	DNA polymerase beta (pol beta) has long been described as a nuclear enzyme involved in DNA repair. A pol beta from the trypanosomatid parasite Crithidia fasciculata, however, is the first example of a mitochondrial enzyme of this type. The mammalian nuclear enzyme functions not only as a nucleotidyl transferase but also has a dRP lyase activity that cleaves 5'-deoxyribose phosphate (dRP) groups from DNA, thus contributing to two consecutive steps of the base excision repair pathway. We find that the mitochondrial pol beta also has dRP lyase activity. Interestingly, the K-m of this enzyme for a dRP-containing substrate is similar to that for the rat enzyme, but its k(cat) is very low. This difference is due to a deficiency of the mitochondrial enzyme in the release of dRP from the enzyme following its cleavage from the DNA.	Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Fox Chase Canc Ctr, Div Med Sci, Philadelphia, PA 19111 USA	Johns Hopkins University; Johns Hopkins Medicine; Fox Chase Cancer Center	Englund, PT (corresponding author), Johns Hopkins Sch Med, Dept Biol Chem, 725 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027608, R37GM027608] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27608] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Elneel K, 2001, J CELL BIOL, V153, P725, DOI 10.1083/jcb.153.4.725; BAILLY V, 1988, BIOCHEM J, V253, P553, DOI 10.1042/bj2530553; Beard WA, 1995, METHOD ENZYMOL, V262, P98; Bogenhagen DF, 2001, PROG NUCLEIC ACID RE, V68, P257; Deterding LJ, 2000, J BIOL CHEM, V275, P10463, DOI 10.1074/jbc.275.14.10463; Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285; Drew ME, 2001, J CELL BIOL, V153, P735, DOI 10.1083/jcb.153.4.735; Engel ML, 1999, P NATL ACAD SCI USA, V96, P8455, DOI 10.1073/pnas.96.15.8455; Feng JA, 1998, BIOCHEMISTRY-US, V37, P9605, DOI 10.1021/bi9808619; FERGUSON M, 1992, CELL, V70, P621, DOI 10.1016/0092-8674(92)90431-B; Hausler T, 1997, EUR J CELL BIOL, V73, P240; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hines JC, 2001, MOL BIOCHEM PARASIT, V115, P63, DOI 10.1016/S0166-6851(01)00272-9; Johnson CE, 1998, J CELL BIOL, V143, P911, DOI 10.1083/jcb.143.4.911; Klingbeil MM, 2002, MOL CELL, V10, P175, DOI 10.1016/S1097-2765(02)00571-3; Klingbeil MM, 2001, PROTIST, V152, P255, DOI 10.1078/1434-4610-00066; LeDoux SP, 2001, PROG NUCLEIC ACID RE, V68, P273; Li CJ, 1997, J BIOL CHEM, V272, P20787, DOI 10.1074/jbc.272.33.20787; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; Maciejewski MW, 2000, J MOL BIOL, V296, P229, DOI 10.1006/jmbi.1999.3455; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Matsumoto Y, 1998, BIOCHEMISTRY-US, V37, P6456, DOI 10.1021/bi9727545; MELENDY T, 1988, CELL, V55, P1083, DOI 10.1016/0092-8674(88)90252-8; Menge KL, 1995, BIOCHEMISTRY-US, V34, P15934, DOI 10.1021/bi00049a008; Morris JC, 2001, INT J PARASITOL, V31, P453, DOI 10.1016/S0020-7519(01)00156-4; Piersen CE, 2000, MUTAT RES-DNA REPAIR, V459, P43, DOI 10.1016/S0921-8777(99)00054-3; Pinz KG, 2000, J BIOL CHEM, V275, P12509, DOI 10.1074/jbc.275.17.12509; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; SHAPIRO TA, 1995, ANNU REV MICROBIOL, V49, P117, DOI 10.1146/annurev.mi.49.100195.001001; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; TORRI AF, 1995, J BIOL CHEM, V270, P3495, DOI 10.1074/jbc.270.8.3495; TORRI AF, 1992, J BIOL CHEM, V267, P4786; TORRI AF, 1994, J BIOL CHEM, V269, P8165; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674	36	15	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37201	37206		10.1074/jbc.M206654200	http://dx.doi.org/10.1074/jbc.M206654200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151410	hybrid			2022-12-27	WOS:000178447100039
J	Walzel, B; Speer, O; Zanolla, E; Eriksson, O; Bernardi, P; Wallimann, T				Walzel, B; Speer, O; Zanolla, E; Eriksson, O; Bernardi, P; Wallimann, T			Novel mitochondrial creatine transport activity - Implications for intracellular creatine compartments and bioenergetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; SKELETAL-MUSCLE; HEART-MITOCHONDRIA; DOWN-REGULATION; PROTEIN-CONTENT; IN-VIVO; KINASE; GENE; EXPRESSION; EVOLUTION	Immunoblotting of isolated mitochondria from rat heart, liver, kidney, and brain with antibodies made against N- and C-terminal peptide sequences of the creatine transporter, together with in situ immunofluorescence staining and immunogold electron microscopy of adult rat myocardium, revealed two highly related polypeptides with molecular masses of similar to70 and similar to55 kDa in mitochondria. These polypeptides were localized by immunoblotting of inner and outer mitochondrial membrane fractions, as well as by immunogold labeling in the mitochondrial inner membrane. In addition, a novel creatine uptake via a mitochondrial creatine transport activity was demonstrated by [Cl-14]creatine uptake studies with isolated mitochondria from rat liver, heart, and kidney showing a saturable low affinity creatine transporter, which was largely inhibited in a concentration- dependent manner by the sulfhydryl-modifying reagent NEM, as well as by the addition of the above anti-creatine transporter antibodies to partially permeabilized mitochondria. Mitochondrial creatine transport was to a significant part dependent on the energetic state of mitochondria and was inhibited by arginine, and to some extent also by lysine, but not by other creatine analogues and related compounds. The existence of an active creatine uptake mechanism in mitochondria indicates that not only creatine kinase isoenzymes, but also creatine transporters and thus a certain proportion of the creatine kinase substrates, might be subcellularly compartmentalized. Our data suggest that mitochondria, shown here to possess creatine transport activity, may harbor such a creatine/phosphocreatine pool.	ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland; Univ Helsinki, Inst Biomed Biochem, Biomedicum, FIN-00014 Helsinki, Finland; Univ Padua, Dept Biomed Sci, I-35131 Padua, Italy	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Helsinki; University of Padua	Wallimann, T (corresponding author), ETH Honggerberg, Inst Cell Biol, HPM F42, CH-8093 Zurich, Switzerland.		Eriksson-Rosenberg, Ove/GVU-6692-2022; Bernardi, Paolo/C-3656-2008; Wallimann, Theo/C-6047-2008	Bernardi, Paolo/0000-0001-9187-3736; Wallimann, Theo/0000-0003-4957-5836				AFOLAYAN A, 1986, COMP BIOCHEM PHYS B, V85, P463, DOI 10.1016/0305-0491(86)90028-3; BARNWELL LFS, 1995, GENE, V159, P287, DOI 10.1016/0378-1119(95)00104-E; Eichler EE, 1996, HUM MOL GENET, V5, P899, DOI 10.1093/hmg/5.7.899; Ellington WR, 2001, ANNU REV PHYSIOL, V63, P289, DOI 10.1146/annurev.physiol.63.1.289; Fiermonte G, 1999, BIOCHEM J, V344, P953, DOI 10.1042/0264-6021:3440953; FITCH CD, 1966, J BIOL CHEM, V241, P3611; Guerrero-Ontiveros ML, 1998, MOL CELL BIOCHEM, V184, P427, DOI 10.1023/A:1006895414925; HEBISCH S, 1986, PFLUG ARCH EUR J PHY, V406, P20, DOI 10.1007/BF00582947; HENRY HO, 2001, CELL BIOL INT, V25, P940; Hochachka PW, 1998, AM J PHYSIOL-REG I, V274, pR868, DOI 10.1152/ajpregu.1998.274.3.R868; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Iyer GS, 1996, GENOMICS, V34, P143, DOI 10.1006/geno.1996.0254; Joubert F, 2000, BIOPHYS J, V79, P1, DOI 10.1016/S0006-3495(00)76269-2; Joubert F, 2001, BIOCHEMISTRY-US, V40, P2129, DOI 10.1021/bi001695j; KAPLAN RS, 1986, J BIOL CHEM, V261, P2767; Kay L, 2000, J BIOL CHEM, V275, P6937, DOI 10.1074/jbc.275.10.6937; Kreis R, 1999, J MAGN RESON, V137, P350, DOI 10.1006/jmre.1998.1683; Menin L, 2001, MOL CELL BIOCHEM, V220, P149, DOI 10.1023/A:1010960309898; MOZO T, 1995, PLANT J, V7, P1015, DOI 10.1046/j.1365-313X.1995.07061015.x; MUNN EA, 1968, J ULTRA MOL STRUCT R, V25, P362, DOI 10.1016/S0022-5320(68)80092-9; Murphy R, 2001, AM J PHYSIOL-CELL PH, V280, pC415, DOI 10.1152/ajpcell.2001.280.3.C415; MUSCATELLO U, 1968, J ULTRA MOL STRUCT R, V25, P73, DOI 10.1016/S0022-5320(68)80061-9; NASH SR, 1994, RECEPTOR CHANNEL, V2, P165; Neubauer S, 1999, CIRCULATION, V100, P1847, DOI 10.1161/01.CIR.100.18.1847; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; Sahlin K, 1997, AM J PHYSIOL-CELL PH, V273, pC172, DOI 10.1152/ajpcell.1997.273.1.C172; Salomons GS, 2001, AM J HUM GENET, V68, P1497, DOI 10.1086/320595; Sandoval N, 1996, GENOMICS, V35, P383, DOI 10.1006/geno.1996.0373; Schlattner U, 1998, MOL CELL BIOCHEM, V184, P125, DOI 10.1023/A:1006851330913; Soboll S, 1997, BBA-BIOENERGETICS, V1320, P27, DOI 10.1016/S0005-2728(97)00004-2; SORA I, 1994, BIOCHEM BIOPH RES CO, V204, P419, DOI 10.1006/bbrc.1994.2475; Steeghs K, 1998, MOL CELL BIOCHEM, V184, P183, DOI 10.1023/A:1006811717709; Tarnopolsky MA, 2001, MUSCLE NERVE, V24, P682, DOI 10.1002/mus.1055; Territo PR, 2001, CELL CALCIUM, V30, P19, DOI 10.1054/ceca.2001.0211; Tran TT, 2000, J BIOL CHEM, V275, P35708, DOI 10.1074/jbc.M005636200; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; VANDEURSEN J, 1994, P NATL ACAD SCI USA, V91, P9091, DOI 10.1073/pnas.91.19.9091; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Wallimann T, 1996, J MUSCLE RES CELL M, V17, P177, DOI 10.1007/BF00124240; Walzel B, 2002, AM J PHYSIOL-ENDOC M, V283, pE390, DOI 10.1152/ajpendo.00428.2001; WALZEL B, 2001, CELL BIOL INT, V25, P949; WALZEL B, 2000, EUR J MED RES S, V5, P28; WOLFEL R, 1989, BRIT J PHARMACOL, V97, P1308; Wyss M, 2000, PHYSIOL REV, V80, P1107, DOI 10.1152/physrev.2000.80.3.1107; Yeung CH, 1996, MOL HUM REPROD, V2, P591, DOI 10.1093/molehr/2.8.591	46	28	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37503	37511		10.1074/jbc.M201168200	http://dx.doi.org/10.1074/jbc.M201168200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145274	hybrid			2022-12-27	WOS:000178447100076
J	Han, R; Smith, TJ				Han, R; Smith, TJ			Cytoplasmic prostaglandin E-2 synthase is dominantly expressed in cultured KAT-50 thyrocytes, cells that express constitutive prostaglandin-endoperoxide H synthase-2 - Basis for low prostaglandin E-2 production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ORBITAL FIBROBLASTS; THYROID-CELLS; PANCREATIC-ISLET; GRAVES-DISEASE; UP-REGULATION; CYCLOOXYGENASE-2; INDUCTION; GENE; IMMUNOGLOBULINS; IDENTIFICATION	The recent identification and cloning of two glutathione-dependent prostaglandin E-2 synthase (PGES) genes has yielded important insights into the terminal step of PGE(2) synthesis. These enzymes form efficient functional pairs with specific members of the prostaglandin-endoperoxide H synthase (PGHS) family. Microsomal PGES (mPGES) is inducible and works more efficiently with PGHS-2, the inflammatory cyclooxygenase, while the cytoplasmic isoform (cPGES) pairs functionally with PGHS-1, the cyclooxygenase that ordinarily exhibits constitutive expression. KAT-50, a well differentiated thyroid epithelial cell line, expresses high levels of PGHS-2 but surprisingly low levels of PGE2 when compared with human orbital fibroblasts. Moreover, PGHS-1 protein cannot be detected in KAT-50. We report here that KAT-50 cells express high basal levels of cPGES but mPGES mRNA and protein are undetectable. Thus, KAT-50 cells express the inefficient PGHS-2/ePGES pair, and this results in modest PGE2 production. The high levels of cPGES and the absence of mPGES expression result from dramatic differences in the activities of their respective gene promoters. When mPGES is expressed in KAT-50 by transiently transfecting the cells, PGE2 production is up-regulated substantially. These observations indicate that naturally occurring cells can express a suboptimal profile of PGHS and PGES isoforms, resulting in diminished levels of PGE2 generation.	Harbor UCLA Med Ctr, Div Mol Med, Dept Med, Torrance, CA 90502 USA; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Smith, TJ (corresponding author), Harbor UCLA Med Ctr, Div Mol Med, Dept Med, Bldg C-2,1124 W Carson St, Torrance, CA 90502 USA.		Smith, Terry/ABG-1360-2020	Smith, Terry/0000-0002-6279-9685	NEI NIH HHS [EY08976, EY11708] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011708, R01EY008976] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; Asano K, 1996, AM J PHYSIOL-LUNG C, V271, pL126, DOI 10.1152/ajplung.1996.271.1.L126; Atwa MA, 1996, EUR J ENDOCRINOL, V135, P322, DOI 10.1530/eje.0.1350322; BETZ M, 1991, J IMMUNOL, V146, P108; Cao HJ, 1999, AM J PHYSIOL-CELL PH, V277, pC1075, DOI 10.1152/ajpcell.1999.277.6.C1075; Cao HJ, 1998, J BIOL CHEM, V273, P29615, DOI 10.1074/jbc.273.45.29615; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DICERBO A, 1992, J CLIN ENDOCR METAB, V74, P585, DOI 10.1210/jc.74.3.585; DiPaola R, 1997, J CLIN ENDOCR METAB, V82, P670, DOI 10.1210/jc.82.2.670; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; FOX BS, 1993, IMMUNOMETHODS, V2, P255; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; Gallois C, 1998, J BIOL CHEM, V273, P23183, DOI 10.1074/jbc.273.36.23183; Gianoukakis AG, 2001, AM J PHYSIOL-CELL PH, V280, pC701, DOI 10.1152/ajpcell.2001.280.3.C701; Han R, 2002, J BIOL CHEM, V277, P16355, DOI 10.1074/jbc.M111246200; Hla T, 1996, PROSTAG OTH LIPID M, V51, P81, DOI 10.1016/0090-6980(95)00158-1; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HU ZQ, 1995, J IMMUNOL, V155, P2134; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Narko K, 1997, ENDOCRINOLOGY, V138, P3638, DOI 10.1210/en.138.9.3638; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45, DOI 10.1615/CritRevNeurobiol.v13.i1.30; OBANION MK, 1991, J BIOL CHEM, V266, P23261; RANKIN JHG, 1976, AM J PHYSIOL, V231, P754, DOI 10.1152/ajplegacy.1976.231.3.754; Robertson RP, 1998, DIABETES, V47, P1379, DOI 10.2337/diabetes.47.9.1379; ROPER RL, 1990, J IMMUNOL, V145, P2644; Smith TJ, 1999, J BIOL CHEM, V274, P15622, DOI 10.1074/jbc.274.22.15622; SMITH TJ, 1984, J CLIN INVEST, V74, P2157, DOI 10.1172/JCI111642; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Sorli CH, 1998, P NATL ACAD SCI USA, V95, P1788, DOI 10.1073/pnas.95.4.1788; Stichtenoth DO, 2001, J IMMUNOL, V167, P469, DOI 10.4049/jimmunol.167.1.469; TAHARA K, 1991, J BIOL CHEM, V266, P440; Tanioka T, 2000, J BIOL CHEM, V275, P32775, DOI 10.1074/jbc.M003504200; Venkataraman GM, 1998, THYROID, V8, P63, DOI 10.1089/thy.1998.8.63; Wang HS, 1996, J BIOL CHEM, V271, P22718, DOI 10.1074/jbc.271.37.22718; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Yang XH, 1997, BBA-GENE STRUCT EXPR, V1350, P287, DOI 10.1016/S0167-4781(96)00225-4	38	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36897	36903		10.1074/jbc.M206949200	http://dx.doi.org/10.1074/jbc.M206949200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145315	hybrid			2022-12-27	WOS:000178275100143
J	Kwok, JBJ; Kapoor, R; Gotoda, T; Iwamoto, Y; Iizuka, Y; Yamada, N; Isaacs, KE; Kushwaha, VV; Church, WB; Schofield, PR; Kapoor, V				Kwok, JBJ; Kapoor, R; Gotoda, T; Iwamoto, Y; Iizuka, Y; Yamada, N; Isaacs, KE; Kushwaha, VV; Church, WB; Schofield, PR; Kapoor, V			A missense mutation in kynurenine aminotransferase-1 in spontaneously hypertensive rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC RECEPTOR ACTIVITY; BLOOD-PRESSURE; GLUTAMATE; MEDULLA; ACID; SHR; RESPONSIVENESS; EXPRESSION; CD36; KAT	Spontaneously hypertensive rats (SHR) are the most extensively used animal model for genetic hypertension, increased stroke damage, and insulin resistance syndromes; however, the identification of target genes has proved difficult. SHR show elevated sympathetic nerve activity, and stimulation of the central blood pressure control centers with glutamate or nicotine results in exaggerated blood pressure responses, effects that appear to be genetically determined. Kynurenic acid, a competitive glutamate antagonist and a non-competitive nicotinic antagonist, can be synthesized in the brain by the enzyme kynurenine aminotransferase-1 (KAT-1). We have previously shown that KAT-1 activity is significantly reduced in SHR compared with normotensive Wistar Kyoto rats (WKY). Here we show that KAT-1 contains a missense mutation, E61G, in all the strains of SHR examined but not in any of the WKY or outbred strains. Previous studies on F2 rats from a cross of stroke-prone SHR and WKY have shown a suggestive level of linkage between elevated blood pressure and the KAT-1 locus on chromosome 3. In addition, the mutant enzyme expressed in Escherichia coli displays altered kinetics. This mutation may explain the enhanced sensitivity to glutamate and nicotine seen in SHR that may be related to an underlying mechanism of hypertension and increased sensitivity to stroke.	Univ New S Wales, Dept Pharmacol & Physiol, Sydney, NSW 2052, Australia; Garvan Inst Med Res, Sydney, NSW 2010, Australia; Tokyo Womens Med Univ, Ctr Diabet, Tokyo 1628666, Japan; Univ Tokyo, Dept Metab Dis, Tokyo 1138655, Japan; Univ Tsukuba, Dept Internal Med, Tsukuba, Ibaraki 3058575, Japan	University of New South Wales Sydney; Garvan Institute of Medical Research; Tokyo Women's Medical University; University of Tokyo; University of Tsukuba	Kapoor, V (corresponding author), Univ New S Wales, Dept Pharmacol & Physiol, Sydney, NSW 2052, Australia.	V.Kapoor@unsw.edu.au	Church, William/H-6040-2013; Schofield, Peter/C-9669-2011	Church, William/0000-0002-8033-5518; Kushwaha, Virag/0000-0002-3383-7785; Schofield, Peter/0000-0003-2967-9662; Kwok, John/0000-0001-9574-6195				ABRAHAM DG, 1995, J BIOL CHEM, V270, P180, DOI 10.1074/jbc.270.1.180; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Azzariti A, 1998, BBA-PROTEIN STRUCT M, V1386, P29, DOI 10.1016/S0167-4838(98)00057-0; Clark JS, 1996, HYPERTENSION, V28, P898, DOI 10.1161/01.HYP.28.5.898; Collison M, 2000, DIABETES, V49, P2222, DOI 10.2337/diabetes.49.12.2222; Colombari E, 2001, HYPERTENSION, V38, P549, DOI 10.1161/01.HYP.38.3.549; DAMPNEY RAL, 1994, PHYSIOL REV, V74, P323, DOI 10.1152/physrev.1994.74.2.323; Erhardt S, 2001, N-S ARCH PHARMACOL, V363, P21; Garrett MR, 2000, PHYSIOL GENOMICS, V3, P33, DOI 10.1152/physiolgenomics.2000.3.1.33; Gotoda T, 1999, NAT GENET, V22, P226, DOI 10.1038/10285; Hilmas C, 2001, J NEUROSCI, V21, P7463, DOI 10.1523/JNEUROSCI.21-19-07463.2001; Ito S, 2000, HYPERTENSION, V35, P413, DOI 10.1161/01.HYP.35.1.413; Jensen RA, 1996, J BACTERIOL, V178, P2161, DOI 10.1128/jb.178.8.2161-2171.1996; Kapoor R, 1997, NEUROREPORT, V8, P3619, DOI 10.1097/00001756-199711100-00039; KAPOOR V, 1994, CLIN EXP PHARMACOL P, V21, P891, DOI 10.1111/j.1440-1681.1994.tb02460.x; Kapoor V, 1996, NEUROREPORT, V7, P1409, DOI 10.1097/00001756-199605310-00017; Kapoor V, 1998, NEUROREPORT, V9, P1431, DOI 10.1097/00001756-199805110-00033; Khan IM, 2001, CLIN EXP HYPERTENS, V23, P555, DOI 10.1081/CEH-100106826; MALHERBE P, 1995, FEBS LETT, V367, P141, DOI 10.1016/0014-5793(95)00546-L; Mashimo T, 1999, AM J HYPERTENS, V12, P1098, DOI 10.1016/S0895-7061(99)00084-9; Nakai T, 1999, BIOCHEMISTRY-US, V38, P2413, DOI 10.1021/bi9819881; PERRY S, 1995, FEBS LETT, V360, P277, DOI 10.1016/0014-5793(95)00123-Q; Rapp JP, 2000, PHYSIOL REV, V80, P135, DOI 10.1152/physrev.2000.80.1.135; Stone TW, 2001, PROG NEUROBIOL, V64, P185, DOI 10.1016/S0301-0082(00)00032-0; Tsuchihashi T, 1998, HYPERTENSION, V31, P73, DOI 10.1161/01.HYP.31.1.73	25	43	43	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					35779	35782		10.1074/jbc.C200303200	http://dx.doi.org/10.1074/jbc.C200303200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145272	hybrid			2022-12-27	WOS:000178275100001
J	Fukuda, M; Kanno, E; Saegusa, C; Ogata, Y; Kuroda, TS				Fukuda, M; Kanno, E; Saegusa, C; Ogata, Y; Kuroda, TS			Slp4-a/granuphilin-a regulates dense-core vesicle exocytosis in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOTAGMIN-IV; MELANOSOME TRANSPORT; NEUROENDOCRINE CELLS; RAB GTPASES; ASHEN MICE; DOMAIN; BINDING; FAMILY; TRANSMEMBRANE; MELANOCYTES	Synaptotagmin-like protein 4-a (Slp4-a)/granuphilin-a was originally identified as a protein specifically associated with insulin-containing vesicles in pancreatic beta-cells (Wang, J., Takeuchi, T., Yokota, H., and Izumi, T. (1999) J. Biol Chem. 274, 28542-28548). Previously, we showed that the N-terminal Slp homology domain of Slp4-a interacts with the GTP-bound form of Rab3A, Rab8, and Rab27A both in vitro and in intact cells (Kuroda, T. S., Fukuda, M., Ariga, H., and Alikoshiba, K. (2002) J. Biol Chem. 277,9212-9218). How Slp4-a-Rab complex controls regulated secretion, and which Rab isoforms dominantly interact with Slp4-a in vivo, however, have remained unknown. In this study, we showed by immunocytochemistry and subcellular fractionation that three Rabs, Rab3A, Rab8, and Rab27A, and Slp4-a are endogenously expressed in neuroendocrine PC12 cells and localized on dense-core vesicles, and we discovered that the Slp4-a.Rab8 and Slp4-a.Rab27A complexes, but not Slp4-a.Rab3A complexes, are formed on dense-core vesicles in PC12 cells, although the majority of Rab8 is present in the cell body and is free of Slp4-a. We further showed that expression of Rab27A, but not of Rab8, promotes high KCl-dependent secretion of neuropeptide Y (NPY) in PC12 cells, whereas expression of Slp4-a, but not of an Slp4-a mutant incapable of Rab27A binding, inhibits NPY secretion in PC12 cells. In contrast, expression of Slp3-a, but not of Slp3-b lacking an N-terminal Rab27A-binding domain, promotes NPY secretion. These findings suggest that the Slp family controls regulated dense-core vesicle exocytosis via binding to Rab27A.	RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, Wako, Saitama 3510198, Japan	RIKEN	Fukuda, M (corresponding author), RIKEN, Inst Phys & Chem Res, Fukuda Initiat Res Unit, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.		Fukuda, MItsunori/I-1511-2015	Fukuda, MItsunori/0000-0002-8620-5853; Kuroda, Taruho/0000-0001-6693-4496				Bahadoran P, 2001, J CELL BIOL, V152, P843, DOI 10.1083/jcb.152.4.843; Berkowitz JKM, 2001, J BIOL CHEM, V276, P18855, DOI 10.1074/jbc.M011167200; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; Coppola T, 2002, MOL BIOL CELL, V13, P1906, DOI 10.1091/mbc.02-02-0025; El-Amraoui A, 2002, EMBO REP, V3, P463, DOI 10.1093/embo-reports/kvf090; Fukuda M, 2001, J BIOL CHEM, V276, P40319, DOI 10.1074/jbc.M105356200; Fukuda M, 1999, J BIOL CHEM, V274, P31421, DOI 10.1074/jbc.274.44.31421; Fukuda M, 1999, J BIOL CHEM, V274, P31428, DOI 10.1074/jbc.274.44.31428; Fukuda M, 1996, J BIOL CHEM, V271, P8430, DOI 10.1074/jbc.271.14.8430; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; Fukuda M, 2002, BIOCHEM J, V365, P173, DOI 10.1042/BJ20011877; Fukuda M, 2002, J BIOL CHEM, V277, P29315, DOI 10.1074/jbc.M201697200; Fukuda M, 2002, BIOCHEM J, V366, P681, DOI 10.1042/BJ20020484; Fukuda M, 2002, J BIOL CHEM, V277, P4601, DOI 10.1074/jbc.C100588200; Fukuda M, 2002, J BIOL CHEM, V277, P12432, DOI 10.1074/jbc.C200005200; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V283, P513, DOI 10.1006/bbrc.2001.4803; Fukuda M, 2001, J NEUROCHEM, V77, P730, DOI 10.1046/j.1471-4159.2001.00266.x; Fukuda M, 2001, BIOCHEM BIOPH RES CO, V281, P1226, DOI 10.1006/bbrc.2001.4512; Haddad EK, 2001, J CELL BIOL, V152, P835, DOI 10.1083/jcb.152.4.835; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; Hume AN, 2002, TRAFFIC, V3, P193, DOI 10.1034/j.1600-0854.2002.030305.x; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; Kuroda TS, 2002, BIOCHEM BIOPH RES CO, V293, P899, DOI 10.1016/S0006-291X(02)00320-0; Kuroda TS, 2002, J BIOL CHEM, V277, P9212, DOI 10.1074/jbc.M112414200; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; Matesic LE, 2001, P NATL ACAD SCI USA, V98, P10238, DOI 10.1073/pnas.181336698; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Provance DW, 2002, TRAFFIC, V3, P124, DOI 10.1034/j.1600-0854.2002.030205.x; Saegusa C, 2002, J BIOL CHEM, V277, P24499, DOI 10.1074/jbc.M202767200; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Stinchcombe JC, 2001, J CELL BIOL, V152, P825, DOI 10.1083/jcb.152.4.825; Strom M, 2002, J BIOL CHEM, V277, P25423, DOI 10.1074/jbc.M202574200; vonPoser C, 1997, J BIOL CHEM, V272, P14314, DOI 10.1074/jbc.272.22.14314; Wang J, 1999, J BIOL CHEM, V274, P28542, DOI 10.1074/jbc.274.40.28542; Weber E, 1996, J BIOL CHEM, V271, P6963, DOI 10.1074/jbc.271.12.6963; Wilson SM, 2000, P NATL ACAD SCI USA, V97, P7933, DOI 10.1073/pnas.140212797; Wu XFS, 2002, NAT CELL BIOL, V4, P271, DOI 10.1038/ncb760; Yi Z, 2002, MOL CELL BIOL, V22, P1858, DOI 10.1128/MCB.22.6.1858-1867.2002; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhang XD, 2002, NEURON, V34, P599, DOI 10.1016/S0896-6273(02)00671-2; Zhao SL, 2002, ENDOCRINOLOGY, V143, P1817, DOI 10.1210/en.143.5.1817	45	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39673	39678		10.1074/jbc.M205349200	http://dx.doi.org/10.1074/jbc.M205349200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176990	hybrid			2022-12-27	WOS:000178662500080
J	Komano, H; Shiraishi, H; Kawamura, Y; Sai, X; Suzuki, R; Serneels, L; Kawaichi, M; Kitamura, T; Yanagisawa, K				Komano, H; Shiraishi, H; Kawamura, Y; Sai, X; Suzuki, R; Serneels, L; Kawaichi, M; Kitamura, T; Yanagisawa, K			A new functional screening system for identification of regulators for the generation of amyloid beta-protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; C-TERMINAL FRAGMENTS; PRECURSOR PROTEIN; ENDOPLASMIC-RETICULUM; INTRACELLULAR DOMAIN; HIPPOCAMPAL-NEURONS; ALZHEIMERS-DISEASE; WILD-TYPE; PRESENILIN-1; CELLS	Presenilin (PS) is essential for gamma-cleavage, which is required for the generation of amyloid beta-protein (Abeta) from the beta-amyloid precursor protein. However, it remains to be clarified how gamma-cleavage is regulated. To elucidate the regulation of PS-mediated gamma-cleavage, we developed a new functional screening method for identifying cDNA that enhances gamma-cleavage. This screening system utilizes our own developed cell line, where the expression of cDNA that enhances gamma-cleavage confers puromycin resistance. The cDNA library is retrovirally delivered to the above-mentioned cell line, allowing the identification of our target cDNAs by a combination of puromycin resistance selection and Abeta assay screening. With this screening method, we isolated several cDNAs enhancing gamma-cleavage, including the previously reported Herp. Here we also demonstrate that Rab1A, identified with this screening, can be a regulator of All generation. Thus, our established screening method is a powerful tool for identifying multiple regulators involved in gamma-cleavage in the All generation pathway, including modulators of gamma-secretase activity or the intracellular trafficking of factors necessary for gamma-cleavage.	Natl Inst Longev Sci, Dept Dementia Res, Obu, Aichi 4748522, Japan; Japan Sci & Technol Corp, Kawaguchi, Saitama 3320012, Japan; Katholieke Univ Leuven, Ctr Human Genet, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium; Nara Inst Sci & Technol, Div Gene Funct Anim, Nara 63001, Japan; Univ Tokyo, Inst Med Sci, Div Cellular Therapy, Adv Clin Res Ctr, Tokyo 1088639, Japan	Japan Science & Technology Agency (JST); KU Leuven; Nara Institute of Science & Technology; University of Tokyo	Komano, H (corresponding author), Natl Inst Longev Sci, Dept Dementia Res, 36-3 Gengo, Obu, Aichi 4748522, Japan.		Kitamura, Toshio/AAA-2071-2021					Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; Chen FS, 2000, J BIOL CHEM, V275, P36794, DOI 10.1074/jbc.M006986200; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; DUGAN JM, 1995, J BIOL CHEM, V270, P10982, DOI 10.1074/jbc.270.18.10982; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Greenfield JP, 1999, P NATL ACAD SCI USA, V96, P742, DOI 10.1073/pnas.96.2.742; Gu YJ, 2001, J BIOL CHEM, V276, P35235, DOI 10.1074/jbc.C100357200; HAASS C, 1993, J BIOL CHEM, V268, P3021; Herreman A, 2000, NAT CELL BIOL, V2, P461, DOI 10.1038/35017105; Iwata H, 2001, J BIOL CHEM, V276, P21678, DOI 10.1074/jbc.M007989200; Jin MJ, 1996, J BIOL CHEM, V271, P30105, DOI 10.1074/jbc.271.47.30105; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kokame K, 2000, J BIOL CHEM, V275, P32846, DOI 10.1074/jbc.M002063200; KOO EH, 1994, J BIOL CHEM, V269, P17386; LAI A, 1995, J BIOL CHEM, V270, P3565, DOI 10.1074/jbc.270.8.3565; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lopez-Perez E, 2000, BIOCHEM BIOPH RES CO, V275, P910, DOI 10.1006/bbrc.2000.3404; Maltese WA, 2001, J BIOL CHEM, V276, P20267, DOI 10.1074/jbc.M007238200; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; MARUYAMA K, 1995, BIOCHEM BIOPH RES CO, V207, P971, DOI 10.1006/bbrc.1995.1280; McConlogue L, 1996, J BIOL CHEM, V271, P1343, DOI 10.1074/jbc.271.3.1343; McPhie DL, 1997, J BIOL CHEM, V272, P24743, DOI 10.1074/jbc.272.40.24743; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Onishi M, 1996, EXP HEMATOL, V24, P324; Paganetti PA, 1996, J NEUROSCI RES, V46, P283, DOI 10.1002/(SICI)1097-4547(19961101)46:3<283::AID-JNR1>3.0.CO;2-G; Sai X, 2002, J BIOL CHEM, V277, P12915, DOI 10.1074/jbc.M112372200; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Sastre M, 2001, EMBO REP, V2, P835, DOI 10.1093/embo-reports/kve180; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Sudoh S, 2000, EUR J BIOCHEM, V267, P2036, DOI 10.1046/j.1432-1327.2000.01206.x; Sudoh S, 1998, J NEUROCHEM, V71, P1535; TAKEBAYASHI K, 1994, J BIOL CHEM, V269, P5150; Taniguchi Y, 2002, P NATL ACAD SCI USA, V99, P4014, DOI 10.1073/pnas.052017699; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Xia WM, 2000, P NATL ACAD SCI USA, V97, P9299, DOI 10.1073/pnas.97.16.9299; Xia WM, 1998, BIOCHEMISTRY-US, V37, P16465, DOI 10.1021/bi9816195; Xu X, 2001, NAT GENET, V27, P23, DOI 10.1038/83717; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I; Zhang ZH, 2000, NAT CELL BIOL, V2, P463, DOI 10.1038/35017108	50	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39627	39633		10.1074/jbc.M205255200	http://dx.doi.org/10.1074/jbc.M205255200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161439	hybrid			2022-12-27	WOS:000178662500074
J	Rangaraj, P; Ludden, PW				Rangaraj, P; Ludden, PW			Accumulation of (99)Mo-containing iron-molybdenum cofactor precursors of nitrogenase on NifNE, NifH, and NifK of Azotobacter vinelandii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO BIOSYNTHESIS; KLEBSIELLA-PNEUMONIAE; GENE-PRODUCT; INVITRO SYNTHESIS; CRYSTALLOGRAPHIC STRUCTURE; DINITROGENASE REDUCTASE; PROTEIN; APODINITROGENASE; HOMOCITRATE; MATURATION	The biosynthesis of the iron-molybdenum cofactor (FeMo-co) of nitrogenase was investigated using the purified in vitro FeMo-co synthesis system and (99)Mo. The purified system involves the addition of all components that are known to be required for FeMo-co synthesis in their purified forms. Here, we report the accumulation of a (99)Mo-containing FeMo-co precursor on NifNE. Apart from NifNE, NifH and NifX also accumulate (99)Mo label. We present evidence that suggests NifH may serve as the entry point for molybdenum incorporation into the FeMo-co biosynthetic pathway. We also present evidence suggesting a role for NifX in specifying the organic acid moiety of FeMo-co.	Univ Wisconsin, Coll Agr & Life Sci, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Coll Agr & Life Sci, Ctr Stuy Nitrogen Fixat, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ludden, PW (corresponding author), Univ Calif Berkeley, Coll Nat Resources, 101 Giannini Hall,Rm 3100, Berkeley, CA 94720 USA.	pludden@nature.berkeley.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035332, R37GM035332] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35332] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen RM, 1999, J BIOL CHEM, V274, P15869, DOI 10.1074/jbc.274.22.15869; ALLEN RM, 1993, J BIOL CHEM, V268, P23670; ALLEN RM, 1995, J BIOL CHEM, V270, P26890, DOI 10.1074/jbc.270.45.26890; BRIGLE KE, 1987, J BACTERIOL, V169, P1547, DOI 10.1128/jb.169.4.1547-1553.1987; BURRIS RH, 1991, J BIOL CHEM, V266, P9339; COUCOUVANIS D, 1993, ACS SYM SER, V535, P304; FILLER WA, 1986, EUR J BIOCHEM, V160, P371, DOI 10.1111/j.1432-1033.1986.tb09981.x; FU WG, 1994, BIOCHEMISTRY-US, V33, P13455, DOI 10.1021/bi00249a034; GAVINI N, 1992, J BIOL CHEM, V267, P21179; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HAWKES TR, 1984, BIOCHEM J, V217, P317, DOI 10.1042/bj2170317; HOMER MJ, 1995, J BIOL CHEM, V270, P24745, DOI 10.1074/jbc.270.42.24745; HOOVER TR, 1988, BIOCHEMISTRY-US, V27, P3647, DOI 10.1021/bi00410a019; HOOVER TR, 1986, J BACTERIOL, V167, P999, DOI 10.1128/jb.167.3.999-1003.1986; HOOVER TR, 1987, NATURE, V329, P855, DOI 10.1038/329855a0; IMPERIAL J, 1989, BIOCHEMISTRY-US, V28, P7796, DOI 10.1021/bi00445a040; IMPERIAL J, 1984, J BACTERIOL, V158, P187, DOI 10.1128/JB.158.1.187-194.1984; IMPERIAL J, 1987, J BACTERIOL, V169, P1784, DOI 10.1128/jb.169.4.1784-1786.1987; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; KIM JS, 1992, SCIENCE, V257, P1677, DOI 10.1126/science.1529354; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; LJONES T, 1972, BIOCHIM BIOPHYS ACTA, V275, P93, DOI 10.1016/0005-2728(72)90027-8; MCLEAN PA, 1983, BIOCHEM J, V211, P589, DOI 10.1042/bj2110589; PAUSTIAN TD, 1990, BIOCHEMISTRY-US, V29, P3515, DOI 10.1021/bi00466a014; PIENKOS PT, 1981, J BACTERIOL, V145, P743, DOI 10.1128/JB.145.2.743-751.1981; Rangaraj P, 1999, J BIOL CHEM, V274, P19778, DOI 10.1074/jbc.274.28.19778; Rangaraj P, 1997, P NATL ACAD SCI USA, V94, P11250, DOI 10.1073/pnas.94.21.11250; Rangaraj P, 1999, J BIOL CHEM, V274, P29413, DOI 10.1074/jbc.274.41.29413; Rangaraj P, 2001, J BIOL CHEM, V276, P15968, DOI 10.1074/jbc.M100907200; ROBERTS GP, 1980, J BACTERIOL, V144, P210, DOI 10.1128/JB.144.1.210-216.1980; ROBINSON AC, 1987, J BIOL CHEM, V262, P14327; ROLL JT, 1995, J BIOL CHEM, V270, P4432, DOI 10.1074/jbc.270.9.4432; Rubio LM, 2002, J BIOL CHEM, V277, P14299, DOI 10.1074/jbc.M107289200; Ruttimann-Johnson C, 2001, J BIOL CHEM, V276, P4522, DOI 10.1074/jbc.M007288200; Shah V. K., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on Nitrogen Fixation, Koln (Cologne), FRG, March 13-20, 1988., P115; Shah VK, 1999, J BACTERIOL, V181, P2797, DOI 10.1128/JB.181.9.2797-2801.1999; SHAH VK, 1994, J BIOL CHEM, V269, P1154; SHAH VK, 1973, BIOCHIM BIOPHYS ACTA, V305, P445, DOI 10.1016/0005-2728(73)90190-4; SHAH VK, 1986, P NATL ACAD SCI USA, V83, P1636, DOI 10.1073/pnas.83.6.1636; SHAH VK, 1977, P NATL ACAD SCI USA, V74, P3249, DOI 10.1073/pnas.74.8.3249; SHAH VK, 1985, J BIOL CHEM, V260, P3891; Siemann S, 2001, EUR J BIOCHEM, V268, P1940, DOI 10.1046/j.1432-1327.2001.02063.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P175; UGALDE RA, 1984, J BACTERIOL, V159, P888, DOI 10.1128/JB.159.3.888-893.1984; WOLLE D, 1992, SCIENCE, V258, P992, DOI 10.1126/science.1359643; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754	46	24	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40106	40111		10.1074/jbc.M204581200	http://dx.doi.org/10.1074/jbc.M204581200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176981	hybrid			2022-12-27	WOS:000178662500132
J	Singh, K; Batuman, OA; Akman, HO; Kedees, MH; Vakil, V; Hussain, MM				Singh, K; Batuman, OA; Akman, HO; Kedees, MH; Vakil, V; Hussain, MM			Differential, tissue-specific, transcriptional regulation of apolipoprotein B secretion by transforming growth factor beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SPECIFIC EXPRESSION; NECROSIS-FACTOR-ALPHA; CACO-2 CELLS; INTRACELLULAR DEGRADATION; CONTAINING LIPOPROTEINS; TRANSGENIC MICE; SMAD PROTEINS; MESSENGER-RNA; AMINO-ACIDS; GENE	Apolipoprotein B (apoB) is required for the assembly and secretion of triglyceride-rich lipoproteins. ApoB synthesis is constitutive, and post-translational mechanisms modulate its secretion. Transforming growth factor 13 (TGF-beta) increased apoll secretion in both differentiated and nondifferentiated Caco-2 cells and decreased secretion in HepG2 cells without affecting apolipoprotein A-I secretion. TGF-beta altered apoll secretion by changing steady-state mRNA levels and protein synthesis. Expression of SAMD3 and SMAD4 differentially regulated apoB secretion in these cells. Thus, SMADs mediate dissimilar secretion of apoll in both the cell lines by affecting gene transcription. We identified a 485-bp element, 55 kb upstream of the apob gene that contains a SMAD binding motif. This motif increased the expression of chloramphenicol acetyltransferase in Caco-2 ells treated with TGF-beta or transfected with SMADs. Hence, TGF-beta activates SMADs that bind to the 485-bp intestinal enhancer element in the apob gene and increase its transcription and secretion in Caco-2 cells. This is the first example showing differential transcriptional regulation of the apob gene by cytokines and dissimilar regulation of one gene in two different cell lines by TGF-beta. In this regulation, the presence of cytokineresponsive motif in the tissue-specific enhancer element confers cell-specific response.	Suny Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 11203 USA; Suny Downstate Med Ctr, Dept Pediat, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	Hussain, MM (corresponding author), Suny Downstate Med Ctr, Dept Anat & Cell Biol, Brooklyn, NY 11203 USA.	mahmood.hussain@downstate.edu			NHLBI NIH HHS [HL-64272] Funding Source: Medline; NIDDK NIH HHS [DK-46900] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064272] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046900, R29DK046900] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antes TJ, 2001, BIOCHEMISTRY-US, V40, P6731, DOI 10.1021/bi0100743; Antes TJ, 2001, BIOCHEMISTRY-US, V40, P6720, DOI 10.1021/bi010073a; Antes TJ, 2001, DNA CELL BIOL, V20, P67, DOI 10.1089/104454901750070265; Antes TJ, 2000, J BIOL CHEM, V275, P26637, DOI 10.1074/jbc.M003025200; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Baker JC, 1997, CURR OPIN GENET DEV, V7, P467, DOI 10.1016/S0959-437X(97)80072-X; Bakillah A, 1997, LIPIDS, V32, P1113, DOI 10.1007/s11745-997-0143-8; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; BISSELL DM, 1995, J CLIN INVEST, V96, P447, DOI 10.1172/JCI118055; Blanchette F, 2001, J CELL PHYSIOL, V188, P264, DOI 10.1002/jcp.1116; Boren J, 1998, J CLIN INVEST, V101, P1197, DOI 10.1172/JCI1785; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALLOW MJ, 1994, P NATL ACAD SCI USA, V91, P2130, DOI 10.1073/pnas.91.6.2130; CHIESA GL, 1993, J BIOL CHEM, V268, P23747; Chin BY, 1999, J BIOL CHEM, V274, P11362, DOI 10.1074/jbc.274.16.11362; Christian JL, 1999, BIOESSAYS, V21, P382, DOI 10.1002/(SICI)1521-1878(199905)21:5<382::AID-BIES5>3.0.CO;2-V; Cianflone K, 1996, J BIOL CHEM, V271, P29136, DOI 10.1074/jbc.271.46.29136; DASHTI N, 1992, J BIOL CHEM, V267, P7160; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DIXON JL, 1993, J LIPID RES, V34, P167; DIXON JL, 1991, J BIOL CHEM, V266, P5080; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; ETTINGER WH, 1994, ARTERIOSCLER THROMB, V14, P8, DOI 10.1161/01.ATV.14.1.8; FAN JL, 1995, ARTERIOSCL THROM VAS, V15, P1889, DOI 10.1161/01.ATV.15.11.1889; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Gillian-Daniel DL, 2002, P NATL ACAD SCI USA, V99, P4337, DOI 10.1073/pnas.072557199; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Han JH, 2000, J BIOL CHEM, V275, P1241, DOI 10.1074/jbc.275.2.1241; Havel RJ, 1995, METABOLIC MOL BASES, V7th, P1841, DOI [10.1036/ommbid.142, DOI 10.1036/OMMBID.142]; Hussain MM, 1996, BBA-LIPID LIPID MET, V1300, P151, DOI 10.1016/0005-2760(96)00041-0; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; Inagaki Y, 2001, J CELL PHYSIOL, V187, P117, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1059>3.0.CO;2-S; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; Kardassis D, 2000, J BIOL CHEM, V275, P41405, DOI 10.1074/jbc.M007896200; Kim E, 1998, J LIPID RES, V39, P703; Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58; LEVY E, 1995, FASEB J, V9, P626, DOI 10.1096/fasebj.9.8.7768354; LEVYWILSON B, 1995, PROG NUCLEIC ACID RE, V50, P161, DOI 10.1016/S0079-6603(08)60814-4; LINTON MF, 1993, J CLIN INVEST, V92, P3029, DOI 10.1172/JCI116927; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Luchoomun J, 1999, J BIOL CHEM, V274, P19565, DOI 10.1074/jbc.274.28.19565; Luchoomun J, 1997, ARTERIOSCL THROM VAS, V17, P2955, DOI 10.1161/01.ATV.17.11.2955; LUDWIG EH, 1987, DNA-J MOLEC CELL BIO, V6, P363, DOI 10.1089/dna.1987.6.363; LUDWIG EH, 1991, DNA CELL BIOL, V10, P329, DOI 10.1089/dna.1991.10.329; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; McCormick SPA, 1996, J BIOL CHEM, V271, P11963, DOI 10.1074/jbc.271.20.11963; Mehran M, 1995, AM J PHYSIOL-GASTR L, V269, pG953, DOI 10.1152/ajpgi.1995.269.6.G953; MOLMENTI EP, 1993, J BIOL CHEM, V268, P14116; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; Murthy S, 1996, AM J PHYSIOL-GASTR L, V270, pG94, DOI 10.1152/ajpgi.1996.270.1.G94; Murthy S, 2000, J BIOL CHEM, V275, P9222, DOI 10.1074/jbc.275.13.9222; Nayak N, 2001, J LIPID RES, V42, P272; Nielsen LB, 1999, J MOL CELL CARDIOL, V31, P695, DOI 10.1006/jmcc.1998.0918; PULLINGER CR, 1989, J LIPID RES, V30, P1065; Saha D, 2001, J BIOL CHEM, V276, P29531, DOI 10.1074/jbc.M100069200; SELBY SL, 1995, ARTERIOSCL THROM VAS, V15, P1900, DOI 10.1161/01.ATV.15.11.1900; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; van 't Hooft FM, 1999, J LIPID RES, V40, P1686; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; Yao ZM, 1997, J LIPID RES, V38, P1937; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574; Zannis VI, 2001, FRONT BIOSCI-LANDMRK, V6, pD456, DOI 10.2741/Zannis; ZHANG ZJ, 1993, J BIOL CHEM, V268, P26920; Zhou ZY, 1998, BBA-LIPID LIPID MET, V1391, P13, DOI 10.1016/S0005-2760(97)00200-2	73	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39515	39524		10.1074/jbc.M205513200	http://dx.doi.org/10.1074/jbc.M205513200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177061	hybrid			2022-12-27	WOS:000178662500060
J	Williams, SJ; Mark, BL; Vocadlo, DJ; James, MNG; Withers, SG				Williams, SJ; Mark, BL; Vocadlo, DJ; James, MNG; Withers, SG			Aspartate 313 in the Streptomyces plicatus hexosaminidase plays a critical role in substrate-assisted catalysis by orienting the 2-acetamido group and stabilizing the transition state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BASED CLASSIFICATION; BETA-N-ACETYLHEXOSAMINIDASE; GLYCOSYL HYDROLASES; CRYSTAL-STRUCTURE; CHITINASE; MECHANISM; CHITOBIASE; SITE; STEREOCHEMISTRY; IDENTIFICATION	SpHex, a retaining family 20 glycosidase from Streptomyces plicatus, catalyzes the hydrolysis of N-acetyl-beta-hexosaminides. Accumulating evidence suggests that the hydrolytic mechanism involves substrate-assisted catalysis wherein the 2-acetamido substituent acts as a nucleophile to form an oxazolinium ion intermediate. The role of a conserved aspartate residue (D313) in the active site of SpHex was investigated through kinetic and structural analyses of two variant enzymes, D313A and D313N. Three-dimensional structures of the wildtype and variant enzymes in product complexes with N-acetyl-D-glucosamine revealed substantial differences. In the D313A variant the 2-acetamido group was found in two conformations of which only one is able to aid in catalysis through anchimeric assistance. The mutation D313N results in a steric clash in the active site between Asn-313 and the 2-acetamido group preventing the 2-acetamido group from providing anchimeric assistance, consistent with the large reduction in catalytic efficiency and the insensitivity of this variant to chemical rescue. By comparison, the D313A mutation results in a shift in a shift in the pH optimum and a modest decrease in activity that can be rescued by using azide as an exogenous nucleophile. These structural and kinetic data provide evidence that Asp-313 stabilizes the transition states flanking the oxazoline intermediate and also assists to correctly orient the 2-acetamido group for catalysis. Based on analogous conserved residues in the family 18 chitinases and family 56 hyaluronidases, the roles played by the Asp-313 residue is likely general for all hexosaminidases using a mechanism involving substrate-assisted catalysis.	Univ British Columbia, Prot Engn Network Ctr Excellence Canada, Vancouver, BC V6T 1Z1, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; Univ Alberta, Canadian Inst Hlth Res Prot Struct, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Canadian Inst Hlth Res Funct, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of British Columbia; University of British Columbia; University of Alberta; University of Alberta	Withers, SG (corresponding author), Univ British Columbia, Prot Engn Network Ctr Excellence Canada, Vancouver, BC V6T 1Z1, Canada.		Williams, Spencer/C-3545-2009; Withers, Stephen G/I-7229-2019; Vocadlo, David J/E-5508-2014	Williams, Spencer/0000-0001-6341-4364; Withers, Stephen G/0000-0002-6722-5701; Vocadlo, David J/0000-0001-6897-5558; Mark, Brian/0000-0002-7344-1355				BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cohen E, 2001, PEST MANAG SCI, V57, P946, DOI 10.1002/ps.363; Davies G. J., 1998, INCOMPREHENSIVE BIOL, P119; Drouillard S, 1997, BIOCHEM J, V328, P945, DOI 10.1042/bj3280945; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; Hou YM, 2001, BIOCHEMISTRY-US, V40, P2201, DOI 10.1021/bi002018s; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1995, ESF CCP4 NEWSLETT, V31, P45; KNAPP S, 1995, J AM CHEM SOC, V118; Kobayashi S, 2001, J AM CHEM SOC, V123, P11825, DOI 10.1021/ja017104+; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAI ECK, 1994, BIOCHEMISTRY-US, V33, P14743, DOI 10.1021/bi00253a012; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEATHERBARROW RJ, 2001, GRAFIT 4 0; Ly HD, 1999, ANNU REV BIOCHEM, V68, P487, DOI 10.1146/annurev.biochem.68.1.487; Mahuran DJ, 1999, BBA-MOL BASIS DIS, V1455, P105, DOI 10.1016/S0925-4439(99)00074-5; Mark BL, 1998, J BIOL CHEM, V273, P19618, DOI 10.1074/jbc.273.31.19618; Mark BL, 2001, J BIOL CHEM, V276, P42131, DOI 10.1074/jbc.M107154200; Mark BL, 2001, J BIOL CHEM, V276, P10330, DOI 10.1074/jbc.M011067200; Markovic-Housley Z, 2000, STRUCTURE, V8, P1025, DOI 10.1016/S0969-2126(00)00511-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MO F, 1978, ACTA CRYSTALLOGR B, V34, P1562, DOI 10.1107/S0567740878006081; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papanikolau Y, 2001, BIOCHEMISTRY-US, V40, P11338, DOI 10.1021/bi010505h; Prag G, 2000, J MOL BIOL, V300, P611, DOI 10.1006/jmbi.2000.3906; ROBBINS PW, 1992, GENE, V111, P69, DOI 10.1016/0378-1119(92)90604-N; Tews I, 1996, NAT STRUCT BIOL, V3, P638, DOI 10.1038/nsb0796-638; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; Tse R, 1996, BIOCHEMISTRY-US, V35, P7599, DOI 10.1021/bi960246+; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; VANSCHELTINGA ACT, 1995, BIOCHEMISTRY-US, V34, P15619, DOI 10.1021/bi00048a003; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; Vocadlo DJ, 2000, BIOCHEMISTRY-US, V39, P117, DOI 10.1021/bi991958d; VOCALDO DJ, 2002, THESIS U BRIT COLUMB; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Zechel D. L., 1999, COMPREHENSIVE NATURA, V5, P279	42	125	128	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40055	40065		10.1074/jbc.M206481200	http://dx.doi.org/10.1074/jbc.M206481200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171933	hybrid			2022-12-27	WOS:000178662500126
J	Hernandez, MP; Sullivan, WP; Toft, DO				Hernandez, MP; Sullivan, WP; Toft, DO			The assembly and intermolecular properties of the hsp70-Hop-hsp90 molecular chaperone complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; ESCHERICHIA-COLI DNAJ; PROGESTERONE-RECEPTOR; TETRATRICOPEPTIDE REPEAT; STEROID-RECEPTORS; TERMINAL DOMAIN; ATP BINDING; GLUCOCORTICOID-RECEPTOR; COGNATE PROTEIN; PEPTIDE BINDING	The highly coordinated interactions of several molecular chaperones, including hsp70 and hsp90, are required for the folding and conformational regulation of a variety of proteins in eukaryotic cells, such as steroid hormone receptors and many other signal transduction regulators. The protein called Hop serves as an adaptor protein for hsp70 and hsp90 and is thought to optimize their functional cooperation. Here we characterize the assembly of the hsp70-Hop-hsp90 complex and reveal interactions that cause conformational changes between the proteins in the complex. We found that hsp40 plays an integral role in the assembly by enhancing the binding of hsp70 to the Hop complex. This is accomplished by stimulating the conversion of hsp70-ATP to hsp70-ADP, the hsp70 conformation favored for Hop binding. The hsp70-Hop-hsp90 complex is highly dynamic, as has been observed previously for hsp90 in its interaction with client proteins. Nonetheless, hsp90 binds with high affinity to Hop (K-d = 90 nm), and this binding is not affected by hsp70. hsp70 binds with lower affinity to Hop (K-d = 1.3 muM) on its own, but this affinity is increased (K-d = 250 nm) in the presence of hsp90. hsp90 also reduces the number of hsp70 binding sites on the Hop dimer from two sites in the absence of hsp90 to one site in its presence. Hop can inhibit the ATP binding and p23 binding activity of hsp90, yet this can be reversed if hsp70 is present in the complex. Taken together, our results suggest that the assembly of hsp70-Hop-hsp90 complexes is selective and influences the conformational state of each protein.	Mayo Clin, Mayo Grad Sch, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic	Toft, DO (corresponding author), Mayo Clin, Mayo Grad Sch, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.	toft.david@mayo.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059284] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK59284] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALNEMRI ES, 1993, BIOCHEMISTRY-US, V32, P5387, DOI 10.1021/bi00071a014; Argon Y, 1999, SEMIN CELL DEV BIOL, V10, P495, DOI 10.1006/scdb.1999.0320; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; CAPLAN AJ, 1992, J BIOL CHEM, V267, P18890; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Chang HCJ, 1997, MOL CELL BIOL, V17, P318, DOI 10.1128/MCB.17.1.318; CHANG HCJ, 1994, J BIOL CHEM, V269, P24983; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; CYR DM, 1994, J BIOL CHEM, V269, P9798; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Dittmar KD, 1996, J BIOL CHEM, V271, P12833, DOI 10.1074/jbc.271.22.12833; Felts SJ, 2000, J BIOL CHEM, V275, P3305, DOI 10.1074/jbc.275.5.3305; Fliss AE, 1999, J BIOL CHEM, V274, P34045, DOI 10.1074/jbc.274.48.34045; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freitag DG, 1997, BIOCHEMISTRY-US, V36, P10221, DOI 10.1021/bi963030g; Gebauer M, 1998, MOL CELL BIOL, V18, P6238, DOI 10.1128/MCB.18.11.6238; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hernandez MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; Hu JM, 2002, J VIROL, V76, P269, DOI 10.1128/JVI.76.1.269-279.2002; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Johnson J, 1996, J STEROID BIOCHEM, V56, P31, DOI 10.1016/0960-0760(95)00221-9; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; KING C, 1995, J BIOL CHEM, V270, P22535, DOI 10.1074/jbc.270.38.22535; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Liu FH, 1999, J BIOL CHEM, V274, P34425, DOI 10.1074/jbc.274.48.34425; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Morishima Y, 2000, J BIOL CHEM, V275, P6894, DOI 10.1074/jbc.275.10.6894; Morishima Y, 2001, BIOCHEMISTRY-US, V40, P1109, DOI 10.1021/bi002399+; Murphy PJM, 2001, J BIOL CHEM, V276, P30092, DOI 10.1074/jbc.M103773200; NEMOTO T, 1995, EUR J BIOCHEM, V233, P1, DOI 10.1111/j.1432-1033.1995.001_1.x; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; OH S, 1993, BIOCHIM BIOPHYS ACTA, V1174, P114, DOI 10.1016/0167-4781(93)90104-L; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Prapapanich V, 1998, MOL CELL BIOL, V18, P944, DOI 10.1128/MCB.18.2.944; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; RAABE T, 1991, NUCLEIC ACIDS RES, V19, P6645, DOI 10.1093/nar/19.23.6645; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Russell R, 1999, BIOCHEMISTRY-US, V38, P4165, DOI 10.1021/bi9824036; Scheibel T, 1999, P NATL ACAD SCI USA, V96, P1297, DOI 10.1073/pnas.96.4.1297; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Schumacher RJ, 1996, BIOCHEMISTRY-US, V35, P14889, DOI 10.1021/bi961825h; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Silverstein AM, 1999, J BIOL CHEM, V274, P36980, DOI 10.1074/jbc.274.52.36980; SMITH DF, 1992, J BIOL CHEM, V267, P1350; Smith DF, 1998, BIOL CHEM, V379, P283; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1990, J BIOL CHEM, V265, P3996; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; van der Spuy J, 2000, BIOCHEM J, V345, P645, DOI 10.1042/0264-6021:3450645; Wearsch PA, 1998, BIOCHEMISTRY-US, V37, P5709, DOI 10.1021/bi9801006; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	75	155	159	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38294	38304		10.1074/jbc.M206566200	http://dx.doi.org/10.1074/jbc.M206566200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161444	hybrid			2022-12-27	WOS:000178529600040
J	Lotharius, J; Barg, S; Wiekop, P; Lundberg, C; Raymon, HK; Brundin, P				Lotharius, J; Barg, S; Wiekop, P; Lundberg, C; Raymon, HK; Brundin, P			Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN SYNAPTOSOMES; CENTRAL-NERVOUS-SYSTEM; PARKINSONS-DISEASE; OXIDATIVE STRESS; LENTIVIRAL VECTOR; PHOSPHOLIPASE-D; NEURONAL DEATH; WILD-TYPE; HIPPOCAMPAL-NEURONS; SUBSTANTIA-NIGRA	Mutations in alpha-synuclein have been linked to rare, autosomal dominant forms of Parkinson's disease. Despite its ubiquitous expression, mutant alpha-synuclein primarily leads to the loss of dopamine-producing neurons in the substantia nigra. alpha-Synuclein is a presynaptic nerve terminal protein of unknown function, although several studies suggest it is important for synaptic plasticity and maintenance. The present study utilized a new human mesencephalic cell line, MESC2.10, to study the effect of A53T mutant alpha-synuclein on dopamine homeostasis. In addition to expressing markers of mature dopamine neurons, differentiated MESC2.10 cells are electrically active, produce dopamine, and express wildtype human alpha-synuclein. Lentivirus-induced overexpression of A53T mutant alpha-synuclein in differentiated MESC2.10 cells resulted in down-regulation of the vesicular dopamine transporter (VMAT2), decreased potassium-induced and increased amphetamine-induced dopamine release, enhanced cytoplasmic dopamine immunofluorescence, and increased intracellular levels of superoxide. These results suggest that mutant alpha-synuclein leads to an impairment in vesicular dopamine storage and consequent accumulation of dopamine in the cytosol, a pathogenic mechanism that underlies the toxicity of the psychostimulant amphetamine and the parkinsonian neurotoxin 1-methyl-4-phenylpyridinium. Interestingly, cells expressing A53T mutant alpha-synuclein were resistant to amphetamine-induced toxicity. Because extravesicular, cytoplasmic dopamine can be easily oxidized into reactive oxygen species and other toxic metabolites, mutations in alpha-synuelein might lead to Parkinson's disease by triggering protracted, low grade dopamine toxicity resulting in terminal degeneration and ultimately cell death.	Lund Univ, Wallenberg Neurosci Ctr, Sect Neuronal Survival, S-22184 Lund, Sweden; Lund Univ, Dept Physiol Sci, S-22184 Lund, Sweden; NeuroSearch AS, Sect Microdialysis, DK-2750 Ballerup, Denmark; Celgene Corp, Signal Res Div, San Diego, CA 92121 USA	Lund University; Lund University; Bristol-Myers Squibb; Celgene Corporation	Brundin, P (corresponding author), Lund Univ, Wallenberg Neurosci Ctr, Sect Neuronal Survival, BMC A10, S-22184 Lund, Sweden.	julie.lotharius@mphy.lu.se	Barg, Sebastian/F-9523-2010	Barg, Sebastian/0000-0003-4661-5724; Lundberg, Cecilia/0000-0002-6959-2564				Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; Bindokas VP, 1996, J NEUROSCI, V16, P1324; Brismar H, 1998, P NATL ACAD SCI USA, V95, P5573, DOI 10.1073/pnas.95.10.5573; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Budd SL, 1997, FEBS LETT, V415, P21, DOI 10.1016/S0014-5793(97)01088-0; BUKRINSKY MI, 1993, P NATL ACAD SCI USA, V90, P6125, DOI 10.1073/pnas.90.13.6125; Carvalho F, 2001, ADDICT BIOL, V6, P213, DOI 10.1080/13556210120056544; Chen J, 1997, NEUROLOGY, V48, P306, DOI 10.1212/WNL.48.2.306; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; CUBELLS JF, 1994, J NEUROSCI, V14, P2260, DOI 10.1523/jneurosci.14-04-02260.1994; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Ericson C, 2002, EXP NEUROL, V173, P22, DOI 10.1006/exnr.2001.7829; Fanarraga ML, 1999, EUR J NEUROSCI, V11, P517; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; FORNSTEDT B, 1990, ACTA NEUROL SCAND, V82, P12; Frohman MA, 1999, CHEM PHYS LIPIDS, V98, P127, DOI 10.1016/S0009-3084(99)00025-0; Galvin JE, 2001, EXP NEUROL, V168, P347, DOI 10.1006/exnr.2000.7615; Gasser T, 2001, J NEUROL, V248, P833, DOI 10.1007/s004150170066; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hansson O, 2001, EUR J NEUROSCI, V14, P1492, DOI 10.1046/j.0953-816x.2001.01767.x; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Hornykiewicz O, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.2_Suppl_2.S2; Hoshimaru M, 1996, P NATL ACAD SCI USA, V93, P1518, DOI 10.1073/pnas.93.4.1518; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Jakowec MW, 2001, DEV NEUROSCI-BASEL, V23, P91, DOI 10.1159/000048700; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jones SR, 1998, J NEUROSCI, V18, P1979; Junn E, 2002, NEUROSCI LETT, V320, P146, DOI 10.1016/S0304-3940(02)00016-2; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Kanda S, 2000, NEUROSCIENCE, V97, P279, DOI 10.1016/S0306-4522(00)00077-4; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kuemmerle S, 1999, ANN NEUROL, V46, P842; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Lezoualc'h F, 1998, J NEUROSCI, V18, P3224; LIANG NY, 1982, BIOCHEM PHARMACOL, V31, P2479, DOI 10.1016/0006-2952(82)90057-0; LIANG NY, 1982, BIOCHEM PHARMACOL, V31, P983, DOI 10.1016/0006-2952(82)90332-X; LIN LFH, 1993, SCIENCE, V260, P1130, DOI 10.1126/science.8493557; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Lotharius J, 2000, J BIOL CHEM, V275, P38581, DOI 10.1074/jbc.M005385200; Lotharius J, 2001, ANN NEUROL, V49, P79, DOI 10.1002/1531-8249(200101)49:1<79::AID-ANA11>3.0.CO;2-D; Lotharius J, 1999, J NEUROSCI, V19, P1284; LOTHARIUS J, 2002, IN PRESS HUMAN MOL G; MAKER HS, 1981, J NEUROCHEM, V36, P589, DOI 10.1111/j.1471-4159.1981.tb01631.x; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Matsuoka Y, 2001, NEUROBIOL DIS, V8, P535, DOI 10.1006/nbdi.2001.0392; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Ohta S, 1996, J CEREBR BLOOD F MET, V16, P915, DOI 10.1097/00004647-199609000-00015; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rathke-Hartlieb S, 2001, J NEUROCHEM, V77, P1181, DOI 10.1046/j.1471-4159.2001.00366.x; RAYMON HK, 1999, SOC NEUR ABSTR; Sah DWY, 1997, NAT BIOTECHNOL, V15, P574, DOI 10.1038/nbt0697-574; Saha AR, 2000, EUR J NEUROSCI, V12, P3073, DOI 10.1046/j.1460-9568.2000.00210.x; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schapira AHV, 2001, ADV NEUROL, V86, P155; SCHMIDT CJ, 1985, J PHARMACOL EXP THER, V233, P539; SCHULDINER S, 1993, MOL PHARMACOL, V44, P1227; SHIBAYAMAIMAZU T, 1993, BRAIN RES, V622, P17, DOI 10.1016/0006-8993(93)90796-P; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; SULZER D, 1995, J NEUROSCI, V15, P4102; Tabrizi SJ, 2000, HUM MOL GENET, V9, P2683, DOI 10.1093/hmg/9.18.2683; Tompkins MM, 1997, BRAIN RES, V775, P24, DOI 10.1016/S0006-8993(97)00874-3; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Trono D, 2000, GENE THER, V7, P20, DOI 10.1038/sj.gt.3301105; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; WAYMIRE JC, 1972, P NATL ACAD SCI USA, V69, P2241, DOI 10.1073/pnas.69.8.2241; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; ZACZEK R, 1991, J PHARMACOL EXP THER, V257, P820; ZACZEK R, 1991, J PHARMACOL EXP THER, V257, P830; Zhou WB, 2000, BRAIN RES, V866, P33, DOI 10.1016/S0006-8993(00)02215-0; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	89	257	282	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38884	38894		10.1074/jbc.M205518200	http://dx.doi.org/10.1074/jbc.M205518200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145295	hybrid, Green Published			2022-12-27	WOS:000178529600111
J	Nielsen, PA; Beahm, DL; Giepmans, BNG; Baruch, A; Hall, JE; Kumar, NM				Nielsen, PA; Beahm, DL; Giepmans, BNG; Baruch, A; Hall, JE; Kumar, NM			Molecular cloning, functional expression, and tissue distribution of a novel human gap junction-forming protein, connexin-31.9 - Interaction with zona occludens protein-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLASTIC CELLS; DIRECT ASSOCIATION; CARDIAC MYOCYTES; TIGHT JUNCTIONS; SMOOTH-MUSCLE; HELA-CELLS; C-SRC; MOUSE; ZO-1; COMMUNICATION	A novel human connexin gene (GJA11) was cloned from a genomic library. The open reading frame encoded a hypothetical protein of 294 amino acid residues with a predicted molecular mass of 31,933, hence referred to as connexin-31.9 (Cx31.9) or all connexin. A clone in GenBank(TM) containing the Cx31.9 gene localized to chromosome 17q21.2. Northern analysis of Cx31.9 showed a major 4.4-kilobase transcript, which was expressed at varying levels in all tissues analyzed. Two monoclonal antibodies generated against different domains of Cx31.9 recognized a 30-33-kDa protein from cells overexpressing Cx31.9. Immunofluorescence of overexpressing cells indicated the presence of Cx31.9 between adjacent cells, consistent with its localization to gap junctions. Double voltage clamp analyses of Cx31.9-overexpressing cells, and of paired Xenopus oocytes injected with Cx31.9 cRNA, demonstrated junctional currents indicative of gap junction channel formation. In contrast to previously characterized connexins, Cx31.9 showed no voltage-dependent gating within a physiologically relevant range. Cx31.9 was detected in human tissues by immunoblot analysis, and immunofluorescence localized Cx31.9 expression to vascular smooth muscle cells. Furthermore, it was demonstrated that Cx31.9 interacted with ZO-1. Thus, Cx31.9 represents a novel connexin gene that in vivo generates a protein with unique voltage gating properties.	Scripps Res Inst, Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Scripps Research Institute; University of California System; University of California Irvine; Netherlands Cancer Institute	Kumar, NM (corresponding author), Scripps Res Inst, Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Giepmans, Ben N.G./R-4564-2016	Giepmans, Ben N.G./0000-0001-5105-5915	NATIONAL EYE INSTITUTE [R01EY012142] Funding Source: NIH RePORTER; NEI NIH HHS [EY12142] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; Beahm DL, 2002, BIOPHYS J, V82, P2016, DOI 10.1016/S0006-3495(02)75550-1; Bevans CG, 1998, J BIOL CHEM, V273, P2808, DOI 10.1074/jbc.273.5.2808; BEYER EC, 1992, J MEMBRANE BIOL, V127, P69, DOI 10.1007/BF00232759; Christ GJ, 1996, CIRC RES, V79, P631, DOI 10.1161/01.RES.79.4.631; Condorelli DF, 1998, EUR J NEUROSCI, V10, P1202, DOI 10.1046/j.1460-9568.1998.00163.x; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Giepmans BNG, 2001, CURR BIOL, V11, P1364, DOI 10.1016/S0960-9822(01)00424-9; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; GIMLICH RL, 1990, J CELL BIOL, V110, P597, DOI 10.1083/jcb.110.3.597; GIOVANNA P, 1991, MOL CELL BIOL, V11, P4796; Guan XJ, 1997, J CELL BIOL, V139, P1785, DOI 10.1083/jcb.139.7.1785; HAEFLIGER JA, 1992, J BIOL CHEM, V267, P2057; HENNEMANN H, 1992, EUR J CELL BIOL, V57, P51; Hungerford JE, 1997, J CELL BIOL, V137, P925, DOI 10.1083/jcb.137.4.925; Itoh M, 1999, J CELL BIOL, V147, P1351, DOI 10.1083/jcb.147.6.1351; Jacob A, 2001, DNA CELL BIOL, V20, P11, DOI 10.1089/10445490150504657; KANTER HL, 1994, J MOL CELL CARDIOL, V26, P861, DOI 10.1006/jmcc.1994.1103; Kausalya PJ, 2001, FEBS LETT, V505, P92, DOI 10.1016/S0014-5793(01)02786-7; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kojima T, 1999, BIOCHEM BIOPH RES CO, V266, P222, DOI 10.1006/bbrc.1999.1778; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kruger O, 2000, DEVELOPMENT, V127, P4179; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Laing JG, 2001, J BIOL CHEM, V276, P23051, DOI 10.1074/jbc.M100303200; Loo LWM, 1999, MOL CARCINOGEN, V25, P187, DOI 10.1002/(SICI)1098-2744(199907)25:3<187::AID-MC5>3.3.CO;2-F; Manthey D, 1999, J BIOL CHEM, V274, P14716, DOI 10.1074/jbc.274.21.14716; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MILLER AG, 1992, J MEMBRANE BIOL, V128, P91; Plum A, 2000, CURR BIOL, V10, P1083, DOI 10.1016/S0960-9822(00)00690-4; REED KE, 1993, J CLIN INVEST, V91, P997, DOI 10.1172/JCI116321; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; STEINBERG TH, 1994, EMBO J, V13, P744, DOI 10.1002/j.1460-2075.1994.tb06316.x; Toyofuku T, 1998, J BIOL CHEM, V273, P1519, DOI 10.1074/jbc.273.3.1519; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Toyofuku T, 2001, J BIOL CHEM, V276, P1780, DOI 10.1074/jbc.M005826200; VEENSTRA RD, 1994, CIRC RES, V75, P483, DOI 10.1161/01.RES.75.3.483; Willecke K, 1999, NOVART FDN SYMP, V219, P76; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Young HE, 2001, ANAT RECORD, V264, P51, DOI 10.1002/ar.1128	45	69	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38272	38283		10.1074/jbc.M205348200	http://dx.doi.org/10.1074/jbc.M205348200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12154091	hybrid			2022-12-27	WOS:000178529600038
J	Kos, M; Denger, S; Reid, G; Gannon, F				Kos, M; Denger, S; Reid, G; Gannon, F			Upstream open reading frames regulate the translation of the multiple mRNA variants of the estrogen receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; EUKARYOTIC MESSENGER-RNAS; SECONDARY STRUCTURE; INTERCISTRONIC DISTANCE; 5'-UNTRANSLATED REGION; PROMOTER USAGE; INITIATION; GENE; REINITIATION; SEQUENCES	It is by now well established that the estrogen receptor alpha (ERalpha) is transcribed from multiple promoters. One direct consequence of multiple promoters is the generation of mRNA variants with different 5'-untranslated regions (5'-UTRs). However, the potential roles of these individual mRNA variants are not known. All 5'-UTRs of ERalpha contain between one and six upstream open reading frames. In this study the effect of the 5'-UTRs of major human and mouse ERa mRNA variants on translation was evaluated. Some of the 5'-UTRs were found to strongly inhibit translation of the downstream open reading frame. Mutation of the upstream AUG codons partially or completely restored translation efficiency. A toeprinting analysis and assessment of the contribution of each AUG codon to the inhibitory effect on translation showed that leaky scanning and reinitiation occurs with these mRNAs. In conclusion, the upstream open reading frames in the 5'-UTRs of ERa mRNAs have the potential to regulate estrogen receptor alpha expression.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Gannon, F (corresponding author), European Mol Biol Org, Meyerhofstr 1, D-69117 Heidelberg, Germany.	Frank.Gannon@embo.org	Gannon, Frank/G-1194-2015; Kos, Martin/E-2534-2011	Kos, Martin/0000-0002-3337-9681; Reid, George/0000-0002-0298-693X				AUCHUS RJ, 1994, BAILLIERE CLIN ENDOC, V8, P433, DOI 10.1016/S0950-351X(05)80260-5; Auwerx J, 1999, CELL, V97, P161; Brand H, 2002, ENDOCRINOLOGY, V143, P3397, DOI 10.1210/en.2001-210832; Denger S, 2001, MOL ENDOCRINOL, V15, P2064, DOI 10.1210/me.15.12.2064; Diba F, 2001, J CELL BIOCHEM, V81, P149, DOI 10.1002/1097-4644(20010401)81:1<149::AID-JCB1031>3.3.CO;2-N; Donaghue C, 1999, MOL ENDOCRINOL, V13, P1934, DOI 10.1210/me.13.11.1934; Flouriot G, 1998, MOL ENDOCRINOL, V12, P1939, DOI 10.1210/me.12.12.1939; George F.W., 1988, P3; GRANDIEN K, 1995, ENDOCRINOLOGY, V136, P2223, DOI 10.1210/en.136.5.2223; GRANT CM, 1994, MOL CELL BIOL, V14, P2616, DOI 10.1128/MCB.14.4.2616; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HENDERSON BE, 1988, CANCER RES, V48, P246; Hess RA, 1997, NATURE, V390, P509, DOI 10.1038/37352; HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174; Kos M, 2000, FEBS LETT, V477, P15, DOI 10.1016/S0014-5793(00)01750-6; Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; Kozak M, 1998, NUCLEIC ACIDS RES, V26, P4853, DOI 10.1093/nar/26.21.4853; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; LUUKKONEN BGM, 1995, J VIROL, V69, P4086, DOI 10.1128/JVI.69.7.4086-4094.1995; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; NORMAN AW, 1987, HORMONES, P550; O'Donnell L, 2001, ENDOCR REV, V22, P289, DOI 10.1210/er.22.3.289; Osterlund MK, 2000, J NEUROCHEM, V75, P1390, DOI 10.1046/j.1471-4159.2000.0751390.x; PEABODY DS, 1986, MOL CELL BIOL, V6, P2695, DOI 10.1128/MCB.6.7.2695; Reynolds K, 1996, J CELL BIOL, V134, P827, DOI 10.1083/jcb.134.4.827; Sambrook J., 2001, MOL CLONING; Svitkin YV, 2001, RNA, V7, P1743; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; WEIGEL RJ, 1995, CELL GROWTH DIFFER, V6, P707; WHITE R, 1987, MOL ENDOCRINOL, V1, P735, DOI 10.1210/mend-1-10-735; ZIMMER A, 1994, J CELL BIOL, V127, P1111, DOI 10.1083/jcb.127.4.1111	41	64	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37131	37138		10.1074/jbc.M206325200	http://dx.doi.org/10.1074/jbc.M206325200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147702	hybrid			2022-12-27	WOS:000178447100030
J	Matsui, E; Musti, KV; Abe, J; Yamasaki, K; Matsui, I; Harata, K				Matsui, E; Musti, KV; Abe, J; Yamasaki, K; Matsui, I; Harata, K			Molecular structure and novel DNA binding sites located in loops of flap endonuclease-1 from Pyrococcus horikoshii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; SUBSTRATE-BINDING; HYPERTHERMOPHILIC ARCHAEON; REPLICATION FORK; CLEAVAGE; 5'-EXONUCLEASE; MUTAGENESIS; AMYLASE; FEN-1; 3'-EXONUCLEASE	The crystal structure of flap endonuclease-1 from Pyrococcus horikoshii (phFEN-1) was determined to a resolution of 3.1 Angstrom. The active cleft of the phFEN-1 molecule is formed with one large loop and four small loops. We examined the function of the conserved residues and positively charged clusters on these loops by kinetic analysis with 45 different mutants. Arg(40) and Arg(42) on small loop 1, a cluster Lys(193)-Lys(195) on small loop 2, and two sites, Arg(94) and Arg(118)-Lys(119), on the large loop were identified as binding sites. Lys(87) on the large loop may play significant roles in catalytic reaction. Furthermore, we successfully elucidated the function of the four DNA binding sites that form productive ES complexes specific for each endo- or exo-type hydrolysis, probably by bending the substrates. For the endo-activity, Arg(94) and Lys(193)-Lys(195) located at the top and bottom of the molecule were key determinants. For the exo-activity, all four sites were needed, but Arg(118)-Lys(119) was dominant. The major binding sites for both the nick substrate and double-stranded DNA might be the same.	Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Tsukuba, Ibaraki 305566, Japan; Natl Inst Adv Ind Sci & Technol, Gene Discovery Res Ctr, Tsukuba, Ibaraki 305566, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST)	Matsui, I (corresponding author), Natl Inst Adv Ind Sci & Technol, Biol Informat Res Ctr, Higashi 1-1-1, Tsukuba, Ibaraki 305566, Japan.		Hu, Ruogu/B-2203-2008; Yamasaki, Kazuhiko/L-7108-2018	Yamasaki, Kazuhiko/0000-0003-0320-9697				Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Barnes CJ, 1996, J BIOL CHEM, V271, P29624, DOI 10.1074/jbc.271.47.29624; Bornarth CJ, 1999, BIOCHEMISTRY-US, V38, P13347, DOI 10.1021/bi991321u; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Frank G, 1998, J BIOL CHEM, V273, P33064, DOI 10.1074/jbc.273.49.33064; Garforth SJ, 1999, P NATL ACAD SCI USA, V96, P38, DOI 10.1073/pnas.96.1.38; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gonzalez JM, 1998, EXTREMOPHILES, V2, P123, DOI 10.1007/s007920050051; HARRINGTON JJ, 1994, EMBO J, V13, P1235, DOI 10.1002/j.1460-2075.1994.tb06373.x; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; HIROMI K, 1970, BIOCHEM BIOPH RES CO, V40, P1, DOI 10.1016/0006-291X(70)91037-5; Hosfield DJ, 1998, J BIOL CHEM, V273, P27154, DOI 10.1074/jbc.273.42.27154; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Kaiser MW, 1999, J BIOL CHEM, V274, P21387, DOI 10.1074/jbc.274.30.21387; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; Kelman Z, 2000, TRENDS BIOCHEM SCI, V25, P521, DOI 10.1016/S0968-0004(00)01687-X; Kim CY, 2001, BIOCHEMISTRY-US, V40, P3208, DOI 10.1021/bi002100n; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Matsui E, 1999, J BIOL CHEM, V274, P18297, DOI 10.1074/jbc.274.26.18297; Matsui I, 1997, J BIOL CHEM, V272, P22456, DOI 10.1074/jbc.272.36.22456; MATSUI I, 1991, J BIOCHEM-TOKYO, V109, P566, DOI 10.1093/oxfordjournals.jbchem.a123420; MATSUI I, 1992, BIOCHEMISTRY-US, V31, P5232, DOI 10.1021/bi00137a019; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; Myllykallio H, 2000, SCIENCE, V288, P2212, DOI 10.1126/science.288.5474.2212; Rao HGV, 1998, J BACTERIOL, V180, P5406, DOI 10.1128/JB.180.20.5406-5412.1998; Rumbaugh JA, 1997, J BIOL CHEM, V272, P22591, DOI 10.1074/jbc.272.36.22591; SAKODA M, 1976, J BIOCHEM-TOKYO, V80, P547, DOI 10.1093/oxfordjournals.jbchem.a131310; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; THOMA JA, 1970, BIOCHEMISTRY-US, V9, P1768, DOI 10.1021/bi00810a016; TURCHI JJ, 1994, P NATL ACAD SCI USA, V91, P9803, DOI 10.1073/pnas.91.21.9803; Tye BK, 2000, P NATL ACAD SCI USA, V97, P2399, DOI 10.1073/pnas.97.6.2399; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	40	30	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37840	37847		10.1074/jbc.M205235200	http://dx.doi.org/10.1074/jbc.M205235200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147694	hybrid			2022-12-27	WOS:000178447100119
J	Nakahara, M; Fujii, H; Maloney, PR; Shimizu, M; Sato, R				Nakahara, M; Fujii, H; Maloney, PR; Shimizu, M; Sato, R			Bile acids enhance low density lipoprotein receptor gene expression via a MAPK cascade-mediated stabilization of mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; LEUCINE ZIPPER PROTEIN; REGULATORY ELEMENT; TRANSCRIPTIONAL REGULATION; NUCLEAR RECEPTORS; KINASE; IDENTIFICATION; ACTIVATION; CYP7A1; CELLS	Recent studies have indicated that bile acids regulate the expression of several genes involved in bile acid and lipid metabolism as ligands for the farnesoid X receptor (FIAR). We report here that bile acids are directly able to govern cholesterol metabolism by a novel mechanism. We show that chenodeoxycholic acid (CDCA) enhances low density lipoprotein (LDL) receptor gene expression in human cultured cell lines (HeLa, Hep G2, and Caco-2). The proteolytic activation of sterol regulatory element-binding protein-2 (SREBP-2), a major regulator for LDL receptor gene expression, is not affected by CDCA. Both deoxycholic acid and lithocholic acid as well as CDCA, but not ursodeoxycholic acid, increase the mRNA level for the LDL receptor, even when Hep G2 cells are cultured with 25-hydroxycholesterol, a potent suppressor of gene expression for the LDL receptor. Although it seems possible that FXR might be involved in genetic regulation, both reporter assays with a reporter gene containing the LDL receptor promoter as well as Northern blot analysis reveal that FXR is not involved in the process. On the other hand, inhibition of mitogen-activated protein (MAP) kinase activities, which are found to be induced by CDCA, abolishes the CDCA-mediated up-regulation of LDL receptor gene expression. We further demonstrate that CDCA stabilizes LDL receptor mRNA and that the MAP kinase inhibitors accelerate its turnover. Taken together, these results indicate that bile acids increase LDL uptake and the intracellular cholesterol levels through the activation of MAP kinase cascades in conjunction with a down-regulation of bile acid biosynthesis by FXR. This work opens up a new avenue for developing pharmaceutical interventions that lower plasma LDL by stabilizing LDL receptor mRNA.	Univ Tokyo, Dept Appl Biol Chem, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; Niigata Univ, Grad Sch Med & Dent Sci, Dept Signal Transduct Res, Niigata 9518510, Japan; GlaxoSmithKline, Nucl Receptor Discovery Res, Res Triangle Pk, NC 27709 USA	University of Tokyo; Niigata University; GlaxoSmithKline	Sato, R (corresponding author), Univ Tokyo, Dept Appl Biol Chem, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan.	aroysato@mail.ece.u-tokyo.ac.jp						Agellon LB, 2002, J BIOL CHEM, V277, P20131, DOI 10.1074/jbc.C200105200; Bouscarel B, 1999, GASTROENTEROLOGY, V117, P433, DOI 10.1053/gast.1999.0029900433; Brady LM, 1996, BIOCHEM J, V316, P765, DOI 10.1042/bj3160765; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CARLSON TL, 1989, BIOCHEM J, V264, P241, DOI 10.1042/bj2640241; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen J, 1999, BIOCHEM BIOPH RES CO, V260, P829, DOI 10.1006/bbrc.1999.0980; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Inoue J, 1998, J BIOCHEM-TOKYO, V123, P1191; Inoue J, 2001, BIOCHEM BIOPH RES CO, V283, P1157, DOI 10.1006/bbrc.2001.4915; KAWABE Y, 1995, BIOCHEM BIOPH RES CO, V208, P405, DOI 10.1006/bbrc.1995.1352; Kliewer SA, 1999, SCIENCE, V284, P757, DOI 10.1126/science.284.5415.757; Knouff C, 2001, J BIOL CHEM, V276, P3856, DOI 10.1074/jbc.M009423200; Kotzka J, 2000, J LIPID RES, V41, P99; Kumar A, 1997, J LIPID RES, V38, P2240; Kumar A, 1998, J BIOL CHEM, V273, P15742, DOI 10.1074/jbc.273.25.15742; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Li C, 1999, J BIOL CHEM, V274, P6747, DOI 10.1074/jbc.274.10.6747; Liu JW, 2000, J BIOL CHEM, V275, P5214, DOI 10.1074/jbc.275.7.5214; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makar RSJ, 2000, J LIPID RES, V41, P762; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MARRIOTT SJ, 1987, J VIROL, V61, P375, DOI 10.1128/JVI.61.2.375-382.1987; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Roth G, 2000, J BIOL CHEM, V275, P33302, DOI 10.1074/jbc.M005425200; Russell DW, 1999, CELL, V97, P539, DOI 10.1016/S0092-8674(00)80763-1; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SATO R, 1994, J BIOL CHEM, V269, P17267; TANIGUCHI T, 1994, J BIOL CHEM, V269, P10071; Wilson GM, 1998, J LIPID RES, V39, P1025; Xu KM, 2000, J BIOL CHEM, V275, P23012, DOI 10.1074/jbc.M001611200; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	40	71	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37229	37234		10.1074/jbc.M206749200	http://dx.doi.org/10.1074/jbc.M206749200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149270	hybrid			2022-12-27	WOS:000178447100043
J	Shiojima, I; Yefremashvili, M; Luo, ZY; Kureishi, Y; Takahashi, A; Tao, JZ; Rosenzweig, A; Kahn, CR; Abel, ED; Walsh, K				Shiojima, I; Yefremashvili, M; Luo, ZY; Kureishi, Y; Takahashi, A; Tao, JZ; Rosenzweig, A; Kahn, CR; Abel, ED; Walsh, K			Akt signaling mediates postnatal heart growth in response to insulin and nutritional status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEFT-VENTRICULAR MASS; REGULATE CARDIAC-HYPERTROPHY; PROTEIN-KINASE-B; P70 S6 KINASE; PHOSPHOINOSITIDE 3-KINASE; CELL-GROWTH; IN-VIVO; CARDIOMYOCYTE HYPERTROPHY; TRANSLATION INITIATION; MOLECULAR MECHANISMS	Akt is a serine-threonine kinase that mediates a variety of cellular responses to external stimuli. During postnatal development, Akt signaling in the heart was up-regulated when the heart was rapidly growing and was down-regulated by caloric restriction, suggesting a role of Akt in nutrient-dependent regulation of cardiac growth. Consistent with this notion, reductions in Akt, 70-kDa S6 kinase 1, and eukaryotic initiation factor 4E-binding protein 1 phosphorylation were observed in mice with cardiac-specific deletion of insulin receptor gene, which exhibit a small heart phenotype. In contrast to wild type animals, caloric restriction in these mice had little effect on Akt phosphorylation in the heart. Furthermore, forced expression of Akt1 in these hearts restored 70-kDa S6 kinase 1 and eukaryotic initiation factor 4E-binding protein 1 phosphorylation to normal levels and rescued the small heart phenotype. Collectively, these results indicate that Akt signaling mediates insulin-dependent physiological heart growth during postnatal development and suggest a mechanism by which heart size is coordinated with overall body size as the nutritional status of the organism is varied.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; St Elizabeths Med Ctr, Div Cardiovasc Res, Boston, MA 02135 USA; Univ Utah, Sch Med, Program Human Biol & Genet, Salt Lake City, UT 84112 USA; Massachusetts Gen Hosp E, Program Cardiovasc Gene Therapy, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Div Res, Boston, MA 02215 USA	Boston University; St. Elizabeth's Medical Center; Utah System of Higher Education; University of Utah; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.	Walsh, K (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St, Boston, MA 02118 USA.		Kahn, Ronald/AAY-2435-2021; Bando, Yasuko K./M-4831-2014	Kahn, Ronald/0000-0002-7583-9228; Bando, Yasuko K./0000-0003-4166-6784; Abel, E. Dale/0000-0001-5290-0738	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061557, R21HL062886, R01HL050692, P01HL066957, R01HL059521] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK092065, R03DK058073] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015052, R01AG017241, R37AG015052] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL66957, HL61557, HL62886, HL50692, HL59521] Funding Source: Medline; NIAMS NIH HHS [AR40197] Funding Source: Medline; NIA NIH HHS [AG15052, AG17241] Funding Source: Medline; NIDDK NIH HHS [R01 DK092065, DK58073] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Belke DD, 2002, J CLIN INVEST, V109, P629, DOI 10.1172/JCI200213946; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bruning JC, 2000, SCIENCE, V289, P2122, DOI 10.1126/science.289.5487.2122; Bruning JC, 1998, MOL CELL, V2, P559, DOI 10.1016/S1097-2765(00)80155-0; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Christensen G, 2000, CIRCULATION, V101, P178, DOI 10.1161/01.CIR.101.2.178; Crisostomo LL, 1999, AM J CARDIOL, V84, P1127, DOI 10.1016/S0002-9149(99)00519-6; DESIMONE G, 1992, J AM COLL CARDIOL, V20, P1251, DOI 10.1016/0735-1097(92)90385-Z; DESIMONE GD, 1994, BRIT HEART J, V71, P287; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Himeno E, 1996, AM HEART J, V131, P313, DOI 10.1016/S0002-8703(96)90360-9; Hixon ML, 2000, J CLIN INVEST, V106, P1011, DOI 10.1172/JCI8252; Hudlicka O, 1996, J VASC RES, V33, P266, DOI 10.1159/000159155; ISNER JM, 1979, CIRCULATION, V60, P1401, DOI 10.1161/01.CIR.60.6.1401; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; Keys A, 1950, BIOL HUMAN STARVATIO; Kim S, 2000, J BIOL CHEM, V275, P25979, DOI 10.1074/jbc.M001975200; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; KOJIMA M, 1994, CIRCULATION, V89, P2204, DOI 10.1161/01.CIR.89.5.2204; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Matsui T, 2002, J BIOL CHEM, V277, P22896, DOI 10.1074/jbc.M200347200; MCMAHON T, 1973, SCIENCE, V179, P1201, DOI 10.1126/science.179.4079.1201; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; Molkentin JD, 2001, ANNU REV PHYSIOL, V63, P391, DOI 10.1146/annurev.physiol.63.1.391; Morisco C, 2000, J BIOL CHEM, V275, P14466, DOI 10.1074/jbc.275.19.14466; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Prasad SVN, 2000, J BIOL CHEM, V275, P4693, DOI 10.1074/jbc.275.7.4693; Proud CG, 1997, BIOCHEM J, V328, P329; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Rakusan, 1984, GROWTH HEART HLTH DI, P131; Richey PA, 1998, J SPORT SCI, V16, P129; Rother KI, 2000, PEDIATR NEPHROL, V14, P558, DOI 10.1007/s004670000351; Schaub MC, 1997, J MOL MED, V75, P901, DOI 10.1007/s001090050182; Schwartzbauer G, 2001, J BIOL CHEM, V276, P35786, DOI 10.1074/jbc.M102479200; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE715, DOI 10.1152/ajpendo.2000.279.4.E715; SHEPARD RJ, 1999, EXERCISE HEART HLTH, P223; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shi YY, 2002, J BIOL CHEM, V277, P15712, DOI 10.1074/jbc.M200043200; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; Shioi T, 2000, EMBO J, V19, P2537, DOI 10.1093/emboj/19.11.2537; Shioi T, 2002, MOL CELL BIOL, V22, P2799, DOI 10.1128/MCB.22.8.2799-2809.2002; SUGDEN PH, 1991, BIOCHEM J, V273, P21, DOI 10.1042/bj2730021; Takahashi A, 2002, MOL CELL BIOL, V22, P4803, DOI 10.1128/MCB.22.13.4803-4814.2002; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Tamura N, 2000, P NATL ACAD SCI USA, V97, P4239, DOI 10.1073/pnas.070371497; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Wang J, 1999, ENDOCRINOLOGY, V140, P3391, DOI 10.1210/en.140.7.3391; Wang LJ, 2001, J BIOL CHEM, V276, P32670, DOI 10.1074/jbc.M102776200; Wang QH, 1999, MOL CELL BIOL, V19, P4008; Weinkove D, 2000, CURR OPIN GENET DEV, V10, P75, DOI 10.1016/S0959-437X(99)00042-8; WHITE MF, 1994, J BIOL CHEM, V269, P1	68	170	176	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37670	37677		10.1074/jbc.M204572200	http://dx.doi.org/10.1074/jbc.M204572200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12163490	hybrid			2022-12-27	WOS:000178447100098
J	Fukuoka, SI; Ishiguro, K; Yanagihara, K; Tanabe, A; Egashira, Y; Sanada, H; Shibata, K				Fukuoka, SI; Ishiguro, K; Yanagihara, K; Tanabe, A; Egashira, Y; Sanada, H; Shibata, K			Identification and expression of a cDNA encoding human alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase (ACMSD) - A key enzyme for the tryptophan-niacine pathway and "quinolinate hypothesis"	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS EXCITANT; ACID SEQUENCE; RATS; METABOLISM; LESIONS; DISEASE; BRAIN	Quinolinate (quinolinic acid) is a potent endogenous excitotoxin of neuronal cells. Elevation of quinolinate levels in the brain has been implicated in the pathogenesis of various neurodegenerative disorders, the so-called "quinolinate hypothesis." Quinolinate is nonenzymatically derived from alpha-amino-beta-carboxymuconate-epsilon-semialdehyde (ACMS). alpha-Amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase (ACMSD) is the only known enzyme that can process ACMS to a benign catabolite and thus prevent the accumulation of quinolinate from ACMS. ACMSD seems to be regulated by nutritional and hormonal signals, but its molecular mechanism has, to date, been largely unknown. Utilizing partial amino acid sequences obtained from highly purified porcine kidney ACMSD, a cDNA encoding human ACMSD was cloned and characterized. The cDNA encodes a unique open reading frame of 336 amino acids and displays little homology to any known enzymes or motifs in mammalian databases, suggesting that ACMSD may contain a new kind of protein fold. Real-time PCR-based quantification of ACMSD revealed very low but significant levels of the expression in the brain. Brain ACMSD messages were down- and up-regulated in response to low protein diet and streptozocin-induced diabetes, respectively. The enzyme activities measured from partially purified brains were closely correlated with the changes in the message levels. Expression of quinolinate phosphoribosyltransferase (QPRT), another enzyme that catabolizes quinolinate, was also found in the brain. This suggests that a pathway does exist by which the levels of quinolinate in the brain are regulated. In this report, we address the molecular basis underlying quirtolinate metabolism and the regulation of ACMSD expression.	Kyoto Univ, Grad Sch Agr, Kyoto 6110011, Japan; Chiba Univ, Grad Sch Sci & Technol, Chiba 2718510, Japan; Univ Shiga Prefecture, Sch Human Cultures, Dept Life Style Studies, Shiga 5228533, Japan	Kyoto University; Chiba University; University Shiga Prefecture	Fukuoka, SI (corresponding author), Kyoto Univ, Grad Sch Agr, Kyoto 6110011, Japan.							AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEAL MF, 1988, J NEUROSCI, V8, P3901; Egashira Y, 1996, J NUTR SCI VITAMINOL, V42, P173, DOI 10.3177/jnsv.42.173; Esaki K, 1996, BIOSCI BIOTECH BIOCH, V60, P1444, DOI 10.1271/bbb.60.1444; FOSTER AC, 1984, EXP NEUROL, V84, P428, DOI 10.1016/0014-4886(84)90239-5; Fukuoka S, 1998, BBA-GENE STRUCT EXPR, V1395, P192, DOI 10.1016/S0167-4781(97)00143-7; FUKUOKA SI, 1990, PANCREAS, V5, P1, DOI 10.1097/00006676-199001000-00001; ICHIYAMA A, 1965, J BIOL CHEM, V240, P740; IKEMURA T, 1991, NUCLEIC ACIDS RES, V19, P4333, DOI 10.1093/nar/19.16.4333; NASU S, 1981, BIOCHIM BIOPHYS ACTA, V677, P109, DOI 10.1016/0304-4165(81)90151-3; Nishizuka Y, 1970, METHODS ENZYMOLOGY A, V17A, P471; PERKINS MN, 1982, BRAIN RES, V247, P184, DOI 10.1016/0006-8993(82)91048-4; PERKINS MN, 1983, BRAIN RES, V259, P172, DOI 10.1016/0006-8993(83)91084-3; SANADA H, 1980, J NUTR SCI VITAMINOL, V26, P449, DOI 10.3177/jnsv.26.449; SCHWARCZ R, 1983, SCIENCE, V219, P316, DOI 10.1126/science.6849138; SCHWARCZ R, 1984, LIFE SCI, V35, P19, DOI 10.1016/0024-3205(84)90148-6; SCHWARCZ R, 1988, P NATL ACAD SCI USA, V85, P4079, DOI 10.1073/pnas.85.11.4079; Schwarcz R., 1987, P19; SCHWARCZ R, 1986, EXCITATORY AMINO ACI, P697; SHIBATA K, 1989, J NUTR, V119, P896, DOI 10.1093/jn/119.6.896; Shibata K, 1999, ADV EXP MED BIOL, V467, P711; Shibata Katsumi, 1998, Vitamins (Kyoto), V72, P85; STONE TW, 1981, EUR J PHARMACOL, V72, P411, DOI 10.1016/0014-2999(81)90587-2; YOUNG AB, 1988, SCIENCE, V241, P981, DOI 10.1126/science.2841762	25	49	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35162	35167		10.1074/jbc.M200819200	http://dx.doi.org/10.1074/jbc.M200819200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12140278	hybrid			2022-12-27	WOS:000178117000065
J	Korolkova, YV; Bocharov, EV; Angelo, K; Maslennikov, IV; Grinenko, OV; Lipkin, AV; Nosyreva, ED; Pluzhnikov, KA; Olesen, SP; Arseniev, AS; Grishin, EV				Korolkova, YV; Bocharov, EV; Angelo, K; Maslennikov, IV; Grinenko, OV; Lipkin, AV; Nosyreva, ED; Pluzhnikov, KA; Olesen, SP; Arseniev, AS; Grishin, EV			New binding site on common molecular scaffold provides HERG channel specificity of scorpion toxin BeKm-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT-SYNDROME; POTASSIUM CHANNEL; K+ CHANNELS; PROGRAM; CHARYBDOTOXIN; RESOLUTION; MUTATIONS; CONSERVATION; PROTEINS; PEPTIDE	The scorpion toxin BeKm-1 is unique among a variety of known short scorpion toxins affecting potassium channels in its selective action on ether-a-go-go-related gene (ERG)-type channels. BeKm-1 shares the common molecular scaffold with other short scorpion toxins. The toxin spatial structure resolved by NMR consists of a short alpha-helix and a triple-stranded antiparallel beta-sheet. By toxin mutagenesis study we identified the residues that are important for the binding of BeKm-1 to the human ERG K+ (HERG) channel. The most critical residues (Tyr-11, Lys-18, Axg-20, Lys-23) are located in the a-helix and following loop whereas the "traditional" functional site of other short scorpion toxins is formed by residues from the beta-sheet. Thus the unique location of the binding site of BeKm-1 provides its specificity toward the HERG channel.	Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen, Denmark	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; University of Copenhagen	Korolkova, YV (corresponding author), Russian Acad Sci, Shemyakin & Ovchinnikov Inst Bioorgan Chem, Miklukhomaklaya 16-10, Moscow 117997, Russia.	july@ibch.ru	Lipkin, Alexey V/F-9028-2014; Olesen, Søren P/H-4206-2011; Olesen, Søren-Peter/B-9621-2012; Maslennikov, Innokentiy/I-2524-2012	Lipkin, Alexey V/0000-0001-7624-8529; Olesen, Søren P/0000-0002-4381-5192; Maslennikov, Innokentiy/0000-0003-4292-5821				ARSENIEV AS, 1984, FEBS LETT, V165, P57, DOI 10.1016/0014-5793(84)80014-9; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Charles AC, 1999, J BIOL CHEM, V274, P7508, DOI 10.1074/jbc.274.11.7508; Choe S, 2002, NAT REV NEUROSCI, V3, P115, DOI 10.1038/nrn727; DARDON H, 2000, PERSPECTIVE DRUG DIS, V15, P41; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dun W, 1999, PFLUG ARCH EUR J PHY, V439, P141, DOI 10.1007/s004240051138; DYKE TR, 1996, BIOCHIM BIOPHYS ACTA, V1293, P31; Fan JS, 1999, BIOPHYS J, V76, P3128, DOI 10.1016/S0006-3495(99)77464-3; Garcia ML, 2001, TOXICON, V39, P739, DOI 10.1016/S0041-0101(00)00214-2; Gasparini S, 1998, J BIOL CHEM, V273, P25393, DOI 10.1074/jbc.273.39.25393; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jacobsen RB, 2000, J BIOL CHEM, V275, P24639, DOI 10.1074/jbc.C900990199; Jaravine VA, 1997, BIOCHEMISTRY-US, V36, P1223, DOI 10.1021/bi9614390; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Korolkova YV, 2001, J BIOL CHEM, V276, P9868, DOI 10.1074/jbc.M005973200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li H, 2000, PEDIATR CARDIOL, V21, P542, DOI 10.1007/s002460010132; MILLER C, 1995, NEURON, V15, P5, DOI 10.1016/0896-6273(95)90057-8; Moss AJ, 2002, CIRCULATION, V105, P794, DOI 10.1161/hc0702.105124; Pardo-Lopez L, 2002, J BIOL CHEM, V277, P16403, DOI 10.1074/jbc.M200460200; Pardo-Lopez L, 2002, FEBS LETT, V510, P45, DOI 10.1016/S0014-5793(01)03218-5; PARK CS, 1992, BIOCHEMISTRY-US, V31, P7749, DOI 10.1021/bi00149a002; PARK CS, 1992, NEURON, V9, P307, DOI 10.1016/0896-6273(92)90169-E; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Rauer H, 1999, J BIOL CHEM, V274, P21885, DOI 10.1074/jbc.274.31.21885; Roden DM, 1999, CARDIOVASC RES, V44, P242, DOI 10.1016/S0008-6363(99)00224-2; SCHAUMANN T, 1990, BIOPOLYMERS, V29, P679, DOI 10.1002/bip.360290403; SIGWORTH FJ, 1995, J NEUROSCI METH, V56, P203, DOI 10.1016/0165-0270(94)00129-5; Sogaard R, 2001, AM J PHYSIOL-CELL PH, V280, pC859; Strobaek D, 2000, BRIT J PHARMACOL, V129, P991, DOI 10.1038/sj.bjp.0703120; Tenenholz TC, 2000, REV PHYSIOL BIOCH P, V140, P135, DOI 10.1007/BFb0035552; Tseng GN, 2001, J MOL CELL CARDIOL, V33, P835, DOI 10.1006/jmcc.2000.1317; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; Vandenberg JI, 2001, TRENDS PHARMACOL SCI, V22, P240, DOI 10.1016/S0165-6147(00)01662-X; Wuthrich K, 1986, NMR PROTEINS NUCL AC	44	53	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43104	43109		10.1074/jbc.M204083200	http://dx.doi.org/10.1074/jbc.M204083200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12151390	hybrid			2022-12-27	WOS:000179081200089
J	Sitry, D; Seeliger, MA; Ko, TK; Ganoth, D; Breward, SE; Itzhaki, LS; Pagano, M; Hershko, A				Sitry, D; Seeliger, MA; Ko, TK; Ganoth, D; Breward, SE; Itzhaki, LS; Pagano, M; Hershko, A			Three different binding sites of Cks1 are required for p27-ubiquitin ligation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT-KINASE INHIBITOR; CELL-CYCLE CONTROL; XENOPUS SUC1/CKS PROTEIN; S-PHASE KINASE; CRYSTAL-STRUCTURE; MUTATIONAL ANALYSIS; UBIQUITIN LIGASES; COMPLEX-FORMATION; CDK2 COMPLEX; P27	Previous studies have shown that the cyclin-dependent kinase (Cdk) inhibitor P27(Kipl) is targeted for degradation by an SCF(Skp2) ubiquitin ligase complex and that this process requires Cks1, a member of the highly conserved Suc1/Cks family of cell cycle regulatory proteins. All proteins of this family have Cdk-binding and anion-binding sites, but only mammalian Cks1 binds to Skp2 and promotes the association of Skp2 with p27 phosphorylated on Thr-187. The molecular mechanisms by which Cks1 promotes the interaction of the Skp2 ubiquitin ligase subunit to p27 remained obscure. Here we show that the Skp2-binding site of Cks1 is located on a region including the alpha2- and alpha1-helices and their immediate vicinity, well separated from the other two binding sites. All three binding sites of Cks1 are required for p27-ubiquitin ligation and for the association of Skp2 with Cdk-bound, Thr-187-phosphorylated p27. Cks1 and Skp2 mutually promote the binding of each other to a peptide similar to the 19 C-terminal amino acids of p27 containing phosphorylated Thr-187. This latter process requires the Skp2- and anion-binding sites of Cks1, but not its Cdk-binding site. It is proposed that the Skp2-Cks1 complex binds initially to the C-terminal region of phosphorylated p27 in a process promoted by the anion-binding site of Cks1. The interaction of Skp2 with the substrate is further strengthened by the association of the Cdk-binding site of Cks1 with Cdk2/cyclin E, to which phosphorylated p27 is bound.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, IL-31096 Haifa, Israel; Univ Cambridge, Chem Lab, MRC, Ctr Prot Engn, Cambridge CB2 1EW, England; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Inst Canc, New York, NY 10016 USA	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; University of Cambridge; New York University; New York University	Hershko, A (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Biochem Unit, POB 9649, IL-31096 Haifa, Israel.	hershko@tx.technion.ac.il	Seeliger, Markus A/D-6409-2013	Seeliger, Markus/0000-0003-0990-1756; pagano, michele/0000-0003-3210-2442	NATIONAL CANCER INSTITUTE [R01CA076584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057587] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA76584] Funding Source: Medline; NIGMS NIH HHS [R01-GM57587] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARVAI AS, 1995, J MOL BIOL, V249, P835, DOI 10.1006/jmbi.1995.0341; Bartek J, 2001, NAT CELL BIOL, V3, pE95, DOI 10.1038/35070160; Bourne Y, 2000, STRUCT FOLD DES, V8, P841, DOI 10.1016/S0969-2126(00)00175-1; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Chiarle R, 2002, AM J PATHOL, V160, P1457, DOI 10.1016/S0002-9440(10)62571-0; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; ENDICOTT JA, 1995, EMBO J, V14, P1004, DOI 10.1002/j.1460-2075.1995.tb07081.x; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; HADWIGER JA, 1989, MOL CELL BIOL, V9, P2034, DOI 10.1128/MCB.9.5.2034; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; HAYLES J, 1986, MOL GEN GENET, V202, P291, DOI 10.1007/BF00331653; HERSHKO A, 1985, BIOCHEM BIOPH RES CO, V128, P1079, DOI 10.1016/0006-291X(85)91050-2; HERSHKO A, 1983, J BIOL CHEM, V258, P2206; Hershko D, 2001, CANCER, V91, P1745, DOI 10.1002/1097-0142(20010501)91:9<1745::AID-CNCR1193>3.0.CO;2-H; Hsiung YG, 2001, MOL CELL BIOL, V21, P2506, DOI 10.1128/MCB.21.7.2506-2520.2001; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; MAYER AN, 1989, BIOCHEMISTRY-US, V28, P166, DOI 10.1021/bi00427a024; Mongay L, 2001, J BIOL CHEM, V276, P25030, DOI 10.1074/jbc.M102184200; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PARGE HE, 1993, SCIENCE, V262, P387, DOI 10.1126/science.8211159; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Seeliger MA, 2002, BIOCHEMISTRY-US, V41, P1202, DOI 10.1021/bi0113465; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V257, P12, DOI 10.1006/bbrc.1999.0409; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Yudkovsky Y, 2000, BIOCHEM BIOPH RES CO, V271, P299, DOI 10.1006/bbrc.2000.2622; ZHANG H, 1995, CELL, V82, P915, DOI 10.1016/0092-8674(95)90271-6; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	41	69	78	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42233	42240		10.1074/jbc.M205254200	http://dx.doi.org/10.1074/jbc.M205254200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12140288	hybrid			2022-12-27	WOS:000178985300118
J	Ablonczy, Z; Crouch, RK; Goletz, PW; Redmond, TM; Knapp, DR; Ma, JX; Rohrer, B				Ablonczy, Z; Crouch, RK; Goletz, PW; Redmond, TM; Knapp, DR; Ma, JX; Rohrer, B			11-cis-retinal reduces constitutive opsin phosphorylation and improves quantum catch in retinoid-deficient mouse rod photoreceptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRIC ANALYSIS; MULTIPLE PHOSPHORYLATION; RECEPTOR KINASE; VISUAL PIGMENT; RHODOPSIN; LIGHT; MODEL; RPE65; DESENSITIZATION; ACTIVATION	Rpe65(-/-) mice produce minimal amounts of 11-cis-retinal, the ligand necessary for the formation of photosensitive visual pigments. Therefore, the apoprotein opsin in these animals has not been exposed to its normal ligand. The Rpe65(-/-) mice contain less than 0.1% of wild type levels of rhodopsin. Mass spectrometric analysis of opsin from Rpe65(-/-) mice revealed unusually high levels of phosphorylation in dark-adapted mice but no other structural alterations. Single flash and flicker electroretinograms (ERGs) from 1-month-old animals showed trace rod function but no cone response. B-wave kinetics of the single-flash ERG are comparable with those of dark-adapted wild type mice containing a full compliment of rhodopsin. Application (intraperitoneal injection) of 11-cis-retinal to Rpe65(-/-) mice increased the rod ERG signal, increased levels of rhodopsin, and decreased opsin phosphorylation. Therefore, exogenous 11-cis-retinal improves photoreceptor function by regenerating rhodopsin and removes constitutive opsin phosphorylation. Our results indicate that opsin, which has not been exposed to 11-cis-retinal, does not generate the activity generally associated with the bleached apoprotein.	Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Physiol & Neurosci, Charleston, SC 29425 USA; NEI, Lab Retinal Cell & Mol Biol, NIH, Bethesda, MD 20892 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Rohrer, B (corresponding author), Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.	rohrer@musc.edu		Redmond, T. Michael/0000-0002-1813-5291	NEI NIH HHS [EY 08239, EY 04939, EY 12231, EY 13520] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY008239, R01EY013520, Z01EY000260, R01EY004939, R01EY012231] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ablonczy Z, 2000, MOL VIS, V6, P109; Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; Ball LE, 1998, PROTEIN SCI, V7, P758; BAYLOR DA, 1974, J PHYSIOL-LONDON, V242, P729, DOI 10.1113/jphysiol.1974.sp010732; Blaukat A, 2000, MOL CELL BIOL, V20, P6837, DOI 10.1128/MCB.20.18.6837-6848.2000; Bohm SK, 1997, BIOCHEM J, V322, P1; Buczylko J, 1996, J BIOL CHEM, V271, P20621, DOI 10.1074/jbc.271.34.20621; CARTERDAWSON LD, 1979, J COMP NEUROL, V188, P245, DOI 10.1002/cne.901880204; CORNWALL MC, 1994, J PHYSIOL-LONDON, V480, P261, DOI 10.1113/jphysiol.1994.sp020358; Crouch R. K., 2000, P59; Ekesten B, 2001, VISION RES, V41, P2425, DOI 10.1016/S0042-6989(01)00140-7; Greene NM, 1997, J BIOL CHEM, V272, P10341; HAMEL CP, 1993, J NEUROSCI RES, V34, P414, DOI 10.1002/jnr.490340406; Harris EW, 2001, INT OPHTHALMOL CLIN, V41, P73, DOI 10.1097/00004397-200101000-00008; HOOD DC, 1992, VISUAL NEUROSCI, V8, P107, DOI 10.1017/S0952523800009275; Hurley JB, 1998, VISION RES, V38, P1341, DOI 10.1016/S0042-6989(97)00459-8; Jeon CJ, 1998, J NEUROSCI, V18, P8936; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; Jones GJ, 1996, J GEN PHYSIOL, V108, P333, DOI 10.1085/jgp.108.4.333; Kennedy MJ, 2001, NEURON, V31, P87, DOI 10.1016/S0896-6273(01)00340-3; KUHN H, 1987, J RECEPTOR RES, V7, P283, DOI 10.3109/10799898709054990; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; Liou GI, 1998, J NEUROSCI, V18, P4511; Ma JX, 1998, BBA-GENE STRUCT EXPR, V1443, P255, DOI 10.1016/S0167-4781(98)00221-8; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; Mendez A, 2000, NEURON, V28, P153, DOI 10.1016/S0896-6273(00)00093-3; NAARENDORP F, 2002, INVEST OPHTHALMOL VI, V43; RATTO GM, 1991, NATURE, V351, P654, DOI 10.1038/351654a0; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2000, METHOD ENZYMOL, V316, P705; Robson JG, 1996, J OPT SOC AM A, V13, P613, DOI 10.1364/JOSAA.13.000613; Rohrer B, 1999, J NEUROSCI, V19, P8919, DOI 10.1523/JNEUROSCI.19-20-08919.1999; Rohrer B, 2001, MOL VIS, V7, P288; Saari JC, 2001, NEURON, V29, P739, DOI 10.1016/S0896-6273(01)00248-3; Schneeweis DM, 2000, VISUAL NEUROSCI, V17, P659, DOI 10.1017/S0952523800175017; Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297; Van Hooser JP, 2002, J BIOL CHEM, V277, P19173, DOI 10.1074/jbc.M112384200; WITKOVSKY P, 1976, J NEUROPHYSIOL, V39, P1272, DOI 10.1152/jn.1976.39.6.1272; Znoiko SL, 2002, INVEST OPHTH VIS SCI, V43, P1604	41	67	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40491	40498		10.1074/jbc.M205507200	http://dx.doi.org/10.1074/jbc.M205507200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12176991	hybrid			2022-12-27	WOS:000178791400044
J	Boesen, TP; Soni, B; Schwartz, TW; Halkier, T				Boesen, TP; Soni, B; Schwartz, TW; Halkier, T			Single-chain vascular endothelial growth factor variant with antagonist activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE DOMAIN RECEPTOR; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; FACTOR VEGF; MITOGENIC ACTIVITY; TYROSINE KINASE; FLT-1 RECEPTOR; ANGIOGENESIS; BINDING; GLYCOSYLATION	Vascular endothelial growth factor is a specific endothelial cell mitogen that is essential for the formation of the vascular system but in the adult individual is involved in several pathological conditions, including cancer. It is a homodimeric protein that activates its receptor by binding two receptor molecules and inducing dimerization. By mixing two vascular endothelial growth factor monomers, each with different substitutions, heterodimers with only one active receptor binding site have previously been prepared. These heterodimers bind the receptor molecule but are unable to induce dimerization and activation. However, preparation of heterodimers is cumbersome, involving separate expression of different monomers, refolding the mixture, and separating heterodimers from homodimers. Here we show that a fully functional ligand can efficiently be expressed as a single protein chain containing two monomers. Single-chain vascular endothelial growth factor is functionally equivalent to the wild-type protein. By monomer-specific mutagenesis, one receptor binding site was altered. This variant competitively and specifically antagonizes the mitogenic effect of the wild-type protein on endothelial cells. The results obtained with the single-chain antagonist show the feasibility of the single-chain approach in directing alterations to single specific regions in natural homodimeric proteins that would be impossible to target in other ways.	Maxygen ApS, DK-2970 Horsholm, Denmark; Univ Copenhagen, Dept Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen N, Denmark	University of Copenhagen	Halkier, T (corresponding author), Maxygen ApS, Agern Alle 1, DK-2970 Horsholm, Denmark.	th@maxygen.dk		Schwartz, Thue W./0000-0002-0261-6904				Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Brower V, 1999, NAT BIOTECHNOL, V17, P963, DOI 10.1038/13654; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CLAFFEY KP, 1995, BBA-PROTEIN STRUCT M, V1246, P1, DOI 10.1016/0167-4838(94)00144-6; Dunk C, 2001, AM J PATHOL, V158, P265, DOI 10.1016/S0002-9440(10)63965-X; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fong GH, 1999, DEVELOPMENT, V126, P3015; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Muller YA, 1998, STRUCTURE, V6, P1153, DOI 10.1016/S0969-2126(98)00116-6; PERETZ D, 1992, BIOCHEM BIOPH RES CO, V182, P1340, DOI 10.1016/0006-291X(92)91880-Y; Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Robinson CJ, 2001, J CELL SCI, V114, P853; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Siemeister G, 1998, P NATL ACAD SCI USA, V95, P4625, DOI 10.1073/pnas.95.8.4625; Siemeister G, 1998, J BIOL CHEM, V273, P11115, DOI 10.1074/jbc.273.18.11115; Wiesmann C, 1998, BIOCHEMISTRY-US, V37, P17765, DOI 10.1021/bi9819327; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; YEO TK, 1991, BIOCHEM BIOPH RES CO, V179, P1568, DOI 10.1016/0006-291X(91)91752-X	33	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40335	40341		10.1074/jbc.M204107200	http://dx.doi.org/10.1074/jbc.M204107200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12151391	hybrid			2022-12-27	WOS:000178791400024
J	Lee, J; Petris, MJ; Thiele, DJ				Lee, J; Petris, MJ; Thiele, DJ			Characterization of mouse embryonic cells deficient in the Ctr1 high affinity copper transporter - Identification of a Ctr1-independent copper transport system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; MOLECULAR CHARACTERIZATION; SCHIZOSACCHAROMYCES-POMBE; FUNCTIONAL EXPRESSION; IRON TRANSPORT; YEAST; GENE; CHAPERONE	The trace metal copper is an essential cofactor for a number of enzymes that have critical roles in biological processes, but it is highly toxic when allowed to accumulate in excess of cellular needs. Consequently, homeostatic copper metabolism is maintained by molecules involved in copper uptake, distribution, excretion, and incorporation into copper-requiring enzymes. Previously, we reported that overexpression of the human or mouse Ctr1 copper transporter stimulates copper uptake in mammalian cells, and deletion of one Ctr1 allele in mice gives rise to tissue-specific defects in copper accumulation and in the activities of copper-dependent enzymes. To investigate the physiological roles for mammalian Ctr1 protein in cellular copper metabolism, we characterized wild type, Ctr1 heterozygous, and Ctr1 homozygous knock-out cells isolated from embryos obtained by the inter-cross of Ctr1 heterozygous mice. Ctr1-deficient mouse embryonic cells are viable but exhibit significant defects in copper uptake and accumulation and in copper-dependent enzyme activities. Interestingly, Ctr1-deficient cells exhibit similar to30% residual copper transport activity that is saturable, with a K-m of similar to10 mum, with biochemical features distinct from that of Ctr1. These observations demonstrate that, although Ctr1 is critical for both cellular copper uptake and embryonic development, mammals possess additional biochemically distinct functional copper transport activities.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Missouri, Dept Nutrit Sci, Columbia, MO 65211 USA	University of Michigan System; University of Michigan; University of Missouri System; University of Missouri Columbia	Thiele, DJ (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	dthiele@umich.edu			NCI NIH HHS [1R24 CA 86307] Funding Source: Medline; NIDDK NIH HHS [DK 59893] Funding Source: Medline; NIGMS NIH HHS [GM 62555] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA086307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062555] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Capaldi RA, 1995, METHOD ENZYMOL, V260, P117, DOI 10.1016/0076-6879(95)60134-1; Casareno RLB, 1998, J BIOL CHEM, V273, P23625, DOI 10.1074/jbc.273.37.23625; Conrad ME, 2000, AM J PHYSIOL-GASTR L, V279, pG767, DOI 10.1152/ajpgi.2000.279.4.G767; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DIX DR, 1994, J BIOL CHEM, V269, P26092; Eisses JF, 2002, J BIOL CHEM, V277, P29162, DOI 10.1074/jbc.M203652200; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Gaither LA, 2000, J BIOL CHEM, V275, P5560, DOI 10.1074/jbc.275.8.5560; Georgatsou E, 1997, J BIOL CHEM, V272, P13786, DOI 10.1074/jbc.272.21.13786; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Hamza I, 2001, P NATL ACAD SCI USA, V98, P6848, DOI 10.1073/pnas.111058498; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Hassett R, 2000, BIOCHEM J, V351, P477, DOI 10.1042/0264-6021:3510477; KAMPFENKEL K, 1995, J BIOL CHEM, V270, P28479, DOI 10.1074/jbc.270.47.28479; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; Kuo YM, 2001, P NATL ACAD SCI USA, V98, P6836, DOI 10.1073/pnas.111057298; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Lamb AL, 2000, BIOCHEMISTRY-US, V39, P14720, DOI 10.1021/bi002207a; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; Lee J, 2000, GENE, V254, P87, DOI 10.1016/S0378-1119(00)00287-0; LEE J, 2002, J BIOL CHEM, V275, P33244; Lee LW, 2001, P NATL ACAD SCI USA, V98, P6842, DOI 10.1073/pnas.111058698; LIN SJ, 1995, P NATL ACAD SCI USA, V92, P3784, DOI 10.1073/pnas.92.9.3784; Linder M, 1991, BIOCH COPPER; Moller LB, 2000, GENE, V257, P13, DOI 10.1016/S0378-1119(00)00394-2; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; OYANAGUI Y, 1984, ANAL BIOCHEM, V142, P290; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; Prohaska JR, 2001, ARCH BIOCHEM BIOPHYS, V393, P170, DOI 10.1006/abbi.2001.2470; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Riggio M, 2002, BBA-GENE STRUCT EXPR, V1576, P127, DOI 10.1016/S0167-4781(02)00337-8; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPENO H, 1995, J BIOL CHEM, V270, P25363, DOI 10.1074/jbc.270.43.25363; Srinivasan C, 1998, BIOCHEMISTRY-US, V37, P7572, DOI 10.1021/bi980418y; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; Zhou B, 1997, P NATL ACAD SCI USA, V94, P7481, DOI 10.1073/pnas.94.14.7481; Zhou H, 2001, J BIOL CHEM, V276, P20529, DOI 10.1074/jbc.M102004200	48	184	186	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40253	40259		10.1074/jbc.M208002200	http://dx.doi.org/10.1074/jbc.M208002200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177073	hybrid			2022-12-27	WOS:000178791400014
J	Shanks, RA; Larocca, MC; Berryman, M; Edwards, JC; Urushidani, T; Navarre, J; Goldenring, JR				Shanks, RA; Larocca, MC; Berryman, M; Edwards, JC; Urushidani, T; Navarre, J; Goldenring, JR			AKAP350 at the Golgi apparatus - II. Association of AKAP350 with a novel chloride intracellular channel (CLIC) family member	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MOLECULAR-CLONING; REGULATORY SUBUNIT; SCAFFOLD PROTEINS; ION CHANNEL; CG-NAP; EXPRESSION; CENTROSOME; CELLS; P64	AKAP350 can scaffold a number of protein kinases and phosphatases at the centrosome and the Golgi apparatus. We performed a yeast two-hybrid screen of a rabbit parietal cell library with a 3.2-kb segment of AKAP350 (nucleotides 3611-6813). This screen yielded a full-length clone of rabbit chloride intracellular channel 1 (CLIC1). CLIC1 belongs to a family of proteins, all of which contain a high degree of homology in their carboxyl termini. All CLIC family members were able to bind a 133-amino acid domain within AKAP350 through the last 120 amino acids in the conserved CLIC carboxyl termini. Antibodies developed against a bovine CLIC, p64, immunoprecipitated AKAP350 from HCA-7 colonic adenocareinoma cell extracts. Antibodies against CLIC proteins recognized at least five CLIC species including a novel 46-kDa CLIC protein. We isolated the human homologue of bovine p64, CLIC5B, from HCA-7 cell cDNA. A splice variant of CLIC5, the predicted molecular mass of CLIC5B corresponds to the molecular mass of the 46-kDa CLIC immunoreactive protein in HCA-7 cells. Antibodies against CLIC5B colocalized with AKAP350 at the Golgi apparatus with minor staining of the centrosomes. AKAP350 and CLIC5B association with Golgi elements was lost following brefeldin A treatment. Furthermore, GFP-CLIC5B-(178-410) targeted to the Golgi apparatus in HCA-7 cells. The results suggest that AKAP350 associates with CLIC proteins and specifically that CLIC5B interacts with AKAP350 at the Golgi apparatus in HCA-7 cells.	Med Coll Georgia, Inst Mol Med & Genet, Dept Med, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Dept Surg, Augusta, GA 30912 USA; Med Coll Georgia, Inst Mol Med & Genet, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; Augusta Vet Affairs Med Ctr, Augusta, GA 30912 USA; Ohio Univ, Coll Osteopath Med, Dept Biomed Sci, Athens, OH 45701 USA; St Louis Univ, Dept Med, St Louis, MO 63106 USA; St Louis Vet Affairs Med Ctr, St Louis, MO 63106 USA; Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Pharmacol & Toxicol, Tokyo 1130033, Japan	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Ohio; Ohio University; Saint Louis University; University of Tokyo	Goldenring, JR (corresponding author), Vanderbilt Univ, Sch Med, Epithelial Biol Program, 4160A MRB III,465 21st Ave So, Nashville, TN 37232 USA.				NIAMS NIH HHS [R01 AR 44838] Funding Source: Medline; NIDDK NIH HHS [DK 43405, DK 48370] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043405, R01DK048370, R01DK043405] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berryman M, 2000, MOL BIOL CELL, V11, P1509, DOI 10.1091/mbc.11.5.1509; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CARR DW, 1991, J BIOL CHEM, V266, P14188; Dodge K, 2000, FEBS LETT, V476, P58, DOI 10.1016/S0014-5793(00)01671-9; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; Edwards JC, 1998, J MEMBRANE BIOL, V163, P119; Edwards JC, 1999, AM J PHYSIOL-RENAL, V276, pF398, DOI 10.1152/ajprenal.1999.276.3.F398; Faux MC, 1996, CELL, V85, P9, DOI 10.1016/S0092-8674(00)81075-2; Fernandez-Salas E, 1999, J BIOL CHEM, V274, P36488, DOI 10.1074/jbc.274.51.36488; Harrop SJ, 2001, J BIOL CHEM, V276, P44993, DOI 10.1074/jbc.M107804200; KERYER G, 1993, EXP CELL RES, V204, P230, DOI 10.1006/excr.1993.1029; LANDRY D, 1993, J BIOL CHEM, V268, P14948; Lapierre LA, 1999, J CELL SCI, V112, P3723; Lester LB, 1997, RECENT PROG HORM RES, V52, P409; Martin ME, 1999, J CELL SCI, V112, P3869; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; Nishizawa T, 2000, J BIOL CHEM, V275, P11164, DOI 10.1074/jbc.275.15.11164; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; Schlesinger PH, 1997, J BIOL CHEM, V272, P18636, DOI 10.1074/jbc.272.30.18636; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; Shanks RA, 2002, J BIOL CHEM, V277, P40967, DOI 10.1074/jbc.M203307200; Takahashi M, 2000, J BIOL CHEM, V275, P34592, DOI 10.1074/jbc.M005285200; Takahashi M, 1999, J BIOL CHEM, V274, P17267, DOI 10.1074/jbc.274.24.17267; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; Tulk BM, 2002, AM J PHYSIOL-CELL PH, V282, pC1103, DOI 10.1152/ajpcell.00402.2001; Tulk BM, 1998, AM J PHYSIOL-RENAL, V274, pF1140, DOI 10.1152/ajprenal.1998.274.6.F1140; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; Witczak O, 1999, EMBO J, V18, P1858, DOI 10.1093/emboj/18.7.1858	28	49	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40973	40980		10.1074/jbc.M112277200	http://dx.doi.org/10.1074/jbc.M112277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12163479	hybrid			2022-12-27	WOS:000178791400105
J	Barrette-Ng, IH; Ng, KKS; Mark, BL; van Aken, D; Cherney, MM; Garen, C; Kolodenko, Y; Gorbalenya, AE; Snijder, EJ; James, MNG				Barrette-Ng, IH; Ng, KKS; Mark, BL; van Aken, D; Cherney, MM; Garen, C; Kolodenko, Y; Gorbalenya, AE; Snijder, EJ; James, MNG			Structure of arterivirus nsp4 - The smallest chymotrypsin-like proteinase with an alpha/beta C-terminal extension and alternate conformations of the oxyanion hole	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EQUINE ARTERITIS VIRUS; SERINE-PROTEASE; CORE PROTEIN; REPLICASE; REFINEMENT; MOLSCRIPT; PROGRAM; DENSITY; BINDING	Arteriviruses are enveloped, positive-stranded RNA viruses and include pathogens of major economic concern to the swine- and horse-breeding industries. The arterivirus replicase gene encodes two large precursor polyproteins that are processed by the viral main proteinase nonstructural protein 4 (nsp4). The three-dimensional structure of the 21-kDa nsp4 from the arterivirus prototype equine arteritis virus has been determined to 2.0 Angstrom resolution. Nsp4 adopts the smallest known chymotrypsin-like fold with a canonical catalytic triad of Ser-120, His-39, and Asp-65, as well as a novel alpha/beta C-terminal extension domain that may play a role in mediating protein-protein interactions. In different copies of nsp4 in the asymmetric unit, the oxyanion hole adopts either a collapsed inactive conformation or the standard active conformation, which may be a novel way of regulating proteolytic activity.	Univ Alberta, Canadian Inst Hlth Res Grp Prot Struct & Funct, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Leiden Univ, Med Ctr, Dept Med Microbiol, Mol Virol Lab, NL-2300 RC Leiden, Netherlands	University of Alberta; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	James, MNG (corresponding author), Univ Alberta, Canadian Inst Hlth Res Grp Prot Struct & Funct, Dept Biochem, Edmonton, AB T6G 2H7, Canada.		Snijder, Eric J./E-6073-2018; Gorbalenya, Alexander E/J-4818-2012	Snijder, Eric J./0000-0003-3297-2309; Gorbalenya, Alexander E/0000-0002-4967-7341; Mark, Brian/0000-0002-7344-1355; Garen, Craig/0000-0002-7772-9890; Ng, Kenneth K.S./0000-0001-7280-8445	NCRR NIH HHS [RR07707] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALLAIRE M, 1994, NATURE, V369, P72, DOI 10.1038/369072a0; Anand K, 2002, EMBO J, V21, P3213, DOI 10.1093/emboj/cdf327; Botner A, 1997, VET REC, V141, P497, DOI 10.1136/vr.141.19.497; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choi HK, 1997, PROTEINS, V27, P345, DOI 10.1002/(SICI)1097-0134(199703)27:3<345::AID-PROT3>3.0.CO;2-C; Delano W.L., 2002, DELANO SCI; DENBOON JA, 1991, J VIROL, V65, P2910, DOI 10.1128/JVI.65.6.2910-2920.1991; DOLL E. R., 1957, CORNELL VET, V47, P3; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Gunasekaran K, 1998, J MOL BIOL, V284, P1505, DOI 10.1006/jmbi.1998.2154; Hayward S, 1998, PROTEINS, V30, P144, DOI 10.1002/(SICI)1097-0134(19980201)30:2<144::AID-PROT4>3.0.CO;2-N; Hayward S, 2001, PROTEIN SCI, V10, P2219, DOI 10.1110/ps.23101; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Matthews DA, 1999, P NATL ACAD SCI USA, V96, P11000, DOI 10.1073/pnas.96.20.11000; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NIENABER VL, 1993, BIOCHEMISTRY-US, V32, P11469, DOI 10.1021/bi00094a001; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pasternak AO, 2001, EMBO J, V20, P7220, DOI 10.1093/emboj/20.24.7220; Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Petersen JFW, 1999, EMBO J, V18, P5463, DOI 10.1093/emboj/18.20.5463; Snijder EJ, 1996, J BIOL CHEM, V271, P4864, DOI 10.1074/jbc.271.9.4864; SNIJDER EJ, 1994, J VIROL, V68, P5755, DOI 10.1128/JVI.68.9.5755-5764.1994; Snijder EJ, 1998, J GEN VIROL, V79, P961, DOI 10.1099/0022-1317-79-5-961; SNIJDER EJ, 2001, FIELDS VIROLOGY, V1, P1205; Stennicke HR, 1996, PROTEIN SCI, V5, P2266, DOI 10.1002/pro.5560051113; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Timoney PJ, 2002, EQUINE RESP DIS; TONG L, 1993, J MOL BIOL, V230, P228, DOI 10.1006/jmbi.1993.1139; van Dinten LC, 1999, J VIROL, V73, P2027, DOI 10.1128/JVI.73.3.2027-2037.1999; Wassenaar ALM, 1997, J VIROL, V71, P9313, DOI 10.1128/JVI.71.12.9313-9322.1997; WENSVOORT G, 1991, VET QUART, V13, P121, DOI 10.1080/01652176.1991.9694296; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Ziebuhr J, 2000, J GEN VIROL, V81, P853, DOI 10.1099/0022-1317-81-4-853	38	56	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39960	39966		10.1074/jbc.M206978200	http://dx.doi.org/10.1074/jbc.M206978200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163505	hybrid			2022-12-27	WOS:000178662500114
J	Gallois-Montbrun, S; Schneider, B; Chen, YX; Giacomoni-Fernandes, V; Mulard, L; Morera, S; Janin, J; Deville-Bonne, D; Veron, M				Gallois-Montbrun, S; Schneider, B; Chen, YX; Giacomoni-Fernandes, V; Mulard, L; Morera, S; Janin, J; Deville-Bonne, D; Veron, M			Improving nucleoside diphosphate kinase for antiviral nucleotide analogs activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; THYMIDINE DIPHOSPHATE; STEADY-STATE; PHOSPHORYLATION; MECHANISM; BINDING; ENZYME	Antiviral nucleoside analog therapies rely on their incorporation by viral DNA polymerases/reverse transcriptase leading to chain termination. The analogs (3'-deoxy-3'-azidothymidine (AZT), 2',3'-didehydro-2',3'dideoxythymidine (d4T), and other dideoxynucleosides) are sequentially converted into triphosphate by cellular kinases of the nucleoside salvage pathway and are often poor substrates of these enzymes. Nucleoside diphosphate (NDP) kinase phosphorylates the diphosphate derivatives of the analogs with an efficiency some 104 lower than for its natural substrates. Kinetic and structural studies of Dictyostelium and human NDP kinases show that the sugar X-OH, absent from all antiviral analogs, is required for catalysis. To improve the catalytic efficiency of NDP kinase on the analogs, we engineered several mutants with a protein OH group replacing the sugar 3'-OH. The substitution of Asn-115 in Ser and Leu-55 in His results in an NDP kinase mutant with an enhanced ability to phosphorylate antiviral derivatives. Transfection of the mutant enzyme in Escherichia coli results in an increased sensitivity to AZT. An x-ray structure at 2.15-Angstrom resolution of the Dictyostelium enzyme bearing the serine substitution in complex with the R-p-alpha-borano-triphosphate derivative of AZT shows that the enhanced activity reflects an improved geometry of binding and a favorable interaction of the X-azido group with the engineered serine.	Inst Pasteur, CNRS, Regulat Enzymat Activ Cellulaires FRE 2364, F-75724 Paris 15, France; CNRS, Lab Enzymol & Biochim Struct, UPR 9063, F-91198 Gif Sur Yvette, France; Inst Pasteur, CNRS, Unite Chim Organ, URA 1228, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Deville-Bonne, D (corresponding author), Inst Pasteur, CNRS, Regulat Enzymat Activ Cellulaires FRE 2364, 25 Rue Dr Roux, F-75724 Paris 15, France.	ddeville@pasteur.fr	Janin, Joel/I-2958-2012; Schneider, Benoit/AAF-3850-2019; Gallois-Montbrun, Sarah/L-9843-2017; Chen, Yuxing/P-4156-2014	Schneider, Benoit/0000-0002-1377-2670; Gallois-Montbrun, Sarah/0000-0002-7870-1814; Chen, Yuxing/0000-0002-7560-1922				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Black ME, 1996, P NATL ACAD SCI USA, V93, P3525, DOI 10.1073/pnas.93.8.3525; Bourdais J, 1996, J BIOL CHEM, V271, P7887, DOI 10.1074/jbc.271.14.7887; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brundiers R, 1999, J BIOL CHEM, V274, P35289, DOI 10.1074/jbc.274.50.35289; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHERFILS J, 1994, BIOCHEMISTRY-US, V33, P9062, DOI 10.1021/bi00197a006; Christians FC, 1999, NAT BIOTECHNOL, V17, P259, DOI 10.1038/7003; DevilleBonne D, 1996, BIOCHEMISTRY-US, V35, P14643, DOI 10.1021/bi960945m; ELWELL LP, 1987, ANTIMICROB AGENTS CH, V31, P274, DOI 10.1128/AAC.31.2.274; Encell LP, 1999, NAT BIOTECHNOL, V17, P143, DOI 10.1038/6142; GALLOISMONTBRUN S, 2002, Patent No. 2382470; GALLOISMONTBRUN S, 2002, Patent No. 10133628; Gonin P, 1999, BIOCHEMISTRY-US, V38, P7265, DOI 10.1021/bi982990v; Guettari N, 1997, VIROLOGY, V235, P398, DOI 10.1006/viro.1997.8706; Janin J, 2000, J BIOENERG BIOMEMBR, V32, P215, DOI 10.1023/A:1005528811303; KATI WM, 1989, SCIENCE, V243, P1591, DOI 10.1126/science.2928795; Keller R, 2002, IMMUNOL LETT, V83, P1, DOI 10.1016/S0165-2478(02)00065-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lacombe ML, 2000, J BIOENERG BIOMEMBR, V32, P247, DOI 10.1023/A:1005584929050; LARDER B, 1992, REVERSE TRANSCRIPTAS, P205; LASCU I, 1993, J BIOL CHEM, V268, P20268; Meyer P, 2000, EMBO J, V19, P3520, DOI 10.1093/emboj/19.14.3520; MORERA S, 1994, BIOCHEMISTRY-US, V33, P459, DOI 10.1021/bi00168a010; MORERA S, 1994, J MOL BIOL, V243, P873, DOI 10.1006/jmbi.1994.1689; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; Neet KE, 1998, J BIOL CHEM, V273, P25527, DOI 10.1074/jbc.273.40.25527; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARENTEAU NL, 2002, ANN NY ACAD SCI, V951, P27; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; ROUSSEL A, 1991, SILICON GRAPHICS DIR; Schneider B, 1998, J BIOL CHEM, V273, P11491, DOI 10.1074/jbc.273.19.11491; Schneider B, 2000, MOL PHARMACOL, V57, P948; Schneider B, 2001, EUR J BIOCHEM, V268, P1964, DOI 10.1046/j.1432-1327.2001.02070.x; Xu YW, 1997, P NATL ACAD SCI USA, V94, P7162, DOI 10.1073/pnas.94.14.7162; Zhu CY, 1998, J BIOL CHEM, V273, P14707, DOI 10.1074/jbc.273.24.14707	36	25	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39953	39959		10.1074/jbc.M206360200	http://dx.doi.org/10.1074/jbc.M206360200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171931	hybrid			2022-12-27	WOS:000178662500113
J	Rallabhandi, P; Hashimoto, K; Mo, YY; Beck, WT; Moitra, PK; D'Arpa, P				Rallabhandi, P; Hashimoto, K; Mo, YY; Beck, WT; Moitra, PK; D'Arpa, P			Sumoylation of topoisomerase I is involved in its partitioning between nucleoli and nucleoplasm and its clearing from nucleoli in response to camptothecin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUMO-1 MODIFICATION; COVALENT MODIFICATION; SUBCELLULAR-LOCALIZATION; PROTEIN SUMO-1; CELL-NUCLEUS; DNA; CONJUGATION; P53; IDENTIFICATION; REDISTRIBUTION	Previous studies identified a small fraction of putatively sumoylated topoisomerase I (TOP1) under basal conditions (similar to1%), and anticancer camptothecins that trap the TOP1-DNA covalent intermediate markedly increase the sumoylation of TOP1 (less than or equal to10%). To study the role of the sumoylation of TOP1, we mutated sites on green fluorescent protein (GFP)-TOP1 corresponding to the consensus sequence for protein sumoylation (WKXE, where Psi is a hydrophobic residue) and assayed the mutants for basal and camptothecin-induced sumoylation. Only one of the eight mutants, K117R, located in the highly charged NH2-terminal region, showed a substantial reduction (similar to5-fold) in basal and camptothecin-induced sumoylation; thus, Lys-117 appears to be the major sumoylation site. A triple mutant having the PsiKXE sequences flanking K117R additionally mutated (K103R/K117R/K153R) showed little if any sumoylation, but was degraded like wild-type GFP-TOP1 during camptothecin treatment. However, K103R/K117R/K153R-GFP-TOP1 was markedly concentrated within nucleoli, depleted from the remainder of nucleus, and failed to be cleared from nucleoli in response to camptothecin treatment. These data are consistent with a model wherein basal transient sumoylation of the NH2-terminal, highly charged, disordered region prevents TOP1 binding to sites in nucleoli, thus driving it to bind in the nucleoplasm; and camptothecin treatment, which increases TOP1 sumoylation, further shifts the binding resulting in delocalization of TOP1 from nucleoli to nucleoplasm.	Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, Bethesda, MD 20814 USA; Univ Illinois, Div Mol Pharmacol, Dept Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Dept Pharmaceut & Pharmacodynam, Chicago, IL 60607 USA	Uniformed Services University of the Health Sciences - USA; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	D'Arpa, P (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Biochem & Mol Biol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.		Mo, Yin-Yuan/R-8255-2019; Mo, Yin-Yuan/B-6141-2011	D'Arpa, Peter/0000-0002-0562-0263				BEIDLER DR, 1995, MOL PHARMACOL, V47, P907; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Buckwalter CA, 1996, CANCER RES, V56, P1674; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chen TC, 2000, CANCER LETT, V153, P169, DOI 10.1016/S0304-3835(00)00366-9; Christensen MO, 2002, J BIOL CHEM, V277, P15661, DOI 10.1074/jbc.C200066200; Danks MK, 1996, CANCER RES, V56, P1664; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; Desai SD, 1997, J BIOL CHEM, V272, P24159, DOI 10.1074/jbc.272.39.24159; Desai SD, 2001, CANCER RES, V61, P5926; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Dundr M, 2001, BIOCHEM J, V356, P297, DOI 10.1042/0264-6021:3560297; Duprez E, 1999, J CELL SCI, V112, P381; Edwards TK, 2000, J BIOL CHEM, V275, P36181, DOI 10.1074/jbc.M006628200; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Hofmann H, 2000, J VIROL, V74, P2510, DOI 10.1128/JVI.74.6.2510-2524.2000; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kirsh O, 2002, EMBO J, V21, P2682, DOI 10.1093/emboj/21.11.2682; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Mao Y, 2000, J BIOL CHEM, V275, P26066, DOI 10.1074/jbc.M001831200; Mao Y, 2001, J BIOL CHEM, V276, P40652, DOI 10.1074/jbc.M104009200; Mao Y, 2000, P NATL ACAD SCI USA, V97, P4046, DOI 10.1073/pnas.080536597; Mao YH, 2002, P NATL ACAD SCI USA, V99, P1235, DOI 10.1073/pnas.022631899; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Mo YY, 2002, J BIOL CHEM, V277, P2958, DOI 10.1074/jbc.M108263200; Mo YY, 2000, EXP CELL RES, V256, P480, DOI 10.1006/excr.2000.4864; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Phair RD, 2000, NATURE, V404, P604, DOI 10.1038/35007077; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rangasamy D, 2000, J BIOL CHEM, V275, P37999, DOI 10.1074/jbc.M007777200; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Shaiu WL, 1998, MOL CELL BIOL, V18, P4358, DOI 10.1128/MCB.18.7.4358; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Straub T, 1998, J BIOL CHEM, V273, P26261, DOI 10.1074/jbc.273.41.26261; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; van Eenennaam H, 2001, MOL BIOL CELL, V12, P3680, DOI 10.1091/mbc.12.11.3680; Wadkins RM, 1998, EXP CELL RES, V241, P332, DOI 10.1006/excr.1998.4033; Wilson VG, 2001, EXP CELL RES, V271, P57, DOI 10.1006/excr.2001.5366	46	41	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40020	40026		10.1074/jbc.M200388200	http://dx.doi.org/10.1074/jbc.M200388200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12149243	hybrid			2022-12-27	WOS:000178662500122
J	Zhao, R; Holmgren, A				Zhao, R; Holmgren, A			A novel antioxidant mechanism of ebselen involving ebselen diselenide, a substrate of mammalian thioredoxin and thioredoxin reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE ORGANOSELENIUM COMPOUND; GLUTATHIONE-PEROXIDASE ACTIVITY; CEREBRAL-ARTERY OCCLUSION; BLIND CLINICAL-TRIAL; SELENOORGANIC COMPOUND; GLUTAREDOXIN SYSTEMS; IMMUNOHISTOCHEMICAL LOCALIZATION; NEUROPROTECTIVE EFFICACY; ISOLATED HEPATOCYTES; PZ-51 EBSELEN	The antioxidant mechanism of ebselen involves recently discovered reductions by mammalian thioredoxin reductase (TrxR) and thioredoxin (Trx) forming ebselen selenol. Here we describe a previously unknown reaction; ebselen reacts with its selenol forming an ebselen diselenide with a rate constant of 372 M(-1)s(-1). The diselenide also was a substrate of TrxR forming the selenol with K-m of 40 mum and k(cat) of 79 min(-1) (k(cat)/K-m of 3.3 x 10(4) m(-1)s(-1)). Trx increased the reduction because of its fast reaction with diselenide (rate constant 1.7 x 10(3) m(-1)s(-1)). Diselenide stimulated the H2O2 reductase activity of TrxR, even more efficiently with Trx present. Because the mechanism of ebselen as an antioxidant has been assumed to involve glutathione peroxidase-like activity, we compared the H2O2 reductase activity of ebselen with the GSH and Trx systems. TrxR at 50 nm, far below the estimated physiological level, gave 8-fold higher activity compared with 1 mm GSH; addition of 5 pm Trx increased this difference to 13-fold. The rate constant of ebselen selenol reacting with H2O2 was estimated to be faster than 350 m(-1)s(-1). We propose novel mechanisms for ebselen antioxidant action involving ebselen selenol and diselenide formation, with the thioredoxin system rather than glutathione as the predominant effector and target.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden	Karolinska Institutet	Holmgren, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, SE-17177 Stockholm, Sweden.							Alam MM, 1998, INT J CHEM KINET, V30, P193, DOI 10.1002/(SICI)1097-4601(1998)30:3<193::AID-KIN4>3.0.CO;2-N; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, METHOD ENZYMOL, V300, P226; BJORNSTEDT M, 1995, J BIOL CHEM, V270, P11761, DOI 10.1074/jbc.270.20.11761; BJORNSTEDT M, 1992, J BIOL CHEM, V267, P8030; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; Bjornstedt M, 1997, BIOMED ENVIRON SCI, V10, P271; COTGREAVE IA, 1987, BIOCHEM PHARMACOL, V36, P2899, DOI 10.1016/0006-2952(87)90200-0; COTGREAVE IA, 1992, CHEM-BIOL INTERACT, V84, P69, DOI 10.1016/0009-2797(92)90121-Z; DAWSON DA, 1995, NEUROSCI LETT, V185, P65, DOI 10.1016/0304-3940(94)11226-9; FISCHER H, 1988, XENOBIOTICA, V18, P1347, DOI 10.3109/00498258809042259; FISCHER H, 1987, B SOC CHIM BELG, V96, P757; HAENEN GRMM, 1990, MOL PHARMACOL, V37, P412; HANSSON HA, 1986, CELL TISSUE RES, V245, P189; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; HOLMGREN A, 1978, BIOCHEMISTRY-US, V17, P4071, DOI 10.1021/bi00612a031; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Imai H, 2001, STROKE, V32, P2149, DOI 10.1161/hs0901.095725; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; LUTHMAN M, 1982, BIOCHEMISTRY-US, V21, P6628, DOI 10.1021/bi00269a003; MAIORINO M, 1988, BIOCHEM PHARMACOL, V37, P2267, DOI 10.1016/0006-2952(88)90591-6; Maulik N, 1998, FREE RADICAL BIO MED, V24, P869, DOI 10.1016/S0891-5849(97)00388-2; MORGENSTERN R, 1992, CHEM-BIOL INTERACT, V84, P77, DOI 10.1016/0009-2797(92)90122-2; MULLER A, 1984, BIOCHEM PHARMACOL, V33, P3235, DOI 10.1016/0006-2952(84)90083-2; MULLER A, 1985, BIOCHEM PHARMACOL, V34, P1185, DOI 10.1016/0006-2952(85)90493-9; MULLER A, 1988, BIOCHEM PHARMACOL, V37, P1103, DOI 10.1016/0006-2952(88)90517-5; Nakamura Y, 2002, J BIOL CHEM, V277, P2687, DOI 10.1074/jbc.M109641200; Namura S, 2001, STROKE, V32, P1906, DOI 10.1161/01.STR.32.8.1906; Ogawa A, 1999, CEREBROVASC DIS, V9, P112, DOI 10.1159/000015908; REN XL, 1993, BIOCHEMISTRY-US, V32, P9701, DOI 10.1021/bi00088a023; ROZELL B, 1985, EUR J CELL BIOL, V38, P79; Saito I, 1998, NEUROSURGERY, V42, P269, DOI 10.1097/00006123-199802000-00038; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; SCHEWE T, 1995, GEN PHARMACOL-VASC S, V26, P1153, DOI 10.1016/0306-3623(95)00003-J; SIES H, 1994, METHOD ENZYMOL, V234, P476; SIES H, 1993, FREE RADICAL BIO MED, V14, P313, DOI 10.1016/0891-5849(93)90028-S; Sies H., 1989, SELENIUM BIOL MED, P153; Takasago T, 1997, BRIT J PHARMACOL, V122, P1251, DOI 10.1038/sj.bjp.0701426; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; URSINI F, 1995, METHOD ENZYMOL, V252, P38; WENDEL A, 1984, BIOCHEM PHARMACOL, V33, P3241, DOI 10.1016/0006-2952(84)90084-4; WILSON SR, 1989, J AM CHEM SOC, V111, P5936, DOI 10.1021/ja00197a065; Yamaguchi T, 1998, STROKE, V29, P12, DOI 10.1161/01.STR.29.1.12; Zhang MJ, 2002, FREE RADICAL BIO MED, V32, P454, DOI 10.1016/S0891-5849(01)00825-5; Zhao R, 2002, P NATL ACAD SCI USA, V99, P8579, DOI 10.1073/pnas.122061399; Zhao R, 1998, J AM CHEM SOC, V120, P2811, DOI 10.1021/ja974136h; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	53	151	157	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39456	39462		10.1074/jbc.M206452200	http://dx.doi.org/10.1074/jbc.M206452200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177067	hybrid			2022-12-27	WOS:000178662500052
J	Lee, DK; Kim, BC; Kim, IY; Cho, EA; Satterwhite, DJ; Kim, SJ				Lee, DK; Kim, BC; Kim, IY; Cho, EA; Satterwhite, DJ; Kim, SJ			The human papilloma virus E7 oncoprotein inhibits transforming growth factor-beta signaling by blocking binding or the Smad complex to its target sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE ARREST; TGF-BETA; TRANSCRIPTIONAL ACTIVATION; TUMOR-SUPPRESSOR; PROTEINS; TGF-BETA-1; EXPRESSION; GENE; PHOSPHORYLATION; INACTIVATION	The human papillomavirus (HPV) oncoprotein E7 is implicated in the etiology of cervical cancer associated with infection by HPV. HPV-positive cells develop resistance to TGF-beta growth inhibitory activity through the inhibition of hypophosphorylation of pRb by papillomavirus type 16 E7 oncoprotein. In this study, we examined whether E7, in addition to its well known effects on pRb, might directly target the Smad proteins that mediate TGF-beta signaling. Here, we show that E7 significantly blocks both Smad transcriptional activity and the ability of TGF-beta to inhibit DNA synthesis. We found that E7 interacts constitutively with Smad2, Smad3, and Smad4. Confocal microscopic studies confirm that E7 and Smads co-localize in vivo. Using a canonical Smad DNA binding sequence, we found that E7 blocks Smad3 binding to its target sequence on DNA. These results suggest that suppression of Smad-mediated signaling by E7 may contribute to HPV-associated carcinogenesis.	NIH, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; Univ Utah, Div Neonatol, Salt Lake City, UT 84132 USA	National Institutes of Health (NIH) - USA; Utah System of Higher Education; University of Utah	Kim, SJ (corresponding author), NIH, Lab Cell Regulat & Carcinogenesis, Bldg 10, Bethesda, MD 20892 USA.							Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; Enzenauer C, 1998, INTERVIROLOGY, V41, P80, DOI 10.1159/000024918; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Farley J, 2000, GYNECOL ONCOL, V78, P113, DOI 10.1006/gyno.2000.5879; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HOWE PH, 1991, MOL CELL BIOL, V11, P1185, DOI 10.1128/MCB.11.3.1185; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8; KIM SJ, 1991, MOL CELL BIOL, V11, P5222, DOI 10.1128/MCB.11.10.5222; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 2000, GENE DEV, V14, P627; Nishihara A, 1999, J BIOL CHEM, V274, P28716, DOI 10.1074/jbc.274.40.28716; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Park SH, 2002, J BIOL CHEM, V277, P5168, DOI 10.1074/jbc.M106451200; Pei XF, 1998, CARCINOGENESIS, V19, P1481, DOI 10.1093/carcin/19.8.1481; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Satterwhite DJ, 2000, BIOCHEM BIOPH RES CO, V276, P686, DOI 10.1006/bbrc.2000.3510; SATTERWHITE DJ, 1994, CELL GROWTH DIFFER, V5, P789; Satterwhite DJ, 2000, CANCER RES, V60, P6989; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; Tada K, 1999, GENES CELLS, V4, P731, DOI 10.1046/j.1365-2443.1999.00293.x; Tsubari M, 1999, MOL CELL BIOL, V19, P3654; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	36	65	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38557	38564		10.1074/jbc.M206786200	http://dx.doi.org/10.1074/jbc.M206786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145312	hybrid			2022-12-27	WOS:000178529600072
J	Cai, XA; Gu, ZL; Zhong, P; Ren, Y; Yan, Z				Cai, XA; Gu, ZL; Zhong, P; Ren, Y; Yan, Z			Serotonin 5-HT1A receptors regulate AMPA receptor channels through inhibiting Ca2+/calmodulin-dependent kinase II in prefrontal cortical pyramidal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; CENTRAL-NERVOUS-SYSTEM; POSTSYNAPTIC DENSITY PROTEIN; GLUTAMATE-RECEPTOR; DENDRITIC SPINES; CHOLINERGIC INTERNEURONS; PHOSPHORYLATION SITES; ANTIPSYCHOTIC-DRUGS; SYNAPTIC PLASTICITY	We have studied the regulation of AMPA (alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) receptor channels by serotonin signaling in pyramidal neurons of prefrontal cortex (PFC). Application of serotonin reduced the amplitude of AMPA-evoked currents, an effect mimicked by 5-HT1A receptor agonists and blocked by 5-HT1A antagonists, indicating the mediation by 5-HT1A receptors. The serotonergic modulation of AMPA receptor currents was blocked by protein kinase A (PKA) activators and occluded by PKA inhibitors. Inhibiting the catalytic activity of protein phosphatase 1 (PP1) also, eliminated the effect of serotonin on AMPA currents. Furthermore, the serotonergic modulation of AMPA currents was occluded by application of the Ca2+/calmodulin-dependent kinase II (CaMKII) inhibitors and blocked by intracellular injection of calmodulin or recombinant CaMKII. Application of serotonin or 5-HT1A agonists to PFC slices reduced CaMKII activity and the phosphorylation of AMPA receptor subunit GluR1 at the CaMKII site in a PP1-dependent manner. We concluded that serotonin, by activating 5-HT1A receptors, suppress glutamatergic signaling through the inhibition of CaMKII, which is achieved by the inhibition of PKA and ensuing activation of PP1. This modulation demonstrates the critical role of CaMKII in serotonergic regulation of PFC neuronal activity, which may explain the neuropsychiatric behavioral phenotypes seen in CaAMKII knockout mice.	SUNY Buffalo, Dept Physiol & Biophys, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Yan, Z (corresponding author), SUNY Buffalo, Dept Physiol & Biophys, Sch Med & Biomed Sci, 124 Sherman Hall, Buffalo, NY 14214 USA.	zhenyan@buffalo.edu	Cai, Xiang/AAD-8012-2021		NIMH NIH HHS [MH63128] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albert PR, 2001, TRENDS ENDOCRIN MET, V12, P453, DOI 10.1016/S1043-2760(01)00498-2; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Andrade R, 1998, ANN NY ACAD SCI, V861, P190, DOI 10.1111/j.1749-6632.1998.tb10191.x; Bachus SE, 1996, J CLIN PSYCHIAT, V57, P72; Bantick RA, 2001, J PSYCHOPHARMACOL, V15, P37, DOI 10.1177/026988110101500108; Barria A, 1997, J BIOL CHEM, V272, P32727, DOI 10.1074/jbc.272.52.32727; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BENSON DL, 1992, NEUROSCIENCE, V46, P825, DOI 10.1016/0306-4522(92)90188-8; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; BREIER A, 1995, SCHIZOPHR RES, V14, P187, DOI 10.1016/0920-9964(94)00043-8; Buhot MC, 1997, CURR OPIN NEUROBIOL, V7, P243, DOI 10.1016/S0959-4388(97)80013-X; Busatto GF, 1997, J PSYCHOPHARMACOL, V11, P3, DOI 10.1177/026988119701100102; Cai X, 2002, J PHYSIOL-LONDON, V540, P743; CHEN C, 1994, SCIENCE, V266, P291, DOI 10.1126/science.7939668; Davidson RJ, 2000, SCIENCE, V289, P591, DOI 10.1126/science.289.5479.591; DUBOVSKY SL, 1995, J CLIN PSYCHIAT, V56, P38; Edagawa Y, 1998, EUR J PHARMACOL, V349, P221, DOI 10.1016/S0014-2999(98)00286-6; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; Feng J, 2001, J NEUROSCI, V21, P6502, DOI 10.1523/JNEUROSCI.21-17-06502.2001; FITZGERALD LW, 1995, J NEUROSCI, V15, P2453, DOI 10.1523/JNEUROSCI.15-03-02453.1995; FUXE K, 1983, NEUROPHARMACOLOGY, V22, P389, DOI 10.1016/0028-3908(83)90188-0; Giese KP, 1998, SCIENCE, V279, P870, DOI 10.1126/science.279.5352.870; GOLDMANRAKIC PS, 1990, J NEUROSCI, V10, P2125; GREENGARD P, 1991, SCIENCE, V253, P1135, DOI 10.1126/science.1716001; Gurevich EV, 1997, BIOL PSYCHIAT, V42, P529, DOI 10.1016/S0006-3223(97)00321-1; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRISON PJ, 1991, LANCET, V337, P450, DOI 10.1016/0140-6736(91)93392-M; Hayashi K, 1999, J NEUROSCI, V19, P3918; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Heisler LK, 1998, P NATL ACAD SCI USA, V95, P15049, DOI 10.1073/pnas.95.25.15049; HEMMINGS HC, 1990, J BIOL CHEM, V265, P20369; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; Kia HK, 1996, J NEUROSCI RES, V46, P697; Kia HK, 1996, J COMP NEUROL, V365, P289; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Lisman JE, 2001, NEURON, V31, P191, DOI 10.1016/S0896-6273(01)00364-6; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Mammen AL, 1997, J BIOL CHEM, V272, P32528, DOI 10.1074/jbc.272.51.32528; Martin GR, 1998, TRENDS PHARMACOL SCI, V19, P2, DOI 10.1016/S0165-6147(97)01143-7; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MELTZER HY, 1995, CLIN NEUROSCI, V3, P64; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; Nishi A, 1999, J NEUROCHEM, V72, P2015, DOI 10.1046/j.1471-4159.1999.0722015.x; OUIMET CC, 1995, P NATL ACAD SCI USA, V92, P3396, DOI 10.1073/pnas.92.8.3396; Parks CL, 1998, P NATL ACAD SCI USA, V95, P10734, DOI 10.1073/pnas.95.18.10734; Raymond JR, 1999, BRIT J PHARMACOL, V127, P1751, DOI 10.1038/sj.bjp.0702723; Roche Katherine W., 1994, Current Opinion in Neurobiology, V4, P383, DOI 10.1016/0959-4388(94)90100-7; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; SAKAI N, 1993, BRAIN RES, V613, P326, DOI 10.1016/0006-8993(93)90921-9; SCHREIBER R, 1993, PROG NEURO-PSYCHOPH, V17, P87, DOI 10.1016/0278-5846(93)90034-P; SHIELDS SM, 1985, J NEUROSCI, V5, P3414; Simpson MDC, 1996, BIOL PSYCHIAT, V39, P919, DOI 10.1016/0006-3223(95)00026-7; Sokolov BP, 1998, J NEUROCHEM, V71, P2454; Stockmeier CA, 1997, ANN NY ACAD SCI, V836, P220, DOI 10.1111/j.1749-6632.1997.tb52362.x; Sumiyoshi T, 1996, BRAIN RES, V708, P209, DOI 10.1016/0006-8993(95)01361-X; Tukey J. W., 1977, EXPLORATORY DATA ANA; WILLIAMS KR, 1986, J BIOL CHEM, V261, P1890; Yan Z, 1999, NAT NEUROSCI, V2, P13, DOI 10.1038/4516; Yan Z, 1996, J NEUROSCI, V16, P2592; Yan Z, 1997, NEURON, V19, P1115, DOI 10.1016/S0896-6273(00)80402-X; Zhabotinsky AM, 2000, BIOPHYS J, V79, P2211, DOI 10.1016/S0006-3495(00)76469-1	69	82	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36553	36562		10.1074/jbc.M203752200	http://dx.doi.org/10.1074/jbc.M203752200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12149253	hybrid			2022-12-27	WOS:000178275100098
J	Ishida, N; Hayashi, K; Hoshijima, M; Ogawa, T; Koga, S; Miyatake, Y; Kumegawa, M; Kimura, T; Takeya, T				Ishida, N; Hayashi, K; Hoshijima, M; Ogawa, T; Koga, S; Miyatake, Y; Kumegawa, M; Kimura, T; Takeya, T			Large scale gene expression analysis of osteoclastogenesis in vitro and elucidation of NFAT2 as a key regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; T-CELL ACTIVATION; TRANSCRIPTION FACTORS; SIGNALING PATHWAYS; CYCLOSPORINE-A; KAPPA-B; NF-AT; DEFECTIVE INTERLEUKIN-1; DIFFERENTIATION FACTOR; NUCLEAR-LOCALIZATION	To understand the molecular events coupling between cell proliferation and differentiation by elucidating genes essential for the process, we conducted a large scale gene expression analysis of an in vitro osteoclastogenesis system consisting of recombinant RANKL and mouse RAW264 cells. The entire process leading to the formation of tartrate resistant acid phosphatase-positive multinucleated cells takes 3 days and plates become fully covered with multinucleated cells at 4 days. Microarray probing at eight time points revealed 635 genes that showed greater than 2-fold differential expression for at least one time point and they could be classified into six groups by the "k-means" clustering analysis. Among a group of 106 early inducible genes (within 2-5 h after RANKL stimulation), four genes including NFAT2 were identified as genes whose enhanced expressions were fairly correlated with an efficient induction of matured osteoclasts. Moreover, cyclosporin A significantly suppressed the multinucleated cell formation accompanying the reduction of the nuclear localization of NFAT2. When the expression of NFAT2 was suppressed by introducing antisense NFAT2, multinucleated cell formation was severely hampered. Functional analysis thus combined with gene analysis by microarray technology elucidated a key role of NFAT2 in osteoclastogenesis in vitro.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan; Sumitomo Pharmaceut Co Ltd, Div Res, Konohana Ku, Osaka 5540022, Japan; Meikai Univ, Sch Dent, Dept Oral Anat, Sakado, Saitama 35002, Japan	Nara Institute of Science & Technology; Meikai University	Takeya, T (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan.		Ogawa, Takuya/ABC-9628-2020	Ogawa, Takuya/0000-0001-9194-3079				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Assuma R, 1998, J IMMUNOL, V160, P403; Awumey EM, 1999, BIOCHEM BIOPH RES CO, V254, P248, DOI 10.1006/bbrc.1998.9785; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200; CHOWDHURY MH, 1991, CALCIFIED TISSUE INT, V49, P275, DOI 10.1007/BF02556217; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; DAVIS RJ, 1994, TRENDS BIOCHEM SCI, V19, P470, DOI 10.1016/0968-0004(94)90132-5; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; Hartigan J., 1975, CLUSTERING ALGORITHM; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Itahana K, 1996, ENDOCRINOLOGY, V137, P5036, DOI 10.1210/en.137.11.5036; Jacinto E, 1998, IMMUNITY, V8, P31, DOI 10.1016/S1074-7613(00)80456-2; Kingsbury TJ, 2000, GENE DEV, V14, P1595; Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271; KOHONEN T, 1997, SPRINGER SERIES INFO, V426; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; Krebs DL, 2000, J CELL SCI, V113, P2813; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Macian F, 2001, ONCOGENE, V20, P2476, DOI 10.1038/sj.onc.1204386; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Meiyanto E, 2001, BIOCHEM BIOPH RES CO, V282, P278, DOI 10.1006/bbrc.2001.4564; Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365-2443.1999.00265.x; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Perry R. L., 2000, FRONT BIOSCI, V5, pD570; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Quackenbush J, 2001, NAT REV GENET, V2, P418, DOI 10.1038/35076576; RALPH P, 1977, J IMMUNOL, V119, P950; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; REDDY SV, 1995, J BONE MINER RES, V10, P601; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; SAMBROOK J, 2001, MOL CLONING, pCH17; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Serfling E, 2000, BBA-MOL CELL RES, V1498, P1, DOI 10.1016/S0167-4889(00)00082-3; Shen XN, 2000, FEBS LETT, V480, P132, DOI 10.1016/S0014-5793(00)01905-0; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Spector D. L., 1998, CELLS LAB MANUAL; Studzinski GP, 1999, INT REV CYTOL, V189, P1, DOI 10.1016/S0074-7696(08)61384-4; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345; Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597	60	325	335	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41147	41156		10.1074/jbc.M205063200	http://dx.doi.org/10.1074/jbc.M205063200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171919	hybrid			2022-12-27	WOS:000178791400125
J	Rosen, GM; Tsai, P; Weaver, J; Porasuphatana, S; Roman, LJ; Starkov, AA; Fiskum, G; Pou, S				Rosen, GM; Tsai, P; Weaver, J; Porasuphatana, S; Roman, LJ; Starkov, AA; Fiskum, G; Pou, S			The role of tetrahydrobiopterin in the regulation of neuronal nitric-oxide synthase-generated superoxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; ELECTRON-TRANSFER; SPIN TRAP; KINETICS; ACTIVATION; REDUCTION; MECHANISM; CATALYSIS; RADICALS; NITRONE	Tetrahydrobiopterin (H4B) is a critical element in the nitric-oxide synthase (NOS) metabolism Of L-arginine to L-citrulline and NO.. It has been hypothesized that in the absence of or under nonsaturating levels Of L-arginine where O-2 reduction is the primary outcome of NOS activation, H4B promotes the generation of H2O2 at the expense of O-2(.-). The experiments were designed to test this hypothesis. To test this theory, two different enzyme preparations, H4B-bound NOS I and H4B-free NOS I, were used. Initial rates of NADPH turnover and O-2 utilization were found to be considerably greater in the H4B-bound NOS I preparation than in the H4B-free NOS I preparation. In contrast, the initial generation of O-2(.-) from the H4B-free NOS I preparation was found to be substantially greater than that measured using the H4B-bound NOS I preparation. Finally, by spin trapping nearly all of the NOS I produced O-2(.-) we found that the initial rate of H2O2 production by H4B-bound NOS I was considerably greater than that for H4B-free NOS I.	Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Khon Kaen Univ, Fac Pharmaceut Sci, Dept Toxicol, Khon Kaen 40002, Thailand; Univ Maryland Baltimore Cty, Dept Chem, Baltimore, MD 21250 USA; Univ Maryland, Sch Pharm, Ctr Low Frequency EPR In Vivo Physiol, Baltimore, MD 21201 USA; Univ Maryland, Inst Biotechnol, Ctr Med Biotechnol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University of Texas System; University of Texas Health San Antonio; Khon Kaen University; University System of Maryland; University of Maryland Baltimore County; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Rosen, GM (corresponding author), Univ Maryland, Sch Pharm, Dept Pharmaceut Sci, 725 W Lombard St, Baltimore, MD 21201 USA.	grosen@umaryland.edu	Starkov, Anatoly/B-2688-2012	Starkov, Anatoly/0000-0002-1334-4828; Weaver, John/0000-0003-3304-001X	NCRR NIH HHS [RR 12257] Funding Source: Medline; NIEHS NIH HHS [T32 ES 07263] Funding Source: Medline; NIGMS NIH HHS [R25 GM 55036, GM 52419] Funding Source: Medline; NINDS NIH HHS [NS 34152] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR012257] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007263] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM055036, R01GM052419] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034152] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; ASADA K, 1974, AGR BIOL CHEM TOKYO, V38, P471, DOI 10.1080/00021369.1974.10861178; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; BIELSKI BHJ, 1977, J PHYS CHEM-US, V81, P1048, DOI 10.1021/j100526a005; CHANCE B, 1952, ARCH BIOCHEM BIOPHYS, V41, P416, DOI 10.1016/0003-9861(52)90470-0; Crane BR, 1997, SCIENCE, V278, P425, DOI 10.1126/science.278.5337.425; Finkel T, 1999, J LEUKOCYTE BIOL, V65, P337, DOI 10.1002/jlb.65.3.337; FINKELSTEIN E, 1979, MOL PHARMACOL, V16, P676; FINKELSTEIN E, 1980, J AM CHEM SOC, V102, P4994, DOI 10.1021/ja00535a029; FREJAVILLE C, 1994, J CHEM SOC CHEM COMM, P1793, DOI 10.1039/c39940001793; Gorren ACF, 2000, BIOCHEMISTRY-US, V39, P11763, DOI 10.1021/bi0007775; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; KLATT P, 1994, J BIOL CHEM, V269, P13861; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KOPPENOL WH, 1976, BIOCHIM BIOPHYS ACTA, V449, P157, DOI 10.1016/0005-2728(76)90130-4; KUTHAN H, 1982, BIOCHEM J, V203, P551, DOI 10.1042/bj2030551; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; Mohanty JG, 1997, J IMMUNOL METHODS, V202, P133, DOI 10.1016/S0022-1759(96)00244-X; Nakamura K, 2001, J BIOL CHEM, V276, P34402, DOI 10.1074/jbc.M103766200; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Nishida CR, 1998, J BIOL CHEM, V273, P5566, DOI 10.1074/jbc.273.10.5566; POU S, 1992, J BIOL CHEM, V267, P24173; Pou S, 1999, J BIOL CHEM, V274, P9573, DOI 10.1074/jbc.274.14.9573; Presta A, 1998, J AM CHEM SOC, V120, P9460, DOI 10.1021/ja9740374; Presta A, 1998, BIOCHEMISTRY-US, V37, P298, DOI 10.1021/bi971944c; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Reif A, 1999, J BIOL CHEM, V274, P24921, DOI 10.1074/jbc.274.35.24921; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Roubaud V, 1997, ANAL BIOCHEM, V247, P404, DOI 10.1006/abio.1997.2067; TRUESDALE GA, 1954, NATURE, V173, P1236, DOI 10.1038/1731236a0; Tsai P, 1999, J CHEM SOC PERK T 2, P1759, DOI 10.1039/a901566c; Vasquez-Vivar J, 1998, P NATL ACAD SCI USA, V95, P9220, DOI 10.1073/pnas.95.16.9220; Vasquez-Vivar J, 1999, J BIOL CHEM, V274, P26736, DOI 10.1074/jbc.274.38.26736; Vasquez-Vivar J, 2001, FREE RADICAL BIO MED, V31, P975, DOI 10.1016/S0891-5849(01)00680-3; Weaver J, 2002, J PHARMACOL EXP THER, V302, P781, DOI 10.1124/jpet.102.035337; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; Wever RMF, 1997, BIOCHEM BIOPH RES CO, V237, P340, DOI 10.1006/bbrc.1997.7069; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; Yoneyama H, 2001, BIOCHEM J, V360, P247, DOI 10.1042/0264-6021:3600247; Zhao HT, 2001, FREE RADICAL BIO MED, V31, P599, DOI 10.1016/S0891-5849(01)00619-0; Zhou MJ, 1997, ANAL BIOCHEM, V253, P169, DOI 10.1006/abio.1997.2392; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	48	89	92	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40275	40280		10.1074/jbc.M200853200	http://dx.doi.org/10.1074/jbc.M200853200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183447	hybrid			2022-12-27	WOS:000178791400017
J	Isoyama, T; Kuge, S; Nomoto, A				Isoyama, T; Kuge, S; Nomoto, A			The core protein of hepatitis C virus is imported into the nucleus by transport receptor Kap123p but inhibits Kap121p-dependent nuclear import of yeast AP1-like transcription factor in yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT EMBRYO FIBROBLASTS; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; MEDIATED APOPTOSIS; NON-A; EXPORT; GENE; RNA; LOCALIZATION; GENOME	The core protein of hepatitis C virus (HCV) is a major component of the viral nucleocapsid. The HCV core protein includes nuclear localization signal-like sequences and has various effects on cellular metabolism, playing roles, for example, in the regulation of transcription, apoptosis, and transformation. To examine the possibility of an effect of the core protein on nucleocytoplasmic transport, we used the yeast Saccharomyces cerevisiae as a model system. The core protein (p23) is processed to p21 and is localized in both the cytoplasm and nucleus in yeast cells, similar to that observed in mammalian cells in several cases. The nuclear import of the core protein requires the activity of small GTPase Ran/Gsp1p and is mediated by Kap123p in yeast cells. When the core protein was expressed in yeast cells, the import of the yeast AP1-like transcription factor Yap1p into the nucleus was inhibited. Experiments in vitro involving Kap121p, also known as Pse1p, a receptor for the nuclear import of Yap1p, indicated that the amount of Yap1p bound to Kap121p was reduced in the presence of core protein. These results suggest that the HCV core protein affects cellular metabolism by disturbing transport of proteins to the nucleus.	Tohoku Univ, Lab Mol & Biochem Toxicol, Grad Sch Pharmaceut Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan; Univ Tokyo, Grad Sch Med, Dept Microbiol, Bunkyo Ku, Tokyo 1130033, Japan	Tohoku University; University of Tokyo	Kuge, S (corresponding author), Tohoku Univ, Lab Mol & Biochem Toxicol, Grad Sch Pharmaceut Sci, Aoba Ku, Aza Aoba, Sendai, Miyagi 9808578, Japan.	skuge@mail.pharm.tohoku.ac.jp						Aitchison JD, 1996, SCIENCE, V274, P624, DOI 10.1126/science.274.5287.624; Arts GJ, 1998, EMBO J, V17, P7430, DOI 10.1093/emboj/17.24.7430; AUSBEL I, 2000, CURRENT PROTOCOLS MO, V3; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; Chang J, 1998, J VIROL, V72, P3060, DOI 10.1128/JVI.72.4.3060-3065.1998; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; Ferrigno P, 1999, METHOD CELL BIOL, V58, P107; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; GRAKOUI A, 1993, J VIROL, V67, P1385, DOI 10.1128/JVI.67.3.1385-1395.1993; HIJIKATA M, 1993, P NATL ACAD SCI USA, V90, P10773, DOI 10.1073/pnas.90.22.10773; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Hussy P, 1996, VIROLOGY, V224, P93, DOI 10.1006/viro.1996.0510; Ikeda M, 2002, J VIROL, V76, P2997, DOI 10.1128/JVI.76.6.2997-3006.2002; Isoyama T, 1999, J GEN VIROL, V80, P2319, DOI 10.1099/0022-1317-80-9-2319; Isoyama T, 2001, J BIOL CHEM, V276, P21863, DOI 10.1074/jbc.M009258200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; Jakel S, 1998, EMBO J, V17, P4491, DOI 10.1093/emboj/17.15.4491; Jakel S, 2002, EMBO J, V21, P377, DOI 10.1093/emboj/21.3.377; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Kashiwakuma T, 1996, J IMMUNOL METHODS, V190, P79, DOI 10.1016/0022-1759(95)00261-8; KATO N, 1990, P NATL ACAD SCI USA, V87, P9524, DOI 10.1073/pnas.87.24.9524; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; Liu QY, 1997, J VIROL, V71, P657, DOI 10.1128/JVI.71.1.657-662.1997; LO SY, 1995, VIROLOGY, V213, P455, DOI 10.1006/viro.1995.0018; LOEB JDJ, 1995, P NATL ACAD SCI USA, V92, P7647, DOI 10.1073/pnas.92.17.7647; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; Moriya K, 2001, CANCER RES, V61, P4365; Naganuma A, 2000, J VIROL, V74, P8744, DOI 10.1128/JVI.74.18.8744-8750.2000; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Pemberton LF, 1998, CURR OPIN CELL BIOL, V10, P392, DOI 10.1016/S0955-0674(98)80016-1; Ray RB, 1996, VIROLOGY, V226, P176, DOI 10.1006/viro.1996.0644; RAY RB, 1995, VIRUS RES, V37, P209, DOI 10.1016/0168-1702(95)00034-N; Ray RB, 1998, J BIOL CHEM, V273, P2256, DOI 10.1074/jbc.273.4.2256; Ray RB, 1996, J VIROL, V70, P4438, DOI 10.1128/JVI.70.7.4438-4443.1996; Ray RB, 1997, J BIOL CHEM, V272, P10983; Ray RB, 2000, VIROLOGY, V271, P197, DOI 10.1006/viro.2000.0295; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Roberts PM, 1998, METHOD CELL BIOL, V53, P545; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Ruggieri A, 1997, VIROLOGY, V229, P68, DOI 10.1006/viro.1996.8420; Rullier A, 2001, MODERN PATHOL, V14, P496, DOI 10.1038/modpathol.3880338; Schlenstedt G, 1997, EMBO J, V16, P6237, DOI 10.1093/emboj/16.20.6237; Seedorf M, 1997, P NATL ACAD SCI USA, V94, P8590, DOI 10.1073/pnas.94.16.8590; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; Shimoike T, 1999, J VIROL, V73, P9718, DOI 10.1128/JVI.73.12.9718-9725.1999; Shiroki K, 1999, J VIROL, V73, P2193, DOI 10.1128/JVI.73.3.2193-2200.1999; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; SUZUKI R, 1995, J GEN VIROL, V76, P53, DOI 10.1099/0022-1317-76-1-53; TAKAMIZAWA A, 1991, J VIROL, V65, P1105, DOI 10.1128/JVI.65.3.1105-1113.1991; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wong DH, 1997, MOL CELL BIOL, V17, P3755, DOI 10.1128/MCB.17.7.3755; Wozniak RW, 1998, TRENDS CELL BIOL, V8, P184, DOI 10.1016/S0962-8924(98)01248-3; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	68	24	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39634	39641		10.1074/jbc.M203939200	http://dx.doi.org/10.1074/jbc.M203939200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167639	hybrid			2022-12-27	WOS:000178662500075
J	Ma, LL; Rudert, WA; Harnaha, J; Wright, M; Machen, J; Lakomy, R; Qian, SG; Lu, LN; Robbins, PD; Trucco, M; Giannoukakis, N				Ma, LL; Rudert, WA; Harnaha, J; Wright, M; Machen, J; Lakomy, R; Qian, SG; Lu, LN; Robbins, PD; Trucco, M; Giannoukakis, N			Immunosuppressive effects of glucosamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LINE; HEXOSAMINE BIOSYNTHESIS PATHWAY; INDUCED INSULIN-RESISTANCE; PROTEIN-KINASE-C; MHC CLASS-II+; GENE-EXPRESSION; DENDRITIC CELLS; O-GLCNAC; TYROSINE PHOSPHORYLATION; N-ACETYLGLUCOSAMINE	Glucosamine is a naturally occurring derivative of glucose and is an essential component of glycoproteins and proteoglycans, important constituents of many eukaryotic proteins. In cells, glucosamine is produced enzymatically by the amidation of glucose 6-phosphate and can then be further modified by acetylation to result in N-acetylglucosamine. Commercially, glucosamine is sold over-the-counter to relieve arthritis. Although there is evidence in favor of the beneficial effects of glucosamine, the mechanism is unknown. Our data demonstrate that glucosamine suppresses the activation of T-lymphoblasts and dendritic cells in vitro as well as allogeneic mixed leukocyte reactivity in a dose-dependent manner. There was no inherent cellular toxicity involved in the inhibition, and the activity was not reproducible with other amine sugars. More importantly, glucosamine administration prolonged allogeneic cardiac allograft survival in vivo. We conclude that, despite its documented effects on insulin sensitivity, glucosamine possesses immunosuppressive activity and could be beneficial as an immunosuppressive agent.	Univ Pittsburgh, Sch Med, Dept Pathol, Inst Diabet,Rangos Res Ctr 5102, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Surg, TE Starzl Transplantat Inst, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Mol Genet, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Biochem, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Inst Diabet, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Div Immunogenet, Dept Pediat, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Giannoukakis, N (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Inst Diabet,Rangos Res Ctr 5102, 3460 5th Ave, Pittsburgh, PA 15213 USA.							AUSSEL C, 1990, IMMUNOPHARMACOLOGY, V20, P97, DOI 10.1016/0162-3109(90)90012-4; BEKESI JG, 1970, CANCER RES, V30, P2905; BERTRAM J, 1981, THROMB RES, V23, P301, DOI 10.1016/0049-3848(81)90019-0; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOSMANN HB, 1971, BIOCHIM BIOPHYS ACTA, V240, P74, DOI 10.1016/0005-2787(71)90515-6; BOSMANN HB, 1972, BIOCHEM PHARMACOL, V21, P1977; CASSEL DL, 1983, CANCER RES, V43, P4582; Cavallo R, 1991, G Batteriol Virol Immunol, V84, P11; CHANG DM, 1995, IMMUNOPHARM IMMUNOT, V17, P437, DOI 10.3109/08923979509016380; Chen MG, 1997, MOL CELL ENDOCRINOL, V135, P67, DOI 10.1016/S0303-7207(97)00191-3; Ciaraldi TP, 1999, ENDOCRINOLOGY, V140, P3971, DOI 10.1210/en.140.9.3971; Comer FI, 1999, BBA-GEN SUBJECTS, V1473, P161, DOI 10.1016/S0304-4165(99)00176-2; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; DANIELS MC, 1993, MOL ENDOCRINOL, V7, P1041, DOI 10.1210/me.7.8.1041; Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222; FARE G, 1967, NATURE, V213, P308, DOI 10.1038/213308a0; FEUILLARD J, 1991, CYTOKINE, V3, P257, DOI 10.1016/1043-4666(91)90025-9; FJELDE A, 1956, EXP CELL RES, V10, P88, DOI 10.1016/0014-4827(56)90075-1; FRIEDMAN S J, 1977, Cancer Research, V37, P1141; FRIEDMAN SJ, 1977, CANCER RES, V37, P1068; FRIEDMAN SJ, 1980, P NATL ACAD SCI-BIOL, V77, P1172, DOI 10.1073/pnas.77.2.1172; Fu FM, 1996, TRANSPLANTATION, V62, P659, DOI 10.1097/00007890-199609150-00021; Gouze JN, 2002, FEBS LETT, V510, P166, DOI 10.1016/S0014-5793(01)03255-0; HART GW, 1995, ADV EXP MED BIOL, V376, P115; Hawkins M, 1997, J CLIN INVEST, V99, P2173, DOI 10.1172/JCI119390; Hirschowitz EA, 2000, GENE THER, V7, P1112, DOI 10.1038/sj.gt.3301210; Hresko RC, 1998, J BIOL CHEM, V273, P20658, DOI 10.1074/jbc.273.32.20658; IRAHARA M, 1987, IMMUNOBIOLOGY, V174, P190, DOI 10.1016/S0171-2985(87)80038-4; JIN YJ, 1990, J IMMUNOL, V144, P647; Kaneto H, 2001, J BIOL CHEM, V276, P31099, DOI 10.1074/jbc.M104115200; KORETZKY GA, 1992, J IMMUNOL, V149, P1138; Lanzavecchia A, 2001, CELL, V106, P263, DOI 10.1016/S0092-8674(01)00455-X; LEVINE BL, 1991, J IMMUNOL, V147, P3474; LEY SC, 1991, EUR J IMMUNOL, V21, P2203, DOI 10.1002/eji.1830210931; LI C, 1991, P NATL ACAD SCI USA, V88, P7739, DOI 10.1073/pnas.88.17.7739; Lippiello L, 2000, CLIN ORTHOP RELAT R, P229, DOI 10.1097/00003086-200012000-00027; Lu L, 1995, TRANSPLANTATION, V60, P1539, DOI 10.1097/00007890-199560120-00028; Lu LN, 1996, J IMMUNOL, V157, P3577; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; McAlindon TE, 2000, JAMA-J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469; McClain DA, 2000, ENDOCRINOLOGY, V141, P1999, DOI 10.1210/en.141.6.1999; MOLNAR Z, 1972, CANCER RES, V32, P380; MOLNAR Z, 1972, CANCER RES, V32, P756; Monauni T, 2000, DIABETES, V49, P926, DOI 10.2337/diabetes.49.6.926; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NG J, 1990, BIOCHIM BIOPHYS ACTA, V1053, P97, DOI 10.1016/0167-4889(90)90031-8; NORDMANN R, 1989, BIOCHEMISTRY-US, V28, P1791, DOI 10.1021/bi00430a055; ONEILL HC, 1988, IMMUNOLOGY, V64, P181; PAPADOGIANNAKIS N, 1989, EUR J IMMUNOL, V19, P1953, DOI 10.1002/eji.1830191029; Patti ME, 1999, DIABETES, V48, P1562, DOI 10.2337/diabetes.48.8.1562; PLAGEMANN PG, 1971, J CELL PHYSIOL, V77, P213, DOI 10.1002/jcp.1040770212; PLAGEMANN PG, 1971, J CELL PHYSIOL, V77, P241, DOI 10.1002/jcp.1040770213; PLAGEMANN PG, 1973, CANCER RES, V33, P482; QUASTEL JH, 1953, NATURE, V171, P252, DOI 10.1038/171252a0; Reginster JY, 2001, LANCET, V357, P251, DOI 10.1016/S0140-6736(00)03610-2; Rencurel F, 1996, BIOCHEM J, V314, P903, DOI 10.1042/bj3140903; Rescigno M, 2001, CELL, V106, P267, DOI 10.1016/S0092-8674(01)00454-8; ROBINSON KA, 1993, DIABETES, V42, P1333, DOI 10.2337/diabetes.42.9.1333; ROONEY JW, 1995, MOL CELL BIOL, V15, P6299; ROSSETTI L, 1995, J CLIN INVEST, V96, P132, DOI 10.1172/JCI118013; Rossetti L, 2000, ENDOCRINOLOGY, V141, P1922, DOI 10.1210/en.141.6.1922; Rovati LC, 1999, LANCET, V354, P1640, DOI 10.1016/S0140-6736(99)90195-2; RUBIN A, 1954, CANCER RES, V14, P456; SCHOLTISSEK C, 1972, BIOCHIM BIOPHYS ACTA, V277, P459, DOI 10.1016/0005-2787(72)90088-3; Shikhman AR, 2001, J IMMUNOL, V166, P5155, DOI 10.4049/jimmunol.166.8.5155; SOULA M, 1992, INT IMMUNOL, V4, P295, DOI 10.1093/intimm/4.2.295; TRAXINGER RR, 1992, J BIOL CHEM, V267, P9718; Uldry M, 2002, FEBS LETT, V524, P199, DOI 10.1016/S0014-5793(02)03058-2; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788; Virkamaki A, 1997, ENDOCRINOLOGY, V138, P2501, DOI 10.1210/en.138.6.2501; WILLIAMS TM, 1992, J IMMUNOL, V148, P2609; YAGITA M, 1989, CELL IMMUNOL, V122, P83, DOI 10.1016/0008-8749(89)90150-0; YAGITA M, 1993, CANCER RES, V53, P5600; YASEEN NR, 1994, MOL CELL BIOL, V14, P6886, DOI 10.1128/MCB.14.10.6886	75	78	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39343	39349		10.1074/jbc.M204924200	http://dx.doi.org/10.1074/jbc.M204924200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176986	hybrid			2022-12-27	WOS:000178662500038
J	van der Luit, AH; Budde, M; Ruurs, P; Verheij, M; van Blitterswijk, WJ				van der Luit, AH; Budde, M; Ruurs, P; Verheij, M; van Blitterswijk, WJ			Alkyl-lysophospholipid accumulates in lipid rafts and induces apoptosis via raft-dependent endocytosis and inhibition of phosphatidylcholine synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTP-PHOSPHOCHOLINE CYTIDYLYLTRANSFERASE; RADIATION-INDUCED APOPTOSIS; CANINE KIDNEY-CELLS; MEMBRANE FLUIDITY; PLASMA-MEMBRANE; CHOLERA-TOXIN; ETHER LIPIDS; A549 CELLS; INTERNALIZATION; TRANSPORT	The synthetic alkyl-lysophospholipid (ALP), 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, is an antitumor agent that acts on cell membranes and can induce apoptosis. We investigated how ALP is taken up by cells, how it affects de novo biosynthesis of phosphatidylcholine (PC), and how critical this is to initiate apoptosis. We compared an ALP-sensitive mouse lymphoma cell line, S49, with an ALP-resistant variant, S49(AR). ALP inhibited PC synthesis at the CTP:phosphocholine cytidylyltransferase (CT) step in S49 cells, but not in S49AR cells. Exogenous lysophosphatidylcholine, providing cells with an alternative way (acylation) to generate PC, rescued cells from ALP-induced apoptosis, indicating that continuous rapid PC turnover is essential for cell survival. Apoptosis induced by other stimuli that do not target PC synthesis remained unaffected by lysophosphatidylcholine. Using monensin, low temperature and albumin back-extraction, we demonstrated that ALP is internalized by endocytosis, a process defective in S49 AR cells. This defect neither involved clathrin-coated pitnor fluid-phase endocytosis, but depended on lipid rafts, because disruption of these microdomains with methyl-beta-cyclodextrin or filipin (sequestering cholesterol) or bacterial sphingomyelinase reduced uptake of ALP. Furthermore, ALP was found accumulated in isolated rafts and disruption of rafts also prevented the inhibition of PC synthesis and apoptosis induction in S49 cells. In summary, ALP is internalized by raft-dependent endocytosis to inhibit PC synthesis, which triggers apoptosis.	Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Dept Radiotherapy, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	van Blitterswijk, WJ (corresponding author), Netherlands Canc Inst, Div Cellular Biochem, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Verheij, Marcel/O-9652-2018					Baburina I, 1998, J BIOL CHEM, V273, P2169, DOI 10.1074/jbc.273.4.2169; Bankaitis VA, 2002, SCIENCE, V295, P290, DOI 10.1126/science.1068446; BAZILL GW, 1990, CANCER RES, V50, P7505; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOGGS KP, 1995, J BIOL CHEM, V270, P11612, DOI 10.1074/jbc.270.19.11612; Clement JM, 1999, BIOCHEM BIOPH RES CO, V257, P643, DOI 10.1006/bbrc.1999.0512; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; Gagescu R, 2000, MOL BIOL CELL, V11, P2775, DOI 10.1091/mbc.11.8.2775; Hao MM, 2000, J BIOL CHEM, V275, P15279, DOI 10.1074/jbc.275.20.15279; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Kabarowski JHS, 2001, SCIENCE, V293, P702, DOI 10.1126/science.1061781; KELLEY EE, 1993, BIOCHEM PHARMACOL, V45, P2435, DOI 10.1016/0006-2952(93)90224-K; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; Mattjus P, 1996, LANGMUIR, V12, P1284, DOI 10.1021/la950861z; McMaster CR, 2001, BIOCHEM CELL BIOL, V79, P681, DOI 10.1139/bcb-79-6-681; Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179; Mollinedo F, 1997, CANCER RES, V57, P1320; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; PAGANO RE, 1985, SCIENCE, V229, P1051, DOI 10.1126/science.4035344; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; POWIS G, 1992, CANCER RES, V52, P2835; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Rosenberger CM, 2000, CURR BIOL, V10, pR823, DOI 10.1016/S0960-9822(00)00788-0; Roth MG, 1999, TRENDS CELL BIOL, V9, P174, DOI 10.1016/S0962-8924(99)01535-4; Ruiter GA, 2001, INT J RADIAT ONCOL, V49, P415, DOI 10.1016/S0360-3016(00)01476-0; Ruiter GA, 1999, CANCER RES, V59, P2457; RUITER GA, 2002, IN PRESS INT J CANC; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Small GW, 1997, LIPIDS, V32, P715, DOI 10.1007/s11745-997-0091-3; Smets LA, 1999, APOPTOSIS, V4, P419, DOI 10.1023/A:1009644208512; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; Torgersen ML, 2001, J CELL SCI, V114, P3737; van Blitterswijk WJ, 2001, BIOCHEM SOC T, V29, P819; van Dijk MCM, 1998, CURR BIOL, V8, P386, DOI 10.1016/S0960-9822(98)70157-5; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VANBLITTERSWIJK WJ, 1987, LIPIDS, V22, P820, DOI 10.1007/BF02535537; VANBLITTERSWIJK WJ, 1987, BIOCHEMISTRY-US, V26, P1746, DOI 10.1021/bi00380a038; VANBLITTERSWIJK WJ, 1994, CURR TOP MEMBR, V40, P413, DOI 10.1016/S0070-2161(08)60990-9; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; Yen CLE, 1999, FASEB J, V13, P135, DOI 10.1096/fasebj.13.1.135; Yen CLE, 2001, FASEB J, V15, P1704, DOI 10.1096/fj.00-0800com; ZHOU X, 1995, EUR J BIOCHEM, V232, P881, DOI 10.1111/j.1432-1033.1995.881zz.x; ZOELLER RA, 1995, J LIPID RES, V36, P1866	54	145	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39541	39547		10.1074/jbc.M203176200	http://dx.doi.org/10.1074/jbc.M203176200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12183451	hybrid			2022-12-27	WOS:000178662500063
J	Ghatak, S; Misra, S; Toole, BP				Ghatak, S; Misra, S; Toole, BP			Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-CARCINOMA CELLS; PROTEIN-KINASE; SURFACE CD44; CANCER CELLS; IN-VIVO; MEDIATED TRANSFORMATION; EPITHELIAL-CELLS; BINDING; ACID; TUMORIGENICITY	Hyaluronan oligosaccharides (molecular weight: similar to2.5 x 10(3)) inhibit growth of several types of tumors in vivo. In vitro, the oligomers inhibit anchorage-independent growth of several tumor cell types. In accordance with this finding, the oligomers also induce apoptosis and stimulate caspase-3 activity under anchorage-independent conditions. Since inhibitors of phosphoinositide 3-kinase (PI 3-kinase) mimic the action of hyaluronan oligomers and since the PI 3-kinase/Akt (protein kinase B) cell survival pathway has previously been implicated in anchorage-independent growth of tumor cells, we examined the effect of oligomers on PI 3-kinase and its downstream activities in TA3/St murine mammary carcinoma and HCT 116 human colon carcinoma cells. We observed that 50-150 mug/ml hyaluronan oligomers inhibit PI 3-kinase activity and phosphorylation of Akt to approximately the same extent as optimal doses of wortmannin and LY294002, known inhibitors of PI, 3-kinase. Similar inhibition of downstream events, i.e. phosphorylation of BAD and FKHR, was also observed. These effects were not observed on treatment with similar concentrations of chitin oligomers, chondroitin sulfate, or hyaluronan polymer. High molecular weight (similar to2 x 10(6)) and low molecular weight (similar to8 x 10(4)) preparations of hyaluronan polymer were equally ineffective. The effects of hyaluronan oligomers on these parameters were similar in magnitude to the effect of treatment with activity-blocking antibody against CD44. We interpret these results to indicate that the oligomers competitively block binding of endogenous hyaluronan polymer to CD44, consequently giving rise to attenuated signaling. Finally, we observed that hyaluronan oligomers, but not chitin oligomers, chondroitin sulfate, or hyaluronan polymer, stimulate expression of PTEN, a phosphatase that degrades the major signaling product of PI 3-kinase action, phosphoinositide 3,4,5-trisphosphate. We conclude that perturbation of hyaluronan-CD44 binding leads to suppression of the PI 3-kinase/Akt cell survival pathway and consequently to inhibition of anchorage-independent growth in culture and tumor growth in vivo.	Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA	Tufts University	Toole, BP (corresponding author), Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA.				NATIONAL CANCER INSTITUTE [R01CA073839] Funding Source: NIH RePORTER; NCI NIH HHS [CA73839] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahrens T, 2001, ONCOGENE, V20, P3399, DOI 10.1038/sj.onc.1204435; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; BARTOLAZZI A, 1994, J EXP MED, V180, P53, DOI 10.1084/jem.180.1.53; BISWAS C, 1984, CANCER LETT, V24, P201, DOI 10.1016/0304-3835(84)90137-X; Bono P, 2001, MOL BIOL CELL, V12, P891, DOI 10.1091/mbc.12.4.891; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Fitzgerald KA, 2000, J IMMUNOL, V164, P2053, DOI 10.4049/jimmunol.164.4.2053; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; GUO YJ, 1994, CANCER RES, V54, P1561; Iida N, 1997, J CELL PHYSIOL, V171, P152, DOI 10.1002/(SICI)1097-4652(199705)171:2<152::AID-JCP5>3.3.CO;2-6; Itano N, 1999, CANCER RES, V59, P2499; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kaufmann SH, 2000, EXP CELL RES, V256, P42, DOI 10.1006/excr.2000.4838; Kincade PW, 1997, CURR OPIN CELL BIOL, V9, P635, DOI 10.1016/S0955-0674(97)80116-0; Kosaki R, 1999, CANCER RES, V59, P1141; Lesley J, 2000, J BIOL CHEM, V275, P26967; Li Y, 2001, BRIT J CANCER, V85, P600, DOI 10.1054/bjoc.2001.1922; Liu NF, 2001, CANCER RES, V61, P5207; Liu NF, 2001, CANCER RES, V61, P1022; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; MACPHERSON JN, 1969, J MED MICROBIOL, V2, P161, DOI 10.1099/00222615-2-2-161; MCGAHON AJ, 1995, METHOD CELL BIOL, V46, P153; Misra S, 1998, J BIOL CHEM, V273, P26638, DOI 10.1074/jbc.273.41.26638; Mohapatra S, 1996, J EXP MED, V183, P1663, DOI 10.1084/jem.183.4.1663; Moore SM, 1998, CANCER RES, V58, P5239; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nguyen KT, 2002, J BIOL CHEM, V277, P11107, DOI 10.1074/jbc.M108166200; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Parise LV, 2000, SEMIN CANCER BIOL, V10, P407, DOI 10.1006/scbi.2000.0337; Peterson RM, 2000, AM J PATHOL, V156, P2159, DOI 10.1016/S0002-9440(10)65086-9; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; Sheng HM, 2001, J BIOL CHEM, V276, P14498, DOI 10.1074/jbc.M010093200; Sleeman JP, 1996, CANCER RES, V56, P3134; Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; SUSA M, 1992, J BIOL CHEM, V267, P22951; Takahashi K, 1995, ONCOGENE, V11, P2223; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Tolkacheva T, 2000, ONCOGENE, V19, P680, DOI 10.1038/sj.onc.1203331; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Toole BP, 2002, J BIOL CHEM, V277, P4593, DOI 10.1074/jbc.R100039200; TOOLE BP, 2000, PROTEOGLYCANS STRUCT, P61; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; UNDERHILL CB, 1983, J BIOL CHEM, V258, P8086; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Yeo TK, 1996, AM J PATHOL, V148, P1733; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yoshida M, 2000, J BIOL CHEM, V275, P497, DOI 10.1074/jbc.275.1.497; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Zeng CX, 1998, INT J CANCER, V77, P396; Zohar R, 2000, J CELL PHYSIOL, V184, P118, DOI 10.1002/(SICI)1097-4652(200007)184:1<118::AID-JCP13>3.3.CO;2-P	58	286	302	2	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38013	38020		10.1074/jbc.M202404200	http://dx.doi.org/10.1074/jbc.M202404200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145277	hybrid			2022-12-27	WOS:000178529600007
J	Zaremberg, V; McMaster, CR				Zaremberg, V; McMaster, CR			Differential partitioning of lipids metabolized by separate yeast glycerol-3-phosphate acyltransferases reveals that phospholipase D generation of phosphatidic acid mediates sensitivity to choline-containing lysolipids and drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLCHOLINE BIOSYNTHESIS; DIHYDROXYACETONE PHOSPHATE; HORMONAL-REGULATION; GENE; SYNTHASE; ENZYMES; CLONING; CHOLINEPHOSPHOTRANSFERASE; PATHWAY	In this study we demonstrate that the GAT1 and GAT2 genes encode the major glycerol-3-phosphate acyltransferase activities in Saccharomyces cerevisiae. Genetic inactivation of either GAT1 or GAT2 did not alter cell growth but inactivation of both resulted in growth cessation. Metabolic analyses of gat1 and gat2 yeast detected that the major differences were: (i) a 50% increase in the rate of triacylglycerol synthesis in gat1 yeast and a corresponding 50% decrease in gat2 yeast, and (ii) a 5-fold increase in glycerophosphocholine production through deacylation of phosphatidylcholine synthesized through the CDP-choline pathway in gat1 yeast, whereas gat2 yeast displayed a 10-fold decrease. To address why we observed alterations in phospholipid turnover specific to phosphatidylcholine produced through the CDP-choline pathway in gat1 and gat2 yeast we tested their sensitivity to various cytotoxic lysolipids and observed that gat2 cells were more sensitive to lysophosphatidylcholine, but not other lysolipids. To pursue the mechanism we analyzed their sensitivity to choline-containing lysolipids or drugs that could not be deacylated and/or reacylated. Our data showed that gat1 and gat2 yeast were resistant and sensitive to lysoplatelet activating factor, platelet activating factor, and the anti-tumor lipid edelfosine, respectively, indicating that their sensitivity to these compounds was not because of differences in rates of phosphatidylcholine deacylation. As growth of gat2 cells was impaired in the presence of ethanol, a phospholipase D (Spo14p) inhibitor, we inferred that phospholipase D may play important biologic and metabolic roles in phenotypes observed in gat yeast. Genetic inactivation of the SPO14 gene resulted in increased susceptibility, whereas expression of Escherichia coli diacylglycerol kinase relieved growth inhibition, to choline-containing lysolipids and drugs. Our results are consistent with a model whereby phosphatidic acid generated from phosphatidylcholine hydrolysis by Spo14p regulates susceptibility to choline-containing lysolipid analogs and drugs.	Dalhousie Univ, IWK Hlth Ctr, Dept Pediat, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada; Dalhousie Univ, IWK Hlth Ctr, Dept Biochem & Mol Biol, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada	Dalhousie University; Dalhousie University	McMaster, CR (corresponding author), Dalhousie Univ, IWK Hlth Ctr, Dept Pediat, Atlantic Res Ctr, Halifax, NS B3H 4H7, Canada.	cmcmaste@is.dal.ca		McMaster, Christopher/0000-0003-0822-5776				AMES BN, 1960, J BIOL CHEM, V235, P769; Athenstaedt K, 1999, J BACTERIOL, V181, P1458, DOI 10.1128/JB.181.5.1458-1463.1999; Athenstaedt K, 2000, J BIOL CHEM, V275, P235, DOI 10.1074/jbc.275.1.235; BAELEE MS, 1984, J BIOL CHEM, V259, P857; Birner R, 2001, MOL BIOL CELL, V12, P997, DOI 10.1091/mbc.12.4.997; Buhman KK, 2001, J BIOL CHEM, V276, P40369, DOI 10.1074/jbc.R100050200; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; de Vet ECJM, 2000, J BIOL CHEM, V275, P6276, DOI 10.1074/jbc.275.9.6276; Dircks LK, 1999, J BIOL CHEM, V274, P34728, DOI 10.1074/jbc.274.49.34728; Dowd SR, 2001, J BIOL CHEM, V276, P3756, DOI 10.1074/jbc.M003694200; Farese RV, 2000, CURR OPIN LIPIDOL, V11, P229, DOI 10.1097/00041433-200006000-00002; Fyrst H, 1999, BIOCHEMISTRY-US, V38, P5864, DOI 10.1021/bi9824590; Gonzalez-Baro MR, 2001, J BIOL CHEM, V276, P43182, DOI 10.1074/jbc.M107885200; Henneberry AL, 1999, BIOCHEM J, V339, P291, DOI 10.1042/0264-6021:3390291; Henneberry AL, 2000, J BIOL CHEM, V275, P29808, DOI 10.1074/jbc.M005786200; Henneberry AL, 2001, MOL BIOL CELL, V12, P511, DOI 10.1091/mbc.12.3.511; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P4357; Igal RA, 2001, J BIOL CHEM, V276, P42205, DOI 10.1074/jbc.M103386200; Kaiser C., 1994, METHODS YEAST GENETI; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; LEE KS, 1994, J BIOL CHEM, V269, P19725; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUSHITA M, 1995, J BIOCHEM-TOKYO, V117, P447, DOI 10.1093/jb/117.2.447; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; Merkel O, 1999, J BIOL CHEM, V274, P28121, DOI 10.1074/jbc.274.40.28121; Mishra S, 2001, BIOCHEM J, V355, P315, DOI 10.1042/0264-6021:3550315; Murakami M, 2000, BBA-MOL CELL BIOL L, V1488, P159, DOI 10.1016/S1388-1981(00)00118-9; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; Oelkers P, 2000, J BIOL CHEM, V275, P15609, DOI 10.1074/jbc.C000144200; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PAULAUSKIS JD, 1988, J BIOL CHEM, V263, P7049; PREISS J, 1986, J BIOL CHEM, V261, P8597; Richard MG, 1998, LIPIDS, V33, P1229, DOI 10.1007/s11745-998-0328-1; Rudge SA, 1998, J CELL BIOL, V140, P81, DOI 10.1083/jcb.140.1.81; Sambrook J., 2001, MOL CLONING LAB MANU; Shen HF, 1997, J BIOL CHEM, V272, P11215; Sul HS, 1998, ANNU REV NUTR, V18, P331, DOI 10.1146/annurev.nutr.18.1.331; TILLMAN TS, 1986, J BIOL CHEM, V261, P9144; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Williams JG, 1998, J BIOL CHEM, V273, P13482, DOI 10.1074/jbc.273.22.13482; Zheng ZF, 2001, J BIOL CHEM, V276, P41710, DOI 10.1074/jbc.M104749200	42	61	63	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					39035	39044		10.1074/jbc.M207753200	http://dx.doi.org/10.1074/jbc.M207753200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167660	hybrid			2022-12-27	WOS:000178529600128
J	Kimura, Y; Koitabashi, S; Kakizuka, A; Fujita, T				Kimura, Y; Koitabashi, S; Kakizuka, A; Fujita, T			Circumvention of chaperone requirement for aggregate formation of a short polyglutamine tract by the co-expression of a long polyglutamine tract	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING PROTEIN; EXPANDED POLYGLUTAMINE; HUNTINGTONS-DISEASE; IN-VITRO; NEURODEGENERATIVE DISEASES; CAENORHABDITIS-ELEGANS; GLUTAMINE REPEATS; CELL-DEATH; TRANSCRIPTION; VIVO	Polyglutamine disease is now recognized as one of the conformational, amyloid-related diseases. In this disease, polyglutamine expansion in proteins has toxic effects on cells and also results in the formation of aggregates. Polyglutamine aggregate formation is accompanied by conversion of the polyglutamine from a soluble to an insoluble form. In yeast, the efficiency of the aggregate formation is determined by the balance of various parameters, including the length of the polyglutamine tract, the function of Hsp104, and the level of polyglutamine, expression. In this study, we found that the co-expression of a long polyglutamine tract, which formed aggregates independently of the function of Hsp104, enhanced the formation of aggregates of a short polyglutamine tract in wild-type cells as well as in Deltahsp104 mutant cells. Thus, the expression of a long polyglutamine tract would be an additional parameter determining the efficiency of aggregate formation of a short polyglutamine tract. The co-localization of aggregates of long and short polyglutamine tracts suggests the possibility that the enhancement occurs due to the seeding of aggregates of the long polyglutamine tracts.	Tokyo Metropolitan Inst Med Sci, Dept Tumor Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; Kyoto Univ, Dept Funct Biol, Gard Sch Biostudies, Kyoto 6068501, Japan	Tokyo Metropolitan Institute of Medical Science; Kyoto University	Kimura, Y (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Tumor Cell Biol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	ykimura@rinshoken.or.jp	Kimura, Yoko/E-6845-2013	Kimura, Yoko/0000-0002-3054-9753				Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Derkatch IL, 2001, CELL, V106, P171, DOI 10.1016/S0092-8674(01)00427-5; Faber PW, 1999, P NATL ACAD SCI USA, V96, P179, DOI 10.1073/pnas.96.1.179; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Higashiyama H, 2002, CELL DEATH DIFFER, V9, P264, DOI 10.1038/sj.cdd.4400955; Hirabayashi M, 2001, CELL DEATH DIFFER, V8, P977, DOI 10.1038/sj.cdd.4400907; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Jackson GR, 1998, NEURON, V21, P633, DOI 10.1016/S0896-6273(00)80573-5; Kakizuka A, 1998, TRENDS GENET, V14, P396, DOI 10.1016/S0168-9525(98)01559-5; Kazantsev A, 1999, P NATL ACAD SCI USA, V96, P11404, DOI 10.1073/pnas.96.20.11404; Kimura Y, 2001, GENES CELLS, V6, P887, DOI 10.1046/j.1365-2443.2001.00472.x; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Kushnirov VV, 1998, CELL, V94, P13, DOI 10.1016/S0092-8674(00)81216-7; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Nakamura K, 2001, HUM MOL GENET, V10, P1441, DOI 10.1093/hmg/10.14.1441; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Osherovich LZ, 2001, CELL, V106, P183, DOI 10.1016/S0092-8674(01)00440-8; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Perutz MF, 2001, NATURE, V412, P143, DOI 10.1038/35084141; Robinson NCG, 1999, MOL CELL BIOL, V19, P3580; Satyal SH, 2000, P NATL ACAD SCI USA, V97, P5750, DOI 10.1073/pnas.100107297; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Shimohata T, 2000, NAT GENET, V26, P29, DOI 10.1038/79139; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; Warrick JM, 1998, CELL, V93, P939, DOI 10.1016/S0092-8674(00)81200-3; Westermark GT, 1999, METHOD ENZYMOL, V309, P3	30	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37536	37541		10.1074/jbc.M201721200	http://dx.doi.org/10.1074/jbc.M201721200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12161426	hybrid			2022-12-27	WOS:000178447100080
J	Zayzafoon, M; Botolin, S; McCabe, LR				Zayzafoon, M; Botolin, S; McCabe, LR			p38 and activating transcription factor-2 involvement in osteoblast osmotic response to elevated extracellular glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-ALPHA-1(I) COLLAGEN GENE; DNA-BINDING ACTIVITY; MAP KINASE PATHWAY; PROTEIN-KINASE; C-JUN; DIABETES-MELLITUS; BONE MASS; TYROSINE PHOSPHORYLATION; MINERAL METABOLISM; INDUCED INHIBITION	Poorly controlled or untreated type I diabetes mellitus is characterized by hyperglycemia and is associated with decreased bone mass and osteoporosis. We have demonstrated that osteoblasts are sensitive to hyperglycemia-associated osmotic stress and respond to elevated extracellular glucose or mannitol by increasing c-jun and collagen I expression. To determine whether MAPKs are involved in this response, MC3T3-E1 osteoblasts were treated with 16.5 mm glucose, mannitol, or contrast dye for 1 h. Immunoblotting of phosphorylated p38 demonstrated activation of p38 MAPK by hyperosmotic stress in vitro and in vivo. Activation peaked at 20 min, remained detectable after 24 h, and was protein kinase C-independent. Activating transcription factor-2 (ATF-2) activation followed the same pattern as phospho-p38. Transactivation of cAMP response element (CRE)- and c-jun promoter (containing a CRE-like element)-reporter constructs increased following hyperosmotic treatment. SB 203580 (a p38 MAPK inhibitor) blocked ATF-2 phosphorylation, CRE transactivation, and c-jun promoter activation. Hyperosmotic activation of collagen I promoter activity was also inhibited by SB 203580, consistent with the involvement of c-jun in collagen I up-regulation. Therefore, we propose that hyperglycemia-induced increases in p38 MAPK activity and ATF-2 phosphorylation contribute to CRE activation and modulation of c-jun and collagen I expression in osteoblasts.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA	Michigan State University	McCabe, LR (corresponding author), Michigan State Univ, Dept Physiol, 2201 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.			McCabe, Laura/0000-0001-5407-162X				ABDELHAFIZ HA, 1992, MOL ENDOCRINOL, V6, P2079, DOI 10.1210/me.6.12.2079; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; AUWERX J, 1988, DIABETES, V37, P8, DOI 10.2337/diabetes.37.1.8; Balint E, 2001, BONE, V28, P21, DOI 10.1016/S8756-3282(00)00426-9; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BOUILLON R, 1991, CALCIFIED TISSUE INT, V49, P155, DOI 10.1007/BF02556109; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BREWSTER JL, 1994, YEAST, V10, P425, DOI 10.1002/yea.320100402; BROWNLEE M, 1984, ANN INTERN MED, V101, P527, DOI 10.7326/0003-4819-101-4-527; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Dunstan CR, 1999, J BONE MINER RES, V14, P953, DOI 10.1359/jbmr.1999.14.6.953; Duzgun SA, 2000, J CELL BIOCHEM, V76, P567, DOI 10.1002/(SICI)1097-4644(20000315)76:4<567::AID-JCB5>3.0.CO;2-W; Emancipator K, 1999, AM J CLIN PATHOL, V112, P665; Fuchs SY, 1999, MOL CELL BIOL, V19, P3289; Fuchs SY, 1996, ONCOGENE, V13, P1531; Fujimoto R, 1999, J BONE MINER METAB, V17, P11, DOI 10.1007/s007740050057; GRINSTEIN S, 1986, J CELL PHYSIOL, V128, P33, DOI 10.1002/jcp.1041280107; Hipskind Robert A., 1998, Frontiers in Bioscience, V3, pD804; Hoffert JD, 2000, J BIOL CHEM, V275, P9070, DOI 10.1074/jbc.275.12.9070; Hu YH, 2000, J MED CHEM, V43, P3045, DOI 10.1021/jm000117y; HUI SL, 1985, J CLIN ENDOCR METAB, V60, P74, DOI 10.1210/jcem-60-1-74; Igarashi M, 1999, J CLIN INVEST, V103, P185, DOI 10.1172/JCI3326; Ishida T, 1999, DIABETES, V48, P595, DOI 10.2337/diabetes.48.3.595; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; KATAI H, 1992, MOL CELL BIOCHEM, V118, P119; Kemink SAG, 2000, J ENDOCRINOL INVEST, V23, P295, DOI 10.1007/BF03343726; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; KRAKAUER JC, 1995, DIABETES, V44, P775, DOI 10.2337/diabetes.44.7.775; KWON HM, 1992, J BIOL CHEM, V267, P6297; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Lee HW, 1998, J MOL CELL CARDIOL, V30, P2495, DOI 10.1006/jmcc.1998.0811; LEVIN ME, 1976, NEW ENGL J MED, V294, P241, DOI 10.1056/NEJM197601292940502; Lewis A, 2002, AM J PHYSIOL-CELL PH, V282, pC271, DOI 10.1152/ajpcell.00427.2001; Ling ZD, 1996, DIABETES, V45, P1774, DOI 10.2337/diabetes.45.12.1774; Lytle C, 1996, AM J PHYSIOL-CELL PH, V270, pC437, DOI 10.1152/ajpcell.1996.270.2.C437; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; McCauley LK, 2001, ENDOCRINOLOGY, V142, P1975, DOI 10.1210/en.142.5.1975; MEYER HE, 1993, AM J EPIDEMIOL, V137, P1203, DOI 10.1093/oxfordjournals.aje.a116622; MOROOKA H, 1995, J BIOL CHEM, V270, P30084; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Obata T, 2000, CRIT CARE MED, V28, pN67, DOI 10.1097/00003246-200004001-00008; ODONNELL ME, 1995, AM J PHYSIOL-CELL PH, V268, pC1067, DOI 10.1152/ajpcell.1995.268.4.C1067; ODONNELL ME, 1993, AM J PHYSIOL, V264, pC1316, DOI 10.1152/ajpcell.1993.264.5.C1316; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; Park CW, 2000, DIABETOLOGIA, V43, P1544, DOI 10.1007/s001250051567; PARKER JC, 1993, AM J PHYSIOL, V265, pC1191, DOI 10.1152/ajpcell.1993.265.5.C1191; Piepkorn B, 1997, HORM METAB RES, V29, P584, DOI 10.1055/s-2007-979106; QUARLES LD, 1992, J BONE MINER RES, V7, P683; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rizoli SB, 2000, AM J PHYSIOL-CELL PH, V279, pC619, DOI 10.1152/ajpcell.2000.279.3.C619; Roger F, 1999, J BIOL CHEM, V274, P34103, DOI 10.1074/jbc.274.48.34103; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; SASAKI T, 1991, ANAT REC, V231, P25, DOI 10.1002/ar.1092310105; Schaffler A, 2000, EUR J CLIN INVEST, V30, P586; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; Shimizu M, 1998, EXP CELL RES, V239, P93, DOI 10.1006/excr.1997.3884; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Takekawa M, 1997, EMBO J, V16, P4973, DOI 10.1093/emboj/16.16.4973; Tsai EY, 1996, MOL CELL BIOL, V16, P459; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Vergeer WP, 2000, ARCH BIOCHEM BIOPHYS, V377, P69, DOI 10.1006/abbi.2000.1760; VERHAEGHE J, 1990, DIABETES, V39, P477, DOI 10.2337/diabetes.39.4.477; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Watts BA, 1998, AM J PHYSIOL-RENAL, V275, pF478, DOI 10.1152/ajprenal.1998.275.4.F478; WILHELM D, 1995, IMMUNOBIOLOGY, V193, P143, DOI 10.1016/S0171-2985(11)80537-1; Zayzafoon M, 2000, J CELL BIOCHEM, V79, P301, DOI 10.1002/1097-4644(20001101)79:2<301::AID-JCB130>3.0.CO;2-0; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103	73	44	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37212	37218		10.1074/jbc.M200129200	http://dx.doi.org/10.1074/jbc.M200129200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149242	hybrid			2022-12-27	WOS:000178447100041
J	Gohler, T; Reimann, M; Cherny, D; Walter, K; Warnecke, G; Kim, E; Deppert, W				Gohler, T; Reimann, M; Cherny, D; Walter, K; Warnecke, G; Kim, E; Deppert, W			Specific interaction of p53 with target binding sites is determined by DNA conformation and is regulated by the C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P53; HUMAN ENKEPHALIN ENHANCER; CRUCIFORM DNA; TRANSCRIPTIONAL ACTIVATION; WILD-TYPE; PROTEIN; GENE; PROMOTER; APOPTOSIS; TRANSACTIVATION	Transcriptional activation of p53-regulated genes is initiated by sequence-specific DNA binding of p53 to target binding sites. Regulation of sequence-specific DNA binding is complex and occurs at various levels. We demonstrate that DNA topology is an important parameter for regulating the selective and highly specific interaction of p53 with its target binding sites. Specific binding of wild-type p53 is greatly enhanced when cognate binding sites are present in a non-linear stem-loop conformation. The C-terminal domain plays a key role in regulating the specific interactions of p53 with target binding sites in a DNA conformation-dependent manner. The C-terminal domain is required for binding to target sites in a non-linear DNA conformation in contrast to the strong inhibitory effects of the C terminus on p53 interaction with linear DNA. We propose that selective binding of p53 to various promoters may be determined by the DNA conformation within p53 cognate sites.	Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Max Planck Inst Biophys Chem, D-37077 Gottingen, Germany; Russian Acad Sci, Inst Mol Genet, Moscow 123182, Russia	Heinrich Pette Institute; University of Hamburg; Max Planck Society; Russian Academy of Sciences	Kim, E (corresponding author), Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, Martinistr 52, D-20251 Hamburg, Germany.							Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; BAKALKIN G, 1995, NUCLEIC ACIDS RES, V23, P362, DOI 10.1093/nar/23.3.362; BELL D, 1991, BIOCHIM BIOPHYS ACTA, V1089, P299, DOI 10.1016/0167-4781(91)90169-M; Bessard ACH, 1998, ONCOGENE, V16, P883, DOI 10.1038/sj.onc.1201598; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Cain C, 2000, J BIOL CHEM, V275, P39944, DOI 10.1074/jbc.M002509200; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cohen SM, 2000, BIOCHEMISTRY-US, V39, P11771, DOI 10.1021/bi001352l; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Cowell IG, 2000, EXP CELL RES, V255, P86, DOI 10.1006/excr.1999.4772; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; DEB SP, 1994, ONCOGENE, V9, P1341; Degtyareva N, 2001, J BIOL CHEM, V276, P8778, DOI 10.1074/jbc.M006795200; Deguin-Chambon V, 2000, ONCOGENE, V19, P5831, DOI 10.1038/sj.onc.1203960; DEMCZUK S, 1993, P NATL ACAD SCI USA, V90, P2574, DOI 10.1073/pnas.90.7.2574; DUBOCHET J, 1971, J ULTRA MOL STRUCT R, V35, P147, DOI 10.1016/S0022-5320(71)80148-X; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elkeles A, 1999, MOL CELL BIOL, V19, P2594; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; GACY AM, 1994, BIOCHEMISTRY-US, V33, P11951, DOI 10.1021/bi00205a034; Gobert C, 1999, P NATL ACAD SCI USA, V96, P10355, DOI 10.1073/pnas.96.18.10355; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; Hecker D, 1996, ONCOGENE, V12, P953; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Hussain SP, 1999, MUTAT RES-FUND MOL M, V428, P23, DOI 10.1016/S1383-5742(99)00028-9; Jackson P, 1998, ONCOGENE, V16, P283, DOI 10.1038/sj.onc.1201491; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; JUVEN T, 1993, ONCOGENE, V8, P3411; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Komiya T, 1999, ANTICANCER RES, V19, P4315; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; MIYASHITA T, 1995, CELL, V80, P293; Morris GF, 1996, P NATL ACAD SCI USA, V93, P895, DOI 10.1073/pnas.93.2.895; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Napierala M, 2002, J BIOL CHEM, V277, P34087, DOI 10.1074/jbc.M202128200; Novac O, 2002, J BIOL CHEM, V277, P11174, DOI 10.1074/jbc.M107902200; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Palecek E, 1997, ONCOGENE, V15, P2201, DOI 10.1038/sj.onc.1201398; Pearson CE, 1996, J CELL BIOCHEM, V63, P1; PEARSON CE, 1995, EMBO J, V14, P1571, DOI 10.1002/j.1460-2075.1995.tb07143.x; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Pluciennik A, 2000, J BIOL CHEM, V275, P28386, DOI 10.1074/jbc.M000154200; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Scherer SJ, 1996, BIOCHEM BIOPH RES CO, V221, P722, DOI 10.1006/bbrc.1996.0663; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SPIRO C, 1993, P NATL ACAD SCI USA, V90, P4606, DOI 10.1073/pnas.90.10.4606; Szak ST, 1999, J BIOL CHEM, V274, P3904, DOI 10.1074/jbc.274.6.3904; Urano T, 1997, CANCER RES, V57, P3281; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; Velasco-Miguel S, 1999, ONCOGENE, V18, P127, DOI 10.1038/sj.onc.1202274; Waga S., 1990, NUCL ACIDS S SER, V22, P81; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WARD GK, 1991, EXP CELL RES, V195, P92, DOI 10.1016/0014-4827(91)90503-M; WARD GK, 1990, EXP CELL RES, V188, P235, DOI 10.1016/0014-4827(90)90165-7; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; ZANNISHADJOPOULOS M, 1988, EMBO J, V7, P1837, DOI 10.1002/j.1460-2075.1988.tb03016.x; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000	70	64	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41192	41203		10.1074/jbc.M202344200	http://dx.doi.org/10.1074/jbc.M202344200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171916	Green Published, hybrid			2022-12-27	WOS:000178791400130
J	Taneja, P; Gu, JM; Peng, R; Carrick, R; Uchiumi, F; Ott, RD; Gustafson, E; Podust, VN; Fanning, E				Taneja, P; Gu, JM; Peng, R; Carrick, R; Uchiumi, F; Ott, RD; Gustafson, E; Podust, VN; Fanning, E			A dominant-negative mutant of human DNA helicase B blocks the onset of chromosomal DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-ALPHA-PRIMASE; SV40 T-ANTIGEN; LARGE TUMOR-ANTIGEN; MOUSE FM3A CELLS; DEPENDENT ADENOSINETRIPHOSPHATASE-B; SINGLE-STRANDED-DNA; PROTEIN-A; BINDING-SITE; RECOMBINATION; SUBUNIT	A cDNA encoding a human ortholog of mouse DNA helicase B, which may play a role in DNA replication, has been cloned and expressed as a recombinant protein. The predicted human DNA helicase B (HDHB) protein contains conserved helicase motifs (superfamily 1) that are strikingly similar to those of bacterial recD and T4 dda proteins. The HDHB gene is expressed at low levels in liver, spleen, kidney, and brain and at higher levels in testis and thymus. Purified recombinant HDHB hydrolyzed ATP and dATP in the presence of single-stranded DNA, displayed robust 5'-3' DNA helicase activity, and interacted physically and functionally with DNA polymerase alpha-primase. HDHB proteins with mutations in the Walker A or B motif lacked ATPase and helicase activity but retained the ability to interact with DNA polymerase alpha-primase, suggesting that the mutants might be dominant over endogenous HDHB in human cells. When purified HDHB protein was microinjected into the nucleus of cells in early G(1), the mutant proteins inhibited DNA synthesis, whereas the wild type protein had no effect. Injection of wild type or mutant protein into cells at G(1)/S did not prevent DNA synthesis. The results suggest that HDHB function is required for S phase entry.	Vanderbilt Univ, Dept Sci Biol, Nashville, TN 37235 USA; Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN 37235 USA	Vanderbilt University; Vanderbilt University	Fanning, E (corresponding author), Vanderbilt Univ, Dept Sci Biol, VU Stn B 351634, Nashville, TN 37235 USA.				NATIONAL CANCER INSTITUTE [P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052948] Funding Source: NIH RePORTER; NCI NIH HHS [CA 68485] Funding Source: Medline; NIGMS NIH HHS [GM 52948] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amundsen SK, 2000, P NATL ACAD SCI USA, V97, P7399, DOI 10.1073/pnas.130192397; BARRY J, 1994, J BIOL CHEM, V269, P33063; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; CARSON MJ, 1985, CELL, V42, P249, DOI 10.1016/S0092-8674(85)80120-3; Chedin F, 2002, MOL MICROBIOL, V43, P823, DOI 10.1046/j.1365-2958.2002.02785.x; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COLLINS KL, 1993, EMBO J, V12, P4555, DOI 10.1002/j.1460-2075.1993.tb06144.x; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; DORNREITER I, 1990, EMBO J, V9, P3329, DOI 10.1002/j.1460-2075.1990.tb07533.x; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DORNREITER I, 1993, MOL CELL BIOL, V13, P809, DOI 10.1128/MCB.13.2.809; EKI T, 1990, J BIOL CHEM, V265, P26; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Foiani M, 1997, TRENDS BIOCHEM SCI, V22, P424; GEORGE JW, 1994, J MOL BIOL, V235, P424, DOI 10.1006/jmbi.1994.1003; GOETZ GS, 1988, J BIOL CHEM, V263, P383; GORBALENYA AE, 1993, CURR OPIN STRUC BIOL, V3, P419, DOI 10.1016/S0959-440X(05)80116-2; HACKER KJ, 1992, J BIOL CHEM, V267, P20674; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Herbig U, 1999, MOL BIOL CELL, V10, P2631, DOI 10.1091/mbc.10.8.2631; Holmes AM, 1999, CELL, V96, P415, DOI 10.1016/S0092-8674(00)80554-1; Huang SG, 1998, BIOCHEMISTRY-US, V37, P15345, DOI 10.1021/bi9810959; Kreuzer KN, 2000, TRENDS BIOCHEM SCI, V25, P165, DOI 10.1016/S0968-0004(00)01559-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; Marintcheva B, 2001, PROG NUCLEIC ACID RE, V70, P77, DOI 10.1016/S0079-6603(01)70014-1; MATSUMOTO K, 1995, BIOCHEMISTRY-US, V34, P7913, DOI 10.1021/bi00024a016; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; MELENDY T, 1993, J BIOL CHEM, V268, P3389; Mosig G, 1998, ANNU REV GENET, V32, P379, DOI 10.1146/annurev.genet.32.1.379; Ott RD, 2002, J VIROL, V76, P5121, DOI 10.1128/JVI.76.10.5121-5130.2002; Ott RD, 2002, MOL CELL BIOL, V22, P5669, DOI 10.1128/MCB.22.16.5669-5678.2002; Qi HY, 2000, GENE DEV, V14, P1777; SAITOH A, 1995, NUCLEIC ACIDS RES, V23, P2014, DOI 10.1093/nar/23.11.2014; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKI M, 1986, BIOCHEMISTRY-US, V25, P3239, DOI 10.1021/bi00359a024; SEKI M, 1995, MOL CELL BIOL, V15, P165, DOI 10.1128/MCB.15.1.165; SEKI M, 1987, BIOCHEMISTRY-US, V26, P2924, DOI 10.1021/bi00384a038; SEKI M, 1988, BIOCHEMISTRY-US, V27, P1766, DOI 10.1021/bi00405a057; Shiratori A, 1999, YEAST, V15, P219, DOI 10.1002/(SICI)1097-0061(199902)15:3<219::AID-YEA349>3.3.CO;2-V; Singleton MR, 2002, J BACTERIOL, V184, P1819, DOI 10.1128/JB.184.7.1819-1826.2002; Soultanas P, 2001, TRENDS BIOCHEM SCI, V26, P47, DOI 10.1016/S0968-0004(00)01734-5; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; Tada S, 2001, NUCLEIC ACIDS RES, V29, P3835, DOI 10.1093/nar/29.18.3835; TAWARAGI Y, 1984, BIOCHEMISTRY-US, V23, P529, DOI 10.1021/bi00298a020; THOEMMES P, 1992, J BIOL CHEM, V267, P6063; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Voitenleitner C, 1999, MOL CELL BIOL, V19, P646; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATANABE Y, 1982, FEBS LETT, V149, P44, DOI 10.1016/0014-5793(82)81067-3; Weisshart K, 2000, J BIOL CHEM, V275, P17328, DOI 10.1074/jbc.M000717200; Weisshart K, 1998, J VIROL, V72, P9771, DOI 10.1128/JVI.72.12.9771-9781.1998; WIEKOWSKI M, 1988, J BIOL CHEM, V263, P436; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; YANCEYWRONA JE, 1992, NUCLEIC ACIDS RES, V20, P6713, DOI 10.1093/nar/20.24.6713	61	35	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40853	40861		10.1074/jbc.M208067200	http://dx.doi.org/10.1074/jbc.M208067200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181327	hybrid			2022-12-27	WOS:000178791400090
J	Chen, YR; Han, J; Kori, R; Kong, ANT; Tan, TH				Chen, YR; Han, J; Kori, R; Kong, ANT; Tan, TH			Phenylethyl isothiocyanate induces apoptotic signaling via suppressing phosphatase activity against c-Jun N-terminal kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; PHENETHYL ISOTHIOCYANATE; GAMMA-RADIATION; CELL-DEATH; JNK; INHIBITION; PATHWAY; TRANSDUCTION; M3/6; 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE	Dietary isothiocyanates induce apoptosis in various cancer cell lines through a c-Jun N-terminal kinase (JNK)dependent mechanism. We found that phenylethyl isothiocyanate (PEITC) was capable of inducing JNK activation and apoptosis in prostate cancer cell lines with distinct p53 statuses. PEITC induced JNK-mediated apoptotic signaling via a different pathway than that used by DNA-damaging agents, because genotoxic-resistant LNCaP prostate cancer cells were equally sensitive to PEITC as parental LNCaP cells. PEITC did not induce significant MKK4 or MKK7 activation and did not activate JNK directly, suggesting that JNK and JNK upstream kinases are not primary targets of PEITC. The JNK dephosphorylation and inactivation rates were decreased in cells exposed to PEITC. Expression levels of M3/6, a JNK-specific phosphatase, were down-regulated by PEITC via a proteasome-dependent mechanism. Taken together, our data suggest that PEITC activates JNK through suppression of JNK dephosphorylation and that PEITC may be an alternative therapeutic agent for cancers that are resistant to genotoxic agents. This study also reveals that JNK phosphatases are potential targets for the development of novel cancer therapeutic agents.	Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmaceut, Piscataway, NJ 08854 USA	Baylor College of Medicine; Rutgers State University New Brunswick	Tan, TH (corresponding author), Baylor Coll Med, Dept Immunol, M929,1 Baylor Plaza, Houston, TX 77030 USA.	ttan@bcm.tmc.edu	Chen, Yi-Rong/CAF-2186-2022; Tan, Tse-Hua/ABD-7080-2021; Tan, Tse-Hua/E-3983-2010; Kong, Ah-Ng Tony/AAX-2828-2020; Chen, Yi-Rong/E-3991-2010; Chen, Yi-Rong/CAH-7991-2022	Chen, Yi-Rong/0000-0002-4307-3002; Tan, Tse-Hua/0000-0003-4969-3170; Tan, Tse-Hua/0000-0003-4969-3170; Chen, Yi-Rong/0000-0002-4307-3002; Chen, Yi-Rong/0000-0002-4307-3002; Han, Jin/0000-0003-0662-006X				Bang YJ, 1998, BIOCHEM BIOPH RES CO, V250, P43, DOI 10.1006/bbrc.1998.9256; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen Y. R., 1999, GENE THER MOL BIOL, V4, P83; Chen YR, 1998, J BIOL CHEM, V273, P1769, DOI 10.1074/jbc.273.3.1769; Chen YR, 1999, MOL PHARMACOL, V56, P1271, DOI 10.1124/mol.56.6.1271; Chen YR, 2000, INT J ONCOL, V16, P651; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chen YR, 2001, ONCOGENE, V20, P367, DOI 10.1038/sj.onc.1204105; Chen YR, 2001, BIOCHEM BIOPH RES CO, V288, P981, DOI 10.1006/bbrc.2001.5862; Chen YR, 1998, ONCOGENE, V17, P173, DOI 10.1038/sj.onc.1201941; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dlugosz JA, 2000, AM J PHYSIOL-RENAL, V279, pF688, DOI 10.1152/ajprenal.2000.279.4.F688; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; GUO Z, 1993, CARCINOGENESIS, V14, P1167, DOI 10.1093/carcin/14.6.1167; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HECHT SS, 1995, J CELL BIOCHEM, P195; Hecht SS, 1999, J NUTR, V129, p768S, DOI 10.1093/jn/129.3.768S; Hu MCT, 1998, J BIOL CHEM, V273, P33561, DOI 10.1074/jbc.273.50.33561; Huang CS, 1998, CANCER RES, V58, P4102; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; ISAACS WB, 1991, CANCER RES, V51, P4716; Ito M, 1999, MOL CELL BIOL, V19, P7539; Johnson RA, 2000, J VIROL, V74, P1158, DOI 10.1128/JVI.74.3.1158-1167.2000; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KOLM RH, 1995, BIOCHEM J, V311, P453, DOI 10.1042/bj3110453; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Loda M, 1996, AM J PATHOL, V149, P1553; Magi-Galluzzi C, 1998, VIRCHOWS ARCH, V432, P407, DOI 10.1007/s004280050184; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; Marti F, 2001, J IMMUNOL, V166, P197, DOI 10.4049/jimmunol.166.1.197; Masuda K, 2001, J BIOL CHEM, V276, P39002, DOI 10.1074/jbc.M104600200; Meriin AB, 1999, MOL CELL BIOL, V19, P2547; Mikalsen SO, 1998, J BIOL CHEM, V273, P10036, DOI 10.1074/jbc.273.16.10036; MORSE MA, 1993, CANCER LETT, V72, P103, DOI 10.1016/0304-3835(93)90018-5; MORSE MA, 1993, CARCINOGENESIS, V14, P1737, DOI 10.1093/carcin/14.9.1737; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Palacios C, 2001, CURR BIOL, V11, P1439, DOI 10.1016/S0960-9822(01)00426-2; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Smith A, 1997, CURR BIOL, V7, P893, DOI 10.1016/S0960-9822(06)00380-0; SMITH TJ, 1990, CANCER RES, V50, P6817; STONER GD, 1991, CANCER RES, V51, P2063; TALALAY P, 1993, ADV ENZYME REGUL, V28, P273; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Theodosiou A, 2002, ONCOGENE, V21, P2387, DOI 10.1038/sj.onc.1205309; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TONKS NK, 1988, J BIOL CHEM, V263, P6722; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WATTENBERG LW, 1987, CARCINOGENESIS, V8, P1971, DOI 10.1093/carcin/8.12.1971; WATTENBERG LW, 1981, CANCER RES, V41, P2991; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu K, 2000, BIOCHEM PHARMACOL, V60, P221, DOI 10.1016/S0006-2952(00)00319-1; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; Yip-Schneider MT, 2001, BIOCHEM BIOPH RES CO, V280, P992, DOI 10.1006/bbrc.2001.4243; Yokoyama A, 1997, BIOCHEM BIOPH RES CO, V239, P746, DOI 10.1006/bbrc.1997.7547; Yu R, 1996, CANCER RES, V56, P2954; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X	63	78	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39334	39342		10.1074/jbc.M202070200	http://dx.doi.org/10.1074/jbc.M202070200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171915	hybrid			2022-12-27	WOS:000178662500037
J	MacDiarmid, CW; Milanick, MA; Eide, DJ				MacDiarmid, CW; Milanick, MA; Eide, DJ			Biochemical properties of vacuolar zinc transport systems of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL-ION-TRANSPORT; PROTON-MOTIVE FORCE; ESCHERICHIA-COLI; GENE ENCODES; H+-ATPASE; YEAST; RESISTANCE; METABOLISM; EXPRESSION; PROTEIN	The yeast vacuole plays an important role in zinc homeostasis by storing zinc for later use under deficient conditions, sequestering excess zinc for its detoxification, and buffering rapid changes in intracellular zinc levels. The mechanisms involved in vacuolar zinc sequestration are only poorly characterized. Here we describe the properties of zinc transport systems in yeast vacuolar membrane vesicles. The major zinc transport activities in these vesicles were ATP-dependent, requiring a H+ gradient generated by the V-ATPase for function. One system we identified was dependent on the ZRC1 gene, which encodes a member of the cation diffusion facilitator family of metal transporters. These data are consistent with the proposed role of Zrc1 as a vacuolar zinc transporter. Zrc1-independent activity was also observed that was not dependent on the closely related vacuolar Cot1 protein. Both Zrc1-dependent and independent activities showed a high specificity for Zn2+ over other physiologically relevant substrates such as Ca2+, Fe2+, and Mn2+. Moreover, these systems had high affinities for zinc with apparent K-m values in the 100-200 nm range. These results provide biochemical insight into the important role of Zrc1 and related proteins in eukaryotic zinc homeostasis.	Univ Missouri, Dept Nutr Sci, Columbia, MO 65211 USA; Univ Missouri, Dept Physiol, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Eide, DJ (corresponding author), Univ Missouri, Dept Nutr Sci, 217 Gwynn Hall, Columbia, MO 65211 USA.		MacDiarmid, Colin/AAV-5920-2021	MacDiarmid, Colin/0000-0001-8578-5756	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058265] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58265] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anton A, 1999, J BACTERIOL, V181, P6876, DOI 10.1128/JB.181.22.6876-6881.1999; Bloss T, 2002, PLANTA, V214, P783, DOI 10.1007/s00425-001-0677-1; BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609; Brocklehurst KR, 1999, MOL MICROBIOL, V31, P893, DOI 10.1046/j.1365-2958.1999.01229.x; Clague MJ, 1998, BIOCHEM J, V336, P271, DOI 10.1042/bj3360271; CONKLIN DS, 1994, MOL GEN GENET, V244, P303, DOI 10.1007/BF00285458; Costello LC, 1997, J BIOL CHEM, V272, P28875, DOI 10.1074/jbc.272.46.28875; EIDE DJ, 1993, MOL GEN GENET, V241, P447, DOI 10.1007/BF00284699; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Gaither LA, 2001, BIOMETALS, V14, P251, DOI 10.1023/A:1012988914300; Gitan RS, 1998, J BIOL CHEM, V273, P28617, DOI 10.1074/jbc.273.44.28617; Gitan RS, 2000, BIOCHEM J, V346, P329, DOI 10.1042/0264-6021:3460329; Guffanti AA, 2002, MOL MICROBIOL, V45, P145, DOI 10.1046/j.1365-2958.2002.02998.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KAKINUMA Y, 1981, J BIOL CHEM, V256, P859; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Krezel A, 1999, ACTA BIOCHIM POL, V46, P567, DOI 10.18388/abp.1999_4129; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; MANOLSON MF, 1994, J BIOL CHEM, V269, P14064; Miyabe S, 2000, BIOCHEM BIOPH RES CO, V276, P879, DOI 10.1006/bbrc.2000.3580; Miyabe S, 2001, BIOCHEM BIOPH RES CO, V282, P79, DOI 10.1006/bbrc.2001.4522; Nelson N, 2000, J EXP BIOL, V203, P89; NIES DH, 1995, J IND MICROBIOL, V14, P186, DOI 10.1007/BF01569902; Ogawa N, 2000, MOL BIOL CELL, V11, P4309, DOI 10.1091/mbc.11.12.4309; OHSUMI Y, 1983, J BIOL CHEM, V258, P5614; OKOROKOV LA, 1985, FEBS LETT, V192, P303, DOI 10.1016/0014-5793(85)80130-7; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Patzer SI, 1998, MOL MICROBIOL, V28, P1199, DOI 10.1046/j.1365-2958.1998.00883.x; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; Ramsay LM, 1997, FEMS MICROBIOL LETT, V152, P293, DOI 10.1016/S0378-1097(97)00213-9; Sensi SL, 1997, J NEUROSCI, V17, P9554; WHITE C, 1987, J GEN MICROBIOL, V133, P727; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044; Zhao H, 1996, P NATL ACAD SCI USA, V93, P2454, DOI 10.1073/pnas.93.6.2454	40	144	154	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39187	39194		10.1074/jbc.M205052200	http://dx.doi.org/10.1074/jbc.M205052200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161436	hybrid			2022-12-27	WOS:000178662500018
J	Adamson, AW; Kim, WJ; Shangary, S; Baskaran, R; Brown, KD				Adamson, AW; Kim, WJ; Shangary, S; Baskaran, R; Brown, KD			ATM is activated in response to N-methyl-N '-nitro-N-nitrosoguanidine-induced DNA alkylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DAMAGE-INDUCED PHOSPHORYLATION; CELL-CYCLE CHECKPOINTS; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; MISMATCH REPAIR; PROTEIN-KINASE; STRAND BREAKS; UP-REGULATION; HUMAN P53; APOPTOSIS	p53 plays an important role in response to ionizing radiation by regulating cell cycle progression and triggering apoptosis. These activities are controlled, in part, by the phosphorylation of p53 by the protein kinase ATM. Recent evidence indicates that the monofunctional DNA alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) also triggers up-regulation and phosphorylation of p53; however, the mechanism(s) responsible for this are unknown. We observed that in MNNG-treated normal human fibroblasts, up-regulation and phosphorylation of p53 was sensitive to the ATM kinase inhibitor wortmannin. ATM-deficient fibroblasts exhibited a delay in p53 up-regulation indicating a role for ATM in triggering the MNNG-induced response. Likewise, a mismatch repair (MMR)-deficient colorectal tumor line failed to show rapid up-regulation of p53. However, unlike ATM-deficient cells, these MMR-deficient cells displayed rapid phosphorylation of the p53 residue serine 15 after MNNG. In vitro kinase assays indicate that ATM is rapidly activated in both normal and MMR-deficient cells in response to MNNG. Using a number of morphological and biochemical approaches, we failed to observe MNNG-induced apoptosis in normal human fibroblasts, suggesting that apoptosis-induced DNA strand breaks are not required for the activation of ATM in response to MNNG. Comet assays indicated that strand breaks accumulated, and p53 up-regulation/phosphorylation occurred quite rapidly (within 30 min) after MNNG treatment, suggesting that DNA strand breaks that arise during the repair process activate ATM. These findings indicate that ATM activation is not limited to the ionizing radiation-induced response and potentially plays an important role in response to DNA alkylation.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA; Univ Pittsburgh, Med Ctr, Dept Biochem & Mol Genet, Pittsburgh, PA 15261 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Brown, KD (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 1901 Perdido St,MEB 7101, New Orleans, LA 70112 USA.							Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Brown KD, 2000, J BIOL CHEM, V275, P6651, DOI 10.1074/jbc.275.9.6651; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN PC, 1978, NATURE, V274, P484, DOI 10.1038/274484a0; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Duckett DR, 1999, P NATL ACAD SCI USA, V96, P12384, DOI 10.1073/pnas.96.22.12384; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ENGELWARD BP, 1993, CARCINOGENESIS, V14, P175; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P143; HARTWELL L, 1994, COLD SPRING HARB SYM, V59, P259, DOI 10.1101/SQB.1994.059.01.030; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HAWN MT, 1995, CANCER RES, V55, P3721; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; KALAMEGHAM R, 1988, CARCINOGENESIS, V9, P1749, DOI 10.1093/carcin/9.10.1749; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Meikrantz W, 1998, CARCINOGENESIS, V19, P369, DOI 10.1093/carcin/19.2.369; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Oakley GG, 2001, MOL BIOL CELL, V12, P1199, DOI 10.1091/mbc.12.5.1199; Ochs K, 2000, CANCER RES, V60, P5815; Pantazis P, 1995, LEUKEMIA RES, V19, P775, DOI 10.1016/0145-2126(95)00048-8; Pegg AE, 1999, ADV EXP MED BIOL, V472, P253; Sarkaria JN, 1998, CANCER RES, V58, P4375; SCHREIBER V, 1995, P NATL ACAD SCI USA, V92, P4753, DOI 10.1073/pnas.92.11.4753; Shangary S, 2000, J BIOL CHEM, V275, P30163, DOI 10.1074/jbc.M004302200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SHILOH Y, 1981, CANCER RES, V41, P5114; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Takagi M, 1998, CANCER RES, V58, P4923; TEO IA, 1982, CARCINOGENESIS, V3, P33, DOI 10.1093/carcin/3.1.33; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tominaga Y, 1997, CARCINOGENESIS, V18, P889, DOI 10.1093/carcin/18.5.889; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Walker LSK, 1999, IMMUNOLOGY, V98, P569, DOI 10.1046/j.1365-2567.1999.00925.x; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	48	55	55	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38222	38229		10.1074/jbc.M204409200	http://dx.doi.org/10.1074/jbc.M204409200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151394	hybrid			2022-12-27	WOS:000178529600032
J	Beigneux, A; Withycombe, SK; Digits, JA; Tschantz, WR; Weinbaum, CA; Griffey, SM; Bergo, M; Casey, PJ; Young, SG				Beigneux, A; Withycombe, SK; Digits, JA; Tschantz, WR; Weinbaum, CA; Griffey, SM; Bergo, M; Casey, PJ; Young, SG			Prenylcysteine lyase deficiency in mice results in the accumulation of farnesylcysteine and geranylgeranylcysteine in brain and liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; PALMITOYL-PROTEIN THIOESTERASE; CARBOXYL METHYLATION; SIGNAL TRANSDUCTION; CELLS; PRENYLATION; TRANSFERASE; EXPRESSION; ANALOGS; CLONING	In in vitro experiments, prenylcysteine lyase (Pcly) cleaves the thioether bond of prenylcysteines to yield free cysteine and the aldehyde of the isoprenoid lipid. However, the importance of this enzyme has not yet been fully defined at the biochemical or physiologic level. In this study, we show that Pcly is expressed at high levels in mouse liver, kidney, heart, and brain. To test whether Pcly deficiency would cause prenylcysteines to accumulate in tissues and result in pathologic consequences, we produced Pcly-deficient cell lines and Pcly-deficient mice (Pcly-/-). Pcly activity levels were markedly reduced in Pcly-/- cells and tissues. Pcly-/- fibroblasts were more sensitive than wild-type fibroblasts to growth inhibition when prenylcysteines were added to the cell culture medium. To determine if the reduced Pcly enzyme activity levels led to an accumulation of prenylcysteines within cells, mass spectrometry was used to measure farnesylcysteine and geranylgeranylcysteine levels in the tissues of Pcly-/- mice and wild-type controls. These studies revealed a striking accumulation of both farnesyleysteine and geranylgeranylcysteine in the brain and liver of Pcly-/- mice. This accumulation did not appear to be accompanied by significant pathologic consequences. Pcly-/- mice were healthy and fertile, and surveys of more than 30 tissues did not uncover any abnormalities. We conclude that prenylcysteine lyase does play a physiologic role in cleaving prenylcysteines in mammals, but the absence of this activity does not lead to major pathologic consequences.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94141 USA; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Calif Davis, Comparat Pathol Lab, Davis, CA 95616 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; Duke University; University of California System; University of California Davis; University of California System; University of California San Francisco	Beigneux, A (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.			Young, Stephen/0000-0001-7270-3176; Casey, Patrick/0000-0002-7366-9309	NHLBI NIH HHS [HL41633] Funding Source: Medline; NIA NIH HHS [AG15451] Funding Source: Medline; NIGMS NIH HHS [GM46372] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL041633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015451] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Bergo MO, 2000, J BIOL CHEM, V275, P17605, DOI 10.1074/jbc.C000079200; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CASEY PJ, 1992, J LIPID RES, V33, P1731; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; Gupta P, 2001, P NATL ACAD SCI USA, V98, P13566, DOI 10.1073/pnas.251485198; HUZOORAKBAR W, 1993, P NATL ACAD SCI USA, V90, P868; JONES DH, 1991, BIOTECHNIQUES, V10, P62; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu JY, 1996, P NATL ACAD SCI USA, V93, P10046, DOI 10.1073/pnas.93.19.10046; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; Parish CA, 1997, BIOCHEMISTRY-US, V36, P2686, DOI 10.1021/bi961844r; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; Sambrook J., 2002, MOL CLONING LAB MANU; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; Soyombo AA, 1997, J BIOL CHEM, V272, P27456, DOI 10.1074/jbc.272.43.27456; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tschantz WR, 2001, J BIOL CHEM, V276, P2321, DOI 10.1074/jbc.C000616200; Tschantz WR, 1999, J BIOL CHEM, V274, P35802, DOI 10.1074/jbc.274.50.35802; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; VOLKER C, 1991, J BIOL CHEM, V266, P21515; YOUNG SG, 2000, ENZYMES, V21, P153; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; ZHANG LL, 1995, J BIOL CHEM, V270, P22859, DOI 10.1074/jbc.270.39.22859; Zhang LL, 1997, J BIOL CHEM, V272, P23354, DOI 10.1074/jbc.272.37.23354	27	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38358	38363		10.1074/jbc.M205183200	http://dx.doi.org/10.1074/jbc.M205183200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151402	hybrid			2022-12-27	WOS:000178529600048
J	Zhang, YJ; Chen, K; Guo, LD; Wu, CY				Zhang, YJ; Chen, K; Guo, LD; Wu, CY			Characterization of PINCH-2, a new focal adhesion protein that regulates the PINCH-1-ILK interaction, cell spreading, and migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-LINKED KINASE; ABL TYROSINE KINASE; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; CAENORHABDITIS-ELEGANS; LIM PROTEIN; GROWTH; CYTOSKELETON; PAXILLIN; DOMAIN	Integrin-linked kinase (ILK) is a multidomain protein that plays important roles at cell-extracellular matrix (ECM) adhesion sites. We describe here a new LIM-domain containing protein (termed as PINCH-2) that forms a complex with ILK. PINCH-2 is co-expressed with PINCH-1 (previously known as PINCH), another member of the PINCH protein family, in a variety of human cells. Immunofluorescent staining of cells with PINCH-2-specific antibodies show that PINCH-2 localizes to both cell-ECM contact sites and the nucleus. Deletion of the first LIM (LIM1) domain of PINCH-2 abolished the ability of PINCH-2 to form a complex with ILK. The ILK-binding defective LIM1-deletion mutant, unlike the wild type PINCH-2 or the ILK-binding competent LIM5-deletion mutant, was incapable of localizing to cell-ECM contact sites, suggesting that ILK binding is required for this process. Importantly, the PINCH-2-ILK and PINCH-1-ILK interactions are mutually exclusive. Overexpression of PINCH-2 significantly inhibited the PINCH-1-ILK interaction and reduced cell spreading and migration. These results identify a novel nuclear and focal adhesion protein that associates with ILK and reveals an important role of PINCH-2 in the regulation of the PINCH-1-ILK interaction, cell shape change, and migration.	Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wu, CY (corresponding author), Univ Pittsburgh, Dept Pathol, 707B Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054639] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065188] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54639] Funding Source: Medline; NIGMS NIH HHS [GM65188] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Calderwood DA, 2000, J BIOL CHEM, V275, P22607, DOI 10.1074/jbc.R900037199; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; GETTNER SN, 1995, J CELL BIOL, V129, P1127, DOI 10.1083/jcb.129.4.1127; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Guo LD, 2001, AM J PATHOL, V159, P1735, DOI 10.1016/S0002-9440(10)63020-9; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hobert O, 1999, J CELL BIOL, V144, P45, DOI 10.1083/jcb.144.1.45; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Huang Y, 2000, J CELL BIOL, V150, P861, DOI 10.1083/jcb.150.4.861; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; KOMORIYA A, 1991, J BIOL CHEM, V266, P15075; Lewis JM, 1996, P NATL ACAD SCI USA, V93, P15174, DOI 10.1073/pnas.93.26.15174; Li FG, 1997, BBA-MOL CELL RES, V1358, P215, DOI 10.1016/S0167-4889(97)00089-X; Li FG, 1999, J CELL SCI, V112, P4589; Lin XY, 2000, MOL BIOL CELL, V11, p515A; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Nikolopoulos SN, 2000, J CELL BIOL, V151, P1435, DOI 10.1083/jcb.151.7.1435; Nikolopoulos SN, 2001, J BIOL CHEM, V276, P23499, DOI 10.1074/jbc.M102163200; Nix DA, 2001, J BIOL CHEM, V276, P34759, DOI 10.1074/jbc.M102820200; Nix DA, 1997, J CELL BIOL, V138, P1139, DOI 10.1083/jcb.138.5.1139; Olski TM, 2001, J CELL SCI, V114, P525; REARDEN A, 1994, BIOCHEM BIOPH RES CO, V201, P1124, DOI 10.1006/bbrc.1994.1822; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Schwartz MA, 2001, J CELL SCI, V114, P2553; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Thomas SM, 1999, J CELL SCI, V112, P181; Tu YZ, 2001, J CELL BIOL, V153, P585, DOI 10.1083/jcb.153.3.585; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Velyvis A, 2001, J BIOL CHEM, V276, P4932, DOI 10.1074/jbc.M007632200; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WILLIAMS BD, 1994, J CELL BIOL, V124, P475, DOI 10.1083/jcb.124.4.475; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Yamaji S, 2001, J CELL BIOL, V153, P1251, DOI 10.1083/jcb.153.6.1251; Yang L, 2000, MOL BIOL CELL, V11, P2007, DOI 10.1091/mbc.11.6.2007; Zamir E, 2001, J CELL SCI, V114, P3583; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	46	90	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38328	38338		10.1074/jbc.M205576200	http://dx.doi.org/10.1074/jbc.M205576200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167643	hybrid			2022-12-27	WOS:000178529600044
J	Failer, BU; Braun, N; Zimmermann, H				Failer, BU; Braun, N; Zimmermann, H			Cloning, expression, and functional characterization of a Ca2+-dependent endoplasmic reticulum nucleoside diphosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUALITY-CONTROL; APYRASE; TRIPHOSPHATE; DIPHOSPHOHYDROLASE; PROTEIN; ATP; IDENTIFICATION; GLYCOSYLATION; TRANSPORT; 5-NUCLEOTIDASE	We have isolated and characterized the cDNA encoding a Ca2+-dependent nucleoside diphosphatase (EC 3.6.1.6) related to two secreted ATP- and ADP-hydrolyzing apyrases of the bloodsucking insects, Cimex lectularius and Phlebotomus papatasi. The rat brain-derived cDNA has an open reading frame of 1209 bp encoding a protein of 403 amino acids and a calculated molecular mass of 45.7 kDa. The mRNA was expressed in all tissues investigated, revealing two major transcripts with varying preponderance. The immunohistochemical analysis of the Myc-His-tagged enzyme expressed in Chinese hamster ovary cells revealed its association with the endoplasmic reticulum And also with pre-Golgi intermediates. Ca2+-dependent nucleoside diphosphatase is a membrane protein with its catalytic site facing the organelle lumen. It hydrolyzes nucleoside 5'-diphosphates in the order UDP >GDP = IDP > > >CDP but not ADP. Nucleoside 5'-triphosphates were hydrolyzed to a minor extent, and no hydrolysis of nucleoside 5'-monophosphates was observed. The enzyme was strongly activated by Ca2+, insensitive to Mg2+, and had a K-m for UDP of 216 muM. Ca2+-dependent nucleoside diphosphatase may support glycosylation reactions related to quality control in the endoplasmic reticulum.	Goethe Univ Frankfurt, Biozentrum, D-60439 Frankfurt, Germany	Goethe University Frankfurt	Zimmermann, H (corresponding author), Goethe Univ Frankfurt, Biozentrum, Marie Curie Str 9, D-60439 Frankfurt, Germany.	h.zimmermann@zoology.uni-frankfurt.de						ABEIJON C, 1993, J CELL BIOL, V122, P307, DOI 10.1083/jcb.122.2.307; Biederbick A, 1999, J CELL SCI, V112, P2473; Biederbick A, 2000, J BIOL CHEM, V275, P19018, DOI 10.1074/jbc.M001245200; Braun N, 2000, BIOCHEM J, V351, P639, DOI 10.1042/0264-6021:3510639; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Castro O, 1999, MOL BIOL CELL, V10, P1019, DOI 10.1091/mbc.10.4.1019; Chadwick BP, 1998, GENOMICS, V50, P357, DOI 10.1006/geno.1998.5317; Dunwiddie TV, 1997, J NEUROSCI, V17, P7673; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Enjyoji K, 1999, NAT MED, V5, P1010, DOI 10.1038/12447; Gao XD, 1999, J BIOL CHEM, V274, P21450, DOI 10.1074/jbc.274.30.21450; Gomord V, 1999, BIOCHIMIE, V81, P607, DOI 10.1016/S0300-9084(99)80118-7; GUILLEN E, 1995, BIOCHEMISTRY-US, V34, P5472, DOI 10.1021/bi00016a018; HEILBRONN A, 1995, CELL TISSUE RES, V280, P123, DOI 10.1007/BF00304517; Helenius A, 2001, PHILOS T ROY SOC B, V356, P147, DOI 10.1098/rstb.2000.0759; Hicks-Berger CA, 2000, J BIOL CHEM, V275, P34041, DOI 10.1074/jbc.M004723200; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Kegel B, 1997, NEUROPHARMACOLOGY, V36, P1189, DOI 10.1016/S0028-3908(97)00115-9; Knofel T, 1999, NAT STRUCT BIOL, V6, P448; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lopez-Avalos MD, 2001, GLYCOBIOLOGY, V11, P413, DOI 10.1093/glycob/11.5.413; Mulero JJ, 2000, BIOCHEMISTRY-US, V39, P12924, DOI 10.1021/bi000960y; Mulero JJ, 1999, J BIOL CHEM, V274, P20064, DOI 10.1074/jbc.274.29.20064; Parkkinen JJ, 1997, J CELL BIOCHEM, V66, P165, DOI 10.1002/(SICI)1097-4644(19970801)66:2<165::AID-JCB4>3.3.CO;2-D; Puglielli L, 1999, J BIOL CHEM, V274, P12665, DOI 10.1074/jbc.274.18.12665; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Shi JD, 2001, J BIOL CHEM, V276, P17474, DOI 10.1074/jbc.M011569200; Trombetta ES, 1999, EMBO J, V18, P3282, DOI 10.1093/emboj/18.12.3282; Valenzuela JG, 1998, J BIOL CHEM, V273, P30583, DOI 10.1074/jbc.273.46.30583; Valenzuela JG, 2001, J EXP BIOL, V204, P229; Wang TF, 1998, J BIOL CHEM, V273, P11392, DOI 10.1074/jbc.273.18.11392; Yang F, 2001, BIOCHEMISTRY-US, V40, P3943, DOI 10.1021/bi002711f; Yeung G, 2000, BIOCHEMISTRY-US, V39, P12916, DOI 10.1021/bi000959z; Zhong XT, 1999, J BIOL CHEM, V274, P32704, DOI 10.1074/jbc.274.46.32704; Zhong XT, 2001, J BIOL CHEM, V276, P41518, DOI 10.1074/jbc.M104415200; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345; Zimmermann H, 2001, DRUG DEVELOP RES, V52, P44, DOI 10.1002/ddr.1097; Zimmermann H, 2001, HANDB EXP PHARM, V151, P209; Zuber C, 2001, P NATL ACAD SCI USA, V98, P10710, DOI 10.1073/pnas.191359198	41	44	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36978	36986		10.1074/jbc.M201656200	http://dx.doi.org/10.1074/jbc.M201656200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12167635	hybrid			2022-12-27	WOS:000178447100011
J	Langevin, C; Jaaro, H; Bressanelli, S; Fainzilber, M; Tuffereau, C				Langevin, C; Jaaro, H; Bressanelli, S; Fainzilber, M; Tuffereau, C			Rabies virus glycoprotein (RVG) is a trimeric ligand for the N-terminal cysteine-rich domain of the mammalian p75 neurotrophin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE-GROWTH-FACTOR; NECROSIS-FACTOR RECEPTOR; OLIGOMERIC STRUCTURE; HIPPOCAMPAL-NEURONS; CELLULAR RECEPTOR; BINDING DOMAIN; P75(NTR); APOPTOSIS; PROTEIN; DEATH	Rabies virus glycoprotein (RVG) is a trimeric and surface-exposed viral coat protein that has been shown to interact with the murine p75 neurotrophin receptor. We have investigated binding of RVG to p75 and describe several features that distinguish the p75-RVG interaction from conventional neurotrophin binding to p75. RVG binds mammalian but not avian p75 and does not bind to any of the Trk neurotrophin receptors. The mammalian p75 specificity of RVG binding may partly explain the phyletic specificity of rabies infection. Radioiodinated nerve growth factor (NGF) and RVG both bind to rat p75 but do not compete with each other's binding site. Although neurotrophins bind to the second and third cysteine-rich domains (CRD) of p75, RVG specifically interacts with high affinity (K-d 30-35 pm) with the first CRD (CRD1). Substitution of Gln(33) in p75-CRD1 by Glu completely abolishes RVG binding. Our data therefore firmly establish RVG as a trimeric high affinity ligand for a non-neurotrophin binding site on p75. Interestingly, the CRD1 in another TNF/NGF family receptor was recently shown to be involved in the binding of the herpes virus glycoprotein gD, suggesting that the CRI)l of TNF/NGF family members may be a widely used binding domain for viral glycoproteins.	CNRS, INRA, UMR 2472, Lab Virol Mol & Struct, F-91198 Gif Sur Yvette, France; Weizmann Inst Sci, Mol Neurobiol Lab, Dept Biol Chem, IL-76100 Rehovot, Israel	Centre National de la Recherche Scientifique (CNRS); Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); INRAE; Universite Paris Saclay; Weizmann Institute of Science	Tuffereau, C (corresponding author), CNRS, INRA, UMR 2472, Lab Virol Mol & Struct, F-91198 Gif Sur Yvette, France.		Jaaro-Peled, Hanna/D-1046-2012	Jaaro-Peled, Hanna/0000-0002-8950-391X; Bressanelli, Stephane/0000-0002-0921-6727; Langevin, Christelle/0000-0002-6013-4460; Fainzilber, Mike/0000-0001-8173-8557				Adkins HB, 1997, P NATL ACAD SCI USA, V94, P11617, DOI 10.1073/pnas.94.21.11617; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BALDWIN AN, 1995, J BIOL CHEM, V270, P4594, DOI 10.1074/jbc.270.9.4594; Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911; Barker PA, 1998, CELL DEATH DIFFER, V5, P346, DOI 10.1038/sj.cdd.4400375; Brann AB, 2002, J BIOL CHEM, V277, P9812, DOI 10.1074/jbc.M109862200; Brann AB, 1999, J NEUROSCI, V19, P8199; Brojatsch J, 1996, CELL, V87, P845, DOI 10.1016/S0092-8674(00)81992-3; Bunone G, 1997, ONCOGENE, V14, P1463, DOI 10.1038/sj.onc.1200972; Carfi A, 2001, MOL CELL, V8, P169, DOI 10.1016/S1097-2765(01)00298-2; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chao MV, 2002, NEURON, V33, P9, DOI 10.1016/S0896-6273(01)00573-6; CHAO MV, 1994, J NEUROBIOL, V25, P1373, DOI 10.1002/neu.480251106; CHAPMAN BS, 1995, PROTEIN SCI, V4, P1696, DOI 10.1002/pro.5560040905; CHARLTON KM, 1994, LYSSAVIRUSES, P95; Della-Bianca V, 2001, J BIOL CHEM, V276, P38929, DOI 10.1074/jbc.M107454200; Dietaschold B, 1996, FIELDS VIROLOGY, P1137; EINFELD D, 1988, P NATL ACAD SCI USA, V85, P8688, DOI 10.1073/pnas.85.22.8688; Fainzilber M, 1996, SCIENCE, V274, P1540, DOI 10.1126/science.274.5292.1540; Frade JM, 1996, NATURE, V383, P166; Friedman WJ, 2000, J NEUROSCI, V20, P6340, DOI 10.1523/JNEUROSCI.20-17-06340.2000; GAUDIN Y, 1992, VIROLOGY, V187, P627, DOI 10.1016/0042-6822(92)90465-2; Handler CG, 1996, J VIROL, V70, P6067, DOI 10.1128/JVI.70.9.6067-6070.1996; Hutson LD, 2001, J NEUROBIOL, V49, P79, DOI 10.1002/neu.1067; Ibanez CF, 2002, TRENDS NEUROSCI, V25, P284, DOI 10.1016/S0166-2236(02)02169-0; Jackson AC, 1999, ACTA NEUROPATHOL, V98, P641, DOI 10.1007/s004010051130; Kong H, 1999, CELL DEATH DIFFER, V6, P1133, DOI 10.1038/sj.cdd.4400587; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee FS, 2001, CURR OPIN NEUROBIOL, V11, P281, DOI 10.1016/S0959-4388(00)00209-9; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; Lee R, 2001, SCIENCE, V294, P1945, DOI 10.1126/science.1065057; LENTZ TL, 1984, SCIENCE, V226, P847, DOI 10.1126/science.6494916; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Naismith JH, 1996, STRUCTURE, V4, P1251, DOI 10.1016/S0969-2126(96)00134-7; NAISMITH JH, 1995, J BIOL CHEM, V270, P13303, DOI 10.1074/jbc.270.22.13303; Perini G, 2002, J EXP MED, V195, P907, DOI 10.1084/jem.20011797; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Shamovsky IL, 1999, PROTEIN SCI, V8, P2223; Thoulouze MI, 1998, J VIROL, V72, P7181, DOI 10.1128/JVI.72.9.7181-7190.1998; Tuffereau C, 1998, EMBO J, V17, P7250, DOI 10.1093/emboj/17.24.7250; Tuffereau C, 2001, J GEN VIROL, V82, P2861, DOI 10.1099/0022-1317-82-12-2861; Tuffereau C, 1998, J VIROL, V72, P1085, DOI 10.1128/JVI.72.2.1085-1091.1998; von Schack D, 2001, NAT NEUROSCI, V4, P977, DOI 10.1038/nn730; WELCHER AA, 1991, P NATL ACAD SCI USA, V88, P159, DOI 10.1073/pnas.88.1.159; Whitbeck JC, 2001, J VIROL, V75, P171, DOI 10.1128/JVI.75.1.171-180.2001; Yaar M, 2002, J BIOL CHEM, V277, P7720, DOI 10.1074/jbc.M110929200; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yamashita T, 1999, NEURON, V24, P585, DOI 10.1016/S0896-6273(00)81114-9; YAN H, 1991, J BIOL CHEM, V266, P12099	51	57	65	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37655	37662		10.1074/jbc.M201374200	http://dx.doi.org/10.1074/jbc.M201374200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12163480	hybrid			2022-12-27	WOS:000178447100096
J	Baggerman, G; Cerstiaens, A; De Loof, A; Schoofs, L				Baggerman, G; Cerstiaens, A; De Loof, A; Schoofs, L			Peptidomics of the larval Drosophila melanogaster central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCUSTA-MIGRATORIA; MOLECULAR-CLONING; ALLATOSTATIN PREPROHORMONE; CARDIOACTIVE PEPTIDE; GENOMIC ORGANIZATION; IDENTIFICATION; NEUROPEPTIDE; HORMONE; EXPRESSION; GENE	Neuropeptides regulate most, if not all, biological processes in the animal kingdom, but only seven have been isolated and sequenced from Drosophila melanogaster. In analogy with the proteomics technology, where all proteins expressed in a cell or tissue are analyzed, the peptidomics approach aims at the simultaneous identification of the whole peptidome of a cell or tissue, ie. all expressed peptides with their posttranslational modifications. Using nanoscale liquid chromatography combined with tandem mass spectrometry and data base mining, we analyzed the peptidome of the larval Drosophila central nervous system at the amino acid sequence level. We were able to provide biochemical evidence for the presence of 28 neuropeptides using an extract of only 50 larval Drosophila central nervous systems. Eighteen of these peptides are encoded in previously cloned or annotated precursor genes, although not all of them were predicted correctly. Eleven of these peptides were never purified before. Eight other peptides are entirely novel and are encoded in five different, not yet annotated genes. This neuropeptide expression profiling study also opens perspectives for other eukaryotic model systems, for which genome projects are completed or in progress.	Katholieke Univ Leuven, Lab Dev Physiol & Mol Biol, B-3000 Louvain, Belgium	KU Leuven	Schoofs, L (corresponding author), Katholieke Univ Leuven, Lab Dev Physiol & Mol Biol, Naamsestr 59, B-3000 Louvain, Belgium.	liliane.schoofs@bio.kuleuven.ac.be	schoofs, liliane/ABD-2943-2020; Schoofs, Liliane/F-2815-2010	Schoofs, Liliane/0000-0002-1673-432X; Baggerman, Geert/0000-0002-0661-931X				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Baggerman G, 2002, PEPTIDES, V23, P635, DOI 10.1016/S0196-9781(01)00657-X; BOGERD J, 1995, J BIOL CHEM, V270, P23038, DOI 10.1074/jbc.270.39.23038; BROECK JV, 2002, PEPTIDES, P635; Brogiolo W, 2001, CURR BIOL, V11, P213, DOI 10.1016/S0960-9822(01)00068-9; Davies SA, 1997, AM J PHYSIOL-REG I, V273, pR823, DOI 10.1152/ajpregu.1997.273.2.R823; De Loof A, 2001, ARCH INSECT BIOCHEM, V47, P129, DOI 10.1002/arch.1044; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901; HORODYSKI FM, 1993, EUR J BIOCHEM, V215, P221, DOI 10.1111/j.1432-1033.1993.tb18026.x; HUESMANN GR, 1995, FEBS LETT, V371, P311, DOI 10.1016/0014-5793(95)00929-4; Kean L, 2002, AM J PHYSIOL-REG I, V282, pR1297, DOI 10.1152/ajpregu.00584.2001; Lenz C, 2000, BIOCHEM BIOPH RES CO, V273, P1126, DOI 10.1006/bbrc.2000.3062; NAMBU JR, 1988, NEURON, V1, P55, DOI 10.1016/0896-6273(88)90209-7; NASSEL DR, 1993, J COMP NEUROL, V331, P183, DOI 10.1002/cne.903310204; Nathoo AN, 2001, P NATL ACAD SCI USA, V98, P14000, DOI 10.1073/pnas.241231298; NICHOLS R, 1988, J BIOL CHEM, V263, P12167; NICHOLS R, 1992, J MOL NEUROSCI, V3, P213, DOI 10.1007/BF03380141; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OUDEJANS RCHM, 1993, PEPTIDES, V14, P877, DOI 10.1016/0196-9781(93)90062-L; Perone MJ, 1997, HISTOL HISTOPATHOL, V12, P1179; Phlippen MK, 2000, J EXP BIOL, V203, P521; SCHAFFER MH, 1990, BIOCHEM J, V269, P315, DOI 10.1042/bj2690315; SCHNEIDER LE, 1988, P NATL ACAD SCI USA, V85, P1993, DOI 10.1073/pnas.85.6.1993; SCHOOFS L, 1991, GEN COMP ENDOCR, V81, P97, DOI 10.1016/0016-6480(91)90129-T; SCHOOFS L, 1991, REGUL PEPTIDES, V36, P111, DOI 10.1016/0167-0115(91)90199-Q; Schoofs L, 1997, PEPTIDES, V18, P145, DOI 10.1016/S0196-9781(96)00236-7; SCHOOFS L, 1993, PEPTIDES, V14, P409, DOI 10.1016/0196-9781(93)90126-2; Siviter RJ, 2000, J BIOL CHEM, V275, P23273, DOI 10.1074/jbc.M002875200; Terhzaz S, 1999, J EXP BIOL, V202, P3667; Torfs P, 2001, EUR J BIOCHEM, V268, P149, DOI 10.1046/j.1432-1327.2001.01858.x; Uttenweiler-Joseph S, 1998, P NATL ACAD SCI USA, V95, P11342, DOI 10.1073/pnas.95.19.11342; Veelaert D, 1997, ENDOCRINOLOGY, V138, P138, DOI 10.1210/en.138.1.138; VEENSTRA JA, 1994, BIOCHEM BIOPH RES CO, V204, P292, DOI 10.1006/bbrc.1994.2458; VEENSTRA JA, 1989, FEBS LETT, V250, P231, DOI 10.1016/0014-5793(89)80727-6; Wei Z, 2000, J INSECT PHYSIOL, V46, P1259, DOI 10.1016/S0022-1910(00)00046-9; Williamson M, 2001, BIOCHEM BIOPH RES CO, V282, P124, DOI 10.1006/bbrc.2001.4565; Zitnan D, 1996, SCIENCE, V271, P88, DOI 10.1126/science.271.5245.88	38	218	244	0	16	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40368	40374		10.1074/jbc.M206257200	http://dx.doi.org/10.1074/jbc.M206257200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171930	hybrid			2022-12-27	WOS:000178791400028
J	Calzada, MJ; Alvarez, MV; Gonzalez-Rodriguez, J				Calzada, MJ; Alvarez, MV; Gonzalez-Rodriguez, J			Agonist-specific structural rearrangements of integrin alpha(IIb)beta(3) - Confirmation of the bent conformation in platelets at rest and after activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; LIGAND-BINDING; MONOCLONAL-ANTIBODIES; FIBRINOGEN RECEPTOR; ELECTRON-MICROSCOPY; GPIIB-IIIA; HUMAN FIBRONECTIN; DISULFIDE BONDS; PLASMA-MEMBRANE; BETA(3) SUBUNIT	Concrete structural features of integrin a,bp, on the surface of platelets (at rest and after activation) have been obtained from epitope maps based on cross-competition among monoclonal antibodies directed against the alpha(IIb) subunit calf-2 domain and the beta(3) subunit betaA domain of alpha(IIb)beta(3). At rest, the observed intersubunit interface is formed by the sequence stretches beta(3)-(150-216), alpha(IIb) light chain-(1-92), and alpha(IIb) heavy chain-(826-856); and the alpha(IIb) interchain interface is formed by the two latter sequence stretches, disulfide-bonded between alpha(IIb) heavy chain Cys(826) and alpha(IIb) light chain Cys(9). These structural features agree with those observed in the alpha(IIb)beta(3) rudimentary connectivity map in solution and with the alpha(v)beta(3) V-shaped crystal structure (Xiong, J.-P., Zhang, R., Dunker, R., Scott, D. L., Joachimiak, A., Goodman, S. L., and Arnaout, M. A. (2001) Science 294, 339-345), but they disagree with the domain disposition suggested by the actual ultrastructural model. The epitope maps in platelets activated by ADP, thrombin receptor activation peptide, and arachidonic acid differ not only from those in platelets at rest, but also among themselves. The structural rearrangements observed confirm the presence in activated platelets of the crystallographically observed knee and argue against the switchblade mechanism proposed for activation (Beglova, N., Blacklow, S. C., Takagi, J., and Springer, T. A. (2002) Nat. Struct. Biol. 9, 282-287), demonstrate the existence of alpha(IIb)beta(3) agonist-specific activation states, explain the specificity for ligand binding and functional inhibition for some agonists, and predict the existence of agonist-specific final effectors and receptor activation mechanisms. The distinct non-reciprocal competition patterns observed at rest and after activation support the agonist-specific activation states and the existence of intrasubunit and intersubunit allosteric effects, previously proposed as the mechanism for alpha(IIb)beta(3) transmembrane activation.	CSIC, Inst Quim Fis, Dept Biofis Mol, E-28006 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC)	Gonzalez-Rodriguez, J (corresponding author), CSIC, Inst Quim Fis, Dept Biofis Mol, Serrano 119, E-28006 Madrid, Spain.	J.Gonzalez-Rodriguez@iqfr.csic.es						BACHELOT C, 1995, SEMIN THROMB HEMOST, V21, P23, DOI 10.1055/s-2007-1000376; Basani RB, 2001, J BIOL CHEM, V276, P13975, DOI 10.1074/jbc.M011511200; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; CALVETE JJ, 1991, BIOCHEM J, V274, P457, DOI 10.1042/bj2740457; CALVETE JJ, 1992, BIOCHEM J, V282, P523, DOI 10.1042/bj2820523; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; CALVETE JJ, 1992, EUR J BIOCHEM, V206, P759, DOI 10.1111/j.1432-1033.1992.tb16982.x; CALVETE JJ, 1991, BIOCHEM J, V273, P767, DOI 10.1042/bj2730767; CALVETE JJ, 1989, BIOCHEM J, V261, P561, DOI 10.1042/bj2610561; CARRELL NA, 1985, J BIOL CHEM, V260, P1743; Chen LL, 1999, J BIOL CHEM, V274, P13167, DOI 10.1074/jbc.274.19.13167; deCastellarnau C, 1997, PLATELETS, V8, P243, DOI 10.1080/09537109777285; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1993, J BIOL CHEM, V268, P23087; FITZGERALD LA, 1987, BIOCHEMISTRY-US, V26, P8158, DOI 10.1021/bi00399a021; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; Garcia AJ, 1998, J BIOL CHEM, V273, P34710, DOI 10.1074/jbc.273.52.34710; GONZALEZRODRIGUEZ J, 1994, BIOCHEMISTRY-US, V33, P266, DOI 10.1021/bi00167a035; Hu DD, 1999, J BIOL CHEM, V274, P4633, DOI 10.1074/jbc.274.8.4633; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; KIEFFER N, 1990, ANNU REV CELL BIOL, V6, P329; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Loftus JC, 1997, J CLIN INVEST, V99, P2302, DOI 10.1172/JCI119408; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; MELERO JA, 1984, EUR J BIOCHEM, V141, P421, DOI 10.1111/j.1432-1033.1984.tb08208.x; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; NERMUT MV, 1988, EMBO J, V7, P4093, DOI 10.1002/j.1460-2075.1988.tb03303.x; NEWMAN PJ, 1987, BLOOD, V69, P668; ORTLEPP S, 1995, EUR J IMMUNOL, V25, P637, DOI 10.1002/eji.1830250302; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; OTOOLE TE, 1991, SCIENCE, V254, P845, DOI 10.1126/science.1948065; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; Rivas G A, 1991, Protein Expr Purif, V2, P248, DOI 10.1016/1046-5928(91)90080-3; RIVAS GA, 1991, EUR BIOPHYS J BIOPHY, V19, P335, DOI 10.1007/BF00183324; Schootemeijer A, 1997, THROMB HAEMOSTASIS, V77, P143; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; Si-Tahar M, 1997, J BIOL CHEM, V272, P11636; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; STODDARD BL, 1992, COLD SPRING HARB SYM, V57, P1; THANNHAUSER TW, 1987, METHOD ENZYMOL, V143, P115; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WIPPLER J, 1994, J BIOL CHEM, V269, P8754; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Yan BX, 2001, BIOCHEMISTRY-US, V40, P8861, DOI 10.1021/bi002902i	50	37	37	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39899	39908		10.1074/jbc.M205886200	http://dx.doi.org/10.1074/jbc.M205886200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12140290	hybrid			2022-12-27	WOS:000178662500107
J	Gobin, SJP; Biesta, P; de Steenwinkel, JEM; Datema, G; Van den Elsen, PJ				Gobin, SJP; Biesta, P; de Steenwinkel, JEM; Datema, G; Van den Elsen, PJ			HLA-G transactivation by cAMP-response element-binding protein (CREB) - An alternative transactivation pathway to the conserved major histocompatibility complex (MHC) class I regulatory routes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G PROMOTER; TRANSCRIPTIONAL REGULATION; GENE; EXPRESSION; SITE; TROPHOBLASTS; SUPPRESSES; PREGNANCY; REGION; CELLS	The expression of HLA-G in extravillous cytotrophoblast cells coincides with a general lack of classical major histocompatibility complex (MHC) class I expression in this tissue. This differential expression of HLA-G and classical HLA class I molecules in trophoblasts suggests a tight transcriptional control of MHC class I genes. Transactivation of the classical MHC class I genes is mediated by two groups of juxtaposed cis-acting elements that can be viewed as regulatory modules. Both modules are divergent in HLA-G, rendering this gene unresponsive to NF-kappaB, IRFI, and class II transactivator (CIITA)-mediated induction pathways. In this study, we searched for alternative regulatory elements in the 1438-bp HLA-G promoter region. HLA-G was not responsive to interferon-a (IFNalpha), IFNbeta, or IFNgamma, despite the presence of an upstream ISRE binding IRF1 in vitro. However, the HLA-G promoter contains three CRE/TRE elements with binding affinity for CREB/ATF and Fos/Jun proteins both in vitro and in vivo. In transient transfection assays, it was shown that HLA-G transactivation is regulated by CREB, CREB-binding protein (CBP), and p300. Moreover, immunohistochemical analysis demonstrated that HLA-G is co-expressed with CREB and CBP in extravillous cytotrophoblasts, revealing the in vivo relevance of this transactivation pathway. This implies a unique regulation of HLA-G transcription among the MHC class I genes.	Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2333 ZA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Gobin, SJP (corresponding author), Leiden Univ, Med Ctr, Dept Immunohematol & Blood Transfus, NL-2333 ZA Leiden, Netherlands.	gobin@LUMC.nl		Van den Elsen, Peter/0000-0002-5196-0082				Bainbridge DRJ, 2000, J REPROD IMMUNOL, V48, P17, DOI 10.1016/S0165-0378(00)00070-X; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; Budworth PR, 1997, MOL ENDOCRINOL, V11, P1669, DOI 10.1210/me.11.11.1669; Carosella ED, 1996, IMMUNOL TODAY, V17, P407, DOI 10.1016/0167-5699(96)30055-8; Chu WJ, 1999, HUM IMMUNOL, V60, P1113, DOI 10.1016/S0198-8859(99)00091-9; Fournel S, 2000, J IMMUNOL, V164, P6100, DOI 10.4049/jimmunol.164.12.6100; Gobin SJP, 1998, J IMMUNOL, V161, P2276; Gobin SJP, 2000, HUM IMMUNOL, V61, P1102, DOI 10.1016/S0198-8859(00)00198-1; Gobin SJP, 1998, IMMUNITY, V9, P531, DOI 10.1016/S1074-7613(00)80636-6; Gobin SJP, 2001, J IMMUNOL, V167, P5175, DOI 10.4049/jimmunol.167.9.5175; Gobin SJP, 1999, J IMMUNOL, V163, P1428; GUILLAUDEUX T, 1993, AM J REPROD IMMUNOL, V30, P228, DOI 10.1111/j.1600-0897.1993.tb00624.x; Heckert LL, 1996, J BIOL CHEM, V271, P31650, DOI 10.1074/jbc.271.49.31650; Knofler M, 2000, ENDOCRINOLOGY, V141, P3737, DOI 10.1210/en.141.10.3737; Le Bouteiller P, 1999, HUM REPROD UPDATE, V5, P223, DOI 10.1093/humupd/5.3.223; Le Bouteiller P, 1999, IMMUNOL REV, V167, P233; Le Bouteiller P, 2001, MICROBES INFECT, V3, P323, DOI 10.1016/S1286-4579(01)01386-7; Le Gal FA, 1999, INT IMMUNOL, V11, P1351, DOI 10.1093/intimm/11.8.1351; LEBOUTEILLER P, 1994, CRIT REV IMMUNOL, V14, P89, DOI 10.1615/CritRevImmunol.v14.i2.10; Lefebvre S, 2001, J BIOL CHEM, V276, P6133, DOI 10.1074/jbc.M008496200; Lila N, 2001, P NATL ACAD SCI USA, V98, P12150, DOI 10.1073/pnas.201407398; LOKE YW, 1991, CURR OPIN IMMUNOL, V3, P762, DOI 10.1016/0952-7915(91)90110-M; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; Moreau P, 1997, HUM IMMUNOL, V52, P41, DOI 10.1016/S0198-8859(96)00242-X; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; O'Callaghan CA, 1998, IMMUNOL REV, V163, P129, DOI 10.1111/j.1600-065X.1998.tb01192.x; Ober C, 1998, AM J HUM GENET, V62, P1, DOI 10.1086/301692; Riteau B, 1999, J REPROD IMMUNOL, V43, P203, DOI 10.1016/S0165-0378(99)00034-0; Rousseau P, 2000, HUM IMMUNOL, V61, P1132, DOI 10.1016/S0198-8859(00)00199-3; SCHMIDT CM, 1993, J IMMUNOL, V151, P2633; Servillo G, 2002, EXP CELL RES, V275, P143, DOI 10.1006/excr.2002.5491; van den Elsen PJ, 1998, IMMUNOGENETICS, V48, P208, DOI 10.1007/s002510050425; Wainwright SD, 2000, J IMMUNOL, V164, P319, DOI 10.4049/jimmunol.164.1.319; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	34	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39525	39531		10.1074/jbc.M112273200	http://dx.doi.org/10.1074/jbc.M112273200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12183445	hybrid			2022-12-27	WOS:000178662500061
J	Louie, TM; Yang, H; Karnchanaphanurach, P; Xie, XS; Xun, LY				Louie, TM; Yang, H; Karnchanaphanurach, P; Xie, XS; Xun, LY			FAD is a preferred substrate and an inhibitor of Escherichia coli general NAD(P)H : flavin oxidoreductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH-FLAVIN OXIDOREDUCTASE; RIBONUCLEOTIDE REDUCTASE; FERREDOXIN-NADP(+) REDUCTASE; FLAVOPROTEIN; PURIFICATION; RESOLUTION; BINDING; FAMILY; IRON	Escherichia coli general NAD(P)H:flavin oxidoreductase (Fre) does not have a bound flavin cofactor; its flavin substrates (riboflavin, FMN, and FAD) are believed to bind to it mainly through the isoalloxazine ring. This interaction was real for riboflavin and FMN, but not for FAD, which bound to Fre much tighter than FMN or riboflavin. Computer simulations of Fre-FAD and Fre-FMN complexes showed that FAD adopted an unusual bent conformation, allowing its ribityl side chain and ADP moiety to form an additional 3.28 H-bonds on average with amino acid residues located in the loop connecting Fbeta5 and Falpha1 of the flavin-binding domain and at the proposed NAD(P)H-binding site. Experimental data supported the overlapping binding sites of FAD and NAD(P)H. AMP, a known competitive inhibitor with respect to NAD(P)H, decreased the affinity of Fre for FAD. FAD behaved as a mixed-type inhibitor with respect to NADPH. The overlapped binding offers a plausible explanation for the large K. values of Fre for NADH and NADPH when FAD is the electron acceptor. Although Fre reduces FMN faster than it reduces FAD, it preferentially reduces FAD when both FAIN and FAD are present. Our data suggest that FAD is a preferred substrate and an inhibitor, suppressing the activities of Fre at low NADH concentrations.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Washington State University; Harvard University	Xun, LY (corresponding author), Washington State Univ, Sch Mol Biosci, Sci Hall 301, Pullman, WA 99164 USA.		Yang, Haw/AHD-0857-2022; Pakawatpanurut, Pasit/E-5419-2010	Yang, Haw/0000-0003-0268-6352; Pakawatpanurut, Pasit/0000-0002-7657-4161	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061577] Funding Source: NIH RePORTER; NIGMS NIH HHS [5-R01-GM61577-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bacher A., 1996, ESCHERICHIA COLI SAL, P657; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; COVES J, 1993, J BIOL CHEM, V268, P18604; COVES J, 1993, EUR J BIOCHEM, V211, P635, DOI 10.1111/j.1432-1033.1993.tb17591.x; Fieschi F, 1995, J BIOL CHEM, V270, P30392, DOI 10.1074/jbc.270.51.30392; Fonseca MV, 2000, J BACTERIOL, V182, P4304, DOI 10.1128/JB.182.15.4304-4309.2000; FONTECAVE M, 1989, J BIOL CHEM, V264, P9164; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; GIBSON QH, 1962, BIOCHEM J, V83, P368, DOI 10.1042/bj0830368; Ingelman M, 1999, BIOCHEMISTRY-US, V38, P7040, DOI 10.1021/bi982849m; Ingelman M, 1997, J MOL BIOL, V268, P147, DOI 10.1006/jmbi.1997.0957; INOUYE S, 1994, FEBS LETT, V347, P163, DOI 10.1016/0014-5793(94)00528-1; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEI BF, 1994, J BACTERIOL, V176, P3552, DOI 10.1128/JB.176.12.3552-3558.1994; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Louie TM, 2002, J BACTERIOL, V184, P3492, DOI 10.1128/JB.184.13.3492-3500.2002; Niviere V, 1999, J BIOL CHEM, V274, P18252, DOI 10.1074/jbc.274.26.18252; Niviere V, 1996, J BIOL CHEM, V271, P16656, DOI 10.1074/jbc.271.28.16656; Niviere V, 1998, BIOCHEMISTRY-US, V37, P11879, DOI 10.1021/bi980396f; OHNISHI K, 1994, J BIOL CHEM, V269, P31418; PENFOUND T, 1996, ESCHERICHIA COLI SAL, P721; Puzon GJ, 2002, BIOCHEM BIOPH RES CO, V294, P76, DOI 10.1016/S0006-291X(02)00438-2; Serre L, 1996, J MOL BIOL, V263, P20, DOI 10.1006/jmbi.1996.0553; VOET D, 1995, BIOCHEMISTRY-US, P176; Xun LY, 2000, APPL ENVIRON MICROB, V66, P481, DOI 10.1128/AEM.66.2.481-486.2000	27	25	29	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39450	39455		10.1074/jbc.M206339200	http://dx.doi.org/10.1074/jbc.M206339200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177066	hybrid			2022-12-27	WOS:000178662500051
J	Nellist, M; Goedbloed, MA; de Winter, C; Verhaaf, B; Jankie, A; Reuser, AJJ; van den Ouweland, AMW; van der Sluijs, P; Halley, DJJ				Nellist, M; Goedbloed, MA; de Winter, C; Verhaaf, B; Jankie, A; Reuser, AJJ; van den Ouweland, AMW; van der Sluijs, P; Halley, DJJ			Identification and characterization of the interaction between tuberin and 14-3-3 zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; CELL-GROWTH; TSC2 GENE; HAMARTIN; PHOSPHORYLATION; PROTEINS; PRODUCT; COMPLEX; ACTIVATION	Tuberous sclerosis is caused by mutations to either the TSC1 or TSC2 tumor suppressor gene. The disease is characterized by a broad phenotypic spectrum that includes seizures, mental retardation, renal dysfunction, and dermatological abnormalities. TSC1 encodes a 130-kDa protein called hamartin, and TSC2 encodes a 200-kDa protein called tuberin. Although it has been shown that hamartin and tuberin form a complex and mediate phosphoinositide 3-kinase/Akt-dependent phosphorylation of the ribosomal protein S6, it is not yet clear how inactivation of either protein leads to tuberous sclerosis. Therefore, to obtain additional insight into tuberin and hamartin function, yeast two-hybrid screening experiments were performed to identify proteins that interact with tuberin. One of the proteins identified was 14-3-3zeta, a member of the 14-3-3zeta protein family. The interaction between tuberin and 14-3-3zeta was confirmed in vitro and by co-immunoprecipitation; multiple sites within tuberin for 14-3-3zeta binding were identified; and it was determined that 14-3-3zeta associated with the tuberin-hamartin complex. Finally, it was shown that the tuberin/14-3-3zeta interaction is regulated by Akt-mediated phosphorylation of tuberin, providing insight into how tuberin may regulate phosphorylation of S6.	Erasmus MC, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Univ Utrecht, Sch Med, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands	Erasmus University Rotterdam; Erasmus MC; Utrecht University	Nellist, M (corresponding author), Erasmus MC, Dept Clin Genet, POB 1738,Dr Molewaterpl 50, NL-3000 DR Rotterdam, Netherlands.	nellist@kgen.fgg.eur.nl						Aicher LD, 2001, J BIOL CHEM, V276, P21017, DOI 10.1074/jbc.C100136200; FORD JC, 1994, SCIENCE, V265, P533, DOI 10.1126/science.8036497; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; GELPERIN D, 1995, P NATL ACAD SCI USA, V92, P11539, DOI 10.1073/pnas.92.25.11539; Gomez M. R., 1999, TUBEROUS SCLEROSIS C; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; GORDON JA, 1991, METHOD ENZYMOL, V201, P477; Hashiguchi M, 2000, J BIOL CHEM, V275, P25247, DOI 10.1074/jbc.M003738200; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Lou Dingyuan, 2001, Molecular Cell Biology Research Communications, V4, P374, DOI 10.1006/mcbr.2001.0307; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; Nellist M, 1999, J BIOL CHEM, V274, P35647, DOI 10.1074/jbc.274.50.35647; NELLIST M, 1993, CELL, V75, P1305; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Zhai JB, 2001, J BIOL CHEM, V276, P41318, DOI 10.1074/jbc.M107709200	29	60	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39417	39424		10.1074/jbc.M204802200	http://dx.doi.org/10.1074/jbc.M204802200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176984	hybrid			2022-12-27	WOS:000178662500047
J	Sarg, B; Koutzamani, E; Helliger, W; Rundquist, I; Lindner, HH				Sarg, B; Koutzamani, E; Helliger, W; Rundquist, I; Lindner, HH			Postsynthetic trimethylation of histone H4 at lysine 20 in mammalian tissues is associated with aging	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE CAPILLARY ELECTROPHORESIS; INTERACTION LIQUID-CHROMATOGRAPHY; ARGININE-RICH HISTONE; HP1 CHROMO DOMAIN; CORE HISTONES; METHYL GROUPS; GLYCINE-RICH; CELL-CYCLE; IN-VIVO; H3	Methylation of the N-terminal region of histories was first described more than 35 years ago, but its biological significance has remained unclear. Proposed functions range from transcriptional regulation to the higher order packing of chromatin in progress of mitotic condensation. Primarily because of the recent discovery of the SET domain-depending H3-specific historic methyl-transferases SUV39H1 and Suv39h1, which selectively methylate lysine 9 of the H3 N terminus, this posttranslational modification has regained scientific interest. In the past, investigations concerning the biological significance of histone methylation were largely limited because of a lack of simple and sensitive analytical procedures for detecting this modification. The present work investigated the methylation pattern of histone H4 both in different mammalian organs of various ages and in cell lines by applying mass spectrometric analysis and a newly developed hydrophilic-interaction liquid chromatographic method enabling the simultaneous separation of methylated and acetylated forms, which obviates the need to work with radioactive materials. In rat kidney and liver the dimethylated lysine 20 was found to be the main methylation product, whereas the monomethyl derivative was present in much smaller amounts. In addition, for the first time a trimethylated form of lysine 20 of H4 was found in mammalian tissue. A significant increase in this trimethylated histone H4 was detected in organs of animals older than 30 days, whereas the amounts of mono- and dimethylated forms did not essentially change in organs from young (10 days old) or old animals (30 and 450 days old). Trimethylated H4 was also detected in transformed cells; although it was present in only trace amounts in logarithmically growing cells, we found an increase in trimethylated lysine 20 in cells in the stationary phase.	Univ Innsbruck, Dept Med Chem & Biochem, A-6020 Innsbruck, Austria; Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, SE-58185 Linkoping, Sweden	University of Innsbruck; Linkoping University	Lindner, HH (corresponding author), Univ Innsbruck, Dept Med Chem & Biochem, Fritz Pregl Str 3, A-6020 Innsbruck, Austria.	herbert.lindner@uibk.ac.at	Koutzamani, Elisavet/N-4112-2015	Koutzamani, Elisavet/0000-0003-3059-5191				ANNUNZIATO AT, 1995, BIOCHEMISTRY-US, V34, P2916, DOI 10.1021/bi00009a023; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; BAXTER CS, 1975, BIOCHEM BIOPH RES CO, V63, P286, DOI 10.1016/S0006-291X(75)80041-6; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; BORUN TW, 1972, J BIOL CHEM, V247, P4288; BYVOET P, 1972, ARCH BIOCHEM BIOPHYS, V148, P558, DOI 10.1016/0003-9861(72)90174-9; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; DELANGE RJ, 1970, BIOCHEM BIOPH RES CO, V40, P989, DOI 10.1016/0006-291X(70)91001-6; DESAI LS, 1970, BIOCHEM J, V119, P165, DOI 10.1042/bj1190165; DESROSIERS R, 1988, J BIOL CHEM, V263, P4686; DUERRE JA, 1985, BIOCHIM BIOPHYS ACTA, V843, P58, DOI 10.1016/0304-4165(85)90049-2; GRIMES S, 1987, EXP CELL RES, V173, P534, DOI 10.1016/0014-4827(87)90293-X; Gupta S, 2000, SEMIN CANCER BIOL, V10, P161; HEMPEL K, 1979, H-S Z PHYSIOL CHEM, V360, P869, DOI 10.1515/bchm2.1979.360.2.869; HENDZEL MJ, 1989, J BIOL CHEM, V264, P19208; HONDA BM, 1975, J BIOL CHEM, V250, P8681; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jenuwein T, 2001, TRENDS CELL BIOL, V11, P266, DOI 10.1016/S0962-8924(01)02001-3; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lindner H, 1996, J CHROMATOGR A, V743, P137, DOI 10.1016/0021-9673(96)00131-8; LINDNER H, 1992, BIOCHEM J, V283, P467, DOI 10.1042/bj2830467; Lindner H, 1997, J CHROMATOGR A, V782, P55, DOI 10.1016/S0021-9673(97)00468-8; LINDNER H, 1992, J CHROMATOGR, V608, P211, DOI 10.1016/0021-9673(92)87126-S; Lindner H, 1998, J BIOL CHEM, V273, P13324, DOI 10.1074/jbc.273.21.13324; OGAWA Y, 1969, J BIOL CHEM, V244, P4387; Paik W. K., 1980, PROTEIN METHYLATION; PAIK WK, 1969, ARCH BIOCHEM BIOPHYS, V134, P632, DOI 10.1016/0003-9861(69)90327-0; Rice JC, 2001, CURR OPIN CELL BIOL, V13, P263, DOI 10.1016/S0955-0674(00)00208-8; SARNOW P, 1981, BIOCHIM BIOPHYS ACTA, V655, P349, DOI 10.1016/0005-2787(81)90045-9; STARBUCK WC, 1968, J BIOL CHEM, V243, P2038; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967; SUNG MT, 1977, BIOCHEMISTRY-US, V16, P279, DOI 10.1021/bi00621a019; THOMAS G, 1975, EUR J BIOCHEM, V51, P609, DOI 10.1111/j.1432-1033.1975.tb03963.x; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; WOLD F, 1981, ANNU REV BIOCHEM, V50, P783, DOI 10.1146/annurev.bi.50.070181.004031; WU RS, 1986, CRIT REV BIOCHEM MOL, V20, P201, DOI 10.3109/10409238609083735	41	190	195	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39195	39201		10.1074/jbc.M205166200	http://dx.doi.org/10.1074/jbc.M205166200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12154089	hybrid			2022-12-27	WOS:000178662500019
J	Huttunen, HJ; Kuja-Panula, J; Rauvala, H				Huttunen, HJ; Kuja-Panula, J; Rauvala, H			Receptor for advanced glycation end products (RAGE) signaling induces CREB-dependent chromogranin expression during neuronal differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROLEUKEMIA CELL-DIFFERENTIATION; PROTEIN-KINASE PATHWAY; NEURITE OUTGROWTH; TRANSCRIPTION FACTOR; NEUROBLASTOMA-CELLS; ALZHEIMERS-DISEASE; SECRETOGRANIN-II; BINDING-PROTEINS; ENDOTHELIAL-CELLS; GENE-EXPRESSION	Receptor for advanced glycation end products (RAGE) mediates neurite outgrowth and cell migration upon stimulation with its ligand, amphoterin. We show here that RAGE-dependent changes in cell morphology are associated with proliferation arrest and changes in gene expression in neuroblastoma cells. Chromogranin B, a component of secretory vesicles in endocrine cells and neurons, was found to be up-regulated by RAGE signaling during differentiation of neuroblastoma cells along with the two other members of the chromogranin family, chromogranin A and secretogranin II. Ligation of RAGE by amphoterin lead to rapid phosphorylation and nuclear localization of cyclic AMP response element-binding protein (CREB), a major regulator of chromogranin expression. Furthermore, inhibition of ERK1/2-Rsk2-dependent CREB phosphorylation efficiently inhibited up-regulation of chromogranin gene expression upon RAGE activation. To further study the effects of RAGE and amphoterin on cellular differentiation, we stimulated embryonic stem cells expressing RAGE or a signaling-deficient mutant of RAGE with amphoterin. Amphoterin was found to promote RAGE-dependent neuronal differentiation of embryonic stem cells characterized by up-regulation of neuronal markers light neurofilament protein and beta-III-tubulin, activation of CREB, and increased expression of chromogranins A and B. These data suggest that RAGE signaling is capable of driving neuronal differentiation involving CREB activation and induction of chromogranin expression.	Univ Helsinki, Programme Mol Neurobiol, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Huttunen, HJ (corresponding author), Univ Helsinki, Programme Mol Neurobiol, Inst Biotechnol, POB 56,Viikinkaari 5, FIN-00014 Helsinki, Finland.		li, tao/B-2402-2008	Huttunen, Henri/0000-0002-9867-4438; Rauvala, Heikki/0000-0001-7809-9811				Abe K, 1996, BRAIN RES, V723, P206, DOI 10.1016/0006-8993(96)00253-3; BAUER D, 1993, NUCLEIC ACIDS RES, V21, P4272, DOI 10.1093/nar/21.18.4272; Bierhaus A, 1997, CIRCULATION, V96, P2262; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Ciesielski-Treska J, 2001, J BIOL CHEM, V276, P13113, DOI 10.1074/jbc.M009711200; Crain BJ, 1996, AM J PATHOL, V149, P1087; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Fages C, 2000, J CELL SCI, V113, P611; FERREIRA A, 1992, J NEUROSCI RES, V32, P516, DOI 10.1002/jnr.490320407; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; FISCHERCOLBRIE R, 1995, PROG NEUROBIOL, V46, P49, DOI 10.1016/0301-0082(94)00060-U; GIUDICI AM, 1992, EUR J CELL BIOL, V58, P383; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Huang CM, 2001, MOL BRAIN RES, V92, P181, DOI 10.1016/S0169-328X(01)00118-8; HUTTNER WB, 1991, TRENDS BIOCHEM SCI, V16, P27, DOI 10.1016/0968-0004(91)90012-K; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; JUNGLING S, 1994, EUR J BIOCHEM, V226, P925, DOI 10.1111/j.1432-1033.1994.00925.x; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; Lamberts SWJ, 2001, FRONT NEUROENDOCRIN, V22, P309, DOI 10.1006/frne.2001.0218; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Li JF, 1998, J BIOL CHEM, V273, P30870, DOI 10.1074/jbc.273.47.30870; Lo LC, 1999, NEURON, V22, P693, DOI 10.1016/S0896-6273(00)80729-1; Lue LF, 2001, EXP NEUROL, V171, P29, DOI 10.1006/exnr.2001.7732; Mahata SK, 1999, NEUROSCIENCE, V88, P405, DOI 10.1016/S0306-4522(98)00225-5; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; Oldfield MD, 2001, J CLIN INVEST, V108, P1853; Ozawa H, 1995, CELL STRUCT FUNCT, V20, P415, DOI 10.1247/csf.20.415; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; Pons S, 2001, DEVELOPMENT, V128, P1481; Rauvala H, 2000, MATRIX BIOL, V19, P377, DOI 10.1016/S0945-053X(00)00084-6; RAUVALA H, 1988, J CELL BIOL, V107, P2293, DOI 10.1083/jcb.107.6.2293; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; RONG LL, 2001, SOC NEUR ABSTR; Sajithlal G, 2002, J BIOL CHEM, V277, P6888, DOI 10.1074/jbc.M107627200; Scammell JG, 2000, MOL BRAIN RES, V75, P8, DOI 10.1016/S0169-328X(99)00269-7; SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI200114002; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shen PJ, 1996, EUR J NEUROSCI, V8, P988, DOI 10.1111/j.1460-9568.1996.tb01586.x; Sparatore B, 1996, BIOCHEM J, V320, P253, DOI 10.1042/bj3200253; Sparatore B, 2001, BIOCHEM J, V357, P569, DOI 10.1042/0264-6021:3570569; Swanson KD, 1999, J BIOL CHEM, V274, P3385, DOI 10.1074/jbc.274.6.3385; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Tang KC, 1998, MOL PHARMACOL, V54, P59, DOI 10.1124/mol.54.1.59; Tropepe V, 2001, NEURON, V30, P65, DOI 10.1016/S0896-6273(01)00263-X; Walton MR, 2000, TRENDS NEUROSCI, V23, P48, DOI 10.1016/S0166-2236(99)01500-3; Weiss C, 2001, NEUROCHEM INT, V38, P43, DOI 10.1016/S0197-0186(00)00046-2; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WU HJ, 1995, J CLIN INVEST, V96, P568, DOI 10.1172/JCI118069; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; YASUHARA O, 1994, NEUROSCI LETT, V170, P13, DOI 10.1016/0304-3940(94)90227-5; Zhai RG, 2001, NEURON, V29, P131, DOI 10.1016/S0896-6273(01)00185-4	62	136	141	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38635	38646		10.1074/jbc.M202515200	http://dx.doi.org/10.1074/jbc.M202515200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167613	hybrid			2022-12-27	WOS:000178529600081
J	Locascio, A; Vega, S; de Frutos, CA; Manzanares, M; Nieto, MA				Locascio, A; Vega, S; de Frutos, CA; Manzanares, M; Nieto, MA			Biological potential of a functional human SNAIL retrogene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SNAIL; E-CADHERIN EXPRESSION; NEURAL CREST; CARCINOMA-CELLS; GENE FAMILY; P-CADHERIN; REPRESSOR; ORGANIZATION; SUPERFAMILY; TRANSITION	Snail genes encode zinc finger transcription factors required for the development of vertebrate and invertebrate embryos. They trigger epithelial to mesenchymal transitions (EMTs), thereby allowing epithelial cells to emigrate from their place of origin and form tissues such as the mesoderm and the neural crest. Snail genes are also involved in the EMTs responsible for the acquisition of invasiveness during tumor progression. This aspect of their activity is associated with their ability to directly repress E-cadherin transcription. Here we describe the existence of an active human Snail retrogene, inserted within an intron of a novel evolutionarily conserved gene and expressed in different human tissues and cell lines. Functional analyses in cell culture show that this retrogene maintains the potential to induce EMTs, conferring migratory and invasive properties to epithelial cells. In light of this data, we have renamed it SNAIL-like, a new player that must be considered in both physiological and pathological studies of SNAIL function in humans.	CSIC, Inst Cajal, E-28002 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)	Manzanares, M (corresponding author), UAM, CSIC, Inst Invest Biomed, Arturo Duperier 4, Madrid 28029, Spain.	mmanzanares@iib.uam.es	Nieto, M. Angela/A-6531-2008; Manzanares, Miguel/AAZ-8305-2021; Manzanares, Miguel/E-1702-2015; Locascio, Annamaria/E-8714-2015; Vega, Sonia/R-1883-2018	Nieto, M. Angela/0000-0002-3538-840X; Manzanares, Miguel/0000-0003-4849-2836; Manzanares, Miguel/0000-0003-4849-2836; Locascio, Annamaria/0000-0001-6956-2157; Vega, Sonia/0000-0002-3895-6265				ADRA CN, 1988, SOMAT CELL MOLEC GEN, V14, P69, DOI 10.1007/BF01535050; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; Brosius J, 1999, GENE, V238, P115, DOI 10.1016/S0378-1119(99)00227-9; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; DAHL HHM, 1990, GENOMICS, V8, P225, DOI 10.1016/0888-7543(90)90275-Y; Duband JL, 1995, ACTA ANAT, V154, P63; Faraldo MLM, 1997, MOL CARCINOGEN, V20, P33, DOI 10.1002/(SICI)1098-2744(199709)20:1<33::AID-MC5>3.0.CO;2-J; Feil R, 1997, BIOCHEM BIOPH RES CO, V237, P752, DOI 10.1006/bbrc.1997.7124; FITZGERALD J, 1992, BIOCHIM BIOPHYS ACTA, V1131, P83, DOI 10.1016/0167-4781(92)90102-6; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; GOMEZ M, 1994, INVAS METAST, V14, P17; GRAU Y, 1984, GENETICS, V108, P347; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Hajra KM, 2002, CANCER RES, V62, P1613; Hay ED, 1995, ACTA ANAT, V154, P8; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; Hemavathy K, 2000, MOL CELL BIOL, V20, P5087, DOI 10.1128/MCB.20.14.5087-5095.2000; Hughes AL, 2000, P NATL ACAD SCI USA, V97, P3319, DOI 10.1073/pnas.050002797; Kataoka H, 2000, NUCLEIC ACIDS RES, V28, P626, DOI 10.1093/nar/28.2.626; Lahn BT, 1999, NAT GENET, V21, P429, DOI 10.1038/7771; LEWIS SA, 1986, J CELL BIOL, V102, P2098, DOI 10.1083/jcb.102.6.2098; Llorens A, 1998, LAB INVEST, V78, P1131; Lozano E, 1998, CELL ADHES COMMUN, V6, P51, DOI 10.3109/15419069809069760; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Manzanares M, 2001, TRENDS GENET, V17, P178, DOI 10.1016/S0168-9525(01)02232-6; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; Nakayama H, 1998, DEV BIOL, V199, P150, DOI 10.1006/dbio.1998.8914; NAVARRO P, 1993, J CELL SCI, V105, P923; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Nieto MA, 2001, MECH DEVELOP, V105, P27, DOI 10.1016/S0925-4773(01)00394-X; Pan YZ, 1999, GENOMICS, V59, P282, DOI 10.1006/geno.1999.5874; Paznekas WA, 1999, GENOMICS, V62, P42, DOI 10.1006/geno.1999.6010; Perez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Saito T, 2001, AM J PATHOL, V159, P2117, DOI 10.1016/S0002-9440(10)63063-5; SARGENT CA, 1994, HUM MOL GENET, V3, P1317, DOI 10.1093/hmg/3.8.1317; SPENCER N, 1980, ANN HUM GENET, V43, P335, DOI 10.1111/j.1469-1809.1980.tb01567.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Twigg SRF, 1999, HUM GENET, V105, P320, DOI 10.1007/s004390051108; VENNSTROM B, 1982, CELL, V28, P135, DOI 10.1016/0092-8674(82)90383-X	48	25	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38803	38809		10.1074/jbc.M205358200	http://dx.doi.org/10.1074/jbc.M205358200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151403	hybrid			2022-12-27	WOS:000178529600101
J	Kominato, Y; Hata, Y; Takizawa, H; Matsumoto, K; Yasui, K; Tsukada, J; Yamamoto, F				Kominato, Y; Hata, Y; Takizawa, H; Matsumoto, K; Yasui, K; Tsukada, J; Yamamoto, F			Alternative promoter identified between a hypermethylated upstream region of repetitive elements and a CpG island in human ABO histo-blood group genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; GROUP ANTIGENS; MESSENGER-RNA; TRANSCRIPTIONAL REPRESSOR; HUMAN CANCER; A-ANTIGEN; CBF/NF-Y; EXPRESSION; BINDING; DIFFERENTIATION	We have studied the expression of human histo-blood group ABO genes during erythroid differentiation, using an ex vivo culture of AC133(-)CD34(+) cells obtained from peripheral blood. 5'-Rapid amplification of cDNA ends analysis of RNA from those cells revealed a novel transcription start site, which appeared to mark an alternative starting exon (1a) comprising 27 bp at the 5'-end of a CpG island in ABO genes. Results from reverse transcription-PCR specific to exon la indicated that the cells of both erythroid and epithelial lineages utilize this exon as the transcription starting exon. Transient transfection experiments showed that the region just upstream from the transcription start site possesses promoter activity in a cell type-specific manner when placed 5' adjacent to the reporter luciferase gene. Results from bisulfite genomic sequencing and reverse transcription-PCR analysis indicated that hypermethylation of the distal promoter region correlated with the absence of transcripts containing exon 1a, whereas hypermethylation in the interspersed repeats 5' adjacent to the distal promoter was commonly observed in all of the cell lines examined. These results suggest that a functional alternative promoter is located between the hypermethylated region of repetitive elements and the CpG island in the ABO genes.	Toyama Med & Pharmaceut Univ, Dept Internal Med 1, Fac Med, Toyama 9300194, Japan; Osaka Red Cross Blood Ctr, Osaka 5368505, Japan; Univ Occupat & Environm Hlth, Sch Med, Dept Internal Med 1, Kitakyushu, Fukuoka 8078555, Japan; Burnham Inst, La Jolla, CA 92037 USA	University of Toyama; Osaka Red Cross Hospital; University of Occupational & Environmental Health - Japan; Sanford Burnham Prebys Medical Discovery Institute	Kominato, Y (corresponding author), Toyama Med & Pharmaceut Univ, Dept Legal Med, Fac Med, 2630 Sugitani, Toyama 9300194, Japan.		Yamamoto, Fumiichiro/F-1478-2016	Yamamoto, Fumiichiro/0000-0001-9690-7034				Atanasova E, 1999, J BIOL CHEM, V274, P21078, DOI 10.1074/jbc.274.30.21078; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BENNETT EP, 1995, BIOCHEM BIOPH RES CO, V206, P318, DOI 10.1006/bbrc.1995.1044; Bony V, 1999, BRIT J HAEMATOL, V107, P263, DOI 10.1046/j.1365-2141.1999.01721.x; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Burset M, 2001, NUCLEIC ACIDS RES, V29, P255, DOI 10.1093/nar/29.1.255; CAMERON HS, 1995, J BIOL CHEM, V270, P20112, DOI 10.1074/jbc.270.34.20112; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; CORDONCARDO C, 1986, LAB INVEST, V55, P444; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Cross SH, 1997, NAT GENET, V16, P256, DOI 10.1038/ng0797-256; DABELSTEEN E, 1982, J INVEST DERMATOL, V79, P3, DOI 10.1111/1523-1747.ep12510411; DAVID L, 1993, CANCER RES, V53, P5494; GINSBURG V, 1972, ADV ENZYMOL RAMB, V36, P131; Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322; GROCE LD, 2002, SCIENCE, V295, P1079; Hata Y, 2002, VOX SANG, V82, P39, DOI 10.1046/j.0042-9007.2001.00134.x; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; HSIEH CH, 1994, MOL CELL BIOL, P5487; Iwamoto S, 1999, GLYCOCONJUGATE J, V16, P659, DOI 10.1023/A:1007085202379; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; JUHL BR, 1986, CANCER, V57, P1768, DOI 10.1002/1097-0142(19860501)57:9<1768::AID-CNCR2820570910>3.0.CO;2-E; KABAT EA, 1973, CARBOHYDRATES SOLUTI, P334; Koda Y, 1997, J BIOL CHEM, V272, P7501, DOI 10.1074/jbc.272.11.7501; Kominato Y, 1997, J BIOL CHEM, V272, P25890, DOI 10.1074/jbc.272.41.25890; Kominato Y, 1999, J BIOL CHEM, V274, P37240, DOI 10.1074/jbc.274.52.37240; Kosugi H, 1999, LEUKEMIA, V13, P1316, DOI 10.1038/sj.leu.2401508; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Landsteiner K., 1900, ZBL BAKT, V27, P357; LEE JS, 1991, NEW ENGL J MED, V324, P1084, DOI 10.1056/NEJM199104183241603; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; MAGEWU AN, 1994, MOL CELL BIOL, V14, P4225, DOI 10.1128/MCB.14.6.4225; MATSUMOTO H, 1993, CANCER-AM CANCER SOC, V72, P75, DOI 10.1002/1097-0142(19930701)72:1<75::AID-CNCR2820720116>3.0.CO;2-Z; Matsumoto K, 2000, STEM CELLS, V18, P196, DOI 10.1634/stemcells.18-3-196; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; Millar DS, 2000, J BIOL CHEM, V275, P24893, DOI 10.1074/jbc.M906538199; MIYAKE M, 1992, NEW ENGL J MED, V327, P14, DOI 10.1056/NEJM199207023270103; MORGAN WTJ, 1969, BRIT MED BULL, V25, P30, DOI 10.1093/oxfordjournals.bmb.a070666; MUMMANENI P, 1995, J BIOL CHEM, V270, P788, DOI 10.1074/jbc.270.2.788; Mummaneni P, 1998, NUCLEIC ACIDS RES, V26, P5163, DOI 10.1093/nar/26.22.5163; Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; ORNTOFT TF, 1990, APMIS S17, V98, P1; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Schenkel-Brunner H, 2000, HUMAN BLOOD GROUPS C, V2nd, P54, DOI [10.1007/978-3-7091-6294-1, DOI 10.1007/978-3-7091-6294-1]; Shimada I, 1999, Leg Med (Tokyo), V1, P217, DOI 10.1016/S1344-6223(99)80041-8; SIEFF C, 1982, BLOOD, V60, P703; TOTH M, 1989, P NATL ACAD SCI USA, V86, P3728, DOI 10.1073/pnas.86.10.3728; Turker MS, 1999, SEMIN CANCER BIOL, V9, P329, DOI 10.1006/scbi.1999.0133; WADA H, 1990, BLOOD, V75, P505, DOI 10.1182/blood.V75.2.505.505; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Watkins W M, 1980, Adv Hum Genet, V10, P1; YAMAMOTO F, 1990, J BIOL CHEM, V265, P19257; YAMAMOTO F, 1990, NATURE, V345, P229, DOI 10.1038/345229a0; YAMAMOTO F, 1995, GLYCOBIOLOGY, V5, P51, DOI 10.1093/glycob/5.1.51; Yin JL, 2001, IMMUNOL CELL BIOL, V79, P213, DOI 10.1046/j.1440-1711.2001.01002.x; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	59	41	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37936	37948		10.1074/jbc.M204238200	http://dx.doi.org/10.1074/jbc.M204238200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151392	hybrid			2022-12-27	WOS:000178447100131
J	Liu, ZY; Chatterjee, TK; Fisher, RA				Liu, ZY; Chatterjee, TK; Fisher, RA			RGS6 interacts with SCG10 and promotes neuronal differentiation - Role of the G gamma subunit-like (GGL) domain of RGS6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN BETA-SUBUNIT; HETEROTRIMERIC G-PROTEINS; SIGNALING RGS; IN-VITRO; REGULATORS; LOCALIZATION; STATHMIN; NUCLEAR; BINDING; COMPLEX	RGS proteins comprise a large family of proteins named for their ability to negatively regulate heterotrimeric G protein signaling. RGS6 is a member of the R7 RGS protein subfamily endowed with DEP (disheveled, Egl-10, pleckstrin) and GGL (G protein gamma subunit-like) domains in addition to the RGS domain present in all RGS proteins. RGS6 exists in multiple splice variant forms with identical RGS domains but possessing complete or incomplete GGL domains and distinct N- and C-terminal domains. Here we report that RGS6 interacts with SCG10, a neuronal growth-associated protein. Using yeast two-hybrid analysis to map protein interaction domains, we identified the GGL domain of RGS6 as the SCG10-interacting region and the stathmin domain of SCG10 as the RGS6-interacting region. Pull-down studies in COS-7 cells expressing: SCG10 and RGS6 splice variants revealed that SCG10 co-precipitated RGS6 proteins with complete GGL domains but not those with incomplete GGL domains, and vice versa. Expression of SCG10-interacting forms of RGS6 with SCG10 in PC12 or COS-7 cells resulted in co-localization of both proteins. RGS6 potentiated the ability of SCG10 to disrupt microtubule organization in PC12 and COS-7 cells. Furthermore, expression of SCG10 and RGS6 each enhanced NGF-induced PC12 cell differentiation, and co-expression of SCG10 with RGS6 produced synergistic effects on NGF-induced PC12 differentiation. These effects of RGS6 on microtubules and neuronal differentiation were observed only with RGS6 proteins with complete GGL domains. Mutation of a critical residue required for interaction of RGS proteins with G proteins did not affect the ability of RGS6 to induce neuronal differentiation. These findings identify SCG10 as a binding partner for the GGL domain of RGS6 and provide the first evidence for regulatory effects of an RGS protein on neuronal differentiation. Our results suggest that RGS6 induces neuronal differentiation by a novel mechanism involving interaction of SCG10 with its GGL domain and independent of RGS6 interactions with heterotrimeric G proteins.	Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA	University of Iowa	Fisher, RA (corresponding author), Univ Iowa, Coll Med, Dept Pharmacol, Iowa City, IA 52242 USA.			Fisher, Rory/0000-0003-3108-4836	NHLBI NIH HHS [HL-41071] Funding Source: Medline; NIDDK NIH HHS [DK-25295] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041071, R29HL041071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antonsson B, 1998, J BIOL CHEM, V273, P8439, DOI 10.1074/jbc.273.14.8439; Burgon PG, 2001, J BIOL CHEM, V276, P32828, DOI 10.1074/jbc.M100960200; Charbaut E, 2001, J BIOL CHEM, V276, P16146, DOI 10.1074/jbc.M010637200; Chatterjee TK, 2000, J BIOL CHEM, V275, P29660, DOI 10.1074/jbc.M000330200; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Chatterjee TK, 2002, MOL CELL BIOL, V22, P4334, DOI 10.1128/MCB.22.12.4334-4345.2002; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Cordes SP, 2001, NAT REV NEUROSCI, V2, P611, DOI 10.1038/35090039; Di Paolo G, 1997, J NEUROSCI RES, V50, P1000, DOI 10.1002/(SICI)1097-4547(19971215)50:6<1000::AID-JNR10>3.0.CO;2-8; DiPaolo G, 1997, J BIOL CHEM, V272, P5175, DOI 10.1074/jbc.272.8.5175; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Gavet O, 1998, J CELL SCI, V111, P3333; He W, 2000, J BIOL CHEM, V275, P37093, DOI 10.1074/jbc.M006982200; Khawaja XZ, 1999, J NEUROCHEM, V72, P174, DOI 10.1046/j.1471-4159.1999.0720174.x; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Levay K, 1999, P NATL ACAD SCI USA, V96, P2503, DOI 10.1073/pnas.96.5.2503; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Nixon AB, 2002, J BIOL CHEM, V277, P18127, DOI 10.1074/jbc.M201065200; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Posner BA, 1999, BIOCHEMISTRY-US, V38, P7773, DOI 10.1021/bi9906367; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1999, P NATL ACAD SCI USA, V96, P6489, DOI 10.1073/pnas.96.11.6489; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; Thomas EA, 1998, J NEUROSCI RES, V52, P118, DOI 10.1002/(SICI)1097-4547(19980401)52:1<118::AID-JNR11>3.0.CO;2-6; WATSON AJ, 1994, J BIOL CHEM, V269, P22150; Witherow DS, 2000, J BIOL CHEM, V275, P24872, DOI 10.1074/jbc.M001535200; Zhang JH, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-03-j0004.2000	30	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37832	37839		10.1074/jbc.M205908200	http://dx.doi.org/10.1074/jbc.M205908200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12140291	hybrid			2022-12-27	WOS:000178447100118
J	Pepio, AM; Thibault, GL; Sossin, WS				Pepio, AM; Thibault, GL; Sossin, WS			Phosphoinositide-dependent kinase phosphorylation of protein kinase C Apl II increases during intermediate facilitation in Aplysia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM FACILITATION; S6 KINASE; ACTIVATION; EXPRESSION; MEMBRANE; ISOFORMS; TRANSLOCATION; MECHANISM; ISOZYMES; NEURONS	Phosphorylation of protein kinase Cs (PKCs) by phosphoinositide-dependent kinase I (PDK) is critical for PKC activity. In the nervous system of the marine mollusk Aplysia, there are only two major PKC isoforms, the calcium-activated PKC Apl I and the calcium-independent PKC Apl II, and both PKCs are persistently activated during intermediate memory. We monitored the PDK-dependent phosphorylation of PKC Apl I and PKC Apl II using phosphopeptide antibodies. During persistent activation of PKCs in Aplysia neurons, there is a significant increase in the amount of PDK-phosphorylated PKC Apl II in the particulate fraction but no increase in the amount of PKC Apl I phosphorylated by PDK. PDK phosphorylation of PKCs was not sensitive to inhibitors of phosphatidylinositol 3-kinase, PKC, or expression of a kinase-inactive PDK. Localization of PDK-phosphorylated PKC Apl II using immunocytochemistry revealed an enrichment of phosphorylated PKC Apl II at the plasma membrane. These data suggest that increased PDK phosphorylation of PKC Apl II is important for persistent kinase activation.	McGill Univ, Dept Neurol & Neurosurg, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	McGill University	Sossin, WS (corresponding author), Elan Pharmaceut, 7475 Lusk Blvd, San Diego, CA 92121 USA.	wayne.sossin@mcgill.ca						Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Burry RW, 1998, J NEUROSCI RES, V53, P214, DOI 10.1002/(SICI)1097-4547(19980715)53:2<214::AID-JNR10>3.0.CO;2-6; Byrne JH, 1996, J NEUROSCI, V16, P425; Dutil EM, 2000, J BIOL CHEM, V275, P10697, DOI 10.1074/jbc.275.14.10697; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Dyer JR, 1998, J BIOL CHEM, V273, P29469, DOI 10.1074/jbc.273.45.29469; EISENSTADT M, 1973, P NATL ACAD SCI USA, V70, P3371, DOI 10.1073/pnas.70.12.3371; Ekinci FJ, 1997, INT J DEV NEUROSCI, V15, P867, DOI 10.1016/S0736-5748(97)00037-3; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; Khan A, 2001, J NEUROSCI, V21, P382, DOI 10.1523/JNEUROSCI.21-02-00382.2001; KLANN E, 1993, P NATL ACAD SCI USA, V90, P8337, DOI 10.1073/pnas.90.18.8337; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Liu KP, 2000, J NEUROSCI, V20, P1365; Manseau F, 2001, J NEUROSCI, V21, P1247; Nakhost A, 1999, J BIOL CHEM, V274, P28944, DOI 10.1074/jbc.274.41.28944; Nakhost A, 1998, J NEUROCHEM, V71, P1221; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.43.25526; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Pascale A, 1996, NEUROSCI LETT, V214, P99, DOI 10.1016/0304-3940(96)12901-3; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; RYBIN VO, 1994, CIRC RES, V74, P299, DOI 10.1161/01.RES.74.2.299; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200; Sossin W S, 1994, Learn Mem, V1, P189; SOSSIN WS, 1994, MOL BRAIN RES, V24, P210, DOI 10.1016/0169-328X(94)90134-1; SOSSIN WS, 1993, J BIOL CHEM, V268, P5763; Sossin WS, 1997, LEARN MEMORY, V3, P389, DOI 10.1101/lm.3.5.389; Sossin WS, 1996, J NEUROCHEM, V67, P220; Sossin WS, 1996, J NEUROSCI, V16, P10; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Sutton MA, 2000, NEURON, V26, P219, DOI 10.1016/S0896-6273(00)81152-6; Sweatt JD, 1998, J NEUROCHEM, V71, P1075; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0	40	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37116	37123		10.1074/jbc.M202264200	http://dx.doi.org/10.1074/jbc.M202264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12140280	hybrid			2022-12-27	WOS:000178447100028
J	Vorberg, I; Priola, SA				Vorberg, I; Priola, SA			Molecular basis of scrapie strain glycoform variation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRION PROTEIN ISOFORMS; TRANSMISSIBLE MINK ENCEPHALOPATHY; CREUTZFELDT-JAKOB-DISEASE; CULTURED-CELLS; AGENT; PRP; BSE; CONVERSION; PHOSPHOLIPASE; CONFORMATIONS	Transmissible spongiform encephalopathies (TSE) are characterized by the conversion of a protease-sensitive host glycoprotein, prion protein or PrP-sen, to a protease-resistant form (PrP-res). PrP-res molecules that accumulate in the brain and lymphoreticular system of the host consist of three differentially glycosylated forms. Analysis of the relative amounts of the PrP-res glycoforms has been used to discriminate TSE strains and has become increasingly important in the differential diagnosis of human TSEs. However, the molecular basis of PrP-res glycoform. variation between different TSE agents is unknown. Here we report that PrP-res itself can dictate strain-specific PrP-res glycoforms. The final PrP-res glycoform pattern, however, can be influenced by the cell and significantly altered by subtle changes in the glycosylation state of PrP-sen. Thus, strain-specific PrP-res glycosylation profiles are likely the consequence of a complex interaction between PrP-res, PrP-sen, and the cell and may indicate the cellular compartment in which the strain-specific formation of PrP-res occurs.	NIAID, Persistent Viral Dis Lab, NIH, Rocky Mt Labs, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Priola, SA (corresponding author), NIAID, Persistent Viral Dis Lab, NIH, Rocky Mt Labs, 903 S 4th St, Hamilton, MT 59840 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000752, ZIAAI000752] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; BESSEN RA, 1992, J VIROL, V66, P2096, DOI 10.1128/JVI.66.4.2096-2101.1992; Bessen RA, 1997, J BIOL CHEM, V272, P15227, DOI 10.1074/jbc.272.24.15227; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; Birkett CR, 2001, EMBO J, V20, P3351, DOI 10.1093/emboj/20.13.3351; BOLTON DC, 1991, J VIROL, V65, P3667, DOI 10.1128/JVI.65.7.3667-3675.1991; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BRUCE ME, 1993, BRIT MED BULL, V49, P822, DOI 10.1093/oxfordjournals.bmb.a072649; Carp RI, 1997, J GEN VIROL, V78, P283, DOI 10.1099/0022-1317-78-1-283; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; CAUGHEY B, 1990, J VIROL, V64, P1093, DOI 10.1128/JVI.64.3.1093-1101.1990; Caughey B, 2001, TRENDS BIOCHEM SCI, V26, P235, DOI 10.1016/S0968-0004(01)01792-3; Caughey B, 2001, ADV PROTEIN CHEM, V57, P139; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chesebro B, 1999, NEURON, V24, P503, DOI 10.1016/S0896-6273(00)81105-8; Chesebro B, 1998, SCIENCE, V279, P42, DOI 10.1126/science.279.5347.42; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; DeArmond SJ, 1997, NEURON, V19, P1337, DOI 10.1016/S0896-6273(00)80424-9; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; HECKER R, 1992, GENE DEV, V6, P1213, DOI 10.1101/gad.6.7.1213; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; KASCSAK RJ, 1986, J VIROL, V59, P676, DOI 10.1128/JVI.59.3.676-683.1986; KOCISKO DA, 1995, P NATL ACAD SCI USA, V92, P3923, DOI 10.1073/pnas.92.9.3923; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Kuczius T, 1999, MOL MED, V5, P406, DOI 10.1007/BF03402129; MCKINLEY MP, 1991, LAB INVEST, V65, P622; MONARI L, 1994, P NATL ACAD SCI USA, V91, P2839, DOI 10.1073/pnas.91.7.2839; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parchi P, 1997, NATURE, V386, P232, DOI 10.1038/386232a0; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; RUBENSTEIN R, 1991, J INFECT DIS, V164, P29, DOI 10.1093/infdis/164.1.29; Rudd PM, 1999, P NATL ACAD SCI USA, V96, P13044, DOI 10.1073/pnas.96.23.13044; Saborio GP, 2001, NATURE, V411, P810, DOI 10.1038/35081095; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; SHINAGAWA M, 1985, MICROBIOL IMMUNOL, V29, P543, DOI 10.1111/j.1348-0421.1985.tb00856.x; Somerville RA, 1999, J GEN VIROL, V80, P1865, DOI 10.1099/0022-1317-80-7-1865; Somerville RA, 1997, NATURE, V386, P564, DOI 10.1038/386564a0; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851	47	64	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36775	36781		10.1074/jbc.M206865200	http://dx.doi.org/10.1074/jbc.M206865200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12138171	hybrid			2022-12-27	WOS:000178275100127
J	Parikh, BA; Coetzer, C; Tumer, NE				Parikh, BA; Coetzer, C; Tumer, NE			Pokeweed antiviral protein regulates the stability of its own mRNA by a mechanism that requires depurination but can be separated from depurination of the alpha-sarcin/ricin loop of rRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL DELETION MUTANT; RICIN-A-CHAIN; SACCHAROMYCES-CEREVISIAE; INACTIVATING PROTEINS; GLYCOSIDASE ACTIVITY; INHIBITION; INFECTION; VIRUS; RETROTRANSPOSITION; LOCALIZATION	Pokeweed antiviral protein (PAP), a single chain ribosome-inactivating protein (RIP) isolated from pokeweed plants (Phytolacca americana), removes specific adenine and guanine residues from the highly conserved, alpha-sarcin/ ricin loop in the large rRNA, resulting in inhibition of protein synthesis. We recently demonstrated that PAP could also inhibit translation of mRNAs and viral RNAs that are capped by binding to the cap structure and depurinating the RNAs downstream of the cap. Cell growth is inhibited when PAP cDNA is expressed in the yeast Saccharomyces cerevisiae under the control of the galactose-inducible GAL1 promoter. Here, we show that overexpression of wild type PAP in yeast leads to a decrease in PAP mRNA abundance. The decrease in mRNA levels is not observed with an active site mutant, indicating that it is due to the N-glycosidase activity of the protein. PAP expression had no effect on steady state levels of mRNA from four different endogenous yeast genes examined, indicating specificity. We demonstrate that PAP can depurinate the rRNA in trans in a translation-independent manner. When rRNA is depurinated and translation is inhibited, the steady state levels of PAP mRNA increase dramatically relative to the U3 snoRNA. Using a PAP variant which depurinates rRNA, inhibits translation but does not destabilize its mRNA, we demonstrate that PAP mRNA is destabilized after its levels are up-regulated by a mechanism that occurs independently of rRNA depurination and translation. We quantify the extent of rRNA depurination in vivo using a novel primer extension assay and show that the temporal pattern of rRNA depurination is similar to the pattern of PAP mRNA destabilization, suggesting that they may occur by a common mechanism. These results provide the first in vivo evidence that a single chain RIP targets not only the large rRNA but also its own mRNA. These findings have implications for understanding the biological function of RIPs.	Rutgers State Univ, Cook Coll, Biotechnol Ctr Agr & Environm, New Brunswick, NJ 08901 USA; Rutgers State Univ, Cook Coll, Dept Plant Biol & Pathol, New Brunswick, NJ 08901 USA; Rutgers State Univ, Grad Program Microbiol & Mol Genet, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Tumer, NE (corresponding author), Rutgers State Univ, Cook Coll, Ctr Biotechnol, 59 Dudley Rd, New Brunswick, NJ 08901 USA.	tumer@aesop.rutgers.edu	Parikh, Bijal/AAA-5839-2019	Parikh, Bijal/0000-0003-2490-8294				ANDREADIS A, 1984, J BIOL CHEM, V259, P8059; ARON GM, 1980, ANTIMICROB AGENTS CH, V17, P1032, DOI 10.1128/AAC.17.6.1032; Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518; BONNESS MS, 1994, PLANT J, V5, P173, DOI 10.1046/j.1365-313X.1994.05020173.x; Carr-Schmid A, 1999, MOL CELL BIOL, V19, P5257; CARRASCO L, 1975, EUR J BIOCHEM, V54, P499, DOI 10.1111/j.1432-1033.1975.tb04162.x; ENDO Y, 1988, J BIOL CHEM, V263, P8735; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; HAGAN KW, 1995, MOL CELL BIOL, V15, P809; HAMIL KG, 1988, MOL CELL BIOL, V8, P4328, DOI 10.1128/MCB.8.10.4328; HARTLEY MR, 1991, FEBS LETT, V290, P65, DOI 10.1016/0014-5793(91)81227-Y; HEYER WD, 1995, MOL CELL BIOL, V15, P2728; Hudak KA, 2000, RNA, V6, P369, DOI 10.1017/S1355838200991337; Hudak KA, 1999, J BIOL CHEM, V274, P3859, DOI 10.1074/jbc.274.6.3859; Hudak KA, 2002, RNA, V8, P1148, DOI 10.1017/S1355838202026638; Hudak KA, 2001, VIROLOGY, V279, P292, DOI 10.1006/viro.2000.0647; HUR Y, 1995, P NATL ACAD SCI USA, V92, P8448, DOI 10.1073/pnas.92.18.8448; LODGE JK, 1993, P NATL ACAD SCI USA, V90, P7089, DOI 10.1073/pnas.90.15.7089; MONTANARO L, 1975, BIOCHEM J, V146, P127, DOI 10.1042/bj1460127; MOORE PA, 1991, MOL CELL BIOL, V11, P5330, DOI 10.1128/MCB.11.10.5330; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; Ogasawara T, 1999, EMBO J, V18, P6522, DOI 10.1093/emboj/18.22.6522; OSBORN RW, 1990, EUR J BIOCHEM, V193, P401, DOI 10.1111/j.1432-1033.1990.tb19353.x; READY MP, 1986, P NATL ACAD SCI USA, V83, P5053, DOI 10.1073/pnas.83.14.5053; SCHNEIDER JC, 1991, METHOD ENZYMOL, V194, P373; Schwartz DC, 2000, COLD SPRING HARBOR M, V39, P807; TOMLINSON JA, 1974, J GEN VIROL, V22, P225, DOI 10.1099/0022-1317-22-2-225; Tumer NE, 1997, P NATL ACAD SCI USA, V94, P3866, DOI 10.1073/pnas.94.8.3866; Tumer NE, 1998, J VIROL, V72, P1036, DOI 10.1128/JVI.72.2.1036-1042.1998; USSERY MA, 1977, ANN NY ACAD SCI, V284, P431, DOI 10.1111/j.1749-6632.1977.tb21979.x; Waurzyniak B, 1997, CLIN CANCER RES, V3, P881; ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0; Zoubenko O, 2000, PLANT MOL BIOL, V44, P219, DOI 10.1023/A:1006443626864; Zoubenko O, 1997, NAT BIOTECHNOL, V15, P992, DOI 10.1038/nbt1097-992	34	45	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41428	41437		10.1074/jbc.M205463200	http://dx.doi.org/10.1074/jbc.M205463200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12171922	hybrid			2022-12-27	WOS:000178985300019
J	Kannan-Thulasiraman, P; Shapiro, DJ				Kannan-Thulasiraman, P; Shapiro, DJ			Modulators of inflammation use nuclear factor-B-K and activator protein-1 sites to induce the caspase-1 and granzyme B inhibitor, proteinase inhibitor 9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; MEDIATED APOPTOSIS; ESTROGEN-RECEPTOR; DENDRITIC CELLS; GENE; INTERLEUKIN-1-BETA; MECHANISM; PROTEASE; SUPERFAMILY	Proteinase inhibitor 9 (PI-9) inhibits caspase-1 (interleukin (IL)-1beta-converting enzyme) and granzyme B, thereby regulating production of the pro-inflammatory cytokine IL-1beta and susceptibility to granzyme B-induced apoptosis. We show that cellular PI-9 mRNA and protein are induced by IL-1beta, lipopolysaccharide, and 12-O-tetradecanoylphorbol-13-acetate. We identified functional imperfect nuclear factor-B-K (NF-B-K) sites at -135 and -88 and a consensus activator protein-1 (AP-1) site at -308 in the PI-9 promoter region. Using transient transfections in HepG2 cells to assay PI-9 promoter mutations, we find that mutational ablation of the AP-1 site or of either NF-B-K site reduces IL-1beta-induced expression of PI-9 by similar to60%. Mutational ablation of the two NF-KB sites and of the AP-1 site nearly abolishes both basal and IL-1beta-induced expression of PI-9. Nuclear extracts from IL-1beta-treated HepG2 cells exhibited strong, IL-1beta-inducible binding to the NF-KB sites and to the AP-1 site. Electrophoretic mobility shift assays show that after IL-1beta treatment c-Jun/c-Fos and JunD bind to the AP-1 site, whereas the p50/p65 heterodimer binds to the two NF-KB sites. Estrogens induce PI-9, but induction of PI-9 by estrogens and IL-1beta is not synergistic. In transiently transfected, estrogen receptor-positive HepG2ER7 cells, estrogens do not interfere with IL-1beta induction, whereas IL-1beta exhibits dose-dependent repression of estrogen-inducible PI-9 expression. Our surprising finding that the pro-inflammatory cytokine IL-1beta strongly induces PI-9 suggests a novel mechanism for regulating inflammation and apoptosis through a negative feedback loop controlling expression of the anti-inflammatory and anti-apoptotic protein, PI-9.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Shapiro, DJ (corresponding author), Univ Illinois, Dept Biochem, 600 S Mathews Ave, Urbana, IL 61801 USA.	djshapir@uiuc.edu			NICHD NIH HHS [HD 16720] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016720] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Annand RR, 1999, BIOCHEM J, V342, P655, DOI 10.1042/0264-6021:3420655; AUBLE DT, 1991, BIOCHEMISTRY-US, V30, P4629, DOI 10.1021/bi00232a039; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Bird CH, 1998, MOL CELL BIOL, V18, P6387, DOI 10.1128/MCB.18.11.6387; BIRD PI, 2002, MOD ASP IMMUNOBIOL, V2, P136; Bladergroen BA, 2001, J IMMUNOL, V166, P3218, DOI 10.4049/jimmunol.166.5.3218; BURGER D, 2001, CYTOKINE REFERENCE C, V1, P319; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; Harnish DC, 2000, ENDOCRINOLOGY, V141, P3403, DOI 10.1210/en.141.9.3403; Hirst CE, 2001, MOL HUM REPROD, V7, P1133, DOI 10.1093/molehr/7.12.1133; Humke EW, 2000, CELL, V103, P99, DOI 10.1016/S0092-8674(00)00108-2; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; Kanamori H, 2000, J BIOL CHEM, V275, P5867, DOI 10.1074/jbc.275.8.5867; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Koj A, 1996, BBA-MOL BASIS DIS, V1317, P84, DOI 10.1016/S0925-4439(96)00048-8; Kordula T, 2000, J NEUROSCI, V20, P7510; Krieg SA, 2001, MOL ENDOCRINOL, V15, P1971, DOI 10.1210/me.15.11.1971; Kumar V, 1997, BASIC PATHOLOGY; Lee SH, 2001, J BIOL CHEM, V276, P34495, DOI 10.1074/jbc.M101415200; LOWIN B, 1994, NATURE, V370, P650, DOI 10.1038/370650a0; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Medema JP, 2001, J EXP MED, V194, P657, DOI 10.1084/jem.194.5.657; Medema JP, 2001, P NATL ACAD SCI USA, V98, P11515, DOI 10.1073/pnas.201398198; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Puren AJ, 1999, P NATL ACAD SCI USA, V96, P2256, DOI 10.1073/pnas.96.5.2256; SCHEINMAN RI, 1995, MOL CELL BIOL, V15, P943; Schumann RR, 1998, BLOOD, V91, P577, DOI 10.1182/blood.V91.2.577.577_577_584; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Sun JR, 1996, J BIOL CHEM, V271, P27802, DOI 10.1074/jbc.271.44.27802; Suzuki T, 1996, J BIOL CHEM, V271, P1626, DOI 10.1074/jbc.271.3.1626; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; Yang XH, 1998, J BIOL CHEM, V273, P34278, DOI 10.1074/jbc.273.51.34278; Young JL, 2000, J EXP MED, V191, P1535, DOI 10.1084/jem.191.9.1535; Zen K, 1999, J BIOL CHEM, V274, P28808, DOI 10.1074/jbc.274.40.28808	43	41	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41230	41239		10.1074/jbc.M200379200	http://dx.doi.org/10.1074/jbc.M200379200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177049	hybrid			2022-12-27	WOS:000178791400134
J	Nobrega, MP; Bandeira, SCB; Beers, J; Tzagoloff, A				Nobrega, MP; Bandeira, SCB; Beers, J; Tzagoloff, A			Characterization of COX19, a widely distributed gene required for expression of mitochondrial cytochrome oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; C-OXIDASE; MEMBRANE SYSTEM; MESSENGER-RNA; PROTEIN; MUTANTS; VECTORS; IMPORT; ATPASE	COX19, a nuclear gene of Saccharomyces cerevisiae, was cloned by transformation of a respiratory-deficient mutant from complementation group G188 of a pet mutant collection. The gene codes for an 11-kDa protein (Cox19p) required for expression of cytochrome oxidase. Because cox19 mutants are able to synthesize the mitochondrial and nuclear gene products of cytochrome oxidase, Cox19p probably functions post-translationally during assembly of the enzyme. Cox19p is present in the cytoplasm and mitochondria, where it exists as a soluble intermembrane protein. This dual location is similar to what was previously reported for Cox17p, a low molecular weight copper protein thought to be required for maturation of the CuA center of subunit 2 of cytochrome oxidase. The similarity in their subcellular distribution, combined with the presence of four cysteines in Cox19p that align with a subset of the cysteines in Cox19p, suggests that like the latter, Cox19p may function in metal transport to mitochondria.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Vale do Paraiba, Inst Pesquisa & Desenvolvimento, BR-12244000 Sao Jose Dos Campos, Brazil	Columbia University; Universidade do Vale do Paraiba	Tzagoloff, A (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.	spud@cubpet2.bio.columbia.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM050187, GM 50187] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barrientos A, 2002, GENE, V286, P53, DOI 10.1016/S0378-1119(01)00803-4; Barros MH, 2001, FEBS LETT, V492, P133, DOI 10.1016/S0014-5793(01)02249-9; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Beinert H, 1997, EUR J BIOCHEM, V245, P521, DOI 10.1111/j.1432-1033.1997.t01-1-00521.x; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; COSTANZO MC, 1995, CURR GENET, V28, P60, DOI 10.1007/BF00311882; DAUM G, 1982, J BIOL CHEM, V257, P3028; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Hell K, 2000, J BIOL CHEM, V275, P4571, DOI 10.1074/jbc.275.7.4571; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; King EJ, 1932, BIOCHEM J, V26, P292, DOI 10.1042/bj0260292; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MANTHEY GM, 1995, EMBO J, V14, P4031, DOI 10.1002/j.1460-2075.1995.tb00074.x; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MULERO JJ, 1993, MOL BIOL CELL, V4, P1327, DOI 10.1091/mbc.4.12.1327; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Saracco SA, 2002, MOL BIOL CELL, V13, P1122, DOI 10.1091/mbc.01-12-0580; Schatz G, 1998, NATURE, V395, P439, DOI 10.1038/26620; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SERAPHIN B, 1988, EMBO J, V7, P1455, DOI 10.1002/j.1460-2075.1988.tb02963.x; SERAPHIN B, 1989, NATURE, V337, P84, DOI 10.1038/337084a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1976, FEBS LETT, V65, P391, DOI 10.1016/0014-5793(76)80154-8; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; TZAGOLOGG A, 1991, J MICROBIOL REV, V54, P211; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yoshikawa S, 2000, J INORG BIOCHEM, V82, P1, DOI 10.1016/S0162-0134(00)00137-9	39	84	88	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40206	40211		10.1074/jbc.M207348200	http://dx.doi.org/10.1074/jbc.M207348200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171940	hybrid			2022-12-27	WOS:000178791400008
J	Gallie, DR; Fortner, D; Peng, J; Puthoff, D				Gallie, DR; Fortner, D; Peng, J; Puthoff, D			ATP-dependent hexameric assembly of the heat shock protein Hsp101 involves multiple interaction domains and a functional C-proximal nucleotide-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MUTATIONAL ANALYSIS; CLPAP PROTEASE; CHAPERONE SYSTEM; ACTIVATED ATPASE; YEAST; THERMOTOLERANCE; SITES; PDZ; ARABIDOPSIS	Members of the Hsp100 family of heat stress proteins are present in species throughout the bacterial, plant, and fungal kingdoms. Most Hsp100 proteins are composed of five domains that include two nucleotide-binding domains required for their ATP-dependent oligomerization. Mutations within the first but not the second nucleotide-binding site disrupt self-assembly of bacterial Hsp100, whereas the reverse is true for yeast Hsp104. We have examined the functional requirements for oligomerization of plant Hsp101 and have found that Hsp101 resembles Hsp104 in that it assembles into a hexameric complex in an ATP-dependent manner. Self-assembly of Hsp101 involves at least three distinct interaction domains located in the N-proximal domain and in the first and second nucleotide-binding domains. The interaction domain in the second nucleotide-binding domain included the Walker A motif, and mutations within this element disrupted self-assembly of Hsp101. In contrast, mutations affecting conserved residues of the Walker A motif within the first nucleotide-binding site did not affect self-assembly. No interaction between Hsp101 and Hsp104 was observed. These results suggest that plant Hsp101 self-assembly involves multiple evolutionarily diverged interaction domains as well as an evolutionarily conserved requirement for a functional C-proximal nucleotide-binding site.	Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA	University of California System; University of California Riverside	Gallie, DR (corresponding author), Univ Calif Riverside, Dept Biochem, Riverside, CA 92521 USA.	drgallie@citrus.ucr.edu	Peng, Jamy/N-1134-2018	Peng, Jamy/0000-0002-4043-8475				Abbas-Terki T, 2001, MOL CELL BIOL, V21, P7569, DOI 10.1128/MCB.21.22.7569-7575.2001; Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; BECKER J, 1994, EUR J BIOCHEM, V219, P11, DOI 10.1111/j.1432-1033.1994.tb19910.x; Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; CLARK KL, 1993, MOL CELL BIOL, V13, P1; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; FLANAGAN JM, 1995, BIOCHEMISTRY-US, V34, P10910, DOI 10.1021/bi00034a025; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; Hong SW, 2000, P NATL ACAD SCI USA, V97, P4392, DOI 10.1073/pnas.97.8.4392; Horwich AL, 1999, P NATL ACAD SCI USA, V96, P11033, DOI 10.1073/pnas.96.20.11033; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kim KI, 2000, J MOL BIOL, V303, P655, DOI 10.1006/jmbi.2000.4165; Kim KI, 1998, BIOCHEM J, V333, P671, DOI 10.1042/bj3330671; KITAGAWA M, 1991, J BACTERIOL, V173, P4247, DOI 10.1128/JB.173.14.4247-4253.1991; LEE YRJ, 1994, PLANT CELL, V6, P1889, DOI 10.1105/tpc.6.12.1889; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; Lindquist S, 1996, P NATL ACAD SCI USA, V93, P5301, DOI 10.1073/pnas.93.11.5301; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Maurizi MR, 1998, BIOCHEMISTRY-US, V37, P7778, DOI 10.1021/bi973093e; Miernyk JA, 1999, PLANT PHYSIOL, V121, P695, DOI 10.1104/pp.121.3.695; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Nieto-Sotelo J, 1999, GENE, V230, P187, DOI 10.1016/S0378-1119(99)00060-8; Pak M, 1999, J BIOL CHEM, V274, P19316, DOI 10.1074/jbc.274.27.19316; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PARSELL DA, 1993, ANNU REV GENET, V27, P437, DOI 10.1146/annurev.ge.27.120193.002253; Queitsch C, 2000, PLANT CELL, V12, P479, DOI 10.1105/tpc.12.4.479; Rohrwild M, 1997, NAT STRUCT BIOL, V4, P133, DOI 10.1038/nsb0297-133; SANCHEZ Y, 1990, SCIENCE, V248, P1112, DOI 10.1126/science.2188365; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; SCHIRMER EC, 1994, PLANT CELL, V6, P1899, DOI 10.1105/tpc.6.12.1899; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schirmer EC, 2001, P NATL ACAD SCI USA, V98, P914, DOI 10.1073/pnas.031568098; Schirmer EC, 1998, J BIOL CHEM, V273, P15546, DOI 10.1074/jbc.273.25.15546; Schlee S, 2001, J MOL BIOL, V306, P889, DOI 10.1006/jmbi.2001.4455; SEOL JH, 1995, J BIOL CHEM, V270, P8087, DOI 10.1074/jbc.270.14.8087; Shin DH, 1996, FEBS LETT, V398, P151, DOI 10.1016/S0014-5793(96)01223-9; Singh SK, 2000, P NATL ACAD SCI USA, V97, P8898, DOI 10.1073/pnas.97.16.8898; SINGH SK, 1994, J BIOL CHEM, V269, P29537; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; Tanguay RL, 1996, J BIOL CHEM, V271, P14316, DOI 10.1074/jbc.271.24.14316; VIERLING E, 1991, ANNU REV PLANT PHYS, V42, P579, DOI 10.1146/annurev.pp.42.060191.003051; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wells DR, 1998, GENE DEV, V12, P3236, DOI 10.1101/gad.12.20.3236; Winter J, 1991, Results Probl Cell Differ, V17, P85; Young TE, 2001, PLANT PHYSIOL, V127, P777, DOI 10.1104/pp.010160; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; Zolkiewski M, 1999, PROTEIN SCI, V8, P1899, DOI 10.1110/ps.8.9.1899	60	10	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39617	39626		10.1074/jbc.M204998200	http://dx.doi.org/10.1074/jbc.M204998200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12151400	hybrid			2022-12-27	WOS:000178662500073
J	Hackzell, A; Uramoto, H; Izumi, H; Kohno, K; Funa, K				Hackzell, A; Uramoto, H; Izumi, H; Kohno, K; Funa, K			p73 independent of c-Myc represses transcription of platelet-derived growth factor beta-receptor through interaction with NF-Y	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING; P53; FAMILY; LIGAND; P63; DIFFERENTIATION; PHENOTYPES; MECHANISM; SUBUNIT; DOMAINS	We recently reported that c-Myc represses the transcription of platelet-derived growth factor (PDGF) beta-receptor (Izumi, H., Molander, C., Penn, L. Z., Ishisaki, A., Kohno, K., and Funa, K. (2001) J. Cell Sci. 114, 15331544). We demonstrate here that the p53 family protein p73alpha represses PDGF beta-receptor transcription essentially by the same mechanism. p73alpha but not p73,6 or p53 represses the transcription in concordance with its ability to bind NF-YC and NF-YB. None of other p73 isoforms (i.e. p73beta, p73gamma, p73is an element of), C-terminal deletion mutants of p73alpha, and p53 is able to bind NF-Y with the exception of p63alpha. This finding suggests that the sterile alpha-motif domain present only in p73alpha and p63alpha is the interaction site. For the repression, the N-terminal transactivation domain of p73alpha is also indispensable, arguing for the importance of the activity of p73alpha in the mechanism. p73alpha binds the C-terminal HAP domain of NF-YC previously found to be the interaction site with c-Myc and TBP. Because c-Myc induces and activates p73alpha (Zaika, A., Irwin, M., Sansome, C., and Moll, U. M. (2001) J. Biol. Chem. 276, 11310-11316) and they bind each other (Uramoto, H., Izumi, H., Ise, T., Tada, M., Uchiumi, T., Kuwano, M., Yasumoto, K., Funa, K., and Kohno, K. (2002) J. Biol. Chem. 277, in press), we examined whether the repression by p73 is dependent on c-Myc. However, Myc-null rat fibroblasts are also susceptible to p73alpha-induced repression. Serum stimulation of NIH3T3 cells gradually decreased the amount of endogenous NF-Y binding to the PDGF beta-receptor promoter, whereas NF-YA expression in the nuclear extracts remains unchanged. Our results indicate that serum stimulation induces c-Myc and p73alpha, leading to the downregulation of PDGF beta-receptor expression by repressing its transcription.	Univ Gothenburg, Inst Anat & Cell Biol, Dept Cell Biol, SE-40530 Gothenburg, Sweden; Univ Occupat & Environm Hlth, Sch Med, Dept Mol Biol, Kitakyushu, Fukuoka 807, Japan	University of Gothenburg; University of Occupational & Environmental Health - Japan	Funa, K (corresponding author), Univ Gothenburg, Inst Anat & Cell Biol, Dept Cell Biol, Box 420, SE-40530 Gothenburg, Sweden.	keiko.funa@anatcell.gu.se						BALLAGI AE, 1995, BIOCHEM BIOPH RES CO, V210, P165, DOI 10.1006/bbrc.1995.1642; BALLAGIPORDANY A, 1991, ANAL BIOCHEM, V196, P89, DOI 10.1016/0003-2697(91)90122-A; Bamberger C, 2001, FEBS LETT, V501, P121, DOI 10.1016/S0014-5793(01)02643-6; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; De Laurenzi V, 2000, BIOCHEM BIOPH RES CO, V273, P342, DOI 10.1006/bbrc.2000.2932; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Fiaschi T, 2001, J BIOL CHEM, V276, P49156, DOI 10.1074/jbc.M107538200; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Ishisaki A, 1997, EUR J BIOCHEM, V246, P142, DOI 10.1111/j.1432-1033.1997.t01-2-00142.x; Izumi H, 2001, J CELL SCI, V114, P1533; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Levrero M, 2000, J CELL SCI, V113, P1661; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Marziali G, 1999, BLOOD, V93, P519, DOI 10.1182/blood.V93.2.519.402a01_519_526; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Molander C, 2001, MOL BIOL REP, V28, P223, DOI 10.1023/A:1015701232589; MORI S, 1994, J BIOL CHEM, V269, P4917; Oster SK, 2000, MOL CELL BIOL, V20, P6768, DOI 10.1128/MCB.20.18.6768-6778.2000; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; RAINES EW, 1990, HDB EXPT PHARM 1, V95, P173; Serra E, 1998, NUCLEIC ACIDS RES, V26, P3800, DOI 10.1093/nar/26.16.3800; Shimizu A, 2001, J BIOL CHEM, V276, P27749, DOI 10.1074/jbc.C100286200; SMITS A, 1993, EUR J NEUROSCI, V5, P986, DOI 10.1111/j.1460-9568.1993.tb00950.x; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; URAMOTO H, 2002, IN PRESS J BIOL CHEM, V277; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zemzoumi K, 1999, J MOL BIOL, V286, P327, DOI 10.1006/jmbi.1998.2496	38	30	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39769	39776		10.1074/jbc.M204483200	http://dx.doi.org/10.1074/jbc.M204483200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167641	hybrid			2022-12-27	WOS:000178662500091
J	Leppanen, A; Penttila, L; Renkonen, O; McEver, RP; Cummings, RD				Leppanen, A; Penttila, L; Renkonen, O; McEver, RP; Cummings, RD			Glycosulfopeptides with O-glycans containing sialylated and polyfucosylated polylactosamine bind with low affinity to P-selectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL HUMAN-LEUKOCYTES; LEUKEMIA HL-60 CELLS; GLYCOPROTEIN LIGAND-1; FUCT-VII; FUCOSYL-TRANSFERASE; ADHESION MOLECULE-1; ESCHERICHIA-COLI; KINETIC-ANALYSIS; PSGL-1; IDENTIFICATION	P-selectin glycoprotein ligand-1 (PSGL-1), a dimeric mucin on leukocytes, is the best characterized ligand for selectins. P-selectin binds stereospecifically to the extreme N terminus of PSGL-1, which contains three clustered tyrosine sulfates (TyrSO(3)(-)) adjacent to a Thr residue with a core 2-based O-glycan expressing sialyl Lewis x (C2-O-sLe(x)). GSP-6, a synthetic glycosulfopeptide modeled after the N terminus of PSGL-1, containing three TyrSO(3)(-) residues and a short, monofucosylated C2-O-sLe(x) bound to P-selectin with high affinity (K-d similar to650 nm). However, PSGL-1 from human HL-60 cells contains higher levels of O-glycans that are sialylated and poly-fucosylated polylactosamines (PFPL). Furthermore, studies with fucosyltransferase-deficient mice suggest that sialylated PFPL structures contribute to binding to P-selectin. To resolve whether sialylated PFPL O-glycans participate in binding of PSGL-1 to human P-selectin, we synthesized glycosulfopeptides, designated GSP-6' and GSP-6", with three TyrSO(3) residues and either difucosylated polylactosamine (C2-O-Le(x)-sLe(x)) or trifucosylated polylactosamine (C2-O-Le(x)-Le(x)-sLe(x)). Binding of the GSPs to P-selectin was measured by affinity chromatography, fluorescence solid-phase assays, and equilibrium gel filtration. Unexpectedly, both GSP-6' and GSP-6" bound to P-selectin with low affinity (K-d similar to37 muM for GSP-6' and K-d similar to50 muM for GSP-6"). Binding of GSP-6' and GSP-6" to P-selectin required fucosylation and, to a lesser extent, sialylation as well as the sulfated peptide backbone of GSP-6' and GSP-6". These results demonstrate that contrary to expectations, a core 2 O-glycan containing sialylated PFPL does not promote high affinity binding of PSGL-1 to P-selectin.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Univ Helsinki, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Helsinki; Oklahoma Medical Research Foundation	Cummings, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 975 NE 10th St,BRC-417, Oklahoma City, OK 73104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048075] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65631] Funding Source: Medline; NIAID NIH HHS [AI48075] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKERS GK, 1973, METHOD ENZYMOL, V27, P441; Andre P, 2000, P NATL ACAD SCI USA, V97, P3400, DOI 10.1073/pnas.040569797; ARUFFO A, 1991, CELL, V67, P35, DOI 10.1016/0092-8674(91)90570-O; ASA D, 1995, J BIOL CHEM, V270, P11662, DOI 10.1074/jbc.270.19.11662; Blixt O, 1999, GLYCOBIOLOGY, V9, P1061, DOI 10.1093/glycob/9.10.1061; Britten CJ, 1998, GLYCOBIOLOGY, V8, P321, DOI 10.1093/glycob/8.4.321; Cummings RD, 1999, BRAZ J MED BIOL RES, V32, P519, DOI 10.1590/S0100-879X1999000500004; Epperson TR, 2000, J BIOL CHEM, V275, P7839, DOI 10.1074/jbc.275.11.7839; Figarella-Branger D, 1999, AM J PATHOL, V155, P1261, DOI 10.1016/S0002-9440(10)65228-5; Goetz DJ, 1997, J CELL BIOL, V137, P509, DOI 10.1083/jcb.137.2.509; Guyer DA, 1996, BLOOD, V88, P2415, DOI 10.1182/blood.V88.7.2415.bloodjournal8872415; Herron MJ, 2000, SCIENCE, V288, P1653, DOI 10.1126/science.288.5471.1653; Homeister JW, 2001, IMMUNITY, V15, P115, DOI 10.1016/S1074-7613(01)00166-2; Huang MC, 2000, J BIOL CHEM, V275, P31353, DOI 10.1074/jbc.M005449200; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; Ju TZ, 2002, J BIOL CHEM, V277, P169, DOI 10.1074/jbc.M109056200; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; McEver RP, 1997, GLYCOCONJUGATE J, V14, P585, DOI 10.1023/A:1018584425879; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; NEEDHAM LK, 1993, P NATL ACAD SCI USA, V90, P1359, DOI 10.1073/pnas.90.4.1359; Nicholson MW, 1998, J BIOL CHEM, V273, P763, DOI 10.1074/jbc.273.2.763; Niemela R, 1998, J BIOL CHEM, V273, P4021, DOI 10.1074/jbc.273.7.4021; PATEL TP, 1995, CIBA F SYMP, V189, P212; PILLER F, 1983, J BIOL CHEM, V258, P2293; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; RENKONEN O, 1990, BIOCHEM CELL BIOL, V68, P1032, DOI 10.1139/o90-152; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; STROUD MR, 1995, BIOCHEM BIOPH RES CO, V209, P777, DOI 10.1006/bbrc.1995.1568; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P758, DOI 10.1021/bi951600r; Stroud MR, 1997, BIOCHEM BIOPH RES CO, V238, P165, DOI 10.1006/bbrc.1997.7254; Toppila S, 1999, EUR J BIOCHEM, V261, P208, DOI 10.1046/j.1432-1327.1999.00257.x; Tu LL, 1996, J IMMUNOL, V157, P3995; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; Weninger W, 2000, IMMUNITY, V12, P665, DOI 10.1016/S1074-7613(00)80217-4; Wild MK, 2001, J BIOL CHEM, V276, P31602, DOI 10.1074/jbc.M104844200; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Xia LJ, 2002, J CLIN INVEST, V109, P939; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	49	48	49	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39749	39759		10.1074/jbc.M206281200	http://dx.doi.org/10.1074/jbc.M206281200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12145302	hybrid			2022-12-27	WOS:000178662500089
J	Swiatecka-Urban, A; Duhaime, M; Coutermarsh, B; Karlson, KH; Collawn, J; Milewski, M; Cutting, GR; Guggino, WB; Langford, G; Stanton, BA				Swiatecka-Urban, A; Duhaime, M; Coutermarsh, B; Karlson, KH; Collawn, J; Milewski, M; Cutting, GR; Guggino, WB; Langford, G; Stanton, BA			PDZ domain interaction controls the endocytic recycling of the cystic fibrosis transmembrane conductance regulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DARBY CANINE KIDNEY; GAMMA-AMINOBUTYRIC-ACID; CL-SECRETION; PROTEIN; CFTR; TRANSPORTERS; EXPRESSION; RECEPTOR; SURFACE; DETERMINANTS	The C terminus of CFTR contains a PDZ interacting domain that is required for the polarized expression of cystic fibrosis transmembrane conductance regulator (CFTR) in the apical plasma membrane of polarized epithelial cells. To elucidate the mechanism whereby the PDZ interacting domain mediates the polarized expression of CFTR, Madin-Darby canine kidney cells were stably transfected with wild type (wt-CFTR) or C-terminally truncated human CFTR (CFTR-DeltaTRL). We tested the hypothesis that the PDZ interacting domain regulates sorting of CFTR from the Golgi to the apical plasma membrane. Pulse-chase studies in combination with domain-selective cell surface biotinylation revealed that newly synthesized wt-CFTR and CFTR-DeltaTRL were targeted equally to the apical and basolateral membranes in a nonpolarized fashion. Thus, the PDZ interacting domain is not an apical sorting motif. Deletion of the PDZ interacting domain reduced the half-life of CFTR in the apical membrane from similar to24 to similar to13 h but had no effect on the half-life of CFTR in the basolateral membrane. Thus, the PDZ interacting domain is an apical membrane retention motif. Next, we examined the hypothesis that the PDZ interacting domain affects the apical membrane half-life of CFTR by altering its endocytosis and/or endocytic recycling. Endocytosis of wt-CFTR and CFTR-DeltaTRL did not differ. However, endocytic recycling of CFTR-DeltaTRL was decreased when compared with wt-CFTR. Thus, deletion of the PDZ interacting domain reduced the half-life of CFTR in the apical membrane by decreasing CFTR endocytic recycling. Our results identify a new role for PDZ proteins in regulating the endocytic recycling of CFTR in polarized epithelial cells.	Dartmouth Coll Sch Med, Dept Physiol, Hanover, NH 03755 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Johns Hopkins Univ, Johns Hopkins Hosp, Ctr Med Genet, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Dartmouth Coll, Dept Biol Sci, Hanover, NH 03755 USA	Dartmouth College; University of Alabama System; University of Alabama Birmingham; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Dartmouth College	Stanton, BA (corresponding author), Dartmouth Coll Sch Med, Dept Physiol, Hanover, NH 03755 USA.	Bruce.A.Stanton@Dartmouth.edu	Milewski, Michal/C-7144-2012; SWIATECKA-URBAN, AGNIESZKA/H-6494-2015; Milewski, Michał/AAK-4243-2021; Swiatecka-Urban, Agnieszka/AAP-6041-2020	Milewski, Michal/0000-0001-7982-2565; SWIATECKA-URBAN, AGNIESZKA/0000-0002-6575-0334; Milewski, Michał/0000-0001-7982-2565; Collawn, James/0000-0002-2528-2759; Langford, George/0000-0001-9737-2182	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047122] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK044003, R01DK045881, P50DK048977, R01DK032753, R01DK044003, R37DK032753] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 47122] Funding Source: Medline; NIDDK NIH HHS [DK 32753, DK-45881, DK 48977, DK44003] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Benharouga M, 2001, J CELL BIOL, V153, P957, DOI 10.1083/jcb.153.5.957; Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Brown D, 2000, AM J PHYSIOL-RENAL, V278, pF192, DOI 10.1152/ajprenal.2000.278.2.F192; Brown D, 2000, KIDNEY INT, V57, P816, DOI 10.1046/j.1523-1755.2000.00920.x; Bunn RC, 1999, MOL BIOL CELL, V10, P819, DOI 10.1091/mbc.10.4.819; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Caplan MJ, 2001, KIDNEY INT, V60, P427, DOI 10.1046/j.1523-1755.2001.060002427.x; Chang XB, 1998, METHOD ENZYMOL, V292, P616; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; de Beauregard MAC, 2000, EUR J CELL BIOL, V79, P795, DOI 10.1078/0171-9335-00116; Deen PMT, 1997, J AM SOC NEPHROL, V8, P1493; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; Fanning AS, 1998, CURR TOP MICROBIOL, V228, P209; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Gage RM, 2001, J BIOL CHEM, V276, P44712, DOI 10.1074/jbc.M107417200; Garza LA, 2000, J BIOL CHEM, V275, P2560, DOI 10.1074/jbc.275.4.2560; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Jilling T, 1997, INT REV CYTOL, V172, P193, DOI 10.1016/S0074-7696(08)62361-X; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Keller P, 2001, NAT CELL BIOL, V3, P140, DOI 10.1038/35055042; Kipp H, 2000, J BIOL CHEM, V275, P15917, DOI 10.1074/jbc.M909875199; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; Kunzelmann K, 1999, Rev Physiol Biochem Pharmacol, V137, P1; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; Li JG, 2002, J BIOL CHEM, V277, P27545, DOI 10.1074/jbc.M200058200; Li Y, 2002, AM J PHYSIOL-RENAL, V282, pF1129, DOI 10.1152/ajprenal.00131.2001; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; Loffing J, 1999, AM J PHYSIOL-LUNG C, V277, pL700, DOI 10.1152/ajplung.1999.277.4.L700; Loffing J, 1998, AM J PHYSIOL-CELL PH, V275, pC913, DOI 10.1152/ajpcell.1998.275.4.C913; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; McCarthy JB, 2001, J BIOL CHEM, V276, P9133, DOI 10.1074/jbc.M008290200; Milewski MI, 2001, J CELL SCI, V114, P719; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Murer H, 2001, MOL MEMBR BIOL, V18, P3, DOI 10.1080/09687680116941; Muth TR, 1998, J BIOL CHEM, V273, P25616, DOI 10.1074/jbc.273.40.25616; Olsen O, 2002, AM J PHYSIOL-CELL PH, V282, pC183, DOI 10.1152/ajpcell.00249.2001; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Perego C, 1997, J BIOL CHEM, V272, P6584, DOI 10.1074/jbc.272.10.6584; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Roush DL, 1998, J BIOL CHEM, V273, P26862, DOI 10.1074/jbc.273.41.26862; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Stanton BA, 1997, WIEN KLIN WOCHENSCHR, V109, P457; Sun F, 2000, J BIOL CHEM, V275, P29539, DOI 10.1074/jbc.M004961200; Wade JB, 2001, AM J PHYSIOL-CELL PH, V280, pC192, DOI 10.1152/ajpcell.2001.280.1.C192; Wagner CA, 2001, CELL PHYSIOL BIOCHEM, V11, P209, DOI 10.1159/000051935; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9; WATTS C, 1988, EMBO J, V7, P1937, DOI 10.1002/j.1460-2075.1988.tb03031.x; Weixel Kelly, 2002, Methods Mol Med, V70, P323; Wu HJ, 2002, J BIOL CHEM, V277, P30928, DOI 10.1074/jbc.M203735200	56	169	173	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					40099	40105		10.1074/jbc.M206964200	http://dx.doi.org/10.1074/jbc.M206964200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167629	hybrid			2022-12-27	WOS:000178662500131
J	Uchida, C; Oda, T; Sugiyama, T; Otani, S; Kitagawa, M; Ichiyama, A				Uchida, C; Oda, T; Sugiyama, T; Otani, S; Kitagawa, M; Ichiyama, A			The role of Sp1 and AP-2 in basal and protein kinase A-induced expression of mitochondrial serine : pyruvate aminotransferase in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR AP-2; ALANINE-GLYOXYLATE AMINOTRANSFERASE; BOVINE CYP11A GENE; RAT-LIVER; SUBCELLULAR-DISTRIBUTION; PEROXISOMAL SERINE; BINDING PROTEIN; CELL-GROWTH; MOLECULAR EVOLUTION; ACTIVATION DOMAINS	Transcription of mitochondrial serine:pyruvate aminotransferase (SPT) mRNA (SPTm-mRNA) in rat liver is unique in that it occurs from the upstream site of the two transcription start sites within the first exon of the SPT gene and is selectively enhanced by cAMP via the protein kinase A (PKA) signaling pathway. In this study, we identified the DNA elements and nuclear factors responsible for the basal and PKA-induced activities of the upstream promoter. By using a luciferase reporter assay with HepG2 cells, DNase I footprinting analysis, and gel shift experiments, we identified the binding sites for Sp1 and AP-2 within the regions -125 to -89 and -14 to +10, respectively. Mutational analyses indicated that these regions are essential for the transcription factor binding and the SPT promoter activity. Expression of AP-2 caused a marked increase in the basal promoter activity to about the same level as that achieved by PKA. On the other hand, both the basal and PKA-induced activities were elevated by overexpression of Sp1, its effect on PKA-induced activity being more pronounced with coexpression of CBP and repressed by E1A oncoprotein. These results suggest that AP-2 and Sp1 regulate basal promoter activity, and Sp1 is also involved in PKA-mediated expression of the rat SPT gene in concert with the transcriptional coactivator CBP.	Hamamatsu Univ Sch Med, Dept Biochem 1, Shizuoka, Japan; Hamamatsu Univ Sch Med, Dept Internal Med 3, Shizuoka, Japan	Hamamatsu University School of Medicine; Hamamatsu University School of Medicine	Uchida, C (corresponding author), Hamamatsu Univ Sch Med, Dept Biochem 1, 1-20-1 Hamamatsu, Shizuoka, Japan.	cuchida@hama-med.ac.jp						ALEMANY J, 1992, BIOCHEM BIOPH RES CO, V183, P659, DOI 10.1016/0006-291X(92)90533-Q; BESSEREAU JL, 1993, EMBO J, V12, P443, DOI 10.1002/j.1460-2075.1993.tb05676.x; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Bosher JM, 1996, ONCOGENE, V13, P1701; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DANPURE CJ, 1990, J CELL SCI, V97, P669; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DYAN WS, 1983, CELL, V35, P79; EGAN C, 1988, MOL CELL BIOL, V8, P3955, DOI 10.1128/MCB.8.9.3955; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Goodman RH, 2000, GENE DEV, V14, P1553; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Ichiyama A, 2000, MOL UROL, V4, P333; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; JOHNSON AD, 1979, P NATL ACAD SCI USA, V76, P5061, DOI 10.1073/pnas.76.10.5061; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Liu Z, 1999, MOL CELL ENDOCRINOL, V153, P183, DOI 10.1016/S0303-7207(99)00036-2; LUMB MJ, 1994, EUR J BIOCHEM, V221, P53, DOI 10.1111/j.1432-1033.1994.tb18714.x; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MONTLEY A, 1995, J CELL BIOL, V131, P65; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; MOSER M, 1995, DEVELOPMENT, V121, P2779; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; NELSON M, 1992, METHOD ENZYMOL, V216, P279; NISHIYAMA K, 1990, EUR J BIOCHEM, V194, P9, DOI 10.1111/j.1432-1033.1990.tb19420.x; NOGUCHI T, 1978, BIOCHEM J, V170, P173, DOI 10.1042/bj1700173; Oda T, 1997, FEBS LETT, V418, P265, DOI 10.1016/S0014-5793(97)01396-3; ODA T, 1993, GENOMICS, V17, P59, DOI 10.1006/geno.1993.1283; ODA T, 1990, J BIOL CHEM, V265, P7513; Oda T, 1996, BIOCHEM BIOPH RES CO, V228, P341, DOI 10.1006/bbrc.1996.1663; Oda T, 2000, CELL BIOCHEM BIOPHYS, V32, P277, DOI 10.1385/CBB:32:1-3:277; ODA T, 1987, Biomedical Research (Tokyo), V8, P5; OHBAYASHI K, 1995, BIOMED RES-TOKYO, V16, P141, DOI 10.2220/biomedres.16.141; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; PARK K, 1993, J BIOL CHEM, V268, P17811; PURDUE PE, 1992, EUR J BIOCHEM, V207, P757, DOI 10.1111/j.1432-1033.1992.tb17106.x; Rohlff C, 1997, J BIOL CHEM, V272, P21137, DOI 10.1074/jbc.272.34.21137; SAFFER JD, 1991, MOL CELL BIOL, V11, P2189, DOI 10.1128/MCB.11.4.2189; Saluja D, 1998, MOL CELL BIOL, V18, P5734, DOI 10.1128/MCB.18.10.5734; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Sugiyama T, 2001, FEBS LETT, V508, P16, DOI 10.1016/S0014-5793(01)03010-1; TAKADA Y, 1990, BIOCHEM J, V268, P517, DOI 10.1042/bj2680517; Takeuchi S, 1999, MOL BRAIN RES, V74, P208, DOI 10.1016/S0169-328X(99)00298-3; UCHIDA C, 1994, J BIOL CHEM, V26, P8849; VALERIO D, 1985, EMBO J, V4, P437, DOI 10.1002/j.1460-2075.1985.tb03648.x; VENEPALLY P, 1995, J BIOL CHEM, V270, P25402, DOI 10.1074/jbc.270.43.25402; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Wankhade S, 2000, J BIOL CHEM, V275, P29701, DOI 10.1074/jbc.M000931200; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; WOBBE CR, 1990, MOL CELL BIOL, V10, P3859, DOI 10.1128/MCB.10.8.3859; Xiao H, 1997, MOL CELL BIOL, V17, P6898, DOI 10.1128/MCB.17.12.6898; Xue HH, 1999, J BIOL CHEM, V274, P16028, DOI 10.1074/jbc.274.23.16028; Xue HH, 1999, J BIOL CHEM, V274, P16020, DOI 10.1074/jbc.274.23.16020; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773; YOKOTA S, 1991, BIOMED RES-TOKYO, V12, P53, DOI 10.2220/biomedres.12.53; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0	64	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39082	39092		10.1074/jbc.M201380200	http://dx.doi.org/10.1074/jbc.M201380200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12169688	hybrid			2022-12-27	WOS:000178662500006
J	Bannach, FG; Gutierrez, A; Fowler, BJ; Bugge, TH; Degen, JL; Parmer, RJ; Miles, LA				Bannach, FG; Gutierrez, A; Fowler, BJ; Bugge, TH; Degen, JL; Parmer, RJ; Miles, LA			Localization of regulatory elements mediating constitutive and cytokine-stimulated plasminogen gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	2nd Annual Conference on Arteriosclerosis, Thrombosis and Vascular Biology	MAY 11-13, 2001	ARLINGTON, VA				ACUTE-PHASE; DEFICIENCY; ACTIVATION; PROMOTER; MICE; ATHEROSCLEROSIS; COAGULATION; THROMBOSIS; PROTEINS; CORONARY	The activity of plasmin, the major enzyme responsible for dissolving fibrin clots, is regulated by plasminogen activators, plasminogen activator inhibitors, alpha(2)-antiplasmin, and inflammatory mediators. Recent studies suggest that plasmin activity can be regulated also at the level of plasminogen gene expression. In this study, we characterized the murine plasminogen promoter and 5'-flanking region. The major transcription start site was identified at -83 bp relative to the ATG translational initiation codon. A series of 5'-flanking sequences up to 2400 bp upstream of the transcription initiation site were fused to the luciferase reporter gene and transfected into hepatocytic cells. A 106-bp 5'-flanking region of the murine plasminogen gene demonstrated sufficient functional promoter activity in plasminogen-expressing cells. IL-6 treatment stimulated luciferase activity driven by the 5'-flanking region, and an intact consensus IL-6-responsive element at -791, was required for maximal stimulation by this cytokine. These results indicate the presence of regulatory elements in the 5'-flanking region of the murine plasminogen promoter that may regulate murine plasminogen gene expression and, hence, plasmin activity.	Scripps Res Inst, Dept Cell Biol, Div Vasc Biol CVN26, La Jolla, CA 92037 USA; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA; Univ Calif San Diego, Dept Med, San Diego, CA 92161 USA; Vet Adm Med Ctr, San Diego, CA 92161 USA	Scripps Research Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Bannach, FG (corresponding author), Scripps Res Inst, Dept Cell Biol, Div Vasc Biol CVN26, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	fbannach@ucsd.edu	Gutierrez-Fernandez, Ana/ABG-6678-2020; Gutierrez-Fernandez, Ana/AAS-9954-2021	Gutierrez-Fernandez, Ana/0000-0002-9287-8843	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063194, R29HL038272, R01HL047826, R01HL038272, R01HL050398, R01HL045934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000699] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-47826, HL-45934, HL-63194, HL-38272, HL-50398] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; Attard FA, 2000, ARCH BIOCHEM BIOPHYS, V378, P57, DOI 10.1006/abbi.2000.1803; Biasiutti FD, 1998, THROMB HAEMOSTASIS, V80, P167, DOI 10.1055/s-0037-1615157; BOHMFALK JF, 1980, SCIENCE, V209, P408, DOI 10.1126/science.7384814; BUGGE TH, 1995, GENE DEV, V9, P794, DOI 10.1101/gad.9.7.794; Carmeliet P, 1996, HAEMOSTASIS, V26, P132; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLLEN D, 1980, THROMB HAEMOSTASIS, V43, P77; DEGEN SJF, 1990, GENOMICS, V8, P49, DOI 10.1016/0888-7543(90)90225-J; Drew AF, 2000, CIRC RES, V87, P133, DOI 10.1161/01.RES.87.2.133; Drew AF, 1998, BLOOD, V91, P1616, DOI 10.1182/blood.V91.5.1616.1616_1616_1624; Fey G H, 1990, Prog Liver Dis, V9, P89; Folsom AR, 2001, ARTERIOSCL THROM VAS, V21, P611, DOI 10.1161/01.ATV.21.4.611; HATTORI M, 1993, AM J PHYSIOL, V264, pG95, DOI 10.1152/ajpgi.1993.264.1.G95; HAVERKATE F, 1995, THROMB HAEMOSTASIS, V73, P561; HEINRICH J, 1995, THROMB HAEMOSTASIS, V73, P374; Jenkins GR, 1997, BLOOD, V89, P2394, DOI 10.1182/blood.V89.7.2394; Kao WWY, 1998, INVEST OPHTH VIS SCI, V39, P502; Kirschning CJ, 1997, IMMUNOBIOLOGY, V198, P124; LACKNER H, 1973, AM J CLIN PATHOL, V60, P175; Lijnen HR, 1998, ARTERIOSCL THROM VAS, V18, P1035, DOI 10.1161/01.ATV.18.7.1035; LIJNEN HR, 1995, BAILLIERE CLIN HAEM, V8, P277, DOI 10.1016/S0950-3536(05)80268-9; Liu SB, 2000, GENE, V250, P137, DOI 10.1016/S0378-1119(00)00179-7; MALGARETTI N, 1990, BIOCHEM BIOPH RES CO, V173, P1013, DOI 10.1016/S0006-291X(05)80887-3; Matsuoka Y, 1998, NEUROSCI LETT, V252, P119, DOI 10.1016/S0304-3940(98)00562-X; Meroni G, 1996, EUR J BIOCHEM, V236, P373, DOI 10.1111/j.1432-1033.1996.00373.x; Mingers AM, 1997, SEMIN THROMB HEMOST, V23, P259, DOI 10.1055/s-2007-996099; Moshage H, 1997, J PATHOL, V181, P257, DOI 10.1002/(SICI)1096-9896(199703)181:3<257::AID-PATH756>3.0.CO;2-U; PETERSEN TE, 1990, J BIOL CHEM, V265, P6104; PHILIPS N, 1995, J BIOL CHEM, V270, P9313, DOI 10.1074/jbc.270.16.9313; Ploplis VA, 1998, BLOOD, V91, P2005, DOI 10.1182/blood.V91.6.2005.2005_2005_2009; PLOPLIS VA, 1995, CIRCULATION, V92, P2585, DOI 10.1161/01.CIR.92.9.2585; Ramharack R, 1998, ARTERIOSCL THROM VAS, V18, P984, DOI 10.1161/01.ATV.18.6.984; RAUM D, 1980, SCIENCE, V208, P1036, DOI 10.1126/science.6990488; RAY BK, 1993, BIOCHEM BIOPH RES CO, V193, P1159, DOI 10.1006/bbrc.1993.1747; Rijken DC, 2001, THROMB RES, V103, pS41, DOI 10.1016/S0049-3848(01)00296-1; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; SAITO H, 1980, P NATL ACAD SCI-BIOL, V77, P6837, DOI 10.1073/pnas.77.11.6837; Sakkinen PA, 1998, THROMB HAEMOSTASIS, V80, P134, DOI 10.1055/s-0037-1615152; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schott D, 1998, NEW ENGL J MED, V339, P1679, DOI 10.1056/NEJM199812033392305; Schwachtgen JL, 1998, BLOOD, V92, P1247, DOI 10.1182/blood.V92.4.1247.416k08_1247_1258; SUH TT, 1994, J BIOL CHEM, V269, P25992; Thomas MA, 1999, EUR J BIOCHEM, V265, P300, DOI 10.1046/j.1432-1327.1999.00732.x; Topper MJ, 1998, AM J VET RES, V59, P542; Tsirka SE, 1997, J NEUROSCI, V17, P543; Twining SS, 1999, BIOCHEM J, V339, P705, DOI 10.1042/0264-6021:3390705; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wu GD, 1997, J BIOL CHEM, V272, P2396; Zhang L, 2002, THROMB HAEMOSTASIS, V87, P493	50	14	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38579	38588		10.1074/jbc.M202509200	http://dx.doi.org/10.1074/jbc.M202509200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	602XK	12149246	hybrid			2022-12-27	WOS:000178529600075
J	Catchpole, S; Tavner, F; Le Cam, L; Sardet, C; Watson, RJ				Catchpole, S; Tavner, F; Le Cam, L; Sardet, C; Watson, RJ			A B-myb promoter corepressor site facilitates in vivo occupation of the adjacent E2F site by p107-E2F and p130-E2F complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; TRANSCRIPTIONAL REPRESSION; IN-VIVO; GENE-EXPRESSION; A PROMOTER; PRB; BINDING; FAMILY; ELEMENT; BETA	Transcription from the B-myb (MybL2 gene) promoter is strictly cell cycle-regulated by repression mediated through an E2F site during G(0)/early G(1). We report here the characterization of a corepressor site (downstream repression site (DRS)) required for this activity that is closely linked to the E2F site. Systematic mutagenesis of the DRS enabled a consensus to be derived, and it is notable that this sequence is compatible with cell cycle gene homology region sequences associated with cell cycle-dependent elements in the cyclin A, cdc2, and CDC25C promoters. The B-myb promoter is inappropriately active during Go in mouse embryo fibroblasts lacking the p107 and p130 pocket proteins, and we show that the ability of transfected p107 and p130 to re-impose repression on the promoter is dependent on the DRS. In contrast, transfected Rb was unable to repress the B-myb promoter. Consistent with the notion that Rb-E2F complexes are unable to bind the B-myb promoter E2F site in vivo, footprinting showed that this site is unoccupied in cells lacking p107 and p130. Chromatin immunoprecipitation assays showed a requirement for the DRS in recruiting p107 and p130 complexes to the B-myb promoter, indicating that in vivo the DRS governs the occupancy of the adjacent E2F site by transcriptional repressors.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Ludwig Inst Canc Res, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Sect Virol & Cell Biol, London W2 1PG, England; Inst Genet Mol, CNRS, UMR 5535, F-34293 Montpellier, France	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Watson, RJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Ludwig Inst Canc Res, Norfolk Pl, London W2 1PG, England.		Le Cam, Laurent/O-1408-2016					Bennett JD, 1996, ONCOGENE, V13, P1073; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Chen X, 1999, MOL CELL BIOL, V19, P4695; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; Classon M, 2000, P NATL ACAD SCI USA, V97, P10820, DOI 10.1073/pnas.190343497; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Dohna CLZ, 2000, FEBS LETT, V484, P77, DOI 10.1016/S0014-5793(00)02133-5; Furukawa Y, 1999, ONCOGENE, V18, P2003, DOI 10.1038/sj.onc.1202500; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Humbert PO, 2000, GENE DEV, V14, P690; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Iavarone A, 1999, MOL CELL BIOL, V19, P916; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KLEHR D, 1991, BIOCHEMISTRY-US, V30, P1264, DOI 10.1021/bi00219a015; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Lucibello FC, 1997, NUCLEIC ACIDS RES, V25, P4921, DOI 10.1093/nar/25.24.4921; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; Moberg K, 1996, MOL CELL BIOL, V16, P1436; Morkel M, 1997, NATURE, V390, P567, DOI 10.1038/37507; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; Otaki M, 2000, BBA-GENE STRUCT EXPR, V1493, P188, DOI 10.1016/S0167-4781(00)00142-1; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Stiegler P, 1998, CANCER RES, V58, P5049; SUGARMAN JL, 1995, MOL CELL BIOL, V15, P3282; Takahashi Y, 2000, GENE DEV, V14, P804; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Uchiumi T, 1997, J BIOL CHEM, V272, P9166; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; WU CL, 1995, MOL CELL BIOL, V15, P2536; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X; ZHU LG, 1995, MOL CELL BIOL, V15, P3552; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	46	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					39015	39024		10.1074/jbc.M202960200	http://dx.doi.org/10.1074/jbc.M202960200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12147683	Green Published, hybrid			2022-12-27	WOS:000178529600126
J	Maggi, LB; Moran, JM; Scarim, AL; Ford, DA; Yoon, JW; Howat, JM; Buller, RML; Corbett, JA				Maggi, LB; Moran, JM; Scarim, AL; Ford, DA; Yoon, JW; Howat, JM; Buller, RML; Corbett, JA			Novel role for calcium-independent phospholipase A(2) in the macrophage antiviral response of inducible nitric-oxide synthase expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; NF-KAPPA-B; DEPENDENT PROTEIN-KINASE; ARACHIDONIC-ACID INCORPORATION; P388D(1) MACROPHAGES; BROMOENOL LACTONE; INTERFERON-GAMMA; ACTIVATION; INHIBITION; INDUCTION	The double-stranded (ds) RNA-dependent protein kinase (PKR) is a primary regulator of antiviral responses; however, the ability of dsRNA to activate nuclear factor-kappaB (NF-kappaB) and dsRNA + interferon gamma (IFN-gamma) to stimulate inducible nitric-oxide synthase (iNOS) expression by macrophages isolated from PKR(-/-) mice suggests that signaling pathways in addition to PKR participate in antiviral activities. We have identified a novel phospholipid-signaling cascade that mediates macrophage activation by dsRNA and viral infection. Bromoenol lactone (BEL), a selective inhibitor of the calcium-independent phospholipase A(2) (iPLA(2)), prevents dsRNA- and virus-induced iNOS expression by RAW 264.7 cells and mouse macrophages. BEL does not modulate dsRNA-induced interleukin 1 expression, nor does it affect dsRNA-induced NF-kappaB activation. Protein kinase A (PKA) and the cAMP response element binding protein (CREB) are downstream targets of iPLA(2), because selective PKA inhibition prevents dsRNA-induced iNOS expression, and the inhibitory actions of BEL on dsRNA-induced iNOS expression are overcome by the direct activation of PKA. In addition, BEL inhibits dsRNA-induced CREB phosphorylation and CRE reporter activation. PKR does not participate in iPLA(2) activation or iNOS expression, because dsRNA stimulates iPLA(2) activity and dsRNA + IFN-gamma induces iNOS expression and nitric oxide production to similar levels by macrophages isolated from PKR(+/+) and PKR(-/-) mice. These findings support a PKR-independent signaling role for iPLA(2) in the antiviral response of macrophages.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Pathol, St Louis, MO 63104 USA; Univ Calgary, Fac Med, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada	Saint Louis University; Saint Louis University; Saint Louis University; University of Calgary	Corbett, JA (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA.	corbettj@slu.edu	Maggi, Leonard/L-5217-2019; Ford, David/D-1819-2018	Maggi, Leonard/0000-0003-0138-0984; Ford, David/0000-0002-0029-1560; McHowat, Jane/0000-0003-3133-3388				ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldassare JJ, 1999, J IMMUNOL, V162, P5367; Balsinde J, 1997, ADV EXP MED BIOL, V407, P99; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; Cabaner C, 1999, BRIT J PHARMACOL, V127, P813, DOI 10.1038/sj.bjp.0702606; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; DANIELS SB, 1986, BIOCHEMISTRY-US, V25, P1436, DOI 10.1021/bi00354a037; Flodstrom M, 2001, VIROLOGY, V281, P205, DOI 10.1006/viro.2000.0801; Gajate C, 1998, MOL PHARMACOL, V53, P602, DOI 10.1124/mol.53.4.602; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Glaser K B, 1990, Adv Exp Med Biol, V275, P1; GODAMBE SA, 1993, CYTOKINE, V5, P327, DOI 10.1016/1043-4666(93)90064-C; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Gross RW, 1998, BIOCHEM SOC T, V26, P345, DOI 10.1042/bst0260345; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Heitmeier MR, 1998, J BIOL CHEM, V273, P15301, DOI 10.1074/jbc.273.24.15301; HIBBS JB, 1990, INT CONGR SER, V897, P189; Hill JR, 1996, ANAL BIOCHEM, V236, P14, DOI 10.1006/abio.1996.0125; Hirasawa K, 1999, J VIROL, V73, P8541, DOI 10.1128/JVI.73.10.8541-8548.1999; Horrocks L A, 1978, Adv Exp Med Biol, V100, P423; Iordanov MS, 2001, MOL CELL BIOL, V21, P61, DOI 10.1128/MCB.21.1.61-72.2001; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; Kaufman RJ, 1999, P NATL ACAD SCI USA, V96, P11693, DOI 10.1073/pnas.96.21.11693; KUEHL FA, 1980, SCIENCE, V210, P978, DOI 10.1126/science.6254151; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Ma ZM, 2001, J BIOL CHEM, V276, P13198, DOI 10.1074/jbc.M010423200; Ma ZM, 2001, PROG NUCLEIC ACID RE, V67, P1, DOI 10.1016/S0079-6603(01)67023-5; Maggi LB, 2000, EMBO J, V19, P3630, DOI 10.1093/emboj/19.14.3630; MALEWICZ B, 1981, BIOCHEM BIOPH RES CO, V101, P404, DOI 10.1016/0006-291X(81)91274-2; McHowat J, 2000, AM J PHYSIOL-HEART C, V278, pH1933, DOI 10.1152/ajpheart.2000.278.6.H1933; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Schwacha MG, 1998, J LEUKOCYTE BIOL, V64, P740, DOI 10.1002/jlb.64.6.740; Walev I, 2000, J IMMUNOL, V164, P5120, DOI 10.4049/jimmunol.164.10.5120; Williams SD, 2001, AM J PHYSIOL-HEART C, V281, pH168, DOI 10.1152/ajpheart.2001.281.1.H168; Williams SD, 1997, FEBS LETT, V420, P33, DOI 10.1016/S0014-5793(97)01482-8; Williams SD, 2000, J LIPID RES, V41, P1585; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; WOLF RA, 1985, J BIOL CHEM, V260, P7295; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x	50	38	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38449	38455		10.1074/jbc.M206247200	http://dx.doi.org/10.1074/jbc.M206247200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167650	hybrid			2022-12-27	WOS:000178529600059
J	Radford, JC; Davies, SA; Dow, JAT				Radford, JC; Davies, SA; Dow, JAT			Systematic G-protein-coupled receptor analysis in Drosophila melanogaster identifies a leucokinin receptor with novel roles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTAL REGULATION; MYOTROPIC PEPTIDES; MALPIGHIAN TUBULES; LEUCOPHAEA-MADERAE; FLUID SECRETION; HEAD EXTRACTS; NEUROPEPTIDES; EXPRESSION; CLONING; FAMILY	Leucokinins are insect neuropeptides that stimulate hindgut motility and renal fluid secretion. Drosophila has a single leucokinin gene, pp, encoding the longest known leucokinin, Drosokinin. To identify its receptor, a genome-wide scan for G-protein-coupled receptors was performed in silico and candidate receptors identified by similarity to known tachykinin receptors. The deduced peptides were expressed, with a transgene for the calcium reporter aequorin, in S2 cells and only one gene (CG10626) encoded a protein that responded to Drosokinin. The properties of the heterologously expressed receptor (action through intracellular calcium with an EC50 of 4 x 10(-11) m and a t(1/2) <1 s) match closely those reported for the action of Drosokinin on Malpighian (renal) tubules. Antibodies raised against the receptor identified known sites of leucokinin action: stellate cells of the Malpighian tubule, two triplets of cells in the pars intercerebralis of the adult central nervous system, and additional cells in larval central nervous system. Western blots and reverse transcription-PCR confirmed these locations, but also identified expression in male and female gonads. These tissues also displayed elevated calcium in response to Drosokinin, demonstrating novel roles for leucokinin. A functional genomic approach has thus yielded the first complete characterization of a leucokinin receptor in an insect.	Univ Glasgow, Div Mol Genet, Inst Biomed & Life Sci, Glasgow G11 6NU, Lanark, Scotland	University of Glasgow	Dow, JAT (corresponding author), Univ Glasgow, Div Mol Genet, Inst Biomed & Life Sci, Glasgow G11 6NU, Lanark, Scotland.	j.a.t.dow@bio.gla.ac.uk	Radford, Jonathan/AAN-5046-2020; Dow, Julian/M-2371-2019	Dow, Julian/0000-0002-9595-5146				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Berman BP, 2002, P NATL ACAD SCI USA, V99, P757, DOI 10.1073/pnas.231608898; BLACKBURN MB, 1995, J INSECT PHYSIOL, V41, P723, DOI 10.1016/0022-1910(95)00005-F; Brody T, 2000, J CELL BIOL, V150, pF83, DOI 10.1083/jcb.150.2.F83; Broeck JV, 2001, PEPTIDES, V22, P241, DOI 10.1016/S0196-9781(00)00376-4; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; COAST GM, 1990, J INSECT PHYSIOL, V36, P481, DOI 10.1016/0022-1910(90)90098-Z; Cox KJA, 1997, J NEUROSCI, V17, P1197; Davies SA, 1995, AM J PHYSIOL-REG I, V269, pR1321, DOI 10.1152/ajpregu.1995.269.6.R1321; DOW JAT, 1994, AM J PHYSIOL, V266, pR1716, DOI 10.1152/ajpregu.1994.266.5.R1716; HAYES TK, 1989, LIFE SCI, V44, P1259, DOI 10.1016/0024-3205(89)90362-7; HAYES TK, 1994, REGUL PEPTIDES, V52, P235, DOI 10.1016/0167-0115(94)90058-2; Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Hofmann K., 1993, BIOL CHEM H-S, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; HOLMAN GM, 1986, COMP BIOCHEM PHYS C, V84, P205, DOI 10.1016/0742-8413(86)90084-8; HOLMAN GM, 1986, COMP BIOCHEM PHYS C, V84, P271, DOI 10.1016/0742-8413(86)90093-9; HOLMAN GM, 1987, COMP BIOCHEM PHYS C, V88, P31, DOI 10.1016/0742-8413(87)90043-0; Holman GM, 1999, PEPTIDES, V20, P1, DOI 10.1016/S0196-9781(98)00150-8; HOLMAN GM, 1987, COMP BIOCHEM PHYS C, V88, P27, DOI 10.1016/0742-8413(87)90042-9; HOLMAN GM, 1984, COMP BIOCHEM PHYS C, V77, P1, DOI 10.1016/0742-8413(84)90122-1; Holmes SP, 2000, INSECT MOL BIOL, V9, P457, DOI 10.1046/j.1365-2583.2000.00208.x; Katanosaka K, 1998, FEBS LETT, V424, P149, DOI 10.1016/S0014-5793(98)00160-4; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; LI XJ, 1992, J BIOL CHEM, V267, P9; LI XJ, 1991, EMBO J, V10, P3221, DOI 10.1002/j.1460-2075.1991.tb04885.x; MacPherson MR, 2001, AM J PHYSIOL-CELL PH, V280, pC394, DOI 10.1152/ajpcell.2001.280.2.C394; MONNIER D, 1992, J BIOL CHEM, V267, P1298; Nieto J, 1998, BIOCHEM BIOPH RES CO, V248, P406, DOI 10.1006/bbrc.1998.8964; O'Donnell MJ, 1998, AM J PHYSIOL-REG I, V274, pR1039, DOI 10.1152/ajpregu.1998.274.4.R1039; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Rosay P, 1997, J CELL SCI, V110, P1683; ROSAY P, 1995, MECH DEVELOP, V51, P329, DOI 10.1016/0925-4773(95)00382-7; Rost B, 1996, METHOD ENZYMOL, V266, P525; SCHOOFS L, 1992, REGUL PEPTIDES, V37, P49, DOI 10.1016/0167-0115(92)90063-Z; Sozen MA, 1997, P NATL ACAD SCI USA, V94, P5207, DOI 10.1073/pnas.94.10.5207; Terhzaz S, 1999, J EXP BIOL, V202, P3667; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; VEENSTRA JA, 1994, BIOCHEM BIOPH RES CO, V202, P715, DOI 10.1006/bbrc.1994.1989; Veenstra JA, 1997, J BIOL CHEM, V272, P10402, DOI 10.1074/jbc.272.16.10402; ZITNAN D, 1993, DEV BIOL, V156, P117, DOI 10.1006/dbio.1993.1063	44	137	141	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38810	38817		10.1074/jbc.M203694200	http://dx.doi.org/10.1074/jbc.M203694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163486	hybrid			2022-12-27	WOS:000178529600102
J	Wen, J; You, KR; Lee, SY; Song, CH; Kim, DG				Wen, J; You, KR; Lee, SY; Song, CH; Kim, DG			Oxidative stress-mediated apoptosis - The anticancer effect of the sesquiterpene lactone parthenolide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ENDOPLASMIC-RETICULUM STRESS; HEPATOCELLULAR-CARCINOMA; CYTOCHROME-C; GENE GADD153; CANCER CELLS; IN-VITRO; GLUTATHIONE; INHIBITION; INDUCTION	The sesquiterpene lactone parthenolide, the principal active component in medicinal plants, has been used conventionally to treat migraines, inflammation, and tumors. However, the antitumor effects of parthenolide and the mechanism(s) involved are poorly understood. We found that parthenolide effectively inhibits hepatoma cell growth in a tumor cell-specific manner and triggers apoptosis of hepatoma cells. Parthenolide triggered apoptosis in invasive sarcomatoid hepatocellular carcinoma cells (SH-J1) as well as in other ordinary hepatoma cells at 5-10 muM concentrations and arrested the cell growth (at G(2)/M) at sublethal concentrations (1-3 muM). During parthenolide-induced apoptosis, depletion of glutathione, generation of reactive oxygen species, reduction of mitochondrial transmembrane potential, activation of caspases (caspases-7, -8, and -9), overexpression of GADD153 (an oxidative stress or anticancer agent inducible gene), and subsequent apoptotic cell death was observed. This induced apoptosis could be effectively inhibited or abrogated by an antioxidant N-acetyl-L-eysteine, whereas L-buthionine-(S,R)-sulfoximine enhanced it. Furthermore, stable overexpression of GADD153 sensitized the cells to apoptosis induced by parthenolide, and this susceptibility could be reversed by transfection with an antisense to GADD153. Parthenolide did not alter the expression of Bcl-2 or Bcl-X-L proteins during apoptosis in hepatoma cells. Oxidative stress may contribute to parthenolide-induced apoptosis and to GADD153 overexpression in a glutathione-sensitive manner. The sensitivity of tumor cells to parthenolide appears to result from the low expression level of the multifunctional detoxification enzyme glutathione S-transferase pi. Finally, parthenolide and its derivatives may be useful chemotherapeutic agents to treat these invasive cancers.	Chonbuk Natl Univ Med Sch & Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Chonju 561712, Chonbuk, South Korea; Chonbuk Natl Univ Med Sch & Hosp, Dept Anat Res, Inst Clin Med, Chonju 561712, Chonbuk, South Korea	Jeonbuk National University; Jeonbuk National University Hospital; Jeonbuk National University; Jeonbuk National University Hospital	Kim, DG (corresponding author), Chonbuk Natl Univ Med Sch & Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, 634-18 Keumam Dong, Chonju 561712, Chonbuk, South Korea.	daeghon@moak.chonbuk.ac.kr						ANDERSON ME, 1983, P NATL ACAD SCI-BIOL, V80, P707, DOI 10.1073/pnas.80.3.707; ARRICK BA, 1983, J CLIN INVEST, V71, P258, DOI 10.1172/JCI110766; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BIGGS MJ, 1982, LANCET, V2, P776; Bork PM, 1997, FEBS LETT, V402, P85, DOI 10.1016/S0014-5793(96)01502-5; DOUROS J, 1978, CANCER CHEMOTH PHARM, V1, P91; Eymin B, 1997, CANCER RES, V57, P686; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; Friedman AD, 1996, CANCER RES, V56, P3250; Fukuda K, 2000, BIOCHEM PHARMACOL, V60, P595, DOI 10.1016/S0006-2952(00)00340-3; Fulda S, 1998, J BIOL CHEM, V273, P33942, DOI 10.1074/jbc.273.51.33942; Gately DP, 1996, J BIOL CHEM, V271, P20588, DOI 10.1074/jbc.271.34.20588; GATELY DP, 1994, BRIT J CANCER, V70, P1102, DOI 10.1038/bjc.1994.455; Goto S, 1999, FREE RADICAL RES, V31, P549, DOI 10.1080/10715769900301121; GROENEWEGEN WA, 1990, J PHARM PHARMACOL, V42, P553, DOI 10.1111/j.2042-7158.1990.tb07057.x; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Grutter MG, 2000, CURR OPIN STRUC BIOL, V10, P649, DOI 10.1016/S0959-440X(00)00146-9; Guillet G, 2000, PHOTOCHEM PHOTOBIOL, V71, P111, DOI 10.1562/0031-8655(2000)071&lt;0111:SIPSIM&gt;2.0.CO;2; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; HALL IH, 1979, J PHARM SCI, V68, P537, DOI 10.1002/jps.2600680505; HARATAKE J, 1991, CANCER, V68, P93, DOI 10.1002/1097-0142(19910701)68:1<93::AID-CNCR2820680119>3.0.CO;2-G; Hehner SP, 1999, J IMMUNOL, V163, P5617; Hwang D, 1996, BIOCHEM BIOPH RES CO, V226, P810, DOI 10.1006/bbrc.1996.1433; JOHNSON ES, 1985, BRIT MED J, V291, P569, DOI 10.1136/bmj.291.6495.569; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Kim DG, 1996, CANCER LETT, V107, P149, DOI 10.1016/0304-3835(96)04407-2; Kim DG, 2002, CANCER GENET CYTOGEN, V132, P120, DOI 10.1016/S0165-4608(01)00543-X; Kim R, 1999, ANTICANCER RES, V19, P1779; Kito M, 2002, BIOCHEM BIOPH RES CO, V291, P861, DOI 10.1006/bbrc.2002.6525; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; LEE KH, 1977, SCIENCE, V196, P533, DOI 10.1126/science.191909; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LUETHY JD, 1994, CANCER RES, V54, pS1902; Maeda T, 1996, CANCER, V77, P51, DOI 10.1002/(SICI)1097-0142(19960101)77:1<51::AID-CNCR10>3.0.CO;2-7; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Meister A., 1988, MECHANISMS DRUG RESI, P99; NAKAJIMA T, 1993, CANCER-AM CANCER SOC, V72, P1872, DOI 10.1002/1097-0142(19930915)72:6<1872::AID-CNCR2820720614>3.0.CO;2-N; Nozaki S, 2001, ONCOGENE, V20, P2178, DOI 10.1038/sj.onc.1204292; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OConnor PM, 1997, CANCER RES, V57, P4285; Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768; PICMAN AK, 1979, CHEM-BIOL INTERACT, V28, P83, DOI 10.1016/0009-2797(79)90116-9; RAO PN, 1980, MOL CELL BIOCHEM, V29, P47; Ross JJ, 1999, PLANTA MED, V65, P126, DOI 10.1055/s-1999-13972; SABURI Y, 1989, CANCER RES, V49, P7020; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; TEW KD, 1994, CANCER RES, V54, P4313; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WOERDENBAG HJ, 1989, BRIT J CANCER, V59, P68, DOI 10.1038/bjc.1989.13; Yang JC, 1998, FREE RADICAL BIO MED, V24, P624, DOI 10.1016/S0891-5849(97)00367-5; YOKOMIZO A, 1995, J BIOL CHEM, V270, P19451, DOI 10.1074/jbc.270.33.19451; You KR, 2002, J BIOL CHEM, V277, P3870, DOI 10.1074/jbc.M109284200; You KR, 2001, HEPATOLOGY, V34, P1119, DOI 10.1053/jhep.2001.29199; ZHANG W, 1995, CANCER LETT, V96, P31, DOI 10.1016/0304-3835(95)03914-I; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	58	280	302	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38954	38964		10.1074/jbc.M203842200	http://dx.doi.org/10.1074/jbc.M203842200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151389	hybrid			2022-12-27	WOS:000178529600119
J	Young, ET; Kacherovsky, N; Van Riper, K				Young, ET; Kacherovsky, N; Van Riper, K			Snf1 protein kinase regulates Adr1 binding to chromatin but not transcription activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPRESSIBLE ALCOHOL-DEHYDROGENASE; YEAST SACCHAROMYCES-CEREVISIAE; ADH2 EXPRESSION; PEROXISOME PROLIFERATION; DNA-BINDING; GLUCONEOGENIC ENZYMES; GLUCOSE REPRESSION; GENE-EXPRESSION; 3 GENES; PHOSPHORYLATION	The yeast transcriptional activator Adr1 controls the expression of genes required for ethanol, glycerol, and fatty acid utilization. We show that Adr1 acts directly on the promoters of ADH2, ACS1, GUT1, CTA1, and POT1 using chromatin immunoprecipitation assays. The yeast homolog of the AMP-activated protein kinase, Snf1; promotes Adr1 chromatin binding in the absence of glucose, and the protein phosphatase complex, Glc7.Reg1, represses its binding in the presence of glucose. A posttranslational process is implicated in the regulation of Adr1 binding activity. Chromatin binding by Adr1 is not the only step in ADH2 transcription that is regulated by glucose repression. Adr1 can bind to chromatin in repressed conditions in the presence of hyperacetylated histones. To study steps subsequent to promoter binding we utilized miniAdr1 transcription factors to characterize Adr1-dependent transcription in vitro. Yeast nuclear extracts prepared from glucose-repressed and glucose-derepressed cells are equally capable of supporting miniAdr1-dependent transcription and pre-initiation complex formation. Nuclear extracts prepared from a snf1 mutant support miniAdr1-dependent transcription but are partially defective in the formation of pre-initiation complexes with Mediator components being particularly depleted. We conclude that Snf1 regulates Adr1-dependent transcription primarily at the level of chromatin binding.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Young, ET (corresponding author), Univ Washington, Dept Biochem, Box 357350, Seattle, WA 98195 USA.	ety@u.washington.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026079] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26079] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMBERG H, 1988, MOL CELL BIOL, V8, P1868, DOI 10.1128/MCB.8.5.1868; BLUMBERG H, 1987, THESIS U WASHINGTON; Bowers PW, 1999, NAT STRUCT BIOL, V6, P478; Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CHERRY JR, 1989, CELL, V56, P409, DOI 10.1016/0092-8674(89)90244-4; Chiang YC, 1996, J BIOL CHEM, V271, P32359, DOI 10.1074/jbc.271.50.32359; CIRIACY M, 1979, MOL GEN GENET, V176, P427, DOI 10.1007/BF00333107; COOK WJ, 1993, CURR GENET, V23, P192, DOI 10.1007/BF00351495; COOK WJ, 1994, MOL CELL BIOL, V14, P629, DOI 10.1128/MCB.14.1.629; DENIS CL, 1991, MOL GEN GENET, V229, P395, DOI 10.1007/BF00267461; DENIS CL, 1992, MOL CELL BIOL, V12, P1507, DOI 10.1128/MCB.12.4.1507; DENIS CL, 1987, MOL GEN GENET, V208, P101, DOI 10.1007/BF00330429; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; Di Mauro E, 2002, J BIOL CHEM, V277, P7002, DOI 10.1074/jbc.M106719200; Dombek KM, 1999, MOL CELL BIOL, V19, P6029; Dombek KM, 1997, MOL CELL BIOL, V17, P1450, DOI 10.1128/MCB.17.3.1450; DOMBEK KM, 1993, MOL CELL BIOL, V13, P4391, DOI 10.1128/MCB.13.7.4391; DONOVIEL MS, 1995, MOL CELL BIOL, V15, P3442; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Grauslund M, 1999, NUCLEIC ACIDS RES, V27, P4391, DOI 10.1093/nar/27.22.4391; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Gurvitz A, 2001, J BIOL CHEM, V276, P31825, DOI 10.1074/jbc.M105989200; Gurvitz Aner, 2000, Molecular Cell Biology Research Communications, V4, P81, DOI 10.1006/mcbr.2000.0261; Haurie V, 2001, J BIOL CHEM, V276, P76, DOI 10.1074/jbc.M008752200; Hecht A, 1999, METHOD ENZYMOL, V304, P399; HEDGES D, 1995, MOL CELL BIOL, V15, P1915; IRANI M, 1987, MOL CELL BIOL, V7, P1233, DOI 10.1128/MCB.7.3.1233; KARNITZ L, 1992, GENETICS, V132, P351; Komarnitsky PB, 1998, MOL CELL BIOL, V18, P5861, DOI 10.1128/MCB.18.10.5861; Kratzer S, 1997, MOL MICROBIOL, V26, P631, DOI 10.1046/j.1365-2958.1997.5611937.x; Kuchin S, 2000, P NATL ACAD SCI USA, V97, P7916, DOI 10.1073/pnas.140109897; Liu Y, 2001, J BIOL CHEM, V276, P7169, DOI 10.1074/jbc.M009586200; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; NAVARRO B, 1994, BIOCHEM BIOPH RES CO, V202, P960, DOI 10.1006/bbrc.1994.2023; RandezGil F, 1997, MOL CELL BIOL, V17, P2502, DOI 10.1128/MCB.17.5.2502; Ranish JA, 1999, GENE DEV, V13, P49, DOI 10.1101/gad.13.1.49; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIMON M, 1992, YEAST, V8, P303, DOI 10.1002/yea.320080407; SIMON MM, 1995, MOL GEN GENET, V249, P289, DOI 10.1007/BF00290529; Sloan JS, 1999, J BIOL CHEM, V274, P37575, DOI 10.1074/jbc.274.53.37575; TAYLOR WE, 1990, P NATL ACAD SCI USA, V87, P4098, DOI 10.1073/pnas.87.11.4098; VALLARI RC, 1992, MOL CELL BIOL, V12, P1663, DOI 10.1128/MCB.12.4.1663; Verdone L, 2002, EMBO J, V21, P1101, DOI 10.1093/emboj/21.5.1101; Verdone L, 1997, J BIOL CHEM, V272, P30828, DOI 10.1074/jbc.272.49.30828; Verdone L, 1996, MOL CELL BIOL, V16, P1978; Vincent O, 2001, MOL CELL BIOL, V21, P5790, DOI 10.1128/MCB.21.17.5790-5796.2001; Vincent O, 1998, EMBO J, V17, P7002, DOI 10.1093/emboj/17.23.7002; Walther K, 2001, MICROBIOL-SGM, V147, P2037, DOI 10.1099/00221287-147-8-2037; Young ET, 1998, J BIOL CHEM, V273, P32080, DOI 10.1074/jbc.273.48.32080; Young ET, 2000, BIOCHEMISTRY-US, V39, P567, DOI 10.1021/bi992049r; YU J, 1989, MOL CELL BIOL, V9, P34, DOI 10.1128/MCB.9.1.34; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603	55	66	67	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38095	38103		10.1074/jbc.M206158200	http://dx.doi.org/10.1074/jbc.M206158200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167649	hybrid			2022-12-27	WOS:000178529600017
J	Gomez, MF; Stevenson, AS; Bonev, AD; Hill-Eubanks, DC; Nelson, MT				Gomez, MF; Stevenson, AS; Bonev, AD; Hill-Eubanks, DC; Nelson, MT			Opposing actions of inositol 1,4,5-trisphosphate and ryanodine receptors on nuclear factor of activated T-cells regulation in smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; DEPENDENT TRANSCRIPTIONAL PATHWAY; NF-AT; CEREBRAL-ARTERIES; PLASMA-MEMBRANE; CA2+ SPARKS; PHOSPHATASE CALCINEURIN; MEDIATED TRANSCRIPTION; INTRACELLULAR CALCIUM; PROTEIN PHOSPHATASE	The nuclear factor of activated T-cells (NFAT), originally identified in T-cells, has since been shown to play a role in mediating Ca2+-dependent gene transcription in diverse cell types outside of the immune system. We have previously shown that nuclear accumulation of NFATc3 is induced in ileal smooth muscle by platelet-derived growth factor in a manner that depends on Ca2+ influx through L-type, voltage-dependent Ca2+ channels. Here we show that NFATc3 is also the predominant NFAT isoform expressed in cerebral artery smooth muscle and is induced to accumulate in the nucleus by UTP and other G(q/11)-coupled receptor agonists. This induction is mediated by calcineurin and is, dependent on sarcoplasmic reticulum Ca2+ release through inositol 1,4,5-trisphosphate receptors and extracellular Ca2+ influx through L-type, voltage-dependent Ca2+ channels. Consistent with results obtained in ileal smooth muscle, depolarization-induced Ca2+ influx fails to induce NFAT nuclear accumulation in cerebral arteries. We also provide evidence that Ca2+ release by ryanodine receptors in the form of Ca2+ sparks may exert an inhibitory influence on UTP-induced NFATc3 nuclear accumulation and further suggest that UTP may act, in part, by inhibiting Ca2+ sparks. These results are consistent with a multifactorial regulation of NFAT nuclear accumulation in smooth muscle that is likely to involve several intracellular signaling pathways, including local effects of sarcoplasmic reticulum. Ca2+ release and effects attributable to global elevations in intracellular Ca2+.	Univ Vermont, Dept Pharmacol, Burlington, VT 05405 USA	University of Vermont	Nelson, MT (corresponding author), Univ Vermont, Dept Pharmacol, 89 Beaumont Ave, Burlington, VT 05405 USA.		Gomez, Maria F/D-3696-2014	Gomez, Maria F/0000-0001-6210-3142; Nelson, Mark/0000-0002-6608-8784	NHLBI NIH HHS [T32 HL/AR 07944, HL63722, HL07647-12, HL44455] Funding Source: Medline; NIDDK NIH HHS [DDK53832] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063722, R01HL044455, T32HL007944] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK053832, R01DK053832] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott KL, 2000, MOL PHARMACOL, V58, P946, DOI 10.1124/mol.58.5.946; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Boss V, 1998, MOL PHARMACOL, V54, P264, DOI 10.1124/mol.54.2.264; Boss V, 1998, J BIOL CHEM, V273, P19664, DOI 10.1074/jbc.273.31.19664; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Chow CW, 2000, MOL CELL BIOL, V20, P5227, DOI 10.1128/MCB.20.14.5227-5234.2000; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; CRABTREE GR, 1994, ANNU REV BIOCHEM, V63, P1045, DOI 10.1146/annurev.bi.63.070194.005145; del Arco PG, 2000, J BIOL CHEM, V275, P13872, DOI 10.1074/jbc.275.18.13872; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Gibson A, 1998, TRENDS PHARMACOL SCI, V19, P266; Gollasch M, 1998, CIRC RES, V83, P1104, DOI 10.1161/01.RES.83.11.1104; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; HO S, 1996, CLIN IMMUNOL IMMUNOP, V80, P40; Iino M, 1999, MOL CELL BIOCHEM, V190, P185, DOI 10.1023/A:1006951317052; IINO M, 1994, EMBO J, V13, P5026, DOI 10.1002/j.1460-2075.1994.tb06831.x; Jaggar JH, 2000, AM J PHYSIOL-CELL PH, V279, pC1528, DOI 10.1152/ajpcell.2000.279.5.C1528; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; Kashishian A, 1998, J BIOL CHEM, V273, P27412, DOI 10.1074/jbc.273.42.27412; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; Knot HJ, 1998, J PHYSIOL-LONDON, V508, P199, DOI 10.1111/j.1469-7793.1998.199br.x; Lewis CJ, 2000, J PHYSIOL-LONDON, V527, P315, DOI 10.1111/j.1469-7793.2000.00315.x; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Liu J, 1997, MOL BIOL CELL, V8, P157, DOI 10.1091/mbc.8.1.157; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Masuda ES, 1997, MOL CELL BIOL, V17, P2066, DOI 10.1128/MCB.17.4.2066; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MAYER EA, 1992, J MEMBRANE BIOL, V125, P107; Miriel VA, 1999, J PHYSIOL-LONDON, V518, P815, DOI 10.1111/j.1469-7793.1999.0815p.x; Mironneau J, 1996, CELL CALCIUM, V20, P153, DOI 10.1016/S0143-4160(96)90104-9; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; NELSON MT, 1995, AM J PHYSIOL, V268, P799; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Pabelick CM, 2001, J APPL PHYSIOL, V91, P488, DOI 10.1152/jappl.2001.91.1.488; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; Putney JW, 2000, CELL MOL LIFE SCI, V57, P1272, DOI 10.1007/PL00000765; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; Seye CI, 1997, ARTERIOSCL THROM VAS, V17, P3602, DOI 10.1161/01.ATV.17.12.3602; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Stevenson AS, 2001, J BIOL CHEM, V276, P15018, DOI 10.1074/jbc.M011684200; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Torgerson TR, 1998, J IMMUNOL, V161, P6084; URQUILLA PR, 1978, STROKE, V9, P133, DOI 10.1161/01.STR.9.2.133; Wada H, 2002, J CELL BIOL, V156, P983, DOI 10.1083/jcb.200106057; WORLEY JF, 1991, AM J PHYSIOL, V261, pH1951, DOI 10.1152/ajpheart.1991.261.6.H1951; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	67	78	78	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37756	37764		10.1074/jbc.M203596200	http://dx.doi.org/10.1074/jbc.M203596200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145283	hybrid			2022-12-27	WOS:000178447100108
J	Jain, S; Tang, XN; Narayanan, CS; Agarwal, Y; Peterson, SM; Brown, CD; Ott, J; Kumar, A				Jain, S; Tang, XN; Narayanan, CS; Agarwal, Y; Peterson, SM; Brown, CD; Ott, J; Kumar, A			Angiotensinogen gene polymorphism at-217 affects basal promoter activity and is associated with hypertension in African-Americans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCER-BINDING-PROTEIN; LEUCINE-ZIPPER; TRANSCRIPTION INITIATION; SERUM ANGIOTENSINOGEN; MOLECULAR-GENETICS; BLOOD-PRESSURE; MESSENGER-RNA; RISK FACTOR; TATA BOX; EXPRESSION	Hypertension is a serious health problem in Western society, in particular for the African-American population. Although previous studies have suggested that the angiotensinogen (AGT) gene locus is involved in human essential hypertension, the molecular mechanisms involved in hypertension in African-Americans remain unknown. We show that an A/G polymorphism at -217 in the promoter of the AGT gene plays a significant role in hypertension in African-Americans. The frequency of the -217A allele was increased significantly in African-American hypertensive subjects compared with normotensive controls. We also show that the nucleotide sequence of this region of the AGT gene promoter bound strongly to CAAT/enhancer-binding protein (C/EBP) family transcription factors when nucleoside A was present at -217. In addition, we show that reporter constructs containing the human AGT gene promoter with nucleoside A at -217 had increased basal transcriptional activity upon transient transfection in HepG2 cells compared with reporter constructs with nucleoside G at -217. Finally, we show that interleukin-6 treatment in the presence or absence of overexpressed C/EBPbeta increased the promoter activities of reporter constructs containing nucleoside A at -217 compared with reporter constructs containing nucleoside G at -217. Because the AGT gene is expressed primarily in liver and adipose tissue, and C/EBP family transcription factors play an important role in gene expression in these tissues, we propose that increased transcriptional activity of the -217A allele of the human AGT gene is associated with hypertension in African-Americans.	New York Med Coll, Dept Pathol, Valhalla, NY 10595 USA; New York Med Coll, Dept Internal Med, Valhalla, NY 10595 USA; SUNY Hlth Sci Ctr, Dept Med, Div Renal, Brooklyn, NY 11203 USA; Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA	New York Medical College; New York Medical College; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Rockefeller University	Kumar, A (corresponding author), New York Med Coll, Dept Pathol, Basic Sci Bldg,Rm 455, Valhalla, NY 10595 USA.		Jain, Sudhir/A-2976-2008		NHGRI NIH HHS [HG00008] Funding Source: Medline; NHLBI NIH HHS [HL59547, HL49884] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059547, R01HL049884] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLOEM LJ, 1995, J CLIN INVEST, V95, P948, DOI 10.1172/JCI117803; Bloem LJ, 1997, HYPERTENSION, V29, P1078, DOI 10.1161/01.HYP.29.5.1078; BONNARDEAUX A, 1994, HYPERTENSION, V24, P63, DOI 10.1161/01.HYP.24.1.63; Brasier AR, 1999, VITAM HORM, V57, P217; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; CAMPBELL DJ, 1986, J CLIN INVEST, V78, P31, DOI 10.1172/JCI112566; CAMPBELL DJ, 1987, ENDOCRINOLOGY, V121, P1616, DOI 10.1210/endo-121-5-1616; CAO Z, 1991, GENE DEV, V5, P1528; Carson P, 2001, CLIN CARDIOL, V24, P183, DOI 10.1002/clc.4960240303; CAULFIELD M, 1995, J CLIN INVEST, V96, P687, DOI 10.1172/JCI118111; Cooper R, 1998, J HYPERTENS, V16, P571, DOI 10.1097/00004872-199816050-00003; Corvol P, 1997, ENDOCR REV, V18, P662, DOI 10.1210/er.18.5.662; CORVOL P, 1995, RECENT PROG HORM RES, V50, P287; Cui Y, 1998, GENE, V224, P97, DOI 10.1016/S0378-1119(98)00512-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Farzaneh-Far A, 2001, J BIOL CHEM, V276, P32466, DOI 10.1074/jbc.M104909200; FUKAMIZU A, 1990, J BIOL CHEM, V265, P7576; GAILLARD I, 1989, DNA-J MOLEC CELL BIO, V8, P87, DOI 10.1089/dna.1.1989.8.87; HATA A, 1994, J CLIN INVEST, V93, P1285, DOI 10.1172/JCI117083; Inoue I, 1997, J CLIN INVEST, V99, P1786, DOI 10.1172/JCI119343; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; KALINYAK JE, 1987, J BIOL CHEM, V262, P460; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; Lee YH, 1997, MOL CELL BIOL, V17, P2038, DOI 10.1128/MCB.17.4.2038; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Lewis P.O., 2001, GENETIC DATA ANAL CO; MANATUNGA AK, 1993, HYPERTENSION, V22, P84, DOI 10.1161/01.HYP.22.1.84; Mosterd A, 1999, NEW ENGL J MED, V340, P1221, DOI 10.1056/NEJM199904223401601; Narayanan CS, 1999, MOL CELL ENDOCRINOL, V148, P79, DOI 10.1016/S0303-7207(98)00236-6; Narayanan CS, 2000, MOL CELL BIOCHEM, V212, P81, DOI 10.1023/A:1007180322263; Narayanan CS, 1998, BIOCHEM BIOPH RES CO, V251, P388, DOI 10.1006/bbrc.1998.9430; OHTANI R, 1992, ENDOCRINOLOGY, V130, P1331, DOI 10.1210/en.130.3.1331; ROTIMI C, 1994, HYPERTENSION, V24, P591, DOI 10.1161/01.HYP.24.5.591; SOUBRIER F, 1990, HYPERTENSION, V16, P712, DOI 10.1161/01.HYP.16.6.712; TAKAHASHI S, 1992, J VET MED SCI, V54, P367, DOI 10.1292/jvms.54.367; TAKANO M, 1993, BIOCHEM PHARMACOL, V45, P201; UMEK RM, 1991, SCIENCE, V251, P288, DOI 10.1126/science.1987644; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; Wu ZD, 1999, CURR OPIN CELL BIOL, V11, P689, DOI 10.1016/S0955-0674(99)00037-X; WUARIN J, 1990, CELL, V63, P1257, DOI 10.1016/0092-8674(90)90421-A; Yanai K, 1996, J BIOL CHEM, V271, P15981, DOI 10.1074/jbc.271.27.15981; Yanai K, 1999, J BIOL CHEM, V274, P34605, DOI 10.1074/jbc.274.49.34605; Zhao YY, 1999, HYPERTENSION, V33, P108, DOI 10.1161/01.HYP.33.1.108	46	68	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36889	36896		10.1074/jbc.M204732200	http://dx.doi.org/10.1074/jbc.M204732200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145290	hybrid			2022-12-27	WOS:000178275100142
J	Kataoka, K; Muta, T; Yamazaki, S; Takeshige, K				Kataoka, K; Muta, T; Yamazaki, S; Takeshige, K			Activation of macrophages by linear (1 -> 3)-beta-D-glucans - Implications for the recognition of fungi by innate immunity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; GEL-FORMING (1->3)-BETA-D-GLUCANS; NUCLEAR MAGNETIC-RESONANCE; BETA-GLUCAN; CELL ACTIVATION; HELICAL CONFORMATION; SIGNAL-TRANSDUCTION; MURINE MACROPHAGES; TLR4; LIPOPOLYSACCHARIDE	Although (1-->3)-beta-D-glucans, which are one of major fungal cell wall components, are known to activate invertebrate innate immune systems, their activities on mammalian cells remain elusive. Here, we report their activities on mouse macrophages. Among the various (1-->3)-p-D-glucans, curdlan, a linear (1-->3)-beta-D-glucan, although not branched beta-glucans, exhibits significant activity to stimulate nuclear factor-kappaB in macrophages. The activity of curdlan is dramatically enhanced by pretreatment with sodium hydroxide or dimethyl sulfoxide, which disrupts multiple-stranded helices of (1-->3)-beta-Dglucans, and is dose-dependently inhibited by a (1-->3)-beta-D-glucan-binding protein and by laminarioligosaccharides with (1-->3)-beta-D-glucosidic linkages. Intriguingly, the activity of curdlan is also augmented by incubation with zymolyase, which releases (1-->3)-beta-D-glucans with a single helical structure from the glucan-networks assembled by multiple-stranded helices. The activation of macrophages culminates in the production of inducible nitric-oxide synthase, tumor necrosis factor-alpha, and macrophage inflammatory protein-2. Furthermore, a dominant-negative mutant of MyD88, an adaptor protein mediating signaling through the Toll-like receptor/inerleukin-1 receptor-like (TIR) domain, inhibits the activation of macrophages by curdlan. These results strongly suggest that macrophages respond to linear (1-->3)-beta-D-glucans, possibly released from fungal cell walls, via a receptor(s) harboring the TIR domain, such as a Toll-like receptor, to induce inflammatory reactions.	Kyushu Univ, Grad Sch Med Sci, Dept Mol & Cellular Biochem, Fukuoka 8128582, Japan	Kyushu University	Muta, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol & Cellular Biochem, Fukuoka 8128582, Japan.	tmuta@mailserver.med.kyushuu.ac.jp						Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Asai K, 1996, CANCER IMMUNOL IMMUN, V42, P275, DOI 10.1007/s002620050282; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; CASTLEY BJ, 1988, CARBOHYD RES, V183, P83; CASU B, 1966, TETRAHEDRON, V22, P3061, DOI 10.1016/S0040-4020(01)82286-9; CHIHARA G, 1969, Nature (London), V222, P687; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; COTE F, 1994, PLANT MOL BIOL, V26, P1379, DOI 10.1007/BF00016481; DICARLO FJ, 1958, SCIENCE, V127, P756, DOI 10.1126/science.127.3301.756-a; GLOVSKY MM, 1983, J RETICULOENDOTH SOC, V33, P401; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; HARADA T, 1968, ARCH BIOCHEM BIOPHYS, V124, P292, DOI 10.1016/0003-9861(68)90330-5; Hashimoto T, 1997, BIOL PHARM BULL, V20, P1006; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kerekgyarto C, 1996, INT J IMMUNOPHARMACO, V18, P347, DOI 10.1016/S0192-0561(96)00038-0; Kiemer AK, 2000, J IMMUNOL, V165, P175, DOI 10.4049/jimmunol.165.1.175; KIHO T, 1985, CARBOHYD RES, V142, P344, DOI 10.1016/0008-6215(85)85038-2; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Muta T., 1996, Progress in Molecular and Subcellular Biology, V15, P154; Muta T, 1996, CURR OPIN IMMUNOL, V8, P41, DOI 10.1016/S0952-7915(96)80103-8; Muta T, 2001, EUR J BIOCHEM, V268, P4580, DOI 10.1046/j.1432-1327.2001.02385.x; MUTA T, 1995, J BIOL CHEM, V270, P892, DOI 10.1074/jbc.270.2.892; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; OGAWA K, 1972, CARBOHYD RES, V23, P399, DOI 10.1016/S0008-6215(00)82709-3; OHNO N, 1990, CARBOHYD RES, V207, P311, DOI 10.1016/0008-6215(90)84058-3; PEARSON A, 1995, P NATL ACAD SCI USA, V92, P4056, DOI 10.1073/pnas.92.9.4056; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Read SM, 1996, CARBOHYD RES, V281, P187, DOI 10.1016/0008-6215(95)00350-9; Ross GD, 1999, IMMUNOPHARMACOLOGY, V42, P61, DOI 10.1016/S0162-3109(99)00013-2; SAITO H, 1977, BIOCHEMISTRY-US, V16, P908, DOI 10.1021/bi00624a015; SAITO H, 1978, MACROMOLECULES, V11, P1244, DOI 10.1021/ma60066a035; SASAKI T, 1978, CANCER RES, V38, P379; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; SEKI N, 1994, J BIOL CHEM, V269, P1370; SHARP JK, 1984, J BIOL CHEM, V259, P1312; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Soltys J, 1999, INFECT IMMUN, V67, P244, DOI 10.1128/IAI.67.1.244-252.1999; SPEERT DP, 1985, J LEUKOCYTE BIOL, V38, P655, DOI 10.1002/jlb.38.5.655; STITELER RD, 1978, J RETICULOENDOTH SOC, V24, P687; Stone BA, 1992, CHEM BIOL 1 3 BETA G; STORM DR, 1977, ANNU REV BIOCHEM, V46, P723, DOI 10.1146/annurev.bi.46.070177.003451; Takaki Y, 2002, J BIOL CHEM, V277, P14281, DOI 10.1074/jbc.M200177200; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Thornton BP, 1996, J IMMUNOL, V156, P1235; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Vassallo R, 2000, J IMMUNOL, V164, P3755, DOI 10.4049/jimmunol.164.7.3755; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Willment JA, 2001, J BIOL CHEM, V276, P43818, DOI 10.1074/jbc.M107715200; ZELENSKI SG, 1974, BOT MAR, V17, P191, DOI 10.1515/botm.1974.17.4.191; Zimmerman JW, 1998, J BIOL CHEM, V273, P22014, DOI 10.1074/jbc.273.34.22014	56	245	256	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36825	36831		10.1074/jbc.M206756200	http://dx.doi.org/10.1074/jbc.M206756200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12140296	hybrid			2022-12-27	WOS:000178275100134
J	Kohno, T; Sasaki, T; Kobayashi, K; Fainzilber, M; Sato, K				Kohno, T; Sasaki, T; Kobayashi, K; Fainzilber, M; Sato, K			Three-dimensional solution structure of the sodium channel agonist/antagonist delta-conotoxin TxVIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						5	POTATO CARBOXYPEPTIDASE INHIBITOR; OMEGA-CONOTOXIN; INACTIVATION GATE; DISTANCE GEOMETRY; NMR-SPECTROSCOPY; PEPTIDE TOXINS; COSY; PROTEINS; VENOM; SITE	The three-dimensional solution structure of delta-conotoxin TxVIX a 27-mer peptide agonist/antagonist of sodium channels, was determined by two-dimensional H-1 NMR spectroscopy with simulated annealing calculations. A total of 20 converged structures of delta-conotoxin TxVIA were obtained on the basis of 360 distance constraints obtained from nuclear Overhauser effect connectivities, 28 torsion angle constraints, and 27 constraints associated with hydrogen bonds and disulfide bonds. The atomic root mean square difference about the averaged coordinate positions is 0.35 +/- 0.07 Angstrom for the backbone atoms (N, C-alpha, C) and 0.98 +/- 0.14 Angstrom for all heavy atoms of the entire peptide. The molecular structure of delta-conotoxin TxVIA is composed of a short triple-stranded antiparallel beta-sheet. The overall beta-sheet topology is +2x, -1, which is the same as those for other conotoxins. However, the three-dimensional structure of delta-conotoxin TxVIIA has an unusual hydrophobic patch on one side of the molecule, which may play an important role in the sodium channel binding. These results provide a molecular basis for understanding the mechanism of sodium channel modulation through the toxin-channel interaction and insight into the discrimination of different ion channels.	Mitsubishi Kagaku Inst Life Sci, MITILS, Machida, Tokyo 1948511, Japan; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel	Mitsubishi Kagaku Institute of Life Sciences (MITILS); Weizmann Institute of Science	Kohno, T (corresponding author), Mitsubishi Kagaku Inst Life Sci, MITILS, 11 Minamiooya, Machida, Tokyo 1948511, Japan.	tkohno@libra.ls.m-kagaku.co.jp		Fainzilber, Mike/0000-0001-8173-8557				BASUS VJ, 1995, FEBS LETT, V370, P163, DOI 10.1016/0014-5793(95)00819-U; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Brunger A. T, 1993, XPLOR MANUAL VERSION; Bulaj G, 2001, BIOCHEMISTRY-US, V40, P13201, DOI 10.1021/bi010683a; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; CATTERALL WA, 1986, ANNU REV BIOCHEM, V55, P953, DOI 10.1146/annurev.biochem.55.1.953; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; DAVIS JH, 1993, BIOCHEMISTRY-US, V32, P7396, DOI 10.1021/bi00080a009; EAHOLTZ G, 1994, NEURON, V12, P1041, DOI 10.1016/0896-6273(94)90312-3; Eaholtz G, 1998, J GEN PHYSIOL, V111, P75, DOI 10.1085/jgp.111.1.75; FAINZILBER M, 1994, J BIOL CHEM, V269, P2574; FAINZILBER M, 1995, J BIOL CHEM, V270, P1123, DOI 10.1074/jbc.270.3.1123; Fozzard HA, 1996, PHYSIOL REV, V76, P887, DOI 10.1152/physrev.1996.76.3.887; GRAY WR, 1988, ANNU REV BIOCHEM, V57, P665, DOI 10.1146/annurev.bi.57.070188.003313; HASSON A, 1993, EUR J NEUROSCI, V5, P56, DOI 10.1111/j.1460-9568.1993.tb00205.x; HILLYARD DR, 1989, BIOCHEMISTRY-US, V28, P358, DOI 10.1021/bi00427a049; HURD RE, 1990, J MAGN RESON, V87, P422, DOI 10.1016/0022-2364(90)90021-Z; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Kellenberger S, 1996, J BIOL CHEM, V271, P30971, DOI 10.1074/jbc.271.48.30971; Kellenberger S, 1997, J GEN PHYSIOL, V109, P589, DOI 10.1085/jgp.109.5.589; Kobayashi K, 2000, BIOCHEMISTRY-US, V39, P14761, DOI 10.1021/bi001506x; KOHNO T, 1995, BIOCHEMISTRY-US, V34, P10256, DOI 10.1021/bi00032a020; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEVRAM V, 1994, BRAIN RES, V640, P48, DOI 10.1016/0006-8993(94)91856-2; LEWIS PN, 1973, BIOCHIM BIOPHYS ACTA, V303, P211, DOI 10.1016/0005-2795(73)90350-4; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MUELLER L, 1987, J MAGN RESON, V72, P191, DOI 10.1016/0022-2364(87)90188-0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OLIVERA BM, 1984, BIOCHEMISTRY-US, V23, P5087, DOI 10.1021/bi00317a001; OLIVERA BM, 1987, BIOCHEMISTRY-US, V26, P2086, DOI 10.1021/bi00382a004; PALLAGHY PK, 1993, J MOL BIOL, V234, P405, DOI 10.1006/jmbi.1993.1595; PATTON DE, 1992, P NATL ACAD SCI USA, V89, P10905, DOI 10.1073/pnas.89.22.10905; PENNINGTON MW, 1992, TOXICON, V30, P755, DOI 10.1016/0041-0101(92)90009-T; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Rohl CA, 1999, BIOCHEMISTRY-US, V38, P855, DOI 10.1021/bi9823380; SABO T, 1992, PEPTIDES CHEM BIOL, P159; Sasaki T, 1999, BIOCHEMISTRY-US, V38, P12876, DOI 10.1021/bi990731f; SEVILLA P, 1993, BIOCHEM BIOPH RES CO, V192, P1238, DOI 10.1006/bbrc.1993.1549; SHON KJ, 1995, BIOCHEMISTRY-US, V34, P4913, DOI 10.1021/bi00015a002; SHON KJ, 1994, BIOCHEMISTRY-US, V33, P11420, DOI 10.1021/bi00204a003; SKALICKY JJ, 1993, PROTEIN SCI, V2, P1591, DOI 10.1002/pro.5560021005; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; VASSILEV P, 1989, P NATL ACAD SCI USA, V86, P8147, DOI 10.1073/pnas.86.20.8147; VASSILEV PM, 1988, SCIENCE, V241, P1658, DOI 10.1126/science.2458625; VONKIENLIN M, 1991, J MAGN RESON, V93, P423, DOI 10.1016/0022-2364(91)90020-T; WEST JW, 1991, SCIENCE, V254, P866, DOI 10.1126/science.1658937; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; WUTHRICH K, 1986, NMR PROTEINS NUCL AC, P125	55	28	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36387	36391		10.1074/jbc.M206833200	http://dx.doi.org/10.1074/jbc.M206833200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145313	hybrid			2022-12-27	WOS:000178275100078
J	Niwa, J; Ishigaki, S; Hishikawa, N; Yamamoto, M; Doyu, M; Murata, S; Tanaka, K; Taniguchi, N; Sobue, G				Niwa, J; Ishigaki, S; Hishikawa, N; Yamamoto, M; Doyu, M; Murata, S; Tanaka, K; Taniguchi, N; Sobue, G			Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CU/ZN SUPEROXIDE-DISMUTASE; UBIQUITIN-PROTEIN LIGASE; ALS-LINKED SOD1; CONJUGATING ENZYME; ALPHA-SYNUCLEIN; MUTATIONS; PARKIN; INCLUSIONS; GENE	Amyotrophic lateral sclerosis (ALS) is a progressive paralytic disorder resulting from the degeneration of motor neurons in the cerebral cortex, brainstem, and spinal cord. The cytopathological hallmark in the remaining motor neurons of ALS is the presence of ubiquitylated inclusions consisting of insoluble protein aggregates. In this paper we report that Dorfin, a RING finger-type E3 ubiquitin ligase, is predominantly localized in the inclusion bodies of familial ALS with a copper/zinc superoxide dismutase (SOD1) mutation as well as sporadic AILS. Dorfin physically bound and ubiquitylated various SOD1 mutants derived from familial AILS patients and enhanced their degradation, but it had no effect on the stability of the wild-type SOD1. The overexpression of Dorfin protected against the toxic effects of mutant SOD1 on neural cells and reduced SOD1 inclusions. Our results indicate that Dorfin protects neurons by recognizing and then ubiquitylating mutant SOD1 proteins followed by targeting them for proteasomal degradation.	Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, Nagoya, Aichi 4668550, Japan; Tokyo Metropolitan Inst Med Sci, Dept Mol Oncol, Bunkyo Ku, Tokyo 1138613, Japan; Osaka Univ, Grad Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan	Nagoya University; Tokyo Metropolitan Institute of Medical Science; Osaka University	Sobue, G (corresponding author), Nagoya Univ, Grad Sch Med, Dept Neurol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	sobueg@med.nagoya-u.ac.jp	Taniguchi, Naoyuki/A-7086-2016; ISHIGAKI, Shinsuke/I-7305-2014; Murata, Shigeo/A-1426-2010; Taniguchi, Naoyuki/I-4182-2014	Murata, Shigeo/0000-0002-3177-3503; Taniguchi, Naoyuki/0000-0001-5889-5968; Ishigaki, Shinsuke/0000-0002-9555-0659				Ardley HC, 2001, J BIOL CHEM, V276, P19640, DOI 10.1074/jbc.M011028200; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; Bredesen DE, 1997, ANN NEUROL, V42, P135, DOI 10.1002/ana.410420202; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Durham HD, 1997, J NEUROPATH EXP NEUR, V56, P523, DOI 10.1097/00005072-199705000-00008; Emery A, 1982, HUMAN MOTOR NEURON D, P139; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Hirano A, 1996, NEUROLOGY, V47, pS63, DOI 10.1212/WNL.47.4_Suppl_2.63S; Hishikawa N, 2001, NEUROPATH APPL NEURO, V27, P362, DOI 10.1046/j.1365-2990.2001.00345.x; Hoffman EK, 1996, J NEUROL SCI, V139, P15, DOI 10.1016/S0022-510X(96)00031-7; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Kato S, 2000, AMYOTROPH LATERAL SC, V1, P163, DOI 10.1080/14660820050515160; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Koide T, 1998, NEUROSCI LETT, V257, P29, DOI 10.1016/S0304-3940(98)00800-3; LEIGH PN, 1991, BRAIN, V114, P775, DOI 10.1093/brain/114.2.775; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; LOWE J, 1994, J NEUROL SCI, V124, P38, DOI 10.1016/0022-510X(94)90175-9; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; Moynihan TP, 1999, J BIOL CHEM, V274, P30963, DOI 10.1074/jbc.274.43.30963; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; MURAYAMA S, 1990, ANN NEUROL, V27, P137, DOI 10.1002/ana.410270208; Newbery HJ, 2002, TRENDS MOL MED, V8, P88, DOI 10.1016/S1471-4914(02)02283-9; Niwa J, 2001, BIOCHEM BIOPH RES CO, V281, P706, DOI 10.1006/bbrc.2001.4414; Pasinelli P, 1998, P NATL ACAD SCI USA, V95, P15763, DOI 10.1073/pnas.95.26.15763; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SCHIFFER D, 1991, J NEUROPATH EXP NEUR, V50, P463, DOI 10.1097/00005072-199107000-00007; Shibata N, 1996, J NEUROPATH EXP NEUR, V55, P481, DOI 10.1097/00005072-199604000-00011; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Tu PH, 1996, P NATL ACAD SCI USA, V93, P3155, DOI 10.1073/pnas.93.7.3155; TYLER HR, 1991, HDB CLIN NEUROLOGY, V59, P169; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	45	155	162	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36793	36798		10.1074/jbc.M206559200	http://dx.doi.org/10.1074/jbc.M206559200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145308	hybrid			2022-12-27	WOS:000178275100130
J	Ng, HH; Xu, RM; Zhang, Y; Struhl, K				Ng, HH; Xu, RM; Zhang, Y; Struhl, K			Ubiquitination of histone H2B by Rad6 is required for efficient Dot1-mediated methylation of histone H3 lysine 79	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSOME CORE PARTICLE; SACCHAROMYCES-CEREVISIAE; YEAST	Dot1 is a non-SET domain protein that methylates histone H3 at lysine 79, a surface-exposed residue that lies within the globular domain. In the context of a nucleosome, H3 lysine 79 is located in close proximity with lysine 123 of histone H2B, a major site for ubiquitination by Rad6. Here we show that Rad6-mediated ubiquitination of H2B lysine 123 is important for efficient methylation of lysine 79, but not lysine 36, of histone H3. in contrast, lysine 79 methylation of H3 is not required for ubiquitination of H2B. Our study provides a new example of trans-histone regulation between modifications on different histones. In addition, it suggests that Rad6 affects telonteric silencing, at least in part, by influencing methylation of histone H3.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Cold Spring Harbor Lab, WM Keck Struct Biol Lab, Cold Spring Harbor, NY 11724 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	Harvard University; Harvard Medical School; Cold Spring Harbor Laboratory; University of North Carolina; University of North Carolina Chapel Hill	Struhl, K (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.		xu, rui/GRX-5734-2022; Ng, Huck Hui/A-1135-2009	Zhang, Yi/0000-0002-2789-0811	NIGMS NIH HHS [GM53720, GM63067] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053720, R01GM063067] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 2002, CELL, V109, P801, DOI 10.1016/S0092-8674(02)00798-5; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; Katan-Khaykovich Y, 2002, GENE DEV, V16, P743, DOI 10.1101/gad.967302; Kelly TJ, 2000, MOL CELL BIOL, V20, P7051, DOI 10.1128/MCB.20.19.7051-7058.2000; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lacoste N, 2002, J BIOL CHEM, V277, P30421, DOI 10.1074/jbc.C200366200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Singer MS, 1998, GENETICS, V150, P613; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; SWERDLOW PS, 1990, MOL CELL BIOL, V10, P4905, DOI 10.1128/MCB.10.9.4905; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	29	328	340	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34655	34657		10.1074/jbc.C200433200	http://dx.doi.org/10.1074/jbc.C200433200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12167634	hybrid			2022-12-27	WOS:000178117000001
J	Balboa, MA; Balsinde, J				Balboa, MA; Balsinde, J			Involvement of calcium-independent phospholipase A(2) in hydrogen peroxide-induced accumulation of free fatty acids in human U937 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE P388D(1) MACROPHAGES; SMOOTH-MUSCLE CELLS; ARACHIDONIC-ACID; PYRROLIDINE INHIBITORS; MEDIATED ACTIVATION; DISTINCT ROLES; CONCANAVALIN-A; PROTEIN-KINASE; RELEASE; ENZYMES	Previous studies have demonstrated that U937 cells are able to mobilize arachidonic acid (AA) and synthesize prostaglandins in response to receptor-directed and soluble stimuli by a mechanism that involves the activation of Group IV cytosolic phospholipase A(2)alpha. In this paper we show that these cells also mobilize AA in response to an oxidative stress induced by H2O2 through a mechanism that appears not to be mediated by cytosolic phospholipase A(2)alpha but by the calcium-independent Group VI phospholipase A(2) (iPLA,). This is supported by the following lines of evidence: (i) the response is essentially calcium-independent, (ii) it is inhibited by bromoenol lactone, and (iii) it is inhibited by an iPLA(2) antisense oligonucleotide. Enzyme assays conducted under a variety of conditions reveal that the specific activity of the iPLA(2) does not change as a result of H2O2 exposure, which argues against the activation of a specific signaling cascade ending in the iPLA(2). Rather, the oxidant acts to perturb membrane homeostasis in a way that the enzyme susceptibility/accessibility to its substrate increases, and this results in altered fatty acid release. In support of this view, not only AA, but also other fatty acids, were found to be liberated in an iPLA(2)-dependent manner in the H2O2-treated cells. Collectively, these studies underscore the importance of the iPLA(2) in modulating homeostatic fatty acid deacylation reactions and document a potentially important route under pathophysiological conditions for increasing free fatty acid levels during oxidative stress.	Univ Valladolid, Sch Med, Inst Mol Biol & Genet, E-47005 Valladolid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid	Balsinde, J (corresponding author), Univ Valladolid, Fac Med, CSIC, Inst Biol & Genet Mol,IBGM, Ave Ramon & Cajal 7, E-47005 Valladolid, Spain.		Balboa, María A./V-9493-2018; Balsinde, Jesús/C-7833-2018	Balboa, María A./0000-0002-2130-5298; Balsinde, Jesús/0000-0002-4157-6714				ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; Atsumi G, 2000, J BIOL CHEM, V275, P18248, DOI 10.1074/jbc.M000271200; Atsumi G, 1998, J BIOL CHEM, V273, P13870, DOI 10.1074/jbc.273.22.13870; Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Balsinde J, 2000, J BIOL CHEM, V275, P22544, DOI 10.1074/jbc.M910163199; Balsinde J, 1997, J BIOL CHEM, V272, P20373, DOI 10.1074/jbc.272.33.20373; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; BALSINDE J, 1990, BIOCHIM BIOPHYS ACTA, V1052, P90, DOI 10.1016/0167-4889(90)90061-H; BALSINDE J, 1988, BIOCHEM BIOPH RES CO, V151, P802, DOI 10.1016/S0006-291X(88)80352-8; Balsinde J, 2002, BIOCHEM J, V364, P695, DOI 10.1042/BJ20020142; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BALSINDE J, 2002, IN PRESS FEBS LETT; Birbes H, 2000, BIOCHEM BIOPH RES CO, V276, P613, DOI 10.1006/bbrc.2000.3479; BOYER CS, 1995, BIOCHEM PHARMACOL, V50, P753, DOI 10.1016/0006-2952(95)00195-6; Cane A, 1998, AM J PHYSIOL-CELL PH, V274, pC1040, DOI 10.1152/ajpcell.1998.274.4.C1040; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Carnevale KA, 2001, J IMMUNOL, V167, P3414, DOI 10.4049/jimmunol.167.6.3414; CHAKRABORTI S, 1995, CELL SIGNAL, V7, P75, DOI 10.1016/0898-6568(94)00061-F; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; DIEZ E, 1994, BIOCHEM J, V301, P721, DOI 10.1042/bj3010721; FERNANDEZ B, 1991, BIOCHEM BIOPH RES CO, V180, P1036, DOI 10.1016/S0006-291X(05)81170-2; Fitzpatrick FA, 2001, J CLIN INVEST, V107, P1347, DOI 10.1172/JCI13241; Ghomashchi F, 2001, BBA-BIOMEMBRANES, V1513, P160, DOI 10.1016/S0005-2736(01)00349-2; Hsu FF, 2000, J BIOL CHEM, V275, P16579, DOI 10.1074/jbc.M908342199; LISTER MD, 1989, J BIOL CHEM, V264, P8520; Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719; Ma ZM, 2002, AM J PHYSIOL-ENDOC M, V282, pE820, DOI 10.1152/ajpendo.00165.2001; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Ono T, 2002, BIOCHEM J, V363, P727, DOI 10.1042/0264-6021:3630727; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; Samanta S, 1998, J NEUROCHEM, V70, P2082; Seno K, 2000, J MED CHEM, V43, P1041, DOI 10.1021/jm9905155; Seno K, 2001, BIOORG MED CHEM LETT, V11, P587, DOI 10.1016/S0960-894X(01)00003-8; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Song JH, 2001, BRAIN RES, V895, P66, DOI 10.1016/S0006-8993(01)02029-7; SPORN PHS, 1992, AM J RESP CELL MOL, V7, P307, DOI 10.1165/ajrcmb/7.3.307; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Wagner BA, 2000, J BIOL CHEM, V275, P22461, DOI 10.1074/jbc.M001434200; Wagner BA, 2002, ARCH BIOCHEM BIOPHYS, V401, P223, DOI 10.1016/S0003-9861(02)00053-X; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4	41	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40384	40389		10.1074/jbc.M206155200	http://dx.doi.org/10.1074/jbc.M206155200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181317	hybrid, Green Submitted			2022-12-27	WOS:000178791400030
J	Zolezzi, F; Fuss, J; Uzawa, S; Linn, S				Zolezzi, F; Fuss, J; Uzawa, S; Linn, S			Characterization of a Schizosaccharomyces pombe strain deleted for a sequence homologue of the human damaged DNA binding 1 (DDB1) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIGMENTOSUM GROUP-E; COMPLEMENTATION GROUP-E; GLOBAL GENOMIC REPAIR; FISSION YEAST; CELL-CYCLE; UV DAMAGE; CHROMOSOME SEGREGATION; EXCISION-REPAIR; PROTEIN DDB; CULLIN 4A	Human damaged DNA-binding protein (DDB) is a heterodimer of p48/DDB2 and p127/DDB1 subunits. Mutations in DDB2 are responsible for Xeroderma Pigmentosum group E, but no mutants of mammalian DDB1 have been described. To study DDB1, the Schizosaccharomyces pombe DDB1 sequence homologue (ddb1(+)) was cloned, and a ddb1 deletion strain was constructed. The gene is not essential; however, mutant cells showed a 37% impairment in colony-forming ability, an elongated phenotype, and abnormal nuclei. The ddb1Delta strain was sensitive to UV irradiation, X-rays, methylmethane sulfonate, and thiabendazole, and these sensitivities were compared with those of the well characterized rad13Delta, rhp51Delta, and cds1Delta mutant strains. Ddb1p showed nuclear and nucleolar localization, and the aberrant nuclear structures observed in the ddb1Delta strain suggest a role for Ddb1p in chromosome segregation.	Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Linn, S (corresponding author), Univ Calif Berkeley, Dept Cell & Mol Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	slinn@socrates.berkeley.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059424] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES 08196] Funding Source: Medline; NIGMS NIH HHS [1R01 GM 59424] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; ALLSHIRE RC, 1987, CELL, V50, P391, DOI 10.1016/0092-8674(87)90493-4; Aravind L, 2000, P NATL ACAD SCI USA, V97, P11319, DOI 10.1073/pnas.200346997; ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BARNITZ JT, 1982, FEBS LETT, V143, P129, DOI 10.1016/0014-5793(82)80288-3; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Butel J S, 1995, Princess Takamatsu Symp, V25, P185; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; CLARKE L, 1990, TRENDS GENET, V6, P150, DOI 10.1016/0168-9525(90)90149-Z; Datta A, 2001, MUTAT RES-DNA REPAIR, V486, P89, DOI 10.1016/S0921-8777(01)00082-9; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; Edwards RJ, 1997, METHOD ENZYMOL, V283, P471; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; Ekwall K, 1996, J CELL SCI, V109, P2637; FAN JB, 1989, NUCLEIC ACIDS RES, V17, P2801, DOI 10.1093/nar/17.7.2801; Freeman-Cook LL, 1999, MOL BIOL CELL, V10, P3171, DOI 10.1091/mbc.10.10.3171; Fujiwara Y, 1999, J BIOL CHEM, V274, P20027, DOI 10.1074/jbc.274.28.20027; Grewal SIS, 1998, GENETICS, V150, P563; HAGAN IM, 1988, J CELL SCI, V89, P343; Hayes S, 1998, MOL CELL BIOL, V18, P240, DOI 10.1128/MCB.18.1.240; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; Humphrey T, 2000, MUTAT RES-FUND MOL M, V451, P211, DOI 10.1016/S0027-5107(00)00051-8; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Itoh T, 1999, J INVEST DERMATOL, V113, P251, DOI 10.1046/j.1523-1747.1999.00652.x; Itoh T, 2001, ONCOGENE, V20, P7041, DOI 10.1038/sj.onc.1204909; Itoh T, 2000, J INVEST DERMATOL, V114, P1022, DOI 10.1046/j.1523-1747.2000.00952.x; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; KEENEY S, 1994, P NATL ACAD SCI USA, V91, P4053, DOI 10.1073/pnas.91.9.4053; KEENEY S, 1993, J BIOL CHEM, V268, P21293; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Krishnamoorthy RR, 1997, BIOCHEMISTRY-US, V36, P960, DOI 10.1021/bi961407c; Lin GY, 2000, J VIROL, V74, P9152, DOI 10.1128/JVI.74.19.9152-9166.2000; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Liu W, 2000, J BIOL CHEM, V275, P21429, DOI 10.1074/jbc.M000961200; MALESZKA R, 1993, YEAST, V9, P53, DOI 10.1002/yea.320090107; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; McCready SJ, 2000, MUTAT RES-FUND MOL M, V451, P197, DOI 10.1016/S0027-5107(00)00050-6; Memisoglu A, 2000, J BACTERIOL, V182, P2104, DOI 10.1128/JB.182.8.2104-2112.2000; Mintz PJ, 1999, EMBO J, V18, P4308, DOI 10.1093/emboj/18.15.4308; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURIS DFR, 1993, NUCLEIC ACIDS RES, V21, P4586, DOI 10.1093/nar/21.19.4586; Nag A, 2001, J VIROL, V75, P10383, DOI 10.1128/JVI.75.21.10383-10392.2001; Nag A, 2001, MOL CELL BIOL, V21, P6738, DOI 10.1128/MCB.21.20.6738-6747.2001; Neuwald AF, 2000, NUCLEIC ACIDS RES, V28, P3570, DOI 10.1093/nar/28.18.3570; Nichols AF, 2000, J BIOL CHEM, V275, P21422, DOI 10.1074/jbc.M000960200; REARDON JT, 1993, J BIOL CHEM, V268, P21301; Rhind N, 1998, GENETICS, V149, P1729; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Shiyanov P, 1999, J BIOL CHEM, V274, P35309, DOI 10.1074/jbc.274.50.35309; Sipiczki M, 2000, GENOME BIOL, V1, DOI [10.1186/gb-2000-1-2-reviews1011, DOI 10.1186/GB-2000-1-2-REVIEWS1011]; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; TODA T, 1984, CURR GENET, V8, P93, DOI 10.1007/BF00420224; TOLLERVEY D, 1993, CELL, V72, P443, DOI 10.1016/0092-8674(93)90120-F; UZAWA S, 1992, J CELL SCI, V101, P267; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Yanagida M, 1998, TRENDS CELL BIOL, V8, P144, DOI 10.1016/S0962-8924(98)01236-7; Yasuhira S, 1999, J BIOL CHEM, V274, P26822, DOI 10.1074/jbc.274.38.26822; ZHAO YQ, 1995, DNA CELL BIOL, V14, P359, DOI 10.1089/dna.1995.14.359; Zolezzi F, 2000, GENE, V245, P151, DOI 10.1016/S0378-1119(00)00022-6	63	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41183	41191		10.1074/jbc.M207890200	http://dx.doi.org/10.1074/jbc.M207890200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181326	hybrid			2022-12-27	WOS:000178791400129
J	Liu, XJ; Jana, M; Dasgupta, S; Koka, S; He, J; Wood, C; Pahan, K				Liu, XJ; Jana, M; Dasgupta, S; Koka, S; He, J; Wood, C; Pahan, K			Human immunodeficiency virus type 1 (HIV-1) Tat induces nitric-oxide synthase in human astroglia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; NF-KAPPA-B; MESSENGER-RNA EXPRESSION; RAT PRIMARY ASTROCYTES; NECROSIS-FACTOR-ALPHA; BLOOD-BRAIN-BARRIER; MICROGLIAL CELLS; PROTEIN-KINASES; GENE-EXPRESSION; GLIAL CULTURES	Human immunodeficiency virus type 1 (HIV-1) infection is known to cause neuronal injury and dementia in a significant proportion of patients. However, the mechanism by which HIV-1 mediates its deleterious effects in the brain is poorly defined. The present study was undertaken to investigate the effect of the HIV-1 tat gene on the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astroglia. Expression of the tat gene as RSV-tat but not that of the CAT gene as RSV-CAT in U373MG astroglial cells led to the induction of NO production and the expression of iNOS protein and mRNA. Induction of NO production by recombinant HIV-1 Tat protein and inhibition of RSV-tat-induced NO production by anti-Tat antibodies suggest that RSV-tat-induced production of NO is dependent on Tat and that Tat is secreted from RSV-tat-transfected astroglia. Similar to U373MG astroglial cells, RSV-tat also induced the production of NO in human primary astroglia. The induction of human iNOS promoter-derived luciferase activity by the expression of RSV-tat suggests that RSV-tat induces the transcription of iNOS. To understand the mechanism of induction of iNOS, we investigated the role of NF-kappaB and C/EBPbeta, transcription factors responsible for the induction of iNOS. Activation of NF-kappaB as well as C/EBPbeta by RSV-tat, stimulation of RSV-tat-induced production of NO by the wild type of p65 and C/EBPbeta, and inhibition of RSV-tat-induced production of NO by Deltap65, a dominant-negative mutant of p65, and DeltaC/EBPbeta, a dominant-negative mutant of C/EBPbeta, suggest that RSV-tat induces iNOS through the activation of NF-kappaB and C/EBPbeta. In addition, we show that extracellular signal-regulated kinase (ERK) but not that p38 mitogen-activated protein kinase (MAPK) is involved in RSV-tat induced production of NO. Interestingly, PD98059, an inhibitor of the ERK pathway, and DeltaERK2, a dominant-negative mutant of ERK2, inhibited RSV-tat-induced production of NO through the inhibition of C/EBPbeta but not that of NF-kappaB. This study illustrates a novel role for HIV-1 tat in inducing the expression of iNOS in human astrocytes that may participate in the pathogenesis of HIV-associated dementia.	Univ Nebraska, Med Ctr, Dept Oral Biol, Lincoln, NE 68583 USA; Univ Nebraska, Nebraska Ctr Virol, Lincoln, NE 68588 USA; Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Pahan, K (corresponding author), Univ Nebraska, Med Ctr, Dept Oral Biol, 40th & Holdrege, Lincoln, NE 68583 USA.			Wood, Charles/0000-0002-4256-1530	NCI NIH HHS [CA76958] Funding Source: Medline; NCRR NIH HHS [P20 RR015635, P20-RR15635] Funding Source: Medline; NINDS NIH HHS [R01 NS039940, R01 NS039940-01A1, NS39940] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076958] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039940] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adamson DC, 1996, SCIENCE, V274, P1917, DOI 10.1126/science.274.5294.1917; Adamson DC, 1999, MOL MED, V5, P98, DOI 10.1007/BF03402144; ALBINA JE, 1993, J IMMUNOL, V150, P5080; ALDOVINI A, 1986, P NATL ACAD SCI USA, V83, P6672, DOI 10.1073/pnas.83.18.6672; Bagasra O, 1996, AIDS, V10, P573, DOI 10.1097/00002030-199606000-00002; Barton CH, 1996, J GEN VIROL, V77, P1643, DOI 10.1099/0022-1317-77-8-1643; BERNTON EW, 1992, AIDS RES HUM RETROV, V8, P495, DOI 10.1089/aid.1992.8.495; Bhat NR, 1998, J NEUROSCI, V18, P1633; Boven LA, 1999, J IMMUNOL, V162, P4319; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang Hsiao-Kuey, 1995, Journal of Biomedical Science, V2, P189, DOI 10.1007/BF02253380; Chu SC, 1998, BIOCHEM BIOPH RES CO, V248, P871, DOI 10.1006/bbrc.1998.9062; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Dong ZY, 1995, J LEUKOCYTE BIOL, V58, P725, DOI 10.1002/jlb.58.6.725; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; Galea E, 1999, FASEB J, V13, P2125, DOI 10.1096/fasebj.13.15.2125; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Giovannoni G, 1998, J NEUROL SCI, V156, P53, DOI 10.1016/S0022-510X(98)00021-5; Glass JD, 1996, ANNU REV NEUROSCI, V19, P1; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; Hori K, 1999, BLOOD, V93, P1843, DOI 10.1182/blood.V93.6.1843.406k40_1843_1850; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; Hsu YW, 2001, J IMMUNOL, V166, P5388, DOI 10.4049/jimmunol.166.9.5388; Hu SX, 1999, J NEUROSCI, V19, P6468; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; Jana M, 2001, J BIOL CHEM, V276, P44527, DOI 10.1074/jbc.M106771200; Johnson RT, 1996, ANN NEUROL, V39, P392, DOI 10.1002/ana.410390319; Jones M, 1998, J NEUROPATH EXP NEUR, V57, P563, DOI 10.1097/00005072-199806000-00004; JUNG M, 1991, VIROL LIFE SCI ADV, V10, P77; KOKA P, 1995, J EXP MED, V182, P941, DOI 10.1084/jem.182.4.941; Kolson DL, 2000, J CLIN INVEST, V106, P11, DOI 10.1172/JCI10553; Kong LY, 1996, CELL IMMUNOL, V172, P77, DOI 10.1006/cimm.1996.0217; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; MCCARTHY M, 1995, J NEUROVIROL, V1, P275, DOI 10.3109/13550289509114024; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Muhl H, 1997, J IMMUNOL, V159, P5063; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Pahan K, 2000, FEBS LETT, V472, P203, DOI 10.1016/S0014-5793(00)01465-4; Pahan K, 1998, J BIOL CHEM, V273, P2591, DOI 10.1074/jbc.273.5.2591; Pahan K, 1998, J BIOL CHEM, V273, P12219, DOI 10.1074/jbc.273.20.12219; Pahan K, 2001, J BIOL CHEM, V276, P7899, DOI 10.1074/jbc.M008262200; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; PETITO CK, 1994, J NEUROPATH EXP NEUR, V53, P86, DOI 10.1097/00005072-199401000-00011; Polazzi E, 1999, J NEUROPATH EXP NEUR, V58, P825, DOI 10.1097/00005072-199908000-00005; RANKI A, 1995, AIDS, V9, P1001, DOI 10.1097/00002030-199509000-00004; SILVA JD, 1997, J BIOL CHEM, V272, P28373; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Strelow LI, 2001, ADV VIRUS RES, V56, P355, DOI 10.1016/S0065-3527(01)56033-9; TARDIEU M, 1992, ANN NEUROL, V32, P11, DOI 10.1002/ana.410320104; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; Wiley CA, 1996, AIDS, V10, P843, DOI 10.1097/00002030-199607000-00007; WILEY CA, 1986, P NATL ACAD SCI USA, V83, P7089, DOI 10.1073/pnas.83.18.7089; XIE QW, 1994, J BIOL CHEM, V269, P4705; YAMAMOTO T, 1980, P NATL ACAD SCI-BIOL, V77, P176, DOI 10.1073/pnas.77.1.176; Zhao ML, 2001, J NEUROIMMUNOL, V115, P182, DOI 10.1016/S0165-5728(00)00463-X	61	119	121	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39312	39319		10.1074/jbc.M205107200	http://dx.doi.org/10.1074/jbc.M205107200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167619	Green Published, Green Accepted, hybrid			2022-12-27	WOS:000178662500034
J	Mambula, SS; Sau, K; Henneke, P; Golenbock, DT; Levitz, SM				Mambula, SS; Sau, K; Henneke, P; Golenbock, DT; Levitz, SM			Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CUTTING EDGE; TNF-ALPHA; CELL ACTIVATION; CRYPTOCOCCUS-NEOFORMANS; HOST-DEFENSE; LIPOPOLYSACCHARIDE LPS; BACTERIAL LIPOPROTEINS; MYD88-DEFICIENT MICE; BEARING PARTICLES; BINDING-PROTEIN	Aspergillus fumigatus causes life-threatening infections in patients with qualitative and quantitative defects in phagocytic function. Here, we examined the contribution of Toll-like receptor (TLR)-2, TLR4, the adapter protein MyD88, and CD14 to signaling in response to the three forms of A. fumigatus encountered during human disease: resting conidia (RC), swollen conidia (SC), and hyphae (H). Compared with elicited peritoneal macrophages obtained from wild-type and heterozygous mice, TLR2(-/-) and MyD88(-/-) macrophages produced significantly less tumor necrosis factor-alpha (TNFalpha) following A. fumigatus stimulation. In contrast, following stimulation with RC, SC, and H, TLR4(-/-) and CD14(-/-) macrophages exhibited no defects in tumor necrosis factor-alpha release. TLR2(-/-), TLR4(-/-), MyD88(-/-), and CD14(-/-) macrophages bound similar numbers of RC and SC compared with wild-type macrophages. RC, SC, and H stimulated greater activation of a nuclear factor kappaB (NFkappaB)-dependent reporter gene and greater release of tumor necrosis factor-alpha from the human monocytic THP-1 cell line stably transfected with CD14 compared with control cells stably transfected with empty vector. A. fumigatus stimulated NFkappaB-dependent reporter gene activity in the human embryonic kidney cell line, HEK293, only if the cells were transfected with TLR2. Moreover, activity increased when TLR2 and CD14 were co-transfected. Taken together, these data suggest that optimal signaling responses to A. fumigatus require TLR2 in both mouse and human cells. In contrast, a role for CD14 was found only in the human cells. MyD88 acts as a central adapter protein mediating signaling responses following stimulation with RC, SC, and H.	Boston Univ, Sch Med, Evans Mem Dept Clin Res, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01605 USA	Boston University; Boston University; University of Massachusetts System; University of Massachusetts Worcester	Levitz, SM (corresponding author), Boston Med Ctr, Rm X626,650 Albany St, Boston, MA 02118 USA.	slevitz@bu.edu			NCRR NIH HHS [RR14466] Funding Source: Medline; NHLBI NIH HHS [HL07501] Funding Source: Medline; NIAID NIH HHS [R01 AI37532, AI-25780, AI-37532] Funding Source: Medline; NIDDK NIH HHS [DK50305] Funding Source: Medline; NIGMS NIH HHS [GM54060] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR014466] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025780, R01AI037532] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054060, R37GM054060] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Bernheiden M, 2001, J ENDOTOXIN RES, V7, P447, DOI 10.1179/096805101101533061; Brieland JK, 2001, INFECT IMMUN, V69, P1554, DOI 10.1128/IAI.69.3.1554-1560.2001; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Byrd-Leifer CA, 2001, EUR J IMMUNOL, V31, P2448, DOI 10.1002/1521-4141(200108)31:8&lt;2448::AID-IMMU2448&gt;3.0.CO;2-N; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Driscoll KE, 2000, TOXICOL LETT, V112, P177, DOI 10.1016/S0378-4274(99)00282-9; Fenton MJ, 1998, J LEUKOCYTE BIOL, V64, P25, DOI 10.1002/jlb.64.1.25; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Flo TH, 2000, J IMMUNOL, V164, P2064, DOI 10.4049/jimmunol.164.4.2064; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; Harrison TS, 1997, J INFECT DIS, V176, P485, DOI 10.1086/514068; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Henneke P, 2001, J IMMUNOL, V167, P7069, DOI 10.4049/jimmunol.167.12.7069; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Hume D A, 2001, BMC Immunol, V2, P11, DOI 10.1186/1471-2172-2-11; KAN VL, 1988, J INFECT DIS, V158, P407, DOI 10.1093/infdis/158.2.407; KAN VL, 1991, J INFECT DIS, V163, P1154, DOI 10.1093/infdis/163.5.1154; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KOZEL TR, 1989, INFECT IMMUN, V57, P3412, DOI 10.1128/IAI.57.11.3412-3417.1989; Latge JP, 2001, TRENDS MICROBIOL, V9, P382, DOI 10.1016/S0966-842X(01)02104-7; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Levitz S M, 1989, Infect Dis Clin North Am, V3, P1; LEVITZ SM, 1994, INFECT IMMUN, V62, P1975, DOI 10.1128/IAI.62.5.1975-1981.1994; LEVITZ SM, 1991, J CLIN INVEST, V87, P528, DOI 10.1172/JCI115027; LEVITZ SM, 1985, J INFECT DIS, V152, P33, DOI 10.1093/infdis/152.1.33; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Mehrad B, 1999, J IMMUNOL, V162, P1633; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Muzio M, 2000, MICROBES INFECT, V2, P251, DOI 10.1016/S1286-4579(00)00303-8; NEWMAN SL, 1995, J IMMUNOL, V154, P753; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Pugin J, 1998, INFECT IMMUN, V66, P1174, DOI 10.1128/IAI.66.3.1174-1180.1998; Schelenz S, 1999, MED MYCOL, V37, P183, DOI 10.1046/j.1365-280X.1999.00219.x; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Shoham S, 2001, J IMMUNOL, V166, P4620, DOI 10.4049/jimmunol.166.7.4620; Stevens DA, 2000, CLIN INFECT DIS, V30, P696, DOI 10.1086/313756; Sugawara S, 2001, INFECT IMMUN, V69, P4951, DOI 10.1128/IAI.69.8.4951-4957.2001; SULTZER BM, 1968, NATURE, V219, P1253, DOI 10.1038/2191253a0; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Wang JE, 2001, INFECT IMMUN, V69, P2402, DOI 10.1128/IAI.69.4.2402-2406.2001; Warris A, 2001, NEW ENGL J MED, V344, P1099, DOI 10.1056/NEJM200104053441415; Weber SM, 2000, J IMMUNOL, V165, P1534, DOI 10.4049/jimmunol.165.3.1534; WRIGHT SD, 1992, J EXP MED, V176, P719, DOI 10.1084/jem.176.3.719; WRIGHT SD, 1989, J EXP MED, V170, P1231, DOI 10.1084/jem.170.4.1231; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang ZG, 1996, J LEUKOCYTE BIOL, V59, P241, DOI 10.1002/jlb.59.2.241; Yoshimura A, 1999, J IMMUNOL, V163, P1; Zarember KA, 2002, J IMMUNOL, V168, P554, DOI 10.4049/jimmunol.168.2.554	63	244	264	0	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39320	39326		10.1074/jbc.M201683200	http://dx.doi.org/10.1074/jbc.M201683200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171914	hybrid			2022-12-27	WOS:000178662500035
J	Haller, D; Russo, MP; Sartor, RB; Jobin, C				Haller, D; Russo, MP; Sartor, RB; Jobin, C			IKK beta and phosphatidylinositol 3-kinase/Akt participate in non-pathogenic gram-negative enteric bacteria-induced RelA phosphorylation and NF-kappa B activation in both primary and intestinal epithelial cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; PROINFLAMMATORY GENE-EXPRESSION; ADHESION MOLECULE-1 ICAM-1; TOLL-LIKE RECEPTOR-4; DEPENDENT TRANSCRIPTION; MUCOSAL INFLAMMATION; INVASIVE BACTERIA; P65 SUBUNIT; TNF-ALPHA; KINASE	Pathogenic and enteroinvasive bacteria have been shown to trigger the lkappaB/NF-kappaB transcriptional system and proinflammatory gene expression in epithelial cells. In this study, we investigated the molecular mechanism of the commensal Gram-negative Bacteroides vulgatus-induced NF-kappaB signal transduction in intestinal epithelial cells (IEC). We report that B. vulgatus induced interleukin-1 receptor-associated kinase-1 degradation, IkappaBalpha phosphorylation/degradation, RelA and Akt phosphorylation, as well as NF-kappaB DNA binding and NF-kappaB transcriptional activity in rat non-transformed IEC-6 cells. B. vulgatus- but not interleukin-1beta-mediated NF-kappaB transcriptional activity was inhibited by dominant negative (dn) toll-like receptor 4. Of importance, B. vulgatus induced IkappaBalpha phosphorylation/degradation and IKKalpha/beta and RelA phosphorylation in primary IEC derived from germ-free or mono-associated HLA-B27 transgenic and wild type rats, demonstrating the physiological relevance of non-pathogenic bacterial signaling in IEC. Adenoviral delivery of dn IKKbeta or treatment with wortmannin inhibited B. vulgatus-induced endogenous RelA Ser-536 and GST-p65TAD (Ser-529/Ser-536) phosphorylation as well as NF-kappaB transcriptional activity in IEC-6 cells, suggesting a critical role of IKKbeta and phosphatidylinositol 3-kinase/Akt in bacteria-induced RelA phosphorylation and NF-kappaB activation. Interestingly, B. vulgatus-induced IkappaBalpha degradation and NF-kappaB transcriptional activity in IEC transwell cultures were inhibited in the presence of lymphocytes. We propose that non-pathogenic B. vulgatus activates the NF-kappaB signaling pathway through both IkappaB degradation and RelA phosphorylation but that immune cells mediate tolerance of IEC to this commensal bacteria.	Univ N Carolina, Div Digest Dis & Nutr, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Jobin, C (corresponding author), Univ N Carolina, Div Digest Dis & Nutr, Dept Med, CB 7038,Glaxo Bldg, Chapel Hill, NC 27599 USA.	Job@med.unc.edu		Haller, Dirk/0000-0002-6977-4085	NIDDK NIH HHS [R01 DK 47700] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047700] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Bhan AK, 1999, IMMUNOL REV, V169, P195, DOI 10.1111/j.1600-065X.1999.tb01316.x; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Blumberg RS, 1999, CURR OPIN IMMUNOL, V11, P648, DOI 10.1016/S0952-7915(99)00032-1; BLUMBERG RS, 1991, J IMMUNOL, V147, P2518; Bocker U, 2000, J BIOL CHEM, V275, P12207, DOI 10.1074/jbc.275.16.12207; Bradham CA, 2001, AM J PHYSIOL-GASTR L, V281, pG1279, DOI 10.1152/ajpgi.2001.281.5.G1279; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Cario E, 2002, AM J PATHOL, V160, P165, DOI 10.1016/S0002-9440(10)64360-X; Cario E, 2000, J IMMUNOL, V164, P966, DOI 10.4049/jimmunol.164.2.966; Chen XM, 2001, GASTROENTEROLOGY, V120, P1774, DOI 10.1053/gast.2001.24850; Cong YZ, 1998, J EXP MED, V187, P855, DOI 10.1084/jem.187.6.855; Eckmann L, 1997, J CLIN INVEST, V100, P296, DOI 10.1172/JCI119535; Elewaut D, 1999, J IMMUNOL, V163, P1457; ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5; Erdman SE, 2001, J IMMUNOL, V166, P1443, DOI 10.4049/jimmunol.166.3.1443; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; GALANG CK, 1994, ONCOGENE, V9, P2913; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Haller D, 2002, MICROBIOL IMMUNOL, V46, P195, DOI 10.1111/j.1348-0421.2002.tb02686.x; Haller D, 2000, GUT, V47, P79, DOI 10.1136/gut.47.1.79; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Hershberg RM, 1997, J CLIN INVEST, V100, P204, DOI 10.1172/JCI119514; Huang GTJ, 1996, J CLIN INVEST, V98, P572, DOI 10.1172/JCI118825; Irie T, 2000, FEBS LETT, V467, P160, DOI 10.1016/S0014-5793(00)01146-7; Jobin C, 2000, AM J PHYSIOL-CELL PH, V278, pC451, DOI 10.1152/ajpcell.2000.278.3.C451; Jobin C, 1997, J IMMUNOL, V158, P226; Jobin C, 1999, J IMMUNOL, V162, P4447; Jobin C, 1999, J IMMUNOL, V163, P3474; Jobin C, 1998, J IMMUNOL, V160, P410; Jobin C, 1998, GUT, V42, P779, DOI 10.1136/gut.42.6.779; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; JUNG HC, 1995, J CLIN INVEST, V95, P55, DOI 10.1172/JCI117676; Kagnoff MF, 1997, J CLIN INVEST, V100, P6, DOI 10.1172/JCI119522; Kim SC, 2001, GASTROENTEROLOGY, V120, pA82, DOI 10.1016/S0016-5085(01)80407-8; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mayo MW, 2002, J BIOL CHEM, V277, P11116, DOI 10.1074/jbc.M108670200; MCCORMICK BA, 1993, J CELL BIOL, V123, P895, DOI 10.1083/jcb.123.4.895; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; ONDERDONK AB, 1981, INFECT IMMUN, V32, P225, DOI 10.1128/IAI.32.1.225-231.1981; PANJA A, 1994, J EXP MED, V179, P943, DOI 10.1084/jem.179.3.943; Rachmilewitz D, 2002, GASTROENTEROLOGY, V122, P1428, DOI 10.1053/gast.2002.32994; Rath HC, 1999, INFECT IMMUN, V67, P2969, DOI 10.1128/IAI.67.6.2969-2974.1999; Rath HC, 1996, J CLIN INVEST, V98, P945, DOI 10.1172/JCI118878; Russo MP, 2002, AM J PHYSIOL-CELL PH, V283, pC347, DOI 10.1152/ajpcell.00166.2001; RUSSO MP, 2001, GASTROENTEROLOGY, V20, P470; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Sartor RB, 1997, AM J GASTROENTEROL, V92, pS5; Savkovic SD, 1997, AM J PHYSIOL-CELL PH, V273, pC1160, DOI 10.1152/ajpcell.1997.273.4.C1160; Schmitz ML, 2001, TRENDS BIOCHEM SCI, V26, P186, DOI 10.1016/S0968-0004(00)01753-9; Schulte R, 1996, INFECT IMMUN, V64, P2106, DOI 10.1128/IAI.64.6.2106-2113.1996; Schwabe RF, 2002, AM J PHYSIOL-GASTR L, V283, pG204, DOI 10.1152/ajpgi.00016.2002; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; TAUROG JD, 1994, J EXP MED, V180, P2359, DOI 10.1084/jem.180.6.2359; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wright SD, 1999, J EXP MED, V189, P605, DOI 10.1084/jem.189.4.605; Zhang GL, 2001, J CLIN INVEST, V107, P13, DOI 10.1172/JCI11837; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	72	149	150	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38168	38178		10.1074/jbc.M205737200	http://dx.doi.org/10.1074/jbc.M205737200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12140289	Green Published, hybrid			2022-12-27	WOS:000178529600026
J	Steen, M; Dahlback, B				Steen, M; Dahlback, B			Thrombin-mediated proteolysis of factor V resulting in gradual B-domain release and exposure of the factor Xa-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-V; ACTIVATED PROTEIN-C; BOVINE FACTOR-V; CATALYZED ACTIVATION; PROTHROMBINASE COMPLEX; FACTOR-VIII; CLEAVAGE REQUIREMENTS; ANTICOAGULANT; PLATELETS; CHAIN	To investigate the relationship between the individual thrombin cleavages in factor V (FV) and the generation of activated factor X (FXa) cofactor activity, recombinant FV mutants having the cleavage sites eliminated separately or in combination were used. After thrombin incubation, the ability of the FV variants to bind FXa and support prothrombin activation was tested. The interaction between FVa and FXa on the surface of phospholipid was investigated with a direct binding assay as well as in a functional prothrombin activation assay. FV mutated at all cleavage sites functioned poorly as FXa cofactor in prothrombin activation, the apparent K-d for FXa being similar to10 nM. Fully activated wild type FVa, yielded an apparent K, of around 0.2 nm. The Arg(709) and Arg(1018) cleavages occurred at low thrombin concentrations and decreased the Kd for FXa binding 5- and 3-fold, respectively. The Arg(1545) cleavage, being less sensitive to thrombin, decreased the Kd for FXa binding similar to20-fold. The K-m for prothrombin was the same for all FV variants, demonstrating B-domain dissociation to result in exposure of binding site for FXa but not for prothrombin. In conclusion, we demonstrate FV activation to be associated with the stepwise release of the B-domain, which results in a gradual exposure of the FXa-binding site.	Lund Univ, Univ Hosp, Wallenberg Lab, Dept Lab Med,Div Clin Chem, SE-20502 Malmo, Sweden	Lund University; Skane University Hospital	Dahlback, B (corresponding author), Lund Univ, Univ Hosp, Wallenberg Lab, Dept Lab Med,Div Clin Chem, SE-20502 Malmo, Sweden.			Dahlback, Bjorn/0000-0003-1546-0328				BAKKER HM, 1994, J BIOL CHEM, V269, P20662; BILLY D, 1995, J BIOL CHEM, V270, P26883, DOI 10.1074/jbc.270.45.26883; BRUIN T, 1987, EUR J BIOCHEM, V170, P305, DOI 10.1111/j.1432-1033.1987.tb13700.x; Camire RM, 1998, BIOCHEMISTRY-US, V37, P11896, DOI 10.1021/bi980520v; CHURCH WR, 1991, J BIOL CHEM, V266, P8384; Dahlback B, 1999, J LAB CLIN MED, V133, P415, DOI 10.1016/S0022-2143(99)90018-5; DAHLBACK B, 1980, J CLIN INVEST, V66, P583, DOI 10.1172/JCI109890; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; Deguchi H, 1997, BIOCHEM J, V321, P729, DOI 10.1042/bj3210729; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1974, J BIOL CHEM, V249, P7791; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; FOWLER WE, 1990, P NATL ACAD SCI USA, V87, P7648, DOI 10.1073/pnas.87.19.7648; Furie B.C., 1976, Methods Enzymol, V45, P191; Heeb MJ, 1996, PROTEIN SCI, V5, P1883, DOI 10.1002/pro.5560050914; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; JENNY RJ, 1994, HAEMOSTASIS THROMBOS, P456; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P6538, DOI 10.1021/bi00187a022; KANE WH, 1988, BLOOD, V71, P539; KAUFMAN RJ, 1990, METHOD ENZYMOL, V185, P487, DOI 10.1016/0076-6879(90)85041-L; KELLER FG, 1995, BIOCHEMISTRY-US, V34, P4118, DOI 10.1021/bi00012a030; Kojima Y, 1998, J BIOL CHEM, V273, P14900, DOI 10.1074/jbc.273.24.14900; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; KUMAR R, 1994, THROMB HAEMOSTASIS, V72, P713; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN KG, 1990, BLOOD, V76, P1; MARQUETTE KA, 1995, BLOOD, V86, P3026; Mertens K, 1999, THROMB HAEMOSTASIS, V82, P209; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICOLAES GAF, 1995, J BIOL CHEM, V270, P21158, DOI 10.1074/jbc.270.36.21158; Rosing J, 1997, THROMB HAEMOSTASIS, V78, P427; ROSING J, 1980, J BIOL CHEM, V255, P274; Rudolph AE, 2000, BIOCHEMISTRY-US, V39, P2861, DOI 10.1021/bi992379b; STENFLO J, 1976, J BIOL CHEM, V251, P355; SUZUKI K, 1982, J BIOL CHEM, V257, P6556; TANS G, 1991, BLOOD, V77, P2641; Thorelli E, 1999, BLOOD, V93, P2552, DOI 10.1182/blood.V93.8.2552.408k15_2552_2558; Thorelli E, 1997, EUR J BIOCHEM, V247, P12, DOI 10.1111/j.1432-1033.1997.00012.x; Thorelli E, 1998, THROMB HAEMOSTASIS, V80, P92, DOI 10.1055/s-0037-1615145; TRACY PB, 1982, BLOOD, V60, P59; Villoutreix BO, 1998, PROTEIN SCI, V7, P1317, DOI 10.1002/pro.5560070607	43	39	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38424	38430		10.1074/jbc.M204972200	http://dx.doi.org/10.1074/jbc.M204972200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163491	hybrid			2022-12-27	WOS:000178529600056
J	Yang, WB; Kilberg, MS				Yang, WB; Kilberg, MS			Biosynthesis, intracellular targeting, and degradation of the EAAC1 glutamate/aspartate transporter in C6 glioma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-GLUTAMATE TRANSPORTER; HIGH-AFFINITY; RAT-BRAIN; PROTEIN; MODULATION; EXPRESSION; CULTURE	Rat C6 glioma cells were used as a model system to study the biosynthesis, intracellular targeting, and degradation of the EAAC1 transporter, a sodium-dependent glutamate/aspartate transport protein that encodes System X- (AG) activity. At steady state, nearly 70% of the EAAC1 transporter was located at the cell surface. The newly synthesized EAAC1 protein was co-translationally N-glycosylated with high mannose oligosaccharide chains that were processed into complex-type sugar chains as the protein matured. The final maturation steps for EAAC1 protein coincided with its plasma membrane arrival, which was first detected at about 45 min after the initial synthesis. The newly synthesized EAAC1 protein was protected from degradation during the maturation and targeting process, as well as during the first 5 h after plasma membrane arrival. After this initial lag period, both the newly synthesized transporter and the total cellular EAAC1 pool were degraded by first order kinetics with a half-life of 6 h. These results represent the first analysis of the synthesis and degradation of the EAAC1 amino acid transporter.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, JHMHC, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, JHMHC, Box 100245, Gainesville, FL 32610 USA.	mkilberg@ufl.edu						ALBERTS B, 1994, MOL BIOL CELL, P500; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; BISSELL MG, 1974, BRAIN RES, V82, P77, DOI 10.1016/0006-8993(74)90894-4; CASADO M, 1993, J BIOL CHEM, V268, P27313; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; Davis KE, 1998, J NEUROSCI, V18, P2475; DEAS J, 1989, BRAIN RES, V483, P84, DOI 10.1016/0006-8993(89)90037-1; Dowd LA, 1996, MOL PHARMACOL, V49, P465; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Harlow E., 1988, ANTIBODIES LAB MANUA; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Kanai Y, 1995, NEUROREPORT, V6, P2357, DOI 10.1097/00001756-199511270-00020; KANAI Y, 1993, TRENDS NEUROSCI, V16, P365, DOI 10.1016/0166-2236(93)90094-3; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KILBERG MS, 1989, METHOD ENZYMOL, V173, P564; LAEMMLI UK, 1970, NATURE, V227, pC1; Lee W, 2000, BIOCHEMISTRY-US, V39, P9358, DOI 10.1021/bi0007021; Lin CLG, 2001, NATURE, V410, P84, DOI 10.1038/35065084; Malandro MS, 1996, ANNU REV BIOCHEM, V65, P305; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; Matthews JC, 1998, AM J PHYSIOL-CELL PH, V274, pC603, DOI 10.1152/ajpcell.1998.274.3.C603; Palos TP, 1996, MOL BRAIN RES, V37, P297, DOI 10.1016/0169-328X(95)00331-L; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; RADIAN R, 1990, J NEUROSCI, V10, P1319; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; VelazFaircloth M, 1996, AM J PHYSIOL-CELL PH, V270, pC67, DOI 10.1152/ajpcell.1996.270.1.C67	27	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38350	38357		10.1074/jbc.M202052200	http://dx.doi.org/10.1074/jbc.M202052200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151387	hybrid			2022-12-27	WOS:000178529600047
J	Bhoite, LT; Allen, JM; Garcia, E; Thomas, LR; Gregory, ID; Voth, WP; Whelihan, K; Rolfes, RJ; Stillman, DJ				Bhoite, LT; Allen, JM; Garcia, E; Thomas, LR; Gregory, ID; Voth, WP; Whelihan, K; Rolfes, RJ; Stillman, DJ			Mutations in the Pho2 (Bas2) transcription factor that differentially affect activation with its partner proteins Bas1, Pho4, and Swi5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOPERATIVE DNA-BINDING; SACCHAROMYCES-CEREVISIAE; HO PROMOTER; HOMEODOMAIN PROTEIN; HIS4 TRANSCRIPTION; ZINC-FINGER; YEAST; REGULATORS; SPECIFICITY; PURINE	The yeast PHO2 gene encodes a homeodomain protein that exemplifies combinatorial control in transcriptional activation. Pho2 alone binds DNA in vitro with low affinity, but in vivo it activates transcription with at least three disparate DNA-binding proteins: the zinc finger protein Swi5, the helix-loop-helix factor Pho4, and Bas1, an myb-like activator. Pho2 + Swi5 activates HO, Pho2 + Pho4 activates PHO5, and Pho2 + Bas1 activates genes in the purine and histidine biosynthesis pathways. We have conducted a genetic screen and identified 23 single amino acid substitutions in Pho2 that differentially affect its ability to activate its specific target genes. Analysis of the mutations suggests that the central portion of Pho2 serves as protein-protein interactive surface, with a requirement for distinct amino acids for each partner protein.	Univ Utah, Dept Pathol, Ctr Hlth Sci, Salt Lake City, UT 84132 USA; Georgetown Univ, Dept Biol, Washington, DC 20057 USA	Utah System of Higher Education; University of Utah; Georgetown University	Stillman, DJ (corresponding author), Univ Utah, Dept Pathol, Ctr Hlth Sci, 30 N 1900 E,Rm5C126 SOM, Salt Lake City, UT 84132 USA.			Stillman, David/0000-0002-5268-2416	NIGMS NIH HHS [R01-GM48624] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048624] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNDT KT, 1987, SCIENCE, V237, P874, DOI 10.1126/science.3303332; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Barbaric S, 1998, MOL CELL BIOL, V18, P2629, DOI 10.1128/MCB.18.5.2629; Barbaric S, 1996, NUCLEIC ACIDS RES, V24, P4479, DOI 10.1093/nar/24.22.4479; BERBEN G, 1988, GENE, V66, P307, DOI 10.1016/0378-1119(88)90367-8; Bhoite LT, 1998, MOL CELL BIOL, V18, P6436, DOI 10.1128/MCB.18.11.6436; BRAZAS RM, 1993, P NATL ACAD SCI USA, V90, P11237, DOI 10.1073/pnas.90.23.11237; BRAZAS RM, 1995, J BIOL CHEM, V270, P29151, DOI 10.1074/jbc.270.49.29151; BREEDEN L, 1987, CELL, V48, P389, DOI 10.1016/0092-8674(87)90190-5; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; DAIGNANFORNIER B, 1992, P NATL ACAD SCI USA, V89, P6746, DOI 10.1073/pnas.89.15.6746; Denis V, 1998, MOL MICROBIOL, V30, P557, DOI 10.1046/j.1365-2958.1998.01087.x; Dohrmann PR, 1996, MOL CELL BIOL, V16, P1746; Dorland S, 2000, GENETICS, V154, P573; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; HANNUM C, 2002, J BIOL CHEM; HIRST K, 1994, EMBO J, V13, P5410, DOI 10.1002/j.1460-2075.1994.tb06876.x; JIANG YW, 1995, GENETICS, V140, P103; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; McBride HJ, 1997, MOL CELL BIOL, V17, P2669, DOI 10.1128/MCB.17.5.2669; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Oshima Y, 1996, GENE, V179, P171, DOI 10.1016/S0378-1119(96)00425-8; Pinson B, 2000, NUCLEIC ACIDS RES, V28, P4665, DOI 10.1093/nar/28.23.4665; Pinson B, 2000, MOL MICROBIOL, V36, P1460, DOI 10.1046/j.1365-2958.2000.01966.x; Rolfes RJ, 1997, J BIOL CHEM, V272, P13343, DOI 10.1074/jbc.272.20.13343; ROLFES RJ, 1993, MOL CELL BIOL, V13, P5099, DOI 10.1128/MCB.13.8.5099; SIKORSKI RS, 1989, GENETICS, V122, P19; TICEBALDWIN K, 1989, SCIENCE, V246, P931, DOI 10.1126/science.2683089; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wolberger C, 1998, CURR OPIN GENET DEV, V8, P552, DOI 10.1016/S0959-437X(98)80010-5; Zhang F, 1997, MOL CELL BIOL, V17, P3272, DOI 10.1128/MCB.17.6.3272	31	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37612	37618		10.1074/jbc.M206125200	http://dx.doi.org/10.1074/jbc.M206125200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145299	hybrid			2022-12-27	WOS:000178447100090
J	Camire, RM				Camire, RM			Prothrombinase assembly and S1 site occupation restore the catalytic activity of FXa impaired by mutation at the sodium-binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR-XA; RUSSELLS VIPER VENOM; FACTOR-VA; CRYSTAL-STRUCTURE; NA+ BINDING; THERMODYNAMIC LINKAGE; ALLOSTERIC REGULATION; BOVINE TRYPSINOGEN; PROTEASE DOMAIN; CA2+ BINDING	Two loop segments (183-189 and 221-225) in the protease domain of factor Xa contribute to the formation of a Na+-binding site. Studies with factor Xa indicate that binding of a single Na+ ion to this site influences its activity by altering the S1 specificity site, and substitution of Tyr(225) with Pro diminishes sensitivity to Na+. Using full-length factor Xa(Y225P), the allosteric relationship between the Na+ site and other structural determinants in factor Xa and prothrombinase was investigated. Direct binding and kinetic measurements with probes that target the S1 specificity pocket indicate that assembly of the mutant in prothrombinase corrected the impaired binding of these probes observed with free factor Xa(Y225P). This appears to result from the apparent allosteric linkage between the factor Va, S1, and Na+-binding sites, since binding of the cofactor to membrane-bound factor Xa(Y225P) enhances binding at the S1 site and vice versa. Additional studies revealed that the internal salt bridge (Ile(16)-Asp(194)) of factor Xa(Y225P) is partially destabilized, a process that is reversible upon occupation of the S1 site. The data establish that alterations at the factor Xa Na+-binding site shift the zymogen-protease equilibrium to a more zymogen-like state, and as a consequence binding of S1-directed probes and factor Va are adversely affected. Therefore, the zymogen-like characteristics of factor Xa(Y225P) have allowed for the apparent allosteric linkage between the S1, factor Va, and Na+ sites to become evident and has provided insight into the structural transitions which accompany the conversion of factor X to factor Xa.	Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Div Hematol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Camire, RM (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Jr Res Inst, Div Hematol, Philadelphia, PA 19104 USA.	camire@email.chop.edu			NHLBI NIH HHS [HL10343-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL010343] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Betz A, 1997, BIOCHEMISTRY-US, V36, P181, DOI 10.1021/bi962060g; Bevington PR., 2002, DATA REDUCTION ERROR; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1975, FEBS LETT, V56, P139, DOI 10.1016/0014-5793(75)80128-1; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; Camire RM, 2000, BLOOD, V96, p448A; Camire RM, 2000, BIOCHEMISTRY-US, V39, P14322, DOI 10.1021/bi001074q; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; DANG QD, 1995, P NATL ACAD SCI USA, V92, P5977, DOI 10.1073/pnas.92.13.5977; De Cristofaro R, 1999, EUR J BIOCHEM, V260, P97, DOI 10.1046/j.1432-1327.1999.00118.x; DeCristofaro R, 1996, J MOL BIOL, V258, P190, DOI 10.1006/jmbi.1996.0242; DICERA E, 1995, J BIOL CHEM, V270, P22089, DOI 10.1074/jbc.270.38.22089; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; Eigenbrot C, 2001, STRUCTURE, V9, P627, DOI 10.1016/S0969-2126(01)00624-4; EVANS SA, 1982, J BIOL CHEM, V257, P3014; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; FURIE B, 1976, J BIOL CHEM, V251, P6807; Gomori G, 1942, J LAB CLIN MED, V27, P955; GOWDA DC, 1994, J BIOL CHEM, V269, P10644; Griffon N, 2001, BIOPHYS CHEM, V90, P89, DOI 10.1016/S0301-4622(01)00129-6; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; Higashi S, 1996, J BIOL CHEM, V271, P26569, DOI 10.1074/jbc.271.43.26569; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JORDAN SP, 1992, BIOCHEMISTRY-US, V31, P5374, DOI 10.1021/bi00138a019; KALAFATIS M, 1993, METHOD ENZYMOL, V222, P224; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KIM DJ, 1994, BIOTECHNOL LETT, V16, P549, DOI 10.1007/BF00128598; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; KRISHNASWAMY S, 1994, BIOCHEMISTRY-US, V33, P7897, DOI 10.1021/bi00191a017; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P3319, DOI 10.1021/bi9623993; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; Larson PJ, 1998, BIOCHEMISTRY-US, V37, P5029, DOI 10.1021/bi972428p; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; Lundblad R L, 1976, Methods Enzymol, V45, P156; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1990, BLOOD, V76, P1; Monnaie D, 2000, BIOCHEMISTRY-US, V39, P5349, DOI 10.1021/bi9926781; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; ORTHNER CL, 1978, ARCH BIOCHEM BIOPHYS, V185, P400, DOI 10.1016/0003-9861(78)90182-0; PERSSON E, 1993, J BIOL CHEM, V268, P22531; Petrovan RJ, 2000, BIOCHEMISTRY-US, V39, P14457, DOI 10.1021/bi0009486; PLAPP BV, 1971, J BIOL CHEM, V246, P939; PRICE PA, 1983, METHOD ENZYMOL, V91, P13; PRZYSIECKI CT, 1987, P NATL ACAD SCI USA, V84, P7856, DOI 10.1073/pnas.84.22.7856; Rezaie AR, 2000, BIOCHEMISTRY-US, V39, P1817, DOI 10.1021/bi992006a; REZAIE AR, 1994, J BIOL CHEM, V269, P21495; Rudolph AE, 2000, BIOCHEMISTRY-US, V39, P2861, DOI 10.1021/bi992379b; Sabharwal AK, 1997, J BIOL CHEM, V272, P22037, DOI 10.1074/jbc.272.35.22037; Schmidt AE, 2002, J BIOL CHEM, V277, P28987, DOI 10.1074/jbc.M201892200; SEGAL IH, 1975, ENZYME KINETICS BEHA; STARK GR, 1960, J BIOL CHEM, V235, P3177; STRAUME M, 1992, METHOD ENZYMOL, V210, P87; SUGO T, 1984, J BIOL CHEM, V259, P5705; Underwood MC, 2000, J BIOL CHEM, V275, P36876, DOI 10.1074/jbc.M001386200; Venkateswarlu D, 2002, BIOPHYS J, V82, P1190, DOI 10.1016/S0006-3495(02)75476-3; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; WALKER RK, 1993, J BIOL CHEM, V268, P13920; WATZKE HH, 1995, MOL BASIS THROMBOSIS, P239; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Zhang EL, 1997, BIOPHYS CHEM, V63, P185, DOI 10.1016/S0301-4622(96)02227-2	70	56	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37863	37870		10.1074/jbc.M203692200	http://dx.doi.org/10.1074/jbc.M203692200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149252	hybrid			2022-12-27	WOS:000178447100122
J	Hasan, MK; Yaguchi, T; Sugihara, T; Kumar, PKR; Taira, K; Reddel, RR; Kaul, SC; Wadhwa, R				Hasan, MK; Yaguchi, T; Sugihara, T; Kumar, PKR; Taira, K; Reddel, RR; Kaul, SC; Wadhwa, R			CARF is a novel protein that cooperates with mouse p19(ARF) (human p14(ARF)) in activating p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARF TUMOR-SUPPRESSOR; ALTERNATIVE PRODUCT; STABILIZES P53; INK4A LOCUS; MDM2; P16(INK4A); SENESCENCE; FIBROBLASTS; APOPTOSIS; PATHWAYS	The INK4a locus on chromosome 9p21 encodes two structurally distinct tumor suppressor proteins, p16(INK4a) and the alternative reading frame protein, ARF (p19(ARF) in mouse and p14(ARF) in human). Each of these proteins has a role in senescence of primary cells and activates pathways for cell cycle control and tumor suppression. The current prevailing model proposes that p19(ARF) activates p53 function by antagonizing its degradation by MDM2. It was, however, recently shown that stabilization of p53 by p14ARF occurs independent of the relocalization of MDM2 to the nucleolus. We have identified a novel collaborator of ARF, CARF. It co-localizes and interacts with ARF in the nucleolus. We demonstrate that CARF is co-regulated with ARF, cooperates with it in activating p53, and thus acts as a novel component of the ARF-p53-p21 pathway.	Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan; Natl Inst Adv Ind Sci & Technol, Gene Funct Res Lab, Tsukuba, Ibaraki 3058566, Japan; Natl Inst Adv Ind Sci & Technol, Inst Mol & Cell Biol, Tsukuba, Ibaraki 3058566, Japan; Chugai Res Inst Med Sci, Ibaraki 3004101, Japan; Childrens Med Res Inst, Westmead, NSW 2145, Australia	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); Chugai Pharmaceutical Co., Ltd.; Chugai Research Institute for Medical Science, Inc.; Children's Medical Research Institute - Australia	Kaul, SC (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, 1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.		Penmetcha, Kumar/K-8834-2017; Reddel, Roger R/A-6635-2014; Wadhwa, Renu/L-8898-2018; Kaul, Sunil C/L-8671-2018	Penmetcha, Kumar/0000-0002-3512-704X; Reddel, Roger R/0000-0002-6302-6107; Wadhwa, Renu/0000-0001-8248-5192; Kaul, Sunil C/0000-0002-0046-3916				Carnero A, 2000, NAT CELL BIOL, V2, P148, DOI 10.1038/35004020; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; James M C, 2000, Prog Cell Cycle Res, V4, P71; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1999, CANCER RES, V59, P2464; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kurokawa K, 1999, ONCOGENE, V18, P2718, DOI 10.1038/sj.onc.1202628; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugihara T, 2001, J BIOL CHEM, V276, P18649, DOI 10.1074/jbc.C100011200; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tolbert D, 2002, MOL CELL BIOL, V22, P370, DOI 10.1128/MCB.22.1.370-377.2002; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	23	55	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37765	37770		10.1074/jbc.M204177200	http://dx.doi.org/10.1074/jbc.M204177200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12154087	hybrid			2022-12-27	WOS:000178447100109
J	Yoshida, M; Kashiwagi, K; Kawai, G; Ishihama, A; Igarashi, K				Yoshida, M; Kashiwagi, K; Kawai, G; Ishihama, A; Igarashi, K			Polyamines enhance synthesis of the RNA polymerase sigma(38) subunit by suppression of an amber termination codon in the open reading frame	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLIGOPEPTIDE-BINDING-PROTEIN; CELL-FREE SYSTEM; ESCHERICHIA-COLI; MESSENGER-RNA; ORNITHINE DECARBOXYLASE; BOVINE LYMPHOCYTES; RIBOSOMAL-SUBUNITS; RAT-LIVER; STIMULATION; SPERMIDINE	The mechanisms by which polyamines stimulate synthesis of the RNA polymerase sigma(38) subunit in Escherichia coli were studied. Polyamine stimulation was observed only in strains in which the 33rd codon of RpoS mRNA is a UAG termination codon instead of a CAG codon for glutamine in wild-type E. coli. Readthrough of the termination codon by Gln-tRNA(supE) was stimulated by polyamines. This stimulation was found to be caused by an increase in both the level of suppressor tRNA(supE) and the binding affinity of Gln-tRNA(supE) for ribosomes. The stimulatory effect was observed with a UAG termination codon but not with UGA and UAA codons. Readthrough of the UAG termination codon at the 270th amino acid position of RpoS mRNA was also stimulated by polyamines, indicating that polyamines stimulate readthrough of a UAG codon regardless of its location within the RpoS mRNA. When cell viability of an E. coli strain having a termination codon in the 33rd position of RpoS mRNA was compared using cells cultured with or without putrescine, it was higher in cells cultured with putrescine than in cells cultured without putrescine. The level of sigma(38) subunit in the cells cultured with putrescine was higher than that in cells cultured without putrescine on days 2, 4, and 8, but the level of sigma(70) subunit was almost the same in cells cultured with or without putrescine. These results confirm that elevated expression of the rpoS gene is important for cell viability at late stationary phase.	Chiba Univ, Grad Sch Pharmaceut Sci, Inage Ku, Chiba 2638522, Japan; Chiba Inst Technol, Fac Engn, Dept Ind Chem, Narashino, Chiba 2758588, Japan; Natl Inst Genet, Dept Mol Genet, Mishima, Shizuoka 4110801, Japan	Chiba University; Chiba Institute of Technology; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Igarashi, K (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Inage Ku, 1-33 Yayoi Cho, Chiba 2638522, Japan.			Igarashi, Kazuei/0000-0003-3751-3187				ATKINS JF, 1975, J BIOL CHEM, V250, P5688; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohen S.S., 1998, GUIDE POLYAMINES, V1st ed.; CUNNINGHAMRUNDLES S, 1975, J BACTERIOL, V124, P791, DOI 10.1128/JB.124.2.791-799.1975; ECHANDI G, 1975, BIOCHEM BIOPH RES CO, V67, P1185, DOI 10.1016/0006-291X(75)90798-6; Eisenstark A, 1996, FREE RADICAL BIO MED, V21, P975, DOI 10.1016/S0891-5849(96)00154-2; EMORY SA, 1990, J BACTERIOL, V172, P4472, DOI 10.1128/jb.172.8.4472-4481.1990; HAFNER EW, 1979, J BIOL CHEM, V254, P2419; HIRASHIMA A, 1979, BIOCHEM BIOPH RES CO, V88, P1046, DOI 10.1016/0006-291X(79)91514-6; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HRYNIEWICZ MM, 1983, MOL GEN GENET, V190, P336, DOI 10.1007/BF00330661; Igarashi K, 1997, J BIOL CHEM, V272, P4058, DOI 10.1074/jbc.272.7.4058; IGARASHI K, 1978, EUR J BIOCHEM, V90, P13, DOI 10.1111/j.1432-1033.1978.tb12569.x; IGARASHI K, 1984, CANCER RES, V44, P5326; IGARASHI K, 1979, BIOCHEM BIOPH RES CO, V91, P440, DOI 10.1016/0006-291X(79)91541-9; IGARASHI K, 1979, EUR J BIOCHEM, V93, P345, DOI 10.1111/j.1432-1033.1979.tb12829.x; IGARASHI K, 1974, EUR J BIOCHEM, V48, P495, DOI 10.1111/j.1432-1033.1974.tb03790.x; ITO K, 1990, J BIOL CHEM, V265, P13036; ITO K, 1986, EUR J BIOCHEM, V156, P505, DOI 10.1111/j.1432-1033.1986.tb09609.x; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; Jishage M, 1997, J BACTERIOL, V179, P959, DOI 10.1128/jb.179.3.959-963.1997; JISHAGE M, 1995, J BACTERIOL, V177, P6832, DOI 10.1128/jb.177.23.6832-6835.1995; KAKEGAWA T, 1986, EUR J BIOCHEM, V158, P265, DOI 10.1111/j.1432-1033.1986.tb09746.x; KASHIWAGI K, 1990, J BIOL CHEM, V265, P8387; Kowal AK, 2001, P NATL ACAD SCI USA, V98, P2268, DOI 10.1073/pnas.031488298; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LENNOX ES, 1955, VIROLOGY, V1, P190, DOI 10.1016/0042-6822(55)90016-7; LINDEROTH N, 1983, BIOCHEM BIOPH RES CO, V117, P616, DOI 10.1016/0006-291X(83)91245-7; Major LL, 2002, FEBS LETT, V514, P84, DOI 10.1016/S0014-5793(02)02301-3; MIYIAMOTO S, 1993, ARCH BIOCHEM BIOPHYS, V300, P63; MORCH MD, 1980, EUR J BIOCHEM, V105, P445, DOI 10.1111/j.1432-1033.1980.tb04519.x; Nagano T, 2000, BIOSCI BIOTECH BIOCH, V64, P2012, DOI 10.1271/bbb.64.2012; NAKAJIMA N, 1981, CELL, V23, P239, DOI 10.1016/0092-8674(81)90288-9; NIELSEN PJ, 1982, J BIOL CHEM, V257, P2316; SAMBROOK J, 1989, MOL CLONING LABORATO, V7, P53; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR H, 1982, P NATL ACAD SCI-BIOL, V79, P7087, DOI 10.1073/pnas.79.23.7087; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WATANABE S, 1991, J BIOL CHEM, V266, P20803; WATANABE Y, 1981, BIOCHIM BIOPHYS ACTA, V656, P134, DOI 10.1016/0005-2787(81)90078-2; YAMASHINO T, 1995, EMBO J, V14, P594, DOI 10.1002/j.1460-2075.1995.tb07035.x; YANIV M, 1975, J BIOL CHEM, V250, P3243; Yoshida M, 2001, J BIOL CHEM, V276, P16289, DOI 10.1074/jbc.M011059200; Yoshida M, 1999, J BIOL CHEM, V274, P22723, DOI 10.1074/jbc.274.32.22723	48	39	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37139	37146		10.1074/jbc.M206668200	http://dx.doi.org/10.1074/jbc.M206668200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147703	hybrid			2022-12-27	WOS:000178447100031
J	Moore, AL; Roe, MW; Melnick, RF; Lidofsky, SD				Moore, AL; Roe, MW; Melnick, RF; Lidofsky, SD			Calcium mobilization evoked by hepatocellular swelling is linked to activation of phospholipase C gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INCREASES INOSITOL 1,4,5-TRISPHOSPHATE; REGULATORY VOLUME DECREASE; GROWTH-FACTOR RECEPTOR; CELL-VOLUME; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; LIVER; TRANSLOCATION; MEMBRANE; RELEASE	Recovery from swelling of hepatocytes and selected other epithelia is triggered by intracellular Ca2+ release from the endoplasmic reticulum, which leads to fluid and electrolyte efflux through volume-sensitive K+ and Cl- channels. The aim of this study was to determine the mechanisms responsible for swelling-mediated hepatocellular Ca2+ mobilization. Swelling of HTC rat hepatoma cells, evoked by exposure to hypotonic medium, elicited transient increases in intracellular levels of inositol 1,4,5-trisphosphate (IP3) and cytosolic [Ca2+]. The latter was attenuated by inhibition of phospholipase C (PLC) with U73122 and by IP3 receptor blockade with 2-aminoethoxydiphenyl borate, but it was unaffected by ryanodine, an inhibitor of intracellular Ca2+-induced Ca2+ release channels. Hypotonic swelling was associated with a transient increase in tyrosine phosphorylation of PLCgamma, with kinetics that paralleled the increases in intracellular IP3 levels and cytosolic [Ca2+]. Confocal imaging of HTC cells exposed to hypotonic medium revealed a swelling-induced association of tyrosine-phosphorylated PLCgamma with the plasma membrane. These findings suggest that activation of PLCgamma by hepatocellular swelling leads to the generation of IP3 and stimulates discharge of Ca2+ from the endoplasmic reticulum via activation of IP3 receptors. By extension, these data support the concept that tyrosine phosphorylation of PLCgamma represents a critical step in adaptive responses to hepatocellular swelling.	Univ Vermont, Coll Med, Dept Med, Burlington, VT 05401 USA; Univ Vermont, Coll Med, Dept Pharmacol, Burlington, VT 05401 USA	University of Vermont; University of Vermont	Lidofsky, SD (corresponding author), Univ Vermont, Coll Med, Dept Med, Burgess 414 MFU, Burlington, VT 05401 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056644, R56DK056644, R29DK047849] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK056644, DK047849] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAQUET A, 1991, FEBS LETT, V278, P103, DOI 10.1016/0014-5793(91)80094-J; Barfod ET, 2001, AM J PHYSIOL-CELL PH, V280, pC836, DOI 10.1152/ajpcell.2001.280.4.C836; BERVEN LA, 1995, BIOCHEM PHARMACOL, V49, P1373, DOI 10.1016/0006-2952(95)00050-A; Dunkelberg JC, 2001, HEPATOLOGY, V33, P1349, DOI 10.1053/jhep.2001.24750; Felix JA, 1996, AM J RESP CELL MOL, V14, P296, DOI 10.1165/ajrcmb.14.3.8845181; Feranchak AP, 1998, J BIOL CHEM, V273, P14906, DOI 10.1074/jbc.273.24.14906; Gregory RB, 2001, BIOCHEM J, V354, P285, DOI 10.1042/0264-6021:3540285; Haussinger D, 1996, Prog Liver Dis, V14, P29; Hirata K, 2002, GASTROENTEROLOGY, V122, P1088, DOI 10.1053/gast.2002.32363; Kim RD, 2001, J SURG RES, V100, P176, DOI 10.1006/jsre.2001.6225; Lehoux S, 1998, HYPERTENSION, V32, P338, DOI 10.1161/01.HYP.32.2.338; Leoni S, 2000, MOL CELL BIOCHEM, V204, P41, DOI 10.1023/A:1007053504960; Lepple-Wienhues A, 1998, J CELL BIOL, V141, P281, DOI 10.1083/jcb.141.1.281; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; Matsuda M, 2001, J CELL BIOL, V153, P599, DOI 10.1083/jcb.153.3.599; Missiaen L, 1996, J BIOL CHEM, V271, P4601; MURTHY KS, 1992, J PHARMACOL EXP THER, V260, P90; Noe B, 1996, GASTROENTEROLOGY, V110, P858, DOI 10.1053/gast.1996.v110.pm8608896; Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349, DOI 10.1091/mbc.6.10.1349; Puceat M, 1996, BIOCHEM J, V318, P723, DOI 10.1042/bj3180723; Rameh LE, 1998, J BIOL CHEM, V273, P23750, DOI 10.1074/jbc.273.37.23750; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Roe MW, 2001, J BIOL CHEM, V276, P30871, DOI 10.1074/jbc.M102362200; Roman RM, 1998, HEPATOLOGY, V28, P1073, DOI 10.1002/hep.510280423; SCHEUER PJ, 1994, LIVER BIOPSY INTERPR, P303; SCHREIBER R, 1995, BIOCHEM J, V309, P19, DOI 10.1042/bj3090019; Shinozuka K, 2001, CLIN EXP PHARMACOL P, V28, P799, DOI 10.1046/j.1440-1681.2001.03525.x; Strassheim D, 2000, J BIOL CHEM, V275, P39767, DOI 10.1074/jbc.M007775200; THEODOROPOULOS PA, 1992, FEBS LETT, V311, P241, DOI 10.1016/0014-5793(92)81111-X; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Wang XJ, 2001, EXP CELL RES, V267, P28, DOI 10.1006/excr.2001.5241; WILLS EJ, 1976, J CLIN PATHOL, V29, P1, DOI 10.1136/jcp.29.1.1; WONDERGEM R, 1994, ALCOHOL CLIN EXP RES, V18, P1230, DOI 10.1111/j.1530-0277.1994.tb00110.x; Wu X, 1997, J MEMBRANE BIOL, V158, P127, DOI 10.1007/s002329900250; Zhang BH, 1999, BIOCHEM BIOPH RES CO, V257, P89, DOI 10.1006/bbrc.1999.0403; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	38	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34030	34035		10.1074/jbc.M205945200	http://dx.doi.org/10.1074/jbc.M205945200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12167665	hybrid			2022-12-27	WOS:000177959100068
J	Reid, J; Murray, I; Watt, K; Betney, R; McEwan, IJ				Reid, J; Murray, I; Watt, K; Betney, R; McEwan, IJ			The androgen receptor interacts with multiple regions of the large subunit of general transcription factor TFIIF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; LIGAND-BINDING DOMAIN; AR SUPPRESSES TRANSCRIPTION; RAP74 SUBUNIT; FACTOR IIF; ACTIVATION; COACTIVATOR; TRANSACTIVATION; PROTEIN; IDENTIFICATION	The androgen receptor (AR) is a ligand-activated transcription factor that regulates genes important for male development and reproductive function. The main determinants for the transactivation function lie within the structurally distinct amino-terminal domain. Previously we identified an interaction between the AR-transactivation domain (amino acids 142-485) and the general transcription factor TFIIF (McEwan, I. J., and Gustafsson, J.-Angstrom. (1997) Proc. Natl Acad. Sci. U. S. A. 94, 8485-8490). We have now mapped the binding sites for the AR-transactivation domain within the RAP74 subunit of TFIIF. Both the amino-terminal 136 amino acids and the carboxyl-terminal 155 amino acids of RAP74 interacted with the AR-transactivation domain and were able to rescue basal transcription after squelching by the AR polypeptide. Competition experiments demonstrated that the AR could interact with the holo-TFIIF protein and that the carboxyl terminus of RAP74 represented the principal receptor-binding site. Point mutations within AR-transactivation domain distinguished the binding sites for RAP74 and the p160 coactivator SRC-la and identified a single copy of a six amino acid repeat motif as being important for RAP74 binding. These data indicate that the AR-transactivation domain can potentially make multiple protein-protein interactions with coactivators and components of the general transcriptional machinery in order to regulate target gene expression.	Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	McEwan, IJ (corresponding author), Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland.	iain.mcewan@abdn.ac.uk						Aarnisalo P, 1998, P NATL ACAD SCI USA, V95, P2122, DOI 10.1073/pnas.95.5.2122; ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; Alen P, 1999, MOL CELL BIOL, V19, P6085; Almlof T, 1997, MOL CELL BIOL, V17, P934, DOI 10.1128/MCB.17.2.934; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Cato ACB, 1998, TRENDS ENDOCRIN MET, V9, P150, DOI 10.1016/S1043-2760(98)00039-3; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; Claessens F, 1996, J BIOL CHEM, V271, P19013, DOI 10.1074/jbc.271.32.19013; CLAY CM, 1993, J BIOL CHEM, V268, P13556; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Dai JL, 1996, MOL ENDOCRINOL, V10, P1582, DOI 10.1210/me.10.12.1582; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; Dotzlaw H, 2002, MOL ENDOCRINOL, V16, P661, DOI 10.1210/me.16.4.661; Fronsdal K, 1998, J BIOL CHEM, V273, P31853, DOI 10.1074/jbc.273.48.31853; Gietz RD, 1994, MOL GENETICS YEAST P; Hayes SA, 2001, CANCER RES, V61, P2112; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Hiipakka RA, 1998, TRENDS ENDOCRIN MET, V9, P317, DOI 10.1016/S1043-2760(98)00081-2; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Huang WB, 1999, J BIOL CHEM, V274, P25756, DOI 10.1074/jbc.274.36.25756; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Irvine RA, 2000, HUM MOL GENET, V9, P267, DOI 10.1093/hmg/9.2.267; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; JOLIET V, 1995, NATURE, V373, P632, DOI 10.1038/373632a0; Jorgensen JS, 2001, MOL ENDOCRINOL, V15, P1496, DOI 10.1210/me.15.9.1496; Jorgensen JS, 2001, MOL ENDOCRINOL, V15, P1505, DOI 10.1210/me.15.9.1505; Kang HY, 2001, P NATL ACAD SCI USA, V98, P3018, DOI 10.1073/pnas.061305498; Kim JB, 1999, MOL CELL BIOL, V19, P5960; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Lee DK, 2000, J BIOL CHEM, V275, P9308, DOI 10.1074/jbc.275.13.9308; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; Lei L, 1999, MOL CELL BIOL, V19, P8372; Lipinski KS, 1998, VIRUS RES, V54, P99, DOI 10.1016/S0168-1702(98)00003-3; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Ma H, 1999, MOL CELL BIOL, V19, P6164; Markus SM, 2002, MOL BIOL CELL, V13, P670, DOI 10.1091/mbc.01-10-0513; Martin ML, 1996, MOL CELL BIOL, V16, P2110; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; McEwan IJ, 2000, BIOCHEM SOC T, V28, P369, DOI 10.1042/0300-5127:0280369; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; Park JJ, 2000, CANCER RES, V60, P5946; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; Reid J, 2002, J BIOL CHEM, V277, P20079, DOI 10.1074/jbc.M201003200; REID J, 2001, THESIS U ABERDEEN; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; Robert F, 1998, MOL CELL, V2, P341, DOI 10.1016/S1097-2765(00)80278-6; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Song CS, 1998, J BIOL CHEM, V273, P21856, DOI 10.1074/jbc.273.34.21856; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; Ueda T, 2002, J BIOL CHEM, V277, P7076, DOI 10.1074/jbc.M108255200; Verrijdt G, 1999, MOL ENDOCRINOL, V13, P1558, DOI 10.1210/me.13.9.1558; WANG BQ, 1995, J BIOL CHEM, V270, P27035, DOI 10.1074/jbc.270.45.27035; WRIGHT APH, 1990, J BIOL CHEM, V265, P14763; Yamamoto A, 2000, J CELL BIOL, V150, P873, DOI 10.1083/jcb.150.4.873; Yan Q, 1999, J BIOL CHEM, V274, P35668, DOI 10.1074/jbc.274.50.35668; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; Zhang M, 1997, P NATL ACAD SCI USA, V94, P5673, DOI 10.1073/pnas.94.11.5673	65	46	47	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41247	41253		10.1074/jbc.M205220200	http://dx.doi.org/10.1074/jbc.M205220200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181312	hybrid			2022-12-27	WOS:000178791400136
J	Dienhart, M; Pfeiffer, K; Schagger, H; Stuart, RA				Dienhart, M; Pfeiffer, K; Schagger, H; Stuart, RA			Formation of the yeast F1F0-ATP synthase dimeric complex does not require the ATPase inhibitor protein, Inh1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL F1F0-ATPASE; SACCHAROMYCES-CEREVISIAE; BOVINE F-1-ATPASE; BINDING; SUBUNIT; LACKING; GENE; IF1; PH	The yeast F1F0-ATP synthase forms dimeric complexes in the mitochondrial inner membrane and in a manner that is supported by the F-0-sector subunits, Su e and Su g. Furthermore, it has recently been demonstrated that the binding of the FFO-ATPase natural inhibitor protein to purified bovine F-1-sectors can promote their dimerization in solution (Cabezon, E., Arechaga, I., Jonathan P., Butler, G., and Walker J. E. (2000) J. Biol. Chem. 275, 28353-28355). It was unclear until now whether the binding of the inhibitor protein to the F-1 domains contributes to the process of F1F0-ATP synthase dimerization in intact mitochondria. Here we have directly addressed the involvement of the yeast inhibitor protein, Inh1, and its known accessory proteins, Stf1 and Stf2, in the formation of the yeast F1F0-ATP synthase dimer. Using mitochondria isolated from null mutants deficient in Inhl, Stf1, and Stf2, we demonstrate that formation of the F1F0-ATP synthase dimers is not adversely affected by the absence of these proteins. Furthermore, we demonstrate that the F1F0-ATPase monomers present in su e null mutant mitochondria can be as effectively inhibited by Inh1, as its dimeric counterpart in wild-type mitochondria. We conclude that dimerization of the F1F0-ATP synthase complexes involves a physical interaction of the membrane-embedded F-0 sectors from two monomeric complexes and in a manner that is independent of inhibitory activity of the Inh1 and accessory proteins.	Marquette Univ, Dept Biol, Milwaukee, WI 53233 USA; Univ Frankfurt Klinikum, Zentrum Biol Chem, D-60590 Frankfurt, Germany	Marquette University; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Stuart, RA (corresponding author), Marquette Univ, Dept Biol, Milwaukee, WI 53233 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061573] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61573] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKASHI A, 1988, J BIOCHEM, V104, P526, DOI 10.1093/oxfordjournals.jbchem.a122504; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arnold I, 1997, FEBS LETT, V411, P195, DOI 10.1016/S0014-5793(97)00691-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cabezon E, 2000, J BIOL CHEM, V275, P28353, DOI 10.1074/jbc.C000427200; Cabezon E, 2000, J BIOL CHEM, V275, P25460, DOI 10.1074/jbc.M003859200; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; HASHIMOTO T, 1990, J BIOENERG BIOMEMBR, V22, P27, DOI 10.1007/BF00762843; HASHIMOTO T, 1990, J BIOCHEM-TOKYO, V108, P17, DOI 10.1093/oxfordjournals.jbchem.a123154; Herrmann J. M., 1994, CELL BIOL LAB HDB, VI, P538; ICHIKAWA N, 1990, J BIOL CHEM, V265, P6274; Iwatsuki H, 2000, J BIOCHEM-TOKYO, V128, P553, DOI 10.1093/oxfordjournals.jbchem.a022787; KLEIN G, 1980, BIOCHEMISTRY-US, V19, P2919, DOI 10.1021/bi00554a016; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lebowitz MS, 1996, ARCH BIOCHEM BIOPHYS, V330, P342, DOI 10.1006/abbi.1996.0261; LILL R, 1990, CELL, V60, P271, DOI 10.1016/0092-8674(90)90742-W; Paumard P, 2002, EMBO J, V21, P221, DOI 10.1093/emboj/21.3.221; ROTHSTEIN RJ, 1980, GENETICS, V94, P871; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Spannagel C, 1998, BBA-BIOMEMBRANES, V1414, P260, DOI 10.1016/S0005-2736(98)00174-6; Velours J, 2000, J BIOENERG BIOMEMBR, V32, P383, DOI 10.1023/A:1005580020547; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WALKER JE, 1994, CURR OPIN STRUC BIOL, V4, P912, DOI 10.1016/0959-440X(94)90274-7; YOSHIDA Y, 1990, EUR J BIOCHEM, V192, P49, DOI 10.1111/j.1432-1033.1990.tb19193.x	27	52	52	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39289	39295		10.1074/jbc.M205720200	http://dx.doi.org/10.1074/jbc.M205720200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167646	hybrid			2022-12-27	WOS:000178662500031
J	Weeber, EJ; Beffert, U; Jones, C; Christian, JM; Forster, E; Sweatt, JD; Herz, J				Weeber, EJ; Beffert, U; Jones, C; Christian, JM; Forster, E; Sweatt, JD; Herz, J			Reelin and ApoE receptors cooperate to enhance hippocampal synaptic plasticity and learning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; LONG-TERM POTENTIATION; APOLIPOPROTEIN-E; CONTEXTUAL FEAR; KNOCKOUT MICE; ALPHA-2-MACROGLOBULIN RECEPTOR; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAY; BRAIN-DEVELOPMENT; DENDRITIC SPINE	Two apolipoprotein E (apoE) receptors, the very low density lipoprotein (VLDL) receptor and apoE receptor 2 (apoER2), are also receptors for Reelin, a signaling protein that regulates neuronal migration during brain development. In the adult brain, Reelin is expressed by GABA-ergic interneurons, suggesting a potential function as a modulator of neurotransmission. ApoE receptors have been indirectly implicated in memory and neurodegenerative disorders because their ligand, apoE, is genetically associated with Alzheimer disease. We have used knockout mice to investigate the role of Reelin and its receptors in cognition and synaptic plasticity. Mice lacking either the VLDL receptor or the apoER2 show contextual fear conditioning deficits. VLDL receptor-deficient mice also have a moderate defect in long term potentiation (LTP), and apoER2 knockouts have a pronounced one. The perfusion of mouse hippocampal slices with Reelin has no effect on baseline synaptic transmission but significantly enhances LTP in area CA1. This Reelin-dependent augmentation of LTP is abolished in VLDL receptor and apoER2 knockout mice. Our results reveal a role for Reelin in controlling synaptic plasticity in the adult brain and suggest that both of its receptors are necessary for Reelin-dependent enhancement of synaptic transmission in the hippocampus. Thus, the impairment of apoE receptor-dependent neuromodulation may contribute to cognitive impairment and synaptic loss in Alzheimer disease.	SW Texas State Univ, Dept Mol Genet, Dallas, TX 75390 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Univ Freiburg, Inst Anat, D-79001 Freiburg, Germany	Texas State University System; Texas State University San Marcos; Baylor College of Medicine; University of Freiburg	Herz, J (corresponding author), SW Texas State Univ, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Joachim.Herz@UTSouthwestern.edu	Weeber, Edwin J/A-5396-2012	Beffert, Uwe/0000-0001-5877-922X; Sweatt, J. David/0000-0003-3567-485X	NHLBI NIH HHS [R37 HL063762, HL20948, HL63762] Funding Source: Medline; NICHD NIH HHS [HD24064] Funding Source: Medline; NIMH NIH HHS [MH57014] Funding Source: Medline; NINDS NIH HHS [NS43408, NS37444] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762, P01HL020948, R01HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408, P01NS037444] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BOYLES JK, 1986, CIRCULATION, V74, P195; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Chen C, 1996, BEHAV NEUROSCI, V110, P1177; Crawley JN, 1997, HORM BEHAV, V31, P197, DOI 10.1006/hbeh.1997.1382; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; Dong LM, 1996, J BIOL CHEM, V271, P19053, DOI 10.1074/jbc.271.32.19053; Drakew A, 2002, EXP NEUROL, V176, P12, DOI 10.1006/exnr.2002.7918; Flaherty DB, 2000, J NEUROSCI RES, V62, P463, DOI 10.1002/1097-4547(20001101)62:3<463::AID-JNR16>3.0.CO;2-7; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; Gu YH, 2002, J NEUROSCI, V22, P2753, DOI 10.1523/JNEUROSCI.22-07-02753.2002; Herz J, 2000, NAT REV NEUROSCI, V1, P51, DOI 10.1038/35036221; HERZ J, 1991, J BIOL CHEM, V266, P21232; Hiesberger T, 1999, NEURON, V24, P481, DOI 10.1016/S0896-6273(00)80861-2; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; Jiang YH, 1998, NEURON, V21, P799, DOI 10.1016/S0896-6273(00)80596-6; KIM JJ, 1993, BEHAV NEUROSCI, V107, P1093, DOI 10.1037/0735-7044.107.6.1093; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; Lambert de Rouvroit C, 1998, Adv Anat Embryol Cell Biol, V150, P1; Liu WS, 2001, P NATL ACAD SCI USA, V98, P3477, DOI 10.1073/pnas.051614698; MAHLEY RW, 1995, METABOLIC MOL BASES, V61, P1953; Morgan SL, 2001, J NEUROPHYSIOL, V86, P1289, DOI 10.1152/jn.2001.86.3.1289; Murphy KPSJ, 2000, J NEUROSCI, V20, P5115; Perez Y, 1999, NEUROSCIENCE, V90, P747, DOI 10.1016/S0306-4522(98)00531-4; Pesold C, 1999, P NATL ACAD SCI USA, V96, P3217, DOI 10.1073/pnas.96.6.3217; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Raber J, 1998, P NATL ACAD SCI USA, V95, P10914, DOI 10.1073/pnas.95.18.10914; Rice DS, 2001, ANNU REV NEUROSCI, V24, P1005, DOI 10.1146/annurev.neuro.24.1.1005; Rice DS, 1998, DEVELOPMENT, V125, P3719; Rodriguez MA, 2000, P NATL ACAD SCI USA, V97, P3550, DOI 10.1073/pnas.050589797; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SCHULZ PE, 1994, J NEUROSCI, V14, P5325; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; Watase K, 2002, NEURON, V34, P905, DOI 10.1016/S0896-6273(02)00733-X; Willnow TE, 1996, EMBO J, V15, P2632, DOI 10.1002/j.1460-2075.1996.tb00623.x; Zhuo M, 2000, J NEUROSCI, V20, P542, DOI 10.1523/JNEUROSCI.20-02-00542.2000	45	473	492	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39944	39952		10.1074/jbc.M205147200	http://dx.doi.org/10.1074/jbc.M205147200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167620	hybrid			2022-12-27	WOS:000178662500112
J	O'Neil, PK; Sun, GL; Yu, H; Ron, Y; Dougherty, JP; Preston, BD				O'Neil, PK; Sun, GL; Yu, H; Ron, Y; Dougherty, JP; Preston, BD			Mutational analysis of HIV-1 long terminal repeats to explore the relative contribution of reverse transcriptase and RNA polymerase II to viral mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CONFORMATION POLYMORPHISM ANALYSIS; DNA-SYNTHESIS; STRAND TRANSFER; VECTOR REPLICATION; CELL-LINE; FIDELITY; GENE; MECHANISM; INVITRO	HIV-1 evolves rapidly, which is thought to result from one or more error-prone steps in the virus life cycle. Because HIV-1 reverse transcriptase (RT) does not possess 3'- to 5'-exonucleolytic proofreading activity and because RT has been shown to be error-prone in cell free systems, it should be an important contributor to the high rate of HIV-1 mutation. However, because RNA polymerase II (pol II) synthesizes viral RNA, it might also contribute significantly to HIV-1 mutagenesis. To assess the relative contributions of RT and RNA pol H to HIV-1 mutagenesis, a system was established to study the rate and nature of mutations in HIV-1 long terminal repeats (LTRs). Owing to the unique nature of replication at the ends of the viral genome, mutational analysis of retroviral LTRs provides an opportunity to evaluate the relative contribution of HIV-1 RT and RNA pol II to viral mutagenesis. Mutational analysis was performed on both LTRs of 215 proviruses, restricted to a single cycle of replication, employing single-stranded conformational polymorphism and DNA sequencing allowing direct identification of mutations in the absence of selection and within autologous viral sequences. A total of 21 independent mutations was identified. Ten mutations were observed in both LTRs, which could have been introduced by either RT or RNA pol II, whereas the other eleven mutations were only present in a single LTR and could only have been introduced by RT. This provides the first direct evidence that HIV-1 RT contributes significantly to HIV-1 mutagenesis and is likely to be the primary engine for HIV-1 mutagenesis. Moreover, mutations were observed at the U3-R border, but the nature of the mutations and their frequency differed from experiments performed using cell-free systems suggesting that other viral and/or cellular factors contribute to fidelity at the ends of the viral genome.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, Piscataway, NJ 08854 USA; Univ Utah, Eccles Inst Human Genet, Dept Biochem & Radiat Oncol, Salt Lake City, UT 84112 USA; Rutgers State Univ, Grad Program Microbiol & Mol Genet, New Brunswick, NJ 08903 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Utah System of Higher Education; University of Utah; Rutgers State University New Brunswick	Dougherty, JP (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet Microbiol & Immunol, 675 Hoes Lane, Piscataway, NJ 08854 USA.				NCI NIH HHS [CA50777] Funding Source: Medline; NIAID NIH HHS [AI34834] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050777, R29CA050777] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI034834, R01AI034834] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Balzarini J, 2001, J VIROL, V75, P5772, DOI 10.1128/JVI.75.13.5772-5777.2001; BEBENECK K, 1993, FIDELITY RETROVIAL R, P85; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BONHOEFFER S, 1995, NATURE, V376, P125, DOI 10.1038/376125a0; BOYER JC, 1992, P NATL ACAD SCI USA, V89, P6919, DOI 10.1073/pnas.89.15.6919; Collins KR, 2002, J VIROL, V76, P1697, DOI 10.1128/JVI.76.4.1697-1706.2002; EIGEN M, 1993, SCI AM, V269, P42, DOI 10.1038/scientificamerican0793-42; FITZGIBBON JE, 1993, J VIROL, V67, P7271, DOI 10.1128/JVI.67.12.7271-7275.1993; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gotte M, 2000, J VIROL, V74, P3579, DOI 10.1128/JVI.74.8.3579-3585.2000; Haase AT, 1999, ANNU REV IMMUNOL, V17, P625, DOI 10.1146/annurev.immunol.17.1.625; Halvas EK, 2000, J VIROL, V74, P10349, DOI 10.1128/JVI.74.22.10349-10358.2000; Hsu ML, 1997, NUCLEIC ACIDS RES, V25, P4532, DOI 10.1093/nar/25.22.4532; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; KATI WM, 1992, J BIOL CHEM, V267, P25988; Klarmann GJ, 1997, J VIROL, V71, P9259, DOI 10.1128/JVI.71.12.9259-9269.1997; Korber B, 2000, SCIENCE, V288, P1789, DOI 10.1126/science.288.5472.1789; MANSKY LM, 1994, J VIROL, V68, P494, DOI 10.1128/JVI.68.1.494-499.1994; MANSKY LM, 1995, J VIROL, V69, P5087, DOI 10.1128/JVI.69.8.5087-5094.1995; Mansky LM, 1996, VIROLOGY, V222, P391, DOI 10.1006/viro.1996.0436; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MENDELMAN LV, 1989, J BIOL CHEM, V264, P14415; MULLIGAN RC, 1981, P NATL ACAD SCI-BIOL, V78, P2072, DOI 10.1073/pnas.78.4.2072; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; PARTHASARATHI S, 1995, J VIROL, V69, P7991, DOI 10.1128/JVI.69.12.7991-8000.1995; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; Peeters M, 2000, AIDS, V14, pS129; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P3890, DOI 10.1021/bi00179a014; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; POZNANSKY M, 1991, J VIROL, V65, P532, DOI 10.1128/JVI.65.1.532-536.1991; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Preston BD, 1996, TRENDS MICROBIOL, V4, P16, DOI 10.1016/0966-842X(96)81500-9; PULSINELLI GA, 1991, J VIROL, V65, P4786, DOI 10.1128/JVI.65.9.4786-4797.1991; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; RICCHETTI M, 1990, EMBO J, V9, P1583, DOI 10.1002/j.1460-2075.1990.tb08278.x; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Rouzine IM, 2001, MICROBIOL MOL BIOL R, V65, P151, DOI 10.1128/MMBR.65.1.151-185.2001; SEKIYA T, 1993, MUTAT RES, V288, P79, DOI 10.1016/0027-5107(93)90209-X; Shankarappa R, 1999, J VIROL, V73, P10489, DOI 10.1128/JVI.73.12.10489-10502.1999; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; Sun GL, 2001, J VIROL, V75, P11902, DOI 10.1128/JVI.75.23.11902-11906.2001; Thomas MJ, 1998, CELL, V93, P627, DOI 10.1016/S0092-8674(00)81191-5; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; USHIJIMA T, 1995, MUTAT RES-ENVIR MUTA, V334, P283, DOI 10.1016/0165-1161(95)90065-9; VARELAECHAVARRIA A, 1992, J BIOL CHEM, V267, P24681; VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092; Vartanian JP, 1997, J MOL BIOL, V270, P139, DOI 10.1006/jmbi.1997.1104; WABL M, 1985, P NATL ACAD SCI USA, V82, P479, DOI 10.1073/pnas.82.2.479; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282; YU H, 1992, J BIOL CHEM, V267, P10888; Yu H, 1996, J VIROL, V70, P4530, DOI 10.1128/JVI.70.7.4530-4537.1996	57	61	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38053	38061		10.1074/jbc.M204774200	http://dx.doi.org/10.1074/jbc.M204774200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151398	hybrid			2022-12-27	WOS:000178529600012
J	Oshiro, T; Koyama, S; Sugiyama, S; Kondo, A; Onodera, Y; Asahara, T; Sabe, H; Kikuchi, A				Oshiro, T; Koyama, S; Sugiyama, S; Kondo, A; Onodera, Y; Asahara, T; Sabe, H; Kikuchi, A			Interaction of POB1, a downstream molecule of small G protein Ral, with PAG2, a paxillin-binding protein, is involved in cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; GTPASE-ACTIVATING PROTEIN; PUTATIVE EFFECTOR PROTEIN; EH-DOMAIN; ACTIN CYTOSKELETON; REGULATE ENDOCYTOSIS; FOCAL ADHESIONS; EPSIN BINDS; MEMBRANE; EPS15	POB1 was previously identified as a RalBP1-binding protein. POB1 and RalBP1 function downstream of small G protein Ral and regulate receptor-mediated endocytosis. To look for additional functions of POB1, we screened for POB1-binding proteins using a yeast two-hybrid method and found that POB1 interacts with mouse ASAP1, which is a human PAG2 homolog. PAG2 is a paxillin-associated protein with ADP-ribosylation factor GTPase-activating protein activity. POB1 formed a complex with PAG2 in intact cells. The carboxyl-terminal region containing the proline-rich motifs of POB1 directly bound to the carboxyl-terminal region including the SH3 domain of PAG2. Substitutions of Pro(423) and Pro(426) with Ala (POB1(PA)) impaired the binding of POB1 to PAG2. Expression of PAG2 inhibited fibronectin-dependent migration and paxillin recruitment to focal contacts of CHO-IR cells. Co-expression with POB1 but not with POB1(PA) suppressed the inhibitory action of PAG2 on cell migration and paxillin localization. These results suggest that POB1 interacts with PAG2 through its proline-rich motif, thereby regulating cell migration.	Hiroshima Univ, Dept Biochem, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Dept Surg, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan; Osaka Biosci Inst, Dept Biol Mol, Suita, Osaka 5650874, Japan	Hiroshima University; Hiroshima University	Kikuchi, A (corresponding author), Hiroshima Univ, Dept Biochem, Grad Sch Biomed Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	akikuchi@hiroshima-u.ac.jp	Onodera, Yasuhito/D-7108-2012; Sabe, Hisataka/GPF-4385-2022; Sabe, Hisataka/A-4066-2012	Onodera, Yasuhito/0000-0002-0064-9016				Andreev J, 1999, MOL CELL BIOL, V19, P2338; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; Bretscher MS, 1998, CURR BIOL, V8, P721, DOI 10.1016/S0960-9822(98)70281-7; Bretscher MS, 1996, CELL, V87, P601, DOI 10.1016/S0092-8674(00)81380-X; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Coda L, 1998, J BIOL CHEM, V273, P3003, DOI 10.1074/jbc.273.5.3003; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Holt MR, 2001, TRENDS CELL BIOL, V11, P38, DOI 10.1016/S0962-8924(00)01876-6; HOPKINS CR, 1994, J CELL BIOL, V125, P1265, DOI 10.1083/jcb.125.6.1265; Iannolo G, 1997, CANCER RES, V57, P240; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kariya K, 2000, J BIOL CHEM, V275, P18399, DOI 10.1074/jbc.M000521200; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; Matsubara K, 1997, FEBS LETT, V410, P169, DOI 10.1016/S0014-5793(97)00633-9; Mazaki Y, 2001, MOL BIOL CELL, V12, P645, DOI 10.1091/mbc.12.3.645; Morinaka K, 1999, ONCOGENE, V18, P5915, DOI 10.1038/sj.onc.1202974; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Okazaki M, 1996, CANCER RES, V56, P2387; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; PETERS PJ, 1995, J CELL BIOL, V128, P1003, DOI 10.1083/jcb.128.6.1003; Radhakrishna H, 1999, J CELL SCI, V112, P855; Roth MG, 1999, CELL, V97, P149, DOI 10.1016/S0092-8674(00)80723-0; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Sengar AS, 1999, EMBO J, V18, P1159, DOI 10.1093/emboj/18.5.1159; Song J, 1998, J CELL SCI, V111, P2257; Springer S, 1999, CELL, V97, P145, DOI 10.1016/S0092-8674(00)80722-9; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Suzuki J, 2000, MOL CELL BIOL, V20, P4658, DOI 10.1128/MCB.20.13.4658-4665.2000; Tang HY, 1997, MOL CELL BIOL, V17, P4294, DOI 10.1128/MCB.17.8.4294; TAYLOR TC, 1992, CELL, V70, P69, DOI 10.1016/0092-8674(92)90534-J; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Wendland B, 1999, EMBO J, V18, P4383, DOI 10.1093/emboj/18.16.4383; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	52	29	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38618	38626		10.1074/jbc.M203453200	http://dx.doi.org/10.1074/jbc.M203453200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12149250	hybrid			2022-12-27	WOS:000178529600079
J	McLoughlin, P; Ehler, E; Carlile, G; Licht, JD; Schafer, BW				McLoughlin, P; Ehler, E; Carlile, G; Licht, JD; Schafer, BW			The LIM-only protein DRAL/FHL2 interacts with and is a corepressor for the promyelocytic leukemia zinc finger protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLZF-RAR-ALPHA; DOMAIN PROTEIN; HISTONE DEACETYLASE; DNA-BINDING; TRANSCRIPTIONAL REPRESSION; SKELETAL-MUSCLE; FUSION PROTEINS; CELL-GROWTH; HUMAN HEART; FHL2	Members of the four-and-a-half-LIM domain (FHL) protein family, which are expressed in a tissue- and stage-specific manner, have been reported previously to function as transcriptional coactivators. One of these is the p53-inducible protein DRAL/FHL2 (where DRAL is down-regulated in rhabdomyosarcoma LIM domain protein). In this work, we identified potential binding partners for DRAL/FHL2 using an inducible yeast two-hybrid system. We present evidence of a functional interaction between the promyelocytic leukemia zinc finger protein (PLZF) and DRAL/FHL2. PLZF is a sequence-specific transcriptional repressor whose function relies on recruitment of corepressors that form part of the histone deacetylase complex involved in chromatin remodeling. DRAL/FHL2 interacts specifically with PLZF in vitro and in vivo and augments transcriptional repression mediated by PLZF. This is the first reported incidence of a bona fide FHL protein-mediated corepression and supports the notion of these proteins having a role as coregulators of tissue-specific gene expression.	Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland; ETH Honggerberg, Inst Cell Biol, CH-8093 Zurich, Switzerland; CUNY Mt Sinai Sch Med, Dept Med, Derald H Ruttenberg Canc Ctr, New York, NY 10029 USA	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Schafer, BW (corresponding author), Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8032 Zurich, Switzerland.		Licht, Jonathan/L-4239-2019	Licht, Jonathan/0000-0002-3942-1369; Ehler, Elisabeth/0000-0001-5646-5964; Schafer, Beat/0000-0001-5988-2915	NCI NIH HHS [R01 CA59936] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; Auerbach D, 1999, MOL BIOL CELL, V10, P1297, DOI 10.1091/mbc.10.5.1297; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Ball HJ, 1999, NUCLEIC ACIDS RES, V27, P4106, DOI 10.1093/nar/27.20.4106; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Brown S, 1999, J BIOL CHEM, V274, P27083, DOI 10.1074/jbc.274.38.27083; Chan KK, 1998, GENE, V210, P345, DOI 10.1016/S0378-1119(97)00644-6; Chan KK, 2000, J CELL BIOCHEM, V76, P499, DOI 10.1002/(SICI)1097-4644(20000301)76:3<499::AID-JCB16>3.0.CO;2-4; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; Chu PH, 2000, MOL CELL BIOL, V20, P7460, DOI 10.1128/MCB.20.20.7460-7462.2000; Chu PH, 2000, MECH DEVELOP, V95, P259, DOI 10.1016/S0925-4773(00)00341-5; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Doucas V, 1999, P NATL ACAD SCI USA, V96, P2627, DOI 10.1073/pnas.96.6.2627; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Fimia GM, 1999, NATURE, V398, P165, DOI 10.1038/18237; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Huber A, 2000, J BIOL CHEM, V275, P5504, DOI 10.1074/jbc.275.8.5504; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kong YF, 1997, MOL CELL BIOL, V17, P4750, DOI 10.1128/MCB.17.8.4750; Kong YF, 2001, CIRCULATION, V103, P2731; Larson RC, 1996, EMBO J, V15, P1021, DOI 10.1002/j.1460-2075.1996.tb00439.x; Li HY, 2001, CELL MOTIL CYTOSKEL, V48, P11, DOI 10.1002/1097-0169(200101)48:1<11::AID-CM2>3.0.CO;2-I; Li HY, 2001, J CELL BIOCHEM, V80, P293, DOI 10.1002/1097-4644(20010301)80:3<293::AID-JCB10>3.3.CO;2-L; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Licht JD, 1996, ONCOGENE, V12, P323; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Louis HA, 1997, J BIOL CHEM, V272, P27484, DOI 10.1074/jbc.272.43.27484; Melnick A, 2002, MOL CELL BIOL, V22, P1804, DOI 10.1128/MCB.22.6.1804-1818.2002; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Ng EKO, 2002, J CELL BIOCHEM, V84, P556, DOI 10.1002/jcb.10041.abs; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Reinhard M, 1999, J BIOL CHEM, V274, P13410, DOI 10.1074/jbc.274.19.13410; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Scholl FA, 2000, J CELL BIOL, V151, P495, DOI 10.1083/jcb.151.3.495; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Tanahashi H, 2000, HUM MOL GENET, V9, P2281, DOI 10.1093/oxfordjournals.hmg.a018919; Taniguchi Y, 1998, MOL CELL BIOL, V18, P644, DOI 10.1128/MCB.18.1.644; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Ward JO, 2001, BLOOD, V98, P3290, DOI 10.1182/blood.V98.12.3290; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Yamada Y, 2000, P NATL ACAD SCI USA, V97, P320, DOI 10.1073/pnas.97.1.320; Yang Q, 2000, BIOCHEM J, V345, P335, DOI 10.1042/0264-6021:3450335; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zhao HH, 2001, J BIOL CHEM, V276, P27907, DOI 10.1074/jbc.M104278200	57	68	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37045	37053		10.1074/jbc.M203336200	http://dx.doi.org/10.1074/jbc.M203336200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145280	hybrid			2022-12-27	WOS:000178447100020
J	Pinton, P; Tsuboi, T; Ainscow, EK; Pozzan, T; Rizzuto, R; Rutter, GA				Pinton, P; Tsuboi, T; Ainscow, EK; Pozzan, T; Rizzuto, R; Rutter, GA			Dynamics of glucose-induced membrane recruitment of protein kinase C beta II in living pancreatic islet beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; INSULIN-SECRETION; POSSIBLE INVOLVEMENT; CA2+ OSCILLATIONS; PLASMA-MEMBRANE; TRANSLOCATION; ACTIVATION; CALCIUM; EXOCYTOSIS; EXPRESSION	The mechanisms by which glucose may affect protein kinase C (PKC) activity in the pancreatic islet beta-cell are presently unclear. By developing adenovirally expressed chimeras encoding fusion proteins between green fluorescent protein and conventional (betaII), novel (delta), or atypical (zeta) PKCs, we show that glucose selectively alters the subcellular localization of these enzymes dynamically in primary islet and MIN6 beta-cells. Examined by laser scanning confocal or total internal reflection fluorescence microscopy, elevated glucose concentrations induced oscillatory translocations of PKCbetaII to spatially confined regions of the plasma membrane. Suggesting that increases in free cytosolic Ca2+ concentrations ([Ca2+](c)) were primarily responsible, prevention of [Ca2+](c) increases with EGTA or diazoxide completely eliminated membrane recruitment, whereas elevation of cytosolic [Ca2+](c) with KCl or tolbutamide was highly effective in redistributing PKC/betaII both to the plasma membrane and to the surface of dense core secretory vesicles. By contrast, the distribution of PKCdelta.EGFP, which binds diacylglycerol but not Ca2+, was unaffected by glucose. Measurement of [Ca2+](c) immediately beneath the plasma membrane with a ratiometric "pericam," fused to synaptic vesicle-associated protein-25, revealed that depolarization induced significantly larger increases in [Ca2+](c) in this domain. These data demonstrate that nutrient stimulation of beta-cells causes spatially and temporally complex changes in the subcellular localization of PKCbetaII, possibly resulting from the generation of Ca2+ microdomains. Localized changes in PKCbetaII activity may thus have a role in the spatial control of insulin exocytosis.	Univ Bristol, Henry Wellcome Signalling Labs, Bristol BS8 1TD, Avon, England; Univ Bristol, Dept Biochem, Bristol BS8 1TD, Avon, England; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Ctr Study Biol Membranes, I-35121 Padua, Italy; Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy; Univ Ferrara, Interdisciplinary Ctr Study Inflammat, I-44100 Ferrara, Italy	University of Bristol; University of Bristol; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Ferrara; University of Ferrara	Rutter, GA (corresponding author), Univ Bristol, Henry Wellcome Signalling Labs, Bristol BS8 1TD, Avon, England.	g.a.rutter@bris.ac.uk	TSUBOI, Takashi/AAD-7976-2019; Pinton, Paolo/J-8025-2012; Rizzuto, Rosario/B-6312-2008	TSUBOI, Takashi/0000-0001-8290-2021; Pinton, Paolo/0000-0001-7108-6508; Rizzuto, Rosario/0000-0001-7044-5097; Rutter, Guy/0000-0001-6360-0343				Ainscow EK, 2000, DIABETES, V49, P1149, DOI 10.2337/diabetes.49.7.1149; Ainscow EK, 2001, BIOCHEM J, V353, P175, DOI 10.1042/0264-6021:3530175; AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; ARKHAMMAR P, 1989, BIOCHEM J, V264, P207, DOI 10.1042/bj2640207; ARKHAMMAR P, 1994, J BIOL CHEM, V269, P2743; AXELROD D, 1981, J CELL BIOL, V89, P141, DOI 10.1083/jcb.89.1.141; BOZEM M, 1987, ENDOCRINOLOGY, V121, P1025, DOI 10.1210/endo-121-3-1025; Bryan J, 1997, CURR OPIN CELL BIOL, V9, P553, DOI 10.1016/S0955-0674(97)80033-6; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; Codazzi F, 2001, CURR BIOL, V11, P1089, DOI 10.1016/S0960-9822(01)00326-8; Corkey BE, 2000, J NUTR, V130, p299S, DOI 10.1093/jn/130.2.299S; Deeney JT, 1996, J BIOL CHEM, V271, P18154, DOI 10.1074/jbc.271.30.18154; EASOM RA, 1989, BIOCHEM J, V264, P27, DOI 10.1042/bj2640027; Emmanouilidou E, 1999, CURR BIOL, V9, P915, DOI 10.1016/S0960-9822(99)80398-4; Feng X, 1998, J BIOL CHEM, V273, P26870, DOI 10.1074/jbc.273.41.26870; Furukawa N, 1999, ENDOCR J, V46, P43, DOI 10.1507/endocrj.46.43; GANESAN S, 1990, P NATL ACAD SCI USA, V87, P9893, DOI 10.1073/pnas.87.24.9893; Genoud S, 1999, J NEUROCHEM, V72, P1699, DOI 10.1046/j.1471-4159.1999.721699.x; Graham ME, 2000, BIOCHIMIE, V82, P469, DOI 10.1016/S0300-9084(00)00196-6; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Kaneto H, 2002, J BIOL CHEM, V277, P3680, DOI 10.1074/jbc.M109647200; Kennedy HJ, 1999, J BIOL CHEM, V274, P13281, DOI 10.1074/jbc.274.19.13281; KHALIL RA, 1994, AM J PHYSIOL, V266, pC1544, DOI 10.1152/ajpcell.1994.266.6.C1544; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Light PE, 2000, P NATL ACAD SCI USA, V97, P9058, DOI 10.1073/pnas.160068997; LORD JM, 1984, BIOCHEM J, V219, P547, DOI 10.1042/bj2190547; Maasch C, 2000, FASEB J, V14, P1653, DOI 10.1096/fj.14.11.1653; MATSCHINSKY FM, 1986, J BIOL CHEM, V261, P14057; Mitchell KJ, 2001, J CELL BIOL, V155, P41, DOI 10.1083/jcb.200103145; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P13216, DOI 10.1021/bi010761u; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; ONODA K, 1990, ENDOCRINOLOGY, V126, P1235; Patel S, 2001, TRENDS BIOCHEM SCI, V26, P482, DOI 10.1016/S0968-0004(01)01896-5; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; Pouli AE, 1998, BIOCHEM J, V333, P193, DOI 10.1042/bj3330193; Quesada I, 2000, J PHYSIOL-LONDON, V525, P159, DOI 10.1111/j.1469-7793.2000.t01-1-00159.x; Rutter Guy A., 2001, Molecular Aspects of Medicine, V22, P247, DOI 10.1016/S0098-2997(01)00013-9; Safayhi H, 1997, MOL ENDOCRINOL, V11, P619, DOI 10.1210/me.11.5.619; Sakai N, 1997, J CELL BIOL, V139, P1465, DOI 10.1083/jcb.139.6.1465; SANDERSON MJ, 1995, CIBA F SYMP, V188, P175; Shimazaki Y, 1996, J BIOL CHEM, V271, P14548, DOI 10.1074/jbc.271.24.14548; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TANIGAWA K, 1982, FEBS LETT, V138, P183, DOI 10.1016/0014-5793(82)80436-5; Tian YM, 1996, MOL CELL ENDOCRINOL, V119, P185, DOI 10.1016/0303-7207(96)03811-7; Toomre D, 2001, TRENDS CELL BIOL, V11, P298, DOI 10.1016/S0962-8924(01)02027-X; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Tsuboi T, 2000, CURR BIOL, V10, P1307, DOI 10.1016/S0960-9822(00)00756-9; Tsuboi T, 2002, J BIOL CHEM, V277, P15957, DOI 10.1074/jbc.C200051200; Tsuboi T, 2001, BIOCHEM BIOPH RES CO, V282, P621, DOI 10.1006/bbrc.2001.4603; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Wasmeier C, 1996, J BIOL CHEM, V271, P18161, DOI 10.1074/jbc.271.30.18161; Wiser O, 1999, P NATL ACAD SCI USA, V96, P248, DOI 10.1073/pnas.96.1.248; WOLF BA, 1990, J CLIN INVEST, V85, P482, DOI 10.1172/JCI114463; Yaney GC, 2000, ENDOCRINOLOGY, V141, P1989, DOI 10.1210/en.141.6.1989; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417; ZAWALICH W, 1983, BIOCHEM BIOPH RES CO, V117, P448, DOI 10.1016/0006-291X(83)91221-4; ZAWALICH WS, 1990, MOL CELL ENDOCRINOL, V70, P119, DOI 10.1016/0303-7207(90)90152-X; Zawalich WS, 2001, MOL CELL ENDOCRINOL, V177, P95, DOI 10.1016/S0303-7207(01)00422-1; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X	65	76	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37702	37710		10.1074/jbc.M204478200	http://dx.doi.org/10.1074/jbc.M204478200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149258	hybrid			2022-12-27	WOS:000178447100102
J	Piontek, K; Antorini, M; Choinowski, T				Piontek, K; Antorini, M; Choinowski, T			Crystal structure of a laccase from the fungus Trametes versicolor at 1.90-angstrom resolution containing a full complement of coppers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHUS-VERNICIFERA LACCASE; X-RAY-DIFFRACTION; ASCORBATE OXIDASE; ELECTRON-TRANSFER; LIGNIN; OXIDATION; SITE; PURIFICATION; ANGSTROM; STATE	Laccase is a polyphenol oxidase, which belongs to the family of blue multicopper oxidases. These enzymes catalyze the one-electron oxidation of four reducing-substrate molecules concomitant with the four-electron reduction of molecular oxygen to water. Laccases oxidize a broad range of substrates, preferably phenolic compounds. In the presence of mediators, fungal laccases exhibit an enlarged substrate range and are then able to oxidize compounds with a redox potential exceeding their own. Until now, only one crystal structure of a laccase in an inactive, type-2 copper-depleted form has been reported. We present here the first crystal structure of an active laccase containing a full complement of coppers, the complete polypeptide chain together with seven carbohydrate moieties. Despite the presence of all coppers in the new structure, the folds of the two laccases are quite similar. The coordination of the type-3 coppers, however, is distinctly different. The geometry of the trinuclear copper cluster in the Trametes versicolor laccase is similar to that found in the ascorbate oxidase and that of mammalian ceruloplasmin structures, suggesting a common reaction mechanism for the copper oxidation and the O-2 reduction. In contrast to most blue copper proteins, the type-1 copper in the T. versicolor laccase has no axial ligand and is only 3-fold coordinated. Previously, a modest elevation of the redox potential was attributed to the lack of an axial ligand. Based on the present structural data and sequence comparisons, a mechanism is presented to explain how laccases could tune their redox potential by as much as 200 MV.	ETH Honggerberg, Swiss Fed Inst Technol, Inst Biochem, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Piontek, K (corresponding author), ETH Honggerberg, Swiss Fed Inst Technol, Inst Biochem, Bldg HPM,Room D 8-1-2, CH-8093 Zurich, Switzerland.	klaus.piontek@bc.biol.ethz.ch						ANDREASSON LE, 1976, BIOCHIM BIOPHYS ACTA, V438, P370, DOI 10.1016/0005-2744(76)90254-0; Antorini M, 2002, BBA-PROTEIN STRUCT M, V1594, P109, DOI 10.1016/S0167-4838(01)00289-8; ANTORINI M, 2000, THESIS ETH ZURICH SW; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BAKER EN, 1988, J MOL BIOL, V203, P1071, DOI 10.1016/0022-2836(88)90129-5; BHAT TN, 1988, J APPL CRYSTALLOGR, V21, P279, DOI 10.1107/S0021889887012755; BOURBONNAIS R, 1990, FEBS LETT, V267, P99, DOI 10.1016/0014-5793(90)80298-W; Call H-P, 1994, Patent (International), Patent No. [WO 94/29510, 9429510]; COLL PM, 1993, APPL ENVIRON MICROB, V59, P2607, DOI 10.1128/AEM.59.8.2607-2613.1993; Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310; EVANS CS, 1985, FEMS MICROBIOL LETT, V27, P339, DOI 10.1111/j.1574-6968.1985.tb00693.x; FAHRAEUS G, 1967, ACTA CHEM SCAND, V21, P2367, DOI 10.3891/acta.chem.scand.21-2367; FARVER O, 1993, BIOCHEMISTRY-US, V32, P7317, DOI 10.1021/bi00079a031; FEE JA, 1968, BIOCHIM BIOPHYS ACTA, V153, P299, DOI 10.1016/0005-2728(68)90175-8; GELLERSTEDT G, 1989, WOOD SCI TECHNOL, V23, P75, DOI 10.1007/BF00350609; Hough MA, 2001, ACTA CRYSTALLOGR D, V57, P355, DOI 10.1107/S0907444900010156; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li KC, 1999, APPL ENVIRON MICROB, V65, P2654; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Machonkin TE, 2001, J AM CHEM SOC, V123, P5507, DOI 10.1021/ja003975s; MALMSTRO.BG, 1970, BIOCHIM BIOPHYS ACTA, V205, P48, DOI 10.1016/0005-2728(70)90060-5; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MESSERSCHMIDT A, 1992, EUR J BIOCHEM, V209, P597, DOI 10.1111/j.1432-1033.1992.tb17325.x; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; Messerschmidt A., 1997, MULTICOPPER OXIDASES; NAKAMURA T, 1968, J BIOCHEM-TOKYO, V64, P267, DOI 10.1093/oxfordjournals.jbchem.a128890; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ong E, 1997, GENE, V196, P113, DOI 10.1016/S0378-1119(97)00215-1; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PETERSEN LC, 1978, BIOCHIM BIOPHYS ACTA, V526, P85, DOI 10.1016/0005-2744(78)90292-9; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SAKURAI T, 1992, BIOCHEM J, V284, P681, DOI 10.1042/bj2840681; Sealey J, 1998, ENZYME MICROB TECH, V23, P422, DOI 10.1016/S0141-0229(98)00056-8; Xu F, 1996, BIOCHEMISTRY-US, V35, P7608, DOI 10.1021/bi952971a; Xu F, 1996, BBA-PROTEIN STRUCT M, V1292, P303, DOI 10.1016/0167-4838(95)00210-3; Xu F, 2000, APPL ENVIRON MICROB, V66, P2052, DOI 10.1128/AEM.66.5.2052-2056.2000; Xu F, 1998, BIOCHEM J, V334, P63, DOI 10.1042/bj3340063; Xu F, 1999, J BIOL CHEM, V274, P12372, DOI 10.1074/jbc.274.18.12372; Yoshida H., 1883, J AM CHEM SOC, V43, P472, DOI [10.1039/CT8834300472, DOI 10.1039/CT8834300472]; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	42	670	698	8	167	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37663	37669		10.1074/jbc.M204571200	http://dx.doi.org/10.1074/jbc.M204571200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12163489	hybrid			2022-12-27	WOS:000178447100097
J	Brengues, M; Pintard, L; Lapeyre, B				Brengues, M; Pintard, L; Lapeyre, B			mRNA decay is rapidly induced after spore germination of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DEGRADATION; BUDDING YEAST; CELL-CYCLE; BINDING-PROTEIN; MAMMALIAN-CELLS; GENE; TURNOVER; IDENTIFICATION; DEADENYLATION; SPORULATION	Spores from the yeast Saccharomyces cerevisiae can germinate and resume their vegetative growth when placed in favorable conditions. Biochemical studies on germination have been limited by the difficulty of obtaining a pure population of spores germinating synchronously. Here, we report that spores can be purified and sorted according to their size by centrifugal elutriation and that these spores are able to germinate synchronously. Synchronizing their development has allowed reevaluating certain parameters of germination, and we demonstrate that both transcription and translation are induced very rapidly after germination induction. Spores contain mRNAs that are stable for several months in spores kept at 4 degreesC. Germination induction leads to very rapid degradation of these mRNAs, thus providing a simple model to study induction of mRNA decay in eukaryotes. mRNAs from the spore are polyadenylated, capped, and cosediment on sucrose gradients with ribosomes and polysomes and with components of the mRNA degradation machinery. The presence of polysomes in the spores led us to evaluate the activity of the translation apparatus in these cells. We present evidence that there is ongoing transcription and translation in nongerminating yeast spores incubated in water at 30 degreesC, suggesting that these activities could play a role in spore long term survival.	CNRS, Ctr Rech Biochim Macromol, F-34293 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Lapeyre, B (corresponding author), CRBM, 1919 Route Mende, F-34293 Montpellier 5, France.		pintard, lionel/AAD-8356-2020; PINTARD, Lionel/AAP-7361-2020; PINTARD, Lionel/H-3756-2018	PINTARD, Lionel/0000-0003-0286-4630; PINTARD, Lionel/0000-0003-0286-4630				ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; BAKER BS, 1976, ANNU REV GENET, V10, P53, DOI 10.1146/annurev.ge.10.120176.000413; BEELMAN CA, 1994, J BIOL CHEM, V269, P9687; BOCHNIG P, 1987, EUR J BIOCHEM, V168, P461, DOI 10.1111/j.1432-1033.1987.tb13439.x; Boeck R, 1998, MOL CELL BIOL, V18, P5062, DOI 10.1128/MCB.18.9.5062; Bonnerot C, 2000, MOL CELL BIOL, V20, P5939, DOI 10.1128/MCB.20.16.5939-5946.2000; Bouveret E, 2000, EMBO J, V19, P1661, DOI 10.1093/emboj/19.7.1661; Chen JJ, 2002, EMBO J, V21, P1414, DOI 10.1093/emboj/21.6.1414; CHOIH SJ, 1977, J BACTERIOL, V131, P63, DOI 10.1128/JB.131.1.63-68.1977; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628; CROSS FR, 1991, CELL, V65, P875, DOI 10.1016/0092-8674(91)90394-E; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; DWORKIN MB, 1985, P NATL ACAD SCI USA, V82, P7636, DOI 10.1073/pnas.82.22.7636; ELLIOTT SG, 1978, P NATL ACAD SCI USA, V75, P4384, DOI 10.1073/pnas.75.9.4384; ESPOSITO RE, 1981, MOL BIOL YEAST SACCH, V2, P211; FELICI F, 1989, MOL CELL BIOL, V9, P3260, DOI 10.1128/MCB.9.8.3260; Gallego C, 1997, EMBO J, V16, P7196, DOI 10.1093/emboj/16.23.7196; Guthrie C, 1991, METHODS ENZYMOL, V194; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARPER JF, 1980, J BACTERIOL, V143, P958, DOI 10.1128/JB.143.2.958-965.1980; HARTWELL LH, 1970, MOL GEN GENET, V106, P347, DOI 10.1007/BF00324052; HASHIMOTO T, 1958, J BACTERIOL, V76, P406, DOI 10.1128/JB.76.4.406-416.1958; Herman PK, 1997, EMBO J, V16, P6171, DOI 10.1093/emboj/16.20.6171; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HEYER WD, 1995, MOL CELL BIOL, V15, P2728; HUTCHISON HT, 1969, J BACTERIOL, V99, P807, DOI 10.1128/JB.99.3.807-814.1969; Johnston LH, 1997, METHOD ENZYMOL, V283, P342; KREGERVANRIJ NJW, 1978, ARCH MICROBIOL, V117, P73, DOI 10.1007/BF00689354; KUPIEC M, 1997, MOL CELLULAR BIOL YE, V2, P889; LAW DTS, 1988, MOL CELL BIOL, V8, P912, DOI 10.1128/MCB.8.2.912; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; MUHLRAD D, 1995, MOL CELL BIOL, V15, P2145; NAGASHIMA TERUYA, 1959, ECOL REV, V15, P75; PERRY RP, 1990, ENZYME, V44, P83, DOI 10.1159/000468749; Pintard L, 2000, MOL CELL BIOL, V20, P1370, DOI 10.1128/MCB.20.4.1370-1381.2000; Primig M, 2000, NAT GENET, V26, P415, DOI 10.1038/82539; ROUSSEAU P, 1972, J BACTERIOL, V109, P1232, DOI 10.1128/JB.109.3.1232-1238.1972; ROUSSEAU P, 1973, CAN J MICROBIOL, V19, P1311, DOI 10.1139/m73-210; ROUSSEAU P, 1973, CAN J MICROBIOL, V19, P547, DOI 10.1139/m73-091; ROUSSEAU P, 1973, J BACTERIOL, V113, P1289, DOI 10.1128/JB.113.3.1289-1295.1973; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; STEELE SD, 1974, CAN J MICROBIOL, V20, P929, DOI 10.1139/m74-142; SURDEJ P, 1994, ANNU REV GENET, V28, P263; SUROSKY RT, 1992, MOL CELL BIOL, V12, P3948, DOI 10.1128/MCB.12.9.3948; TRON T, 1995, J BIOL CHEM, V270, P9961, DOI 10.1074/jbc.270.17.9961; Tucker M, 2000, ANNU REV BIOCHEM, V69, P571, DOI 10.1146/annurev.biochem.69.1.571; Tucker M, 2002, EMBO J, V21, P1427, DOI 10.1093/emboj/21.6.1427; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; XU G, 1992, EXPERIENTIA, V48, P786, DOI 10.1007/BF02124304	53	25	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40505	40512		10.1074/jbc.M206700200	http://dx.doi.org/10.1074/jbc.M206700200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12181322	hybrid			2022-12-27	WOS:000178791400046
J	Kojic, ZAB; Terness, P				Kojic, ZAB; Terness, P			A novel human erythrocyte glycosylphosphatidylinositol (GPI)-anchored glycoprotein ACA - Isolation, purification, primary structure determination, and molecular parameters of its lipid structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; TRYPANOSOMA-BRUCEI; MEMBRANE ANCHOR; BIOSYNTHESIS; PROTEIN; ACETYLCHOLINESTERASE; SENSITIVITY; PHOSPHATIDYLINOSITOLS; PALMITOYLATION; RESISTANCE	A method has been elaborated to isolate and purify up to homogeneity a novel membrane glycoprotein containing a glycosyl-phosphatidylinositol (GPI) anchor by means of salting out with ammonium sulfate (40-80% saturation), followed by preparative SDS-PAGE, chromatography and acetone precipitation. The preparation obtained was homogeneous upon electrophoresis in the presence of 0.1% SDS after reduction with 2-mercaptoethanol. It is protein-soluble at its isoelectrical point (pH 5.5) with molecular mass of 65,000 daltons. The isolated protein is linked to the membrane via glycosylphosphatidylinositol susceptible to cleavage by purified phospholipase C. The hydrophobic portion of the glycolipid membrane anchor of the protein was radiolabeled with the photoactivated reagent 3-(trifluoromethyl)-3-(m-[I-125]iodophenyl)diazirine and hydrolyzed with glycosyl-phosphatidylinositol-specific phospholipase C, followed by enzymatic deacetylation of the remaining lipid. Thin-layer chromatography showed that the generated radiolabeled fragment migrates with the same mobility as that of variant surface glycoprotein (VSG), obtained in the same manner. In this study we describe a novel erythrocyte membrane GPI-linked protein with the structural feature of an anchor that, in contrast to other GPI-linked erythrocyte proteins, has a non-acetylated inositol ring and diacylglycerol rather than alkylacyl glycerol as a lipid tail of the anchor.	Univ Heidelberg, Inst Immunol, Dept Transplantat Immunol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Kojic, ZAB (corresponding author), Univ Heidelberg, Inst Immunol, Dept Transplantat Immunol, Neuenheimer Feld 305, D-69120 Heidelberg, Germany.							BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen R, 1998, P NATL ACAD SCI USA, V95, P9512, DOI 10.1073/pnas.95.16.9512; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; DODGE JT, 1963, ARCH BIOCHEM BIOPHYS, V100, P119, DOI 10.1016/0003-9861(63)90042-0; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; FERGUSON MAJ, 1992, BIOCHEM J, V284, P297, DOI 10.1042/bj2840297; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; FUKOMI K, 1992, J BIOL CHEM, V264, P10988; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MOOLENAAR WH, 1986, NATURE, V323, P171, DOI 10.1038/323171a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Nosjean O, 1997, BBA-REV BIOMEMBRANES, V1331, P153, DOI 10.1016/S0304-4157(97)00005-1; RATNOFF WD, 1992, CLIN EXP IMMUNOL, V87, P415; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROBERTS WL, 1986, BIOCHEMISTRY-US, V25, P3091, DOI 10.1021/bi00359a004; Rudd PM, 1997, J BIOL CHEM, V272, P7229, DOI 10.1074/jbc.272.11.7229; SAHR KE, 1990, J BIOL CHEM, V265, P4434; Singh N, 1996, J BIOL CHEM, V271, P12879, DOI 10.1074/jbc.271.22.12879; TOUTANT JP, 1990, EUR J BIOCHEM, V187, P31, DOI 10.1111/j.1432-1033.1990.tb15274.x; WALTER EI, 1990, J IMMUNOL, V144, P1030; WIELAND OH, 1984, METHOD ENZYMAT AN, V1, P504	25	7	10	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40472	40478		10.1074/jbc.M202416200	http://dx.doi.org/10.1074/jbc.M202416200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12167612	hybrid			2022-12-27	WOS:000178791400042
J	Lei, S; Liapakis, G; Xu, R; Guarnieri, F; Ballesteros, JA; Javitch, JA				Lei, S; Liapakis, G; Xu, R; Guarnieri, F; Ballesteros, JA; Javitch, JA			beta(2) adrenergic receptor activation - Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; ALPHA-HELICES; BETA(2)-ADRENERGIC RECEPTOR; CONSTITUTIVE ACTIVATION; STRUCTURAL INSTABILITY; CONFORMATIONAL-CHANGES; RHODOPSIN; SIDE; MECHANISMS; SEGMENT-6	In many rhodopsin-like G-protein-coupled receptors, agonist binding to a cluster of aromatic residues in TM6 may promote receptor activation by altering the configuration of the TM6 Pro-kink and by the subsequent movement of the cytoplasmic end of TM6 away from TM3. We hypothesized that the highly conserved Cys(6.47), in the vicinity of the conserved Pro(6.50), modulates the configuration of the aromatic cluster and the TM6 Pro-kink through specific interactions in its different rotamer configurations. In the beta2 adrenergic receptor, mutation Of Cys(6.47) to Thr, which in an alpha-helix has a different rotamer distribution from Cys and Ser, produced a constitutively active receptor, whereas the Ser mutant was similar to wild-type receptor. Use of the biased Monte Carlo technique of Conformational Memories showed that the rotamer changes among Cys/Ser/Thr(6.47), Trp(6.48), and Phe(6.52) are highly correlated, representing a rotamer "toggle switch" that may modulate the TM6 Pro-kink. Differential modulation of the accessibility Of Cys(6.47) and an engineered Cys(6.52) in wild type and a constitutively active background provides experimental support for the association of this rotamer switch with receptor activation.	Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Sarnoff Corp, Princeton, NJ 08543 USA; Novasite Pharmaceut Inc, San Diego, CA 92121 USA; Univ Crete, Sch Med, Dept Pharmacol, Iraklion 71110, Greece	Columbia University; Columbia University; Columbia University; Sarnoff Corporation; University of Crete	Javitch, JA (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Mol Recognit, 630 W 168th St, New York, NY 10032 USA.		Shi, Lei/AAV-1321-2020; Xu, Rui/I-8098-2012	Shi, Lei/0000-0002-4137-096X; 	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH054137] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 54137, MH 57324] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alewijnse AE, 2000, MOL PHARMACOL, V57, P890; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Ballesteros JA, 2000, BIOPHYS J, V79, P2754, DOI 10.1016/S0006-3495(00)76514-3; BALLESTEROS JA, 1992, BIOPHYS J, V62, P107, DOI 10.1016/S0006-3495(92)81794-0; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; CHABRE M, 1979, PHOTOCHEM PHOTOBIOL, V30, P295, DOI 10.1111/j.1751-1097.1979.tb07150.x; COHEN GB, 1993, BIOCHEMISTRY-US, V32, P6111, DOI 10.1021/bi00074a024; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; GRAY TM, 1984, J MOL BIOL, V175, P75, DOI 10.1016/0022-2836(84)90446-7; GUARNIERI F, 1995, J COMPUT CHEM, V16, P648, DOI 10.1002/jcc.540160512; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; Jayasinghe S, 2001, PROTEIN SCI, V10, P455, DOI 10.1110/ps.43501; Jensen AD, 2001, J BIOL CHEM, V276, P9279, DOI 10.1074/jbc.M004871200; Liapakis G, 2000, J BIOL CHEM, V275, P37779, DOI 10.1074/jbc.M002092200; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; Lovell SC, 2000, PROTEINS, V40, P389, DOI 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Rasmussen SGF, 1999, MOL PHARMACOL, V56, P175, DOI 10.1124/mol.56.1.175; RATH P, 1994, BIOPHYS J, V66, P2085, DOI 10.1016/S0006-3495(94)81003-3; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; Scheer A, 1996, EMBO J, V15, P3566, DOI 10.1002/j.1460-2075.1996.tb00726.x; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; Singh J., 1992, ATLAS PROTEIN SIDE C; STAEHELIN M, 1983, J BIOL CHEM, V258, P3496; Stapley BJ, 1997, J MOL BIOL, V272, P456, DOI 10.1006/jmbi.1997.1250; Visiers I, 2000, PROTEIN ENG, V13, P603, DOI 10.1093/protein/13.9.603; Visiers I, 2002, METHOD ENZYMOL, V343, P329; Word JM, 1999, J MOL BIOL, V285, P1711, DOI 10.1006/jmbi.1998.2400; Zauhar RJ, 2000, BIOPOLYMERS, V53, P233, DOI 10.1002/(SICI)1097-0282(200003)53:3<233::AID-BIP3>3.3.CO;2-W	39	62	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40989	40996		10.1074/jbc.M206801200	http://dx.doi.org/10.1074/jbc.M206801200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12167654	hybrid			2022-12-27	WOS:000178791400107
J	Poirier, MA; Li, HL; Macosko, J; Cai, SW; Amzel, M; Ross, CA				Poirier, MA; Li, HL; Macosko, J; Cai, SW; Amzel, M; Ross, CA			Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; IN-VITRO; PALLIDOLUYSIAN ATROPHY; DISEASE; AGGREGATION; OLIGOMERS; INHIBITION; ANTIBODIES; MECHANISM; REPEATS	The pathology of Huntington's disease is characterized by neuronal degeneration and inclusions containing N-terminal fragments of mutant huntingtin (htt). To study htt aggregation, we examined purified htt fragments in vitro, finding globular and protofibrillar intermediates participating in the genesis of mature fibrils. These intermediates were high in beta-structure. Furthermore, Congo Red, a dye that stains amyloid fibrils, prevented the assembly of mutant htt into mature fibrils, but not the formation of protofibrils. Other proteins capable of forming ordered aggregates, such as amyloid beta and alpha-synuclein, form similar intermediates, suggesting that the mechanisms of mutant htt aggregation and possibly htt toxicity may overlap with other neurodegenerative disorders.	Johns Hopkins Univ, Sch Med, Dept Psychiat, Div Neurobiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biochem & Biophys, Baltimore, MD 21205 USA; Lawrence Berkeley Natl Lab, Donner Lab, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Massachusetts, Dept Chem, N Dartmouth, MA 02747 USA	Johns Hopkins University; Johns Hopkins University; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of Massachusetts System; University Massachusetts Dartmouth	Ross, CA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat, Div Neurobiol, 615 Ross Res Bldg,720 Rutland Ave, Baltimore, MD 21205 USA.	caross@jhu.edu	Ross, Christopher A/H-8395-2013	Li, Huilin/0000-0001-8085-8928; Amzel, L. Mario/0000-0002-0129-9572	NIGMS NIH HHS [GM 40633] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschuler EL, 1997, J PEPT RES, V50, P73; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Fu FN, 1998, BIOCHEMISTRY-US, V37, P5267, DOI 10.1021/bi9723966; Gusella JF, 2000, NAT REV NEUROSCI, V1, P109, DOI 10.1038/35039051; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; HARIS P, 2000, INFRARED ANAL PEPTID; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Heiser V, 2000, P NATL ACAD SCI USA, V97, P6739, DOI 10.1073/pnas.110138997; Kazantsev A, 2002, NAT GENET, V30, P367, DOI 10.1038/ng864; Khoshnan A, 2002, P NATL ACAD SCI USA, V99, P1002, DOI 10.1073/pnas.022631799; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Kuemmerle S, 1999, ANN NEUROL, V46, P842; Masino L, 2002, FEBS LETT, V513, P267, DOI 10.1016/S0014-5793(02)02335-9; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; Paulson HL, 2000, BRAIN PATHOL, V10, P293, DOI 10.1111/j.1750-3639.2000.tb00263.x; Peters MF, 2001, J BIOL CHEM, V276, P3188, DOI 10.1074/jbc.M008099200; Peters MF, 1999, NEUROSCI LETT, V275, P129, DOI 10.1016/S0304-3940(99)00758-2; Rivetti C, 1999, EMBO J, V18, P4464, DOI 10.1093/emboj/18.16.4464; Rochet JC, 2000, BIOCHEMISTRY-US, V39, P10619, DOI 10.1021/bi001315u; Ross CA, 1997, MEDICINE, V76, P305, DOI 10.1097/00005792-199709000-00001; Rubinsztein DC, 1996, AM J HUM GENET, V59, P16; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Sisodia SS, 1998, CELL, V95, P1, DOI 10.1016/S0092-8674(00)81743-2; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	35	294	302	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41032	41037		10.1074/jbc.M205809200	http://dx.doi.org/10.1074/jbc.M205809200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171927	hybrid			2022-12-27	WOS:000178791400112
J	Wong, MD; Lin, YF; Rosen, BP				Wong, MD; Lin, YF; Rosen, BP			The soft metal ion binding sites in the Staphylococcus aureus pI258 CadC Cd(II)/Pb(II)/Zn(II)-responsive repressor are formed between subunits of the homdimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CADMIUM RESISTANCE; PLASMID PI258; METALLOREGULATORY PROTEINS; SMTB; IDENTIFICATION; DNA; COMPLEX; QUANTITIES; SEQUENCE; ATPASE	The Staphylococcus aureus plasmid pI258 CadC is a homodimeric repressor that binds Cd(II), Pb(II), and Zn(II) and regulates expression of the cadAC operon. CadC binds two Cd(II) ions per dimer, with a tetrathiolate binding site composed of residues Cys(7), Cys(11), Cys(58), and Cys(60). It is not known whether each site consists of residues from a single monomer or from residues contributed by both subunits. To examine whether Cys(7) and Cys(11) are spatially proximate to Cys(58) and Cys(60) of the same subunit or of the other subunit, homodimers with the same cysteine mutation in each subunit and heterodimers containing different cysteine mutations in the two subunits were reacted with 4,6-bis(bromomethyl)-3,7-dimethyl-1,5-diazabicyclo[3.3.0]octa-3,6- diene-2,8-dione, which cross-links thiol groups that are within 3-6 Angstrom of each other. Cys(7) or Cys(11) cross-linked only with Cys(58) or Cys(60) on the other subunit. The data demonstrate that Cys(7) and Cys" from one monomer are within 3-6 A of either Cys(51) or Cys(60) in the other monomer. The results of this study strongly indicate that each of the two Cd(II) binding sites in the CadC homodimer is composed of Cys(7) and Cys(11) from one monomer and Cys(58) and Cys(60) from the other monomer.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Rosen, BP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.		Lin, Yung-Feng/H-3289-2019	Rosen, Barry P./0000-0002-5230-4271	NIAID NIH HHS [AI 45428] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Archer M, 1999, PROTEIN SCI, V8, P1536, DOI 10.1110/ps.8.7.1536; Bhattacharjee H, 1996, J BIOL CHEM, V271, P24465, DOI 10.1074/jbc.271.40.24465; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Busenlehner LS, 2002, J MOL BIOL, V319, P685, DOI 10.1016/S0022-2836(02)00299-1; Busenlehner LS, 2002, J BIOL INORG CHEM, V7, P551, DOI 10.1007/s00775-001-0336-9; Busenlehner LS, 2001, BIOCHEMISTRY-US, V40, P4426, DOI 10.1021/bi010006g; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Cook WJ, 1998, J MOL BIOL, V275, P337, DOI 10.1006/jmbi.1997.1443; DELAGRAVE S, 1995, BIO-TECHNOL, V13, P151, DOI 10.1038/nbt0295-151; ENDO G, 1995, J BACTERIOL, V177, P4437, DOI 10.1128/jb.177.15.4437-4441.1995; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HELMANN JD, 1990, SCIENCE, V247, P946, DOI 10.1126/science.2305262; Kar SR, 2001, BIOCHEMISTRY-US, V40, P13378, DOI 10.1021/bi011289f; KOSOWER NS, 1980, BIOCHIM BIOPHYS ACTA, V622, P201, DOI 10.1016/0005-2795(80)90031-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li S, 2002, J BIOL CHEM, V277, P25992, DOI 10.1074/jbc.M201619200; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORBY AP, 1993, NUCLEIC ACIDS RES, V21, P921, DOI 10.1093/nar/21.4.921; MORNET D, 1985, P NATL ACAD SCI USA, V82, P1658, DOI 10.1073/pnas.82.6.1658; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; POOLE RK, 1989, J GEN MICROBIOL, V135, P1865; RAO CP, 1986, INORG CHEM, V25, P428, DOI 10.1021/ic00224a011; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sambrook J., 2002, MOL CLONING LAB MANU; SANFRANCISCO MJD, 1990, NUCLEIC ACIDS RES, V18, P619; Shi WP, 1996, J BIOL CHEM, V271, P9291, DOI 10.1074/jbc.271.16.9291; SHI WP, 1994, J BIOL CHEM, V269, P19826; Sun Y, 2002, MOL MICROBIOL, V44, P1323, DOI 10.1046/j.1365-2958.2002.02961.x; Sun Y, 2001, J BIOL CHEM, V276, P14955, DOI 10.1074/jbc.M010595200; Thelwell C, 1998, P NATL ACAD SCI USA, V95, P10728, DOI 10.1073/pnas.95.18.10728; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TSAI KJ, 1992, J BACTERIOL, V174, P116, DOI 10.1128/jb.174.1.116-121.1992; TSAI KJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P267, DOI 10.1006/abbi.1993.1421; Turner JS, 1996, NUCLEIC ACIDS RES, V24, P3714, DOI 10.1093/nar/24.19.3714; VanZile ML, 2000, BIOCHEMISTRY-US, V39, P11818, DOI 10.1021/bi001140o; Xu C, 1999, METALS AND GENETICS, P5	37	19	22	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40930	40936		10.1074/jbc.M206536200	http://dx.doi.org/10.1074/jbc.M206536200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12176999	hybrid			2022-12-27	WOS:000178791400099
J	Chelli, M; Alizon, M				Chelli, M; Alizon, M			Rescue of HIV-1 receptor function through cooperation between different forms of the CCR5 chemokine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; PROTEIN-COUPLED RECEPTORS; MEMBRANE-FUSION; INFLUENZA HEMAGGLUTININ; EXTRACELLULAR DOMAINS; ENVELOPE GLYCOPROTEIN; CORECEPTOR FUNCTION; GP120; INFECTION; CXCR4	Interaction of the human immunodeficiency virus (HIV-1) envelope glycoproteins with the CCR5 chemokine receptor, a G-protein-coupled receptor, triggers a membrane fusion process and virus entry. Cooperation for HIV-1 receptor activity was observed when two forms of CCR5 were coexpressed, either the wild-type (WT) receptor and a defective mutant with deletion of the amino-terminal (NT) extracellular domain or the latter DeltaNT mutant and a human-mouse CCR5 chimera bearing the NT domain from human CCR5. Cooperation was most efficient when the two forms of CCR5 were in a 1:1 ratio. It was not observed between the CCR5 DeltaNT mutant and a chimeric receptor (5444) in which the NT domain of CCR5 was in the context of another G-protein-coupled receptor, the HIV-1 receptor CXCR4. These results suggested that physical association between two forms of CCR5 was required for their cooperation. Coimmunoprecipitation experiments in transfected cell lysates indeed showed that the DeltaNT CCR5 mutant formed oligomeric complexes with the WT CCR5 or the HMMM chimera but not with the CXCR4-derived chimera 5444. These observations suggest that the formation of CCR5 oligomers is a constitutive process independent from activation by chemokine ligands. The interaction of HIV-1 with independent subunits of CCR5 oligomers could favor the local recruitment of fusiogenic proteins and the formation of a fusion pore.	Univ Paris 05, CNRS, UMR 8404,Dept Cell Biol, INSERM,U567,Inst Cochin, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Alizon, M (corresponding author), Univ Paris 05, CNRS, UMR 8404,Dept Cell Biol, INSERM,U567,Inst Cochin, F-75014 Paris, France.		Chelli, Mario/L-7389-2015	Chelli, Mario/0000-0003-2939-6961				Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Baik SSW, 1999, VIROLOGY, V259, P267, DOI 10.1006/viro.1999.9779; Bandres JC, 1998, J VIROL, V72, P2500, DOI 10.1128/JVI.72.3.2500-2504.1998; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Bentz J, 2000, BIOPHYS J, V78, P227, DOI 10.1016/S0006-3495(00)76587-8; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Berson JF, 1998, SEMIN IMMUNOL, V10, P237, DOI 10.1006/smim.1998.0130; Bieniasz PD, 1997, EMBO J, V16, P2599, DOI 10.1093/emboj/16.10.2599; Blanpain C, 2002, MOL BIOL CELL, V13, P723, DOI 10.1091/mbc.01-03-0129; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Brelot A, 2001, AIDS, V15, pS3, DOI 10.1097/00002030-200100005-00002; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; CANN AJ, 1992, J VIROL, V66, P305, DOI 10.1128/JVI.66.1.305-309.1992; Chelli M, 2001, J BIOL CHEM, V276, P46975, DOI 10.1074/jbc.M106432200; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; CLAVEL F, 1994, J VIROL, V68, P1179, DOI 10.1128/JVI.68.2.1179-1185.1994; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; Doms RW, 2001, AIDS, V15, pS34, DOI 10.1097/00002030-200102001-00051; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8; Hoffman T L, 1998, AIDS, V12 Suppl A, pS17; Hoffman TL, 1999, P NATL ACAD SCI USA, V96, P6359, DOI 10.1073/pnas.96.11.6359; ISSAFRAS H, 2002, IN PRESS J BIOL CHEM; Kuhmann SE, 2000, J VIROL, V74, P7005, DOI 10.1128/JVI.74.15.7005-7015.2000; Lapham CK, 1996, SCIENCE, V274, P602, DOI 10.1126/science.274.5287.602; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; Liao ZH, 2001, AIDS RES HUM RETROV, V17, P1009, DOI 10.1089/088922201300343690; Loetscher P, 2000, Adv Immunol, V74, P127; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Milligan G, 2001, J CELL SCI, V114, P1265; Mirzabekov T, 1999, J BIOL CHEM, V274, P28745, DOI 10.1074/jbc.274.40.28745; Monck JR, 1996, CURR OPIN CELL BIOL, V8, P524, DOI 10.1016/S0955-0674(96)80031-7; Moore JP, 2000, NAT REV MOL CELL BIO, V1, P40, DOI 10.1038/35036060; Murphy PM, 2000, PHARMACOL REV, V52, P145; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Picard L, 1997, J VIROL, V71, P5003, DOI 10.1128/JVI.71.7.5003-5011.1997; Platt EJ, 1998, J VIROL, V72, P2855, DOI 10.1128/JVI.72.4.2855-2864.1998; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; Poignard P, 2001, ANNU REV IMMUNOL, V19, P253, DOI 10.1146/annurev.immunol.19.1.253; Pontow S, 2001, J VIROL, V75, P11503, DOI 10.1128/JVI.75.23.11503-11514.2001; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Salzwedel K, 2000, P NATL ACAD SCI USA, V97, P12794, DOI 10.1073/pnas.230438497; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; Simmons G, 2000, IMMUNOL REV, V177, P112, DOI 10.1034/j.1600-065X.2000.17719.x; Singer II, 2001, J VIROL, V75, P3779, DOI 10.1128/JVI.75.8.3779-3790.2001; Trkola A, 1999, J VIROL, V73, P8966, DOI 10.1128/JVI.73.11.8966-8974.1999; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; Tsuji Y, 2000, J BIOL CHEM, V275, P28144; Ugolini S, 1997, J IMMUNOL, V159, P3000; Venkatesan S, 2002, J BIOL CHEM, V277, P2287, DOI 10.1074/jbc.M108321200; Vicente-Manzanares M, 1998, EUR J IMMUNOL, V28, P2197, DOI 10.1002/(SICI)1521-4141(199807)28:07<2197::AID-IMMU2197>3.0.CO;2-F; Vila-Coro AJ, 2000, P NATL ACAD SCI USA, V97, P3388, DOI 10.1073/pnas.050457797; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; WESTERVELT P, 1991, P NATL ACAD SCI USA, V88, P3097, DOI 10.1073/pnas.88.8.3097; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Xiao XD, 1999, P NATL ACAD SCI USA, V96, P7496, DOI 10.1073/pnas.96.13.7496; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	64	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39388	39396		10.1074/jbc.M205394200	http://dx.doi.org/10.1074/jbc.M205394200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12154092	hybrid			2022-12-27	WOS:000178662500043
J	Pan, JL; Hinzmann, B; Yan, W; Wu, FY; Morser, J; Wu, QY				Pan, JL; Hinzmann, B; Yan, W; Wu, FY; Morser, J; Wu, QY			Genomic structures of the human and murine corin genes and functional GATA elements in their promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATRIAL-NATRIURETIC-FACTOR; HOLT-ORAM-SYNDROME; SERINE-PROTEASE; TRANSCRIPTION FACTOR; PRESSURE-OVERLOAD; CARDIAC TRANSCRIPTION; TRANSMEMBRANE DOMAIN; SEQUENCE SIMILARITY; PEPTIDE GENE; EXPRESSION	Corin is a multiple-domain type II transmembrane serine protease highly expressed in the heart. It converts pro-atrial natriuretic peptide to atrial natriuretic peptide, a cardiac hormone that regulates blood volume and pressure. Here we describe the genomic structures of the human and murine corin genes and functional analysis of their promoters. Both corin genes contain 22 exons and span >200 kb. Their intron/exon boundaries are well conserved, with most exons encoding distinct structural domains, supporting the idea that corin evolved as a result of exon duplication and rearrangement. Comparison of the 5'-flanking regions of the human and murine corin genes revealed several conserved sequences, including binding sites for TBX5, GATA, NKX2.5, and Kruppel-like transcription factors. Transfection experiments with reporter gene constructs driven by the human or murine corin 5'-flanking region indicated that the sequences from -405 to -15 in human and from -646 to -77 in mouse are sufficient to promote high levels of gene expression in murine cardiomyocytes. In contrast, these sequences produced only minimal levels of expression in HeLa cells. Within these sequences, we identified a conserved GATA element that bound to GATA-4. Mutation of the core sequence impaired both GATA-4 binding and gene expression. These data indicate that the GATA element and its binding to GATA-4 are essential for cardiac expression of the human and murine corin genes.	Berlex Biosci, Dept Cardiovasc Res, Richmond, CA 94806 USA; metaGen Pharmaceut, D-13347 Berlin, Germany		Pan, JL (corresponding author), Berlex Biosci, Dept Cardiovasc Res, 2600 Hilltop Dr, Richmond, CA 94806 USA.			Wu, Qingyu/0000-0003-0561-9315				APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; Bhavsar PK, 2000, J MOL CELL CARDIOL, V32, P95, DOI 10.1006/jmcc.1999.1058; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bonfield JK, 1995, NUCLEIC ACIDS RES, V23, P4992, DOI 10.1093/nar/23.24.4992; BRENNER BM, 1990, PHYSIOL REV, V70, P665, DOI 10.1152/physrev.1990.70.3.665; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Charron F, 1999, SEMIN CELL DEV BIOL, V10, P85, DOI 10.1006/scdb.1998.0281; CHEN CY, 1995, J BIOL CHEM, V270, P15628, DOI 10.1074/jbc.270.26.15628; DEBOLD AJ, 1981, LIFE SCI, V28, P89, DOI 10.1016/0024-3205(81)90370-2; DOOLITTLE RF, 1995, ANNU REV BIOCHEM, V64, P287, DOI 10.1146/annurev.bi.64.070195.001443; Durocher D, 1998, DEV GENET, V22, P250, DOI 10.1002/(SICI)1520-6408(1998)22:3<250::AID-DVG7>3.0.CO;2-5; Ghosh TK, 2001, HUM MOL GENET, V10, P1983, DOI 10.1093/hmg/10.18.1983; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Hauschka SD, 2001, MOL CELL, V8, P1, DOI 10.1016/S1097-2765(01)00297-0; Hautala N, 2001, CIRCULATION, V103, P730; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; Hiroi Y, 2001, NAT GENET, V28, P276, DOI 10.1038/90123; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; INAGAMI T, 1989, J BIOL CHEM, V264, P3043; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; Kawamura S, 1999, EUR J BIOCHEM, V262, P755, DOI 10.1046/j.1432-1327.1999.00431.x; Kim DR, 2001, BBA-GENE STRUCT EXPR, V1518, P204, DOI 10.1016/S0167-4781(01)00184-1; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; KOOP BF, 1994, NAT GENET, V7, P48, DOI 10.1038/ng0594-48; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; Liang PQ, 1997, J BIOL CHEM, V272, P28050, DOI 10.1074/jbc.272.44.28050; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Marttila M, 2001, ENDOCRINOLOGY, V142, P4693, DOI 10.1210/en.142.11.4693; McBride K, 2001, CAN J PHYSIOL PHARM, V79, P673, DOI 10.1139/cjpp-79-8-673; Molkentin JD, 2000, J BIOL CHEM, V275, P38949, DOI 10.1074/jbc.R000029200; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; PAN JL, 1993, J BIOL CHEM, V268, P22600; PaoloniGiacobino A, 1997, GENOMICS, V44, P309, DOI 10.1006/geno.1997.4845; REDONDO JM, 1990, SCIENCE, V247, P1225, DOI 10.1126/science.2156339; ROSENZWEIG A, 1991, ANNU REV BIOCHEM, V60, P229, DOI 10.1146/annurev.biochem.60.1.229; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Scott HS, 2001, NAT GENET, V27, P59, DOI 10.1038/83768; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Shimoyama M, 1999, CIRCULATION, V100, P2449, DOI 10.1161/01.CIR.100.24.2449; Stein B, 1998, AM HEART J, V135, P914, DOI 10.1016/S0002-8703(98)70054-7; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; TREISMAN R, 1992, TRENDS BIOCHEM SCI, V17, P423, DOI 10.1016/0968-0004(92)90013-Y; Wallrapp C, 2000, CANCER RES, V60, P2602; Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4; Wilkins MR, 1997, LANCET, V349, P1307, DOI 10.1016/S0140-6736(96)07424-7; Wu F, 2002, J BIOL CHEM, V277, P16900, DOI 10.1074/jbc.M201503200; WU JP, 1989, J BIOL CHEM, V264, P6472; Yamaoka K, 1998, J BIOL CHEM, V273, P11895, DOI 10.1074/jbc.273.19.11895; Yan W, 1999, J BIOL CHEM, V274, P14926, DOI 10.1074/jbc.274.21.14926; Yan W, 2000, P NATL ACAD SCI USA, V97, P8525, DOI 10.1073/pnas.150149097	53	55	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38390	38398		10.1074/jbc.M205686200	http://dx.doi.org/10.1074/jbc.M205686200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12154094	hybrid			2022-12-27	WOS:000178529600052
J	Waarts, BL; Bittman, R; Wilschut, J				Waarts, BL; Bittman, R; Wilschut, J			Sphingolipid and cholesterol dependence of alphavirus membrane fusion - Lack of correlation with lipid raft formation in target liposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMLIKI-FOREST-VIRUS; GPI-ANCHORED PROTEINS; CLASS-I MOLECULES; MODEL MEMBRANES; ENVELOPE GLYCOPROTEIN; LOW-PH; CELL-MEMBRANES; DOMAINS RAFTS; SINDBIS VIRUS; TRITON X-100	Semliki Forest virus (SFV) and Sindbis virus (SIN) are enveloped viruses that infect their host cells by receptor-mediated endocytosis and subsequent fusion from within acidic endosomes. Fusion of the viral envelope requires the presence of both cholesterol and sphingolipids in the target membrane. This is suggestive of a possible involvement of sphingolipid-cholesterol microdomains, or "lipid rafts," in the membrane fusion and cell entry process of the virus. In this study, large unilamellar vesicles (LUVs) were prepared from synthetic sphingolipids and sterols that vary with respect to their capacity to promote microdomain formation, as assessed by gradient flotation analysis in the presence of Triton X-100. SFV and SIN fused with LUVs irrespective of the presence or absence of Triton X-100-insoluble microdomains. These results suggest that SFV and SIN do not require the presence of lipid rafts for fusion with target membranes. Furthermore, it is not necessary for sphingolipids to reside in a detergent-insoluble complex with cholesterol to promote SFV or SIN fusion.	Univ Groningen, Dept Med Microbiol, Mol Virol Sect, NL-9713 AV Groningen, Netherlands; Acad Hosp, Dept Med Microbiol, Mol Virol Sect, NL-9713 AV Groningen, Netherlands; CUNY Queens Coll, Dept Chem & Biochem, Flushing, NY 11367 USA	University of Groningen; University of Groningen; City University of New York (CUNY) System; Queens College NY (CUNY)	Wilschut, J (corresponding author), Univ Groningen, Dept Med Microbiol, Mol Virol Sect, Ant Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	j.c.wilschut@med.rug.nl			NHLBI NIH HHS [HL-16660] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016660, R37HL016660] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmed SN, 1997, BIOCHEMISTRY-US, V36, P10944, DOI 10.1021/bi971167g; Ahn A, 2002, J VIROL, V76, P3267, DOI 10.1128/JVI.76.7.3267-3275.2002; Alfsen A, 2001, J IMMUNOL, V166, P6257, DOI 10.4049/jimmunol.166.10.6257; Bavari S, 2002, J EXP MED, V195, P593, DOI 10.1084/jem.20011500; Benting J, 1999, FEBS LETT, V462, P47, DOI 10.1016/S0014-5793(99)01501-X; Bittman R, 2000, J LIPID RES, V41, P2089; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOETTCHER C, 1961, ANAL CHIM ACTA, V24, P203, DOI 10.1016/0003-2670(61)80041-X; BRON R, 1993, EMBO J, V12, P693, DOI 10.1002/j.1460-2075.1993.tb05703.x; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown RE, 1998, J CELL SCI, V111, P1; Campbell SM, 2001, J CLIN VIROL, V22, P217, DOI 10.1016/S1386-6532(01)00193-7; Chatterjee S, 2001, EMBO J, V20, P1583, DOI 10.1093/emboj/20.7.1583; CHIA NC, 1993, J AM CHEM SOC, V115, P12050, DOI 10.1021/ja00078a049; CORVER J, 1995, J VIROL, V69, P3220, DOI 10.1128/JVI.69.5.3220-3223.1995; Dietrich C, 2001, BIOPHYS J, V80, P1417, DOI 10.1016/S0006-3495(01)76114-0; GAROFF H, 1994, ARCH VIROL, P329; Hammache D, 1999, J VIROL, V73, P5244, DOI 10.1128/JVI.73.6.5244-5248.1999; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HELENIUS A, 1980, J CELL BIOL, V84, P404, DOI 10.1083/jcb.84.2.404; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; Hug P, 2000, J VIROL, V74, P6377, DOI 10.1128/JVI.74.14.6377-6385.2000; Kielian M, 2000, Subcell Biochem, V34, P409; KIELIAN M, 1985, J CELL BIOL, V101, P2284, DOI 10.1083/jcb.101.6.2284; KIELIAN M, 1995, ADV VIRUS RES, V45, P113, DOI 10.1016/S0065-3527(08)60059-7; KIELIAN MC, 1984, J VIROL, V52, P281, DOI 10.1128/JVI.52.1.281-283.1984; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Lescar J, 2001, CELL, V105, P137, DOI 10.1016/S0092-8674(01)00303-8; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; Lu YE, 2000, J VIROL, V74, P7708, DOI 10.1128/JVI.74.17.7708-7719.2000; Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025; MARSH M, 1980, J MOL BIOL, V142, P439, DOI 10.1016/0022-2836(80)90281-8; MARSH M, 1983, CELL, V32, P931, DOI 10.1016/0092-8674(83)90078-8; MAYER LD, 1985, BIOCHIM BIOPHYS ACTA, V817, P193, DOI 10.1016/0005-2736(85)90084-7; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; MCINTOSH TJ, 1992, BIOCHEMISTRY-US, V31, P2012, DOI 10.1021/bi00122a017; MOESBY L, 1995, BIOCHEMISTRY-US, V34, P10319, DOI 10.1021/bi00033a001; Mukherjee S, 2000, TRAFFIC, V1, P203, DOI 10.1034/j.1600-0854.2000.010302.x; NIEVA JL, 1994, EMBO J, V13, P2797, DOI 10.1002/j.1460-2075.1994.tb06573.x; Norkin LC, 1999, IMMUNOL REV, V168, P13, DOI 10.1111/j.1600-065X.1999.tb01279.x; OMAR A, 1988, VIROLOGY, V166, P17, DOI 10.1016/0042-6822(88)90141-9; Parton RG, 1999, IMMUNOL REV, V168, P23, DOI 10.1111/j.1600-065X.1999.tb01280.x; Patra SK, 1999, J LIPOSOME RES, V9, P247, DOI 10.3109/08982109909024788; PHALEN T, 1991, J CELL BIOL, V112, P615, DOI 10.1083/jcb.112.4.615; Pletnev SV, 2001, CELL, V105, P127, DOI 10.1016/S0092-8674(01)00302-6; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Ramstedt B, 1999, BIOPHYS J, V76, P908, DOI 10.1016/S0006-3495(99)77254-1; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; Rinia HA, 2001, FEBS LETT, V501, P92, DOI 10.1016/S0014-5793(01)02636-9; Samsonov AV, 2001, BIOPHYS J, V81, P1486, DOI 10.1016/S0006-3495(01)75803-1; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SMABY JM, 1994, BIOCHEMISTRY-US, V33, P9135, DOI 10.1021/bi00197a016; Smit JM, 1999, J VIROL, V73, P8476, DOI 10.1128/JVI.73.10.8476-8484.1999; Smit JM, 2001, FEBS LETT, V498, P57, DOI 10.1016/S0014-5793(01)02495-4; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; WAHLBERG JM, 1992, J VIROL, V66, P7309, DOI 10.1128/JVI.66.12.7309-7318.1992; WHITE J, 1980, P NATL ACAD SCI-BIOL, V77, P3273, DOI 10.1073/pnas.77.6.3273; WILSCHUT J, 1995, MOL MEMBR BIOL, V12, P143, DOI 10.3109/09687689509038510; Xu XL, 2001, J BIOL CHEM, V276, P33540, DOI 10.1074/jbc.M104776200; Xu XL, 2000, BIOCHEMISTRY-US, V39, P843, DOI 10.1021/bi992543v	64	72	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38141	38147		10.1074/jbc.M206998200	http://dx.doi.org/10.1074/jbc.M206998200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12138173	hybrid			2022-12-27	WOS:000178529600023
J	Col, E; Gilquin, B; Caron, C; Khochbin, S				Col, E; Gilquin, B; Caron, C; Khochbin, S			Tat-controlled protein acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE-ACETYLTRANSFERASE ACTIVITY; HIV-1 TAT; STIMULATES TRANSCRIPTION; ONCOPROTEIN E1A; P300; TRANSACTIVATOR; BINDING; INTERACTS; CBP; ACTIVATION	Human immunodeficiency virus, type 1-encoded transactivator protein Tat is known to be a substrate of and to interact with several nuclear histone acetyltransferases (HATs). Here we show that Tat is a general inhibitor of histone acetylation by cellular HATs and that for at least one of them, the CREB-binding protein (CBP), it induces a substrate selectivity. Indeed, in the presence of Tat, the acetylation of histones by CBP was severely inhibited, while that of p53 and MyoD remained unaffected. The C-terminal domain of Tat, dispensable for the activation of viral transcription, was found to be necessary and sufficient to interfere with histone acetylation. These results demonstrate that Tat is able to selectively modulate cellular protein acetylation by nuclear HATs and therefore to take over this specific signaling system in cells.	Fac Med, Lab Biol Mol & Cellulaire Differenciat, INSERM,U309,Equipe Chromatine & Express Genes, Inst Albert Bonniot, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Caron, C (corresponding author), Fac Med, Lab Biol Mol & Cellulaire Differenciat, INSERM,U309,Equipe Chromatine & Express Genes, Inst Albert Bonniot, F-38706 La Tronche, France.		Khochbin, Saadi/M-8090-2013; GILQUIN, Benoit/A-6234-2014	Khochbin, Saadi/0000-0002-0455-0857; GILQUIN, benoit/0000-0001-8138-7021				Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Col E, 2001, J BIOL CHEM, V276, P28179, DOI 10.1074/jbc.M101385200; Cotter MA, 2000, MOL CELL BIOL, V20, P5722, DOI 10.1128/MCB.20.15.5722-5735.2000; Creaven M, 1999, BIOCHEMISTRY-US, V38, P8826, DOI 10.1021/bi9907274; Deng LW, 2000, VIROLOGY, V277, P278, DOI 10.1006/viro.2000.0593; Dorr A, 2002, EMBO J, V21, P2715, DOI 10.1093/emboj/21.11.2715; Furia B, 2002, J BIOL CHEM, V277, P4973, DOI 10.1074/jbc.M107848200; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Kiernan RE, 1999, EMBO J, V18, P6106, DOI 10.1093/emboj/18.21.6106; Li M, 2000, MOL CELL BIOL, V20, P8254, DOI 10.1128/MCB.20.21.8254-8263.2000; Li Q, 1999, EMBO J, V18, P5634, DOI 10.1093/emboj/18.20.5634; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Marzio G, 1998, P NATL ACAD SCI USA, V95, P13519, DOI 10.1073/pnas.95.23.13519; Mujtaba S, 2002, MOL CELL, V9, P575, DOI 10.1016/S1097-2765(02)00483-5; Nakatani Y, 2002, STRUCTURE, V10, P443, DOI 10.1016/S0969-2126(02)00754-2; Ott M, 1999, CURR BIOL, V9, P1489, DOI 10.1016/S0960-9822(00)80120-7; Perissi V, 1999, P NATL ACAD SCI USA, V96, P3652, DOI 10.1073/pnas.96.7.3652; Polesskaya A, 2001, MOL CELL BIOL, V21, P5312, DOI 10.1128/MCB.21.16.5312-5320.2001; Ren XD, 2001, J VIROL, V75, P8251, DOI 10.1128/JVI.75.17.8251-8258.2001; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X; Weissman JD, 1998, P NATL ACAD SCI USA, V95, P11601, DOI 10.1073/pnas.95.20.11601; Weissman JD, 2001, BBA-PROTEIN STRUCT M, V1546, P156, DOI 10.1016/S0167-4838(01)00135-2	29	19	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37955	37960		10.1074/jbc.M206694200	http://dx.doi.org/10.1074/jbc.M206694200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12154097	hybrid			2022-12-27	WOS:000178447100133
J	Ohashi, S; Koike, K; Omori, A; Ichinose, S; Ohara, S; Kobayashi, S; Sato, TA; Anzai, K				Ohashi, S; Koike, K; Omori, A; Ichinose, S; Ohara, S; Kobayashi, S; Sato, TA; Anzai, K			Identification of mRNA/protein (mRNP) complexes containing Pur alpha, mStaufen, Fragile X Protein, and myosin Va and their association with rough endoplasmic reticulum equipped with a kinesin motor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; MENTAL-RETARDATION PROTEIN; SINGLE-STRANDED-DNA; CULTURED HIPPOCAMPAL-NEURONS; LONG-TERM POTENTIATION; ACTIN-BASED TRANSPORT; MESSENGER-RNA; BC1 RNA; RIBONUCLEOPROTEIN PARTICLE; INHIBITS TRANSLATION	Puralpha, which is involved in diverse aspects of cellular functions, is strongly expressed in neuronal cytoplasm. Previously, we have reported that this protein controls BC1 RNA expression and its subsequent distribution within dendrites and that Puralpha is associated with polyribosomes. Here, we report that, following treatment with EDTA, Puralpha was released from polyribosomes in mRNA/protein complexes (mRNPs), which also contained mStaufen, Fragile X Mental Retardation Protein (FMRP), myosin Va, and other proteins with unknown functions. As the coimmunoprecipitation of these proteins by an anti-Puralpha antibody was abolished by RNase treatment, Puralpha may assist mRNP assembly in an RNA-dependent manner and be involved in targeting mRNPs to polyribosomes in cooperation with other RNA-binding proteins. The immunoprecipitation of mStaufen- and FMRP-containing mRNPs provided additional evidence that the anti-Puralpha detected structurally or functionally related mRNA subsets, which are distributed in the somatodendritic compartment. Furthermore, mRNPs appear to reside on rough endoplasmic reticulum equipped with a kinesin motor. Based on our present findings, we propose that this rough endoplasmic reticulum structure may form the molecular machinery that mediates and regulates multistep transport of polyribosomes along microtubules and actin filaments, as well as localized translation in the somatodendritic compartment.	Nihon Univ, Div Biochem, Coll Pharm, Chiba 2748555, Japan; Mitsubishi Kasei Inst Life Sci, Tokyo 1948511, Japan; Kitasato Univ, Dept Biochem, Sch Med, Kanagawa 2288555, Japan; Columbia Univ, Dept Otolaryngol Pathol, New York, NY 10032 USA	Nihon University; Kitasato University; Columbia University	Anzai, K (corresponding author), Nihon Univ, Div Biochem, Coll Pharm, Chiba 2748555, Japan.							ASHLEY CT, 1993, NAT GENET, V4, P244, DOI 10.1038/ng0793-244; Bohl F, 2000, EMBO J, V19, P5514, DOI 10.1093/emboj/19.20.5514; Brown V, 2001, CELL, V107, P477, DOI 10.1016/S0092-8674(01)00568-2; Ceman S, 1999, MOL CELL BIOL, V19, P7925; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; Deshler JO, 1997, SCIENCE, V276, P1128, DOI 10.1126/science.276.5315.1128; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; DESMOND NL, 1990, SYNAPSE, V5, P139, DOI 10.1002/syn.890050208; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; Eberhart DE, 1996, HUM MOL GENET, V5, P1083, DOI 10.1093/hmg/5.8.1083; Evans LL, 1998, J CELL SCI, V111, P2055; Feng Y, 1997, J NEUROSCI, V17, P1539; Feng Y, 1997, MOL CELL, V1, P109, DOI 10.1016/S1097-2765(00)80012-X; FERREIRA A, 1992, J CELL BIOL, V117, P595, DOI 10.1083/jcb.117.3.595; FIFKOVA E, 1992, INT REV CYTOL, V139, P267, DOI 10.1016/S0074-7696(08)61414-X; Gallia GL, 2001, J CELL BIOCHEM, V83, P355, DOI 10.1002/jcb.1247; Gallia GL, 2000, NUCLEIC ACIDS RES, V28, P3197, DOI 10.1093/nar/28.17.3197; GAO FB, 1994, P NATL ACAD SCI USA, V91, P11207, DOI 10.1073/pnas.91.23.11207; HARDY SJS, 1969, BIOCHEMISTRY-US, V8, P2897, DOI 10.1021/bi00835a031; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Kanai Y, 2000, J NEUROSCI, V20, P6374, DOI 10.1523/JNEUROSCI.20-17-06374.2000; Keene JD, 2001, P NATL ACAD SCI USA, V98, P7018, DOI 10.1073/pnas.111145598; Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5; Kiebler MA, 1999, J NEUROSCI, V19, P288, DOI 10.1523/JNEUROSCI.19-01-00288.1999; Kobayashi S, 2000, BIOCHEM BIOPH RES CO, V277, P341, DOI 10.1006/bbrc.2000.3683; KOBAYASHI S, 1991, J BIOL CHEM, V266, P4726; Kohrmann M, 1999, MOL BIOL CELL, V10, P2945, DOI 10.1091/mbc.10.9.2945; Krichevsky AM, 2001, NEURON, V32, P683, DOI 10.1016/S0896-6273(01)00508-6; Laggerbauer B, 2001, HUM MOL GENET, V10, P329, DOI 10.1093/hmg/10.4.329; Latham VM, 2001, CURR BIOL, V11, P1010, DOI 10.1016/S0960-9822(01)00291-3; Li YM, 2001, BIOL PHARM BULL, V24, P231, DOI 10.1248/bpb.24.231; Li ZZ, 2001, NUCLEIC ACIDS RES, V29, P2276, DOI 10.1093/nar/29.11.2276; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Marion RM, 1999, MOL CELL BIOL, V19, P2212; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; Muramatsu T, 1998, BIOCHEM BIOPH RES CO, V247, P7, DOI 10.1006/bbrc.1998.8657; Muslimov IA, 1997, J NEUROSCI, V17, P4722; Nadano D, 2000, JPN J CANCER RES, V91, P802, DOI 10.1111/j.1349-7006.2000.tb01017.x; Ohashi S, 2000, J NEUROCHEM, V75, P1781, DOI 10.1046/j.1471-4159.2000.0751781.x; PFISTER KK, 1989, J CELL BIOL, V108, P1453, DOI 10.1083/jcb.108.4.1453; PHILLIPS CL, 1995, J MUSCLE RES CELL M, V16, P379, DOI 10.1007/BF00114503; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; Severt WL, 1999, J CELL SCI, V112, P3691; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; Siomi MC, 1996, MOL CELL BIOL, V16, P3825; Steward O, 2001, P NATL ACAD SCI USA, V98, P7062, DOI 10.1073/pnas.131146398; Steward O, 2001, ANNU REV NEUROSCI, V24, P299, DOI 10.1146/annurev.neuro.24.1.299; STEWARD O, 1982, J NEUROSCI, V2, P284; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Tang SJ, 2001, NEURON, V32, P463, DOI 10.1016/S0896-6273(01)00493-7; Walikonis RS, 2000, J NEUROSCI, V20, P4069; Weiler IJ, 1997, P NATL ACAD SCI USA, V94, P5395, DOI 10.1073/pnas.94.10.5395; Wickham L, 1999, MOL CELL BIOL, V19, P2220; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z	54	184	194	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37804	37810		10.1074/jbc.M203608200	http://dx.doi.org/10.1074/jbc.M203608200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147688	hybrid			2022-12-27	WOS:000178447100115
J	Villalonga, P; Lopez-Alcala, C; Chiloeches, A; Gil, J; Marais, R; Bachs, O; Agell, N				Villalonga, P; Lopez-Alcala, C; Chiloeches, A; Gil, J; Marais, R; Bachs, O; Agell, N			Calmodulin prevents activation of Ras by PKC in 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; CELL-CYCLE; BINDING; PHOSPHORYLATION; PATHWAYS; CLEAVAGE; CALCIUM; GAP	We have shown previously (Villalonga, P., Lopez-Alcala, C., Bosch, M., Chiloeches, A., Rocamora, N., Gil, J., Marais, R., Marshall, C. J., Bachs, 0., and Agell, N. (2001) Mol. Cell. Biol. 21,7345-7354) that calmodulin negatively regulates Ras activation in fibroblasts. Hence, anti-calmodulin drugs (such as W13, trifluoroperazine, or W7) are able to induce Ras/ERK pathway activation under low levels of growth factors. We show here that cell treatment with protein kinase C (PKC) inhibitors abolishes W13-induced activation of Ras, Raf-1, and ERK. Consequently, PKC activity is essential for achieving the synergism between calmodulin inhibition and growth factors to activate Ras. Furthermore, whereas the activation of PKC by 12-O-tetradecanoylphorbol-13-acetate (TPA) does not induce Ras activation in 3T3 cells, activation is observed if calmodulin is simultaneously inhibited. This indicates that calmodulin is preventing Ras activation by PKC. Treatment of cells with epidermal growth factor receptor or platelet-derived growth factor receptor tyrosine kinase inhibitors does not abrogate the activation of Ras by calmodulin inhibition. This implies that epidermal growth factor receptor and platelet-derived growth factor receptor tyrosine kinase activities are dispensable for the activation of Ras by TPA plus W13, and, therefore, Ras activation is not a consequence of the transactivation of those receptors by the combination of the anti-calmodulin drug plus TPA. Furthermore, K-Ras, the isoform previously shown to bind to calmodulin, is the only one activated by TPA when calmodulin is inhibited. These data suggest that direct interaction between K-Ras and calmodulin may account for the inability of PKC to activate Ras in 3T3 fibroblasts. In vitro experiments showed that the phosphorylation of K-Ras by PKC was inhibited by calmodulin, suggesting that calmodulin-dependent modulation of K-Ras phosphorylation by PKC could be the mechanism underlying K-Ras activation in fibroblasts treated with TPA plus W13.	Univ Barcelona, Fac Med, Dept Biol Cellular & Anat Patol, Inst Invest Biomed August Pi & Sunyer, Barcelona 08036, Spain; Inst Canc Res, Canc Res Campaign, Ctr Cell & Mol Biol, London SW3 6JB, England; Univ Barcelona, Dept Ciencias Fisiol 2, Barcelona 08907, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Barcelona	Agell, N (corresponding author), Univ Barcelona, Fac Med, Dept Cellular Biol, C Casanova 143, Barcelona 08036, Spain.	agell@medicina.ub.es	Agell, Neus/E-9640-2016; Chiloeches, Antonio/Z-5993-2019; Villalonga, Priam/K-4350-2014	Agell, Neus/0000-0002-1205-6074; Villalonga, Priam/0000-0002-7190-6884; Marais, Richard/0000-0001-7484-4183; Antonio, Chiloeches Galvez/0000-0001-7162-330X; Gil, Joan/0000-0002-3686-3903				Agell N, 1998, CELL CALCIUM, V23, P115, DOI 10.1016/S0143-4160(98)90109-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; BACHS O, 1994, CELL CALCIUM, V16, P289, DOI 10.1016/0143-4160(94)90092-2; BALLESTER R, 1987, J BIOL CHEM, V262, P2688; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Bosch M, 1998, J BIOL CHEM, V273, P22145, DOI 10.1074/jbc.273.34.22145; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; Chen NY, 2001, J BIOL CHEM, V276, P46722, DOI 10.1074/jbc.M107156200; Choudhury S, 1996, CANCER LETT, V109, P149, DOI 10.1016/S0304-3835(96)04439-4; Cleghon V, 1996, GENE DEV, V10, P566, DOI 10.1101/gad.10.5.566; Coffer PJ, 1998, BIOCHEM J, V335, P1; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Diaz-Rodriguez E, 2000, BIOCHEM J, V346, P359, DOI 10.1042/0264-6021:3460359; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; Downward J, 1992, CURR OPIN GENET DEV, V2, P13, DOI 10.1016/S0959-437X(05)80315-6; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; El-Shemerly MYM, 1997, J BIOL CHEM, V272, P30599, DOI 10.1074/jbc.272.49.30599; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Genot E, 2000, CURR OPIN IMMUNOL, V12, P289, DOI 10.1016/S0952-7915(00)00089-3; HERGET T, 1994, EUR J BIOCHEM, V225, P549, DOI 10.1111/j.1432-1033.1994.t01-1-00549.x; Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; NAKAFUKU M, 1992, J BIOL CHEM, V267, P19448; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; Olson MF, 2000, SEMIN IMMUNOL, V12, P63, DOI 10.1006/smim.2000.0208; PANDIELLA A, 1992, J BIOL CHEM, V267, P24028; Rebollo A, 1999, BLOOD, V94, P2971, DOI 10.1182/blood.V94.9.2971.421k43_2971_2980; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Roovers K, 2000, BIOESSAYS, V22, P818, DOI 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.3.CO;2-Y; SANJOSE E, 1992, J BIOL CHEM, V267, P15237; Schlondorff J, 1999, J CELL SCI, V112, P3603; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; Schubert C, 1996, J BIOL CHEM, V271, P15311, DOI 10.1074/jbc.271.26.15311; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; Villalonga P, 2001, MOL CELL BIOL, V21, P7345, DOI 10.1128/MCB.21.21.7345-7354.2001	51	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37929	37935		10.1074/jbc.M202245200	http://dx.doi.org/10.1074/jbc.M202245200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151388	Green Published, hybrid			2022-12-27	WOS:000178447100130
J	Fuda, H; Lee, YC; Shimizu, C; Javitt, NB; Strott, CA				Fuda, H; Lee, YC; Shimizu, C; Javitt, NB; Strott, CA			Mutational analysis of human hydroxysteroid sulfotransferase SULT2B1 isoforms reveals that exon 1B of the SULT2B1 gene produces cholesterol sulfotransferase, whereas exon 1A yields pregnenolone sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; HUMAN LIVER; SULFATE; NEUROSTEROIDS; DIFFERENTIATION; TRANSCRIPTION; EXPRESSION; CLONING	As a result of an alternative exon 1, the gene for human hydroxysteroid sulfotransferase (SULTB1) encodes for two peptides differing only at their amino termini. The SULT2B1b isoform preferentially sulfonates cholesterol. Conversely, the SULT2B1a isoform avidly sulfonates pregnenolone but not cholesterol. The outstanding structural feature that distinguishes the SULT2B1 isoforms from the prototypical SLTLT2A1 isozyme is the presence of extended amino- and carboxyl-terminal ends in the former. Investigating the functional significance of this unique characteristic reveals that removal of 53 amino acids from the relatively long carboxyl-terminal end that is common to both SULT2B1 isoforms has no effect on the catalytic activity of either isoform. On the other hand, removal of 23 amino acids from the amino-terminal end that is unique to SULT2B1b results in loss of cholesterol sulfotransferase activity, whereas removal of 8 amino acids from the amino-terminal end that is unique to SULT2B1a has no effect on pregnenolone sulfotransferase activity. Deletion analysis along with site-directed mutagenesis of SLTLT2B1b reveal that the amino acid segment 19-23 residues from the amino terminus and particularly isoleucines at positions 21 and 23 are crucial for cholesterol catalysis. In the gene for SULT2B1, exon 1B encodes for only the unique amino-terminal region of SULT2B1b; however, exon 1A encodes for the unique amino-terminal end of SULT2B1a plus an additional 48 amino acids. Thus, if the gene for SULT2B1 employs exon 1B, cholesterol sulfotransferase is synthesized, whereas if exon 1A is used, pregnenolone sulfotransferase is produced.	NICHD, Sect Steroid Regulat, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Strott, CA (corresponding author), NICHD, Sect Steroid Regulat, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A36, Bethesda, MD 20892 USA.	chastro@mail.nih.gov		Javitt, Norman B/0000-0001-9265-3508	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000194] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AKSOY IA, 1993, DRUG METAB DISPOS, V21, P268; Alomary AA, 2001, INT REV NEUROBIOL, V46, P97; Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; Engel SR, 2001, INT REV NEUROBIOL, V46, P321; Falany CN, 1997, FASEB J, V11, P206, DOI 10.1096/fasebj.11.4.9068609; FALANY CN, 1994, J STEROID BIOCHEM, V48, P369, DOI 10.1016/0960-0760(94)90077-9; Fuda H, 2002, BIOCHEM J, V365, P497, DOI 10.1042/BJ20020044; Geese WJ, 2001, BIOCHEM BIOPH RES CO, V288, P280, DOI 10.1006/bbrc.2001.5746; Hanley K, 2001, J LIPID RES, V42, P390; Her C, 1998, GENOMICS, V53, P284, DOI 10.1006/geno.1998.5518; HER C, 1995, GENOMICS, V29, P16, DOI 10.1006/geno.1995.1210; Javitt NB, 2001, ENDOCRINOLOGY, V142, P2978, DOI 10.1210/en.142.7.2978; JETTEN AM, 1989, J INVEST DERMATOL, V92, P203, DOI 10.1111/1523-1747.ep12276731; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kawabe S, 1998, J INVEST DERMATOL, V111, P1098, DOI 10.1046/j.1523-1747.1998.00441.x; Kuroki T, 2000, MUTAT RES-REV MUTAT, V462, P189, DOI 10.1016/S1383-5742(00)00036-3; Meloche CA, 2001, J STEROID BIOCHEM, V77, P261, DOI 10.1016/S0960-0760(01)00064-4; Nagata K, 2000, ANNU REV PHARMACOL, V40, P159, DOI 10.1146/annurev.pharmtox.40.1.159; Pedersen LC, 2002, J BIOL CHEM, V277, P17928, DOI 10.1074/jbc.M111651200; Plassart-Schiess E, 2001, BRAIN RES REV, V37, P133, DOI 10.1016/S0165-0173(01)00113-8; RADOMINSKA A, 1990, BIOCHEM J, V272, P597, DOI 10.1042/bj2720597; Rikke BA, 1996, BBA-GENE STRUCT EXPR, V1307, P331, DOI 10.1016/0167-4781(96)00065-6; Sakakibara Y, 1998, BIOCHEM BIOPH RES CO, V247, P681, DOI 10.1006/bbrc.1998.8872; Weinshilboum RM, 1997, FASEB J, V11, P3, DOI 10.1096/fasebj.11.1.9034160; Yoshinari K, 2001, J BIOCHEM MOL TOXIC, V15, P67, DOI 10.1002/jbt.1	25	72	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36161	36166		10.1074/jbc.M207165200	http://dx.doi.org/10.1074/jbc.M207165200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145317	hybrid			2022-12-27	WOS:000178275100051
J	Hossain, S; Singh, S; Lue, NF				Hossain, S; Singh, S; Lue, NF			Functional analysis of the C-terminal extension of telomerase reverse transcriptase - A putative "Thumb" domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT GENE; TETRAHYMENA TELOMERASE; YEAST TELOMERASE; SACCHAROMYCES-CEREVISIAE; IN-VITRO; MAMMALIAN TELOMERASE; RNA-POLYMERASE; PROTEIN; PROCESSIVITY; COMPONENT	Telomerase is an RNA-protein complex responsible for the extension of one strand of telomere terminal repeats. The catalytic protein subunit of telomerase, known generically as telomerase reverse transcriptase (TERT), exhibits significant homology to reverse transcriptases (RTs) encoded by retroviruses and retroelements. The mechanisms of telomerase may therefore be similar to those of the conventional reverse transcriptases. In this report, we explore potential similarity between these two classes of proteins in a region with no evident sequence similarity. Previous analysis has implicated a C-terminal domain of retroviral RTs (known as the "thumb" domain) in template-primer binding and in processivity control. The equivalent region of TERTs, although similar to one another, does not exhibit significant sequence homology to retroviral RTs. However, we found that removal of this region of yeast TERT similarly resulted in a decrease in the stability of telomerase-DNA complex and in the processivity of telomerase-mediated nucleotide addition. Moreover, the C-terminal domain of TERT exhibits a nucleic acid binding activity when recombinantly expressed and purified. Finally, amino acid substitutions of conserved residues in this region of TERT were found to impair telomerase activity and processivity. We suggest that mechanistic similarity between telomerase and retroviral RTs may extend beyond the regions with apparent sequence similarity.	Cornell Univ, Weill Med Coll, William Randolph Hearst Microbiol Res Ctr, Dept Immunol & Microbiol, New York, NY 10021 USA	Cornell University	Lue, NF (corresponding author), Cornell Univ, Weill Med Coll, William Randolph Hearst Microbiol Res Ctr, Dept Immunol & Microbiol, New York, NY 10021 USA.		Lue, Neal/AAO-6759-2020	Lue, Neal/0000-0001-9700-6895; Singh, Sunitha/0000-0002-9418-9849				ARAI K, 2002, IN PRESS J BIOL CHEM; Bachand F, 2001, MOL CELL BIOL, V21, P1888, DOI 10.1128/MCB.21.5.1888-1897.2001; Beattie TL, 2000, MOL BIOL CELL, V11, P3329, DOI 10.1091/mbc.11.10.3329; Beattie TL, 1998, CURR BIOL, V8, P177, DOI 10.1016/S0960-9822(98)70067-3; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; Bosoy D, 2001, J BIOL CHEM, V276, P46305, DOI 10.1074/jbc.M108168200; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bryan TM, 2000, J BIOL CHEM, V275, P24199, DOI 10.1074/jbc.M003246200; Bryan TM, 1998, P NATL ACAD SCI USA, V95, P8479, DOI 10.1073/pnas.95.15.8479; Chen JL, 2000, CELL, V100, P503, DOI 10.1016/S0092-8674(00)80687-X; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Counter CM, 1997, P NATL ACAD SCI USA, V94, P9202, DOI 10.1073/pnas.94.17.9202; Fitzgerald MS, 1999, P NATL ACAD SCI USA, V96, P14813, DOI 10.1073/pnas.96.26.14813; Gandhi L, 1998, GENE DEV, V12, P721, DOI 10.1101/gad.12.5.721; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Haering CH, 2000, P NATL ACAD SCI USA, V97, P6367, DOI 10.1073/pnas.130187397; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; Lai CK, 2001, MOL CELL BIOL, V21, P990, DOI 10.1128/MCB.21.4.990-1000.2001; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lendvay TS, 1996, GENETICS, V144, P1399; Lingner J, 1996, P NATL ACAD SCI USA, V93, P10712, DOI 10.1073/pnas.93.20.10712; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Lue NF, 1998, NUCLEIC ACIDS RES, V26, P1495, DOI 10.1093/nar/26.6.1495; Lue NF, 1998, NUCLEIC ACIDS RES, V26, P1487, DOI 10.1093/nar/26.6.1487; LUE NF, 1987, P NATL ACAD SCI USA, V84, P8839, DOI 10.1073/pnas.84.24.8839; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Miller MC, 2000, EMBO J, V19, P4412, DOI 10.1093/emboj/19.16.4412; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nakayama JI, 1997, CELL, V88, P875, DOI 10.1016/S0092-8674(00)81933-9; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Oguchi K, 1999, FEBS LETT, V457, P465, DOI 10.1016/S0014-5793(99)01083-2; Peng Y, 2001, MOL CELL, V7, P1201, DOI 10.1016/S1097-2765(01)00268-4; Shu W, 1999, BIOCHEMISTRY-US, V38, P5378, DOI 10.1021/bi990199w; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; Tzfati Y, 2000, SCIENCE, V288, P863, DOI 10.1126/science.288.5467.863; VirtaPearlman V, 1996, GENE DEV, V10, P3094, DOI 10.1101/gad.10.24.3094; WEINRICH SL, 1997, NAT GENET, V17, P198; Xia JQ, 2000, MOL CELL BIOL, V20, P5196, DOI 10.1128/MCB.20.14.5196-5207.2000; Zhou JL, 2000, MOL CELL BIOL, V20, P1947, DOI 10.1128/MCB.20.6.1947-1955.2000	49	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36174	36180		10.1074/JBC.m201976200	http://dx.doi.org/10.1074/JBC.m201976200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12151386	hybrid			2022-12-27	WOS:000178275100053
J	Kawar, ZS; Van Die, I; Cummings, RD				Kawar, ZS; Van Die, I; Cummings, RD			Molecular cloning and enzymatic characterization of a UDP-GalNAc : GlcNAc beta-R beta 1,4-N-acetylgalactosaminyltransferase from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHINESE-HAMSTER OVARY; ASPARAGINE-LINKED OLIGOSACCHARIDES; BETA-4-GALACTOSYLTRANSFERASE GENE FAMILY; N-ACETYLGALACTOSAMINE-TRANSFERASE; SNAIL LYMNAEA-STAGNALIS; GOLGI VESICLE MEMBRANES; CIRCULATORY HALF-LIFE; SCHISTOSOMA-MANSONI; ALPHA-LACTALBUMIN; LUTROPIN OLIGOSACCHARIDES	A common terminal structure in glycans from animal glycoproteins and glycolipids is the lactosamine sequence Galbeta4GlcNAc-R (LacNAc or LN). An alternative sequence that occurs in vertebrate as well as in invertebrate glycoconjugates is GalNAcbeta4GlcNAc-R (LacdiNAc or LDN). Whereas genes encoding beta4GalTs responsible for LN synthesis have been reported, the beta4GalNAcT(s) responsible for LDN synthesis has not been identified. Here we report the identification of a gene from Caenorhabditis elegans encoding a UDP-GalNAc:GlcNAcbeta-R beta1,4-N-acetylgalactosaminyltransferase (Cebeta4GalNAcT) that synthesizes the LDN structure. Cebeta4GalNAcT is a member of the beta4GalT family, and its cDNA is predicted to encode a 383-amino acid type 2 membrane glycoprotein. A soluble, epitope-tagged recombinant form of Cebeta4GalNAcT expressed in CHO-Lec8 cells was active using UDP-GalNAc, but not UDPGal, as a donor toward a variety of acceptor substrates containing terminal beta-linked GlcNAc in both N- and O-glycan type structures. The LDN structure of the product was verified by co-chromatography with authentic standards and H-1 NMR spectroscopy. Moreover, Chinese hamster ovary CHO-Lec8 and CHO-Lec2 cells expressing Cebeta4GalNAcT acquired LDN determinants on endogenous glycoprotein N-glycans, demonstrating that the enzyme is active in mammalian cells as an authentic beta4GalNAcT. The identification and availability of this novel enzyme should enhance our understanding of the structure and function of LDN-containing glycoconjugates.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Vrije Univ Amsterdam Med Ctr, NL-1081 BT Amsterdam, Netherlands; Dept Mol Cell Biol, NL-1081 BT Amsterdam, Netherlands	University of Oklahoma System; University of Oklahoma Health Sciences Center; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Cummings, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma Ctr Med Glycobiol, 975 NE 10th St,BRC Rm 417, Oklahoma City, OK 73104 USA.	richard-cummings@ouhsc.edu			NICHD NIH HHS [R01 CH/HD54832-01] Funding Source: Medline	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Almeida R, 1997, J BIOL CHEM, V272, P31979, DOI 10.1074/jbc.272.51.31979; Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Angata T, 2002, J BIOL CHEM, V277, P24466, DOI 10.1074/jbc.M202833200; Asano M, 1997, EMBO J, V16, P1850, DOI 10.1093/emboj/16.8.1850; BAENZIGER JU, 1992, P NATL ACAD SCI USA, V89, P334, DOI 10.1073/pnas.89.1.334; Bakker H, 1997, J BIOL CHEM, V272, P18580, DOI 10.1074/jbc.272.30.18580; BAKKER H, 1994, J BIOL CHEM, V269, P30326; Bakker H, 1997, GLYCOBIOLOGY, V7, P539, DOI 10.1093/glycob/7.4.539; BERGWERFF AA, 1992, FEBS LETT, V314, P389, DOI 10.1016/0014-5793(92)81512-K; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BREW K, 1968, P NATL ACAD SCI USA, V59, P491, DOI 10.1073/pnas.59.2.491; Cho SK, 1997, J BIOL CHEM, V272, P13622, DOI 10.1074/jbc.272.21.13622; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; DELL A, 1995, J BIOL CHEM, V270, P24116, DOI 10.1074/jbc.270.41.24116; DEUTSCHER SL, 1986, J BIOL CHEM, V261, P96; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; Do KY, 1997, GLYCOBIOLOGY, V7, P183, DOI 10.1093/glycob/7.2.183; DO KY, 1995, J BIOL CHEM, V270, P18447, DOI 10.1074/jbc.270.31.18447; DO SI, 1992, J BIOCHEM BIOPH METH, V24, P153, DOI 10.1016/0165-022X(94)90068-X; Dodd RB, 2001, GLYCOBIOLOGY, V11, p71R, DOI 10.1093/glycob/11.5.71R; EASTON EW, 1992, FEBS LETT, V308, P46, DOI 10.1016/0014-5793(92)81047-P; Fiete D, 1997, P NATL ACAD SCI USA, V94, P11256, DOI 10.1073/pnas.94.21.11256; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; Figdor CG, 2002, NAT REV IMMUNOL, V2, P77, DOI 10.1038/nri723; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Grabenhorst E, 1998, J BIOL CHEM, V273, P30985, DOI 10.1074/jbc.273.47.30985; GREEN ED, 1985, P NATL ACAD SCI USA, V82, P7850, DOI 10.1073/pnas.82.23.7850; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; Guerardel Y, 2001, BIOCHEM J, V357, P167, DOI 10.1042/0264-6021:3570167; Guo S, 2001, GLYCOBIOLOGY, V11, P813, DOI 10.1093/glycob/11.10.813; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Ju TZ, 2002, J BIOL CHEM, V277, P169, DOI 10.1074/jbc.M109056200; KANG S, 1993, J PARASITOL, V79, P815, DOI 10.2307/3283717; Kotani N, 2001, BIOCHEM J, V357, P827, DOI 10.1042/0264-6021:3570827; Lee JH, 2001, J BIOL CHEM, V276, P13924, DOI 10.1074/jbc.M010046200; Leffler H, 2001, Results Probl Cell Differ, V33, P57; Li QX, 1997, DEV BIOL, V181, P257, DOI 10.1006/dbio.1996.8444; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; Manzella SM, 1996, J BIOL CHEM, V271, P12117, DOI 10.1074/jbc.271.21.12117; MANZELLA SM, 1995, J BIOL CHEM, V270, P21665, DOI 10.1074/jbc.270.37.21665; MENGELING BJ, 1995, P NATL ACAD SCI USA, V92, P502, DOI 10.1073/pnas.92.2.502; Morelle W, 2000, GLYCOBIOLOGY, V10, P941, DOI 10.1093/glycob/10.9.941; MULDER H, 1995, EUR J BIOCHEM, V227, P175, DOI 10.1111/j.1432-1033.1995.tb20374.x; Nagayama Y, 1998, J BIOL CHEM, V273, P33423, DOI 10.1074/jbc.273.50.33423; Nakamura N, 2001, J NEUROCHEM, V76, P29, DOI 10.1046/j.1471-4159.2001.00004.x; NEELEMAN AP, 1994, GLYCOBIOLOGY, V4, P641, DOI 10.1093/glycob/4.5.641; Neeleman AP, 1996, P NATL ACAD SCI USA, V93, P10111, DOI 10.1073/pnas.93.19.10111; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; Nomura T, 1998, J BIOL CHEM, V273, P13570, DOI 10.1074/jbc.273.22.13570; Nyame AK, 1999, GLYCOBIOLOGY, V9, P1029, DOI 10.1093/glycob/9.10.1029; Nyame AK, 2000, EXP PARASITOL, V96, P202, DOI 10.1006/expr.2000.4573; NYAME K, 1989, J BIOL CHEM, V264, P3235; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Opat AS, 2001, BIOCHIMIE, V83, P763, DOI 10.1016/S0300-9084(01)01312-8; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; POWELL JT, 1976, J BIOL CHEM, V251, P3645; POWELL JT, 1976, J BIOL CHEM, V251, P3653; Ramakrishnan B, 2002, J BIOL CHEM, V277, P20833, DOI 10.1074/jbc.M111183200; Ramakrishnan B, 2002, J MOL BIOL, V318, P491, DOI 10.1016/S0022-2836(02)00020-7; Ramakrishnan B, 2001, J MOL BIOL, V310, P205, DOI 10.1006/jmbi.2001.4757; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; Saarinen J, 1999, EUR J BIOCHEM, V259, P829, DOI 10.1046/j.1432-1327.1999.00105.x; SASAKI H, 1987, J BIOL CHEM, V262, P12059; Sato T, 1998, P NATL ACAD SCI USA, V95, P472, DOI 10.1073/pnas.95.2.472; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SMITH PL, 1993, J BIOL CHEM, V268, P795; SMITH PL, 1992, P NATL ACAD SCI USA, V89, P329, DOI 10.1073/pnas.89.1.329; SMITH PL, 1990, P NATL ACAD SCI USA, V87, P7275, DOI 10.1073/pnas.87.18.7275; SRIVATSAN J, 1994, J PARASITOL, V80, P884, DOI 10.2307/3283435; SRIVATSAN J, 1992, GLYCOBIOLOGY, V2, P445, DOI 10.1093/glycob/2.5.445; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; Van den Nieuwenhof IM, 1999, GLYCOBIOLOGY, V9, P115, DOI 10.1093/glycob/9.2.115; Van den Nieuwenhof IM, 2000, EUR J BIOCHEM, V267, P4753, DOI 10.1046/j.1432-1327.2000.01528.x; van Die I, 1999, FEBS LETT, V450, P52, DOI 10.1016/S0014-5793(99)00462-7; van Remoortere A, 2001, INFECT IMMUN, V69, P2396, DOI 10.1128/IAI.69.4.2396-2401.2001; VandenEijnden DH, 1997, BIOCHEM SOC T, V25, P887, DOI 10.1042/bst0250887; VanDie I, 1997, GLYCOBIOLOGY, V7, pR5; vanDie I, 1996, GLYCOBIOLOGY, V6, P157, DOI 10.1093/glycob/6.2.157; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Xia GQ, 2000, J BIOL CHEM, V275, P38402, DOI 10.1074/jbc.M007821200; YAN SB, 1993, GLYCOBIOLOGY, V3, P597, DOI 10.1093/glycob/3.6.597; Zhu GF, 1998, GLYCOBIOLOGY, V8, P831, DOI 10.1093/glycob/8.8.831	87	62	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34924	34932		10.1074/jbc.M206112200	http://dx.doi.org/10.1074/jbc.M206112200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12167666	hybrid			2022-12-27	WOS:000178117000036
J	Nishida, T; Yasuda, H				Nishida, T; Yasuda, H			PIAS1 and PIASx alpha function as SUMO-E3 ligases toward androgen receptor and repress androgen receptor-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; COVALENT MODIFICATION; GENE ACTIVATION; CONJUGATION; INHIBITOR; ENZYME; PML; P53; IDENTIFICATION; COREGULATOR	The androgen receptor (AR) has been shown to be modified by SUMO-1, a ubiquitin-like protein. Recently we showed that PIAS family proteins function as SUMO-E3 ligases. Here we provide evidence that PIAS1 and PIASxalpha act as specific SUMO-E3 ligases for the AR. PIAS1 and PIASxalpha but not PIAS3 or PIASxbeta enhanced the sumoylation of AR in intact cells and in vitro. PIAS1 and PIASxalpha bound Ubc9, the E2 enzyme for SUMO-1, in a RING finger-like domain-dependent manner. Consistent with previous studies (Kahyo, T., Nishida, T., and Yasuda, H. (2001) Mol. Cell 8, 713-718), the RING finger-like domain of the SUMO-E3 was required for ligase activity. The binding of a ligand, e.g. testosterone, to the AR was required for the sumoylation of AR in intact cells. Although AR-dependent transcription was enhanced by PIAS proteins without sumoylation of the receptor, PIAS1 and PIASxalpha repressed AR-dependent transcription in a manner dependent on the ectopic expression of SUMO-1 and their RING finger-like domain. Furthermore, the sumoylation sites of the AR were necessary for the full repressive effect on AR-dependent transactivation, indicating that the sumoylation of AR was crucial for the repression of transactivation of the AR. Thus, PIAS1 and PIASxalpha modulate the AR-dependent transactivation, which, at least in part, can be attributed to their SUMO-E3 activity toward AR.	Univ Tokyo, Dept Chem, Sch Sci, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Div Mol Biol, Hachioji, Tokyo 1920392, Japan	University of Tokyo; Tokyo University of Pharmacy & Life Sciences	Yasuda, H (corresponding author), Univ Tokyo, Dept Chem, Sch Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.							BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Duprez E, 1999, J CELL SCI, V112, P381; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Junicho A, 2000, BIOCHEM BIOPH RES CO, V278, P9, DOI 10.1006/bbrc.2000.3753; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kotaja N, 2002, MOL CELL BIOL, V22, P5222, DOI 10.1128/MCB.22.14.5222-5234.2002; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Poukka H, 1999, J BIOL CHEM, V274, P19441, DOI 10.1074/jbc.274.27.19441; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Tan JA, 2002, J BIOL CHEM, V277, P16993, DOI 10.1074/jbc.M109217200	39	173	176	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41311	41317		10.1074/jbc.M206741200	http://dx.doi.org/10.1074/jbc.M206741200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12177000	hybrid			2022-12-27	WOS:000178985300005
J	Noda, M; Yamashita, S; Takahashi, N; Eto, K; Shen, LM; Izumi, K; Daniel, S; Tsubamoto, Y; Nemoto, T; Iino, M; Kasai, H; Sharp, GWG; Kadowaki, T				Noda, M; Yamashita, S; Takahashi, N; Eto, K; Shen, LM; Izumi, K; Daniel, S; Tsubamoto, Y; Nemoto, T; Iino, M; Kasai, H; Sharp, GWG; Kadowaki, T			Switch to anaerobic glucose metabolism with NADH accumulation in the beta-cell model of mitochondrial diabetes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETION; LACTATE-DEHYDROGENASE; PANCREATIC-ISLETS; DNA; MELLITUS; LINE; PREVALENCE; DEAFNESS; RELEASE; GENE	To elucidate the mechanism underlying diabetes caused by mitochondrial gene mutations, we created a model by applying 0.4 mug/ml ethidium bromide (EtBr) to the murine pancreatic beta cell line betaHC9; in this model, transcription of mitochondrial DNA, but not that of nuclear DNA, was suppressed in association with impairment of glucose-stimulated insulin release (Hayakawa, T., Noda, M., Yasuda, K., Yorifuji, H., Taniguchi, S., Miwa, I., Sakura, H., Terauchi, Y., Hayashi, J.-L, Sharp, G. W. G., Kanazawa, Y., Akanuma, Y., Yazaki, Y., and Kadowaki, T. (1998) J. Biol Chem. 273,20300-20307). To elucidate fully the metabolism-secretion coupling in these cells, we measured glucose oxidation, utilization, and lactate production. We also evaluated NADH autofluorescence in betaHC9 cells using two-photon excitation laser microscopy. In addition, we recorded the membrane potential and determined the ATP and ADP contents of the cells. The results indicated 22.2 mm glucose oxidation to be severely decreased by EtBr treatment compared with control cells (by 63% on day 4 and by 78% on day 6; both p < 0.01). By contrast, glucose utilization was only marginally decreased. Lactate production under 22.2 mm glucose was increased by 2.9- and 3.5-fold by EtBr treatment on days 4 and 6, respectively (both p < 0.01). Cellular NADH at 2.8 mm glucose was increased by 35 and 43% by EtBr on days 4 and 6 (both p < 0.01). These data suggest that reduced expression of the mitochondrial electron transport system causes NADH accumulation in 13 cells, thereby halting the tricarboxylic acid cycle on one hand, and on the other hand facilitating anaerobic glucose metabolism. Glucose-induced insulin secretion was lost rapidly along with the EtBr treatment with concomitant losses of membrane potential depolarization and the [Ca2+](i) increase, whereas glibenclamide-induced changes persisted. This is the first report to demonstrate the connection between metabolic alteration of electron transport system and that of tricarboxylic acid cycle and its impact on insulin secretion.	Univ Tokyo, Grad Sch Med Sci, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; Japan Sci & Technol Corp, CREST, Bunkyo Ku, Tokyo 1130033, Japan; Natl Inst Physiol Sci, Dept Cell Physiol, Okazaki, Aichi 4448585, Japan; Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA	University of Tokyo; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Cornell University	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med Sci, Dept Metab Dis, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		Noda, Mitsuhiko/W-3905-2019; Nemoto, Tomomi/B-4412-2012	Noda, Mitsuhiko/0000-0003-0413-4631; Nemoto, Tomomi/0000-0001-6102-1495; Kasai, Haruo/0000-0003-2327-9027				AIZAWA T, 1994, AM J PHYSIOL, V266, pC622, DOI 10.1152/ajpcell.1994.266.3.C622; AKAZAWA H, 1994, DIABETES RES CLIN PR, V24, pS23; Alcazar O, 2000, BIOCHEM J, V352, P373, DOI 10.1042/0264-6021:3520373; ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11; DEITEMARY P, 1996, J BIOL CHEM, V271, P20559; DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163; EIZIRIK DL, 1989, DIABETOLOGIA, V32, P769; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Hayakawa T, 1998, J BIOL CHEM, V273, P20300, DOI 10.1074/jbc.273.32.20300; HAYAKAWA T, 1979, J GEN APPL MICROBIOL, V25, P255, DOI 10.2323/jgam.25.255; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403; Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374; KIKUCHI M, 1974, DIABETES, V23, P550, DOI 10.2337/diab.23.6.550; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Liang Y, 1996, AM J PHYSIOL-ENDOC M, V270, pE846, DOI 10.1152/ajpendo.1996.270.5.E846; Maassen JA, 1996, DIABETOLOGIA, V39, P375; MCDANIEL ML, 1974, DIABETOLOGIA, V10, P303; MIWA I, 1991, BIOCHEM BIOPH RES CO, V180, P709, DOI 10.1016/S0006-291X(05)81123-4; Nemoto T, 2001, NAT CELL BIOL, V3, P253, DOI 10.1038/35060042; Noda M, 1996, DIABETES, V45, P1766, DOI 10.2337/diabetes.45.12.1766; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194; Tian D, 1998, J BIOL CHEM, V273, P24861, DOI 10.1074/jbc.273.38.24861; Tsuruzoe K, 1998, DIABETES, V47, P621, DOI 10.2337/diabetes.47.4.621; VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368; VIONNET N, 1993, LANCET, V342, P1429, DOI 10.1016/0140-6736(93)92792-R; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; ZYLBER E, 1969, J MOL BIOL, V44, P195, DOI 10.1016/0022-2836(69)90414-8	32	59	61	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					41817	41826		10.1074/jbc.M207690200	http://dx.doi.org/10.1074/jbc.M207690200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12169697	hybrid			2022-12-27	WOS:000178985300067
J	Riley, AM; Morris, SA; Nerou, EP; Correa, V; Potter, BVL; Taylor, CW				Riley, AM; Morris, SA; Nerou, EP; Correa, V; Potter, BVL; Taylor, CW			Interactions of inositol 1,4,5-trisphosphate (IP3) receptors with synthetic poly(ethylene glycol)-linked dimers of IP3 suggest close spacing of the IP3-binding sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITE; TRISPHOSPHATE RECEPTORS; CA2+; DETERMINANTS; RECOGNITION; INHIBITION; EXPRESSION; MOLECULES; PROTEIN; CELLS	The distances between the inositol 1,4,5-trisphosphate (IP3)-binding sites of tetrameric IP3 receptors were probed using dimers of IP3 linked by poly(ethylene glycol) (PEG) molecules of differing lengths (1-8 nm). Each of the dimers potently stimulated Ca-45(2+) release from permeabilized cells expressing predominantly type 1 (SH-SY5Y cells) or type 2 (hepatocytes) IP3 receptors. The shortest dimers, with PEG linkers of an effective length of 1.5 nm or less, were the most potent, being 3-4-fold more potent than IP3. In radioligand binding experiments using cerebellar membranes, the shortest dimers bound with highest affinity, although the longest dimer (8 nm) also bound with almost 4-fold greater affinity than IP3. The affinity of monomeric IP3 with only the PEG attached was 2-fold weaker than IP3, confirming that the increased affinity of the dimers requires the presence of both IP3 motifs. The increased affinity of the long dimer probably results from the linked IP3 molecules binding to sites on different receptors, because the dimer bound with greater affinity than IP3 to cerebellar membranes, where receptors are densely packed, but with the same affinity as IP3 to purified receptors. IP3 and the IP3 dimers, irrespective of their length, bound with similar affinity to a monomeric IP3-binding domain of the type 1 IP3 receptor expressed in bacteria. Short dimers therefore bind with increased affinity only when the receptor is tetrameric. We conclude that the four IP3-binding sites of an IP3 receptor may be separated by as little as 1.5 nm and are therefore likely to be placed centrally in this large (25 x 25 nm) structure, consistent with previous work indicating a close association between the central pore and the IP3-binding sites of the IP3 receptor.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England; Univ Bath, Dept Pharm & Pharmacol, Wolfson Lab Med Chem, Bath BA2 7AY, Avon, England	University of Cambridge; University of Bath	Taylor, CW (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	cwt1000@cam.ac.uk	Riley, Andrew M/F-3526-2013; Potter, Barry/AAX-4781-2020; Potter, Barry VL/A-1845-2012; Taylor, Colin/G-2447-2010	Riley, Andrew M/0000-0001-9003-3540; Morris, Stephen/0000-0002-7640-8657; Taylor, Colin/0000-0001-7771-1044				Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; CHADWICK CC, 1990, P NATL ACAD SCI USA, V87, P2132, DOI 10.1073/pnas.87.6.2132; Correa V, 2001, MOL PHARMACOL, V59, P1206, DOI 10.1124/mol.59.5.1206; DESMEDT H, 1994, J BIOL CHEM, V269, P21691; Hamada K, 2002, J BIOL CHEM, V277, P21115, DOI 10.1074/jbc.C200244200; HIRATA M, 1990, J BIOL CHEM, V265, P8404; Jiang QX, 2002, EMBO J, V21, P3575, DOI 10.1093/emboj/cdf380; Joseph SK, 1997, J BIOL CHEM, V272, P1579, DOI 10.1074/jbc.272.3.1579; JOSEPH SK, 1995, BIOCHEM J, V307, P859, DOI 10.1042/bj3070859; JOSEPH SK, 1995, J BIOL CHEM, V270, P23310, DOI 10.1074/jbc.270.40.23310; Katayama E, 1996, EMBO J, V15, P4844, DOI 10.1002/j.1460-2075.1996.tb00865.x; KNOLL D, 1983, J BIOL CHEM, V258, P5710; Kramer RH, 1998, NATURE, V395, P710, DOI 10.1038/27227; Loidl G, 1999, P NATL ACAD SCI USA, V96, P5418, DOI 10.1073/pnas.96.10.5418; MAEDA N, 1990, EMBO J, V9, P61, DOI 10.1002/j.1460-2075.1990.tb08080.x; Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; Morris SA, 2002, BIOCHEM J, V367, P113, DOI 10.1042/BJ20020675; Nerou EP, 2001, BIOCHEM J, V355, P59, DOI 10.1042/bj3550059; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Patel S, 1997, P NATL ACAD SCI USA, V94, P11627, DOI 10.1073/pnas.94.21.11627; Portoghese PS, 2001, J MED CHEM, V44, P2259, DOI 10.1021/jm010158+; Rajeswaran WG, 2001, J MED CHEM, V44, P4563, DOI 10.1021/jm0102405; Ramos-Franco J, 1999, J GEN PHYSIOL, V114, P243, DOI 10.1085/jgp.114.2.243; RICHARDSON A, 1993, J BIOL CHEM, V268, P11528; Riley AM, 2000, CHEM COMMUN, P983, DOI 10.1039/b002312o; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schaschke N, 2001, CHEM BIOL, V8, P313, DOI 10.1016/S1074-5521(01)00011-4; Swatton JE, 1999, BIOCHEM J, V344, P55, DOI 10.1042/0264-6021:3440055; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; YAMASHITA K, 1995, J AM CHEM SOC, V117, P6249, DOI 10.1021/ja00128a011; Yoshikawa F, 1999, J BIOL CHEM, V274, P328, DOI 10.1074/jbc.274.1.328; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277; Yoshikawa F, 1999, BIOCHEM BIOPH RES CO, V257, P792, DOI 10.1006/bbrc.1999.0498	34	23	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40290	40295		10.1074/jbc.M206925200	http://dx.doi.org/10.1074/jbc.M206925200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183463	hybrid			2022-12-27	WOS:000178791400019
J	Guaita, S; Puig, I; Franci, C; Garrido, M; Dominguez, D; Batlle, E; Sancho, E; Dedhar, S; de Herreros, AG; Baulida, J				Guaita, S; Puig, I; Franci, C; Garrido, M; Dominguez, D; Batlle, E; Sancho, E; Dedhar, S; de Herreros, AG; Baulida, J			Snail induction of epithelial to mesenchymal transition in tumor cells is accompanied by MUC1 repression and ZEB1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN EXPRESSION; TRANSCRIPTION FACTOR SNAIL; ZINC-FINGER; MECHANISMS; CARCINOMA; ADHESION; REVEALS; GENES; ZFH-1	E-cadherin protein plays a key role in the establishment and maintenance of adherent junctions. Recent evidence implicates the transcription factor Snail in the blockage of E-cadherin expression in fibroblasts and some epithelial tumor cells through direct binding to three E-boxes in the E-cadherin promoter. Transfection of Snail into epithelial cells leads to a more fibroblastic phenotype. Cells expressing Snail presented a scattered flattened phenotype with low intercellular contacts. Other epithelial markers like Cytokeratin 18 or MUC1 were also repressed. The effects of Snail on MUC1 transcription were mediated by two E-boxes present in the proximal promoter. Snail also induced expression of the mesenchymal markers fibronectin and LEF1 and the transcription repressor ZEB1. ZEB1 and Snail had a similar pattern of expression in epithelial cell lines, and both were induced by overexpression of ILK1, a kinase that causes the loss of E-cadherin and the acquisition of a fibroblastic phenotype. Snail overexpression in several cell lines raised ZEB1 RNA levels and increased the activity of ZEB1 promoter. ZEB1 could also repress E-cadherin and MUC1 promoters but less strongly than Snail. However, since ZEB1 expression persisted after Snail was down-regulated, ZEB1 may regulate epithelial genes in several tumor cell lines.	Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, E-08003 Barcelona, Spain; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6H 3Z6, Canada	Pompeu Fabra University; University of British Columbia	de Herreros, AG (corresponding author), Univ Pompeu Fabra, Inst Municipal Invest Med, Unitat Biol Cellular & Mol, C Doctor Aiguader 80, E-08003 Barcelona, Spain.	agarcia@imim.es; jbaulida@imim.es	Batlle, Eduard/K-8080-2014; de Herreros, A Garcia/H-3104-2014; Sancho, Elena/ABH-4867-2020	Batlle, Eduard/0000-0003-2422-0326; de Herreros, A Garcia/0000-0001-5270-0808; Sancho, Elena/0000-0002-8182-513X; Puig Borreil, Isabel/0000-0001-5614-4298; Dedhar, Shoukat/0000-0003-4355-1657; Dominguez-Sola, David/0000-0001-9569-8402				Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Casal J, 1996, P NATL ACAD SCI USA, V93, P10327, DOI 10.1073/pnas.93.19.10327; Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Gray S, 1996, GENE DEV, V10, P700, DOI 10.1101/gad.10.6.700; Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hay ED, 1995, ACTA ANAT, V154, P8; Hennig G, 1996, J BIOL CHEM, V271, P595, DOI 10.1074/jbc.271.1.595; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Ji XD, 1997, CELL GROWTH DIFFER, V8, P773; Jiao W, 2002, BRIT J CANCER, V86, P98, DOI 10.1038/sj.bjc.6600017; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; LAI ZC, 1991, MECH DEVELOP, V34, P123, DOI 10.1016/0925-4773(91)90049-C; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Oda H, 1998, DEV BIOL, V203, P435, DOI 10.1006/dbio.1998.9047; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Postigo AA, 2000, P NATL ACAD SCI USA, V97, P6391, DOI 10.1073/pnas.97.12.6391; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Takagi T, 1998, DEVELOPMENT, V125, P21; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M	29	380	397	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39209	39216		10.1074/jbc.M206400200	http://dx.doi.org/10.1074/jbc.M206400200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161443	hybrid			2022-12-27	WOS:000178662500021
J	Ouanounou, G; Malo, M; Stinnakre, J; Kreger, AS; Molgo, J				Ouanounou, G; Malo, M; Stinnakre, J; Kreger, AS; Molgo, J			Trachynilysin, a neurosecretory protein isolated from stonefish (Synanceia trachynis) venom, forms nonselective pores in the membrane of NG108-15 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUANTAL ACETYLCHOLINE-RELEASE; ALPHA-LATROTOXIN CHANNELS; WIDOW SPIDER VENOM; NEUROBLASTOMA-CELLS; SYNAPTIC VESICLES; HORRIDA VENOM; PHARMACOLOGICAL PROPERTIES; NEUROMUSCULAR-JUNCTION; COUPLED RECEPTOR; LETHAL FACTOR	Trachynilysin, a protein toxin isolated from the venom of the stonefish Synanceia trachynis, has been reported to elicit massive acetylcholine release from motor nerve endings of isolated neuromuscular preparations and to increase both cytosolic Ca2+ and catecholamine release from chromaffin cells. In the present study, we used the patch clamp technique to investigate the effect of trachynilysin on the cytoplasmic membrane of differentiated NG108-15 cells in culture. Trachynilysin increased membrane conductance the most when the negativity of the cell holding membrane potential was reduced. The trachynilysin-induced current was carried by cations and reversed at about -3 mV in standard physiological solutions, which led to strong membrane depolarization and Ca2+ influx. La3+ blocked the trachynilysin current in a dose-, voltage-, and time-dependent manner, and antibodies raised against the toxin antagonized its effect on the cell membrane. The inside-out configuration of the patch clamp technique allowed the recording of single channel activity from which various multiples of 22 pS elementary conductance were resolved. These results indicate that trachynilysin forms pores in the NG108-15 cell membrane, and they advance our understanding of the toxin's mode of action on motor nerve endings and neurosecretory cells.	CNRS, UPR 9040, Lab Neurobiol Cellulaire & Mol, F-91198 Gif Sur Yvette, France; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; University System of Maryland; University of Maryland Baltimore	Molgo, J (corresponding author), CNRS, UPR 9040, Lab Neurobiol Cellulaire & Mol, 1 Ave Terrasse, F-91198 Gif Sur Yvette, France.			Ouanounou, Gilles/0000-0001-5658-7005	NIGMS NIH HHS [GM-43728] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashton AC, 2001, J BIOL CHEM, V276, P44695, DOI 10.1074/jbc.M108088200; BELMONTE G, 1993, J MEMBRANE BIOL, V131, P11, DOI 10.1007/BF02258530; Bittner MA, 1998, J NEUROSCI, V18, P2914; CHAMEAU P, 1997, TOXICON, V35, P1662; CHANG DC, 1983, BIOPHYS J, V43, P149, DOI 10.1016/S0006-3495(83)84335-5; Chen DS, 1997, BIOCHEM J, V325, P685, DOI 10.1042/bj3250685; Colasante C, 1996, EUR J NEUROSCI, V8, P2149, DOI 10.1111/j.1460-9568.1996.tb00736.x; Davletov BA, 1998, EMBO J, V17, P3909, DOI 10.1093/emboj/17.14.3909; DAVLETOV BA, 1995, J BIOL CHEM, V270, P23903, DOI 10.1074/jbc.270.41.23903; Davletov BA, 1996, J BIOL CHEM, V271, P23239, DOI 10.1074/jbc.271.38.23239; EISENBERG RS, 1984, MEMBRANES CHANNELS N; FINKELSTEIN A, 1976, SCIENCE, V193, P1009, DOI 10.1126/science.948756; GARNIER P, 1995, TOXICON, V33, P143, DOI 10.1016/0041-0101(94)00151-W; Ghadessy FJ, 1996, J BIOL CHEM, V271, P25575, DOI 10.1074/jbc.271.41.25575; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hamprecht B, 1977, Int Rev Cytol, V49, P99; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; HURLBUT WP, 1994, J MEMBRANE BIOL, V138, P91, DOI 10.1007/BF00211072; KASAI H, 1992, J PHYSIOL-LONDON, V448, P161, DOI 10.1113/jphysiol.1992.sp019035; Khvotchev M, 2000, NEUROSCIENCE, V101, P793, DOI 10.1016/S0306-4522(00)00378-X; Krasnoperov VG, 1996, BIOCHEM BIOPH RES CO, V227, P868, DOI 10.1006/bbrc.1996.1598; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; KREGER AS, 1991, TOXICON, V29, P733, DOI 10.1016/0041-0101(91)90065-Y; Lang JC, 1998, EMBO J, V17, P648, DOI 10.1093/emboj/17.3.648; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATTEOLI M, 1988, P NATL ACAD SCI USA, V85, P7366, DOI 10.1073/pnas.85.19.7366; Meunier FA, 2000, J CELL SCI, V113, P1119; Mirzabekov TA, 1996, J BIOL CHEM, V271, P1988, DOI 10.1074/jbc.271.4.1988; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; Orlova EV, 2000, NAT STRUCT BIOL, V7, P48, DOI 10.1038/71247; Ouanounou G, 2000, CYBIUM, V24, P149; OUANOUNOU G, 1999, TOXICON, V37, P1234; POH CH, 1991, COMP BIOCHEM PHYS B, V99, P793, DOI 10.1016/0305-0491(91)90143-2; ROBBINS J, 1990, PFLUG ARCH EUR J PHY, V416, P130, DOI 10.1007/BF00370234; ROBELLO M, 1989, BIOCHIM BIOPHYS ACTA, V978, P179, DOI 10.1016/0005-2736(89)90112-0; ROBELLO M, 1987, J MEMBRANE BIOL, V95, P55, DOI 10.1007/BF01869630; ROSENTHAL L, 1989, PHARMACOL THERAPEUT, V42, P115, DOI 10.1016/0163-7258(89)90024-7; ROUZAIREDUBOIS B, 1990, CELL SIGNAL, V2, P387, DOI 10.1016/0898-6568(90)90069-M; ROUZAIREDUBOIS B, 1990, PFLUG ARCH EUR J PHY, V416, P393, DOI 10.1007/BF00370745; Schiavo G, 2000, PHYSIOL REV, V80, P717, DOI 10.1152/physrev.2000.80.2.717; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; Ushkaryov Y, 2002, TOXICON, V40, P1, DOI 10.1016/S0041-0101(01)00204-5; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; Van Renterghem C, 2000, EUR J NEUROSCI, V12, P3953, DOI 10.1046/j.1460-9568.2000.00282.x; VANDERKLOOT W, 1994, PHYSIOL REV, V74, P899, DOI 10.1152/physrev.1994.74.4.899; Volynski KE, 2000, J BIOL CHEM, V275, P41175, DOI 10.1074/jbc.M005857200; WANKE E, 1986, BIOCHEM BIOPH RES CO, V134, P320, DOI 10.1016/0006-291X(86)90565-6	50	21	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39119	39127		10.1074/jbc.M203433200	http://dx.doi.org/10.1074/jbc.M203433200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177053	hybrid			2022-12-27	WOS:000178662500010
J	Ramachander, R; Kim, CA; Phillips, ML; Mackereth, CD; Thanos, CD; McIntosh, LP; Bowie, JU				Ramachander, R; Kim, CA; Phillips, ML; Mackereth, CD; Thanos, CD; McIntosh, LP; Bowie, JU			Oligomerization-dependent association of the SAM domains from Schizosaccharomyces pombe Byr2 and Ste4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE PHOSPHORYLATION; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; TYROSINE KINASE; POINTED DOMAIN; PROTEIN; RECEPTOR; TEL; IDENTIFICATION; GENE	SAM (sterile alpha motif) domains are protein-protein interaction modules found in a large number of regulatory proteins. Byr2 and Ste4 are two SAM domain-containing proteins in the mating pheromone response pathway of the fission yeast, Schizosaccharomyces pombe. Byr2 is a mitogen-activated protein kinase kinase kinase that is regulated by Ste4. Tu et al (Tu, H., Barr, M., Dong, D. L., and Wigler, M. (1997) Mol. Cell. Biol. 17, 5876-5887) showed that the isolated SAM domain of Byr2 binds a fragment of Ste4 that contains both a leucine zipper (Ste4-LZ) domain as well as a SAM domain, suggesting that Byr2-SAM and Ste4-SAM may form a hetero-oligomer. Here, we show that the individual SAM domains of Ste4 and Byr2 are monomeric at low concentrations and bind to each other in a 1:1 stoichiometry with a relatively weak dissociation constant of 56 +/- 3 mum. Inclusion of the Ste4-LZ domain, which determines the oligomeric state of Ste4, has a dramatic effect on binding affinity, however. We find that the Ste4-LZ domain is trimeric and, when included with the Ste4-SAM domain, yields a 3:1 Ste4-LZ-SAM:Byr2-SAM complex with a tight dissociation constant of 19 +/- 4 nm. These results suggest that the Ste4-LZ-SAM protein may recognize multiple binding sites on Byr2-SAM, indicating a new mode of oligomeric organization for SAM domains. The fact that high affinity binding occurs only with the addition of an oligomerization domain suggests that it may be necessary to include ancillary oligomerization modules when searching for binding partners of SAM domains.	Univ Calif Los Angeles, Dept Chem & Biochem, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, US DOE, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA; Univ British Columbia, Dept Biochem, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Sunesis Pharmaceut, San Francisco, CA 94080 USA	University of California System; University of California Los Angeles; United States Department of Energy (DOE); University of California System; University of California Los Angeles; University of British Columbia; University of British Columbia; University of British Columbia	Bowie, JU (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Inst Mol Biol, Boyer Hall,611 Charles E Young Dr E, Los Angeles, CA 90095 USA.	bowie@mbi.ucla.edu	Mackereth, Cameron D./F-7946-2013	Mackereth, Cameron D./0000-0002-0776-7947	NATIONAL CANCER INSTITUTE [R01CA081000] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA81000] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baker DA, 2001, NATURE, V411, P330, DOI 10.1038/35077122; Barr MM, 1996, MOL CELL BIOL, V16, P5597; Bauman P, 1998, BIOCHIMIE, V80, P621, DOI 10.1016/S0300-9084(98)80015-1; Bauman P, 1998, BIOCHEM BIOPH RES CO, V244, P468, DOI 10.1006/bbrc.1998.8292; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; Cohn E. J., 1943, PROTEINS AMINO ACIDS, P370; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUBENDORFF JW, 1991, J MOL BIOL, V219, P45, DOI 10.1016/0022-2836(91)90856-2; FODOR SPA, 1989, J AM CHEM SOC, V111, P5509, DOI 10.1021/ja00197a001; Golub TR, 1996, MOL CELL BIOL, V16, P4107; HUGHES D, 1993, SIGNAL TRANSDUCTION; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Kasten M, 2001, ONCOGENE, V20, P1832, DOI 10.1038/sj.onc.1204295; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; Kyba M, 1998, DEV GENET, V22, P74, DOI 10.1002/(SICI)1520-6408(1998)22:1<74::AID-DVG8>3.3.CO;2-V; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; MACKERETH CD, 2002, IN PRESS J BIOMOL NM; MASUDA T, 1995, J BIOL CHEM, V270, P1979, DOI 10.1074/jbc.270.5.1979; Myszka DG, 1998, ANAL BIOCHEM, V265, P326, DOI 10.1006/abio.1998.2937; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; OKAZAKI N, 1991, NUCLEIC ACIDS RES, V19, P7043, DOI 10.1093/nar/19.25.7043; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; Poirel H, 2000, ONCOGENE, V19, P4802, DOI 10.1038/sj.onc.1203830; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; Schatz PJ, 1996, METHOD ENZYMOL, V267, P171; Scheffzek K, 2001, STRUCTURE, V9, P1043, DOI 10.1016/S0969-2126(01)00674-8; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schultz J, 1997, PROTEIN SCI, V6, P249; Seidel JJ, 2002, GENE DEV, V16, P127, DOI 10.1101/gad.950902; Slupsky CM, 1998, BIOCHEM CELL BIOL, V76, P379, DOI 10.1139/bcb-76-2-3-379; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; Smalla M, 1999, PROTEIN SCI, V8, P1954, DOI 10.1110/ps.8.10.1954; Stapleton D, 1999, NAT STRUCT BIOL, V6, P44; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Thanos CD, 1999, J BIOL CHEM, V274, P37301, DOI 10.1074/jbc.274.52.37301; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597	46	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39585	39593		10.1074/jbc.M207273200	http://dx.doi.org/10.1074/jbc.M207273200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171939	hybrid			2022-12-27	WOS:000178662500069
J	Senthilkumar, R; Chaerkady, R; Sharma, KK				Senthilkumar, R; Chaerkady, R; Sharma, KK			Identification and properties of anti-chaperone-like peptides derived from oxidized bovine lens beta(L)-crystallins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOPEPTIDASE-III; BETA-CRYSTALLIN; CALPAIN-II; RAT LENS; PROTEINS; POLYPEPTIDES; PURIFICATION; ENDOPEPTIDASE; PROTEOLYSIS; HYDROLYSIS	Thermal aggregation of beta(L)-crystallin was higher in the presence of peptide fragments generated from oxidized and trypsin-digested beta(L)-crystallin compared with thermal aggregation of the control proteins without oxidized beta(L)-crystallin fragments. Increased aggregation of beta(L)-crystallin was also observed despite the presence of alpha-crystallin (which has anti-aggregating properties) in the system. Self-aggregation of the oxidized beta(L)-crystallin fragments per se was not observed under the experimental conditions. Reverse-phase HPLC analysis of the precipitate obtained after heating a mixture of beta(L)-crystallin and oxidized beta(L)-crystallin fragments revealed that more than one peptide co-precipitates with beta(L)-crystallin. Electrospray mass spectrometry analysis of the peptides revealed that the molecular weight(s) of the peptides ranged from 1400-1800. Tandem mass spectrometry and a data base search revealed that two of the peptides originated from betaA4-crystallin (LTIFEQENFLGR, residues 121-132) and betaB3-crystallin (AINGTWVGYEFPGYR, residues 153-167) respectively. Oxidized synthetic peptides representing the same sequence were also found to enhance the aggregation of beta(L)-crystallin in a manner similar to oxidized lens beta(L)-crystallin peptides. These data suggest that the polypeptides generated after oxidation and proteolysis of beta(L)-crystallins interact with denaturing proteins and facilitate their aggregation and light scattering, thus behaving like anti-chaperones.	Univ Missouri, Mason Eye Inst, Columbia, MO 65212 USA; Univ Missouri, Dept Biochem, Columbia, MO 65212 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Sharma, KK (corresponding author), Univ Missouri, Mason Eye Inst, 1 Hosp Dr, Columbia, MO 65212 USA.	sharmak@health.missouri.edu	Chaerkady, Raghothama/D-5718-2011		NEI NIH HHS [EY 09855, EY 11981] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011981, R01EY009855, R29EY009855] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AUGESTEYN RC, 1981, MECHANISMS CATARACT, P71; BARBER GW, 1973, EXP EYE RES, V16, P85, DOI 10.1016/0014-4835(73)90303-5; BARBER GW, 1979, EXP EYE RES, V29, P663; BENEDEK GB, 1971, APPL OPTICS, V10, P459, DOI 10.1364/AO.10.000459; Bhattacharyya J, 2001, J PEPT RES, V57, P428, DOI 10.1034/j.1399-3011.2001.00871.x; BUCKINGHAM RH, 1972, EXP EYE RES, V14, P297, DOI 10.1016/0014-4835(72)90020-6; Das KP, 1996, J BIOL CHEM, V271, P10449, DOI 10.1074/jbc.271.18.10449; David L L, 1989, Lens Eye Toxic Res, V6, P725; DAVID LL, 1986, EXP EYE RES, V42, P227, DOI 10.1016/0014-4835(86)90057-6; DAVID LL, 1984, INVEST OPHTH VIS SCI, V25, P1275; DAVID LL, 1992, BIOCHIM BIOPHYS ACTA, V1139, P210, DOI 10.1016/0925-4439(92)90136-B; DILLEY KJ, 1974, EXP EYE RES, V19, P59, DOI 10.1016/0014-4835(74)90073-6; FLESHMAN KR, 1984, EXP EYE RES, V39, P543, DOI 10.1016/0014-4835(84)90054-X; Fujino T, 2000, BBA-PROTEIN STRUCT M, V1478, P102, DOI 10.1016/S0167-4838(00)00004-2; GARNER WH, 1979, DOC OPHTHALMOL P, V18, P91; GEHRKE CW, 1987, J ASSOC OFF ANA CHEM, V70, P171; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HARDING JJ, 1976, EXP EYE RES, V22, P1, DOI 10.1016/0014-4835(76)90033-6; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; HORWITZ J, 1983, BIOCHEM BIOPH RES CO, V113, P65, DOI 10.1016/0006-291X(83)90432-1; KATO Y, 1992, J BIOL CHEM, V267, P23646; Mitton KP, 1996, J BIOL CHEM, V271, P31803, DOI 10.1074/jbc.271.50.31803; RAY K, 1985, P NATL ACAD SCI USA, V82, P7545, DOI 10.1073/pnas.82.22.7545; ROY D, 1982, EXP EYE RES, V34, P909, DOI 10.1016/0014-4835(82)90070-7; ROY D, 1978, EXP EYE RES, V26, P445, DOI 10.1016/0014-4835(78)90131-8; SHANG F, 1994, CURR EYE RES, V13, P423, DOI 10.3109/02713689408999870; Sharma KK, 1996, CURR EYE RES, V15, P363, DOI 10.3109/02713689608995826; SHARMA KK, 1986, CURR EYE RES, V5, P373, DOI 10.3109/02713688609025176; SHARMA KK, 1993, EUR J BIOCHEM, V216, P631, DOI 10.1111/j.1432-1033.1993.tb18183.x; SHARMA KK, 1995, EXP EYE RES, V61, P413; SHEARER TR, 1992, CURR EYE RES, V11, P357, DOI 10.3109/02713689209001789; SIEW EL, 1981, EXP EYE RES, V33, P603, DOI 10.1016/S0014-4835(81)80100-5; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8; SPECTOR A, 1984, INVEST OPHTH VIS SCI, V25, P130; SPECTOR A, 1963, J BIOL CHEM, V238, P1353; SPIES JR, 1948, ANAL CHEM, V20, P30, DOI 10.1021/ac60013a006; SRIVASTAVA OP, 1988, EXP EYE RES, V47, P525, DOI 10.1016/0014-4835(88)90092-9; SRIVASTAVA OP, 1994, INVEST OPHTH VIS SCI, V35, P207; Srivastava OP, 1996, CURR EYE RES, V15, P511, DOI 10.3109/02713689609000762; SRIVASTAVA OP, 1983, EXP EYE RES, V37, P597, DOI 10.1016/0014-4835(83)90135-5; TAKEMOTO L, 1994, CURR EYE RES, V13, P35, DOI 10.3109/02713689409042396; TAKEMOTO L, 1994, ARCH BIOCHEM BIOPHYS, V315, P133, DOI 10.1006/abbi.1994.1481; TAKEMOTO LJ, 1983, CURR EYE RES, V2, P849; TAYLOR A, 1993, TRENDS BIOCHEM SCI, V18, P167; WANG KY, 1994, J BIOL CHEM, V269, P13601; Yates Jr, 1999, METH MOL B, V112, P553; YOSHIDA H, 1985, INVEST OPHTH VIS SCI, V26, P653	49	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39136	39143		10.1074/jbc.M204684200	http://dx.doi.org/10.1074/jbc.M204684200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12176982	hybrid			2022-12-27	WOS:000178662500012
J	Shigi, N; Suzuki, T; Tamakoshi, M; Oshima, T; Watanabe, K				Shigi, N; Suzuki, T; Tamakoshi, M; Oshima, T; Watanabe, K			Conserved bases in the T Psi C loop of tRNA are determinants for thermophile-specific 2-thiouridylation at position 54	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA; THERMUS-THERMOPHILUS; EXTREME THERMOPHILE; MODIFIED NUCLEOSIDES; SEQUENCE; 5-METHYLAMINOMETHYL-2-THIOURIDINE; RIBOTHYMIDINE; TRANSCRIPTION; BIOSYNTHESIS; REPLACEMENT	2-Thioribothymidine (s(2)T) is a post-transcriptionally modified nucleoside of U54 specifically found in thermophilic bacterial tRNAs. The 2-thiocarbonyl group of s(2)T54 is known to be responsible for the thermostability of tRNA. The s(2)T54 content in tRNA varies depending on the cultivation temperature, a feature that confers thermal adaptation of protein synthesis in Thermus thermophilus. Little is known about the biosynthesis Of s(2)T, including the sulfur donor, modification enzyme, and the tRNA structural requirements. To characterize 2-thiolation at position 54 in tRNA, we constructed an in vivo expression system using tRNA(Asp) with an altered sequence and a host-vector for T. thermophilus. We were able to detect in vivo activity of s(2)T54 thiolase using phenyl mercuric gel electrophoresis followed by Northern hybridization. 2-Thiolation at position 54 was identified in the precursor form of the tRNA, indicating that 2-thiolation precedes tRNA processing. To ascertain the elements that determine 2-thiolation in tRNA, systematic site-directed mutagenesis was carried out using the tRNA(Asp) gene. Conserved residues C56 and A58 were identified as major determinants of 2-thiolation, whereas tertiary interaction between the T and D loops and non-conserved nucleosides in the T loop were revealed not to be important for the reaction.	Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Kashiwa, Chiba 2778562, Japan; Tokyo Univ Pharm & Life Sci, Dept Mol Biol, Hachioji, Tokyo 1920392, Japan	University of Tokyo; Tokyo University of Pharmacy & Life Sciences	Watanabe, K (corresponding author), Univ Tokyo, Grad Sch Frontier Sci, Dept Integrated Biosci, Biosci Bldg 301,5-1-5 Kashiwanoha, Kashiwa, Chiba 2778562, Japan.		Shigi, Naoki/L-7135-2018; Suzuki, Tsutomu/J-1776-2015	Shigi, Naoki/0000-0003-4452-8264; Suzuki, Tsutomu/0000-0002-9731-1731				Altman Sidney, 1995, P67; Bjork Glenn R., 1995, P165; BJORK GR, 1975, J BACTERIOL, V124, P92; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Curran J. F., 1998, MODIFICATION EDITING, P493; DAVANLOO P, 1979, NUCLEIC ACIDS RES, V6, P1571, DOI 10.1093/nar/6.4.1571; Deutscher MP, 2001, PROG NUCLEIC ACID RE, V66, P67; DONISKELLER H, 1980, NUCLEIC ACIDS RES, V8, P3133, DOI 10.1093/nar/8.14.3133; ELSEVIERS D, 1984, NUCLEIC ACIDS RES, V12, P3521, DOI 10.1093/nar/12.8.3521; EMILSSON V, 1992, NUCLEIC ACIDS RES, V20, P4499, DOI 10.1093/nar/20.17.4499; Grosjean H, 1996, J MOL BIOL, V255, P67, DOI 10.1006/jmbi.1996.0007; Gu XR, 1996, BIOCHEMISTRY-US, V35, P11652, DOI 10.1021/bi9612125; Hagervall TG, 1998, J MOL BIOL, V284, P33, DOI 10.1006/jmbi.1998.2162; Henkin TM, 1996, ANNU REV GENET, V30, P35, DOI 10.1146/annurev.genet.30.1.35; HISHINUMA F, 1978, J GEN MICROBIOL, V104, P193, DOI 10.1099/00221287-104-2-193; IGLOI GL, 1988, BIOCHEMISTRY-US, V27, P3842, DOI 10.1021/bi00410a048; Inokuchi Hachiro, 1995, P17; KEALEY JT, 1994, BIOCHIMIE, V76, P1133, DOI 10.1016/0300-9084(94)90042-6; KEITH G, 1993, NUCLEIC ACIDS RES, V21, P4399, DOI 10.1093/nar/21.18.4399; KNAPP G, 1978, CELL, V14, P221, DOI 10.1016/0092-8674(78)90109-5; KOWALAK JA, 1994, BIOCHEMISTRY-US, V33, P7869, DOI 10.1021/bi00191a014; KOYAMA Y, 1986, J BACTERIOL, V166, P338, DOI 10.1128/jb.166.1.338-340.1986; KUCHINO Y, 1987, METHOD ENZYMOL, V155, P379; KUMAGAI I, 1980, P NATL ACAD SCI-BIOL, V77, P1922, DOI 10.1073/pnas.77.4.1922; Nordlund ME, 2000, RNA, V6, P844, DOI 10.1017/S1355838200992422; Qiu FH, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.18.e20; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; SCHAEFER KP, 1973, P NATL ACAD SCI USA, V70, P3626, DOI 10.1073/pnas.70.12.3626; Sengupta R, 2000, NUCLEIC ACIDS RES, V28, P1374, DOI 10.1093/nar/28.6.1374; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; SUDDATH FL, 1974, NATURE, V248, P20, DOI 10.1038/248020a0; SULLIVAN MA, 1985, J BACTERIOL, V161, P368, DOI 10.1128/JB.161.1.368-376.1985; TAKADA T, 1993, APPL ENVIRON MICROB, V59, P2737, DOI 10.1128/AEM.59.8.2737-2739.1993; Tamakoshi M, 1999, FEMS MICROBIOL LETT, V173, P431, DOI 10.1016/S0378-1097(99)00101-9; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WAKITA K, 1994, NUCLEIC ACIDS RES, V22, P347, DOI 10.1093/nar/22.3.347; WATANABE K, 1976, BIOCHEM BIOPH RES CO, V72, P1137, DOI 10.1016/S0006-291X(76)80250-1; WATANABE K, 1983, BIOCHEMISTRY-US, V22, P98, DOI 10.1021/bi00270a014; WATANABE K, 1974, FEBS LETT, V43, P59, DOI 10.1016/0014-5793(74)81105-1; WATANABE K, 1980, J BIOCHEM-TOKYO, V87, P1; WATANABE K, 1979, BIOCHEM BIOPH RES CO, V91, P671, DOI 10.1016/0006-291X(79)91574-2; WATANABE K, 1976, NUCLEIC ACIDS RES, V3, P1703, DOI 10.1093/nar/3.7.1703; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Yokoyama S, 1987, Adv Biophys, V23, P115, DOI 10.1016/0065-227X(87)90006-2	44	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39128	39135		10.1074/jbc.M207323200	http://dx.doi.org/10.1074/jbc.M207323200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177072	hybrid			2022-12-27	WOS:000178662500011
J	Zhou, J; Gupta, K; Yao, J; Ye, KQ; Panda, D; Giannakakou, P; Joshi, HC				Zhou, J; Gupta, K; Yao, J; Ye, KQ; Panda, D; Giannakakou, P; Joshi, HC			Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MITOTIC BLOCK; MULTIDRUG-RESISTANCE; DYNAMIC INSTABILITY; SIGNAL-TRANSDUCTION; GAMMA-TUBULIN; BETA-TUBULIN; TAXOL; ACTIVATION; PHARMACOKINETICS	We have previously discovered the opium alkaloid noscapine as a microtubule interacting agent that binds to tubulin, alters the dynamics of microtubule assembly, and arrests mammalian cells at mitosis (Ye, K., Ke, Y., Keshava, N., Shanks, J., Kapp, J. A., Tekmal, R. R., Petros, J., and Joshi, H. C. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 1601-1606; Ye, K., Zhou, J., Landen, J. W., Bradbury, E. M., and Joshi, H. C. (2001) J. BioL Chem. 276, 46697-46700; Zhou, J., Panda, D., Landen, J. W., Wilson, L., and Joshi, H. C. (2002) J. Biol. Chem. 277, 17200-17208). Here we show that noscapine does not compete with paclitaxel for tubulin binding and can efficiently inhibit the proliferation of both paclitaxel-sensitive and paclitaxel-resistant human ovarian carcinoma cells (i.e. the parental cell line 1A9 and two derivative cell lines, 1A9PTX10 and 1A9PTX22, which harbor beta-tubulin mutations that impair paclitaxel-tubulin interaction (Giannakakou, P., Sackett, D. L., Kang, Y. K., Zhan, Z., Buters, J. T., Fojo, T., and Poruchynsky, M. S. (1997) J. Biol. Chem. 272,17118-17125). Strikingly, these cells undergo apoptotic death upon noscapine treatment, accompanied by activation of the c-Jun NH2-terminal kinases (JNK). Furthermore, inhibition of JNK activity by treatment with antisense oligonucleotide or transfection with dominant-negative JNK blocks noscapine-induced apoptosis. These findings thus indicate a great potential for noscapine in the treatment of paclitaxel-resistant human cancers. In addition, our results suggest that the JNK pathway plays an essential role in microtubule inhibitor-induced apoptosis.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Biochem Cel & Dev Biol, Atlanta, GA 30322 USA; Indian Inst Technol, Bhupat & Jyoti Mehta Sch Biosci & Bioengn, Bombay 400076, Maharashtra, India	Emory University; Emory University; Emory University; Emory University; Indian Institute of Technology System (IIT System); Indian Institute of Technology (IIT) - Bombay	Joshi, HC (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, 615 Michael St, Atlanta, GA 30322 USA.	joshi@cellbio.emory.edu						ADLER V, 1992, J BIOL CHEM, V267, P17001; BHALLA K, 1993, LEUKEMIA, V7, P563; BONFOCO E, 1995, EXP CELL RES, V218, P189, DOI 10.1006/excr.1995.1147; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; Burkhart CA, 2001, BBA-REV CANCER, V1471, pO1, DOI 10.1016/S0304-419X(00)00022-6; Crown J, 2000, LANCET, V355, P1176, DOI 10.1016/S0140-6736(00)02074-2; DAHLSTROM B, 1982, EUR J CLIN PHARMACOL, V22, P535, DOI 10.1007/BF00609627; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; EVA A, 1982, NATURE, V295, P116, DOI 10.1038/295116a0; Fan MY, 2001, CANCER RES, V61, P4450; Figueroa-Masot XA, 2001, J NEUROSCI, V21, P4657, DOI 10.1523/JNEUROSCI.21-13-04657.2001; Giannakakou P, 1997, J BIOL CHEM, V272, P17118, DOI 10.1074/jbc.272.27.17118; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAIKALA V, 1986, EUR J CLIN PHARMACOL, V31, P367, DOI 10.1007/BF00981140; Haskell CM., 1995, CANC TREATMENT, P78; Heatwole V M, 1999, Methods Mol Biol, V115, P141; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Jordan MA, 1996, CANCER RES, V56, P816; Jordan MA, 1999, METHOD CELL BIOL, V61, P267; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; Joshi HC, 2001, METHOD CELL BIOL, V67, P179; KARLSSON MO, 1990, EUR J CLIN PHARMACOL, V39, P275, DOI 10.1007/BF00315110; Kawamura KI, 1996, BRIT J CANCER, V73, P183, DOI 10.1038/bjc.1996.33; Ke Y, 2000, CANCER IMMUNOL IMMUN, V49, P217, DOI 10.1007/s002620000109; McIntosh J. Richard, 1994, V13, P413; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Panda D, 2000, BIOCHEMISTRY-US, V39, P5075, DOI 10.1021/bi992217f; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; Rowinsky EK, 1997, ANNU REV MED, V48, P353; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shiah SG, 1999, CANCER RES, V59, P391; Shtil AA, 1999, ONCOGENE, V18, P377, DOI 10.1038/sj.onc.1202305; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Snyder JP, 2001, P NATL ACAD SCI USA, V98, P5312, DOI 10.1073/pnas.051309398; Stone AA, 2000, EXP CELL RES, V254, P110, DOI 10.1006/excr.1999.4731; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; VANTELLINGEN O, 1992, ANTICANCER RES, V12, P1699; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; WOODS CM, 1995, MOL MED, V1, P506, DOI 10.1007/BF03401588; Ye KQ, 2001, J BIOL CHEM, V276, P46697, DOI 10.1074/jbc.C100550200; Ye KQ, 1998, P NATL ACAD SCI USA, V95, P1601, DOI 10.1073/pnas.95.4.1601; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhou J, 2002, J BIOL CHEM, V277, P17200, DOI 10.1074/jbc.M110369200; Zhou J, 2002, J CELL SCI, V115, P3547, DOI 10.1242/jcs.00029; Zhou J, 2002, J CELL BIOCHEM, V84, P472, DOI 10.1002/jcb.10033	51	56	62	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39777	39785		10.1074/jbc.M203927200	http://dx.doi.org/10.1074/jbc.M203927200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12183452	hybrid			2022-12-27	WOS:000178662500092
J	Dvoretsky, A; Abusamhadneh, EM; Howarth, JW; Rosevear, PR				Dvoretsky, A; Abusamhadneh, EM; Howarth, JW; Rosevear, PR			Solution structure of calcium-saturated cardiac troponin C bound to cardiac troponin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESIDUAL DIPOLAR COUPLINGS; REGULATORY DOMAIN; CENTRAL HELIX; CONFORMATIONAL EXCHANGE; PROTEIN STRUCTURES; CRYSTAL-STRUCTURE; COMPLEX; NMR; PHOSPHORYLATION; RESOLUTION	Cardiac troponin C (TnC) is composed of two globular domains connected by a flexible linker. In solution, linker flexibility results in an ill defined orientation of the two globular domains relative to one another. We have previously shown a decrease in linker flexibility in response to cardiac troponin I (cTnI) binding. To investigate the relative orientation of calcium-saturated TnC domains when bound to cTnI, H-1-(15) N residual dipolar couplings were measured in two different alignment media. Similarity in alignment tensor orientation for the two TnC domains supports restriction of domain motion in the presence of cTnI. The relative spatial orientation of TnC domains bound to TnI was calculated from measured residual dipolar couplings and long-range distance restraints utilizing a rigid body molecular dynamics protocol. The relative domain orientation is such that hydrophobic pockets face each other, forming a latch to constrain separate helical segments of TnI. We have utilized this structure to successfully explain the observed functional consequences of linker region deletion mutants. Together, these studies suggest that, although linker plasticity is important, the ability of TnC to function in muscle contraction can be correlated with a preferred domain orientation and interdomain distance.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, MSB 2015, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Rosevear, PR (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, MSB 2015, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044324] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 44324] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Abbott MB, 2000, J BIOL CHEM, V275, P20610, DOI 10.1074/jbc.M909252199; Abbott MB, 2000, FEBS LETT, V469, P168, DOI 10.1016/S0014-5793(00)01271-0; Abbott MB, 2001, BIOCHEMISTRY-US, V40, P5992, DOI 10.1021/bi0100642; Abusamhadneh E, 2001, FEBS LETT, V506, P51, DOI 10.1016/S0014-5793(01)02790-9; Al-Hashimi HM, 2000, J MAGN RESON, V143, P402, DOI 10.1006/jmre.2000.2049; Andersson P, 1998, J MAGN RESON, V133, P364, DOI 10.1006/jmre.1998.1492; BABU A, 1993, J BIOL CHEM, V268, P19232; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Clore GM, 1998, J MAGN RESON, V131, P159, DOI 10.1006/jmre.1997.1345; Clore GM, 2002, J MAGN RESON, V154, P329, DOI 10.1006/jmre.2001.2489; DOBROWOLSKI Z, 1991, J BIOL CHEM, V266, P5703; Dong WJ, 2000, PROTEIN SCI, V9, P280; Dong WJ, 1999, J BIOL CHEM, V274, P31382, DOI 10.1074/jbc.274.44.31382; Finley N, 1999, FEBS LETT, V453, P107, DOI 10.1016/S0014-5793(99)00693-6; Gaponenko V, 1999, J BIOL CHEM, V274, P16681, DOI 10.1074/jbc.274.24.16681; Gasmi-Seabrook GMC, 1999, BIOCHEMISTRY-US, V38, P8313, DOI 10.1021/bi9902642; Hansen MR, 2000, METHOD ENZYMOL, V317, P220; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; Houdusse A, 1997, STRUCTURE, V5, P1695, DOI 10.1016/S0969-2126(97)00315-8; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; KLEERKOPER Q, 1995, BIOCHEMISTRY-US, V34, P13343, DOI 10.1021/bi00041a010; Kranz JK, 2002, J BIOL CHEM, V277, P16351, DOI 10.1074/jbc.C200139200; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li MX, 1999, BIOCHEMISTRY-US, V38, P8289, DOI 10.1021/bi9901679; Luo Y, 2000, J MOL BIOL, V296, P899, DOI 10.1006/jmbi.1999.3495; MOIR AJG, 1977, BIOCHEM J, V167, P333, DOI 10.1042/bj1670333; OLAH GA, 1994, BIOCHEMISTRY-US, V33, P8233, DOI 10.1021/bi00193a009; Paakkonen K, 2000, EUR J BIOCHEM, V267, P6665, DOI 10.1046/j.1432-1327.2000.01763.x; POTTER JD, 1977, J BIOL CHEM, V252, P2452; Ruckert M, 2000, J AM CHEM SOC, V122, P7793, DOI 10.1021/ja001068h; SHENG Z, 1991, J BIOL CHEM, V266, P5711; Tung CS, 2000, PROTEIN SCI, V9, P1312; VANEERD JP, 1975, BIOCHEM BIOPH RES CO, V64, P122, DOI 10.1016/0006-291X(75)90227-2; Vassylyev DG, 1998, P NATL ACAD SCI USA, V95, P4847, DOI 10.1073/pnas.95.9.4847; Wang GS, 2000, EMBO J, V19, P5635, DOI 10.1093/emboj/19.21.5635	37	25	26	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38565	38570		10.1074/jbc.M205306200	http://dx.doi.org/10.1074/jbc.M205306200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12147696	hybrid			2022-12-27	WOS:000178529600073
J	Labonte, P; Axelrod, V; Agarwal, A; Aulabaugh, A; Amin, A; Mak, P				Labonte, P; Axelrod, V; Agarwal, A; Aulabaugh, A; Amin, A; Mak, P			Modulation of hepatitis C virus RNA-dependent RNA polymerase activity by structure-based site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO INITIATION; CRYSTAL-STRUCTURE; NS5B; IDENTIFICATION; REQUIREMENTS; MECHANISM	The hepatitis C virus (HCV) encodes an RNA-dependent RNA polymerase (NS5B), which is indispensable for the viral genome replication. Although structural comparison among HCV NS5B, poliovirus 3D-pol, and human immunodeficiency virus-reverse transcriptase RNA-dependent polymerase reveals the canonical palm, fingers, and thumb domains, the crystal structure of HCV NS5B highlights the presence of a unique A1-loop, which extends from the fingers to the thumb domain (amino acids 12-46), providing many contact points for the proposed "closed" conformation of the enzyme. The polymerase also possesses a tunnel, which starts at the active site and terminates on the back surface of the enzyme. This tunnel of 19 A contains five basic amino acids, which may be engaged in NTP trafficking. In the present study, we exploited the crystal structure of the enzyme to elucidate the involvement of these two structural motifs in enzyme activity by site-directed mutagenesis. As predicted, the replacement of leucine 30 located in the Lambda1-loop is detrimental to the NS5B activity. Heparin-Sepharose column chromatography and analytical ultracentrifugation experiments strongly suggest a local alteration in the structure of the Leu-30 mutant. An analysis of amino acid substitutions in Arg-222 and Lys-151 within the putative NTP tunnel indicates that Arg-222 was critical in delivering NTPs to the active site, whereas Lys-151 was dispensable. Interestingly, the substitution of lysine 151 for a glutamic acid resulted in an enzyme that was consistently more active in de novo synthesis as well as by "copy-back" mechanism of a self-primed substrate when compared with the wild type NS5B enzyme. Burst kinetic analyses indicate that the gain in function of K151E enzyme was primarily the result of the formation of more productive preinitiation complexes that were used for the elongation reaction. In contrast to the recent observations, both the wild type and mutant enzymes were monomeric in solution, whereas molecules of higher order were apparent in the presence of RNA template.	Wyeth, Dept Infect Dis, Pearl River, NY 10965 USA; Wyeth, Dept Biol Chem, Pearl River, NY 10965 USA	Pfizer; Pfizer	Mak, P (corresponding author), Wyeth Res, 85 Bolton St,R231A, Cambridge, MA 02140 USA.	makp@wyeth.com						BARTENSCHLAGER R, 1993, J VIROL, V67, P3835, DOI 10.1128/JVI.67.7.3835-3844.1993; Bartenschlager R, 1997, ANTIVIR CHEM CHEMOTH, V8, P281, DOI 10.1177/095632029700800401; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; BLUMENTHAL T, 1980, P NATL ACAD SCI-BIOL, V77, P2601, DOI 10.1073/pnas.77.5.2601; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; Bressanelli S, 2002, J VIROL, V76, P3482, DOI 10.1128/JVI.76.7.3482-3492.2002; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Carroll SS, 2000, BIOCHEMISTRY-US, V39, P8243, DOI 10.1021/bi991992s; Clarke B, 1997, J GEN VIROL, V78, P2397, DOI 10.1099/0022-1317-78-10-2397; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Kao CC, 1996, J VIROL, V70, P6826, DOI 10.1128/JVI.70.10.6826-6830.1996; Kao CC, 1999, VIROLOGY, V253, P1, DOI 10.1006/viro.1998.9517; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; KIM DW, 1995, BIOCHEM BIOPH RES CO, V215, P160, DOI 10.1006/bbrc.1995.2447; Kim MJ, 2000, J VIROL, V74, P10312, DOI 10.1128/JVI.74.22.10312-10322.2000; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Makeyev EV, 2000, EMBO J, V19, P124, DOI 10.1093/emboj/19.1.124; MURPHY FA, 1995, CLASSIFICATION NOMEN, P424; Oh JW, 1999, J VIROL, V73, P7694, DOI 10.1128/JVI.73.9.7694-7702.1999; Qin WP, 2002, J BIOL CHEM, V277, P2132, DOI 10.1074/jbc.M106880200; Qin WP, 2001, HEPATOLOGY, V33, P728, DOI 10.1053/jhep.2001.22765; Reichard O, 1998, LANCET, V351, P83, DOI 10.1016/S0140-6736(97)06088-1; Sarbah SA, 2000, J CLIN GASTROENTEROL, V30, P125, DOI 10.1097/00004836-200003000-00005; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Sun JH, 1996, VIROLOGY, V226, P1, DOI 10.1006/viro.1996.0622; Tomei L, 2000, J GEN VIROL, V81, P759, DOI 10.1099/0022-1317-81-3-759; Wang QM, 2002, J VIROL, V76, P3865, DOI 10.1128/JVI.76.8.3865-3872.2002; *WHO, 1998, LANCET, V351, P1415; Yuan ZH, 1997, BIOCHEM BIOPH RES CO, V232, P231, DOI 10.1006/bbrc.1997.6249; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	36	57	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38838	38846		10.1074/jbc.M204657200	http://dx.doi.org/10.1074/jbc.M204657200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145289	hybrid			2022-12-27	WOS:000178529600105
J	Tsai, AL; Palmer, G; Wu, G; Peng, S; Okeley, NM; van der Donk, WA; Kulmacz, RJ				Tsai, AL; Palmer, G; Wu, G; Peng, S; Okeley, NM; van der Donk, WA; Kulmacz, RJ			Structural characterization of arachidonyl radicals formed by aspirin-treated prostaglandin H synthase-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CYCLOOXYGENASE ACTIVE-SITE; HIGHER OXIDATION-STATES; TYROSYL RADICALS; RIBONUCLEOTIDE REDUCTASE; ENDOPEROXIDE SYNTHASE; HYDROGEN ABSTRACTION; ROTATIONAL BARRIERS; PEROXIDASE REACTION	Peroxide-generated tyrosyl radicals in both prostaglandin H synthase (PGHS) isozymes have been demonstrated to couple the peroxidase and cyclooxygenase activities by serving as the immediate oxidant for arachidonic acid (AA) in cyclooxygenase catalysis. Acetylation of Ser-530 of PGHS-1 by aspirin abolishes all oxygenase activity and transforms the peroxide-induced tyrosyl radical from a functional 33-35-gauss (G) wide doublet/wide singlet to a 26-G narrow singlet unable to oxidize AA. In contrast, aspirin-treated PGHS-2 (ASA-PGHS-2) no longer forms prostaglandins but retains oxygenase activity forming 11(R)- and 15(R)-hydroperoxyeicosatetraenoic acid and also retains the EPR line-shape of the native peroxide-induced 29-30-G wide singlet radical. To evaluate the functional role of the wide singlet radical in ASA-PGHS-2, we have examined the ability of this radical to oxidize AA in single-turnover EPR studies. Anaerobic addition of AA to ASA-PGHS-2 immediately after formation of the wide singlet radical generated either a 7-line EPR signal similar to the pentadienyl AA radical obtained in native PGHS-2 or a 26-28-G singlet radical. These EPR signals could be accounted for by a pentadienyl radical and a strained allyl radical, respectively. Experiments using 11d-AA, 13(R)d-AA, 15d-AA, 13,15d(2)-AA, and octadeuterated AA (d(8)-AA) confirmed that the unpaired electron in the pentadienyl radical is delocalized over C11, C13, and C15. A 6-line EPR radical was observed when 16d(2)-AA was used, indicating only one strongly interacting C16 hydrogen. These results support a functional role for peroxide-generated tyrosyl radicals in lipoxygenase catalysis by ASA-PGHS-2 and also indicate that the AA radical in ASA-PGHS-2 is more constrained than the corresponding radical in native PGHS-2.	Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, Houston, TX 77030 USA; Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77251 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	University of Texas System; University of Texas Health Science Center Houston; Rice University; University of Illinois System; University of Illinois Urbana-Champaign	Tsai, AL (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Internal Med, Div Hematol, 6431 Fannin St, Houston, TX 77030 USA.		van der Donk, Wilfred/K-2961-2015	van der Donk, Wilfred/0000-0002-5467-7071	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052170] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44911, GM52170, GM55807] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bally T, 1999, REV COMP CH, V13, P1, DOI 10.1002/9780470125908.ch1; BASCETTA E, 1982, J CHEM SOC CHEM COMM, P110, DOI 10.1039/c39820000110; BOLTON JR, 1965, J CHEM PHYS, V43, P309, DOI 10.1063/1.1696475; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Clish CB, 1999, P NATL ACAD SCI USA, V96, P8247, DOI 10.1073/pnas.96.14.8247; DAVIES AG, 1981, J CHEM SOC PERK T 2, P633, DOI 10.1039/p29810000633; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; FORT RC, 1993, J ORG CHEM, V58, P211, DOI 10.1021/jo00053a038; Gerfen GJ, 1998, J AM CHEM SOC, V120, P3823, DOI 10.1021/ja972166e; HALES BJ, 1993, METHOD ENZYMOL, V227, P384; HELLER C, 1962, J CHEM PHYS, V37, P243, DOI 10.1063/1.1701312; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; HOGANSON CW, 1992, BIOCHEMISTRY-US, V31, P11874, DOI 10.1021/bi00162a028; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1991, MOL PHARMACOL, V40, P833; KULMACZ RJ, 1994, BIOCHEMISTRY-US, V33, P5428, DOI 10.1021/bi00184a011; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; Kulmacz RJ, 1987, PROSTAGLANDINS RELAT, P209; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LECOMTE M, 1994, J BIOL CHEM, V269, P13207; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; MACINNES I, 1985, J CHEM SOC PERK T 2, P1073; MAIER G, 1983, CHEM BER-RECL, V116, P732, DOI 10.1002/cber.19831160230; Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933; MANCINI JA, 1994, FEBS LETT, V342, P33, DOI 10.1016/0014-5793(94)80579-2; MCCONNELL HM, 1956, J CHEM PHYS, V24, P764, DOI 10.1063/1.1742605; MEADE EA, 1993, J BIOL CHEM, V268, P6610; NELSON MJ, 1994, BIOCHEMISTRY-US, V33, P4966, DOI 10.1021/bi00182a027; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; Peng S, 2001, J AM CHEM SOC, V123, P3609, DOI 10.1021/ja015599x; Peng S, 2002, J AM CHEM SOC, V124, P10785, DOI 10.1021/ja026880u; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; ROGERS AS, 1973, J AM CHEM SOC, V95, P6913; ROTH GJ, 1983, BIOCHEMISTRY-US, V22, P4672, DOI 10.1021/bi00289a010; Rowlinson SW, 2000, J BIOL CHEM, V275, P6586, DOI 10.1074/jbc.275.9.6586; Schneider C, 2000, J BIOL CHEM, V275, P4743, DOI 10.1074/jbc.275.7.4743; Schneider C, 2002, J BIOL CHEM, V277, P478, DOI 10.1074/jbc.M107471200; SMITH WL, 1992, BIOCHEMISTRY-US, V31, P3, DOI 10.1021/bi00116a001; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; STEPHEN MJ, 1960, J CHEM PHYS, V32, P1435, DOI 10.1063/1.1730936; SUSTMANN R, 1979, CHEM BER-RECL, V112, P1440, DOI 10.1002/cber.19791120437; Thuresson ED, 2000, J BIOL CHEM, V275, P8501, DOI 10.1074/jbc.275.12.8501; TSAI AL, 1994, J BIOL CHEM, V269, P5085; Tsai AL, 1998, J BIOL CHEM, V273, P3888, DOI 10.1074/jbc.273.7.3888; Tsai AL, 2000, PROSTAG OTH LIPID M, V62, P231, DOI 10.1016/S0090-6980(00)00083-6; TSAI AL, 1995, J BIOL CHEM, V270, P10503, DOI 10.1074/jbc.270.18.10503; VANDEROUDERAA FJ, 1980, EUR J BIOCHEM, V109, P1; Wade D, 1999, CHEM-BIOL INTERACT, V117, P191, DOI 10.1016/S0009-2797(98)00097-0; WENNOGLE LP, 1995, FEBS LETT, V371, P315, DOI 10.1016/0014-5793(95)00930-8; Wu WM, 2000, BIOCHEMISTRY-US, V39, P9561, DOI 10.1021/bi000658p; Xiao GS, 1997, BIOCHEMISTRY-US, V36, P1836, DOI 10.1021/bi962476u	53	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38311	38321		10.1074/jbc.M206961200	http://dx.doi.org/10.1074/jbc.M206961200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12167656	hybrid			2022-12-27	WOS:000178529600042
J	Zhou, YQ; Chen, YQ; Fisher, JH; Wang, MH				Zhou, YQ; Chen, YQ; Fisher, JH; Wang, MH			Activation of the RON receptor tyrosine kinase by macrophage-stimulating protein inhibits inducible cyclooxygenase-2 expression in murine macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; NITRIC-OXIDE; PHOSPHATIDYLINOSITOL-3 KINASE; GENE-PRODUCT; LIPOPOLYSACCHARIDE; MSP; IDENTIFICATION; REQUIREMENT; INVOLVEMENT; INDUCTION	The RON receptor tyrosine kinase is activated by macrophage-stimulating protein, which regulates macrophage migration, phagocytosis, and nitric oxide production. We report here the inhibitory effect of RON on lipopolysaccharide (LPS)-induced cyclooxygenase (Cox)2 expression in mouse macrophages. In RON-expressing macrophages treated with macrophage stimulating protein, LPS-induced prostaglandin E-2 (PGE(2)) production was significantly reduced. The inhibition was accompanied by reduction of Cox-2 protein and mRNA expression. Transcriptional studies indicated that RON activation inhibits LPS-induced luciferase activity driven by the Cox-2 gene promoter. To determine whether RON activation affects LPS-induced NF-kappaB pathway, which is important for Cox-2 expression. Western blot analyses were performed showing that RON activation inhibits LPS-induced IkappaBalpha degradation. The decreased IkappaBalpha degradation was due to reduced IkappaBalpha phosphorylation at Ser-32 as determined by IkappaBalpha (Ser-32) phosphor-antibody. Moreover, we found that LPS-induced IKKbeta activity, an enzyme responsible for phosphorylation of IkappaBalpha, was inhibited upon RON activation. Interestingly, these inhibitory effects were not regulated by RON-mediated phosphatidylinositol-3 kinase. These results suggest that RON activation inhibits LPS-induced macrophage Cox-2 expression. The inhibitory effect is mediated by impairing LPS-activated cascade enzymes that activate NF-kappaB. The inhibition of Cox-2 expression might represent a novel mechanism for the inhibitory functions of RON in vivo against LPS-induced inflammation and septic shock.	Zhejiang Univ, Sch Med, Affiliated Teaching Hosp 1, Div Neurosurg, Hangzhou 310003, Peoples R China; Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Med, Denver, CO 80204 USA; Univ Colorado, Sch Med, Denver Hlth Med Ctr, Dept Immunol, Denver, CO 80204 USA	Zhejiang University; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Denver Health Medical Center; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Wang, MH (corresponding author), UCHSC Denver Hlth Med Ctr, Dept Med, Mail A008-4000,777 Bannock St, Denver, CO 80204 USA.	ming-hai.wang@uchsc.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043516] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI43516] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barrios-Rodiles M, 1999, J IMMUNOL, V163, P963; BEZERRA JA, 1993, HEPATOLOGY, V18, P394, DOI 10.1016/0270-9139(93)90024-H; Chen YQ, 1998, J IMMUNOL, V161, P4950; Clancy R, 2000, J IMMUNOL, V165, P1582, DOI 10.4049/jimmunol.165.3.1582; CORRELL PH, 1997, GENES FUNCTION, V1, P1; DAcquisto F, 1997, FEBS LETT, V418, P175, DOI 10.1016/S0014-5793(97)01377-X; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; Gaudino G, 1995, ONCOGENE, V11, P2627; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; HAN S, 1991, BIOCHEMISTRY-US, V30, P9768, DOI 10.1021/bi00104a029; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; IWAMA A, 1994, BLOOD, V83, P3160, DOI 10.1182/blood.V83.11.3160.bloodjournal83113160; IWAMA A, 1995, BLOOD, V86, P3394, DOI 10.1182/blood.V86.9.3394.bloodjournal8693394; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kojima M, 2000, ONCOGENE, V19, P1225, DOI 10.1038/sj.onc.1203427; Kurihara N, 1996, BLOOD, V87, P3704, DOI 10.1182/blood.V87.9.3704.bloodjournal8793704; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pharmtox.35.1.655; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; LEONARD EJ, 1978, EXP CELL RES, V114, P117, DOI 10.1016/0014-4827(78)90043-5; Leonard EJ, 1997, CIBA F SYMP, V212, P183; Liu QP, 1999, J IMMUNOL, V163, P6606; Liu SF, 1999, CIRCULATION, V100, P1330, DOI 10.1161/01.CIR.100.12.1330; Muraoka RS, 1999, J CLIN INVEST, V103, P1277, DOI 10.1172/JCI6091; Nanney LB, 1998, J INVEST DERMATOL, V111, P573, DOI 10.1046/j.1523-1747.1998.00332.x; NUSSLER AK, 1993, J LEUKOCYTE BIOL, V54, P171, DOI 10.1002/jlb.54.2.171; O'Connell MA, 1998, J BIOL CHEM, V273, P30410, DOI 10.1074/jbc.273.46.30410; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; Patel R, 1999, J IMMUNOL, V162, P4191; Pistritto G, 1999, BIOCHEM BIOPH RES CO, V263, P570, DOI 10.1006/bbrc.1999.1413; RONSIN C, 1993, ONCOGENE, V8, P1195; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Simon L.S, 1999, AM J MED, V106, p37S, DOI [10.1016/S0002-9343(99)00115-1, DOI 10.1016/S0002-9343(99)00115-1]; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Waltz SE, 2001, J CLIN INVEST, V108, P567, DOI 10.1172/JCI11881; Wang MH, 1996, ONCOGENE, V13, P2167; WANG MH, 1994, J BIOL CHEM, V269, P14027; WANG MH, 1995, P NATL ACAD SCI USA, V92, P3933, DOI 10.1073/pnas.92.9.3933; Wang MH, 2000, J IMMUNOL, V164, P3815, DOI 10.4049/jimmunol.164.7.3815; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; Wang MH, 1997, J BIOL CHEM, V272, P16999, DOI 10.1074/jbc.272.27.16999; WANG MH, 1994, J BIOL CHEM, V269, P13806; Wang MH, 1996, J CLIN INVEST, V97, P720, DOI 10.1172/JCI118470; WANG MH, 1994, J BIOL CHEM, V269, P3436; YOSHIMURA T, 1993, J BIOL CHEM, V268, P15461; Zhang YK, 1999, J BIOL CHEM, V274, P34657, DOI 10.1074/jbc.274.49.34657	50	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38104	38110		10.1074/jbc.M206167200	http://dx.doi.org/10.1074/jbc.M206167200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12177064	hybrid			2022-12-27	WOS:000178529600018
J	Tanji, C; Yamamoto, H; Yorioka, N; Kohno, N; Kikuchi, K; Kikuchi, A				Tanji, C; Yamamoto, H; Yorioka, N; Kohno, N; Kikuchi, K; Kikuchi, A			A-kinase anchoring protein AKAP220 binds to glycogen synthase kinase-3 beta (GSK-3 beta) and mediates protein kinase A-dependent inhibition of GSK-3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; BETA-CATENIN; SUBSTRATE-SPECIFICITY; XENOPUS EMBRYOS; GROWTH-FACTOR; PHOSPHORYLATION; INACTIVATION; INSULIN; ENCODES; YEAST	Glycogen synthase kinase-3 (GSK-3) is regulated by various extracellular ligands and phosphorylates many substrates, thereby regulating cellular functions. Using yeast two-hybrid screening, we found that GSK-3beta binds to AKAP220, which is known to act as an A-kinase anchoring protein. GSK-3beta formed a complex with AKAP220 in intact cells at the endogenous level. Cyclic AMP-dependent protein kinase (PKA) and type 1 protein phosphatase (PP1) were also detected in this complex, suggesting that AKAP220, GSK-3beta, PKA, and PP1 form a quaternary complex. It has been reported that PKA phosphorylates GSK-3beta, thereby decreasing its activity. When COS cells were treated with dibutyryl cyclic AMP to activate PKA, the activity of GSK-3beta bound to AKAP220 decreased more markedly than the total GSK-3beta activity. Calyculin A, a protein phosphatase inhibitor, also inhibited the activity of GSK-3beta bound to AKAP220 more strongly than the total GSK-3beta activity. These results suggest that PKA and PP1 regulate the activity of GSK-3beta efficiently by forming a complex with AKAP220.	Hiroshima Univ, Dept Biochem, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan; Hiroshima Univ, Dept Mol & Internal Med, Grad Sch Biomed Sci, Minami Ku, Hiroshima 7348551, Japan; Hokkaido Univ, Div Biochem Oncol & Immunol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Hiroshima University; Hiroshima University; Hokkaido University	Kikuchi, A (corresponding author), Hiroshima Univ, Dept Biochem, Grad Sch Biomed Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.		Hiyama, Eiso/A-2013-2019	Hiyama, Eiso/0000-0001-9179-5037				Andoh T, 2000, MOL CELL BIOL, V20, P6712, DOI 10.1128/MCB.20.18.6712-6720.2000; Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Dale TC, 1998, BIOCHEM J, V329, P209; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Fraser IDC, 1998, EMBO J, V17, P2261, DOI 10.1093/emboj/17.8.2261; GOODE N, 1992, J BIOL CHEM, V267, P16878; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Kikuchi A, 1999, CELL SIGNAL, V11, P777, DOI 10.1016/S0898-6568(99)00054-6; Kikuchi A, 2000, BIOCHEM BIOPH RES CO, V268, P243, DOI 10.1006/bbrc.1999.1860; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Lester LB, 1996, J BIOL CHEM, V271, P9460, DOI 10.1074/jbc.271.16.9460; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Mizunuma M, 2001, EMBO J, V20, P1074, DOI 10.1093/emboj/20.5.1074; Murai H, 1996, FEBS LETT, V392, P153, DOI 10.1016/0014-5793(96)00806-X; NEIGEBORN L, 1991, GENE DEV, V5, P533, DOI 10.1101/gad.5.4.533; PERRIMON N, 1989, DEV BIOL, V135, P287, DOI 10.1016/0012-1606(89)90180-2; Plyte SE, 1996, MOL CELL BIOL, V16, P179; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Reinton N, 2000, DEV BIOL, V223, P194, DOI 10.1006/dbio.2000.9725; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; Schillace RV, 1999, CURR BIOL, V9, P321, DOI 10.1016/S0960-9822(99)80141-9; Schillace RV, 2001, J BIOL CHEM, V276, P12128, DOI 10.1074/jbc.M010398200; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; SHERO JH, 1991, GENE DEV, V5, P549, DOI 10.1101/gad.5.4.549; SIMPSON P, 1988, DEVELOPMENT, V103, P391; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tanaka T, 1998, FEBS LETT, V426, P248, DOI 10.1016/S0014-5793(98)00346-9; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443	46	96	102	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36955	36961		10.1074/jbc.M206210200	http://dx.doi.org/10.1074/jbc.M206210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147701	hybrid			2022-12-27	WOS:000178447100008
J	Kawate, H; Landis, DM; Loeb, LA				Kawate, H; Landis, DM; Loeb, LA			Distribution of mutations in human thymidylate synthase yielding resistance to 5-fluorodeoxyuridine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; DNA-REPLICATION; INHIBITORS; FIDELITY; MUTANTS; POLYMERASE; COMPLEXES; THYMITAQ	Thymidylate synthase (TS) catalyzes methylation of dUMP to dTMP and is the target of cancer chemotherapeutic agents (e.g. 5-fluorouracil). Here, we used error-prone PCR to mutagenize the full-length human TS cDNA and then selected mutants resistant to 5-fluorodeoxyuridine in a bacterial complementation system. We found that resistant mutants contained 1-5 amino acid substitutions and that these substitutions were located along the entire length of the polypeptide. Mutations were frequent near the active site Cys(195) and in the catalytically important Arg(50) loop; however, many mutations were also distributed throughout the remainder of the cDNA. Mutants containing a single amino acid replacement identified the following 14 residues as unreported sites of resistance: Glu(23), Thr(51), Thr(53), Val(84), Lys(93), Asp(110), Asp(116), Pro(194), Ser(206), Met(219), His(250), Asp(254), Tyr(258), and Lys(284). Many of these residues are distant from the active site and/or have no documented function in catalysis or resistance. We conclude that mutations distributed throughout the linear sequence and three-dimensional structure of human TS can confer resistance to 5-fluorodeoxyuridine. Our findings imply that long range interactions within proteins affect catalysis at the active site and that mutations at a distance can yield variant proteins with desired properties.	Univ Washington, Dept Pathol, Joseph Gottstein Mem Canc Res Lab, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Loeb, LA (corresponding author), Univ Washington, Dept Pathol, Joseph Gottstein Mem Canc Res Lab, Box 357705, Seattle, WA 98195 USA.	laloeb@u.washington.edu			NATIONAL CANCER INSTITUTE [R01CA078885] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042570] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78885] Funding Source: Medline; NIAID NIH HHS [AI42570] Funding Source: Medline; NIEHS NIH HHS [ES007033] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahmad SI, 1998, ANNU REV MICROBIOL, V52, P591, DOI 10.1146/annurev.micro.52.1.591; Almog R, 2001, PROTEIN SCI, V10, P988, DOI 10.1110/ps.47601; BARBOUR KW, 1992, MOL PHARMACOL, V42, P242; BECKMAN RA, 1985, BIOCHEMISTRY-US, V24, P5810, DOI 10.1021/bi00342a019; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CARRERAS CW, 1995, ANNU REV BIOCHEM, V64, P721, DOI 10.1146/annurev.bi.64.070195.003445; CLIMIE S, 1990, J BIOL CHEM, V265, P18776; Danenberg PV, 1999, SEMIN ONCOL, V26, P621; Dixon M., 1964, ENZYMES, P328; Edman L, 2000, P NATL ACAD SCI USA, V97, P8266, DOI 10.1073/pnas.130589397; Kitchens ME, 1999, MOL PHARMACOL, V56, P1063, DOI 10.1124/mol.56.5.1063; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1979, J BIOL CHEM, V254, P5718; Landis DM, 1998, J BIOL CHEM, V273, P25809, DOI 10.1074/jbc.273.40.25809; Landis DM, 2001, CANCER RES, V61, P666; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Osborne MJ, 2001, BIOCHEMISTRY-US, V40, P9846, DOI 10.1021/bi010621k; Patel PH, 2001, J BIOL CHEM, V276, P5044, DOI 10.1074/jbc.M008701200; Phan J, 2001, J BIOL CHEM, V276, P14170, DOI 10.1074/jbc.M009493200; Phan J, 2001, BIOCHEMISTRY-US, V40, P1897, DOI 10.1021/bi002413i; POGOLOTTI AL, 1986, J MED CHEM, V29, P478, DOI 10.1021/jm00154a009; Rustum YM, 1997, J CLIN ONCOL, V15, P389, DOI 10.1200/JCO.1997.15.1.389; Sayre PH, 2001, J MOL BIOL, V313, P813, DOI 10.1006/jmbi.2001.5074; Schiffer CA, 1995, BIOCHEMISTRY-US, V34, P16279, DOI 10.1021/bi00050a007; Sotelo-Mundo RR, 1999, BIOCHEMISTRY-US, V38, P1087, DOI 10.1021/bi981881d; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; Tong YZ, 1998, J BIOL CHEM, V273, P11611, DOI 10.1074/jbc.273.19.11611; Tong YZ, 1998, J BIOL CHEM, V273, P31209, DOI 10.1074/jbc.273.47.31209; WAHBA AJ, 1961, J BIOL CHEM, V236, pPC11	30	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36304	36311		10.1074/jbc.M204956200	http://dx.doi.org/10.1074/jbc.M204956200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12147691	hybrid			2022-12-27	WOS:000178275100067
J	Prioleau, C; Visiers, I; Ebersole, BJ; Weinstein, H; Sealfon, SC				Prioleau, C; Visiers, I; Ebersole, BJ; Weinstein, H; Sealfon, SC			Conserved helix 7 tyrosine acts as a multistate conformational switch in the 5HT2C receptor - Identification of a novel "locked-on" phenotype and double revertant mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA(2) ADRENERGIC-RECEPTOR; SEROTONIN 5-HT2A RECEPTOR; MUSCARINIC ACETYLCHOLINE-RECEPTOR; MU-OPIOID RECEPTOR; CONSTITUTIVE ACTIVATION; HORMONE RECEPTOR; BETA(2)-ADRENERGIC RECEPTOR; TRANSMEMBRANE HELIX; ARGININE-CAGE	Studies in many rhodopsin-like G-protein-coupled receptors are providing a general scheme of the structural processes underlying receptor activation. Microdomains in several receptors have been identified that appear to function as activation switches. However, evidence is emerging that these receptor proteins exist in multiple conformational states. To study the molecular control of this switching process, we investigated the function of a microdomain involving the conserved helix 7 tyrosine in the serotonin 5HT2C receptor. This tyrosine of the NPXXY motif was substituted for all naturally occurring amino acids. Three distinct constitutively active receptor phenotypes were found: moderate, high, and "locked-on" constitutive activity. In contrast to the activity of the other receptor mutants, the high basal signaling of the locked-on Y7.53N mutant was neither increased by agonists nor decreased by inverse agonists. The Y7.53F mutant was uncoupled. Computational modeling based on the rhodopsin crystal structure suggested that Y7.53 interacts with the conserved aromatic ring at position 7.60 in the recently identified helix 8 domain. This provided a basis for seeking revertant mutations to correct the defective function of the Y7.53F receptor. When the Y7.53F receptor was mutated at position 7.60, the wild-type phenotype was restored. These results suggest that Y7.53 and Y7.60 contribute to a common functional microdomain connecting helices 7 and 8 that influences the switching of the 5HT2C receptor among multiple active and inactive conformations.	CUNY Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Pharmacol & Biol Chem, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Sealfon, SC (corresponding author), CUNY Mt Sinai Sch Med, Dept Neurol, Box 1137,1 Gustave L Levy Pl, New York, NY 10029 USA.	stuart.sealfon@mssm.edu	WEINSTEIN, HAREL/O-8245-2019	WEINSTEIN, HAREL/0000-0003-3473-9818; SEALFON, Stuart/0000-0001-5791-1217	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA012923] Funding Source: NIH RePORTER; NIDA NIH HHS [P01-DA12923] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; Arora KK, 1996, MOL ENDOCRINOL, V10, P979, DOI 10.1210/me.10.8.979; Ballesteros J, 1998, J BIOL CHEM, V273, P10445, DOI 10.1074/jbc.273.17.10445; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Ballesteros JA, 2001, MOL PHARMACOL, V60, P1, DOI 10.1124/mol.60.1.1; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; BARKER EL, 1994, J BIOL CHEM, V269, P11687; Berg KA, 1998, MOL PHARMACOL, V54, P94, DOI 10.1124/mol.54.1.94; Biebermann H, 1998, FASEB J, V12, P1461, DOI 10.1096/fasebj.12.14.1461; Bohm SK, 1997, J BIOL CHEM, V272, P2363; Burstein ES, 1998, J BIOL CHEM, V273, P24322, DOI 10.1074/jbc.273.38.24322; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; Chen SH, 2002, BIOCHEMISTRY-US, V41, P588, DOI 10.1021/bi011868k; Cordeaux Y, 2001, J BIOL CHEM, V276, P28667, DOI 10.1074/jbc.M008644200; Dias JA, 2001, ARCH MED RES, V32, P510, DOI 10.1016/S0188-4409(01)00333-2; Duong TH, 1999, J COMPUT PHYS, V151, P358, DOI 10.1006/jcph.1999.6222; Ebersole BJ, 2002, METHOD ENZYMOL, V343, P123; Elling CE, 1999, P NATL ACAD SCI USA, V96, P12322, DOI 10.1073/pnas.96.22.12322; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Feng YH, 1998, BIOCHEMISTRY-US, V37, P15791, DOI 10.1021/bi980863t; Fianagan CA, 1999, J BIOL CHEM, V274, P28880, DOI 10.1074/jbc.274.41.28880; Freire E, 1999, P NATL ACAD SCI USA, V96, P10118, DOI 10.1073/pnas.96.18.10118; Gabilondo AM, 1996, EUR J PHARMACOL, V307, P243, DOI 10.1016/0014-2999(96)00247-6; Gerber BO, 2001, J BIOL CHEM, V276, P3394, DOI 10.1074/jbc.M007748200; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Ghanouni P, 2001, P NATL ACAD SCI USA, V98, P5997, DOI 10.1073/pnas.101126198; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Go WY, 1998, AM J PHYSIOL-GASTR L, V275, pG56, DOI 10.1152/ajpgi.1998.275.1.G56; Grotewiel MS, 1999, N-S ARCH PHARMACOL, V359, P21, DOI 10.1007/PL00005318; Huang P, 2001, BIOCHEMISTRY-US, V40, P13501, DOI 10.1021/bi010917q; Hukovic N, 1998, J BIOL CHEM, V273, P21416, DOI 10.1074/jbc.273.33.21416; HUNYADY L, 1995, J BIOL CHEM, V270, P16602, DOI 10.1074/jbc.270.28.16602; Javitch JA, 1997, J BIOL CHEM, V272, P18546, DOI 10.1074/jbc.272.30.18546; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P232, DOI 10.1016/S0165-6147(00)89032-X; Kitanovic S, 2001, MOL ENDOCRINOL, V15, P390, DOI 10.1210/me.15.3.390; KJELSBERG MA, 1992, J BIOL CHEM, V267, P1430; Konvicka K, 1998, BIOPHYS J, V75, P601, DOI 10.1016/S0006-3495(98)77551-4; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Laporte SA, 1996, MOL PHARMACOL, V49, P89; LeGouill C, 1997, J BIOL CHEM, V272, P21289, DOI 10.1074/jbc.272.34.21289; Li J, 2001, BIOCHEMISTRY-US, V40, P12039, DOI 10.1021/bi0100945; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lu ZL, 2001, J BIOL CHEM, V276, P34098, DOI 10.1074/jbc.M104217200; Lu ZL, 2000, J BIOL CHEM, V275, P5682, DOI 10.1074/jbc.275.8.5682; Lu ZL, 2002, TRENDS PHARMACOL SCI, V23, P140, DOI 10.1016/S0165-6147(00)01973-8; Ma BY, 1999, PROTEIN ENG, V12, P713, DOI 10.1093/protein/12.9.713; Marie J, 2001, J BIOL CHEM, V276, P41100, DOI 10.1074/jbc.M104875200; Miettinen HM, 1999, J BIOL CHEM, V274, P27934, DOI 10.1074/jbc.274.39.27934; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Peleg G, 2001, P NATL ACAD SCI USA, V98, P8469, DOI 10.1073/pnas.151239698; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; Rosendorff A, 2000, MOL BRAIN RES, V84, P90, DOI 10.1016/S0169-328X(00)00227-8; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SALTZMAN AG, 1991, BIOCHEM BIOPH RES CO, V181, P1469, DOI 10.1016/0006-291X(91)92105-S; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; Sealfon SC, 1997, ENDOCR REV, V18, P180, DOI 10.1210/er.18.2.180; Seifert R, 2001, J PHARMACOL EXP THER, V297, P1218; Shapiro DA, 2002, J BIOL CHEM, V277, P11441, DOI 10.1074/jbc.M111675200; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Shichida Y, 2000, METHOD ENZYMOL, V315, P347; Shinozaki H, 2001, MOL ENDOCRINOL, V15, P972, DOI 10.1210/me.15.6.972; SLICE LW, 1994, J BIOL CHEM, V269, P21755; Struthers M, 2000, BIOCHEMISTRY-US, V39, P7938, DOI 10.1021/bi000771f; Tao YX, 2000, MOL ENDOCRINOL, V14, P1272, DOI 10.1210/me.14.8.1272; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Visiers I, 2002, METHOD ENZYMOL, V343, P329; Visiers I, 2002, INT J QUANTUM CHEM, V88, P65, DOI 10.1002/qua.10078; Vogel R, 2002, BIOCHEMISTRY-US, V41, P3529, DOI 10.1021/bi016023n; Wang JF, 1997, MOL PHARMACOL, V52, P306, DOI 10.1124/mol.52.2.306; Ward SDC, 2002, J BIOL CHEM, V277, P2247, DOI 10.1074/jbc.M107647200; WARD WHJ, 1990, TRENDS PHARMACOL SCI, V11, P280, DOI 10.1016/0165-6147(90)90009-W; WESTPHAL RS, 1995, MOL PHARMACOL, V48, P200; ZHOU W, 1994, MOL PHARMACOL, V45, P165; ZHUKOVSKY EA, 1991, SCIENCE, V251, P558, DOI 10.1126/science.1990431	79	100	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36577	36584		10.1074/jbc.M206223200	http://dx.doi.org/10.1074/jbc.M206223200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145300	hybrid			2022-12-27	WOS:000178275100101
J	Sun, L; Pan, XM; Wada, J; Haas, CS; Wuthrich, RP; Danesh, FR; Chugh, SS; Kanwar, YS				Sun, L; Pan, XM; Wada, J; Haas, CS; Wuthrich, RP; Danesh, FR; Chugh, SS; Kanwar, YS			RETRACTED: Isolation and functional analysis of mouse UbA52 gene and its relevance to diabetic nephropathy (Retracted article. See vol. 294, pg. 10382, 2019)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							PROTEASOME PROTEOLYTIC PATHWAY; UBIQUITIN MESSENGER-RNA; RESPONSE ELEMENT; SKELETAL-MUSCLE; TRANSCRIPTION; ACTIVATION; EXPRESSION; PROMOTER; STRESS; FUSION	In delineating the mechanism(s) of diabetic nephropathy various novel genes have been isolated, whereas others remain to be discovered. We identified several up-regulated genes in the kidneys of diabetic newborn mice. Among them was UbA52, a ubiquitin ribosomal fusion protein. Its mRNA expression in the kidney was proportional to blood glucose levels. By in situ hybridization and immunohistochemistry, UbA52 was exclusively localized to renal tubules, and its expression was markedly increased in diabetic mice. The up-regulated UbA52 mRNA and protein expression were also observed in Madin-Darby canine kidney cells, a tubular cell line, treated with 30 mm glucose in both cell lysates and ribosomal fractions. To explore the mechanism(s) of its increased expression, UbA52 genomic DNA was isolated. A transcription start site at -22 by from the initiation codon was identified and confirmed by primer extension analysis. The UbA52 promoter region included glucose response-related E-box sequences and stress response elements (STRE). Unlike in humans, mouse UbA52 gene had no introns in the coding or 5'-ATG-flanking regions. To identify the DNA segment with maximal promoter activity, deletion constructs were prepared using a pSEAP vector system and transfected into COS7 kidney cells. Maximal activity was confined to -198 to +68 bp, which included E-boxes and STRE motifs. A dose-dependent increase in the promoter activity was observed in cells exposed to high glucose. Mutations in the first E-box (CAGCTG --> TGGCTG) or STRE (CCCCT --> CATCT) resulted in a decrease in the SEAP activity under high glucose ambience. Given the presence of glucose-responsive motifs in the promoter region and decrease in the SEAP activity in E-box mutants in the presence of glucose, these data suggest that UbA52, a ribosomal fusion protein, may be relevant in the pathogenesis of diabetic nephropathy.	Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Okayama Univ, Dept Med, Okayama 7008558, Japan	Northwestern University; Northwestern University; Okayama University	Kanwar, YS (corresponding author), Northwestern Univ, Sch Med, Dept Pathol, 303 E Chicago Ave, Chicago, IL 60611 USA.	y-kanwar@northwestern.edu	WADA, Jun/B-2023-2011	WADA, Jun/0000-0003-1468-5170; Danesh, Farhad/0000-0001-6849-5239	NIDDK NIH HHS [DK-28492, DK-60635] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028492, R01DK028492, R01DK060635] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akarsu E, 2001, DIABETES CARE, V24, P100, DOI 10.2337/diacare.24.1.100; BAKER RT, 1991, NUCLEIC ACIDS RES, V19, P1035, DOI 10.1093/nar/19.5.1035; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Chen S, 2001, KIDNEY INT, V59, P673, DOI 10.1046/j.1523-1755.2001.059002673.x; Du J, 2000, J BIOL CHEM, V275, P19661, DOI 10.1074/jbc.M907258199; Feliers D, 2001, KIDNEY INT, V60, P495, DOI 10.1046/j.1523-1755.2001.060002495.x; FORNACE AJ, 1989, NUCLEIC ACIDS RES, V17, P1215, DOI 10.1093/nar/17.3.1215; Gooch JL, 2001, J BIOL CHEM, V276, P42492, DOI 10.1074/jbc.M102994200; Hasegawa J, 1999, J BIOL CHEM, V274, P1100, DOI 10.1074/jbc.274.2.1100; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Kamynina E, 2001, AM J PHYSIOL-RENAL, V281, pF469, DOI 10.1152/ajprenal.2001.281.3.F469; Kanwar YS, 1996, J CLIN INVEST, V98, P2478, DOI 10.1172/JCI119066; Kirschner LS, 2000, BIOCHEM BIOPH RES CO, V270, P1106, DOI 10.1006/bbrc.2000.2568; Koo SH, 2000, J BIOL CHEM, V275, P5200, DOI 10.1074/jbc.275.7.5200; Larbaud D, 1996, AM J PHYSIOL-ENDOC M, V271, pE505, DOI 10.1152/ajpendo.1996.271.3.E505; Liu ZQ, 2000, BIOCHEM BIOPH RES CO, V276, P1255, DOI 10.1006/bbrc.2000.3609; Marinovic AC, 2000, BIOCHEM BIOPH RES CO, V274, P537, DOI 10.1006/bbrc.2000.3171; MARINOVIC AC, 2000, J AM SOC NEPHROL, V11, P624; Mitch WE, 1999, AM J PHYSIOL-CELL PH, V276, pC1132, DOI 10.1152/ajpcell.1999.276.5.C1132; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Natarajan R, 2002, DIABETOLOGIA, V45, P125, DOI 10.1007/s125-002-8253-x; Page R, 1997, BIOCHEM BIOPH RES CO, V232, P49, DOI 10.1006/bbrc.1997.6224; Portois L, 1999, J BIOL CHEM, V274, P8181, DOI 10.1074/jbc.274.12.8181; PRICE RG, 1987, RENAL BASEMENT MEMBR, P439; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; Reddy MA, 2002, J BIOL CHEM, V277, P9920, DOI 10.1074/jbc.M111305200; REDMAN KL, 1994, INSECT BIOCHEM MOLEC, V24, P191, DOI 10.1016/0965-1748(94)90085-X; SHERTON CC, 1971, ANAL BIOCHEM, V41, P506; Sivaraman L, 2000, BREAST CANCER RES TR, V62, P185, DOI 10.1023/A:1006410111706; Sun L, 1999, BIOCHEM GENET, V37, P139, DOI 10.1023/A:1018778320235; SUN L, 2001, KIDNEY INT, V60, P2129; Travers MT, 2001, BIOCHEM J, V359, P273, DOI 10.1042/0264-6021:3590273; Voziyan PA, 2002, J BIOL CHEM, V277, P3397, DOI 10.1074/jbc.M109935200; Wada J, 1998, P NATL ACAD SCI USA, V95, P144, DOI 10.1073/pnas.95.1.144; WADA J, 2002, KIDNEY INT S1, V61, P73; WILKINSON KD, 1995, ANNU REV NUTR, V15, P161, DOI 10.1146/annurev.nu.15.070195.001113; Yang QW, 2000, P NATL ACAD SCI USA, V97, P9896, DOI 10.1073/pnas.160266197; Zahringer H, 2000, MOL MICROBIOL, V35, P397, DOI 10.1046/j.1365-2958.2000.01706.x	38	25	33	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29953	29962		10.1074/jbc.M204665200	http://dx.doi.org/10.1074/jbc.M204665200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12171997	hybrid			2022-12-27	WOS:000177509300076
J	Perrot, V; Vazquez-Prado, J; Gutkind, JS				Perrot, V; Vazquez-Prado, J; Gutkind, JS			Plexin B regulates Rho through the guanine nucleotide exchange factors leukemia-associated rho GEF (LARG) and PDZ-RhoGEF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; AXON GUIDANCE; ACTIVE RAC; SEMAPHORIN RECEPTORS; MOLECULAR-BASIS; P115 RHOGEF; BINDING; CYTOSKELETON; GTPASES; FAMILY	Plexins represent a novel family of transmembrane receptors that transduce attractive and repulsive signals mediated by the axon-guiding molecules semaphorins. Emerging evidence implicates Rho GTPases in these biological events. However, Plexins lack any known catalytic activity in their conserved cytoplasmic tails, and how they transduce signals from semaphorins to Rho is still unknown. Here we show that Plexin B2 associates directly with two members of a recently identified family of Dbl homology/pleckstrin homology containing guanine nucleotide exchange factors for Rho, PDZ-RhoGEF, and Leukemia-associated Rho GEF (LARG). This physical interaction is mediated by their PDZ domains and a PDZ-binding motif found only in Plexins of the B family. In addition, we show that ligand-induced dimerization of Plexin B is sufficient to stimulate endogenous RhoA potently and to induce the reorganization of the cytoskeleton. Moreover, overexpression of the PDZ domain of PDZ-RhoGEF but not its regulator of G protein signaling domain prevents cell rounding and neurite retraction of differentiated PC12 cells induced by activation of endogenous Plexin 131 by semaphorin 4D. The association of Plexins with LARG and PDZ-RhoGEF thus provides a direct molecular mechanism by which semaphorins acting on Plexin B can control Rho, thereby regulating the actin-cytoskeleton during axonal guidance and cell migration.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 9000 Rockville Pike,Bldg 30,Rm 211, Bethesda, MD 20892 USA.		VAZQUEZ-PRADO, JOSE/C-1630-2017; Gutkind, J. Silvio/J-1201-2016; Gutkind, J. Silvio/A-1053-2009	VAZQUEZ-PRADO, JOSE/0000-0001-5797-6643; Gutkind, J. Silvio/0000-0002-5150-4482; 	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000558, Z01DE000551] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aoki J, 1999, BIOCHEM J, V340, P365, DOI 10.1042/0264-6021:3400365; BISMUTH G, 2002, SCI STKE, pRE4; Chikumi H, 2002, J BIOL CHEM, V277, P12463, DOI 10.1074/jbc.M108504200; Christensen CRL, 1998, CANCER RES, V58, P1238; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Fukuhara S, 2000, FEBS LETT, V485, P183, DOI 10.1016/S0014-5793(00)02224-9; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1998, SCIENCE, V280, P2112, DOI 10.1126/science.280.5372.2112; Hu HL, 2001, NEURON, V32, P39, DOI 10.1016/S0896-6273(01)00453-6; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Liu BP, 2001, CURR OPIN CELL BIOL, V13, P619, DOI 10.1016/S0955-0674(00)00260-X; Myung CS, 2000, P NATL ACAD SCI USA, V97, P9311, DOI 10.1073/pnas.97.16.9311; Nakamura F, 2000, J NEUROBIOL, V44, P219, DOI 10.1002/1097-4695(200008)44:2<219::AID-NEU11>3.0.CO;2-W; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X; Vikis HG, 2000, P NATL ACAD SCI USA, V97, P12457, DOI 10.1073/pnas.220421797; Vikis HG, 2002, GENE DEV, V16, P836, DOI 10.1101/gad.966402; Whitford KL, 2001, NEURON, V32, P1, DOI 10.1016/S0896-6273(01)00459-7; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Yu HH, 1999, NEURON, V22, P11, DOI 10.1016/S0896-6273(00)80672-8; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	29	182	190	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					43115	43120		10.1074/jbc.M206005200	http://dx.doi.org/10.1074/jbc.M206005200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12183458	hybrid			2022-12-27	WOS:000179081200091
J	Duchene, J; Schanstra, JP; Pecher, C; Pizard, A; Susini, C; Esteve, JP; Bascands, JL; Girolami, JP				Duchene, J; Schanstra, JP; Pecher, C; Pizard, A; Susini, C; Esteve, JP; Bascands, JL; Girolami, JP			A novel protein-protein interaction between a G protein-coupled receptor and the phosphatase SHP-2 is involved in bradykinin-induced inhibition of cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE; MESANGIAL CELLS; KINASE CASCADES; DNA-SYNTHESIS; GROWTH-FACTOR; B-2 RECEPTOR; B2 RECEPTOR; ACTIVATION; BINDING; PHOSPHORYLATION	Mitogenic G protein-coupled receptor (GPCR) signaling has been extensively studied. In contrast, little is known about anti-mitogenic GPCR signaling. We show here that anti-mitogenic signaling of a GPCR, the bradykinin B2 receptor, involves a novel direct protein-protein interaction. The antiproliferative effect of bradykinin was accompanied by a transient increase in protein-tyrosine phosphatase activity. Using surface plasmon resonance analysis, we observed that an immunoreceptor tyrosine-based inhibitory motif (ITIM) located in the C-terminal part of the B2 receptor interacted specifically with the protein-tyrosine phosphatase SHP-2. The interaction was confirmed in primary culture renal mesangial cells by co-immunoprecipitation of a B2 receptor-SHP-2 complex. The extent of the interaction was transiently. increased by stimulation with bradykinin, which was accompanied by an increase in specific SHP-2 phosphatase activity. Mutational analysis of the key ITIM residue confirmed that the B2 receptor ITIM sequence is required for interaction with SHP-2, SHP-2 activation, and the anti-mitogenic effect of bradykinin. Finally, in mesangial cells transfected with a dominant-negative form of SHP-2, bradykinin lost the ability to inhibit cell proliferation. These observations demonstrate that bradykinin inhibits cell proliferation by a novel mechanism involving a direct protein-protein interaction between a GPCR (the B2 receptor) and SHP-2.	CHU Rangueil, INSERM, U388, Inst Louis Bugnard,IFR 31, F-31403 Toulouse, France; CHU Rangueil, INSERM, U531, Inst Louis Bugnard,IFR 31, F-31403 Toulouse, France; INSERM, U367, Paris, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Schanstra, JP (corresponding author), CHU Rangueil, INSERM, U388, Inst Louis Bugnard,IFR 31, 1 Av J Poulhes, F-31403 Toulouse, France.	schans@toulouse.inserm.fr	Pizard, Anne CM/P-4754-2016; Schanstra, Joost P/X-7724-2018; Bascands, Jean-loup/G-3260-2013; Duchene, Johan/Q-9472-2019	Pizard, Anne CM/0000-0003-2705-6365; Schanstra, Joost P/0000-0002-7471-372X; Duchene, Johan/0000-0002-3973-0022; Bascands, Jean-loup/0000-0002-1667-5913				Alric C, 2000, INT J MOL MED, V5, P85; Alric C, 1999, IMMUNOPHARMACOLOGY, V45, P57, DOI 10.1016/S0162-3109(99)00151-4; Bascands JL, 1996, J AM SOC NEPHROL, V7, P81; Bruhns P, 1999, J IMMUNOL, V162, P3168; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dixon BS, 1997, AM J PHYSIOL-CELL PH, V273, pC7, DOI 10.1152/ajpcell.1997.273.1.C7; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; EMOND C, 1990, EUR J PHARMACOL, V190, P381, DOI 10.1016/0014-2999(90)94203-A; Famiglietti SJ, 1999, IMMUNOL LETT, V68, P35, DOI 10.1016/S0165-2478(99)00027-9; Fathy DB, 1999, J BIOL CHEM, V274, P29603, DOI 10.1074/jbc.274.42.29603; Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70; Fukunaga K, 2000, J BIOL CHEM, V275, P5208, DOI 10.1074/jbc.275.7.5208; GODIN C, 1991, BIOCHEM PHARMACOL, V42, P117, DOI 10.1016/0006-2952(91)90689-3; GOLDSTEIN RH, 1984, J BIOL CHEM, V259, P9263; Golser R, 2000, J BIOL CHEM, V275, P5291, DOI 10.1074/jbc.275.8.5291; Graness A, 2000, BIOCHEM J, V347, P441, DOI 10.1042/0264-6021:3470441; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hua CT, 1998, J BIOL CHEM, V273, P28332, DOI 10.1074/jbc.273.43.28332; Lopez F, 2001, FASEB J, V15, P2300, DOI 10.1096/fj.00-0867fje; Lorenz U, 1996, P NATL ACAD SCI USA, V93, P9624, DOI 10.1073/pnas.93.18.9624; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Maile LA, 2002, J BIOL CHEM, V277, P8955, DOI 10.1074/jbc.M109258200; Malek RL, 2001, J BIOL CHEM, V276, P5692, DOI 10.1074/jbc.M003964200; Marrero MB, 1999, BIOCHEM J, V343, P335, DOI 10.1042/0264-6021:3430335; Marrero MB, 1998, AM J PHYSIOL-CELL PH, V275, pC1216, DOI 10.1152/ajpcell.1998.275.5.C1216; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Olcese L, 1996, J IMMUNOL, V156, P4531; OWEN NE, 1983, CELL, V32, P979, DOI 10.1016/0092-8674(83)90082-X; PATEL KV, 1992, CANCER RES, V52, P334; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pizard A, 1999, J BIOL CHEM, V274, P12738, DOI 10.1074/jbc.274.18.12738; Pizard A, 1998, J BIOL CHEM, V273, P1309, DOI 10.1074/jbc.273.3.1309; RIVARD N, 1995, J BIOL CHEM, V270, P11017, DOI 10.1074/jbc.270.18.11017; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Stofega MR, 2000, MOL ENDOCRINOL, V14, P1338, DOI 10.1210/me.14.9.1338; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Venema RC, 1998, J BIOL CHEM, V273, P7703, DOI 10.1074/jbc.273.13.7703; Venema VJ, 1998, BIOCHEM BIOPH RES CO, V246, P70, DOI 10.1006/bbrc.1998.8574; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664	47	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40375	40383		10.1074/jbc.M202744200	http://dx.doi.org/10.1074/jbc.M202744200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177051	hybrid			2022-12-27	WOS:000178791400029
J	Kluck, CJ; Patzelt, H; Genevaux, P; Brehmer, D; Rist, W; Schneider-Mergener, J; Bukau, B; Mayer, MP				Kluck, CJ; Patzelt, H; Genevaux, P; Brehmer, D; Rist, W; Schneider-Mergener, J; Bukau, B; Mayer, MP			Structure-function analysis of HscC, the Escherichia coli member of a novel subfamily of specialized Hsp70 chaperones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNAJ MOLECULAR CHAPERONE; SUBSTRATE-SPECIFICITY; NUCLEOTIDE EXCHANGE; GENE-EXPRESSION; NASCENT CHAIN; ATPASE DOMAIN; SWISS-MODEL; BINDING; SEQUENCE; MODULATION	Hsp70 chaperones assist protein folding processes through nucleotide-controlled cycles of substrate binding and release. In our effort to understand the structure-function relationship within the Hsp70 family of proteins, we characterized the Escherichia coli member of a novel Hsp70 subfamily, HscC, and identified considerable differences to the well studied E. coli homologue, DnaK, which together suggest that HscC is a specialized chaperone. The basal ATPase cycle of HscC had k(cat) and K-m values that were 8- and 10,000-fold higher than for DnaK. The HscC ATPase was not affected by the nucleotide exchange factor of DnaK GrpE and stimulated 8-fold by Dj1C, a DnaJ protein with a putative transmembrane domain, but not by other DnaJ proteins tested. Substrate binding dynamics and substrate specificity differed significantly between HscC and DnaK. These differences are explicable by distinct structural variations. HscC does not have general chaperone activity because it did not assist refolding of a denatured model substrate. In vivo, HscC failed to complement temperature sensitivity of DeltadnaK cells. Deletion of hscC caused a slow growth phenotype that was suppressed after several generations. Triple knock-outs of all E. coli genes encoding Hsp70 proteins (DeltadnaK DeltahscA DeltahscC) were viable, indicating that Hsp70 proteins are not strictly essential for viability. An extensive search for DeltahscC phenotypes revealed a hypersensitivity to Cd2+ ions and UV irradiation, suggesting roles of HscC in the cellular response to these stress treatments. Together our data show that the Hsp70 structure exhibits an astonishing degree of adaptive variations to accommodate requirements of a specialized function.	Heidelberg Univ, Zentrum Mol Biol, D-69120 Heidelberg, Germany; Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Univ Geneva, Ctr Med Univ Geneva, Dept Biochim Med, CH-1211 Geneva, Switzerland; Univ Klinikum Berlin, Charite, Inst Med Immunol, D-10098 Berlin, Germany; Jerini AG, D-10115 Berlin, Germany	Ruprecht Karls University Heidelberg; University of Freiburg; University of Geneva; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Shire Pharmaceuticals Limited	Mayer, MP (corresponding author), Heidelberg Univ, Zentrum Mol Biol, Neuenheimer Feld 282, D-69120 Heidelberg, Germany.	M.Mayer@zmbh.uni-heidelberg.de	Mayer, Matthias P./B-9340-2013; Genevaux, Pierre/A-4851-2015	Mayer, Matthias P./0000-0002-7859-3112; Bukau, Bernd/0000-0003-0521-7199; Patzelt, Holger/0000-0001-9886-8374; Rist, Wolfgang/0000-0002-0626-3544; GENEVAUX, Pierre/0000-0001-7539-3126				Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Courcelle J, 2001, GENETICS, V158, P41; CRAIG E, 1999, MOL CHAPERONES FOLDI, P139; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; Gassler CS, 2001, J BIOL CHEM, V276, P32538, DOI 10.1074/jbc.M105328200; Genevaux P, 2001, J BIOL CHEM, V276, P7906, DOI 10.1074/jbc.M003855200; Genevaux P, 2001, J BACTERIOL, V183, P5747, DOI 10.1128/JB.183.19.5747-5750.2001; Gisler SM, 1998, J MOL BIOL, V279, P833, DOI 10.1006/jmbi.1998.1815; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUPTA RS, 1993, J MOL EVOL, V37, P573; HA JH, 1995, BIOCHEMISTRY-US, V34, P11635, DOI 10.1021/bi00036a040; HA JH, 1999, MOL CHAPERONES FOLDI, P573; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hesterkamp T, 1998, EMBO J, V17, P4818, DOI 10.1093/emboj/17.16.4818; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; Itoh T, 1999, DNA Res, V6, P299, DOI 10.1093/dnares/6.5.299; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; Laufen T., 1998, MOL CHAPERONES PROTE, P241; Lopez-Buesa P, 1998, P NATL ACAD SCI USA, V95, P15253, DOI 10.1073/pnas.95.26.15253; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 2002, ADV PROTEIN CHEM, V59, P1; Mayer MP, 1999, J MOL BIOL, V289, P1131, DOI 10.1006/jmbi.1999.2844; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; McCarty JS, 1996, J MOL BIOL, V256, P829, DOI 10.1006/jmbi.1996.0129; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Pierpaoli EV, 1998, BIOCHEMISTRY-US, V37, P16741, DOI 10.1021/bi981762y; PRENTKI P, 1991, GENE, V103, P17, DOI 10.1016/0378-1119(91)90385-O; Prols F, 2001, EXP CELL RES, V269, P42, DOI 10.1006/excr.2001.5294; Rudiger S, 2000, J MOL BIOL, V304, P245, DOI 10.1006/jmbi.2000.4193; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Salanoubat M, 2002, NATURE, V415, P497, DOI 10.1038/415497a; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Schonfeld HJ, 1995, PROG COLL POL SCI S, V99, P7; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Silberg JJ, 2000, J BIOL CHEM, V275, P7779, DOI 10.1074/jbc.275.11.7779; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Tomoyasu T, 1998, MOL MICROBIOL, V30, P567, DOI 10.1046/j.1365-2958.1998.01090.x; UEGUCHI C, 1994, P NATL ACAD SCI USA, V91, P1054, DOI 10.1073/pnas.91.3.1054; UEGUCHI C, 1995, J BACTERIOL, V177, P3894, DOI 10.1128/jb.177.13.3894-3896.1995; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]	55	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41060	41069		10.1074/jbc.M206520200	http://dx.doi.org/10.1074/jbc.M206520200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183460	hybrid			2022-12-27	WOS:000178791400115
J	Lange, U; Loffler-Walz, C; Englert, HC; Hambrock, A; Russ, U; Quast, U				Lange, U; Loffler-Walz, C; Englert, HC; Hambrock, A; Russ, U; Quast, U			The stereoenantiomers of a pinacidil analog open or close cloned ATP-sensitive K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFONYLUREA RECEPTOR SUR2B; PANCREATIC BETA-CELLS; POTASSIUM CHANNELS; HIGH-AFFINITY; BINDING; GLIBENCLAMIDE; MUSCLE; CYANOGUANIDINES; ENANTIOMERS; NUCLEOTIDES	ATP-dependent K+ channels (K-ATP channels) are composed of pore-forming subunits Kir6.x and sulfonylurea receptors (SURs). Cyanoguanidines such as pinacidil and P1075 bind to SUR and enhance MgATP binding to and hydrolysis by SUR, thereby opening K-ATP channels. In the vasculature, openers of K-ATP channels produce vasorelaxation. Some novel eyanoguanidines, however, selectively reverse opener-induced vasorelaxation, suggesting that they might be K-ATP channel blockers. Here we have analyzed the interaction of the enantiomers of a racemic cyanoguanidine blocker, PNU-94750, with Kir6.2/SUR channels. In patch clamp experiments, the R-enantiomer (PNU-96293) inhibited Kir6.2/SUR2 channels (IC50 similar to50 nm in the whole cell configuration), whereas the S-enantiomer (PNU-96179) was a weak opener. Radioligand binding studies showed that the R-enantiomer was more potent and that it was negatively allosterically coupled to MgATP binding, whereas the S-enantiomer was weaker and positively coupled. Binding experiments also suggested that both enantiomers bound to the P1075 site of SUR. This is the first report to show that the enantiomers of a K-ATP channel modulator affect channel activity and coupling to MgATP binding in opposite directions and that these opposite effects are apparently mediated by binding to the same (opener) site of SUR.	Univ Tubingen, Dept Pharmacol & Toxicol, D-72074 Tubingen, Germany; Aventis Pharma Deutschland GMBH, D-65926 Frankfurt, Germany	Eberhard Karls University of Tubingen; Sanofi-Aventis	Quast, U (corresponding author), Univ Tubingen, Dept Pharmacol & Toxicol, Wilhelmstr 56, D-72074 Tubingen, Germany.							Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Ashcroft FM, 2000, TRENDS PHARMACOL SCI, V21, P439; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; BARLOW R, 1990, TRENDS PHARMACOL SCI, V11, P148, DOI 10.1016/0165-6147(90)90065-G; BECHEM M, 1988, TRENDS PHARMACOL SCI, V9, P257, DOI 10.1016/0165-6147(88)90156-3; Bevington P. R., 1969, DATA REDUCTION ERROR, P56; Bienengraeber M, 2000, FASEB J, V14, P1943, DOI 10.1096/fj.00-0027com; BRAY KM, 1992, J BIOL CHEM, V267, P11689; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Christopoulos A, 1998, TRENDS PHARMACOL SCI, V19, P351, DOI 10.1016/S0165-6147(98)01240-1; Coghlan MJ, 2001, J MED CHEM, V44, P1627, DOI 10.1021/jm000484+; Dabrowski M, 2001, DIABETOLOGIA, V44, P747, DOI 10.1007/s001250051684; Dorschner H, 1999, MOL PHARMACOL, V55, P1060; Draper NR., 1981, APPLIED REGRESSION A, P458; EDWARDS G, 1993, ANNU REV PHARMACOL, V33, P597, DOI 10.1146/annurev.pa.33.040193.003121; GARRINO MG, 1988, BRIT J PHARMACOL, V93, P61, DOI 10.1111/j.1476-5381.1988.tb11405.x; Gribble FM, 1997, J PHYSIOL-LONDON, V504, P35, DOI 10.1111/j.1469-7793.1997.00035.x; Gribble FM, 2002, BIOCHEM SOC T, V30, P333, DOI 10.1042/bst0300333; Gribble FM, 1998, DIABETES, V47, P1412, DOI 10.2337/diabetes.47.9.1412; Hambrock A, 2002, BRIT J PHARMACOL, V136, P995, DOI 10.1038/sj.bjp.0704801; Hambrock A, 2001, MOL PHARMACOL, V60, P190, DOI 10.1124/mol.60.1.190; Hambrock A, 1998, BRIT J PHARMACOL, V125, P577, DOI 10.1038/sj.bjp.0702109; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HUMPHREY SJ, 1996, Patent No. 5567722; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Inagaki N, 1996, NEURON, V16, P1011, DOI 10.1016/S0896-6273(00)80124-5; Isomoto S, 1996, J BIOL CHEM, V271, P24321, DOI 10.1074/jbc.271.40.24321; Khan SA, 1997, J PHARMACOL EXP THER, V283, P1207; Lawson K, 2000, KIDNEY INT, V57, P838, DOI 10.1046/j.1523-1755.2000.00923.x; Loffler-Walz C, 2002, MOL PHARMACOL, V61, P407, DOI 10.1124/mol.61.2.407; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Manley PW, 2001, BRIT J PHARMACOL, V133, P275, DOI 10.1038/sj.bjp.0704071; MANLEY PW, 1992, J MED CHEM, V35, P2327, DOI 10.1021/jm00090a025; QUAST U, 1993, MOL PHARMACOL, V43, P474; QUAST U, 1993, EUR J PHARM-MOLEC PH, V245, P165, DOI 10.1016/0922-4106(93)90124-R; Quast U, 2001, N-S ARCH PHARMACOL, V363, pR72; QUAST U, 1996, POTASSIUM CHANNELS T, P173; Russ U, 2001, J PHARMACOL EXP THER, V299, P1049; Russ U, 1999, MOL PHARMACOL, V56, P955, DOI 10.1124/mol.56.5.955; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schwanstecher M, 1998, EMBO J, V17, P5529, DOI 10.1093/emboj/17.19.5529; SCHWANSTECHER M, 1992, BRIT J PHARMACOL, V106, P295, DOI 10.1111/j.1476-5381.1992.tb14331.x; SCHWANSTECHER M, 1991, N-S ARCH PHARMACOL, V343, P83; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Striessnig J, 1998, TRENDS PHARMACOL SCI, V19, P108, DOI 10.1016/S0165-6147(98)01171-7; TRIGGLE DJ, 1987, ANNU REV PHARMACOL, V27, P347; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Zingman LV, 2001, NEURON, V31, P233, DOI 10.1016/S0896-6273(01)00356-7	52	5	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40196	40205		10.1074/jbc.M206685200	http://dx.doi.org/10.1074/jbc.M206685200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171936	hybrid			2022-12-27	WOS:000178791400007
J	Lim, R; Winteringham, LN; Williams, JH; McCulloch, RK; Ingley, E; Tiao, JYH; Lalonde, JP; Tsai, SW; Tilbrook, PA; Sun, Y; Wu, XH; Morris, SW; Klinken, SP				Lim, R; Winteringham, LN; Williams, JH; McCulloch, RK; Ingley, E; Tiao, JYH; Lalonde, JP; Tsai, SW; Tilbrook, PA; Sun, Y; Wu, XH; Morris, SW; Klinken, SP			MADM, a novel adaptor protein that mediates phosphorylation of the 14-3-3 binding site of myeloid leukemia factor 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							J2E ERYTHROID-CELLS; MYELODYSPLASTIC SYNDROME; NUCLEAR-LOCALIZATION; SERINE PHOSPHORYLATION; KINASE RAF; GENE; ASSOCIATION; CLONING; MLF1; ERYTHROPOIETIN	A yeast two-hybrid screen was conducted to identify binding partners of Mlf1, an oncoprotein recently identified in a translocation with nucleophosmin that causes acute myeloid leukemia. Two proteins isolated in this screen were 14-3-3zeta and a novel adaptor, Madm. Mlf1 contains a classic RSXSXP sequence for 14-3-3 binding and is associated with 14-3-3 via this phosphorylated motif. Madm co-immunoprecipitated with Mlf1 and co-localized in the cytoplasm. In addition, Madm recruited a serine kinase, which phosphorylated both Madm and Mlf1 including the RSXSXP motif. In contrast to wildtype Mlf1, the oncogenic fusion protein nucleophosmin (NPM)-MLF1 did not bind 14-3-3zeta, had altered Madm binding, and localized exclusively in the nucleus. Ectopic expression of Madm in M1 myeloid cells suppressed cytokine-induced differentiation unlike Mlf1, which promotes maturation. Because the Mlf1 binding region of Madm and its own dimerization domain overlapped, the levels of Madm and Mlf1 may affect complex formation and regulate differentiation. In summary, this study has identified two partner proteins of Mlf1 that may influence its subcellular localization and biological function.	Royal Perth Hosp, Western Australian Inst Med Res, Med Res Fdn, Lab Canc Med, Perth, WA 6000, Australia; Curtin Univ Technol, Sch Biomed Sci, Bentley, WA 6102, Australia; Univ Western Australia, Dept Biochem, Nedlands, WA 6009, Australia; St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Mt Sinai Sch Med, Inst Gene Therapy & Mol Med, New York, NY 10029 USA	Royal Perth Hospital; University of Western Australia; Curtin University; University of Western Australia; St Jude Children's Research Hospital; St Jude Children's Research Hospital; Icahn School of Medicine at Mount Sinai	Klinken, SP (corresponding author), Western Australian Inst Med Res, Lab Canc Med, Level 6 MRF Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.	pklinken@cyllene.uwa.edu.au	Winteringham, Louise/H-6105-2014; Endersby, Raelene/A-2969-2013; Ingley, Evan/C-2401-2013	Endersby, Raelene/0000-0003-3554-2769; Ingley, Evan/0000-0002-8112-9134; Williams, James/0000-0002-0950-1958; Tiao, Jim/0000-0001-6692-9697; Winteringham, Louise/0000-0002-8117-5069	NATIONAL CANCER INSTITUTE [R01CA076301, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765, CA 76301] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN A, 1992, TRENDS BIOCHEM SCI, V17, P198; Briggs LJ, 2001, BIOCHEM J, V353, P69, DOI 10.1042/bj3530069; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hardin SC, 1998, BIOTECHNIQUES, V24, P344, DOI 10.2144/98243bm01; HAWLEY RG, 1994, GENE THER, V1, P136; Hitzler JK, 1999, AM J PATHOL, V155, P53, DOI 10.1016/S0002-9440(10)65098-5; Hooper JD, 2000, GENOMICS, V66, P113, DOI 10.1006/geno.2000.6167; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; KEIL U, 1995, CELL GROWTH DIFFER, V6, P439; KLINKEN SP, 1988, P NATL ACAD SCI USA, V85, P8506, DOI 10.1073/pnas.85.22.8506; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Lopez-Girona A, 1999, NATURE, V397, P172, DOI 10.1038/16488; Matsumoto N, 2000, LEUKEMIA, V14, P1757, DOI 10.1038/sj.leu.2401897; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; PATTERSON M, 1986, MOL CELL BIOL, V6, P1590, DOI 10.1128/MCB.6.5.1590; Peng CY, 1998, CELL GROWTH DIFFER, V9, P197; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; Robertson H, 1997, BIOCHEM BIOPH RES CO, V240, P46, DOI 10.1006/bbrc.1997.7608; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Tilbrook PA, 1997, EMBO J, V16, P1610, DOI 10.1093/emboj/16.7.1610; TSAI S, 1994, GENE DEV, V8, P2831, DOI 10.1101/gad.8.23.2831; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Williams JH, 1999, EMBO J, V18, P5559, DOI 10.1093/emboj/18.20.5559; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yoneda-Kato N, 1999, ONCOGENE, V18, P3716, DOI 10.1038/sj.onc.1202711; YonedaKato N, 1996, ONCOGENE, V12, P265; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597	36	38	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40997	41008		10.1074/jbc.M206041200	http://dx.doi.org/10.1074/jbc.M206041200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12176995	hybrid, Green Published			2022-12-27	WOS:000178791400108
J	Diaz, O; Berquand, A; Dubois, M; Di Agostino, S; Sette, C; Bourgoin, S; Lagarde, M; Nemoz, G; Prigent, AF				Diaz, O; Berquand, A; Dubois, M; Di Agostino, S; Sette, C; Bourgoin, S; Lagarde, M; Nemoz, G; Prigent, AF			The mechanism of docosahexaenoic acid-induced phospholipase D activation in human lymphocytes involves exclusion of the enzyme from lipid rafts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; INSOLUBLE MEMBRANE DOMAINS; UNSATURATED FATTY-ACIDS; ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEINS; T-CELL RECEPTOR; PLASMA-MEMBRANES; SIGNAL-TRANSDUCTION; ANTIGEN RECEPTORS; TYROSINE KINASES	Docosahexaenoic acid (DHA), an n-3 polyunsaturated fatty acid that inhibits T lymphocyte activation, has been shown to stimulate phospholipase D (PLD) activity in stimulated human peripheral blood mononuclear cells (PBMC). To elucidate the mechanisms underlying the DHA-induced PLD activation, we first characterized the PLD expression pattern of PBMC. We show that these cells express PLD1 and PLD2 at the protein and mRNA level and are devoid of oleate-dependent PLD activity. DHA enrichment of PBMC increased the DHA content of cell phospholipids, which was directly correlated with the extent of PLD activation. The DHA-induced PLD activation was independent of conventional protein kinase C but inhibited by brefeldin A, which suggests ADP-ribosylation factor (ARF)-dependent mechanism. Furthermore, DHA enrichment dose-dependently stimulated ARF translocation to cell membranes. Whereas 50% of the guanosine 5'-3-O-(thio)triphosphate plus ARF-dependent PLD activity and a substantial part of PLD1 protein were located to the detergent-insoluble membranes, so-called rafts, of non-enriched PBMC, DHA treatment strongly displaced them toward detergent-soluble membranes where ARF is present. Collectively, these results suggest that the exclusion of PLD1 from lipid rafts, due to their partial disorganization by DHA, and its relocalization in the vicinity of ARF, is responsible for its activation. This PLD activation might be responsible for the immunosuppressive effect of DHA because it is known to transmit antiproliferative signals in lymphoid cells.	Inst Natl Sci Appl, INSERM, U352, Lab Biochim & Pharmacol, F-69621 Villeurbanne, France; Univ Roma Tor Vergata, Cattedra Anat Umana, Dipartimento Sanita Pubbl & Biol Cellulare, I-00173 Rome, Italy; Univ Laval, CHUL, Ctr Rech, St Foy, PQ G1V 4G2, Canada	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National des Sciences Appliquees de Lyon - INSA Lyon; University of Rome Tor Vergata; Laval University	Prigent, AF (corresponding author), Inst Natl Sci Appl, INSERM, U352, Lab Biochim & Pharmacol, Batiment Louis Pasteur,11 Ave Jean Capelle, F-69621 Villeurbanne, France.		diaz, olivier/M-8112-2014; Sette, Claudio/S-4307-2019; Di Agostino, Silvia/S-8566-2019; Di Agostino, Silvia/H-1121-2018	diaz, olivier/0000-0002-3451-9914; Sette, Claudio/0000-0003-2864-8266; Di Agostino, Silvia/0000-0003-3730-1125; Bourgoin, Sylvain/0000-0001-9779-0368				Bacon KB, 1998, J IMMUNOL, V160, P1894; Bechoua S, 1998, J LIPID RES, V39, P873; Belluzzi A, 1996, NEW ENGL J MED, V334, P1557, DOI 10.1056/NEJM199606133342401; BOUKHCHACHE D, 1982, BIOCHIM BIOPHYS ACTA, V713, P386, DOI 10.1016/0005-2760(82)90257-0; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; Calder PC, 2001, CURR OPIN CLIN NUTR, V4, P115, DOI 10.1097/00075197-200103000-00006; CALDER PC, 1995, BIOCHEM SOC T, V23, P301; CALDWELL KK, 1988, ANAL BIOCHEM, V175, P177, DOI 10.1016/0003-2697(88)90376-4; CHALIFA V, 1990, J BIOL CHEM, V265, P17512; Czarny M, 2000, FEBS LETT, V467, P326, DOI 10.1016/S0014-5793(00)01174-1; ENDRES S, 1993, J LEUKOCYTE BIOL, V54, P599, DOI 10.1002/jlb.54.6.599; FRA AM, 1994, J BIOL CHEM, V269, P30745; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; GENTRY MK, 1975, ANAL BIOCHEM, V64, P624, DOI 10.1016/0003-2697(75)90478-9; Gibbs TC, 2000, J CELL PHYSIOL, V182, P77, DOI 10.1002/(SICI)1097-4652(200001)182:1<77::AID-JCP9>3.0.CO;2-B; Gilbert JJ, 1998, J IMMUNOL, V161, P6575; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; Horejsi V, 1999, IMMUNOL TODAY, V20, P356, DOI 10.1016/S0167-5699(99)01489-9; Huang ZH, 1997, BIOCHEM J, V325, P553, DOI 10.1042/bj3250553; Ilangumaran S, 1999, MOL BIOL CELL, V10, P891, DOI 10.1091/mbc.10.4.891; Ilangumaran S, 1998, BLOOD, V91, P3901; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Janes PW, 2000, SEMIN IMMUNOL, V12, P23, DOI 10.1006/smim.2000.0204; Kasai T, 1998, J IMMUNOL, V161, P6469; Kim JH, 1999, FEBS LETT, V454, P42, DOI 10.1016/S0014-5793(99)00745-0; Kim JH, 1999, BIOCHEMISTRY-US, V38, P3763, DOI 10.1021/bi982478+; Langlet C, 2000, CURR OPIN IMMUNOL, V12, P250, DOI 10.1016/S0952-7915(00)00084-4; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; Marcil J, 1997, J BIOL CHEM, V272, P20660, DOI 10.1074/jbc.272.33.20660; Martin TFJ, 2001, CURR OPIN CELL BIOL, V13, P493, DOI 10.1016/S0955-0674(00)00241-6; MAY CL, 1993, BIOCHEM BIOPH RES CO, V195, P823, DOI 10.1006/bbrc.1993.2119; Meacci E, 2000, FEBS LETT, V473, P10, DOI 10.1016/S0014-5793(00)01486-1; Meier KE, 1999, BBA-MOL CELL BIOL L, V1439, P199, DOI 10.1016/S1388-1981(99)00095-5; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Nakashima S, 1999, CHEM PHYS LIPIDS, V98, P153, DOI 10.1016/S0009-3084(99)00027-4; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Reid PA, 1997, IMMUNOLOGY, V90, P250, DOI 10.1046/j.1365-2567.1997.00150.x; Resta R, 1997, CELL SIGNAL, V9, P131, DOI 10.1016/S0898-6568(96)00132-5; Robineau S, 2000, P NATL ACAD SCI USA, V97, P9913, DOI 10.1073/pnas.170290597; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Steed PM, 1998, FASEB J, V12, P1309, DOI 10.1096/fasebj.12.13.1309; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; Stulnig TM, 2001, J BIOL CHEM, V276, P37335, DOI 10.1074/jbc.M106193200; VANDERHEIDE JJH, 1993, NEW ENGL J MED, V329, P769, DOI 10.1056/NEJM199309093291105; Xavier R, 1998, IMMUNITY, V8, P723, DOI 10.1016/S1074-7613(00)80577-4; Xu LZ, 2000, BIOCHEM BIOPH RES CO, V273, P77, DOI 10.1006/bbrc.2000.2907; Zakaroff-Girard A, 1999, J LEUKOCYTE BIOL, V65, P381, DOI 10.1002/jlb.65.3.381; Zurier RB, 1999, PROSTAG LEUKOTR ESS, V60, P371, DOI 10.1016/S0952-3278(99)80015-5	55	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39368	39378		10.1074/jbc.M202376200	http://dx.doi.org/10.1074/jbc.M202376200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12140281	hybrid			2022-12-27	WOS:000178662500041
J	Kikawa, KD; Vidale, DR; Van Etten, RL; Kinch, MS				Kikawa, KD; Vidale, DR; Van Etten, RL; Kinch, MS			Regulation of the EphA2 kinase by the low molecular weight tyrosine phosphatase induces transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL-CELL KINASE; PHOSPHOTYROSYL PHOSPHATASE; E-CADHERIN; PROTEIN; OVEREXPRESSION; PHOSPHORYLATION; EXPRESSION; GROWTH; ECK; ACTIVATION	Intracellular signaling by protein tyrosine phosphorylation is generally understood to govern many aspects of cellular behavior. The biological consequences of this signaling pathway are important because the levels of protein tyrosine phosphorylation are frequently elevated in cancer cells. In the classic paradigm, tyrosine kinases promote tumor cell growth, survival, and invasiveness, whereas tyrosine phosphatases negatively regulate these same behaviors. Here, we identify one particular tyrosine phosphatase, low molecular weight tyrosine phosphatase (LAW-PTP), which is frequently overexpressed in transformed cells. We also show that overexpression of LMW-PTP is sufficient to confer transformation upon non-transformed epithelial cells. Notably, we show that the EphA2 receptor tyrosine kinase is a prominent substrate for LMW-PTP and that the oncogenic activities of LMW-PTP result from altered EphA2 expression and function. These results suggest a role for LMW-PTP in transformation progression and link its oncogenic potential to EphA2.	Medimmune Inc, Gaithersburg, MD 20878 USA; Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Chem, W Lafayette, IN 47907 USA	AstraZeneca; Medimmune; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Kinch, MS (corresponding author), Medimmune Inc, 35 W Watkins Mill Rd, Gaithersburg, MD 20878 USA.	kinchm@medimmune.com		Kinch, Michael/0000-0003-3939-3756	NATIONAL CANCER INSTITUTE [U01CA091318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027003] Funding Source: NIH RePORTER; NCI NIH HHS [1 U01 CA91318] Funding Source: Medline; NIGMS NIH HHS [GM27003] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRES AC, 1995, INT J CANCER, V63, P288, DOI 10.1002/ijc.2910630224; BIRCHMEIER W, 1995, BIOESSAYS, V17, P97, DOI 10.1002/bies.950170203; BRYSON GLM, 1995, GENOMICS, V30, P133; Carles-Kinch K, 2002, CANCER RES, V62, P2840; Cates CA, 1996, CANCER LETT, V110, P49, DOI 10.1016/S0304-3835(96)04459-X; Clark GJ, 1996, ONCOGENE, V12, P169; COBB BS, 1993, ONCOGENE, V8, P2897; EASTY DJ, 1995, CANCER RES, V55, P2528; Fiaschi T, 2001, J BIOL CHEM, V276, P49156, DOI 10.1074/jbc.M107538200; Hess AR, 2001, CANCER RES, V61, P3250; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jacob ANK, 1999, CANCER DETECT PREV, V23, P325; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; LIU XQ, 1994, RECENT PROG HORM RES, V49, P149; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; PAINE TM, 1992, INT J CANCER, V50, P463, DOI 10.1002/ijc.2910500323; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rosenberg IM, 1997, AM J PHYSIOL-GASTR L, V273, pG824, DOI 10.1152/ajpgi.1997.273.4.G824; SHEVRIN DH, 1989, PROSTATE, V15, P187, DOI 10.1002/pros.2990150212; Shimizu H, 2001, BIOCHEM BIOPH RES CO, V289, P602, DOI 10.1006/bbrc.2001.6007; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Sun XG, 1999, CELL GROWTH DIFFER, V10, P343; VOLBERG T, 1991, CELL REGUL, V2, P105, DOI 10.1091/mbc.2.2.105; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; WO YYP, 1992, BIOCHEMISTRY-US, V31, P1712, DOI 10.1021/bi00121a019; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zantek ND, 2001, CLIN CANCER RES, V7, P3640; Zelinski DP, 2001, CANCER RES, V61, P2301; Zhang M, 1998, J BIOL CHEM, V273, P21714, DOI 10.1074/jbc.273.34.21714; ZHANG ZT, 1994, J BIOL CHEM, V269, P25947	33	116	136	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39274	39279		10.1074/jbc.M207127200	http://dx.doi.org/10.1074/jbc.M207127200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167657	hybrid			2022-12-27	WOS:000178662500029
J	Kim, M; Ahn, JW; Song, KW; Paek, KH; Pai, HS				Kim, M; Ahn, JW; Song, KW; Paek, KH; Pai, HS			Forkhead-associated domains of the tobacco NtFHA1 transcription activator and the yeast Fhl1 forkhead transcription factor are functionally conserved	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-RIBOSOMAL-RNA; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; FHA DOMAIN; ZEAXANTHIN EPOXIDASE; PROTEIN PHOSPHATASE; GENE-PRODUCT; HEAD PROTEIN; KINASE; BOP1	NtFHA1 encodes a novel protein containing the forkhead-associated (FHA) domain and the acidic domain in Nicotiana tabacum. NtFHA1 functions as a transactivator and is targeted to the nucleus. The sequence of the FHA domain of NtFHA1 is significantly homologous to that of the Fhl1 forkhead transcription factor of yeast. FHL1 was previously identified as a suppressor of RNA polymerase III mutations, and the fhl1 deletion mutant exhibited severe growth defects and impaired rRNA processing. Ectopic expression of the FHA domain of NtFHA1 (but not its mutant form) resulted in severe growth retardation in yeast. Similarly, expression of Fhl1, its FHA domain, or chimeric Fhl1 containing the NtFHA1 FHA domain also inhibited yeast growth. Yeast cells overexpressing the FHA domains of NtFHA1 and Fhl1 contained lower levels of mature rRNAs and exhibited rRNA-processing defects, similar to the fhl1 null mutant. Chimeric Fhl1 (but not the mutant form with a small deletion in its FHA domain) fully complemented the growth and rRNA-processing defects of the fhl1 null mutant, demonstrating that the FHA domain of NtFHA1 can functionally substitute for the FHA domain of Fhl1. These results demonstrate that the FHA domains of NtFHA1 and Fhl1 are conserved in their structure and function and that the FHA domain of Fhl1 is critically involved in regulation of rRNA processing in yeast. NtFHA1 function in plants may be analogous to Fhl1 function in yeast.	Korea Res Inst Biosci & Biotechnol, Lab Plant Genom, Taejon 305333, South Korea; Yonsei Univ, Dept Biochem, Seoul 120749, South Korea; Korea Univ, Grad Sch Biotechnol, Seoul 136701, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Yonsei University; Korea University	Pai, HS (corresponding author), Korea Res Inst Biosci & Biotechnol, Lab Plant Genom, POB 115, Taejon 305600, South Korea.							Audran C, 1998, PLANT PHYSIOL, V118, P1021, DOI 10.1104/pp.118.3.1021; Burbidge A, 1997, J EXP BOT, V48, P1749, DOI 10.1093/jexbot/48.314.1749; CHEREL I, 1995, YEAST, V11, P261, DOI 10.1002/yea.320110308; de la Cruz J, 1998, EMBO J, V17, P1128, DOI 10.1093/emboj/17.4.1128; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; HERMANNLEDENMAT S, 1994, MOL CELL BIOL, V14, P2905, DOI 10.1128/MCB.14.5.2905; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Hollenhorst PC, 2000, GENETICS, V154, P1533; Koranda M, 2000, NATURE, V406, P94, DOI 10.1038/35017589; Lee YJ, 2001, PLANT CELL, V13, P2175, DOI 10.1105/tpc.13.10.2175; Li J, 2000, J CELL SCI, V113, P4143; Li J, 1999, P NATL ACAD SCI USA, V96, P7821, DOI 10.1073/pnas.96.14.7821; Liao H, 2000, J MOL BIOL, V304, P941, DOI 10.1006/jmbi.2000.4291; MORAS D, 1993, NATURE, V364, P572, DOI 10.1038/364572a0; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Pestov DG, 2001, NUCLEIC ACIDS RES, V29, P3621, DOI 10.1093/nar/29.17.3621; Pic A, 2000, EMBO J, V19, P3750, DOI 10.1093/emboj/19.14.3750; Pike BL, 2001, J BIOL CHEM, V276, P14019, DOI 10.1074/jbc.M009558200; Reichheld JP, 1996, P NATL ACAD SCI USA, V93, P13819, DOI 10.1073/pnas.93.24.13819; STONE JM, 1994, SCIENCE, V266, P793, DOI 10.1126/science.7973632; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; SUN C, 1994, EMBO J, V13, P3127, DOI 10.1002/j.1460-2075.1994.tb06611.x; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; Weaver PL, 1997, MOL CELL BIOL, V17, P1354, DOI 10.1128/MCB.17.3.1354; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; ZHENG P, 1993, MOL CELL BIOL, V13, P5829, DOI 10.1128/MCB.13.9.5829; ZHU GF, 1993, MOL CELL BIOL, V13, P1779, DOI 10.1128/MCB.13.3.1779; Zhu GF, 2000, NATURE, V406, P90, DOI 10.1038/35017581	30	13	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38781	38790		10.1074/jbc.M201559200	http://dx.doi.org/10.1074/jbc.M201559200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12149245	hybrid			2022-12-27	WOS:000178529600098
J	Cecconi, I; Scaloni, A; Rastelli, G; Moroni, M; Vilardo, PG; Costantino, L; Cappiello, M; Garland, D; Carper, D; Petrash, JM; Del Corso, A; Mura, U				Cecconi, I; Scaloni, A; Rastelli, G; Moroni, M; Vilardo, PG; Costantino, L; Cappiello, M; Garland, D; Carper, D; Petrash, JM; Del Corso, A; Mura, U			Oxidative modification of aldose reductase induced by copper ion - Definition of the metal-protein interaction mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CATALYZED OXIDATION; DNA; COMPLEXES; RADICALS; DAMAGE; INTERCONVERSION; INHIBITION; KINETICS; RAT	Aldose reductase (ALR2) is susceptible to oxidative inactivation by copper ion. The mechanism underlying the reversible modification of ALR2 was studied by mass spectrometry, circular dichroism, and molecular modeling approaches on the enzyme purified from bovine lens and on wild type and mutant recombinant forms of the human placental and rat lens ALR2. Two equivalents of copper ion were required to inactivate ALR2: one remained weakly bound to the oxidized protein whereas the other was strongly retained by the inactive enzyme. Cys(303) appeared to be the essential residue for enzyme inactivation, because the human C303S mutant was the only enzyme form tested that was not inactivated by copper treatment. The final products of human and bovine ALR2 oxidation contained the intramolecular disulfide bond Cys(298)-Cys(303). However, a Cys(80)-Cys(303) disulfide could also be formed. Evidence for an intramolecular rearrangement of the Cys(80)-Cys(303) disulfide to the more stable product Cys(111)-Cys(303) is provided. Molecular modeling of the holoenzyme supports the observed copper sequestration as well as the generation of the Cys(80)-Sys(303) disulfide. However, no evidence of conditions favoring the formation of the Cys(298)-Cys(303) disulfide was observed. Our proposal is that the generation of the Cys(298)Cys(303) disulfide, either directly or by rearrangement of the Cys(80)-Cys(303) disulfide, may be induced by the release of the cofactor from ALR2 undergoing oxidation. The occurrence of a less interactive site for the cofactor would also provide the rationale for the lack of activity of the disulfide enzyme forms.	Univ Pisa, Dept Fisiol & Biochim, I-56100 Pisa, Italy; CNR, IABBAM, Proteom & Mass Spectrometry, I-80147 Naples, Italy; Univ Modean & Reggio Emilia, Dipartimento Sci Farmaceut, I-41100 Modena, Italy; NEI, NIH, Bethesda, MD 20892 USA; Washington Univ, Sch Med, Dept Ophthalmol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Visual Sci, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA	University of Pisa; Consiglio Nazionale delle Ricerche (CNR); Universita di Modena e Reggio Emilia; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Mura, U (corresponding author), Univ Pisa, Dept Fisiol & Biochim, Via S Maria 55, I-56100 Pisa, Italy.	umura@dfb.unipi.it	Cappiello, Mario/L-3877-2019; Rastelli, Giulio/D-2224-2015; Costantino, Luca/D-7608-2015	Rastelli, Giulio/0000-0002-2474-0607; Costantino, Luca/0000-0001-5334-8084; Mura, Umberto/0000-0001-8280-6275; CAPPIELLO, MARIO/0000-0002-8864-5043; Scaloni, Andrea/0000-0001-9362-8515				AQVIST J, 1990, J PHYS CHEM-US, V94, P8021, DOI 10.1021/j100384a009; ARUOMA OI, 1991, BIOCHEM J, V273, P601, DOI 10.1042/bj2730601; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; BOHREN KM, 1994, BIOCHEMISTRY-US, V33, P2021, DOI 10.1021/bi00174a007; BOHREN KM, 1993, ENZYMOLOGY MOL BIOL, V4, P267; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREWER GJ, 1992, MEDICINE, V71, P139, DOI 10.1097/00005792-199205000-00004; CAPPIELLO M, 1994, EXP EYE RES, V58, P491, DOI 10.1006/exer.1994.1042; CAPPIELLO M, 1995, BIOCHEM BIOPH RES CO, V207, P775, DOI 10.1006/bbrc.1995.1254; Cappiello M, 1996, J BIOL CHEM, V271, P33539, DOI 10.1074/jbc.271.52.33539; CASE DA, 1999, AMBER6; Cecconi I, 1998, BIOCHEMISTRY-US, V37, P14167, DOI 10.1021/bi981159f; CIEPLAK P, 1995, J COMPUT CHEM, V16, P1357, DOI 10.1002/jcc.540161106; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DELCORSO A, 1990, ARCH BIOCHEM BIOPHYS, V283, P512, DOI 10.1016/0003-9861(90)90675-O; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GARLAND D, 1990, EXP EYE RES, V50, P677, DOI 10.1016/0014-4835(90)90113-9; GIANNESSI M, 1993, ARCH BIOCHEM BIOPHYS, V300, P423, DOI 10.1006/abbi.1993.1057; GRIMSHAW CE, 1995, BIOCHEMISTRY-US, V34, P14366, DOI 10.1021/bi00044a013; GRIMSHAW CE, 1995, BIOCHEMISTRY-US, V34, P14356, DOI 10.1021/bi00044a012; GRIMSHAW CE, 1990, BIOCHEMISTRY-US, V29, P9947, DOI 10.1021/bi00494a027; GUSS JM, 1992, ACTA CRYSTALLOGR B, V48, P790, DOI 10.1107/S0108768192004270; GUTTERIDGE JMC, 1982, BIOCHEM PHARMACOL, V31, P2801, DOI 10.1016/0006-2952(82)90136-8; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HARMAN D, 1965, J GERONTOL, V20, P151, DOI 10.1093/geronj/20.2.151; HAY BP, 1993, COORDIN CHEM REV, V126, P177, DOI 10.1016/0010-8545(93)85036-4; INAGAKI K, 1982, CHEM PHARM BULL, V30, P3244; JORGENSEN WL, 1987, J AM CHEM SOC, V109, P1891, DOI 10.1021/ja00241a001; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KOBAYASHI S, 1988, BIOCHIM BIOPHYS ACTA, V949, P143, DOI 10.1016/0167-4781(88)90065-6; KUBISESKI TJ, 1992, J BIOL CHEM, V267, P6510; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI YB, 1994, CARCINOGENESIS, V15, P1421, DOI 10.1093/carcin/15.7.1421; LIN J, 1977, JPN J OPHTHALMOL, V41, P130; Linder MC, 1996, AM J CLIN NUTR, V63, P797; LIU SQ, 1992, BIOCHIM BIOPHYS ACTA, V1120, P329, DOI 10.1016/0167-4838(92)90256-D; OGIHARA H, 1995, PEDIATR RES, V37, P219, DOI 10.1203/00006450-199502000-00016; OLD SE, 1990, P NATL ACAD SCI USA, V87, P4942, DOI 10.1073/pnas.87.13.4942; PETRASH JM, 1992, J BIOL CHEM, V267, P24833; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Pierloot K, 1997, J AM CHEM SOC, V119, P218, DOI 10.1021/ja962381f; Ryde U, 1996, J MOL BIOL, V261, P586, DOI 10.1006/jmbi.1996.0484; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHADE SZ, 1990, J BIOL CHEM, V265, P3628; Schlegel HB., 2009, GAUSSIAN 09 REVISION; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; TALLIS GA, 1990, CLIN CHEM, V36, P568; TARLE I, 1993, J BIOL CHEM, V268, P25687; Ueda J, 1996, ARCH BIOCHEM BIOPHYS, V325, P65, DOI 10.1006/abbi.1996.0008; Urzhumtsev A, 1997, STRUCTURE, V5, P601, DOI 10.1016/S0969-2126(97)00216-5; Vilardo PG, 2001, BIOCHEMISTRY-US, V40, P11985, DOI 10.1021/bi0104975; Vinci F, 2000, PROTEIN SCI, V9, P525; WEAST RC, 1985, HDB CHEM PHYSICS; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; WILSON DK, 1993, P NATL ACAD SCI USA, V90, P9847, DOI 10.1073/pnas.90.21.9847; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	56	52	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42017	42027		10.1074/jbc.M206945200	http://dx.doi.org/10.1074/jbc.M206945200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12183464	hybrid			2022-12-27	WOS:000178985300091
J	Guillet, V; Ohta, N; Cabantous, S; Newton, A; Samama, JP				Guillet, V; Ohta, N; Cabantous, S; Newton, A; Samama, JP			Crystallographic and biochemical studies of DivK reveal novel features of an essential response regulator in Caulobacter crescentus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; CELL-DIVISION; SECONDARY STRUCTURE; BACTERIAL CHEMOTAXIS; MAGNESIUM-BINDING; HISTIDINE KINASES; CRYSTAL-STRUCTURE; CHEY; PROTEIN; DIFFERENTIATION	DivK is an essential response regulator in the Gramnegative bacterium Caulobacter crescentus and functions in a complex phosphorelay system that precisely controls the sequence of developmental events during the cell division cycle. Structure determinations of this single domain response regulator at different pH values demonstrated that the five-stranded alpha/beta fold of the DivK protein is fully defined only at acidic pH. The crystal structures of the apoprotein and of metal-bound DivK complexes at higher pH values revealed a synergistic pH- and cation binding-induced flexibility of the beta4-alpha4 loop and of the alpha4 helix. This motion increases the solvent accessibility of the single cysteine residue in the protein. Solution state studies demonstrated a 200-fold pH-dependent increase in the affinity of manganese for the protein between pH 6.0 and 8.5 that seems to involve deprotonation of an acido-basic couple. Taken together, these results suggest that flexibility of critical regions of the protein, ionization of the cysteine 99 residue and improved K-D values for the catalytic metal ion are coupled events. We propose that the molecular events observed in the isolated protein may be required for DivK activation and that they may be achieved in vivo through the specific protein-protein interactions between the response regulator and its cognate kinases.	CNRS, IPBS, Grp Cristallog Biol, F-31077 Toulouse, France; Princeton Univ, Lewis Thomas Lab, Dept Mol Biol, Princeton, NJ 08544 USA	Centre National de la Recherche Scientifique (CNRS); Princeton University	Samama, JP (corresponding author), CNRS, IPBS, Grp Cristallog Biol, F-31077 Toulouse, France.	Jean-Pierre.Samama@igbmc.u-strasbg.fr	Cabantous, Stephanie/M-3282-2014; Cabantous, Stephanie/AAB-5113-2020; Guillet, Valérie/C-6058-2011	Cabantous, Stephanie/0000-0002-8406-9421; Cabantous, Stephanie/0000-0002-8406-9421; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058794] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58794] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Appleby JL, 1998, J BACTERIOL, V180, P3563, DOI 10.1128/JB.180.14.3563-3569.1998; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BELLSOLELL L, 1994, J MOL BIOL, V238, P489, DOI 10.1006/jmbi.1994.1308; Birck C, 1999, STRUCTURE, V7, P1505, DOI 10.1016/S0969-2126(00)88341-0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabantous S, 2002, ACTA CRYSTALLOGR D, V58, P1249, DOI 10.1107/S0907444902008338; DEGNEN ST, 1972, J MOL BIOL, V64, P671, DOI 10.1016/0022-2836(72)90090-3; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Feher VA, 1999, NATURE, V400, P289, DOI 10.1038/22357; FEHER VA, 1995, PROTEIN SCI, V4, P1801, DOI 10.1002/pro.5560040915; Foussard M, 2001, MICROBES INFECT, V3, P417, DOI 10.1016/S1286-4579(01)01390-9; GANGULI S, 1995, J BIOL CHEM, V270, P17386, DOI 10.1074/jbc.270.29.17386; Gouet P, 1999, STRUCTURE, V7, P1517, DOI 10.1016/S0969-2126(00)88342-2; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; HECHT GB, 1995, EMBO J, V14, P3915, DOI 10.1002/j.1460-2075.1995.tb00063.x; HOCH JA, 1993, ANNU REV MICROBIOL, V47, P441, DOI 10.1146/annurev.micro.47.1.441; Hoch JA, 1995, 2 COMPONENT SIGNAL T; HUGUENEL ED, 1982, DIFFERENTIATION, V21, P71, DOI 10.1111/j.1432-0436.1982.tb01199.x; Hung D, 2000, PROKARYOTIC DEVELOPMENT, P361; Jacobs C, 2001, P NATL ACAD SCI USA, V98, P4095, DOI 10.1073/pnas.051609998; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Lee SY, 2001, J BIOL CHEM, V276, P16425, DOI 10.1074/jbc.M101002200; LESLIE AGW, 1987, P CCP4 STUD WEEK SER, P39; LUKAT GS, 1990, BIOCHEMISTRY-US, V29, P5436, DOI 10.1021/bi00475a004; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Madhusudan, 1996, STRUCTURE, V4, P679, DOI 10.1016/S0969-2126(96)00074-3; MOY FJ, 1994, BIOCHEMISTRY-US, V33, P10731, DOI 10.1021/bi00201a022; NEWTON A, 2002, IN PRESS HISTIDINE K; Ohta N, 2000, PROKARYOTIC DEVELOPMENT, P341; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROUSSEL A, 1989, SILICON GRAPHIC GEOM, P71; Sola M, 1999, J MOL BIOL, V285, P675, DOI 10.1006/jmbi.1998.2326; SOMMER JM, 1991, GENETICS, V129, P623; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK AM, 1993, BIOCHEMISTRY-US, V32, P13375, DOI 10.1021/bi00212a001; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; West AH, 2001, TRENDS BIOCHEM SCI, V26, P369, DOI 10.1016/S0968-0004(01)01852-7; Wheeler RT, 1999, MOL CELL, V4, P683, DOI 10.1016/S1097-2765(00)80379-2; Wu JG, 1998, P NATL ACAD SCI USA, V95, P1443, DOI 10.1073/pnas.95.4.1443; Zhu XY, 1996, J BACTERIOL, V178, P4208, DOI 10.1128/jb.178.14.4208-4215.1996; Zhu XY, 1997, J BIOL CHEM, V272, P5000, DOI 10.1074/jbc.272.8.5000; Zundel CJ, 1998, FEBS LETT, V441, P242, DOI 10.1016/S0014-5793(98)01556-7	46	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 1	2002	277	44					42003	42010		10.1074/jbc.M204789200	http://dx.doi.org/10.1074/jbc.M204789200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	610WR	12176983	hybrid			2022-12-27	WOS:000178985300089
J	Nakhost, A; Kabir, N; Forscher, P; Sossin, WS				Nakhost, A; Kabir, N; Forscher, P; Sossin, WS			Protein kinase C isoforms are translocated to microtubules in neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEINS; APLYSIA NEURONS; GROWTH CONES; CELLS; ACTIN; BINDING; PKC; ORGANIZATION; CYTOSKELETON; LOCALIZATION	Activation of protein kinase C (PKC) increases microtubule (MT) growth lifetimes, resulting in extension of a nocodazole-sensitive population of MTs in Aplysia growth cones. We examined whether the two phorbol ester-activated PKCs in Aplysia, the Ca2+-activated PKC Apl I and the Ca2+-independent PKC Apl 11, are associated with these MTs. Phorbol esters translocated PKC to the Triton X-100-insoluble fraction, and a significant portion of this translocated pool was sensitive to low concentrations of nocodazole. Low doses of nocodazole had no effect on the amount of PKC in the Triton X-100-insoluble fraction in the absence of phorbol esters, whereas higher doses of nocodazole reduced basal levels of PKC Apl II. The F-actin cytoskeletal disrupter, latrunculin A, removed both PKCs from the Triton X-100-insoluble fraction in both control and phorbol ester-treated nervous systems. PKC Apl 11 also directly interacted with purified MTs. In detergent-extracted cells, both PKCs immunolocalized predominantly with MTs. PKCs were associated with newly formed MTs invading the actin-rich peripheral growth cone domain after PKC activation. Our results are consistent with a central role for PKCs in regulating MT extension.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Yale Univ, New Haven, CT 06520 USA	McGill University; Yale University	Sossin, WS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Rm 776,3801 Rue Univ, Montreal, PQ H3A 2B4, Canada.		Kabir, Nurul/I-2240-2014	Kabir, Nurul/0000-0003-4735-4028	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028695] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS 28695, R01 NS051786] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALLEN LAH, 1995, EMBO J, V14, P1109, DOI 10.1002/j.1460-2075.1995.tb07094.x; BERSHADSKY AD, 1995, J CELL SCI, V108, P1183; Blobe GC, 1996, J BIOL CHEM, V271, P15823, DOI 10.1074/jbc.271.26.15823; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; GarciaRocha M, 1997, EXP CELL RES, V230, P1, DOI 10.1006/excr.1996.3364; Hosotani T, 2001, GENES CELLS, V6, P775, DOI 10.1046/j.1365-2443.2001.00461.x; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Jordan MA, 1998, METHOD ENZYMOL, V298, P252, DOI 10.1016/S0076-6879(98)98024-7; Kabir N, 2001, J CELL BIOL, V152, P1033, DOI 10.1083/jcb.152.5.1033; Keenan C, 1998, CELL SIGNAL, V10, P225, DOI 10.1016/S0898-6568(97)00121-6; KILEY SC, 1995, J CELL SCI, V108, P1003; Kiley SC, 1997, CELL GROWTH DIFFER, V8, P231; KNOX RJ, 1992, NEURON, V8, P883, DOI 10.1016/0896-6273(92)90202-O; KRUGER KE, 1991, J NEUROSCI, V11, P2303; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; Minamide LS, 1997, J BIOL CHEM, V272, P8303, DOI 10.1074/jbc.272.13.8303; Nakhost A, 1998, J NEUROCHEM, V71, P1221; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Prekeris R, 1996, J CELL BIOL, V132, P77, DOI 10.1083/jcb.132.1.77; Rochlin MW, 1996, J NEUROSCI, V16, P3236; Rosner H, 1996, NEUROSCI LETT, V219, P175, DOI 10.1016/S0304-3940(96)13201-8; Schaefer AW, 2002, J CELL BIOL, V158, P139, DOI 10.1083/jcb.200203038; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; SCHLIWA M, 1981, P NATL ACAD SCI-BIOL, V78, P4329, DOI 10.1073/pnas.78.7.4329; Sim ATR, 1999, CELL CALCIUM, V26, P209, DOI 10.1054/ceca.1999.0072; SOSSIN WS, 1994, MOL BRAIN RES, V24, P210, DOI 10.1016/0169-328X(94)90134-1; SOSSIN WS, 1993, J BIOL CHEM, V268, P5763; Sossin WS, 1996, J NEUROSCI, V16, P10; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; STRONG JA, 1987, NATURE, V325, P714, DOI 10.1038/325714a0; Szalay J, 2001, J HISTOCHEM CYTOCHEM, V49, P49, DOI 10.1177/002215540104900106; Volkov Y, 1998, J IMMUNOL, V161, P6487; Volkov Y, 2001, NAT IMMUNOL, V2, P508, DOI 10.1038/88700; WatermanStorer CM, 1997, J CELL BIOL, V139, P417, DOI 10.1083/jcb.139.2.417	35	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40633	40639		10.1074/jbc.M205099200	http://dx.doi.org/10.1074/jbc.M205099200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12183453	hybrid			2022-12-27	WOS:000178791400062
J	Xiong, WF; Tapprich, WE; Cox, GS				Xiong, WF; Tapprich, WE; Cox, GS			Mechanism of gonadotropin gene expression - Identification of a novel negative regulatory element at the transcription start site of the glycoprotein hormone alpha-subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; MAJOR LATE PROMOTER; CIS-ACTING ELEMENT; PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; PITUITARY-SPECIFIC EXPRESSION; CAMP-RESPONSIVE ENHANCER; CELL-SPECIFIC EXPRESSION; TISSUE-SPECIFIC ENHANCER; PROTEIN-BINDING DOMAINS; HUMAN-LUNG-TUMOR	Regulation of the glycoprotein hormone a-subunit (GPHalpha) gene has been studied extensively in pituitary and placental cell lines, but little is known of the transcriptional regulators important for its ectopic expression. To investigate the molecular basis for ectopic expression, it was critical to define cis-regulatory elements and their cognate trans-acting factors that modulate promoter activity in epithelial cell types that do not normally express GPH. DNA-mediated transient expression of promoter-reporter constructs was used to identify a novel negative regulatory element located at the GPHa gene transcription start site. Truncation or site-directed mutagenesis of this element produced up to a 10-fold increase in promoter activity. Electrophoretic mobility shift analysis detected a protein that binds specifically to a DNA motif encompassing the cap site. Based on competitive DNA binding studies with mutated oligonucleotides, it was determined that bases from -5 to -2 and +4 to +11 are critical for protein binding. The DNA sequence flanking the transcription start site from -9 to +11 is an imperfect palindrome; consequently, this motif is referred to as the cap site diad element (CSDE) and the cognate factor as the cap site-binding protein (CSBP). CSBP activity was present at different levels in nuclear extracts prepared from a variety of cell types. Significantly, the ratio of activities exhibited by the GPHa promoter with a mutated CSDE compared with the promoter with a wild-type CSDE was dependent on the transfected cell line and its content of CSBP. These results indicate that a negative regulatory element centered at the GPHa gene cap site and its cognate DNA-binding protein make a significant contribution to the production of a-subunit in a variety of tumor tissues. A detailed understanding of this cis/trans pair may further suggest a mechanism to explain, at least in part, how this gene becomes activated in nonendocrine tumors.	Univ Nebraska, Nebraska Med Ctr 984525, Dept Biochem & Mol Biol, Omaha, NE 68198 USA; Univ Nebraska, Dept Biol, Omaha, NE 68182 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System	Cox, GS (corresponding author), Univ Nebraska, Nebraska Med Ctr 984525, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.							AKERBLOM IE, 1988, SCIENCE, V241, P350, DOI 10.1126/science.2838908; AKERBLOM IE, 1990, MOL ENDOCRINOL, V4, P589, DOI 10.1210/mend-4-4-589; ANDERSEN B, 1990, J BIOL CHEM, V265, P21874; AYER DE, 1990, MOL CELL BIOL, V10, P3635, DOI 10.1128/MCB.10.7.3635; BARNHART KM, 1994, MOL ENDOCRINOL, V8, P878, DOI 10.1210/me.8.7.878; Blackman M R, 1978, Adv Intern Med, V23, P85; BOKAR JA, 1988, J BIOL CHEM, V263, P19740; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUNSTEIN GD, 1973, ANN INTERN MED, V78, P39, DOI 10.7326/0003-4819-78-1-39; BROOKS AR, 1991, J BIOL CHEM, V266, P7848; CAMPAIN JA, 1994, CELL GROWTH DIFFER, V5, P827; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CLAY CM, 1993, J BIOL CHEM, V268, P13556; COLE LA, 1981, CANCER RES, V41, P1615; COSGROVE DE, 1989, BIOCHIM BIOPHYS ACTA, V1007, P44, DOI 10.1016/0167-4781(89)90128-0; COSGROVE DE, 1990, ARCH BIOCHEM BIOPHYS, V280, P95, DOI 10.1016/0003-9861(90)90523-2; Cox GS, 1998, BBA-GENE STRUCT EXPR, V1396, P67, DOI 10.1016/S0167-4781(97)00175-9; COX GS, 1987, MOL CELL BIOL, V7, P1592, DOI 10.1128/MCB.7.5.1592; Cox GS, 1997, BIOCHEM BIOPH RES CO, V233, P425, DOI 10.1006/bbrc.1997.6474; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DEUTSCH PJ, 1987, J BIOL CHEM, V262, P12169; FIDDES J C, 1981, Journal of Molecular and Applied Genetics, V1, P3; FITCH WM, 1976, FED PROC, V35, P2092; FRENKEL B, 1993, BIOCHEMISTRY-US, V32, P13636, DOI 10.1021/bi00212a031; GARFINKEL S, 1990, J BIOL CHEM, V265, P10309; GHOSH NK, 1977, NATURE, V267, P435, DOI 10.1038/267435a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HORN F, 1992, MOL CELL BIOL, V12, P2143, DOI 10.1128/MCB.12.5.2143; HUSSA RO, 1978, J CLIN ENDOCR METAB, V46, P69, DOI 10.1210/jcem-46-1-69; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; JACKSON SM, 1995, MOL ENDOCRINOL, V9, P278, DOI 10.1210/me.9.3.278; JAMESON JL, 1989, J BIOL CHEM, V264, P16190; JAMESON JL, 1988, J BIOL CHEM, V263, P9879; JAMESON JL, 1993, ENDOCR REV, V14, P203, DOI 10.1210/er.14.2.203; JAMESON JL, 1989, MOL ENDOCRINOL, V3, P763, DOI 10.1210/mend-3-5-763; KUMAR S, 1992, J NATL CANCER I, V84, P42, DOI 10.1093/jnci/84.1.42; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEWIS EJ, 1987, P NATL ACAD SCI USA, V84, P3550, DOI 10.1073/pnas.84.11.3550; LIEBLICH JM, 1977, NATURE, V265, P746, DOI 10.1038/265746a0; LIEBLICH JM, 1976, NATURE, V260, P530, DOI 10.1038/260530a0; LIM HH, 1992, BIOCHEM J, V287, P415, DOI 10.1042/bj2870415; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Maniatis T., 1989, MOL CLONING LAB MANU; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; OCRAN KW, 1990, MOL ENDOCRINOL, V4, P766, DOI 10.1210/mend-4-5-766; OPREY J, 1993, MOL CELL BIOL, V13, P6290, DOI 10.1128/MCB.13.10.6290; PATTILLO R A, 1977, Science (Washington D C), V196, P1456, DOI 10.1126/science.867042; Patton GA, 2000, CRIT CARE MED, V28, P1231, DOI 10.1097/00003246-200004000-00060; Pestell RG, 1996, CELL GROWTH DIFFER, V7, P1337; PIERCE JW, 1991, MOL CELL BIOL, V11, P1431, DOI 10.1128/MCB.11.3.1431; PURNELL BA, 1993, MOL CELL BIOL, V13, P2593, DOI 10.1128/MCB.13.4.2593; RABSON AS, 1973, JNCI-J NATL CANCER I, V50, P669; REES LH, 1975, J ENDOCRINOL, V67, P143, DOI 10.1677/joe.0.0670143; RIVERA RT, 1989, J CELL BIOL, V108, P2423, DOI 10.1083/jcb.108.6.2423; ROBERSON MS, 1994, MOL CELL BIOL, V14, P2985, DOI 10.1128/MCB.14.5.2985; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSEN SW, 1974, NEW ENGL J MED, V290, P1441, DOI 10.1056/NEJM197406272902601; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; RUDDON RW, 1979, CANCER RES, V39, P3885; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARAPURA VD, 1990, ENDOCRINOLOGY, V127, P1352, DOI 10.1210/endo-127-3-1352; SCHODERBEK WE, 1992, MOL ENDOCRINOL, V6, P893, DOI 10.1210/me.6.6.893; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHETH NA, 1997, BRIT J CANCER, V30, P566; SHORT JM, 1986, J BIOL CHEM, V261, P9721; SILVER BJ, 1987, P NATL ACAD SCI USA, V84, P2198, DOI 10.1073/pnas.84.8.2198; STEGER DJ, 1991, MOL ENDOCRINOL, V5, P243, DOI 10.1210/mend-5-2-243; TSUJII T, 1995, MOL CELL ENDOCRINOL, V113, P123, DOI 10.1016/0303-7207(95)03613-C; TSUKADA T, 1987, J BIOL CHEM, V262, P8743; WEINTRAUB BD, 1973, J CLIN INVEST, V52, P335; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	78	4	4	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40235	40246		10.1074/jbc.M207177200	http://dx.doi.org/10.1074/jbc.M207177200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177069	hybrid			2022-12-27	WOS:000178791400012
J	Greenstone, HL; Santoro, F; Lusso, P; Berger, EA				Greenstone, HL; Santoro, F; Lusso, P; Berger, EA			Human herpesvirus 6 and measles virus employ distinct CD46 domains for receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE COFACTOR PROTEIN; DECAY-ACCELERATING FACTOR; RECOMBINANT VACCINIA VIRUS; MONOCLONAL-ANTIBODIES; CELLULAR RECEPTOR; COMPLEMENT ACTIVATION; MULTIPLE ISOFORMS; BINDING DOMAINS; MCP; SITES	We employed a quantitative cell fusion assay to identify structural domains of CD46 required for its function as a receptor for human herpesvirus 6 (HHV-6). We examined the activities of recombinant variants of CD46, including different isoforms as well as engineered truncations and molecular chimeras with decay-accelerating factor, a related protein in the family of regulators of complement activation (RCA). We observed strong receptor activity for all four CD46 isoforms, which differ in the membrane-proximal extracellular and cytoplasmic domains, indicating that the critical determinants for HHV-6 receptor activity reside outside the C-terminal portion of CD46. Analysis of the short consensus repeat (SCR) regions that comprise most of the extracellular portion of CD46 indicated a strong dependence on SCRs 2 and 3 and no requirement for SCRs 1 or 4. Fusion-inhibition studies with SCR-specific monoclonal antibodies supported the essential role of SCRs 2 and 3 in HHV-6 receptor activity. These findings contrast markedly with fusion mediated by measles virus glycoproteins for which we observed a strict dependence on SCRs 1 and 2, consistent with previous reports. These results expand the emerging notion that CD46 and other members of the RCA family are co-opted in distinct manners by different infectious pathogens.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; San Raffaele Sci Inst, Dept Biol & Technol Res, Unit Human Virol, I-20132 Milan, Italy	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Berger, EA (corresponding author), NIAID, Viral Dis Lab, NIH, Bldg 4,Rm 237, Bethesda, MD 20892 USA.							ADAMS EM, 1991, J IMMUNOL, V147, P3005; Alkhatib G, 1996, J VIROL, V70, P5487, DOI 10.1128/JVI.70.8.5487-5494.1996; ANDREWS PW, 1985, ANN HUM GENET, V49, P31, DOI 10.1111/j.1469-1809.1985.tb01673.x; Atabani SF, 2001, J INFECT DIS, V184, P1, DOI 10.1086/321009; Belyakov IM, 1998, J VIROL, V72, P8264, DOI 10.1128/JVI.72.10.8264-8272.1998; BRODER CC, 1993, VIROLOGY, V193, P483, DOI 10.1006/viro.1993.1151; Buchholz CJ, 1997, J BIOL CHEM, V272, P22072, DOI 10.1074/jbc.272.35.22072; Campadelli-Fiume G, 1999, EMERG INFECT DIS, V5, P353, DOI 10.3201/eid0503.990306; Chakrabarti S, 1997, BIOTECHNIQUES, V23, P1094, DOI 10.2144/97236st07; CHO SW, 1991, CLIN EXP IMMUNOL, V83, P257; Christiansen D, 2000, J GEN VIROL, V81, P911, DOI 10.1099/0022-1317-81-4-911; Christiansen D, 2000, MOL IMMUNOL, V37, P687, DOI 10.1016/S0161-5890(01)00002-5; CLARKSON NA, 1995, J VIROL, V69, P5497, DOI 10.1128/JVI.69.9.5497-5501.1995; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Giannakis E, 2002, J IMMUNOL, V168, P4585, DOI 10.4049/jimmunol.168.9.4585; Hourcade D, 2000, IMMUNOPHARMACOLOGY, V49, P103, DOI 10.1016/S0162-3109(00)80296-9; Hsu EC, 1999, VIROLOGY, V258, P314, DOI 10.1006/viro.1999.9712; Hsu EC, 1997, J VIROL, V71, P6144, DOI 10.1128/JVI.71.8.6144-6154.1997; IWATA K, 1995, J BIOL CHEM, V270, P15148, DOI 10.1074/jbc.270.25.15148; Jacobson S, 1998, J NEUROVIROL, V4, P471, DOI 10.3109/13550289809113491; Kallstrom H, 2001, CELL MICROBIOL, V3, P133, DOI 10.1046/j.1462-5822.2001.00095.x; Karnauchow TM, 1998, J VIROL, V72, P9380, DOI 10.1128/JVI.72.11.9380-9383.1998; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; Kondo K, 2002, J MED VIROL, V67, P364, DOI 10.1002/jmv.10082; Lea SM, 1998, J BIOL CHEM, V273, P30443, DOI 10.1074/jbc.273.46.30443; Lindahl G, 2000, CURR OPIN IMMUNOL, V12, P44, DOI 10.1016/S0952-7915(99)00049-7; Liszewski MK, 2000, J BIOL CHEM, V275, P37692, DOI 10.1074/jbc.M004650200; LUBLIN DM, 1991, J EXP MED, V174, P35, DOI 10.1084/jem.174.1.35; Lusso P, 1996, ANTIVIR RES, V31, P1, DOI 10.1016/0166-3542(96)00949-7; Maisner A, 1996, J VIROL, V70, P4973, DOI 10.1128/JVI.70.8.4973-4977.1996; MAISNER A, 1994, J VIROL, V68, P6299, DOI 10.1128/JVI.68.10.6299-6304.1994; Manchester M, 2000, VIROLOGY, V274, P5, DOI 10.1006/viro.2000.0469; Manchester M, 1997, VIROLOGY, V233, P174, DOI 10.1006/viro.1997.8581; MANCHESTER M, 1995, P NATL ACAD SCI USA, V92, P2303, DOI 10.1073/pnas.92.6.2303; MANCHESTER M, 1994, P NATL ACAD SCI USA, V91, P2161, DOI 10.1073/pnas.91.6.2161; Martino TA, 1998, VIROLOGY, V244, P302, DOI 10.1006/viro.1998.9122; MOLINA H, 1991, J BIOL CHEM, V266, P12173; NANICHE D, 1993, J VIROL, V67, P6025, DOI 10.1128/JVI.67.10.6025-6032.1993; NOWICKI B, 1993, J EXP MED, V178, P2115, DOI 10.1084/jem.178.6.2115; NUSSBAUM O, 1995, J VIROL, V69, P3341, DOI 10.1128/JVI.69.6.3341-3349.1995; NUSSBAUM O, 1994, J VIROL, V68, P5411, DOI 10.1128/JVI.68.9.5411-5422.1994; PHAM T, 1995, INFECT IMMUN, V63, P1663, DOI 10.1128/IAI.63.5.1663-1668.1995; Powell RM, 1999, J GEN VIROL, V80, P3145, DOI 10.1099/0022-1317-80-12-3145; SALAHUDDIN SZ, 1986, SCIENCE, V234, P596, DOI 10.1126/science.2876520; Santoro F, 1999, CELL, V99, P817, DOI 10.1016/S0092-8674(00)81678-5; Seya T, 1999, INT J BIOCHEM CELL B, V31, P1255, DOI 10.1016/S1357-2725(99)00092-8; SEYA T, 1990, J IMMUNOL, V145, P238; SEYA T, 1995, IMMUNOLOGY, V84, P619; Shafren DR, 1997, J VIROL, V71, P4736, DOI 10.1128/JVI.71.6.4736-4743.1997; Shafren DR, 1998, J IMMUNOL, V160, P2318; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; Yamanishi K, 1996, BAILLIERE CLIN INF D, V3, P507	54	52	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39112	39118		10.1074/jbc.M206488200	http://dx.doi.org/10.1074/jbc.M206488200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171934	hybrid			2022-12-27	WOS:000178662500009
J	Janausch, IG; Garcia-Moreno, I; Unden, G				Janausch, IG; Garcia-Moreno, I; Unden, G			Function of DcuS from Escherichia coli as a fumarate-stimulated histidine protein kinase in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2-COMPONENT REGULATORY SYSTEM; SENSOR-KINASE; RHIZOBIUM-MELILOTI; GENE-EXPRESSION; OXYGEN SENSOR; TRANSFORMATION; TRANSPORT; PLASMIDS; DOMAIN; KDPD	The two-component regulatory system DcuSR of Escherichia coli controls the expression of genes of C-4-dicarboxylate metabolism in response to extracellular C-4-dicarboxylates such as fumarate or succinate. DcuS is a membrane-integral sensor kinase, and the sensory and kinase domains are located on opposite sides of the cytoplasmic membrane. The intact DcuS protein (HiS(6)-DcuS) was overproduced and isolated in detergent containing buffer. His(6)-DcuS was reconstituted into liposomes made from E. coli phospholipids. Reconstituted His(6)-DcuS catalyzed, in contrast to the detergent-solubilized sensor, autophosphorylation by [gamma-P-33]ATp with an approximate K-D of 0.16 mm for ATP. Up to 7% of the reconstituted DcuS was phosphorylated. Phosphorylation was stimulated up to 5.9-fold by C4-dicarboxylates, but not by other carboxylates. The phosphoryl group of DcuS was rapidly transferred to the response regulator DcuR. Upon phosphorylation, DcuR bound specifically to dcuB promoter DNA. The reconstituted DeuSR system therefore represents a defined in vitro system, which is capable of the complete transmembrane signal transduction by the DcuSR two-component system from the stimulus (fumarate) to the DNA, including signal transfer across the phospholipid membrane.	Univ Mainz, Inst Mikrobiol & Weinforsch, D-55099 Mainz, Germany	Johannes Gutenberg University of Mainz	Unden, G (corresponding author), Univ Mainz, Inst Mikrobiol & Weinforsch, Becherweg 15, D-55099 Mainz, Germany.							Aizawa S, 2000, J BACTERIOL, V182, P1459, DOI 10.1128/JB.182.6.1459-1471.2000; Amsler CD., 1995, 2 COMPONENT SIGNAL T, P89; Bird TH, 1999, J BIOL CHEM, V274, P16343, DOI 10.1074/jbc.274.23.16343; BOTT M, 1995, MOL MICROBIOL, V18, P533, DOI 10.1111/j.1365-2958.1995.mmi_18030533.x; CHEN WP, 1993, NUCLEIC ACIDS RES, V21, P2260, DOI 10.1093/nar/21.9.2260; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; Emmerich R, 1999, EUR J BIOCHEM, V263, P455, DOI 10.1046/j.1432-1327.1999.00517.x; ENGEL P, 1994, EUR J BIOCHEM, V222, P605, DOI 10.1111/j.1432-1033.1994.tb18903.x; Georgellis D, 1999, J BIOL CHEM, V274, P35950, DOI 10.1074/jbc.274.50.35950; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Golby P, 1999, J BACTERIOL, V181, P1238, DOI 10.1128/JB.181.4.1238-1248.1999; Golby P, 1998, J BACTERIOL, V180, P6586, DOI 10.1128/JB.180.24.6586-6596.1998; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Heermann R, 2000, J BIOL CHEM, V275, P17080, DOI 10.1074/jbc.M000093200; Himpens S, 2000, MICROBIOL-SGM, V146, P3091, DOI 10.1099/00221287-146-12-3091; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; INOUE H, 1990, GENE, V96, P23, DOI 10.1016/0378-1119(90)90336-P; Janausch IG, 2002, BBA-BIOENERGETICS, V1553, P39, DOI 10.1016/S0005-2728(01)00233-X; Jung K, 1998, J BIOL CHEM, V273, P17406, DOI 10.1074/jbc.273.28.17406; Jung K, 1997, J BIOL CHEM, V272, P10847; Jung K, 2001, J BIOL CHEM, V276, P40896, DOI 10.1074/jbc.M107871200; Jung K, 2001, J BACTERIOL, V183, P3800, DOI 10.1128/JB.183.12.3800-3803.2001; Kaspar S, 1999, MOL MICROBIOL, V33, P858, DOI 10.1046/j.1365-2958.1999.01536.x; Kaspar S, 2002, ARCH MICROBIOL, V177, P313, DOI 10.1007/s00203-001-0393-z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOIS AF, 1993, J BACTERIOL, V175, P1103, DOI 10.1128/JB.175.4.1103-1109.1993; Miller J.H., 1992, SHORT COURSE BACTERI, P150; NINFA AJ, 1995, 2 COMPONENT SIGNAL T, P65; Parac TN, 2001, J BIOMOL NMR, V19, P91, DOI 10.1023/A:1008301425100; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; RIGAUD JL, 1995, BBA-BIOENERGETICS, V1231, P223, DOI 10.1016/0005-2728(95)00091-V; Sambrook J., 2002, MOL CLONING LAB MANU; SCHRODER I, 1994, J BACTERIOL, V176, P4985, DOI 10.1128/jb.176.16.4985-4992.1994; SIX S, 1994, J BACTERIOL, V176, P6470, DOI 10.1128/JB.176.21.6470-6478.1994; Stock J.B., 1995, 2 COMPONENT SIGNAL T, P25; Tran QH, 1998, EUR J BIOCHEM, V251, P538, DOI 10.1046/j.1432-1327.1998.2510538.x; Tuckerman JR, 2001, J MOL BIOL, V308, P449, DOI 10.1006/jmbi.2001.4591; Zientz E, 1998, J BACTERIOL, V180, P5421, DOI 10.1128/JB.180.20.5421-5425.1998; Zientz E, 1996, J BACTERIOL, V178, P7241, DOI 10.1128/jb.178.24.7241-7247.1996	40	55	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39809	39814		10.1074/jbc.M204482200	http://dx.doi.org/10.1074/jbc.M204482200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167640	hybrid			2022-12-27	WOS:000178662500096
J	Kahya, N; Wiersma, DA; Poolman, B; Hoekstra, D				Kahya, N; Wiersma, DA; Poolman, B; Hoekstra, D			Spatial organization of bacteriorhodopsin in model membranes - Light-induced mobility changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE CORRELATION SPECTROSCOPY; FRACTURE ELECTRON-MICROSCOPY; PURPLE-MEMBRANE; HALOBACTERIUM-HALOBIUM; PROTON TRANSLOCATION; ION-TRANSPORT; PROTEIN; RESOLUTION; MECHANISM; PEPTIDE	Bacteriorhodopsin is a proton-transporting membrane protein in Halophilic archaea, and it is considered a prototype of membrane transporters and a model for G-protein-coupled receptors. Oligomerization of the protein has been reported, but it is unknown whether this feature is correlated with, for instance, light activation. Here, we have addressed this issue by reconstituting bacteriorhodopsin into giant unilamellar vesicles. The dynamics of the fully active protein was investigated using fluorescence correlation spectroscopy and freeze fracture electron microscopy. At low protein-to-lipid ratios (<1:10 w/w), a decrease in mobility was observed upon protein photoactivation. This process occurred on a second time scale and was fully reversible, i.e. when the dark-adapted state was reestablished the lateral diffusion rate of the protein was returned to that prior to activation. A similar decrease in lateral mobility as observed upon photoactivation was obtained when bacteriorhodopsin was reconstituted at high protein-to-lipid ratios (> 1:10 w/w). We interpret the shifts in mobility during light adaptation as being caused by transient photoinduced oligomerization of bacteriorhodopsin. These observations are fully supported by freeze-fracture electron microscopy, and the size of the clusters during photoactivation was estimated to consist of two or three trimers.	Univ Groningen, Ctr Mat Sci, Ultrafast Laser & Spect Lab, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Biochem, Groningen Biomol Sci & Biotechnol Inst, NL-9747 AG Groningen, Netherlands; Univ Groningen, Dept Membrane Cell Biol, NL-9713 AV Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	Kahya, N (corresponding author), Univ Groningen, Ctr Mat Sci, Ultrafast Laser & Spect Lab, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.		Wiersma, Douwe/AAU-6535-2020; Poolman, Bert/D-1882-2012					ANGELOVA MI, 1986, FARADAY DISCUSS, V81, P303; BAUER PJ, 1976, BIOPHYS STRUCT MECH, V2, P79, DOI 10.1007/BF00535654; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P358; CASADIO R, 1980, BIOCHEMISTRY-US, V19, P3374, DOI 10.1021/bi00555a043; CHERRY RJ, 1978, J MOL BIOL, V121, P283, DOI 10.1016/S0022-2836(78)80010-2; DENCHER NA, 1979, FEBS LETT, V108, P307, DOI 10.1016/0014-5793(79)80552-9; DENCHER NA, 1982, METHOD ENZYMOL, V88, P5; Dracheva S, 1996, FEBS LETT, V382, P209, DOI 10.1016/0014-5793(96)00181-0; Duke TAJ, 1999, P NATL ACAD SCI USA, V96, P10104, DOI 10.1073/pnas.96.18.10104; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; Eskandari S, 1998, P NATL ACAD SCI USA, V95, P11235, DOI 10.1073/pnas.95.19.11235; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GULIKKRZYWICKI T, 1987, J BIOL CHEM, V262, P15580; Haupts U, 1999, ANNU REV BIOPH BIOM, V28, P367, DOI 10.1146/annurev.biophys.28.1.367; HEYN MP, 1975, BIOCHEM BIOPH RES CO, V67, P897, DOI 10.1016/0006-291X(75)90761-5; HIRAKI K, 1981, PHOTOCHEM PHOTOBIOL, V33, P429, DOI 10.1111/j.1751-1097.1981.tb05442.x; Kahya N, 2001, BIOPHYS J, V81, P1464, DOI 10.1016/S0006-3495(01)75801-8; Kirkpatrick P, 2002, NAT REV DRUG DISCOV, V1, P7, DOI 10.1038/nrd711; KOPPEL DE, 1974, PHYS REV A, V10, P1938, DOI 10.1103/PhysRevA.10.1938; KUBO R, 1985, STAT PHYSICS, V2, P10; Kuhlbrandt W, 2000, NATURE, V406, P569, DOI 10.1038/35020654; Lanyi JK, 1997, J BIOL CHEM, V272, P31209, DOI 10.1074/jbc.272.50.31209; Lanyi JK, 2001, CURR OPIN STRUC BIOL, V11, P415, DOI 10.1016/S0959-440X(00)00226-8; Luecke H, 1999, SCIENCE, V286, P255, DOI 10.1126/science.286.5438.255; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; MAGDE D, 1972, PHYS REV LETT, V29, P705, DOI 10.1103/PhysRevLett.29.705; Martin I, 1999, BIOCHEMISTRY-US, V38, P9337, DOI 10.1021/bi9829534; Mollaaghababa R, 2000, BIOCHEMISTRY-US, V39, P1120, DOI 10.1021/bi991963h; OESTERHELT D, 1971, NATURE-NEW BIOL, V233, P149, DOI 10.1038/newbio233149a0; Oesterhelt D, 1998, CURR OPIN STRUC BIOL, V8, P489, DOI 10.1016/S0959-440X(98)80128-0; Oesterhelt D, 1974, Methods Enzymol, V31, P667; Okada T, 2001, TRENDS BIOCHEM SCI, V26, P318, DOI 10.1016/S0968-0004(01)01799-6; Pecheur EI, 1997, BIOCHEMISTRY-US, V36, P3773, DOI 10.1021/bi9622128; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; Royant A, 2000, NATURE, V406, P645, DOI 10.1038/35020599; Sass HJ, 2000, NATURE, V406, P649, DOI 10.1038/35020607; Schwille P, 2001, CELL BIOCHEM BIOPHYS, V34, P383, DOI 10.1385/CBB:34:3:383; STERNBERG B, 1989, BIOCHIM BIOPHYS ACTA, V980, P117, DOI 10.1016/0005-2736(89)90207-1; STERNBERG B, 1993, J STRUCT BIOL, V110, P196, DOI 10.1006/jsbi.1993.1022; Subramaniam S, 1999, J STRUCT BIOL, V128, P19, DOI 10.1006/jsbi.1999.4178; Subramaniam S, 2000, NATURE, V406, P653, DOI 10.1038/35020614; Veenhoff LM, 2002, TRENDS BIOCHEM SCI, V27, P242, DOI 10.1016/S0968-0004(02)02077-7; VONDERWOUDE I, 1997, P NATL ACAD SCI USA, V94, P1160; Widengren J., 1996, Bioimaging, V4, P149, DOI 10.1002/1361-6374(199609)4:3<149::AID-BIO5>3.3.CO;2-4	45	47	48	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39304	39311		10.1074/jbc.M202635200	http://dx.doi.org/10.1074/jbc.M202635200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167614	hybrid			2022-12-27	WOS:000178662500033
J	Odemis, V; Moepps, B; Gierschik, P; Engele, J				Odemis, V; Moepps, B; Gierschik, P; Engele, J			Interleukin-6 and cAMP induce stromal cell-derived factor-1 chemotaxis in astroglia by up-regulating CXCR4 cell surface expression - Implications for brain inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CXCR4; CENTRAL-NERVOUS-SYSTEM; ENDOTHELIAL GROWTH-FACTOR; FUNCTIONAL EXPRESSION; CHROMOSOMAL LOCALIZATION; EMBRYONIC EXPRESSION; NEURONAL APOPTOSIS; MOLECULAR-CLONING; HIV-1 CORECEPTOR; HUMAN ASTROCYTES	The chemokine stromal cell-derived factor-1 (SDF-1) and its receptor CXCR4 control the migration of neurons and microglial cells in the central nervous system. Although functional CXCR4 is also expressed by astroglia, recent studies have failed to observe a chemotactic response of these cells to SDF-1. Here, we demonstrate that SDF-1-dependent chemotaxis can be induced by treating cultured cortical astroglia with either dibutyryl cyclic AMP (dbcAMP; 10(-4) M) or interleukin-6 (IL-6; 10 ng/ml). Flow cytometric analysis revealed that both the dbcAMP- and IL-6-induced onset of SDF-1-dependent chemotaxis of astroglia are due to the increased cell surface expression of CXCR4. In addition, dbcAMP and IL-6 also increased CXCR4 transcript levels, further suggesting that both treatments primarily affect CXCR4 surface expression in astroglia by stimulation of gene expression. Moreover, unlike the case with IL-6 and dbcAMP, which allowed for an optimal chemotactic response to SDF-1 only after 48 h, a similar chemotactic response, associated with an increase in CXCR4 cell surface expression, already occurred after 24 h when astroglial cultures were maintained with medium conditioned by IL-6- or dbcAMP-pretreated astrocytes, indicating that the stimulatory effects of IL-6 and cAMP on CXCR4 cell surface expression involve a secondary mechanism. The findings that elevated extracellular levels of IL-6 or factors positively coupled to cAMP result in increased CXCR4 cell surface expression levels and subsequent SDF-1-dependent chemotaxis in central nervous system astrocytes point to a crucial role of this chemokine during reactive gliosis and human immunodeficiency virus-mediated dementia.	Univ Ulm, Abt Pharmakol & Toxikol, D-89069 Ulm, Germany; Univ Ulm, Abt Anat & Zellbiol, D-89069 Ulm, Germany	Ulm University; Ulm University	Engele, J (corresponding author), Univ Leipzig, Inst Anat, Liebigstr 13, D-04103 Leipzig, Germany.							Andjelkovic AV, 1999, GLIA, V28, P225, DOI 10.1002/(SICI)1098-1136(199912)28:3<225::AID-GLIA6>3.0.CO;2-6; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bajetto A, 1999, J NEUROCHEM, V73, P2348, DOI 10.1046/j.1471-4159.1999.0732348.x; Bajetto A, 2001, J NEUROCHEM, V77, P1226, DOI 10.1046/j.1471-4159.2001.00350.x; Bezzi P, 2001, NAT NEUROSCI, V4, P702, DOI 10.1038/89490; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Boutet A, 2001, GLIA, V34, P165, DOI 10.1002/glia.1051.abs; Broxmeyer HE, 1999, ANN NY ACAD SCI, V872, P142, DOI 10.1111/j.1749-6632.1999.tb08460.x; Cole SW, 1999, J IMMUNOL, V162, P1392; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Engele J, 1996, NEUROSCIENCE, V73, P397, DOI 10.1016/0306-4522(96)00045-0; FEDERSPPIEL B, 1993, GENOMICS, V16, P707, DOI 10.1006/geno.1993.1251; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Forster R, 1998, J IMMUNOL, V160, P1522; Franke B, 1998, HISTOCHEM CELL BIOL, V110, P595, DOI 10.1007/s004180050322; Gleichmann M, 2000, EUR J NEUROSCI, V12, P1857, DOI 10.1046/j.1460-9568.2000.00048.x; GODISKA R, 1995, J NEUROIMMUNOL, V58, P167, DOI 10.1016/0165-5728(95)00008-P; Gupta SK, 1998, J BIOL CHEM, V273, P4282, DOI 10.1074/jbc.273.7.4282; Hesselgesser J, 1998, CURR BIOL, V8, P595, DOI 10.1016/S0960-9822(98)70230-1; Hesselgesser J, 1999, J NEUROVIROL, V5, P13, DOI 10.3109/13550289909029741; Hesselgesser J, 1997, CURR BIOL, V7, P112, DOI 10.1016/S0960-9822(06)00055-8; Honczarenko M, 1999, BLOOD, V94, P2990, DOI 10.1182/blood.V94.9.2990.421k36_2990_2998; Jazin EE, 1997, J NEUROIMMUNOL, V79, P148, DOI 10.1016/S0165-5728(97)00117-3; Kaul M, 1999, P NATL ACAD SCI USA, V96, P8212, DOI 10.1073/pnas.96.14.8212; Lavi E, 1997, AM J PATHOL, V151, P1035; Lazarini F, 2000, EUR J NEUROSCI, V12, P117, DOI 10.1046/j.1460-9568.2000.00894.x; Lin CL, 1998, EUR J IMMUNOL, V28, P4114, DOI 10.1002/(SICI)1521-4141(199812)28:12<4114::AID-IMMU4114>3.0.CO;2-C; LIPTON SA, 1991, NEURON, V7, P111, DOI 10.1016/0896-6273(91)90079-F; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Meucci O, 1996, J NEUROSCI, V16, P4080; Meucci O, 1998, P NATL ACAD SCI USA, V95, P14500, DOI 10.1073/pnas.95.24.14500; Nagasawa T, 1998, SEMIN IMMUNOL, V10, P179, DOI 10.1006/smim.1998.0128; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Oh JW, 2001, J IMMUNOL, V166, P2695, DOI 10.4049/jimmunol.166.4.2695; Ohtani Y, 1998, NEUROSCI LETT, V249, P163, DOI 10.1016/S0304-3940(98)00425-X; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Rempel SA, 2000, CLIN CANCER RES, V6, P102; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Salcedo R, 1999, AM J PATHOL, V154, P1125, DOI 10.1016/S0002-9440(10)65365-5; Sarau HM, 1997, J PHARMACOL EXP THER, V283, P411; SCHILLING K, 1991, P NATL ACAD SCI USA, V88, P5665, DOI 10.1073/pnas.88.13.5665; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; SMEYNE RJ, 1992, NEURON, V8, P13, DOI 10.1016/0896-6273(92)90105-M; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tanabe S, 1997, J IMMUNOL, V159, P905; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; Waltenberger J, 1996, J MOL CELL CARDIOL, V28, P1523, DOI 10.1006/jmcc.1996.0142; Wu VW, 1998, J NEUROSCI RES, V51, P675, DOI 10.1002/(SICI)1097-4547(19980315)51:6<675::AID-JNR2>3.3.CO;2-N; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	57	68	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39801	39808		10.1074/jbc.M200472200	http://dx.doi.org/10.1074/jbc.M200472200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12171912	hybrid			2022-12-27	WOS:000178662500095
J	Vetcher, AA; Napierala, M; Iyer, RR; Chastain, PD; Griffith, JD; Wells, RD				Vetcher, AA; Napierala, M; Iyer, RR; Chastain, PD; Griffith, JD; Wells, RD			Sticky DNA, a long GAA center dot GAA center dot TTC triplex that is formed intramolecularly, in the sequence of intron 1 of the frataxin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FRIEDREICH ATAXIA GENE; REPEAT EXPANSION; SUPERCOILED PLASMIDS; MOLECULAR-GENETICS; PROTEIN COMPLEXES; B-DNA; TRANSCRIPTION; PATHOGENESIS; RECOMBINATION; VISUALIZATION	Friedreich's ataxia is caused by the massive expansion of GAA.TTC repeats in intron I of the frataxin-(X25) gene. Our prior investigations showed that long GAA.TTC repeats formed very stable triplex structures which caused two repeat tracts to adhere to each other (sticky DNA). This process was dependent on negative supercoiling and the presence of divalent metal ions. Herein, we have investigated the formation of sticky DNA from plasmid monomers and dimers; sticky DNA is formed only when two tracts of sufficiently long (GAA.TTC)(n) (n = 59-270) are present in a single plasmid DNA and are in the direct repeat orientation. If the inserts are in the indirect (inverted) repeat orientation, no sticky DNA was observed. Furthermore, kinetic studies support the intramolecular nature of sticky DNA formation. Electron microscopy investigations also provide strong data for sticky DNA as a single long triplex. Hence, these results give new insights into our understanding of the capacity of sticky DNA to inhibit transcription and thereby reduce the level of frataxin protein as related to the etiology of Friedreich's ataxia.	Texas A&M Univ, Inst Biosci & Technol, Ctr Genome Res, Med Ctr, Houston, TX 77030 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	Texas A&M University System; University of North Carolina; University of North Carolina Chapel Hill	Wells, RD (corresponding author), Texas A&M Univ, Inst Biosci & Technol, Ctr Genome Res, Med Ctr, 2121 W Holcombe Blvd, Houston, TX 77030 USA.		Chastain, Paul/AAN-2692-2020	Chastain, Paul/0000-0001-6782-6788; Vetcher, Alexandre/0000-0002-4828-8571	NIEHS NIH HHS [ES11347] Funding Source: Medline; NIGMS NIH HHS [GM31819, GM52982] Funding Source: Medline; NINDS NIH HHS [NS37554] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011347] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM052982, R01GM031819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037554] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bidichandani SI, 1998, AM J HUM GENET, V62, P111, DOI 10.1086/301680; Bidichandani SI, 1997, AM J HUM GENET, V60, P1251; BLISKA JB, 1987, J MOL BIOL, V194, P205, DOI 10.1016/0022-2836(87)90369-X; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Campuzano V, 1997, HUM MOL GENET, V6, P1771, DOI 10.1093/hmg/6.11.1771; Cossee M, 1997, NAT GENET, V15, P337, DOI 10.1038/ng0497-337; Durr A, 1996, NEW ENGL J MED, V335, P1169, DOI 10.1056/NEJM199610173351601; Filla A, 1996, AM J HUM GENET, V59, P554; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; FUJITA R, 1989, GENOMICS, V4, P110, DOI 10.1016/0888-7543(89)90323-6; GRIFFITH JD, 1978, ANNU REV BIOPHYS BIO, V7, P19, DOI 10.1146/annurev.bb.07.060178.000315; HANAUER A, 1990, AM J HUM GENET, V46, P133; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1989, J BIOL CHEM, V264, P5950; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; JAMES AA, 1982, J MOL BIOL, V160, P411, DOI 10.1016/0022-2836(82)90305-9; KANG S, 1992, J BIOL CHEM, V267, P20887; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LE DT, 1987, NUCLEIC ACIDS RES, V15, P7749; LILLEY D, 1986, NATURE, V320, P14, DOI 10.1038/320014a0; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Montermini L, 1997, ANN NEUROL, V41, P675, DOI 10.1002/ana.410410518; Montermini L, 1997, HUM MOL GENET, V6, P1261, DOI 10.1093/hmg/6.8.1261; Napierala M, 2002, J BIOL CHEM, V277, P34087, DOI 10.1074/jbc.M202128200; Ohshima K, 1998, J BIOL CHEM, V273, P14588, DOI 10.1074/jbc.273.23.14588; Ohshima K, 1996, J BIOL CHEM, V271, P16773, DOI 10.1074/jbc.271.28.16773; Ohshima K, 1999, NEUROLOGY, V53, P1854, DOI 10.1212/WNL.53.8.1854; Pandolfo M, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P373; Pandolfo M, 1998, NEUROMUSCULAR DISORD, V8, P409, DOI 10.1016/S0960-8966(98)00039-X; Pandolfo M, 1999, ARCH NEUROL-CHICAGO, V56, P1201, DOI 10.1001/archneur.56.10.1201; Pandolfo M, 2000, Neurologia, V15, P325; Pandolfo M, 1998, ADV GENET, V38, P31, DOI 10.1016/S0065-2660(08)60141-8; POLISKY B, 1975, P NATL ACAD SCI USA, V72, P3310, DOI 10.1073/pnas.72.9.3310; Sakamoto N, 1999, MOL CELL, V3, P465, DOI 10.1016/S1097-2765(00)80474-8; Sakamoto N, 2001, J BIOL CHEM, V276, P27178, DOI 10.1074/jbc.M101852200; Sakamoto N, 2001, J BIOL CHEM, V276, P27171, DOI 10.1074/jbc.M101879200; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SHIMIZU M, 1989, J BIOL CHEM, V264, P5944; SHIMIZU M, 1990, BIOCHEMISTRY-US, V29, P4704, DOI 10.1021/bi00471a027; Shin C, 1996, BIOCHEMISTRY-US, V35, P968, DOI 10.1021/bi952163j; SINDEN R. R., 1994, DNA STRUCTURE FUNCTI; SINGLETON CK, 1982, ANAL BIOCHEM, V122, P253, DOI 10.1016/0003-2697(82)90277-9; Soyfer V. N., 1995, TRIPLE HELICAL NUCL; THRESHER R, 1992, METHOD ENZYMOL, V211, P481; Vasquez KM, 1998, TRENDS BIOCHEM SCI, V23, P4, DOI 10.1016/S0968-0004(97)01158-4; Vetcher AA, 2002, J BIOL CHEM, V277, P39228, DOI 10.1074/jbc.M205210200; WANG YH, 1991, BIOCHEMISTRY-US, V30, P5443, DOI 10.1021/bi00236a017; Wells R.D., 1998, GENETIC INSTABILITIE; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; ZACHARIAS W, 1988, P NATL ACAD SCI USA, V85, P7069, DOI 10.1073/pnas.85.19.7069	52	50	52	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39217	39227		10.1074/jbc.M205209200	http://dx.doi.org/10.1074/jbc.M205209200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161437	hybrid, Green Published			2022-12-27	WOS:000178662500022
J	Baltzis, D; Lit, SY; Koromilas, AE				Baltzis, D; Lit, SY; Koromilas, AE			Functional characterization of pkr gene products expressed in cells from mice with a targeted deletion of the N terminus or C terminus domain of PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; PROTEIN-KINASE PKR; DSRNA BINDING DOMAIN; KAPPA-B; INITIATION FACTOR-2-ALPHA; TRANSLATIONAL CONTROL; INTERFERON ACTION; VACCINIA VIRUS; ACTIVATION; MECHANISM	The interferon-inducible double-stranded RNA (dsRNA)-activated protein kinase, PKR, plays an important role in messenger (m) RNA translation by phosphorylating the a subunit of eukaryotic initiation factor 2. Through this capacity PKR is thought to be a mediator of the antiviral and antiproliferative actions of interferon. In addition to translational function, PKR has been implicated in many signaling pathways to gene transcription by modulating the activities of a number of transcription factors, including NF-kappaB and STATs. However, experiments with two different PKR knockout (PKR-/-) mouse models have failed to verify many of the biological functions attributed to PKR. In addition, results with cells from the two PKR-/- mice have been contradictory and confusing. Here, we show that the first PKR-/- mouse with deletion of exons 2 and 3, corresponding to the N terminus domain of PKR (N-PYR-/-), expresses a truncated protein, resulting from the translation of the exon-skipped mouse PKR (ES-mPKR) mRNA. The ES-mPKR protein is defective in dsRNA binding but remains catalytically active both in vitro and in vivo. Furthermore, we show that the second PKR-/- mouse with a targeted deletion of exon 12, which corresponds to the C terminus of the molecule (C-PKR-/-), expresses a truncated mPKR produced by alternative splicing of exon 12. Although the spliced form of mPKR (SF-mPKR) is catalytically inactive, it retains the dsRNA-binding properties of the wild type mPKR. Reverse transcription-PCRs demonstrate that SF-mPKR mRNA is expressed in several normal mouse tissues, and appears to be under developmental control during embryogenesis. Our data demonstrate that both PKR-/- models are incomplete knockouts, and expression of the PKR variants may account, at least in part, for the significant signaling differences between cells from the two PKR-/- mice.	McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada	Lady Davis Institute; McGill University	Koromilas, AE (corresponding author), McGill Univ, Sir Mortimer B Davis Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine St, Montreal, PQ H3T 1E2, Canada.	antonis.koromilas@mcgill.ca						Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Abraham N, 1998, EXP CELL RES, V244, P394, DOI 10.1006/excr.1998.4201; Adams A, 1997, METHODS YEAST GENETI; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; Bass BL, 1997, RNA, V3, P947; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Bonnet MC, 2000, MOL CELL BIOL, V20, P4532, DOI 10.1128/MCB.20.13.4532-4542.2000; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; Durbin RK, 2002, VIRAL IMMUNOL, V15, P41, DOI 10.1089/088282402317340224; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Goh KC, 2000, EMBO J, V19, P4292, DOI 10.1093/emboj/19.16.4292; ICELY PL, 1991, J BIOL CHEM, V266, P16073; Iordanov MS, 2001, MOL CELL BIOL, V21, P61, DOI 10.1128/MCB.21.1.61-72.2001; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Ishii T, 2001, ONCOGENE, V20, P1900, DOI 10.1038/sj.onc.1204267; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2000, COLD SPRING HARBOR M, V39, P503; KawagishiKobayashi M, 1997, MOL CELL BIOL, V17, P4146, DOI 10.1128/MCB.17.7.4146; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Li SY, 2001, J BIOL CHEM, V276, P13881, DOI 10.1074/jbc.M008140200; MEURS EF, 1992, J VIROL, V66, P5805, DOI 10.1128/JVI.66.10.5805-5814.1992; Nanduri S, 2000, EMBO J, V19, P5567, DOI 10.1093/emboj/19.20.5567; Ramana CV, 2000, EMBO J, V19, P263, DOI 10.1093/emboj/19.2.263; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; Ron D, 2000, COLD SPRING HARBOR M, V39, P547; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SMITH GE, 1980, ANAL BIOCHEM, V109, P123, DOI 10.1016/0003-2697(80)90019-6; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stojdl DF, 2000, J VIROL, V74, P9580, DOI 10.1128/JVI.74.20.9580-9585.2000; Tan SL, 1999, J INTERF CYTOK RES, V19, P543, DOI 10.1089/107999099313677; TANAKA H, 1994, P NATL ACAD SCI USA, V91, P7995, DOI 10.1073/pnas.91.17.7995; THOMIS DC, 1992, VIROLOGY, V188, P33, DOI 10.1016/0042-6822(92)90732-5; Wong AHT, 1997, EMBO J, V16, P1291, DOI 10.1093/emboj/16.6.1291; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Zamanian-Daryoush M, 2000, MOL CELL BIOL, V20, P1278, DOI 10.1128/MCB.20.4.1278-1290.2000; Zhu SH, 1996, J BIOL CHEM, V271, P24989, DOI 10.1074/jbc.271.40.24989	43	61	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38364	38372		10.1074/jbc.M203564200	http://dx.doi.org/10.1074/jbc.M203564200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161430	hybrid			2022-12-27	WOS:000178529600049
J	Kawauchi, J; Zhang, C; Nobori, K; Hashimoto, Y; Adachi, MT; Noda, A; Sunamori, M; Kitajima, S				Kawauchi, J; Zhang, C; Nobori, K; Hashimoto, Y; Adachi, MT; Noda, A; Sunamori, M; Kitajima, S			Transcriptional repressor activating transcription factor 3 protects human umbilical vein endothelial cells from tumor necrosis factor-alpha-induced apoptosis through down-regulation of p53 transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; C-JUN; AP-1 REPRESSOR; IN-VIVO; EXPRESSION; ATF3; PROMOTER; BINDING; DEATH; INDUCTION	Activating transcription factor 3 (ATF3) is a transcriptional repressor that is rapidly induced in cells exposed to a wide range of stress stimuli. To clarify the role of ATF3 in determining cell fate, we overexpressed it in human umbilical vein endothelial cells (HUVECs) by adenovirus-mediated gene transfer. ATF3 protected these cells from tumor necrosis factor (TNF)-alpha-induced apoptosis, as measured by flow cytometric analysis, trypan blue exclusion assay, and cleavage of procaspase 3 and poly(ADP-ribose) polymerase. Northern blot and nuclear run on assay showed that the transcription of tumor suppressor gene p53 was down-regulated in the ATF3-overexpressing cells. In the transient expression assay, ATF3 suppressed the p53 gene promoter activity through its specific binding to an atypical AP-1 element, PF-1 site, in the p53 gene promoter. Furthermore, the cell-protecting effect of ATF3 was remarkably reduced in p53-deficient cells. These results demonstrate that overexpression of ATF3 suppresses TNF-alpha-induced cell death of HUVECs, at least in part, through down-regulating the transcription of p53 gene. ATF3 may function as a cell survival factor of endothelial cells during vascular inflammation and atherogenesis.	Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Cardiothorac Surg, Bunkyo Ku, Tokyo 1138510, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Cardiovasc Regulat, Bunkyo Ku, Tokyo 1138510, Japan; Kobe Univ, Sch Med, Dept Radiat Biophys & Genet, Chuo Ku, Kobe, Hyogo 6500017, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Kobe University	Kitajima, S (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Biochem Genet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	kita.bgen@mri.tmd.ac.jp		Noda, Asao/0000-0002-9029-9813				Allen-Jennings AE, 2001, J BIOL CHEM, V276, P29507, DOI 10.1074/jbc.M100986200; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Aronheim A, 1997, MOL CELL BIOL, V17, P3094, DOI 10.1128/MCB.17.6.3094; Cai Y, 2000, BLOOD, V96, P2140, DOI 10.1182/blood.V96.6.2140.h8002140_2140_2148; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; Ewen ME, 1996, BBA-REV CANCER, V1242, P181, DOI 10.1016/0304-419X(95)00010-D; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; GINSBERG D, 1990, ONCOGENE, V5, P1285; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hai T, 1999, GENE EXPRESSION, V7, P321; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HSU JC, 1992, MOL CELL BIOL, V12, P4654, DOI 10.1128/MCB.12.10.4654; HSU JC, 1991, P NATL ACAD SCI USA, V88, P3511, DOI 10.1073/pnas.88.9.3511; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Karsan A, 1996, J Atheroscler Thromb, V3, P75; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Metzler B, 2000, AM J PATHOL, V156, P1875, DOI 10.1016/S0002-9440(10)65061-4; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nawa T, 2002, ATHEROSCLEROSIS, V161, P281, DOI 10.1016/S0021-9150(01)00639-6; NAWA T, 2000, BIOCHEM BIOPH RES CO, V87, P565; Noda A, 2000, ONCOGENE, V19, P21, DOI 10.1038/sj.onc.1203230; Okamoto Y, 2001, AM J PATHOL, V159, P639, DOI 10.1016/S0002-9440(10)61735-X; Piu F, 2001, MOL CELL BIOL, V21, P3012, DOI 10.1128/MCB.21.9.3012-3024.2001; POLUNOVSKY VA, 1994, EXP CELL RES, V214, P584, DOI 10.1006/excr.1994.1296; Potapova O, 2001, J BIOL CHEM, V276, P28546, DOI 10.1074/jbc.M102075200; Reisman D, 1998, SEMIN CANCER BIOL, V8, P317, DOI 10.1006/scbi.1998.0094; ROBAYE B, 1991, AM J PATHOL, V138, P447; ROZEK D, 1993, MOL CELL BIOL, V13, P5490, DOI 10.1128/MCB.13.9.5490; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shtil AA, 1999, ONCOGENE, V18, P377, DOI 10.1038/sj.onc.1202305; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Yan CH, 2002, J BIOL CHEM, V277, P10804, DOI 10.1074/jbc.M112069200; Yeung MC, 1998, J BIOL CHEM, V273, P25198, DOI 10.1074/jbc.273.39.25198; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943	49	99	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					39025	39034		10.1074/jbc.M202974200	http://dx.doi.org/10.1074/jbc.M202974200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161427	hybrid			2022-12-27	WOS:000178529600127
J	Won, J; Yim, Y; Kim, TK				Won, J; Yim, Y; Kim, TK			Sp1 and Sp3 recruit histone deacetylase to repress transcription of human telomerase reverse transcriptase (hTERT) promoter in normal human somatic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMORTAL HUMAN-CELLS; HUMAN TUMOR-CELLS; GENE PROMOTER; REPLICATIVE SENESCENCE; MULTIPROTEIN COMPLEX; C-MYC; ACTIVATION; EXPRESSION; INHIBITOR; ELEMENTS	Activation of telomerase is crucial for cells to gain immortality. In human cells, telomerase activity is tightly regulated by the expression of its catalytic subunit, human telomerase reverse transcriptase (hTERT). In most normal human somatic cells, hTERT is not expressed, and its suppression acts as an important gatekeeper against tumorigenesis. Here we describe the systematic analyses of hTERT promoter to understand the transcriptional repression mechanism of the hTERT gene in normal human somatic cells. Through the serial deletion analysis of hTERT promoter in normal human fibroblasts, we identified a critical repressive element on the hTERT promoter. The repressive element formed DNA-protein complexes with Sp1 and Sp3 in nuclear extracts. Using formaldehyde cross-linked chromatin immunoprecipitation analysis, we found that Sp1 and Sp3 were associated with the endogenously repressed hTERT promoter in human fibroblasts. Furthermore, Sp1 and Sp3 interacted with histone deacetylase (HDAC) in these cells. Overexpression of dominant-negative mutants of Sp1 and Sp3, which contained mainly the HDAC2-binding domain, relieved the HDAC-mediated repression of the hTERT promoter. Taken together, these results suggest that Sp1 and Sp3 associate with the hTERT promoter, recruiting HDAC for the localized deacetylation of nucleosomal histones and transcriptional silencing of the hTERT gene in normal human somatic cells.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Inst Chem & Cell Biol, Boston, MA 02115 USA; Seoul Natl Univ, Inst Mol Biol & Genet, Natl Creat Res Initiat Ctr Genet Reprogramming, Seoul 151742, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea	Harvard University; Harvard Medical School; Seoul National University (SNU); Korea Advanced Institute of Science & Technology (KAIST)	Yim, Y (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Inst Chem & Cell Biol, Boston, MA 02115 USA.							BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Conn KJ, 1996, J BIOL CHEM, V271, P28853, DOI 10.1074/jbc.271.46.28853; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Dahiya A, 2000, MOL CELL BIOL, V20, P6799, DOI 10.1128/MCB.20.18.6799-6805.2000; Dean G, 2000, J BIOL CHEM, V275, P32664, DOI 10.1074/jbc.275.42.32664; DeLuca P, 1996, J BIOL CHEM, V271, P8533, DOI 10.1074/jbc.271.15.8533; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Fujimoto K, 2000, NUCLEIC ACIDS RES, V28, P2557, DOI 10.1093/nar/28.13.2557; Gunes C, 2000, CANCER RES, V60, P2116; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; Hodny Z, 2000, BIOCHEM J, V346, P93, DOI 10.1042/0264-6021:3460093; Horikawa I, 1999, CANCER RES, V59, P826; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Ishii Y, 1999, MECH AGEING DEV, V110, P175, DOI 10.1016/S0047-6374(99)00054-8; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Klapper W, 2001, MECH AGEING DEV, V122, P695, DOI 10.1016/S0047-6374(01)00223-8; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Li J, 2001, J VIROL, V75, P8400, DOI 10.1128/JVI.75.18.8400-8406.2001; Li RG, 1996, J BIOL CHEM, V271, P18925, DOI 10.1074/jbc.271.31.18925; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh S, 1999, BIOCHEM BIOPH RES CO, V263, P361, DOI 10.1006/bbrc.1999.1366; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; Pagliuca A, 1998, J BIOL CHEM, V273, P7668, DOI 10.1074/jbc.273.13.7668; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; SHAY JW, 1995, MOL MED TODAY, V1, P378, DOI 10.1016/S1357-4310(95)93872-9; Shay JW, 1999, J NATL CANCER I, V91, P4, DOI 10.1093/jnci/91.1.4; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; Sowa Y, 1999, CANCER RES, V59, P4266; Sridhar P, 1999, MOL CELL BIOL, V19, P4219; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Ulaner GA, 1998, CANCER RES, V58, P4168; Vines CR, 2000, ENDOCRINOLOGY, V141, P938, DOI 10.1210/en.141.3.938; Walker GE, 2001, ENDOCRINOLOGY, V142, P3817, DOI 10.1210/en.142.9.3817; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zaid A, 1999, J BIOENERG BIOMEMBR, V31, P129, DOI 10.1023/A:1005499727732; Zhang AJ, 2000, CANCER RES, V60, P6230; Zhang XL, 1999, GENE DEV, V13, P2388, DOI 10.1101/gad.13.18.2388	50	150	155	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38230	38238		10.1074/jbc.M206064200	http://dx.doi.org/10.1074/jbc.M206064200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151407	hybrid			2022-12-27	WOS:000178529600033
J	Jaikaran, DCJ; Collins, CH; MacMillan, AM				Jaikaran, DCJ; Collins, CH; MacMillan, AM			Adenosine to inosine editing by ADAR2 requires formation of a ternary complex on the GluR-B R/G site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; GLUTAMATE-RECEPTOR RNA; IN-VITRO; UNWINDING ACTIVITY; BINDING DOMAINS; DEAMINASE; CLONING; GENE; PURIFICATION; CONVERSION	RNA editing by members of the ADAR (adenosine deaminase that acts on RNA) enzyme family involves hydrolytic deamination of adenosine to inosine within the context of a double-stranded pre-mRNA substrate. Editing of the human GluR-B transcript is catalyzed by, the enzyme ADAR2 at the Q/R and R/G sites. We have established a minimal RNA substrate for editing based on the RIG site and have characterized the interaction of ADAR2 with this RNA by gel shift, kinetic, and cross-linking analyses. Gel shift analysis revealed that two complexes are formed on the RNA as protein concentration is increased; the ADAR monomers can be crosslinked to one another in an RNA-dependent fashion. We performed a detailed kinetic study of the editing reaction; the data from this study are consistent with a reaction scheme in which formation of an ADAR2.RNA ternary complex is required for efficient RNA editing and in which formation of this complex is rate determining. These observations suggest that RNA adenosine deaminases function as homodimers on their RNA substrates and may partially explain regulation of RNA editing in these systems.	Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; Univ Toronto, Dept Chem, Toronto, ON M5S 3H6, Canada	University of Alberta; University of Toronto	MacMillan, AM (corresponding author), Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada.							BASS B, 1992, RNA WORLD, P383; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; CARTER CW, 1995, BIOCHIMIE, V77, P92, DOI 10.1016/0300-9084(96)88110-7; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; EGEBJERG J, 1994, P NATL ACAD SCI USA, V91, P10270, DOI 10.1073/pnas.91.22.10270; Gerber A, 1997, RNA, V3, P453; Gerber AP, 2001, TRENDS BIOCHEM SCI, V26, P376, DOI 10.1016/S0968-0004(01)01827-8; Gerber AP, 1999, SCIENCE, V286, P1146, DOI 10.1126/science.286.5442.1146; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; Hough RF, 1997, RNA, V3, P356; Hurst SR, 1995, RNA, V1, P1051; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; LAU PP, 1994, P NATL ACAD SCI USA, V91, P8522, DOI 10.1073/pnas.91.18.8522; Liu Y, 1997, J BIOL CHEM, V272, P4419, DOI 10.1074/jbc.272.7.4419; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; MALEY GF, 1990, J BIOL CHEM, V265, P47; MELCHER T, 1995, J BIOL CHEM, V270, P8566, DOI 10.1074/jbc.270.15.8566; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; Morse DP, 1997, BIOCHEMISTRY-US, V36, P8429, DOI 10.1021/bi9709607; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; Ohman M, 2000, RNA, V6, P687, DOI 10.1017/S1355838200000200; Polson AG, 1996, NATURE, V380, P454; POLSON AG, 1991, BIOCHEMISTRY-US, V30, P11507, DOI 10.1021/bi00113a004; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; Rueter S.M., 1998, MODIFICATION EDITING, P343; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SCOTT J, 1995, PREMRNA PROCESSING, P157; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0; Yang JH, 1997, P NATL ACAD SCI USA, V94, P4354, DOI 10.1073/pnas.94.9.4354; Yi-Brunozzi HY, 2001, J BIOL CHEM, V276, P37827	42	33	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37624	37629		10.1074/jbc.M204126200	http://dx.doi.org/10.1074/jbc.M204126200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12163487	hybrid, Green Accepted			2022-12-27	WOS:000178447100092
J	Willis, DM; Loewy, AP; Charlton-Kachigian, N; Shao, JS; Ornitz, DM; Towler, DA				Willis, DM; Loewy, AP; Charlton-Kachigian, N; Shao, JS; Ornitz, DM; Towler, DA			Regulation of osteocalcin gene expression by a novel Ku antigen transcription factor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; STRAND BREAK REPAIR; VITAMIN-D-RECEPTOR; DNA-BINDING; OSTEOBLAST DIFFERENTIATION; HOMEODOMAIN PROTEINS; MASS-SPECTROMETRY; PROMOTER; MSX2; ELEMENT	We previously described an osteocalcin (OC) fibroblast growth factor (FGF) response element (FRE) DNA binding activity as a target of Msx2 transcriptional regulation. We now identify Ku70, Ku80, and Tbdn100, a variant of Tubedown-1, as constituents of the purified OCFRE-binding complex. Northern and Western blot analyses demonstrate expression of Ku and Tbdn100 in MC3T3E1 osteoblasts. FGF2 treatment regulates Ku, but not Tbdn100, protein accumulation. Gel supershift studies confirm sequence-specific DNA binding of Ku in the OCFRE complex; chromatin immunoprecipitation assays confirm association of Ku and Tbdn100 with the endogenous OC promoter. In the promoter region -154 to -113, the OCFRE is juxtaposed to OSE2, an osteoblast-specific element that binds Runx2 (Osf2, Cbfa1). Expression of the Ku-Tbdn100 complex up-regulates both the basal and Runx2-dependent transcription driven by this 42-bp OC promoter element, reconstituted in CV-1 cells. Synergistic transactivation occurs in the presence of activated FGF receptor 2 signaling. Msx2 suppresses Ku- and Runx2-dependent transcription; suppression is dependent upon the Msx2 homeodomain NH2-terminal arm and extension. Pull-down assays confirm physical interactions between Ku and these coregulatory transcription factors, consistent with the functional interactions identified. Finally, cultured Ku70 -/- calvarial cells exhibit a profound, selective deficiency in OC expression as compared with wild-type calvarial cells, confirming the biochemical data showing a role for Ku in OC transcription. In toto, these data indicate that a novel Ku antigen complex assembles on the OC promoter, functioning in concert with Msx2 and Runx2 to regulate OC gene expression.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Towler, DA (corresponding author), Washington Univ, Med Ctr, Div Bone & Mineral Dis, Barnes Jewish Hosp, N Campus,216 S Kingshighway Blvd, St Louis, MO 63110 USA.	dtowler@im.wustl.edu		Ornitz, David/0000-0003-1592-7629; Towler, Dwight/0000-0003-2107-7923	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043731] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052446] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR43731] Funding Source: Medline; NIDDK NIH HHS [R01 DK52446] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aoki Y, 1998, AM J PHYSIOL-LUNG C, V275, pL1164, DOI 10.1152/ajplung.1998.275.6.L1164; Aslam F, 1999, ENDOCRINOLOGY, V140, P63, DOI 10.1210/en.140.1.63; Banerjee C, 1996, ENDOCRINOLOGY, V137, P1991, DOI 10.1210/en.137.5.1991; Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Bidder M, 1998, J BONE MINER RES, V13, P609, DOI 10.1359/jbmr.1998.13.4.609; Blyth K, 2001, ONCOGENE, V20, P295, DOI 10.1038/sj.onc.1204090; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Camara-Clayette V, 1999, NUCLEIC ACIDS RES, V27, P1656, DOI 10.1093/nar/27.7.1656; Camara-Clayette V, 2001, BIOCHEM J, V356, P171, DOI 10.1042/0264-6021:3560171; Chung U, 1996, J BIOL CHEM, V271, P8593, DOI 10.1074/jbc.271.15.8593; Cooper MP, 2000, GENE DEV, V14, P907; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dodig M, 1999, DEV BIOL, V209, P298, DOI 10.1006/dbio.1999.9258; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Gendron RL, 2000, DEV DYNAM, V218, P300, DOI 10.1002/(SICI)1097-0177(200006)218:2<300::AID-DVDY5>3.0.CO;2-K; Giampuzzi M, 2000, J BIOL CHEM, V275, P36341, DOI 10.1074/jbc.M003362200; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; Gorlich D, 1997, CURR OPIN CELL BIOL, V9, P412, DOI 10.1016/S0955-0674(97)80015-4; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; HEINRICHS AAJ, 1993, BIOCHEMISTRY-US, V32, P11436, DOI 10.1021/bi00093a022; HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887; Hopyan S, 1999, J ORTHOPAED RES, V17, P633, DOI 10.1002/jor.1100170503; Ishikawa Y, 2000, JPN J CANCER RES, V91, P1345, DOI 10.1111/j.1349-7006.2000.tb00924.x; Jacobson RH, 2000, SCIENCE, V288, P1422, DOI 10.1126/science.288.5470.1422; Jayaraman L, 2000, J BIOL CHEM, V275, P40710, DOI 10.1074/jbc.M005799200; Johnson KD, 2002, METHODS, V26, P27, DOI 10.1016/S1046-2023(02)00005-1; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Li BM, 2000, J BIOL CHEM, V275, P39800; Lian JB, 1998, J CELL BIOCHEM, P62, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<62::AID-JCB10>3.0.CO;2-S; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Lorenzi MV, 1996, P NATL ACAD SCI USA, V93, P8956, DOI 10.1073/pnas.93.17.8956; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; Meyer T, 1997, J BIOL CHEM, V272, P30709, DOI 10.1074/jbc.272.49.30709; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; Newberry EP, 1999, BIOCHEMISTRY-US, V38, P10678, DOI 10.1021/bi990967j; Newberry EP, 1997, J BIOL CHEM, V272, P29607, DOI 10.1074/jbc.272.47.29607; Newberry EP, 1996, MOL ENDOCRINOL, V10, P1029, DOI 10.1210/me.10.8.1029; Newberry EP, 1997, MOL ENDOCRINOL, V11, P1129, DOI 10.1210/me.11.8.1129; Newberry EP, 1998, BIOCHEMISTRY-US, V37, P16360, DOI 10.1021/bi981878u; Nishishita T, 1998, J BIOL CHEM, V273, P10901, DOI 10.1074/jbc.273.18.10901; Ochem AE, 1997, J BIOL CHEM, V272, P29919, DOI 10.1074/jbc.272.47.29919; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Peterson SE, 2001, NAT GENET, V27, P64, DOI 10.1038/83778; Petroski MD, 1998, J VIROL, V72, P8181, DOI 10.1128/JVI.72.10.8181-8190.1998; Reddy SV, 1998, BLOOD, V91, P1793, DOI 10.1182/blood.V91.5.1793.1793_1793_1801; Rifas L, 1997, P NATL ACAD SCI USA, V94, P7549, DOI 10.1073/pnas.94.14.7549; Rowley A, 2000, METHODS, V20, P383, DOI 10.1006/meth.2000.0951; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; Schild-Poulter C, 2001, J BIOL CHEM, V276, P16848, DOI 10.1074/jbc.M100768200; Sneddon WB, 1999, J CELL BIOCHEM, V73, P400, DOI 10.1002/(SICI)1097-4644(19990601)73:3<400::AID-JCB11>3.0.CO;2-O; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; Tuteja R, 2000, CRIT REV BIOCHEM MOL, V35, P1, DOI 10.1080/10409230091169177; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Wang JS, 1998, J BIOL CHEM, V273, P31068, DOI 10.1074/jbc.273.47.31068; WANG JS, 1994, J CELL SCI, V107, P3223; Woodard RL, 2001, J BIOL CHEM, V276, P15423, DOI 10.1074/jbc.M010752200; Xiao GZ, 1998, J BIOL CHEM, V273, P32988, DOI 10.1074/jbc.273.49.32988; Xiao GZ, 1997, MOL ENDOCRINOL, V11, P1103, DOI 10.1210/me.11.8.1103; Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393; Zhang PL, 1999, DNA CELL BIOL, V18, P197, DOI 10.1089/104454999315411; Zhang R, 1997, J BIOL CHEM, V272, P110, DOI 10.1074/jbc.272.1.110; Zhang ZM, 2001, J BIOL CHEM, V276, P38231	82	70	79	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37280	37291		10.1074/jbc.M206482200	http://dx.doi.org/10.1074/jbc.M206482200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145306	hybrid			2022-12-27	WOS:000178447100049
J	Chen, WB; Lenschow, W; Tiede, K; Fischer, JW; Kalthoff, H; Ungefroren, H				Chen, WB; Lenschow, W; Tiede, K; Fischer, JW; Kalthoff, H; Ungefroren, H			Smad4/DPC4-dependent regulation of biglycan gene expression by transforming growth factor-beta in pancreatic tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TGF-BETA; ENDOTHELIAL-CELLS; SMAD PROTEINS; CANCER-CELLS; TRANSCRIPTIONAL ACTIVATION; PROTEOGLYCANS BIGLYCAN; EXTRACELLULAR-MATRIX; ENHANCED EXPRESSION; MESANGIAL CELLS; CARCINOMA CELLS	Overexpression of the small leucine-rich proteoglycan biglycan (BGN) in fibrosis and desmoplasia results from enhanced activity of transforming growth factor-P (TGF-beta). In pancreatic adenocarcinoma, the tumor cells themselves may contribute to, BGN synthesis in vivo, since 8 of 18 different pancreatic carcinoma cell lines constitutively expressed BGN mRNA, as shown by reverse transcription-PCR analysis. In PANC-1 cells, TGF-beta1 dramatically stimulated BGN mRNA accumulation through a BGN transcription-independent, cycloheximide-sensitive mechanism and strongly increased the synthesis and release of the proteoglycan form of BGN. The ability of TGF-beta1 to induce BGN mRNA was critically dependent on Smad signaling, since 1) the upregulation of BGN mRNA was preceded by a marked increase in Smad2 phosphorylation in TGF-beta1-treated PANC-1 cells, 2) TGF-beta1 was unable to induce BGN mRNA in pancreatic carcinoma cell lines that carry homozygous deletions of the Smad4/DPC4 gene, 3) inhibition of the Smad pathway in PANC-1 cells by transfection with a dominant negative Smad4/DPC4 mutant significantly reduced TGF-beta1-induced BGN mRNA expression, 4) stable reintroduction of wild type Smad4/DPC4 into Smad4-null CFPAC-1 cells restored the TGF-beta1 effect, and 5) overexpression of Smad2 and Smad3 in PANC-1 cells augmented TGF-beta1 induction of BGN mRNA, whereas forced expression of Smad7, an inhibitory Smad, effectively blocked it. These results clearly show that a functional Smad pathway is crucial for TGF-beta regulation of BGN mRNA expression. Since BGN has been shown to inhibit growth of pancreatic cancer cells, the Smad4/DPC4 mediation of the TGF-beta effect may represent a novel tumor suppressor function for Smad4/DPC4: antiproliferation via expression of autoinhibitory BGN.	Univ Kiel, Clin Gen Surg & Thorac Surg, Res Unit Mol Oncol, D-24105 Kiel, Germany; Univ Dusseldorf, Inst Pharmacol & Clin Pharmacol, D-40225 Dusseldorf, Germany	University of Kiel; Heinrich Heine University Dusseldorf	Ungefroren, H (corresponding author), Univ Kiel, Clin Gen Surg & Thorac Surg, Res Unit Mol Oncol, Arnold Heller Str 7, D-24105 Kiel, Germany.		Kalthoff, Holger/B-1618-2010					BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Chin BY, 2001, AM J PHYSIOL-RENAL, V280, pF495, DOI 10.1152/ajprenal.2001.280.3.F495; Dai JL, 1999, MOL CARCINOGEN, V26, P37, DOI 10.1002/(SICI)1098-2744(199909)26:1<37::AID-MC5>3.0.CO;2-6; Dai JL, 1998, CANCER RES, V58, P4592; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Duff EK, 1998, BRIT J CANCER, V78, P1615, DOI 10.1038/bjc.1998.731; Evanko SP, 1998, AM J PATHOL, V152, P533; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FRIESS H, 1993, CANCER RES, V53, P2704; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Grady WM, 1999, CANCER RES, V59, P320; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hakkinen L, 1996, J DENT RES, V75, P1767, DOI 10.1177/00220345960750101001; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heegaard AM, 1997, J BONE MINER RES, V12, P2050, DOI 10.1359/jbmr.1997.12.12.2050; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hocking AM, 1998, MATRIX BIOL, V17, P1; Hocking AM, 1996, J BIOL CHEM, V271, P19571, DOI 10.1074/jbc.271.32.19571; Howard BD, 2000, CANCER GENE THER, V7, P927, DOI 10.1038/sj.cgt.7700180; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Inagaki Y, 2001, J CELL PHYSIOL, V187, P117, DOI 10.1002/1097-4652(2001)9999:9999<00::AID-JCP1059>3.0.CO;2-S; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; KALTHOFF H, 1991, ONCOGENE, V6, P1015; Kinsella MG, 1997, J BIOL CHEM, V272, P318; Kinsella MG, 2000, J BIOL CHEM, V275, P13924, DOI 10.1074/jbc.275.18.13924; Kleeff J, 1999, ONCOGENE, V18, P5363, DOI 10.1038/sj.onc.1202909; Kleeff J, 1999, BIOCHEM BIOPH RES CO, V255, P268, DOI 10.1006/bbrc.1999.0171; Komarova EA, 1998, ONCOGENE, V17, P1089, DOI 10.1038/sj.onc.1202303; KRULL NB, 1993, HEPATOLOGY, V18, P581, DOI 10.1016/0270-9139(93)90359-U; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; NAKAMURA T, 1992, KIDNEY INT, V41, P1213, DOI 10.1038/ki.1992.183; NAKAO A, 1997, NATURE, V389, P549; Nelimarkka L, 1997, J BIOL CHEM, V272, P12730, DOI 10.1074/jbc.272.19.12730; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Scott IC, 2000, J BIOL CHEM, V275, P30504, DOI 10.1074/jbc.M004846200; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Ungefroren H, 1996, J BIOL CHEM, V271, P15787, DOI 10.1074/jbc.271.26.15787; Ungefroren H, 1998, CANCER RES, V58, P1741; Usui T, 1998, INVEST OPHTH VIS SCI, V39, P1981; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; Voss M, 1999, INT J ONCOL, V14, P93; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Weber CK, 2001, GASTROENTEROLOGY, V121, P657, DOI 10.1053/gast.2001.27222; WESTERGRENTHORSSON G, 1993, J CLIN INVEST, V92, P632, DOI 10.1172/JCI116631; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zhang W, 2000, J BIOL CHEM, V275, P39237, DOI 10.1074/jbc.M003339200; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0	65	75	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36118	36128		10.1074/jbc.M203709200	http://dx.doi.org/10.1074/jbc.M203709200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12140283	hybrid			2022-12-27	WOS:000178275100046
J	Kupke, T				Kupke, T			Molecular characterization of the 4 '-phosphopantothenoylcysteine synthetase domain of bacterial Dfp flavoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COVALENTLY BOUND PYRUVATE; COENZYME-A BIOSYNTHESIS; ESCHERICHIA-COLI K-12; PHOSPHOPANTOTHENOYLCYSTEINE DECARBOXYLASE; PANTOTHENATE SYNTHETASE; CRYSTAL-STRUCTURE; PURIFICATION; ENZYME; GENE; IDENTIFICATION	In bacteria, coenzyme A is synthesized in five steps from pantothenate. The flavoprotein Dfp catalyzes the synthesis of the coenzyme A precursor 4'-phosphopantetheine in the presence of 4'-phosphopantothenate, cysteine, CTP, and Mg2+ (Strauss, E., Kinsland, C., Ge, Y., McLafferty, F. W., and Begley, T. P. (2001) J. Biol. Chem. 276,13513-13516). It has been shown that the NH2-terminal domain of Dfp has 4'-phosphopantothenoylcysteine decarboxylase activity (Kupke, T., Uebele, M., Schmid, D., Jung, G., Blaesse, M., and Steinbacher, S. (2000) J. Biol. Chem. 275, 31838-31846). Here I demonstrate that the COOH-terminal CoaB domain of Dfp catalyzes the synthesis of 4'-phosphopantothenoylcysteine. The exchange of conserved amino acid residues within the CoaB domain revealed that the synthesis of 4'-phosphopantothenoylcysteine occurs in two half-reactions. Using the mutant protein His-CoaB N210D the putative acyl-cytidylate intermediate of 4'-phosphopantothenate was detectable. The same intermediate was detectable for the wild-type CoaB enzyme if cysteine was omitted in the reaction mixture. Exchange of the conserved Lys(289) residue, which is part of the strictly conserved (KXKK292)-K-289 motif of the CoaB domain, resulted in complete loss of activity with neither the acyl-cytidylate intermediate nor 4'-phosphopantothenoylcysteine being detectable. Gel filtration experiments indicated that CoaB forms dimers. Residues that are important for dimerization are conserved in CoaB proteins from eubacteria, Archaea, and eukaryotes.	Univ Tubingen, Lehrstuhl Mikrobiol Genet, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Kupke, T (corresponding author), Univ Tubingen, Lehrstuhl Mikrobiol Genet, Morgenstelle 15, D-72076 Tubingen, Germany.		Zhang, Ning/F-1387-2014	Kupke, Thomas/0000-0003-2341-1710				ABIKO Y, 1967, J BIOCHEM-TOKYO, V61, P300, DOI 10.1093/oxfordjournals.jbchem.a128548; ABIKO Y, 1967, J BIOCHEM, V61, P290, DOI 10.1093/oxfordjournals.jbchem.a128547; ABIKO Y, 1968, J BIOCHEM-TOKYO, V64, P115, DOI 10.1093/oxfordjournals.jbchem.a128855; ABIKO Y, 1967, J BIOCHEM-TOKYO, V61, P309, DOI 10.1093/oxfordjournals.jbchem.a128549; Begley TP, 2001, VITAM HORM, V61, P157; Blaesse M, 2000, EMBO J, V19, P6299, DOI 10.1093/emboj/19.23.6299; BROWN GM, 1959, J BIOL CHEM, V234, P370; Cormack B., 1991, CURRENT PROTOCOLS MO, V1, P851; Daugherty M, 2002, J BIOL CHEM, V277, P21431, DOI 10.1074/jbc.M201708200; Geerlof A, 1999, J BIOL CHEM, V274, P27105, DOI 10.1074/jbc.274.38.27105; Hernandez-Acosta P, 2002, J BIOL CHEM, V277, P20490, DOI 10.1074/jbc.M201557200; Kupke T, 2000, J BIOL CHEM, V275, P31838, DOI 10.1074/jbc.M004273200; KUPKE T, 1994, J BIOL CHEM, V269, P5653; Kupke T, 2001, J BIOL CHEM, V276, P19190, DOI 10.1074/jbc.M100776200; Kupke T, 2001, J BIOL CHEM, V276, P27597, DOI 10.1074/jbc.M103342200; Mishra PK, 2001, J BACTERIOL, V183, P2774, DOI 10.1128/JB.183.9.2774-2778.2001; Miyatake K, 1979, Methods Enzymol, V62, P215; SCANDURRA R, 1987, FEBS LETT, V212, P79, DOI 10.1016/0014-5793(87)81560-0; SCANDURRA R, 1974, EUR J BIOCHEM, V49, P1, DOI 10.1111/j.1432-1033.1974.tb03805.x; SCHIGGER H, 1987, ANAL BIOCHEM, V166, P368; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; SPITZER ED, 1988, J BACTERIOL, V170, P872, DOI 10.1128/jb.170.2.872-876.1988; SPITZER ED, 1985, J BACTERIOL, V164, P994, DOI 10.1128/JB.164.3.994-1003.1985; Strauss E, 2001, J AM CHEM SOC, V123, P6449, DOI 10.1021/ja016020y; Strauss E, 2001, J BIOL CHEM, V276, P13513, DOI 10.1074/jbc.C100033200; SUZUKI T, 1967, J BIOCHEM-TOKYO, V62, P642, DOI 10.1093/oxfordjournals.jbchem.a128719; VANPOELJE PD, 1990, ANNU REV BIOCHEM, V59, P29, DOI 10.1146/annurev.bi.59.070190.000333; von Delft F, 2001, STRUCTURE, V9, P439, DOI 10.1016/S0969-2126(01)00604-9; WILLIAMSON JM, 1979, J BIOL CHEM, V254, P8074; YANG HC, 1987, BIOCHEMISTRY-US, V26, P4076, DOI 10.1021/bi00387a050; Zheng RJ, 2001, BIOCHEMISTRY-US, V40, P12904, DOI 10.1021/bi011522+	31	28	30	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36137	36145		10.1074/jbc.M206188200	http://dx.doi.org/10.1074/jbc.M206188200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12140293	hybrid			2022-12-27	WOS:000178275100048
J	Guhan, N; Muniyappa, K				Guhan, N; Muniyappa, K			The RecA intein of Mycobacterium tuberculosis promotes cleavage of ectopic DNA sites - Implications for the dispersal of inteins in natural populations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CODED HOMING ENDONUCLEASES; GROUP-II INTRON; PI-SCEI; DIRECTED MUTAGENESIS; PYROCOCCUS-FURIOSUS; PROTEIN; IDENTIFICATION; PURIFICATION; MOBILITY; BINDING	The RecA intein of Mycobacterium tuberculosis, a novel double-stranded DNA endonuclease, requires both Mn2+ and ATP for efficient cleavage of the intein-less recA allele. In this study, we show that Mg2+ alone was sufficient to stimulate PI-MtuI to cleave double-stranded DNA at ectopic sites. In the absence of Mg2+, PI-MtuI formed complexes with topologically different forms of DNA containing ectopic recognition sequences with equal affinity but failed to cleave DNA. We observed that PI-MtuI was able to inflict double-strand breaks robustly within the ectopic recognition sequence to generate either a blunt end or 1-2-nucleotide 3'-hydroxyl overhangs. Mutational analyses of the presumptive metal ion-binding ligands (Asp(121), Asp(222), and Glu(220)) together with immunoprecipitation assays provided compelling evidence to link both the Mg2+- and Mn2+ and ATP-dependent endonuclease activities to PI-MtuI. The kinetic mechanism of PI-MtuI promoted cleavage of ectopic DNA sites proceeded through a sequential mechanism with transient accumulation of nicked circular duplex DNA as an intermediate. Together, these data suggest that PI-MtuI, like group II introns, might mediate ectopic DNA transposition and hence its lateral transfer in natural populations.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Muniyappa, K (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	kmbc@biochem.iisc.ernet.in						Aiyar A, 1996, Methods Mol Biol, V57, P177; Bakshi RP, 2001, J MOL ENDOCRINOL, V26, P193, DOI 10.1677/jme.0.0260193; Belfort M, 1995, J BIOL CHEM, V270, P30237, DOI 10.1074/jbc.270.51.30237; Belfort M, 1997, NUCLEIC ACIDS RES, V25, P3379, DOI 10.1093/nar/25.17.3379; Chevalier BS, 2001, NUCLEIC ACIDS RES, V29, P3757, DOI 10.1093/nar/29.18.3757; Chevalier BS, 2001, NAT STRUCT BIOL, V8, P312, DOI 10.1038/86181; Christ F, 1999, EMBO J, V18, P6908, DOI 10.1093/emboj/18.24.6908; CUNNINGHAM RP, 1980, CELL, V20, P223, DOI 10.1016/0092-8674(80)90250-0; Dalgaard JZ, 1997, NUCLEIC ACIDS RES, V25, P4626, DOI 10.1093/nar/25.22.4626; DALGAARD JZ, 1994, J BIOL CHEM, V269, P28885; DAVIS EO, 1994, EMBO J, V13, P699, DOI 10.1002/j.1460-2075.1994.tb06309.x; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; DAVIS EO, 1991, J BACTERIOL, V173, P5653, DOI 10.1128/jb.173.18.5653-5662.1991; Dickson L, 2001, P NATL ACAD SCI USA, V98, P13207, DOI 10.1073/pnas.231494498; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Gimble FS, 2000, FEMS MICROBIOL LETT, V185, P99; GIMBLE FS, 1995, J BIOL CHEM, V270, P5849, DOI 10.1074/jbc.270.11.5849; GIMBLE FS, 1992, NATURE, V357, P301, DOI 10.1038/357301a0; Guhan N, 2002, J BIOL CHEM, V277, P16257, DOI 10.1074/jbc.M112365200; Jurica MS, 1999, CELL MOL LIFE SCI, V55, P1304, DOI 10.1007/s000180050372; Jurica NS, 1998, MOL CELL, V2, P469, DOI 10.1016/S1097-2765(00)80146-X; Komori K, 1999, NUCLEIC ACIDS RES, V27, P4175, DOI 10.1093/nar/27.21.4175; Komori K, 1999, NUCLEIC ACIDS RES, V27, P4167, DOI 10.1093/nar/27.21.4167; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu XQ, 2000, ANNU REV GENET, V34, P61, DOI 10.1146/annurev.genet.34.1.61; Maxam A M, 1980, Methods Enzymol, V65, P499; MAYER H, 1981, NUCLEIC ACIDS RES, V9, P4833, DOI 10.1093/nar/9.19.4833; MUELLER JE, 1993, NUCLEASES, P111; Munoz E, 2001, MOL MICROBIOL, V41, P645, DOI 10.1046/j.1365-2958.2001.02540.x; Noren CJ, 2000, ANGEW CHEM INT EDIT, V39, P450; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schottler S, 2000, BIOCHEMISTRY-US, V39, P15895, DOI 10.1021/bi001775n; Wang JS, 1997, NUCLEIC ACIDS RES, V25, P3767, DOI 10.1093/nar/25.19.3767	33	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40352	40361		10.1074/jbc.M205697200	http://dx.doi.org/10.1074/jbc.M205697200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12167644	hybrid, Green Submitted			2022-12-27	WOS:000178791400026
J	Murakami, M; Fleischmann, B; De Felipe, C; Freichel, M; Trost, C; Ludwig, A; Wissenbach, U; Schwegler, H; Hofmann, F; Hescheler, J; Flockerzi, V; Cavalie, A				Murakami, M; Fleischmann, B; De Felipe, C; Freichel, M; Trost, C; Ludwig, A; Wissenbach, U; Schwegler, H; Hofmann, F; Hescheler, J; Flockerzi, V; Cavalie, A			Pain perception in mice lacking the beta 3 subunit of voltage-activated calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TYPE; OMEGA-CONOTOXIN; ALPHA(1) SUBUNIT; CA2+ CHANNELS; SPINAL-CORD; P-TYPE; EXPRESSION; NEURONS; CURRENTS; MOUSE	The importance of voltage-activated calcium channels in pain processing has been suggested by the spinal antinociceptive action of blockers of N- and P/Q-type calcium channels as well as by gene targeting of the alpha1B subunit (N-type). The accessory beta3 subunits of calcium channels are preferentially associated with the alpha1B subunit in neurones. Here we show that deletion of the beta3 subunit by gene targeting affects strongly the pain processing of mutant mice. We pinpoint this defect in the pain-related behavior and ascending pain pathways of the spinal cord in vivo and at the level of calcium channel currents and proteins in single dorsal root ganglion neurones in vitro. The pain induced by chemical inflammation is preferentially damped by deletion of beta3 subunits, whereas responses to acute thermal and mechanical harmful stimuli are reduced moderately or not at all, respectively. The defect results in a weak wind-up of spinal cord activity during intense afferent nerve stimulation. The molecular mechanism responsible for the phenotype was traced to low expression of N-type calcium channels (alpha1B) and functional alterations of calcium channel currents in neurones projecting to the spinal cord.	Univ Saarland, D-66421 Homburg, Germany; Univ Magdeburg, Inst Anat, D-39120 Magdeburg, Germany; Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany; Univ Miguel Hernandez, Inst Neurosci, Alacant 03550, Spain; Univ Cologne, Inst Neurophysiol, D-50931 Cologne, Germany; Tohoku Univ, Sch Med, Sendai, Miyagi 980, Japan	Saarland University; Otto von Guericke University; Technical University of Munich; Universidad Miguel Hernandez de Elche; University of Cologne; Tohoku University	Cavalie, A (corresponding author), Univ Saarland, D-66421 Homburg, Germany.	adolfo.cavalie@uniklinik-saarland.de	de Felipe, Carmen/D-3813-2012					BERROW NS, 1995, J PHYSIOL-LONDON, V482, P481, DOI 10.1113/jphysiol.1995.sp020534; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Brice NL, 1999, J PHYSIOL-LONDON, V515, P685, DOI 10.1111/j.1469-7793.1999.685ab.x; Burgess DL, 1999, MOL CELL NEUROSCI, V13, P293, DOI 10.1006/mcne.1999.0748; CARBONE E, 1987, J PHYSIOL-LONDON, V386, P547, DOI 10.1113/jphysiol.1987.sp016551; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Cox B, 2000, Curr Rev Pain, V4, P488; Dascal N, 2001, TRENDS ENDOCRIN MET, V12, P391, DOI 10.1016/S1043-2760(01)00475-1; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; Diaz A, 1997, PAIN, V69, P93, DOI 10.1016/S0304-3959(96)03271-X; DIOCHOT S, 1995, NEUROSCIENCE, V69, P627, DOI 10.1016/0306-4522(95)00267-M; Dolphin AC, 1998, J PHYSIOL-LONDON, V506, P3, DOI 10.1111/j.1469-7793.1998.003bx.x; DUNLAP K, 1981, J PHYSIOL-LONDON, V317, P519, DOI 10.1113/jphysiol.1981.sp013841; Feng ZP, 2001, J BIOL CHEM, V276, P45051, DOI 10.1074/jbc.M107784200; GOHIL K, 1994, BRAIN RES, V653, P258, DOI 10.1016/0006-8993(94)90398-0; Gregg RG, 1996, P NATL ACAD SCI USA, V93, P13961, DOI 10.1073/pnas.93.24.13961; GRUNER W, 1994, J NEUROSCI, V14, P2800; Gurnett CA, 1996, J BIOL CHEM, V271, P27975, DOI 10.1074/jbc.271.45.27975; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hatakeyama S, 2001, NEUROREPORT, V12, P2423, DOI 10.1097/00001756-200108080-00027; Herrero JF, 2000, PROG NEUROBIOL, V61, P169, DOI 10.1016/S0301-0082(99)00051-9; HOFMANN F, 1994, ANNU REV NEUROSCI, V17, P399, DOI 10.1146/annurev.neuro.17.1.399; Honore P, 1999, J NEUROSCI, V19, P7670, DOI 10.1523/JNEUROSCI.19-17-07670.1999; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; Hullin R, 1999, CIRCULATION, V100, P155, DOI 10.1161/01.CIR.100.2.155; Hunt SP, 2001, NAT REV NEUROSCI, V2, P83, DOI 10.1038/35053509; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; Iwashima Y, 2001, BIOCHEM BIOPH RES CO, V280, P923, DOI 10.1006/bbrc.2000.4122; Jun K, 1999, P NATL ACAD SCI USA, V96, P15245, DOI 10.1073/pnas.96.26.15245; Kang MG, 2001, J BIOL CHEM, V276, P32917, DOI 10.1074/jbc.M100787200; KERR LM, 1988, EUR J PHARMACOL, V146, P181, DOI 10.1016/0014-2999(88)90501-8; Kim C, 2001, MOL CELL NEUROSCI, V18, P235, DOI 10.1006/mcne.2001.1013; Lambert RC, 1997, J NEUROSCI, V17, P6621; Ludwig A, 1997, J NEUROSCI, V17, P1339; Luo ZD, 2001, J NEUROSCI, V21, P1868, DOI 10.1523/JNEUROSCI.21-06-01868.2001; MALMBERG AB, 1994, J NEUROSCI, V14, P4882; MALMBERG AB, 1995, PAIN, V60, P83, DOI 10.1016/0304-3959(94)00094-U; Marquart A, 1997, FEBS LETT, V407, P137, DOI 10.1016/S0014-5793(97)00316-5; MIRANDA HF, 1992, EUR J PHARMACOL, V217, P137, DOI 10.1016/0014-2999(92)90833-P; Moreno H, 1997, P NATL ACAD SCI USA, V94, P14042, DOI 10.1073/pnas.94.25.14042; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Morimoto H, 1996, JPN J PHARMACOL, V71, P161, DOI 10.1254/jjp.71.161; Murakami M, 1996, EUR J BIOCHEM, V236, P138, DOI 10.1111/j.1432-1033.1996.t01-1-00138.x; Murakami M, 2000, J CARDIOVASC PHARM, V36, pS69, DOI 10.1097/00005344-200000006-00015; Murakami M, 2001, EUR J PHARMACOL, V419, P175, DOI 10.1016/S0014-2999(01)00985-2; Murakami M, 2001, BRAIN RES, V903, P231, DOI 10.1016/S0006-8993(01)02427-1; Muth JN, 2001, TRENDS PHARMACOL SCI, V22, P526, DOI 10.1016/S0165-6147(00)01797-1; Namkung Y, 1998, P NATL ACAD SCI USA, V95, P12010, DOI 10.1073/pnas.95.20.12010; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; Rice ASC, 2001, PAIN, V94, P215, DOI 10.1016/S0304-3959(01)00407-9; Saegusa H, 2001, EMBO J, V20, P2349, DOI 10.1093/emboj/20.10.2349; Saegusa H, 2000, P NATL ACAD SCI USA, V97, P6132, DOI 10.1073/pnas.100124197; Schneider T, 1997, TRENDS PHARMACOL SCI, V18, P8, DOI 10.1016/S0165-6147(96)01001-2; SCOTT RH, 1986, NEUROSCI LETT, V69, P59, DOI 10.1016/0304-3940(86)90414-3; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; SCROGGS RS, 1992, J PHYSIOL-LONDON, V445, P639, DOI 10.1113/jphysiol.1992.sp018944; Seisenberger C, 2000, J BIOL CHEM, V275, P39193, DOI 10.1074/jbc.M006467200; Vanegas H, 2000, PAIN, V85, P9, DOI 10.1016/S0304-3959(99)00241-9; WELLING A, 1993, J PHYSIOL-LONDON, V471, P749, DOI 10.1113/jphysiol.1993.sp019926; Westenbroek RE, 1998, J NEUROSCI, V18, P6319; Wilson SG, 2001, BEHAV BRAIN RES, V125, P65, DOI 10.1016/S0166-4328(01)00281-9; YU C, 1992, J NEUROPHYSIOL, V67, P561, DOI 10.1152/jn.1992.67.3.561; Zamponi GW, 1998, P NATL ACAD SCI USA, V95, P4035, DOI 10.1073/pnas.95.7.4035	64	56	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40342	40351		10.1074/jbc.M203425200	http://dx.doi.org/10.1074/jbc.M203425200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12161429	hybrid			2022-12-27	WOS:000178791400025
J	Furukawa, Y; Nishimura, N; Furukawa, Y; Satoh, M; Endo, H; Iwase, S; Yamada, H; Matsuda, M; Kano, Y; Nakamura, M				Furukawa, Y; Nishimura, N; Furukawa, Y; Satoh, M; Endo, H; Iwase, S; Yamada, H; Matsuda, M; Kano, Y; Nakamura, M			Apaf-1 is a mediator of E2F-1-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; CELL-DEATH; TRANSCRIPTIONAL TARGET; DEPENDENT APOPTOSIS; ECTOPIC EXPRESSION; PROMOTES APOPTOSIS; IN-VITRO; E2F-1; PROTEIN; RELEASE	E2F-1 is capable of promoting both cell cycle progression and apoptosis. The latter is important for suppressing untoward expansion of proliferating cells. In this study, we investigated its underlying mechanisms. E2F1-induced apoptosis was accompanied by caspase-9 activation and inhibited by a specific inhibitor of caspase-9 in K562 sublines overexpressing E2F-1. E2F-1 enhanced the expression of Apaf-1 without the cytosolic accumulation of cytochrome c. Apaf-l-deficient melanoma cell lines were resistant to E2F-1, indicating that Apaf-1 is an essential element of E2F-1-mediated apoptosis. Finally, we isolated the promoter region of the Apaf-1 gene and found a putative binding site for E2F. A chromatin immunoprecipitation assay revealed that E2F-1 bound to Apaf-1 promoter upon E2F-1 overexpression, suggesting that Apaf-1 is under transcriptional regulation of E2F-1. These data demonstrate a novel mechanism of apoptosis in which an increase in Apaf-1 levels results in direct activation of caspase-9 without mitochondrial damage, leading to the initiation of a caspase cascade.	Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Biochem, Minami Kawachi, Tochigi 3290498, Japan; Jikei Univ, Sch Med, Inst DNA Med, Tokyo 1058461, Japan; Jikei Univ, Sch Med, Dept Internal Med, Tokyo 1058461, Japan; Tochigi Canc Ctr, Div Med Oncol, Utsunomiya, Tochigi 3200834, Japan	Jichi Medical University; Jichi Medical University; Jikei University; Jikei University; Tochigi Prefectural Cancer Center	Furukawa, Y (corresponding author), Jichi Med Sch, Ctr Mol Med, Div Stem Cell Regulat, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.	furuyu@jichi.ac.jp	Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Chang YC, 2000, ONCOGENE, V19, P4713, DOI 10.1038/sj.onc.1203833; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936; Dirks PB, 1998, ONCOGENE, V17, P867, DOI 10.1038/sj.onc.1202008; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Du W, 1996, EMBO J, V15, P3684, DOI 10.1002/j.1460-2075.1996.tb00738.x; Fearnhead HO, 1998, P NATL ACAD SCI USA, V95, P13664, DOI 10.1073/pnas.95.23.13664; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Fueyo J, 1998, NAT MED, V4, P685, DOI 10.1038/nm0698-685; Furukawa Y, 2000, BRIT J HAEMATOL, V110, P663, DOI 10.1046/j.1365-2141.2000.02253.x; Furukawa Y, 1999, ONCOGENE, V18, P2003, DOI 10.1038/sj.onc.1202500; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Halaban R, 2000, J EXP MED, V191, P1005, DOI 10.1084/jem.191.6.1005; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; IRVIN M, 2000, NATURE, V407, P645; Kel AE, 2001, J MOL BIOL, V309, P99, DOI 10.1006/jmbi.2001.4650; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; LEIST M, 1994, J IMMUNOL, V153, P1778; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lissy NA, 2000, NATURE, V407, P642, DOI 10.1038/35036608; Moreno CS, 1999, IMMUNITY, V10, P143, DOI 10.1016/S1074-7613(00)80015-1; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Mundle SD, 2000, BRIT J HAEMATOL, V109, P376, DOI 10.1046/j.1365-2141.2000.01937.x; Otsuki T, 2001, HUM MOL GENET, V10, P2651, DOI 10.1093/hmg/10.23.2651; Perkins C, 1998, CANCER RES, V58, P4561; Perkins CL, 2000, CANCER RES, V60, P1645; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Phillips AC, 1997, GENE DEV, V11, P1853, DOI 10.1101/gad.11.14.1853; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Shapiro HM, 2000, METHODS, V21, P271, DOI 10.1006/meth.2000.1007; Sheikh MS, 2000, J CELL PHYSIOL, V182, P171, DOI 10.1002/(SICI)1097-4652(200002)182:2<171::AID-JCP5>3.0.CO;2-3; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	49	121	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39760	39768		10.1074/jbc.M200805200	http://dx.doi.org/10.1074/jbc.M200805200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12149244	hybrid			2022-12-27	WOS:000178662500090
J	Ikeda, M; Beitz, E; Kozono, D; Guggino, WB; Agre, P; Yasui, M				Ikeda, M; Beitz, E; Kozono, D; Guggino, WB; Agre, P; Yasui, M			Characterization of aquaporin-6 as a nitrate channel in mammalian cells - Requirement of pore-lining residue threonine 63	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL DETERMINANTS; WATER PERMEATION; PROTON PUMP; PROTEIN; ACID; PERMEABILITY; CONDUCTANCE; SELECTIVITY; MECHANISM; MEMBRANES	Aquaporins (AQP) were originally regarded as plasma membrane channels that are freely permeated by water or small uncharged solutes but not by ions. Unlike other aquaporins, AQP6 overexpressed in Xenopus laevis oocytes was previously found to exhibit Hg2+ or pH-activated ion conductance. AQP6 could not be analyzed electrophysiologically in mammalian cells, however, because the protein is restricted to intracellular vesicles. Here we report that addition of a green fluorescence protein (GFP) tag to the N terminus of rat AQP6 (GFP-AQP6) redirects the protein to the plasma membranes of transfected mammalian cells. This permitted measurement of rapid, reversible, pH-induced anion currents by GFP-AQP6 in human embryonic kidney 293 cells. Surprisingly, anion selectivity relative to Cl- revealed high nitrate permeability even at pH 7.4; P-NO3/P-CI > 9.8. Site-directed mutation of a pore-lining threonine to isoleucine at position 63 at the midpoint of the channel reduced NO3-/Cl- selectivity. Moreover, no anomalous mole-fraction behavior was observed with NO3-/Cl- mixtures, suggesting a single ion-binding pore in each subunit. Our studies indicate that AQP6 exhibits a new form of anion permeation with marked specificity for nitrate conferred by a specific pore-lining residue, observations that imply that the primary role of AQP6 may be in cellular regulation rather than simple fluid transport.	Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Yasui, M (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat & Biol Chem, 420 Physiol Bldg,725 N Wolfe St, Baltimore, MD 21205 USA.	myasui@jhmi.edu	Yasui, Masato/L-3312-2013	Ikeda, Masahiro/0000-0003-2539-8812	NATIONAL EYE INSTITUTE [R01EY011239] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048268, R01HL033991, R37HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032753, R01DK032753] Funding Source: NIH RePORTER; NEI NIH HHS [EY11239] Funding Source: Medline; NHLBI NIH HHS [HL48268, HL33991] Funding Source: Medline; NIDDK NIH HHS [DK32753] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Agre P, 1997, SCIENCE, V275, P1490, DOI 10.1126/science.275.5305.1490; Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Anthony TL, 2000, MOL PHARMACOL, V57, P576, DOI 10.1124/mol.57.3.576; ARAI H, 1989, BIOCHEMISTRY-US, V28, P3075, DOI 10.1021/bi00433a051; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; de Groot BL, 2001, SCIENCE, V294, P2353, DOI 10.1126/science.1062459; Dutzler R, 2002, NATURE, V415, P287, DOI 10.1038/415287a; FATT P, 1958, J PHYSIOL-LONDON, V142, P516, DOI 10.1113/jphysiol.1958.sp006034; Fu DX, 2000, SCIENCE, V290, P481, DOI 10.1126/science.290.5491.481; GLICKMAN J, 1983, J CELL BIOL, V97, P1303, DOI 10.1083/jcb.97.4.1303; HAGIWARA S, 1974, J MEMBRANE BIOL, V18, P61, DOI 10.1007/BF01870103; HARIKUMAR P, 1983, J BIOL CHEM, V258, P403; Hazama A, 2002, J BIOL CHEM, V277, P29224, DOI 10.1074/jbc.M204258200; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; IKEDA M, 1993, J MEMBRANE BIOL, V136, P231; Jentsch TJ, 2002, NATURE, V415, P276, DOI 10.1038/415276a; Klemm AR, 1998, BBA-BIOMEMBRANES, V1373, P17, DOI 10.1016/S0005-2736(98)00082-0; Kozono D, 2002, J CLIN INVEST, V109, P1395, DOI 10.1172/JCI200215851; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Promeneur D, 2000, AM J PHYSIOL-RENAL, V279, pF1014, DOI 10.1152/ajprenal.2000.279.6.F1014; Saparov SM, 2001, J BIOL CHEM, V276, P31515, DOI 10.1074/jbc.M104267200; SCHWARTZ GJ, 1986, ANNU REV PHYSIOL, V48, P153; STOFFEKOVA K, 1998, AM J PHYSIOL, V275, pC1113; Sui HX, 2001, NATURE, V414, P872, DOI 10.1038/414872a; Tajkhorshid E, 2002, SCIENCE, V296, P525, DOI 10.1126/science.1067778; Tewari KP, 2000, AM J PHYSIOL-CELL PH, V279, pC40, DOI 10.1152/ajpcell.2000.279.1.C40; TOJO A, 1994, AM J PHYSIOL-RENAL, V267, pF509, DOI 10.1152/ajprenal.1994.267.4.F509; Valles PG, 2000, KIDNEY INT, V58, P1641, DOI 10.1046/j.1523-1755.2000.00325.x; Walsh MA, 1998, ACTA CRYSTALLOGR D, V54, P522, DOI 10.1107/S0907444997013656; Yanochko GM, 2002, J NEUROSCI, V22, P2530, DOI 10.1523/JNEUROSCI.22-07-02530.2002; Yasui M, 1999, NATURE, V402, P184, DOI 10.1038/46045; Yasui M, 1999, P NATL ACAD SCI USA, V96, P5808, DOI 10.1073/pnas.96.10.5808	33	149	154	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39873	39879		10.1074/jbc.M207008200	http://dx.doi.org/10.1074/jbc.M207008200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177001	hybrid			2022-12-27	WOS:000178662500104
J	Jang, W; Chiem, B; Gomer, RH				Jang, W; Chiem, B; Gomer, RH			A secreted cell number counting factor represses intracellular glucose levels to regulate group size in Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; S6 KINASE; DISCOIDEUM; GROWTH; CHEMOTAXIS; CAMP; ACTIVATION; MECHANISM; RECEPTOR; PROTEINS	Developing Dictyostelium cells form evenly sized groups of similar to2 x 10(4) cells. A secreted 450-kDa protein complex called counting factor (CF) regulates group size by repressing cell-cell adhesion and myosin polymerization and by increasing cAMP-stimulated cAMP production, actin polymerization, and cell motility. We find that CF regulates group size in part by repressing internal glucose levels. Transformants lacking bioactive CF and wild-type cells with extracellular CF depleted by antibodies have high glucose levels, whereas transformants oversecreting CF have low glucose levels. A component of CF, countin, affects group size in a manner similar to CF, and a 1-min exposure of cells to countin decreases glucose levels. Adding 1 mm exogenous glucose negates the effect of high levels of extracellular CF on group size and mimics the effect of depleting CF on glucose levels, cell-cell adhesion, cAMP pulse size, actin polymerization, myosin assembly, and motility. These results suggest that glucose is a downstream component in part of the CF signaling pathway and may be relevant to the observed role of the insulin pathway in tissue size regulation in higher eukaryotes.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, Howard Hughes Med Inst, Houston, TX 77005 USA	Rice University; Howard Hughes Medical Institute; Rice University	Gomer, RH (corresponding author), Rice Univ, Dept Biochem & Cell Biol, MS-140,6100 S Main St, Houston, TX 77005 USA.			Gomer, Richard/0000-0003-2361-4307; Jang, Wonhee/0000-0003-2470-8137				BAUMANN P, 1969, BIOCHEMISTRY-US, V8, P5011, DOI 10.1021/bi00840a050; Bohni R, 1999, CELL, V97, P865, DOI 10.1016/S0092-8674(00)80799-0; Brazill DT, 1998, J BIOL CHEM, V273, P8161, DOI 10.1074/jbc.273.14.8161; Brock DA, 1996, DEVELOPMENT, V122, P2569; Brock DA, 1999, GENE DEV, V13, P1960, DOI 10.1101/gad.13.15.1960; Brock DA, 2002, DEVELOPMENT, V129, P3657; Brown JM, 2000, TRENDS GENET, V16, P191, DOI 10.1016/S0168-9525(00)01977-6; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; DHARMAWARDHANE S, 1989, CELL MOTIL CYTOSKEL, V13, P57, DOI 10.1002/cm.970130107; Gao T, 2002, J BIOL CHEM, V277, P32596, DOI 10.1074/jbc.M203075200; GARROD DR, 1972, J EMBRYOL EXP MORPH, V28, P463; Gomer RH, 2001, NAT REV MOL CELL BIO, V2, P48, DOI 10.1038/35048058; GUSTAFSON GL, 1972, CRIT REV MICROBIOL, V1, P453; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; JAIN R, 1992, GENE DEV, V6, P390, DOI 10.1101/gad.6.3.390; Kawabe J, 2000, J HYPERTENS, V18, P1457, DOI 10.1097/00004872-200018100-00014; Kessin R.H., 2001, DICTYOSTELIUM EVOLUT; Kishi Y, 2000, EXP CELL RES, V261, P187, DOI 10.1006/excr.2000.5061; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; LEHNINGER A, 1993, PRINCIPLES BIOCH, P759; LOOMIS WF, 1988, DEV GENET, V9, P549, DOI 10.1002/dvg.1020090431; Loomis WF., 1975, DICTYOSTELIUM DISCOI; Ma H, 1997, EMBO J, V16, P4317, DOI 10.1093/emboj/16.14.4317; MAKMAN RS, 1965, J BIOL CHEM, V240, P1309; MEHDY MC, 1985, MOL CELL BIOL, V5, P705, DOI 10.1128/MCB.5.4.705; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; NEWELL PC, 1988, J CELL SCI, V89, P123; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Patel J, 2001, BIOCHEM J, V358, P497, DOI 10.1042/0264-6021:3580497; PETERKOFSKY A, 1971, P NATL ACAD SCI USA, V68, P2794, DOI 10.1073/pnas.68.11.2794; PITT GS, 1992, CELL, V69, P305, DOI 10.1016/0092-8674(92)90411-5; Roisin-Bouffay C, 2000, MOL CELL, V6, P953, DOI 10.1016/S1097-2765(05)00082-1; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SHAFFER BM, 1957, Q J MICROSC SCI, V98, P393; Tang L, 2002, P NATL ACAD SCI USA, V99, P1371, DOI 10.1073/pnas.022516099; Tang L, 2001, J BIOL CHEM, V276, P27663, DOI 10.1074/jbc.M102205200; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; VARNUMFINNEY B, 1987, CELL MOTIL CYTOSKEL, V8, P7, DOI 10.1002/cm.970080103; VERKERKEVANWIJK I, 1997, DICTYOSTELIUM MODEL, P145; WRIGHT BE, 1972, J BIOL CHEM, V247, P7875; YUEN IS, 1995, J CELL BIOL, V129, P1251, DOI 10.1083/jcb.129.5.1251	43	20	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39202	39208		10.1074/jbc.M205635200	http://dx.doi.org/10.1074/jbc.M205635200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161440	hybrid			2022-12-27	WOS:000178662500020
J	Sklyarova, T; De Corte, V; Meerschaert, K; Devriendt, L; Vanloo, B; Bailey, J; Cook, LJ; Goethals, M; Van Damme, J; Puype, M; Vandekerckhove, J; Gettemans, J				Sklyarova, T; De Corte, V; Meerschaert, K; Devriendt, L; Vanloo, B; Bailey, J; Cook, LJ; Goethals, M; Van Damme, J; Puype, M; Vandekerckhove, J; Gettemans, J			Fragmin60 encodes an actin-binding protein with a C2 domain and controls actin Thr-203 phosphorylation in Physarum plasmodia and sclerotia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE-RICH REPEAT; PHOSPHOLIPID-BINDING; CELL-CYCLE; CAENORHABDITIS-ELEGANS; CRYSTAL-STRUCTURE; CA2+ BINDING; BARBED ENDS; GELSOLIN; CALCIUM; SYNAPTOTAGMIN	We report the isolation of a cDNA clone encoding a 60-kDa protein termed fragmin60 that cross-reacts with firagmin antibodies. Unlike other gelsolin-related proteins, fragmin60 contains a unique N-terminal domain that shows similarity with C2 domains of aczonin, protein kinase C, and synaptotagmins. The fragmin60 C2 domain binds three calcium ions, one with nanomolar affinity and two with micromolar affinity. Actin binding by fragmin60 requires higher calcium concentrations than does binding of actin by a fragmin60 mutant lacking the C2 domain, suggesting that the C2 domain secures the actin binding moiety in a conformation preventing actin binding at low calcium concentrations. The fragmin60 C2 domain does not bind phospholipids but interacts with the endogenous homologue of Saccharomyces cerevisiae S-phase kinase-associated protein (Skp1), as shown by pull-down assays and co-expression in mammalian cells. Recombinant fragmin60 promotes in vitro phosphorylation of actin Thr-203 by the actin-fragmin kinase. We further show that in vivo phosphorylation of actin in the fragmin60-actin complex occurs in sclerotia, a dormant stage of Physarum development, as well as in plasmodia. Our findings indicate that we have cloned a novel type of gelsolin-related actin-binding protein that is involved in controlling regulation of actin phosphorylation in vivo.	Univ Ghent, Fac Med & Hlth Sci, Dept Biochem, Romalaere Inst, B-9000 Ghent, Belgium; Univ Leicester, Dept Genet, Leicester LE1 7RH, Leics, England	Ghent University; University of Leicester	Gettemans, J (corresponding author), Univ Ghent, Fac Med & Hlth Sci, Dept Biochem, Romalaere Inst, Albert Baertsoenkaai 3, B-9000 Ghent, Belgium.	jan.gettemans@rug.ac.be						AMPE C, 1987, EMBO J, V6, P4149, DOI 10.1002/j.1460-2075.1987.tb02761.x; ANDRE E, 1988, J BIOL CHEM, V263, P722; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAILEY J, 1987, PROTOPLASMA, V141, P101, DOI 10.1007/BF01272891; Bailey J, 1999, ARCH MICROBIOL, V172, P364, DOI 10.1007/s002030050773; BAZARI WL, 1988, P NATL ACAD SCI USA, V85, P4986, DOI 10.1073/pnas.85.14.4986; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; BRUNDAGE RA, 1993, AM J PHYSIOL, V265, pC1527, DOI 10.1152/ajpcell.1993.265.6.C1527; CAMPBELL HD, 1993, P NATL ACAD SCI USA, V90, P11386, DOI 10.1073/pnas.90.23.11386; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; Constantin B, 1998, J CELL SCI, V111, P1695; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DeCorte V, 1996, EUR J BIOCHEM, V241, P901; Eichinger L, 1996, EMBO J, V15, P5547, DOI 10.1002/j.1460-2075.1996.tb00939.x; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Fukuda M, 2000, BIOCHEM BIOPH RES CO, V276, P626, DOI 10.1006/bbrc.2000.3520; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; Furuhashi K, 1998, BIOCHEM BIOPH RES CO, V242, P653, DOI 10.1006/bbrc.1997.8044; Galan JM, 2001, MOL CELL BIOL, V21, P3105, DOI 10.1128/MCB.21.9.3105-3117.2001; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GETTEMANS J, 1992, EMBO J, V11, P3185, DOI 10.1002/j.1460-2075.1992.tb05395.x; GETTEMANS J, 1995, J BIOL CHEM, V270, P2644, DOI 10.1074/jbc.270.6.2644; Gevaert K, 1996, ELECTROPHORESIS, V17, P918, DOI 10.1002/elps.1150170513; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; Hall A, 1998, SCIENCE, V280, P2074, DOI 10.1126/science.280.5372.2074; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HASEGAWA T, 1980, BIOCHEMISTRY-US, V19, P2677, DOI 10.1021/bi00553a021; KOZAROV E, 1995, J BIOL CHEM, V270, P3022, DOI 10.1074/jbc.270.7.3022; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE S, 1988, ANAL BIOCHEM, V168, P148, DOI 10.1016/0003-2697(88)90022-X; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Lopez-Lluch G, 2001, BIOCHEM J, V357, P39, DOI 10.1042/0264-6021:3570039; MAEKAWA S, 1989, J BIOL CHEM, V264, P7458; Marks PW, 1998, J CELL SCI, V111, P2129; MATSUDAIRA PT, 1978, ANAL BIOCHEM, V87, P386, DOI 10.1016/0003-2697(78)90688-7; MCGOUGH A, 1995, J STRUCT BIOL, V115, P144, DOI 10.1006/jsbi.1995.1038; Meerschaert K, 1998, EMBO J, V17, P5923, DOI 10.1093/emboj/17.20.5923; Nakatani Y, 2000, J BIOL CHEM, V275, P1161, DOI 10.1074/jbc.275.2.1161; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nalefski EA, 2001, BIOCHEMISTRY-US, V40, P3089, DOI 10.1021/bi001968a; ORITA S, 1995, BIOCHEM BIOPH RES CO, V206, P439, DOI 10.1006/bbrc.1995.1062; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; Pestonjamasp KN, 1997, J CELL BIOL, V139, P1255, DOI 10.1083/jcb.139.5.1255; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; Sassi S, 2001, GLYCOBIOLOGY, V11, P283, DOI 10.1093/glycob/11.4.283; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Slater SJ, 2002, J BIOL CHEM, V277, P15277, DOI 10.1074/jbc.M112207200; SOUTHWICK FS, 1986, J BIOL CHEM, V261, P14191; Steinbacher S, 1999, EMBO J, V18, P2923, DOI 10.1093/emboj/18.11.2923; Stocker S, 1999, MOL BIOL CELL, V10, P161, DOI 10.1091/mbc.10.1.161; SUN HQ, 1994, J BIOL CHEM, V269, P9473; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; T'Jampens D, 2002, FEBS LETT, V516, P20, DOI 10.1016/S0014-5793(02)02456-0; T'Jampens D, 1999, EUR J BIOCHEM, V265, P240, DOI 10.1046/j.1432-1327.1999.00721.x; TJampens D, 1997, J CELL SCI, V110, P1215; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Wang JS, 1997, MOL BIOL CELL, V8, P121, DOI 10.1091/mbc.8.1.121; WATTS RG, 1995, CELL MOTIL CYTOSKEL, V30, P136, DOI 10.1002/cm.970300205; Wilson SA, 1998, NUCLEIC ACIDS RES, V26, P3460, DOI 10.1093/nar/26.15.3460; YAMAMOTO K, 1982, J CELL BIOL, V95, P711, DOI 10.1083/jcb.95.3.711; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0; Zhang XY, 1998, BIOCHEMISTRY-US, V37, P12395, DOI 10.1021/bi9807512; Zheng L, 2000, J BIOL CHEM, V275, P19700, DOI 10.1074/jbc.M001945200	74	12	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39840	39849		10.1074/jbc.M207052200	http://dx.doi.org/10.1074/jbc.M207052200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167630	Green Published, hybrid			2022-12-27	WOS:000178662500100
J	Suzuki, C; Murakami, G; Fukuchi, M; Shimanuki, T; Shikauchi, Y; Imamura, T; Miyazono, K				Suzuki, C; Murakami, G; Fukuchi, M; Shimanuki, T; Shikauchi, Y; Imamura, T; Miyazono, K			Smurf1 regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; UBIQUITIN LIGASE COMPLEX; SIGNALING PATHWAYS; C2 DOMAIN; DEPENDENT DEGRADATION; TUMOR-SUPPRESSOR; I RECEPTOR; PROTEINS; ASSOCIATION; ANTAGONIST	Smad ubiquitin regulatory factor 1 (Smurf1), a HECT-type E3 ubiquitin ligase, interacts with inhibitory Smad7 and induces cytoplasmic localization of Smad7. Smurf1 then associates with transforming growth factor-beta type I receptor (TbetaR-1) and enhances the turnover of this receptor. However, the mechanisms of the nuclear export and plasma membrane localization of the Smurf1-Smad7 complex have not been elucidated. We show here that Smurf1 targets Smad7 to the plasma membrane through its N-terminal conserved 2 (C2) domain. Both wild-type Smurf1 (Smurf1(WT)) and Smurf1 lacking the C2 domain (Smurf1(DeltaC2)) bound to Smad7 and translocated nuclear Smad7 to the cytoplasm. However, unlike Smurf1(WT), Smurf1(DeltaC2) did not move to the plasma membrane and failed to recruit Smad7 to the cell surface TbetaR-II-TbetaR-I complex. Moreover, although Smurf1(DeltaC2) induced ubiquitination of Smad7, it failed to induce the ubiquitination and degradation of TbetaR-1 and did not enhance the inhibitory activity of Smad7. Thus, these results suggest that the plasma membrane localization of Smad7 by Smurf1 requires the C2 domain of Smurf1 and is essential for the inhibitory effect of Smad7 in the transforming growth factor-beta signaling pathway.	Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, Tokyo 1130033, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 1708455, Japan	University of Tokyo; Japanese Foundation for Cancer Research	Miyazono, K (corresponding author), Univ Tokyo, Grad Sch Med, Dept Mol Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.							Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; Das P, 1999, CYTOKINE GROWTH F R, V10, P179, DOI 10.1016/S1359-6101(99)00014-3; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DIETL P, 1994, MOL PHARMACOL, V45, P300; Ebisawa T, 1999, J CELL SCI, V112, P3519; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; FROLIK CA, 1984, J BIOL CHEM, V259, P995; Fukuchi M, 2001, MOL BIOL CELL, V12, P1431, DOI 10.1091/mbc.12.5.1431; Hanyu A, 2001, J CELL BIOL, V155, P1017, DOI 10.1083/jcb.200106023; Harvey KF, 1999, TRENDS CELL BIOL, V9, P166, DOI 10.1016/S0962-8924(99)01541-X; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Imamura T, 1997, NATURE, V389, P622, DOI 10.1038/39355; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Kawabata M, 1998, EMBO J, V17, P4056, DOI 10.1093/emboj/17.14.4056; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Miyazono K, 2000, ADV IMMUNOL, V75, P115, DOI 10.1016/S0065-2776(00)75003-6; Murillas R, 2002, J BIOL CHEM, V277, P2897, DOI 10.1074/jbc.M110047200; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Ochoa WF, 2001, J MOL BIOL, V311, P837, DOI 10.1006/jmbi.2001.4910; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Podos SD, 2001, DEV CELL, V1, P567, DOI 10.1016/S1534-5807(01)00057-0; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Snyder PM, 2001, J BIOL CHEM, V276, P28321, DOI 10.1074/jbc.M011487200; Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460-2075.1996.tb01013.x; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	39	143	156	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39919	39925		10.1074/jbc.M201901200	http://dx.doi.org/10.1074/jbc.M201901200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12151385	hybrid			2022-12-27	WOS:000178662500109
J	Zhou, MI; Wang, HM; Ross, JJ; Kuzmin, I; Xu, CG; Cohen, HT				Zhou, MI; Wang, HM; Ross, JJ; Kuzmin, I; Xu, CG; Cohen, HT			The von Hippel-Lindau tumor suppressor stabilizes novel plant homeodomain protein Jade-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL-CELL CARCINOMA; FACTOR MESSENGER-RNA; GENE-PRODUCT; KINASE-C; GROWTH; VHL; MUTATIONS; DISEASE; BINDING; FINGER	The von Hippel-Lindau disease gene (VHL) is the causative gene for most adult renal cancers. However, the mechanism by which VHL protein functions as a renal tumor suppressor remains largely unknown. To identify low occupancy VHL protein partners with potential relevance to renal cancer, we screened a human kidney library against human VHL p30 using a yeast two-hybrid approach. Jade-1 (gene for Apoptosis and Differentiation in Epithelia) encodes a previously uncharacterized 64-kDa protein that interacts strongly with VHL protein and is most highly expressed in kidney. Jade-1 protein is short-lived and contains a candidate destabilizing (PEST) motif and plant homeodomains that are not required for the VHL interaction. Jade-1 is abundant in proximal tubule cells, which are clear-cell renal cancer precursors, and expression increases with differentiation. Jade-1 is expressed in cytoplasm and the nucleus diffusely and in speckles, where it partly colocalizes with VHL. VHL reintroduction into renal cancer cells increases endogenous Jade-1 protein abundance up to 10-fold. Furthermore, VHL increases Jade-1 protein half-life up to 3-fold. Thus, direct protein stabilization is identified as a new VHL function. Moreover, Jade-1 protein represents a novel candidate regulatory factor in VHL-mediated renal tumor suppression.	Boston Univ, Med Ctr, Evans Biomed Res Ctr, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; Boston Univ, Sch Med, Nephrol Sect, Boston, MA 02118 USA; Boston Univ, Sch Med, Hematol Oncol Sect, Boston, MA 02118 USA; NCI, Frederick Canc Res Ctr, NIH, Frederick, MD 21702 USA	Boston University; Boston University; Boston University; Boston University; Boston University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Cohen, HT (corresponding author), Boston Univ, Med Ctr, Evans Biomed Res Ctr, X-535,650 Albany St, Boston, MA 02118 USA.	htcohen@bu.edu		Cohen, Herbert/0000-0003-1900-8718	NATIONAL CANCER INSTITUTE [F32CA079133, R01CA079830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007053] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA079830, R01-CA79830, F32-CA79133] Funding Source: Medline; NIDDK NIH HHS [T32-DK07053] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; Baba M, 2001, ONCOGENE, V20, P2727, DOI 10.1038/sj.onc.1204397; Bjorses P, 2000, AM J HUM GENET, V66, P378, DOI 10.1086/302765; Bjorses P, 1999, HUM MOL GENET, V8, P259, DOI 10.1093/hmg/8.2.259; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Clifford SC, 2001, HUM MOL GENET, V10, P1029, DOI 10.1093/hmg/10.10.1029; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Cohen HT, 1999, BIOCHEM BIOPH RES CO, V266, P43, DOI 10.1006/bbrc.1999.1767; Cohen HT, 1997, J BIOL CHEM, V272, P2901, DOI 10.1074/jbc.272.5.2901; Cohen HT, 1999, CURR OPIN NEPHROL HY, V8, P325, DOI 10.1097/00041552-199905000-00008; CROSSEY PA, 1994, HUM MOL GENET, V3, P1303; Davidowitz EJ, 2001, MOL CELL BIOL, V21, P865, DOI 10.1128/MCB.21.3.865-874.2001; Devarajan P, 2001, J BIOL CHEM, V276, P40599, DOI 10.1074/jbc.M103424200; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GABIG TG, 1994, J BIOL CHEM, V269, P29515; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589; Gorospe M, 1999, MOL CELL BIOL, V19, P1289; Hayashi Y, 2000, SEMIN HEMATOL, V37, P368, DOI 10.1016/S0037-1963(00)90017-9; Helbing CC, 1997, CANCER RES, V57, P1255; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Ivanov SV, 1998, P NATL ACAD SCI USA, V95, P12596, DOI 10.1073/pnas.95.21.12596; Kamada M, 2001, CANCER RES, V61, P4184; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; KOKEN MHM, 1995, CR ACAD SCI III-VIE, V318, P733; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koochekpour S, 1999, MOL CELL BIOL, V19, P5902; Kroll SL, 1999, J BIOL CHEM, V274, P30109, DOI 10.1074/jbc.274.42.30109; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Levy AP, 1996, J BIOL CHEM, V271, P25492, DOI 10.1074/jbc.271.41.25492; Li ZB, 2002, J BIOL CHEM, V277, P4656, DOI 10.1074/jbc.M108269200; Lieberthal W, 1998, AM J PHYSIOL-RENAL, V275, pF691, DOI 10.1152/ajprenal.1998.275.5.F691; Lieubeau-Teillet B, 1998, CANCER RES, V58, P4957; Linder B, 2000, J MOL BIOL, V299, P369, DOI 10.1006/jmbi.2000.3766; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; LoghmanAdham M, 1997, KIDNEY INT, V52, P229, DOI 10.1038/ki.1997.325; Los M, 1996, LAB INVEST, V75, P231; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Nagase T, 2001, DNA RES, V8, P85, DOI 10.1093/dnares/8.2.85; Nakamura T, 2000, P NATL ACAD SCI USA, V97, P7284, DOI 10.1073/pnas.97.13.7284; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Okuda H, 2001, J BIOL CHEM, V276, P43611, DOI 10.1074/jbc.M107880200; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pioli PA, 2001, J BIOL CHEM, V276, P40346, DOI 10.1074/jbc.M105391200; Pitkanen J, 2000, J BIOL CHEM, V275, P16802, DOI 10.1074/jbc.M908944199; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SCHINDLER U, 1993, PLANT J, V4, P137, DOI 10.1046/j.1365-313X.1993.04010137.x; Schoenfeld AR, 2000, ONCOGENE, V19, P5851, DOI 10.1038/sj.onc.1203985; Schoenfeld AR, 2001, INT J CANCER, V91, P457, DOI 10.1002/1097-0215(20010215)91:4<457::AID-IJC1072>3.0.CO;2-P; Schultz DC, 2001, GENE DEV, V15, P428, DOI 10.1101/gad.869501; Shiao YH, 2000, CANCER RES, V60, P2816; Szelci J, 2000, J STEROID BIOCHEM, V72, P89, DOI 10.1016/S0960-0760(00)00025-X; Tsuchiya H, 1996, CANCER RES, V56, P2881; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Zaika A, 1999, J BIOL CHEM, V274, P27474, DOI 10.1074/jbc.274.39.27474	68	63	67	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39887	39898		10.1074/jbc.M205040200	http://dx.doi.org/10.1074/jbc.M205040200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12169691	hybrid			2022-12-27	WOS:000178662500106
J	Brini, M; Manni, S; Carafoli, E				Brini, M; Manni, S; Carafoli, E			Recombinant expression of the plasma membrane Na+/Ca2+ exchanger affects local and global Ca2+ homeostasis in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CALCIUM CURRENT; CARDIAC NA+-CA2+ EXCHANGER; SODIUM-CALCIUM; ENDOPLASMIC-RETICULUM; CYTOSOLIC CA2+; I-CRAC; RELEASE; MYOCYTES; OVEREXPRESSION; INACTIVATION	The cardiac type Na+/Ca2+ exchanger (NCX1) has been transiently expressed in Chinese hamster ovary cells, which do not contain an endogenous exchanger, together with aequorin chimeras that are targeted to different intracellular compartments to investigate intracellular Ca2+ homeostasis. The expression of NCX decreased the endoplasmic reticulum Ca2+ concentration, [Ca2+](er), in resting cells, showing that the exchanger was operative under these conditions. It induced a greater reduction in the height of the mitochondrial and cytosolic Ca2+ transients in agonist-stimulated cells than would have been expected from the [Ca2+](er) decrease. It also had a major effect on the sub-plasma membrane Ca2+ concentration, [Ca2+](pm): after a transient [Ca2+](pm) rise induced by the activation of capacitative Ca2+ influx, [Ca2+](pm) settled to a value about 3-fold higher than in controls. The sustained [Ca2+](pm) increase after the transient was due to the operation of the exchanger, either directly by operating in the Ca2+ entry mode, or indirectly by removing the Ca2+ inhibition on the capacitative Ca2+ influx channels.	Univ Padua, Dept Biochem, I-35121 Padua, Italy; Univ Padua, Ctr Study Biomembranes, Natl Res Council, I-35121 Padua, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy	University of Padua; University of Padua; Veneto Institute Molecular Medicine	Brini, M (corresponding author), Univ Padua, Dept Biochem, Viale G Colombo 3, I-35121 Padua, Italy.		Brini, Marisa/K-5189-2016; Carafoli, Ernesto/K-5192-2016; Manni, Sabrina/AAE-9182-2021	Carafoli, Ernesto/0000-0002-7826-0094; Brini, Marisa/0000-0001-5141-0243; MANNI, SABRINA/0000-0001-6804-0680	Telethon [GP0193Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		AdachiAkahane S, 1997, J GEN PHYSIOL, V109, P717, DOI 10.1085/jgp.109.6.717; Barrero MJ, 1997, J BIOL CHEM, V272, P27694, DOI 10.1074/jbc.272.44.27694; BERLIN JR, 1989, CIRC RES, V65, P115, DOI 10.1161/01.RES.65.1.115; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BLAUSTEIN MP, 1977, BIOPHYS J, V20, P79, DOI 10.1016/S0006-3495(77)85538-0; Brini M, 2000, EMBO J, V19, P4926, DOI 10.1093/emboj/19.18.4926; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Brini M, 1999, MICROSC RES TECHNIQ, V46, P380, DOI 10.1002/(SICI)1097-0029(19990915)46:6<380::AID-JEMT6>3.0.CO;2-Y; Chernaya G, 1996, J BIOL CHEM, V271, P5378, DOI 10.1074/jbc.271.10.5378; Condrescu M, 1997, J GEN PHYSIOL, V109, P41, DOI 10.1085/jgp.109.1.41; DOSTAL DE, 1992, AM J PHYSIOL, V263, P851; Fang Y, 1998, AM J PHYSIOL-CELL PH, V275, pC50, DOI 10.1152/ajpcell.1998.275.1.C50; Fang Y, 1999, CELL CALCIUM, V26, P15, DOI 10.1054/ceca.1999.0046; Hirose K, 1999, SCIENCE, V284, P1527, DOI 10.1126/science.284.5419.1527; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Hoyt KR, 1998, MOL PHARMACOL, V53, P742, DOI 10.1124/mol.53.4.742; Iwamoto T, 1998, EUR J CELL BIOL, V76, P228, DOI 10.1016/S0171-9335(98)80038-1; Iwamoto T, 1996, J BIOL CHEM, V271, P22391, DOI 10.1074/jbc.271.37.22391; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; Li L, 2000, J BIOL CHEM, V275, P20903, DOI 10.1074/jbc.M000995200; Litwin S, 1996, ANN NY ACAD SCI, V779, P451, DOI 10.1111/j.1749-6632.1996.tb44820.x; MALGAROLI A, 1987, J CELL BIOL, V105, P2145, DOI 10.1083/jcb.105.5.2145; Marsault R, 1997, EMBO J, V16, P1575, DOI 10.1093/emboj/16.7.1575; MATSUOKA S, 1992, J GEN PHYSIOL, V100, P963, DOI 10.1085/jgp.100.6.963; MIURA Y, 1989, J GEN PHYSIOL, V93, P1129, DOI 10.1085/jgp.93.6.1129; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; Opuni K, 2000, J BIOL CHEM, V275, P21549, DOI 10.1074/jbc.M003158200; Rizzuto R, 1995, METHOD ENZYMOL, V260, P417, DOI 10.1016/0076-6879(95)60155-4; Santacruz-Toloza L, 2000, J BIOL CHEM, V275, P182, DOI 10.1074/jbc.275.1.182; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; Terracciano CMN, 1998, J PHYSIOL-LONDON, V512, P651, DOI 10.1111/j.1469-7793.1998.651bd.x; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	38	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38693	38699		10.1074/jbc.M206075200	http://dx.doi.org/10.1074/jbc.M206075200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12145298	hybrid			2022-12-27	WOS:000178529600087
J	Cordero, JB; Cozzolino, M; Lu, Y; Vidal, M; Slatopolsky, E; Stahl, PD; Barbieri, MA; Dusso, A				Cordero, JB; Cozzolino, M; Lu, Y; Vidal, M; Slatopolsky, E; Stahl, PD; Barbieri, MA; Dusso, A			1,25-dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL HUMAN KERATINOCYTES; VITAMIN-D ANALOGS; FACTOR-ALPHA; EGF RECEPTOR; TYROSINE KINASES; EXPRESSION; ACTIVATION; ENDOCYTOSIS; CARCINOMA; PRECURSOR	1,25(OH)(2)D-3 antiproliferative properties are widely known. However, the molecular bases of these properties are only partially elucidated. Since 1,25(OH)(2)D-3 effectively arrests growth in many tumors and hyperplastic tissues whose growth is driven by co-expression of EGFR and its ligand TGF-alpha, it was hypothesized that 1,25(OH)(2)D-3 could affect the TGF-alpha/EGFR-autocrine growth loop. This study examined 1,25(OH)(2)D-3 regulation of EGFR-growth signals, using human epidermoid A431 cells, in which the overexpression of EGFR and TGF-a constitute the major autocrine mitogenic signal. 1,25(OH)(2)D-3 inhibited autocrine and EGF-induced A431 cell proliferation. Furthermore, 1,25(OH)(2)D-3 changed the cellular localization of both TGF-alpha and EGFR and inhibited ligand-dependent phosphorylation of EGFR and ERK1/2. In addition, 1,25(OH)(2)D-3 impaired autocrine and EGF-induced nuclear translocation of activated EGFR and, consequently, its binding to AT-rich DNA sequences and transcriptional activation of the cyclin D1 promoter. These results demonstrate that 1,25(OH)(2)D-3 alters EGFR membrane trafficking and down-regulates EGFR growth signaling.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Internal Med, Div Renal, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Barbieri, MA (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Campus Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.	Alejandro.Barbieri@cellbiology.wustl.edu; adusso@im.wustl.edu	Cozzolino, Mario/AAB-9965-2022; Dusso, Adriana S/E-8617-2011; Stahl, Philip/D-6315-2012	Cozzolino, Mario/0000-0002-8494-6252; Cordero, Julia/0000-0003-1701-9480	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020015, R01AI035884, R37AI020015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042259] Funding Source: NIH RePORTER; NIAID NIH HHS [AI35884, AI20015] Funding Source: Medline; NIGMS NIH HHS [GM42259] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Albanell J, 2001, CANCER RES, V61, P6500; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; Brown AJ, 1999, AM J PHYSIOL-RENAL, V277, pF157, DOI 10.1152/ajprenal.1999.277.2.F157; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Busse D, 2001, SEMIN ONCOL, V28, P47, DOI 10.1053/sonc.2001.28550; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; Cozzolino M, 2001, KIDNEY INT, V60, P2109, DOI 10.1046/j.1523-1755.2001.00042.x; DERYNCK R, 1987, CANCER RES, V47, P707; DRIMAN DK, 1992, HUM PATHOL, V23, P1360, DOI 10.1016/0046-8177(92)90055-8; Dusso AS, 2001, KIDNEY INT, V59, P855; El-Obeid A, 2002, BIOCHEM BIOPH RES CO, V290, P349, DOI 10.1006/bbrc.2001.6210; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; GENTRY LE, 1987, MOL CELL BIOL, V7, P1585, DOI 10.1128/MCB.7.5.1585; GUSTERSON B, 1985, INT J CANCER, V36, P689; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; Jensen SS, 2001, MOL ENDOCRINOL, V15, P1370, DOI 10.1210/me.15.8.1370; KAMIO T, 1990, HUM PATHOL, V21, P277, DOI 10.1016/0046-8177(90)90227-V; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KRAGBALLE K, 1989, ARCH DERMATOL, V125, P1647, DOI 10.1001/archderm.125.12.1647; KREMER R, 1989, ENDOCRINOLOGY, V125, P935, DOI 10.1210/endo-125-2-935; KUMAR V, 1995, CELL BIOL INT, V19, P373, DOI 10.1006/cbir.1995.1083; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; LIPPONEN P, 1994, BRIT J CANCER, V69, P1120, DOI 10.1038/bjc.1994.220; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; MATSUMOTO K, 1990, BIOCHEM BIOPH RES CO, V166, P916, DOI 10.1016/0006-291X(90)90898-W; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; Segaert S, 1998, J INVEST DERMATOL, V111, P551, DOI 10.1046/j.1523-1747.1998.00367.x; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; TERVAHAUTA A, 1994, INT J GYNECOL PATHOL, V13, P234, DOI 10.1097/00004347-199407000-00007; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; Verstuyf A, 2000, EXPERT OPIN INV DRUG, V9, P443, DOI 10.1517/13543784.9.3.443; Wang QM, 1996, CANCER RES, V56, P264; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; WILEY HS, 1991, J BIOL CHEM, V266, P11083; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3; Yabushita H, 1996, J Obstet Gynaecol Res, V22, P529; Zhao XY, 2001, STEROIDS, V66, P293, DOI 10.1016/S0039-128X(00)00164-1; Zugmaier G, 1996, BRIT J CANCER, V73, P1341, DOI 10.1038/bjc.1996.256	46	90	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38965	38971		10.1074/jbc.M203736200	http://dx.doi.org/10.1074/jbc.M203736200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12181310	hybrid			2022-12-27	WOS:000178529600120
J	Madison, DL; Yaciuk, P; Kwok, RPS; Lundblad, JR				Madison, DL; Yaciuk, P; Kwok, RPS; Lundblad, JR			Acetylation of the adenovirus-transforming protein E1A determines nuclear localization by disrupting association with importin-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY EPITHELIAL-CELLS; REGION 1A PROTEINS; HISTONE ACETYLTRANSFERASE ACTIVITY; TERMINAL BINDING-PROTEIN; RNA-POLYMERASE-II; COREPRESSOR CTBP; ONCOPROTEIN E1A; CRYSTALLOGRAPHIC ANALYSIS; TRANSCRIPTION INITIATION; CELLULAR PHOSPHOPROTEIN	Posttranslational modifications may alter the biochemical functions of a protein by modifying associations with other macromolecules, allosterically altering intrinsic catalytic activities, or determining subcellular localization. The adenovirus-transforming protein E1A is acetylated by its cellular targets, the co-activators CREB-binding protein, p300, and p300/CREB-binding protein-associated factor in vitro and also in vivo at a single lysine residue (Lys(239)) within a multifunctional carboxyl-terminal domain necessary for both nuclear localization and interaction with the transcriptional corepressor carboxyl-terminal binding protein (CtBP). In contrast to a previous report, we demonstrate that acetylation of Lys(239) does not disrupt CtBP binding and that 12 S E1A-mediated repression of CREB-binding protein-dependent transcription does not require recruitment of CtBP. Instead we find that the cytoplasmic fraction of E1-transformed 293 cells is enriched for acetylated E1A with relative exclusion from the nuclear compartment. Whereas wild type 12 S E1A binds importin-alpha3, binding affinity was markedly reduced both by single amino acid substitution mutations and acetylation at Lys(239). This is the first demonstration that acetylation may alter nuclear partitioning by direct interference with nuclear import receptor recognition. The finding that the cytoplasmic fraction of E1A is acetylated indicates that E1A may exert its pleiotropic effects on cellular transformation in part by affecting cytoplasmic processes.	Oregon Hlth & Sci Univ, Div Mol Med, Dept Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; St Louis Univ, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA; Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	Oregon Health & Science University; Oregon Health & Science University; Saint Louis University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Lundblad, JR (corresponding author), Oregon Hlth & Sci Univ, Div Mol Med, Dept Med, HRC-3,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	lundblad@ohsu.edu			NIDDK NIH HHS [DK051732, DK060133] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK051732, R01DK060133] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BRIZZARD BL, 1994, BIOTECHNIQUES, V16, P730; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; Chakravarti D, 1999, CELL, V96, P393, DOI 10.1016/S0092-8674(00)80552-8; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Conti E, 2000, STRUCTURE, V8, P329, DOI 10.1016/S0969-2126(00)00107-6; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOUGLAS JL, 1995, J VIROL, V69, P8061, DOI 10.1128/JVI.69.12.8061-8065.1995; DOUGLAS JL, 1994, CELL GROWTH DIFFER, V5, P475; Douglas JL, 1996, VIROLOGY, V220, P339, DOI 10.1006/viro.1996.0322; Fax P, 2001, VIROLOGY, V285, P30, DOI 10.1006/viro.2001.0926; FELDMAN LT, 1983, MOL CELL BIOL, V3, P829, DOI 10.1128/MCB.3.5.829; Felzien LK, 1999, MOL CELL BIOL, V19, P4241; Flint J, 1997, ANNU REV GENET, V31, P177, DOI 10.1146/annurev.genet.31.1.177; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Goodman RH, 2000, GENE DEV, V14, P1553; Gopalakrishnan S, 1997, CELL GROWTH DIFFER, V8, P541; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grand RJA, 1998, VIROLOGY, V244, P230, DOI 10.1006/viro.1998.9081; Grand RJA, 1999, ONCOGENE, V18, P449, DOI 10.1038/sj.onc.1202304; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hamamori Y, 1999, CELL, V96, P405, DOI 10.1016/S0092-8674(00)80553-X; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; Harlow E., 1988, ANTIBODIES LAB MANUA, P148; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; Koehler JA, 2001, BIOCHEM BIOPH RES CO, V283, P888, DOI 10.1006/bbrc.2001.4889; Kohler M, 1997, FEBS LETT, V417, P104, DOI 10.1016/S0014-5793(97)01265-9; Kohler M, 2001, VIROLOGY, V289, P186, DOI 10.1006/viro.2001.1151; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; KRIPPL B, 1985, P NATL ACAD SCI USA, V82, P7480, DOI 10.1073/pnas.82.22.7480; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; LYONS RH, 1987, MOL CELL BIOL, V7, P2451, DOI 10.1128/MCB.7.7.2451; Marmorstein R, 2001, J MOL BIOL, V311, P433, DOI 10.1006/jmbi.2001.4859; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Molloy DP, 1998, J BIOL CHEM, V273, P20867, DOI 10.1074/jbc.273.33.20867; Molloy DP, 2001, BBA-PROTEIN STRUCT M, V1546, P55, DOI 10.1016/S0167-4838(00)00071-6; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; NEVINS JR, 1995, CURR TOP MICROBIOL, V199, P25; O'Connor MJ, 1999, J VIROL, V73, P3574; Perissi V, 1999, P NATL ACAD SCI USA, V96, P3652, DOI 10.1073/pnas.96.7.3652; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; RICHTER JD, 1985, P NATL ACAD SCI USA, V82, P8434, DOI 10.1073/pnas.82.24.8434; RICHTER JD, 1988, J VIROL, V62, P1948, DOI 10.1128/JVI.62.6.1948-1955.1988; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SHENK T, 1991, ADV CANCER RES, V57, P47; SLAVICEK JM, 1989, J VIROL, V63, P4047, DOI 10.1128/JVI.63.9.4047-4050.1989; SMITH CL, 1989, J VIROL, V63, P1569, DOI 10.1128/JVI.63.4.1569-1577.1989; Sollerbrant K, 1996, NUCLEIC ACIDS RES, V24, P2578, DOI 10.1093/nar/24.13.2578; SONG CZ, 1995, P NATL ACAD SCI USA, V92, P10330, DOI 10.1073/pnas.92.22.10330; Song CZ, 1997, MOL CELL BIOL, V17, P2186, DOI 10.1128/MCB.17.4.2186; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Soutoglou E, 2001, EMBO J, V20, P1984, DOI 10.1093/emboj/20.8.1984; SPINDLER KR, 1984, J VIROL, V52, P706, DOI 10.1128/JVI.52.2.706-710.1984; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Thompson PR, 2001, J BIOL CHEM, V276, P33721, DOI 10.1074/jbc.M104736200; Touitou R, 2001, J VIROL, V75, P7749, DOI 10.1128/JVI.75.16.7749-7755.2001; Turnell AS, 2000, EMBO J, V19, P4759, DOI 10.1093/emboj/19.17.4759; Turner J, 1998, EMBO J, V17, P5129, DOI 10.1093/emboj/17.17.5129; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Vo N, 2001, MOL CELL BIOL, V21, P6181, DOI 10.1128/MCB.21.18.6181-6188.2001; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; Weigert R, 1999, NATURE, V402, P429, DOI 10.1038/46587; WILLIAMS J, 1995, CURR TOP MICROBIOL, V199, P149; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Zhang QH, 2000, P NATL ACAD SCI USA, V97, P14323, DOI 10.1073/pnas.011283598; Zhang ZY, 2001, MOL BIOL CELL, V12, P699, DOI 10.1091/mbc.12.3.699	91	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38755	38763		10.1074/jbc.M207512200	http://dx.doi.org/10.1074/jbc.M207512200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12161448	hybrid			2022-12-27	WOS:000178529600095
J	Betson, M; Lozano, E; Zhang, JK; Braga, VMM				Betson, M; Lozano, E; Zhang, JK; Braga, VMM			Rac activation upon cell-cell contact formation is dependent on signaling from the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL GTPASES RHO; E-CADHERIN; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIN POLYMERIZATION; ADHESION; PROTEIN; EXPRESSION; LOCALIZATION; POLARITY; MATRIX	Cadherins are transmembrane receptors that mediate cell-cell adhesion. They play an essential role in embryonic development and maintenance of tissue architecture. The Rho family small GTPases regulate actin cytoskeletal dynamics in different cell types. The function of two family members, Rho and Rac, is required for the stability of cadherins at cell-cell contacts. Consistent with the published data we have found that Rac is activated upon induction of intercellular adhesion in epithelial cells. This activation is dependent on functional cadherins (Nakagawa, M., Fukata, M., Yamaga, M., Itoh, N., and Kaibuchi, K. (2001) J. Cell Sci. 114, 1829-1838; Noren, N. K., Niessen, C. M., Gumbiner, B. M., and Burridge, K. (2001) J. Biol. Chem. 276, 3305-3308). Here we show for the first time that clustering of cadherins using antibody-coated beads is sufficient to promote Rac activation. In the presence of Latrunculin B, Rac can be partially activated by antibody-clustered cadherins. These results suggest that actin polymerization is not required for initial Rac activation. Contrary to what has been described before, phosphatidylinositol 3-kinases are not involved in Rac activation following cell-cell adhesion in keratinocytes. Interestingly, inhibition of epidermal growth factor receptor signaling efficiently blocks the increased Rac-GTP levels observed after contact formation. We conclude that cadherin-dependent adhesion can activate Rac via epidermal growth factor receptor signaling.	UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Braga, VMM (corresponding author), Univ London Imperial Coll Sci Technol & Med, Cell & Mol Biol Sect, Div Biomed Sci, Fac Med, Sir Alexander Fleming Bldg,Exhibit Rd, London SW7 2AZ, England.	v.braga@ic.ac.uk	Lozano, Encarnacion/C-5161-2008; Betson, Martha/D-3818-2014; Braga, Vania MM/C-7345-2008	Betson, Martha/0000-0002-4220-3290; Lozano, Encarnacion/0000-0003-0254-0935; Braga, Vania/0000-0003-0546-7163				Adams CL, 1998, CURR OPIN CELL BIOL, V10, P572, DOI 10.1016/S0955-0674(98)80031-8; Adams JC, 2000, J CELL BIOL, V150, P807, DOI 10.1083/jcb.150.4.807; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amsler K, 1999, AM J PHYSIOL-CELL PH, V276, pC91, DOI 10.1152/ajpcell.1999.276.1.C91; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Braga V, 2000, EXP CELL RES, V261, P83, DOI 10.1006/excr.2000.5050; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BRAGA VMM, 1995, CELL ADHES COMMUN, V3, P201, DOI 10.3109/15419069509081287; Braga VMM, 2000, MOL BIOL CELL, V11, P3703, DOI 10.1091/mbc.11.11.3703; BUSE P, 1995, J BIOL CHEM, V270, P28223; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Cha D, 1996, J INVEST DERMATOL, V106, P590, DOI 10.1111/1523-1747.ep12345083; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Cox EA, 2001, MOL BIOL CELL, V12, P265, DOI 10.1091/mbc.12.2.265; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Geijsen N, 1999, BLOOD, V94, P1121, DOI 10.1182/blood.V94.3.1121.415k04_1121_1130; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HIRAI Y, 1989, DEVELOPMENT, V105, P271; HODIVALA KJ, 1994, J CELL BIOL, V124, P589, DOI 10.1083/jcb.124.4.589; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; KAUFMANN R, 1989, J CELL BIOL, V109, P1807, DOI 10.1083/jcb.109.4.1807; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Ko KS, 2001, J CELL SCI, V114, P1155; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Lambert M, 2002, J CELL BIOL, V157, P469, DOI 10.1083/jcb.200107104; Lampugnani MG, 2002, MOL BIOL CELL, V13, P1175, DOI 10.1091/mbc.01-07-0368; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Lin R, 1999, J BIOL CHEM, V274, P23633, DOI 10.1074/jbc.274.33.23633; Nakagawa M, 2001, J CELL SCI, V114, P1829; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Oksvold MP, 2000, J HISTOCHEM CYTOCHEM, V48, P21, DOI 10.1177/002215540004800103; Pece S, 1999, J BIOL CHEM, V274, P19347, DOI 10.1074/jbc.274.27.19347; Pece S, 2000, J BIOL CHEM, V275, P41227, DOI 10.1074/jbc.M006578200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Sako Y, 1998, J CELL BIOL, V140, P1227, DOI 10.1083/jcb.140.5.1227; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; SHIMOYAMA Y, 1989, J CELL BIOL, V109, P1787, DOI 10.1083/jcb.109.4.1787; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; Steinberg MS, 1999, CURR OPIN CELL BIOL, V11, P554, DOI 10.1016/S0955-0674(99)00027-7; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Wenk MB, 2000, J CELL BIOL, V150, P913, DOI 10.1083/jcb.150.4.913; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Zheng Y, 2001, TRENDS BIOCHEM SCI, V26, P724, DOI 10.1016/S0968-0004(01)01973-9	57	103	106	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					36962	36969		10.1074/jbc.M207358200	http://dx.doi.org/10.1074/jbc.M207358200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147707	hybrid			2022-12-27	WOS:000178447100009
J	Kumar, RA; Koc, A; Cerny, RL; Gladyshev, VN				Kumar, RA; Koc, A; Cerny, RL; Gladyshev, VN			Reaction mechanism, evolutionary analysis, and role of zinc in Drosophila Methionine-R-sulfoxide reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; ANTIOXIDANT DEFENSE; ESCHERICHIA-COLI; SULFENIC ACID; OXIDATION; ENZYME; STEREOSPECIFICITY; MSRA	Methionine residues in proteins are susceptible to oxidation, and the resulting methionine sulfoxides can be reduced back to methionines by methionine-S-sulfoxide reductase (MsrA) and methionine-R-sulfoxide reductase (MsrB). Herein, we have identified two MsrB families that differ by the presence of zinc. Evolutionary analyses suggested that the zinc-containing MsrB proteins are prototype enzymes and that the metal was lost in certain MsrB proteins later in evolution. Zinc-containing Drosophila MsrB was further characterized. The enzyme was found to employ a catalytic Cys(124) thiolate, which directly interacted with methionine sulfoxide, resulting in methionine and a Cys(124) sulfenic acid intermediate. A subsequent reaction of this intermediate with Cys(69) generated an intramolecular disulfide. Dithiothreitol could reduce either the sulfenic acid or the disulfide, but the disulfide was a preferred substrate for thioredoxin, a natural electron donor. Interestingly, the C69S mutant could complement MsrA/MsrB deficiency in yeast, and the corresponding natural form of mouse MsrB was active with thioredoxin. These data indicate that MsrB proteins employ alternative mechanisms for sulfenic acid reduction. Four other conserved cysteines in Drosophila MsrB (Cys(51), Cys(54), Cys(101), and Cys(104)) were found to coordinate structural zinc. Mutation of any one or a combination of these residues resulted in complete loss of metal and catalytic activity, demonstrating an essential role of zinc in Drosophila MsrB. In contrast, two conserved histidines were important for thioredoxin-dependent activity, but were not involved in zinc binding. A Drosophila MsrA gene was also cloned, and the recombinant enzyme was found to be metal-free and specific for methionine S-sulfoxide and to employ a similar sulfenic acid/disulfide mechanism.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; Univ Nebraska, Dept Chem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, N151 Beadle Ctr, Lincoln, NE 68588 USA.		Gladyshev, Vadim N/J-6187-2013; KOÇ, AHMET/ABI-3322-2020; Gladyshev, Vadim N/A-9894-2013	KOÇ, AHMET/0000-0003-3484-2137; Gladyshev, Vadim/0000-0002-0372-7016				Boschi-Muller S, 2000, J BIOL CHEM, V275, P35908, DOI 10.1074/jbc.M006137200; Brot N, 2000, BIOPOLYMERS, V55, P288, DOI 10.1002/1097-0282(2000)55:4<288::AID-BIP1002>3.0.CO;2-M; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; Grimaud R, 2001, J BIOL CHEM, V276, P48915, DOI 10.1074/jbc.M105509200; Hoshi T, 2001, J PHYSIOL-LONDON, V531, P1, DOI 10.1111/j.1469-7793.2001.0001j.x; Kryukov GV, 2002, P NATL ACAD SCI USA, V99, P4245, DOI 10.1073/pnas.072603099; LAVINE TF, 1947, J BIOL CHEM, V169, P477; Levine RL, 2000, IUBMB LIFE, V50, P301, DOI 10.1080/15216540051081056; Lowther WT, 2000, BIOCHEMISTRY-US, V39, P13307, DOI 10.1021/bi0020269; Lowther WT, 2000, P NATL ACAD SCI USA, V97, P6463, DOI 10.1073/pnas.97.12.6463; Lowther WT, 2002, NAT STRUCT BIOL, V9, P348, DOI 10.1038/nsb783; MINETTI G, 1994, ITAL J BIOCHEM, V43, P273; Moskovitz J, 2000, J BIOL CHEM, V275, P14167, DOI 10.1074/jbc.275.19.14167; Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998; Olry A, 2002, J BIOL CHEM, V277, P12016, DOI 10.1074/jbc.M112350200; Petropoulos I, 2001, BIOCHEM J, V355, P819, DOI 10.1042/bj3550819; Poole LB, 2002, METHOD ENZYMOL, V348, P122, DOI 10.1016/S0076-6879(02)48632-6; Raftery MJ, 2001, J BIOL CHEM, V276, P33393, DOI 10.1074/jbc.M101566200; Ruan H, 2002, P NATL ACAD SCI USA, V99, P2748, DOI 10.1073/pnas.032671199; Sharov VS, 1999, FEBS LETT, V455, P247, DOI 10.1016/S0014-5793(99)00888-1; Sharov VS, 2000, FREE RADICAL BIO MED, V29, P986, DOI 10.1016/S0891-5849(00)00400-7; Singh VK, 2001, MICROBIOL-SGM, V147, P3037, DOI 10.1099/00221287-147-11-3037; Stadtman ER, 2001, ANN NY ACAD SCI, V928, P22; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Tete-Favier F, 2000, STRUCTURE, V8, P1167, DOI 10.1016/S0969-2126(00)00526-8; Weissbach H, 2002, ARCH BIOCHEM BIOPHYS, V397, P172, DOI 10.1006/abbi.2001.2664	27	138	148	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37527	37535		10.1074/jbc.M203496200	http://dx.doi.org/10.1074/jbc.M203496200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12145281	hybrid, Green Published			2022-12-27	WOS:000178447100079
J	Li, XD; Meriane, M; Triki, I; Shekarabi, M; Kennedy, TE; Larose, L; Lamarche-Vane, N				Li, XD; Meriane, M; Triki, I; Shekarabi, M; Kennedy, TE; Larose, L; Lamarche-Vane, N			The adaptor protein Nck-1 couples the netrin-1 receptor DCC (deleted in colorectal cancer) to the activation of the small GTPase Rac1 through an atypical mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AXON GUIDANCE; TYROSINE KINASES; UNC-5; CELL; DOMAINS; CDC42; RHO; IMMUNOGLOBULIN; MIGRATIONS; HOMOLOG	Netrins are a family of secreted proteins that guide the migration of cells and axonal growth cones during development. DCC (deleted in colorectal cancer) is a receptor for netrin-1 implicated in mediating these responses. Here, we show that DCC interacts constitutively with the SH3/SH2 adaptor Nck in commissural neurons. This interaction is direct and requires the SH3 but not SH2 domains of Nck-1. Moreover, both DCC and Nck-1 associate with the actin cytoskeleton, and this association is mediated by DCC. A dominant negative Nck-1 inhibits the ability of DCC to induce neurite outgrowth in N1E-115 cells and to activate Rac1 in fibroblasts in response to netrin-1. These studies provide evidence for an important role of mammalian Nck-1 in a novel signaling pathway from an extracellular guidance cue to changes in the actin-based cytoskeleton responsible for axonal guidance.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; McGill Univ, Polypeptide Hormone Lab, Montreal, PQ H3A 2B2, Canada	McGill University; McGill University; McGill University	Lamarche-Vane, N (corresponding author), Strathcona Anat Bldg,3640 Univ St, Montreal, PQ H3A 2B2, Canada.	nathalie.lamarche@mcgill.ca						Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Desai CJ, 1999, DEVELOPMENT, V126, P1527; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; Hummel T, 2000, GENE DEV, V14, P863; Jenna S, 2002, J BIOL CHEM, V277, P6366, DOI 10.1074/jbc.M105516200; Kebache S, 2002, P NATL ACAD SCI USA, V99, P5406, DOI 10.1073/pnas.082483399; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kitamura T, 1996, BIOCHEM BIOPH RES CO, V219, P509, DOI 10.1006/bbrc.1996.0264; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Li W, 2000, HISTOL HISTOPATHOL, V15, P947, DOI 10.14670/HH-15.947; Li XD, 2002, J BIOL CHEM, V277, P15207, DOI 10.1074/jbc.M109913200; Lussier G, 1997, J BIOL CHEM, V272, P2688, DOI 10.1074/jbc.272.5.2688; Merz DC, 2001, GENETICS, V158, P1071; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Patel BN, 2002, CURR OPIN CELL BIOL, V14, P221, DOI 10.1016/S0955-0674(02)00308-3; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Shekarabi M, 2002, MOL CELL NEUROSCI, V19, P1, DOI 10.1006/mcne.2001.1075; Song HJ, 2001, NAT CELL BIOL, V3, pE81, DOI 10.1038/35060164; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	34	86	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37788	37797		10.1074/jbc.M205428200	http://dx.doi.org/10.1074/jbc.M205428200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149262	hybrid			2022-12-27	WOS:000178447100113
J	Paszty, K; Penheiter, AR; Verma, AK; Padanyi, R; Filoteo, AG; Penniston, JT; Enyedi, A				Paszty, K; Penheiter, AR; Verma, AK; Padanyi, R; Filoteo, AG; Penniston, JT; Enyedi, A			Asp(1080) upstream of the calmodulin-binding domain is critical for autoinhibition of hPMCA4b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE CA2+ PUMP; CA-2+ PUMP; INTERACTS; CA2+-ATPASE; ACTIVATION; CONTAINS; ENZYME; REGION; SITE	The role of the plasma membrane Ca2+ pump (PMCA) is to remove excess Ca2+ from the cytosol to maintain low intracellular Ca2+ levels. Asp(1080) lies within an acidic sequence between the C-terminal inhibitory region and the catalytic core of PMCAs and is part of the caspase-3 recognition site of isoforin 4b. Caspase-3 cuts immediately after this residue and activates the pump by removing the inhibitory region (Paszty, K., Verma, A. K., Padanyi, R., Filoteo, A. G., Penniston, J. T., and Enyedi, A. (2002) J. Biol. Chem. 277, 6822-6829). Asp(1080) had not been believed to have any other role, but here we show that it also plays a critical role in the autoinhibition and calmodulin activation of PMCA4b. Site-specific mutation of Asp(1080) to Asn, Ala, or Lys in PMCA4b resulted in a substantial increase in the basal activity in the absence of calmodulin. All Asp(1080) mutants exhibited an increased affinity for calmodulin because of an increase in the rate of activation by calmodulin. This rate was higher when the inhibition was weaker, showing that a strong inhibitory interaction slows the activation rate. In contrast, mutating the nearby Asp(1077) had no effect on basal activity or calmodulin activation. We propose that the conserved Asp(1080), even though it is neither in the regulatory domain nor in the catalytic core, plays an essential role in inhibition by stabilizing the inhibited state of the enzyme.	Natl Med Ctr, Inst Haematol & Immunol, H-1113 Budapest, Hungary; Hungarian Acad Sci, Membrane Res Grp, H-1051 Budapest, Hungary; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Hungarian Academy of Sciences; Mayo Clinic	Enyedi, A (corresponding author), Natl Med Ctr, Inst Haematol & Immunol, Dioszegi U 64, H-1113 Budapest, Hungary.		Pászty, Katalin/X-3785-2019; Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376; Paszty, Katalin/0000-0003-2457-8555	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28835] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ba-Thein W, 2001, BIOCHEM J, V356, P241, DOI 10.1042/0264-6021:3560241; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; Caride AJ, 1999, J BIOL CHEM, V274, P35227, DOI 10.1074/jbc.274.49.35227; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; ENYEDI A, 1993, J BIOL CHEM, V268, P17120; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; Enyedi A, 1997, J BIOL CHEM, V272, P27525, DOI 10.1074/jbc.272.44.27525; Enyedi A, 1996, J BIOL CHEM, V271, P32461, DOI 10.1074/jbc.271.50.32461; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; GRAF E, 1981, J BIOL CHEM, V256, P1587; HOFMANN F, 1993, J BIOL CHEM, V268, P10252; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; Paszty K, 2002, J BIOL CHEM, V277, P6822, DOI 10.1074/jbc.M109548200; Penheiter AR, 2002, J BIOL CHEM, V277, P17728, DOI 10.1074/jbc.M111608200; PENNISTON JT, 1982, BIOCHIM BIOPHYS ACTA, V688, P735, DOI 10.1016/0005-2736(82)90286-3; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; VERMA AK, 1994, J BIOL CHEM, V269, P1687; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; ZVARITCH E, 1995, J BIOL CHEM, V270, P2679, DOI 10.1074/jbc.270.6.2679	23	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36146	36151		10.1074/jbc.M205457200	http://dx.doi.org/10.1074/jbc.M205457200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145294	hybrid			2022-12-27	WOS:000178275100049
J	Lavoie, C; Mercier, JF; Salahpour, A; Umapathy, D; Breit, A; Villeneuve, LR; Zhu, WZ; Xiao, RP; Lakatta, EG; Bouvier, M; Hebert, TE				Lavoie, C; Mercier, JF; Salahpour, A; Umapathy, D; Breit, A; Villeneuve, LR; Zhu, WZ; Xiao, RP; Lakatta, EG; Bouvier, M; Hebert, TE			beta(1)/beta(2)-adrenergic receptor heterodimerization regulates beta(2)-adrenergic receptor internalization and ERK signaling efficacy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; FUNCTIONAL GABA(B) RECEPTOR; PROTEIN-COUPLED RECEPTORS; BETA-2-ADRENERGIC RECEPTORS; BETA(1)-ADRENERGIC RECEPTOR; BETA-1-ADRENERGIC RECEPTOR; VENTRICULAR CARDIOMYOCYTES; HETEROMERIC COMPLEXES; MOUSE CARDIOMYOCYTES; CARDIAC MYOCYTES	beta(1)- and beta(2)-adrenergic receptors (beta(1)AR and beta(2)AR) are co-expressed in numerous tissues where they play a central role in the responses of various organs to sympathetic stimulation. Although the two receptor subtypes share some signaling pathways, each has been shown to have specific signaling and regulatory properties. Given the recent recognition that many G protein-coupled receptors can form homo- and heterodimers, the present study was undertaken to determine whether the beta(1)AR and beta(2)AR can form dimers in cells and, if so, to investigate the potential functional consequences of such heterodimerization. Using co-immunoprecipitation and bioluminescence resonance energy transfer, we show that beta(1)AR and beta(2)AR can form heterodimers in HEK 293 cells co-expressing the two receptors. Functionally, beta-adrenergic stimulated adenylyl cyclase activity was found to be identical in cells expressing beta(1)AR, beta(2)AR, or both receptors at similar levels, indicating that heterodimerization did not affect this signaling pathway. When considering ERK1/2 MAPK activity, a significant agonist-promoted activation was detected in beta(2)AR- but not beta(1)AR-expressing cells. Similarly to what was observed in cells expressing the beta(1)AR alone, no beta-adrenergic stimulated ERK1/2 phosphorylation was observed in cells co-expressing the two receptors. A similar inhibition of agonist-promoted internalization of the beta(2)AR was observed upon co-expression of the beta(1)AR, which by itself internalized to a lesser extent. Taken together, our data suggest that heterodimerization between beta(1)AR and beta(2)AR inhibits the agonist-promoted internalization of the beta(2)AR and its ability to activate the ERK1/2 MAPK signaling pathway.	Inst Cardiol Montreal, Ctr Rech, Montreal, PQ H1T 1C8, Canada; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Grp Rech Syst Nerveux Auton, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Anesthesiol, Montreal, PQ H3C 3J7, Canada; NIA, Cardiovasc Sci Lab, Gerontol Res Ctr, NIH, Baltimore, MD 21224 USA	Universite de Montreal; Institut de Cardiologie de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Hebert, TE (corresponding author), Inst Cardiol Montreal, Ctr Rech, 5000 Rue Belanger Est, Montreal, PQ H1T 1C8, Canada.	hebertt@icm.umontreal.ca	Xiao, Rui-Ping/AAE-2629-2019; Bouvier, Michel/H-2758-2014; Lakatta, Edward G/AAL-1447-2020; Yimei, Wang/AAE-4083-2019	Bouvier, Michel/0000-0003-1128-0100; Lakatta, Edward/0000-0002-4772-0035	NATIONAL INSTITUTE ON AGING [ZIAAG000287, Z01AG000287] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Billinton A, 2001, TRENDS NEUROSCI, V24, P277, DOI 10.1016/S0166-2236(00)01815-4; Boivin V, 2001, KIDNEY INT, V59, P515, DOI 10.1046/j.1523-1755.2001.059002515.x; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BRODDE OE, 1983, CIRC RES, V53, P752, DOI 10.1161/01.RES.53.6.752; Chesley A, 2000, CIRC RES, V87, P1172, DOI 10.1161/01.RES.87.12.1172; Communal C, 1998, CIRCULATION, V98, P1329, DOI 10.1161/01.CIR.98.13.1329; DELMONTE F, 1993, CIRCULATION, V88, P854, DOI 10.1161/01.CIR.88.3.854; Dunigan CD, 2000, METH MOL B, V136, P329; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; GREEN SA, 1992, MOL PHARMACOL, V41, P889; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; Lemire I, 1998, J MOL CELL CARDIOL, V30, P1827, DOI 10.1006/jmcc.1998.0746; LEVY FO, 1993, P NATL ACAD SCI USA, V90, P10798, DOI 10.1073/pnas.90.22.10798; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Magne S, 2001, J BIOL CHEM, V276, P39539, DOI 10.1074/jbc.M100954200; Mason DA, 1999, J BIOL CHEM, V274, P12670, DOI 10.1074/jbc.274.18.12670; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Nelson G, 2001, CELL, V106, P381, DOI 10.1016/S0092-8674(01)00451-2; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; Ostrom RS, 2001, J BIOL CHEM, V276, P42063, DOI 10.1074/jbc.M105348200; Pavoine C, 1999, J BIOL CHEM, V274, P628, DOI 10.1074/jbc.274.2.628; Petrecca K, 1998, J ANAT, V192, P517, DOI 10.1046/j.1469-7580.1998.19240517.x; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Rohrer DK, 1996, P NATL ACAD SCI USA, V93, P7375, DOI 10.1073/pnas.93.14.7375; Rousseau G, 1996, MOL PHARMACOL, V49, P752; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sabri A, 2000, CIRC RES, V86, P1047, DOI 10.1161/01.RES.86.10.1047; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SANO M, 1993, LIFE SCI, V52, P1063, DOI 10.1016/0024-3205(93)90199-D; Scarselli M, 2001, J BIOL CHEM, V276, P30308, DOI 10.1074/jbc.M102297200; Shiina T, 2000, J BIOL CHEM, V275, P29082, DOI 10.1074/jbc.M909757199; Shiina T, 2001, LIFE SCI, V68, P2251, DOI 10.1016/S0024-3205(01)01013-X; SUZUKI T, 1992, MOL PHARMACOL, V41, P542; Tsao PI, 2001, PHARMACOL THERAPEUT, V89, P139, DOI 10.1016/S0163-7258(00)00107-8; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; Zhang SJ, 2000, J BIOL CHEM, V275, P21773, DOI 10.1074/jbc.M909484199; Zheng M, 2000, J BIOL CHEM, V275, P40635, DOI 10.1074/jbc.M006325200; Zhu WZ, 2001, P NATL ACAD SCI USA, V98, P1607, DOI 10.1073/pnas.98.4.1607; Zou YZ, 1999, J BIOL CHEM, V274, P9760, DOI 10.1074/jbc.274.14.9760	60	182	187	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					35402	35410		10.1074/jbc.M204163200	http://dx.doi.org/10.1074/jbc.M204163200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12140284	hybrid			2022-12-27	WOS:000178117000096
J	Paul-Pletzer, K; Yamamoto, T; Bhat, MB; Ma, JJ; Ikemoto, N; Jimenez, LS; Morimoto, H; Williams, PG; Parness, J				Paul-Pletzer, K; Yamamoto, T; Bhat, MB; Ma, JJ; Ikemoto, N; Jimenez, LS; Morimoto, H; Williams, PG; Parness, J			Identification of a dantrolene-binding sequence on the skeletal muscle ryanodine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; MALIGNANT HYPERTHERMIA; SARCOPLASMIC-RETICULUM; POSTULATED ROLE; FUNCTIONAL-CHARACTERIZATION; DIHYDROPYRIDINE RECEPTOR; DOMAIN-III; CONTRACTION; EXPRESSION; PROTEINS	Dantrolene is a drug that suppresses intracellular Ca2+ release from sarcoplasmic reticulum (SR) in skeletal muscle and is used as a therapeutic agent in individuals susceptible to malignant hyperthermia. Although its precise mechanism of action has not been elucidated, we have identified the N-terminal region (amino acids 1-1400) of the skeletal muscle isoform of the ryanodine receptor (RyR1), the primary Ca2+ release channel in SR, as a molecular target for dantrolene using the photoaffinity analog [H-3]azidodantrolene. Here, we demonstrate that heterologously expressed RyR1 retains its capacity to be specifically labeled wit [H-3]azidodantrolene, indicating that muscle specific factors are not required for this ligand-receptor interaction. Synthetic domain peptides of RyR1 previously shown to affect RyR1 function in vitro and in vivo were exploited as potential drug binding site mimics and used in photoaffinity labeling experiments. Only DP1 and DP1-2s, peptides containing the amino acid sequence corresponding to RyR1 residues 590-609, were specifically labeled by [H-3]azidodantrolene. A monoclonal anti-RyR1 antibody that recognizes RyR1 and its 1400-amino acid N-terminal fragment recognizes DP1 and DP1-2s in both Western blots and immunoprecipitation assays and specifically inhibits [H-3]azidodantrolene photolabeling of RyR1 and its N-terminal fragment in SR. Our results indicate that synthetic domain peptides can mimic a native, ligand-binding conformation in vitro and that the dantrolene-binding site and the epitope for the monoclonal antibody on RyR1 are equivalent and composed of amino acids 590-609.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Anesthesia, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, Piscataway, NJ 08854 USA; Boston Biomed Res Inst, Watertown, MA 02472 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Cleveland Clin Fdn, Ctr Anesthesiol Res, Cleveland, OH 44195 USA; Rutgers State Univ, Dept Chem, Piscataway, NJ 08854 USA; EO Lawrence Berkeley Lab, Natl Tritum Labelling Fac, Berkeley, CA 94720 USA; Univ Calif San Francisco, Sch Pharm, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Cleveland Clinic Foundation; Rutgers State University New Brunswick; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California San Francisco	Parness, J (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Anesthesia, Staged res Annex 2,Rm 117,661 Hoes Ln, Piscataway, NJ 08854 USA.				NCRR NIH HHS [P41 RR01237] Funding Source: Medline; NIAMS NIH HHS [AR-16922, 5 R01 AR45593] Funding Source: Medline; NIA NIH HHS [R01 AG-15556] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR016922, R01AR045593] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015556] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; Bhat MB, 1999, BIOPHYS J, V77, P808, DOI 10.1016/S0006-3495(99)76933-X; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; CAMPBELL KP, 1987, J BIOL CHEM, V262, P6460; De Ferrari GV, 2001, BIOCHEMISTRY-US, V40, P10447, DOI 10.1021/bi0101392; Denborough M, 1998, LANCET, V352, P1131, DOI 10.1016/S0140-6736(98)03078-5; El-Hayek R, 1999, J BIOL CHEM, V274, P33341, DOI 10.1074/jbc.274.47.33341; Froemming GR, 2001, FRONT BIOSCI-LANDMRK, V6, pD65, DOI 10.2741/froemmin; Fruen BR, 1997, J BIOL CHEM, V272, P26965, DOI 10.1074/jbc.272.43.26965; HAWKES MJ, 1989, MEMBRANE BIOCHEM, V8, P133, DOI 10.3109/09687688909025827; Hayek SM, 2000, BIOCHEM J, V351, P57, DOI 10.1042/0264-6021:3510057; Hosoi E, 2001, J IMMUNOL, V167, P4887, DOI 10.4049/jimmunol.167.9.4887; Ikemoto N, 2002, FRONT BIOSCI-LANDMRK, V7, pD671, DOI 10.2741/ikemoto; Ikemoto N, 2000, TRENDS CARDIOVAS MED, V10, P310, DOI 10.1016/S1050-1738(01)00067-6; Jurkat-Rott K, 2000, MUSCLE NERVE, V23, P4, DOI 10.1002/(SICI)1097-4598(200001)23:1<4::AID-MUS3>3.0.CO;2-D; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langosch D, 2001, J MOL BIOL, V311, P709, DOI 10.1006/jmbi.2001.4889; Leong P, 1998, J BIOL CHEM, V273, P7791, DOI 10.1074/jbc.273.14.7791; Leong P, 1998, J BIOL CHEM, V273, P29958, DOI 10.1074/jbc.273.45.29958; Lokuta AJ, 2002, FEBS LETT, V511, P90, DOI 10.1016/S0014-5793(01)03312-9; MacLennan DH, 2000, EUR J BIOCHEM, V267, P5291, DOI 10.1046/j.1432-1327.2000.01566.x; McCarthy TV, 2000, HUM MUTAT, V15, P410, DOI 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D; Nasu T, 1996, GEN PHARMACOL, V27, P513, DOI 10.1016/0306-3623(95)00102-6; Nelson TE, 1996, ANESTHESIOLOGY, V84, P1368, DOI 10.1097/00000542-199606000-00013; Palnitkar SS, 1999, J MED CHEM, V42, P1872, DOI 10.1021/jm9805079; Palnitkar SS, 1997, BIOCHEM J, V326, P847, DOI 10.1042/bj3260847; Paul-Pletzer K, 2001, BIOCHEMISTRY-US, V40, P531, DOI 10.1021/bi001502s; Protasi F, 2002, FRONT BIOSCI, V7, pD650, DOI 10.2741/protasi; Sambuughin N, 2001, NEUROMUSCULAR DISORD, V11, P530, DOI 10.1016/S0960-8966(01)00202-4; Sambuughin N, 2001, AM J HUM GENET, V69, P204, DOI 10.1086/321270; SENGUPTA C, 1980, FEBS LETT, V117, P37, DOI 10.1016/0014-5793(80)80908-2; Shevchenko S, 1998, J MEMBRANE BIOL, V161, P33, DOI 10.1007/s002329900312; Shoshan-Barmatz V, 1998, INT REV CYTOL, V183, P185, DOI 10.1016/S0074-7696(08)60145-X; Szentesi P, 2001, J GEN PHYSIOL, V118, P355, DOI 10.1085/jgp.118.4.355; TAKESHIMA H, 1993, ANN NY ACAD SCI, V707, P165, DOI 10.1111/j.1749-6632.1993.tb38051.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Villen J, 2002, CHEMBIOCHEM, V3, P175, DOI 10.1002/1439-7633(20020301)3:2/3<175::AID-CBIC175>3.0.CO;2-W; Wabl M, 1996, CURR OPIN IMMUNOL, V8, P89, DOI 10.1016/S0952-7915(96)80110-5; Wu YL, 1997, J BIOL CHEM, V272, P25051, DOI 10.1074/jbc.272.40.25051; Yamamoto T, 2000, J BIOL CHEM, V275, P11618, DOI 10.1074/jbc.275.16.11618; Yamamoto T, 2002, J BIOL CHEM, V277, P993, DOI 10.1074/jbc.M105837200; Yamamoto T, 2002, J BIOL CHEM, V277, P984, DOI 10.1074/jbc.M102347200; Yamamoto T, 2002, BIOCHEMISTRY-US, V41, P1492, DOI 10.1021/bi015581z; Yamazawa T, 1997, J BIOL CHEM, V272, P8161, DOI 10.1074/jbc.272.13.8161; Zhao FY, 2001, J BIOL CHEM, V276, P13810, DOI 10.1074/jbc.M006104200	45	104	112	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 20	2002	277	38					34918	34923		10.1074/jbc.M205487200	http://dx.doi.org/10.1074/jbc.M205487200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	595PB	12167662	hybrid			2022-12-27	WOS:000178117000035
J	de Bruyn, KMT; Rangarajan, S; Reedquist, KA; Figdor, CG; Bos, JL				de Bruyn, KMT; Rangarajan, S; Reedquist, KA; Figdor, CG; Bos, JL			The small GTPase Rap1 is required for Mn2+- and antibody-induced LFA-1-and VIA-4-mediated cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTION-ASSOCIATED ANTIGEN-1; PROTEIN-KINASE-II; MONOCLONAL-ANTIBODY; LEUKOCYTE ADHESION; INDUCED ACTIVATION; MOLECULE-1 ICAM-1; CYTOPLASMIC TAIL; INTEGRIN LFA-1; LYMPHOCYTES-T; BINDING	In T-lymphocytes the Ras-like small GTPase Rap1 plays an essential role in stimulus-induced inside-out activation of integrin LFA-1 (alpha(L)beta(2)) and VLA-4 (alpha(4)beta(1)). Here we show that Rap1 is also involved in the direct activation of these integrins by divalent cations or activating antibodies. Inhibition of Rap1 either by Rap GTPase-activating protein (RapGAP) or the Rap1 binding domain of RalGDS abolished both Mn2+- and KIM185 (anti-LFA-1)-induced LFA-1-mediated cell adhesion to intercellular adhesion molecule 1. Mn2+- and TS2/16 (anti-VLA-4)-induced VLA-4-mediated adhesion were inhibited as well. Interestingly, both Mn2+, KIM185 and TS2/16 failed to induce elevated levels of Rap1GTP. These findings indicate that available levels of GTP-bound Rap1 are required for the direct activation of LFA-1 and VLA-4. Pharmacological inhibition studies demonstrated that both Mn2+- and KIM185-induced adhesion as well as Rap1-induced adhesion require intracellular calcium but not signaling activity of the MEK-ERK pathway. Moreover, functional calmodulin signaling was shown to be a prerequisite for Rap1-induced adhesion. From these results we conclude that in addition to stimulus-induced inside-out activation of integrins, active Rap1 is required for cell adhesion induced by direct activation of integrins LFA-1 and VLA-4. We suggest that Rap1 determines the functional availability of integrins for productive binding to integrin ligands.	Univ Utrecht, Med Ctr, Dept Physiol Chem, NL-3508 AB Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3508 AB Utrecht, Netherlands; Univ Nijmegen, Med Ctr, Dept Tumor Immunol, NL-6500 HB Nijmegen, Netherlands	Utrecht University; Utrecht University; Radboud University Nijmegen	Bos, JL (corresponding author), Univ Utrecht, Med Ctr, Dept Physiol Chem, Univ Weg 100,POB 85060, NL-3508 AB Utrecht, Netherlands.	j.l.bos@med.uu.nl	Figdor, Carl G/A-4232-2010	Figdor, Carl G/0000-0002-2366-9212				ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; Arai A, 2001, J BIOL CHEM, V276, P10453, DOI 10.1074/jbc.M004627200; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Bilato C, 1997, J CLIN INVEST, V100, P693, DOI 10.1172/JCI119582; Blystone SD, 1999, J CELL BIOL, V145, P889, DOI 10.1083/jcb.145.4.889; Bobe R, 1998, FEBS LETT, V423, P259, DOI 10.1016/S0014-5793(98)00106-9; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Bouvard D, 1998, J CELL SCI, V111, P657; Carey KD, 2000, MOL CELL BIOL, V20, P8409, DOI 10.1128/MCB.20.22.8409-8419.2000; Caron E, 2000, CURR BIOL, V10, P974, DOI 10.1016/S0960-9822(00)00641-2; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DUSTIN ML, 1990, BIOESSAYS, V12, P421, DOI 10.1002/bies.950120905; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; ELICES MJ, 1990, CELL, V60, P577, DOI 10.1016/0092-8674(90)90661-W; Fagerholm SC, 2001, FEBS LETT, V491, P131, DOI 10.1016/S0014-5793(01)02182-2; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; KASSNER PD, 1994, J BIOL CHEM, V269, P19859; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Lacabaratz-Porret C, 1998, BIOCHEM J, V332, P173, DOI 10.1042/bj3320173; Liu SC, 2000, J CELL SCI, V113, P3563; Loomis-Husselbee JW, 1998, BIOCHEM J, V331, P947, DOI 10.1042/bj3310947; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MEDEMA RH, 1992, MOL CELL BIOL, V12, P3425, DOI 10.1128/MCB.12.8.3425; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; Qi WW, 1998, J BIOL CHEM, V273, P15271, DOI 10.1074/jbc.273.24.15271; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; ROTHLEIN R, 1986, J EXP MED, V163, P1132, DOI 10.1084/jem.163.5.1132; Sampath R, 1998, J BIOL CHEM, V273, P33588, DOI 10.1074/jbc.273.50.33588; Schmidt A, 2001, MOL CELL BIOL, V21, P438, DOI 10.1128/MCB.21.2.438-448.2001; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STAUNTON DE, 1989, NATURE, V339, P61, DOI 10.1038/339061a0; Stewart MP, 1996, J IMMUNOL, V156, P1810; Stewart MP, 1998, J CELL BIOL, V140, P699, DOI 10.1083/jcb.140.3.699; Tominaga Y, 1998, J IMMUNOL, V161, P4016; Tsuchida J, 1997, FEBS LETT, V416, P212, DOI 10.1016/S0014-5793(97)01206-4; van Kooyk Y, 2000, CURR OPIN CELL BIOL, V12, P542, DOI 10.1016/S0955-0674(00)00129-0; van Kooyk Y, 1999, J BIOL CHEM, V274, P26869, DOI 10.1074/jbc.274.38.26869; VANDEWIELVANKEMENADE E, 1992, J CELL BIOL, V117, P461, DOI 10.1083/jcb.117.2.461; VANKOOYK Y, 1989, NATURE, V342, P811, DOI 10.1038/342811a0; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	50	94	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					29468	29476		10.1074/jbc.M204990200	http://dx.doi.org/10.1074/jbc.M204990200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	12171996	hybrid, Green Published			2022-12-27	WOS:000177509300017
J	Fan, GB; Siebert, F; Sheves, M; Vogel, R				Fan, GB; Siebert, F; Sheves, M; Vogel, R			Rhodopsin with 11-cis-locked chromophore is capable of forming an active state photoproduct	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFRARED DIFFERENCE SPECTROSCOPY; LIGHT-STABLE RHODOPSIN; SCHIFF-BASE COUNTERION; METARHODOPSIN-II; BOVINE RHODOPSIN; CRYSTAL-STRUCTURE; MOLECULAR-ORIGIN; ALPHA-SUBUNIT; ISOMERIZATION; ACTIVATION	The visual pigment rhodopsin is characterized by an 11-cis retinal chromophore bound to Lys-296 via a protonated Schiff base. Following light absorption the C-11=C-12 double bond isomerizes to trans configuration and triggers protein conformational alterations. These alterations lead to the formation of an active intermediate (Meta II), which binds and activates the visual G protein, transducin. We have examined by UV-visible and Fourier transform IR spectroscopy the photochemistry of a rhodopsin analogue with an 11-cis-locked chromophore, where cis to trans isomerization around the C-11=C-12 double bond is prevented by a 6-member ring structure (Rh-6.10). Despite this lock, the pigment was found capable of forming an active photoproduct with a characteristic protein conformation similar to that of native Meta II. This intermediate is further characterized by a protonated Schiff base and protonated Glu-113, as well as by its ability to bind a transducin-derived peptide previously shown to interact efficiently with native Meta II. The yield of this active photointermediate is pH-dependent and decreases with increasing pH. This study shows that with the C-11=C-12 double bond being locked, isomerization around the C-9=C-10 or the C-13=C-14 double bonds may well lead to an activation of the receptor. Additionally, prolonged illumination at pH 7.5 produces a new photoproduct absorbing at 385 nm, which, however, does not exhibit the characteristic active protein conformation.	Univ Freiburg, Inst Mol Med & Zellforsch, Biophys Grp, D-79104 Freiburg, Germany; Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel	University of Freiburg; Weizmann Institute of Science	Sheves, M (corresponding author), Inst Mol Med & Zellforsch, Arbeitsgrp Biophys, Hermann Herder Str 9, D-79104 Freiburg, Germany.							AKITA H, 1980, J AM CHEM SOC, V102, P6372; ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; BHATTACHARYA S, 1992, J BIOL CHEM, V267, P6763; BIRGE RR, 1995, BIOPHYS CHEM, V55, P115, DOI 10.1016/0301-4622(94)00145-A; Borhan B, 2000, SCIENCE, V288, P2209, DOI 10.1126/science.288.5474.2209; BOUNDS D, 1967, NATURE, V216, P1178; CHANG CH, 1985, BIOPHYS J, V47, P509, DOI 10.1016/S0006-3495(85)83944-8; DEGRIP WJ, 1990, EUR J BIOCHEM, V191, P211; DELANEY JK, 1995, P NATL ACAD SCI USA, V92, P2101, DOI 10.1073/pnas.92.6.2101; DeLange F, 1997, EUR J BIOCHEM, V243, P174, DOI 10.1111/j.1432-1033.1997.0174a.x; DeLange F, 1998, BIOCHEMISTRY-US, V37, P1411, DOI 10.1021/bi972397y; FAHMY K, 1995, BIOPHYS CHEM, V56, P171, DOI 10.1016/0301-4622(95)00030-2; FAHMY K, 1993, P NATL ACAD SCI USA, V90, P10206, DOI 10.1073/pnas.90.21.10206; Fahmy K, 1998, BIOPHYS J, V75, P1306, DOI 10.1016/S0006-3495(98)74049-4; FANG JM, 1983, J AM CHEM SOC, V105, P5162, DOI 10.1021/ja00353a068; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FOSTER KW, 1989, BIOCHEMISTRY-US, V28, P819, DOI 10.1021/bi00428a061; FUKADA Y, 1984, BIOCHEMISTRY-US, V23, P5826, DOI 10.1021/bi00319a023; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; JAGER F, 1994, BIOCHEMISTRY-US, V33, P10878; Jang GF, 2001, J BIOL CHEM, V276, P26148, DOI 10.1074/jbc.M102212200; KANDORI H, 1989, BIOCHEMISTRY-US, V28, P6460, DOI 10.1021/bi00441a045; LAMOLA AA, 1974, BIOCHEMISTRY-US, V13, P738, DOI 10.1021/bi00701a016; LEWIS J, 1995, J AM CHEM SOC, V917, P918; LEWIS JW, 1995, J AM CHEM SOC, V35, P289; Martin EL, 1996, J BIOL CHEM, V271, P361, DOI 10.1074/jbc.271.1.361; MATTHEWS RG, 1963, J GEN PHYSIOL, V47, P215, DOI 10.1085/jgp.47.2.215; MIZUKAMI T, 1993, P NATL ACAD SCI USA, V90, P4072, DOI 10.1073/pnas.90.9.4072; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; Nishimura S, 1998, BIOCHEMISTRY-US, V37, P15816, DOI 10.1021/bi981451n; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; RATH P, 1993, BIOCHEMISTRY-US, V32, P10277, DOI 10.1021/bi00090a001; Rieke F, 1996, BIOPHYS J, V71, P2553, DOI 10.1016/S0006-3495(96)79448-1; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; SCHOENLEIN RW, 1991, SCIENCE, V254, P412, DOI 10.1126/science.1925597; SHEIKH SP, 1996, NATURE, V383, P747; SHICHIDA Y, 1988, BIOCHEMISTRY-US, V27, P6495, DOI 10.1021/bi00417a044; STEINBERG G, 1993, BIOPHYS J, V64, P1499, DOI 10.1016/S0006-3495(93)81518-2; TAKAHASHI T, 1991, BIOCHEM BIOPH RES CO, V178, P1273, DOI 10.1016/0006-291X(91)91031-7; VANDERSTEEN R, 1989, RECL TRAV CHIM PAY B, V108, P20; Vogel R, 2001, J BIOL CHEM, V276, P38487, DOI 10.1074/jbc.M105423200; Vogel R, 2000, BIOCHEMISTRY-US, V39, P8895, DOI 10.1021/bi000852b; Vogel R, 2002, J BIOL CHEM, V277, P40222, DOI 10.1074/jbc.M205032200; Vogel R, 2002, BIOCHEMISTRY-US, V41, P3529, DOI 10.1021/bi016023n; Vogel R, 2001, BIOCHEMISTRY-US, V40, P13342, DOI 10.1021/bi0113667; ZHANG Q, 1996, J AM CHEM SOC, V118, P12828; ZHUKOVSKY EA, 1989, SCIENCE, V246, P928, DOI 10.1126/science.2573154	48	20	20	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40229	40234		10.1074/jbc.M205033200	http://dx.doi.org/10.1074/jbc.M205033200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177057	hybrid			2022-12-27	WOS:000178791400011
J	Yik, JHN; Saxena, A; Weigel, JA; Weigel, PH				Yik, JHN; Saxena, A; Weigel, JA; Weigel, PH			Nonpalmitoylated human asialoglycoprotein receptors recycle constitutively but are defective in coated pit-mediated endocytosis, dissociation, and delivery of ligand to lysosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISOLATED RAT HEPATOCYTES; INTRACELLULAR SIGNALING PATHWAYS; ACYL-COENZYME-A; GALACTOSYL RECEPTORS; FATTY ACYLATION; TRANSFERRIN RECEPTORS; ATP DEPLETION; PROTEINS; INACTIVATION; PALMITOYLATION	The hepatic asialoglycoprotein receptor (ASGP-R) internalizes desialylated glycoproteins via the clathrin-coated pit pathway and mediates their delivery to lysosomes for degradation. The human ASGP-R contains two subunits, H1 and H2. Cytoplasmic residues Cys(36) in H1, as well as Cys(54) and Cys(58) in H2 are palmitoylated (Zeng, F.-Y., and Weigel, P. H. (1996) J. BioL Chem. 271, 32454). In order to study the function(s) of ASGP-R palmitoylation, we mutated these Cys residues to Ser and generated stably transfected SK-Hep-1 cell lines expressing either wild-type or nonpalmitoylated ASGP-Rs. Compared with wild-type ASGP-Rs, palmitoylation-defective ASGP-Rs showed normal ligand binding, intracellular distribution and trafficking patterns, and pH-induced dissociation profiles in vitro. However, continuous ASOR uptake, and the uptake of prebound cell surface ASOR were slower in cells expressing palmitoylation-defective ASGP-Rs than in cells expressing wild-type ASGP-Rs. Unlike native ASGP-Rs in hepatocytes or hepatoma cells, which mediate endocytosis via the clathrin-coated pit pathway and are almost completely inhibited by hypertonic medium, only similar to40% of the ASOR uptake in SK-Hep-1 cells expressing wild-type ASGP-Rs was inhibited by hyperosmolarity. This result suggests the existence of an alternate nonclathrin-mediated internalization pathway, such as transcytosis, for the entry of ASGP-R-ASOR complexes into these cells. In contrast, ASOR uptake mediated by cells expressing palmitoylation-defective ASGP-Rs showed only a marginal difference under hypertonic conditions, indicating that most of the nonpalmitoylated ASGP-Rs were not internalized and processed normally through the clathrin-coated pit pathway. Furthermore, cells expressing wild-type ASGP-Rs were able to degrade the internalized ASOR, whereas ASOR dissociation was impaired and degradation was barely detectable in cells expressing nonpalmitoylated ASGP-Rs. We conclude that palmitoylation of the ASGP-R is required for its efficient endocytosis of ligand by the clathrin-dependent endocytic pathway and, in particular, for the proper dissociation and delivery of ligand to lysosomes.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.	paul-weigel@ouhsc.edu	Yik, Jasper/C-7343-2009	Yik, Jasper/0000-0001-7532-629X	NIGMS NIH HHS [GM 49695] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; Blanpain C, 2001, J BIOL CHEM, V276, P23795, DOI 10.1074/jbc.M100583200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREITFELD PP, 1985, INT REV CYTOL, V97, P47, DOI 10.1016/S0074-7696(08)62348-7; CIECHANOVER A, 1983, J CELL BIOCHEM, V23, P107, DOI 10.1002/jcb.240230111; GEFFEN I, 1992, INT REV CYTOL, V137B, P181; GEFFEN I, 1989, EMBO J, V8, P2855, DOI 10.1002/j.1460-2075.1989.tb08433.x; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; HANSEN SH, 1993, J CELL BIOL, V123, P89, DOI 10.1083/jcb.123.1.89; HEFFELFINGER SC, 1992, IN VITRO CELL DEV-AN, V28A, P136; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; Joseph M, 1996, INDIAN J BIOCHEM BIO, V33, P343; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; MCABEE DD, 1991, J CELL BIOCHEM, V45, P59, DOI 10.1002/jcb.240450113; MCABEE DD, 1988, BIOCHEMISTRY-US, V27, P2061, DOI 10.1021/bi00406a037; MCABEE DD, 1987, J BIOL CHEM, V262, P1942; MCABEE DD, 1990, J BIOL CHEM, V265, P629; MEDH JD, 1991, J BIOL CHEM, V266, P8771; Michel CC, 1999, PHYSIOL REV, V79, P703, DOI 10.1152/physrev.1999.79.3.703; Morello JP, 1996, BIOCHEM CELL BIOL, V74, P449, DOI 10.1139/o96-049; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; Nichols BJ, 2001, TRENDS CELL BIOL, V11, P406, DOI 10.1016/S0962-8924(01)02107-9; OKA JA, 1989, J BIOL CHEM, V264, P12016; Owen DJ, 2000, CURR OPIN CELL BIOL, V12, P467, DOI 10.1016/S0955-0674(00)00118-6; Pol A, 1997, BIOCHEM J, V323, P435, DOI 10.1042/bj3230435; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; Sanderson M, 2000, ALBION, V32, P365, DOI 10.2307/4053835; SANDVIG K, 1987, J CELL BIOL, V105, P679, DOI 10.1083/jcb.105.2.679; Saxena A, 2001, MOL BIOL CELL, V12, p215A; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; Setiadi H, 1998, J CELL BIOL, V142, P859, DOI 10.1083/jcb.142.3.859; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1985, P NATL ACAD SCI USA, V82, P6465, DOI 10.1073/pnas.82.19.6465; Stockert R J, 1991, Targeted Diagn Ther, V4, P41; STOCKERT RJ, 1995, PHYSIOL REV, V75, P591, DOI 10.1152/physrev.1995.75.3.591; STOCKERT RJ, 1995, J BIOL CHEM, V270, P16107, DOI 10.1074/jbc.270.27.16107; Tanaka K, 1998, ENDOCRINOLOGY, V139, P803, DOI 10.1210/en.139.2.803; TRAN D, 1987, P NATL ACAD SCI USA, V84, P7957, DOI 10.1073/pnas.84.22.7957; VANDEURS B, 1989, INT REV CYTOL, V117, P131; Weigel P H, 1993, Subcell Biochem, V19, P125; WEIGEL PH, 1982, J BIOL CHEM, V257, P1201; WEIGEL PH, 1983, ANAL BIOCHEM, V133, P437, DOI 10.1016/0003-2697(83)90106-9; WEIGEL PH, 1994, MOL BIOL CELL, V5, P227, DOI 10.1091/mbc.5.2.227; Weigel PH, 2002, BBA-GEN SUBJECTS, V1572, P341, DOI 10.1016/S0304-4165(02)00318-5; WEIGEL PH, 1983, J BIOL CHEM, V258, P5095; WEIGEL PH, 1993, J BIOL CHEM, V268, P27186; WEIGEL PH, 1992, MECH CONTROL GLYCOCO, P421; WU GY, 1987, J BIOL CHEM, V262, P4429; Yik JHN, 2002, J BIOL CHEM, V277, P23076, DOI 10.1074/jbc.M202748200; ZENG FY, 1995, J BIOL CHEM, V270, P21388, DOI 10.1074/jbc.270.36.21388; Zeng FY, 1996, BIOCHEM BIOPH RES CO, V218, P325, DOI 10.1006/bbrc.1996.0057; Zeng FY, 1996, J BIOL CHEM, V271, P32454, DOI 10.1074/jbc.271.50.32454; ZENG FY, 1995, J BIOL CHEM, V270, P21382, DOI 10.1074/jbc.270.36.21382; ZIJDERHANDBLEEKEMOLEN JE, 1987, J CELL BIOL, V104, P1647, DOI 10.1083/jcb.104.6.1647	58	15	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40844	40852		10.1074/jbc.M204780200	http://dx.doi.org/10.1074/jbc.M204780200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12171918	hybrid			2022-12-27	WOS:000178791400089
J	Li, HH; Lyles, DS; Pan, W; Alexander, E; Thomas, MJ; Sorci-Thomas, MG				Li, HH; Lyles, DS; Pan, W; Alexander, E; Thomas, MJ; Sorci-Thomas, MG			ApoA-I structure on discs and spheres - Variable helix registry and conformational states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HIGH-DENSITY-LIPOPROTEIN; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; RESONANCE ENERGY-TRANSFER; BELT MODEL; COMPLEXES; ORIENTATION	Apolipoprotein A-I (apoA-I) readily forms discoidal high density lipoprotein (HDL) particles with phospholipids serving as an ideal transporter of plasma cholesterol. In the lipid-bound conformation, apoA-I activates the enzyme lecithin:cholesterol acyltransferase stimulating the formation of cholesterol esters from free cholesterol. As esterification proceeds cholesterol esters accumulate within the hydrophobic core of the discoidal phospholipid bilayer transforming it into a spherical HDL particle. To investigate the change in apoA-I conformation as it adapts to a spherical surface, fluorescence resonance energy transfer studies were performed. Discoidal rHDL particles containing two lipid-bound apoA-I molecules were prepared with acceptor and donor fluorescent probes attached to cysteine residues located at specific positions. Fluorescence quenching was measured for probe combinations located within repeats 5 and 5 (residue 132), repeats 5 and 6 (residues 132 and 154), and repeats 6 and 6 (residue 154). Results from these experiments indicated that each of the 2 molecules of discoidal bound apoA-I exists in multiple conformations and support the concept of a "variable registry" rather than a "fixed helix-helix registry." Additionally, discoidal rHDL were transformed in vitro to core-containing particles by incubation with lecithin:cholesterol acyltransferase. Compositional analysis showed that core-containing particles contained 11% less phospholipid and 633% more cholesterol ester and a total of 3 apoA-I molecules per particle. Spherical particles showed a lowering of acceptor to donor probe quenching when compared with starting rHDL. Therefore, we conclude that as lipid-bound apoA-I adjusts from a discoidal to a spherical surface its intermolecular interactions are significantly reduced presumably to cover the increased surface area of the particle.	Wake Forest Univ, Baptist Med Ctr, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Baptist Med Ctr, Dept Immunol & Microbiol, Winston Salem, NC 27157 USA; Wake Forest Univ, Baptist Med Ctr, Dept Biochem, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Sorci-Thomas, MG (corresponding author), Wake Forest Univ, Baptist Med Ctr, Dept Pathol, Med Ctr Blvd, Winston Salem, NC 27157 USA.			Sorci-Thomas, Mary/0000-0002-6464-5006; Lyles, Douglas/0000-0002-8401-3073	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL049373, R01HL064963, R01HL060079, R01HL064163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R55AI015892, R01AI015892] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64163, HL49373, HL-60079, HL64963] Funding Source: Medline; NIAID NIH HHS [AI15892] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; Calabresi L, 1997, BIOCHEMISTRY-US, V36, P12428, DOI 10.1021/bi970505a; Chisholm JW, 1999, J LIPID RES, V40, P1512; Clay MA, 2000, J BIOL CHEM, V275, P9019, DOI 10.1074/jbc.275.12.9019; de la Llera-Moya M, 2001, J LIPID RES, V42, P1969; Garda HA, 2002, J BIOL CHEM, V277, P19773, DOI 10.1074/jbc.M110089200; Gursky O, 1996, P NATL ACAD SCI USA, V93, P2991, DOI 10.1073/pnas.93.7.2991; JONAS A, 1988, J LIPID RES, V29, P1349; JONAS A, 1990, J BIOL CHEM, V265, P22123; Klon AE, 2000, BIOPHYS J, V79, P1679, DOI 10.1016/S0006-3495(00)76417-4; Koppaka V, 1999, J BIOL CHEM, V274, P14541, DOI 10.1074/jbc.274.21.14541; Li HH, 2000, J BIOL CHEM, V275, P37048, DOI 10.1074/jbc.M005336200; Li HH, 2001, J LIPID RES, V42, P2084; Libby P, 2001, AM J CARDIOL, V88, p3N; Maiorano JN, 2000, J BIOL CHEM, V275, P17374, DOI 10.1074/jbc.M000044200; Navab M, 2001, CIRCULATION, V104, P2386, DOI 10.1161/circ.104.20.2386; NICHOLS AV, 1985, BIOCHIM BIOPHYS ACTA, V834, P285, DOI 10.1016/0005-2760(85)90001-3; Panagotopulos SE, 2001, J BIOL CHEM, V276, P42965, DOI 10.1074/jbc.M106462200; Rogers DP, 1998, BIOCHEMISTRY-US, V37, P945, DOI 10.1021/bi9713512; RUDEL LL, 1990, J LIPID RES, V31, P1873; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; Segrest JP, 2000, CURR OPIN LIPIDOL, V11, P105, DOI 10.1097/00041433-200004000-00002; Tricerri MA, 2001, BIOCHEMISTRY-US, V40, P5065, DOI 10.1021/bi002815q; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; VANLOO B, 1992, BIOCHIM BIOPHYS ACTA, V1128, P258, DOI 10.1016/0005-2760(92)90316-N	25	65	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39093	39101		10.1074/jbc.M206770200	http://dx.doi.org/10.1074/jbc.M206770200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167653	hybrid			2022-12-27	WOS:000178662500007
J	Palmby, TR; Abe, K; Der, CJ				Palmby, TR; Abe, K; Der, CJ			Critical role of the pleckstrin homology and cysteine-rich domains in Vav signaling and transforming activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY PROTEINS; RAS TRANSFORMATION; STRUCTURAL BASIS; EXCHANGE FACTOR; DBL FAMILY; ACTIVATION; BINDING; PROTOONCOGENE; MOLECULES; RAC1	Vav family proteins are members of the Dbl family of guanine nucleotide exchange factors and activators of Rho family small GTPases. In addition to the Dbl homology (DH) domain important for guanine nucleotide exchange factor catalytic function, all Dbl family proteins contain an adjacent pleckstrin homology (PH) domain that serves to regulate DH domain activity. Although the role of the PH domain in Vav function has been evaluated extensively, its precise role and whether it serves a distinct role in different Vav proteins remain unresolved. Additionally, the precise role of an adjacent cysteine-rich domain (CRD) in regulating DH domain function is also unclear. In this study, we evaluated the contribution of these putative protein-protein or protein-lipid interaction domains to Vav signaling and transforming activity. In contrast to previous observations, we found that the PH domain is critical for Vav transforming activity. Similarly, the CRD was also essential and served a function distinct from that of the PH domain. Although mutation of either domain reduced Vav membrane association, addition of plasma membrane targeting sequences to either the CRD or PH domain mutant proteins did not restore Vav transforming activity. This result contrasts with other Dbl family proteins, where a membrane targeting sequence alone was sufficient to restore the loss of function caused by mutation of the PH domain. Furthermore, green fluorescent protein fusion proteins containing the PH domain or CRD, or both, failed to target to the plasma membrane, suggesting that these two domains also serve regulatory functions independent of promoting membrane localization. Finally, we found that phosphatidylinositol 3-kinase activation may promote Vav membrane association via phosphatidylinositol 3,4,5-triphosphate binding to the PH domain.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Der, CJ (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.	cjder@med.unc.edu		Der, Channing/0000-0002-7751-2747	NATIONAL CANCER INSTITUTE [R01CA042978, R01CA063071, R01CA055008] Funding Source: NIH RePORTER; NCI NIH HHS [CA63071, CA42978, CA55008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Booden MA, 2002, MOL CELL BIOL, V22, P2487, DOI 10.1128/MCB.22.8.2487-2497.2002; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COX AD, 1995, METHOD ENZYMOL, V255, P195; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Das B, 2000, J BIOL CHEM, V275, P15074, DOI 10.1074/jbc.M907269199; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; Groysman M, 1998, ONCOGENE, V17, P1597, DOI 10.1038/sj.onc.1202074; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; HAUSER CA, 1994, METHOD ENZYMOL, V238, P271; Hurley JH, 2000, ANNU REV BIOPH BIOM, V29, P49, DOI 10.1146/annurev.biophys.29.1.49; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Liu XH, 1998, CELL, V95, P269, DOI 10.1016/S0092-8674(00)81757-2; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rossman KL, 2000, METHOD ENZYMOL, V325, P25; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; Snyder JT, 2001, J BIOL CHEM, V276, P45868, DOI 10.1074/jbc.M106731200; Snyder JT, 2002, NAT STRUCT BIOL, V9, P468, DOI 10.1038/nsb796; SOLSKI PA, 1995, METHOD ENZYMOL, V250, P435; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; VAN AL, 1997, GENE DEV, V11, P2295; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	53	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39350	39359		10.1074/jbc.M202641200	http://dx.doi.org/10.1074/jbc.M202641200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177050	hybrid, Green Published			2022-12-27	WOS:000178662500039
J	Yamao, T; Noguchi, T; Takeuchi, O; Nishiyama, U; Morita, H; Hagiwara, T; Akahori, H; Kato, T; Inagaki, K; Okazawa, H; Hayashi, Y; Matozaki, T; Takeda, K; Akira, S; Kasuga, M				Yamao, T; Noguchi, T; Takeuchi, O; Nishiyama, U; Morita, H; Hagiwara, T; Akahori, H; Kato, T; Inagaki, K; Okazawa, H; Hayashi, Y; Matozaki, T; Takeda, K; Akira, S; Kasuga, M			Negative regulation of platelet clearance and of the macrophage phagocytic response by the transmembrane glycoprotein SHPS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN-ASSOCIATED PROTEIN; TYROSINE-PHOSPHATASE SHP-1; COLONY-STIMULATING FACTOR; ALPHA SIRP-ALPHA; MYELOID CELLS; RECEPTOR; FAMILY; ADHESION; ASSOCIATION; KINASE	SHPS-1 is a receptor-type glycoprotein that binds and activates the protein-tyrosine phosphatases SHP-1 and SHP-2, and thereby negatively modulates intracellular signaling initiated by various cell surface receptors coupled to tyrosine kinases. SHPS-1 also regulates intercellular communication in the neural and immune systems through its association with CD47 (integrin-associated protein) on adjacent cells. Furthermore, recent studies with fibroblasts derived from mice expressing an SHPS-1 mutant that lacks most of the cytoplasmic region suggested that the intact protein contributes to cytoskeletal function. Mice homozygous for this SHPS-1 mutation have now been shown to manifest thrombocytopenia. These animals did not exhibit a defect in megakaryocytopoiesis or in platelet production. However, platelets were cleared from the bloodstream more rapidly in the mutant mice than in wild-type animals. Furthermore, peritoneal macrophages from the mutant mice phagocytosed red blood cells more effectively than did those from wild-type mice; in addition, they exhibited an increase both in the rate of cell spreading and in the formation of filopodia-like structures at the cell periphery. These results indicate that SHPS-1 both contributes to the survival of circulating platelets and down-regulates the macrophage phagocytic response.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis,Chuo Ku, Kobe, Hyogo 6500017, Japan; Kobe Univ, Grad Sch Med, Dept Biomed Informat, Div Surg Pathol,Chuo Ku, Kobe, Hyogo 6500017, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Biosignal Res Ctr, Maebashi, Gumma 3718512, Japan; Kirin Brewery Co Ltd, Pharmaceut Res Labs, Takasaki, Gumma 3701295, Japan; Kirin Brewery Co Ltd, Pharmaceut Dev Labs, Takasaki, Gumma 3701295, Japan; Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 5650871, Japan	Kobe University; Kobe University; Gunma University; Kirin Brewery Company Limited; Kirin Brewery Company Limited	Noguchi, T (corresponding author), Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	noguchi@med.kobe-u.ac.jp	Okazawa, Hideki/C-3836-2011; Takeuchi, Osamu/AAG-9359-2019; Okazawa, Hideki/E-3055-2010; Takeuchi, Osamu/D-6007-2011; Akira, Shizuo/C-3134-2009	Takeuchi, Osamu/0000-0002-1260-6232; 				Adams S, 1998, J IMMUNOL, V161, P1853; AULT KA, 1995, EXP HEMATOL, V23, P996; Babic I, 2000, J IMMUNOL, V164, P3652, DOI 10.4049/jimmunol.164.7.3652; Baker GR, 1998, BLOOD, V91, P89, DOI 10.1182/blood.V91.1.89.89_89_99; Blazar BR, 2001, J EXP MED, V194, P541, DOI 10.1084/jem.194.4.541; Brooke GP, 1998, EUR J IMMUNOL, V28, P1, DOI 10.1002/(SICI)1521-4141(199801)28:01&lt;1::AID-IMMU1&gt;3.0.CO;2-V; BROWN E, 1990, J CELL BIOL, V111, P2785, DOI 10.1083/jcb.111.6.2785; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Comu S, 1997, J NEUROSCI, V17, P8702; Francois B, 1997, AM J MED, V103, P114, DOI 10.1016/S0002-9343(97)00136-8; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Greenberg S, 1999, J LEUKOCYTE BIOL, V66, P712, DOI 10.1002/jlb.66.5.712; Gresham HD, 2000, J EXP MED, V191, P515, DOI 10.1084/jem.191.3.515; Hagiwara T, 1998, EXP HEMATOL, V26, P228; Han X, 2000, J BIOL CHEM, V275, P37984, DOI 10.1074/jbc.M002334200; Inagaki K, 2000, EMBO J, V19, P6721, DOI 10.1093/emboj/19.24.6721; Jiang PH, 1999, J BIOL CHEM, V274, P559, DOI 10.1074/jbc.274.2.559; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kim CH, 1999, J EXP MED, V190, P681, DOI 10.1084/jem.190.5.681; Kruger J, 2000, J IMMUNOL, V165, P5847, DOI 10.4049/jimmunol.165.10.5847; Lienard H, 1999, J BIOL CHEM, V274, P32493, DOI 10.1074/jbc.274.45.32493; Massol P, 1998, EMBO J, V17, P6219, DOI 10.1093/emboj/17.21.6219; McMillan R, 2000, SEMIN HEMATOL, V37, P239, DOI 10.1016/S0037-1963(00)90102-1; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Mi ZP, 2000, J COMP NEUROL, V416, P335; NASH RA, 1995, BLOOD, V86, P1765, DOI 10.1182/blood.V86.5.1765.bloodjournal8651765; NEIMAN JC, 1987, ARCH PATHOL LAB MED, V111, P563; Ochi F, 1997, BIOCHEM BIOPH RES CO, V239, P483, DOI 10.1006/bbrc.1997.7489; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Ohnishi H, 1996, J BIOL CHEM, V271, P25569, DOI 10.1074/jbc.271.41.25569; Oldenborg PA, 2001, J EXP MED, V193, P855, DOI 10.1084/jem.193.7.855; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Roach TIA, 1998, CURR BIOL, V8, P1035, DOI 10.1016/S0960-9822(07)00426-5; ROSALES C, 1992, J IMMUNOL, V149, P2759; Saginario C, 1998, MOL CELL BIOL, V18, P6213, DOI 10.1128/MCB.18.11.6213; Sano S, 1997, FEBS LETT, V411, P327, DOI 10.1016/S0014-5793(97)00724-2; Seiffert M, 1999, BLOOD, V94, P3633, DOI 10.1182/blood.V94.11.3633.423k01_3633_3643; Seiffert M, 2001, BLOOD, V97, P2741, DOI 10.1182/blood.V97.9.2741; Shibuya K, 1998, BLOOD, V91, P37, DOI 10.1182/blood.V91.1.37.37_37_45; Takeda H, 1998, ONCOGENE, V16, P3019, DOI 10.1038/sj.onc.1201839; Ticchioni M, 2001, FASEB J, V15, P341, DOI 10.1096/fj.99-0833com; Timms JF, 1999, CURR BIOL, V9, P927, DOI 10.1016/S0960-9822(99)80401-1; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Turner CE, 2001, CURR BIOL, V11, pR875, DOI 10.1016/S0960-9822(01)00521-8; VANNUCCHI AM, 1990, BLOOD, V76, P1473; Veillette A, 1998, J BIOL CHEM, V273, P22719, DOI 10.1074/jbc.273.35.22719; Wu CJ, 2000, ONCOGENE, V19, P3999, DOI 10.1038/sj.onc.1203748; Yamao T, 1997, BIOCHEM BIOPH RES CO, V231, P61, DOI 10.1006/bbrc.1996.6047	48	104	118	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39833	39839		10.1074/jbc.M203287200	http://dx.doi.org/10.1074/jbc.M203287200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12167615	hybrid			2022-12-27	WOS:000178662500099
J	Zheng, QL; Van Die, I; Cummings, RD				Zheng, QL; Van Die, I; Cummings, RD			Molecular cloning and characterization of a novel alpha 1,2-fucosyltransferase (CE2FT-1) from Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-L-FUCOSE; D-GALACTOSIDE 2-ALPHA-L-FUCOSYL-TRANSFERASE; GROUP ALPHA(1,2)FUCOSYLTRANSFERASE GENE; SCHISTOSOME TRICHOBILHARZIA-OCELLATA; CYSTEINE PROTEASE GENE; EPITHELIAL INVAGINATION; TRANSFERASE GENES; UDP-GALACTOSE; HUMAN-SERUM; EXPRESSION	Here we report the discovery of a unique fucosyltransferase (FT) in Caenorhabditis elegans. In studying the activities of FTs in extracts of adult C. elegans, we detected activity toward the unusual disaccharide acceptors Galbeta1-4Xyl-R and Galbeta1-6GlcNAc-R to generate products with the general structure Fucalpha1-2Galbeta1-R. We identified a gene encoding a unique alpha1,2FT (designated CE2FT-1), which contains an open reading frame encoding a predicted protein of 355 amino acids with the type 2 topology and domain structure typical of other glycosyltransferases. The predicted cDNA for CE2FT-1 has very low identity (5-10%) at the amino acid level to alpha1,2FT sequences in humans, rabbits, and mice. Recombinant CE2FT-1 expressed in human 293T cells has high alpha1,2FT activity toward the simple acceptor Galbeta-O-phenyl acceptor to generate Fucalpha1-2Galbeta-R, which in this respect resembles mammalian alpha1,2FTs. However, CE2FT-1 is otherwise completely different from known alpha1,2FTs in its acceptor specificity, since it is unable to fucosylate either Galbeta1-4GIcbeta-R or free lactose and prefers the unusual acceptors Galbetal-4XyIbeta-R and Galbeta1-6GlcNAc-R. Promoter analysis of the CE2FT-1 gene using green fluorescent protein reporter constructs demonstrates that CE2FT-1 is expressed in single cells of early stage embryos and exclusively in the 20 intestinal cells of L1-L-4 and adult worms. These and other results suggest that multiple fucosyltransferase genes in C. elegans may encode enzymes with unique activities, expression, and developmental roles.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Free Univ Amsterdam, Med Ctr, Dept Mol Cell Biol, NL-1081 BT Amsterdam, Netherlands; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; Vrije Universiteit Amsterdam; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Cummings, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 975 NE 10th ST,BRC417, Oklahoma City, OK 73104 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD037549] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD037549] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Almeida R, 1999, J BIOL CHEM, V274, P26165, DOI 10.1074/jbc.274.37.26165; Apoil PA, 2000, MOL BIOL EVOL, V17, P337, DOI 10.1093/oxfordjournals.molbev.a026314; AROIAN RV, 1993, MOL CELL BIOL, V13, P626, DOI 10.1128/MCB.13.1.626; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Britton C, 1998, J MOL BIOL, V283, P15, DOI 10.1006/jmbi.1998.2093; Britton C, 1999, MOL BIOCHEM PARASIT, V103, P171, DOI 10.1016/S0166-6851(99)00121-8; Brockhausen I., 1997, GLYCOSCIENCES STATUS, P79; Bry L, 1996, SCIENCE, V273, P1380, DOI 10.1126/science.273.5280.1380; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; Bureau V, 2001, EUR J BIOCHEM, V268, P1006, DOI 10.1046/j.1432-1327.2001.01962.x; Chandrasekaran EV, 1996, BIOCHEMISTRY-US, V35, P8914, DOI 10.1021/bi952193m; Chen SH, 1999, J BIOL CHEM, V274, P288, DOI 10.1074/jbc.274.1.288; DeBose-Boyd RA, 1998, GLYCOBIOLOGY, V8, P905, DOI 10.1093/glycob/8.9.905; Domino SE, 1997, BIOCHEM J, V327, P105, DOI 10.1042/bj3270105; Domino SE, 2001, MOL CELL BIOL, V21, P8336, DOI 10.1128/MCB.21.24.8336-8345.2001; Domino SE, 2001, J BIOL CHEM, V276, P23748, DOI 10.1074/jbc.M100735200; FIELD MC, 1995, GLYCOBIOLOGY, V5, P463, DOI 10.1093/glycob/5.5.463; FIELDS C, 1990, NUCLEIC ACIDS RES, V18, P1509, DOI 10.1093/nar/18.6.1509; Guerardel Y, 2001, BIOCHEM J, V357, P167, DOI 10.1042/0264-6021:3570167; Hashmi S, 2002, J BIOL CHEM, V277, P3477, DOI 10.1074/jbc.M106117200; Herman T, 1999, P NATL ACAD SCI USA, V96, P968, DOI 10.1073/pnas.96.3.968; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Hokke CH, 1998, GLYCOBIOLOGY, V8, P393, DOI 10.1093/glycob/8.4.393; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEPENDU J, 1985, AM J HUM GENET, V37, P749; Lin B, 2000, BBA-MOL CELL BIOL L, V1487, P275, DOI 10.1016/S1388-1981(00)00103-7; Lin B, 2001, ARCH BIOCHEM BIOPHYS, V388, P207, DOI 10.1006/abbi.2001.2303; LINDENBERG S, 1990, J REPROD FERTIL, V89, P431, DOI 10.1530/jrf.0.0890431; Lowe JB, 1997, KIDNEY INT, V51, P1418, DOI 10.1038/ki.1997.194; Lowe JB, 2001, CELL, V104, P809, DOI 10.1016/S0092-8674(01)00277-X; MASUTANI H, 1995, J BIOCHEM-TOKYO, V118, P541, DOI 10.1093/oxfordjournals.jbchem.a124942; MCEVER RP, 1997, J CLIN INVEST, V100, P97; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NEELEMAN AP, 1994, GLYCOBIOLOGY, V4, P641, DOI 10.1093/glycob/4.5.641; Okajima T, 1999, J BIOL CHEM, V274, P22915, DOI 10.1074/jbc.274.33.22915; Oriol R, 1999, GLYCOBIOLOGY, V9, P323, DOI 10.1093/glycob/9.4.323; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; RAY C, 1992, MOL BIOCHEM PARASIT, V51, P239, DOI 10.1016/0166-6851(92)90074-T; REZAIE AR, 1992, PROTEIN EXPRES PURIF, V3, P453, DOI 10.1016/1046-5928(92)90062-2; ROUQUIER S, 1995, J BIOL CHEM, V270, P4632, DOI 10.1074/jbc.270.9.4632; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; Soejima M, 1999, EUR J BIOCHEM, V266, P274, DOI 10.1046/j.1432-1327.1999.00865.x; STEARNS DJ, 1988, J BIOL CHEM, V263, P826; van der Wel H, 2001, J BIOL CHEM, V276, P33952, DOI 10.1074/jbc.M102555200; VANDENEIJNDEN DH, 1988, J BIOL CHEM, V263, P12461; VanDie I, 1997, GLYCOBIOLOGY, V7, pR5; Wang G, 1999, MICROBIOL-SGM, V145, P3245, DOI 10.1099/00221287-145-11-3245; Warren CE, 2002, J BIOL CHEM, V277, P22829, DOI 10.1074/jbc.M201390200; Warren CE, 2001, GLYCOBIOLOGY, V11, P979, DOI 10.1093/glycob/11.11.979; WHITE S, 1994, BIOL REPROD, V50, P73, DOI 10.1095/biolreprod50.1.73; YAMAGATA T, 1991, BIOCHEM BIOPH RES CO, V181, P1004, DOI 10.1016/0006-291X(91)92036-J; Yanagidani S, 1997, J BIOCHEM-TOKYO, V121, P626	56	25	27	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39823	39832		10.1074/jbc.M207487200	http://dx.doi.org/10.1074/jbc.M207487200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12163507	hybrid			2022-12-27	WOS:000178662500098
J	Hattan, D; Nesti, E; Cachero, TG; Morielli, AD				Hattan, D; Nesti, E; Cachero, TG; Morielli, AD			Tyrosine phosphorylation of Kv1.2 modulates its interaction with the actin-binding protein cortactin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; ION-CHANNEL; K+ CHANNEL; ACETYLCHOLINE-RECEPTOR; DOWN-REGULATION; CURRENT-DENSITY; SODIUM-CHANNEL; LOCALIZATION; KINASE; SRC	Tyrosine phosphorylation evokes functional changes in a variety of ion channels. Modulation of the actin cytoskeleton also affects the function of some channels. Little is known about how these avenues of ion channel regulation may interact. We report that the potassium channel Kv1.2 associates with the actin-binding protein cortactin and that the binding is modulated by tyrosine phosphorylation. Immunocytochemical and biochemical analyses show that Kv1.2 and cortactin co-localize to the cortical actin cytoskeleton at the leading edges of the cell. Binding assays using purified recombinant proteins reveal a 19-amino acid span within the carboxyl terminus of Kv1.2 that is necessary for direct cortactin binding. Phosphorylation of specific tyrosines within the C terminus of Kv1.2 attenuates that binding. In HEK293 cells, activation of the M1 muscarinic acetylcholine receptor evokes tyrosine phosphorylation-dependent suppression of Kv1.2 ionic current. We show that M1 receptor activation also reduces the interaction of cortactin with Kv1.2 and that mutant Kv1.2 channels deficient for cortactin binding exhibit strongly attenuated ionic current. These results demonstrate a dynamic, phosphorylation-dependent interaction,between Kv1.2 and the actin cytoskeleton-binding protein cortactin and suggest a role for that interaction in the regulation of Kv1.2 ionic current.	Univ Vermont, Coll Med, Dept Pharmacol, Burlington, VT 05405 USA	University of Vermont	Morielli, AD (corresponding author), Univ Vermont, Coll Med, Dept Pharmacol, Given Bldg,Rm E-317,89 Beaumont Ave, Burlington, VT 05405 USA.	moriell@zoo.uvm.edu		Nesti, Edmund/0000-0002-1474-193X	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016435] Funding Source: NIH RePORTER; NCRR NIH HHS [1P20RR16435] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Alkon DL, 1998, TRENDS NEUROSCI, V21, P529, DOI 10.1016/S0166-2236(98)01277-6; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; Burke NA, 1999, J GEN PHYSIOL, V113, P71, DOI 10.1085/jgp.113.1.71; Cachero TG, 1998, CELL, V93, P1077, DOI 10.1016/S0092-8674(00)81212-X; Cantiello HF, 1996, EXP PHYSIOL, V81, P505, DOI 10.1113/expphysiol.1996.sp003953; Chien AJ, 1998, J BIOENERG BIOMEMBR, V30, P377, DOI 10.1023/A:1021941706726; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; HOPFIELD JF, 1988, NATURE, V336, P677, DOI 10.1038/336677a0; Huang C, 1997, J BIOL CHEM, V272, P19248, DOI 10.1074/jbc.272.31.19248; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; HUANG XY, 1994, P NATL ACAD SCI USA, V91, P624, DOI 10.1073/pnas.91.2.624; ISMAILOV II, 1995, KIDNEY INT, V48, P1167, DOI 10.1038/ki.1995.400; Jing J, 1997, J BIOL CHEM, V272, P14021, DOI 10.1074/jbc.272.22.14021; Kaksonen M, 2000, J CELL SCI, V113, P4421; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Li DQ, 2000, J BIOL CHEM, V275, P11597, DOI 10.1074/jbc.275.16.11597; Maruoka ND, 2000, FEBS LETT, V473, P188, DOI 10.1016/S0014-5793(00)01521-0; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; MOLDAY LL, 1990, J BIOL CHEM, V265, P18690; Moody WJ, 1998, J NEUROBIOL, V37, P97, DOI 10.1002/(SICI)1097-4695(199810)37:1<97::AID-NEU8>3.0.CO;2-3; Naisbitt S, 1999, NEURON, V23, P569, DOI 10.1016/S0896-6273(00)80809-0; O'Connell CB, 1999, J CELL BIOL, V144, P305, DOI 10.1083/jcb.144.2.305; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; PAULMICHL M, 1991, P NATL ACAD SCI USA, V88, P7892, DOI 10.1073/pnas.88.17.7892; Petrecca K, 2000, J NEUROSCI, V20, P8736; PRAT AG, 1995, AM J PHYSIOL, V6, pC1152; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schafer DA, 1998, J CELL BIOL, V143, P1919, DOI 10.1083/jcb.143.7.1919; SHEETZ MP, 1980, BILAYER SHELL MODEL; SHENG M, 1994, J NEUROSCI, V14, P2408; Sheng M, 1997, BIOESSAYS, V19, P847, DOI 10.1002/bies.950191004; SIEGELBAUM SA, 1994, CURR BIOL, V4, P242, DOI 10.1016/S0960-9822(00)00054-3; SMITH PR, 1991, P NATL ACAD SCI USA, V88, P6971, DOI 10.1073/pnas.88.16.6971; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Spitzer NC, 1998, J NEUROBIOL, V37, P190, DOI 10.1002/(SICI)1097-4695(199810)37:1<190::AID-NEU14>3.3.CO;2-2; SRINIVASAN Y, 1988, NATURE, V333, P177, DOI 10.1038/333177a0; Stevens CF, 1998, CURR BIOL, V8, pR151, DOI 10.1016/S0960-9822(98)70097-1; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tsai W, 1999, EMBO J, V18, P109, DOI 10.1093/emboj/18.1.109; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; TSAUR ML, 1992, NEURON, V8, P1055, DOI 10.1016/0896-6273(92)90127-Y; UNDROVINAS AI, 1995, AM J PHYSIOL-HEART C, V269, pH203, DOI 10.1152/ajpheart.1995.269.1.H203; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; WANG H, 1994, J NEUROSCI, V14, P4588; Wechsler A, 1998, EMBO J, V17, P3931, DOI 10.1093/emboj/17.14.3931; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 1998, J CELL SCI, V111, P2433; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417	55	56	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38596	38606		10.1074/jbc.M205005200	http://dx.doi.org/10.1074/jbc.M205005200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151401	hybrid			2022-12-27	WOS:000178529600077
J	Rani, MRS; Hibbert, L; Sizemore, N; Stark, GR; Ransohoff, RM				Rani, MRS; Hibbert, L; Sizemore, N; Stark, GR; Ransohoff, RM			Requirement of phosphoinositide 3-kinase and Akt for interferon-beta-mediated induction of the beta-R1 (SCYB11) gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; VAV PROTOONCOGENE PRODUCT; PHOSPHATIDYLINOSITOL 3-KINASE; TUMOR-SUPPRESSOR; PROTEIN-KINASE; CELL-SURVIVAL; 1-PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTIONAL ACTIVATION; TYROSINE PHOSPHORYLATION; GLUCOSE-TRANSPORT	We previously reported (Rani, M. R., Asthagiri, A. R., Singh, A., Sizemore, N., Sathe, S. S., Li, X., DiDonato, J. D., Stark, G. R., and Ransohoff, R. M. (2001) J. Biol. Chem. 276, 44365-44368) that IFN-beta induction of beta-R1 in fibrosarcoma cells required transcription factors ISGF-3 and NF-kappaB. IFN-beta treatment did not augment the abundance of NF-kappaB, but led to phosphorylation of the NF-kappaB subunit p65 and induced a nuclear activity capable of phosphorylating a p65-GST fusion construct in the carboxy-terminal transactivation domain (TAD), residues 354-551. We now present evidence for the involvement of phosphoinositide 3-kinase (PI3K) in this pat way. Pretreatment of HT1080-derived fibrosarcoma cells with pharmacological inhibitors of PI3K (wortmannin or LY294002) selectively inhibited IFN-beta-induced beta-R1 mRNA accumulation in a dose-dependent manner. In stably transfected cell lines, bovine p85, the regulatory subunit of PI3K, functioned as a dominant-negative inhibitor of interferon (IFN) signaling via PI3K and selectively suppressed IFN-beta-mediated induction of beta-R1. Overexpression of PTEN (phosphatase and tensin homologue mutated on chromosome ten), an antagonist of PI3K, blocked induction of a beta-R1 promoter-reporter construct. Studies with PTEN mutants suggested that the lipid kinase activity of PI3K was essential for IFN-beta-induced transcription of beta-R1. Consistent with this finding, a dominant-negative mutant of the serine-threonine kinase Akt, a downstream effector of PI3K, selectively blocked IFN-beta-mediated induction of the beta-R1 promoter reporter. Furthermore, IFN-beta-mediated phosphorylation of GST-p65 was blocked by pretreatment with LY294002. These data suggest that IFN-beta acts through PI3K to enhance the transactivation competence of NF-kappaB complexes through phosphorylation of p65 within the TAD. The results provide novel insight into the role of PI3K in the transcriptional response to IFN-beta.	Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Ransohoff, RM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, NC30, Cleveland, OH 44195 USA.				NCI NIH HHS [2PO1 CA62220] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GHISLAIN J, 1995, J BIOL CHEM, V270, P21785, DOI 10.1074/jbc.270.37.21785; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Holland KA, 1997, J BIOL CHEM, V272, P21045, DOI 10.1074/jbc.272.34.21045; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; OKADA T, 1994, J BIOL CHEM, V269, P3568; Ozes ON, 1999, NATURE, V401, P82; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; Platanias LC, 1996, J BIOL CHEM, V271, P23630, DOI 10.1074/jbc.271.39.23630; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Rani MRS, 1999, J BIOL CHEM, V274, P32507, DOI 10.1074/jbc.274.45.32507; Rani MRS, 1996, J BIOL CHEM, V271, P22878, DOI 10.1074/jbc.271.37.22878; Rani MRS, 1999, J BIOL CHEM, V274, P1891, DOI 10.1074/jbc.274.4.1891; Rani MRS, 2001, J BIOL CHEM, V276, P44365, DOI 10.1074/jbc.C100417200; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sakurai H, 1999, J BIOL CHEM, V274, P10641, DOI 10.1074/jbc.274.15.10641; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Uddin S, 1997, J IMMUNOL, V158, P2390; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; UDDIN S, 1995, J BIOL CHEM, V270, P15938, DOI 10.1074/jbc.270.27.15938; Uddin S, 2000, BIOCHEM BIOPH RES CO, V270, P158, DOI 10.1006/bbrc.2000.2402; Uddin S, 1997, FEBS LETT, V403, P31, DOI 10.1016/S0014-5793(97)00023-9; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yang CH, 2001, J BIOL CHEM, V276, P13756, DOI 10.1074/jbc.M011006200	43	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38456	38461		10.1074/jbc.M203204200	http://dx.doi.org/10.1074/jbc.M203204200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12169689	hybrid			2022-12-27	WOS:000178529600060
J	Rocnik, EF; van der Veer, E; Cao, H; Hegele, RA; Pickering, JG				Rocnik, EF; van der Veer, E; Cao, H; Hegele, RA; Pickering, JG			Functional linkage between the endoplasmic reticulum protein Hsp47 and procollagen expression in human vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-BINDING HEAT-SHOCK-PROTEIN-47; NEWLY SYNTHESIZED COLLAGEN; MOLECULAR CHAPERONE HSP47; INTRACELLULAR DEGRADATION; FIBRILLAR COLLAGEN; I PROCOLLAGEN; GENE CBP2; STRESS; HYDROXYLATION; SECRETION	Hsp47 is a heat stress protein that interacts with procollagen in the lumen of the endoplasmic reticulum, which is vital for collagen elaboration and embryonic viability. The precise actions of Hsp47 remain unclear, however. To evaluate the effects of Hsp47 on collagen production we infected human vascular smooth muscle cells (SMCs) with a retrovirus containing Hsp47 cDNA. SMCs overexpressing Hsp47 secreted type I procollagen faster than SMCs transduced with empty vector, yielding a greater accumulation of proal(l) collagen in the extracellular milieu. Interestingly, the amount of intracellular proal (I) collagen was also increased. This was associated with an unexpected increase in the rate of proalpha1 (I) collagen chain synthesis and 2.5-fold increase in proalpha1(I) collagen mRNA expression, without a change in fibronectin expression. This amplification of procollagen expression, synthesis, and secretion by Hsp47 imparted SMCs with an enhanced capacity to elaborate a fibrillar collagen network. The effects of Hsp47 were qualitatively distinct from, and independent of, those of ascorbate and the combination of both factors yielded an even more intricate fibril network. Given the in vitro impact of altered Hsp47 expression on procollagen production, we sought evidence for interindividual variability in Hsp47 expression and identified a common, single nucleotide polymorphism in the Hsp47 gene promoter among African Americans that significantly reduced promoter activity. Together, these findings indicate a novel means by which type I collagen production is regulated by the endoplasmic reticulum, constituent, Hsp47, and suggest a potential basis for inherent differences in collagen production within the population.	Univ Western Ontario, London Hlth Sci Ctr, Robarts Res Inst, Vasc Biol Grp,Dept Med Cardiol, London, ON N6A 5A5, Canada; Univ Western Ontario, London Hlth Sci Ctr, Robarts Res Inst, Vasc Biol Grp,Dept Biochem, London, ON N6A 5A5, Canada; Univ Western Ontario, London Hlth Sci Ctr, Robarts Res Inst, Vasc Biol Grp,Dept Med Biophys, London, ON N6A 5A5, Canada	London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario); London Health Sciences Centre; Western University (University of Western Ontario)	Pickering, JG (corresponding author), Univ Western Ontario, London Hlth Sci Ctr, Robarts Res Inst, Vasc Biol Grp,Dept Med Cardiol, 339 Windermere Rd, London, ON N6A 5A5, Canada.	gpickering@robarts.ca	Pickering, J. Geoffrey/G-3341-2011; Hegele, Robert/G-3301-2011; Hegele, Robert/AAF-6482-2020	Pickering, J. Geoffrey/0000-0001-6474-3274; Hegele, Robert/0000-0003-2861-5325				Abe K, 2000, NEPHROL DIAL TRANSPL, V15, P529, DOI 10.1093/ndt/15.4.529; BERG RA, 1983, ARCH BIOCHEM BIOPHYS, V226, P681, DOI 10.1016/0003-9861(83)90338-7; BERG RA, 1980, P NATL ACAD SCI-BIOL, V77, P4746, DOI 10.1073/pnas.77.8.4746; BIENKOWSKI RS, 1984, COLLAGEN REL RES, V4, P399; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; CLARKE EP, 1991, J BIOL CHEM, V266, P17230; Dafforn TR, 2001, J BIOL CHEM, V276, P49310, DOI 10.1074/jbc.M108896200; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; Davis R, 2000, BIOTECHNOL PROGR, V16, P736, DOI 10.1021/bp000107q; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; DOMBROWSKI KE, 1989, BIOCHEMISTRY-US, V28, P7107, DOI 10.1021/bi00443a048; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; FERREIRA LR, 1994, J CELL BIOCHEM, V56, P518, DOI 10.1002/jcb.240560412; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Fitzgerald J, 1999, J BIOL CHEM, V274, P27392, DOI 10.1074/jbc.274.39.27392; FLEISCHMAJER R, 1990, J STRUCT BIOL, V105, P162, DOI 10.1016/1047-8477(90)90110-X; Hendershot LM, 2000, CURR BIOL, V10, pR912, DOI 10.1016/S0960-9822(00)00850-2; Hosokawa N, 1998, J BIOCHEM-TOKYO, V124, P654, DOI 10.1093/oxfordjournals.jbchem.a022162; IKEGAWA S, 1995, CYTOGENET CELL GENET, V71, P182, DOI 10.1159/000134103; Ikegawa S, 1997, GENE, V194, P301, DOI 10.1016/S0378-1119(97)00209-6; Iwashita T, 2000, HUM PATHOL, V31, P1498, DOI 10.1053/hupa.2000.20378; Kageyama K, 2002, J BIOL CHEM, V277, P19255, DOI 10.1074/jbc.M112377200; KIVIRIKKO KI, 1989, FASEB J, V3, P1609, DOI 10.1096/fasebj.3.5.2537773; Koide T, 1999, J BIOL CHEM, V274, P34523, DOI 10.1074/jbc.274.49.34523; Koide T, 2000, J BIOL CHEM, V275, P27957; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; Li SH, 1999, CIRC RES, V85, P338, DOI 10.1161/01.RES.85.4.338; Li SH, 2001, CIRC RES, V89, P517, DOI 10.1161/hh1801.097165; Macdonald JR, 2001, J BIOL CHEM, V276, P25399, DOI 10.1074/jbc.M102471200; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; Nagai N, 1999, GENE, V227, P241, DOI 10.1016/S0378-1119(98)00592-7; Naitoh M, 2001, BIOCHEM BIOPH RES CO, V280, P1316, DOI 10.1006/bbrc.2001.4257; NAKAI A, 1992, J CELL BIOL, V117, P903, DOI 10.1083/jcb.117.4.903; NANDAN D, 1990, ARCH BIOCHEM BIOPHYS, V278, P291, DOI 10.1016/0003-9861(90)90263-X; NATSUME T, 1994, J BIOL CHEM, V269, P31224; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Razzaque MS, 1998, NEPHRON, V80, P434, DOI 10.1159/000045217; RENNARD SI, 1982, J INVEST DERMATOL, V79, pS77, DOI 10.1111/1523-1747.ep12545844; Rocnik E, 2000, CIRCULATION, V101, P1229, DOI 10.1161/01.CIR.101.11.1229; Rocnik E, 2001, ARTERIOSCL THROM VAS, V21, P40, DOI 10.1161/01.ATV.21.1.40; Rocnik EF, 1998, J CLIN INVEST, V101, P1889, DOI 10.1172/JCI1025; SAGA S, 1987, J CELL BIOL, V105, P517, DOI 10.1083/jcb.105.1.517; Satoh M, 1996, J CELL BIOL, V133, P469, DOI 10.1083/jcb.133.2.469; Sauk JJ, 1998, CONNECT TISSUE RES, V37, P105, DOI 10.3109/03008209809028904; SAUK JJ, 1994, J BIOL CHEM, V269, P3941; SUDBECK BD, 1994, J BIOL CHEM, V269, P30022; Tasab M, 2000, EMBO J, V19, P2204, DOI 10.1093/emboj/19.10.2204; Tomita M, 1999, J BIOCHEM, V126, P1118, DOI 10.1093/oxfordjournals.jbchem.a022557; TSCHANK G, 1991, BIOCHEM J, V275, P469, DOI 10.1042/bj2750469; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wilson R, 1998, J BIOL CHEM, V273, P9637, DOI 10.1074/jbc.273.16.9637	51	49	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38571	38578		10.1074/jbc.M206689200	http://dx.doi.org/10.1074/jbc.M206689200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12163502	hybrid			2022-12-27	WOS:000178529600074
J	Tanaka, T; Mizukoshi, T; Taniyama, C; Kohda, D; Arai, K; Masai, H				Tanaka, T; Mizukoshi, T; Taniyama, C; Kohda, D; Arai, K; Masai, H			DNA binding of PriA protein requires cooperation of the N-terminal D-loop/arrested-fork binding and C-terminal helicase domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; DEPENDENT ATPASE ACTIVITY; REPLICATION FACTOR-Y; HOMOLOGOUS RECOMBINATION; PHI-X174-TYPE PRIMOSOME; GENETIC-ANALYSIS; STRAND SYNTHESIS; D-LOOPS; INITIATION; MUTANTS	PriA protein is essential for RecA-dependent DNA replication induced by stalled replication forks in Escherichia coli. PriA is a DEXH-type DNA helicase, ATPase activity of which depends on its binding to structured DNA including a D-loop-like structure. Here, we show that the N-terminal 181-amino acid polypeptide can form a complex with D-loop in gel shift assays and have identified a unique motif present in the N-terminal segment of PriA that plays a role in its DNA binding. We have also identified residues in the C terminus proximal helicase domain essential for D-loop binding. PriA proteins mutated in this domain do not bind to D-loop, despite the presence of the N-terminal DNA-binding motif. Those mutants that cannot bind to D-loop in vitro do not support a recombination-dependent mode of DNA replication in vivo, indicating that binding to a D-loop-like structure is essential for the ability of PriA to initiate DNA replication and repair from stalled replication forks. We propose that binding of the PriA protein to stalled replication forks requires proper configuration of the N-terminal fork-recognition and C-terminal helicase domains and that the latter may stabilize binding and increase binding specificity.	Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, Tokyo 1138613, Japan; Univ Tokyo, Inst Med Sci, Dept Mol & Dev Biol, Tokyo 1088639, Japan; Biomol Engn Res Inst, Suita, Osaka 5650874, Japan; JST, CREST, Tokyo 1088639, Japan	Tokyo Metropolitan Institute of Medical Science; University of Tokyo; Japan Science & Technology Agency (JST)	Masai, H (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Cell Biol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.		Kohda, Daisuke/I-4990-2019	Kohda, Daisuke/0000-0001-8234-3776				AlDeib AA, 1996, J BACTERIOL, V178, P6782, DOI 10.1128/jb.178.23.6782-6789.1996; ASAI T, 1993, EMBO J, V12, P3287, DOI 10.1002/j.1460-2075.1993.tb05998.x; ASAI T, 1994, J BACTERIOL, V176, P1807, DOI 10.1128/jb.176.7.1807-1812.1994; Gregg AV, 2002, MOL CELL, V9, P241, DOI 10.1016/S1097-2765(02)00455-0; HONG XK, 1993, J BACTERIOL, V175, P6731, DOI 10.1128/jb.175.20.6731-6734.1993; IMBER R, 1983, P NATL ACAD SCI-BIOL, V80, P7132, DOI 10.1073/pnas.80.23.7132; Jones JM, 1997, EMBO J, V16, P6886, DOI 10.1093/emboj/16.22.6886; Jones JM, 1999, J MOL BIOL, V289, P503, DOI 10.1006/jmbi.1999.2783; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; KOGOMA T, 1986, J BACTERIOL, V166, P361, DOI 10.1128/jb.166.2.361-363.1986; Kogoma T, 1996, J BACTERIOL, V178, P1258, DOI 10.1128/jb.178.5.1258-1264.1996; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE EH, 1990, P NATL ACAD SCI USA, V87, P4620, DOI 10.1073/pnas.87.12.4620; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; Liu J, 1996, J BIOL CHEM, V271, P15656, DOI 10.1074/jbc.271.26.15656; Liu JI, 1999, P NATL ACAD SCI USA, V96, P3552, DOI 10.1073/pnas.96.7.3552; LLOYD RG, 1991, J BACTERIOL, V173, P1004, DOI 10.1128/jb.173.3.1004-1011.1991; LLOYD RG, 1991, J BACTERIOL, V173, P5414, DOI 10.1128/jb.173.17.5414-5418.1991; MAGEE TR, 1990, J BACTERIOL, V172, P1834, DOI 10.1128/jb.172.4.1834-1839.1990; Mahdi AA, 1997, NUCLEIC ACIDS RES, V25, P3875, DOI 10.1093/nar/25.19.3875; MASAI H, 1989, J BIOL CHEM, V264, P8082; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; MASAI H, 1988, J BIOL CHEM, V263, P15016; Masai H, 1999, BIOCHIMIE, V81, P847, DOI 10.1016/S0300-9084(99)00211-4; McCool JD, 2001, P NATL ACAD SCI USA, V98, P8203, DOI 10.1073/pnas.121007698; McGlynn P, 1997, J MOL BIOL, V270, P212, DOI 10.1006/jmbi.1997.1120; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MIRANDE M, 1988, J BIOL CHEM, V263, P18443; NOMURA N, 1991, GENE, V108, P15; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; Nurse P, 1999, J BIOL CHEM, V274, P25026, DOI 10.1074/jbc.274.35.25026; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; OUZOUNIS CA, 1991, NUCLEIC ACIDS RES, V19, P6953, DOI 10.1093/nar/19.24.6953; Polard P, 2002, NUCLEIC ACIDS RES, V30, P1593, DOI 10.1093/nar/30.7.1593; Sandler SJ, 2000, GENETICS, V155, P487; Sandler SJ, 1996, GENETICS, V143, P5; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; SHLOMAI J, 1980, J BIOL CHEM, V255, P6794; Singleton MR, 2001, CELL, V107, P79, DOI 10.1016/S0092-8674(01)00501-3; TORREY TA, 1987, MOL GEN GENET, V208, P420, DOI 10.1007/BF00328133; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P3342, DOI 10.1073/pnas.72.9.3342; ZAVITZ KH, 1993, J BIOL CHEM, V268, P4337; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933; ZIPURSKY SL, 1980, P NATL ACAD SCI-BIOL, V77, P6521, DOI 10.1073/pnas.77.11.6521; ZIPURSKY SL, 1981, P NATL ACAD SCI-BIOL, V78, P6111, DOI 10.1073/pnas.78.10.6111	46	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38062	38071		10.1074/jbc.M204397200	http://dx.doi.org/10.1074/jbc.M204397200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12151393	hybrid			2022-12-27	WOS:000178529600013
J	Kinsella, TM; Ohashi, CT; Harder, AG; Yam, GC; Li, WQ; Peelle, B; Pali, ES; Bennett, MK; Molineaux, SM; Anderson, DA; Masuda, ES; Payan, DG				Kinsella, TM; Ohashi, CT; Harder, AG; Yam, GC; Li, WQ; Peelle, B; Pali, ES; Bennett, MK; Molineaux, SM; Anderson, DA; Masuda, ES; Payan, DG			Retrovirally delivered random cyclic peptide libraries yield inhibitors of interleukin-4 signaling in human B cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; IGE	Inteins are polypeptide sequences found in a small set of primarily bacterial proteins that promote the splicing of Ranking pre-protein sequences to generate mature protein products. Inteins can be engineered in a "split and inverted" configuration such that the protein splicing product is a cyclic polypeptide consisting of the sequence linking two intein subdomains. We have engineered a split intein into a retroviral expression system to enable the intracellular delivery of a library of random cyclic peptides in human cells. Cyclization of peptides could be detected in cell lysates using mass spectrometry. A functional genetic screen to identify 5-amino acid-long cyclic peptides that block interleukin-4 mediated IgE class switching in B cells yielded 13 peptides that selectively inhibited germ line epsilon transcription. These results demonstrate the generation of cyclic peptide libraries in human cells and the power of functional screening to rapidly identify biologically active peptides.	Rigel Inc, San Francisco, CA 94080 USA		Payan, DG (corresponding author), Rigel Inc, 240 E Grand Ave, San Francisco, CA 94080 USA.	dgpayan@rigel.com		Masuda, Esteban/0000-0002-3175-2868				Evans TC, 2000, J BIOL CHEM, V275, P9091, DOI 10.1074/jbc.275.13.9091; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Lorens JB, 2000, MOL THER, V1, P438, DOI 10.1006/mthe.2000.0063; Lorens JB, 2001, CURR OPIN BIOTECH, V12, P613, DOI 10.1016/S0958-1669(01)00269-5; Losman JA, 1999, J IMMUNOL, V162, P3770; Monticelli S, 2001, ALLERGY, V56, P270, DOI 10.1034/j.1398-9995.2001.00129.x; Oettgen HC, 2001, J ALLERGY CLIN IMMUN, V107, P429, DOI 10.1067/mai.2001.113759; Peelle B, 2001, J PROTEIN CHEM, V20, P507, DOI 10.1023/A:1012514715338; Peelle B, 2001, CHEM BIOL, V8, P521, DOI 10.1016/S1074-5521(01)00031-X; Perler FB, 2000, CURR OPIN BIOTECH, V11, P377, DOI 10.1016/S0958-1669(00)00113-0; RYAN MD, 1991, J GEN VIROL, V72, P2727, DOI 10.1099/0022-1317-72-11-2727; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; Schreiber SL, 2000, SCIENCE, V287, P1964, DOI 10.1126/science.287.5460.1964; Scott CP, 1999, P NATL ACAD SCI USA, V96, P13638, DOI 10.1073/pnas.96.24.13638; Scott CP, 2001, CHEM BIOL, V8, P801, DOI 10.1016/S1074-5521(01)00052-7; Stavnezer J, 2000, CURR TOP MICROBIOL, V245, P127; SWOFT SE, 1999, CURRENT PROTOCOLS IM, P1; Trabi M, 2002, TRENDS BIOCHEM SCI, V27, P132, DOI 10.1016/S0968-0004(02)02057-1; Vera MD, 2002, MED RES REV, V22, P102, DOI 10.1002/med.10003	19	76	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37512	37518		10.1074/jbc.M206162200	http://dx.doi.org/10.1074/jbc.M206162200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12167667	hybrid			2022-12-27	WOS:000178447100077
J	O'Brian, JJ; Ram, ML; Kiarash, A; Cala, SE				O'Brian, JJ; Ram, ML; Kiarash, A; Cala, SE			Mass spectrometry of cardiac calsequestrin characterizes microheterogeneity unique to heart and indicative of complex intracellular transit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; RAT SKELETAL-MUSCLE; CASEIN KINASE-II; CLATHRIN-COATED VESICLES; AMINO-ACID SEQUENCE; RYANODINE RECEPTOR; ENDOPLASMIC-RETICULUM; PHOSPHORYLATION SITE; MOLECULAR-CLONING; RELEASE CHANNEL	Cardiac calsequestrin concentrates in junctional sarcoplasmic reticulum in heart and skeletal muscle cells by an undefined mechanism. During transit through the secretory pathway, it undergoes an as yet uncharacterized glycosylation and acquires phosphate on CK2-sensitive sites. In this study, we have shown that active calsequestrin phosphorylation occurred in nonmuscle cells as well as muscle cells, reflecting a widespread cellular process. To characterize this post-translational modification and resolve individual molecular mass species, we subjected purified calsequestrin to mass spectrometry using electrospray ionization. Mass spectra showed that calsequestrin glycan structure in nonmuscle cells was that expected for an endoplasmic reticulum-localized glycoprotein and showed that each glycoform existed as four mass peaks representing molecules that also had 0-3 phosphorylation sites occupied. In heart, mass peaks indicated carbohydrate modifications characteristic of transit through Golgi compartments. Phosphorylation did not occur on every glycoform present, suggesting a far more complex movement of calsequestrin molecules in heart cells. Significant amounts of calsequestrin contained glycan with only a single mannose residue, indicative of a novel post-endoplasmic reticulum mannosidase activity. In conclusion, glyco- and phosphoforms of calsequestrin chart a complex cellular transport in heart, with calsequestrin following trafficking pathways not present or not accessible to the same molecules in nonmuscle.	Wayne State Univ, Dept Med, Program Mol & Cellular Cardiol, Detroit, MI 48201 USA	Wayne State University	Cala, SE (corresponding author), Wayne State Univ, Dept Med, Program Mol & Cellular Cardiol, Elliman Bldg,Rm 1107,421 E Canfield Ave, Detroit, MI 48201 USA.	s.cala@wayne.edu			NHLBI NIH HHS [R01 HL062586, HL62586] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062586] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alconada A, 1996, EMBO J, V15, P6096, DOI 10.1002/j.1460-2075.1996.tb00998.x; CAIN SE, 2000, BIOCHIM BIOPHYS ACTA, V1496, P296; Cala S E, 1990, Semin Cell Biol, V1, P265; CALA SE, 1983, J BIOL CHEM, V258, P1932; CALA SE, 1991, J BIOL CHEM, V266, P391; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1197; CAMPBELL KP, 1980, BIOCHIM BIOPHYS ACTA, V602, P97, DOI 10.1016/0005-2736(80)90293-X; DAMIANI E, 1990, J MUSCLE RES CELL M, V11, P522, DOI 10.1007/BF01745219; FLIEGEL L, 1989, BIOCHEM CELL BIOL, V67, P696, DOI 10.1139/o89-104; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; FRANZINIARMSTRONG C, 1980, FED PROC, V39, P2403; FRANZINIARMSTRONG C, 1975, FED PROC, V34, P1382; Gatti G, 2001, J CELL BIOL, V154, P525, DOI 10.1083/jcb.200103002; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; JORGENSEN AO, 1979, J CELL BIOL, V80, P372, DOI 10.1083/jcb.80.2.372; JORGENSEN AO, 1977, J CELL BIOL, V74, P287, DOI 10.1083/jcb.74.1.287; JORGENSEN AO, 1983, J CELL BIOL, V97, P1573, DOI 10.1083/jcb.97.5.1573; Kobayashi YM, 1999, J BIOL CHEM, V274, P28660, DOI 10.1074/jbc.274.40.28660; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU YH, 1977, J BIOL CHEM, V252, P5565; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; MEGGIO F, 1984, EUR J BIOCHEM, V138, P379, DOI 10.1111/j.1432-1033.1984.tb07926.x; MEISSNER G, 1975, BIOCHIM BIOPHYS ACTA, V389, P51, DOI 10.1016/0005-2736(75)90385-5; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Nori A, 1997, AM J PHYSIOL-CELL PH, V272, pC1420, DOI 10.1152/ajpcell.1997.272.5.C1420; Nori A, 1999, AM J PHYSIOL-CELL PH, V277, pC974, DOI 10.1152/ajpcell.1999.277.5.C974; Nori A, 2000, EXP CELL RES, V260, P40, DOI 10.1006/excr.2000.4989; OTSU K, 1990, J BIOL CHEM, V265, P13472; Petersen CM, 1997, J BIOL CHEM, V272, P3599, DOI 10.1074/jbc.272.6.3599; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUBERT U, 1994, J MOL BIOL, V236, P16, DOI 10.1006/jmbi.1994.1114; SCOTT BT, 1988, J BIOL CHEM, V263, P8958; SEILER S, 1984, J BIOL CHEM, V259, P8550; STRUCK DK, 1977, J BIOL CHEM, V252, P1007; THOMAS K, 1989, J BIOL CHEM, V264, P3140; Waites CL, 2001, J CELL BIOL, V152, P1159, DOI 10.1083/jcb.152.6.1159; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WAUGH RA, 1974, J CELL BIOL, V63, P337, DOI 10.1083/jcb.63.1.337; YANO K, 1994, MOL CELL BIOCHEM, V135, P61, DOI 10.1007/BF00925961; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389; ZUBRZYCKA E, 1976, J BIOL CHEM, V251, P7733	50	23	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37154	37160		10.1074/jbc.M204370200	http://dx.doi.org/10.1074/jbc.M204370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147690	hybrid			2022-12-27	WOS:000178447100033
J	Poelarends, GJ; Konings, WN				Poelarends, GJ; Konings, WN			The transmembrane domains of the ABC multidrug transporter LmrA form a cytoplasmic exposed, aqueous chamber within the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESISTANCE P-GLYCOPROTEIN; CYSTEINE-SCANNING MUTAGENESIS; LACTOCOCCUS-LACTIS; BINDING; GENE; ACCESSIBILITY; SPECTROSCOPY; EXPRESSION; REVEALS; SYSTEMS	The ABC multidrug transporter LmrA of Lactococcus lactis consists of six putative transmembrane segments (TMS) and a nucleotide binding domain. LmrA functions as a homodimer in which the two membrane domains form the solute translocation path across the membrane. To obtain structural information of LmrA a cysteine scanning accessibility approach was used. Cysteines were introduced in the cysteine-less wild-type LmrA in each hydrophilic loop and in TMS 6, and each membrane-embedded aromatic residue was mutated to cysteine. Of the 41 constructed single cysteine mutants, only one mutant, L301C, was not expressed. Most single-cysteine mutants were capable of drug transport and only three mutants, F37C, M299C, and N300C, were inactive, indicating that none of the aromatic residues in the transmembrane regions of LmrA are crucial for substrate binding or transport. Modification of the active mutants with N-ethylmaleimide blocked the transport activity in five mutants (S132C, L174C, S206C, S234C, and L292C). All cysteine residues in external and internal loops were accessible to fluorescein maleimide. The labeling experiments also showed that this thiol reagent cannot cross the membrane under the conditions used and confirmed the presence of six TMSs in each monomeric half of the transporter. Surprisingly, several single cysteines in the predicted TMSs could also be labeled by the bulky fluorescein maleimide molecule, suggesting unrestricted accessibility via an aqueous pathway. The periodicity of fluorescein maleimide accessibility of residues 291 to 308 in TMS 6 showed that this membrane-spanning a-helix has one face of the helix exposed to an aqueous cavity along its full-length. This finding, together with the solvent accessibility of 11 of 15 membrane-embedded aromatic residues, indicates that the transmembrane domains of the LmrA transporter form, under nonenergized conditions, an aqueous chamber within the membrane, which is open to the intracellular milieu.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Konings, WN (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.	w.n.konings@biol.rug.nl	Konings, Wilhelmus N./C-7063-2013	Poelarends, Gerrit/0000-0002-6917-6368				Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996; GOTTESMAN MM, 1993, CANCER RES, V53, P747; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; Grimard V, 2001, BIOCHEMISTRY-US, V40, P11876, DOI 10.1021/bi010017+; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Joseph-Liauzun E, 1998, J BIOL CHEM, V273, P2146, DOI 10.1074/jbc.273.4.2146; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Loo TW, 1999, BBA-BIOMEMBRANES, V1461, P315, DOI 10.1016/S0005-2736(99)00165-0; Loo TW, 2001, J BIOL CHEM, V276, P14972, DOI 10.1074/jbc.M100407200; Loo TW, 2000, J BIOL CHEM, V275, P39272, DOI 10.1074/jbc.M007741200; Margolles A, 1999, BIOCHEMISTRY-US, V38, P16298, DOI 10.1021/bi990855s; Meuller J, 1999, J BIOL CHEM, V274, P19072, DOI 10.1074/jbc.274.27.19072; Mordoch SS, 1999, J BIOL CHEM, V274, P19480, DOI 10.1074/jbc.274.27.19480; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; PAWAGI AB, 1994, J MOL BIOL, V235, P554, DOI 10.1006/jmbi.1994.1013; Poelarends GJ, 2000, DRUG RESIST UPDATE, V3, P330, DOI 10.1054/drup.2000.0173; POELARENDS GJ, 2002, ABC PROTEINS BACTERI, P243; Putman M, 2000, MICROBIOL MOL BIOL R, V64, P672, DOI 10.1128/MMBR.64.4.672-693.2000; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Shapiro AB, 1997, EUR J BIOCHEM, V250, P122, DOI 10.1111/j.1432-1033.1997.00122.x; Slotboom DJ, 2001, J BIOL CHEM, V276, P10775, DOI 10.1074/jbc.M011064200; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; van Veen HW, 1998, NATURE, V391, P291, DOI 10.1038/34669; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; Vigano C, 2000, J BIOL CHEM, V275, P10962, DOI 10.1074/jbc.275.15.10962; ZHOU JD, 1995, J MOL BIOL, V251, P237, DOI 10.1006/jmbi.1995.0431	30	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 8	2002	277	45					42891	42898		10.1074/jbc.M206508200	http://dx.doi.org/10.1074/jbc.M206508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	612MZ	12183459	hybrid			2022-12-27	WOS:000179081200062
J	Richter, W; Conti, M				Richter, W; Conti, M			Dimerization of the type 4 cAMP-specific phosphodiesterases is mediated by the upstream conserved regions (UCRs)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; PROTEIN-KINASE; CATALYTIC DOMAIN; PHOSPHORYLATION; BINDING; ACTIVATION; INTERACTS; PDE4; IDENTIFICATION; PURIFICATION	The cAMP-specific PDE4 family consists of four genes, each expressed as several splice variants. These variants are termed long and short forms depending on the presence or absence of two unique N-terminal domains called upstream conserved regions 1 and 2 (UCR1 and 2). UCR1 and UCR2 have been shown to form a module necessary for the activation of PDE4 upon phosphorylation by the cAMP-dependent kinase (PKA). Here we have uncovered PDE4 oligomerization as a novel function for the UCR1/UCR2 module. Using several different approaches including gel filtration, sucrose density gradient centrifugation, pull-down of differentially tagged PDE constructs, and yeast two-hybrid assay, we show that the long PDE4 splice variant PDE4D3 behaves as a dimer, whereas the short splice variant PDE4D2 is a monomer. Internal deletions of either the C-terminal portion of UCR1 or the N-terminal portion of UCR2 abolishes dimerization of PDE4D3 indicating that both domains are involved in this intermolecular interaction. The dimerization, however, is structurally distinguishable from a previously described intramolecular interaction involving the same domains. PKA phosphorylation and site-directed mutagenesis shown to ablate the latter do not interfere with dimerization. Therefore, dimerization of the long PDE4 forms may be an additional function of the UCR domains that further explains differences in the regulatory properties between the long and short PDE4 splice variants.	Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, Stanford, CA 94305 USA	Stanford University	Conti, M (corresponding author), Stanford Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Biol, 300 Pasteur Dr, Stanford, CA 94305 USA.	marco.conti@stanford.edu		Richter, Wito/0000-0001-5588-9060	NICHD NIH HHS [HD 20788] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ahmad F, 2000, J IMMUNOL, V164, P4678, DOI 10.4049/jimmunol.164.9.4678; Beard MB, 2000, J BIOL CHEM, V275, P10349, DOI 10.1074/jbc.275.14.10349; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bolger GB, 1997, BIOCHEM J, V328, P539; Chu DM, 1997, J BIOL CHEM, V272, P31922, DOI 10.1074/jbc.272.50.31922; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Fink TL, 1999, J BIOL CHEM, V274, P34613, DOI 10.1074/jbc.274.49.34613; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; Francis SH, 1998, METHODS, V14, P81, DOI 10.1006/meth.1997.0567; Grange M, 2000, J BIOL CHEM, V275, P33379, DOI 10.1074/jbc.M006329200; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Houslay MD, 2001, PROG NUCLEIC ACID RE, V69, P249, DOI 10.1016/S0079-6603(01)69049-4; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; Kenan Y, 2000, J BIOL CHEM, V275, P12331, DOI 10.1074/jbc.275.16.12331; Kovala T, 1997, BIOCHEMISTRY-US, V36, P2968, DOI 10.1021/bi9613483; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lario PL, 2001, ARCH BIOCHEM BIOPHYS, V394, P54, DOI 10.1006/abbi.2001.2513; Lim J, 1999, J BIOL CHEM, V274, P19677, DOI 10.1074/jbc.274.28.19677; MacKenzie SJ, 2000, J BIOL CHEM, V275, P16609, DOI 10.1074/jbc.275.22.16609; MANGANIELLO VC, 1995, ARCH BIOCHEM BIOPHYS, V322, P1, DOI 10.1006/abbi.1995.1429; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; Nemoz G, 1996, FEBS LETT, V384, P97, DOI 10.1016/0014-5793(96)00300-6; OConnell JC, 1996, BIOCHEM J, V318, P255, DOI 10.1042/bj3180255; Rich TC, 2001, P NATL ACAD SCI USA, V98, P13049, DOI 10.1073/pnas.221381398; Richter W, 2000, PROTEIN EXPRES PURIF, V19, P375, DOI 10.1006/prep.2000.1260; Rocque WJ, 1997, PROTEIN EXPRES PURIF, V9, P191, DOI 10.1006/prep.1996.0683; Saldou Natalie, 1998, Cell Biochemistry and Biophysics, V28, P187, DOI 10.1007/BF02737811; Sette C, 1996, J BIOL CHEM, V271, P16526, DOI 10.1074/jbc.271.28.16526; Shakur Y, 2000, J BIOL CHEM, V275, P38749, DOI 10.1074/jbc.M001734200; SHARMA RK, 1986, J BIOL CHEM, V261, P1322; SIEGEL LM, 1966, BIOCHIM BIOPHYS ACTA, V112, P346, DOI 10.1016/0926-6585(66)90333-5; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; Tcheudji JFK, 2001, J MOL BIOL, V310, P781, DOI 10.1006/jmbi.2001.4813; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Verde I, 2001, J BIOL CHEM, V276, P11189, DOI 10.1074/jbc.M006546200; Xu RX, 2000, SCIENCE, V288, P1822, DOI 10.1126/science.288.5472.1822; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Zaccolo M, 2002, CURR OPIN CELL BIOL, V14, P160, DOI 10.1016/S0955-0674(02)00316-2; Zaccolo M, 2002, SCIENCE, V295, P1711, DOI 10.1126/science.1069982	44	75	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40212	40221		10.1074/jbc.M203585200	http://dx.doi.org/10.1074/jbc.M203585200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12177055	hybrid			2022-12-27	WOS:000178791400009
J	Carr, KM; Kaguni, JM				Carr, KM; Kaguni, JM			Escherichia coli DnaA protein loads a single DnaB helicase at a DnaA box hairpin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BINDING-PROTEIN; N-TERMINAL DOMAIN; REPLICATION-FORK; CHROMOSOMAL ORIGIN; GENE-PRODUCT; PHYSICAL-PROPERTIES; NUCLEIC-ACIDS; ABC-PRIMOSOME; COMPLEX; INITIATION	The molecular engine that drives bidirectional replication fork movement from the Escherichia coli replication origin (oriC) is the replicative helicase, DnaB. At oriC, two and only two helicase molecules are loaded, one for each replication fork. DnaA participates in helicase loading; DnaC is also involved, because it must be in a complex with DnaB for delivery of the helicase. Since DnaA induces a local unwinding of oriC, one model is that the limited availability of single-stranded DNA at oriC restricts the number of DnaB molecules that can bind. In this report, we determined that one DnaB helicase or one DnaB-DnaC complex is bound to a single-stranded DNA in a biologically relevant DNA replication system. These results indicate that the availability of single-stranded DNA is not a limiting factor and support a model in which the site of entry for DnaB is altered so that it cannot be reused. We also show that 2-4 DnaA monomers are bound on the single-stranded DNA at a specific site that carries a DnaA box sequence in a hairpin structure.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Kaguni, JM (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.			Kaguni, Jon/0000-0002-3096-4447	NIGMS NIH HHS [GM33992, R01 GM033992] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAI K, 1981, J BIOL CHEM, V256, P5247; BAKER TA, 1987, J BIOL CHEM, V262, P6877; Barcena M, 2001, EMBO J, V20, P1462, DOI 10.1093/emboj/20.6.1462; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; BUJALOWSKI W, 1987, J MOL BIOL, V195, P897, DOI 10.1016/0022-2836(87)90493-1; Carr KM, 2001, J BIOL CHEM, V276, P44919, DOI 10.1074/jbc.M107463200; Chang P, 2000, J BIOL CHEM, V275, P26187, DOI 10.1074/jbc.M001800200; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; Donate LE, 2000, J MOL BIOL, V303, P383, DOI 10.1006/jmbi.2000.4132; Fang LH, 1999, MOL CELL, V4, P541, DOI 10.1016/S1097-2765(00)80205-1; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; FUNNELL BE, 1987, J BIOL CHEM, V262, P10327; GILLE H, 1991, EMBO J, V10, P1579, DOI 10.1002/j.1460-2075.1991.tb07678.x; HU GX, 1993, DNA CELL BIOL, V12, P763, DOI 10.1089/dna.1993.12.763; Jezewska MJ, 1997, BIOCHEMISTRY-US, V36, P10320, DOI 10.1021/bi970712a; Jezewska MJ, 1998, BIOCHEMISTRY-US, V37, P3116, DOI 10.1021/bi972564u; Jezewska MJ, 1996, BIOCHEMISTRY-US, V35, P2129, DOI 10.1021/bi952345d; Jezewska MJ, 1998, J BIOL CHEM, V273, P10515, DOI 10.1074/jbc.273.17.10515; Kaguni JM, 1997, MOL CELLS, V7, P145; Kaplan DL, 2000, J MOL BIOL, V301, P285, DOI 10.1006/jmbi.2000.3965; Katayama T, 1995, MOL MICROBIOL, V18, P813, DOI 10.1111/j.1365-2958.1995.18050813.x; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; Kozlov AG, 2002, BIOCHEMISTRY-US, V41, P6032, DOI 10.1021/bi020122z; LANKA E, 1983, NUCLEIC ACIDS RES, V11, P987, DOI 10.1093/nar/11.4.987; LOHMAN TM, 1994, BIOCHEMISTRY-US, V33, P6167, DOI 10.1021/bi00186a016; Lu YB, 1996, P NATL ACAD SCI USA, V93, P12902, DOI 10.1073/pnas.93.23.12902; Ludlam AV, 2001, J BIOL CHEM, V276, P27345, DOI 10.1074/jbc.M101940200; Marszalek J, 1996, J BIOL CHEM, V271, P18535, DOI 10.1074/jbc.271.31.18535; MARSZALEK J, 1994, J BIOL CHEM, V269, P4883; MARSZALEK J, 1992, J BIOL CHEM, V267, P19334; MASAI H, 1995, EUR J BIOCHEM, V230, P384; MASAI H, 1990, J BIOL CHEM, V265, P15134; Messer W., 1996, ESCHERICHIA COLI SAL, V2nd ed., P1579; NAKAYAMA N, 1984, J BIOL CHEM, V259, P88; NOMURA N, 1991, GENE, V108, P15; OVERMAN LB, 1988, BIOCHEMISTRY-US, V27, P456, DOI 10.1021/bi00401a067; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; SantaLucia J, 1998, P NATL ACAD SCI USA, V95, P1460, DOI 10.1073/pnas.95.4.1460; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7124; SUN WL, 1993, J BIOL CHEM, V268, P8026; Sun WL, 1996, J BACTERIOL, V178, P6701, DOI 10.1128/jb.178.23.6701-6705.1996; Sutton MD, 1998, J BIOL CHEM, V273, P34255, DOI 10.1074/jbc.273.51.34255; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921	48	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39815	39822		10.1074/jbc.M205031200	http://dx.doi.org/10.1074/jbc.M205031200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12161435	hybrid			2022-12-27	WOS:000178662500097
J	Huang, JH; Zhao, Q; Mooney, SM; Lee, FS				Huang, JH; Zhao, Q; Mooney, SM; Lee, FS			Sequence determinants in hypoxia-inducible factor-1 alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIF-ALPHA; DEGRADATION DOMAIN; FACTOR 1-ALPHA; PROTEIN; VHL; HIF-1-ALPHA; COMPLEX; BINDING; SYSTEM; OXYGEN	Hypoxia-inducible factor (HIF) is a heterodimeric transcription factor induced by hypoxia. Under normoxic conditions, site-specific proline hydroxylation of the alpha subunits of HIF allows recognition by the von Hippel-Lindau tumor suppressor protein (VHL), a component of an E3 ubiquitin ligase complex that targets these subunits for degradation by the ubiquitin-proteasome pathway. Under hypoxic conditions, this hydroxylation is inhibited, allowing the a subunits of HIF to escape VHL-mediated degradation. Three enzymes, prolyl hydroxylase domain-containing proteins 1, 2, and 3 (PHD1, -2, and -3; also known as HIF prolyl hydroxylase 3, 2, and 1, respectively), have recently been identified that catalyze proline hydroxylation of HIF a subunits. These enzymes hydroxylate specific prolines in HIF a subunits in the context of a strongly conserved LXXLAP sequence motif (where X indicates any amino acid and P indicates the hydroxylacceptor proline). We report here that PHD2 has the highest specific activity toward the primary hydroxylation site of HIF-lalpha. Furthermore, and unexpectedly, mutations can be tolerated at the - 5, -2, and - 1 positions (relative to proline) of the LXXLAP motif. Thus, these results provide evidence that the only obligatory residue for proline hydroxylation in HIF-1a is the hydroxylacceptor proline itself.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs 605, Philadelphia, PA 19104 USA	University of Pennsylvania	Lee, FS (corresponding author), Univ Penn, Sch Med, Dept Pathol & Lab Med, Stellar Chance Labs 605, 422 Curie Blvd, Philadelphia, PA 19104 USA.	franklee@mail.med.upenn.edu		Lee, Frank/0000-0003-2511-1834	NCI NIH HHS [R01 CA090261, R01-CA090261] Funding Source: Medline; NIDDK NIH HHS [R01-DK55672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Enslen H, 2001, BIOL CELL, V93, P5, DOI 10.1016/S0248-4900(01)01156-X; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hon WC, 2002, NATURE, V417, P975, DOI 10.1038/nature00767; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Kaelin WG, 2002, GENE DEV, V16, P1441, DOI 10.1101/gad.1003602; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lipscomb EA, 2001, J BIOL CHEM, V276, P5085, DOI 10.1074/jbc.M008407200; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Marchetti S, 2002, J CELL SCI, V115, P2075; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Maxwell PH, 2001, ADV EXP MED BIOL, V502, P365; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; McNeill LA, 2002, BIOORG MED CHEM LETT, V12, P1547, DOI 10.1016/S0960-894X(02)00219-6; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Schofield CJ, 1999, CURR OPIN STRUC BIOL, V9, P722, DOI 10.1016/S0959-440X(99)00036-6; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Srinivas V, 1999, BIOCHEM BIOPH RES CO, V260, P557, DOI 10.1006/bbrc.1999.0878; Tan S, 2001, PROTEIN EXPRES PURIF, V21, P224, DOI 10.1006/prep.2000.1363; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Taylor MS, 2001, GENE, V275, P125, DOI 10.1016/S0378-1119(01)00633-3; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tyers M, 1999, P NATL ACAD SCI USA, V96, P12230, DOI 10.1073/pnas.96.22.12230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; West CM, 2002, GLYCOBIOLOGY, V12, p17R, DOI 10.1093/glycob/12.2.17R; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Yu F, 2001, CANCER RES, V61, P4136	46	247	255	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39792	39800		10.1074/jbc.M206955200	http://dx.doi.org/10.1074/jbc.M206955200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12181324	Green Accepted, hybrid			2022-12-27	WOS:000178662500094
J	Egawa, K; Maegawa, H; Shi, K; Nakamura, T; Obata, T; Yoshizaki, T; Morino, K; Shimizu, S; Nishio, Y; Suzuki, E; Kashiwagi, A				Egawa, K; Maegawa, H; Shi, K; Nakamura, T; Obata, T; Yoshizaki, T; Morino, K; Shimizu, S; Nishio, Y; Suzuki, E; Kashiwagi, A			Membrane localization of 3-phosphoinositide-dependent protein kinase-1 stimulates activities of Akt and atypical protein kinase C but does not stimulate glucose transport and glycogen synthesis in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUT4 TRANSLOCATION; IN-VIVO; INSULIN; ACTIVATION; PHOSPHORYLATION; 3-KINASE; RAF; REQUIREMENT; INHIBITION; EXPRESSION	It is reported that 3-phosphoinositide-dependent protein kinase-1 (PDK-1) is activated in a phosphatidylinositol 3,4,5-trisphosphate-dependent manner and phosphorylates Akt, p70S6 kinase, and atypical protein kinase C (PKC), but its function on insulin signaling is still unclear. We cloned a full-length pdk-1 cDNA from a human brain cDNA library, and the adenovirus to overexpress wild type PDK-1 (PDK-1WT) or membrane-targeted PDK-1 (PDK-1CAAX) was constructed. Overexpressed PDK-1WT existed mainly at cytosol, and PDK-1CAAX was located at the plasma membrane. In 3T3-L1 adipocytes, insulin induced mobility shift of PDk-1 protein, but overexpressed PDK-1WT and CAAX were shifted at the basal state. Insulin stimulated tyrosine phosphorylation of PDK-1WT, but PDK-1CAAX was already tyrosine-phosphorylated at the basal state. Overexpression of PDK-1WT led to a full activation of PKCzeta/lambda without insulin stimulation but showed only the minimum effects to stimulate phosphorylation of Akt and GSK-3. In contrast, the overexpression of PDK-1CAAX caused phosphorylation of Akt and GSK-3 more strongly without insulin stimulation. However, PDK-1CAAX did not affect 2-deoxyglucose uptake and inhibited glycogen synthesis, surprisingly. Finally, PDK-1CAAX expression inhibited insulin-induced ERK1/2 phosphorylation in a dose-dependent manner. Taken together, the translocation of PDK-1 from cytosol to the plasma membrane is critical for Akt and GSK-3 activation. On the other hand, only atypical PKC and Akt activation was insufficient for stimulation of glucose transport, and constitutive activation of Akt-GSK-3 pathway may inhibit glycogen synthesis and MAPK cascade in 3T3-L1 adipocytes.	Shiga Univ Med Sci, Dept Med 3, Shiga 5202192, Japan; Shiga Univ Med Sci, Dept Anat, Shiga 5202192, Japan	Shiga University of Medical Science; Shiga University of Medical Science	Maegawa, H (corresponding author), Shiga Univ Med Sci, Dept Med 3, Shiga 5202192, Japan.	maegawa@belle.shiga-med.ac.jp	Kashiwagi, Atsunori/H-8712-2019; MORINO, KATSUTARO/I-3207-2019	MORINO, KATSUTARO/0000-0003-2420-3817; Maegawa, Hiroshi/0000-0002-4611-8149				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; Bandyopadhyay G, 1999, MOL ENDOCRINOL, V13, P1766, DOI 10.1210/me.13.10.1766; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Egawa K, 2000, ENDOCRINOLOGY, V141, P1930, DOI 10.1210/en.141.6.1930; Guan KL, 2000, J BIOL CHEM, V275, P27354; HARUTA T, 1995, J BIOL CHEM, V270, P27991; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; KLIP A, 1984, AM J PHYSIOL, V247, pE291, DOI 10.1152/ajpendo.1984.247.3.E291; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V209, P343, DOI 10.1006/bbrc.1995.1509; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kotani K, 2000, J BIOL CHEM, V275, P26390, DOI 10.1074/jbc.M002537200; Morino K, 2001, ENDOCRINOLOGY, V142, P2669, DOI 10.1210/en.142.6.2669; Nagai Y, 2002, AM J PHYSIOL-ENDOC M, V282, pE1180, DOI 10.1152/ajpendo.00471.2001; Nakamura T, 2001, J CLIN ENDOCR METAB, V86, P1795, DOI 10.1210/jc.86.4.1795; Obata T, 2000, J BIOL CHEM, V275, P36108, DOI 10.1074/jbc.M005497200; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Sharma PM, 1997, MOL CELL BIOL, V17, P7386, DOI 10.1128/MCB.17.12.7386; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	32	28	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38863	38869		10.1074/jbc.M203132200	http://dx.doi.org/10.1074/jbc.M203132200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12147684	hybrid			2022-12-27	WOS:000178529600108
J	Elfering, SL; Sarkela, TM; Giulivi, C				Elfering, SL; Sarkela, TM; Giulivi, C			Biochemistry of mitochondrial nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; RAT-LIVER MITOCHONDRIA; FATTY-ACID ACYLATION; CELLULAR PROTEINS; MYRISTIC ACID; PHOSPHORYLATION; PURIFICATION; MYRISTOYLATION; IDENTIFICATION; MACROPHAGES	We reported that the generation of nitric oxide by mitochondria is catalyzed by a constitutive, mitochondrial nitric-oxide synthase (mtNOS). Given that this production may establish the basis for a novel regulatory pathway of energy metabolism, oxygen consumption, and oxygen free radical production, it becomes imperative to identify unequivocally and characterize this enzyme to provide a basis for its regulation. The mitochondrial localization of mtNOS was supported by following the hepatic distribution of mtNOS, immunoblotting submitochondrial fractions, and immunohistochemistry of liver tissues. mtNOS was identified as brain NOSalpha by various methods (mass spectrometry of proteolytic fragments, amino acid analysis, molecular weight, pI, and analysis of PCR fragments), excluding the occurrence of a novel isoform. or other splice variants. Distribution of mtNOS transcript indicated its occurrence in liver, brain, heart, muscle, kidney, lung, testis, and spleen. In contrast to brain NOS, mtNOS has two post-translational modifications: acylation with myristic acid and phosphorylation at the C terminus. The former modification is a reversible and post-translational process, which may serve for subcellular targeting or membrane anchoring. The latter modification could be linked to enzymatic regulation. These results are discussed in terms of the role that nitric oxide may have in cellular bioenergetics.	Univ Minnesota, Dept Chem, Duluth, MN 55812 USA	University of Minnesota System; University of Minnesota Duluth	Giulivi, C (corresponding author), Univ Minnesota, Dept Chem, 10 Univ Dr, Duluth, MN 55812 USA.	cgiulivi@d.umn.edu	Hu, Ruogu/B-2203-2008; Giulivi, Cecilia/AAV-6774-2021; Giulivi, Cecilia/ABB-7809-2020	Giulivi, Cecilia/0000-0003-1033-7435	NIEHS NIH HHS [ES011407-01] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R03ES011407] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ADAM M, 1984, J BIOL CHEM, V259, P5460; Bates TE, 1996, BIOCHEM BIOPH RES CO, V218, P40, DOI 10.1006/bbrc.1996.0008; BATES TE, 1995, BIOCHEM BIOPH RES CO, V213, P896, DOI 10.1006/bbrc.1995.2213; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; BREDT DS, 1992, J BIOL CHEM, V267, P10976; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1997, DEV NEUROSCI-BASEL, V19, P224, DOI 10.1159/000111211; BRUNE B, 1991, BIOCHEM BIOPH RES CO, V181, P921, DOI 10.1016/0006-291X(91)91279-L; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CHANCE B, 1963, 5 P INT C BIOCH USSR, V5, P3; CHEUNG CW, 1981, ARCH BIOCHEM BIOPHYS, V209, P643, DOI 10.1016/0003-9861(81)90324-6; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DOYLE MP, 1981, J INORG BIOCHEM, V14, P351, DOI 10.1016/S0162-0134(00)80291-3; FORSTERMANN U, 1992, EUR J PHARM-MOLEC PH, V225, P161, DOI 10.1016/0922-4106(92)90096-E; French S, 2001, AM J PHYSIOL-HEART C, V280, pH2863, DOI 10.1152/ajpheart.2001.280.6.H2863; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GAMBLE JG, 1973, J BIOL CHEM, V248, P610; GEISOW MJ, 1989, PROTEIN SEQUENCING P, P85; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giulivi C, 1999, FASEB J, V13, pA1554; Giulivi C, 1998, BIOCHEM J, V332, P673, DOI 10.1042/bj3320673; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; JAWORSKI JG, 1974, ARCH BIOCHEM BIOPHYS, V162, P166, DOI 10.1016/0003-9861(74)90115-5; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; KOBZIK L, 1995, BIOCHEM BIOPH RES CO, V211, P375, DOI 10.1006/bbrc.1995.1824; Kotake Y, 1996, METHOD ENZYMOL, V268, P222; Kotake Y, 1996, BBA-GEN SUBJECTS, V1289, P362, DOI 10.1016/0304-4165(95)00172-7; LIU JW, 1994, J BIOL CHEM, V269, P11691; Liu RM, 1998, AM J PHYSIOL-LUNG C, V274, pL330, DOI 10.1152/ajplung.1998.274.3.L330; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSTY CJ, 1978, EUR J BIOCHEM, V85, P373, DOI 10.1111/j.1432-1033.1978.tb12249.x; MAGEE AI, 1984, BIOCHIM BIOPHYS ACTA, V798, P156, DOI 10.1016/0304-4165(84)90298-8; MAGEE AI, 1982, BIOCHIM BIOPHYS ACTA, V694, P279, DOI 10.1016/0304-4157(82)90008-9; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Michell BJ, 2001, J BIOL CHEM, V276, P17625, DOI 10.1074/jbc.C100122200; MINEGOLOMB D, 1996, NITRIC OXIDE SYNTHAS, P173; MURPHY ME, 1994, METHOD ENZYMOL, V233, P240; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; NAKANE PK, 1996, NITRIC OXIDE SYNTHAS, P54; OGURA T, 1993, BIOCHEM BIOPH RES CO, V193, P1014, DOI 10.1006/bbrc.1993.1726; OLSON EN, 1986, J BIOL CHEM, V261, P2458; OLSON EN, 1985, J BIOL CHEM, V260, P3784; Pedersen P L, 1978, Methods Cell Biol, V20, P411, DOI 10.1016/S0091-679X(08)62030-0; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; RAIJMAN L, 1976, ARCH BIOCHEM BIOPHYS, V175, P270, DOI 10.1016/0003-9861(76)90508-7; REINHART PH, 1982, BIOCHEM J, V204, P731, DOI 10.1042/bj2040731; Sarkela TM, 2001, J BIOL CHEM, V276, P6945, DOI 10.1074/jbc.M007625200; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P1687, DOI 10.1073/pnas.76.4.1687; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; SIMON SM, 1992, J BIOL CHEM, V267, P3922; Steffen M, 2001, BIOCHEM J, V356, P395, DOI 10.1042/0264-6021:3560395; STUCKI JW, 1989, J BIOL CHEM, V264, P6376; STUEHR DJ, 1987, J IMMUNOL, V139, P518; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; TOWLER D, 1986, BIOCHEMISTRY-US, V25, P878, DOI 10.1021/bi00352a021; Tsukamoto H, 1999, AM J PHYSIOL-GASTR L, V277, pG1240, DOI 10.1152/ajpgi.1999.277.6.G1240; WALL L, 1986, J BIOL CHEM, V261, P5981; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x	64	290	306	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38079	38086		10.1074/jbc.M205256200	http://dx.doi.org/10.1074/jbc.M205256200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12154090	hybrid			2022-12-27	WOS:000178529600015
J	Fukuda, R; Hirota, K; Fan, F; Do Jung, Y; Ellis, LM; Semenza, GL				Fukuda, R; Hirota, K; Fan, F; Do Jung, Y; Ellis, LM; Semenza, GL			Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR 1-ALPHA HIF-1-ALPHA; TUMOR-SUPPRESSOR PROTEIN; CAP-BINDING PROTEIN; TRANSCRIPTIONAL ACTIVITY; TRANSLATION INITIATION; PROLYL HYDROXYLATION; UP-REGULATION; HIF-ALPHA; IN-VIVO	Stimulation of human colon cancer cells with insulin-like growth factor 1 (IGF-1) induces expression of the VEGF gene, encoding vascular endothelial growth factor. In this article we demonstrate that exposure of HCT116 human colon carcinoma cells to IGF-1 induces the expression of HIF-1alpha, the regulated subunit of hypoxia-inducible factor 1, a known transactivator of the VEGF gene. In contrast to hypoxia, which induces HIF-1alpha expression by inhibiting its ubiquitination and degradation, IGF-1 did not inhibit these processes, indicating an effect on HIF-1alpha protein synthesis. IGF-1 stimulation of HIF-1alpha protein and VEGF mRNA expression was inhibited by treating cells with inhibitors of phosphatidylinositol 3-kinase and MAP kinase signaling pathways. These inhibitors also blocked the IGF-1-induced phosphorylation of the translational regulatory proteins 4E-BP1, p70 S6 kinase, and eIF-4E, thus providing a mechanism for the modulation of HIF-1alpha protein synthesis. Forced expression of a constitutively active form of the MAP kinase kinase, MEK2, was sufficient to induce HIF-1alpha protein and VEGF mRNA expression. Involvement of the MAP kinase pathway represents a novel mechanism for the induction of HIF-1alpha protein expression in human cancer cells.	Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21287 USA; Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center	Semenza, GL (corresponding author), Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, CMSC-1004,600 N Wolfe St, Baltimore, MD 21287 USA.		高, 雨莉/HGU-8187-2022; Hirota, Kiichi/E-9181-2010	Hirota, Kiichi/0000-0003-1110-0827	NCI NIH HHS [R01-CA74821] Funding Source: Medline; NIDDK NIH HHS [R01-DK39869] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074821] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039869] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akagi Y, 1998, CANCER RES, V58, P4008; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Feldser D, 1999, CANCER RES, V59, P3915; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kerbel RS, 2000, EUR J CANCER, V36, P1248, DOI 10.1016/S0959-8049(00)00092-7; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Rak J, 2000, CANCER RES, V60, P490; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Schramek H, 1997, J BIOL CHEM, V272, P11426; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Shi YY, 2002, J BIOL CHEM, V277, P15712, DOI 10.1074/jbc.M200043200; Sodhi A, 2000, CANCER RES, V60, P4873; Sodhi A, 2001, BIOCHEM BIOPH RES CO, V287, P292, DOI 10.1006/bbrc.2001.5532; Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Viloria-Petit A, 2001, CANCER RES, V61, P5090; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Warren RS, 1996, J BIOL CHEM, V271, P29483, DOI 10.1074/jbc.271.46.29483; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Wu YP, 2002, CANCER RES, V62, P1030; Zagzag D, 2000, CANCER-AM CANCER SOC, V88, P2606, DOI 10.1002/1097-0142(20000601)88:11<2606::AID-CNCR25>3.0.CO;2-W; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268; Zhong H, 1999, CANCER RES, V59, P5830; Zimmer SG, 2000, ANTICANCER RES, V20, P1343	42	662	701	2	33	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38205	38211		10.1074/jbc.M203781200	http://dx.doi.org/10.1074/jbc.M203781200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12149254	hybrid			2022-12-27	WOS:000178529600030
J	Islas-Osuna, MA; Ellis, TP; Marnell, LL; Mittelmeier, TM; Dieckmann, CL				Islas-Osuna, MA; Ellis, TP; Marnell, LL; Mittelmeier, TM; Dieckmann, CL			Cbp1 is required for translation of the mitochondrial cytochrome b mRNA of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COB MESSENGER-RNA; IN-VIVO ANALYSIS; YEAST MITOCHONDRIA; 5'-UNTRANSLATED REGION; IDENTIFICATION; TRANSCRIPTS; EXPRESSION; STABILITY; GENES; ENDONUCLEASE	Expression of the yeast mitochondrial cytochrome b gene (COB) is controlled by at least 15 nuclear-encoded proteins. One of these proteins, Cbp1, is required for COB mRNA stability. Deltacbp1 null strains fail to accumulate mature COB mRNA and cannot respire. Since Deltacbp1 null strains lack mature COB transcripts, the hypothesis that Cbp1 also plays a role in translation of these mRNAs could not be tested previously. 5'-End trimming of precursor COB RNA and other mitochondrial transcripts is dependent on Pet127. pet127 mutants accumulate high levels of precursor COB mRNA and have no mature mRNA. pet127 mutants respire well; this phenotype implies that COB precursor RNA is translated efficiently. With the expectation that a Deltacbp1Deltapet127 strain might accumulate substantial levels of COB RNA, the double null strain was constructed and analyzed to test the hypothesis that Cbp1 is required for translation of COB RNA. The Deltacbp1Deltapet127 strain does accumulate levels of COB precursor mRNA that are similar to60% of the level of COB mRNA in the wild-type strain. However, cytochrome b protein is not synthesized, and thus the Deltacbp1Deltapet127 strain does not respire. These results suggest that Cbp1 is required for translation of COB RNAs.	Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA; Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA	University of Arizona; University of Arizona	Dieckmann, CL (corresponding author), Univ Arizona, Dept Biochem & Mol Biophys, 1007 E Lowell St,LSS Bldg Room 454, Tucson, AZ 85721 USA.	dieckman@u.arizona.edu	Islas-Osuna, María A./AAI-3764-2020	Islas-Osuna, María A./0000-0002-7170-3366	NIGMS NIH HHS [GM34893] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034893] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bonnefoy N, 2001, MOL CELL BIOL, V21, P2359, DOI 10.1128/MCB.21.7.2359-2372.2001; BROWN NG, 1994, MOL CELL BIOL, V14, P1045, DOI 10.1128/MCB.14.2.1045; CAPONIGRO G, 1993, MOL CELL BIOL, V13, P5141, DOI 10.1128/MCB.13.9.5141; CHEN JY, 1988, J BIOL CHEM, V263, P13677; CHEN W, 1994, J BIOL CHEM, V269, P16574; Chen W, 1999, GENETICS, V151, P1315; Chen W, 1997, MOL CELL BIOL, V17, P6203, DOI 10.1128/MCB.17.11.6203; CHRISTIANSON T, 1983, J BIOL CHEM, V258, P4025; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; DIECKMANN CL, 1994, INT REV CYTOL, V152, P145, DOI 10.1016/S0074-7696(08)62556-5; DIECKMANN CL, 1982, P NATL ACAD SCI-BIOL, V79, P1805, DOI 10.1073/pnas.79.6.1805; FOX TD, 1991, METHOD ENZYMOL, V194, P149; Grivell LA, 1999, FEBS LETT, V452, P57, DOI 10.1016/S0014-5793(99)00532-3; Groom K R, 1996, Methods Enzymol, V264, P86, DOI 10.1016/S0076-6879(96)64011-7; LABOUESSE M, 1984, EUR J BIOCHEM, V144, P85, DOI 10.1111/j.1432-1033.1984.tb08434.x; Mackie GA, 1998, NATURE, V395, P720, DOI 10.1038/27246; MICHAELIS U, 1991, MOL GEN GENET, V230, P177, DOI 10.1007/BF00290666; MITTELMEIER TM, 1990, CURR GENET, V18, P421, DOI 10.1007/BF00309911; MITTELMEIER TM, 1993, MOL CELL BIOL, V13, P4203, DOI 10.1128/MCB.13.7.4203; MITTELMEIER TM, 1995, MOL CELL BIOL, V15, P780; RODEL G, 1986, CURR GENET, V11, P41, DOI 10.1007/BF00389424; ROSE MD, 1990, METHODS YEAST GENETI, P179; STAPLES RR, 1993, GENETICS, V135, P981; WEBER ER, 1990, J BIOL CHEM, V265, P1594; Wiesenberger G, 1997, MOL CELL BIOL, V17, P2816, DOI 10.1128/MCB.17.5.2816	25	37	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					37987	37990		10.1074/jbc.M206132200	http://dx.doi.org/10.1074/jbc.M206132200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12149267	hybrid			2022-12-27	WOS:000178529600004
J	Ederth, J; Artsimovitch, I; Isaksson, LA; Landick, R				Ederth, J; Artsimovitch, I; Isaksson, LA; Landick, R			The downstream DNA jaw of bacterial RNA polymerase facilitates both transcriptional initiation and pausing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3.3 ANGSTROM RESOLUTION; PROMOTER OPEN COMPLEX; ESCHERICHIA-COLI; ELONGATION COMPLEX; STRUCTURAL BASIS; TERMINATION; MECHANISM; SITE; REGION; MUTANTS	Regulation of RNA polymerase during initiation, elongation, and termination of transcription is mediated in part by interactions with intrinsic regulatory signals encoded in the RNA and DNA that contact the enzyme. These interactions include contacts to an 8-9-bp RNA: DNA hybrid within the active-site cleft of the enzyme, contacts to the melted nontemplate DNA strand in the vicinity of the hybrid, contacts to exiting RNA upstream of the hybrid, and contacts to similar to20 bp of duplex DNA downstream of the active site. Based on characterization of an amino acid substitution (G1161R) and a deletion (Delta1149-1190) in the jaw domain of the bacterial RNA polymerase largest subunit (beta'), we report here that contacts of the jaw domain to downstream DNA at the leading edge of the transcription complex contribute to regulation during all three phases of transcription. The results provide insight into the role of the jaw domain-downstream DNA contact in transcriptional initiation and pausing and suggest possible explanations for the previously reported isolation of the jaw mutants based on reduced ColEI plasmid replication.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Stockholm, Dept Microbiol, S-10691 Stockholm, Sweden	University of Wisconsin System; University of Wisconsin Madison; Stockholm University	Landick, R (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.		Artsimovitch, Irina/L-3467-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038660, R29GM038660, R37GM038660] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38660] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; Barker MM, 2001, J BACTERIOL, V183, P6315, DOI 10.1128/JB.183.21.6315-6323.2001; Barker MM, 2001, J MOL BIOL, V305, P673, DOI 10.1006/jmbi.2000.4327; Barker MM, 2001, J MOL BIOL, V305, P689, DOI 10.1006/jmbi.2000.4328; Barne KA, 1997, EMBO J, V16, P4034, DOI 10.1093/emboj/16.13.4034; Bartlett MS, 1998, J MOL BIOL, V279, P331, DOI 10.1006/jmbi.1998.1779; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; CHAN CL, 1989, J BIOL CHEM, V264, P20796; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; Chan CL, 1997, J MOL BIOL, V268, P54, DOI 10.1006/jmbi.1997.0935; Craig ML, 1998, J MOL BIOL, V283, P741, DOI 10.1006/jmbi.1998.2129; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Darst SA, 2002, P NATL ACAD SCI USA, V99, P4296, DOI 10.1073/pnas.052054099; Ederth J, 2002, MOL GENET GENOMICS, V267, P587, DOI 10.1007/s00438-002-0689-y; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; Geetha V, 1997, PROTEIN SCI, V6, P2538; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; Keene RG, 1999, NUCLEIC ACIDS RES, V27, P3173, DOI 10.1093/nar/27.15.3173; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Korzheva N, 1998, COLD SPRING HARB SYM, V63, P337, DOI 10.1101/sqb.1998.63.337; LAFLAMME SE, 1985, NUCLEIC ACIDS RES, V13, P8425, DOI 10.1093/nar/13.23.8425; Landick R, 1996, METHOD ENZYMOL, V274, P334; Landick R, 2001, CELL, V105, P567, DOI 10.1016/S0092-8674(01)00381-6; LEE DN, 1990, J BIOL CHEM, V265, P15145; LEIRMO S, 1991, J MOL BIOL, V220, P555, DOI 10.1016/0022-2836(91)90100-K; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; Mekler V, 2002, CELL, V108, P599, DOI 10.1016/S0092-8674(02)00667-0; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; Nechaev S, 1999, J MOL BIOL, V289, P815, DOI 10.1006/jmbi.1999.2782; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Palangat M, 2001, J MOL BIOL, V311, P265, DOI 10.1006/jmbi.2001.4842; Pan T, 1999, P NATL ACAD SCI USA, V96, P9545, DOI 10.1073/pnas.96.17.9545; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; Saecker RM, 2002, J MOL BIOL, V319, P649, DOI 10.1016/S0022-2836(02)00293-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TELESNITSKY A, 1989, BIOCHEMISTRY-US, V28, P5210, DOI 10.1021/bi00438a044; TOMIZAWA J, 1990, J MOL BIOL, V212, P683, DOI 10.1016/0022-2836(90)90230-J; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; Zakharova N, 1998, J BIOL CHEM, V273, P24912, DOI 10.1074/jbc.273.38.24912; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9; Zhou YN, 1998, P NATL ACAD SCI USA, V95, P2908, DOI 10.1073/pnas.95.6.2908	52	72	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37456	37463		10.1074/jbc.M207038200	http://dx.doi.org/10.1074/jbc.M207038200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12147705	hybrid			2022-12-27	WOS:000178447100070
J	Harndahl, L; Jing, XJ; Ivarsson, R; Degerman, E; Ahren, B; Manganiello, VC; Renstrom, E; Holst, LS				Harndahl, L; Jing, XJ; Ivarsson, R; Degerman, E; Ahren, B; Manganiello, VC; Renstrom, E; Holst, LS			Important role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic beta-cell exocytosis and release of insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; PROTEIN-KINASE-A; ISLET HORMONE-SECRETION; GLUCAGON-LIKE PEPTIDE-1; ADENYLATE-CYCLASE; IN-VITRO; RAT; AMP; EXPRESSION; ACTIVATION	Cyclic AMP potentiates glucose-stimulated insulin release and mediates the stimulatory effects of hormones such as glucagon-like peptide 1 (GLP-1) on pancreatic beta-cells. By inhibition of cAMP-degrading phosphodiesterase (PDE) and, in particular, selective inhibition of PDE3 activity, stimulatory effects on insulin secretion have been observed. Molecular and functional information on beta-cell PDE3 is, however, scarce. To provide such information, we have studied the specific effects of the PDE3B isoform by adenovirus-mediated overexpression. In rat islets and rat insulinoma cells, approximate 10-fold overexpression of PDE3B was accompanied by a 6-8-fold increase in membrane-associated PDE3B activity. The cAMP concentration was significantly lowered in transduced cells (INS-1(832/13)), and insulin secretion in response to stimulation with high glucose (11.1 mM) was reduced by 40% (islets) and 50% (INS-1). Further, the ability of GLP-1 (100 nM) to augment glucose-stimulated insulin secretion was inhibited by similar to30% (islets) and 70% (INS-1). Accordingly, when stimulating with cAMP, a substantial decrease (65%) in exocytotic capacity was demonstrated in patch-clamped single beta-cells. In untransduced insulinoma cells, application of the PDE3-selective inhibitor OPC3911 (10 muM) was shown to increase glucose-stimulated insulin release as well as cAMP-enhanced exocytosis. The findings suggest a significant role of PDE3B as an important regulator of insulin secretory processes.	Lund Univ, Dept Cell & Mol Biol, Ctr Biomed, SE-22184 Lund, Sweden; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA; Lund Univ, Dept Med, Biomed Ctr, SE-22184 Lund, Sweden; Lund Univ, Dept Physiol Sci, Biomed Ctr, SE-22184 Lund, Sweden	Lund University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Lund University; Lund University	Harndahl, L (corresponding author), Lund Univ, Dept Cell & Mol Biol, Ctr Biomed, C11, SE-22184 Lund, Sweden.		Tuluc, Petronel/C-2527-2011		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL002540, ZIAHL002540] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad M, 2000, BRIT J PHARMACOL, V129, P1228, DOI 10.1038/sj.bjp.0703165; Ahren B, 2000, DIABETOLOGIA, V43, P393, DOI 10.1007/s001250051322; Ahren B, 1998, BIOESSAYS, V20, P642, DOI 10.1002/(SICI)1521-1878(199808)20:8<642::AID-BIES7>3.0.CO;2-K; AMMALA C, 1993, J PHYSIOL-LONDON, V472, P665, DOI 10.1113/jphysiol.1993.sp019966; AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Barg S, 1999, P NATL ACAD SCI USA, V96, P5539, DOI 10.1073/pnas.96.10.5539; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRISSON GR, 1972, J CLIN INVEST, V51, P232, DOI 10.1172/JCI106808; CERASI E, 1970, Hormone and Metabolic Research, V2, P246; CHARLES MA, 1973, SCIENCE, V179, P569, DOI 10.1126/science.179.4073.569; Choi YH, 2001, BIOCHEM J, V353, P41, DOI 10.1042/0264-6021:3530041; DEGERMAN E, 1990, P NATL ACAD SCI USA, V87, P533, DOI 10.1073/pnas.87.2.533; Degerman E, 1997, J BIOL CHEM, V272, P6823, DOI 10.1074/jbc.272.11.6823; ElMetwally M, 1997, EUR J PHARMACOL, V324, P227, DOI 10.1016/S0014-2999(97)00076-9; Erdogan S, 1997, BIOCHEM J, V321, P165, DOI 10.1042/bj3210165; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GRILL V, 1975, DIABETES, V24, P746, DOI 10.2337/diabetes.24.8.746; GRILL V, 1973, FEBS LETT, V33, P311, DOI 10.1016/0014-5793(73)80218-2; Gromada J, 1998, PFLUG ARCH EUR J PHY, V435, P583, DOI 10.1007/s004240050558; Han P, 1999, J BIOL CHEM, V274, P22337, DOI 10.1074/jbc.274.32.22337; Harris TE, 1997, BIOCHEM BIOPH RES CO, V232, P648, DOI 10.1006/bbrc.1997.6344; HELLMAN B, 1974, BIOCHIM BIOPHYS ACTA, V372, P127, DOI 10.1016/0304-4165(74)90079-8; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; HOWELL SL, 1994, DIABETOLOGIA, V37, P30; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; Liu H, 1998, BRIT J PHARMACOL, V125, P1501, DOI 10.1038/sj.bjp.0702227; MALAISSE WJ, 1984, ENDOCRINOLOGY, V115, P2015, DOI 10.1210/endo-115-5-2015; Manganiello VC, 1999, THROMB HAEMOSTASIS, V82, P407, DOI 10.1055/s-0037-1615860; Moens K, 1996, DIABETES, V45, P257, DOI 10.2337/diabetes.45.2.257; MURAD F, 1971, P NATL ACAD SCI USA, V68, P736, DOI 10.1073/pnas.68.4.736; Parker JC, 1997, BIOCHEM BIOPH RES CO, V236, P665, DOI 10.1006/bbrc.1997.7034; Parker JC, 1995, BIOCHEM BIOPH RES CO, V217, P916, DOI 10.1006/bbrc.1995.2858; PERSAUD SJ, 1990, BIOCHEM BIOPH RES CO, V173, P833, DOI 10.1016/S0006-291X(05)80862-9; PIPELEERS DG, 1985, ENDOCRINOLOGY, V117, P824, DOI 10.1210/endo-117-3-824; RASCON A, 1994, J BIOL CHEM, V269, P11962; REINHARDT RR, 1995, J CLIN INVEST, V95, P1528, DOI 10.1172/JCI117825; Renstrom E, 1997, J PHYSIOL-LONDON, V502, P105, DOI 10.1111/j.1469-7793.1997.105bl.x; SHAFIEENICK R, 1995, BRIT J PHARMACOL, V115, P1486, DOI 10.1111/j.1476-5381.1995.tb16641.x; Shakur Y, 2000, J BIOL CHEM, V275, P38749, DOI 10.1074/jbc.M001734200; SHARP GWG, 1979, DIABETOLOGIA, V16, P287, DOI 10.1007/BF01223617; Smith RM, 1974, CRITICAL STABILITY C, V1-6; SNYDER PB, 1999, EMERGING THERAPEUTIC, V3, P587; TAIRA M, 1993, J BIOL CHEM, V268, P18573; THORENS B, 1993, DIABETES, V42, P1219, DOI 10.2337/diabetes.42.9.1219; Zhao AZ, 1998, J CLIN INVEST, V102, P869, DOI 10.1172/JCI3920; Zhao AZ, 1997, P NATL ACAD SCI USA, V94, P3223, DOI 10.1073/pnas.94.7.3223	49	65	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37446	37455		10.1074/jbc.M205401200	http://dx.doi.org/10.1074/jbc.M205401200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12169692	hybrid			2022-12-27	WOS:000178447100069
J	Hoover, DM; Boulegue, C; Yang, D; Oppenheim, JJ; Tucker, K; Lu, WY; Lubkowski, J				Hoover, DM; Boulegue, C; Yang, D; Oppenheim, JJ; Tucker, K; Lu, WY; Lubkowski, J			The structure of human macrophage inflammatory protein-3 alpha/CCL20 - Linking antimicrobial and CC chemokine receptor-6-binding activities with human beta-defensins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOTACTIC PROTEIN-1; CRYSTAL-STRUCTURE; RECEPTOR-BINDING; DENDRITIC CELLS; 3-DIMENSIONAL STRUCTURE; SELECTIVE RECRUITMENT; HUMAN BETA-DEFENSIN-2; T-CELLS; IDENTIFICATION; MIP-3-ALPHA	Human macrophage inflammatory protein-3alpha (MIP-3alpha; CCL20) is a CC-type chemokine that binds to and activates CC chemokine receptor-6 (CCR6). Although MIP-3a does not share the binding site of CCR6 with any other chemokine, human beta-defensin-1 and -2, small cationic antimicrobial peptides, have also been found to bind to and activate CCR6. Conversely, we have found that MIP-3a possesses antibacterial activity of greater potency than human beta-defensin-1 and -2 against Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 29213, while having no activity against the fungus Candida albicans. There is no clear sequence similarity between,beta-defensins and the chemokine MIP-3alpha, beyond an abundance of cationic residues and the presence of disulfide bonds. Nonetheless, there are structural similarities between these three proteins that allow their overlap of chemotactic and antimicrobial activities. In this report, we describe the x-ray crystal structure of human MIP-3a refined to a resolution of 1.7 Angstrom and compare it with the crystal structures of human beta-defensin-1 and -2. Molecules of MIP-3alpha and the beta-defensins seem to share few structural motifs that are likely associated with their common biological activities.	NCI, Macromol Crystallog Lab, Frederick, MD 21702 USA; NCI, Mol Immunoregulat Lab, Frederick, MD 21702 USA; NCI, Opportunist Infect Lab, Div Canc Treatment, Centers & Diag Dev Therapeut Program, Frederick, MD 21702 USA; Univ Maryland, Inst Human Virol, Inst Biotechnol, Baltimore, MD 21201 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore	Lubkowski, J (corresponding author), NCI, Macromol Crystallog Lab, POB B,Ft Detrick, Frederick, MD 21702 USA.		Boulegue, Cyril/A-4092-2009; Lu, Wuyuan/J-8452-2017; Lu, Wuyuan/B-2268-2010	Lu, Wuyuan/0000-0003-1318-9968; 	NCI NIH HHS [N01-CO-1240] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Aoukaty A, 1998, IMMUNOLOGY, V95, P618; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Carruthers LM, 2000, METHOD ENZYMOL, V321, P66; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Caux C, 2002, TRANSPLANTATION, V73, pS7, DOI 10.1097/00007890-200201151-00005; Charbonnier AS, 1999, J EXP MED, V190, P1755, DOI 10.1084/jem.190.12.1755; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; Cole AM, 2001, J IMMUNOL, V167, P623, DOI 10.4049/jimmunol.167.2.623; Cook DN, 2000, IMMUNITY, V12, P495, DOI 10.1016/S1074-7613(00)80201-0; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Dealwis C, 1998, P NATL ACAD SCI USA, V95, P6941, DOI 10.1073/pnas.95.12.6941; Demeler B, 2000, METHOD ENZYMOL, V321, P38; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; FALK W, 1980, J IMMUNOL METHODS, V33, P239, DOI 10.1016/S0022-1759(80)80014-7; GANZ T, 1985, J CLIN INVEST, V76, P1427, DOI 10.1172/JCI112120; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Harrison JK, 2001, J BIOL CHEM, V276, P21632, DOI 10.1074/jbc.M010261200; HARWIG SSL, 1994, METHOD ENZYMOL, V236, P160; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; Hiratsuka T, 1998, BIOCHEM BIOPH RES CO, V249, P943, DOI 10.1006/bbrc.1998.9239; Homey B, 2000, J IMMUNOL, V164, P6621, DOI 10.4049/jimmunol.164.12.6621; Hoover DM, 2000, J BIOL CHEM, V275, P32911, DOI 10.1074/jbc.M006098200; Hoover DM, 2000, PROTEIN PEPTIDE LETT, V7, P73; Hoover DM, 2001, J BIOL CHEM, V276, P39021, DOI 10.1074/jbc.M103830200; Horuk R, 2001, CYTOKINE GROWTH F R, V12, P313, DOI 10.1016/S1359-6101(01)00014-4; Iwasaki A, 2000, J EXP MED, V191, P1381, DOI 10.1084/jem.191.8.1381; Jarnagin K, 1999, BIOCHEMISTRY-US, V38, P16167, DOI 10.1021/bi9912239; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawasaki S, 2001, J IMMUNOL, V166, P2055, DOI 10.4049/jimmunol.166.3.2055; Koopmann W, 1997, J BIOL CHEM, V272, P10103; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; Liao F, 1997, BIOCHEM BIOPH RES CO, V236, P212, DOI 10.1006/bbrc.1997.6936; Liao F, 1999, J IMMUNOL, V162, P186; Lilie H, 1998, CURR OPIN BIOTECH, V9, P497, DOI 10.1016/S0958-1669(98)80035-9; Lowman HB, 1996, J BIOL CHEM, V271, P14344, DOI 10.1074/jbc.271.24.14344; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; Lukacs NW, 2001, J EXP MED, V194, P551, DOI 10.1084/jem.194.4.551; Matsui T, 2001, CLIN EXP IMMUNOL, V125, P155, DOI 10.1046/j.1365-2249.2001.01542.x; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Mayer MR, 2001, J BIOL CHEM, V276, P13911, DOI 10.1074/jbc.M011202200; Meunier S, 1997, BIOCHEMISTRY-US, V36, P4412, DOI 10.1021/bi9627929; Miteva M, 1999, FEBS LETT, V462, P155, DOI 10.1016/S0014-5793(99)01520-3; Mizoue LS, 2001, J BIOL CHEM, V276, P33906, DOI 10.1074/jbc.M101348200; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ohnishi Y, 2000, J INTERF CYTOK RES, V20, P691, DOI 10.1089/10799900050116390; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perez-Canadillas JM, 2001, J BIOL CHEM, V276, P28372, DOI 10.1074/jbc.M103121200; Power CA, 1997, J EXP MED, V186, P825, DOI 10.1084/jem.186.6.825; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Rossi DL, 1997, J IMMUNOL, V158, P1033; Scheerens H, 2001, EUR J IMMUNOL, V31, P1465, DOI 10.1002/1521-4141(200105)31:5<1465::AID-IMMU1465>3.0.CO;2-E; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; Schutyser E, 2000, J IMMUNOL, V165, P4470, DOI 10.4049/jimmunol.165.8.4470; Serafini B, 2000, AM J PATHOL, V157, P1991, DOI 10.1016/S0002-9440(10)64838-9; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Shimizu Y, 2001, HEPATOLOGY, V34, P311, DOI 10.1053/jhep.2001.26631; Tanaka Y, 1999, EUR J IMMUNOL, V29, P633, DOI 10.1002/(SICI)1521-4141(199902)29:02<633::AID-IMMU633>3.0.CO;2-I; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Varona R, 1998, FEBS LETT, V440, P188, DOI 10.1016/S0014-5793(98)01450-1; Williams G, 1996, J BIOL CHEM, V271, P9579, DOI 10.1074/jbc.271.16.9579; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yang L, 2000, BIOPHYS J, V79, P2002, DOI 10.1016/S0006-3495(00)76448-4; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	74	191	208	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37647	37654		10.1074/jbc.M203907200	http://dx.doi.org/10.1074/jbc.M203907200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12149255	hybrid			2022-12-27	WOS:000178447100095
J	Ma, TH; Vetrivel, L; Yang, H; Pedemonte, N; Zegarra-Moran, O; Galietta, LJV; Verkman, AS				Ma, TH; Vetrivel, L; Yang, H; Pedemonte, N; Zegarra-Moran, O; Galietta, LJV; Verkman, AS			High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHANNEL; CURRENTS	Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator (CFTR) protein that reduce cAMP-stimulated Cl- conductance in airway and other epithelia. The purpose of this investigation was to identify new classes of potent CFTR activators. A collection of 60,000 diverse drug-like compounds was screened at 10 pm together with a low concentration of forskolin (0.5 muM) in Fisher rat thyroid epithelial cells co-expressing human CFTR and a green fluorescent protein-based Cl- sensor. Primary screening yielded 57 strong activators (greater activity than reference compound apigenin), most of which were unrelated in chemical structure to known CFTR activators, and 284 weaker activators. Secondary analysis of the strong activators included analysis of CFTR specificity, forskolin requirement, transepithelial short-circuit current, activation kinetics, dose response, toxicity, and activation mechanism. Three compounds, the most potent being a dihydroisoquinoline, activated CFTR by elevating cellular cAMP, probably by phosphodiesterase inhibition. Fourteen compounds activated CFTR without cAMP elevation or phosphatase inhibition, suggesting direct CFTR interaction. The most potent compounds had tetrahydrocarbazol, hydroxycoumarin, and thiazolidine core structures. These compounds induced CFTR Cl- currents rapidly (<5 min) with K-d down to 200 nm and were CFTR-selective, reversible, and nontoxic. Several compounds, the most potent being a trifluoromethylphenylbenzamine, activated the CF-causing mutant G551D, but with much weaker affinity (K-d > 10 muM). When added for 10 min, none of the compounds activated DeltaPhe(508)-CFTR in transfected cells grown at 37 degreesC (with DeltaPhe(508)-CFTR trapped in the endoplasmic reticulum). However, after correction of trafficking by 48 h of growth at 27 degreesC, tetrahydrocarbazol and N-phenyltriazine derivatives strongly stimulated Cl- conductance with K-d < 1 &mu;M. The new activators identified here may be useful in defining molecular mechanisms of CFTR activation and as lead compounds in CF drug development.	Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Physiol, San Francisco, CA 94143 USA; Ist Giannina Gaslini, Genet Mol Lab, I-16148 Genoa, Italy	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Genoa; IRCCS Istituto Giannina Gaslini	Verkman, AS (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.		Pedemonte, Nicoletta/B-3607-2010; Galietta, Luis JV/HCG-8692-2022	Pedemonte, Nicoletta/0000-0002-5161-1720; Galietta, Luis/0000-0001-8686-3461	NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, P50HL060288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035124, R37DK035124] Funding Source: NIH RePORTER; NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL60288] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline; Telethon [E.0593] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon)		Bachmann A, 2000, BRIT J PHARMACOL, V131, P433, DOI 10.1038/sj.bjp.0703600; Becq F, 1999, J BIOL CHEM, V274, P27415, DOI 10.1074/jbc.274.39.27415; Chappe V, 1998, BRIT J PHARMACOL, V123, P683, DOI 10.1038/sj.bjp.0701648; Galietta LJV, 1998, AM J PHYSIOL-LUNG C, V275, pL917, DOI 10.1152/ajplung.1998.275.5.L917; Galietta LJV, 2001, J BIOL CHEM, V276, P19723, DOI 10.1074/jbc.M101892200; Hwang TC, 1999, TRENDS PHARMACOL SCI, V20, P448, DOI 10.1016/S0165-6147(99)01386-3; Hwang TC, 1997, AM J PHYSIOL-CELL PH, V273, pC988, DOI 10.1152/ajpcell.1997.273.3.C988; ILLEK B, 1995, AM J PHYSIOL-CELL PH, V268, pC886, DOI 10.1152/ajpcell.1995.268.4.C886; Illek B, 2000, AM J PHYSIOL-CELL PH, V279, pC1838, DOI 10.1152/ajpcell.2000.279.6.C1838; Morello JP, 2000, J CLIN INVEST, V105, P887, DOI 10.1172/JCI8688; Naren AP, 2000, J CLIN INVEST, V105, P377, DOI 10.1172/JCI8631; Partridge CJ, 2001, J BIOL CHEM, V276, P35947, DOI 10.1074/jbc.M104762200; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Schultz BD, 1999, PHYSL REV S, V79, P109; Singh S, 2001, J PHARMACOL EXP THER, V296, P600; Wang SS, 2000, CELL, V103, P169, DOI 10.1016/S0092-8674(00)00096-9	16	164	198	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37235	37241		10.1074/jbc.M205932200	http://dx.doi.org/10.1074/jbc.M205932200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12161441	hybrid			2022-12-27	WOS:000178447100044
J	Scott, MGH; Le Rouzic, E; Perianin, A; Pierotti, V; Enslen, H; Benichou, S; Marullo, S; Benmerah, A				Scott, MGH; Le Rouzic, E; Perianin, A; Pierotti, V; Enslen, H; Benichou, S; Marullo, S; Benmerah, A			Differential nucleocytoplasmic shuttling of beta-arrestins - Characterization of a leucine-rich nuclear export signal in beta-arrestin2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; CLATHRIN-COATED VESICLES; BETA(2)-ADRENERGIC RECEPTOR; REGULATED KINASES; CRYSTAL-STRUCTURE; VISUAL ARRESTIN; ENDOCYTOSIS; LOCALIZATION; ACTIVATION; ADAPTER	beta-arrestins (betaarrs) are two highly homologous proteins that uncouple G protein-coupled receptors from their cognate G proteins, serve as adaptor molecules linking G protein-coupled receptors to clathrin-coat components (AP-2 complex and clathrin), and act as scaffolding proteins for ERK1/2 and JNK3 cascades. A striking difference between the two betaarrs (betaarr1 and betaarr2) is that betaarr1 is evenly distributed throughout the cell, whereas betaarr2 shows an apparent cytoplasmic localization at steady state. Here, we investigate the molecular determinants underlying this differential distribution. betaarr2 is constitutively excluded from the nucleus by a leptomycin B-sensitive pathway because of the presence of a classical leucine-rich nuclear export signal in its C terminus (L395/L397) that is absent in betaarr1. In addition, using a nuclear import assay in yeast we showed that betaarr2 is actively imported into the nucleus, suggesting that betaarr2 undergoes constitutive nucleocytoplasmic shuttling. In cells expressing betaarr2, JNK3 is mostly cytosolic. A point mutation of the nuclear export signal (L395A) in betaarr2, which was sufficient to redistribute betaarr2 from the cytosol to the nucleus, also caused the nuclear relocalization of JNK3. These data indicate that the nucleocytoplasmic shuttling of betaarr2 controls the subcellular distribution of JNK3.	Inst Cochin, Dept Cell Biol, F-75679 Paris 14, France; Inst Cochin, Dept Infect Dis, F-75679 Paris, France; Inst Fer A Moulin, INSERM, U536, F-75005 Paris, France; Fac Necker Enfants Malad, INSERM, F-75730 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Marullo, S (corresponding author), Inst Cochin, Dept Cell Biol, Pavillon Gustave Roussy, F-75679 Paris 14, France.		benmerah, alexandre/H-3742-2017; Marullo, Stefano/C-6142-2008; Enslen, Hervé/AAH-4492-2021; Scott, Mark/R-3521-2019; Enslen, Hervé/M-3400-2017	benmerah, alexandre/0000-0003-0188-8016; Marullo, Stefano/0000-0001-9604-9973; Enslen, Hervé/0000-0001-9741-5293; Enslen, Hervé/0000-0001-9741-5293; Benichou, Serge/0000-0003-3602-3530; Scott, Mark G.H./0000-0002-1557-1856				ATTRAMADAL H, 1992, J BIOL CHEM, V267, P17882; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Benmerah A, 2000, J BIOL CHEM, V275, P3288, DOI 10.1074/jbc.275.5.3288; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Brydon L, 1999, MOL ENDOCRINOL, V13, P2025, DOI 10.1210/me.13.12.2025; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; CHIN DJ, 1989, P NATL ACAD SCI USA, V86, P9289, DOI 10.1073/pnas.86.23.9289; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Depienne C, 2001, J BIOL CHEM, V276, P18102, DOI 10.1074/jbc.M009029200; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Formstecher E, 2001, DEV CELL, V1, P239, DOI 10.1016/S1534-5807(01)00035-1; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Hyman J, 2000, J CELL BIOL, V149, P537, DOI 10.1083/jcb.149.3.537; Kallal L, 2000, TRENDS PHARMACOL SCI, V21, P175, DOI 10.1016/S0165-6147(00)01477-2; Kim YM, 2002, J BIOL CHEM, V277, P16837, DOI 10.1074/jbc.M201379200; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Menard L, 1997, MOL PHARMACOL, V51, P800, DOI 10.1124/mol.51.5.800; Miller WE, 2001, CURR OPIN CELL BIOL, V13, P139, DOI 10.1016/S0955-0674(00)00190-3; Mundell SJ, 2000, J BIOL CHEM, V275, P12900, DOI 10.1074/jbc.275.17.12900; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; Potter RM, 2002, J BIOL CHEM, V277, P8970, DOI 10.1074/jbc.M111086200; Poupon V, 2002, J BIOL CHEM, V277, P8941, DOI 10.1074/jbc.M108385200; Rhee Y, 2000, NAT BIOTECHNOL, V18, P433, DOI 10.1038/74500; Scott MGH, 2002, J BIOL CHEM, V277, P3552, DOI 10.1074/jbc.M106586200; Vecchi M, 2001, J CELL BIOL, V153, P1511, DOI 10.1083/jcb.153.7.1511	41	159	165	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37693	37701		10.1074/jbc.M207552200	http://dx.doi.org/10.1074/jbc.M207552200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12167659	hybrid			2022-12-27	WOS:000178447100101
J	Trigueros, S; Roca, J				Trigueros, S; Roca, J			Failure to relax negative supercoiling of DNA is a primary cause of mitotic hyper-recombination in topoisomerase-deficient yeast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; GENE; CLONING; TRANSFORMATION; TRANSCRIPTION; REPLICATION; MECHANISM; MUTANTS; RDNA	In the yeast Saccharomyces cerevisiae, DNA topoisomerases I and II can functionally substitute for each other in removing positive and negative DNA supercoils. Yeast Deltatop1 top2(ts) mutants grow slowly and present structural instability in the genome; over half of the rDNA repeats are excised in the form of extrachromosomal rings, and small circular minichromosomes strongly multimerize. Because these traits can be reverted by the extrachromosomal expression of either eukaryotic topoisomerase I or II, their origin is attributed to the persistence of unconstrained DNA supercoiling. Here, we examine whether the expression of the Escherichia coli topA gene, which encodes the bacterial topoisomerase I that removes only negative supercoils, compensates the phenotype of Deltatop1 top2(ts) yeast cells. We found that Deltatop1 top2(ts) mutants expressing E. coli topoisomerase I grow faster and do not manifest rDNA excision and minichromosome multimerization. Furthermore, the recombination frequency in repeated DNA sequences, which is increased by nearly two orders of magnitude in Deltatop1 top2(ts) mutants relative to the parental TOP+ cells, is restored to normal levels when the bacterial topoisomerase is expressed. These results indicate that the suppression of mitotic hyper-recombination caused by eukaryotic topoisomerases I and II is effected mainly by the relaxation of negative rather than positive supercoils; they also highlight the potential of unconstrained negative supercoiling to promote homologous recombination.	Consejo Super Invest Cientificas, Inst Biol Mol Barcelona, E-08034 Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB)	Roca, J (corresponding author), Consejo Super Invest Cientificas, Inst Biol Mol Barcelona, Jordi Girona 18-26, E-08034 Barcelona, Spain.	jrbbmc@cid.csic.es	Roca, Joaquim/AAP-1077-2020; Trigueros, Sonia/O-7358-2014	Roca, Joaquim/0000-0003-1462-954X; Trigueros, Sonia/0000-0001-5621-7303				BJORNSTI MA, 1987, P NATL ACAD SCI USA, V84, P8971, DOI 10.1073/pnas.84.24.8971; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; DINARDO S, 1984, P NATL ACAD SCI-BIOL, V81, P2616, DOI 10.1073/pnas.81.9.2616; DINARDO S, 1982, CELL, V31, P43, DOI 10.1016/0092-8674(82)90403-2; Gangloff S, 1999, EMBO J, V18, P1701, DOI 10.1093/emboj/18.6.1701; GIAEVER GN, 1988, CELL, V55, P849, DOI 10.1016/0092-8674(88)90140-7; GOTO T, 1985, P NATL ACAD SCI USA, V82, P7178, DOI 10.1073/pnas.82.21.7178; Harmon FG, 1999, MOL CELL, V3, P611, DOI 10.1016/S1097-2765(00)80354-8; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; KIM RA, 1992, J BIOL CHEM, V267, P17178; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Masse E, 1999, J BIOL CHEM, V274, P16654, DOI 10.1074/jbc.274.23.16654; PRADO F, 1995, GENETICS, V139, P109; ROCA J, 1992, NUCLEIC ACIDS RES, V20, P4671, DOI 10.1093/nar/20.17.4671; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SAAVEDRA RA, 1986, CELL, V45, P65, DOI 10.1016/0092-8674(86)90538-6; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sherman F., 1983, METHODS YEAST GENETI; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; THRASH C, 1985, P NATL ACAD SCI USA, V82, P4374, DOI 10.1073/pnas.82.13.4374; Trigueros S, 2001, J BIOL CHEM, V276, P2243, DOI 10.1074/jbc.M008930200; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; WANG JC, 1990, CELL, V62, P403, DOI 10.1016/0092-8674(90)90002-V; WANG JC, 1991, J BIOL CHEM, V266, P6659; WORLAND ST, 1989, J BIOL CHEM, V264, P4412; Zechiedrich EL, 2000, J BIOL CHEM, V275, P8103, DOI 10.1074/jbc.275.11.8103	31	22	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37207	37211		10.1074/jbc.M206663200	http://dx.doi.org/10.1074/jbc.M206663200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12151411	hybrid			2022-12-27	WOS:000178447100040
J	Wade, WN; Willingham, MC; Koumenis, C; Cramer, SD				Wade, WN; Willingham, MC; Koumenis, C; Cramer, SD			p27(Kip1) is essential for the antiproliferative action of 1,25-dihydroxyvitamin D-3 in primary, but not immortalized, mouse embryonic fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CANCER-CELLS; IN-VITRO; VITAMIN-D-3; INDUCTION; GROWTH; P21; DIFFERENTIATION; PROLIFERATION; TRANSCRIPTION	1alpha,25-Dihydroxyvitamin D-3 (1,25(OH)(2)D-3) inhibits the growth of numerous cancer cell types. The intracellular proteins that mediate 1,25(OH)(2)D-3-induced growth inhibition are poorly defined, although it is speculated that p21 and p27 are involved. We tested the requirement of p21 and p27 by treating primary wild-type, p21(-/-), and p27(-/-) mouse embryonic fibroblasts (MEFs) with 100 nM 1,25(OH)(2)D-3. In response to treatment, the wild-type and p21(-/-) MEFs exhibited 54 and 60% growth inhibition (p < 0.05), respectively, whereas the growth of p27(-/-)MEFs was unaffected. Western analyses indicated that p27 expression is induced by 1,25(OH)(2)D-3 treatment in wild-type and p21(-/-) MEFs. p21 expression is also induced by 1,25(OH)(2)D-3 treatment in wild-type and p27(-/-) MEFs, although the effect is less robust than for p27. Next, we spontaneously immortalized each MEF strain, which resulted in a gain of responsiveness to 1,25(OH)(2)D-3 by the p27(-/-) MEFs, as exhibited by 87% growth inhibition (p < 0.05). Both wild-type and p21(-/-) MEFs retained responsiveness (43 and 72% growth inhibition (p < 0.05), respectively). These data from primary and immortalized MEFs demonstrate that there are both p27-dependent and -independent pathways that mediate the antiproliferative action of 1,25(OH)(2)D-3.	Wake Forest Univ, Dept Canc Biol, Sch Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Dept Pathol, Sch Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Dept Radiat Oncol, Sch Med, Winston Salem, NC 27157 USA; Wake Forest Univ, Dept Urol, Sch Med, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest University; Wake Forest University; Wake Forest University	Cramer, SD (corresponding author), Wake Forest Univ, Dept Canc Biol, Sch Med, 1 Med Ctr Blvd, Winston Salem, NC 27157 USA.		Koumenis, Constantinos/B-2002-2008	Koumenis, Costas/0000-0001-5945-4726	NATIONAL CANCER INSTITUTE [T32CA079448] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK052623] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA79448] Funding Source: Medline; NIDDK NIH HHS [R29-DK52623] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BENO DWA, 1995, J BIOL CHEM, V270, P3642, DOI 10.1074/jbc.270.8.3642; Berry DM, 1996, J BIOL CHEM, V271, P16090, DOI 10.1074/jbc.271.27.16090; Campbell MJ, 1997, J MOL ENDOCRINOL, V19, P15, DOI 10.1677/jme.0.0190015; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fife RS, 1997, CANCER LETT, V120, P65, DOI 10.1016/S0304-3835(97)00298-X; Geng Y, 1996, ONCOGENE, V12, P1173; Hershberger PA, 1999, CANCER RES, V59, P2644; JIANG HP, 1994, ONCOGENE, V9, P3397; Kawa S, 1997, BRIT J CANCER, V76, P884, DOI 10.1038/bjc.1997.479; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Mitchell JH, 2000, NUTR CANCER, V38, P223, DOI 10.1207/S15327914NC382_12; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; WADHWA R, 1993, BIOCHEM BIOPH RES CO, V197, P202, DOI 10.1006/bbrc.1993.2461; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719; Wang QM, 1997, CANCER RES, V57, P2851; Wang QM, 1996, CANCER RES, V56, P264; Zhuang SH, 1998, ENDOCRINOLOGY, V139, P1197, DOI 10.1210/en.139.3.1197	22	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 4	2002	277	40					37301	37306		10.1074/jbc.M204162200	http://dx.doi.org/10.1074/jbc.M204162200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	601LH	12163488	hybrid			2022-12-27	WOS:000178447100051
J	Chu, X; Cheung, JY; Barber, DL; Birnbaumer, L; Rothblum, LI; Conrad, K; Abrasonis, V; Chan, YM; Stahl, R; Carey, DJ; Miller, BA				Chu, X; Cheung, JY; Barber, DL; Birnbaumer, L; Rothblum, LI; Conrad, K; Abrasonis, V; Chan, YM; Stahl, R; Carey, DJ; Miller, BA			Erythropoietin modulates calcium influx through TRPC2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR-FREE CALCIUM; MURINE ERYTHROLEUKEMIA-CELLS; HUMAN ERYTHROID PRECURSORS; CAPACITATIVE CA2+ ENTRY; CENTRAL-NERVOUS-SYSTEM; MOLECULAR MECHANISMS; HUMAN ERYTHROBLASTS; CATION CHANNEL; RECEPTOR; DIFFERENTIATION	Mammalian isoforms of calcium-permeable Drosophila transient receptor potential channels (TRPC) are involved in the sustained phase of calcium entry in non-excitable cells. Erythropoietin (Epo) stimulates a rise in intracellular calcium ([Ca](i)) via activation of voltage-independent calcium channel(s) in erythroid cells. Here, involvement of murine orthologs of classical TRPC in the Epo-modulated increase in [Ca](i) was examined. RTPCR of TRPC 1-6 revealed high expression of only TRPC2 in Epo-dependent cell lines HCD-57 and Ba/F3 Epo-R, in which Epo stimulates a rise in [Ca](i). Using RT-PCR, Western blotting, and immunolocalization, expression of the longest isoform of mTRPC2, clone 14, was demonstrated in HCD-57 cells, Ba/F3 Epo-R cells, and primary murine erythroblasts. To determine whether erythropoietin is capable of modulating calcium influx through TRPC2, CHO cells were cotransfected with Epo-R subcloned into pTracer-CMV and either murine TRPC2 clone 14 or TRPC6, a negative control, into pQBI50. Successful transfection of Epo-R was verified in single cells by detection of green fluorescent protein from pTracer-CMV using digital video imaging, and successful transfection of TRPC was confirmed by detection of blue fluorescent protein fused through a flexible linker to TRPC. [Ca](i) changes were simultaneously monitored in cells loaded with Rhod-2 or Fura Red. Epo stimulation of CHO cells cotransfected with Epo-R and TRPC2 resulted in a rise in [Ca](i) above base line (372 +/- 71%), which was significantly greater (p less than or equal to 0.0007) than that seen in cells transfected with TRPC6 or empty pQBI50 vector. This rise in [Ca](i) required Epo and extracellular calcium. These results identify a calcium-permeable channel, TRPC2, in erythroid cells and demonstrate modulation of calcium influx through this channel by erythropoietin.	Sigfried & Janet Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, Danville, PA 17822 USA; Geisinger Med Clin, Dept Med, Danville, PA 17822 USA; Geisinger Med Clin, Dept Pediat, Danville, PA 17822 USA; Ontario Canc Inst, Div Cell & Mol Biol, Toronto, ON M5G 2M9, Canada; NIEHS, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA	Geisinger Medical Center; Geisinger Medical Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Miller, BA (corresponding author), Sigfried & Janet Weis Ctr Res, Geisinger Clin, Henry Hood Res Program, 100 N Acad Ave, Danville, PA 17822 USA.			Barber, Dwayne/0000-0001-5528-8150	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046778, R56DK046778] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046991] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925, R01NS037716, R01NS041363] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 58672] Funding Source: Medline; NIDDK NIH HHS [DK 46778] Funding Source: Medline; NIGMS NIH HHS [GM 46991] Funding Source: Medline; NINDS NIH HHS [NS 37716, NS 41363, NS 21925] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Barber DL, 2001, BLOOD, V97, P2230, DOI 10.1182/blood.V97.8.2230; BILLESTRUP N, 1995, P NATL ACAD SCI USA, V92, P2725, DOI 10.1073/pnas.92.7.2725; Cerami A, 2001, SEMIN ONCOL, V28, P66, DOI 10.1053/sonc.2001.25401; Cheung JY, 1997, BLOOD, V89, P92, DOI 10.1182/blood.V89.1.92.92_92_100; CHEUNG JY, 1992, J CLIN INVEST, V90, P1850, DOI 10.1172/JCI116061; Cheung JY, 2001, NEPHRON, V87, P215, DOI 10.1159/000045918; Dame C, 2001, BIOL NEONATE, V79, P228; Damen JE, 1996, EXP HEMATOL, V24, P1455; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GILLO B, 1993, BLOOD, V81, P783; Hara Y, 2002, MOL CELL, V9, P163, DOI 10.1016/S1097-2765(01)00438-5; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; HENSOLD JO, 1991, BLOOD, V77, P1362; Hofmann T, 2000, BIOCHEM J, V351, P115, DOI 10.1042/0264-6021:3510115; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Kina T, 2000, BRIT J HAEMATOL, V109, P280, DOI 10.1046/j.1365-2141.2000.02037.x; Koshimura K, 1999, J NEUROCHEM, V72, P2565, DOI 10.1046/j.1471-4159.1999.0722565.x; KRYSTAL G, 1983, EXP HEMATOL, V11, P649; KUREBAYASHI N, 1993, BIOPHYS J, V64, P1934, DOI 10.1016/S0006-3495(93)81564-9; LEVENSON R, 1980, P NATL ACAD SCI-BIOL, V77, P5948, DOI 10.1073/pnas.77.10.5948; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; MASUDA S, 1993, J BIOL CHEM, V268, P11208; MILLER BA, 1989, BLOOD, V73, P1188; Miller BA, 1999, J BIOL CHEM, V274, P20465, DOI 10.1074/jbc.274.29.20465; MILLER BA, 1988, J CLIN INVEST, V82, P309, DOI 10.1172/JCI113588; MISITI J, 1979, J CLIN INVEST, V64, P1573, DOI 10.1172/JCI109618; MITANI A, 1994, J NEUROCHEM, V62, P626; MLADENOVIC J, 1988, J LAB CLIN MED, V112, P23; Montell C, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.90.re1; Ogilvie M, 2000, J BIOL CHEM, V275, P39754, DOI 10.1074/jbc.M004999200; Sano Y, 2001, SCIENCE, V293, P1327, DOI 10.1126/science.1062473; SAWYER ST, 1984, J BIOL CHEM, V259, P2769; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Stowers L, 2002, SCIENCE, V295, P1493, DOI 10.1126/science.1069259; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Vannier B, 1999, P NATL ACAD SCI USA, V96, P2060, DOI 10.1073/pnas.96.5.2060; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; Wu Yiming, 1997, American Journal of Physiology, V273, pH2161; YOSHINO M, 1995, BRAIN RES, V695, P179, DOI 10.1016/0006-8993(95)00743-A; Zhang MY, 1998, BLOOD, V92, P1225, DOI 10.1182/blood.V92.4.1225.416k20_1225_1234; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	44	50	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 13	2002	277	37					34375	34382		10.1074/jbc.M205541200	http://dx.doi.org/10.1074/jbc.M205541200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	592WD	12167663	hybrid			2022-12-27	WOS:000177959100110
J	Ji, SN; Frank, SJ; Messina, JL				Ji, SN; Frank, SJ; Messina, JL			Growth hormone-induced differential desensitization of STAT5, ERK, and Akt phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; INSULIN-LIKE; GH RECEPTOR; RAT-LIVER; NEGATIVE REGULATORS; TRUNCATED ISOFORM; BINDING PROTEIN; FEMALE RATS; IM-9 CELLS	Secretion of growth hormone (GH) in adult male rats is characterized by high peak and undetectable trough levels, both of which are required for male-specific pattern of liver gene expression and GH-induced phosphorylation of STAT5. The present study suggests that regulation of GH receptor (GHR) levels in rat hepatoma cells by repeated GH stimulation determines GH responsiveness via the JAK2/STAT5 pathway. A short exposure to GH rapidly reduced GHR levels which resulted in an equal desensitization of the JAK2/STAT5 pathway. Recovery of GH-induced STAT5 phosphorylation correlated with the time-dependent recovery of GHR levels during incubation in the absence of GH. Acute GH also induced phosphorylation of ERK1/2 and Akt, and this induction was also inhibited by prior exposure to GH. However, unlike the JAK2/STAT5 pathway, the effect of GH to activate the MEK/ERK and phosphatidylinositol 3-kinase/Akt pathways did not recover following prolonged incubation in the absence of GH. Thus, GH administration desensitizes the JAK2/STAT5 pathway, possibly because of down-regulation of GHR, whereas an additional post-receptor mechanism is required for the prolonged refractoriness of the MEK/ERK and phosphatidylinositol 3-kinase/Akt pathways toward a second GH stimulation. Our study suggests that both receptor and post-receptor mechanisms are important in GH-induced homologous desensitization.	Univ Alabama Birmingham, Div Mol & Cellular Pathol, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Div Endocrinol & Metab, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Vet Affairs Med Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Messina, JL (corresponding author), Univ Alabama Birmingham, Div Mol & Cellular Pathol, Dept Pathol, Volker Hall,G019,1670 Univ Blvd, Birmingham, AL 35294 USA.	messina@path.uab.edu			NIDDK NIH HHS [DK40456, DK46395, DK58259] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046395, R56DK058259, R01DK046395, R29DK046395, R01DK058259, R01DK040456] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amit T, 1997, J CLIN ENDOCR METAB, V82, P3813, DOI 10.1210/jc.82.11.3813; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; Argetsinger LS, 1996, PHYSIOL REV, V76, P1089, DOI 10.1152/physrev.1996.76.4.1089; BICK T, 1992, ENDOCRINOLOGY, V131, P423, DOI 10.1210/en.131.1.423; BIRNBAUM RS, 1979, HORM METAB RES, V11, P136, DOI 10.1055/s-0028-1092695; BJORGELL P, 1984, ENDOCRINOLOGY, V115, P1151; CHIPKIN SR, 1989, ENDOCRINOLOGY, V125, P450, DOI 10.1210/endo-125-1-450; EDEN S, 1978, ACTA ENDOCRINOL-COP, V88, P676, DOI 10.1530/acta.0.0880676; EDEN S, 1978, ACTA PHYSIOL SCAND, P1; FRANK SJ, 1994, ENDOCRINOLOGY, V135, P148, DOI 10.1210/en.135.1.148; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; Gebert CA, 1999, MOL ENDOCRINOL, V13, P213, DOI 10.1210/me.13.2.213; Gebert CA, 1999, MOL ENDOCRINOL, V13, P38, DOI 10.1210/me.13.1.38; Gebert CA, 1997, MOL ENDOCRINOL, V11, P400, DOI 10.1210/me.11.4.400; Goldsmith JF, 1997, AM J PHYSIOL-ENDOC M, V273, pE932, DOI 10.1152/ajpendo.1997.273.5.E932; GRONOWSKI AM, 1994, J BIOL CHEM, V269, P7874; Han YL, 1996, J BIOL CHEM, V271, P5947, DOI 10.1074/jbc.271.10.5947; Hansen JA, 1999, MOL ENDOCRINOL, V13, P1832, DOI 10.1210/me.13.11.1832; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; JANSSON JO, 1985, ENDOCR REV, V6, P128, DOI 10.1210/edrv-6-2-128; Ji SN, 1999, J BIOL CHEM, V274, P13434, DOI 10.1074/jbc.274.19.13434; Jiang J, 1998, BIOCHEM BIOPH RES CO, V253, P774, DOI 10.1006/bbrc.1998.9793; Karlsson H, 1999, MOL CELL ENDOCRINOL, V154, P37, DOI 10.1016/S0303-7207(99)00101-X; Kilgour E, 1996, BIOCHEM J, V315, P517, DOI 10.1042/bj3150517; Liang L, 1999, ENDOCRINOLOGY, V140, P1972, DOI 10.1210/en.140.5.1972; Liang L, 2000, ENDOCRINOLOGY, V141, P3328, DOI 10.1210/en.141.9.3328; Love DW, 1998, ENDOCRINOLOGY, V139, P1965, DOI 10.1210/en.139.4.1965; Maamra M, 1999, J BIOL CHEM, V274, P14791, DOI 10.1074/jbc.274.21.14791; MacKenzie S, 1997, BIOCHEM J, V324, P159, DOI 10.1042/bj3240159; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MESSINA JL, 1989, ENDOCRINOLOGY, V124, P754, DOI 10.1210/endo-124-2-754; Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611; MEYER DJ, 1994, J BIOL CHEM, V269, P4701; Ram PA, 1999, J BIOL CHEM, V274, P35553, DOI 10.1074/jbc.274.50.35553; Ram PA, 1996, J BIOL CHEM, V271, P5929, DOI 10.1074/jbc.271.10.5929; Ram PK, 2000, J BIOL CHEM, V275, P39487, DOI 10.1074/jbc.M004755200; SCHWARTZ Y, 1991, P NATL ACAD SCI USA, V88, P6790, DOI 10.1073/pnas.88.15.6790; Shoba LNN, 2001, ENDOCRINOLOGY, V142, P3980, DOI 10.1210/en.142.9.3980; SILVA CM, 1994, J BIOL CHEM, V269, P27532; SMAL J, 1989, P NATL ACAD SCI USA, V86, P4705, DOI 10.1073/pnas.86.12.4705; Smit LS, 1996, MOL ENDOCRINOL, V10, P519, DOI 10.1210/me.10.5.519; Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206; Strous GJ, 1996, EMBO J, V15, P3806, DOI 10.1002/j.1460-2075.1996.tb00754.x; TANNENBAUM GS, 1976, ENDOCRINOLOGY, V98, P562, DOI 10.1210/endo-98-3-562; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; VANDERKUUR J, 1995, J BIOL CHEM, V270, P7587, DOI 10.1074/jbc.270.13.7587; Vanderkuur JA, 1997, ENDOCRINOLOGY, V138, P4301, DOI 10.1210/en.138.10.4301; WAXMAN DJ, 1995, MOL PHARMACOL, V48, P790; WAXMAN DJ, 1995, J BIOL CHEM, V270, P13262, DOI 10.1074/jbc.270.22.13262; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yoshimura A, 1998, LEUKEMIA, V12, P1851, DOI 10.1038/sj.leu.2401238; Yoshimura A, 1998, CYTOKINE GROWTH F R, V9, P197, DOI 10.1016/S1359-6101(98)00019-7	53	42	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 9	2002	277	32					28384	28393		10.1074/jbc.M111723200	http://dx.doi.org/10.1074/jbc.M111723200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	582GX	12161450	hybrid			2022-12-27	WOS:000177342600007
J	Cavarec, L; Kamphausen, T; Dubourg, B; Callebaut, I; Lemeunier, F; Metivier, D; Feunteun, J; Fischer, G; Modjtahedi, N				Cavarec, L; Kamphausen, T; Dubourg, B; Callebaut, I; Lemeunier, F; Metivier, D; Feunteun, J; Fischer, G; Modjtahedi, N			Identification and characterization of Moca-cyp - A Drosophilia melanogaster nuclear cyclophilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS-TRANS-ISOMERASE; PRE-MESSENGER-RNA; A-INSENSITIVE CYCLOPHILIN; CYCLOSPORINE-A; BINDING-PROTEIN; HOMOLOGOUS DOMAIN; CRYSTAL-STRUCTURE; BRUGIA-MALAYI; IMMUNOPHILINS; TRANSCRIPTION	Cyclophilins are enzymes catalyzing the cis-trans isomerization of peptidyl-prolyl bonds and belong to the enzyme class of peptidyl-prolyl cis-trans isomerases (PPIases), which includes two more families (FK506 binding proteins and parvulins). We report the characterization of a novel cyclophilin (Moca-cyp) isolated from Drosophila melanogaster. The single-copy Moca-cyp gene, which is localized on chromosome 3R, was cloned and sequenced. The sequence alignment of the gene against Moca-cyp cDNA allowed us to define its intron/exon structure and to identify a variant cDNA corresponding to an alternatively spliced mRNA. By embryo in situ RNA hybridization and immunostaining, we show that the expression of Moca-cyp is regulated during embryogenesis of Drosophila. The 120-kDa nuclear Moca-cyp protein belongs to a subfamily of large cyclophilins sharing structural and enzymatic features: their highly conserved N-terminal PPIase domain is extended by a positively charged and divergent C-terminal tail. Compared with cyclophilin 18, the enzymatic activity carried by the PPIase domain of Moca-cyp is low, exhibits characteristic substrate specificity, and shows a reduced sensitivity to the drug cyclosporin A (CsA). The reduced affinity for CsA is one of the typical features linking members of this subfamily and is probably the consequence of two amino acid substitutions within their active site. Another structural feature shared by members of this subfamily is a conserved polypeptidic segment ("moca" domain) that we report for the first time. The moca domain is located within the C-terminal tail and is the exclusive hallmark of a group of large cyclophilins found in multicellular organisms of the animal kingdom.	Inst Gustave Roussy, UMR 1599, Lab Genet Oncol, F-94805 Villejuif, France; Max Planck Forsch Stelle Enzymol Prot Faltung, D-06120 Halle An Der Saale, Germany; Univ Paris 06, CNRS, UMR7590, Lab Mineral & Cristallog Paris, F-75252 Paris 05, France; Univ Paris 07, CNRS, UMR7590, Lab Mineral & Cristallog Paris, F-75252 Paris 05, France; CNRS, Lab Populat Genet & Evolut, F-91198 Gif Sur Yvette, France	UNICANCER; Gustave Roussy; Max Planck Society; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Institut de Recherche pour le Developpement (IRD); Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Modjtahedi, N (corresponding author), Inst Gustave Roussy, UMR 1599, Lab Genet Oncol, PR1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	nazanine@igr.fr	Feunteun, Jean/AAZ-1267-2020; MODJTAHEDI, Nazanine/D-4377-2017	Feunteun, Jean/0000-0003-1212-9189				Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON SK, 1993, P NATL ACAD SCI USA, V90, P542, DOI 10.1073/pnas.90.2.542; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; Bannister AJ, 2000, CELL MOL LIFE SCI, V57, P1184, DOI 10.1007/PL00000758; BAYLEY ST, 1994, INT J ONCOL, V5, P425; Bourquin JP, 1997, NUCLEIC ACIDS RES, V25, P2055, DOI 10.1093/nar/25.11.2055; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; Ellis PJ, 2000, BIOCHEMISTRY-US, V39, P592, DOI 10.1021/bi991730q; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FISCHER G, 1994, ANGEW CHEM INT EDIT, V33, P1415, DOI 10.1002/anie.199414151; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; Galat A, 1999, ARCH BIOCHEM BIOPHYS, V371, P149, DOI 10.1006/abbi.1999.1434; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; Giardina SL, 1996, BLOOD, V87, P2269, DOI 10.1182/blood.V87.6.2269.bloodjournal8762269; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; Hani J, 1999, J BIOL CHEM, V274, P108, DOI 10.1074/jbc.274.1.108; Horowitz DS, 2002, EMBO J, V21, P470, DOI 10.1093/emboj/21.3.470; Hunter T, 1998, CELL, V92, P141, DOI 10.1016/S0092-8674(00)80906-X; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIEFFER LJ, 1992, J BIOL CHEM, V267, P5503; Lemeunier F., 2000, P137; Leverson JD, 1998, MOL CELL, V1, P203, DOI 10.1016/S1097-2765(00)80021-0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Ma D, 2002, J BIOL CHEM, V277, P14925, DOI 10.1074/jbc.M112293200; Ma D, 1998, MOL BIOCHEM PARASIT, V92, P361, DOI 10.1016/S0166-6851(98)00006-1; Maniatis T., 1982, MOL CLONING; Mi HF, 1996, FEBS LETT, V398, P201, DOI 10.1016/S0014-5793(96)01248-3; Mikol V, 1998, PROTEIN SCI, V7, P1310, DOI 10.1002/pro.5560070606; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Misteli T, 1997, NATURE, V387, P523, DOI 10.1038/387523a0; MODJTAHEDI N, 1985, CANCER RES, V45, P4372; Mortillaro MJ, 1998, J BIOL CHEM, V273, P8183, DOI 10.1074/jbc.273.14.8183; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Nestel FP, 1996, GENE, V180, P151, DOI 10.1016/S0378-1119(96)00436-2; Page AP, 1996, BIOCHEM J, V317, P179, DOI 10.1042/bj3170179; PAGE AP, 1995, BIOCHEMISTRY-US, V34, P11545, DOI 10.1021/bi00036a030; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Proudfoot N, 2000, TRENDS BIOCHEM SCI, V25, P290, DOI 10.1016/S0968-0004(00)01591-7; RINFRET A, 1994, BIOCHEMISTRY-US, V33, P1668, DOI 10.1021/bi00173a008; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Santos AN, 2000, BIOL REPROD, V62, P1, DOI 10.1095/biolreprod62.1.1; Schiene C, 2000, CURR OPIN STRUC BIOL, V10, P40, DOI 10.1016/S0959-440X(99)00046-9; Schiene-Fischer C, 2001, FEBS LETT, V495, P1, DOI 10.1016/S0014-5793(01)02326-2; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; Snyder SH, 1998, NEURON, V21, P283, DOI 10.1016/S0896-6273(00)80538-3; Tacke R, 1999, CURR OPIN CELL BIOL, V11, P358, DOI 10.1016/S0955-0674(99)80050-7; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; Taylor P, 1998, FEBS LETT, V425, P361, DOI 10.1016/S0014-5793(98)00264-6; Teigelkamp S, 1998, RNA, V4, P127; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YANG WM, 1995, J BIOL CHEM, V270, P15187, DOI 10.1074/jbc.270.25.15187; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	71	15	16	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					41171	41182		10.1074/jbc.M203757200	http://dx.doi.org/10.1074/jbc.M203757200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12154086	hybrid			2022-12-27	WOS:000178791400128
J	Moreira, LA; Ito, J; Ghosh, A; Devenport, M; Zieler, H; Abraham, EG; Crisanti, A; Nolan, T; Catteruccia, F; Jacobs-Lorena, M				Moreira, LA; Ito, J; Ghosh, A; Devenport, M; Zieler, H; Abraham, EG; Crisanti, A; Nolan, T; Catteruccia, F; Jacobs-Lorena, M			Bee venom phospholipase inhibits malaria parasite development in transgenic mosquitoes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YELLOW-FEVER MOSQUITO; AEDES-AEGYPTI; GERMLINE TRANSFORMATION; ANOPHELES-GAMBIAE; SALIVARY-GLANDS; GENE-EXPRESSION; BLOOD MEAL; MIDGUT; VECTOR; GUT	Malaria kills millions of people every year, and new control measures are urgently needed. The recent demonstration that (effector) genes can be introduced into the mosquito germ line to diminish their ability to transmit the malarift parasite offers new hope toward the fight of the disease (Ito, J., Ghosh, AL, Moreira, L. A., Wimmer, E. A. & Jacobs-Lorena, M. (2002) Nature, 417, 452-455). Because of the high selection pressure that an effector gene imposes on the parasite population, development of resistant strains is likely to occur. In search of additional antiparasitic effector genes, we have generated transgenic Anopheles stephensi mosquitoes that express the bee venom phospholipase A2 (PLA2) gene from the gut-specific and blood-inducible Anopheles gambiae carboxypeptidase (AgCP) promoter. Northern blot analysis indicated that the PLA2 mRNA is specifically expressed in the guts of transgenic mosquitoes with peak expression at similar to4 h after blood ingestion. Western blot and immunofluorescence analyses detected PLA2 protein in the midgut epithelia of transgenic mosquitoes from 8 to 24 h after a blood meal. Importantly, transgene expression reduced Plasmodium berghei oocyst formation by 87% on average and greatly impaired transmission of the parasite to naive mice. The results indicate that PLA2 may be used as an additional effector gene to block the development, of the malaria parasite in mosquitoes.	Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, London SW7 2AZ, England	Case Western Reserve University; Imperial College London	Jacobs-Lorena, M (corresponding author), Case Western Reserve Univ, Sch Med, Dept Genet, 10900 Euclid Ave, Cleveland, OH 44106 USA.		Nolan, Tony/I-4925-2012	Nolan, Tony/0000-0002-2982-8333; Catteruccia, Flaminia/0000-0003-3295-6683; Crisanti, Andrea/0000-0002-2406-4426				BLACK IV, 1996, BIOL DIS VECTORS, P438; Capurro MD, 2000, AM J TROP MED HYG, V62, P427, DOI 10.4269/ajtmh.2000.62.427; Catteruccia F, 2000, NATURE, V405, P959, DOI 10.1038/35016096; Coates CJ, 1998, P NATL ACAD SCI USA, V95, P3748, DOI 10.1073/pnas.95.7.3748; Edwards MJ, 1997, INSECT BIOCHEM MOLEC, V27, P1063, DOI 10.1016/S0965-1748(97)00093-3; Ghosh A, 2000, PARASITOL TODAY, V16, P196, DOI 10.1016/S0169-4758(99)01626-9; Ghosh AK, 2001, P NATL ACAD SCI USA, V98, P13278, DOI 10.1073/pnas.241491198; Handler AM, 1999, INSECT MOL BIOL, V8, P449, DOI 10.1046/j.1365-2583.1999.00139.x; Horn C, 2000, DEV GENES EVOL, V210, P630, DOI 10.1007/s004270000110; Ito J, 2002, NATURE, V417, P452, DOI 10.1038/417452a; Jasinskiene N, 1998, P NATL ACAD SCI USA, V95, P3743, DOI 10.1073/pnas.95.7.3743; Kokoza V, 2000, P NATL ACAD SCI USA, V97, P9144, DOI 10.1073/pnas.160258197; KUCHLER K, 1989, EUR J BIOCHEM, V184, P249, DOI 10.1111/j.1432-1033.1989.tb15014.x; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; Lemos FJA, 1996, INSECT BIOCHEM MOLEC, V26, P651, DOI 10.1016/S0965-1748(96)00014-8; Moreira LA, 2000, P NATL ACAD SCI USA, V97, P10895, DOI 10.1073/pnas.97.20.10895; Nolan T, 2002, J BIOL CHEM, V277, P8759, DOI 10.1074/jbc.C100766200; Pinkerton AC, 2000, INSECT MOL BIOL, V9, P1, DOI 10.1046/j.1365-2583.2000.00133.x; Shahabuddin M, 1998, PARASITOL TODAY, V14, P493, DOI 10.1016/S0169-4758(98)01348-9; Webster D, 2001, J PUBLIC HEALTH POL, V22, P23, DOI 10.2307/3343552; Zieler H, 2001, J EXP BIOL, V204, P4157	21	141	156	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 25	2002	277	43					40839	40843		10.1074/jbc.M206647200	http://dx.doi.org/10.1074/jbc.M206647200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	607KU	12167627	hybrid			2022-12-27	WOS:000178791400088
J	Noguchi, K; Fukazawa, H; Murakami, Y; Uehara, Y				Noguchi, K; Fukazawa, H; Murakami, Y; Uehara, Y			Nek11, a new member of the NIMA family of kinases, involved in DNA replication and genotoxic stress responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE REGULATION; POLO-LIKE KINASE-1; PROTEIN-KINASE; ASPERGILLUS-NIDULANS; SUBSTRATE-SPECIFICITY; MITOTIC REGULATOR; DAMAGE CHECKPOINT; TYR15 PHOSPHORYLATION; EXPRESSION PATTERN; MURINE NEK3	DNA replication and genotoxic stresses activate various checkpoint-associated protein kinases, and checkpoint dysfunction often leads to cell lethality. Here, we have identified new members of the mammalian NIMA family of kinases, termed Nek11L and Nek11S (NIMA-related kinase 11 Lone and Short isoform) as novel DNA replication/damage stresses-responsive kinases. Molecular cloning and biochemical studies showed that the catalytic domain of Nek11 is most similar to Nek4 and Nek3, and substrate specificity of Nek11L is distinguishable from those of NIMA and Nek2. The expression of nek11L mRNA increased through S to G(2)/M phase, and subcellular localization of Nek11 protein altered between interphase and prometaphase, suggesting multiple roles of Nek11. We found an activation of Nek11 kinase activity when cells were treated with various DNA-damaging agents and replication inhibitors, and this activation of Nek11 was suppressed by caffeine in HeLaS3 cells. The transient expression of wild-type Nek11L enhanced the aphidicolin-induced S-phase arrest, whereas the aphidicolin-induced S-phase arrest was reduced in the U2OS cell lines expressing kinase-negative Nek11L (K61R), and these cells were more sensitive to aphidicolin-induced cell lethality. Collectively, these results suggest that Nek11 has a role in the S-phase checkpoint downstream of the caffeine-sensitive pathway.	Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, Tokyo 1628640, Japan	National Institute of Infectious Diseases (NIID)	Uehara, Y (corresponding author), Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.							Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Arama E, 1998, ONCOGENE, V16, P1813, DOI 10.1038/sj.onc.1201710; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; Biggins S, 2001, GENE DEV, V15, P3118, DOI 10.1101/gad.934801; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Chen A, 1999, GENE, V234, P127, DOI 10.1016/S0378-1119(99)00165-1; Cliby WA, 2002, J BIOL CHEM, V277, P1599, DOI 10.1074/jbc.M106287200; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Holland PM, 2002, J BIOL CHEM, V277, P16229, DOI 10.1074/jbc.M108662200; JONES DGL, 1990, GENE, V90, P87, DOI 10.1016/0378-1119(90)90442-T; Kandli M, 2000, GENOMICS, V68, P187, DOI 10.1006/geno.2000.6293; Kimura M, 2001, CYTOGENET CELL GENET, V94, P33, DOI 10.1159/000048779; Krien MJE, 1998, J CELL SCI, V111, P967; Krien MJE, 2002, EMBO J, V21, P1713, DOI 10.1093/emboj/21.7.1713; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; LEVEDAKOU EN, 1994, ONCOGENE, V9, P1977; Li MZ, 1999, CYTOGENET CELL GENET, V87, P271, DOI 10.1159/000015445; Liu QH, 2000, GENE DEV, V14, P1448; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; LU KP, 1994, EMBO J, V13, P2103, DOI 10.1002/j.1460-2075.1994.tb06486.x; LU KP, 1993, J BIOL CHEM, V268, P8769; LU KP, 1994, J BIOL CHEM, V269, P6603; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; OSMANI SA, 1987, J CELL BIOL, V104, P1495, DOI 10.1083/jcb.104.6.1495; Osmani SA, 1996, BIOCHEM J, V317, P633, DOI 10.1042/bj3170633; PU RT, 1995, J BIOL CHEM, V270, P18110, DOI 10.1074/jbc.270.30.18110; Roig J, 2002, GENE DEV, V16, P1640, DOI 10.1101/gad.972202; Sarkaria JN, 1999, CANCER RES, V59, P4375; SCHULTZ SJ, 1994, CELL GROWTH DIFFER, V5, P625; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Tanaka K, 1999, J BIOL CHEM, V274, P13491, DOI 10.1074/jbc.274.19.13491; Tanaka K, 1997, EXP CELL RES, V237, P264, DOI 10.1006/excr.1997.3788; Upadhya P, 2000, P NATL ACAD SCI USA, V97, P217, DOI 10.1073/pnas.97.1.217; van Vugt MATM, 2001, J BIOL CHEM, V276, P41656, DOI 10.1074/jbc.M101831200; Ye XS, 1997, EMBO J, V16, P182, DOI 10.1093/emboj/16.1.182; Ye XS, 1996, EMBO J, V15, P3599, DOI 10.1002/j.1460-2075.1996.tb00729.x	50	58	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39655	39665		10.1074/jbc.M204599200	http://dx.doi.org/10.1074/jbc.M204599200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12154088	hybrid			2022-12-27	WOS:000178662500078
J	Rasanen, TL; Alhonen, L; Sinervirta, R; Keinanen, T; Herzig, KH; Suppola, S; Khomutov, AR; Vepsalainen, J; Janne, J				Rasanen, TL; Alhonen, L; Sinervirta, R; Keinanen, T; Herzig, KH; Suppola, S; Khomutov, AR; Vepsalainen, J; Janne, J			A polyamine analogue prevents acute pancreatitis and restores early liver regeneration in transgenic rats with activated polyamine catabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE DECARBOXYLASE GENE; SPERMIDINE/SPERMINE N-1-ACETYLTRANSFERASE; MICE; EXPRESSION; HYPUSINE; CELLS; OVEREXPRESSION; INHIBITION; METABOLISM; GROWTH	We recently generated a transgenic rat model for acute pancreatitis, which was apparently caused by a massive depletion of pancreatic polyamines spermidine and spermine due to inducible activation of their catabolism (Alhonen, L., Parkkinen, J. J., Keinanen, T., Sinervirta, R., Herzig, K. H., and Janne, J. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 8290-8295). When subjected to partial hepatectomy, these animals showed striking activation of polyamine catabolism at 24 h postoperatively with a profound decrease in hepatic spermidine and spermine pools and failure to initiate liver regeneration. Here we show that pancreatitis in this model could be totally prevented, as judged by histopathology and plasma a-amylase activity, by administration of 1-methylspermidine, a metabolically stable analogue of spermidine. Similarly, the analogue, given prior to partial hepatectomy, restored early liver regeneration in the transgenic rats, as indicated by a dramatic increase in the number of proliferating cell nuclear antigen-positive hepatocytes from about 1% to more than 40% in response to the drug. The present results suggest that the extremely high concentration of spermidine in the pancreas, in fact the highest in the mammalian body, may have a critical role in maintaining organ integrity. The failure to initiate liver regeneration in the absence of sufficient hepatic polyamine pools similarly indicates that polyamines are required for proper commencement of the regenerative process.	Univ Kuopio, AI Virtanen Inst Mol Sci, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Chem, FIN-70211 Kuopio, Finland; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Moscow 117984, Russia	University of Eastern Finland; University of Eastern Finland; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Janne, J (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, POB 1627, FIN-70211 Kuopio, Finland.		Khomutov, Alex/G-2128-2015; Keinänen, Tuomo/AAC-5630-2019	Khomutov, Alex/0000-0001-6833-7855				Alhonen L, 2000, P NATL ACAD SCI USA, V97, P8290, DOI 10.1073/pnas.140122097; Alhonen L, 2002, BIOCHEM J, V362, P149, DOI 10.1042/0264-6021:3620149; Bergeron RJ, 1998, J MED CHEM, V41, P3901, DOI 10.1021/jm980390o; BERNACKI RJ, 1992, CANCER RES, V52, P2424; BYERS TL, 1994, BIOCHEM J, V303, P363, DOI 10.1042/bj3030363; CASERO RA, 1993, FASEB J, V7, P653, DOI 10.1096/fasebj.7.8.8500690; HAKOVIRTA H, 1993, MOL ENDOCRINOL, V7, P1430, DOI 10.1210/me.7.11.1430; HALMEKYTO M, 1993, BIOCHEM J, V291, P505, DOI 10.1042/bj2910505; HALMEKYTO M, 1991, J BIOL CHEM, V266, P19746; Higgins GM, 1931, ARCH PATHOL, V12, P186; HYVONEN T, 1992, J CHROMATOGR-BIOMED, V574, P17, DOI 10.1016/0378-4347(92)80093-6; JANNE J, 1991, ANN MED, V23, P241, DOI 10.3109/07853899109148056; Khomutov AR, 1996, TETRAHEDRON, V52, P13751, DOI 10.1016/0040-4020(96)00836-8; LAKANEN JR, 1992, J MED CHEM, V35, P724, DOI 10.1021/jm00082a013; Lukkarinen J, 1997, STROKE, V28, P639, DOI 10.1161/01.STR.28.3.639; NIEDERAU C, 1986, J CLIN INVEST, V78, P1056, DOI 10.1172/JCI112661; PARK MH, 1981, P NATL ACAD SCI-BIOL, V78, P2869, DOI 10.1073/pnas.78.5.2869; Pietila M, 1997, J BIOL CHEM, V272, P18746, DOI 10.1074/jbc.272.30.18746; Suppola S, 1999, BIOCHEM J, V338, P311, DOI 10.1042/0264-6021:3380311; Suppola S, 2001, BIOCHEM J, V358, P343, DOI 10.1042/0264-6021:3580343; THEOCHARIS SE, 1994, DIGEST DIS SCI, V39, P245, DOI 10.1007/BF02090193; Varnado BL, 2000, BIOORG CHEM, V28, P395, DOI 10.1006/bioo.2000.1195	22	56	62	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39867	39872		10.1074/jbc.M205967200	http://dx.doi.org/10.1074/jbc.M205967200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12181316	hybrid			2022-12-27	WOS:000178662500103
J	Szymkiewicz, I; Kowanetz, K; Soubeyran, P; Dinarina, A; Lipkowitz, S; Dikic, I				Szymkiewicz, I; Kowanetz, K; Soubeyran, P; Dinarina, A; Lipkowitz, S; Dikic, I			CIN85 participates in Cbl-b-mediated down-regulation of receptor tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-RECEPTOR; PROTEIN C-CBL; ADAPTER PROTEIN; NEGATIVE REGULATION; EGF RECEPTOR; PLASMA-MEMBRANE; CELL-ADHESION; SH3 DOMAINS; A431 CELLS; UBIQUITINATION	The Cbl family of ubiquitin ligases in mammals contains three members, Cbl, Cbl-b, and Chl-3, that are involved in down-regulation of receptor tyrosine kinases (RTKs) by mediating receptor ubiquitination and degradation. More recently, a novel pathway has been identified whereby Cbl promotes internalization of EGF receptor via a CIN85/endophilin pathway that is functionally separable from the ubiquitin ligase activity of Cbl (1). Here we show that Cbl-b, but not Chl-3, utilize the same mechanism to down-regulate multiple RTKs. CIN85 was shown to bind to the minimal binding domain identified in the carboxyl terminus of Cbl-b. Ligand-induced phosphorylation of Cbl-b further increased their interactions and led to a rapid and sustained recruitment of CIN85 in the complex with EGF or PDGF receptors. Inhibition of binding between CIN85 and Cbl-b was sufficient to impair Cbl-b-mediated internalization of EGF receptors, while being dispensable for Cbl-b-directed polyubiquitination of EGF receptors. Moreover, CIN85 and Cbl/Cbl-b were constitutively associated with activated PDGF, EGF, or c-Kit receptors in several tumor cell lines. Our data reveal a common pathway utilized by Cbl and Cbl-b that may have an important and redundant function in negative regulation of ligand-activated as well as oncogenically activated RTKs in vivo.	Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; NCI, Canc Genet Branch, Ctr Canc Res, Gaithersburg, MD 20899 USA	Ludwig Institute for Cancer Research; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Dikic, I (corresponding author), Ludwig Inst Canc Res, Box 595,Husargatan 3, S-75124 Uppsala, Sweden.		Dikic, Ivan/O-4650-2015; Pilecka, Iwona/AAT-9114-2021; Soubeyran, Philippe/P-1758-2018	Dikic, Ivan/0000-0001-8156-9511; Pilecka, Iwona/0000-0002-5057-346X; Soubeyran, Philippe/0000-0002-5876-3217				Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bartkiewicz M, 1999, J BIOL CHEM, V274, P30887, DOI 10.1074/jbc.274.43.30887; Borinstein SC, 2000, CELL SIGNAL, V12, P769, DOI 10.1016/S0898-6568(00)00129-7; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200; de Melker AA, 2001, J CELL SCI, V114, P2167; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Ettenberg SA, 2001, J BIOL CHEM, V276, P27677, DOI 10.1074/jbc.M102641200; Gout I, 2000, EMBO J, V19, P4015, DOI 10.1093/emboj/19.15.4015; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Joazeiro CAP, 2000, SCIENCE, V289, P2061, DOI 10.1126/science.289.5487.2061; Keane MM, 1999, ONCOGENE, V18, P3365, DOI 10.1038/sj.onc.1202753; KEANE MM, 1995, ONCOGENE, V10, P2367; Kirsch KH, 2001, J BIOL CHEM, V276, P4957, DOI 10.1074/jbc.M005784200; Klapper LN, 2000, CANCER RES, V60, P3384; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Liu YC, 2002, TRENDS IMMUNOL, V23, P140, DOI 10.1016/S1471-4906(01)02157-3; Liu YC, 1998, CELL SIGNAL, V10, P377, DOI 10.1016/S0898-6568(97)00179-4; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Oksvold MP, 2001, EUR J CELL BIOL, V80, P285, DOI 10.1078/0171-9335-00160; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; REISS M, 1991, CANCER RES, V51, P6254; Sanjay A, 2001, J CELL BIOL, V152, P181, DOI 10.1083/jcb.152.1.181; Sjoblom T, 2001, CANCER RES, V61, P5778; SORKIN A, 1989, BIOCHIM BIOPHYS ACTA, V1011, P88, DOI 10.1016/0167-4889(89)90083-9; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; THOMPSON DM, 1985, CANCER SURV, V4, P767; Tsujimura T, 1999, BLOOD, V93, P1319, DOI 10.1182/blood.V93.4.1319.404k11_1319_1329; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Watanabe S, 2000, BIOCHEM BIOPH RES CO, V278, P167, DOI 10.1006/bbrc.2000.3760; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; Xue LZ, 1998, CELL SIGNAL, V10, P339, DOI 10.1016/S0898-6568(98)00011-4; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zell T, 1998, CURR BIOL, V8, P814, DOI 10.1016/S0960-9822(98)70323-9	46	97	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39666	39672		10.1074/jbc.M205535200	http://dx.doi.org/10.1074/jbc.M205535200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12177062	hybrid			2022-12-27	WOS:000178662500079
J	Wolfert, MA; Murray, TF; Boons, GJ; Moore, JN				Wolfert, MA; Murray, TF; Boons, GJ; Moore, JN			The origin of the synergistic effect of muramyl dipeptide with endotoxin and peptidoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; TOLL-LIKE RECEPTOR-4; CELL WALL COMPONENTS; LIPOPOLYSACCHARIDE LPS; BACTERIAL PEPTIDOGLYCAN; STAPHYLOCOCCUS-AUREUS; CUTTING EDGE; ALPHA GENE; TNF-ALPHA; CD14	Although the basis for the high mortality rate for patients with mixed bacterial infections is likely to be multifactorial, there is evidence for a synergistic effect of muramyldipeptide (MDP) with lipopolysaccharide (LPS) on the synthesis of proinflammatory cytokines by mononuclear phagocytes. In this study, co-incubation of human Mono Mac 6 cells with MDP and either LPS or peptidoglycan (PGN) resulted in an apparent synergistic effect on tumor necrosis factor-alpha (TNF-alpha) secretion. Although incubation of cells with MDP alone produced minimal TNF-alpha, it caused significant expression of TNF-alpha mRNA. These findings suggest that the majority of TNF-alpha mRNA induced by MDP alone is not translated into protein. Furthermore, simultaneous incubation of cells with MDP and either LPS or PGN resulted in TNF-alpha mRNA expression that approximated the sum of the amounts expressed in response to MDP, LPS, and PGN individually. These findings indicate that the apparent synergistic effect of MDP on TNF-alpha production induced by either LPS or PGN is due to removal of a block in translation of the mRNA expressed in response to MDP. In subsequent studies, the effects of MDP alone and its effect on the production of TNF-alpha by LPS and PGN were determined to be independent of CD14, Toll-like receptor 2, and Toll-like receptor 4. These findings indicate that MDP acts through receptor(s) other than those primarily responsible for transducing the effects of LPS and PGN. Successful treatment of patients having mixed bacterial infections is likely to require interventions that address the mechanisms involved in responses induced by a variety of bacterial cell wall components.	Univ Georgia, Coll Vet Med, Dept Large Anim Med, Athens, GA 30602 USA; Univ Georgia, Coll Vet Med, Dept Physiol & Pharmacol, Athens, GA 30602 USA; Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Wolfert, MA (corresponding author), Univ Georgia, Coll Vet Med, Dept Large Anim Med, Athens, GA 30602 USA.		Wolfert, Margreet A/J-1726-2016; Boons, Geert-Jan P H/J-3211-2016	Wolfert, Margreet A/0000-0003-4864-0026; Boons, Geert-Jan P H/0000-0003-3111-5954				BASCHANG G, 1989, TETRAHEDRON, V45, P6331, DOI 10.1016/S0040-4020(01)89512-0; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; BEUTLER B, 1992, AM J MED SCI, V303, P129, DOI 10.1097/00000441-199202000-00015; BIRAGYN A, 1995, J IMMUNOL, V155, P674; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Crawford EK, 1997, J BIOL CHEM, V272, P21120, DOI 10.1074/jbc.272.34.21120; Crowe M, 1998, EUR J CLIN MICROBIOL, V17, P377, DOI 10.1007/s100960050089; Dziarski R, 2000, CHEM IMMUNOL, V74, P83; Dziarski R, 1998, J BIOL CHEM, V273, P8680, DOI 10.1074/jbc.273.15.8680; Flak TA, 2000, INFECT IMMUN, V68, P1235, DOI 10.1128/IAI.68.3.1235-1242.2000; Gao JJ, 2001, J IMMUNOL, V166, P6855, DOI 10.4049/jimmunol.166.11.6855; Gupta D, 1996, J BIOL CHEM, V271, P23310, DOI 10.1074/jbc.271.38.23310; Jiang QQ, 2000, J IMMUNOL, V165, P3541, DOI 10.4049/jimmunol.165.7.3541; JONGENEEL CV, 1995, IMMUNOBIOLOGY, V193, P210, DOI 10.1016/S0171-2985(11)80545-0; JUAN TSC, 1995, J BIOL CHEM, V270, P17237, DOI 10.1074/jbc.270.29.17237; KITCHENS RL, 1995, J BIOL CHEM, V270, P9904, DOI 10.1074/jbc.270.17.9904; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LICHTMAN SN, 1994, HEPATOLOGY, V19, P1013, DOI 10.1002/hep.1840190429; Mijatovic T, 2000, EUR J BIOCHEM, V267, P6004, DOI 10.1046/j.1432-1327.2000.01676.x; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; RIBI EE, 1979, CANCER RES, V39, P4756; ROBERTS FJ, 1991, REV INFECT DIS, V13, P34; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Siriwardena A, 2001, J AM CHEM SOC, V123, P8145, DOI 10.1021/ja0104655; Takeuchi O, 2000, INT IMMUNOL, V12, P113, DOI 10.1093/intimm/12.1.113; Tapping RI, 2000, J IMMUNOL, V165, P5780, DOI 10.4049/jimmunol.165.10.5780; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; Tsubery H, 2000, BIOCHEMISTRY-US, V39, P11837, DOI 10.1021/bi000386q; van Langevelde P, 1999, ANTIMICROB AGENTS CH, V43, P2984, DOI 10.1128/AAC.43.12.2984; Wang JE, 2001, SHOCK, V16, P178, DOI 10.1097/00024382-200116030-00002; Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199; WEIDEMANN B, 1997, INFECT IMMUN, V65, P558; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200; Yang SH, 2001, INFECT IMMUN, V69, P2045, DOI 10.1128/IAI.69.4.2045-2053.2001; Yoshimura A, 1999, J IMMUNOL, V163, P1	37	128	137	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 18	2002	277	42					39179	39186		10.1074/jbc.M204885200	http://dx.doi.org/10.1074/jbc.M204885200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	605EA	12151399	hybrid			2022-12-27	WOS:000178662500017
J	Kamradt, MC; Chen, F; Sam, S; Cryns, VL				Kamradt, MC; Chen, F; Sam, S; Cryns, VL			The small heat shock protein alpha B-crystallin negatively regulates apoptosis during myogenic differentiation by inhibiting caspase-3 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESMIN-RELATED MYOPATHY; SKELETAL-MUSCLE; CYTOCHROME-C; MYOCYTE DIFFERENTIATION; PROTECTIVE ACTIVITY; CELL-DEATH; EXPRESSION; HSP27; PHOSPHORYLATION; NECROSIS	Myoblasts-respond to growth factor deprivation either by differentiating into multinucleated myotubes or by undergoing apoptosis; hence, the acquisition of apoptosis resistance by myogenic precursors is essential for their development. Here we demonstrate that the expression of the small heat shock protein alphaB-crystallin is selectively induced in C2C12 myoblasts that are resistant to differentiation-induced apoptosis, and we show that this induction occurs at an early stage in their differentiation in vitro. In contrast, the expression of several known anti-apoptotic proteins (FLIP, XLAP, Bcl-x(L)) was not altered during myogenesis. We also demonstrate that ectopic expression of alphaB-crystallin, but not the closely related small heat shock protein Hsp27, renders C2C12 myoblasts resistant to differentiation-induced apoptosis. Furthermore, we show that the myopathy-causing R120G alphaB-crystallin mutant is partly impaired in its cytoprotective function, whereas a pseudophosphorylation alphaB-crystallin mutant that mimics stress-induced phosphorylation is completely devoid of anti-apoptotic activity. Finally, we demonstrate that alphaB-crystallin negatively regulates apoptosis during myogenesis by inhibiting the proteolytic activation of caspase-3, whereas the R120G and pseudophosphorylation mutants are defective in this function. Taken together, our findings indicate that alphaB-crystallin is a novel negative regulator of myogenic apoptosis that directly links the differentiation program to apoptosis resistance.	Northwestern Univ, Div Endocrinol, Feinberg Sch Med, Dept Med,Ctr Endocrinol Metab & Mol Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Cryns, VL (corresponding author), Northwestern Univ, Div Endocrinol, Feinberg Sch Med, Dept Med,Ctr Endocrinol Metab & Mol Med, Tarry 15-755,303 E Chicago Ave, Chicago, IL 60611 USA.	v-cryns@northwestern.edu			NATIONAL CANCER INSTITUTE [T32CA070085] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031957] Funding Source: NIH RePORTER; NCI NIH HHS [5T32-CA70085] Funding Source: Medline; NINDS NIH HHS [NS31957] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Benjamin IJ, 1997, DEV DYNAM, V208, P75; Benndorf R, 2001, J BIOL CHEM, V276, P26753, DOI 10.1074/jbc.M103001200; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Burgess DH, 1999, CELL DEATH DIFFER, V6, P256, DOI 10.1038/sj.cdd.4400489; Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840; Clark JI, 2000, CURR OPIN STRUC BIOL, V10, P52, DOI 10.1016/S0959-440X(99)00048-2; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Der Perng M, 1999, J BIOL CHEM, V274, P33235, DOI 10.1074/jbc.274.47.33235; Dominov JA, 1998, J CELL BIOL, V142, P537, DOI 10.1083/jcb.142.2.537; DUBIN RA, 1991, MOL CELL BIOL, V11, P4340, DOI 10.1128/MCB.11.9.4340; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; GOPALSRIVASTAVA R, 1993, MOL CELL BIOL, V13, P7144, DOI 10.1128/MCB.13.11.7144; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; KAUFMAN SJ, 1988, P NATL ACAD SCI USA, V85, P9606, DOI 10.1073/pnas.85.24.9606; Lawlor MA, 2000, MOL CELL BIOL, V20, P3256, DOI 10.1128/MCB.20.9.3256-3265.2000; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Plater ML, 1996, J BIOL CHEM, V271, P28558, DOI 10.1074/jbc.271.45.28558; Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; SCHAART G, 1989, DEVELOPMENT, V107, P585; Sugiyama Y, 2000, J BIOL CHEM, V275, P1095, DOI 10.1074/jbc.275.2.1095; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang J, 1997, CANCER RES, V57, P351; Wang XJ, 2001, CIRC RES, V89, P84, DOI 10.1161/hh1301.092688	33	237	256	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38731	38736		10.1074/jbc.M201770200	http://dx.doi.org/10.1074/jbc.M201770200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12140279	hybrid			2022-12-27	WOS:000178529600092
J	Tu, C; Qian, MZ; An, HQ; Wadhwa, NR; Duda, D; Yoshioka, C; Pathak, Y; McKenna, R; Laipis, PJ; Silverman, DN				Tu, C; Qian, MZ; An, HQ; Wadhwa, NR; Duda, D; Yoshioka, C; Pathak, Y; McKenna, R; Laipis, PJ; Silverman, DN			Kinetic analysis of multiple proton shuttles in the active site of human carbonic anhydrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTED MUTAGENESIS; CATALYTIC PROPERTIES; STRUCTURAL-CHANGES; REFINED STRUCTURE; CHEMICAL RESCUE; SKELETAL-MUSCLE; MUTANTS; RESOLUTION; MECHANISM; RESIDUES	We have prepared a site-specific mutant of human carbonic anhydrase (HCA) II with histidine residues at positions 7 and 64 in the active site cavity. Using a different isozyme, we have placed histidine residues in HCA III at positions 64 and 67 and in another mutant at positions 64 and 7. Each of these histidine residues can act as a proton transfer group in catalysis when it is the only nonliganding histidine in the active site cavity, except His(7) in HCA III. Using an O-18 exchange method to measure rate constants for intramolecular proton transfer, we have found that inserting two histidine residues into the active site cavity of either isozyme II or III of carbonic anhydrase results in rates of proton transfer to the zinc-bound hydroxide that are antagonistic or suppressive with respect to the corresponding single mutants. The crystal structure of Y7H HCA II, which contains both His(7) and His(64) within the active site cavity, shows the conformation of the side chain of His(64) moved from its position in the wild type and hydrogen-bonded through an intervening water molecule with the side chain of His(7). This suggests a cause of decreased proton transfer in catalysis.	Univ Florida, Coll Med, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Silverman, DN (corresponding author), Univ Florida, Coll Med, Ctr Hlth, Box 100267, Gainesville, FL 32601 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM25154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelroth P, 2001, BIOCHEMISTRY-US, V40, P14538, DOI 10.1021/bi011585s; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; CHEN X, 1993, BIOCHEMISTRY-US, V32, P7861, DOI 10.1021/bi00082a004; Christianson DW, 1996, ACCOUNTS CHEM RES, V29, P331, DOI 10.1021/ar9501232; Duda D, 2001, BIOCHEMISTRY-US, V40, P1741, DOI 10.1021/bi002295z; Duda DM, 2002, ACTA CRYSTALLOGR D, V58, P849, DOI 10.1107/S0907444902003700; ENGBERG P, 1985, ARCH BIOCHEM BIOPHYS, V241, P628, DOI 10.1016/0003-9861(85)90589-2; ERIKSSON AE, 1993, PROTEINS, V16, P29, DOI 10.1002/prot.340160104; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; HECK RW, 1994, J BIOL CHEM, V269, P24742; Jackman JE, 1996, BIOCHEMISTRY-US, V35, P16421, DOI 10.1021/bi961786+; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jude KM, 2002, BIOCHEMISTRY-US, V41, P2485, DOI 10.1021/bi015808q; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; KHALIFAH RG, 1977, BIOCHEMISTRY-US, V16, P2241, DOI 10.1021/bi00629a031; Kresge AJ, 1999, METHODS ENZYMOL, V308, P276; LIANG ZW, 1993, EUR J BIOCHEM, V211, P821, DOI 10.1111/j.1432-1033.1993.tb17614.x; Lindskog S, 1997, PHARMACOL THERAPEUT, V74, P1, DOI 10.1016/S0163-7258(96)00198-2; LOGRASSO PV, 1991, BIOCHEMISTRY-US, V30, P8463, DOI 10.1021/bi00098a025; LOGRASSO PV, 1993, BIOCHEMISTRY-US, V32, P5786, DOI 10.1021/bi00073a010; Lu DS, 1998, J AM CHEM SOC, V120, P4006, DOI 10.1021/ja973397o; Luecke H, 1999, SCIENCE, V286, P255, DOI 10.1126/science.286.5438.255; Mallis RJ, 2000, FEBS LETT, V482, P237, DOI 10.1016/S0014-5793(00)02022-6; McPherson A, 1982, PREPARATION ANAL PRO; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILDVAN AS, 1992, ARCH BIOCHEM BIOPHYS, V294, P327, DOI 10.1016/0003-9861(92)90692-P; Mitchell DM, 1996, BIOCHEMISTRY-US, V35, P13089, DOI 10.1021/bi961416l; NAIR SK, 1991, J AM CHEM SOC, V113, P9455, DOI 10.1021/ja00025a005; Otwinowski Z., 2000, INT TABLES CRYSTALLO, VF, P226; Qian MZ, 1997, BIOCHEMISTRY-US, V36, P15758, DOI 10.1021/bi972081q; REN XL, 1995, BIOCHEMISTRY-US, V34, P8492, DOI 10.1021/bi00026a033; SILVERMAN DN, 1993, BIOCHEMISTRY-US, V32, P10757, DOI 10.1021/bi00091a029; SILVERMAN DN, 1982, METHOD ENZYMOL, V87, P732; SIMONSSON I, 1979, EUR J BIOCHEM, V93, P409, DOI 10.1111/j.1432-1033.1979.tb12837.x; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANHAUSER SM, 1992, GENE, V117, P113, DOI 10.1016/0378-1119(92)90498-E; TU CK, 1986, J BIOL CHEM, V261, P100; TU CK, 1994, J BIOL CHEM, V269, P23002; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; TU CK, 1983, J BIOL CHEM, V258, P8867; Warren MS, 1996, BIOCHEMISTRY-US, V35, P8855, DOI 10.1021/bi9528715	44	14	17	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38870	38876		10.1074/jbc.M205791200	http://dx.doi.org/10.1074/jbc.M205791200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12171926	hybrid			2022-12-27	WOS:000178529600109
J	Wechsler, J; Choi, YH; Krall, J; Ahmad, F; Manganiello, VC; Movsesian, MA				Wechsler, J; Choi, YH; Krall, J; Ahmad, F; Manganiello, VC; Movsesian, MA			Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; SARCOPLASMIC-RETICULUM; GENE-TRANSFER; IN-VITRO; CAMP; ACTIVATION; PHOSPHORYLATION; INSULIN; PHOSPHOLAMBAN; IDENTIFICATION	PDE3A cyclic nucleotide phosphodiesterases regulate cAMP- and cGMP-mediated intracellular signaling in cardiac myocytes. We used antibodies to different regions of PDE3A to demonstrate the presence of three PDE3A isoforms in these cells. These isoforms, whose apparent molecular weights are 136,000, 118,000, and 94,000 ("PDE3A-136,"PDE3A-118," and "PDE3A-94"), are identical save for the deletion of different lengths of N-terminal sequence containing two membrane-association domains and sites for phosphorylation/activation by protein kinase B ("PK-B") and protein kinase A ("PK-A"). PDE3A-136 contains both membrane-association domains and the PK-B and PK-A sites. PDE3-118 contains only the downstream membrane-association domain and the PK-A sites. PDE3A-94 lacks both membrane localization domains and the PK-B and PK-A sites. The three isoforms are translated from two mRNAs derived from the PDE3A1 gene: PDE3A-136 is translated from PDE3A1 mRNA, whereas PDE3A-118 and PDE3A-94 are translated from PDE3A2 mRNA. Experiments involving in vitro transcription/translation indicate that PDE3A-118 and PDE3A-94 may be translated from different AUGs in PDE3A2 mRNA. These findings suggest that alternative transcriptional and post-transcriptional processing of the PDE3A gene results in the generation of two mRNAs and three protein isoforms in cardiac myocytes that differ with respect to intracellular localization and may be regulated through different signaling pathways.	Vet Affairs Salt Lake City Hlth Care Syst, Cardiol Sect, Salt Lake City, UT 84148 USA; Univ Utah, Sch Med, Dept Internal Med Cardiol, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Pharmacol, Salt Lake City, UT 84132 USA; NHLBI, Pulm Crit Care Med Branch, NIH, Bethesda, MD 20892 USA	US Department of Veterans Affairs; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Movsesian, MA (corresponding author), Vet Affairs Salt Lake City Hlth Care Syst, Cardiol Sect 111C, 500 Foothill Blvd, Salt Lake City, UT 84148 USA.	matthew.movsesian@med.va.gov	Khan, Faiyaz Ahmad/AAW-7944-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL002540, Z01HL002540] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahmad F, 2000, J IMMUNOL, V164, P4678, DOI 10.4049/jimmunol.164.9.4678; BOHM M, 1994, CARDIOVASC RES, V28, P1713, DOI 10.1093/cvr/28.11.1713; Choi YH, 2001, BIOCHEM J, V353, P41, DOI 10.1042/0264-6021:3530041; del Monte F, 2002, CIRCULATION, V105, P904, DOI 10.1161/hc0802.105564; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; FISCHMEISTER R, 1990, MOL PHARMACOL, V38, P426; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; GRANT PG, 1988, P NATL ACAD SCI USA, V85, P9071, DOI 10.1073/pnas.85.23.9071; HAYES JS, 1980, J BIOL CHEM, V255, P5113; Hoffmann R, 1998, BIOCHEM J, V333, P139, DOI 10.1042/bj3330139; Hoffmann R, 1999, EMBO J, V18, P893, DOI 10.1093/emboj/18.4.893; Huston E, 2000, J BIOL CHEM, V275, P28063; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; KASUYA J, 1995, J BIOL CHEM, V270, P14305, DOI 10.1074/jbc.270.24.14305; Kenan Y, 2000, J BIOL CHEM, V275, P12331, DOI 10.1074/jbc.275.16.12331; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Krall J, 1999, J MOL CELL CARDIOL, V31, P971, DOI 10.1006/jmcc.1999.0926; LAZOU A, 1994, CIRC RES, V75, P932, DOI 10.1161/01.RES.75.5.932; Liu HG, 1999, J BIOL CHEM, V274, P10557, DOI 10.1074/jbc.274.15.10557; LOPEZAPARICIO P, 1993, BIOCHEM BIOPH RES CO, V193, P1137, DOI 10.1006/bbrc.1993.1744; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; McPhee I, 1999, J BIOL CHEM, V274, P11796, DOI 10.1074/jbc.274.17.11796; MEACCI E, 1992, P NATL ACAD SCI USA, V89, P3721, DOI 10.1073/pnas.89.9.3721; Minamisawa S, 1999, CELL, V99, P313, DOI 10.1016/S0092-8674(00)81662-1; Movsesian MA, 1999, J AM COLL CARDIOL, V34, P318, DOI 10.1016/S0735-1097(99)00220-X; Rahn T, 1996, J BIOL CHEM, V271, P11575, DOI 10.1074/jbc.271.19.11575; RAPUNDALO ST, 1989, CIRC RES, V64, P104, DOI 10.1161/01.RES.64.1.104; RASCON A, 1994, J BIOL CHEM, V269, P11962; REINHARDT RR, 1995, J CLIN INVEST, V95, P1528, DOI 10.1172/JCI117825; Rondinone CM, 2000, J BIOL CHEM, V275, P10093, DOI 10.1074/jbc.275.14.10093; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Shakur Y, 2001, PROG NUCLEIC ACID RE, V66, P241; Shakur Y, 2000, J BIOL CHEM, V275, P38749, DOI 10.1074/jbc.M001734200; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; SMITH CJ, 1991, J BIOL CHEM, V266, P13385; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V190, P516, DOI 10.1006/bbrc.1993.1078; Wu WH, 2000, J BIOL CHEM, V275, P40113, DOI 10.1074/jbc.M004108200; XIAO RP, 1994, J BIOL CHEM, V269, P19151; XIAO RP, 1993, CIRC RES, V73, P286, DOI 10.1161/01.RES.73.2.286; Zhao AZ, 1998, J CLIN INVEST, V102, P869, DOI 10.1172/JCI3920	40	95	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 11	2002	277	41					38072	38078		10.1074/jbc.M203647200	http://dx.doi.org/10.1074/jbc.M203647200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	602XK	12154085	hybrid			2022-12-27	WOS:000178529600014
J	Sekine, O; Nishio, Y; Egawa, K; Nakamura, T; Maegawa, H; Kashiwagi, A				Sekine, O; Nishio, Y; Egawa, K; Nakamura, T; Maegawa, H; Kashiwagi, A			Insulin activates CCAAT/enhancer binding proteins and proinflammatory gene expression through the phosphatidylinositol 3-kinase pathway in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; NF-KAPPA-B; ENDOTHELIAL DYSFUNCTION; HEART-DISEASE; RABBIT MODEL; ATHEROSCLEROSIS; RESISTANCE; PHOSPHORYLATION; AKT; INFLAMMATION	Phosphatidylinositol 3-kinase (PI3K) is a key molecule mediating signals of insulin in vascular smooth muscle cells (VSMCs). To examine the effect of chronic activation of PI3K on the gene expression of VSMCs, membrane-targeted p110CAAX, a catalytic subunit of PI3K, was overexpressed in rat VSMCs by adenovirus-mediated gene transfer. Similar to insulin's effects, cells overexpressing p110CAAX exhibited a 10- to 15-fold increase in monocyte chemoattractant protein-1 (MCP-1) mRNA expression as compared with the control cells. Electrophoretic mobility shift assay analysis showed that the overexpression of p110CAAX activated neither the NF-kappaB binding nor the activator protein (AP-1) binding activities. We found that two CCAAT/enhancer binding protein (C/EBP) binding sites located between 2.6 and 3.6 kb upstream of the MCP-1 gene were responsible for the induction by p110CAAX. The overexpression of C/EBP-beta and C/EBP-delta but not C/EBP-alpha caused 6- to 8-fold induction of MCP-1 promoter activity. Consistently, the overexpression of p110CAAX as well as insulin induced mRNA expression and nuclear expression of C/EBP-beta and C/EBP-delta in VSMCs. These results clearly indicate that the activation of PI3K induced proinflammatory gene expression through activating C/EBP-beta and C/EBP-delta but not NF-kappaB, which may explain the proinflammatory effect of insulin in the insulin-resistant state.	Shiga Univ Med Sci, Div Endocrinol & Metab, Dept Med, Otsu, Shiga 5202192, Japan; Shiga Univ Med Sci, Dept Anat, Otsu, Shiga 5202192, Japan	Shiga University of Medical Science; Shiga University of Medical Science	Nishio, Y (corresponding author), Shiga Univ Med Sci, Div Endocrinol & Metab, Dept Med, Otsu, Shiga 5202192, Japan.		Kashiwagi, Atsunori/H-8712-2019	Maegawa, Hiroshi/0000-0002-4611-8149				BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Bustos C, 1998, J AM COLL CARDIOL, V32, P2057, DOI 10.1016/S0735-1097(98)00487-2; Chen XL, 1998, CIRC RES, V83, P952; Despres JP, 1996, NEW ENGL J MED, V334, P952, DOI 10.1056/NEJM199604113341504; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; Festa A, 2000, CIRCULATION, V102, P42, DOI 10.1161/01.CIR.102.1.42; FONTBONNE A, 1988, INT J OBESITY, V12, P557; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; Hanlon M, 2001, J BIOL CHEM, V276, P38449, DOI 10.1074/jbc.M102165200; HernandezPresa M, 1997, CIRCULATION, V95, P1532; Hu HM, 2000, J BIOL CHEM, V275, P16373, DOI 10.1074/jbc.M910269199; Jiang ZY, 1999, J CLIN INVEST, V104, P447, DOI 10.1172/JCI5971; Kuboki K, 2000, CIRCULATION, V101, P676, DOI 10.1161/01.CIR.101.6.676; Landry DB, 1997, AM J PATHOL, V151, P1085; Libby P, 2001, AM J CARDIOL, V88, p3J; Merola M, 1996, J INTERF CYTOK RES, V16, P783, DOI 10.1089/jir.1996.16.783; Montagnani M, 2001, J BIOL CHEM, V276, P30392, DOI 10.1074/jbc.M103702200; Nakamura T, 2001, J CLIN ENDOCR METAB, V86, P1795, DOI 10.1210/jc.86.4.1795; Obata T, 1996, CIRC RES, V79, P1167, DOI 10.1161/01.RES.79.6.1167; Ozes ON, 1999, NATURE, V401, P82; Piwien-Pilipuk G, 2001, J BIOL CHEM, V276, P19664, DOI 10.1074/jbc.M010193200; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SCHERRER U, 1994, J CLIN INVEST, V94, P2511, DOI 10.1172/JCI117621; Shinozaki K, 1999, DIABETES, V48, P2437, DOI 10.2337/diabetes.48.12.2437; Shinozaki K, 2000, CIRC RES, V87, P566, DOI 10.1161/01.RES.87.7.566; Steinberg HO, 1996, J CLIN INVEST, V97, P2601, DOI 10.1172/JCI118709; STOUT RW, 1975, CIRC RES, V36, P319, DOI 10.1161/01.RES.36.2.319; STOUT RW, 1990, DIABETES CARE, V13, P631, DOI 10.2337/diacare.13.6.631; TAKAGI Y, 1995, ATHEROSCLEROSIS, V113, P19, DOI 10.1016/0021-9150(94)05422-F; TAKEYA M, 1993, HUM PATHOL, V24, P534, DOI 10.1016/0046-8177(93)90166-E; Tomita H, 1998, ARTERIOSCL THROM VAS, V18, P1456, DOI 10.1161/01.ATV.18.9.1456; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; Wang YP, 2000, KIDNEY INT, V57, P2011, DOI 10.1046/j.1523-1755.2000.00051.x; WEGNER M, 1992, SCIENCE, V256, P370, DOI 10.1126/science.256.5055.370; WHITE MF, 1994, J BIOL CHEM, V269, P1; Wu TJ, 2002, AM J EPIDEMIOL, V155, P65, DOI 10.1093/aje/155.1.65	42	63	64	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 27	2002	277	39					36631	36639		10.1074/jbc.M206266200	http://dx.doi.org/10.1074/jbc.M206266200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	598KN	12145301	hybrid			2022-12-27	WOS:000178275100108
